Cervicovaginal - - O
foetal - - B-MUT
fibronectin - - I-MUT
in - - O
the - - O
prediction - - O
of - - O
preterm - - O
labour - - O
in - - O
a - - O
low-risk - - O
population - - O
. - - O

Varicella-zoster - - B-MUT
virus - - I-MUT
( - - I-MUT
VZV - - I-MUT
) - - I-MUT
glycoprotein - - I-MUT
gI - - I-MUT
is - - O
a - - O
type - - B-MUT
1 - - I-MUT
transmembrane - - I-MUT
glycoprotein - - I-MUT
which - - O
is - - O
one - - O
component - - O
of - - O
the - - O
heterodimeric - - O
gE - - B-MUT
: - - O
gI - - B-MUT
Fc - - I-MUT
receptor - - I-MUT
complex - - O
. - - O

A - - O
segment - - O
of - - O
mRNA - - O
encoding - - O
the - - O
leader - - O
peptide - - O
of - - O
the - - O
CPA1 - - B-MUT
gene - - I-MUT
confers - - O
repression - - O
by - - O
arginine - - O
on - - O
a - - O
heterologous - - O
yeast - - O
gene - - O
transcript - - O
. - - O

In - - O
addition - - O
, - - O
lexical - - O
priming - - O
was - - O
examined - - O
by - - O
presenting - - O
an - - O
identity - - O
prime - - O
earlier - - O
in - - O
the - - O
text - - O
. - - O

Lower - - O
extremity - - O
weight - - O
bearing - - O
under - - O
various - - O
standing - - O
conditions - - O
in - - O
independently - - O
ambulatory - - O
patients - - O
with - - O
hemiparesis - - O
. - - O

Insulin-like - - B-MUT
growth - - I-MUT
factor - - I-MUT
1 - - I-MUT
( - - O
IGF-1 - - B-MUT
) - - O
in - - O
burn - - O
patients - - O
. - - O

This - - O
approach - - O
enables - - O
the - - O
sources - - O
of - - O
error - - O
in - - O
the - - O
calculation - - O
of - - O
nutrient - - O
utilization - - O
to - - O
be - - O
readily - - O
identified - - O
, - - O
and - - O
their - - O
effect - - O
on - - O
precision - - O
to - - O
be - - O
assessed - - O
in - - O
different - - O
nutritional - - O
and - - O
metabolic - - O
states - - O
. - - O

We - - O
identify - - O
the - - O
"M - - O
region" - - O
of - - O
the - - O
muscle-specific - - B-MUT
Xenopus - - I-MUT
cardiac - - I-MUT
actin - - I-MUT
gene - - I-MUT
promoter - - I-MUT
from - - O
-282 - - O
to - - O
-348 - - O
as - - O
necessary - - O
for - - O
the - - O
embryonic - - O
expression - - O
of - - O
a - - O
cardiac - - B-MUT
actin-beta-globin - - I-MUT
reporter - - I-MUT
gene - - I-MUT
injected - - O
into - - O
fertilized - - O
eggs - - O
. - - O

We - - O
found - - O
that - - O
120 - - O
bp - - O
of - - O
the - - O
enhancer's - - O
transcriptional - - O
core - - O
becomes - - O
DNase - - B-MUT
I - - I-MUT
hypersensitive - - O
early - - O
in - - O
B-cell - - O
development - - O
. - - O

Biochemical - - O
experiments - - O
have - - O
shown - - O
that - - O
CopG - - B-MUT
co-operatively - - O
associates - - O
to - - O
its - - O
target - - O
DNA - - O
at - - O
low - - O
protein - - O
: - - O
DNA - - O
ratios - - O
, - - O
completely - - O
protecting - - O
four - - O
helical - - O
turns - - O
on - - O
the - - O
same - - O
face - - O
of - - O
the - - O
double - - O
helix - - O
in - - O
both - - O
directions - - O
from - - O
the - - O
inverted - - O
repeat - - O
that - - O
constitutes - - O
the - - O
CopG - - B-MUT
primary - - O
target - - O
. - - O

3 - - O
. - - O

Competition - - O
needs - - O
to - - O
be - - O
better - - O
studied - - O
, - - O
since - - O
in - - O
Central - - O
America - - O
and - - O
Caribean - - O
islands - - O
this - - O
kind - - O
of - - O
study - - O
has - - O
favored - - O
the - - O
biological - - O
control - - O
of - - O
planorbid - - O
species - - O
. - - O

Echocardiography - - O
revealed - - O
right - - O
ventricular - - O
diastolic - - O
collapse - - O
( - - O
RVDC - - O
) - - O
without - - O
physical - - O
signs - - O
of - - O
cardiac - - O
tamponade - - O
. - - O

Structure - - O
and - - O
expression - - O
of - - O
a - - O
gene - - O
from - - O
Arabidopsis - - O
thaliana - - O
encoding - - O
a - - O
protein - - O
related - - O
to - - O
SNF1 - - B-MUT
protein - - B-MUT
kinase - - I-MUT
. - - O

Our - - O
results - - O
indicate - - O
that - - O
the - - O
retroplasmid - - O
reverse - - B-MUT
transcriptase - - I-MUT
is - - O
uniquely - - O
adapted - - O
to - - O
initiate - - O
cDNA - - O
synthesis - - O
by - - O
recognizing - - O
a - - O
3' - - O
CCA - - O
sequence - - O
. - - O

TNF-alpha - - B-MUT
exposure - - O
markedly - - O
increased - - O
activity - - O
of - - O
several - - O
RNA-binding - - O
proteins - - O
, - - O
especially - - O
a - - O
novel - - O
Mr - - O
50 - - O
, - - O
000-55 - - O
, - - O
000 - - O
RNA-binding - - O
protein - - O
. - - O

The - - O
LMW - - B-MUT
FGF-2 - - I-MUT
up-regulated - - O
the - - O
PKC - - B-MUT
epsilon - - I-MUT
levels - - O
by - - O
1 - - O
. - - O
6-fold - - O
; - - O
by - - O
contrast - - O
the - - O
HMW - - B-MUT
isoform - - I-MUT
down-regulated - - O
the - - O
level - - O
of - - O
this - - O
PKC - - B-MUT
isotype - - I-MUT
by - - O
about - - O
3-fold - - O
and - - O
increased - - O
the - - O
amount - - O
of - - O
PKC - - B-MUT
delta - - I-MUT
by - - O
1 - - O
. - - O
7-fold - - O
. - - O

Urine - - O
samples - - O
collected - - O
after - - O
the - - O
administration - - O
of - - O
these - - O
supplements - - O
can - - O
test - - O
positive - - O
. - - O

In - - O
the - - O
ultramarathon - - O
runner - - O
the - - O
testosterone - - O
levels - - O
sharply - - O
rose - - O
at - - O
the - - O
beginning - - O
of - - O
the - - O
training - - O
session - - O
( - - O
from - - O
the - - O
7 - - O
, - - O
20 - - O
ng - - O
ml - - O
to - - O
11 - - O
, - - O
50 - - O
ng - - O
ml - - O
after - - O
20' - - O
training - - O
) - - O
, - - O
and - - O
subsequently - - O
decrease - - O
after - - O
3 - - O
hours - - O
( - - O
9 - - O
, - - O
20 - - O
ng - - O
ml - - O
) - - O
and - - O
at - - O
the - - O
end - - O
of - - O
the - - O
6 - - O
hours - - O
training - - O
( - - O
4 - - O
, - - O
60 - - O
ng - - O
ml - - O
) - - O
. - - O

A - - O
significant - - O
direct - - O
relationship - - O
was - - O
observed - - O
between - - O
the - - O
percent - - O
area - - O
density - - O
of - - O
smooth - - O
muscle - - O
and - - O
the - - O
percent - - O
change - - O
in - - O
peak - - O
urinary - - O
flow - - O
rate - - O
. - - O

60th - - O
birthday - - O
of - - O
colonel - - O
prof - - O
. - - O
e - - O
. - - O
cerny - - O
m - - O
. - - O
d - - O
. - - O

In - - O
a - - O
previous - - O
study - - O
( - - O
Brandl - - O
, - - O
C - - O
. - - O

Thrombolysis - - O
was - - O
followed - - O
by - - O
a - - O
similar - - O
increase - - O
of - - O
platelet - - O
activity - - O
with - - O
maximal - - O
values - - O
reached - - O
at - - O
the - - O
3rd - - O
hour - - O
in - - O
both - - O
groups - - O
( - - O
196 - - O
+ - - O
- - - O
43 - - O
IU - - O
ml - - O
in - - O
Group - - O
1 - - O
and - - O
192 - - O
+ - - O
- - - O
39 - - O
in - - O
Group - - O
2 - - O
: - - O
p - - O
< - - O
001versus - - O
baseline - - O
and - - O
p - - O
NS - - O
between - - O
the - - O
groups - - O
) - - O
. - - O

The - - O
latter - - O
was - - O
determined - - O
as - - O
follows - - O
: - - O
Type - - O
I-solid - - O
tumor - - O
tissue - - O
without - - O
significant - - O
peripheral - - O
isolated - - O
tumor - - O
cells - - O
; - - O
Type - - O
II-solid - - O
tumor - - O
tissue - - O
associated - - O
with - - O
peripheral - - O
isolated - - O
tumor - - O
cells - - O
; - - O
Type - - O
III-isolated - - O
tumor - - O
cells - - O
only - - O
. - - O

Comparison - - O
of - - O
the - - O
nucleotide - - O
sequences - - O
between - - O
the - - O
human - - O
and - - O
bovine - - O
DNA - - O
showed - - O
that - - O
the - - O
sequence - - O
similarity - - O
extended - - O
2400 - - O
bp - - O
downstream - - O
from - - O
the - - O
coding - - O
region - - O
. - - O

Periodic - - O
breathing - - O
and - - O
apnea - - O
in - - O
preterm - - O
infants - - O
. - - O

Antivitamin - - O
K - - O
agents - - O
. - - O

Simultaneously - - O
a - - O
greater - - O
NA - - O
was - - O
found - - O
with - - O
no - - O
change - - O
in - - O
plasma - - O
epinephrine - - O
response - - O
. - - O

The - - O
behavior - - O
of - - O
different - - O
types - - O
of - - O
polytetrafluoroethylene - - O
( - - O
PTFE - - O
) - - O
prostheses - - O
in - - O
the - - O
reparative - - O
scarring - - O
process - - O
of - - O
abdominal - - O
wall - - O
defects - - O
. - - O

IX - - O
. - - O

The - - O
murine - - B-MUT
Mov-34 - - I-MUT
gene - - I-MUT
: - - O
full-length - - O
cDNA - - O
and - - O
genomic - - O
organization - - O
. - - O

Among - - O
the - - O
mixed - - O
race - - O
persons - - O
one - - O
Chukcha-Eskimo - - O
had - - O
AS - - O
, - - O
one - - O
Eskimo-Russian - - O
had - - O
psoriatic - - O
arthritis - - O
( - - O
PsA - - O
) - - O
. - - O

To - - O
examine - - O
the - - O
basis - - O
for - - O
the - - O
apparent - - O
differences - - O
in - - O
postsegregational - - O
killing - - O
between - - O
the - - O
two - - O
E - - O
. - - O
coli - - O
strains - - O
, - - O
transformation - - O
assays - - O
were - - O
carried - - O
out - - O
to - - O
determine - - O
the - - O
relative - - O
sensitivities - - O
of - - O
the - - O
strains - - O
to - - O
the - - O
ParE - - B-MUT
toxin - - I-MUT
protein - - I-MUT
. - - O

The - - O
mHIF-1 - - B-MUT
alpha - - I-MUT
structural - - I-MUT
gene - - I-MUT
is - - O
composed - - O
of - - O
15 - - O
exons - - O
. - - O

Variability - - O
within - - O
Down's - - O
syndrome - - O
( - - O
trisomy-21 - - O
) - - O
: - - O
empirically - - O
observed - - O
sex - - O
differences - - O
in - - O
IQs - - O
. - - O

The - - O
participants - - O
were - - O
homosexual - - O
men - - O
in - - O
hepatitis - - O
B - - O
vaccine - - O
trials - - O
in - - O
Amsterdam - - O
( - - O
n - - O
= - - O
74 - - O
) - - O
, - - O
New - - O
York - - O
City - - O
( - - O
n - - O
= - - O
120 - - O
) - - O
, - - O
and - - O
San - - O
Francisco - - O
( - - O
n - - O
= - - O
168 - - O
) - - O
. - - O

Very - - O
small - - O
deletions - - O
within - - O
the - - O
conserved - - O
region - - O
completely - - O
abolished - - O
transforming - - O
activity - - O
of - - O
dbl - - B-MUT
, - - O
while - - O
extensive - - O
deletion - - O
outside - - O
of - - O
this - - O
region - - O
had - - O
no - - O
effect - - O
. - - O

Studies - - O
on - - O
the - - O
organic - - O
matrix - - O
of - - O
human - - O
ear - - O
ossicles - - O
. - - O

These - - O
differences - - O
are - - O
smaller - - O
than - - O
those - - O
described - - O
in - - O
standard - - O
textbooks - - O
. - - O

The - - O
algorithm - - O
also - - O
limited - - O
TG - - O
to - - O
20 - - O
and - - O
64% - - O
, - - O
apoB - - B-MUT
to - - O
6 - - O
and - - O
20% - - O
, - - O
and - - O
Lp - - B-MUT
( - - I-MUT
a - - I-MUT
) - - I-MUT
to - - O
15 - - O
and - - O
56% - - O
, - - O
of - - O
low- - - O
and - - O
high-risk - - O
groups - - O
, - - O
respectively - - O
. - - O

Like - - O
other - - O
members - - O
of - - O
this - - O
family - - O
, - - O
the - - O
AP-4 - - B-MUT
HLH - - B-MUT
motif - - I-MUT
and - - O
the - - O
adjacent - - O
basic - - O
domain - - O
are - - O
necessary - - O
and - - O
sufficient - - O
to - - O
confer - - O
site-specific - - O
DNA - - O
binding - - O
. - - O

Following - - O
the - - O
patients - - O
during - - O
a - - O
course - - O
of - - O
therapy - - O
with - - O
a - - O
selective - - O
vasodilator - - O
calcium - - O
antagonist - - O
, - - O
the - - O
beta-adrenergic - - O
reflex - - O
vasodilation - - O
became - - O
substantially - - O
attenuated - - O
but - - O
was - - O
preserved - - O
during - - O
a - - O
placebo - - O
course - - O
of - - O
therapy - - O
. - - O

Two - - O
members - - O
of - - O
the - - O
Cbl - - B-MUT
family - - I-MUT
have - - O
since - - O
been - - O
defined - - O
in - - O
mammals - - O
( - - O
c-Cbl - - B-MUT
and - - O
Cbl-b - - B-MUT
) - - O
, - - O
one - - O
in - - O
C - - O
. - - O
elegans - - O
( - - O
Sli-1 - - B-MUT
) - - O
and - - O
one - - O
in - - O
Drosophila - - O
( - - O
D-Cbl - - B-MUT
) - - O
. - - O

Fourteen - - O
healthy - - O
male - - O
volunteers - - O
completed - - O
the - - O
study - - O
. - - O

Comparisons - - O
of - - O
the - - O
four - - O
operon - - O
control - - O
regions - - O
studied - - O
indicate - - O
that - - O
the - - O
NarL - - B-MUT
heptamers - - I-MUT
are - - O
arranged - - O
with - - O
diverse - - O
orientations - - O
and - - O
spacing - - O
. - - O

Hybridization - - O
of - - O
plasmid-transformed - - O
Escherichia - - O
coli - - O
RR1 - - O
colonies - - O
with - - O
32P-labeled - - O
viral - - O
genome - - O
RNAs - - O
demonstrated - - O
the - - O
presence - - O
of - - O
DNA - - O
clones - - O
representative - - O
of - - O
each - - O
of - - O
the - - O
10 - - O
reovirus - - O
RNAs - - O
and - - O
10 - - O
of - - O
the - - O
11 - - O
constituent - - O
segments - - O
of - - O
the - - O
rotavirus - - O
genome - - O
. - - O

Sci - - O
. - - O

The - - O
secondary - - O
, - - O
but - - O
not - - O
the - - O
primary - - O
, - - O
antibody - - O
responses - - O
of - - O
male - - O
C57Bl - - O
6 - - O
mice - - O
were - - O
higher - - O
among - - O
mice - - O
housed - - O
alone - - O
compared - - O
to - - O
mice - - O
housed - - O
in - - O
groups - - O
; - - O
differences - - O
were - - O
observed - - O
for - - O
both - - O
IgM - - O
and - - B-MUT
IgG - - O
anti-KLH - - B-MUT
antibodies - - I-MUT
. - - I-MUT

TaV - - O
particles - - O
have - - O
a - - O
buoyant - - O
density - - O
of - - O
1 - - O
. - - O
296 - - O
g - - O
cm3 - - O
in - - O
CsCl - - O
and - - O
consist - - O
of - - O
two - - O
capsid - - O
proteins - - O
of - - O
56 - - O
and - - O
6 - - O
kDa - - O
. - - O

Demonstration - - O
of - - O
tissue - - O
lesions - - O
after - - O
intramuscular - - O
injection - - O
by - - O
determination - - O
of - - O
creatine - - B-MUT
kinase - - I-MUT
in - - O
blood - - O
. - - O

These - - O
six - - O
amino - - O
acids - - O
are - - O
part - - O
of - - O
an - - O
amphipathic - - O
helix - - O
that - - O
is - - O
highly - - O
conserved - - O
among - - O
nuclear - - B-MUT
hormone - - I-MUT
receptors - - I-MUT
and - - O
contains - - O
the - - O
core - - O
domain - - O
of - - O
the - - O
ligand-dependent - - O
transactivation - - O
function - - O
, - - O
AF-2 - - B-MUT
. - - O

Therefore - - O
, - - O
it - - O
is - - O
important - - O
to - - O
control - - O
hypertension - - O
and - - O
keep - - O
appropriate - - O
renal - - O
blood - - O
flow - - O
during - - O
living - - O
renal - - O
transplantation - - O
surgery - - O
. - - O

Neither - - O
mutant - - O
exhibited - - O
derepression - - O
of - - O
the - - O
silent - - B-MUT
mating - - I-MUT
type - - I-MUT
loci - - I-MUT
. - - O

Transcriptional - - O
activation - - O
of - - O
the - - O
chicken - - B-MUT
lysozyme - - I-MUT
gene - - I-MUT
by - - O
NF-kappa - - B-MUT
Bp65 - - I-MUT
( - - O
RelA - - B-MUT
) - - O
and - - O
c-Rel - - B-MUT
, - - O
but - - O
not - - O
by - - O
NF-kappa - - B-MUT
Bp50 - - I-MUT
. - - O

Current - - O
diagnostic - - O
uses - - O
of - - O
computerized - - O
tomography - - O
in - - O
clinical - - O
medicine - - O
. - - O

59 - - O
cases - - O
of - - O
surgically - - O
resectable - - O
cancers - - O
( - - O
T1 - - O
, - - O
T2 - - O
, - - O
T3 - - O
, - - O
N0 - - O
, - - O
N1 - - O
) - - O
had - - O
a - - O
minimum - - O
followup - - O
of - - O
two - - O
years - - O
( - - O
average - - O
4 - - O
years - - O
+ - - O
- - - O
3 - - O
months - - O
) - - O
. - - O

Re-examining - - O
methylbenzene - - O
( - - O
toluene - - O
) - - O
as - - O
a - - O
treatment - - O
for - - O
Ancylostomum - - O
caninum - - O
. - - O

Mean - - O
fluorosis - - O
scores - - O
, - - O
however - - O
, - - O
were - - O
similar - - O
. - - O

The - - O
subgroup - - O
innervating - - O
the - - O
medial - - O
rectus - - O
lies - - O
exclusively - - O
along - - O
the - - O
medial - - O
face - - O
of - - O
the - - O
oculomotor - - O
nucleus - - O
, - - O
with - - O
no - - O
aberrant - - O
neurons - - O
in - - O
the - - O
medial - - O
longitudinal - - O
fasciculus - - O
, - - O
as - - O
have - - O
been - - O
found - - O
in - - O
other - - O
mammals - - O
. - - O

Responsiveness - - O
to - - O
beta-2 - - O
agonist - - O
therapy - - O
was - - O
retained - - O
with - - O
both - - O
agents - - O
( - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
05 - - O
) - - O
. - - O

POU-domain - - B-MUT
proteins - - I-MUT
, - - O
such - - O
as - - O
the - - O
pituitary-specific - - B-MUT
factor - - I-MUT
Pit-1 - - I-MUT
, - - O
are - - O
members - - O
of - - O
the - - O
homeodomain - - B-MUT
family - - I-MUT
of - - O
proteins - - O
which - - O
are - - O
important - - O
in - - O
development - - O
and - - O
homeostasis - - O
, - - O
acting - - O
constitutively - - O
or - - O
in - - O
response - - O
to - - O
signal-transduction - - O
pathways - - O
to - - O
either - - O
repress - - O
or - - O
activate - - O
the - - O
expression - - O
of - - O
specific - - O
genes - - O
. - - O

The - - O
TCF-1 - - B-MUT
alpha - - I-MUT
binding - - I-MUT
site - - I-MUT
was - - O
also - - O
required - - O
for - - O
TCR - - B-MUT
alpha - - I-MUT
enhancer - - I-MUT
activity - - O
in - - O
transcriptionally - - O
active - - O
extracts - - O
from - - O
Jurkat - - O
but - - O
not - - O
HeLa - - O
cells - - O
, - - O
confirming - - O
that - - O
TCF-1 - - B-MUT
alpha - - I-MUT
is - - O
a - - O
T-cell-specific - - B-MUT
transcription - - I-MUT
factor - - I-MUT
. - - O

The - - O
interleukin - - B-MUT
2 - - I-MUT
receptor - - I-MUT
alpha-chain - - I-MUT
( - - O
IL-2R - - B-MUT
alpha - - I-MUT
) - - O
gene - - O
is - - O
rapidly - - O
and - - O
potently - - O
induced - - O
in - - O
T - - O
cells - - O
in - - O
response - - O
to - - O
mitogenic - - O
stimuli - - O
. - - O

Prediction - - O
of - - O
the - - O
times - - O
of - - O
sandfly - - O
development - - O
. - - O

A - - O
mixture - - O
of - - O
human - - B-MUT
albumin - - I-MUT
5% - - O
and - - O
hydroxy-ethyl-starch - - O
was - - O
used - - O
as - - O
a - - O
solution - - O
for - - O
dilution - - O
. - - O

The - - O
localization - - O
of - - O
this - - O
proteoglycan - - B-MUT
locus - - I-MUT
in - - O
the - - O
human - - O
genome - - O
and - - O
the - - O
availability - - O
of - - O
new - - O
RFLPs - - O
provide - - O
the - - O
tools - - O
for - - O
future - - O
studies - - O
of - - O
human - - O
diseases - - O
where - - O
the - - O
HSPG2 - - B-MUT
proteoglycan - - I-MUT
gene - - I-MUT
is - - O
suspected - - O
to - - O
be - - O
involved - - O
. - - O

Several - - O
7SL - - B-MUT
RNA-encoding - - I-MUT
sequences - - I-MUT
and - - O
various - - O
intergenic - - O
spacers - - O
were - - O
amplified - - O
from - - O
the - - O
individual - - O
HindIII - - B-MUT
fragments - - I-MUT
of - - O
about - - O
1 - - O
. - - O
3 - - O
and - - O
2 - - O
. - - O
8 - - O
kb - - O
. - - O

Tctex-1 - - B-MUT
binding - - O
required - - O
the - - O
first - - O
19 - - O
amino - - O
acids - - O
of - - O
Fyn - - B-MUT
and - - O
integrity - - O
of - - O
two - - O
lysine - - O
residues - - O
within - - O
this - - O
sequence - - O
that - - O
were - - O
previously - - O
shown - - O
to - - O
be - - O
important - - O
for - - O
Fyn - - B-MUT
interactions - - O
with - - O
the - - O
immunoreceptor - - B-MUT
tyrosine-based - - I-MUT
activation - - I-MUT
motifs - - I-MUT
( - - O
ITAMs - - B-MUT
) - - O
of - - O
lymphocyte - - B-MUT
Ag - - I-MUT
receptors - - I-MUT
. - - O

Hydroxypropyl - - O
methacrylate - - O
, - - O
a - - O
new - - O
water-miscible - - O
embedding - - O
medium - - O
for - - O
electron - - O
microscopy - - O
. - - O

Significant - - O
correlations - - O
between - - O
mental - - O
status - - O
as - - O
measured - - O
by - - O
the - - O
Mini-Mental - - O
State - - O
Examination - - O
and - - O
NA - - O
mI - - O
, - - O
mI - - O
Cr - - O
and - - O
NA - - O
were - - O
found - - O
. - - O

Treatment - - O
for - - O
this - - O
condition - - O
often - - O
involves - - O
use - - O
of - - O
a - - O
wax - - O
softening - - O
or - - O
dispersing - - O
agent - - O
( - - O
cerumenolytic - - O
) - - O
before - - O
syringing - - O
. - - O

Like - - O
humans - - O
, - - O
the - - O
PITSLRE - - B-MUT
PK - - I-MUT
genes - - I-MUT
in - - I-MUT
chickens - - I-MUT
must - - O
be - - O
closely - - O
linked - - O
, - - O
based - - O
on - - O
fluorescent - - O
in - - O
situ - - O
hybridization - - O
( - - O
FISH - - O
) - - O
localization - - O
of - - O
these - - O
genes - - O
to - - O
a - - O
single - - O
chicken - - O
microchromosome - - O
. - - O

PURPOSE - - O
: - - O
To - - O
evaluate - - O
the - - O
kinetics - - O
of - - O
erythropoietin - - B-MUT
( - - O
EPO - - B-MUT
) - - O
production - - O
and - - O
address - - O
the - - O
pathogenesis - - O
of - - O
anemia - - O
of - - O
prematurity - - O
, - - O
we - - O
measured - - O
EPO - - B-MUT
levels - - O
in - - O
infants - - O
during - - O
the - - O
first - - O
year - - O
of - - O
life - - O
. - - O

Protein - - B-MUT
kinases - - I-MUT
play - - O
pivotal - - O
roles - - O
in - - O
the - - O
control - - O
of - - O
many - - O
cellular - - O
processes - - O
. - - O

In - - O
the - - O
former - - O
cells - - O
, - - O
ets-2 - - B-MUT
was - - O
a - - O
CSF-1 - - B-MUT
immediate-early - - B-MUT
response - - I-MUT
gene - - I-MUT
, - - O
and - - O
phosphorylated - - O
ets-2 - - B-MUT
was - - O
detected - - O
after - - O
2 - - O
to - - O
4 - - O
h - - O
, - - O
coincident - - O
with - - O
expression - - O
of - - O
ets-2 - - B-MUT
protein - - I-MUT
. - - O

In - - O
particular - - O
, - - O
unc-86 - - B-MUT
encodes - - O
a - - O
POU-type - - B-MUT
homeodomain - - I-MUT
protein - - I-MUT
needed - - O
for - - O
the - - O
production - - O
of - - O
the - - O
touch - - O
cells - - O
, - - O
while - - O
mec-3 - - B-MUT
encodes - - O
a - - O
LIM-type - - B-MUT
homeodomain - - I-MUT
protein - - I-MUT
needed - - O
for - - O
the - - O
differentiation - - O
of - - O
the - - O
touch - - O
cells - - O
. - - O

Mutation - - O
analysis - - O
implicated - - O
multiple - - O
segments - - O
of - - O
the - - O
5' - - O
untranslated - - O
region - - O
as - - O
contributing - - O
to - - O
the - - O
inhibitory - - O
effect - - O
. - - O

Pathology - - O
of - - O
neuritis - - O
caudae - - O
equinae - - O
in - - O
the - - O
horse - - O
. - - O

Two - - O
new - - O
glucosidase - - B-MUT
inhibitors - - O
( - - O
BAY - - O
m - - O
1099 - - O
and - - O
BAY - - O
o - - O
1248 - - O
) - - O
were - - O
studied - - O
in - - O
volunteers - - O
and - - O
type - - O
II - - O
diabetics - - O
under - - O
various - - O
conditions - - O
. - - O

The - - O
characteristics - - O
of - - O
the - - O
VirD1 - - O
VirD2-mediated - - O
cleavage - - O
reaction - - O
strongly - - O
resemble - - O
those - - O
observed - - O
with - - O
relaxosomes - - O
of - - O
IncP - - O
plasmids - - O
involved - - O
in - - O
initiation - - O
of - - O
transfer - - O
DNA - - O
replication - - O
during - - O
bacterial - - O
conjugation - - O
. - - O

To - - O
define - - O
the - - O
number - - O
and - - O
nature - - O
of - - O
the - - O
E6 - - B-MUT
and - - O
E7 - - B-MUT
gene - - I-MUT
products - - O
expressed - - O
in - - O
BPV-1-transformed - - O
cells - - O
, - - O
we - - O
performed - - O
immunoprecipitation - - O
experiments - - O
with - - O
antisera - - O
raised - - O
to - - O
bacterially - - O
expressed - - O
BPV-1 - - B-MUT
E6 - - I-MUT
and - - O
E7 - - B-MUT
fusion - - I-MUT
proteins - - I-MUT
. - - O

These - - O
results - - O
suggest - - O
that - - O
UBP41 - - B-MUT
may - - O
play - - O
an - - O
important - - O
role - - O
in - - O
the - - O
recycling - - O
of - - O
ubiquitin - - B-MUT
by - - O
hydrolysis - - O
of - - O
branched - - B-MUT
poly-ubiquitin - - I-MUT
chains - - I-MUT
generated - - O
by - - O
the - - O
action - - O
of - - O
26 - - B-MUT
S - - I-MUT
proteasome - - I-MUT
on - - O
poly-ubiquitinated - - O
protein - - O
substrates - - O
, - - O
as - - O
well - - O
as - - O
in - - O
the - - O
production - - O
of - - O
free - - O
ubiquitin - - B-MUT
from - - O
linear - - B-MUT
poly-ubiquitin - - I-MUT
chains - - I-MUT
and - - O
of - - O
certain - - O
ribosomal - - O
proteins - - O
from - - O
ubiquitin - - B-MUT
fusion - - I-MUT
proteins - - I-MUT
. - - O

Results - - O
of - - O
the - - O
ECAT - - O
Angina - - O
Pectoris - - O
Study - - O
Group - - O
. - - O

Conversely - - O
, - - O
activation - - O
of - - O
Oct-3 - - B-MUT
4 - - I-MUT
promoter - - I-MUT
by - - I-MUT
RAR - - O
: - - B-MUT
RXR - - O
heterodimers - - B-MUT
was - - I-MUT
completely - - O
abolished - - O
by - - O
EAR-3 - - O
COUP-TFI - - B-MUT
and - - I-MUT
by - - I-MUT
ARP-1 - - O
COUP-TFII - - O
. - - B-MUT

At - - O
both - - O
water - - O
temperatures - - O
, - - O
VO2 - - O
increased - - O
linearly - - O
with - - O
increasing - - O
swimming - - O
velocity - - O
. - - O

To - - O
see - - O
if - - O
a - - O
pulse - - O
oximeter - - O
can - - O
monitor - - O
the - - O
fetus - - O
during - - O
labour - - O
we - - O
recruited - - O
100 - - O
Caucasian - - O
women - - O
in - - O
normal - - O
uncomplicated - - O
labour - - O
. - - O

In - - O
adult - - O
tissues - - O
, - - O
it - - O
was - - O
less - - O
restricted - - O
, - - O
indicating - - O
that - - O
RAFTK - - B-MUT
expression - - O
is - - O
developmentally - - O
up-regulated - - O
. - - O

A - - O
cytosolic - - O
variant - - O
of - - O
the - - O
protein - - O
underwent - - O
efficient - - O
transphosphorylation - - O
, - - O
yet - - O
failed - - O
to - - O
activate - - O
appreciably - - O
either - - O
p70 - - B-MUT
( - - I-MUT
S6k - - I-MUT
) - - I-MUT
or - - O
MAP - - B-MUT
kinase - - I-MUT
following - - O
treatment - - O
with - - O
FK1012 - - O
. - - O

Recent - - O
studies - - O
have - - O
shown - - O
the - - O
rat - - O
larynx - - O
to - - O
be - - O
an - - O
important - - O
organ - - O
in - - O
the - - O
evaluation - - O
of - - O
irritancy - - O
of - - O
inhaled - - O
materials - - O
. - - O

Taken - - O
together - - O
, - - O
our - - O
data - - O
suggest - - O
that - - O
Rat7p - - B-MUT
Nup159p - - I-MUT
is - - I-MUT
anchored - - O
within - - O
the - - O
NPC - - O
through - - B-MUT
its - - O
coiled-coil - - O
region - - O
and - - O
adjacent - - O
sequences - - O
. - - O

The - - O
experiment - - O
results - - O
showed - - O
: - - O
( - - O
i - - O
) - - O
not - - O
only - - O
1O2 - - O
, - - O
but - - O
also - - O
free - - O
radicals - - O
( - - O
O2- - - O
. - - O
. - - O
OH - - O
and - - O
YHPD- - - O
. - - O
) - - O
can - - O
be - - O
formed - - O
by - - O
the - - O
aid - - O
of - - O
YHPD - - O
; - - O
and - - O
( - - O
ii - - O
) - - O
as - - O
to - - O
the - - O
ability - - O
of - - O
producing - - O
1O2 - - O
, - - O
YHPD - - O
less - - O
than - - O
BHPD - - O
, - - O
while - - O
for - - O
generating - - O
O2- - - O
. - - O
and - - O
. - - O
OH - - O
, - - O
YHPD - - O
greater - - O
than - - O
BHPD - - O
. - - O

There - - O
is - - O
now - - O
a - - O
significative - - O
difference - - O
between - - O
age - - O
group - - O
1-5 - - O
and - - O
the - - O
others - - O
( - - O
p - - O
Less - - O
Than - - O
0 - - O
, - - O
02 - - O
) - - O
. - - O

Role - - O
of - - O
histoclinical - - O
studies - - O
in - - O
the - - O
prophylaxis - - O
of - - O
spontaneous - - O
abortions - - O
. - - O

Our - - O
results - - O
indicate - - O
that - - O
RA-mediated - - O
repression - - O
of - - O
the - - O
hMGP - - B-MUT
gene - - I-MUT
is - - O
due - - O
to - - O
binding - - O
of - - O
liganded - - O
RAR - - B-MUT
RXR - - I-MUT
to - - I-MUT
a - - O
novel - - O
negative - - O
RA - - O
response - - B-MUT
element - - I-MUT
. - - I-MUT

The - - O
mean - - O
waiting - - O
time - - O
to - - O
receive - - O
the - - O
pancreas - - O
transplant - - O
was - - O
244 - - O
days - - O
for - - O
SPK - - O
and - - O
167 - - O
days - - O
for - - O
PAK - - O
recipients - - O
( - - O
P - - O
= - - O
0 - - O
. - - O
001 - - O
) - - O
. - - O

An - - O
AP-1 - - B-MUT
binding - - I-MUT
sequence - - I-MUT
is - - O
essential - - O
for - - O
regulation - - O
of - - O
the - - O
human - - B-MUT
alpha2 - - I-MUT
( - - I-MUT
I - - I-MUT
) - - I-MUT
collagen - - I-MUT
( - - O
COL1A2 - - B-MUT
) - - O
promoter - - O
activity - - O
by - - O
transforming - - B-MUT
growth - - I-MUT
factor-beta - - I-MUT
. - - O

The - - O
prevalence - - O
of - - O
hepatitis - - O
C - - O
virus - - O
( - - O
HCV - - O
) - - O
infection - - O
is - - O
relatively - - O
low - - O
in - - O
childhood - - O
, - - O
with - - O
anti-HCV - - O
prevalence - - O
rates - - O
of - - O
0 - - O
. - - O
1-0 - - O
. - - O
4% - - O
in - - O
the - - O
Western - - O
world - - O
. - - O

Hybridization - - O
of - - O
a - - O
probe - - O
from - - O
this - - O
region - - O
to - - O
electrophoretic - - O
blots - - O
of - - O
RNAs - - O
from - - O
different - - O
human - - O
tissues - - O
showed - - O
a - - O
predominant - - O
2 - - O
. - - O
8-kilobase - - O
( - - O
kb - - O
) - - O
message - - O
accompanied - - O
by - - O
weaker - - O
bands - - O
4 - - O
. - - O
1 - - O
and - - O
2 - - O
. - - O
1 - - O
kb - - O
in - - O
size - - O
. - - O

Both - - O
strains - - O
grew - - O
very - - O
poorly - - O
, - - O
or - - O
not - - O
at - - O
all - - O
, - - O
on - - O
nonfermentable - - O
carbon - - O
sources - - O
and - - O
exhibited - - O
, - - O
at - - O
most - - O
, - - O
only - - O
5% - - O
of - - O
wild-type - - B-MUT
ubiquinol-cytochrome - - I-MUT
c - - I-MUT
oxidoreductase - - I-MUT
activity - - O
. - - O

Consciousness - - O
is - - O
connected - - O
with - - O
attention - - O
, - - O
working - - O
memory - - O
and - - O
perception - - O
. - - O

SIT - - B-MUT
( - - O
SHP2-interacting - - B-MUT
transmembrane - - I-MUT
adaptor - - I-MUT
protein - - I-MUT
) - - O
is - - O
a - - O
recently - - O
identified - - O
transmembrane - - O
adaptor - - O
protein - - O
, - - O
which - - O
is - - O
expressed - - O
in - - O
lymphocytes - - O
. - - O

Certain - - O
transcript - - O
patterns - - O
in - - O
Epifagus - - O
plastids - - O
are - - O
highly - - O
complex - - O
and - - O
similar - - O
to - - O
those - - O
of - - O
tobacco - - O
operons - - O
. - - O

The - - O
putative - - O
immunity - - O
protein - - O
was - - O
detected - - O
among - - O
the - - O
[ - - O
35S - - O
] - - O
methionine-labelled - - O
proteins - - O
produced - - O
by - - O
minicells - - O
carrying - - O
cni - - B-MUT
cloned - - O
under - - O
lac - - B-MUT
promoter - - I-MUT
control - - O
, - - O
and - - O
when - - O
the - - O
gene - - O
was - - O
subcloned - - O
into - - O
expression - - O
vectors - - O
under - - O
the - - O
control - - O
of - - O
a - - O
bacteriophage - - O
T7 - - O
promoter - - O
. - - O

This - - O
region - - O
includes - - O
verA - - B-MUT
, - - O
a - - O
structural - - O
gene - - O
previously - - O
shown - - O
to - - O
be - - O
required - - O
for - - O
ST - - B-MUT
biosynthesis - - O
, - - O
and - - O
24 - - O
additional - - O
closely - - O
spaced - - O
transcripts - - O
ranging - - O
in - - O
size - - O
from - - O
0 - - O
. - - O
6 - - O
to - - O
7 - - O
. - - O
2 - - O
kb - - O
that - - O
are - - O
coordinately - - O
induced - - O
only - - O
under - - O
ST-producing - - O
conditions - - O
. - - O

In - - O
transformed - - O
E - - O
. - - O
coli - - O
, - - O
constitutive - - B-MUT
CAT - - I-MUT
expression - - O
is - - O
maintained - - O
when - - O
as - - O
little - - O
as - - O
0 - - O
. - - O
3 - - O
kilobase - - O
of - - O
DNA - - O
from - - O
the - - O
3' - - O
end - - O
of - - O
the - - O
1 - - O
. - - O
6-kilobase - - O
segment - - O
is - - O
inserted - - O
in - - O
the - - O
correct - - O
orientation - - O
in - - O
front - - O
of - - O
the - - O
CAT - - B-MUT
gene - - I-MUT
. - - O

Comparison - - O
of - - O
sequences - - O
of - - O
ovine - - O
and - - O
bovine - - O
, - - O
rat - - O
and - - O
guinea-pig - - B-MUT
alpha - - I-MUT
s1-casein - - I-MUT
mRNAs - - I-MUT
has - - O
revealed - - O
a - - O
greater - - O
homology - - O
in - - O
the - - O
3' - - O
and - - O
especially - - O
5' - - O
non - - O
coding - - O
regions - - O
. - - O

The - - O
determination - - O
of - - O
physical - - O
performance - - O
capacity - - O
was - - O
based - - O
on - - O
W170 - - O
, - - O
W85% - - O
and - - O
on - - O
predicted - - O
VO2 - - O
max - - O
measured - - O
with - - O
continuously - - O
increasing - - O
work - - O
load - - O
on - - O
a - - O
bicycle - - O
ergometer - - O
. - - O

The - - O
effects - - O
of - - O
a - - O
1- - - O
or - - O
24-hour - - O
pretreatment - - O
regimen - - O
with - - O
monophosphoryl - - O
lipid - - O
A - - O
( - - O
MLA - - O
, - - O
35 - - O
micrograms - - O
kg - - O
i - - O
. - - O
v - - O
. - - O
) - - O
on - - O
myocardial - - O
stunning - - O
produced - - O
by - - O
repetitive - - O
coronary - - O
occlusions - - O
were - - O
studied - - O
in - - O
barbital-anesthetized - - O
dogs - - O
. - - O

The - - O
spermicide - - O
nonoxynol-9 - - O
is - - O
a - - O
member - - O
of - - O
a - - O
homologous - - O
series - - O
of - - O
alkylphenol-ethoxylates - - O
( - - O
polyethoxyethanols - - O
) - - O
of - - O
general - - O
formula - - O
C9H19-C6H6-O- - - O
( - - O
CH2CH2O - - O
) - - O
n-1 - - O
CH2CH2OH - - O
. - - O

According - - O
to - - O
their - - O
functional - - O
properties - - O
the - - O
latter - - O
neurons - - O
were - - O
subdivided - - O
into - - O
: - - O
( - - O
a - - O
) - - O
neurons - - O
responding - - O
to - - O
stimuli - - O
near - - O
the - - O
eyes - - O
; - - O
( - - O
b - - O
) - - O
neurons - - O
triggered - - O
by - - O
complex - - O
visual - - O
stimuli - - O
; - - O
( - - O
c - - O
) - - O
neurons - - O
inhibited - - O
by - - O
visual - - O
stimuli - - O
. - - O

To - - O
our - - O
knowledge - - O
, - - O
type - - O
IV - - O
renal - - O
tubular - - O
acidosis - - O
has - - O
not - - O
been - - O
reported - - O
previously - - O
in - - O
association - - O
with - - O
Alport's - - O
syndrome - - O
in - - O
an - - O
adult - - O
patient - - O
. - - O

Observers - - O
with - - O
brain - - O
injury - - O
and - - O
control - - O
participants - - O
performed - - O
a - - O
vigilance - - O
task - - O
during - - O
which - - O
they - - O
received - - O
periodic - - O
whiffs - - O
of - - O
unscented - - O
air - - O
or - - O
air - - O
scented - - O
with - - O
peppermint - - O
. - - O

To - - O
explore - - O
the - - O
functional - - O
relationship - - O
between - - O
c-fos - - B-MUT
and - - O
Rb - - B-MUT
, - - O
a - - O
eukaryotic - - O
expression - - O
plasmid - - O
was - - O
constructed - - O
containing - - O
the - - O
c-fos - - B-MUT
gene - - I-MUT
under - - O
control - - O
of - - O
the - - O
SV40 - - O
promoter - - O
complex - - O
. - - O

The - - O
neuroleptic-induced - - O
increase - - O
in - - O
central - - O
DA - - O
turnover - - O
( - - O
an - - O
indicator - - O
for - - O
the - - O
degree - - O
of - - O
DA - - B-MUT
receptor - - I-MUT
blocking - - O
) - - O
was - - O
found - - O
to - - O
be - - O
positively - - O
correlated - - O
with - - O
the - - O
therapeutic - - O
effect - - O
of - - O
neuroleptics - - O
and - - O
the - - O
development - - O
of - - O
hypokinetic-rigid - - O
symptoms - - O
. - - O

Effects - - O
of - - O
Trypanosoma - - O
vivax - - O
on - - O
pregnancy - - O
of - - O
Yankasa - - O
sheep - - O
and - - O
the - - O
results - - O
of - - O
homidum - - O
chloride - - O
chemotherapy - - O
. - - O

The - - O
two - - O
main - - O
experimental - - O
variables - - O
were - - O
the - - O
attended - - O
hemifield - - O
( - - O
left - - O
or - - O
right - - O
) - - O
and - - O
the - - O
proportion - - O
of - - O
trials - - O
requiring - - O
a - - O
shift - - O
within - - O
that - - O
hemifield - - O
( - - O
20% - - O
or - - O
80% - - O
) - - O
. - - O

155 - - O
aa - - O
, - - O
shares - - O
78% - - O
identity - - O
with - - O
the - - O
analogous - - O
region - - O
of - - O
Xenopus - - O
laevis - - O
FGF3 - - B-MUT
and - - O
72% - - O
identity - - O
with - - O
the - - O
product - - O
of - - O
the - - O
more - - O
distantly - - O
related - - O
human - - O
gene - - O
. - - O

J - - O
. - - O

Removal - - O
of - - O
all - - O
core - - B-MUT
histone - - I-MUT
tail - - O
domains - - O
by - - O
limited - - O
trypsin - - B-MUT
proteolysis - - O
or - - O
acetylation - - O
of - - O
the - - O
core - - B-MUT
histone - - I-MUT
tails - - O
significantly - - O
relieves - - O
this - - O
inhibition - - O
and - - O
allows - - O
TFIIIA - - B-MUT
to - - O
exhibit - - O
high-affinity - - O
binding - - O
to - - O
nucleosomal - - O
DNA - - O
. - - O

Agonist-induced - - B-MUT
receptor - - I-MUT
internalization - - O
, - - O
determined - - O
as - - O
the - - O
percent - - O
of - - O
total - - O
[ - - O
125I - - O
] - - O
Tyr0-oCRF - - B-MUT
bound - - O
located - - O
in - - O
the - - O
acid-resistant - - O
fraction - - O
of - - O
transfected - - O
Cos - - O
7 - - O
cells - - O
, - - O
increased - - O
with - - O
time - - O
( - - O
0-60 - - O
min - - O
at - - O
37 - - O
degrees - - O
C - - O
) - - O
for - - O
both - - O
wild-type - - O
and - - O
variant - - O
oCRF1 - - B-MUT
. - - O

Pharmacology - - O
studies - - O
with - - O
potassium - - O
chloride - - O
and - - O
acetylcholine - - O
suggest - - O
that - - O
raveron - - O
acts - - O
as - - O
a - - O
calcium - - O
antagonist - - O
by - - O
blocking - - O
the - - O
influx - - O
of - - O
extracellular - - O
calcium - - O
. - - O

Surprisingly - - O
, - - O
Northern - - O
( - - O
RNA - - O
) - - O
blot - - O
analysis - - O
and - - O
reverse - - O
transcriptase-PCRs - - O
performed - - O
after - - O
transfection - - O
of - - O
COS-7 - - O
or - - O
HeLa - - O
cells - - O
with - - O
these - - O
viral - - O
RNAs - - O
revealed - - O
that - - O
Y88S - - B-MUT
and - - O
Y88L - - B-MUT
RNAs - - I-MUT
replicated - - O
at - - O
only - - O
very - - O
low - - O
levels - - O
. - - O

Comparison - - O
of - - O
the - - O
genomic - - O
DNA - - O
sequence - - O
with - - O
that - - O
of - - O
the - - O
four - - O
different - - O
mRNAs - - O
indicates - - O
that - - O
these - - O
transcripts - - O
are - - O
produced - - O
by - - O
alternative - - O
splicing - - O
of - - O
the - - O
murine - - O
pre-mRNA - - O
according - - O
to - - O
a - - O
cassette - - O
model - - O
. - - O

The - - O
STAT - - B-MUT
protein - - I-MUT
accumulation - - O
resulting - - O
from - - O
C - - B-MUT
EBP - - I-MUT
expression - - I-MUT
was - - O
tightly - - O
coupled - - O
to - - O
the - - O
morphological - - O
conversion - - O
of - - O
fibroblasts - - O
to - - O
adipocytes - - O
and - - O
represents - - O
an - - O
expression - - O
profile - - O
identical - - O
to - - O
that - - O
reported - - O
for - - O
mature - - O
adipocytes - - O
in - - O
vivo - - O
. - - O

To - - O
illustrate - - O
its - - O
performance - - O
, - - O
measurements - - O
of - - O
photoluminescence - - O
in - - O
GaAs - - O
AlGaAs - - O
heterostructures - - O
are - - O
presented - - O
. - - O

RNA - - B-MUT
polymerase - - I-MUT
bound - - O
to - - O
the - - O
+10A - - B-MUT
promoter - - I-MUT
partially - - O
protects - - O
a - - O
20 - - O
base-pair - - O
sequence - - O
from - - O
DNase - - B-MUT
I - - I-MUT
digestion - - O
upstream - - O
of - - O
the - - O
start - - O
site - - O
. - - O

Further - - O
, - - O
the - - O
ability - - O
of - - O
recombinant - - B-MUT
beta - - I-MUT
and - - I-MUT
or - - I-MUT
gamma - - I-MUT
chains - - I-MUT
to - - I-MUT
function - - O
in - - O
defined - - O
biochemical - - O
assays - - O
of - - O
beta - - O
gamma - - B-MUT
activity - - I-MUT
was - - O
assessed - - O
for - - O
membrane - - O
extracts - - O
and - - O
supernatant - - O
fractions - - O
from - - O
infected - - O
Sf9 - - O
cells - - O
. - - O

TRAF2 - - B-MUT
is - - O
known - - O
to - - O
associate - - O
with - - O
TRADD - - B-MUT
, - - O
and - - O
expression - - O
of - - O
a - - O
dominant-negative - - O
N-terminal - - O
deletion - - O
TRAF2 - - B-MUT
mutant - - I-MUT
was - - O
found - - O
to - - O
partially - - O
inhibit - - O
LMP1-induced - - O
JNK - - B-MUT
activation - - O
in - - O
293 - - O
cells - - O
. - - O

A - - O
portion - - O
of - - O
Region - - O
II - - O
also - - O
resembles - - O
part - - O
of - - O
the - - O
human - - O
c-jun - - B-MUT
oncoprotein's - - O
leucine - - O
zipper - - O
, - - O
which - - O
in - - O
turn - - O
, - - O
has - - O
been - - O
demonstrated - - O
to - - O
be - - O
the - - O
heterodimerization - - O
site - - O
between - - O
the - - O
jun - - B-MUT
and - - O
fos - - B-MUT
oncoproteins - - I-MUT
. - - O

Buflomedil - - O
( - - O
i - - O
. - - O
v - - O
. - - O
) - - O
induced - - O
a - - O
dose-dependent - - O
increase - - O
of - - O
cardiac - - O
output - - O
at - - O
0 - - O
. - - O
16-0 - - O
. - - O
64 - - O
mg - - O
kg - - O
, - - O
biphasic - - O
changes - - O
at - - O
1 - - O
. - - O
28 - - O
and - - O
2 - - O
. - - O
56 - - O
mg - - O
kg - - O
and - - O
a - - O
marked - - O
decrease - - O
and - - O
subsequent - - O
slight - - O
increase - - O
at - - O
a - - O
large - - O
dose - - O
of - - O
5 - - O
. - - O
12 - - O
mg - - O
kg - - O
. - - O

These - - O
results - - O
indicate - - O
that - - O
both - - O
naturally - - O
acquired - - O
and - - O
passive - - O
( - - O
modified - - O
immune - - O
serum - - O
globulin - - O
) - - O
antibodies - - O
to - - O
type - - B-MUT
III - - I-MUT
group - - I-MUT
B - - I-MUT
Streptococcus - - I-MUT
antigen - - I-MUT
are - - O
partially - - O
protective - - O
against - - O
intra-amniotic - - O
infection - - O
. - - O

The - - O
rates - - O
of - - O
total - - O
energy - - O
use - - O
( - - O
mean - - O
+ - - O
- - - O
SD - - O
= - - O
39 - - O
. - - O
3 - - O
+ - - O
- - - O
1 - - O
. - - O
2 - - O
vs - - O
35 - - O
. - - O
7 - - O
+ - - O
- - - O
1 - - O
. - - O
3 - - O
kJ - - O
X - - O
min-1 - - O
; - - O
P - - O
less - - O
than - - O
0 - - O
. - - O
05 - - O
) - - O
were - - O
significantly - - O
higher - - O
at - - O
-10 - - O
degrees - - O
C - - O
than - - O
at - - O
22 - - O
degrees - - O
C - - O
. - - O

In - - O
addition - - O
to - - O
the - - O
protein-tyrosine - - B-MUT
kinase - - I-MUT
domain - - I-MUT
, - - O
p56lck - - B-MUT
possesses - - O
Src - - B-MUT
homology - - I-MUT
2 - - I-MUT
and - - I-MUT
3 - - I-MUT
( - - O
SH2 - - B-MUT
and - - O
SH3 - - B-MUT
) - - O
domains - - O
as - - O
well - - O
as - - O
a - - O
unique - - O
N-terminal - - O
region - - O
. - - O

Each - - O
binding - - O
site - - O
, - - O
however - - O
, - - O
was - - O
different - - O
in - - O
its - - O
preference - - O
for - - O
binding - - O
partners - - O
. - - O

An - - O
ASIC-chip - - O
for - - O
stereoscopic - - O
depth - - O
analysis - - O
in - - O
video-real-time - - O
based - - O
on - - O
visual - - O
cortical - - O
cell - - O
behavior - - O
. - - O

Picture - - O
the - - O
smell - - O
. - - O

We - - O
have - - O
isolated - - O
a - - O
cDNA - - O
encoding - - O
human - - B-MUT
MEKK3 - - I-MUT
. - - O

Human - - B-MUT
acid - - I-MUT
ceramidase - - I-MUT
( - - I-MUT
( - - I-MUT
AC - - I-MUT
) - - I-MUT
N-acylsphingosine - - I-MUT
amidohydrolase - - I-MUT
, - - O
EC - - B-MUT
3 - - I-MUT
. - - I-MUT
5 - - I-MUT
. - - O

Mutagenesis - - O
of - - O
SNT1 - - B-MUT
( - - I-MUT
IRS - - I-MUT
) - - I-MUT
CX - - I-MUT
identified - - O
three - - O
classes - - O
of - - O
effector - - O
motifs - - O
within - - O
SNT - - B-MUT
critical - - O
for - - O
both - - O
sustained - - O
ERK - - B-MUT
activation - - O
and - - O
neuronal - - O
differentiation - - O
: - - O
1 - - O
) - - O
four - - O
phosphotyrosine - - O
motifs - - O
that - - O
mediate - - O
recruitment - - O
of - - O
Grb2 - - B-MUT
, - - O
2 - - O
) - - O
two - - O
phosphotyrosine - - O
motifs - - O
that - - O
mediate - - O
recruitment - - O
of - - O
Shp2 - - B-MUT
, - - O
and - - O
3 - - O
) - - O
a - - O
C-terminal - - O
motif - - O
that - - O
functions - - O
by - - O
helping - - O
to - - O
recruit - - O
Sos - - B-MUT
. - - O

Indium-111 - - O
leukocyte - - O
imaging - - O
in - - O
patients - - O
with - - O
rheumatoid - - O
arthritis - - O
. - - O

The - - O
potential - - O
impact - - O
of - - O
using - - O
a - - O
rapid - - O
diagnostic - - O
test - - O
( - - O
Strep - - O
A - - O
OIA - - O
) - - O
on - - O
detection - - O
and - - O
treatment - - O
of - - O
group - - O
A - - O
beta-hemolytic - - O
streptococcal - - O
( - - O
GABHS - - O
) - - O
pharyngitis - - O
in - - O
a - - O
large-volume - - O
pediatric - - O
and - - O
adolescent - - O
clinic - - O
was - - O
examined - - O
. - - O

The - - O
only - - O
isolate - - O
of - - O
Aeromonas - - O
hydrophila - - O
produced - - O
cytotoxic - - O
enterotoxin - - B-MUT
and - - O
was - - O
invasive - - O
. - - O

On - - O
Days - - O
1 - - O
and - - O
14 - - O
, - - O
most - - O
young - - O
and - - O
elderly - - O
subjects - - O
exhibited - - O
monoexponential - - O
decline - - O
in - - O
bevantolol - - O
plasma - - O
concentrations - - O
after - - O
absorption - - O
phase - - O
. - - O

Although - - O
the - - O
mechanism - - O
of - - O
action - - O
of - - O
ICRF-159 - - O
and - - O
187 - - O
has - - O
not - - O
been - - O
clearly - - O
defined - - O
, - - O
it - - O
is - - O
evident - - O
from - - O
both - - O
preclinical - - O
and - - O
early - - O
clinical - - O
studies - - O
that - - O
these - - O
compounds - - O
are - - O
of - - O
interest - - O
. - - O

Our - - O
results - - O
indicate - - O
that - - O
the - - O
KRAB - - B-MUT
domain - - I-MUT
present - - O
in - - O
the - - O
non-finger - - O
region - - O
of - - O
many - - O
ZFP - - B-MUT
genes - - I-MUT
quenches - - O
transcription - - O
possibly - - O
due - - O
to - - O
specific - - O
protein-protein - - O
interactions - - O
between - - O
the - - O
KRAB-A - - B-MUT
domain - - I-MUT
and - - O
components - - O
of - - O
the - - O
proximal - - O
transcriptional - - O
apparatus - - O
. - - O

A - - O
new - - O
variant - - O
of - - O
the - - O
EMG-BFB - - O
method - - O
( - - O
multichannel - - O
) - - O
is - - O
offered - - O
which - - O
has - - O
made - - O
it - - O
possible - - O
to - - O
use - - O
the - - O
method - - O
not - - O
only - - O
for - - O
training - - O
weakened - - O
muscles - - O
and - - O
reducing - - O
spasticity - - O
in - - O
their - - O
antagonists - - O
but - - O
also - - O
for - - O
improving - - O
motor - - O
coordination - - O
. - - O

We - - O
investigated - - O
the - - O
incidence - - O
of - - O
congenital - - O
color - - O
deficiency - - O
among - - O
Koreans - - O
by - - O
the - - O
use - - O
of - - O
H-R-R - - O
pseudoisochromatic - - O
plates - - O
. - - O

We - - O
suggest - - O
that - - O
sensitivity - - O
to - - O
photoperiod - - O
in - - O
pallid - - O
bats - - O
, - - O
as - - O
in - - O
several - - O
other - - O
mammals - - O
, - - O
is - - O
mediated - - O
by - - O
the - - O
pineal - - O
gland - - O
. - - O

The - - O
debate - - O
over - - O
electives--1899 - - O
. - - O

This - - O
report - - O
presents - - O
an - - O
analysis - - O
of - - O
the - - O
vocal - - O
repertoire - - O
of - - O
howler - - O
monkeys - - O
( - - O
Alouatta - - O
palliata - - O
) - - O
observed - - O
during - - O
a - - O
field - - O
study - - O
in - - O
southwestern - - O
Panama - - O
. - - O

Additionally - - O
, - - O
deletion - - O
analysis - - O
of - - O
the - - O
UCP2 - - B-MUT
promoter-PLAP - - I-MUT
constructs - - I-MUT
indicated - - O
that - - O
the - - O
minimal - - O
region - - O
exhibiting - - O
the - - O
promoter - - O
activity - - O
was - - O
located - - O
between - - O
nt - - O
-33 - - O
and - - O
+100 - - O
, - - O
and - - O
that - - O
a - - O
strong - - O
enhancer - - O
was - - O
present - - O
within - - O
601 - - O
bp - - O
of - - O
the - - O
5'-promoter - - O
region - - O
. - - O

The - - O
sequence - - O
analysis - - O
of - - O
both - - O
products - - O
of - - O
individual - - O
phi - - O
80 - - O
site-specific - - O
recombination - - O
events - - O
in - - O
vivo - - O
shows - - O
that - - O
recombination - - O
with - - O
a - - O
secondary - - O
attachment - - O
( - - O
att - - O
) - - O
site - - O
generates - - O
several - - O
different - - O
novel - - O
joints - - O
at - - O
the - - O
mismatched - - O
position - - O
: - - O
one - - O
recombination - - O
event - - O
resulted - - O
in - - O
a - - O
single - - O
base-pair - - O
deletion - - O
and - - O
two - - O
other - - O
recombination - - O
events - - O
resulted - - O
in - - O
two - - O
different - - O
single - - O
base-pair - - O
substitutions - - O
. - - O

Epidermal - - B-MUT
growth - - I-MUT
factor - - I-MUT
receptor - - I-MUT
transcriptionally - - O
up-regulates - - O
vascular - - B-MUT
endothelial - - I-MUT
growth - - I-MUT
factor - - I-MUT
expression - - O
in - - O
human - - O
glioblastoma - - O
cells - - O
via - - O
a - - O
pathway - - O
involving - - O
phosphatidylinositol - - B-MUT
3'-kinase - - I-MUT
and - - O
distinct - - O
from - - O
that - - O
induced - - O
by - - O
hypoxia - - O
. - - O

A - - O
candidate - - O
gene - - O
for - - O
Bcg - - B-MUT
, - - O
designated - - O
natural - - B-MUT
resistance-associated - - I-MUT
macrophage - - I-MUT
protein - - I-MUT
( - - O
Nramp - - B-MUT
) - - O
, - - O
has - - O
been - - O
isolated - - O
and - - O
shown - - O
to - - O
encode - - O
a - - O
novel - - O
macrophage-specific - - O
membrane - - O
protein - - O
, - - O
which - - O
is - - O
altered - - O
in - - O
susceptible - - O
animals - - O
. - - O

The - - O
triple - - O
combination - - O
of - - O
nizatidine - - O
, - - O
clarithromycin - - O
, - - O
and - - O
bismuth - - O
subcitrate - - O
resulted - - O
in - - O
an - - O
ulcer - - O
healing - - O
rate - - O
of - - O
98% - - O
and - - O
an - - O
H - - O
. - - O
pylori - - O
eradication - - O
rate - - O
of - - O
90% - - O
. - - O

Connector - - B-MUT
enhancer - - I-MUT
of - - I-MUT
KSR - - I-MUT
( - - O
CNK - - B-MUT
) - - O
is - - O
a - - O
multidomain - - O
protein - - O
required - - O
for - - O
RAS - - B-MUT
signaling - - O
. - - O

Continued - - O
absorption - - O
of - - O
amino - - O
acids - - O
by - - O
the - - O
NBB - - O
carrier - - O
( - - O
for - - O
neutral - - O
amino - - O
acids - - O
) - - O
, - - O
the - - O
Y+ - - O
system - - O
( - - O
for - - O
dibasic - - O
amino - - O
acids - - O
) - - O
, - - O
and - - O
the - - O
PHE - - O
carrier - - O
were - - O
operative - - O
even - - O
during - - O
the - - O
actively - - O
purging - - O
stage - - O
of - - O
watery - - O
diarrhoea - - O
due - - O
to - - O
cholera - - O
. - - O

Weaned - - O
rats - - O
were - - O
fed - - O
a - - O
normal - - O
diet - - O
or - - O
a - - O
low-protein - - O
, - - O
low-energy - - O
diet - - O
, - - O
and - - O
injected - - O
with - - O
saline - - O
or - - O
thyroxine - - O
( - - O
5 - - O
micrograms - - O
100 - - O
g - - O
BW - - O
) - - O
for - - O
22 - - O
days - - O
. - - O

They - - O
also - - O
occur - - O
in - - O
similar - - O
locations - - O
in - - O
the - - O
promoters - - O
of - - O
several - - O
other - - O
ribosomal - - B-MUT
protein - - I-MUT
genes - - I-MUT
. - - O

In - - O
the - - O
present - - O
work - - O
, - - O
the - - O
complete - - O
genome - - O
sequences - - O
of - - O
Pyrococcus - - O
horikoshii - - O
and - - O
Pyrococcus - - O
abyssi - - O
, - - O
two - - O
species - - O
in - - O
a - - O
genus - - O
of - - O
hyperthermophilic - - O
archaeon - - O
( - - O
archaebacterium - - O
) - - O
, - - O
were - - O
compared - - O
to - - O
detect - - O
large - - O
genome - - O
polymorphisms - - O
linked - - O
with - - O
restriction-modification - - B-MUT
gene - - I-MUT
homologs - - I-MUT
. - - O

For - - O
the - - O
first - - O
group - - O
, - - O
the - - O
maximal - - O
decrease - - O
in - - O
plasma - - O
potassium - - O
elicited - - O
by - - O
salbutamol - - O
was - - O
0 - - O
. - - O
80 - - O
+ - - O
- - - O
0 - - O
. - - O
19 - - O
, - - O
0 - - O
. - - O
48 - - O
+ - - O
- - - O
0 - - O
. - - O
22 - - O
, - - O
and - - O
0 - - O
. - - O
78 - - O
+ - - O
- - - O
0 - - O
. - - O
46 - - O
mmol - - O
l - - O
, - - O
and - - O
for - - O
the - - O
second - - O
group - - O
, - - O
maximal - - O
decrement - - O
was - - O
1 - - O
. - - O
31 - - O
+ - - O
- - - O
0 - - O
. - - O
37 - - O
, - - O
0 - - O
. - - O
70 - - O
+ - - O
- - - O
0 - - O
. - - O
24 - - O
, - - O
and - - O
0 - - O
. - - O
84 - - O
+ - - O
- - - O
0 - - O
. - - O
17 - - O
mmol - - O
l - - O
for - - O
the - - O
iv - - O
, - - O
po - - O
, - - O
and - - O
it - - O
routes - - O
, - - O
respectively - - O
. - - O

A - - O
similar - - O
chimera - - O
was - - O
assembled - - O
from - - O
the - - O
two - - O
halves - - O
of - - O
the - - O
molecule - - O
expressed - - O
separately - - O
in - - O
different - - O
bacteria - - O
and - - O
refolded - - O
together - - O
. - - O

The - - O
lemdr1 - - B-MUT
gene - - I-MUT
was - - O
cloned - - O
in - - O
the - - O
expression - - O
vector - - O
pALTNEO - - O
and - - O
transfected - - O
into - - O
wild-type - - O
L - - O
. - - O
enriettii - - O
and - - O
the - - O
resulting - - O
transfected - - O
cells - - O
were - - O
resistant - - O
to - - O
vinblastine - - O
but - - O
at - - O
lower - - O
levels - - O
than - - O
in - - O
the - - O
selected - - O
mutant - - O
cells - - O
. - - O

The - - O
predicted - - O
amino - - O
acid - - O
sequence - - O
is - - O
78 - - O
. - - O
0% - - O
identical - - O
to - - O
the - - O
cytoplasmic - - B-MUT
dynein - - I-MUT
heavy - - I-MUT
chain - - I-MUT
of - - I-MUT
Neurospora - - I-MUT
crassa - - I-MUT
, - - O
70 - - O
. - - O
2% - - O
identical - - O
to - - O
that - - O
of - - O
Aspergillus - - O
nidulans - - O
and - - O
24 - - O
. - - O
8% - - O
identical - - O
to - - O
that - - O
of - - O
Saccharomyces - - O
cerevisiae - - O
. - - O

Dose - - O
standardisation - - O
of - - O
botulinum - - B-MUT
toxin - - I-MUT
. - - O

These - - O
cells - - O
produced - - O
P2Y - - B-MUT
( - - I-MUT
11 - - I-MUT
) - - I-MUT
mRNA - - I-MUT
during - - O
culture - - O
. - - O

In - - O
contrast - - O
, - - O
an - - O
amino-terminal - - O
fragment - - O
containing - - O
the - - O
C - - B-MUT
H1 - - I-MUT
domain - - I-MUT
was - - I-MUT
sufficient - - O
for - - O
coactivation - - O
of - - O
Zta - - O
transcription - - B-MUT
and - - O
viral - - O
reactivation - - O
function - - O
. - - O

The - - O
pathogenesis - - O
of - - O
Dupuytren's - - O
contracture - - O
. - - O

The - - O
uptake - - O
of - - O
fluorine-18 - - O
fluorodeoxyglucose - - O
( - - O
F-18 - - O
FDG - - O
) - - O
by - - O
a - - O
malignant - - O
tumor - - O
depends - - O
on - - O
the - - O
blood - - O
glucose - - O
level - - O
. - - O

The - - O
inhibition - - O
of - - O
StAR - - B-MUT
gene - - I-MUT
transcription - - O
by - - O
DAX-1 - - B-MUT
was - - O
dose-dependent - - O
reducing - - O
transcription - - O
to - - O
6% - - O
of - - O
control - - O
levels - - O
. - - O

Mibefradil - - O
( - - O
Ro - - O
40-5967 - - O
) - - O
is - - O
a - - O
novel - - O
calcium - - O
antagonist - - O
from - - O
a - - O
new - - O
chemical - - O
class - - O
and - - O
is - - O
the - - O
first - - O
that - - O
selectively - - O
blocks - - O
the - - O
T-type - - O
calcium - - O
channel - - O
. - - O

These - - O
results - - O
suggest - - O
that - - O
5 - - O
KE - - O
X - - O
3 - - O
W - - O
may - - O
be - - O
the - - O
optimal - - O
regimen - - O
to - - O
augment - - O
the - - O
antitumor - - O
immunity - - O
of - - O
RNL - - O
. - - O

Taken - - O
together - - O
, - - O
these - - O
results - - O
suggest - - O
that - - O
silymarin - - O
may - - O
exert - - O
a - - O
strong - - O
anticarcinogenic - - O
effect - - O
against - - O
PCA - - O
and - - O
that - - O
this - - O
effect - - O
is - - O
likely - - O
to - - O
involve - - O
impairment - - O
of - - O
erbB1-SHC-mediated - - O
signaling - - O
pathway - - O
, - - O
induction - - O
of - - O
CDKIs - - B-MUT
, - - O
and - - O
a - - O
resultant - - O
G1 - - O
arrest - - O
. - - O

Articles - - O
addressing - - O
valvular - - O
heart - - O
disease - - O
or - - O
heart - - O
failure - - O
secondary - - O
to - - O
acute - - O
myocardial - - O
infarction - - O
or - - O
Chagas' - - O
disease - - O
were - - O
excluded - - O
. - - O

We - - O
further - - O
show - - O
that - - O
proteolytic - - O
targeting - - O
by - - O
calpain - - B-MUT
II - - I-MUT
and - - O
the - - O
proteasome - - O
involves - - O
different - - O
structural - - O
elements - - O
of - - O
YY1 - - B-MUT
. - - O

These - - O
findings - - O
suggest - - O
that - - O
a - - O
range - - O
of - - O
microenvironmental - - O
conditions - - O
exist - - O
within - - O
purified - - O
water - - O
systems - - O
, - - O
leading - - O
to - - O
variable - - O
populations - - O
of - - O
bacteria - - O
. - - O

Like - - O
their - - O
yeast - - O
counterpart - - O
, - - O
the - - O
mouse - - O
GCN2 - - B-MUT
isoforms - - O
contain - - O
HisRS-related - - B-MUT
sequences - - I-MUT
juxtaposed - - O
to - - O
the - - O
kinase - - O
catalytic - - O
domain - - O
. - - O

Vitamin - - O
D3 - - O
plus - - O
nicotine - - O
treatment - - O
produced - - O
parallel - - O
increases - - O
in - - O
cardiac - - O
mass - - O
and - - O
elastic - - O
modulus - - O
, - - O
with - - O
a - - O
significant - - O
correlation - - O
between - - O
the - - O
two - - O
. - - O

Microvessels - - O
were - - O
counted - - O
in - - O
a - - O
x200 - - O
field - - O
( - - O
0 - - O
. - - O
754 - - O
mm2 - - O
) - - O
in - - O
the - - O
area - - O
of - - O
maximal - - O
angiogenesis - - O
. - - O

In - - O
endemic - - O
BL - - O
, - - O
the - - O
RB2 - - B-MUT
p130 - - O
gene - - B-MUT
is - - O
mutated - - O
in - - O
most - - O
of - - O
the - - O
cases - - O
, - - O
and - - O
the - - O
protein - - O
is - - O
restricted - - O
to - - O
the - - O
cytoplasm - - O
. - - O

French - - O
bean - - O
contains - - O
a - - O
small - - O
family - - O
of - - O
genes - - B-MUT
encoding - - I-MUT
PAL - - I-MUT
and - - O
two - - O
of - - O
these - - O
genes - - O
, - - O
PAL2 - - B-MUT
and - - O
PAL3 - - B-MUT
, - - O
have - - O
been - - O
shown - - O
to - - O
be - - O
differentially - - O
expressed - - O
at - - O
the - - O
mRNA - - O
level - - O
in - - O
bean - - O
tissues - - O
. - - O

The - - O
avian - - O
cellular - - O
homolog - - O
of - - O
the - - O
oncogene - - B-MUT
jun - - I-MUT
. - - O

The - - O
availability - - O
of - - O
cryoprecipitate - - O
and - - O
DDAVP - - O
offers - - O
an - - O
alternative - - O
and - - O
effective - - O
treatment - - O
for - - O
the - - O
temporary - - O
reversal - - O
of - - O
uremic - - O
bleeding - - O
in - - O
patients - - O
who - - O
require - - O
urgent - - O
invasive - - O
procedures - - O
. - - O

The - - O
intranodal - - O
mesothelial - - O
cells - - O
occupied - - O
the - - O
sinusoids - - O
of - - O
the - - O
lymph - - O
nodes - - O
and - - O
were - - O
initially - - O
suspected - - O
of - - O
being - - O
metastatic - - O
from - - O
the - - O
ovarian - - O
tumor - - O
in - - O
each - - O
case - - O
. - - O

A - - O
total - - O
of - - O
7 - - O
( - - O
4 - - O
males - - O
and - - O
3 - - O
females - - O
) - - O
patients - - O
were - - O
included - - O
in - - O
this - - O
retrospective - - O
study - - O
to - - O
determine - - O
the - - O
sensitivity - - O
of - - O
radioimmunoscintigraphy - - O
with - - O
I-131 - - O
labeled - - O
anti - - O
CEA - - B-MUT
CA - - I-MUT
19-9 - - I-MUT
monoclonal - - O
antibodies - - O
. - - O

Patients - - O
with - - O
detectable - - O
serum - - O
TNF - - B-MUT
levels - - O
had - - O
significantly - - O
lower - - O
serum - - O
T3 - - O
concentrations - - O
compared - - O
to - - O
those - - O
with - - O
undetectable - - O
levels - - O
[ - - O
1 - - O
. - - O
072 - - O
+ - - O
- - - O
0 - - O
. - - O
588 - - O
vs - - O
. - - O

We - - O
find - - O
that - - O
the - - O
measured - - O
Nusselt - - O
number - - O
decreased - - O
about - - O
20% - - O
over - - O
the - - O
range - - O
of - - O
Pr - - O
spanned - - O
in - - O
the - - O
experiment - - O
. - - O

Sodium - - O
dodecyl - - O
sulphate-induced - - O
cleavage - - O
by - - O
eukaryotic - - B-MUT
topoisomerase - - I-MUT
I - - I-MUT
is - - O
known - - O
to - - O
yield - - O
enzyme - - O
covalently - - O
attached - - O
to - - O
the - - O
3' - - O
cut - - O
end - - O
of - - O
the - - O
DNA - - O
. - - O

To - - O
identify - - O
some - - O
of - - O
the - - O
genes - - O
expressed - - O
in - - O
LPS-activated - - O
coelomocytes - - O
, - - O
we - - O
sequenced - - O
randomly - - O
chosen - - O
clones - - O
from - - O
a - - O
directionally - - O
constructed - - O
cDNA - - O
library - - O
to - - O
produce - - O
a - - O
set - - O
of - - O
expressed - - O
sequence - - O
tags - - O
( - - O
ESTs - - O
) - - O
. - - O

Adding - - O
10 - - O
mmol - - O
SDS - - O
l - - O
led - - O
to - - O
transient - - O
inhibition - - O
of - - O
acidification - - O
, - - O
metal - - O
solubilization - - O
and - - O
sulfur - - O
oxidation - - O
. - - O

Overexpression - - O
of - - O
CARP - - B-MUT
in - - O
cardiomyocytes - - O
suppresses - - O
cardiac - - B-MUT
troponin - - I-MUT
C - - I-MUT
and - - O
atrial - - B-MUT
natriuretic - - I-MUT
factor - - I-MUT
transcription - - O
. - - O

It - - O
contained - - O
seven - - O
extra - - O
amino - - O
acids - - O
of - - O
FVVLNLQ - - B-MUT
; - - O
this - - O
short - - O
stretch - - O
of - - O
extra - - O
sequence - - O
was - - O
found - - O
between - - O
Gln - - O
( - - O
421 - - O
) - - O
and - - O
Phe - - O
( - - O
422 - - O
) - - O
within - - O
the - - O
SET - - B-MUT
( - - O
Suvar3-9 - - B-MUT
, - - I-MUT
Enhancer-of-zeste - - I-MUT
, - - I-MUT
Trithorax - - I-MUT
) - - O
interacting - - O
domain - - O
( - - O
SID - - B-MUT
) - - O
of - - O
rMTM - - B-MUT
. - - O

Therapeutic - - O
use - - O
of - - O
continuous - - O
subcutaneous - - O
infusion - - O
of - - O
recombinant - - B-MUT
human - - I-MUT
erythropoietin - - I-MUT
in - - O
malnourished - - O
predialysis - - O
anemic - - O
patients - - O
with - - O
diabetic - - O
nephropathy - - O
. - - O

Circulating - - O
platelets - - O
may - - O
be - - O
activated - - O
by - - O
exposed - - O
triple-helical - - O
collagen - - B-MUT
in - - O
atherosclerotic - - O
lesions - - O
in - - O
Mg-deficient - - O
ruminants - - O
. - - O

Elevated - - O
maternal - - B-MUT
alpha - - I-MUT
fetoproteins - - I-MUT
and - - O
oligoamnios - - O
: - - O
fetal - - O
prognosis - - O
. - - O

These - - O
analyses - - O
demonstrate - - O
that - - O
the - - O
dUTPase - - B-MUT
isoforms - - O
are - - O
encoded - - O
by - - O
the - - O
same - - O
gene - - O
with - - O
isoform-specific - - O
transcripts - - O
arising - - O
through - - O
the - - O
use - - O
of - - O
alternative - - O
5' - - O
exons - - O
. - - O

Overexpression - - O
of - - O
the - - O
bZip - - O
interaction - - O
domain - - O
of - - O
CBP - - B-MUT
specifically - - O
abolishes - - O
the - - O
positive - - O
cross - - O
talk - - O
between - - O
TR - - B-MUT
and - - O
p45 - - B-MUT
NF-E2 - - I-MUT
. - - I-MUT

Of - - O
these - - O
179 - - O
samples - - O
, - - O
Mobiluncus - - O
SP - - O
was - - O
observed - - O
in - - O
35 - - O
( - - O
19 - - O
. - - O
6% - - O
) - - O
using - - O
Gram - - O
staining - - O
and - - O
in - - O
18 - - O
( - - O
10 - - O
. - - O
1% - - O
) - - O
this - - O
microorganism - - O
was - - O
isolated - - O
in - - O
agar - - O
RLK - - O
and - - O
anaerobic - - O
atmosphere - - O
. - - O

The - - O
phi - - B-MUT
AP3 - - I-MUT
factor - - I-MUT
is - - O
a - - O
nuclear - - O
phosphoprotein - - O
; - - O
the - - O
extent - - O
of - - O
its - - O
phosphorylation - - O
is - - O
regulated - - O
during - - O
the - - O
cell - - O
cycle - - O
. - - O

As - - O
the - - O
half-life - - O
of - - O
the - - O
compound - - O
did - - O
never - - O
exceed - - O
8-9 - - O
h - - O
, - - O
the - - O
data - - O
do - - O
not - - O
support - - O
any - - O
change - - O
of - - O
pidotimod - - O
administration - - O
schedule - - O
( - - O
every - - O
24-12 - - O
h - - O
) - - O
. - - O

Studies - - O
also - - O
have - - O
alluded - - O
to - - O
a - - O
relationship - - O
between - - O
the - - O
MSMR - - O
cyst - - O
and - - O
certain - - O
signs - - O
or - - O
symptoms - - O
of - - O
disease - - O
. - - O

One - - O
member - - O
of - - O
this - - O
multigene - - O
family - - O
, - - O
GATA-3 - - B-MUT
, - - O
is - - O
most - - O
abundantly - - O
expressed - - O
in - - O
T - - O
lymphocytes - - O
, - - O
a - - O
cellular - - O
target - - O
for - - O
human - - O
immunodeficiency - - O
virus - - O
type - - O
1 - - O
( - - O
HIV-1 - - O
) - - O
infection - - O
and - - O
replication - - O
. - - O

There - - O
were - - O
minimal - - O
negative - - O
effects - - O
on - - O
hematological - - O
parameters - - O
, - - O
acid-base - - O
status - - O
, - - O
and - - O
blood - - O
gases - - O
. - - O

A - - O
crucial - - O
transcription - - O
factor - - O
in - - O
this - - O
process - - O
is - - O
STAT6 - - B-MUT
, - - O
which - - O
binds - - O
to - - O
a - - O
specific - - O
DNA - - O
element - - O
upon - - O
cytokine - - O
activation - - O
. - - O

Using - - O
Ki-ras-transformed - - O
3T3 - - O
cells - - O
as - - O
a - - O
model - - O
system - - O
, - - O
we - - O
show - - O
that - - O
both - - O
RA - - O
and - - O
the - - O
'dissociating' - - O
retinoids - - O
inhibit - - O
anchorage-independent - - O
cell - - O
proliferation - - O
, - - O
suggesting - - O
that - - O
retinoid-induced - - O
growth - - O
inhibition - - O
may - - O
be - - O
related - - O
to - - O
AP1 - - B-MUT
transrepression - - O
. - - O

Ovarian - - O
tumors - - O
in - - O
pregnancy - - O
. - - O

Altogether - - O
, - - O
our - - O
results - - O
indicate - - O
that - - O
the - - O
transcriptional - - O
activity - - O
of - - O
Cut - - B-MUT
proteins - - I-MUT
is - - O
modulated - - O
by - - O
PKC - - B-MUT
. - - O

References - - O
for - - O
occupational - - O
fitness - - O
of - - O
adolescents - - O
with - - O
diseases - - O
of - - O
the - - O
respiratory - - O
tract - - O
and - - O
lungs - - O
. - - O

Lysosomal - - O
enzymes - - O
that - - O
degrade - - O
cartilage - - O
are - - O
released - - O
. - - O

We - - O
have - - O
previously - - O
mapped - - O
the - - O
defect - - O
in - - O
RIIIS - - O
J - - O
to - - O
distal - - O
mouse - - O
Chr - - O
11 - - O
, - - O
distinct - - O
from - - O
the - - O
Vwf - - O
locus - - B-MUT
on - - I-MUT
Chr - - O
6 - - O
. - - O

Plasma - - B-MUT
renin - - I-MUT
activity - - O
rose - - O
and - - O
the - - O
plasma - - O
aldosterone - - O
level - - O
fell - - O
after - - O
taking - - O
lisinopril - - O
. - - O

In - - O
addition - - O
a - - O
significant - - O
Treatment - - O
X - - O
Strain - - O
interaction - - O
was - - O
due - - O
to - - O
the - - O
larger - - O
defecation - - O
numbers - - O
displayed - - O
by - - O
the - - O
taurine-injected - - O
MR - - O
rats - - O
relative - - O
to - - O
the - - O
saline-injected - - O
MR - - O
rats - - O
. - - O

Retroviral - - O
transduction - - O
of - - O
T - - B-MUT
T - - I-MUT
( - - I-MUT
L - - I-MUT
) - - I-MUT
causes - - I-MUT
a - - O
rapidly - - O
fatal - - O
myeloproliferative - - O
disease - - O
in - - O
a - - O
murine - - O
bone - - O
marrow - - O
transplant - - O
( - - O
BMT - - O
) - - O
model - - O
, - - O
whereas - - O
T - - O
T - - B-MUT
( - - I-MUT
F - - I-MUT
) - - I-MUT
causes - - I-MUT
a - - I-MUT
long-latency - - O
, - - O
pre-B-cell - - O
lymphoblastic - - O
lymphoma - - O
. - - O

Typical - - O
configurations - - O
of - - O
psychosocial - - O
stress - - O
factors - - O
of - - O
psychiatrically - - O
conspicuous - - O
children - - O
and - - O
adolescents - - O
. - - O

The - - O
mutant - - O
allele - - O
of - - O
the - - O
alpha - - B-MUT
1-tubulin - - I-MUT
gene - - I-MUT
was - - O
designated - - O
tua1-1 - - B-MUT
. - - O

Treatment - - O
includes - - O
both - - O
medical - - O
and - - O
surgical - - O
options - - O
, - - O
with - - O
medical - - O
therapy - - O
further - - O
subclassified - - O
into - - O
pharmacologic - - O
and - - O
pneumatic - - O
dilation - - O
. - - O

Similarly - - O
approximately - - O
300 - - O
bp - - O
of - - O
sequence - - O
downstream - - O
of - - O
the - - O
translation - - O
terminator - - O
TGA - - O
of - - O
the - - O
beta-tubulin - - B-MUT
2 - - I-MUT
( - - O
BTU2 - - B-MUT
) - - O
gene - - O
could - - O
substitute - - O
for - - O
the - - O
3' - - O
region - - O
of - - O
the - - O
H4-I - - B-MUT
gene - - I-MUT
. - - O

The - - O
gene - - O
was - - O
uniquely - - O
mapped - - O
with - - O
odds - - O
> - - O
1 - - O
, - - O
000 - - O
: - - O
1 - - O
on - - O
chromosome - - O
3p - - O
in - - O
Centre - - O
d'Etude - - O
du - - O
Polymorphisme - - O
Humain - - O
pedigrees - - O
. - - O

Furthermore - - O
, - - O
the - - O
soluble - - O
forms - - O
of - - O
ATF6 - - B-MUT
and - - O
the - - O
G13 - - B-MUT
gene - - I-MUT
product - - I-MUT
are - - O
unable - - O
to - - O
bind - - O
to - - O
several - - O
point - - O
mutants - - O
of - - O
the - - O
cis-acting - - O
ER - - B-MUT
stress - - I-MUT
response - - I-MUT
element - - I-MUT
in - - O
vitro - - O
that - - O
hardly - - O
respond - - O
to - - O
ER - - O
stress - - O
in - - O
vivo - - O
. - - O

A - - O
retrospective - - O
study - - O
of - - O
banked - - O
sera - - O
from - - O
19 - - O
cats - - O
with - - O
the - - O
eosinophilic - - O
granuloma - - O
complex - - O
revealed - - O
that - - O
68% - - O
of - - O
affected - - O
cats - - O
had - - O
circulating - - O
antibodies - - O
to - - O
components - - O
of - - O
normal - - O
cat - - O
epithelium - - O
. - - O

Elimination - - O
of - - O
natural - - O
antibodies - - O
in - - O
discordant - - O
xenografts - - O
. - - O

The - - O
first - - O
one - - O
is - - O
a - - O
TPA-responsive - - B-MUT
element - - I-MUT
that - - O
controls - - O
the - - O
base-line - - O
ST3 - - B-MUT
promoter - - I-MUT
activity - - O
but - - O
is - - O
not - - O
required - - O
for - - O
its - - O
activation - - O
. - - O

Cyclic - - B-MUT
AMP-dependent - - I-MUT
protein - - I-MUT
kinase - - I-MUT
binding - - O
to - - O
A-kinase - - B-MUT
anchoring - - O
proteins - - O
in - - O
living - - O
cells - - O
by - - O
fluorescence - - O
resonance - - O
energy - - O
transfer - - O
of - - O
green - - O
fluorescent - - O
protein - - O
fusion - - O
proteins - - O
. - - O

RESULTS - - O
: - - O
In - - O
the - - O
pregnant - - O
group - - O
, - - O
serum - - O
PP14 - - B-MUT
concentrations - - O
were - - O
markedly - - O
increased - - O
after - - O
ET - - O
, - - O
and - - O
a - - O
significant - - O
difference - - O
between - - O
the - - O
pregnant - - O
group - - O
and - - O
the - - O
nonpregnant - - O
group - - O
was - - O
observed - - O
8 - - O
days - - O
following - - O
ET - - O
( - - O
p - - O
< - - O
0 - - O
. - - O
01 - - O
) - - O
. - - O

Paf1p - - B-MUT
may - - O
therefore - - O
be - - O
required - - O
for - - O
both - - O
positive - - O
and - - O
negative - - O
regulation - - O
of - - O
subsets - - O
of - - O
yeast - - O
genes - - O
. - - O

The - - O
sign - - O
of - - O
Leser-Trelat - - O
: - - O
does - - O
it - - O
exist - - O
? - - O
The - - O
sign - - O
of - - O
Leser-Trelat - - O
is - - O
usually - - O
regarded - - O
as - - O
a - - O
reliable - - O
cutaneous - - O
marker - - O
of - - O
internal - - O
malignancy - - O
. - - O

We - - O
have - - O
initiated - - O
studies - - O
to - - O
identify - - O
candidate - - O
signal - - O
transducers - - O
that - - O
associate - - O
with - - O
the - - O
cytosolic - - O
domain - - O
( - - O
cd - - O
) - - O
of - - O
the - - O
IL-1R - - B-MUT
. - - O

To - - O
test - - O
whether - - O
or - - O
not - - O
SOCS-3 - - B-MUT
also - - O
binds - - O
to - - O
the - - O
IGFIR - - B-MUT
, - - O
we - - O
cloned - - O
human - - B-MUT
SOCS-3 - - I-MUT
by - - O
reverse - - O
transcription-polymerase - - O
chain - - O
reaction - - O
from - - O
human - - O
skeletal - - O
muscle - - O
mRNA - - O
. - - O

The - - O
CD4 - - B-MUT
count - - O
at - - O
which - - O
remission - - O
occurs - - O
may - - O
reflect - - O
severe - - O
immunodeficiency - - O
such - - O
that - - O
risk - - O
for - - O
AIDS-related - - O
infection - - O
is - - O
high - - O
. - - O

Platelet - - O
counts - - O
and - - O
function - - O
as - - O
well - - O
as - - O
fibrinogen - - B-MUT
and - - O
von - - B-MUT
Willebrand - - I-MUT
factor - - I-MUT
( - - O
vWF - - B-MUT
) - - O
levels - - O
were - - O
determined - - O
in - - O
each - - O
sample - - O
. - - O

Developmental - - O
toxicity - - O
of - - O
the - - O
class - - O
III - - O
antiarrhythmic - - O
agent - - O
almokalant - - O
in - - O
mice - - O
. - - O

The - - O
absence - - O
of - - O
other - - O
regions - - O
of - - O
hybridization - - O
suggests - - O
that - - O
there - - O
are - - O
no - - O
closely - - O
related - - O
sequences - - O
( - - O
e - - O
. - - O
g - - O
. - - O
, - - O
reverse - - O
transcribed - - O
pseudogenes - - O
) - - O
scattered - - O
throughout - - O
the - - O
genome - - O
and - - O
that - - O
if - - O
there - - O
are - - O
closely - - O
related - - O
genes - - O
, - - O
they - - O
must - - O
be - - O
clustered - - O
near - - O
GSTT2 - - B-MUT
. - - O

Recent - - O
advances - - O
have - - O
shown - - O
that - - O
volatile - - O
sulfur - - O
is - - O
a - - O
result - - O
of - - O
ecological - - O
interactions - - O
and - - O
transformation - - O
processes - - O
through - - O
planktonic - - O
food - - O
webs - - O
. - - O

Cdk2 - - B-MUT
and - - O
MAPK - - B-MUT
precipitates - - O
from - - O
untreated - - O
tumor - - O
lysates - - O
phosphorylated - - O
recombinant - - B-MUT
wild-type - - I-MUT
p27 - - I-MUT
but - - O
not - - O
the - - O
T187A - - O
mutant - - O
in - - O
vitro - - O
. - - O

Ribonuclease - - B-MUT
protection - - O
assays - - O
revealed - - O
that - - O
hmg1 - - B-MUT
and - - O
hmg2 - - B-MUT
are - - O
differentially - - O
expressed - - O
in - - O
a - - O
developmentally- - - O
and - - O
spatially-modulated - - O
manner - - O
during - - O
morphogenesis - - O
of - - O
specialized - - O
terpenoid-containing - - O
pigment - - O
glands - - O
in - - O
embryos - - O
. - - O

SERS - - O
spectra - - O
were - - O
obtained - - O
by - - O
vacuum - - O
evaporation - - O
and - - O
casting - - O
of - - O
p-NTP - - O
onto - - O
silver - - O
island - - O
films - - O
, - - O
and - - O
also - - O
from - - O
colloidal - - O
silver - - O
solutions - - O
. - - O

From - - O
these - - O
results - - O
, - - O
it - - O
is - - O
concluded - - O
that - - O
EDLF - - O
has - - O
clear - - O
vasoconstrictor - - O
properties - - O
which - - O
are - - O
not - - O
due - - O
to - - O
adrenergic - - O
or - - O
calcium - - O
entry - - O
mechanisms - - O
and - - O
that - - O
there - - O
are - - O
differences - - O
in - - O
the - - O
vasoconstrictor - - O
effects - - O
of - - O
EDLFs - - O
with - - O
respect - - O
to - - O
different - - O
vascular - - O
beds - - O
. - - O

Taken - - O
together - - O
, - - O
our - - O
data - - O
suggest - - O
that - - O
Dbf8p - - B-MUT
plays - - O
an - - O
essential - - O
role - - O
in - - O
chromosome - - O
segregation - - O
. - - O

The - - O
HOI - - O
induced - - O
a - - O
nearly - - O
fourfold - - O
increase - - O
in - - O
ANF - - B-MUT
in - - O
the - - O
elderly - - O
, - - O
whereas - - O
that - - O
for - - O
the - - O
young - - O
was - - O
threefold - - O
. - - O

The - - O
sequence - - O
data - - O
now - - O
permit - - O
a - - O
detailed - - O
interpretation - - O
of - - O
the - - O
X-ray - - O
crystallographic - - O
structure - - O
of - - O
the - - O
enzyme - - O
and - - O
the - - O
cloning - - O
and - - O
expression - - O
of - - O
the - - O
clostridial - - O
gene - - O
will - - O
facilitate - - O
site-directed - - O
mutagenesis - - O
. - - O

Dissolution - - O
of - - O
the - - O
Pt-30%Ir - - O
microelectrode - - O
tip - - O
was - - O
observed - - O
by - - O
scanning - - O
electron - - O
microscopy - - O
at - - O
charge - - O
densities - - O
as - - O
low - - O
as - - O
200 - - O
microC - - O
cm2 - - O
X - - O
ph - - O
( - - O
1 - - O
A - - O
cm2 - - O
) - - O
, - - O
whereas - - O
erosion - - O
of - - O
activated - - O
iridium - - O
microelectrodes - - O
occurred - - O
only - - O
at - - O
the - - O
highest - - O
charge - - O
and - - O
current - - O
densities - - O
( - - O
3200 - - O
microC - - O
cm2 - - O
X - - O
ph - - O
, - - O
16 - - O
A - - O
cm2 - - O
) - - O
. - - O

The - - O
steepness - - O
of - - O
the - - O
standard - - O
O2 - - O
dissociation - - O
curve - - O
becomes - - O
greater - - O
during - - O
the - - O
training - - O
period - - O
( - - O
increase - - O
in - - O
Hill's - - O
n - - O
from - - O
2 - - O
. - - O
68 - - O
+ - - O
- - - O
0 - - O
. - - O
10 - - O
to - - O
2 - - O
. - - O
96 - - O
+ - - O
- - - O
0 - - O
. - - O
15 - - O
) - - O
. - - O

Subcutaneous - - O
administration - - O
of - - O
the - - O
somatostatin - - B-MUT
analogue - - O
, - - O
octreotide - - O
, - - O
100 - - O
micrograms - - O
thrice - - O
daily - - O
, - - O
resulted - - O
in - - O
a - - O
sustained - - O
improvement - - O
in - - O
diarrhoea - - O
and - - O
disappearance - - O
of - - O
faecal - - O
incontinence - - O
without - - O
reducing - - O
calcitonin - - B-MUT
levels - - O
. - - O

The - - O
fracture - - O
groups - - O
were - - O
significantly - - O
older - - O
and - - O
had - - O
more - - O
years - - O
since - - O
menopause - - O
than - - O
the - - O
control - - O
groups - - O
. - - O

Total - - O
serum - - O
calcium - - O
was - - O
7 - - O
. - - O
8 - - O
+ - - O
- - - O
0 - - O
. - - O
8 - - O
mg - - O
dl - - O
, - - O
whereas - - O
ionized - - O
calcium - - O
was - - O
5 - - O
. - - O
7 - - O
+ - - O
- - - O
0 - - O
. - - O
7 - - O
mg - - O
dl - - O
, - - O
phosphorus - - O
3 - - O
. - - O
2 - - O
+ - - O
- - - O
1 - - O
. - - O
2 - - O
mg - - O
dl - - O
, - - O
and - - O
alkaline - - O
phosphatase - - O
149 - - O
+ - - O
- - - O
48 - - O
. - - B-MUT
6 - - I-MUT
U - - O
liter - - O
. - - O

CONCLUSION - - O
: - - O
TNF - - B-MUT
alpha - - I-MUT
, - - O
TGF - - B-MUT
beta - - I-MUT
, - - O
PDGF - - B-MUT
and - - O
IL-1beta - - B-MUT
increased - - O
LDLr - - B-MUT
gene - - I-MUT
expression - - O
by - - O
increasing - - O
sterol-independent - - O
and - - O
mitogenesis-independent - - O
gene - - O
transcription - - O
. - - O

Cell - - O
viability - - O
and - - O
lysosomal - - O
enzymes - - O
. - - O

Automatic - - O
view - - O
box - - O
. - - O

Reporter - - O
constructs - - O
function - - O
in - - O
a - - O
parallel - - O
manner - - O
, - - O
demonstrating - - O
the - - O
key - - O
role - - O
of - - O
the - - O
AhR - - B-MUT
in - - O
constitutive - - O
as - - O
well - - O
as - - O
TCDD-induced - - O
expression - - O
of - - O
Cyp1B1 - - B-MUT
in - - O
mouse - - O
embryo - - O
fibroblasts - - O
. - - O

At - - O
baseline - - O
, - - O
serum - - O
levels - - O
of - - O
lycopene - - O
and - - O
FLOP - - O
were - - O
abnormally - - O
high - - O
and - - O
serum - - O
FLOP - - O
was - - O
correlated - - O
significantly - - O
with - - O
plasma - - O
cyclosporine - - O
levels - - O
( - - O
r - - O
= - - O
0 - - O
. - - O
646 - - O
, - - O
p - - O
= - - O
0 - - O
. - - O
016 - - O
) - - O
. - - O

2 - - O
. - - O
numerous - - O
narrow - - O
shunt - - O
vessels - - O
departing - - O
continuously - - O
from - - O
the - - O
primary - - O
arteries - - O
to - - O
feed - - O
a - - O
secondary - - O
arterial - - O
system - - O
which - - O
parallels - - O
the - - O
primary - - O
one - - O
. - - O

Pmt2 - - B-MUT
is - - O
a - - O
member - - O
of - - O
a - - O
six-protein - - O
family - - O
in - - O
yeast - - O
that - - O
catalyzes - - O
the - - O
first - - O
step - - O
in - - O
O - - O
mannosylation - - O
of - - O
target - - O
proteins - - O
. - - O

Promoter - - O
activity - - O
was - - O
high - - O
in - - O
cell - - O
lines - - O
that - - O
expressed - - O
high - - O
levels - - O
of - - O
endogenous - - O
D3 - - B-MUT
mRNA - - I-MUT
, - - O
as - - O
indicated - - O
by - - O
Northern - - O
blot - - O
analyses - - O
, - - O
and - - O
was - - O
significantly - - O
reduced - - O
when - - O
the - - O
promoter - - O
was - - O
truncated - - O
to - - O
-122 - - O
bp - - O
. - - O

Sequencing - - O
analysis - - O
has - - O
shown - - O
that - - O
each - - O
rap1t - - B-MUT
allele - - I-MUT
contains - - O
a - - O
nonsense - - O
mutation - - O
within - - O
a - - O
discrete - - O
region - - O
between - - O
amino - - O
acids - - O
663 - - O
and - - O
684 - - O
. - - O

This - - O
protein - - O
is - - O
present - - O
in - - O
both - - O
HeLa - - O
nuclear - - O
extracts - - O
and - - O
S100 - - O
extracts - - O
but - - O
absent - - O
from - - O
SR - - B-MUT
protein - - I-MUT
preparations - - O
, - - O
suggesting - - O
that - - O
it - - O
is - - O
not - - O
a - - O
classical - - O
SR - - B-MUT
protein - - I-MUT
. - - O

Finally - - O
a - - O
10-nucleotide - - O
region - - O
flanking - - O
the - - O
exon - - O
4 - - O
protein-binding - - O
site - - O
is - - O
homologous - - O
to - - O
instability - - O
elements - - O
within - - O
five - - O
other - - O
transcripts - - O
, - - O
suggesting - - O
that - - O
a - - O
common - - O
coding - - O
region - - O
determinant - - O
may - - O
exist - - O
. - - O

Alternating - - O
proline - - O
alanine - - O
sequence - - O
of - - O
beta - - O
B1 - - B-MUT
subunit - - I-MUT
originates - - I-MUT
from - - O
a - - O
repetitive - - O
DNA - - O
sequence - - O
. - - O

The - - O
distribution - - O
and - - O
organization - - O
of - - O
projections - - O
from - - O
the - - O
spinal - - O
cervical - - O
enlargement - - O
to - - O
subnucleus - - O
reticularis - - O
dorsalis - - O
( - - O
SRD - - O
) - - O
and - - O
the - - O
neighbouring - - O
Cuneate - - O
nucleus - - O
( - - O
Cu - - O
) - - O
area - - O
was - - O
studied - - O
in - - O
the - - O
rat - - O
by - - O
using - - O
microinjections - - O
of - - O
Phaseolus - - B-MUT
vulgaris - - I-MUT
leucoagglutinin - - I-MUT
( - - O
PHA-L - - B-MUT
) - - O
into - - O
different - - O
laminae - - O
around - - O
the - - O
C7 - - O
level - - O
. - - O

Retreatment - - O
of - - O
these - - O
2 - - O
dogs - - O
resulted - - O
in - - O
a - - O
similar - - O
, - - O
but - - O
blunted - - O
, - - O
response - - O
to - - O
human - - B-MUT
immunoglobulin - - I-MUT
. - - O

Cloning - - O
and - - O
sequence - - O
analyses - - O
revealed - - O
a - - O
second - - O
cDNA - - O
with - - O
a - - O
95-nt - - O
deletion - - O
in - - O
the - - O
region - - O
coding - - O
for - - O
the - - O
putative - - O
second - - O
intracellular - - O
loop - - O
and - - O
the - - O
fourth - - O
transmembrane - - O
domain - - O
of - - O
the - - O
5-HT2C-R - - B-MUT
. - - O

The - - O
relative - - O
toxicity - - O
of - - O
nickel - - O
oxide - - O
( - - O
NiO - - O
) - - O
, - - O
nickel - - O
sulfate - - O
hexahydrate - - O
( - - O
NiSO4 - - O
. - - O
6H2O - - O
) - - O
, - - O
and - - O
nickel - - O
subsulfide - - O
( - - O
Ni3S2 - - O
) - - O
was - - O
studied - - O
in - - O
F344 - - O
N - - O
rats - - O
and - - O
B6C3F1 - - O
mice - - O
after - - O
inhalation - - O
exposure - - O
for - - O
6 - - O
hr - - O
day - - O
, - - O
5 - - O
days - - O
week - - O
, - - O
for - - O
13 - - O
weeks - - O
. - - O

In - - O
the - - O
region - - O
Walgau - - O
with - - O
mixed - - O
industrial-rural - - O
population - - O
an - - O
iodine - - O
deficiency - - O
I - - O
was - - O
found - - O
in - - O
81% - - O
and - - O
an - - O
iodine - - O
deficiency - - O
II - - O
in - - O
45% - - O
. - - O

We - - O
propose - - O
that - - O
plasmids - - O
of - - O
the - - O
pLS1 - - O
family - - O
( - - O
pE194 - - O
, - - O
pADB201 - - O
, - - O
and - - O
pLB4 - - O
) - - O
share - - O
functional - - O
and - - O
structural - - O
characteristics - - O
for - - O
the - - O
regulation - - O
of - - O
their - - O
copy - - O
numbers - - O
. - - O

Reye's - - O
syndrome - - O
: - - O
reports - - O
of - - O
7 - - O
cases - - O
in - - O
the - - O
period - - O
1982-1987 - - O
. - - O

The - - O
new - - O
FIGO - - O
definition - - O
of - - O
cervical - - O
cancer - - O
stage - - O
IA - - O
: - - O
a - - O
critique - - O
. - - O

In - - O
one - - O
of - - O
these - - O
tumors - - O
the - - O
observed - - O
rearrangement - - O
was - - O
not - - O
due - - O
to - - O
the - - O
insertion - - O
of - - O
an - - O
intact - - O
MoMuLV - - O
provirus - - O
. - - O

Among - - O
six - - O
different - - O
library - - O
isolates - - O
containing - - O
6 - - B-MUT
. - - I-MUT
5- - - I-MUT
to - - I-MUT
7-kb - - I-MUT
IAP - - I-MUT
units - - I-MUT
, - - O
some - - O
restriction - - O
sites - - O
were - - O
highly - - O
conserved - - O
whereas - - O
others - - O
varied - - O
in - - O
both - - O
occurrence - - O
and - - O
position - - O
. - - O

Immunochemotherapy - - O
with - - O
schizophyllan - - O
( - - O
SPG - - O
) - - O
combined - - O
with - - O
chemotherapeutic - - O
agents - - O
was - - O
evaluated - - O
in - - O
two - - O
syngeneic - - O
tumor-C3H - - O
He - - O
mouse - - O
systems - - O
. - - O

Mutation - - O
of - - O
the - - O
octamer - - O
element - - O
also - - O
significantly - - O
reduced - - O
the - - O
ability - - O
of - - O
HDAC1 - - B-MUT
to - - O
confer - - O
repression - - O
of - - O
inducible - - O
HLA-DRA - - B-MUT
promoter - - I-MUT
activation - - O
. - - O

Outflow - - O
obstruction - - O
of - - O
pancreatic - - O
juice - - O
, - - O
i - - O
. - - O
e - - O
. - - O
, - - O
"relative - - O
stenosis - - O
of - - O
the - - O
minor - - O
papilla - - O
, - - O
" - - O
was - - O
considered - - O
to - - O
be - - O
present - - O
in - - O
the - - O
patients - - O
with - - O
type - - O
II - - O
papilla - - O
, - - O
and - - O
, - - O
therefore - - O
, - - O
the - - O
patients - - O
with - - O
type - - O
II - - O
papilla - - O
might - - O
suffer - - O
from - - O
acute - - O
pancreatitis - - O
resulting - - O
from - - O
poor - - O
drainage - - O
of - - O
pancreatic - - O
juice - - O
and - - O
excessive - - O
pressure - - O
in - - O
the - - O
dorsal - - O
duct - - O
. - - O

Natl - - O
. - - O

Pharmacological - - O
and - - O
pharmacokinetic - - O
characteristics - - O
of - - O
the - - O
non-ionic - - O
monomeric - - O
X-ray - - O
contrast - - O
agent - - O
iopromide - - O
( - - O
Ultravist - - O
, - - O
CAS - - O
73334-07-3 - - O
) - - O
were - - O
evaluated - - O
in - - O
preclinical - - O
studies - - O
. - - O

The - - O
membrane-distal - - O
cytoplasmic - - O
region - - O
of - - O
human - - B-MUT
granulocyte - - I-MUT
colony-stimulating - - I-MUT
factor - - I-MUT
receptor - - I-MUT
is - - O
required - - O
for - - O
STAT3 - - B-MUT
but - - O
not - - O
STAT1 - - B-MUT
homodimer - - I-MUT
formation - - O
. - - O

The - - O
mean - - O
value - - O
of - - O
the - - O
CD79b - - B-MUT
to - - O
the - - O
CD79b - - B-MUT
internally - - O
deleted - - O
ratio - - O
was - - O
0 - - O
. - - O
64 - - O
+ - - O
- - - O
0 - - O
. - - O
20 - - O
SD - - O
in - - O
normal - - O
donors - - O
and - - O
0 - - O
. - - O
44 - - O
+ - - O
- - - O
0 - - O
. - - O
27 - - O
SD - - O
in - - O
B-CLL - - O
( - - O
P - - O
= - - O
. - - O
01 - - O
) - - O
. - - O

Amino - - O
acid - - O
sequence - - O
of - - O
one - - O
human - - O
liver - - O
clone - - O
( - - O
HL-14 - - O
) - - O
was - - O
identical - - O
to - - O
the - - O
rabbit - - B-MUT
skeletal - - I-MUT
muscle - - I-MUT
phosphatase - - I-MUT
2A - - I-MUT
cDNA - - I-MUT
( - - O
with - - O
97% - - O
nucleotide - - O
identity - - O
) - - O
. - - O

Factor - - B-MUT
XI - - I-MUT
deficiency - - O
is - - O
a - - O
rare - - O
hereditary - - O
bleeding - - O
disorder - - O
affecting - - O
the - - O
intrinsic - - O
pathway - - O
. - - O

The - - O
effect - - O
of - - O
ibopamine - - O
and - - O
furosemide - - O
in - - O
130 - - O
patients - - O
with - - O
NYHA - - O
Class - - O
I - - O
and - - O
II - - O
heart - - O
failure - - O
were - - O
studied - - O
in - - O
a - - O
parallel - - O
, - - O
double-blind - - O
, - - O
randomized - - O
placebo-controlled - - O
multi-centre - - O
trial - - O
. - - O

The - - O
assembly - - O
of - - O
sequence - - O
ready - - O
, - - O
high-resolution - - O
physical - - O
maps - - O
and - - O
construction - - O
of - - O
minimally - - O
overlapping - - O
contigs - - O
for - - O
the - - O
human - - O
as - - O
well - - O
as - - O
model - - O
genomes - - O
requires - - O
accurate - - O
determination - - O
of - - O
the - - O
extent - - O
of - - O
overlap - - O
between - - O
adjacent - - O
clones - - O
as - - O
well - - O
as - - O
their - - O
relative - - O
orientation - - O
. - - O

The - - O
SSB-poly - - O
( - - O
dT - - O
) - - O
affinity - - O
is - - O
too - - O
high - - O
to - - O
measure - - O
in - - O
buffers - - O
containing - - O
even - - O
5 - - O
M - - O
NaCl - - O
; - - O
however - - O
, - - O
in - - O
1 - - O
. - - O
8-2 - - O
. - - O
5 - - O
M - - O
NaBr - - O
, - - O
we - - O
measure - - O
alpha - - O
log - - O
Kobsd - - O
alpha - - O
log - - O
[ - - O
NaBr - - O
] - - O
= - - O
-5 - - O
. - - O
7 - - O
+ - - O
- - - O
0 - - O
. - - O
7 - - O
, - - O
with - - O
a - - O
lower - - O
value - - O
of - - O
omega - - O
T - - O
O - - O
= - - O
130 - - O
+ - - O
- - - O
70 - - O
. - - O

Selenium - - O
is - - O
an - - O
essential - - O
element - - O
for - - O
humans - - O
, - - O
animals - - O
and - - O
some - - O
species - - O
of - - O
microorganisms - - O
. - - O

Consistent - - O
with - - O
this - - O
, - - O
we - - O
show - - O
that - - O
peptides - - O
representing - - O
docking - - O
sites - - O
within - - O
the - - O
target - - O
substrates - - O
Elk-1 - - B-MUT
and - - O
p90 - - B-MUT
( - - I-MUT
rsk - - I-MUT
) - - I-MUT
inhibit - - O
ERK-dependent - - O
activation - - O
of - - O
MKP-3 - - B-MUT
. - - O

Acute - - O
type - - O
A - - O
hepatitis - - O
in - - O
three - - O
patients - - O
with - - O
chronic - - O
HBV - - O
infection - - O
. - - O

A - - O
potential - - O
TATA - - O
box - - O
is - - O
located - - O
29 - - O
base - - O
pairs - - O
upstream - - O
of - - O
the - - O
first - - O
transcription - - O
initiation - - O
site - - O
. - - O

Use - - O
of - - O
radioactive - - O
isotopes - - O
in - - O
the - - O
chemistry - - O
of - - O
proteins - - O
. - - O

Mutations - - O
at - - O
two - - O
neighboring - - O
sites - - O
, - - O
serine - - O
242 - - O
and - - O
threonine - - O
255 - - O
, - - O
exacerbated - - O
the - - O
effect - - O
. - - O

Preface - - O
. - - O

Light - - O
microscopical - - O
and - - O
routine - - O
immunohistochemical - - O
studies - - O
of - - O
a - - O
cervical - - O
neoplasm - - O
in - - O
a - - O
32 - - O
year - - O
old - - O
woman - - O
initially - - O
suggested - - O
a - - O
histiocytic - - O
lymphoma - - O
, - - O
but - - O
histochemical - - O
staining - - O
for - - O
chloroacetate - - B-MUT
esterase - - I-MUT
established - - O
the - - O
correct - - O
diagnosis - - O
. - - O

All - - O
of - - O
the - - O
newly - - O
acquired - - O
proviruses - - O
identified - - O
in - - O
mosaic - - O
founder - - O
SWR - - B-MUT
J-RF - - I-MUT
J - - I-MUT
mice - - I-MUT
that - - I-MUT
could - - O
be - - O
transmitted - - O
through - - O
the - - O
germ - - O
line - - O
were - - O
also - - O
present - - O
in - - O
somatic - - O
tissues - - O
, - - O
demonstrating - - O
that - - O
viral - - O
integration - - O
occurred - - O
before - - O
the - - O
germ - - O
line - - O
was - - O
set - - O
aside - - O
from - - O
the - - O
somatic - - O
lineages - - O
. - - O

Autoionization - - O
rates - - O
and - - O
energy - - O
levels - - O
of - - O
triplet - - O
nf - - O
, - - O
v - - O
= - - O
1 - - O
Rydberg - - O
states - - O
of - - O
H2 - - O
. - - O

At - - O
20 - - O
days - - O
( - - O
D - - O
) - - O
and - - O
at - - O
3 - - O
months - - O
post-TBI - - O
, - - O
irradiated - - O
rats - - O
had - - O
a - - O
significantly - - O
lower - - O
percentage - - O
of - - O
avoidance - - O
than - - O
controls - - O
but - - O
no - - O
statistical - - O
difference - - O
was - - O
found - - O
at - - O
5 - - O
months - - O
post-TBI - - O
. - - O
b - - O
Two-way - - O
avoidance - - O
test - - O
: - - O
this - - O
test - - O
was - - O
performed - - O
only - - O
after - - O
TBI - - O
. - - O

Monitoring - - O
changes - - O
in - - O
the - - O
heart - - O
rate - - O
of - - O
the - - O
premature - - O
fetus - - O
during - - O
tocolysis - - O
with - - O
the - - O
beta-adrenomimetics - - O
partusisten - - O
and - - O
Pre-par - - O
. - - O

Thin-layer - - O
chromatographic - - O
methods - - O
were - - O
up-dated - - O
for - - O
pharmacokinetic - - O
studies - - O
of - - O
imipramine - - O
in - - O
plasma - - O
and - - O
urine - - O
. - - O

This - - O
study - - O
was - - O
designed - - O
to - - O
compare - - O
the - - O
efficacy - - O
of - - O
efegatran - - O
plus - - O
streptokinase - - B-MUT
versus - - O
heparin - - O
plus - - O
accelerated - - O
tissue - - B-MUT
plasminogen - - I-MUT
activator - - I-MUT
( - - O
TPA - - B-MUT
) - - O
in - - O
coronary - - O
reperfusion - - O
in - - O
acute - - O
MI - - O
. - - O

Based - - O
on - - O
the - - O
current - - O
literature - - O
, - - O
the - - O
mechanisms - - O
involved - - O
in - - O
the - - O
toxicity - - O
of - - O
OA - - O
indicate - - O
three - - O
major - - O
effects - - O
: - - O
( - - O
1 - - O
) - - O
inhibition - - O
of - - O
mitochondrial - - O
respiration - - O
correlated - - O
with - - O
a - - O
depletion - - O
of - - O
ATP - - O
; - - O
( - - O
2 - - O
) - - O
inhibition - - O
of - - O
tRNA-synthetase - - B-MUT
accompanied - - O
by - - O
a - - O
reduced - - O
protein - - O
synthesis - - O
; - - O
and - - O
( - - O
3 - - O
) - - O
enhanced - - O
lipid - - O
peroxidation - - O
. - - O

And - - O
, - - O
most - - O
importantly - - O
, - - O
reconstitution - - O
of - - O
a - - O
consensus - - B-MUT
CRE - - I-MUT
, - - O
within - - O
the - - O
21-bp - - O
enhancers - - O
increases - - O
binding - - O
of - - O
CREB - - B-MUT
ATF - - O
proteins - - B-MUT
but - - O
abrogates - - O
basal - - O
repression - - O
of - - O
LTR-directed - - O
transcription - - O
in - - O
vitro - - O
. - - O

The - - O
cause - - O
of - - O
death - - O
is - - O
often - - O
quite - - O
apparent - - O
from - - O
the - - O
pathological - - O
and - - O
toxicological - - O
findings - - O
; - - O
however - - O
, - - O
the - - O
manner - - O
of - - O
death - - O
often - - O
gives - - O
the - - O
examining - - O
official - - O
some - - O
difficulty - - O
. - - O

In - - O
doses - - O
of - - O
0 - - O
. - - O
03-0 - - O
. - - O
3 - - O
mg - - O
kg - - O
i - - O
. - - O
v - - O
. - - O
, - - O
SG-75 - - O
did - - O
not - - O
significantly - - O
affect - - O
pulse - - O
pressure - - O
, - - O
heart - - O
rate - - O
, - - O
aortic - - O
blood - - O
flow - - O
, - - O
left - - O
ventricular - - O
pressure - - O
( - - O
LVP - - O
) - - O
and - - O
LVdP - - O
dt - - O
max - - O
. - - O

The - - O
RNA - - O
aptamer - - O
contains - - O
three - - O
stems - - O
separated - - O
by - - O
a - - O
pair - - O
of - - O
two-base - - O
bulges - - O
, - - O
and - - O
adopts - - O
an - - O
unanticipated - - O
fold - - O
in - - O
which - - O
both - - O
junctional - - O
sites - - O
are - - O
anchored - - O
through - - O
base - - O
triple - - O
formation - - O
. - - O

Phase - - O
II - - O
study - - O
of - - O
VP-16 - - O
( - - O
capsule - - O
) - - O
in - - O
solid - - O
tumors - - O
. - - O

These - - O
results - - O
suggest - - O
that - - O
leader-mRNA - - O
fusion - - O
in - - O
coronavirus - - O
transcription - - O
does - - O
not - - O
require - - O
direct - - O
RNA-RNA - - O
interaction - - O
between - - O
complementary - - O
sequences - - O
. - - O

Activation - - O
of - - O
nuclear - - B-MUT
factor - - I-MUT
( - - I-MUT
NF - - I-MUT
) - - I-MUT
-kappaB - - I-MUT
and - - O
subsequent - - O
proinflammatory - - O
gene - - O
expression - - O
in - - O
human - - O
airway - - O
epithelial - - O
cells - - O
can - - O
be - - O
evoked - - O
by - - O
oxidative - - O
stress - - O
. - - O

A - - O
cAMP-responsive - - B-MUT
element-like - - I-MUT
( - - O
CRE-like - - B-MUT
, - - O
TGACGTGA - - B-MUT
) - - O
promoter - - O
sequence - - O
and - - O
a - - O
protein - - B-MUT
kinase - - I-MUT
A - - I-MUT
signaling - - O
pathway - - O
are - - O
involved - - O
in - - O
this - - O
induction - - O
, - - O
and - - O
activation - - O
of - - O
both - - O
CRE - - B-MUT
binding - - I-MUT
protein - - I-MUT
( - - O
CREB - - B-MUT
) - - O
and - - O
activating - - B-MUT
transcription - - I-MUT
factor-2 - - I-MUT
( - - O
ATF-2 - - B-MUT
) - - O
is - - O
required - - O
in - - O
the - - O
above - - O
process - - O
. - - O

These - - O
data - - O
suggest - - O
that - - O
a - - O
major - - O
part - - O
of - - O
the - - O
reduction - - O
in - - O
food - - O
intake - - O
in - - O
hyperphagic - - O
rats - - O
eating - - O
a - - O
quinine-adulterated - - O
diet - - O
is - - O
due - - O
to - - O
postingestional - - O
events - - O
. - - O

Similarly - - O
, - - O
we - - O
examined - - O
whether - - O
the - - O
ELK1 - - B-MUT
, - - O
SAP1a - - B-MUT
, - - O
FLI1 - - B-MUT
, - - O
EWS-FLI1 - - B-MUT
, - - O
ETS1 - - B-MUT
, - - O
ETS2 - - B-MUT
, - - O
PEA3 - - B-MUT
and - - O
PU - - B-MUT
. - - I-MUT
1 - - I-MUT
proteins - - I-MUT
can - - O
form - - O
ternary - - O
complexes - - O
with - - O
SRF - - B-MUT
on - - O
the - - O
Egr1 - - B-MUT
SREI - - B-MUT
and - - I-MUT
II - - I-MUT
. - - O

In - - O
Arabidopsis - - O
, - - O
the - - O
induction - - O
of - - O
a - - O
dehydration-responsive - - B-MUT
gene - - I-MUT
, - - O
rd22 - - B-MUT
, - - O
is - - O
mediated - - O
by - - O
abscisic - - O
acid - - O
( - - O
ABA - - O
) - - O
and - - O
requires - - O
protein - - O
biosynthesis - - O
for - - O
ABA-dependent - - B-MUT
gene - - I-MUT
expression - - O
. - - O

Like - - O
the - - O
elicitors - - O
of - - O
the - - O
hypersensitive - - O
reaction - - O
( - - O
HR - - O
) - - O
produced - - O
by - - O
E - - O
. - - O
chrysanthemi - - O
( - - O
HarpinEch - - O
) - - O
and - - O
E - - O
. - - O
amylovora - - O
( - - O
HarpinEa - - O
) - - O
, - - O
the - - O
deduced - - O
36-kDa - - O
protein - - O
does - - O
not - - O
possess - - O
a - - O
typical - - O
signal - - O
sequence - - O
, - - O
but - - O
it - - O
contains - - O
a - - O
putative - - O
membrane-spanning - - O
domain - - O
. - - O

During - - O
skeletal - - O
muscle - - O
development - - O
, - - O
different - - O
types - - O
of - - O
muscle - - O
fibers - - O
are - - O
generated - - O
, - - O
which - - O
express - - O
different - - O
combinations - - O
of - - O
muscle-specific - - O
gene - - O
products - - O
. - - O

This - - O
resulted - - O
in - - O
a - - O
complete - - O
inhibition - - O
of - - O
Site-1 - - O
cleavage - - O
that - - O
was - - O
restored - - O
by - - O
concomitant - - O
overexpression - - O
of - - O
full-length - - O
SCAP - - B-MUT
. - - O

Elimination - - O
of - - O
Haemophilus - - O
influenzae - - O
type - - O
b - - O
meningitis - - O
after - - O
introduction - - O
of - - O
vaccination - - O
. - - O

MK-801 - - O
administration - - O
resulted - - O
in - - O
a - - O
biphasic - - O
response - - O
in - - O
seizure - - O
latency - - O
. - - O

The - - O
functional - - O
homology - - O
of - - O
Cwg2 - - B-MUT
with - - O
Cdc43 - - B-MUT
, - - O
which - - O
has - - O
been - - O
implicated - - O
in - - O
the - - O
control - - O
of - - O
cell - - O
polarity - - O
, - - O
suggests - - O
a - - O
link - - O
between - - O
two - - O
morphogenetic - - O
events - - O
such - - O
as - - O
establishment - - O
of - - O
cell - - O
polarity - - O
and - - O
cell - - O
wall - - O
biosynthesis - - O
. - - O

Using - - O
anchored - - O
PCR - - O
, - - O
a - - O
VL - - B-MUT
element - - I-MUT
rearranged - - O
to - - O
CL2 - - B-MUT
was - - O
isolated - - O
. - - O

The - - O
Schistosoma - - B-MUT
mansoni - - I-MUT
homologue - - I-MUT
( - - O
SmSmad2 - - B-MUT
) - - O
was - - O
overexpressed - - O
in - - O
bacteria - - O
as - - O
a - - O
Sj26-GST - - B-MUT
fusion - - I-MUT
protein - - I-MUT
and - - O
used - - O
to - - O
raise - - O
specific - - O
antibodies - - O
. - - O

In - - O
addition - - O
, - - O
5' - - O
deletions - - O
removing - - O
all - - O
but - - O
34 - - O
bp - - O
upstream - - O
of - - O
the - - O
transcription - - O
start - - O
point - - O
retained - - O
greater - - O
than - - O
90% - - O
promoter - - O
activity - - O
, - - O
suggesting - - O
that - - O
the - - O
-35 - - O
hexamer - - O
was - - O
not - - O
essential - - O
for - - O
promoter - - O
activity - - O
. - - O

This - - O
loss - - O
was - - O
independent - - O
of - - O
drug - - O
concentration - - O
and - - O
a - - O
correction - - O
factor - - O
was - - O
employed - - O
to - - O
calculate - - O
the - - O
true - - O
free - - O
diazepam - - O
concentration - - O
. - - O

Coexposure - - O
to - - O
FP - - O
also - - O
resulted - - O
in - - O
a - - O
more - - O
pronounced - - O
and - - O
sustained - - O
activation - - O
of - - O
the - - O
mitogen-activated - - B-MUT
protein - - I-MUT
kinase - - I-MUT
kinase - - I-MUT
extracellular - - I-MUT
signal-regulated - - I-MUT
protein - - I-MUT
kinase - - I-MUT
cascade - - I-MUT
after - - O
PMA - - O
treatment - - O
, - - O
although - - O
disruption - - O
of - - O
this - - O
pathway - - O
by - - O
the - - O
mitogen-activated - - O
protein - - B-MUT
kinase - - I-MUT
kinase - - I-MUT
1 - - I-MUT
inhibitor - - I-MUT
U0126 - - O
did - - O
not - - O
prevent - - O
potentiation - - O
of - - O
apoptosis - - O
. - - O

Indeed - - O
, - - O
it - - O
is - - O
shown - - O
that - - O
it - - O
mediates - - O
the - - O
formation - - O
of - - O
disulfide-linked - - O
homodimers - - O
and - - O
that - - O
the - - O
formation - - O
of - - O
homo- - - O
and - - O
heterodimers - - O
are - - O
mutually - - O
excluded - - O
. - - O

We - - O
enrolled - - O
253 - - O
HIV-antibody - - B-MUT
positive - - O
heroin - - O
addicts - - O
without - - O
HIV-related - - O
disease - - O
( - - O
n - - O
= - - O
81 - - O
) - - O
or - - O
with - - O
persistent - - O
generalized - - O
lymphadenopathy - - O
( - - O
n - - O
= - - O
172 - - O
) - - O
in - - O
a - - O
prospective - - O
study - - O
to - - O
evaluate - - O
clinical - - O
progression - - O
to - - O
AIDS - - O
related - - O
complex - - O
( - - O
ARC - - O
) - - O
or - - O
AIDS - - O
and - - O
to - - O
identify - - O
factors - - O
of - - O
possible - - O
prognostic - - O
relevance - - O
. - - O

Functional - - O
tests - - O
using - - O
a - - O
reporter - - O
gene - - O
, - - O
containing - - O
Stat5-binding - - B-MUT
elements - - I-MUT
, - - O
confirmed - - O
that - - O
while - - O
the - - O
variant - - O
form - - O
was - - O
inactive - - O
by - - O
itself - - O
, - - O
it - - O
could - - O
inhibit - - O
the - - O
function - - O
of - - O
the - - O
full-length - - O
receptor - - O
. - - O

The - - O
monkey - - B-MUT
LHR - - I-MUT
cDNA - - I-MUT
displayed - - O
83-94% - - O
overall - - O
sequence - - O
homology - - O
with - - O
the - - O
other - - O
mammalian - - B-MUT
LHR - - I-MUT
cDNAs - - I-MUT
. - - O

In - - O
hypertensive - - O
nephrosclerosis - - O
, - - O
therapy - - O
containing - - O
an - - O
ACEI - - O
alone - - O
or - - O
in - - O
combination - - O
significantly - - O
reduces - - O
the - - O
incidence - - O
of - - O
renal - - O
events - - O
. - - O

Removal - - O
of - - O
beta - - B-MUT
2-microglobulin - - I-MUT
by - - O
hemodialysis - - O
and - - O
hemofiltration - - O
: - - O
a - - O
four - - O
year - - O
follow - - O
up - - O
. - - O

Most - - O
of - - O
the - - O
patients - - O
presented - - O
with - - O
Transient - - O
Ischemic - - O
Attacks - - O
( - - O
64% - - O
) - - O
or - - O
Reversible - - O
Ischemic - - O
Neurologic - - O
Deficits - - O
( - - O
19% - - O
) - - O
. - - O

Another - - O
segment - - O
of - - O
CRL3 - - B-MUT
( - - O
-296 - - O
to - - O
-184 - - O
) - - O
, - - O
also - - O
displaying - - O
enhancer - - O
function - - O
, - - O
contained - - O
tandem - - O
repeated - - O
sequences - - O
( - - O
DR-A1 - - B-MUT
and - - O
DR-A2 - - B-MUT
) - - O
. - - O

In - - O
Klinefelter's - - O
syndrome - - O
( - - O
47XXY - - O
) - - O
, - - O
serum - - O
testosterone - - O
levels - - O
are - - O
at - - O
the - - O
lower - - O
end - - O
of - - O
the - - O
normal - - O
range - - O
and - - O
dihydrotestosterone - - O
levels - - O
are - - O
low - - O
. - - O

Whereas - - O
the - - O
muscle - - O
isoform - - O
consists - - O
of - - O
997 - - O
amino - - O
acids - - O
and - - O
terminates - - O
with - - O
the - - O
sequence - - B-MUT
Ala-Ile-Leu-Glu - - I-MUT
, - - O
the - - O
second - - O
isoform - - O
is - - O
1043 - - O
amino - - O
acids - - O
in - - O
length - - O
due - - O
to - - O
the - - O
replacement - - O
of - - O
these - - O
last - - O
4 - - O
amino - - O
acids - - O
with - - O
a - - O
50-amino - - O
acid - - O
sequence - - O
that - - O
contains - - O
a - - O
potential - - O
transmembrane - - O
domain - - O
followed - - O
by - - O
a - - O
consensus - - O
sequence - - O
for - - O
an - - O
N-linked - - O
glycosylation - - O
site - - O
. - - O

Homology - - O
with - - O
the - - O
human - - O
protein - - O
is - - O
only - - O
34% - - O
in - - O
the - - O
tandem - - O
repeat - - O
domain - - O
, - - O
mainly - - O
showing - - O
conservation - - O
of - - O
serines - - O
and - - O
threonines - - O
, - - O
presumed - - O
sites - - O
of - - O
O-linked - - O
carbohydrate - - O
attachment - - O
. - - O

Efficacy - - O
of - - O
a - - O
three- - - O
versus - - O
a - - O
five-week - - O
alcohol - - O
treatment - - O
program - - O
. - - O

An - - O
overexpression - - O
of - - O
the - - O
betaAPP - - B-MUT
gene - - I-MUT
in - - O
certain - - O
areas - - O
of - - O
the - - O
AD - - O
brain - - O
has - - O
been - - O
suggested - - O
to - - O
be - - O
an - - O
important - - O
factor - - O
in - - O
the - - O
neuropathology - - O
of - - O
AD - - O
. - - O

Widening - - O
of - - O
the - - O
abdominal - - O
aortic - - O
wall - - O
on - - O
an - - O
ultrasound - - O
examination - - O
was - - O
the - - O
key - - O
to - - O
the - - O
incidental - - O
diagnosis - - O
of - - O
a - - O
clinically - - O
unsuspected - - O
type - - O
B - - O
dissection - - O
. - - O

Activity - - O
of - - O
acid - - B-MUT
hydrolases - - I-MUT
of - - O
peripheral - - O
blood - - O
leukocytes - - O
in - - O
focal - - O
and - - O
segmental - - O
pneumonia - - O
in - - O
children - - O
. - - O

These - - O
techniques - - O
have - - O
been - - O
used - - O
by - - O
many - - O
people - - O
for - - O
many - - O
years - - O
and - - O
no - - O
claim - - O
is - - O
being - - O
made - - O
for - - O
any - - O
innovation - - O
in - - O
this - - O
regard - - O
. - - O

In - - O
conclusion - - O
, - - O
primary - - O
chemotherapy - - O
based - - O
on - - O
high - - O
dose - - O
MTX - - O
and - - O
ara-C - - O
is - - O
highly - - O
efficient - - O
in - - O
PCNSL - - O
. - - O

His - - O
HC - - B-MUT
II - - I-MUT
activity - - O
and - - O
antigen - - O
levels - - O
were - - O
49% - - O
and - - O
50% - - O
, - - O
respectively - - O
, - - O
and - - O
his - - O
daughter - - O
also - - O
showed - - O
similar - - O
low - - O
levels - - O
. - - O

In - - O
this - - O
study - - O
, - - O
we - - O
identified - - O
four - - O
distinct - - O
E2F - - B-MUT
complexes - - I-MUT
present - - O
in - - O
aged - - O
and - - O
senescent - - O
normal - - O
, - - O
human - - O
diploid - - O
fibroblasts - - O
. - - O

Our - - O
results - - O
show - - O
that - - O
, - - O
from - - O
a - - O
thermodynamical - - O
standpoint - - O
, - - O
melatonin - - O
may - - O
directly - - O
scavenge - - O
hydroxyl - - O
radicals - - O
both - - O
in - - O
vacuum - - O
and - - O
in - - O
aqueous - - O
solution - - O
. - - O

Selected - - O
topics - - O
in - - O
pediatric - - O
ultrasonography--1992 - - O
. - - O

We - - O
report - - O
here - - O
on - - O
the - - O
molecular - - O
nature - - O
of - - O
an - - O
EMS-induced - - O
mutant - - O
, - - O
mn1-89 - - B-MUT
, - - O
a - - O
leaky - - O
semidominant - - O
allele - - O
of - - O
the - - O
Miniature1 - - B-MUT
( - - O
Mn1 - - B-MUT
) - - O
seed - - O
locus - - O
that - - O
encodes - - O
a - - O
seed-specific - - B-MUT
cell - - I-MUT
wall - - I-MUT
invertase - - I-MUT
, - - O
INCW2 - - B-MUT
. - - O

These - - O
data - - O
indicate - - O
that - - O
although - - O
218leu - - O
retains - - O
normal - - O
transactivation - - O
activity - - O
on - - O
a - - O
p53 - - B-MUT
promoter - - I-MUT
in - - O
yeast - - O
at - - O
physiological - - O
temperatures - - O
, - - O
it - - O
is - - O
not - - O
capable - - O
of - - O
normal - - O
p53 - - B-MUT
function - - O
in - - O
the - - O
presence - - O
of - - O
a - - O
248trp - - B-MUT
allele - - I-MUT
in - - O
SNU-C5 - - O
cells - - O
. - - O

Increase - - O
in - - O
urinary - - O
calcium - - O
and - - O
oxalate - - O
after - - O
fructose - - O
infusion - - O
. - - O

These - - O
results - - O
would - - O
suggest - - O
that - - O
a - - O
high - - O
UV - - O
sensitivity - - O
is - - O
associated - - O
with - - O
high - - O
phaeomelanin - - O
and - - O
low - - O
eumelanin - - O
levels - - O
, - - O
and - - O
point - - O
to - - O
the - - O
eumelanin - - O
phaeomelanin - - O
ratio - - O
as - - O
a - - O
novel - - O
chemical - - O
parameter - - O
that - - O
could - - O
be - - O
used - - O
for - - O
predicting - - O
individuals - - O
at - - O
high - - O
risk - - O
for - - O
skin - - O
cancer - - O
and - - O
melanoma - - O
. - - O

METHODS - - O
: - - O
This - - O
retrospective - - O
review - - O
comprised - - O
2711 - - O
eyes - - O
that - - O
had - - O
LASIK - - O
between - - O
September - - O
1996 - - O
and - - O
September - - O
1999 - - O
. - - O

The - - O
Saccharomyces - - O
cerevisiae - - O
spindle - - O
pole - - O
body - - O
duplication - - O
gene - - B-MUT
MPS1 - - I-MUT
is - - O
part - - O
of - - O
a - - O
mitotic - - O
checkpoint - - O
. - - O

These - - O
features - - O
were - - O
considered - - O
consistent - - O
with - - O
a - - O
diagnosis - - O
of - - O
Rothmund-Thomson - - O
syndrome - - O
. - - O

Transfection - - O
analyses - - O
indicated - - O
that - - O
the - - O
expression - - O
of - - O
Tbxas1 - - B-MUT
is - - O
controlled - - O
by - - O
a - - O
short - - O
( - - O
70-bp - - O
) - - O
positive - - O
regulatory - - O
sequence - - O
and - - O
several - - O
upstream - - O
repressive - - O
elements - - O
. - - O

Clinical - - O
aspects - - O
and - - O
therapy - - O
. - - O

Effect - - O
of - - O
variations - - O
in - - O
time - - O
interval - - O
between - - O
treatment - - O
with - - O
BCG - - O
and - - O
quartz - - O
dust - - O
on - - O
translocation - - O
of - - O
quartz - - O
dust - - O
from - - O
the - - O
lungs - - O
to - - O
their - - O
regional - - O
lymph - - O
nodes - - O
. - - O

To - - O
the - - O
problem - - O
of - - O
the - - O
stimulation - - O
of - - O
the - - O
growth - - O
of - - O
transplantable - - O
tumors - - O
of - - O
animals - - O
previously - - O
treated - - O
with - - O
antineoplastic - - O
antibiotics - - O
. - - O

Despite - - O
the - - O
absence - - O
of - - O
exercise-induced - - O
asthma - - O
( - - O
EIA - - O
) - - O
while - - O
breathing - - O
WH - - O
air - - O
, - - O
asthmatic - - O
patients - - O
still - - O
had - - O
significantly - - O
higher - - O
mean - - O
GH - - O
increments - - O
than - - O
normal - - O
subjects - - O
( - - O
9 - - O
. - - O
2 - - O
vs - - O
2 - - O
. - - O
3 - - O
ng - - O
ml - - O
, - - O
P - - O
less - - O
than - - O
0 - - O
. - - O
05 - - O
) - - O
. - - O

The - - O
cut-off - - O
percentage - - O
positivity - - O
value - - O
was - - O
established - - O
using - - O
500 - - O
brucellosis-positive - - O
and - - O
500 - - O
brucellosis-negative - - O
serum - - O
samples - - O
, - - O
confirmed - - O
with - - O
reference - - O
to - - O
the - - O
sample - - O
data - - O
using - - O
the - - O
indirect - - O
ELISA - - O
kit - - O
. - - O

As - - O
a - - O
sequence-specific - - O
DNA - - O
binding - - O
transcription - - O
factor - - O
, - - O
p53 - - B-MUT
specifically - - O
binds - - O
to - - O
a - - O
20-bp - - B-MUT
consensus - - I-MUT
motif - - I-MUT
5'-PuPuPuC - - I-MUT
( - - I-MUT
A - - I-MUT
T - - I-MUT
) - - I-MUT
( - - I-MUT
T - - I-MUT
A - - I-MUT
) - - I-MUT
GPyPyPyPuPuPuC - - I-MUT
( - - I-MUT
A - - I-MUT
T - - I-MUT
) - - I-MUT
( - - I-MUT
T - - I-MUT
A - - I-MUT
) - - I-MUT
GPyPyPy-3' - - I-MUT
. - - I-MUT

Airflow - - O
was - - O
measured - - O
with - - O
a - - O
custom-designed - - O
turbine - - O
and - - O
a - - O
45-ft - - O
. - - O
-long - - O
cable - - O
to - - O
reach - - O
the - - O
volume-measuring - - O
module - - O
. - - O

Viral - - O
RNA - - O
, - - O
molecularly - - O
cloned - - O
proviral - - O
DNA - - O
, - - O
and - - O
virus-specific - - O
protein - - O
of - - O
avian - - O
retrovirus - - O
MH2 - - O
were - - O
analyzed - - O
. - - O

To - - O
study - - O
the - - O
mechanisms - - O
as - - O
well - - O
as - - O
magnitude - - O
of - - O
the - - O
transmembrane - - O
transfer - - O
of - - O
bacterial - - O
products - - O
from - - O
the - - O
dialysate - - O
, - - O
we - - O
developed - - O
a - - O
computerized - - O
in - - O
vitro - - O
dialysis - - O
model - - O
which - - O
provides - - O
continuous - - O
pressure - - O
recording - - O
from - - O
the - - O
arterial - - O
, - - O
venous - - O
, - - O
dialysate - - O
inflow - - O
and - - O
outflow - - O
ports - - O
. - - O

Mutations - - O
in - - O
the - - O
RP2 - - B-MUT
locus - - I-MUT
at - - I-MUT
Xp11 - - I-MUT
. - - I-MUT
3 - - I-MUT
were - - O
found - - O
in - - O
a - - O
further - - O
10-20% - - O
of - - O
XLRP - - O
patients - - O
, - - O
as - - O
predicted - - O
from - - O
linkage - - O
studies - - O
. - - O

There - - O
was - - O
a - - O
close - - O
correlation - - O
between - - O
plasma - - O
clearance - - O
of - - O
NT - - O
by - - O
10-hydroxylation - - O
and - - O
the - - O
D - - O
metabolic - - O
ratio - - O
( - - O
D - - O
4-OH-D - - O
in - - O
urine - - O
) - - O
in - - O
the - - O
Ghanaians - - O
( - - O
rs - - O
= - - O
-0 - - O
. - - O
95 - - O
; - - O
P - - O
less - - O
than - - O
0 - - O
. - - O
01 - - O
) - - O
and - - O
Swedes - - O
( - - O
rs - - O
= - - O
-0 - - O
. - - O
84 - - O
; - - O
P - - O
less - - O
than - - O
0 - - O
. - - O
01 - - O
) - - O
. - - O

METHODS - - O
: - - O
We - - O
studied - - O
20 - - O
symptomatic - - O
patients - - O
with - - O
HOCM - - O
( - - O
12 - - O
men - - O
) - - O
, - - O
mean - - O
age - - O
52 - - O
+ - - O
- - - O
17 - - O
years - - O
, - - O
before - - O
and - - O
after - - O
septal - - O
reduction - - O
using - - O
echocardiography - - O
and - - O
electrocardiogram - - O
( - - O
ECG - - O
) - - O
. - - O

The - - O
intensity - - O
of - - O
the - - O
SSTEs - - O
is - - O
an - - O
order - - O
of - - O
magnitude - - O
larger - - O
than - - O
that - - O
of - - O
the - - O
MSEs - - O
and - - O
determines - - O
the - - O
signal - - O
contrast - - O
if - - O
both - - O
effects - - O
are - - O
selected - - O
simultaneously - - O
. - - O

The - - O
limit - - O
between - - O
the - - O
cecum - - O
and - - O
the - - O
ascending - - O
colon - - O
was - - O
externally - - O
marked - - O
by - - O
the - - O
sulcus - - O
cecocolicus - - O
dorsalis - - O
and - - O
ventralis - - O
. - - O

Special - - O
issues - - O
devoted - - O
to - - O
the - - O
biosynthesis - - O
of - - O
woody - - O
plant - - O
biopolymers - - O
and - - O
related - - O
substances - - O
. - - O

Interestingly - - O
, - - O
Csx - - B-MUT
Nkx2 - - I-MUT
. - - I-MUT

Consequently - - O
, - - O
it - - O
is - - O
not - - O
known - - O
how - - O
knee - - O
loading - - O
changes - - O
following - - O
ACL - - O
transection - - O
, - - O
and - - O
how - - O
it - - O
contributes - - O
to - - O
cartilage - - O
degeneration - - O
. - - O

Increased - - O
PTHRP - - B-MUT
production - - O
by - - O
a - - O
tyrosine - - B-MUT
kinase - - I-MUT
oncogene - - I-MUT
, - - O
Tpr-Met - - B-MUT
: - - O
role - - O
of - - O
the - - O
Ras - - B-MUT
signaling - - O
pathway - - O
. - - O

The - - O
95% - - O
confidence - - O
values - - O
( - - O
2SD - - O
) - - O
for - - O
the - - O
change - - O
in - - O
Ros - - O
required - - O
to - - O
exclude - - O
natural - - O
variability - - O
were - - O
0 - - O
. - - O
39 - - O
, - - O
0 - - O
. - - O
50 - - O
and - - O
0 - - O
. - - O
53 - - O
cmH2O - - O
l-1 - - O
s - - O
, - - O
respectively - - O
. - - O

Expression - - O
of - - O
the - - O
proapoptotic - - B-MUT
protein - - I-MUT
Bax - - I-MUT
under - - O
the - - O
control - - O
of - - O
a - - O
GAL10 - - B-MUT
promoter - - I-MUT
in - - O
Saccharomyces - - O
cerevisiae - - O
resulted - - O
in - - O
galactose-inducible - - O
cell - - O
death - - O
. - - O

TSA - - O
treatment - - O
, - - O
however - - O
, - - O
did - - O
not - - O
detectably - - O
alter - - O
enhancer - - O
factor - - O
binding - - O
or - - O
the - - O
positioning - - O
of - - O
nuc-1 - - B-MUT
on - - O
the - - O
majority - - O
of - - O
the - - O
chromatin - - O
templates - - O
indicating - - O
that - - O
protein - - O
acetylation - - O
and - - O
chromatin - - O
remodeling - - O
may - - O
be - - O
limiting - - O
steps - - O
that - - O
occur - - O
only - - O
on - - O
transcriptionally - - O
competent - - O
templates - - O
, - - O
or - - O
that - - O
remodeling - - O
of - - O
nuc-1 - - B-MUT
requires - - O
additional - - O
factors - - O
. - - O

I - - O
. - - O

We - - O
analyzed - - O
the - - O
modular - - O
organization - - O
of - - O
DNA - - B-MUT
polymerase - - I-MUT
beta - - I-MUT
and - - O
found - - O
that - - O
residues - - O
making - - O
contact - - O
with - - O
DNA - - O
phosphates - - O
were - - O
localized - - O
to - - O
five - - O
modules - - O
. - - O

The - - O
effects - - O
initiated - - O
from - - O
the - - O
nucleus - - O
accumbens - - O
septi - - O
were - - O
most - - O
marked - - O
. - - O

Using - - O
various - - O
techniques - - O
, - - O
we - - O
have - - O
undertaken - - O
a - - O
systematic - - O
analysis - - O
of - - O
the - - O
natural - - O
TATA-less - - O
human - - B-MUT
DNA - - I-MUT
polymerase - - I-MUT
beta - - I-MUT
( - - O
beta-pol - - B-MUT
) - - O
gene - - O
promoter - - O
. - - O

The - - O
incidence - - O
of - - O
hepatitis - - B-MUT
B - - I-MUT
antigen - - I-MUT
following - - O
transfusion - - O
was - - O
about - - O
2 - - O
. - - O
8 - - O
per - - O
cent - - O
. - - O

Molecular - - O
neurochemistry - - O
of - - O
addictive - - O
drugs - - O
. - - O

Radiolabelled - - O
palmitate - - O
was - - O
not - - O
incorporated - - O
into - - O
the - - O
mutated - - O
protein - - O
, - - O
showing - - O
that - - O
lipid - - O
modification - - O
occurs - - O
at - - O
the - - O
Cys-22 - - O
residue - - O
. - - O

METHODS - - O
: - - O
Fibrotic - - O
changes - - O
involving - - O
bone - - O
marrow - - O
were - - O
evaluated - - O
histologically - - O
semiquantitatively - - O
using - - O
reticulin - - O
fiber - - O
impregnation - - O
( - - O
method - - O
of - - O
Gomori - - O
) - - O
. - - O

LPO - - O
and - - O
SOD - - B-MUT
levels - - O
were - - O
measured - - O
at - - O
five - - O
points - - O
before - - O
and - - O
during - - O
the - - O
operation - - O
. - - O

Acute - - O
experiments - - O
on - - O
nembutal-anesthetized - - O
cats - - O
( - - O
50 - - O
mg - - O
kg - - O
) - - O
were - - O
employed - - O
to - - O
investigate - - O
the - - O
effect - - O
of - - O
1 - - O
T - - O
pulsating - - O
magnetic - - O
field - - O
( - - O
PMF - - O
) - - O
on - - O
neuromuscular - - O
system - - O
of - - O
the - - O
leg - - O
. - - O

In - - O
contrast - - O
, - - O
2 - - O
, - - O
397 - - O
( - - O
74% - - O
) - - O
had - - O
one - - O
or - - O
more - - O
risk - - O
factors - - O
( - - O
not - - O
low - - O
risk - - O
) - - O
; - - O
of - - O
these - - O
, - - O
5 - - O
. - - O
3% - - O
died - - O
in - - O
6 - - O
weeks - - O
( - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
001 - - O
) - - O
. - - O

Activation - - O
of - - O
alpha - - B-MUT
4 - - I-MUT
beta - - I-MUT
1 - - I-MUT
with - - O
TS2 - - B-MUT
16 - - I-MUT
inhibited - - I-MUT
the - - O
cytoplasmic - - O
protrusions - - O
and - - O
cell - - O
migration - - O
but - - O
did - - O
not - - O
affect - - O
the - - O
pattern - - O
of - - O
phosphorylation - - O
. - - O

Mitomycin-C - - O
can - - O
cause - - O
severe - - O
necrosis - - O
and - - O
ulceration - - O
when - - O
extravasated - - O
inadvertently - - O
into - - O
skin - - O
and - - O
soft - - O
tissues - - O
following - - O
IV - - O
drug - - O
administration - - O
. - - O

The - - O
transposon-inactivated - - O
gene - - O
, - - O
designated - - O
pilP - - B-MUT
, - - O
is - - O
525 - - O
bp - - O
long - - O
, - - O
potentially - - O
encoding - - O
a - - O
19 - - O
. - - O
1-kDa - - O
protein - - O
precursor - - O
that - - O
contains - - O
a - - O
typical - - O
membrane - - O
lipoprotein - - O
leader - - O
sequence - - O
. - - O

Isolation - - O
of - - O
Aeromonas - - O
from - - O
faeces - - O
. - - O

The - - O
seco-steroid - - O
hormone - - O
1 - - O
, - - O
25-dihydroxyvitamin - - O
D3 - - O
is - - O
known - - O
to - - O
induce - - O
the - - O
expression - - O
of - - O
a - - O
calcium - - O
binding - - O
protein - - O
termed - - O
calbindin-D28K - - B-MUT
in - - O
a - - O
variety - - O
of - - O
target - - O
tissues - - O
. - - O

In - - O
all - - O
cases - - O
the - - O
antigenemia - - O
was - - O
transient - - O
and - - O
cleared - - O
by - - O
28th - - O
day - - O
post-vaccination - - O
. - - O

The - - O
interferon - - B-MUT
( - - O
IFN - - B-MUT
) - - O
-induced - - O
double-stranded - - B-MUT
RNA - - I-MUT
( - - I-MUT
dsRNA - - I-MUT
) - - I-MUT
-activated - - I-MUT
Ser - - I-MUT
Thr - - I-MUT
protein - - I-MUT
kinase - - I-MUT
( - - I-MUT
PKR - - O
) - - B-MUT
plays - - O
a - - O
role - - O
in - - O
the - - O
antiviral - - O
and - - O
antiproliferative - - O
effects - - O
of - - O
IFN - - O
. - - B-MUT

Differential - - O
association - - O
of - - O
products - - O
of - - O
alternative - - O
transcripts - - O
of - - O
the - - O
candidate - - O
tumor - - B-MUT
suppressor - - I-MUT
ING1 - - I-MUT
with - - O
the - - O
mSin3 - - B-MUT
HDAC1 - - O
transcriptional - - B-MUT
corepressor - - O
complex - - O
. - - O

Identical - - O
components - - O
of - - O
yeast - - O
transcription - - B-MUT
factor - - I-MUT
IIIB - - I-MUT
are - - O
required - - O
and - - O
sufficient - - O
for - - O
transcription - - O
of - - O
TATA - - O
box-containing - - O
and - - O
TATA-less - - O
genes - - O
. - - O

DNA-binding - - O
activity - - O
was - - O
not - - O
increased - - O
by - - O
the - - O
addition - - O
of - - O
forskolin - - O
to - - O
thecal - - O
or - - O
luteal - - O
cells - - O
. - - O

Badcock - - O
and - - O
Westheimer - - O
( - - O
Spatial - - O
Vision - - O
1 - - O
( - - O
1 - - O
) - - O
, - - O
3-11 - - O
, - - O
1985 - - O
) - - O
showed - - O
that - - O
a - - O
thin - - O
vertical - - O
line - - O
induces - - O
nearby - - O
zones - - O
of - - O
attraction - - O
and - - O
repulsion - - O
; - - O
this - - O
study - - O
extends - - O
those - - O
results - - O
by - - O
more - - O
closely - - O
examining - - O
the - - O
horizontal - - O
and - - O
vertical - - O
extents - - O
of - - O
the - - O
repulsion - - O
zone - - O
and - - O
by - - O
using - - O
an - - O
illusory - - O
contour - - O
to - - O
induce - - O
repulsion - - O
. - - O

Forty-one - - O
ASA - - O
physical - - O
status - - O
I - - O
or - - O
II - - O
adult - - O
patients - - O
undergoing - - O
a - - O
variety - - O
of - - O
1-1 - - O
. - - O
5 - - O
h - - O
surgical - - O
procedures - - O
were - - O
randomly - - O
allocated - - O
to - - O
receive - - O
CCA - - O
with - - O
desflurane - - O
or - - O
isoflurane - - O
with - - O
ventilation - - O
being - - O
either - - O
spontaneous - - O
or - - O
controlled - - O
. - - O

The - - O
codon - - O
usage - - O
is - - O
particularly - - O
marked - - O
for - - O
the - - O
gag - - B-MUT
, - - O
pol - - B-MUT
, - - O
and - - O
env - - B-MUT
genes - - I-MUT
. - - O

Premature - - O
initiation - - O
of - - O
mitosis - - O
in - - O
yeast - - O
lacking - - O
RCC1 - - B-MUT
or - - O
an - - O
interacting - - O
GTPase - - B-MUT
. - - O

Position-independent - - O
expression - - O
of - - O
a - - O
human - - B-MUT
nerve - - I-MUT
growth - - I-MUT
factor-luciferase - - I-MUT
reporter - - I-MUT
gene - - I-MUT
cloned - - O
on - - O
a - - O
yeast - - O
artificial - - O
chromosome - - O
vector - - O
. - - O

Judicious - - O
use - - O
of - - O
laboratory - - O
testing - - O
, - - O
including - - O
monitoring - - O
of - - O
CD4 - - B-MUT
cell - - O
counts - - O
, - - O
is - - O
recommended - - O
. - - O

Plasma - - O
Al - - O
was - - O
obtained - - O
during - - O
each - - O
baseline - - O
and - - O
drug - - O
course - - O
. - - O

The - - O
exploratory - - O
behaviour - - O
in - - O
normal - - O
and - - O
aggressive - - O
mice - - O
. - - O

31 - - O
, - - O
1997 - - O
, - - O
40 - - O
patients - - O
had - - O
died - - O
( - - O
35 - - O
in - - O
the - - O
ERA-II - - O
group - - O
and - - O
5 - - O
in - - O
the - - O
ERA-III - - O
group - - O
) - - O
, - - O
for - - O
a - - O
crude - - O
mortality - - O
rate - - O
of - - O
8 - - O
. - - O
0% - - O
. - - O

The - - O
relatively - - O
scanty - - O
number - - O
of - - O
examples - - O
, - - O
which - - O
could - - O
be - - O
justified - - O
by - - O
the - - O
variety - - O
and - - O
complexity - - O
of - - O
combined - - O
exposure - - O
, - - O
allows - - O
to - - O
conclude - - O
that - - O
life-style - - O
factors - - O
have - - O
considerable - - O
influence - - O
on - - O
interindividual - - O
differences - - O
in - - O
susceptibility - - O
to - - O
xenobiotics - - O
toxicity - - O
. - - O

However - - O
, - - O
the - - O
action - - O
of - - O
each - - O
cognate - - O
ligand - - O
and - - O
the - - O
accessory - - O
cellular - - O
factors - - O
that - - O
can - - O
differentially - - O
regulate - - O
the - - O
transcriptional - - O
responses - - O
of - - O
a - - O
heterodimer-DNA - - O
complex - - O
are - - O
not - - O
well - - O
understood - - O
. - - O

REM - - O
dream - - O
content - - O
was - - O
scored - - O
for - - O
categories - - O
suggesting - - O
the - - O
predominant - - O
influence - - O
of - - O
the - - O
left - - O
hemisphere - - O
, - - O
e - - O
. - - O
g - - O
. - - O
, - - O
good - - O
ego - - O
functioning - - O
, - - O
verbalization - - O
, - - O
or - - O
the - - O
right - - O
hemisphere - - O
, - - O
e - - O
. - - O
g - - O
. - - O
, - - O
music - - O
, - - O
spatial - - O
salience - - O
, - - O
bizarreness - - O
. - - O

We - - O
suggest - - O
that - - O
FlgN - - B-MUT
and - - O
FliT - - B-MUT
are - - O
substrate-specific - - O
flagellar - - O
chaperones - - O
that - - O
prevent - - O
oligomerization - - O
of - - O
the - - O
HAPs - - B-MUT
by - - O
binding - - O
to - - O
their - - O
helical - - O
domains - - O
before - - O
export - - O
. - - O

LY290181 - - O
appears - - O
to - - O
inhibit - - O
uPA - - B-MUT
promoter - - I-MUT
activation - - O
by - - O
blocking - - O
phorbol - - O
ester-stimulated - - O
binding - - O
of - - O
nuclear - - O
proteins - - O
to - - O
the - - O
uPA - - B-MUT
PEA3 - - B-MUT
12-0-tetradecanoylphorbol - - O
13-acetate - - B-MUT
responsive - - I-MUT
element - - I-MUT
( - - I-MUT
TRE - - O
) - - B-MUT
. - - O

Forty-five - - O
cases - - O
were - - O
surgically - - O
by - - O
direct - - O
approach - - O
to - - O
the - - O
tumour - - O
, - - O
while - - O
two - - O
cases - - O
were - - O
treated - - O
only - - O
with - - O
a - - O
shunt - - O
. - - O

In - - O
line - - O
with - - O
the - - O
small - - O
values - - O
for - - O
QS - - O
QC - - O
, - - O
our - - O
results - - O
further - - O
indicate - - O
that - - O
even - - O
large - - O
, - - O
well-perfused - - O
, - - O
occluded - - O
air - - O
spaces - - O
in - - O
the - - O
lung - - O
will - - O
hardly - - O
affect - - O
the - - O
recovered - - O
ventilation - - O
perfusion - - O
distribution - - O
obtained - - O
from - - O
inert - - O
gas - - O
data - - O
when - - O
CDCSF6 - - O
exceeds - - O
0 - - O
. - - O
1 - - O
ml - - O
. - - O
min-1 - - O
. - - O
mmHg-1 - - O
. - - O

All - - O
13 - - O
patients - - O
showed - - O
endoscopic - - O
evidence - - O
of - - O
oesophagitis - - O
, - - O
moderate - - O
in - - O
4 - - O
and - - O
severe - - O
in - - O
9 - - O
. - - O

A - - O
transformation-competent - - O
mutant - - O
, - - O
like - - O
the - - O
wild-type - - B-MUT
E5 - - I-MUT
protein - - I-MUT
, - - O
bound - - O
the - - O
receptor - - O
and - - O
induced - - O
receptor - - O
tyrosine - - O
phosphorylation - - O
and - - O
down-regulation - - O
. - - O

The - - O
location - - O
of - - O
the - - O
IBS - - O
within - - O
the - - O
catB - - B-MUT
structural - - I-MUT
gene - - I-MUT
, - - O
the - - O
cooperativity - - O
observed - - O
in - - O
footprinting - - O
studies - - O
and - - O
phasing - - O
studies - - O
suggest - - O
that - - O
the - - O
IBS - - O
participates - - O
in - - O
the - - O
interaction - - O
of - - O
CatR - - B-MUT
with - - O
the - - O
upstream - - O
binding - - O
sites - - O
by - - O
looping - - O
out - - O
the - - O
intervening - - O
DNA - - O
. - - O

The - - O
initial - - O
inpatient - - O
experience - - O
for - - O
individuals - - O
with - - O
HIV-related - - O
TB - - O
may - - O
be - - O
pivotal - - O
to - - O
the - - O
acceptance - - O
of - - O
and - - O
participation - - O
in - - O
ongoing - - O
TB - - O
care - - O
. - - O

T - - O
. - - O
, - - O
Patel - - O
, - - O
S - - O
. - - O

DNA - - O
sequence - - O
analysis - - O
showed - - O
that - - O
the - - O
gene - - O
was - - O
525 - - O
bp - - O
long - - O
and - - O
encoded - - O
a - - O
175-amino-acid - - O
protein - - O
with - - O
a - - O
molecular - - O
weight - - O
of - - O
19 - - O
, - - O
094 - - O
containing - - O
a - - O
21-residue - - O
typical - - O
lipoprotein - - O
signal - - O
peptide - - O
and - - O
consensus - - O
prolipoprotein - - O
processing - - O
site - - O
. - - O

Zn - - B-MUT
( - - I-MUT
II - - I-MUT
) - - I-MUT
coordination - - I-MUT
domain - - I-MUT
mutants - - I-MUT
of - - I-MUT
T4 - - I-MUT
gene - - I-MUT
32 - - I-MUT
protein - - I-MUT
. - - O

All - - O
of - - O
the - - O
indigo-producing - - O
bacteria - - O
had - - O
an - - O
indoxyl - - B-MUT
phosphatase - - I-MUT
with - - O
a - - O
pI - - O
of - - O
6 - - O
. - - O
4 - - O
. - - O

Xylose- - - O
and - - O
arabinose-containing - - O
polymers - - O
were - - O
better - - O
digested - - O
than - - O
was - - O
cellulose - - B-MUT
for - - O
both - - O
breads - - O
. - - O

Saturable - - O
spermidine - - O
transport - - O
in - - O
stk2 - - B-MUT
: - - O
: - - O
lacZ - - B-MUT
mutants - - I-MUT
had - - O
an - - O
approximately - - O
fivefold-lower - - O
affinity - - O
and - - O
twofold-lower - - O
Vmax - - O
than - - O
in - - O
the - - O
parental - - O
strain - - O
. - - O

Unlike - - O
other - - O
progenitor - - O
cells - - O
of - - O
the - - O
brain - - O
, - - O
SVZa - - O
progenitor - - O
cells - - O
have - - O
the - - O
capacity - - O
to - - O
divide - - O
even - - O
though - - O
they - - O
express - - O
a - - O
neuronal - - O
phenotype - - O
. - - O

The - - O
decrease - - O
of - - O
TNF - - B-MUT
receptors - - I-MUT
by - - O
IL-4 - - B-MUT
was - - O
accompanied - - O
by - - O
down-regulation - - O
of - - O
TNF-induced - - O
activities - - O
, - - O
including - - O
cytotoxicity - - O
, - - O
caspase-3 - - B-MUT
activation - - O
, - - O
NF-kappaB - - B-MUT
and - - O
AP-1 - - B-MUT
activation - - O
, - - O
and - - O
c-Jun - - B-MUT
N-terminal - - I-MUT
kinase - - I-MUT
induction - - O
. - - O

Here - - O
we - - O
report - - O
on - - O
the - - O
isolation - - O
of - - O
ICK2 - - B-MUT
, - - O
and - - O
show - - O
that - - O
it - - O
interacts - - O
with - - O
Cdc2aAt - - B-MUT
, - - O
but - - O
not - - O
with - - O
a - - O
second - - O
CDK - - B-MUT
from - - I-MUT
Arabidopsis - - I-MUT
, - - O
Cdc2bAt - - B-MUT
. - - O

Rac - - B-MUT
causes - - O
uncapping - - O
of - - O
actin - - B-MUT
filaments - - I-MUT
( - - O
F-actin - - B-MUT
) - - O
at - - O
the - - O
plus-ends - - O
, - - O
through - - O
phosphatidylinositol - - O
4 - - O
, - - O
5 - - O
bisphosphate - - O
( - - O
PIP2 - - O
) - - O
, - - O
and - - O
eventually - - O
induces - - O
membrane - - O
ruffling - - O
. - - O

Assays - - O
of - - O
total - - O
cholesterol - - O
as - - O
well - - O
as - - O
the - - O
HDL - - B-MUT
, - - O
HDL2 - - B-MUT
, - - O
LDL - - B-MUT
, - - O
triglycerides - - O
, - - O
endothelin-1 - - B-MUT
, - - O
lipoprotein - - B-MUT
( - - I-MUT
a - - I-MUT
) - - I-MUT
, - - O
estradiol - - O
and - - O
FSH - - B-MUT
were - - O
also - - O
obtained - - O
at - - O
baseline - - O
before - - O
receiving - - O
ERT - - O
and - - O
after - - O
3 - - O
months - - O
of - - O
ERT - - O
. - - O

These - - O
transcripts - - O
have - - O
a - - O
unique - - O
5'untranslated - - O
region - - O
and - - O
NH2-terminal - - O
sequence - - O
and - - O
encode - - O
a - - O
predicted - - O
protein - - O
of - - O
121 - - O
kD - - O
. - - O

Trinipatch - - O
is - - O
a - - O
small - - O
, - - O
transparent - - O
, - - O
matricial - - O
, - - O
monolayer - - O
patch - - O
with - - O
an - - O
absorption - - O
promoter - - O
, - - O
marketed - - O
in - - O
two - - O
dose-strengths - - O
( - - O
5 - - O
mg - - O
24 - - O
h - - O
and - - O
10 - - O
mg - - O
24 - - O
h - - O
) - - O
by - - O
Laboratoires - - O
Synthelabo - - O
. - - O

CONCLUSION - - O
: - - O
Some - - O
Gulf - - O
War - - O
veterans - - O
may - - O
have - - O
delayed - - O
, - - O
chronic - - O
neurotoxic - - O
syndromes - - O
from - - O
wartime - - O
exposure - - O
to - - O
combinations - - O
of - - O
chemicals - - O
that - - O
inhibit - - O
butyrylcholinesterase - - B-MUT
and - - O
neuropathy - - B-MUT
target - - I-MUT
esterase - - I-MUT
. - - O

The - - O
activity - - O
of - - O
6-fluoroquinolones - - O
and - - O
their - - O
nonfluorinated - - O
derivatives - - O
is - - O
compared - - O
in - - O
general - - O
. - - O

Lars - - O
has - - O
AIDS--a - - O
more - - O
dignified - - O
life - - O
with - - O
care - - O
at - - O
home - - O
. - - O

Transcriptional - - O
regulators - - O
utilizing - - O
the - - O
POU - - B-MUT
domain - - I-MUT
DNA-binding - - O
motif - - O
have - - O
been - - O
shown - - O
to - - O
form - - O
multi-protein - - O
complexes - - O
dependent - - O
on - - O
the - - O
POU - - B-MUT
domain - - I-MUT
itself - - O
and - - O
its - - O
flexible - - O
recognition - - O
of - - O
various - - O
octamer - - O
sequence - - O
elements - - O
. - - O

These - - O
elements - - O
comprise - - O
a - - O
binding - - O
site - - O
for - - O
Krox - - B-MUT
proteins - - I-MUT
, - - O
one - - O
for - - O
nuclear - - B-MUT
factor - - I-MUT
1 - - I-MUT
, - - O
an - - O
octamer - - O
motif - - O
that - - O
binds - - O
POU-homeodomain - - B-MUT
proteins - - I-MUT
, - - O
and - - O
a - - O
novel - - O
TN - - B-MUT
control - - I-MUT
element - - I-MUT
. - - O

In - - O
this - - O
study - - O
the - - O
splenectomized - - O
captive - - O
born - - O
cynomolgus - - O
appeared - - O
to - - O
be - - O
capable - - O
of - - O
supplementing - - O
rhesus - - O
as - - O
an - - O
antimalarial - - O
drug - - O
testing - - O
model - - O
. - - O

It - - O
has - - O
been - - O
calculated - - O
that - - O
600 - - O
, - - O
000 - - O
new - - O
cases - - O
of - - O
lung - - O
cancer - - O
occur - - O
worldwide - - O
every - - O
year - - O
, - - O
most - - O
of - - O
them - - O
due - - O
to - - O
smoking - - O
. - - O

In - - O
this - - O
manuscript - - O
we - - O
demonstrate - - O
that - - O
two - - O
tandem - - B-MUT
Ets - - I-MUT
sites - - I-MUT
in - - O
the - - O
mouse - - B-MUT
GL - - I-MUT
alpha - - I-MUT
promoter - - I-MUT
bind - - O
the - - O
transcription - - B-MUT
factors - - I-MUT
Elf-1 - - I-MUT
and - - O
PU - - B-MUT
. - - I-MUT
1 - - I-MUT
, - - O
and - - O
that - - O
the - - O
3' - - O
site - - O
is - - O
essential - - O
for - - O
expression - - O
of - - O
a - - O
luciferase - - B-MUT
reporter - - I-MUT
gene - - I-MUT
driven - - O
by - - O
the - - O
GL - - B-MUT
alpha - - I-MUT
promoter - - I-MUT
. - - O

The - - O
mean - - O
total - - O
white - - O
cell - - O
count - - O
increased - - O
from - - O
a - - O
baseline - - O
of - - O
11 - - O
. - - O
3 - - O
x - - O
10 - - O
( - - O
9 - - O
) - - O
L - - O
( - - O
SD - - O
2 - - O
. - - O
3 - - O
) - - O
to - - O
16 - - O
. - - O
2 - - O
x - - O
10 - - O
( - - O
9 - - O
) - - O
L - - O
( - - O
SD - - O
4 - - O
. - - O
6 - - O
) - - O
on - - O
day - - O
1 - - O
, - - O
normalising - - O
thereafter - - O
. - - O

The - - O
level - - O
of - - O
serum - - B-MUT
creatine - - I-MUT
kinase - - I-MUT
was - - O
significantly - - O
high - - O
2 - - O
days - - O
after - - O
ESWIB - - O
, - - O
but - - O
it - - O
recovered - - O
in - - O
a - - O
week - - O
. - - O

The - - O
results - - O
show - - O
that - - O
nerve - - O
and - - O
roots - - O
differ - - O
considerably - - O
both - - O
in - - O
the - - O
force - - O
they - - O
sustain - - O
before - - O
failure - - O
and - - O
in - - O
the - - O
other - - O
biomechanics - - O
they - - O
exhibit - - O
. - - O

FLP - - B-MUT
and - - O
Cre - - B-MUT
recombinase - - I-MUT
function - - O
in - - O
Xenopus - - O
embryos - - O
. - - O

We - - O
detected - - O
no - - O
effect - - O
of - - O
deleting - - O
YCL024W - - B-MUT
, - - O
either - - O
alone - - O
or - - O
in - - O
combination - - O
with - - O
deletion - - O
of - - O
GIN4 - - B-MUT
. - - O

Recombinant - - B-MUT
AROM-p64 - - I-MUT
displayed - - O
high - - O
binding - - O
to - - O
single-stranded - - O
DNA - - O
and - - O
poly - - O
( - - O
A - - O
) - - O
homopolymers - - O
suggesting - - O
that - - O
this - - O
protein - - O
could - - O
play - - O
a - - O
role - - O
in - - O
mRNA - - O
maturation - - O
metabolism - - O
. - - O

In - - O
our - - O
studies - - O
, - - O
we - - O
utilized - - O
HIV-1 - - O
HXB2 - - B-MUT
and - - O
HIV-1 - - O
Z2Z6 - - B-MUT
core - - I-MUT
enhancers - - I-MUT
because - - O
the - - O
Z2Z6 - - O
strain - - O
has - - O
a - - O
single - - O
point - - O
mutation - - O
flanking - - O
the - - O
right - - O
ETS-binding - - B-MUT
site - - I-MUT
. - - O

Four - - O
short - - O
nucleotide - - O
sequences - - O
( - - O
boxes - - B-MUT
I - - I-MUT
to - - I-MUT
IV - - I-MUT
) - - O
contribute - - O
to - - O
the - - O
light - - O
responsiveness - - O
of - - O
the - - O
parsley - - B-MUT
chalcone - - I-MUT
synthase - - I-MUT
promoter - - I-MUT
. - - O

ZEBRA - - B-MUT
and - - O
cellular - - O
AP-1 - - B-MUT
bZip - - I-MUT
activators - - I-MUT
, - - O
such - - O
as - - O
c-Fos - - B-MUT
, - - O
have - - O
homologous - - O
DNA-binding - - O
domains - - O
, - - O
and - - O
their - - O
DNA-binding - - O
specificities - - O
overlap - - O
. - - O

Drug - - O
effect - - O
, - - O
measured - - O
as - - O
postural - - O
sway - - O
, - - O
was - - O
also - - O
similar - - O
in - - O
the - - O
patients - - O
with - - O
cirrhosis - - O
and - - O
control - - O
subjects - - O
; - - O
therefore - - O
the - - O
ratio - - O
of - - O
effect - - O
area - - O
under - - O
the - - O
curve - - O
to - - O
concentration - - O
area - - O
under - - O
the - - O
curve - - O
, - - O
a - - O
measure - - O
of - - O
sensitivity - - O
, - - O
did - - O
not - - O
differ - - O
significantly - - O
between - - O
the - - O
patients - - O
with - - O
cirrhosis - - O
and - - O
the - - O
control - - O
subjects - - O
. - - O

Damage - - O
to - - O
the - - O
BBB - - O
was - - O
judged - - O
by - - O
extravasation - - O
of - - O
Evans - - O
Blue - - O
( - - O
EB - - O
) - - O
dye - - O
, - - O
which - - O
was - - O
administered - - O
either - - O
2 - - O
, - - O
3 - - O
, - - O
24 - - O
or - - O
48 - - O
h - - O
after - - O
onset - - O
of - - O
MCAo - - O
. - - O

At - - O
the - - O
carboxyl - - O
terminus - - O
, - - O
deletion - - O
as - - O
far - - O
as - - O
residue - - O
388 - - O
did - - O
not - - O
affect - - O
in - - O
vitro - - O
TRF - - B-MUT
. - - I-MUT
C - - I-MUT
assembly - - O
, - - O
although - - O
trans-activating - - O
activity - - O
was - - O
abolished - - O
. - - O

The - - O
procedure - - O
facilitated - - O
the - - O
retention - - O
of - - O
a - - O
mandibular - - O
molar - - O
with - - O
a - - O
Class - - O
III - - O
FI - - O
in - - O
a - - O
manner - - O
acceptable - - O
to - - O
both - - O
the - - O
patient - - O
and - - O
the - - O
clinician - - O
. - - O

Histological - - O
signs - - O
of - - O
the - - O
flare-up - - O
reaction - - O
were - - O
already - - O
present - - O
at - - O
6 - - O
hr - - O
after - - O
i - - O
. - - O
v - - O
. - - O
challenge - - O
and - - O
lasted - - O
for - - O
at - - O
least - - O
4 - - O
days - - O
. - - O

Moxidectin - - O
( - - O
at - - O
3 - - O
times - - O
the - - O
therapeutic - - O
dose - - O
) - - O
did - - O
not - - O
have - - O
deleterious - - O
effects - - O
on - - O
cow - - O
reproductive - - O
performance - - O
as - - O
examined - - O
( - - O
eg - - O
, - - O
at - - O
folliculogenesis - - O
, - - O
ovulation - - O
, - - O
and - - O
the - - O
early - - O
embryonic - - O
phase - - O
of - - O
development - - O
) - - O
. - - O

To - - O
this - - O
end - - O
, - - O
an - - O
expression - - O
cassette - - O
consisting - - O
of - - O
the - - O
gene - - O
for - - O
a - - O
green - - B-MUT
fluorescent - - I-MUT
protein - - I-MUT
( - - O
GFP - - B-MUT
) - - O
flanked - - O
at - - O
its - - O
3' - - O
end - - O
by - - O
EAV-specific - - O
transcription-regulating - - O
sequences - - O
was - - O
constructed - - O
. - - O

Promoter - - O
recognition - - O
algorithms - - O
identified - - O
divergent - - O
promoter - - O
elements - - O
within - - O
the - - O
CpG - - O
island - - O
, - - O
which - - O
lies - - O
between - - O
the - - O
ATM - - B-MUT
and - - O
E14 - - B-MUT
NPAT - - I-MUT
genes - - I-MUT
, - - I-MUT
and - - O
provide - - O
evidence - - O
for - - O
a - - O
putative - - O
second - - O
ATM - - O
promoter - - B-MUT
located - - I-MUT
within - - O
intron - - O
3 - - O
, - - O
immediately - - O
upstream - - O
of - - O
the - - O
first - - O
coding - - O
exon - - O
. - - O

A - - O
retrospective - - O
epidemiological - - O
study - - O
is - - O
reported - - O
concerning - - O
burn - - O
injuries - - O
in - - O
775 - - O
children - - O
hospitalized - - O
at - - O
the - - O
unit - - O
of - - O
burn - - O
care - - O
of - - O
Casablanca - - O
between - - O
1985 - - O
and - - O
1993 - - O
. - - O

Thus - - O
, - - O
SAG - - B-MUT
appears - - O
to - - O
control - - O
cell - - O
cycle - - O
progression - - O
in - - O
yeast - - O
by - - O
promoting - - O
ubiquitination - - O
and - - O
degradation - - O
of - - O
cell - - O
cycle - - O
regulatory - - O
proteins - - O
. - - O

The - - O
main - - O
issues - - O
are - - O
the - - O
need - - O
to - - O
explain - - O
a - - O
number - - O
of - - O
still - - O
unknown - - O
mechanisms - - O
, - - O
to - - O
determine - - O
which - - O
"natural - - O
diet" - - O
carries - - O
the - - O
minimum - - O
coronary - - O
risk - - O
and - - O
whether - - O
"new" - - O
foods - - O
produced - - O
by - - O
modern - - O
technology - - O
are - - O
really - - O
needed - - O
to - - O
contrast - - O
this - - O
epidemic - - O
. - - O

BACKGROUND - - O
: - - O
Diazepam - - O
, - - O
one - - O
of - - O
the - - O
benzodiazepine - - O
group - - O
of - - O
tranquilizers - - O
, - - O
is - - O
used - - O
as - - O
an - - O
adjunctive - - O
drug - - O
for - - O
sedation - - O
and - - O
for - - O
relief - - O
of - - O
anxiety - - O
in - - O
the - - O
treatment - - O
of - - O
epilepsy - - O
. - - O

Hippocampal - - O
stimulation - - O
overlapping - - O
conditioned - - O
stimulus - - O
preexposure - - O
produced - - O
attenuation - - O
of - - O
latent - - O
inhibition - - O
, - - O
as - - O
did - - O
stimulation - - O
presented - - O
during - - O
conditioning - - O
after - - O
preexposure - - O
. - - O

Taken - - O
together - - O
, - - O
our - - O
results - - O
indicate - - O
that - - O
thrombin-stimulated - - O
vascular - - O
smooth - - O
muscle - - O
proliferation - - O
is - - O
delayed - - O
and - - O
requires - - O
the - - O
de - - O
novo - - O
expression - - O
of - - O
one - - O
or - - O
more - - O
autocrine - - O
mitogens - - O
. - - O

However - - O
, - - O
five - - O
new - - O
mutation - - O
sites - - O
( - - O
S61 - - B-MUT
, - - O
SL1 - - B-MUT
, - - O
S29 - - B-MUT
, - - O
SL11 - - B-MUT
, - - O
SL196 - - B-MUT
and - - O
SL126 - - B-MUT
) - - O
are - - O
unique - - O
to - - O
the - - O
nrdB - - B-MUT
intron - - O
and - - O
disrupt - - O
self-splicing - - O
. - - O

The - - O
murine - - O
chromosomal - - O
locations - - O
of - - O
the - - O
five - - O
NMDA - - B-MUT
receptor - - I-MUT
channel - - I-MUT
subunits - - I-MUT
, - - O
the - - O
epsilon - - B-MUT
1 - - I-MUT
( - - O
Grin2a - - B-MUT
) - - O
, - - O
epsilon - - B-MUT
2 - - I-MUT
( - - O
Grin2b - - B-MUT
) - - O
, - - O
epsilon - - B-MUT
3 - - I-MUT
( - - O
Grin2c - - B-MUT
) - - O
, - - O
epsilon - - B-MUT
4 - - I-MUT
( - - O
Grin2d - - B-MUT
) - - O
and - - O
zeta - - B-MUT
1 - - I-MUT
( - - O
Grinl - - B-MUT
) - - O
subunits - - O
, - - O
were - - O
determined - - O
using - - O
an - - O
interspecific - - O
backcross - - O
mapping - - O
panel - - O
derived - - O
from - - O
crosses - - O
of - - O
[ - - O
( - - O
C57BL - - O
6JxM - - O
. - - O
spretus - - O
) - - O
F1xC57BL - - O
6J - - O
] - - O
mice - - O
. - - O

Surprisingly - - O
, - - O
however - - O
, - - O
TCR-mediated - - O
tyrosine - - O
phosphorylation - - O
of - - O
phospholipase - - B-MUT
C - - I-MUT
gamma - - I-MUT
1 - - I-MUT
remains - - O
intact - - O
in - - O
the - - O
Jurkat - - O
cells - - O
expressing - - O
the - - O
A2 - - B-MUT
HCP - - I-MUT
chimera - - I-MUT
. - - O

Serum - - B-MUT
creatine - - I-MUT
kinase - - I-MUT
( - - O
SCK - - B-MUT
) - - O
was - - O
measured - - O
in - - O
ten - - O
subjects - - O
in - - O
the - - O
laboratory - - O
before - - O
and - - O
after - - O
the - - O
performance - - O
of - - O
bicycle - - O
ergometry - - O
and - - O
a - - O
lifting - - O
task - - O
. - - O

N - - O
. - - O
, - - O
and - - O
Fanning - - O
, - - O
E - - O
. - - O

This - - O
indicates - - O
that - - O
under - - O
certain - - O
experimental - - O
conditions - - O
cdc2 - - B-MUT
p58 - - I-MUT
and - - I-MUT
cdc2 - - O
p62 - - B-MUT
may - - I-MUT
express - - I-MUT
some - - O
differences - - O
in - - O
their - - O
catalytic - - O
activity - - O
. - - O

Plasma - - B-MUT
histaminase - - I-MUT
in - - O
patients - - O
of - - O
bronchial - - O
asthma - - O
and - - O
the - - O
effect - - O
of - - O
prednisolone - - O
administration - - O
on - - O
it - - O
. - - O

40 - - O
. - - O
3 - - O
+ - - O
- - - O
10 - - O
. - - O
1 - - O
mg - - O
l - - O
( - - O
SD - - O
) - - O
vs - - O
31 - - O
. - - O
2 - - O
+ - - O
- - - O
8 - - O
. - - O
0 - - O
, - - O
P - - O
less - - O
than - - O
0 - - O
. - - O
01 - - O
) - - O
. - - O
beta - - O
2m - - O
was - - O
not - - O
significantly - - O
higher - - O
in - - O
patients - - O
with - - O
bone - - O
cysts - - O
( - - O
37 - - O
. - - O
7 - - O
+ - - O
- - - O
11 - - O
. - - O
4 - - O
mg - - O
l - - O
vs - - O
37 - - O
. - - O
0 - - O
+ - - O
- - - O
10 - - O
. - - O
0 - - O
) - - O
, - - O
but - - O
median - - O
duration - - O
of - - O
dialysis - - O
was - - O
significantly - - O
( - - O
P - - O
less - - O
than - - O
0 - - O
. - - O
01 - - O
) - - O
longer - - O
in - - O
patients - - O
with - - O
bone - - O
cysts - - O
( - - O
90 - - O
vs - - O
57 - - O
months - - O
) - - O
. - - O
beta - - O
2m - - O
was - - O
lower - - O
in - - O
patients - - O
maintained - - B-MUT
on - - I-MUT
dialysis - - O
for - - O
less - - O
than - - O
1 - - O
year - - O
and - - O
whose - - O
residual - - O
urine - - O
volume - - O
was - - O
greater - - O
than - - O
0 - - O
. - - O
1 - - O
litre - - O
per - - O
day - - O
. - - O

The - - O
susceptibility - - O
of - - O
Aspergillus - - O
fumigatus - - O
to - - O
mulundocandin - - O
, - - O
an - - O
echinocandin-like - - O
compound - - O
, - - O
and - - O
other - - O
antifungal - - O
agents - - O
was - - O
assessed - - O
by - - O
the - - O
National - - O
Committee - - O
for - - O
Clinical - - O
Laboratory - - O
Standards - - O
( - - O
NCCLS - - O
) - - O
M38-P - - O
method - - O
, - - O
a - - O
2 - - O
, - - O
3-bis - - O
( - - O
2-methoxy-4-nitro-5-sulfophenyl - - O
) - - O
-5- - - O
[ - - O
( - - O
phenyl-amino - - O
) - - O
carbonyl - - O
] - - O
-2H-tetrazolium - - O
hydroxide - - O
( - - O
XTT - - O
) - - O
-based - - O
colorimetric - - O
assay - - O
, - - O
and - - O
determination - - O
of - - O
morphologic - - O
alterations - - O
by - - O
microscopy - - O
. - - O

The - - O
authors - - O
report - - O
a - - O
case - - O
in - - O
which - - O
stereotactic - - O
irrigation - - O
of - - O
a - - O
brain - - O
cyst - - O
was - - O
temporally - - O
associated - - O
with - - O
respiratory - - O
distress - - O
. - - O

Number - - O
of - - O
patients - - O
infected - - O
with - - O
nontuberculous - - O
mycobacteria - - O
( - - O
NTM - - O
) - - O
is - - O
increasing - - O
world-wide - - O
in - - O
recent - - O
years - - O
. - - O

An - - O
F222W - - B-MUT
: - - I-MUT
W21F - - I-MUT
rGST - - I-MUT
A1-1 - - I-MUT
double - - I-MUT
mutant - - I-MUT
provides - - O
a - - O
direct - - O
fluorescence - - O
probe - - O
of - - O
changes - - O
in - - O
the - - O
environment - - O
of - - O
the - - O
C-terminal - - O
residue - - O
. - - O

Comparison - - O
of - - O
the - - O
plant - - B-MUT
nuclear - - I-MUT
tRNA - - I-MUT
3' - - I-MUT
processing - - I-MUT
enzyme - - I-MUT
with - - O
the - - O
plant - - O
mitochondrial - - O
one - - O
suggests - - O
that - - O
both - - O
activities - - O
are - - O
different - - O
enzymes - - O
. - - O

DtxR - - B-MUT
is - - O
an - - O
iron-dependent - - O
sequence-specific - - O
DNA-binding - - O
protein - - O
that - - O
binds - - O
to - - O
the - - O
tox - - B-MUT
operator - - I-MUT
, - - O
an - - O
inverted-repeat - - O
nucleotide - - O
sequence - - O
located - - O
upstream - - O
from - - O
the - - O
diphtheria - - B-MUT
toxin - - I-MUT
gene - - I-MUT
. - - O

Cerebral125 - - B-MUT
albumin - - I-MUT
was - - O
increased - - O
to - - O
similar - - O
proportions - - O
in - - O
those - - O
groups - - O
submitted - - O
to - - O
hyperosmolality - - O
. - - O

Laboratory - - O
studies - - O
using - - O
Ca45 - - O
labeled - - O
teeth - - O
and - - O
biologically - - O
stained - - O
teeth - - O
confirmed - - O
that - - O
the - - O
dentifrice - - O
did - - O
not - - O
decalcify - - O
enamel - - O
or - - O
bleach - - O
teeth - - O
. - - O

Autonomic - - O
dysfunctions - - O
were - - O
restricted - - O
to - - O
tonic - - O
pupils - - O
. - - O

Results - - O
from - - O
the - - O
mechanism - - O
study - - O
have - - O
revealed - - O
that - - O
YY1 - - B-MUT
is - - O
able - - O
to - - O
inhibit - - O
transactivation - - O
mediated - - O
by - - O
either - - O
AP1 - - B-MUT
or - - O
the - - O
Sp1-related - - B-MUT
protein - - I-MUT
, - - O
and - - O
YY1 - - B-MUT
suppressive - - O
activity - - O
is - - O
DNA - - O
binding - - O
dependent - - O
. - - O

The - - O
men - - O
self-selected - - O
a - - O
prescribed - - O
diet - - O
at - - O
home - - O
emphasizing - - O
saturated - - O
fat - - O
as - - O
the - - O
visible - - O
fat - - O
for - - O
1 - - O
week - - O
. - - O

By - - O
analyzing - - O
the - - O
RanGAP - - B-MUT
activity - - O
of - - O
a - - O
series - - O
of - - O
recombinantly - - O
expressed - - O
rna1p - - B-MUT
mutant - - I-MUT
derivatives - - O
, - - O
we - - O
show - - O
that - - O
the - - O
highly - - O
acidic - - O
sequence - - O
in - - O
the - - O
C-terminal - - O
domain - - O
of - - O
both - - O
yeast - - O
proteins - - O
is - - O
indispensable - - O
for - - O
activating - - O
Ran-mediated - - O
GTP - - O
hydrolysis - - O
. - - O

One - - O
patients - - O
had - - O
plasma - - B-MUT
C-peptide - - I-MUT
greater - - O
than - - O
3 - - O
pM - - O
and - - O
was - - O
therefore - - O
excluded - - O
from - - O
analysis - - O
. - - O

NF-kappa - - B-MUT
B - - I-MUT
p65 - - B-MUT
, - - O
p50 - - B-MUT
, - - O
and - - O
Rel - - B-MUT
functionally - - O
synergize - - O
with - - O
C - - B-MUT
EBP - - I-MUT
alpha - - I-MUT
, - - I-MUT
C - - O
EBP - - B-MUT
beta - - I-MUT
, - - I-MUT
and - - I-MUT
C - - O
EBP - - O
delta - - B-MUT
. - - I-MUT

Cryoglobulinemia - - O
in - - O
Raynaud's - - O
syndrome - - O
. - - O

Freezing - - O
of - - O
plasma - - O
to - - O
obtain - - O
better - - O
yield - - O
of - - O
factor - - B-MUT
VIII - - I-MUT
: - - O
C - - O
. - - O

A - - O
polymorphic - - O
dinucleotide - - O
( - - O
GT - - O
CA - - O
) - - O
n - - O
repeat - - O
contained - - O
in - - O
the - - O
NHE5 - - O
cosmid - - O
was - - O
identified - - O
and - - O
developed - - O
into - - O
a - - O
microsatellite - - O
PCR - - O
marker - - O
. - - O

In - - O
the - - O
VA-SMV - - O
mode - - O
, - - O
the - - O
connection - - O
was - - O
made - - O
with - - O
valved - - O
conduits - - O
from - - O
the - - O
LV - - O
apex - - O
( - - O
inflow - - O
) - - O
to - - O
the - - O
ascending - - O
aorta - - O
( - - O
outflow - - O
) - - O
( - - O
n - - O
= - - O
11 - - O
) - - O
or - - O
to - - O
the - - O
DAo - - O
( - - O
n - - O
= - - O
12 - - O
) - - O
. - - O

To - - O
circumvent - - O
this - - O
problem - - O
, - - O
a - - O
simple - - O
two-step - - O
strategy - - O
was - - O
devised - - O
by - - O
which - - O
essential - - O
cis-acting - - O
sites - - O
like - - O
the - - O
a - - O
sequence - - O
can - - O
be - - O
readily - - O
deleted - - O
from - - O
their - - O
natural - - O
loci - - O
in - - O
large - - O
viral - - O
DNA - - O
genomes - - O
. - - O

The - - O
reduction - - O
in - - O
saturated - - O
fatty - - O
acids - - O
intake - - O
led - - O
to - - O
modest - - O
( - - O
but - - O
in - - O
group - - O
1 - - O
significant - - O
) - - O
0 - - O
. - - O
15 - - O
mmol - - O
l - - O
( - - O
2 - - O
. - - O
5% - - O
) - - O
reduction - - O
in - - O
total - - O
serum - - O
cholesterol - - O
level - - O
. - - O

We - - O
cloned - - O
a - - O
DNA - - O
fragment - - O
encoding - - O
the - - O
N-terminal - - O
part - - O
of - - O
a - - O
protein - - O
with - - O
significant - - O
similarity - - O
to - - O
members - - O
of - - O
the - - O
LysR - - B-MUT
family - - I-MUT
of - - I-MUT
transcriptional - - I-MUT
regulators - - I-MUT
( - - O
LTTRs - - B-MUT
) - - O
. - - O

Advances - - O
in - - O
hemophilia - - O
treatment - - O
: - - O
a - - O
hepatitis-safe - - O
factor - - B-MUT
VIII - - I-MUT
concentrate - - O
. - - O

The - - O
records - - O
from - - O
1948 - - O
through - - O
1967 - - O
of - - O
344 - - O
previously - - O
untreated - - O
patients - - O
with - - O
squamous - - O
cell - - O
carcinoma - - O
of - - O
the - - O
oral - - O
cavity - - O
, - - O
oropharynx - - O
, - - O
supraglottic - - O
larynx - - O
and - - O
hypopharynx - - O
who - - O
had - - O
clinically - - O
positive - - O
cervical - - O
lymph - - O
node - - O
metastases - - O
staged - - O
N1 - - O
, - - O
N2A - - O
, - - O
or - - O
N2B - - O
, - - O
and - - O
whose - - O
initial - - O
neck - - O
treatment - - O
consisted - - O
of - - O
external - - O
radiation - - O
therapy - - O
alone - - O
were - - O
reviewed - - O
. - - O

A - - O
comparative - - O
analysis - - O
of - - O
the - - O
reported - - O
MOCT-associated - - O
malignant - - O
melanomas - - O
emphasizes - - O
the - - O
singularity - - O
of - - O
our - - O
case - - O
in - - O
the - - O
amelanotic - - O
character - - O
of - - O
the - - O
melanoma - - O
, - - O
its - - O
lymphotropism - - O
and - - O
the - - O
coexistence - - O
of - - O
invasive - - O
squamous - - O
cell - - O
carcinoma - - O
. - - O

The - - O
remaining - - O
RAD+ - - B-MUT
cells - - O
progressed - - O
to - - O
form - - O
microcolonies - - O
( - - O
< - - O
30 - - O
cells - - O
) - - O
containing - - O
aberrantly - - O
shaped - - O
inviable - - O
cells - - O
. - - O

Increasing - - O
the - - O
phosphorus - - O
content - - O
of - - O
the - - O
diet - - O
improved - - O
the - - O
reabsorption - - O
of - - O
calcium - - O
and - - O
magnesium - - O
. - - O

Characterization - - O
of - - O
an - - O
EcR - - B-MUT
USP - - I-MUT
heterodimer - - I-MUT
target - - I-MUT
site - - I-MUT
that - - I-MUT
mediates - - O
ecdysone - - O
responsiveness - - O
of - - O
the - - O
Drosophila - - O
Lsp-2 - - B-MUT
gene - - I-MUT
. - - I-MUT

Drug - - O
inhibition - - O
of - - O
whole - - O
blood - - O
aspirin - - B-MUT
esterase - - I-MUT
. - - O

The - - O
actuarial - - O
local - - O
control - - O
rates - - O
at - - O
10 - - O
years - - O
for - - O
the - - O
three - - O
treatment - - O
groups - - O
were - - O
as - - O
follows - - O
: - - O
subtotal - - O
excision - - O
alone - - O
, - - O
18% - - O
; - - O
subtotal - - O
excision - - O
plus - - O
postoperative - - O
radiation - - O
therapy - - O
, - - O
82% - - O
; - - O
and - - O
total - - O
excision - - O
alone - - O
, - - O
77% - - O
. - - O

It - - O
is - - O
related - - O
to - - O
a - - O
variety - - O
of - - O
mammalian - - O
Golgi-associated - - O
proteins - - O
and - - O
to - - O
the - - O
yeast - - O
Uso1p - - B-MUT
, - - O
an - - O
essential - - O
protein - - O
involved - - O
in - - O
docking - - O
of - - O
endoplasmic - - O
reticulum-derived - - O
vesicles - - O
to - - O
the - - O
cis-Golgi - - O
. - - O

We - - O
found - - O
three - - O
out - - O
of - - O
four - - O
original - - O
( - - O
Volkan's - - O
) - - O
groups - - O
of - - O
linking - - O
objects - - O
, - - O
but - - O
also - - O
an - - O
additional - - O
one - - O
, - - O
hitherto - - O
undescribed - - O
, - - O
comprising - - O
objects - - O
used - - O
for - - O
designing - - O
a - - O
memorial - - O
shrine - - O
to - - O
the - - O
deceased - - O
. - - O

To - - O
examine - - O
whether - - O
thiamine - - O
( - - O
vitamin - - O
B1 - - O
) - - O
deficiency - - O
is - - O
associated - - O
with - - O
recurrent - - O
aphthous - - O
stomatitis - - O
, - - O
we - - O
studied - - O
vitamin - - O
B1 - - O
levels - - O
in - - O
70 - - O
patients - - O
with - - O
recurrent - - O
aphthous - - O
stomatitis - - O
and - - O
in - - O
50 - - O
members - - O
of - - O
a - - O
control - - O
group - - O
. - - O

The - - O
upstream - - O
delta-alpha - - O
breakpoint - - O
is - - O
flanked - - O
by - - O
the - - O
direct - - O
repeats - - O
of - - O
the - - O
acceptor - - O
splice - - O
site - - O
, - - O
whereas - - O
the - - O
down-stream - - O
alpha-delta - - O
breakpoint - - O
is - - O
located - - O
in - - O
the - - O
adjacent - - O
intron - - O
. - - O

Like - - O
Epo - - B-MUT
, - - O
HNF-4 - - B-MUT
is - - O
expressed - - O
in - - O
kidney - - O
, - - O
liver - - O
, - - O
and - - O
Hep3B - - O
cells - - O
but - - O
not - - O
in - - O
HeLa - - O
cells - - O
. - - O

The - - O
centromeric - - O
YAC - - O
contig - - O
, - - O
which - - O
consists - - O
of - - O
23 - - O
overlapping - - O
YACs - - O
and - - O
orders - - O
19 - - O
sequence-tagged - - O
sites - - O
( - - O
STSs - - O
) - - O
, - - O
covers - - O
a - - O
minimum - - O
of - - O
2 - - O
. - - O
2 - - O
Mb - - O
and - - O
spans - - O
the - - O
Ewing - - O
sarcoma - - O
breakpoint - - O
. - - O
c-ets - - B-MUT
1 - - I-MUT
and - - O
Fli-1 - - B-MUT
, - - O
two - - O
members - - O
of - - O
the - - O
ets - - B-MUT
family - - I-MUT
, - - O
have - - O
been - - O
linked - - O
within - - O
400 - - O
kb - - O
of - - O
intervening - - O
DNA - - O
within - - O
this - - O
contig - - O
, - - O
which - - O
also - - O
comprises - - O
a - - O
polymorphic - - O
microsatellite - - O
, - - O
D11S912 - - B-MUT
( - - I-MUT
CA - - I-MUT
) - - I-MUT
n - - I-MUT
, - - O
which - - O
we - - O
have - - O
localized - - O
within - - O
the - - O
Fli-1 - - B-MUT
gene - - I-MUT
. - - O

Null - - O
alleles - - O
of - - O
SAS4 - - B-MUT
and - - O
SAS5 - - B-MUT
bypassed - - O
the - - O
role - - O
of - - O
the - - O
Abf1p - - B-MUT
binding - - I-MUT
site - - I-MUT
of - - O
the - - O
HMR-E - - B-MUT
silencer - - I-MUT
but - - O
not - - O
the - - O
role - - O
of - - O
the - - O
ACS - - B-MUT
or - - O
Rap1p - - B-MUT
binding - - I-MUT
site - - I-MUT
. - - O

For - - O
signal - - O
durations - - O
less - - O
than - - O
10 - - O
ms - - O
, - - O
however - - O
, - - O
the - - O
SoNo - - O
and - - O
S - - O
pi - - O
No - - O
threshold - - O
functions - - O
converged - - O
and - - O
the - - O
masking-level - - O
difference - - O
decreased - - O
. - - O

The - - O
initial - - O
patients - - O
treated - - O
with - - O
AZQ - - O
and - - O
mitroxantrone - - O
experienced - - O
prolonged - - O
bone - - O
marrow - - O
suppression - - O
and - - O
, - - O
therefore - - O
, - - O
subsequent - - O
cohorts - - O
were - - O
treated - - O
with - - O
G-CSF - - B-MUT
, - - O
5 - - O
micrograms - - O
kg - - O
, - - O
beginning - - O
the - - O
day - - O
after - - O
completion - - O
of - - O
the - - O
third - - O
cycle - - O
of - - O
chemotherapy - - O
. - - O

The - - O
basal - - O
promoter - - O
strength - - O
of - - O
constructs - - O
that - - O
contained - - O
deletions - - O
in - - O
the - - O
U5 - - B-MUT
region - - I-MUT
of - - O
the - - O
LTR - - B-MUT
was - - O
analyzed - - O
by - - O
chloramphenicol - - B-MUT
acetyltransferase - - I-MUT
( - - O
CAT - - B-MUT
) - - O
assays - - O
following - - O
transfection - - O
of - - O
HeLa - - O
cells - - O
or - - O
Jurkat - - O
T-cells - - O
in - - O
the - - O
presence - - O
or - - O
absence - - O
of - - O
viral - - O
transactivator - - O
tax - - B-MUT
protein - - O
. - - O

In - - O
Schizosaccharomyces - - O
pombe - - O
, - - O
the - - O
activity - - O
of - - O
the - - O
M-phase-inducing - - O
Cdc2 - - B-MUT
Cdc13 - - I-MUT
cyclin-dependent - - I-MUT
kinase - - I-MUT
is - - I-MUT
inhibited - - O
by - - O
Wee1 - - O
and - - B-MUT
Mik1 - - O
tyrosine - - B-MUT
kinases - - B-MUT
, - - I-MUT
and - - O
activated - - O
by - - O
Cdc25 - - O
and - - B-MUT
Pyp3 - - O
tyrosine - - B-MUT
phosphatases - - B-MUT
. - - I-MUT

Measurement - - O
of - - O
the - - O
time - - O
constant - - O
of - - O
VO2 - - O
and - - O
oxygen - - O
pulse - - O
during - - O
constant - - O
work - - O
rate - - O
exercise - - O
are - - O
useful - - O
for - - O
the - - O
objective - - O
evaluation - - O
of - - O
the - - O
training - - O
effect - - O
of - - O
patients - - O
with - - O
COPD - - O
. - - O

By - - O
order - - O
of - - O
decreasing - - O
rate - - O
, - - O
finger - - O
flexors - - O
, - - O
jaw - - O
, - - O
crossed - - O
adductors - - O
, - - O
and - - O
triceps - - O
reflexes - - O
were - - O
less - - O
frequently - - O
elicited - - O
in - - O
both - - O
groups - - O
. - - O

The - - O
direct - - O
effects - - O
of - - O
transmitter - - O
release - - O
were - - O
( - - O
a - - O
) - - O
an - - O
early - - O
fall - - O
in - - O
MAP - - O
followed - - O
by - - O
a - - O
late - - O
pressor - - O
effect - - O
; - - O
and - - O
( - - O
b - - O
) - - O
an - - O
early - - O
bradycardia - - O
followed - - O
by - - O
a - - O
late - - O
tachycardia - - O
. - - O

66 - - O
: - - O
469-479 - - O
, - - O
1992 - - O
) - - O
. - - O

A - - O
724-bp - - O
segment - - O
of - - O
the - - O
5'-flanking - - O
region - - O
consisting - - O
of - - O
the - - O
proximal - - O
E-box - - O
flanked - - O
upstream - - O
by - - O
a - - O
mammalian-specific - - O
352-bp - - O
region - - O
was - - O
sufficient - - O
for - - O
maximal - - O
transcriptional - - O
activation - - O
in - - O
postconfluent - - O
BC3H1 - - O
myoblasts - - O
. - - O

Arachnoid - - O
cyst - - O
. - - O

Glutathione - - B-MUT
peroxidase - - I-MUT
in - - O
human - - O
red - - O
cells - - O
in - - O
health - - O
and - - O
disease - - O
. - - O

It - - O
encodes - - O
a - - O
protein - - O
with - - O
three - - O
zinc - - O
fingers - - O
similar - - O
to - - O
those - - O
of - - O
the - - O
transcription - - B-MUT
factor - - I-MUT
Sp1 - - I-MUT
. - - O

Liver - - O
regional - - O
blood - - O
volume - - O
( - - O
LRBV - - O
) - - O
is - - O
altered - - O
by - - O
several - - O
disease - - O
states - - O
and - - O
various - - O
drugs - - O
. - - O

The - - O
ESEM - - O
differs - - O
from - - O
conventional - - O
SEM - - O
in - - O
that - - O
no - - O
sample - - O
preparation - - O
is - - O
needed - - O
, - - O
eliminating - - O
artifactual - - O
changes - - O
. - - O

Enhancers - - O
containing - - O
disrupted - - O
Ets-1 - - B-MUT
binding - - I-MUT
sites - - I-MUT
were - - O
tested - - O
in - - O
transient - - O
expression - - O
assays - - O
in - - O
the - - O
murine - - O
T-cell - - O
line - - O
EL4 - - O
. - - O
E1 - - O
; - - O
alterations - - O
in - - O
the - - O
LVb - - B-MUT
element - - I-MUT
affected - - O
constitutive - - O
enhancer - - O
activity - - O
, - - O
while - - O
mutation - - O
of - - O
either - - O
the - - O
LVb - - B-MUT
or - - O
LVc - - B-MUT
element - - I-MUT
disrupted - - O
phorbol - - O
ester-induced - - O
enhancer - - O
activity - - O
. - - O

The - - O
presence - - O
of - - O
truncated - - O
receptor - - O
isoforms - - O
in - - O
diverse - - O
species - - O
suggests - - O
that - - O
these - - O
proteins - - O
may - - O
have - - O
important - - O
functional - - O
roles - - O
in - - O
regulating - - O
EGFR - - B-MUT
activity - - O
. - - O

The - - O
results - - O
confirm - - O
and - - O
extend - - O
previous - - O
work - - O
by - - O
other - - O
researchers - - O
. - - O

In - - O
the - - O
final - - O
model - - O
, - - O
grade - - O
( - - O
p - - O
= - - O
0 - - O
. - - O
0002 - - O
) - - O
, - - O
peritoneal - - O
cytologic - - O
results - - O
( - - O
p - - O
= - - O
0 - - O
. - - O
0002 - - O
) - - O
, - - O
progesterone - - B-MUT
receptor - - I-MUT
status - - O
( - - O
p - - O
= - - O
0 - - O
. - - O
004 - - O
) - - O
, - - O
and - - O
age - - O
as - - O
a - - O
continuous - - O
variable - - O
( - - O
p - - O
= - - O
0 - - O
. - - O
008 - - O
) - - O
were - - O
most - - O
closely - - O
associated - - O
with - - O
disease-free - - O
survival - - O
. - - O

The - - O
lack - - O
of - - O
change - - O
in - - O
the - - O
ratio - - O
of - - O
the - - O
two - - O
spliced - - O
products - - O
expressed - - O
from - - O
either - - O
the - - O
normal - - O
or - - O
the - - O
5'-rearranged - - B-MUT
myb - - I-MUT
further - - O
indicates - - O
that - - O
the - - O
insertion - - O
of - - O
the - - O
unique - - O
121 - - O
amino - - O
acids - - O
in - - O
the - - O
larger - - O
myb - - B-MUT
transcripts - - I-MUT
is - - O
not - - O
a - - O
consequence - - O
of - - O
tumor-specific - - O
activation - - O
of - - O
the - - O
mouse - - B-MUT
myb - - I-MUT
oncogene - - I-MUT
. - - O

Removal - - O
of - - O
beta - - B-MUT
2-microglobulin - - I-MUT
by - - O
hemodialysis - - O
and - - O
hemofiltration - - O
: - - O
a - - O
four - - O
year - - O
follow - - O
up - - O
. - - O

A - - O
single - - O
MEF-2 - - B-MUT
site - - I-MUT
is - - O
a - - O
major - - O
positive - - O
regulatory - - O
element - - O
required - - O
for - - O
transcription - - O
of - - O
the - - O
muscle-specific - - O
subunit - - O
of - - O
the - - O
human - - B-MUT
phosphoglycerate - - I-MUT
mutase - - I-MUT
gene - - I-MUT
in - - O
skeletal - - O
and - - O
cardiac - - O
muscle - - O
cells - - O
. - - O

The - - O
statistical - - O
analysis - - O
consist - - O
of - - O
the - - O
F - - O
test - - O
followed - - O
by - - O
Snedecor - - O
's - - O
contrast - - O
test - - O
. - - O

In - - O
conclusion - - O
, - - O
USPIO-enhanced - - O
MRI - - O
data - - O
were - - O
capable - - O
to - - O
characterize - - O
tumor - - O
microvessel - - O
properties - - O
in - - O
this - - O
breast - - O
cancer - - O
model - - O
: - - O
microvascular - - O
permeability - - O
( - - O
determined - - O
using - - O
USPIO - - O
) - - O
correlated - - O
significantly - - O
with - - O
tumor - - O
grade - - O
. - - O

Furthermore - - O
, - - O
the - - O
PH - - B-MUT
and - - O
PTB - - O
domains - - O
are - - O
highly - - O
homologous - - O
( - - O
at - - O
least - - O
40% - - O
identical - - O
) - - O
to - - O
those - - O
found - - O
in - - O
insulin - - B-MUT
receptor - - I-MUT
substrates - - I-MUT
1 - - I-MUT
, - - I-MUT
2 - - I-MUT
, - - I-MUT
and - - I-MUT
3 - - I-MUT
( - - O
IRS-1 - - B-MUT
, - - O
IRS-2 - - B-MUT
, - - O
and - - O
IRS-3 - - B-MUT
) - - O
. - - O

The - - O
authors - - O
describe - - O
the - - O
technique - - O
of - - O
transverse - - O
axial - - O
tomography - - O
of - - O
the - - O
spine - - O
and - - O
give - - O
a - - O
detailed - - O
description - - O
of - - O
the - - O
axial - - O
anatomy - - O
of - - O
the - - O
normal - - O
lumbar - - O
spine - - O
from - - O
L-4 - - O
to - - O
the - - O
sacrum - - O
. - - O

Here - - O
we - - O
report - - O
the - - O
cloning - - O
of - - O
the - - O
protein - - O
that - - O
binds - - O
to - - O
enhancer - - B-MUT
site - - I-MUT
III - - I-MUT
. - - O

Foxp1 - - B-MUT
and - - O
Foxp2 - - B-MUT
are - - O
expressed - - O
at - - O
high - - O
levels - - O
in - - O
the - - O
lung - - O
as - - O
early - - O
as - - O
E12 - - O
. - - O
5 - - O
of - - O
mouse - - O
development - - O
with - - O
Foxp2 - - B-MUT
expression - - O
restricted - - O
to - - O
the - - O
airway - - O
epithelium - - O
. - - O

In - - O
the - - O
unclipped - - O
group - - O
arterial - - O
pressure - - O
decreased - - O
50 - - O
mmHg - - O
to - - O
normal - - O
by - - O
24 - - O
h - - O
and - - O
was - - O
associated - - O
with - - O
increased - - O
diuresis - - O
and - - O
a - - O
small - - O
decrease - - O
in - - O
blood - - O
volume - - O
( - - O
9 - - O
. - - O
8% - - O
) - - O
. - - O

The - - O
mean - - O
times - - O
to - - O
detection - - O
of - - O
all - - O
mycobacteria - - O
with - - O
BACTEC - - O
9000 - - O
MB - - O
and - - O
BACTEC - - O
460 - - O
TB - - O
were - - O
similar - - O
( - - O
10 - - O
. - - O
3 - - O
and - - O
10 - - O
. - - O
0 - - O
days - - O
, - - O
respectively - - O
) - - O
. - - O

The - - O
alpha - - B-MUT
inhibin - - I-MUT
promoter - - I-MUT
containing - - O
a - - O
mutated - - O
CRE - - B-MUT
was - - O
not - - O
regulated - - O
by - - O
forskolin - - O
in - - O
granulosa - - O
cells - - O
and - - O
did - - O
not - - O
bind - - O
the - - O
CREB - - B-MUT
protein - - I-MUT
. - - O

We - - O
show - - O
also - - O
that - - O
RA - - O
represses - - O
the - - O
transcriptional - - O
activity - - O
of - - O
a - - O
reporter - - O
gene - - O
containing - - O
a - - O
TPA - - B-MUT
responding - - O
AP1 - - B-MUT
binding - - I-MUT
site - - I-MUT
driving - - O
the - - O
HSV - - B-MUT
tk - - I-MUT
promoter - - I-MUT
. - - O

We - - O
also - - O
compared - - O
the - - O
sequence - - O
with - - O
the - - O
partly - - O
homologous - - O
products - - O
of - - O
the - - O
S - - O
. - - O
cerevisiae - - O
genes - - O
TPS2 - - B-MUT
and - - O
TSL1 - - B-MUT
which - - O
code - - O
for - - O
the - - O
larger - - O
subunits - - O
of - - O
the - - O
trehalose - - B-MUT
synthase - - I-MUT
complex - - I-MUT
and - - O
with - - O
a - - O
TSL1 - - B-MUT
homologue - - I-MUT
, - - O
TPS3 - - B-MUT
, - - O
of - - O
unknown - - O
function - - O
. - - O

Seventy-two - - O
hours - - O
after - - O
administration - - O
of - - O
vitamin - - O
K1 - - O
, - - O
plasma - - O
concentrations - - O
of - - O
the - - O
vitamin - - O
were - - O
not - - O
different - - O
from - - O
normal - - O
. - - O

Methanesulfonyl - - O
fluoride - - O
( - - O
MSF - - O
) - - O
: - - O
a - - O
double-blind - - O
, - - O
placebo-controlled - - O
study - - O
of - - O
safety - - O
and - - O
efficacy - - O
in - - O
the - - O
treatment - - O
of - - O
senile - - O
dementia - - O
of - - O
the - - O
Alzheimer - - O
type - - O
. - - O

FDA - - O
regulations - - O
for - - O
growth - - B-MUT
factors - - I-MUT
and - - O
related - - O
products - - O
. - - O

Six - - O
distinct - - O
Ets - - B-MUT
mRNAs - - I-MUT
were - - O
identified - - O
: - - O
Ets2 - - B-MUT
, - - O
Fli1 - - B-MUT
, - - O
GABPalpha - - B-MUT
, - - O
SAP1 - - B-MUT
, - - O
Elk1 - - B-MUT
, - - O
and - - O
PE1 - - B-MUT
. - - O

The - - O
histidine-tagged - - O
gene - - O
, - - O
rpoCHIS - - B-MUT
, - - O
was - - O
used - - O
to - - O
replace - - O
the - - O
wild-type - - O
allele - - O
in - - O
the - - O
chromosome - - O
of - - O
S - - O
. - - O
coelicolor - - O
and - - O
S - - O
. - - O
lividans - - O
. - - O

Identification - - O
of - - O
a - - O
spliced - - O
gene - - O
from - - O
Kaposi's - - O
sarcoma-associated - - O
herpesvirus - - O
encoding - - O
a - - O
protein - - O
with - - O
similarities - - O
to - - O
latent - - B-MUT
membrane - - I-MUT
proteins - - I-MUT
1 - - I-MUT
and - - I-MUT
2A - - I-MUT
of - - I-MUT
Epstein-Barr - - I-MUT
virus - - I-MUT
. - - O

To - - O
identify - - O
these - - O
sites - - O
, - - O
the - - O
deduced - - O
amino - - O
acid - - O
sequence - - O
of - - O
the - - O
3T3-L1 - - O
adipocyte - - B-MUT
insulin - - I-MUT
receptor - - I-MUT
of - - O
the - - O
mouse - - O
was - - O
determined - - O
. - - O

Wild - - B-MUT
type - - I-MUT
HA-p190 - - I-MUT
induced - - O
a - - O
phenotype - - O
of - - O
rounded - - O
cells - - O
with - - O
long - - O
, - - O
beaded - - O
extensions - - O
similar - - O
to - - O
that - - O
seen - - O
when - - O
Rho - - B-MUT
function - - O
is - - O
disrupted - - O
by - - O
ADP-ribosylation - - O
. - - O

Following - - O
2 - - O
. - - O
5 - - O
Gy - - O
, - - O
HbO2 - - B-MUT
changes - - O
were - - O
minimal - - O
. - - O

In - - O
summary - - O
, - - O
the - - O
data - - O
establish - - O
that - - O
the - - O
previously - - O
reported - - O
human - - B-MUT
MAdCAM-1 - - I-MUT
cDNA - - I-MUT
does - - O
indeed - - O
encode - - O
the - - O
human - - O
homologue - - O
of - - O
mouse - - B-MUT
MAdCAM-1 - - I-MUT
, - - O
despite - - O
gross - - O
dissimilarities - - O
in - - O
the - - O
MAdCAM-1 - - B-MUT
C-terminal - - O
structures - - O
. - - O

Upstream - - O
of - - O
the - - O
dra - - B-MUT
gene - - I-MUT
an - - O
open - - O
reading - - O
frame - - O
of - - O
313 - - O
amino - - O
acids - - O
was - - O
identified - - O
. - - O

Chemical - - O
uptake - - O
into - - O
human - - O
stratum - - O
corneum - - O
in - - O
vivo - - O
from - - O
volatile - - O
and - - O
non-volatile - - O
solvents - - O
. - - O

Diet - - O
therapy - - O
with - - O
soy - - O
proteins - - O
for - - O
chronic - - O
stomach - - O
ulcers - - O
. - - O

This - - O
may - - O
result - - O
in - - O
more - - O
reabsorption - - O
and - - O
hence - - O
reduced - - O
renal - - O
clearance - - O
. - - O

In - - O
patients - - O
who - - O
had - - O
received - - O
no - - O
previous - - O
drug - - O
treatment - - O
, - - O
log - - O
baseline - - O
plasma - - B-MUT
renin - - I-MUT
activity - - O
and - - O
change - - O
in - - O
mean - - O
blood - - O
pressure - - O
after - - O
SQ - - O
20881 - - O
correlated - - O
significantly - - O
( - - O
r - - O
= - - O
0 - - O
. - - O
651 - - O
, - - O
P - - O
less - - O
than - - O
0 - - O
. - - O
05 - - O
) - - O
. - - O

We - - O
conclude - - O
that - - O
sequences - - O
outside - - O
of - - O
the - - O
hLEF - - B-MUT
HMG - - I-MUT
box - - I-MUT
mediate - - O
cell- - - O
and - - O
context-specific - - O
activation - - O
of - - O
the - - O
TCR - - B-MUT
alpha - - I-MUT
enhancer - - I-MUT
and - - O
may - - O
facilitate - - O
interactions - - O
between - - O
hLEF - - B-MUT
and - - O
other - - O
T-cell-specific - - O
factors - - O
recruited - - O
to - - O
the - - O
enhancer - - O
. - - O

More - - O
mRNA - - O
corresponding - - O
to - - O
nagB - - B-MUT
and - - O
nagA - - B-MUT
is - - O
detected - - O
than - - O
that - - O
corresponding - - O
to - - O
the - - O
distal - - O
genes - - O
, - - O
nagC - - B-MUT
and - - O
nagD - - B-MUT
. - - O

However - - O
, - - O
its - - O
participation - - O
in - - O
collagen - - B-MUT
binding - - O
has - - O
not - - O
been - - O
shown - - O
. - - O

Development - - O
of - - O
a - - O
provisional - - O
information-retrieval - - O
descriptor - - O
language - - O
for - - O
"Roentgenology - - O
and - - O
Medical - - O
Radiology" - - O
for - - O
use - - O
in - - O
the - - O
Medinform - - O
system - - O
. - - O

The - - O
sequenced - - O
genomic - - O
region - - O
thus - - O
accounts - - O
for - - O
essentially - - O
all - - O
of - - O
the - - O
longest - - O
known - - O
transcript - - O
( - - O
4 - - O
. - - O
5 - - O
kb - - O
) - - O
, - - O
although - - O
the - - O
precise - - O
ends - - O
of - - O
this - - O
transcript - - O
have - - O
not - - O
been - - O
defined - - O
. - - O

Neonatal - - O
Chagas - - O
disease - - O
: - - O
laboratory - - O
diagnosis - - O
during - - O
the - - O
first - - O
year - - O
of - - O
life - - O
. - - O

This - - O
study - - O
evaluates - - O
the - - O
feasibility - - O
of - - O
indirect - - O
mesenteric - - O
lymphangiography - - O
as - - O
a - - O
colonoscopic - - O
technique - - O
in - - O
a - - O
canine - - O
model - - O
. - - O

The - - O
gonadotrope-specific - - O
and - - O
regulated - - O
expression - - O
of - - O
the - - O
GnRH - - B-MUT
receptor - - I-MUT
( - - O
GnRH-R - - B-MUT
) - - O
gene - - O
is - - O
dependent - - O
on - - O
multiple - - O
transcription - - O
factors - - O
that - - O
interact - - O
with - - O
the - - O
noncanonical - - B-MUT
GnRH-R - - I-MUT
activating - - I-MUT
sequence - - I-MUT
( - - O
GRAS - - B-MUT
) - - O
, - - O
the - - O
activator - - B-MUT
protein-1 - - I-MUT
( - - O
AP-1 - - B-MUT
) - - O
element - - O
, - - O
and - - O
the - - O
steroidogenic - - B-MUT
factor-1 - - I-MUT
( - - O
SF-1 - - B-MUT
) - - O
binding - - O
site - - O
. - - O

FK506 - - O
is - - O
10- - - O
to - - O
100-fold - - O
more - - O
potent - - O
than - - O
cyclosporin - - O
A - - O
in - - O
preventing - - O
organ - - O
rejection - - O
and - - O
in - - O
toxicity - - O
. - - O

Comparison - - O
of - - O
the - - O
deduced - - O
amino - - O
acid - - O
sequences - - O
with - - O
protein - - O
sequences - - O
of - - O
T - - O
. - - O
pyriformis - - O
H2As - - B-MUT
showed - - O
only - - O
two - - O
and - - O
three - - O
differences - - O
respectively - - O
, - - O
in - - O
a - - O
total - - O
of - - O
137 - - O
amino - - O
acids - - O
for - - O
H2A1 - - B-MUT
, - - O
and - - O
132 - - O
amino - - O
acids - - O
for - - O
H2A2 - - B-MUT
, - - O
indicating - - O
the - - O
two - - O
genes - - O
arose - - O
before - - O
the - - O
divergence - - O
of - - O
these - - O
two - - O
species - - O
. - - O

Anecdotal - - O
observations - - O
scattered - - O
throughout - - O
the - - O
literature - - O
have - - O
often - - O
provided - - O
clues - - O
to - - O
underlying - - O
variations - - O
in - - O
humans' - - O
ability - - O
to - - O
handle - - O
dietary - - O
chemicals - - O
. - - O

Fewer - - O
recombination - - O
events - - O
are - - O
detected - - O
in - - O
four - - O
different - - O
B - - O
and - - O
T - - O
cell - - O
lines - - O
that - - O
do - - O
not - - O
undergo - - O
switch - - O
recombination - - O
of - - O
their - - O
endogenous - - O
genes - - O
. - - O

These - - O
observations - - O
establish - - O
that - - O
RsmC - - B-MUT
negatively - - O
regulates - - O
rsmB - - B-MUT
transcription - - O
but - - O
positively - - O
affects - - O
RsmA - - B-MUT
production - - O
. - - O

The - - O
relations - - O
among - - O
various - - O
negative - - O
emotional - - O
and - - O
behavioral - - O
characteristics - - O
( - - O
e - - O
. - - O
g - - O
. - - O
, - - O
aggression - - O
, - - O
anxiety - - O
, - - O
undercompliance - - O
, - - O
depressive - - O
mood - - O
) - - O
and - - O
adjustment - - O
were - - O
examined - - O
through - - O
use - - O
of - - O
data - - O
from - - O
the - - O
31-year-old - - O
New - - O
York - - O
Longitudinal - - O
Study - - O
. - - O

This - - O
was - - O
most - - O
pronounced - - O
during - - O
the - - O
initial - - O
phase - - O
of - - O
Erk - - B-MUT
activation - - O
. - - O

Institution - - O
of - - O
both - - O
intravenous - - O
and - - O
intracisternal - - O
administration - - O
of - - O
amphotericin - - O
B - - O
and - - O
possibly - - O
concomitant - - O
intravenous - - O
administration - - O
of - - O
dexamethasone - - O
may - - O
be - - O
warranted - - O
in - - O
situations - - O
in - - O
which - - O
the - - O
association - - O
of - - O
C - - O
. - - O
immitis - - O
with - - O
CNS - - O
vasculitis - - O
or - - O
encephalitis - - O
appears - - O
likely - - O
before - - O
serologic - - O
or - - O
cultural - - O
confirmation - - O
of - - O
C - - O
. - - O
immitis - - O
infection - - O
involving - - O
the - - O
CNS - - O
is - - O
available - - O
. - - O

Increasing - - O
mean - - O
arterial - - O
pressure - - O
by - - O
phenylephrine - - O
infusion - - O
to - - O
levels - - O
much - - O
greater - - O
than - - O
produced - - O
by - - O
NMA - - O
and - - O
NNA - - O
caused - - O
only - - O
small - - O
reductions - - O
in - - O
cardiac - - O
output - - O
. - - O

The - - O
nucleotide - - O
sequence - - O
of - - O
22 - - O
, - - O
846 - - O
bp - - O
of - - O
the - - O
left - - O
arm - - O
of - - O
chromosome - - O
IV - - O
is - - O
described - - O
. - - O

The - - O
application - - O
of - - O
these - - O
microelectrodes - - O
to - - O
the - - O
measurement - - O
of - - O
rapid - - O
, - - O
transient - - O
changes - - O
in - - O
retinal - - O
[ - - O
K+ - - O
] - - O
o - - O
is - - O
presented - - O
. - - O

From - - O
all - - O
clinically - - O
important - - O
yeasts - - O
species - - O
, - - O
a - - O
total - - O
of - - O
96% - - O
were - - O
identified - - O
by - - O
ATB - - O
method - - O
according - - O
to - - O
conventional - - O
methods - - O
. - - O

To - - O
account - - O
for - - O
this - - O
observation - - O
, - - O
other - - O
possible - - O
causes - - O
include - - O
increased - - O
CSF - - O
pulsation - - O
in - - O
children - - O
creating - - O
motion - - O
artifact - - O
, - - O
changes - - O
in - - O
arterial - - O
oxygen - - O
concentration - - O
intrinsic - - O
to - - O
propofol - - O
or - - O
related - - O
to - - O
the - - O
supplemental - - O
oxygen - - O
normally - - O
administered - - O
, - - O
or - - O
changes - - O
in - - O
CSF - - O
protein - - O
levels - - O
related - - O
to - - O
propofol - - O
binding - - O
to - - O
proteins - - O
for - - O
uptake - - O
into - - O
CSF - - O
. - - O

A - - O
gas-liquid - - O
chromatographic - - O
method - - O
for - - O
the - - O
determination - - O
of - - O
p-chlorophenoxyisobutyric - - O
( - - O
CPIB - - O
) - - O
acid - - O
in - - O
blood - - O
plasma - - O
is - - O
described - - O
. - - O

The - - O
fatigue - - O
exercise - - O
showed - - O
relatively - - O
high - - O
blood - - O
lactate - - O
concentration - - O
[ - - O
12 - - O
. - - O
5 - - O
( - - O
SD - - O
2 - - O
. - - O
6 - - O
) - - O
mmol - - O
x - - O
l - - O
( - - O
-1 - - O
) - - O
] - - O
and - - O
an - - O
increase - - O
of - - O
serum - - B-MUT
creatine - - I-MUT
kinase - - I-MUT
( - - O
CK - - B-MUT
) - - O
activity - - O
delayed - - O
by - - O
2 - - O
days - - O
[ - - O
540 - - O
( - - O
SD - - O
407 - - O
) - - O
U - - O
x - - O
l - - O
( - - O
-1 - - O
) - - O
] - - O
. - - O

However - - O
, - - O
the - - O
presence - - O
of - - O
effacement - - O
seems - - O
to - - O
be - - O
a - - O
more - - O
reliable - - O
and - - O
practical - - O
parameter - - O
that - - O
will - - O
be - - O
preferred - - O
in - - O
that - - O
prediction - - O
. - - O

We - - O
have - - O
investigated - - O
the - - O
role - - O
of - - O
NGF - - B-MUT
in - - O
regulating - - O
gene - - O
transcription - - O
in - - O
PC12 - - O
and - - O
INS-1 - - O
cells - - O
, - - O
in - - O
order - - O
to - - O
define - - O
if - - O
there - - O
are - - O
NGF-regulated - - O
genes - - O
per - - O
se - - O
. - - O

Chloroplast - - B-MUT
mutator - - I-MUT
( - - O
chm - - B-MUT
) - - O
of - - O
Arabidopsis - - O
is - - O
a - - O
recessive - - O
nuclear - - O
mutation - - O
that - - O
causes - - O
green - - O
and - - O
white - - O
variegation - - O
in - - O
leaves - - O
and - - O
is - - O
inherited - - O
in - - O
a - - O
non-Mendelian - - O
fashion - - O
. - - O

In - - O
three - - O
of - - O
the - - O
seven - - O
, - - O
inhalation - - O
of - - O
2 - - O
ml - - O
normal - - O
saline - - O
produced - - O
FEV1 - - O
falls - - O
of - - O
25% - - O
to - - O
30% - - O
, - - O
but - - O
these - - O
falls - - O
were - - O
not - - O
as - - O
great - - O
as - - O
each - - O
subject's - - O
reactions - - O
to - - O
the - - O
test - - O
solutions - - O
. - - O

As - - O
demonstrated - - O
by - - O
gel - - O
mobility - - O
shift - - O
analysis - - O
and - - O
supershift - - O
experiments - - O
, - - O
FIRE1 - - B-MUT
, - - O
located - - O
between - - O
-516 - - O
and - - O
-498 - - O
, - - O
is - - O
responsible - - O
for - - O
binding - - O
NF-Y - - B-MUT
. - - O

The - - O
less-polar - - O
mycolic - - O
acid-containing - - O
Rhodococcus - - O
species - - O
showed - - O
chromatographic - - O
patterns - - O
that - - O
partially - - O
overlapped - - O
( - - O
in - - O
elution - - O
times - - O
) - - O
the - - O
patterns - - O
of - - O
Nocardia - - O
asteroides - - O
, - - O
N - - O
. - - O
otitidiscaviarum - - O
, - - O
and - - O
N - - O
. - - O
brasiliensis - - O
, - - O
but - - O
the - - O
larger - - O
number - - O
of - - O
peaks - - O
in - - O
the - - O
last - - O
species - - O
made - - O
separation - - O
between - - O
the - - O
genera - - O
possible - - O
. - - O

Electrophile - - B-MUT
Response - - I-MUT
Elements - - I-MUT
( - - O
EpREs - - B-MUT
) - - O
, - - O
located - - O
in - - O
5'-flanking - - O
sequences - - O
of - - O
both - - O
the - - O
GCSh - - B-MUT
and - - O
GCSl - - B-MUT
subunit - - I-MUT
genes - - I-MUT
, - - O
are - - O
hypothesized - - O
to - - O
at - - O
least - - O
partially - - O
mediate - - O
gene - - O
induction - - O
following - - O
xenobiotic - - O
exposure - - O
. - - O

Extreme - - O
potency - - O
of - - O
botulinum - - B-MUT
toxin - - I-MUT
. - - O

It - - O
appears - - O
that - - O
the - - O
pulmonary - - O
gas - - O
exchange - - O
parenchyma - - O
of - - O
these - - O
smallest - - O
mammals - - O
is - - O
well - - O
suited - - O
to - - O
supply - - O
the - - O
organism - - O
with - - O
the - - O
comparatively - - O
high - - O
levels - - O
of - - O
O2 - - O
required - - O
by - - O
the - - O
high - - O
metabolic - - O
rates - - O
, - - O
exhibiting - - O
a - - O
structural - - O
adaptation - - O
of - - O
the - - O
lung - - O
to - - O
higher - - O
VO2 - - O
. - - O

The - - O
development - - O
and - - O
histostructural - - O
organization - - O
of - - O
intrahepatic - - O
biliary - - O
ducts - - O
were - - O
studied - - O
on - - O
a - - O
human - - O
embryofetal - - O
material - - O
6 - - O
to - - O
32 - - O
weeks - - O
old - - O
. - - O

Labile - - O
LTR-binding - - B-MUT
proteins - - I-MUT
appear - - O
to - - O
be - - O
essential - - O
for - - O
c-myc - - B-MUT
hyperexpression - - O
, - - O
since - - O
both - - O
LTR-enhanced - - O
transcription - - O
and - - O
the - - O
activities - - O
of - - O
LTR-binding - - B-MUT
proteins - - I-MUT
are - - O
specifically - - O
decreased - - O
after - - O
inhibition - - O
of - - O
protein - - O
synthesis - - O
( - - O
A - - O
. - - O

Age - - O
at - - O
POI - - O
and - - O
asymptote - - O
were - - O
achieved - - O
later - - O
for - - O
Line - - O
RBC2 - - O
than - - O
for - - O
Line - - O
F - - O
. - - O

Disorders - - O
of - - O
platelet - - O
function - - O
in - - O
chronic - - O
myeloid - - O
leukemias - - O
. - - O

Hepatitis - - B-MUT
B - - I-MUT
surface - - I-MUT
antigen - - I-MUT
was - - O
detected - - O
in - - O
2 - - O
patients - - O
, - - O
with - - O
negative - - O
hepatitis - - B-MUT
C - - I-MUT
virus - - I-MUT
antibody - - I-MUT
. - - O

Clinical - - O
and - - O
angiographic - - O
examinations - - O
in - - O
occlusion - - O
disease - - O
of - - O
the - - O
great - - O
intestinal - - O
arteries - - O
. - - O

Prevention - - O
, - - O
differential - - O
diagnosis - - O
and - - O
therapy - - O
of - - O
travel - - O
diarrhea - - O
. - - O

CONCLUSIONS - - O
: - - O
Two - - O
consecutive - - O
sets - - O
of - - O
transrectal - - O
ultrasound - - O
guided - - O
sextant - - O
biopsies - - O
of - - O
the - - O
prostate - - O
performed - - O
in - - O
a - - O
single - - O
office - - O
visit - - O
represent - - O
a - - O
cost-effective - - O
biopsy - - O
strategy - - O
for - - O
men - - O
presenting - - O
with - - O
an - - O
abnormal - - O
digital - - O
rectal - - O
examination - - O
and - - O
or - - O
elevated - - O
serum - - O
PSA - - B-MUT
. - - I-MUT

We - - O
compare - - O
the - - O
results - - O
of - - O
this - - O
algorithm - - O
with - - O
the - - O
results - - O
obtained - - O
with - - O
two - - O
other - - O
algorithms - - O
, - - O
the - - O
optimal - - O
algorithm - - O
for - - O
monochannel - - O
nonoverlapping - - O
noise - - O
and - - O
the - - O
optimal - - O
algorithm - - O
for - - O
multichannel - - O
additive - - O
noise - - O
, - - O
and - - O
we - - O
show - - O
that - - O
in - - O
both - - O
cases - - O
improvement - - O
can - - O
be - - O
obtained - - O
. - - O

A - - O
safe - - O
and - - O
simple - - O
system - - O
for - - O
the - - O
detection - - O
of - - O
sudden - - O
infant - - O
death - - O
syndrome - - O
( - - O
SIDS - - O
) - - O
is - - O
proposed - - O
. - - O

Transactivation - - O
of - - O
naturally - - O
occurring - - O
HIV-1 - - O
long - - O
terminal - - O
repeats - - O
by - - O
the - - O
JNK - - B-MUT
signaling - - O
pathway - - O
. - - O

Histological - - O
examination - - O
revealed - - O
a - - O
small - - O
simple - - O
renal - - O
cyst - - O
associated - - O
with - - O
renal - - O
cell - - O
carcinoma - - O
. - - O

Those - - O
dosages - - O
that - - O
inhibited - - O
mean - - O
NTE - - B-MUT
activity - - O
in - - O
spinal - - O
cord - - O
greater - - O
than - - O
or - - O
equal - - O
to - - O
72% - - O
and - - O
brain - - O
greater - - O
than - - O
or - - O
equal - - O
to - - O
66% - - O
of - - O
control - - O
values - - O
within - - O
44 - - O
hr - - O
postexposure - - O
produced - - O
marked - - O
spinal - - O
cord - - O
pathology - - O
14 - - O
days - - O
postexposure - - O
in - - O
greater - - O
than - - O
or - - O
equal - - O
to - - O
90% - - O
of - - O
similarly - - O
dosed - - O
animals - - O
. - - O

RESULTS - - O
: - - O
An - - O
herpetic - - O
seroconversion - - O
is - - O
observed - - O
with - - O
presence - - O
of - - O
type - - O
I - - O
herpes - - O
simplex - - O
virus - - O
( - - O
HSV - - O
I - - O
) - - O
nucleic - - O
acids - - O
in - - O
the - - O
recipient's - - O
aqueous - - O
humor - - O
. - - O

Plasma - - O
NE - - O
was - - O
also - - O
low - - O
in - - O
the - - O
anephric - - O
group - - O
( - - O
289 - - O
mg - - O
liter - - O
+ - - O
- - - O
126 - - O
( - - O
1 - - O
SD - - O
) - - O
vs - - O
612 - - O
+ - - O
- - - O
189 - - O
, - - O
P - - O
= - - O
0 - - O
. - - O
033 - - O
, - - O
resting - - O
) - - O
. - - O
( - - O
ABSTRACT - - O
TRUNCATED - - O
AT - - O
250 - - O
WORDS - - O
) - - O

A - - O
gene - - O
homologous - - O
to - - O
the - - O
Escherichia - - B-MUT
coli - - I-MUT
dnaA - - I-MUT
gene - - I-MUT
was - - O
isolated - - O
from - - O
Pseudomonas - - O
putida - - O
and - - O
its - - O
transcription - - O
was - - O
investigated - - O
in - - O
E - - O
. - - O
coli - - O
as - - O
well - - O
as - - O
in - - O
P - - O
. - - O
putida - - O
. - - O

CONCLUSION - - O
: - - O
More - - O
than - - O
50% - - O
of - - O
patients - - O
with - - O
perennial - - O
rhinitis - - O
and - - O
CRS - - O
do - - O
not - - O
improve - - O
after - - O
surgery - - O
, - - O
a - - O
response - - O
that - - O
may - - O
be - - O
predicted - - O
by - - O
more - - O
cells - - O
expressing - - O
IL-5 - - B-MUT
mRNA - - I-MUT
in - - O
the - - O
ethmoid - - O
sinuses - - O
. - - O

Concussion - - O
of - - O
the - - O
spinal - - O
cord - - O
. - - O

Relatively - - O
large - - O
DNA - - O
rearrangements - - O
spanning - - O
the - - O
region - - O
with - - O
tandem - - O
direct - - O
repeats - - O
encoding - - O
the - - O
carboxy-terminal - - B-MUT
histone - - I-MUT
H1-like - - I-MUT
structure - - I-MUT
of - - O
AlgP - - B-MUT
were - - O
detected - - O
in - - O
several - - O
strains - - O
upon - - O
conversion - - O
from - - O
the - - O
mucoid - - O
to - - O
the - - O
nonmucoid - - O
phenotype - - O
. - - O

This - - O
approach - - O
places - - O
gHoxb-1 - - B-MUT
into - - O
the - - O
normal - - O
embryonic - - O
spatiotemporal - - O
context - - O
in - - O
which - - O
lab - - O
acts - - O
. - - O

IVOX - - O
was - - O
named - - O
as - - O
an - - O
acronym - - O
for - - O
intravascular - - O
oxygenator - - O
. - - O

EGFR - - B-MUT
levels - - O
were - - O
found - - O
to - - O
be - - O
elevated - - O
5- - - O
, - - O
3 - - O
. - - O

However - - O
, - - O
serial - - O
passages - - O
of - - O
fetal - - O
lamb - - O
kidney - - O
( - - O
FLK - - O
) - - O
cells - - O
, - - O
which - - O
are - - O
sensitive - - O
to - - O
infection - - O
with - - O
BLV - - O
, - - O
after - - O
transient - - O
transfection - - O
revealed - - O
that - - O
mutation - - O
of - - O
a - - O
second - - O
tyrosine - - O
residue - - O
in - - O
the - - O
N-terminal - - O
motif - - O
completely - - O
prevented - - O
the - - O
propagation - - O
of - - O
the - - O
virus - - O
. - - O

Serum - - O
levels - - O
of - - O
IgG - - B-MUT
and - - O
IgM - - B-MUT
were - - O
also - - O
raised - - O
, - - O
but - - O
contrary - - O
to - - O
the - - O
findings - - O
of - - O
other - - O
observers - - O
IgA - - B-MUT
levels - - O
were - - O
normal - - O
. - - O

The - - O
performance - - O
of - - O
three - - O
commonly - - O
used - - O
chemical - - O
cartridge - - O
respirators - - O
for - - O
SO2 - - O
was - - O
measured - - O
under - - O
working - - O
conditions - - O
in - - O
a - - O
copper - - O
smelter - - O
. - - O

The - - O
promoter - - O
region - - O
( - - O
P1 - - O
) - - O
corresponding - - O
to - - O
the - - O
main - - O
group - - O
of - - O
transcription - - O
initiation - - O
sites - - O
is - - O
devoid - - O
of - - O
TATA - - O
and - - O
CAAT - - O
boxes - - O
but - - O
has - - O
putative - - O
binding - - O
sites - - O
for - - O
the - - O
transcription - - B-MUT
factor - - I-MUT
SP1 - - I-MUT
and - - O
is - - O
embedded - - O
in - - O
a - - O
large - - O
G - - O
+ - - O
C-rich - - O
domain - - O
of - - O
a - - O
CpG - - O
island - - O
, - - O
features - - O
shared - - O
by - - O
the - - O
promoters - - O
of - - O
constitutively - - O
expressed - - O
housekeeping - - O
genes - - O
. - - O

We - - O
find - - O
that - - O
our - - O
response - - O
function - - O
is - - O
well - - O
approximated - - O
by - - O
the - - O
GSER - - O
only - - O
within - - O
a - - O
particular - - O
frequency - - O
range - - O
determined - - O
by - - O
the - - O
material - - O
parameters - - O
of - - O
both - - O
the - - O
bead - - O
and - - O
the - - O
network - - O
. - - O

THE - - O
SCALING - - O
OF - - O
SONG - - O
FREQUENCY - - O
IN - - O
CICADAS - - O
. - - O

HIV - - O
infectiousness - - O
and - - O
the - - O
AIDS - - O
epidemic - - O
. - - O

Endocytosis - - O
and - - O
lysosomal - - O
targeting - - O
of - - O
epidermal - - B-MUT
growth - - I-MUT
factor - - I-MUT
receptors - - I-MUT
are - - O
mediated - - O
by - - O
distinct - - O
sequences - - O
independent - - O
of - - O
the - - O
tyrosine - - B-MUT
kinase - - I-MUT
domain - - I-MUT
. - - O

Expansins - - B-MUT
are - - O
a - - O
family - - O
of - - O
proteins - - O
that - - O
catalyse - - O
long-term - - O
extension - - O
of - - O
isolated - - O
plant - - O
cell - - O
walls - - O
due - - O
to - - O
an - - O
as - - O
yet - - O
unknown - - O
biochemical - - O
mechanism - - O
. - - O

The - - O
patterns - - O
of - - O
early - - O
mRNA - - O
and - - O
protein - - O
expression - - O
in - - O
these - - O
seven - - O
mutants - - O
were - - O
examined - - O
, - - O
and - - O
it - - O
was - - O
found - - O
that - - O
mutation - - O
of - - O
the - - O
T' - - B-MUT
( - - I-MUT
135 - - I-MUT
) - - I-MUT
acceptor - - I-MUT
site - - I-MUT
resulted - - O
in - - O
the - - O
utilization - - O
of - - O
cryptic - - O
splice - - O
sites - - O
and - - O
the - - O
generation - - O
of - - O
new - - O
T' - - B-MUT
species - - I-MUT
. - - O

Problems - - O
common - - O
to - - O
pediatrics - - O
and - - O
anesthesiology - - O
. - - O

Shc - - B-MUT
stimulates - - O
Ras - - B-MUT
mitogen-activated - - I-MUT
protein - - I-MUT
kinase - - I-MUT
( - - I-MUT
MAPK - - O
) - - B-MUT
through - - O
forming - - O
a - - O
complex - - O
with - - O
Grb2 - - O
at - - B-MUT
the - - O
phosphorylated - - O
tyrosine - - O
( - - O
Y - - O
) - - O
residue - - O
317 - - O
. - - O

Cholangiography - - O
was - - O
performed - - O
in - - O
all - - O
cases - - O
and - - O
classified - - O
by - - O
a - - O
scoring - - O
system - - O
specifically - - O
developed - - O
for - - O
pediatric - - O
patients - - O
. - - O

Frog - - O
type - - O
I - - O
( - - O
Ft - - O
I - - O
) - - O
and - - O
frog - - O
type - - O
II - - O
( - - O
Ft - - O
II - - O
) - - O
slowly - - O
adapting - - O
( - - O
SA - - O
) - - O
units - - O
produced - - O
spikes - - O
only - - O
at - - O
the - - O
indentation - - O
phase - - O
, - - O
and - - O
the - - O
threshold - - O
response - - O
phase - - O
( - - O
TRP - - O
) - - O
, - - O
i - - O
. - - O
e - - O
. - - O
. - - O
the - - O
phase - - O
of - - O
the - - O
first - - O
spike - - O
was - - O
for - - O
ca - - O
. - - O

We - - O
describe - - O
here - - O
a - - O
Drosophila - - B-MUT
melanogaster - - I-MUT
FAK - - I-MUT
homologue - - I-MUT
, - - O
DFak56 - - B-MUT
, - - O
which - - O
maps - - O
to - - O
band - - O
56D - - O
on - - O
the - - O
right - - O
arm - - O
of - - O
the - - O
second - - O
chromosome - - O
. - - O

Chem - - O
. - - O

A - - O
single - - O
N-glycosylation - - O
site - - O
present - - O
in - - O
chicken - - B-MUT
gp42 - - I-MUT
is - - O
conserved - - O
among - - O
all - - O
five - - O
of - - O
these - - O
proteins - - O
: - - O
carbohydrate - - O
analysis - - O
of - - O
gp42 - - B-MUT
revealed - - O
the - - O
presence - - O
of - - O
a - - O
complex - - O
type - - O
glycan - - O
chain - - O
at - - O
this - - O
site - - O
. - - O

Different - - O
doses - - O
of - - O
15-methyl-PGF2 - - O
alpha - - O
( - - O
0 - - O
. - - O
125-10 - - O
mg - - O
) - - O
were - - O
used - - O
to - - O
induce - - O
luteolysis - - O
and - - O
oestrus - - O
in - - O
7 - - O
heifers - - O
with - - O
28 - - O
treatments - - O
on - - O
day - - O
8-12 - - O
of - - O
the - - O
oestrous - - O
cycle - - O
. - - O

BSE - - O
and - - O
farmworkers - - O
. - - O

The - - O
distribution - - O
of - - O
the - - O
sites - - O
of - - O
recombinational - - O
resolution - - O
is - - O
inversely - - O
correlated - - O
with - - O
that - - O
of - - O
the - - O
gradient - - O
of - - O
sequence - - O
divergence - - O
, - - O
with - - O
only - - O
approximately - - O
7% - - O
of - - O
the - - O
X - - O
recombinants - - O
resolved - - O
within - - O
the - - O
3' - - O
third - - O
of - - O
the - - O
X - - O
blocks - - O
where - - O
two - - O
diverged - - O
Alu - - B-MUT
family - - I-MUT
repeats - - I-MUT
reside - - O
. - - O

A - - O
pre-boutonniere - - O
deformity - - O
was - - O
simulated - - O
by - - O
dividing - - O
the - - O
central - - O
slip - - O
. - - O

First - - O
, - - O
human - - O
erythroid - - O
K562 - - O
cells - - O
stably - - O
integrated - - O
with - - O
various - - O
HS-40 - - B-MUT
mutants - - I-MUT
cis - - O
linked - - O
to - - O
a - - O
human - - B-MUT
alpha-globin - - I-MUT
promoter-growth - - I-MUT
hormone - - I-MUT
hybrid - - I-MUT
gene - - I-MUT
were - - O
analyzed - - O
by - - O
genomic - - O
footprinting - - O
and - - O
expression - - O
analysis - - O
. - - O

Electron - - O
microscopic - - O
picture - - O
of - - O
the - - O
cerebral - - O
cortex - - O
in - - O
rats - - O
cooled - - O
to - - O
22 - - O
degrees - - O
C - - O
. - - O

Enterococcus - - O
faecium - - O
strains - - O
with - - O
vanA-mediated - - O
glycopeptide - - O
resistance - - O
were - - O
isolated - - O
by - - O
enrichment - - O
culture - - O
from - - O
the - - O
intestines - - O
and - - O
feces - - O
of - - O
several - - O
animal - - O
species - - O
, - - O
mainly - - O
horses - - O
and - - O
dogs - - O
( - - O
8% - - O
positive - - O
) - - O
, - - O
chickens - - O
( - - O
7% - - O
positive - - O
) - - O
, - - O
and - - O
pigs - - O
( - - O
6% - - O
positive - - O
) - - O
. - - O

Poly - - O
( - - O
dT - - O
) - - O
and - - O
denatured - - O
calf - - O
thymus - - O
DNA - - O
were - - O
more - - O
effective - - O
than - - O
were - - O
other - - O
polynucleotides - - O
tested - - O
in - - O
promoting - - O
accumulation - - O
of - - O
19 - - O
HDP* - - B-MUT
; - - O
( - - O
dT - - O
) - - O
8 - - O
was - - O
as - - O
effective - - O
as - - O
were - - O
longer - - O
molecules - - O
of - - O
( - - O
dT - - O
) - - O
n - - O
, - - O
but - - O
( - - O
dT - - O
) - - O
4 - - O
and - - O
( - - O
dT - - O
) - - O
6 - - O
were - - O
much - - O
less - - O
effective - - O
, - - O
indicating - - O
that - - O
the - - O
binding - - O
site - - O
involved - - O
in - - O
19 - - O
HDP* - - B-MUT
accumulation - - O
covered - - O
between - - O
6 - - O
and - - O
8 - - O
residues - - O
of - - O
( - - O
dT - - O
) - - O
n - - O
. - - O

Studies - - O
on - - O
powdered - - O
preparations - - O
. - - O

Ultraviolet - - O
light-induced - - O
kinin - - B-MUT
formation - - O
in - - O
human - - O
skin - - O
. - - O

Effect - - O
of - - O
bromazepam - - O
on - - O
growth - - B-MUT
hormone - - I-MUT
and - - O
prolactin - - B-MUT
secretion - - O
in - - O
normal - - O
subjects - - O
. - - O

In - - O
this - - O
study - - O
, - - O
we - - O
have - - O
cloned - - O
a - - O
region - - O
that - - O
complements - - O
the - - O
exoenzyme - - O
S-deficient - - O
phenotype - - O
of - - O
strain - - O
388 - - O
exs1 - - B-MUT
: - - O
: - - O
Tn1 - - B-MUT
, - - O
a - - O
chromosomal - - B-MUT
Tn1 - - I-MUT
insertional - - I-MUT
mutation - - I-MUT
. - - O

Cytoprotection - - O
with - - O
amifostine - - O
in - - O
radiotherapy - - O
or - - O
radio-chemotherapy - - O
of - - O
head - - O
and - - O
neck - - O
tumors - - O
. - - O

The - - O
BAL - - O
concentrations - - O
of - - O
the - - O
nine - - O
cytokines - - O
evaluated - - O
for - - O
the - - O
more - - O
and - - O
less - - O
affected - - O
lungs - - O
were - - O
compared - - O
: - - O
interleukin-6 - - B-MUT
( - - O
IL-6 - - B-MUT
) - - O
, - - O
IL-8 - - B-MUT
, - - O
IL-12 - - B-MUT
, - - O
tumor - - B-MUT
necrosis - - I-MUT
factor-alpha - - I-MUT
( - - O
TNF-alpha - - B-MUT
) - - O
, - - O
and - - O
interferon - - B-MUT
gamma - - I-MUT
( - - O
IFN-gamma - - B-MUT
) - - O
showed - - O
significant - - O
differences - - O
( - - O
p - - O
ranged - - O
between - - O
0 - - O
. - - O

Comparison - - O
of - - O
the - - O
cDNA-predicted - - O
avian - - B-MUT
TnIcardiac - - I-MUT
amino - - I-MUT
acid - - I-MUT
sequences - - I-MUT
with - - O
known - - O
TnI - - B-MUT
sequences - - I-MUT
indicated - - O
1 - - O
) - - O
that - - O
the - - O
presence - - O
of - - O
an - - O
N-terminal - - O
extension - - O
sequence - - O
carrying - - O
a - - O
dual - - O
protein - - B-MUT
kinase - - I-MUT
A - - I-MUT
phosphorylation - - O
target - - O
site - - O
and - - O
an - - O
adjacent - - O
proline-rich - - O
segment - - O
is - - O
an - - O
ancient - - O
cardiac-specific - - O
feature - - O
of - - O
TnI - - B-MUT
which - - O
has - - O
been - - O
conserved - - O
since - - O
the - - O
bird - - O
mammal - - O
divergence - - O
, - - O
2 - - O
) - - O
that - - O
features - - O
of - - O
the - - O
near-N-terminal - - O
troponin - - O
C - - B-MUT
( - - I-MUT
TnC - - O
) - - B-MUT
-binding - - O
site - - O
sequence - - O
suggest - - O
isoform-specific - - O
adaptation - - O
of - - O
TnI - - O
and - - B-MUT
TnC - - O
, - - B-MUT
and - - O
3 - - O
) - - O
that - - O
the - - O
avian - - O
TnIcardiac - - O
internal - - B-MUT
actin - - O
TnC-binding - - B-MUT
, - - I-MUT
actomyosin-inhibitory - - I-MUT
, - - I-MUT
domain - - I-MUT
shows - - I-MUT
significant - - I-MUT
sequence - - O
divergence - - O
from - - O
mammalian - - O
TnIcardiac - - O
sequences - - B-MUT
, - - I-MUT
including - - I-MUT
the - - O
absence - - O
of - - O
a - - O
protein - - O
kinase - - O
C - - B-MUT
target - - I-MUT
site - - I-MUT
which - - O
is - - O
a - - O
cardiac-specific - - O
feature - - O
of - - O
TnI - - O
in - - O
mammals - - B-MUT
. - - O

Certain - - O
spt10 - - B-MUT
spontaneous - - O
alleles - - O
are - - O
good - - O
suppressors - - O
but - - O
have - - O
a - - O
normal - - O
growth - - O
rate - - O
, - - O
suggesting - - O
that - - O
the - - O
SPT10 - - B-MUT
protein - - I-MUT
may - - O
have - - O
two - - O
distinct - - O
functions - - O
. - - O

Genomic - - O
libraries - - O
were - - O
stored - - O
as - - O
frozen - - O
cultures - - O
in - - O
a - - O
96-well - - O
format - - O
, - - O
each - - O
well - - O
containing - - O
approximately - - O
300-600 - - O
colonies - - O
( - - O
12 - - O
plates - - O
for - - O
small - - O
library - - O
, - - O
four - - O
for - - O
medium-size - - O
library - - O
and - - O
four - - O
for - - O
large - - O
library - - O
) - - O
. - - O

In - - O
summary - - O
, - - O
the - - O
efficacies - - O
of - - O
adjuvant - - O
carboplatin - - O
and - - O
of - - O
abdominal - - O
radiotherapy - - O
seem - - O
to - - O
be - - O
identical - - O
. - - O

Immobilized - - O
dimers - - O
of - - O
N-cadherin-Fc - - B-MUT
chimera - - I-MUT
mimic - - O
cadherin-mediated - - O
cell - - O
contact - - O
formation - - O
: - - O
contribution - - O
of - - O
both - - O
outside-in - - O
and - - O
inside-out - - O
signals - - O
. - - O

In - - O
contrast - - O
, - - O
gel - - O
mobility - - O
shift - - O
experiments - - O
have - - O
failed - - O
to - - O
reveal - - O
that - - O
HAP2 - - B-MUT
or - - O
HAP3 - - B-MUT
binds - - O
to - - O
domain - - O
1 - - O
or - - O
that - - O
hap3 - - B-MUT
mutations - - O
affect - - O
the - - O
complexes - - O
bound - - O
to - - O
it - - O
. - - O

The - - O
PDH - - B-MUT
complex-encoding - - I-MUT
genes - - I-MUT
were - - O
identified - - O
by - - O
hybridization - - O
experiments - - O
and - - O
sequence - - O
analysis - - O
in - - O
two - - O
separate - - O
gene - - O
regions - - O
in - - O
the - - O
genome - - O
of - - O
Z - - O
. - - O
mobilis - - O
. - - O

None - - O
of - - O
the - - O
patients - - O
was - - O
obese - - O
. - - O

Sensory - - O
evoked - - O
field - - O
potentials - - O
were - - O
recorded - - O
from - - O
the - - O
mesencephalic - - O
reticular - - O
formation - - O
( - - O
MRF - - O
) - - O
, - - O
central - - O
gray - - O
( - - O
CG - - O
) - - O
and - - O
somatosensory - - O
cortex - - O
( - - O
SCX - - O
) - - O
, - - O
following - - O
incremental - - O
doses - - O
of - - O
halothane - - O
in - - O
freely-moving - - O
rats - - O
. - - O

Mucosal - - O
application - - O
of - - O
NCX-4016 - - O
, - - O
however - - O
, - - O
did - - O
not - - O
cause - - O
PD - - O
reduction - - O
and - - O
luminal - - O
H+ - - O
loss - - O
, - - O
but - - O
produced - - O
a - - O
marked - - O
hyperemia - - O
, - - O
resulting - - O
in - - O
no - - O
damage - - O
in - - O
the - - O
stomach - - O
of - - O
both - - O
normal - - O
and - - O
STZ-diabetic - - O
rats - - O
. - - O

A - - O
role - - O
for - - O
glycogen - - B-MUT
synthase - - I-MUT
kinase-3 - - I-MUT
in - - O
the - - O
control - - O
of - - O
gene - - O
expression - - O
. - - O

CONCLUSION - - O
: - - O
Our - - O
study - - O
shows - - O
that - - O
( - - O
1 - - O
) - - O
total - - O
body - - O
BMD - - O
and - - O
femoral - - O
neck - - O
BMD - - O
were - - O
significantly - - O
higher - - O
in - - O
the - - O
study - - O
group - - O
that - - O
performed - - O
weight-bearing - - O
exercises - - O
than - - O
in - - O
control - - O
subjects - - O
, - - O
( - - O
2 - - O
) - - O
swimming - - O
exercise - - O
had - - O
no - - O
effect - - O
on - - O
BMD - - O
, - - O
and - - O
( - - O
3 - - O
) - - O
although - - O
swimming - - O
is - - O
not - - O
a - - O
bone-building - - O
exercise - - O
, - - O
it - - O
can - - O
significantly - - O
improve - - O
shoulder - - O
, - - O
back - - O
, - - O
and - - O
grip - - O
muscle - - O
strength - - O
. - - O

Adjuvant - - O
therapy - - O
for - - O
colon - - O
cancer - - O
Surgery - - O
alone - - O
may - - O
fail - - O
to - - O
cure - - O
a - - O
considerable - - O
number - - O
of - - O
locally - - O
advanced - - O
colon - - O
cancers - - O
. - - O

Several - - O
particular - - O
features - - O
of - - O
this - - O
polypeptide - - O
fragment - - O
from - - O
the - - O
hamster - - B-MUT
lysyl-tRNA - - I-MUT
synthetase - - I-MUT
suggest - - O
that - - O
it - - O
is - - O
implicated - - O
in - - O
the - - O
assembly - - O
of - - O
that - - O
enzyme - - O
within - - O
the - - O
multisynthetase - - O
complex - - O
. - - O

Identification - - O
of - - O
an - - O
AfsA - - B-MUT
homologue - - I-MUT
( - - O
BarX - - B-MUT
) - - O
from - - O
Streptomyces - - O
virginiae - - O
as - - O
a - - O
pleiotropic - - O
regulator - - O
controlling - - O
autoregulator - - O
biosynthesis - - O
, - - O
virginiamycin - - O
biosynthesis - - O
and - - O
virginiamycin - - O
M1 - - O
resistance - - O
. - - O

The - - O
deduced - - O
amino - - O
acid - - O
sequence - - O
was - - O
highly - - O
conserved - - O
across - - O
the - - O
wide - - O
range - - O
of - - O
eukaryotes - - O
( - - O
vertebrates - - O
, - - O
invertebrates - - O
, - - O
fungi - - O
, - - O
plants - - O
and - - O
protozoa - - O
) - - O
in - - O
which - - O
this - - O
gene - - O
has - - O
now - - O
been - - O
identified - - O
. - - O

We - - O
observed - - O
NP - - B-MUT
NMP4 - - I-MUT
CIZ - - I-MUT
expression - - I-MUT
in - - I-MUT
osteocytes - - O
, - - O
osteoblasts - - O
, - - O
and - - O
chondrocytes - - O
in - - O
rat - - O
bone - - O
. - - O

Southwestern - - O
blot - - O
analysis - - O
demonstrated - - O
that - - O
this - - O
phosphoprotein - - O
can - - O
bind - - O
the - - O
kappa - - B-MUT
B - - I-MUT
element - - I-MUT
directly - - O
and - - O
specifically - - O
. - - O

The - - O
therapeutic - - O
action - - O
of - - O
cyclosporin - - O
A - - O
( - - O
Sandimmun - - O
) - - O
: - - O
its - - O
application - - O
in - - O
rheumatoid - - O
arthritis - - O
. - - O

Results - - O
of - - O
this - - O
study - - O
indicate - - O
that - - O
GLC - - O
of - - O
short - - O
chain - - O
fatty - - O
acids - - O
produced - - O
on - - O
agar - - O
medium - - O
by - - O
anaerobes - - O
, - - O
combined - - O
with - - O
simple - - O
tests - - O
such - - O
as - - O
Gram's - - O
stain - - O
and - - O
colonial - - O
morphology - - O
, - - O
may - - O
allow - - O
fir - - O
direct - - O
presumptive - - O
genus - - O
identification - - O
from - - O
an - - O
initial - - O
pure - - O
agar - - O
culture - - O
. - - O

Moreover - - O
, - - O
the - - O
mass - - O
estimated - - O
with - - O
the - - O
QCM - - O
response - - O
through - - O
the - - O
Sauerbrey - - O
equation - - O
and - - O
the - - O
mass - - O
which - - O
can - - O
be - - O
measured - - O
thanks - - O
to - - O
other - - O
analytical - - O
techniques - - O
, - - O
in - - O
our - - O
case - - O
an - - O
enzymatic - - O
assay - - O
, - - O
are - - O
different - - O
: - - O
the - - O
deposited - - O
mass - - O
is - - O
generally - - O
overestimated - - O
by - - O
the - - O
QCM - - O
. - - O

The - - O
Wnt - - B-MUT
signaling - - O
pathway - - O
functions - - O
reiteratively - - O
during - - O
animal - - O
development - - O
to - - O
control - - O
cell - - O
fate - - O
decisions - - O
. - - O

The - - O
relationship - - O
of - - O
human - - O
umbilical - - O
arterial - - O
and - - O
venous - - O
plasma - - O
levels - - O
of - - O
corticosteroids - - O
to - - O
gestational - - O
age - - O
. - - O

Oseltamivir - - O
( - - O
GS4104 - - O
) - - O
, - - O
which - - O
can - - O
be - - O
administered - - O
orally - - O
, - - O
is - - O
the - - O
prodrug - - O
of - - O
GS4071 - - O
, - - O
a - - O
potent - - O
and - - O
selective - - O
inhibitor - - O
of - - O
influenzavirus - - B-MUT
neuraminidases - - I-MUT
. - - O

BACKGROUND - - O
: - - O
Defensins - - B-MUT
, - - O
also - - O
known - - O
as - - O
human - - B-MUT
neutrophil - - I-MUT
peptides - - I-MUT
, - - O
are - - O
antimicrobial - - O
peptides - - O
present - - O
in - - O
the - - O
azurophil - - O
granules - - O
of - - O
neutrophils - - O
. - - O

We - - O
also - - O
show - - O
by - - O
immunogold - - O
electron - - O
microscopy - - O
immunocytochemistry - - O
that - - O
amphiphysin - - B-MUT
I - - I-MUT
is - - O
localized - - O
in - - O
the - - O
nerve - - O
terminal - - O
cytomatrix - - O
and - - O
is - - O
partially - - O
associated - - O
with - - O
endocytic - - O
intermediates - - O
. - - O

The - - O
human - - B-MUT
gp39 - - I-MUT
promoter - - I-MUT
. - - O

The - - O
metabolic - - O
clearance - - O
rate - - O
of - - O
progesterone - - O
was - - O
295 - - O
+ - - O
- - - O
49 - - O
( - - O
S - - O
. - - O
E - - O
. - - O
) - - O
1 - - O
day - - O
. - - O

The - - O
SCMV - - B-MUT
SNE - - I-MUT
sites - - I-MUT
contain - - O
potential - - O
overlapping - - O
core - - O
recognition - - O
binding - - O
motifs - - O
for - - O
SRF - - B-MUT
, - - O
Rel - - B-MUT
NFkappaB - - I-MUT
, - - I-MUT
ETS - - O
, - - B-MUT
and - - O
YY1 - - O
class - - B-MUT
transcription - - I-MUT
factors - - I-MUT
but - - I-MUT
fail - - O
to - - O
respond - - O
to - - O
either - - O
serum - - O
or - - O
tumor - - O
necrosis - - B-MUT
factor - - I-MUT
alpha - - I-MUT
. - - I-MUT

Disulfiram - - O
and - - O
the - - O
drug-induced - - O
effects - - O
on - - O
motility - - O
. - - O

Resistance - - O
training - - O
shifts - - O
the - - O
power - - O
curve - - O
in - - O
a - - O
positive - - O
direction - - O
when - - O
the - - O
measurements - - O
are - - O
determined - - O
with - - O
absolute - - O
loads - - O
, - - O
but - - O
the - - O
increased - - O
power - - O
may - - O
not - - O
be - - O
transferred - - O
to - - O
an - - O
absolute - - O
performance - - O
task - - O
like - - O
the - - O
SSP - - O
. - - O

The - - O
authors - - O
concluded - - O
that - - O
ultrasonic - - O
Doppler-cardiography - - O
can - - O
be - - O
used - - O
for - - O
measuring - - O
the - - O
relative - - O
changes - - O
in - - O
the - - O
stroke - - O
volume - - O
. - - O

The - - O
c-Ets-1 - - B-MUT
oncoprotein - - I-MUT
is - - O
a - - O
transcription - - O
activator - - O
that - - O
specifically - - O
binds - - O
to - - O
DNA - - O
. - - O

Internally - - O
oriented - - O
patients' - - O
scores - - O
on - - O
Rotter's - - O
Internal-External - - O
Locus - - O
of - - O
Control - - O
Scale - - O
remained - - O
the - - O
same - - O
over - - O
treatment - - O
but - - O
those - - O
of - - O
externally - - O
oriented - - O
patients - - O
shifted - - O
toward - - O
greater - - O
internal - - O
control - - O
. - - O

Percent - - O
identities - - O
of - - O
the - - O
mouse - - B-MUT
PP2 - - I-MUT
to - - O
mouse - - B-MUT
Y1 - - I-MUT
, - - O
mouse - - B-MUT
Y4 - - I-MUT
PP1 - - I-MUT
and - - I-MUT
human - - O
Y2 - - B-MUT
receptors - - I-MUT
are - - I-MUT
53 - - O
, - - O
42 - - O
, - - O
and - - O
31 - - O
, - - O
respectively - - O
. - - O

ZK7 - - B-MUT
and - - O
HZF16 - - B-MUT
genes - - I-MUT
appear - - O
to - - O
be - - O
the - - O
splice - - O
variants - - O
transcribed - - O
from - - O
the - - O
same - - O
gene - - O
. - - O

Evidence - - O
for - - O
two - - O
distinctive - - O
clinical - - O
, - - O
epidemiological - - O
, - - O
and - - O
immunological - - O
types - - O
of - - O
infection - - O
. - - O

Positional - - O
cloning - - O
has - - O
already - - O
produced - - O
the - - O
sequences - - O
of - - O
more - - O
than - - O
70 - - O
human - - O
genes - - O
associated - - O
with - - O
specific - - O
diseases - - O
. - - O

15 - - O
, - - O
2500-2508 - - O
; - - O
O'Neill - - O
, - - O
T - - O
. - - O

Serum - - O
lipid - - O
changes - - O
during - - O
pregnancy - - O
due - - O
to - - O
oral - - O
calcium - - O
administration - - O
. - - O

The - - O
protein - - O
is - - O
composed - - O
of - - O
two - - O
major - - O
domains - - O
separated - - O
by - - O
a - - O
hydrophobic - - O
linker - - O
region - - O
of - - O
20 - - O
amino - - O
acid - - O
residues - - O
. - - O

MEK - - B-MUT
itself - - O
is - - O
activated - - O
via - - O
serine - - O
phosphorylation - - O
by - - O
upstream - - B-MUT
activator - - I-MUT
kinases - - I-MUT
, - - O
including - - O
c-raf - - B-MUT
, - - O
mos - - B-MUT
and - - O
MEK - - B-MUT
kinase - - I-MUT
. - - O

A - - O
protein - - O
lacking - - O
the - - O
SH2 - - B-MUT
and - - O
RING - - O
finger - - O
domains - - O
has - - O
no - - O
activity - - O
, - - O
but - - O
a - - O
chimeric - - O
protein - - O
with - - O
the - - O
SH2 - - B-MUT
and - - O
RING - - O
finger - - O
domains - - O
of - - O
SLI-1 - - B-MUT
replaced - - O
by - - O
the - - O
equivalent - - O
domains - - O
of - - O
c-Cbl - - B-MUT
has - - O
activity - - O
. - - O

Sequence - - O
analysis - - O
revealed - - O
that - - O
the - - O
MEMA - - B-MUT
protein - - I-MUT
is - - O
identical - - O
with - - O
a - - O
160 - - B-MUT
kDa - - I-MUT
nuclear - - I-MUT
'domain - - I-MUT
rich - - I-MUT
in - - I-MUT
serines' - - I-MUT
( - - I-MUT
DRS - - I-MUT
) - - I-MUT
protein - - I-MUT
occurring - - O
free - - O
in - - O
the - - O
nucleoplasm - - O
and - - O
in - - O
U2-ribonucleoprotein - - B-MUT
structures - - I-MUT
. - - O

The - - O
central - - O
globular - - O
domain - - O
is - - O
highly - - O
similar - - O
to - - O
those - - O
regions - - O
from - - O
other - - O
H1 - - B-MUT
molecules - - I-MUT
, - - O
and - - O
the - - O
carboxyl-terminal - - O
domain - - O
contains - - O
a - - O
repeating - - O
hexapeptide - - O
motif - - O
, - - O
variants - - O
of - - O
which - - O
are - - O
conserved - - O
among - - O
H1 - - B-MUT
molecules - - I-MUT
. - - O

Neither - - O
side - - O
effect - - O
nor - - O
abnormal - - O
laboratory - - O
findings - - O
due - - O
to - - O
this - - O
drug - - O
were - - O
observed - - O
. - - O

One - - O
group - - O
( - - O
n - - O
= - - O
9 - - O
) - - O
was - - O
premedicated - - O
with - - O
midazolam - - O
, - - O
0 - - O
. - - O
1 - - O
mg - - O
kg-1 - - O
, - - O
and - - O
atropine - - O
0 - - O
. - - O
2-0 - - O
. - - O
4 - - O
mg - - O
i - - O
. - - O
m - - O
. - - O

No - - O
evidence - - O
for - - O
the - - O
presence - - O
of - - O
introns - - O
within - - O
the - - O
acvA - - B-MUT
gene - - I-MUT
has - - O
been - - O
found - - O
. - - O

The - - O
effects - - O
of - - O
tap - - O
( - - O
TW - - O
) - - O
or - - O
carbonated - - O
( - - O
CW - - O
) - - O
water - - O
on - - O
arterial - - O
pH - - O
, - - O
partial - - O
pressure - - O
of - - O
carbon - - O
dioxide - - O
( - - O
PCO2 - - O
) - - O
and - - O
plasma - - O
lactate - - O
were - - O
determined - - O
in - - O
heat-stressed - - O
broilers - - O
. - - O

Weak - - O
promoter - - O
activity - - O
was - - O
observed - - O
for - - O
the - - O
promoter - - O
of - - O
the - - O
C1 - - B-MUT
and - - I-MUT
C2 - - I-MUT
ORFs - - I-MUT
( - - O
C1-C2 - - B-MUT
gene - - I-MUT
) - - O
and - - O
for - - O
the - - O
promoter - - O
of - - O
the - - O
V1 - - B-MUT
ORF - - I-MUT
. - - O

These - - O
results - - O
strongly - - O
suggested - - O
that - - O
similar - - O
, - - O
if - - O
not - - O
identical - - O
, - - O
the - - O
CArG - - B-MUT
box - - I-MUT
binding - - I-MUT
proteins - - I-MUT
interact - - O
with - - O
the - - O
functionally - - O
different - - O
promoter - - O
element - - O
in - - O
the - - O
VLC1 - - B-MUT
, - - O
cardiac - - B-MUT
alpha-actin - - I-MUT
, - - O
and - - O
c-fos - - B-MUT
genes - - I-MUT
. - - O

The - - O
ORFII - - B-MUT
gene - - I-MUT
product - - I-MUT
is - - O
targeted - - O
to - - O
the - - O
chloroplast - - O
, - - O
which - - O
is - - O
consistent - - O
with - - O
previous - - O
data - - O
indicating - - O
the - - O
presence - - O
of - - O
PMSR - - B-MUT
activity - - O
in - - O
the - - O
chloroplast - - O
. - - O

BACKGROUND - - O
: - - O
The - - O
aim - - O
of - - O
this - - O
study - - O
was - - O
to - - O
determine - - O
the - - O
response - - O
rates - - O
and - - O
toxicity - - O
of - - O
two - - O
regimens - - O
containing - - O
granulocyte-macrophage-colony - - B-MUT
stimulating - - I-MUT
factor - - I-MUT
( - - O
GM-CSF - - B-MUT
) - - O
in - - O
combination - - O
with - - O
interleukin-2 - - B-MUT
( - - O
IL-2 - - B-MUT
) - - O
in - - O
the - - O
treatment - - O
of - - O
patients - - O
with - - O
metastatic - - O
renal - - O
cell - - O
carcinoma - - O
. - - O

( - - O
1998 - - O
) - - O
J - - O
. - - O

For - - O
this - - O
purpose - - O
, - - O
a - - O
simple - - O
respiration-control - - O
device - - O
has - - O
been - - O
developed - - O
that - - O
enables - - O
the - - O
patient - - O
to - - O
monitor - - O
breath-holding - - O
during - - O
successive - - O
scans - - O
. - - O

Additional - - O
education - - O
and - - O
research - - O
is - - O
needed - - O
to - - O
provide - - O
further - - O
direction - - O
for - - O
intervention - - O
and - - O
incorporation - - O
into - - O
practice - - O
. - - O

The - - O
438 - - B-MUT
bp - - I-MUT
EcoRI - - I-MUT
fragment - - I-MUT
, - - O
which - - O
was - - O
detected - - O
by - - O
Southern - - O
hybridization - - O
, - - O
reveals - - O
an - - O
open - - O
reading - - O
frame - - O
which - - O
encodes - - O
a - - O
protein - - O
of - - O
103 - - O
amino - - O
acids - - O
. - - O

In - - O
the - - O
meantime - - O
, - - O
one - - O
has - - O
succeeded - - O
to - - O
establish - - O
the - - O
deammonification - - O
processes - - O
in - - O
a - - O
continuous - - O
flow - - O
moving-bed - - O
pilot - - O
plant - - O
. - - O

Restoration - - O
of - - O
impaired - - O
immune - - O
functions - - O
in - - O
aging - - O
animals - - O
. - - O

While - - O
this - - O
Saccharomyces - - O
cerevisiae - - O
SIN4 - - B-MUT
gene - - I-MUT
product - - I-MUT
is - - O
a - - O
component - - O
of - - O
a - - O
mediator - - O
complex - - O
associated - - O
with - - O
RNA - - B-MUT
polymerase - - I-MUT
II - - I-MUT
, - - O
various - - O
studies - - O
suggest - - O
the - - O
involvement - - O
of - - O
Sin4 - - B-MUT
in - - O
the - - O
alteration - - O
of - - O
higher-order - - O
chromatin - - O
structure - - O
. - - O

A - - O
high-resolution - - O
restriction - - O
map - - O
of - - O
over - - O
200 - - O
kb - - O
of - - O
contiguous - - O
DNA - - O
containing - - O
N-myc - - B-MUT
has - - O
been - - O
generated - - O
by - - O
subcloning - - O
YACs - - O
into - - O
cosmids - - O
. - - O

While - - O
the - - O
latter - - O
corresponded - - O
to - - O
a - - O
protein - - O
of - - O
824 - - O
amino - - O
acids - - O
, - - O
an - - O
upstream - - O
open - - O
reading - - O
frame - - O
( - - O
uORF - - O
) - - O
within - - O
the - - O
5' - - O
leader - - O
could - - O
potentially - - O
encode - - O
a - - O
54 - - O
amino - - O
acid - - O
peptide - - O
. - - O

In - - O
summary - - O
, - - O
the - - O
no-adverse-effect-level - - O
for - - O
this - - O
study - - O
was - - O
determined - - O
to - - O
be - - O
1000 - - O
ppm - - O
, - - O
based - - O
on - - O
decreased - - O
weight - - O
gain - - O
in - - O
female - - O
rats - - O
, - - O
and - - O
on - - O
slight - - O
organ - - O
weight - - O
changes - - O
in - - O
both - - O
sexes - - O
at - - O
3000 - - O
ppm - - O
. - - O

A - - O
secondary - - O
spread - - O
of - - O
an - - O
imported - - O
methicillin-resistant - - O
Staphylococcus - - O
aureus - - O
strain - - O
( - - O
MRSA - - O
) - - O
to - - O
two - - O
other - - O
patients - - O
occurred - - O
within - - O
a - - O
Danish - - O
surgical - - O
ward - - O
in - - O
spite - - O
of - - O
isolation - - O
of - - O
a - - O
multitraumatized - - O
index-patient - - O
immediately - - O
after - - O
arrival - - O
from - - O
a - - O
hospital - - O
in - - O
the - - O
Mediterranean - - O
area - - O
. - - O

The - - O
FMN - - O
moiety - - O
but - - O
not - - O
the - - O
[ - - O
3Fe-4S - - O
] - - O
cluster - - O
of - - O
the - - O
subunit - - O
appears - - O
to - - O
participate - - O
in - - O
this - - O
reaction - - O
. - - O

It - - O
thus - - O
appears - - O
that - - O
MAPK - - B-MUT
functions - - O
in - - O
meiotic - - O
maturation - - O
by - - O
preventing - - O
unfertilized - - O
eggs - - O
from - - O
proceeding - - O
into - - O
parthenogenetic - - O
development - - O
. - - O

Tolterodine - - O
users - - O
were - - O
7 - - O
. - - O
5 - - O
times - - O
more - - O
likely - - O
to - - O
have - - O
received - - O
another - - O
spasmolytic - - O
drug - - O
( - - O
RR - - O
7 - - O
. - - O
5 - - O
, - - O
95% - - O
CI - - O
4 - - O
. - - O
8 - - O
to - - O
11 - - O
. - - O
9 - - O
) - - O
. - - O

Effect - - O
of - - O
immune - - O
lymphocytes - - O
and - - O
of - - O
rabbit-anti-lymphocyte - - B-MUT
globulin - - I-MUT
( - - O
RAMLG - - B-MUT
) - - O
on - - O
infected - - O
macrophages - - O
exposed - - O
to - - O
increased - - O
incubation - - O
temperature - - O
in - - O
vitro - - O
. - - O

The - - O
Menopause-Rating-Scale - - O
( - - O
MRS - - O
I - - O
) - - O
was - - O
used - - O
in - - O
clinical - - O
practice - - O
since - - O
1992 - - O
. - - O

CONCLUSION - - O
: - - O
Patients - - O
wit - - O
clinically - - O
palpable - - O
neck - - O
disease - - O
( - - O
N1-3 - - O
) - - O
, - - O
histological - - O
evidence - - O
of - - O
metastatic - - O
nodal - - O
disease - - O
, - - O
extracapsular - - O
spread - - O
, - - O
and - - O
three - - O
or - - O
more - - O
positive - - O
lymph - - O
nodes - - O
are - - O
at - - O
greater - - O
risk - - O
of - - O
developing - - O
failure - - O
at - - O
distant - - O
sites - - O
. - - O

Cardiac - - O
disease - - O
was - - O
not - - O
detected - - O
with - - O
M-mode - - O
, - - O
2-dimensional - - O
real-time - - O
or - - O
pulsed-wave - - O
Doppler - - O
echocardiography - - O
. - - O

Bupropion - - O
to - - O
aid - - O
smoking - - O
cessation - - O
. - - O

One - - O
extract - - O
with - - O
the - - O
lowest - - O
PCA - - O
content - - O
was - - O
non-carcinogenic - - O
. - - O

The - - O
derivatives - - O
of - - O
the - - O
latter - - O
two - - O
cell - - O
lines - - O
showed - - O
increased - - O
expression - - O
of - - O
the - - O
p27Kip1 - - B-MUT
protein - - I-MUT
and - - O
inhibition - - O
of - - O
cell - - O
growth - - O
. - - O

Interestingly - - O
, - - O
the - - O
interaction - - O
of - - O
ZAP-70 - - B-MUT
with - - O
the - - O
motif - - O
was - - O
dependent - - O
on - - O
the - - O
presence - - O
of - - O
both - - O
ZAP-70 - - B-MUT
SH2 - - B-MUT
domains - - I-MUT
and - - O
both - - O
of - - O
the - - O
tyrosine - - O
residues - - O
in - - O
the - - O
motif - - O
, - - O
suggesting - - O
that - - O
ZAP-70 - - B-MUT
interacts - - O
with - - O
two - - O
phosphotyrosine - - O
residues - - O
and - - O
that - - O
the - - O
binding - - O
of - - O
the - - O
two - - O
SH2 - - B-MUT
domains - - I-MUT
is - - O
cooperative - - O
. - - O

The - - O
baroreflex - - O
latency - - O
( - - O
from - - O
the - - O
ECG - - O
R-wave - - O
to - - O
the - - O
integrated - - O
MSNA - - O
burst - - O
peak - - O
) - - O
was - - O
constant - - O
at - - O
approximately - - O
1 - - O
. - - O
20 - - O
s - - O
during - - O
sleep - - O
, - - O
suggesting - - O
that - - O
pulse-synchronicity - - O
was - - O
maintained - - O
. - - O

One - - O
CKD - - O
patient's - - O
journey - - O
. - - O

The - - O
mode - - O
of - - O
resistance - - O
to - - O
quinupristin - - O
dalfopristin - - O
was - - O
not - - O
evident - - O
( - - O
sat - - O
A-negative - - O
by - - O
PCR - - O
) - - O
; - - O
and - - O
these - - O
cases - - O
illustrate - - O
the - - O
existence - - O
of - - O
streptogramin-resistant - - O
isolates - - O
before - - O
the - - O
introduction - - O
of - - O
this - - O
antimicrobial - - O
class - - O
into - - O
human - - O
clinical - - O
practice - - O
. - - O

The - - O
conservation - - O
of - - O
both - - O
the - - O
G-box - - O
and - - O
H-box - - O
in - - O
different - - O
CHS - - B-MUT
promoters - - I-MUT
emphasizes - - O
their - - O
importance - - O
as - - O
regulatory - - O
motifs - - O
. - - O

In - - O
the - - O
past - - O
decade - - O
, - - O
there - - O
have - - O
been - - O
enormous - - O
advances - - O
in - - O
the - - O
use - - O
of - - O
Bayesian - - O
methodology - - O
for - - O
analysis - - O
of - - O
epidemiologic - - O
data - - O
, - - O
and - - O
there - - O
are - - O
now - - O
many - - O
practical - - O
advantages - - O
to - - O
the - - O
Bayesian - - O
approach - - O
. - - O

Binding - - O
affinities - - O
of - - O
different - - O
nucleotide - - O
mono- - - O
, - - O
di- - - O
and - - O
triphosphates - - O
and - - O
non-hydrolyzable - - O
analogs - - O
indicate - - O
that - - O
the - - O
beta-phosphate - - O
moiety - - O
is - - O
required - - O
for - - O
substrate - - O
binding - - O
. - - O

The - - O
LTR-binding - - O
activities - - O
of - - O
VBP - - B-MUT
, - - O
a1 - - B-MUT
EBP - - I-MUT
, - - I-MUT
and - - O
B-cell - - O
nuclear - - O
extract - - O
protein - - O
were - - O
compared - - O
and - - O
mapped - - O
by - - O
gel - - O
shift - - O
, - - O
DNase - - O
I - - B-MUT
footprinting - - I-MUT
, - - O
and - - O
methylation - - O
interference - - O
assays - - O
. - - O

The - - O
importance - - O
of - - O
temporal - - O
factors - - O
on - - O
the - - O
presence - - O
and - - O
severity - - O
of - - O
ethanol - - O
withdrawal - - O
signs - - O
in - - O
the - - O
rat - - O
was - - O
quantified - - O
using - - O
rating - - O
scale - - O
, - - O
tremor - - O
, - - O
and - - O
acoustic - - O
startle - - O
paradigms - - O
. - - O

In - - O
this - - O
study - - O
26 - - O
patients - - O
( - - O
20 - - O
females - - O
and - - O
6 - - O
males - - O
) - - O
were - - O
evaluated - - O
. - - O

BACKGROUND - - O
AND - - O
DESIGN - - O
: - - O
Fifty-nine - - O
melanocytic - - O
nevi - - O
with - - O
eccentric - - O
foci - - O
of - - O
hyperpigmentation - - O
( - - O
"small - - O
dark - - O
dots" - - O
) - - O
that - - O
measured - - O
primarily - - O
1 - - O
to - - O
2 - - O
mm - - O
in - - O
diameter - - O
were - - O
prospectively - - O
examined - - O
to - - O
determine - - O
the - - O
histologic - - O
correlates - - O
of - - O
the - - O
dark - - O
dots - - O
. - - O

Phosphocreatine - - O
hydrolysis - - O
during - - O
submaximal - - O
exercise - - O
: - - O
the - - O
effect - - O
of - - O
FIO2 - - O
. - - O

Present - - O
results - - O
reveal - - O
a - - O
frequency-dependent - - O
inhibition - - O
of - - O
ganglionic - - O
transmission - - O
by - - O
diltiazem - - O
, - - O
and - - O
suggest - - O
that - - O
diltiazem - - O
may - - O
depress - - O
excessive - - O
sympathetic - - O
activity - - O
without - - O
affecting - - O
normal - - O
ganglionic - - O
transmission - - O
. - - O

Thus - - O
, - - O
quantitative - - O
analysis - - O
of - - O
thallium-201 - - O
uptake - - O
and - - O
washout - - O
provided - - O
objective - - O
evidence - - O
for - - O
improved - - O
myocardial - - O
perfusion - - O
after - - O
coronary - - O
angioplasty - - O
. - - O

However - - O
, - - O
artificially - - O
ventilated - - O
rats - - O
, - - O
pretreated - - O
with - - O
MK-801 - - O
, - - O
were - - O
more - - O
sensitive - - O
( - - O
lethal - - O
cocaine - - O
dose - - O
, - - O
76 - - O
. - - O
6 - - O
+ - - O
- - - O
8 - - O
. - - O
0 - - O
mg - - O
kg - - O
, - - O
n - - O
= - - O
5 - - O
) - - O
than - - O
vehicle - - O
pretreated - - O
rats - - O
( - - O
129 - - O
. - - O
4 - - O
+ - - O
- - - O
15 - - O
. - - O
8 - - O
mg - - O
kg - - O
, - - O
n - - O
= - - O
6 - - O
) - - O
, - - O
indicating - - O
that - - O
MK-801 - - O
may - - O
increase - - O
both - - O
the - - O
respiratory - - O
and - - O
the - - O
cardiac - - O
toxicity - - O
of - - O
cocaine - - O
in - - O
urethane - - O
anesthetized - - O
rats - - O
. - - O

However - - O
, - - O
overexpression - - O
of - - O
both - - O
the - - O
STE4 - - B-MUT
and - - O
STE18 - - B-MUT
proteins - - I-MUT
did - - O
not - - O
generate - - O
a - - O
stronger - - O
pheromone - - O
response - - O
than - - O
overexpression - - O
of - - O
STE4 - - B-MUT
in - - O
the - - O
presence - - O
of - - O
wild-type - - O
levels - - O
of - - O
STE18 - - B-MUT
. - - O

In - - O
a - - O
gel - - O
retardation - - O
assay - - O
using - - O
HepG2 - - O
nuclear - - O
extracts - - O
, - - O
the - - O
5' - - O
flanking - - O
sequence - - O
from - - O
-74 - - O
to - - O
-46 - - O
showed - - O
a - - O
shifted - - O
band - - O
. - - O

In - - O
an - - O
attempt - - O
to - - O
reduce - - O
the - - O
incidence - - O
of - - O
NSAID-induced - - O
gastrointestinal - - O
lesions - - O
, - - O
the - - O
following - - O
approaches - - O
have - - O
been - - O
proposed - - O
: - - O
( - - O
i - - O
) - - O
use - - O
of - - O
the - - O
prostaglandin - - O
analogue - - O
misoprostol - - O
, - - O
which - - O
is - - O
an - - O
antiulcer - - O
drug - - O
which - - O
has - - O
been - - O
proven - - O
to - - O
be - - O
as - - O
effective - - O
in - - O
the - - O
prevention - - O
of - - O
NSAID-induced - - O
gastric - - O
and - - O
duodenal - - O
ulcers - - O
as - - O
in - - O
the - - O
reduction - - O
of - - O
serious - - O
upper - - O
gastrointestinal - - O
complications - - O
; - - O
( - - O
ii - - O
) - - O
histamine - - B-MUT
H2 - - I-MUT
receptor - - I-MUT
antagonists - - O
( - - O
H2 - - O
antagonists - - O
) - - O
, - - O
e - - O
. - - O
g - - O
. - - O
ranitidine - - O
, - - O
cimetidine - - O
and - - O
famotidine - - O
, - - O
which - - O
are - - O
useful - - O
in - - O
the - - O
prevention - - O
of - - O
NSAID-induced - - O
duodenal - - O
ulcers - - O
during - - O
long - - O
term - - O
treatment - - O
, - - O
but - - O
not - - O
in - - O
the - - O
prevention - - O
of - - O
NSAID-induced - - O
gastric - - O
ulcers - - O
; - - O
( - - O
iii - - O
) - - O
proton - - O
pump - - O
inhibitors - - O
, - - O
e - - O
. - - O
g - - O
omeprazole - - O
, - - O
and - - O
pantoprazole - - O
, - - O
whose - - O
efficacy - - O
in - - O
preventing - - O
NSAID-associated - - O
ulcers - - O
has - - O
been - - O
recently - - O
demonstrated - - O
; - - O
and - - O
( - - O
iv - - O
) - - O
barrier - - O
agents - - O
, - - O
e - - O
. - - O
g - - O
. - - O
sucralfate - - O
, - - O
which - - O
cannot - - O
be - - O
recommended - - O
as - - O
prophylactic - - O
agents - - O
to - - O
prevent - - O
NSAID-induced - - O
gastropathy - - O
. - - O

SRC-1 - - B-MUT
can - - O
relieve - - O
the - - O
NF-kappaB-mediated - - O
repression - - O
of - - O
GR - - B-MUT
activity - - O
. - - O

Two - - O
other - - O
patients - - O
underwent - - O
PRFR - - O
. - - O

Biol - - O
. - - O

Thin - - O
melanomas - - O
can - - O
metastasize - - O
and - - O
be - - O
lethal - - O
. - - O

The - - O
chromosomal - - O
localization - - O
on - - O
distal - - O
chromosome - - O
7 - - O
places - - O
it - - O
in - - O
a - - O
cluster - - O
of - - O
imprinted - - O
genes - - O
, - - O
flanked - - O
by - - O
the - - O
previously - - O
described - - O
Tapa1 - - B-MUT
and - - O
Kcnq1 - - B-MUT
genes - - I-MUT
. - - O

Consistent - - O
with - - O
this - - O
interpretation - - O
, - - O
a - - O
mutant - - O
form - - O
of - - O
XRN1 - - B-MUT
, - - O
which - - O
encodes - - O
a - - O
5'-3' - - O
exonuclease - - O
, - - O
was - - O
identified - - O
as - - O
an - - O
extragenic - - O
suppressor - - O
that - - O
increases - - O
the - - O
half-life - - O
of - - O
rhis4 - - B-MUT
mRNA - - I-MUT
, - - O
leading - - O
to - - O
a - - O
10-fold - - O
increase - - O
in - - O
steady-state - - O
mRNA - - O
levels - - O
compared - - O
to - - O
the - - O
wild-type - - B-MUT
HIS4 - - I-MUT
mRNA - - I-MUT
level - - O
. - - O

Chlamydia - - O
trachomatis - - O
and - - O
Chlamydia - - O
psittaci - - O
were - - O
not - - O
affected - - O
by - - O
methanol - - O
fixation - - O
. - - O

Topological - - O
and - - O
Mutational - - O
Analysis - - O
of - - O
Saccharomyces - - B-MUT
cerevisiae - - I-MUT
Ste14p - - I-MUT
, - - O
Founding - - O
Member - - O
of - - O
the - - O
Isoprenylcysteine - - B-MUT
Carboxyl - - I-MUT
Methyltransferase - - I-MUT
Family - - I-MUT
. - - O

The - - O
pexB - - B-MUT
upstream - - I-MUT
region - - I-MUT
contained - - O
245 - - O
nucleotides - - O
within - - O
which - - O
sequences - - O
approximating - - O
the - - O
consensus - - O
for - - O
cyclic - - B-MUT
AMP - - I-MUT
receptor - - I-MUT
protein - - I-MUT
and - - O
integration - - B-MUT
host - - I-MUT
factor - - I-MUT
binding - - I-MUT
sites - - I-MUT
were - - O
discernible - - O
. - - O

Transient - - O
transfections - - O
of - - O
a - - O
construct - - O
expressing - - O
the - - O
RNA - - O
transcript - - O
defined - - O
by - - O
clone - - O
B1 - - O
. - - O
1 - - O
into - - O
D17 - - O
cells - - O
led - - O
to - - O
the - - O
expression - - O
of - - O
an - - O
Env - - B-MUT
Mlvi-4 - - I-MUT
fusion - - I-MUT
protein - - I-MUT
with - - I-MUT
an - - O
apparent - - O
molecular - - O
mass - - O
of - - O
33 - - O
kDa - - O
. - - O

This - - O
study - - O
suggests - - O
that - - O
PSP - - O
is - - O
more - - O
common - - O
than - - O
previously - - O
considered - - O
, - - O
is - - O
commonly - - O
misdiagnosed - - O
and - - O
that - - O
the - - O
majority - - O
of - - O
cases - - O
are - - O
not - - O
initially - - O
referred - - O
to - - O
neurologists - - O
. - - O

While - - O
TGF-beta1 - - B-MUT
does - - O
not - - O
alter - - O
the - - O
mitogen-induced - - O
expression - - O
and - - O
abundance - - O
of - - O
G1 - - O
phase - - O
cyclin - - B-MUT
D1 - - I-MUT
and - - O
cdks - - B-MUT
4 - - I-MUT
and - - I-MUT
2 - - I-MUT
in - - O
MCs - - O
, - - O
it - - O
inhibits - - O
cyclin - - B-MUT
E-cdk - - I-MUT
2 - - I-MUT
activity - - O
, - - O
thus - - O
preventing - - O
mitogen-elicited - - O
phosphorylation - - O
and - - O
inactivation - - O
of - - O
pRb - - B-MUT
in - - O
G1 - - O
phase - - O
and - - O
transition - - O
to - - O
S - - O
phase - - O
. - - O

The - - O
application - - O
of - - O
the - - O
biotechnology - - O
at - - O
the - - O
plants - - O
for - - O
treatment - - O
of - - O
the - - O
surface - - O
storm - - O
waters - - O
from - - O
the - - O
industrial - - O
zone - - O
Telychka - - O
of - - O
the - - O
city - - O
of - - O
Kyiv - - O
has - - O
allowed - - O
the - - O
content - - O
of - - O
petroleum - - O
in - - O
water - - O
dropped - - O
to - - O
the - - O
Dnieper - - O
to - - O
be - - O
constantly - - O
reduced - - O
50-100 - - O
times - - O
. - - O

Structural - - O
organization - - O
and - - O
expression - - O
of - - O
the - - O
mouse - - B-MUT
estrogen - - I-MUT
receptor - - I-MUT
. - - O

These - - O
data - - O
suggest - - O
that - - O
dopaminergic - - O
regulation - - O
of - - O
adrenal - - O
zona - - O
glomerulosa - - O
corticosteroid - - O
and - - O
renal - - B-MUT
renin - - I-MUT
secretion - - O
is - - O
absent - - O
in - - O
patients - - O
with - - O
high - - O
spinal - - O
cord - - O
transections - - O
, - - O
suggesting - - O
that - - O
intact - - O
neural - - O
pathways - - O
from - - O
the - - O
central - - O
nervous - - O
system - - O
are - - O
necessary - - O
for - - O
metoclopramide - - O
stimulation - - O
of - - O
aldosterone - - O
and - - O
renin - - B-MUT
secretion - - O
in - - O
men - - O
. - - O

Thus - - O
, - - O
VF - - O
resistant - - O
to - - O
defibrillation - - O
is - - O
not - - O
necessarily - - O
associated - - O
with - - O
both - - O
toxic - - O
plasma - - O
drug - - O
level - - O
and - - O
remarkably - - O
decreased - - O
conduction - - O
. - - O

Wegener's - - O
granulomatosis - - O

Comparison - - O
of - - O
elastase-1 - - B-MUT
with - - O
amylase - - B-MUT
, - - O
lipase - - B-MUT
, - - O
and - - O
trypsin-like - - O
immunoreactivity - - O
in - - O
the - - O
diagnosis - - O
of - - O
acute - - O
pancreatitis - - O
. - - O

The - - O
Sox - - B-MUT
gene - - I-MUT
family - - I-MUT
( - - O
Sry - - B-MUT
like - - O
HMG - - B-MUT
box - - I-MUT
gene - - I-MUT
) - - O
is - - O
characterised - - O
by - - O
a - - O
conserved - - O
DNA - - O
sequence - - O
encoding - - O
a - - O
domain - - O
of - - O
approximately - - O
80 - - O
amino - - O
acids - - O
which - - O
is - - O
responsible - - O
for - - O
sequence - - O
specific - - O
DNA - - O
binding - - O
. - - O

The - - O
dose - - O
was - - O
50 - - O
Gy - - O
20 - - O
fractions - - O
5 - - O
weeks - - O
. - - O

Vasoactive - - B-MUT
intestinal - - I-MUT
peptide - - I-MUT
and - - O
pituitary - - B-MUT
adenylate - - I-MUT
cyclase-activating - - I-MUT
polypeptide - - I-MUT
inhibit - - O
nuclear - - B-MUT
factor-kappa - - I-MUT
B-dependent - - I-MUT
gene - - I-MUT
activation - - O
at - - O
multiple - - O
levels - - O
in - - O
the - - O
human - - O
monocytic - - O
cell - - O
line - - O
THP-1 - - O
. - - O

Homozygous - - O
protein - - B-MUT
C - - I-MUT
( - - O
PC - - B-MUT
) - - O
deficiency - - O
is - - O
reported - - O
in - - O
two - - O
siblings - - O
( - - O
girl - - O
and - - O
boy - - O
) - - O
who - - O
received - - O
their - - O
proper - - O
diagnoses - - O
at - - O
the - - O
ages - - O
of - - O
7 - - O
4 - - O
12 - - O
and - - O
1 - - O
3 - - O
12 - - O
years - - O
respectively - - O
. - - O

A - - O
subsequent - - O
screen - - O
for - - O
the - - O
loss - - O
of - - O
the - - O
positively - - O
selectable - - O
target - - O
locus - - O
marker - - O
detects - - O
the - - O
desired - - O
replacement - - O
at - - O
modest - - O
frequency - - O
( - - O
> - - O
2% - - O
) - - O
. - - O

Here - - O
we - - O
report - - O
the - - O
isolation - - O
and - - O
characterization - - O
of - - O
the - - O
forkhead - - B-MUT
homologue - - I-MUT
in - - I-MUT
rhabdomyosarcoma - - I-MUT
( - - O
FKHR - - B-MUT
) - - O
, - - O
a - - O
recently - - O
described - - O
member - - O
of - - O
the - - O
hepatocyte - - B-MUT
nuclear - - I-MUT
factor - - I-MUT
3 - - I-MUT
forkhead - - I-MUT
homeotic - - I-MUT
gene - - I-MUT
family - - I-MUT
, - - O
as - - O
a - - O
nuclear - - O
hormone - - B-MUT
receptor - - I-MUT
( - - I-MUT
NR - - O
) - - B-MUT
intermediary - - O
protein - - O
. - - O

Ultrastructural - - O
and - - O
morphometric - - O
study - - O
of - - O
the - - O
myeloid - - O
parenchyma - - O
cells - - O
of - - O
mice - - O
prior - - O
and - - O
after - - O
X-ray - - O
exposure - - O
. - - O

Cloning - - O
of - - O
higher - - B-MUT
plant - - I-MUT
omega-3 - - I-MUT
fatty - - I-MUT
acid - - I-MUT
desaturases - - I-MUT
. - - O

To - - O
determine - - O
the - - O
true - - O
molecular - - O
identity - - O
of - - O
SFD - - B-MUT
, - - O
both - - O
the - - O
50- - - O
and - - O
57-kDa - - O
polypeptides - - O
were - - O
directly - - O
sequenced - - O
. - - O

Synchronous - - O
extracts - - O
showed - - O
no - - O
significant - - O
migration - - O
inhibition - - O
in - - O
allogeneic - - O
assays - - O
. - - O

In - - O
order - - O
to - - O
decipher - - O
the - - O
pathway - - O
that - - O
leads - - O
to - - O
Hox - - B-MUT
gene - - I-MUT
induction - - O
, - - O
we - - O
have - - O
investigated - - O
whether - - O
a - - O
Hox - - B-MUT
gene - - I-MUT
regulator - - O
, - - O
the - - O
leucine - - O
zipper - - O
transcription - - O
factor - - O
MafB - - B-MUT
Kr - - I-MUT
, - - I-MUT
is - - O
itself - - O
transcriptionally - - O
regulated - - O
by - - O
the - - O
environmental - - O
signals - - O
. - - O

Eight - - O
cats - - O
infected - - O
with - - O
H - - O
. - - O
pylori - - O
were - - O
used - - O
in - - O
the - - O
study - - O
. - - O

However - - O
, - - O
subcutaneously - - O
administered - - O
pneumococci - - O
gave - - O
a - - O
lower - - O
mortality - - O
than - - O
pneumococci - - O
given - - O
intravenously - - O
or - - O
intraperitoneally - - O
. - - O

Their - - O
mean - - O
IOP - - O
was - - O
15 - - O
. - - O
3 - - O
( - - O
SD - - O
3 - - O
. - - O
7 - - O
) - - O
mmHg - - O
prior - - O
to - - O
induction - - O
of - - O
anesthesia - - O
, - - O
13 - - O
. - - O
5 - - O
( - - O
SD - - O
3 - - O
. - - O
5 - - O
) - - O
mmHg - - O
after - - O
loss - - O
of - - O
eyelash - - O
reflex - - O
following - - O
injection - - O
of - - O
methohexitone - - O
, - - O
16 - - O
. - - O
1 - - O
( - - O
SD - - O
2 - - O
. - - O
4 - - O
) - - O
mmHg - - O
after - - O
cessation - - O
of - - O
muscle - - O
fasciculations - - O
induced - - O
by - - O
suxamethonium - - O
, - - O
19 - - O
. - - O
2 - - O
( - - O
SD - - O
5 - - O
. - - O
6 - - O
) - - O
mmHg - - O
after - - O
cessation - - O
of - - O
convulsion - - O
and - - O
15 - - O
. - - O
5 - - O
( - - O
SD - - O
4 - - O
. - - O
4 - - O
) - - O
mmHg - - O
following - - O
resumption - - O
of - - O
regular - - O
spontaneous - - O
respiration - - O
. - - O

The - - O
ligand - - O
for - - O
RXR - - B-MUT
, - - O
9-cis - - O
retinoic - - O
acid - - O
, - - O
has - - O
the - - O
opposite - - O
effect - - O
of - - O
destabilizing - - O
the - - O
heterodimeric-DNA - - O
complex - - O
. - - O

The - - O
majority - - O
of - - O
PI - - B-MUT
kinase - - I-MUT
activity - - O
appeared - - O
to - - O
be - - O
cbl-associated - - O
after - - O
PRL - - B-MUT
stimulation - - O
. - - O

Current - - O
world - - O
literature - - O
. - - O

Defects - - O
of - - O
fibrillin - - B-MUT
( - - O
FBN1 - - B-MUT
) - - O
, - - O
a - - O
glycoprotein - - O
component - - O
of - - O
the - - O
extracellular - - O
microfibril - - O
, - - O
cause - - O
Marfan - - O
syndrome - - O
. - - O

The - - O
substrates - - O
for - - O
glycan - - O
synthesis - - O
in - - O
the - - O
lumen - - O
of - - O
the - - O
Golgi - - O
are - - O
nucleotide - - O
sugars - - O
that - - O
must - - O
be - - O
transported - - O
from - - O
the - - O
cytosol - - O
by - - O
specific - - O
membrane-bound - - O
transporters - - O
. - - O

DNA - - O
binding - - O
and - - O
glutathione - - B-MUT
S-transferase - - I-MUT
pull-down - - O
assays - - O
demonstrate - - O
that - - O
binding - - O
requires - - O
Elk-1 - - B-MUT
( - - I-MUT
1-212 - - I-MUT
) - - I-MUT
but - - O
not - - O
the - - O
C-terminal - - O
transactivation - - O
domain - - O
. - - O

( - - O
1994 - - O
, - - O
Hum - - O
. - - O

The - - O
synergistic - - O
effect - - O
due - - O
to - - O
the - - O
5'-3' - - O
cooperation - - O
was - - O
at - - O
least - - O
fourfold - - O
greater - - O
than - - O
the - - O
sum - - O
of - - O
the - - O
contributions - - O
of - - O
the - - O
individual - - O
UTRs - - O
. - - O

At - - O
Cabras - - O
( - - O
Oristano - - O
) - - O
, - - O
a - - O
town - - O
characterized - - O
by - - O
a - - O
high - - O
incidence - - O
of - - O
thalassaemia - - O
and - - O
G6PD - - B-MUT
deficiency - - O
less - - O
than - - O
half - - O
the - - O
people - - O
between - - O
18 - - O
and - - O
35 - - O
have - - O
a - - O
fair - - O
knowledge - - O
of - - O
genetic - - O
diseases - - O
and - - O
of - - O
their - - O
prevention - - O
. - - O

These - - O
motifs - - O
include - - O
a - - O
Chi - - B-MUT
motif - - I-MUT
and - - O
a - - O
Chi-like - - B-MUT
element - - I-MUT
previously - - O
found - - O
in - - O
the - - O
recombination - - O
hotspot - - O
region - - O
of - - O
the - - O
Bcl-2 - - B-MUT
proto-oncogene - - I-MUT
and - - O
close - - O
to - - O
chromosomal - - O
breakpoints - - O
in - - O
T-ALL - - O
lines - - O
. - - O

16 - - O
subjects - - O
were - - O
repatch - - O
tested - - O
to - - O
ethylmercury - - O
chloride - - O
( - - O
EtHgCl - - O
) - - O
and - - O
to - - O
solutions - - O
containing - - O
EtHgCl - - O
mixed - - O
with - - O
L-cysteine - - O
and - - O
glutathione - - O
, - - O
respectively - - O
. - - O

Adhesion - - O
, - - O
phagocytosis - - O
, - - O
chemotactic - - O
and - - O
random - - O
migration - - O
, - - O
nitroblue - - O
tetrazolium - - O
dye - - O
reduction - - O
of - - O
peritoneal - - O
exudate - - O
neutrophils - - O
and - - O
macrophages - - O
, - - O
fibrinogen - - B-MUT
level - - O
, - - O
gelation - - O
of - - O
soluble - - O
fibrin - - B-MUT
and - - O
serial - - O
dilution - - O
protamine - - O
sulfate - - O
test - - O
were - - O
investigated - - O
in - - O
115 - - O
New - - O
Zealand - - O
white - - O
rabbits - - O
with - - O
experimentally - - O
induced - - O
Shwartzman - - O
phenomenon - - O
in - - O
the - - O
colon - - O
, - - O
and - - O
in - - O
control - - O
animals - - O
. - - O

Corticosteroid - - O
therapy - - O
is - - O
known - - O
to - - O
be - - O
hazardous - - O
in - - O
patients - - O
with - - O
occult - - O
infection - - O
but - - O
the - - O
mechanism - - O
by - - O
which - - O
the - - O
host - - O
parasite - - O
relationship - - O
is - - O
altered - - O
by - - O
steroids - - O
is - - O
not - - O
known - - O
. - - O
We - - O
have - - O
used - - O
an - - O
intestinal - - O
protozoal - - O
parasite - - O
, - - O
Giardia - - O
muris - - O
, - - O
to - - O
examine - - O
the - - O
effects - - O
of - - O
corticosteroids - - O
on - - O
the - - O
number - - O
of - - O
parasites - - O
in - - O
the - - O
intestine - - O
in - - O
the - - O
course - - O
of - - O
a - - O
primary - - O
infection - - O
. - - O

Each - - O
recombinant - - O
product - - O
was - - O
a - - O
fusion - - O
protein - - O
with - - O
a - - O
B - - B-MUT
domain - - I-MUT
of - - O
Staphylococcal - - B-MUT
protein - - I-MUT
A - - I-MUT
( - - O
SPA - - B-MUT
) - - O
. - - O

The - - O
C5 - - B-MUT
alpha-chain - - I-MUT
was - - O
encoded - - O
by - - O
49 - - O
kilobases - - O
containing - - O
26 - - O
exons - - O
; - - O
the - - O
beta-chain - - O
was - - O
encoded - - O
by - - O
29 - - O
kilobases - - O
containing - - O
16 - - O
exons - - O
. - - O

METHODS - - O
: - - O
Four - - O
hundred - - O
fifty - - O
patients - - O
with - - O
the - - O
diagnosis - - O
of - - O
squamous - - O
cell - - O
carcinoma - - O
of - - O
the - - O
oral - - O
cavity - - O
received - - O
their - - O
primary - - O
treatment - - O
at - - O
Roswell - - O
Park - - O
Cancer - - O
Center - - O
( - - O
RPCI - - O
) - - O
from - - O
1971 - - O
to - - O
1991 - - O
. - - O

Eighty - - O
patients - - O
presenting - - O
to - - O
HGGM - - O
with - - O
non-Hodgkin's - - O
lymphomas - - O
between - - O
1962 - - O
and - - O
1986 - - O
, - - O
were - - O
reviewed - - O
. - - O

In - - O
contrast - - O
, - - O
dig1 - - B-MUT
dig2 - - B-MUT
cells - - O
constitutively - - O
invade - - O
agar - - O
medium - - O
, - - O
whereas - - O
a - - O
dig1 - - B-MUT
dig2 - - B-MUT
ste12 - - B-MUT
triple - - O
mutant - - O
does - - O
not - - O
, - - O
indicating - - O
that - - O
Dig1 - - B-MUT
and - - O
Dig2 - - B-MUT
share - - O
a - - O
role - - O
in - - O
negatively - - O
regulating - - O
the - - O
invasive - - O
growth - - O
pathway - - O
. - - O

During - - O
presentation - - O
of - - O
happy - - O
facial - - O
expressions - - O
, - - O
we - - O
detected - - O
a - - O
signal - - O
increase - - O
predominantly - - O
in - - O
the - - O
left - - O
anterior - - O
cingulate - - O
gyrus - - O
, - - O
bilateral - - O
posterior - - O
cingulate - - O
gyri - - O
, - - O
medial - - O
frontal - - O
cortex - - O
and - - O
right - - O
supramarginal - - O
gyrus - - O
, - - O
brain - - O
regions - - O
previously - - O
implicated - - O
in - - O
visuospatial - - O
and - - O
emotion - - O
processing - - O
tasks - - O
. - - O

In - - O
contrast - - O
to - - O
behavioral - - O
deviation - - O
( - - O
the - - O
avoidance - - O
conditioning - - O
lost - - O
) - - O
, - - O
the - - O
haloperidol - - O
intrastriatal - - O
microinjections - - O
did - - O
not - - O
affect - - O
the - - O
DA - - O
synaptic - - O
level - - O
in - - O
rostral - - O
neostriatum - - O
. - - O

Considerably - - O
high - - O
levels - - O
of - - O
IgE - - B-MUT
antibodies - - I-MUT
was - - O
also - - O
established - - O
while - - O
other - - O
pollens - - O
did - - O
not - - O
show - - O
such - - O
correspondence - - O
. - - O

Coexpression - - O
of - - O
mouse - - O
PKR - - B-MUT
( - - I-MUT
1-515 - - I-MUT
) - - I-MUT
WT - - I-MUT
as - - O
a - - O
Gal4 - - B-MUT
DNA-binding - - O
domain - - O
fusion - - O
with - - O
either - - O
the - - O
catalytic-deficient - - O
human - - O
PKR - - B-MUT
( - - I-MUT
1-551 - - I-MUT
) - - I-MUT
K296R - - O
mutant - - O
, - - O
the - - O
RNA-binding-deficient - - O
human - - O
PKR - - B-MUT
( - - I-MUT
1-551 - - I-MUT
) - - I-MUT
K64E - - I-MUT
K296R - - I-MUT
double - - I-MUT
mutant - - O
, - - O
or - - O
wild-type - - O
mouse - - O
PKR - - O
( - - B-MUT
1-515 - - I-MUT
) - - I-MUT
WT - - I-MUT
as - - I-MUT
full-length - - O
PKR-Gal4 - - O
activation - - B-MUT
domain - - O
fusions - - O
resulted - - O
in - - O
activation - - O
of - - O
the - - O
HIS3 - - O
and - - B-MUT
lacZ - - O
reporters - - B-MUT
. - - O

Overexpression - - O
of - - O
either - - O
DAP-1 - - B-MUT
or - - O
sentrin - - B-MUT
causes - - O
apoptosis - - O
of - - O
TNF-sensitive - - O
L929 - - O
fibroblast - - O
cell - - O
line - - O
, - - O
as - - O
well - - O
as - - O
TNF-resistant - - O
osteosarcoma - - O
cell - - O
line - - O
, - - O
U2OS - - O
. - - O

An - - O
association - - O
between - - O
hSIE - - B-MUT
and - - O
Stat-3 - - B-MUT
after - - O
MHC-I - - B-MUT
ligation - - O
was - - O
directly - - O
demonstrated - - O
by - - O
precipitating - - O
Stat-3 - - B-MUT
from - - O
nuclear - - O
extracts - - O
with - - O
biotinylated - - O
hSIE - - B-MUT
probe - - O
and - - O
avidin-coupled - - O
agarose - - O
. - - O

The - - O
mechanism - - O
by - - O
which - - O
large - - O
molecules - - O
, - - O
such - - O
as - - O
the - - O
diphosphonate - - O
99mTc-labeled - - O
EHDP - - O
or - - O
99mTc-labeled - - O
pyrophosphate - - O
, - - O
pass - - O
through - - O
capillaries - - O
in - - O
bone - - O
is - - O
by - - O
passive - - O
diffusion - - O
. - - O

We - - O
have - - O
isolated - - O
cDNA - - O
clones - - O
from - - O
rat - - O
brain - - O
and - - O
human - - O
liver - - O
encoding - - O
a - - O
putative - - O
isoform - - O
of - - O
the - - O
Na - - B-MUT
, - - I-MUT
K-ATPase - - I-MUT
beta - - I-MUT
subunit - - I-MUT
. - - O

I - - O
. - - O

Src - - B-MUT
activation - - O
induced - - O
by - - O
FGF1 - - B-MUT
was - - O
blocked - - O
by - - O
the - - O
SH2 - - B-MUT
domain - - I-MUT
of - - O
Src - - B-MUT
and - - O
PP2 - - B-MUT
, - - O
a - - O
specific - - O
inhibitor - - O
of - - O
Src - - B-MUT
. - - O

In - - O
a - - O
third - - O
experiment - - O
, - - O
crossover - - O
AM - - O
between - - O
dissimilar - - O
textures - - O
was - - O
investigated - - O
, - - O
and - - O
it - - O
was - - O
found - - O
that - - O
the - - O
more - - O
salient - - O
textures - - O
carried - - O
the - - O
AM - - O
. - - O

Muscle - - O
action - - O
potential - - O
and - - O
masticatory - - O
rhythm - - O
of - - O
anterior - - O
temporal - - O
and - - O
masseter - - O
muscles - - O
in - - O
children - - O
and - - O
adults - - O
. - - O

Chemical - - O
constituents - - O
of - - O
the - - O
gentianaceae - - O
V - - O
: - - O
tetraoxygenated - - O
xanthones - - O
of - - O
Swertia - - O
chirata - - O
Buch - - O
. - - O
-Ham - - O
. - - O

However - - O
, - - O
although - - O
deletion - - O
of - - O
Fp1 - - B-MUT
in - - O
the - - O
hCRBP1 - - B-MUT
gene - - I-MUT
yielded - - O
increased - - O
CAT - - B-MUT
activity - - O
, - - O
pointing - - O
toward - - O
a - - O
negative - - O
regulatory - - O
function - - O
exerted - - O
by - - O
this - - O
element - - O
, - - O
its - - O
insertion - - O
upstream - - O
of - - O
the - - O
p12 - - B-MUT
basal - - I-MUT
promoter - - I-MUT
results - - O
in - - O
an - - O
impressive - - O
positive - - O
stimulation - - O
of - - O
CAT - - B-MUT
gene - - I-MUT
expression - - O
. - - O

Mutational - - O
analyses - - O
have - - O
demonstrated - - O
the - - O
importance - - O
of - - O
sequences - - O
within - - O
the - - O
327 - - O
bp - - O
segment - - O
that - - O
contain - - O
a - - O
putative - - O
cyclic - - B-MUT
AMP - - I-MUT
responsive - - I-MUT
element - - I-MUT
binding - - I-MUT
protein - - I-MUT
( - - O
CREB - - B-MUT
) - - O
binding - - O
site - - O
for - - O
TGF-beta - - B-MUT
1 - - I-MUT
and - - O
PMA - - O
responsiveness - - O
and - - O
putative - - O
PU-1 - - B-MUT
and - - O
Sp1 - - B-MUT
binding - - I-MUT
sites - - I-MUT
for - - O
basal - - O
promoter - - O
activity - - O
. - - O

Response - - O
durations - - O
were - - O
short - - O
. - - O

Thus - - O
, - - O
Xlim-1 - - B-MUT
not - - O
only - - O
contains - - O
a - - O
unique - - O
tyrosine-rich - - O
activation - - O
domain - - O
but - - O
also - - O
contains - - O
a - - O
negative - - O
regulatory - - O
domain - - O
in - - O
CT239-403 - - B-MUT
, - - O
suggesting - - O
a - - O
complex - - O
regulatory - - O
mechanism - - O
underlying - - O
the - - O
transcriptional - - O
activity - - O
of - - O
Xlim-1 - - B-MUT
in - - O
the - - O
organizer - - O
. - - O

The - - O
predicted - - O
amino - - O
acid - - O
sequence - - O
exhibited - - O
70% - - O
identity - - O
to - - O
that - - O
of - - O
Bacillus - - B-MUT
stearothermophilus - - I-MUT
TyrTS - - I-MUT
and - - O
55% - - O
identity - - O
to - - O
that - - O
of - - O
E - - B-MUT
. - - I-MUT
coli - - I-MUT
TyrTS - - I-MUT
, - - O
while - - O
identity - - O
to - - O
a - - O
second - - O
cryptic - - O
B - - B-MUT
. - - I-MUT
subtilis - - I-MUT
TyrTS - - I-MUT
gene - - I-MUT
, - - O
designated - - O
tyrZ - - B-MUT
, - - O
was - - O
only - - O
27% - - O
. - - O

Behaviorally - - O
, - - O
a - - O
pain-tolerant - - O
group - - O
( - - O
PT - - O
= - - O
29 - - O
Ss - - O
) - - O
tolerated - - O
the - - O
entire - - O
3-min - - O
test - - O
( - - O
means - - O
= - - O
180 - - O
+ - - O
- - - O
0 - - O
sec - - O
) - - O
, - - O
while - - O
a - - O
pain-sensitive - - O
group - - O
( - - O
PS - - O
= - - O
13 - - O
Ss - - O
) - - O
averaged - - O
only - - O
50 - - O
. - - O
31 - - O
+ - - O
- - - O
20 - - O
. - - O
81 - - O
sec - - O
of - - O
the - - O
cold-pressor - - O
test - - O
( - - O
t - - O
= - - O
16 - - O
. - - O
75 - - O
, - - O
P - - O
less - - O
than - - O
0 - - O
. - - O
0001 - - O
) - - O
, - - O
replicating - - O
our - - O
earlier - - O
studies - - O
. - - O

Sequence - - O
conservation - - O
is - - O
greatest - - O
for - - O
residues - - O
located - - O
near - - O
the - - O
active - - O
centers - - O
of - - O
the - - O
exo - - B-MUT
and - - O
pol - - B-MUT
domains - - I-MUT
of - - O
the - - O
E - - B-MUT
. - - I-MUT
coli - - I-MUT
DNA - - I-MUT
polymerase - - I-MUT
I - - I-MUT
structure - - O
. - - O

This - - O
study - - O
compared - - O
the - - O
gross - - O
and - - O
fine - - O
motor - - O
performance - - O
of - - O
14 - - O
traumatically - - O
brain-injured - - O
children - - O
( - - O
five - - O
to - - O
15 - - O
years - - O
old - - O
, - - O
with - - O
loss - - O
of - - O
consciousness - - O
for - - O
at - - O
least - - O
24 - - O
hours - - O
) - - O
to - - O
14 - - O
normal - - O
children - - O
group - - O
matched - - O
for - - O
age - - O
and - - O
sex - - O
. - - O

The - - O
plateau - - O
MO2 - - O
value - - O
was - - O
that - - O
predicted - - O
by - - O
allometric - - O
relation - - O
. - - O

One - - O
was - - O
allowed - - O
fresh - - O
drinking - - O
water - - O
ad - - O
libitum - - O
whilst - - O
the - - O
other - - O
received - - O
Aludrox - - O
in - - O
their - - O
drinking - - O
water - - O
. - - O

Although - - O
the - - O
gene - - O
is - - O
substantially - - O
smaller - - O
than - - O
the - - O
human - - O
genes - - O
for - - O
other - - O
mitochondrial - - O
enzymes - - O
, - - O
its - - O
intron - - O
exon - - O
organization - - O
is - - O
very - - O
similar - - O
, - - O
especially - - O
to - - O
that - - O
of - - O
P450scc - - O
. - - B-MUT

This - - O
and - - O
previous - - O
results - - O
suggest - - O
that - - O
the - - O
CRE - - B-MUT
and - - O
Sp1 - - B-MUT
site - - I-MUT
may - - O
synergistically - - O
activate - - O
TH - - B-MUT
transcription - - O
in - - O
a - - O
promoter - - O
context-dependent - - O
manner - - O
. - - O

The - - O
same - - O
rhythmic - - O
structure - - O
enables - - O
a - - O
prediction - - O
to - - O
be - - O
made - - O
concerning - - O
when - - O
vowels - - O
of - - O
stressed - - O
syllables - - O
will - - O
be - - O
auditorily - - O
perceived - - O
. - - O

In - - O
order - - O
to - - O
evaluate - - O
the - - O
function - - O
of - - O
the - - O
hypothalamic-pituitary-thyroid - - O
( - - O
HPT - - O
) - - O
-axis - - O
in - - O
unipolar - - O
depression - - O
, - - O
the - - O
authors - - O
measured - - O
basal - - O
0800h - - O
plasma - - O
levels - - O
of - - O
free - - O
thyroxine - - O
( - - O
FT4 - - O
) - - O
, - - O
free - - O
triiodothyronine - - O
( - - O
FT3 - - O
) - - O
, - - O
and - - O
thyroid - - B-MUT
stimulating - - I-MUT
hormone - - I-MUT
( - - O
TSH - - B-MUT
) - - O
by - - O
means - - O
of - - O
the - - O
new - - O
, - - O
ultrasensitive - - O
assays - - O
( - - O
TSH-IRMA - - O
) - - O
in - - O
69 - - O
healthy - - O
controls - - O
, - - O
62 - - O
minor - - O
, - - O
101 - - O
simple - - O
major - - O
, - - O
and - - O
57 - - O
melancholic - - O
depressed - - O
subjects - - O
. - - O

We - - O
have - - O
previously - - O
shown - - O
that - - O
LBP-1 - - B-MUT
represses - - O
HIV-1 - - O
transcription - - O
by - - O
inhibiting - - O
the - - O
binding - - O
of - - O
TFIID - - B-MUT
to - - O
the - - O
TATA - - O
box - - O
. - - O

Leptinaemia - - O
does - - O
not - - O
correlate - - O
with - - O
the - - O
actual - - O
or - - O
mean - - O
blood - - O
pressure - - O
reading - - O
nor - - O
with - - O
stage - - O
of - - O
hypertension - - O
according - - O
to - - O
the - - O
WHO - - O
classification - - O
. - - O

Hex - - B-MUT
is - - O
expressed - - O
in - - O
the - - O
developing - - O
liver - - O
coincident - - O
with - - O
the - - O
forkhead - - B-MUT
winged - - O
helix - - B-MUT
transcription - - I-MUT
factor - - O
, - - O
Hepatocyte - - O
Nuclear - - B-MUT
Factor - - I-MUT
3beta - - I-MUT
( - - I-MUT
HNF3beta - - O
) - - B-MUT
. - - O

The - - O
SEN1 - - B-MUT
gene - - I-MUT
corresponds - - O
to - - O
a - - O
6 - - O
, - - O
336-bp - - O
open - - O
reading - - O
frame - - O
coding - - O
for - - O
a - - O
2 - - O
, - - O
112-amino-acid - - O
protein - - O
( - - O
molecular - - O
mass - - O
, - - O
239 - - O
kDa - - O
) - - O
. - - O

In - - O
contrast - - O
, - - O
transcription - - O
initiating - - O
from - - O
opuE - - B-MUT
P-1 - - I-MUT
( - - O
sigma - - B-MUT
A - - I-MUT
) - - O
rose - - O
in - - O
proportion - - O
to - - O
the - - O
external - - O
osmolarity - - O
and - - O
was - - O
maintained - - O
at - - O
high - - O
levels - - O
. - - O

A - - O
synthetic - - O
oligonucleotide - - O
containing - - O
the - - O
SRE - - B-MUT
sequence - - I-MUT
from - - O
the - - O
mouse - - B-MUT
c-fos - - I-MUT
gene - - I-MUT
promoter - - I-MUT
( - - O
-299 - - O
to - - O
-322 - - O
) - - O
was - - O
radioactively - - O
labeled - - O
, - - O
used - - O
as - - O
a - - O
probe - - O
for - - O
the - - O
mobility - - O
shift - - O
assay - - O
and - - O
Southwestern - - O
( - - O
DNA-protein - - O
) - - O
blotting - - O
, - - O
and - - O
also - - O
used - - O
for - - O
sequence-specific - - O
affinity - - O
chromatography - - O
. - - O

As - - O
extensively - - O
examined - - O
with - - O
the - - O
myogenin - - B-MUT
promoter - - I-MUT
, - - O
presence - - O
of - - O
one - - O
or - - O
multiple - - O
copies - - O
of - - O
Me - - B-MUT
in - - O
the - - O
vectors - - O
elevated - - O
the - - O
expression - - O
activity - - O
in - - O
myotubes - - O
by - - O
4 - - O
. - - O
5- - - O
to - - O
19-fold - - O
over - - O
those - - O
without - - O
Me - - B-MUT
, - - O
but - - O
not - - O
significantly - - O
in - - O
myoblasts - - O
. - - O

The - - O
proteins - - O
differ - - O
in - - O
the - - O
presence - - O
or - - O
absence - - O
of - - O
a - - O
21-amino-acid - - O
sequence - - O
located - - O
24 - - O
amino - - O
acids - - O
C - - O
terminal - - O
of - - O
the - - O
translational - - O
initiation - - O
codon - - O
. - - O

Subunit - - O
composition - - O
and - - O
domain - - O
structure - - O
of - - O
the - - O
Spo0A - - B-MUT
sporulation - - I-MUT
transcription - - I-MUT
factor - - I-MUT
of - - I-MUT
Bacillus - - I-MUT
subtilis - - I-MUT
. - - O

Cytosolic - - B-MUT
acetyl-CoA - - I-MUT
synthetase - - I-MUT
( - - O
AceCS1 - - B-MUT
) - - O
activates - - O
acetate - - O
to - - O
supply - - O
the - - O
cells - - O
with - - O
acetyl-CoA - - O
for - - O
lipid - - O
synthesis - - O
. - - O

Previous - - O
experience - - O
and - - O
contextual - - O
cues - - O
are - - O
essential - - O
elements - - O
in - - O
the - - O
generation - - O
of - - O
a - - O
subjective - - O
prediction - - O
. - - O

Increases - - O
in - - O
the - - O
perfusate - - O
PCO2 - - O
but - - O
not - - O
in - - O
the - - O
perfusate - - O
H+ - - O
were - - O
highly - - O
correlated - - O
with - - O
decreases - - O
in - - O
both - - O
myocardial - - O
contractility - - O
and - - O
oxygen - - O
consumption - - O
( - - O
r2 - - O
= - - O
. - - O
88 - - O
) - - O
. - - O

Although - - O
previous - - O
data - - O
have - - O
suggested - - O
that - - O
Rev - - B-MUT
uses - - O
the - - O
same - - O
export - - O
pathway - - O
as - - O
uracil-rich - - B-MUT
small - - I-MUT
nuclear - - I-MUT
RNAs - - I-MUT
and - - O
5S - - B-MUT
ribosomal - - I-MUT
RNA - - I-MUT
, - - O
the - - O
CTE - - B-MUT
seems - - O
to - - O
interact - - O
with - - O
evolutionarily - - O
conserved - - O
factors - - O
that - - O
are - - O
essential - - O
for - - O
cellular - - O
mRNA - - O
export - - O
. - - O

These - - O
exons - - O
were - - O
identified - - O
by - - O
cloning - - O
and - - O
sequencing - - O
cDNAs - - O
obtained - - O
by - - O
polymerase - - B-MUT
chain - - O
reaction - - O
amplification - - O
of - - O
a - - O
fibroblast - - O
cDNA - - O
library - - O
. - - O

Analysis - - O
of - - O
the - - O
sequences - - O
with - - O
the - - O
BLAST - - O
and - - O
GRAIL - - O
programs - - O
provided - - O
additional - - O
independent - - O
evidence - - O
that - - O
15 - - O
of - - O
these - - O
17 - - O
clones - - O
contain - - O
coding - - O
sequences - - O
and - - O
that - - O
nine - - O
other - - O
clones - - O
are - - O
likely - - O
to - - O
contain - - O
sequences - - O
coding - - O
for - - O
portions - - O
of - - O
new - - O
genes - - O
. - - O

Consanguinity - - O
and - - O
migration - - O
in - - O
the - - O
marriages - - O
of - - O
the - - O
region - - O
of - - O
Nunoa - - O
, - - O
Santiago - - O
, - - O
1850-1960 - - O
. - - O

Approximately - - O
50% - - O
of - - O
the - - O
residues - - O
are - - O
conserved - - O
among - - O
all - - O
three - - O
sequences - - O
, - - O
yet - - O
all - - O
three - - O
viruses - - O
have - - O
retained - - O
response - - O
elements - - O
for - - O
glucocorticoids - - O
, - - O
two - - O
positionally - - O
conserved - - O
CCAAT - - O
boxes - - O
, - - O
and - - O
positionally - - O
conserved - - O
TATA - - O
boxes - - O
. - - O

TMBr-1 - - B-MUT
is - - O
identical - - O
to - - O
striated - - B-MUT
muscle - - I-MUT
alpha-tropomyosin - - I-MUT
from - - O
amino - - O
acids - - O
1 - - O
through - - O
258 - - O
but - - O
contains - - O
a - - O
novel - - O
COOH-terminal - - O
region - - O
from - - O
amino - - O
acids - - O
259 - - O
through - - O
281 - - O
. - - O

Most - - O
of - - O
the - - O
prepeptide - - O
portion - - O
of - - O
the - - O
precursor - - O
polypeptide - - O
is - - O
encoded - - O
by - - O
the - - O
next - - O
three - - O
exons - - O
, - - O
and - - O
the - - O
mature - - O
form - - O
of - - O
IL-1 - - B-MUT
alpha - - I-MUT
is - - O
encoded - - O
by - - O
the - - O
remaining - - O
three - - O
exons - - O
. - - O

The - - O
assessment - - O
using - - O
7 - - O
H - - O
9 - - O
liquid - - O
medium - - O
by - - O
the - - O
former - - O
author - - O
demonstrated - - O
the - - O
potent - - O
activities - - O
of - - O
both - - O
CS-940* - - O
and - - O
sparfloxacin - - O
( - - O
SPFX - - O
) - - O
, - - O
followed - - O
by - - O
AM-1155* - - O
, - - O
ciprofloxacin - - O
( - - O
CPFX - - O
) - - O
, - - O
levofloxacin - - O
( - - O
LVFX - - O
) - - O
, - - O
OPC-17116* - - O
, - - O
NM-394* - - O
in - - O
sequence - - O
. - - O

Its - - O
expression - - O
pattern - - O
is - - O
representative - - O
of - - O
many - - O
B - - O
cell-specific - - O
proteins - - O
, - - O
which - - O
are - - O
essential - - O
for - - O
B - - O
cell - - O
development - - O
and - - O
activation - - O
but - - O
are - - O
down-regulated - - O
after - - O
B - - O
cells - - O
become - - O
terminally - - O
differentiated - - O
plasma - - O
cells - - O
. - - O

The - - O
implications - - O
for - - O
estimates - - O
of - - O
cortical - - O
magnification - - O
and - - O
possible - - O
differences - - O
in - - O
the - - O
specializations - - O
of - - O
foveal - - O
and - - O
peripheral - - O
vision - - O
are - - O
discussed - - O
. - - O

Pargyline - - O
, - - O
a - - O
monoamine - - B-MUT
oxidase - - I-MUT
inhibitor - - O
, - - O
reduces - - O
peak - - O
3 - - O
transiently - - O
( - - O
max - - O
. - - O

The - - O
stoichiometry - - O
of - - O
the - - O
complexes - - O
formed - - O
with - - O
the - - O
dodeca-satellite - - B-MUT
C - - I-MUT
strand - - I-MUT
suggests - - O
that - - O
, - - O
in - - O
DDP1 - - B-MUT
, - - O
the - - O
15 - - O
consecutive - - O
KH - - B-MUT
domains - - I-MUT
are - - O
organized - - O
such - - O
that - - O
they - - O
define - - O
two - - O
nucleic - - O
acid - - O
binding - - O
surfaces - - O
. - - O

CONCLUSIONS - - O
: - - O
In - - O
addition - - O
to - - O
the - - O
superiority - - O
of - - O
octafluoropropane-filled - - O
microspheres - - O
to - - O
air-filled - - O
microspheres - - O
for - - O
LV - - O
opacification - - O
, - - O
the - - O
efficacy - - O
of - - O
OCTA - - O
is - - O
relatively - - O
unaffected - - O
by - - O
impaired - - O
LV - - O
function - - O
and - - O
is - - O
less - - O
susceptible - - O
to - - O
the - - O
effects - - O
of - - O
poor - - O
echogenicity - - O
than - - O
AIR - - O
. - - O

Overexpression - - O
of - - O
BAG-1 - - B-MUT
also - - O
protected - - O
certain - - O
cell - - O
lines - - O
from - - O
heat - - O
shock-induced - - O
cell - - O
death - - O
. - - O

Thus - - O
, - - O
VDR - - B-MUT
acts - - O
selectively - - O
on - - O
the - - O
two - - O
components - - O
required - - O
for - - O
activation - - O
of - - O
this - - O
promoter - - O
enhancer - - O
: - - O
it - - O
competes - - O
with - - O
NFAT1 - - O
for - - B-MUT
binding - - O
to - - O
the - - O
composite - - O
site - - O
, - - O
positioning - - O
itself - - O
adjacent - - O
to - - O
Jun-Fos - - O
on - - B-MUT
the - - O
DNA - - O
. - - O

The - - O
nucleosomal - - O
response - - O
associated - - O
with - - O
immediate-early - - B-MUT
gene - - I-MUT
induction - - O
is - - O
mediated - - O
via - - O
alternative - - O
MAP - - B-MUT
kinase - - I-MUT
cascades - - I-MUT
: - - O
MSK1 - - B-MUT
as - - O
a - - O
potential - - O
histone - - B-MUT
H3 - - I-MUT
HMG-14 - - I-MUT
kinase - - I-MUT
. - - I-MUT

More - - O
importantly - - O
, - - O
this - - O
fusion - - O
converted - - O
a - - O
less - - O
effective - - O
vaccine - - O
into - - O
one - - O
with - - O
significant - - O
potency - - O
against - - O
established - - O
E7-expressing - - O
metastatic - - O
tumors - - O
. - - O

Its - - O
organization - - O
and - - O
regulation - - O
indicate - - O
that - - O
the - - O
S - - B-MUT
. - - I-MUT
pombe - - I-MUT
URA1 - - I-MUT
gene - - I-MUT
product - - I-MUT
appears - - O
very - - O
similar - - O
to - - O
the - - O
S - - B-MUT
. - - I-MUT
cerevisiae - - I-MUT
URA2 - - I-MUT
gene - - I-MUT
product - - I-MUT
. - - O

Elimination - - O
of - - O
ETH1 - - B-MUT
in - - O
apn1 - - B-MUT
strains - - O
also - - O
increased - - O
spontaneous - - O
mutation - - O
rates - - O
9- - - O
or - - O
31-fold - - O
compared - - O
to - - O
the - - O
wild - - O
type - - O
as - - O
determined - - O
by - - O
reversion - - O
to - - O
adenine - - O
or - - O
lysine - - O
prototrophy - - O
, - - O
respectively - - O
. - - O

The - - O
MCAD - - B-MUT
nuclear - - I-MUT
receptor - - I-MUT
response - - I-MUT
element - - I-MUT
1 - - I-MUT
( - - O
NRRE-1 - - B-MUT
) - - O
interacts - - O
in - - O
vitro - - O
with - - O
ERR - - B-MUT
alpha - - I-MUT
expressed - - O
in - - O
COS-7 - - O
cells - - O
. - - O

Fulminant - - O
hepatitis - - O
A - - O
in - - O
chronic - - O
HBV - - O
carrier - - O
. - - O

Srb10 - - B-MUT
is - - O
a - - O
physiological - - O
regulator - - O
of - - O
Gcn4 - - B-MUT
stability - - O
because - - O
both - - O
phosphorylation - - O
and - - O
turnover - - O
of - - O
Gcn4 - - B-MUT
are - - O
diminished - - O
in - - O
srb10 - - B-MUT
mutants - - I-MUT
. - - O

An - - O
apparent - - O
N-terminal - - O
transit - - O
peptide - - O
in - - O
the - - O
coding - - O
region - - O
and - - O
a - - O
3' - - O
poly - - O
( - - O
A - - O
) - - O
tail - - O
exist - - O
in - - O
the - - O
cDNA - - O
clone - - O
indicated - - O
that - - O
this - - O
chloroplast - - O
protein - - O
as - - O
nuclear - - O
encoded - - O
. - - O

These - - O
sites - - O
are - - O
also - - O
potential - - O
keratan - - O
sulfate - - O
attachment - - O
sites - - O
. - - O

The - - O
concept - - O
of - - O
"structural - - O
identifiability" - - O
is - - O
employed - - O
in - - O
this - - O
analysis - - O
to - - O
determine - - O
which - - O
model - - O
parameters - - O
can - - O
be - - O
and - - O
which - - O
cannot - - O
be - - O
determined - - O
"uniquely" - - O
from - - O
given - - O
input-output - - O
data - - O
; - - O
a - - O
step-by-step - - O
procedure - - O
based - - O
on - - O
an - - O
extension - - O
of - - O
this - - O
concept - - O
is - - O
presented - - O
for - - O
adapting - - O
the - - O
overall - - O
approach - - O
to - - O
the - - O
experimental - - O
design - - O
problem - - O
. - - O

DNA - - O
sequence - - O
analysis - - O
revealed - - O
that - - O
these - - O
clones - - O
encode - - O
two - - O
distinct - - O
forms - - O
of - - O
translocase - - B-MUT
. - - O

Protamine - - B-MUT
and - - O
heparin - - O
doses - - O
, - - O
their - - O
sum - - O
( - - O
Sigma-dose - - O
) - - O
and - - O
differential - - O
( - - O
Delta-dose - - O
) - - O
doses - - O
, - - O
and - - O
activated - - O
clotting - - O
times - - O
were - - O
tabulated - - O
. - - O

In - - O
addition - - O
, - - O
we - - O
found - - O
that - - O
cell-specific - - O
suppression - - O
of - - O
RA-stimulated - - O
zif268 - - B-MUT
gene - - I-MUT
expression - - O
can - - O
be - - O
attributed - - O
to - - O
a - - O
29 - - O
base - - O
pair - - O
nucleotide - - O
sequence - - O
, - - O
located - - O
downstream - - O
of - - O
the - - O
RA-responsive - - B-MUT
region - - I-MUT
in - - O
the - - O
zif268 - - B-MUT
gene - - I-MUT
. - - O

This - - O
structure - - O
of - - O
cucumisin - - B-MUT
suggests - - O
that - - O
it - - O
is - - O
probably - - O
synthesized - - O
as - - O
an - - O
inactive - - O
precursor - - O
. - - O

Identification - - O
and - - O
estimation - - O
of - - O
monosaccharides - - O
and - - O
disaccharides - - O
in - - O
urine - - O
by - - O
gas-liquid - - O
chromatography - - O
. - - O

In - - O
the - - O
current - - O
model - - O
, - - O
Wingless - - B-MUT
Wnt - - I-MUT
signal - - I-MUT
stabilizes - - O
Armadillo - - O
beta-catenin - - B-MUT
, - - I-MUT
which - - I-MUT
then - - O
accumulates - - O
in - - O
nuclei - - O
and - - O
binds - - O
TCF - - O
LEF - - O
family - - B-MUT
proteins - - I-MUT
, - - I-MUT
forming - - I-MUT
bipartite - - I-MUT
transcription - - O
factors - - O
which - - O
activate - - O
transcription - - O
of - - O
Wingless - - O
Wnt - - O
responsive - - O
genes - - B-MUT
. - - I-MUT

In - - O
DNA - - O
strand - - O
exchange - - O
reactions - - O
using - - O
oligonucleotides - - O
, - - O
we - - O
found - - O
that - - O
Rec2 - - B-MUT
exhibited - - O
a - - O
pairing - - O
bias - - O
that - - O
is - - O
opposite - - O
that - - O
of - - O
RecA - - B-MUT
. - - O

The - - O
ability - - O
of - - O
U6-U57 - - B-MUT
mutants - - I-MUT
to - - O
influence - - O
the - - O
fidelity - - O
of - - O
both - - O
branch - - O
site - - O
and - - O
3' - - O
splice - - O
site - - O
recognition - - O
suggests - - O
that - - O
this - - O
nucleotide - - O
may - - O
participate - - O
in - - O
the - - O
formation - - O
of - - O
the - - O
active - - O
site - - O
( - - O
s - - O
) - - O
of - - O
the - - O
spliceosome - - O
. - - O

Endorphins - - B-MUT
and - - O
legal - - O
issues - - O
. - - O

Human - - O
brain - - O
cDNA - - O
library - - O
screening - - O
and - - O
5' - - O
rapid - - O
amplification - - O
of - - O
cDNA - - O
ends - - O
yielded - - O
full-length - - B-MUT
DENTT - - I-MUT
cDNA - - I-MUT
containing - - O
an - - O
1899-bp - - O
open - - O
reading - - O
frame - - O
encoding - - O
a - - O
predicted - - O
633-amino-acid - - O
protein - - O
with - - O
four - - O
potential - - O
nuclear - - O
localization - - O
signals - - O
( - - O
NLSs - - O
) - - O
and - - O
two - - O
coiled-coil - - O
regions - - O
. - - O

The - - O
orientations - - O
of - - O
the - - O
contact - - O
surfaces - - O
and - - O
their - - O
locations - - O
relative - - O
to - - O
the - - O
object's - - O
center - - O
of - - O
mass - - O
were - - O
varied - - O
. - - O

The - - O
carboxyl-terminal - - O
portion - - O
of - - O
UKLF - - B-MUT
contains - - O
three - - O
zinc - - O
fingers - - O
of - - O
the - - O
Cys2-His2 - - O
type - - O
and - - O
binds - - O
in - - O
vitro - - O
to - - O
the - - O
CACCC - - B-MUT
motif - - I-MUT
of - - O
the - - O
beta-globin - - B-MUT
promoter - - I-MUT
and - - O
to - - O
the - - O
Sp1 - - B-MUT
recognition - - I-MUT
sequence - - I-MUT
. - - O

Since - - O
myoglobin - - B-MUT
is - - O
co-extracted - - O
with - - O
the - - O
hemoglobin - - B-MUT
, - - O
the - - O
2 - - O
heme - - O
pigments - - O
are - - O
separated - - O
in - - O
one - - O
portion - - O
of - - O
the - - O
extract - - O
by - - O
precipitating - - O
the - - O
hemoglobin - - B-MUT
in - - O
an - - O
85% - - O
( - - O
NH4 - - O
) - - O
2SO4 - - O
solution - - O
. - - O

Cloning - - O
and - - O
characterization - - O
of - - O
the - - O
murine - - B-MUT
beta - - I-MUT
( - - I-MUT
3 - - I-MUT
) - - I-MUT
integrin - - I-MUT
gene - - I-MUT
promoter - - O
: - - O
identification - - O
of - - O
an - - O
interleukin-4 - - B-MUT
responsive - - I-MUT
element - - I-MUT
and - - O
regulation - - O
by - - O
STAT-6 - - B-MUT
. - - O

Polarised - - O
expression - - O
of - - O
human - - O
intestinal - - O
N-benzoyl-L-tyrosyl-p-aminobenzoic - - B-MUT
acid - - I-MUT
hydrolase - - I-MUT
( - - O
human - - B-MUT
meprin - - I-MUT
) - - O
alpha - - O
and - - O
beta - - O
subunits - - O
in - - O
Madin-Darby - - O
canine - - O
kidney - - O
cells - - O
. - - O

ME1a1 - - B-MUT
, - - O
a - - O
16-base-pair - - O
nuclear - - O
factor - - O
binding - - O
site - - O
residing - - O
between - - O
the - - O
c-MYC - - B-MUT
P1 - - I-MUT
and - - I-MUT
P2 - - I-MUT
transcription - - I-MUT
initiation - - I-MUT
sites - - I-MUT
, - - O
is - - O
required - - O
for - - O
P2 - - B-MUT
activity - - O
. - - O

Protein - - B-MUT
tyrosine - - I-MUT
kinases - - I-MUT
( - - O
PTKs - - B-MUT
) - - O
are - - O
implicated - - O
in - - O
the - - O
control - - O
of - - O
cell - - O
growth - - O
by - - O
virtue - - O
of - - O
their - - O
frequent - - O
appearance - - O
as - - O
products - - O
of - - O
retroviral - - O
oncogenes - - O
, - - O
as - - O
intracellular - - O
signal - - O
transducers - - O
, - - O
and - - O
as - - O
growth - - B-MUT
factor - - I-MUT
receptors - - I-MUT
or - - O
components - - O
thereof - - O
. - - O

Experiments - - O
with - - O
epitope-tagged - - O
proteins - - O
show - - O
that - - O
UEV1A - - B-MUT
is - - O
a - - O
nuclear - - O
protein - - O
, - - O
whereas - - O
both - - O
Kua - - B-MUT
and - - O
Kua-UEV - - B-MUT
localize - - O
to - - O
cytoplasmic - - O
structures - - O
, - - O
indicating - - O
that - - O
the - - O
Kua - - B-MUT
domain - - I-MUT
determines - - O
the - - O
cytoplasmic - - O
localization - - O
of - - O
Kua-UEV - - B-MUT
. - - O

Abnormal - - O
technetium - - O
Tc - - O
99m - - O
medronate - - O
scans - - O
in - - O
patients - - O
with - - O
previously - - O
undiagnosed - - O
polyarthralgias - - O
suggested - - O
inflammatory - - O
arthropathy - - O
and - - O
influenced - - O
management - - O
decisions - - O
with - - O
favorable - - O
therapeutic - - O
outcomes - - O
. - - O

However - - O
, - - O
regional - - O
MVO2 - - O
increased - - O
to - - O
about - - O
the - - O
same - - O
extent - - O
in - - O
the - - O
CFX - - O
( - - O
from - - O
6 - - O
. - - O
0 - - O
+ - - O
- - - O
0 - - O
. - - O
7 - - O
to - - O
12 - - O
. - - O
4 - - O
+ - - O
- - - O
0 - - O
. - - O
9 - - O
ml - - O
O2 - - O
. - - O
min-1 - - O
times - - O
100 - - O
g-1 - - O
) - - O
and - - O
the - - O
LAD - - O
region - - O
( - - O
from - - O
7 - - O
. - - O
0 - - O
+ - - O
- - - O
0 - - O
. - - O
6 - - O
to - - O
14 - - O
. - - O
5 - - O
+ - - O
- - - O
1 - - O
. - - O
3 - - O
ml - - O
O2 - - O
. - - O
min-1 - - O
times - - O
100 - - O
g-1 - - O
) - - O
. - - O

Among - - O
the - - O
patients - - O
grades - - O
1-2-3 - - O
, - - O
81% - - O
had - - O
a - - O
good - - O
out - - O
come - - O
without - - O
any - - O
neurological - - O
abnormality - - O
, - - O
among - - O
the - - O
patients - - O
graded - - O
4-5 - - O
, - - O
only - - O
27% - - O
had - - O
a - - O
fair - - O
out - - O
come - - O
. - - O

1st - - O
data - - O
on - - O
the - - O
immunosuppressive - - O
therapy - - O
of - - O
scleroderma - - O
. - - O

Sulphur - - O
amino - - O
acids - - O
( - - O
g - - O
16 - - O
g - - O
N - - O
) - - O
were - - O
higher - - O
in - - O
the - - O
isolates - - O
than - - O
in - - O
the - - O
flours - - O
. - - O

These - - O
components - - O
both - - O
had - - O
a - - O
median - - O
R2 - - O
of - - O
0 - - O
. - - O
84 - - O
, - - O
compared - - O
to - - O
median - - O
R2s - - O
ranging - - O
from - - O
0 - - O
. - - O
37 - - O
to - - O
0 - - O
. - - O
83 - - O
for - - O
five - - O
commonly - - O
used - - O
ad - - O
hoc - - O
EEG - - O
components - - O
. - - O

By - - O
DNase - - B-MUT
I - - I-MUT
footprint - - O
analysis - - O
of - - O
the - - O
PNR - - B-MUT
element - - I-MUT
, - - O
a - - O
palindrome - - O
of - - O
two - - O
high-affinity - - O
Ets-binding - - B-MUT
sites - - I-MUT
( - - O
CTTCCCTGGAAG - - B-MUT
) - - O
was - - O
identified - - O
. - - O

Toxicity - - O
during - - O
the - - O
therapeutic - - O
period - - O
was - - O
not - - O
significant - - O
in - - O
the - - O
study - - O
group - - O
compared - - O
with - - O
the - - O
historical - - O
control - - O
, - - O
treated - - O
with - - O
the - - O
same - - O
regimen - - O
without - - O
G-CSF - - B-MUT
. - - O

Transcripts - - O
from - - O
a - - O
second - - O
POU-domain - - B-MUT
gene - - I-MUT
, - - O
Oct-25 - - B-MUT
, - - O
were - - O
present - - O
at - - O
low - - O
levels - - O
in - - O
oocytes - - O
and - - O
early - - O
embryos - - O
and - - O
were - - O
dramatically - - O
upregulated - - O
during - - O
early - - O
gastrulation - - O
. - - O

Moreover - - O
, - - O
exons - - O
2a - - O
and - - O
2b - - O
share - - O
the - - O
same - - O
5' - - O
sequence - - O
but - - O
differ - - O
from - - O
each - - O
other - - O
by - - O
the - - O
use - - O
of - - O
two - - O
distinct - - O
donor - - O
splice - - O
sites - - O
171 - - O
bp - - O
apart - - O
in - - O
the - - O
gene - - O
. - - O

Discrimination - - O
between - - O
HIV-1 - - O
and - - O
HIV-2 - - O
showed - - O
evidence - - O
for - - O
the - - O
presence - - O
of - - O
HIV-1 - - O
only - - O
. - - O

The - - O
functional - - O
mature - - O
domain - - O
of - - O
pediocin - - B-MUT
AcH - - I-MUT
( - - I-MUT
Lys+1 - - I-MUT
to - - I-MUT
Cys+44 - - I-MUT
) - - I-MUT
is - - O
targeted - - O
into - - O
the - - O
E - - O
. - - O
coli - - O
sec - - O
machinery - - O
and - - O
secreted - - O
to - - O
the - - O
periplasm - - O
in - - O
active - - O
form - - O
when - - O
fused - - O
in - - O
frame - - O
to - - O
the - - O
COOH - - O
terminus - - O
of - - O
the - - O
secretory - - B-MUT
protein - - I-MUT
maltose-binding - - I-MUT
protein - - I-MUT
( - - O
MBP - - B-MUT
) - - O
. - - O

In - - O
yeast - - O
, - - O
the - - O
products - - O
of - - O
the - - O
UPF1 - - B-MUT
and - - O
UPF3 - - B-MUT
genes - - I-MUT
are - - O
required - - O
for - - O
this - - O
decay - - O
pathway - - O
, - - O
and - - O
in - - O
this - - O
report - - O
we - - O
focus - - O
on - - O
the - - O
identification - - O
and - - O
characterization - - O
of - - O
additional - - O
factors - - O
required - - O
for - - O
rapid - - O
decay - - O
of - - O
nonsense-containing - - O
mRNAs - - O
. - - O

Unified - - O
theory - - O
of - - O
segregated-stack - - O
organic - - O
charge-transfer - - O
solids - - O
: - - O
Magnetic - - O
properties - - O
. - - O

Furthermore - - O
, - - O
microinjection - - O
of - - O
dominant - - O
negative - - O
forms - - O
of - - O
Rac - - B-MUT
and - - O
Cdc42 - - B-MUT
or - - O
of - - O
the - - O
Rho - - B-MUT
inhibitor - - O
C3 - - B-MUT
transferase - - I-MUT
blocked - - O
serum-induced - - O
DNA - - O
synthesis - - O
. - - O

In - - O
gel - - O
retardation - - O
assays - - O
, - - O
an - - O
RCS - - O
cell-specific - - O
protein - - O
and - - O
another - - O
closely - - O
related - - O
protein - - O
expressed - - O
only - - O
in - - O
RCS - - O
cells - - O
and - - O
primary - - O
chondrocytes - - O
bound - - O
to - - O
a - - O
10-bp - - O
sequence - - O
within - - O
the - - O
18-mer - - O
. - - O

Copyright - - O
2001 - - O
Academic - - O
Press - - O
. - - O

It - - O
is - - O
surprising - - O
that - - O
dnaE173 - - O
, - - O
a - - O
potent - - O
mutator - - O
mutation - - O
specific - - O
for - - O
sequence - - O
substitution - - O
as - - O
well - - O
as - - O
single-base - - O
frameshift - - O
, - - O
did - - O
not - - O
enhance - - O
the - - O
frequency - - O
of - - O
the - - O
hot-spot - - O
frameshift - - O
mutation - - O
. - - O

However - - O
, - - O
the - - O
relative - - O
positions - - O
of - - O
the - - O
VV - - O
genes - - O
( - - O
genus - - O
Orthopoxvirus - - O
) - - O
are - - O
different - - O
than - - O
those - - O
of - - O
the - - O
corresponding - - O
ORFs - - O
in - - O
SFV - - O
( - - O
genus - - O
Leporipoxvirus - - O
) - - O
, - - O
indicating - - O
complex - - O
rearrangements - - O
of - - O
DNA - - O
in - - O
the - - O
genome - - O
of - - O
one - - O
or - - O
both - - O
of - - O
these - - O
viruses - - O
subsequent - - O
to - - O
their - - O
divergence - - O
from - - O
a - - O
common - - O
ancestor - - O
. - - O

CONCLUSION - - O
: - - O
There - - O
are - - O
no - - O
differences - - O
in - - O
the - - O
measurement - - O
data - - O
derived - - O
from - - O
this - - O
method - - O
and - - O
actual - - O
measurement - - O
data - - O
from - - O
an - - O
object - - O
created - - O
by - - O
the - - O
computer-aided - - O
dental - - O
design - - O
program - - O
. - - O

Ki-ras - - B-MUT
and - - O
p53 - - B-MUT
mutations - - I-MUT
in - - O
pancreatic - - O
ductal - - O
adenocarcinoma - - O
. - - O

Eleven - - O
healthy - - O
, - - O
normotensive - - O
males - - O
undergoing - - O
routine - - O
restorative - - O
dental - - O
care - - O
were - - O
evaluated - - O
during - - O
treatment - - O
for - - O
possible - - O
hemodynamic - - O
alterations - - O
in - - O
response - - O
to - - O
potential - - O
sympathetic - - O
nervous - - O
system - - O
stimulation - - O
. - - O

CSR - - O
is - - O
directed - - O
to - - O
specific - - O
heavy - - O
chain - - O
isotypes - - O
by - - O
cytokines - - O
and - - O
B - - O
cell - - O
activators - - O
that - - O
induce - - O
transcription - - O
from - - O
the - - O
unrearranged - - O
, - - O
or - - O
germline - - O
( - - O
GL - - O
) - - O
, - - O
C - - O
( - - O
H - - O
) - - O
region - - O
genes - - O
. - - O

As - - O
predicted - - O
by - - O
the - - O
Wing - - O
and - - O
Kristofferson - - O
model - - O
, - - O
the - - O
durations - - O
of - - O
successive - - O
ISIs - - O
tended - - O
to - - O
be - - O
negatively - - O
correlated - - O
. - - O

Based - - O
on - - O
sequence - - O
homology - - O
, - - O
the - - O
genes - - O
were - - O
identified - - O
as - - O
TEF - - B-MUT
, - - O
encoding - - O
translation - - B-MUT
elongation - - I-MUT
factor-1 - - I-MUT
alpha - - I-MUT
and - - O
RPS7 - - B-MUT
, - - O
encoding - - O
ribosomal - - B-MUT
protein - - I-MUT
S7 - - B-MUT
. - - O

Symptomatic - - O
hyperventilators - - O
had - - O
a - - O
larger - - O
number - - O
of - - O
sighs - - O
and - - O
abnormally - - O
wide - - O
fluctuations - - O
in - - O
baseline - - O
for - - O
inspiratory - - O
time - - O
, - - O
expiratory - - O
time - - O
, - - O
and - - O
PETCO2 - - O
. - - O

As - - O
the - - O
high-affinity - - O
Mg2+ - - O
binding - - O
sites - - O
are - - O
filled - - O
, - - O
the - - O
primer - - O
terminus - - O
migrates - - O
from - - O
the - - O
exonuclease - - B-MUT
site - - I-MUT
to - - O
a - - O
highly - - O
based - - O
stacked - - O
polymerase - - B-MUT
active - - I-MUT
site - - I-MUT
. - - O

A - - O
population - - O
pharmacokinetic - - O
study - - O
of - - O
cyclosporin - - O
in - - O
organ - - O
transplant - - O
patients - - O
, - - O
including - - O
elderly - - O
allograft - - O
recipients - - O
up - - O
to - - O
75 - - O
years - - O
of - - O
age - - O
, - - O
did - - O
not - - O
identify - - O
age - - O
as - - O
a - - O
covariable - - O
influencing - - O
cyclosporin - - O
pharmacokinetics - - O
. - - O

The - - O
same - - O
response - - O
occurs - - O
whether - - O
acrylamide - - O
is - - O
given - - O
immediately - - O
after - - O
nerve - - O
ligation - - O
or - - O
1 - - O
week - - O
later - - O
. - - O

This - - O
strategy - - O
was - - O
used - - O
to - - O
place - - O
both - - O
the - - O
Tn903 - - B-MUT
neo - - I-MUT
gene - - I-MUT
and - - O
the - - O
Rhodosporidium - - B-MUT
toruloides - - I-MUT
phenylalanine - - I-MUT
ammonia - - I-MUT
lyase - - I-MUT
( - - O
PAL - - B-MUT
) - - O
-encoding - - O
gene - - O
under - - O
the - - O
transcriptional - - O
control - - O
of - - O
pPGK - - B-MUT
: - - O
: - - O
REP2 - - B-MUT
. - - O

Early - - O
heparin - - O
therapy - - O
in - - O
60 - - O
children - - O
with - - O
acute - - O
meningococcemia - - O
. - - O

The - - O
highest - - O
decrease - - O
in - - O
mutagenic - - O
activity - - O
was - - O
observed - - O
when - - O
enzymatic - - O
bleaching - - O
was - - O
used - - O
together - - O
with - - O
chlorine - - O
. - - O

Regarding - - O
gestational - - O
risk - - O
, - - O
3 - - O
, - - O
243 - - O
drugs - - O
used - - O
( - - O
34% - - O
) - - O
belonged - - O
to - - O
category - - O
A - - O
risk - - O
, - - O
1 - - O
, - - O
923 - - O
( - - O
22 - - O
. - - O
6% - - O
) - - O
to - - O
category - - O
B - - O
, - - O
3 - - O
, - - O
798 - - O
( - - O
39 - - O
. - - O
7% - - O
) - - O
to - - O
category - - O
C - - O
, - - O
289 - - O
( - - O
3 - - O
. - - O
0% - - O
) - - O
to - - O
category - - O
D - - O
, - - O
and - - O
55 - - O
( - - O
0 - - O
. - - O
6% - - O
) - - O
to - - O
category - - O
X - - O
. - - O

These - - O
same - - O
regions - - O
showed - - O
remarkable - - O
homology - - O
to - - O
two - - O
invertebrate - - O
proteins - - O
, - - O
CNC - - B-MUT
and - - O
skin-1 - - B-MUT
, - - O
postulated - - O
to - - O
regulate - - O
embryonic - - O
development - - O
in - - O
Drosophila - - O
melanogaster - - O
and - - O
Caenorhabditis - - O
elegans - - O
, - - O
respectively - - O
. - - O

Using - - O
a - - O
MOS-Hypersil - - O
reversed-phase - - O
column - - O
with - - O
a - - O
phosphate - - O
buffer--acetonitrile - - O
mobile - - O
phase - - O
, - - O
baseline - - O
separation - - O
of - - O
antipyrine - - O
, - - O
its - - O
metabolites - - O
3-hydroxymethylantipyrine - - O
, - - O
norantipyrine - - O
and - - O
4-hydroxyantipyrine - - O
, - - O
and - - O
the - - O
internal - - O
standard - - O
, - - O
phenacetin - - O
, - - O
was - - O
achieved - - O
within - - O
6 - - O
min - - O
. - - O

The - - O
other - - O
element - - O
bound - - O
RBP-J - - B-MUT
kappa - - I-MUT
with - - O
low - - O
affinity - - O
. - - O

Copyright - - O
2001 - - O
S - - O
. - - O

In - - O
addition - - O
, - - O
on - - O
the - - O
Cohler's - - O
maternal - - O
scale - - O
, - - O
Korean - - O
mothers - - O
were - - O
found - - O
to - - O
view - - O
their - - O
infants - - O
as - - O
more - - O
passive - - O
and - - O
dependent - - O
than - - O
American - - O
mothers - - O
did - - O
( - - O
P - - O
less - - O
than - - O
0 - - O
. - - O
00 - - O
) - - O
. - - O

A - - O
2 - - O
years - - O
and - - O
9 - - O
months - - O
old - - O
female - - O
patient - - O
, - - O
with - - O
the - - O
diagnosis - - O
of - - O
Weaver - - O
syndrome - - O
is - - O
reported - - O
. - - O

Actins - - B-MUT
show - - O
two - - O
different - - O
forms - - O
of - - O
N-terminal - - O
processing - - O
dependent - - O
on - - O
their - - O
N-terminal - - O
sequence - - O
. - - O

Ex - - O
vivo - - O
MAO - - B-MUT
inhibition - - O
data - - O
indicated - - O
DPGPEA - - O
to - - O
be - - O
an - - O
inhibitor - - O
of - - O
MAO-B - - B-MUT
, - - O
although - - O
the - - O
effect - - O
was - - O
much - - O
weaker - - O
than - - O
seen - - O
with - - O
tranylcypromine - - O
or - - O
pargyline - - O
. - - O

For - - O
this - - O
purpose - - O
, - - O
the - - O
writhing - - O
test - - O
, - - O
capsaicin - - O
and - - O
formalin - - O
induced-pain - - O
in - - O
mice - - O
were - - O
used - - O
. - - O

Brain - - O
pH - - O
following - - O
3 - - O
h - - O
of - - O
cerebral - - O
focal - - O
ischemia - - O
changed - - O
from - - O
a - - O
normal - - O
value - - O
of - - O
7 - - O
. - - O
0 - - O
to - - O
6 - - O
. - - O
5 - - O
and - - O
6 - - O
. - - O
2 - - O
in - - O
animals - - O
studied - - O
under - - O
barbiturate - - O
and - - O
halothane - - O
anesthesia - - O
, - - O
respectively - - O
. - - O

The - - O
CHARGE - - O
association - - O
is - - O
a - - O
collection - - O
of - - O
multisystem - - O
congenital - - O
anomalies - - O
including - - O
choanal - - O
atresia - - O
. - - O

No - - O
specific - - O
subgroup - - O
of - - O
clients - - O
benefited - - O
more - - O
from - - O
URD - - O
, - - O
although - - O
a - - O
prospective - - O
study - - O
employing - - O
random - - O
assignment - - O
might - - O
be - - O
more - - O
successful - - O
in - - O
identifying - - O
such - - O
a - - O
group - - O
. - - O

Because - - O
of - - O
this - - O
latter - - O
phenomenon - - O
, - - O
we - - O
were - - O
able - - O
to - - O
identify - - O
a - - O
particular - - O
cysteine - - O
motif - - O
that - - O
was - - O
repeated - - O
multiple - - O
times - - O
in - - O
Dfurin2 - - B-MUT
but - - O
present - - O
only - - O
twice - - O
in - - O
mammalian - - B-MUT
furin - - I-MUT
. - - O

We - - O
have - - O
synthesized - - O
[ - - O
7 - - O
, - - O
7-2H2 - - O
] - - O
-19-OHA - - O
with - - O
high - - O
deuterium - - O
content - - O
and - - O
, - - O
together - - O
with - - O
[ - - O
7 - - O
, - - O
7-2H2 - - O
] - - O
A - - O
and - - O
[ - - O
9 - - O
, - - O
11-2H2 - - O
] - - O
estrone - - O
( - - O
E1 - - O
) - - O
, - - O
have - - O
developed - - O
a - - O
quantitative - - O
assay - - O
of - - O
serum - - O
level - - O
19-OHA - - O
, - - O
A - - O
, - - O
and - - O
E1 - - O
using - - O
the - - O
gas - - O
chromatography - - O
mass - - O
spectrometry-mass - - O
fragmentography - - O
method - - O
to - - O
monitor - - O
individual - - O
subjects - - O
throughout - - O
pregnancy - - O
. - - O

The - - O
human - - B-MUT
purH - - I-MUT
cDNA - - I-MUT
is - - O
1776 - - O
base - - O
pairs - - O
in - - O
length - - O
encoding - - O
for - - O
a - - O
591-amino - - O
acid - - O
polypeptic - - O
( - - O
Mr - - O
= - - O
64 - - O
, - - O
425 - - O
) - - O
. - - O

Incorporation - - O
of - - O
0 - - O
. - - O
1 - - O
or - - O
0 - - O
. - - O
2 - - O
M - - O
sodium - - O
dihydrogen - - O
phosphate - - O
in - - O
the - - O
sugar - - O
solutions - - O
resulted - - O
in - - O
a - - O
decrease - - O
in - - O
the - - O
shelf-life - - O
of - - O
diltiazem - - O
. - - O

Moloney - - O
murine - - O
leukemia - - O
virus - - O
( - - O
MMLV - - O
) - - O
-derived - - O
pUCMoTiN-based - - O
retroviral - - O
vectors - - O
were - - O
engineered - - O
to - - O
allow - - O
constitutive - - O
and - - O
Tat - - B-MUT
( - - O
trans-activator - - B-MUT
of - - I-MUT
transcription - - I-MUT
) - - O
-inducible - - O
expression - - O
of - - O
five - - O
hammerhead - - B-MUT
ribozymes - - I-MUT
targeted - - O
against - - O
highly - - O
conserved - - O
sequences - - O
within - - O
the - - O
group - - B-MUT
antigen - - I-MUT
( - - O
Gag - - B-MUT
) - - O
, - - O
protease - - B-MUT
( - - O
Pro - - B-MUT
) - - O
, - - O
reverse - - B-MUT
transcriptase - - I-MUT
( - - O
RT - - B-MUT
) - - O
, - - O
tat - - B-MUT
, - - O
and - - O
envelope - - B-MUT
( - - O
Env - - B-MUT
) - - O
coding - - O
regions - - O
of - - O
human - - O
immunodeficiency - - O
virus - - O
type-1 - - O
( - - O
HIV-1 - - O
) - - O
RNA - - O
. - - O

Spleen - - O
weight - - O
in - - O
rats - - O
during - - O
tumour - - O
growth - - O
and - - O
in - - O
homograft - - O
rejection - - O
. - - O

We - - O
have - - O
found - - O
out - - O
that - - O
one-year-old - - O
carps - - O
are - - O
extremely - - O
sensitive - - O
to - - O
ichthiomycin - - O
in - - O
concentrations - - O
between - - O
25-125 - - O
micrograms - - O
dm3 - - O
. - - O

Remarkably - - O
, - - O
U21 - - B-MUT
contains - - O
a - - O
long - - O
stretch - - O
( - - O
13 - - O
nt - - O
. - - O
) - - O
of - - O
complementarity - - O
to - - O
a - - O
highly - - O
conserved - - O
sequence - - O
in - - O
28S - - B-MUT
rRNA - - I-MUT
. - - O

The - - O
humanized - - B-MUT
LL2 - - I-MUT
( - - O
hLL2 - - B-MUT
) - - O
, - - O
lacking - - O
light - - B-MUT
chain - - I-MUT
variable - - I-MUT
region - - I-MUT
glycosylation - - O
, - - O
exhibited - - O
immunoreactivities - - O
that - - O
were - - O
comparable - - O
to - - O
that - - O
of - - O
chimeric - - B-MUT
LL2 - - I-MUT
( - - O
cLL2 - - B-MUT
) - - O
, - - O
which - - O
was - - O
shown - - O
previously - - O
to - - O
have - - O
antigen-binding - - O
properties - - O
similar - - O
to - - O
its - - O
murine - - O
counterpart - - O
, - - O
suggesting - - O
that - - O
the - - O
VK-appended - - O
oligosaccharides - - O
found - - O
in - - O
mLL2 - - B-MUT
are - - O
not - - O
necessary - - O
for - - O
antigen - - O
binding - - O
. - - O

Once - - O
HIT - - O
II - - O
is - - O
suspected - - O
, - - O
heparin - - O
( - - O
and - - O
low-molecular-weight - - O
heparins - - O
) - - O
should - - O
be - - O
stopped - - O
immediately - - O
. - - O

Whereas - - O
creatine - - B-MUT
kinase - - I-MUT
activity - - O
declined - - O
exponentially - - O
from - - O
a - - O
single - - O
peak - - O
, - - O
myoglobin - - B-MUT
appeared - - O
in - - O
multiple - - O
episodes - - O
inadequately - - O
represented - - O
by - - O
a - - O
single - - O
peak - - O
value - - O
and - - O
having - - O
no - - O
clear - - O
clinical - - O
correlation - - O
. - - O

Twelve - - O
genomic - - O
fragments - - O
containing - - O
novel - - O
response - - O
elements - - O
are - - O
described - - O
, - - O
and - - O
the - - O
transcription - - O
unit - - O
associated - - O
with - - O
one - - O
of - - O
them - - O
, - - O
NN-84AG - - B-MUT
, - - O
was - - O
characterized - - O
in - - O
detail - - O
. - - O

Analysis - - O
of - - O
the - - O
consensus - - O
binding - - O
sequence - - O
and - - O
the - - O
DNA-binding - - O
domain - - O
of - - O
ZF5 - - B-MUT
. - - O

Sequencing - - O
of - - O
the - - O
TP53 - - B-MUT
transcripts - - I-MUT
from - - O
exons - - O
2 - - O
to - - O
10 - - O
, - - O
however - - O
, - - O
did - - O
not - - O
reveal - - O
mutations - - O
of - - O
the - - O
remaining - - O
allele - - O
in - - O
any - - O
of - - O
these - - O
tumors - - O
. - - O

Pneumothorax - - O
following - - O
lung - - O
abscess - - O
in - - O
the - - O
renal - - O
transplant - - O
patient - - O
. - - O

The - - O
iterative - - O
method - - O
proposed - - O
by - - O
Bengtsson - - O
[ - - O
Appl - - O
. - - O

CONCLUSION - - O
: - - O
The - - O
alpha2-adrenergic - - O
antagonist - - O
idazoxan - - O
increases - - O
glucose-induced - - O
sympathetic - - O
activity - - O
but - - O
not - - O
energy - - O
expenditure - - O
in - - O
obese - - O
subjects - - O
. - - O

These - - O
losses - - O
account - - O
for - - O
the - - O
resistance - - O
of - - O
EDS-IV - - O
collagen - - B-MUT
to - - O
cyanogen - - O
bromide - - O
and - - O
mammalian - - B-MUT
collagenase - - I-MUT
digestion - - O
. - - O

Relations - - O
between - - O
cellular - - O
electrical - - O
activity - - O
and - - O
cardiac - - O
mechanical - - O
activity - - O
in - - O
man - - O
, - - O
the - - O
dog - - O
and - - O
the - - O
rabbit - - O
. - - O

Expression - - O
of - - O
p130 - - B-MUT
( - - I-MUT
Cas - - I-MUT
) - - I-MUT
( - - O
Cas - - B-MUT
) - - O
, - - O
a - - O
major - - O
binding - - O
protein - - O
for - - O
the - - O
Crk - - B-MUT
SH2-domain - - B-MUT
, - - O
also - - O
induced - - O
JNK - - B-MUT
activation - - O
, - - O
which - - O
was - - O
blocked - - O
by - - O
the - - O
SH2-mutant - - B-MUT
of - - O
Crk - - B-MUT
. - - O

Skeletal - - B-MUT
muscle - - I-MUT
metaboreceptor - - I-MUT
responses - - O
are - - O
impaired - - O
in - - O
heart - - O
failure - - O
. - - O

The - - O
purified - - O
recombinant - - O
protein - - O
was - - O
assayed - - O
for - - O
its - - O
enzyme - - O
activity - - O
by - - O
monitoring - - O
transfer - - O
of - - O
[ - - O
3H - - O
] - - O
methyl - - O
groups - - O
from - - O
the - - O
substrate - - O
DNA - - O
to - - O
the - - O
MGMT - - B-MUT
protein - - I-MUT
; - - O
the - - O
activity - - O
was - - O
found - - O
to - - O
be - - O
stable - - O
at - - O
90 - - O
degrees - - O
C - - O
for - - O
at - - O
least - - O
30 - - O
min - - O
. - - O

This - - O
interaction - - O
involved - - O
the - - O
SH3 - - B-MUT
region - - I-MUT
of - - O
p50 - - B-MUT
( - - I-MUT
csk - - I-MUT
) - - I-MUT
and - - O
a - - O
proline-rich - - O
region - - O
( - - O
PPPLPERTPESFVLADM - - B-MUT
) - - O
outside - - O
the - - O
catalytic - - O
region - - O
of - - O
PTP-PEST - - B-MUT
. - - O

SETTING--Delhi - - O
, - - O
urban - - O
India - - O
, - - O
1985-6 - - O
. - - O

The - - O
mean - - O
( - - O
+ - - O
- - - O
sd - - O
) - - O
intra-vesicular - - O
pressure - - O
( - - O
IVP - - O
) - - O
and - - O
maximal - - O
urethral - - O
closure - - O
pressures - - O
( - - O
MUCP - - O
) - - O
were - - O
10 - - O
. - - O
3 - - O
( - - O
+ - - O
- - - O
1 - - O
. - - O
7 - - O
) - - O
and - - O
129 - - O
. - - O
8 - - O
( - - O
+ - - O
- - - O
19 - - O
. - - O
6 - - O
) - - O
cmH2O - - O
, - - O
respectively - - O
, - - O
and - - O
the - - O
ratio - - O
between - - O
MUCP - - O
and - - O
IVP - - O
was - - O
13 - - O
. - - O
2 - - O
( - - O
+ - - O
- - - O
2 - - O
. - - O
5 - - O
) - - O
. - - O

Data - - O
from - - O
in - - O
vitro - - O
splicing - - O
assays - - O
, - - O
UV - - O
crosslinking - - O
and - - O
RNA-binding - - O
competition - - O
experiments - - O
indicates - - O
a - - O
strong - - O
correlation - - O
between - - O
the - - O
binding - - O
affinities - - O
of - - O
PSI - - B-MUT
for - - O
the - - O
SELEX - - O
sequences - - O
and - - O
their - - O
ability - - O
to - - O
modulate - - O
splicing - - O
of - - O
P - - B-MUT
element - - I-MUT
IVS3 - - I-MUT
in - - O
vitro - - O
. - - O

Use - - O
of - - O
subcutaneous - - O
deferoxamine - - O
in - - O
a - - O
child - - O
with - - O
hemochromatosis - - O
associated - - O
with - - O
congenital - - O
dyserythropoietic - - O
anemia - - O
, - - O
type - - O
I - - O
. - - O

The - - O
primary - - O
CT - - O
findings - - O
were - - O
misinterpreted - - O
as - - O
a - - O
brain - - O
infarct - - O
or - - O
possibly - - O
a - - O
tumour - - O
. - - O

If - - O
hnRNP - - B-MUT
K - - I-MUT
is - - O
a - - O
transcription - - O
factor - - O
, - - O
then - - O
interactions - - O
with - - O
the - - O
RNA - - B-MUT
polymerase - - I-MUT
II - - I-MUT
transcription - - O
apparatus - - O
are - - O
predicted - - O
. - - O

Methyl - - O
formate - - O
was - - O
used - - O
as - - O
the - - O
solvent - - O
of - - O
biodegradable - - O
oligoesters - - O
for - - O
the - - O
fabrication - - O
of - - O
microspheres - - O
with - - O
encapsulated - - O
bovine - - B-MUT
serum - - I-MUT
albumin - - I-MUT
( - - O
BSA - - B-MUT
) - - O
. - - O

We - - O
report - - O
here - - O
that - - O
constitutively - - O
active - - O
Mek1 - - B-MUT
could - - O
activate - - O
p96h2bk - - B-MUT
in - - O
the - - O
absence - - O
of - - O
oncogenic - - B-MUT
Ras - - I-MUT
. - - O

Botulinum - - B-MUT
toxin - - I-MUT
A - - I-MUT
in - - O
the - - O
treatment - - O
of - - O
hemiplegic - - O
spastic - - O
foot - - O
drop--clinical - - O
and - - O
functional - - O
outcomes - - O
. - - O

Mutational - - O
analysis - - O
of - - O
the - - O
P2-proximal - - B-MUT
CTCF - - I-MUT
binding - - I-MUT
site - - I-MUT
and - - O
transient-cotransfection - - O
experiments - - O
demonstrate - - O
that - - O
CTCF - - B-MUT
is - - O
a - - O
transcriptional - - O
repressor - - O
of - - O
the - - O
human - - B-MUT
c-myc - - I-MUT
gene - - I-MUT
. - - O

To - - O
determine - - O
whether - - O
the - - O
excess - - O
prevalence - - O
of - - O
human - - O
immunodeficiency - - O
virus - - O
type - - O
1 - - O
( - - O
HIV-1 - - O
) - - O
infection - - O
in - - O
US - - O
black - - O
and - - O
Hispanic - - O
homosexual - - O
men - - O
relative - - O
to - - O
white - - O
men - - O
can - - O
be - - O
explained - - O
by - - O
differences - - O
in - - O
sociodemographic - - O
factors - - O
, - - O
history - - O
of - - O
sexually - - O
transmitted - - O
diseases - - O
, - - O
or - - O
sexual - - O
and - - O
drug-use - - O
behaviors - - O
, - - O
the - - O
authors - - O
conducted - - O
a - - O
cross-sectional - - O
analysis - - O
of - - O
baseline - - O
HIV-1 - - O
seroprevalence - - O
and - - O
HIV-1 - - O
risk - - O
factors - - O
among - - O
4 - - O
, - - O
475 - - O
non-Hispanic - - O
white - - O
, - - O
234 - - O
Hispanic - - O
white - - O
, - - O
and - - O
194 - - O
black - - O
homosexual - - O
men - - O
from - - O
four - - O
centers - - O
in - - O
the - - O
United - - O
States - - O
( - - O
Baltimore - - O
Washington - - O
, - - O
DC - - O
, - - O
Pittsburgh - - O
, - - O
Chicago - - O
, - - O
and - - O
Los - - O
Angeles - - O
) - - O
. - - O

Antibodies - - O
raised - - O
against - - O
a - - O
bacterially - - O
produced - - O
beta - - B-MUT
gal-trk - - I-MUT
receptor - - I-MUT
kinase - - I-MUT
fusion - - I-MUT
protein - - I-MUT
recognized - - O
a - - O
44 - - O
kd - - O
phosphoprotein - - O
phosphorylated - - O
on - - O
serine - - O
, - - O
threonine - - O
and - - O
tyrosine - - O
in - - O
extracts - - O
of - - O
trk-2h - - B-MUT
transformed - - O
NIH3T3 - - O
cells - - O
. - - O

Potscoital - - O
test - - O
. - - O

Fibular - - O
dimelia - - O
with - - O
deficiency - - O
of - - O
the - - O
tibia - - O
. - - O

Thus - - O
, - - O
although - - O
p28 - - B-MUT
may - - O
play - - O
only - - O
a - - O
limited - - O
role - - O
during - - O
the - - O
early - - O
embryonic - - O
cleavages - - O
, - - O
it - - O
may - - O
function - - O
later - - O
in - - O
development - - O
to - - O
establish - - O
a - - O
somatic - - O
type - - O
of - - O
cell - - O
cycle - - O
. - - O

In - - O
Denmark - - O
only - - O
1-3 - - O
cases - - O
of - - O
transfusion-associated - - O
hepatitis - - O
NANB - - O
( - - O
TAH-NANB - - O
) - - O
are - - O
registered - - O
annually - - O
or - - O
about - - O
1 - - O
case - - O
per - - O
100 - - O
, - - O
000 - - O
units - - O
transfused - - O
. - - O

These - - O
indications - - O
of - - O
deregulated - - O
signalling - - O
in - - O
the - - O
absence - - O
of - - O
tyrosine - - O
118 - - O
were - - O
substantiated - - O
by - - O
sustained - - O
activation - - O
of - - O
STAT3 - - B-MUT
. - - O

Interestingly - - O
, - - O
this - - O
mutant - - O
cell - - O
line - - O
lacks - - O
expression - - O
of - - O
the - - O
IKK - - B-MUT
regulatory - - I-MUT
protein - - I-MUT
, - - O
IKKgamma - - B-MUT
. - - O

Membrane-bound - - O
Steel - - B-MUT
factor - - I-MUT
induces - - O
more - - O
persistent - - O
tyrosine - - B-MUT
kinase - - I-MUT
activation - - O
and - - O
longer - - O
life - - O
span - - O
of - - O
c-kit - - B-MUT
gene-encoded - - O
protein - - O
than - - O
its - - O
soluble - - O
form - - O
. - - O

Replacement - - B-MUT
variant - - I-MUT
histone - - I-MUT
genes - - I-MUT
contain - - O
intervening - - O
sequences - - O
. - - O

Transcriptional - - O
regulation - - O
of - - O
the - - O
GluR2 - - B-MUT
gene - - I-MUT
: - - O
neural-specific - - O
expression - - O
, - - O
multiple - - O
promoters - - O
, - - O
and - - O
regulatory - - O
elements - - O
. - - O

Determination - - O
of - - O
lead - - O
in - - O
blood - - O
. - - O

The - - O
central - - O
( - - O
R - - O
) - - O
domain - - O
is - - O
responsible - - O
for - - O
receptor-binding - - O
activity - - O
whereas - - O
the - - O
N-terminal - - O
( - - O
T - - O
) - - O
domain - - O
mediates - - O
translocation - - O
, - - O
the - - O
process - - O
by - - O
which - - O
the - - O
C-terminal - - O
cytotoxic - - O
domain - - O
is - - O
transported - - O
from - - O
the - - O
receptor - - O
to - - O
the - - O
site - - O
of - - O
its - - O
cytotoxicity - - O
. - - O

To - - O
determine - - O
whether - - O
interaction - - O
of - - O
arsenite - - O
with - - O
the - - O
hormone-binding - - O
domain - - O
results - - O
in - - O
receptor - - O
activation - - O
, - - O
COS-1 - - O
cells - - O
were - - O
transiently - - O
cotransfected - - O
with - - O
the - - O
chimeric - - B-MUT
receptors - - I-MUT
GAL-ER - - I-MUT
, - - O
which - - O
contains - - O
the - - O
hormone-binding - - O
domain - - O
of - - O
ERalpha - - B-MUT
and - - O
the - - O
DNA-binding - - O
domain - - O
of - - O
the - - O
transcription - - O
factor - - O
GAL4 - - B-MUT
, - - O
and - - O
a - - O
GAL4-responsive - - O
CAT - - B-MUT
reporter - - I-MUT
gene - - I-MUT
. - - O

The - - O
JHRLSS - - O
has - - O
been - - O
used - - O
in - - O
prior - - O
studies - - O
to - - O
assess - - O
RLS - - O
severity - - O
, - - O
but - - O
has - - O
not - - O
previously - - O
been - - O
validated - - O
in - - O
relation - - O
to - - O
direct - - O
measures - - O
of - - O
the - - O
morbidity - - O
associated - - O
with - - O
RLS - - O
. - - O

VP-16 - - O
, - - O
ifosfamide - - O
and - - O
cisplatin - - O
( - - O
VIP - - O
) - - O
for - - O
extensive - - O
small - - O
cell - - O
lung - - O
cancer - - O
. - - O

Measurements - - O
were - - O
compared - - O
with - - O
two - - O
computerised - - O
treatment - - O
planning - - O
systems--Theraplan - - O
VO5B - - O
and - - O
ADAC - - O
Pinnacle3 - - O
V4 - - O
. - - O
0b - - O
. - - O

The - - O
experimentally - - O
mapped - - O
regions - - O
of - - O
RPB5 - - B-MUT
involved - - O
in - - O
these - - O
interactions - - O
correspond - - O
to - - O
distinct - - O
and - - O
surface-exposed - - O
alpha-helical - - O
structures - - O
. - - O

The - - O
role - - O
of - - O
daunorubicin - - O
in - - O
induction - - O
therapy - - O
for - - O
adult - - O
acute - - O
myeloid - - O
leukemia - - O
. - - O

These - - O
data - - O
suggest - - O
that - - O
hypocitraturia - - O
in - - O
type - - O
I - - O
renal - - O
tubular - - O
acidosis - - O
may - - O
be - - O
due - - O
to - - O
a - - O
defect - - O
in - - O
proximal - - O
tubule - - O
function - - O
. - - O

Each - - O
expressed - - O
domain - - O
, - - O
as - - O
well - - O
as - - O
FKBP-33 - - B-MUT
itself - - O
, - - O
possesses - - O
peptidyl-prolyl - - B-MUT
cis-trans - - I-MUT
isomerase - - I-MUT
activity - - O
, - - O
though - - O
with - - O
much - - O
lower - - O
specific - - O
activities - - O
than - - O
FKBP-12 - - B-MUT
. - - O

5- - - O
( - - O
Dimethylaminopropyl - - O
) - - O
-19 - - O
, - - O
11-dihydro-5H-benzo - - O
[ - - O
2 - - O
, - - O
3 - - O
] - - O
pyrido - - O
[ - - O
6 - - O
, - - O
7-b - - O
] - - O
azepine - - O
. - - O

The - - O
induction - - O
of - - O
RNKP-1 - - B-MUT
expression - - O
in - - O
the - - O
Con - - O
A-cultured - - O
spleen - - O
cells - - O
is - - O
accompanied - - O
by - - O
increases - - O
in - - O
both - - O
NK - - O
and - - O
lymphokine-activated - - O
killer - - O
lymphocyte - - O
activities - - O
. - - O

Cephradine - - O
250 - - O
mg - - O
at - - O
night - - O
for - - O
12 - - O
months - - O
was - - O
given - - O
as - - O
a - - O
prophylactic - - O
measure - - O
to - - O
33 - - O
female - - O
patients - - O
of - - O
mean - - O
age - - O
41 - - O
. - - O
6 - - O
years - - O
, - - O
who - - O
had - - O
a - - O
history - - O
in - - O
the - - O
preceding - - O
12 - - O
months - - O
of - - O
between - - O
three - - O
and - - O
24 - - O
( - - O
median - - O
= - - O
7 - - O
) - - O
episodes - - O
of - - O
frequency - - O
and - - O
or - - O
dysuria - - O
. - - O

Sterile - - O
mutants - - O
of - - O
Saccharomyces - - O
cerevisiae - - O
were - - O
isolated - - O
from - - O
alpha - - O
* - - O
cells - - O
having - - O
the - - O
a - - B-MUT
alpha - - I-MUT
aar1-6 - - I-MUT
genotype - - I-MUT
( - - O
exhibiting - - O
alpha - - O
mating - - O
ability - - O
and - - O
weak - - O
a - - O
mating - - O
ability - - O
as - - O
a - - O
result - - O
of - - O
a - - O
defect - - O
in - - O
a1-alpha - - O
2 - - B-MUT
repression - - I-MUT
) - - O
. - - O

Four - - O
cases - - O
of - - O
synovial - - O
chondromatosis - - O
are - - O
presented - - O
. - - O

We - - O
report - - O
here - - O
that - - O
out - - O
of - - O
the - - O
major - - O
pro-inflammatory - - O
cytokines - - O
examined - - O
, - - O
IL-1alpha - - B-MUT
, - - O
IL-1beta - - B-MUT
, - - O
TNF-alpha - - B-MUT
and - - O
IL-6 - - B-MUT
, - - O
only - - O
IL-6 - - B-MUT
was - - O
generated - - O
and - - O
secreted - - O
in - - O
PKCeta - - O
-expressing - - O
cells - - O
without - - O
any - - O
additional - - O
inducer - - O
in - - O
serum-supplemented - - O
cultures - - O
( - - O
10% - - O
FCS - - O
) - - O
. - - O

Twenty-nine - - O
days - - O
after - - O
injection - - O
of - - O
5 - - O
. - - O
8 - - O
mCi - - O
of - - O
Tc-99m - - O
, - - O
which - - O
gives - - O
28 - - O
rads - - O
to - - O
the - - O
testis - - O
, - - O
the - - O
number - - O
of - - O
sperm - - O
hads - - O
decreased - - O
to - - O
70% - - O
of - - O
control - - O
. - - O

Fluorometric - - O
methods - - O
can - - O
also - - O
provide - - O
information - - O
about - - O
porphyrin - - O
binding - - O
sites - - O
that - - O
is - - O
useful - - O
in - - O
understanding - - O
porphyrin - - O
transport - - O
and - - O
clearance - - O
. - - O

Homozygous - - O
individuals - - O
usually - - O
develop - - O
purpura - - O
fulminans - - O
as - - O
newborns - - O
; - - O
heterozygous - - O
protein - - O
C-deficient - - O
individuals - - O
are - - O
at - - O
increased - - O
risk - - O
for - - O
venous - - O
thrombosis - - O
and - - O
pulmonary - - O
embolism - - O
. - - O

DAF16 - - B-MUT
is - - O
known - - O
to - - O
be - - O
a - - O
component - - O
of - - O
a - - O
signaling - - O
pathway - - O
that - - O
has - - O
been - - O
partially - - O
dissected - - O
genetically - - O
and - - O
includes - - O
homologues - - O
of - - O
the - - O
insulin - - B-MUT
IGF-1 - - I-MUT
receptor - - I-MUT
, - - I-MUT
PtdIns - - O
3-kinase - - B-MUT
and - - I-MUT
PKB - - O
. - - B-MUT

The - - O
prevalence - - O
of - - O
CPAF - - O
was - - O
similar - - O
in - - O
type - - O
1 - - O
and - - O
type - - O
2 - - O
diabetes - - O
, - - O
was - - O
greater - - O
in - - O
women - - O
than - - O
in - - O
men - - O
, - - O
and - - O
was - - O
significantly - - O
greater - - O
after - - O
repeated - - O
administrations - - O
than - - O
after - - O
one - - O
single - - O
administration - - O
of - - O
chlorpropamide - - O
. - - O

The - - O
identification - - O
of - - O
viable - - O
myocardium - - O
with - - O
both - - O
99mTc-tetrofosmin - - O
and - - O
201Tl - - O
can - - O
be - - O
greatly - - O
enhanced - - O
to - - O
a - - O
similar - - O
degree - - O
if - - O
the - - O
severity - - O
of - - O
reduction - - O
in - - O
activity - - O
within - - O
nonreversible - - O
defects - - O
is - - O
considered - - O
. - - O

Molecular - - O
analysis - - O
of - - O
a - - O
novel - - O
schizosaccharomyces - - O
pombe - - O
gene - - O
containing - - O
two - - O
RNP - - B-MUT
consensus-sequence - - I-MUT
RNA-binding - - I-MUT
domains - - I-MUT
. - - O

Interestingly - - O
, - - O
a - - O
decreased - - O
transcription - - O
from - - O
the - - O
endogenous - - O
c-Myb - - B-MUT
promoter - - I-MUT
was - - O
observed - - O
in - - O
several - - O
HTLV-I - - O
transformed - - O
T-cell - - O
lines - - O
. - - O

The - - O
role - - O
of - - O
pharmacological - - O
profiling - - O
in - - O
safety - - O
assessment - - O
. - - O

The - - O
tumor-suppressor - - B-MUT
protein - - I-MUT
p53 - - I-MUT
is - - O
involved - - O
in - - O
maintaining - - O
genomic - - O
stability - - O
. - - O

Catch-up - - O
growth - - O
and - - O
craniofacial - - O
dimensions - - O
following - - O
administration - - O
of - - O
the - - O
antineoplastic - - O
agent - - O
vincristine - - O
to - - O
young - - O
rats - - O
. - - O

Previous - - O
experimental - - O
evidence - - O
had - - O
indicated - - O
that - - O
Reg1 - - B-MUT
might - - O
target - - O
Glc7 - - B-MUT
to - - O
nuclear - - O
substrates - - O
such - - O
as - - O
the - - O
Snf1 - - B-MUT
kinase - - I-MUT
complex - - I-MUT
. - - O

The - - O
main - - O
causes - - O
of - - O
liver - - O
disease - - O
in - - O
the - - O
patients - - O
with - - O
HCC - - O
were - - O
hepatitis - - O
C - - O
virus - - O
( - - O
HCV - - O
) - - O
( - - O
77% - - O
) - - O
, - - O
alcohol - - O
abuse - - O
( - - O
73% - - O
) - - O
, - - O
and - - O
the - - O
combination - - O
of - - O
HCV - - O
and - - O
alcohol - - O
abuse - - O
( - - O
50% - - O
) - - O
. - - O

Recommendations - - O
to - - O
deal - - O
with - - O
these - - O
and - - O
related - - O
issues - - O
are - - O
presented - - O
. - - O

The - - O
changes - - O
after - - O
treatment - - O
were - - O
observed - - O
chiefly - - O
by - - O
electromyography - - O
while - - O
sensory - - O
and - - O
motor - - O
improvement - - O
were - - O
also - - O
recorded - - O
as - - O
auxiliary - - O
indicators - - O
. - - O

Specific - - O
class - - B-MUT
I - - I-MUT
and - - I-MUT
II - - I-MUT
histone - - I-MUT
deacetylases - - I-MUT
( - - O
HDACs - - B-MUT
) - - O
interact - - O
in - - O
vivo - - O
with - - O
BCoR - - B-MUT
, - - O
suggesting - - O
that - - O
BCoR - - B-MUT
may - - O
functionally - - O
link - - O
these - - O
two - - O
classes - - O
of - - O
HDACs - - B-MUT
. - - O

Preliminary - - O
report - - O
. - - O

Using - - O
varying - - O
conditions - - O
, - - O
three - - O
distinct - - O
complexes - - O
were - - O
shown - - O
to - - O
interact - - O
specifically - - O
with - - O
the - - O
NIP - - B-MUT
region - - I-MUT
, - - O
although - - O
only - - O
one - - O
correlates - - O
with - - O
repressor - - O
activity - - O
. - - O

Localization - - O
of - - O
the - - O
brachial - - O
plexus - - O
with - - O
the - - O
nerve - - O
stimulator - - O
is - - O
equally - - O
effective - - O
at - - O
the - - O
interscalene - - O
, - - O
supraclavicular - - O
, - - O
and - - O
axillary - - O
sites - - O
. - - O

Although - - O
the - - O
OC - - B-MUT
promoter - - I-MUT
is - - O
activated - - O
in - - O
a - - O
C - - O
terminus - - O
dependent - - O
manner - - O
, - - O
the - - O
MDR - - B-MUT
, - - O
LTR - - O
and - - O
BSP - - B-MUT
promoters - - I-MUT
are - - O
repressed - - O
by - - O
three - - O
distinct - - O
mechanisms - - O
, - - O
either - - O
independent - - O
of - - O
or - - O
involving - - O
the - - O
AML - - B-MUT
C - - I-MUT
terminus - - I-MUT
, - - O
or - - O
requiring - - O
only - - O
the - - O
conserved - - O
C-terminal - - B-MUT
pentapeptide - - I-MUT
VWRPY - - I-MUT
. - - O

We - - O
critically - - O
assess - - O
current - - O
systematic - - O
uncertainties - - O
and - - O
determine - - O
the - - O
primordial - - O
Li - - O
abundance - - O
within - - O
new - - O
, - - O
much - - O
tighter - - O
limits - - O
: - - O
&parl0 - - O
; - - O
Li&solm0 - - O
; - - O
H&parr0 - - O
; - - O
p - - O
= - - O
1 - - O
. - - O
23+0 - - O
. - - O
68-0 - - O
. - - O
32x10-10 - - O
. - - O

In - - O
64% - - O
a - - O
small - - O
cardiac - - O
vein - - O
does - - O
not - - O
exist - - O
, - - O
but - - O
its - - O
origin - - O
, - - O
the - - O
right - - O
marginal - - O
vein - - O
, - - O
joins - - O
the - - O
system - - O
of - - O
anterior - - O
cardiac - - O
veins - - O
. - - O

These - - O
results - - O
indicate - - O
that - - O
the - - O
cis-regulatory - - O
elements - - O
required - - O
for - - O
developmental - - O
control - - O
of - - O
the - - O
HaG3-A - - B-MUT
helianthinin - - I-MUT
gene - - I-MUT
are - - O
located - - O
in - - O
a - - O
2 - - O
. - - O
4 - - O
kb - - O
upstream - - O
region - - O
of - - O
this - - O
gene - - O
. - - O

Transcriptional - - O
regulation - - O
of - - O
the - - O
yeast - - B-MUT
PHO8 - - I-MUT
promoter - - I-MUT
in - - O
comparison - - O
to - - O
the - - O
coregulated - - O
PHO5 - - B-MUT
promoter - - I-MUT
. - - O

The - - O
trk-2h - - B-MUT
oncogene - - I-MUT
, - - O
isolated - - O
from - - O
the - - O
human - - O
breast - - O
carcinoma - - O
cell - - O
line - - O
MDA-MB - - O
231 - - O
by - - O
genomic - - O
DNA-transfection - - O
into - - O
NIH3T3 - - O
cells - - O
, - - O
consists - - O
of - - O
the - - O
trk - - B-MUT
proto-oncogene - - I-MUT
receptor - - I-MUT
kinase - - I-MUT
domain - - I-MUT
fused - - O
to - - O
a - - O
N-terminal - - O
41 - - O
amino - - O
acid - - O
activating - - O
sequence - - O
( - - O
Kozma - - O
, - - O
S - - O
. - - O
C - - O
. - - O
, - - O
Redmond - - O
, - - O
S - - O
. - - O
M - - O
. - - O
S - - O
. - - O
, - - O
Xiao-Chang - - O
, - - O
F - - O
. - - O
, - - O
Saurer - - O
, - - O
S - - O
. - - O
M - - O
. - - O
, - - O
Groner - - O
, - - O
B - - O
. - - O
and - - O
Hynes - - O
, - - O
N - - O
. - - O
E - - O
. - - O

Substrates - - O
include - - O
the - - O
p21 - - B-MUT
( - - I-MUT
ras - - I-MUT
) - - I-MUT
proteins - - I-MUT
, - - O
nuclear - - B-MUT
lamins - - I-MUT
, - - O
and - - O
a - - O
series - - O
of - - O
retinal - - O
proteins - - O
. - - O

Transcription - - O
of - - O
the - - O
metH - - B-MUT
gene - - I-MUT
in - - I-MUT
Salmonella - - I-MUT
typhimurium - - I-MUT
and - - I-MUT
Escherichia - - I-MUT
coli - - I-MUT
is - - O
positively - - O
regulated - - O
by - - O
the - - O
metR - - B-MUT
gene - - I-MUT
product - - I-MUT
, - - O
a - - O
DNA - - O
binding - - O
protein - - O
. - - O

Morphine-dependent - - O
and - - O
control - - O
rats - - O
in - - O
an - - O
oral - - O
free-choice - - O
protocol - - O
were - - O
treated - - O
with - - O
gamma-vinyl - - O
GABA - - O
( - - O
GVG - - O
) - - O
, - - O
60 - - O
, - - O
120 - - O
and - - O
240 - - O
mg - - O
kg - - O
IP - - O
, - - O
for - - O
3 - - O
days - - O
over - - O
three - - O
successive - - O
periods - - O
. - - O

Approximately - - O
20% - - O
of - - O
ALCLs - - O
that - - O
express - - O
ALK - - B-MUT
do - - O
not - - O
contain - - O
the - - O
t - - O
( - - O
2 - - O
; - - O
5 - - O
) - - O
, - - O
suggesting - - O
that - - O
other - - O
genetic - - O
abnormalities - - O
can - - O
result - - O
in - - O
aberrant - - O
ALK - - B-MUT
expression - - O
. - - O

Furthermore - - O
, - - O
loss - - O
of - - O
methylation - - O
also - - O
greatly - - O
reduced - - O
the - - O
association - - O
of - - O
another - - O
yeast - - B-MUT
B-type - - I-MUT
subunit - - I-MUT
, - - O
Rts1p - - B-MUT
. - - O

Cytogenetic - - O
and - - O
molecular - - O
characterization - - O
of - - O
random - - O
chromosomal - - O
rearrangements - - O
activating - - O
the - - O
drug - - O
resistance - - O
gene - - O
, - - O
MDR1 - - B-MUT
P-glycoprotein - - I-MUT
, - - I-MUT
in - - O
drug-selected - - O
cell - - O
lines - - O
and - - O
patients - - O
with - - O
drug - - O
refractory - - O
ALL - - O
. - - O

The - - O
husband - - O
in - - O
one - - O
of - - O
the - - O
married - - O
couples - - O
was - - O
treated - - O
for - - O
hepatitis - - O
of - - O
unidentified - - O
etiology - - O
in - - O
an - - O
Infectology - - O
Department - - O
four - - O
years - - O
ago - - O
. - - O

These - - O
genetic - - O
alterations - - O
do - - O
not - - O
affect - - O
synthesis - - O
of - - O
the - - O
major - - O
c-myc - - B-MUT
protein - - I-MUT
, - - O
p64 - - B-MUT
, - - O
which - - O
is - - O
initiated - - O
from - - O
the - - O
first - - O
AUG - - O
codon - - O
in - - O
exon - - O
2 - - O
. - - O

Its - - O
application - - O
in - - O
Madagascar - - O
: - - O
advantages - - O
and - - O
disadvantages - - O
. - - O

This - - O
paper - - O
describes - - O
the - - O
results - - O
of - - O
an - - O
initial - - O
study - - O
on - - O
the - - O
application - - O
of - - O
linear - - O
solvation - - O
energy - - O
relationships - - O
( - - O
LSERs - - O
) - - O
to - - O
the - - O
prediction - - O
of - - O
internal - - O
standard - - O
compounds - - O
in - - O
reversed-phase - - O
liquid - - O
chromatographic - - O
( - - O
RPLC - - O
) - - O
method - - O
development - - O
. - - O

What's - - O
new - - O
in - - O
gynecologic - - O
and - - O
obstetrical - - O
surgery - - O
. - - O

Treatment - - O
with - - O
heparin - - O
, - - O
plasminogen - - B-MUT
activators - - O
and - - O
fibrinogenolytic - - O
agents - - O
was - - O
disappointing - - O
although - - O
renal - - O
function - - O
has - - O
stabilized - - O
in - - O
one - - O
patient - - O
on - - O
long - - O
term - - O
oral - - O
anticoagulant - - O
therapy - - O
. - - O

M - - O
. - - O

There - - O
was - - O
a - - O
weak - - O
significant - - O
correlation - - O
between - - O
TGF - - B-MUT
beta - - I-MUT
1 - - I-MUT
levels - - O
and - - O
normal - - O
cell - - O
radiosensitivity - - O
( - - O
lymphocyte - - O
SF2 - - O
) - - O
. - - O

We - - O
now - - O
provide - - O
evidence - - O
for - - O
physical - - O
and - - O
functional - - O
interaction - - O
between - - O
Doa4 - - B-MUT
and - - O
the - - O
proteasome - - O
. - - O

We - - O
describe - - O
a - - O
genetic - - O
system - - O
for - - O
further - - O
characterizing - - O
the - - O
role - - O
of - - O
the - - O
extreme - - O
C-terminus - - O
of - - O
the - - O
beta - - O
subunit - - O
of - - O
E - - B-MUT
. - - I-MUT
coli - - I-MUT
RNA - - I-MUT
polymerase - - I-MUT
. - - O

The - - O
single - - O
site - - O
of - - O
glycosylation - - O
is - - O
located - - O
near - - O
the - - O
C-terminus - - O
in - - O
the - - O
N-glycosylation - - B-MUT
sequon - - I-MUT
-Asn-Cys-Ser- - - I-MUT
in - - O
which - - O
Cys - - O
forms - - O
part - - O
of - - O
a - - O
disulphide - - O
bridge - - O
. - - O

P - - O
. - - O

Mental - - O
rotation - - O
of - - O
paired - - O
figures - - O
engendered - - O
activation - - O
in - - O
the - - O
left - - O
superior - - O
parietal - - O
lobule - - O
and - - O
the - - O
right - - O
frontal - - O
medial - - O
gyrus - - O
. - - O

When - - O
combined - - O
with - - O
independent - - O
activating - - O
mutations - - O
in - - O
the - - O
c-abl - - B-MUT
kinase - - I-MUT
domain - - I-MUT
or - - O
NH2-terminus - - O
, - - O
the - - O
G128R - - B-MUT
mutation - - O
blocked - - O
transformation - - O
by - - O
the - - O
double - - O
mutant - - O
, - - O
suggesting - - O
that - - O
the - - O
G128R - - B-MUT
mutant - - I-MUT
was - - O
unable - - O
to - - O
transform - - O
cells - - O
for - - O
trivial - - O
reasons - - O
. - - O

The - - O
csbA - - B-MUT
fusion - - I-MUT
was - - O
maximally - - O
expressed - - O
during - - O
early - - O
stationary - - O
phase - - O
in - - O
cells - - O
grown - - O
in - - O
Luria - - O
broth - - O
containing - - O
5% - - O
glucose - - O
and - - O
0 - - O
. - - O
2% - - O
glutamine - - O
. - - O

9 - - O
. - - O
7 - - O
( - - O
95% - - O
CI - - O
: - - O
9 - - O
. - - O
6-9 - - O
. - - O
7 - - O
) - - O
micromol - - O
L - - O
among - - O
women - - O
( - - O
P - - O
= - - O
0 - - O
. - - O
003 - - O
) - - O
. - - O

A - - O
single - - O
protease-resistant - - O
structure - - O
formed - - O
by - - O
the - - O
entirety - - O
of - - O
both - - O
PDZ - - B-MUT
repeats - - I-MUT
1 - - I-MUT
and - - I-MUT
2 - - I-MUT
( - - O
PDZ1-2 - - B-MUT
) - - O
contains - - O
the - - O
protein - - B-MUT
4 - - I-MUT
. - - I-MUT
1-binding - - I-MUT
site - - I-MUT
. - - O

All - - O
other - - O
changes - - O
at - - O
the - - O
3- - - O
, - - O
5- - - O
, - - O
and - - O
6-positions - - O
, - - O
as - - O
well - - O
as - - O
the - - O
replacement - - O
of - - O
the - - O
phenyl - - O
group - - O
at - - O
position - - O
2 - - O
, - - O
caused - - O
a - - O
marked - - O
decrease - - O
of - - O
activity - - O
. - - O

Thomas' - - O
Hospital - - O
solution - - O
( - - O
with - - O
95% - - O
O2 - - O
: - - O
5% - - O
CO2 - - O
) - - O
can - - O
meet - - O
the - - O
metabolic - - O
demand - - O
of - - O
the - - O
ischaemic - - O
myocardium - - O
and - - O
thus - - O
increase - - O
the - - O
safe - - O
duration - - O
of - - O
cardiac - - O
arrest - - O
. - - O

The - - O
cleavage - - O
dipeptides - - O
of - - O
C1YVV - - B-MUT
NIa - - I-MUT
protease - - I-MUT
are - - O
Q - - B-MUT
( - - I-MUT
E - - I-MUT
) - - I-MUT
S - - I-MUT
( - - I-MUT
A - - I-MUT
, - - I-MUT
G - - I-MUT
) - - I-MUT
. - - I-MUT

Using - - O
mouse-human - - O
somatic - - O
hybrids - - O
and - - O
FISH - - O
analysis - - O
, - - O
the - - O
PE-2 - - B-MUT
gene - - I-MUT
is - - O
localized - - O
to - - O
human - - O
chromosome - - O
19q13 - - O
. - - O
2 - - O
, - - O
a - - O
region - - O
involved - - O
in - - O
translocations - - O
and - - O
deletions - - O
in - - O
leukemias - - O
and - - O
several - - O
solid - - O
tumors - - O
, - - O
suggesting - - O
that - - O
this - - O
novel - - O
ETS - - B-MUT
factor - - I-MUT
may - - O
play - - O
a - - O
role - - O
in - - O
carcinogenesis - - O
. - - O

Maximum - - O
number - - O
of - - O
strains - - O
( - - O
39 - - O
. - - O
1% - - O
) - - O
were - - O
resistant - - O
in - - O
S - - O
. - - O
bareilly - - O
serotype - - O
, - - O
followed - - O
by - - O
S - - O
. - - O
typhimurium - - O
( - - O
21 - - O
. - - O
7% - - O
) - - O
and - - O
least - - O
in - - O
S - - O
. - - O
typhi - - O
( - - O
17 - - O
. - - O
4% - - O
) - - O
. - - O

Use - - O
of - - O
prostaglandin - - O
F2 - - O
alpha - - O
( - - O
PGF2 - - O
alpha - - O
) - - O
in - - O
cattle - - O
breeding - - O
. - - O

Interestingly - - O
, - - O
these - - O
response - - O
elements - - O
display - - O
dramatically - - O
reduced - - O
affinity - - O
for - - O
retinoic - - B-MUT
acid - - I-MUT
receptor-retinoid-X - - I-MUT
receptor - - I-MUT
heterodimers - - I-MUT
. - - O

Mutations - - O
within - - O
the - - O
C - - O
terminus - - O
of - - O
c-fos - - B-MUT
at - - O
serine - - O
residues - - O
that - - O
are - - O
phosphorylation - - O
targets - - O
for - - O
growth - - B-MUT
factors - - I-MUT
and - - O
MAP - - B-MUT
kinase - - I-MUT
completely - - O
abrogate - - O
transactivation - - O
and - - O
block - - O
potentiation - - O
by - - O
MAP - - B-MUT
kinase - - I-MUT
. - - O

Efficacy - - O
and - - O
field - - O
evaluation - - O
of - - O
Bacillus - - O
thuringiensis - - O
( - - O
H-14 - - O
) - - O
and - - O
B - - O
. - - O
sphaericus - - O
against - - O
floodwater - - O
mosquitoes - - O
in - - O
California - - O
. - - O

The - - O
range - - O
of - - O
200 - - O
000-300 - - O
000 - - O
spermatozoa - - O
microl - - O
appeared - - O
to - - O
be - - O
a - - O
reasonable - - O
compromise - - O
for - - O
both - - O
criteria - - O
. - - O

The - - O
characterized - - O
Aplysia - - B-MUT
Afurin2 - - I-MUT
is - - O
a - - O
candidate - - O
PC - - B-MUT
that - - O
may - - O
play - - O
an - - O
important - - O
role - - O
in - - O
the - - O
processing - - O
of - - O
egg-laying - - B-MUT
hormone - - I-MUT
( - - O
ELH - - B-MUT
) - - O
-related - - O
precursors - - O
in - - O
the - - O
secretory - - O
cells - - O
of - - O
the - - O
atrial - - O
gland - - O
. - - O

A - - O
role - - O
for - - O
RalGDS - - B-MUT
and - - O
a - - O
novel - - O
Ras - - B-MUT
effector - - O
in - - O
the - - O
Ras-mediated - - O
inhibition - - O
of - - O
skeletal - - O
myogenesis - - O
. - - O

Analyses - - O
of - - O
hGMR - - B-MUT
beta - - I-MUT
subunit - - I-MUT
mutants - - I-MUT
revealed - - O
two - - O
cytoplasmic - - O
regions - - O
involved - - O
in - - O
activation - - O
of - - O
the - - O
c-myc - - B-MUT
promoter - - I-MUT
, - - O
one - - O
is - - O
essential - - O
and - - O
the - - O
other - - O
is - - O
dispensable - - O
but - - O
enhances - - O
the - - O
activity - - O
. - - O

Previously - - O
, - - O
we - - O
reported - - O
that - - O
scanthrough - - O
translation - - O
, - - O
where - - O
the - - O
initiating - - O
AUG - - O
of - - O
a - - O
primary - - O
open - - O
reading - - O
frame - - O
is - - O
bypassed - - O
, - - O
is - - O
most - - O
likely - - O
to - - O
account - - O
for - - O
the - - O
presentation - - O
of - - O
cryptic - - O
epitopes - - O
from - - O
alternative - - O
reading - - O
frames - - O
within - - O
the - - O
influenza - - B-MUT
A - - I-MUT
PR - - I-MUT
8 - - I-MUT
34 - - I-MUT
nucleoprotein - - I-MUT
gene - - I-MUT
. - - I-MUT

Lowering - - O
of - - O
the - - O
renal - - O
blood - - O
flow - - O
alters - - O
the - - O
glomerular - - O
and - - O
tubular - - O
excretion - - O
processes - - O
. - - O

We - - O
find - - O
that - - O
BCL-6 - - B-MUT
POZ - - B-MUT
domain - - I-MUT
mutations - - O
that - - O
disrupt - - O
the - - O
interaction - - O
with - - O
N-CoR - - B-MUT
and - - O
SMRT - - B-MUT
no - - O
longer - - O
repress - - O
transcription - - O
. - - O

Maternal - - O
p - - O
, - - O
p'DDE - - O
and - - O
beta-HCH - - O
levels - - O
were - - O
also - - O
associated - - O
with - - O
newborn - - O
levels - - O
, - - O
but - - O
levels - - O
of - - O
PCBs - - O
were - - O
not - - O
. - - O

Children - - O
who - - O
developed - - O
lower - - O
respiratory - - O
tract - - O
infections - - O
or - - O
PCP - - O
had - - O
increased - - O
rates - - O
of - - O
decline - - O
of - - O
CD4 - - B-MUT
cell - - O
counts - - O
during - - O
the - - O
first - - O
6 - - O
months - - O
of - - O
life - - O
. - - O

Selective - - O
stimulation - - O
of - - O
central - - O
alpha-autoreceptors - - B-MUT
following - - O
treatment - - O
with - - O
alpha-methyldopa - - O
and - - O
FLA - - O
136 - - O
. - - O

OBJECTIVE - - O
: - - O
Our - - O
goal - - O
was - - O
to - - O
determine - - O
whether - - O
chlamydia-infected - - O
women - - O
have - - O
a - - O
higher - - O
rate - - O
of - - O
febrile - - O
complications - - O
after - - O
postpartum - - O
tubal - - O
ligation - - O
. - - O

The - - O
pre-mRNA - - O
splicing - - O
factor - - O
U2AF - - B-MUT
( - - O
U2 - - B-MUT
small - - I-MUT
nuclear - - I-MUT
ribonucleoprotein - - I-MUT
particle - - I-MUT
[ - - I-MUT
snRNP - - I-MUT
] - - I-MUT
auxiliary - - I-MUT
factor - - I-MUT
) - - O
plays - - O
a - - O
critical - - O
role - - O
in - - O
3' - - O
splice - - O
site - - O
selection - - O
. - - O

The - - O
Euglena - - B-MUT
ribosomal - - I-MUT
protein - - I-MUT
gene - - I-MUT
cluster - - I-MUT
resembles - - O
the - - O
S-10 - - B-MUT
ribosomal - - I-MUT
protein - - I-MUT
operon - - I-MUT
of - - I-MUT
Escherichia - - I-MUT
coli - - I-MUT
in - - O
gene - - O
organization - - O
and - - O
follows - - O
the - - O
exact - - O
linear - - O
order - - O
of - - O
the - - O
analogous - - O
genes - - O
in - - O
the - - O
tobacco - - O
and - - O
liverwort - - O
chloroplast - - O
genomes - - O
. - - O

The - - O
linear - - O
plasmid - - O
pCLU1 - - O
from - - O
the - - O
yeast - - O
Kluyveromyces - - O
lactis - - O
normally - - O
replicates - - O
in - - O
the - - O
cytoplasm - - O
, - - O
with - - O
the - - O
aid - - O
of - - O
the - - O
helper - - O
linear - - O
plasmid - - O
pGKL2 - - O
, - - O
using - - O
terminal - - B-MUT
protein - - I-MUT
( - - O
TP - - B-MUT
) - - O
as - - O
a - - O
primer - - O
. - - O

A - - O
high-efficiency - - O
cross-flow - - O
micronebulizer - - O
interface - - O
for - - O
capillary - - O
electrophoresis - - O
and - - O
inductively - - O
coupled - - O
plasma - - O
mass - - O
spectrometry - - O
. - - O

This - - O
hypothesis - - O
is - - O
consistent - - O
with - - O
the - - O
occurrence - - O
of - - O
PEA3 - - B-MUT
binding - - I-MUT
sites - - I-MUT
in - - O
the - - O
PEA3 - - B-MUT
promoter - - I-MUT
and - - O
with - - O
the - - O
ability - - O
of - - O
PEA3 - - B-MUT
to - - O
transactivate - - O
this - - O
promoter - - O
. - - O

DMCM - - O
also - - O
permits - - O
extension - - O
of - - O
the - - O
possibilities - - O
of - - O
obtaining - - O
and - - O
transplanting - - O
donor - - O
organs - - O
. - - O

The - - O
sequences - - O
showed - - O
extensive - - O
homologies - - O
with - - O
squalene - - B-MUT
synthase - - I-MUT
genes - - I-MUT
and - - O
enzymes - - O
from - - O
a - - O
number - - O
of - - O
other - - O
organisms - - O
and - - O
extreme - - O
amino - - O
acid - - O
conservation - - O
within - - O
the - - O
binding - - O
and - - O
catalytic - - O
domains - - O
. - - O

When - - O
10 - - O
fields - - O
were - - O
analysed - - O
, - - O
a - - O
strong - - O
relationship - - O
was - - O
found - - O
between - - O
the - - O
presence - - O
of - - O
bacteria - - O
on - - O
Gram - - O
staining - - O
and - - O
the - - O
final - - O
diagnosis - - O
of - - O
VAP - - O
( - - O
for - - O
PSB - - O
and - - O
PTC - - O
respectively - - O
: - - O
sensitivity - - O
74 - - O
and - - O
81% - - O
, - - O
specificity - - O
94 - - O
and - - O
100% - - O
, - - O
positive - - O
predictive - - O
value - - O
91 - - O
and - - O
100% - - O
, - - O
negative - - O
predictive - - O
value - - O
82 - - O
and - - O
88% - - O
) - - O
. - - O

They - - O
correspond - - O
to - - O
nucleotides - - O
equivalent - - O
to - - O
base-pair - - O
C1-G72 - - O
and - - O
discriminator - - O
base - - O
A73 - - O
in - - O
the - - O
amino - - O
acid-acceptor - - O
branch - - O
of - - O
the - - O
molecule - - O
. - - O

As - - O
a - - O
reflection - - O
of - - O
uncertainties - - O
in - - O
the - - O
estimates - - O
for - - O
individual - - O
sources - - O
, - - O
the - - O
90th - - O
percentiles - - O
of - - O
PCDD - - O
F - - O
releases - - O
for - - O
1999 - - O
ranged - - O
up - - O
to - - O
4 - - O
. - - O
1 - - O
g - - O
I-TEQ - - O
y - - O
. - - O

The - - O
evaluation - - O
was - - O
performed - - O
using - - O
a - - O
retrospective - - O
study - - O
design - - O
with - - O
newborn - - O
blood - - O
samples - - O
from - - O
three - - O
screening - - O
centres - - O
. - - O

Two - - O
distinct - - O
Salmonella - - B-MUT
fimbrins - - I-MUT
, - - O
AgfA - - B-MUT
and - - O
SefA - - B-MUT
, - - O
comprising - - O
thin - - O
aggregative - - O
fimbriae - - O
SEF17 - - B-MUT
and - - O
SEF14 - - B-MUT
, - - O
respectively - - O
, - - O
were - - O
each - - O
genetically - - O
engineered - - O
to - - O
carry - - O
PT3 - - B-MUT
, - - O
an - - O
alpha-helical - - O
16-amino - - O
acid - - O
Leishmania - - O
T-cell - - O
epitope - - O
derived - - O
from - - O
the - - O
metalloprotease - - B-MUT
gp63 - - B-MUT
. - - O

The - - O
MRS - - O
II - - O
meets - - O
a - - O
high - - O
methodological - - O
standard - - O
as - - O
an - - O
instrument - - O
standardized - - O
in - - O
the - - O
population - - O
. - - O

Duration - - O
of - - O
remission - - O
in - - O
advanced - - O
gastric - - O
cancer - - O
patients - - O
responding - - O
to - - O
sequential - - O
dose - - O
of - - O
MTX - - O
and - - O
5-FU - - O
. - - O

Northern - - O
analysis - - O
indicated - - O
differential - - O
expression - - O
by - - O
tissue - - O
with - - O
highest - - O
expression - - O
in - - O
the - - O
heart - - O
. - - O

These - - O
data - - O
show - - O
that - - O
the - - O
spv - - B-MUT
virulence - - I-MUT
genes - - I-MUT
belong - - O
simultaneously - - O
to - - O
several - - O
regulons - - O
in - - O
the - - O
cell - - O
, - - O
raising - - O
the - - O
possibility - - O
that - - O
spv - - B-MUT
expression - - O
can - - O
be - - O
fine-tuned - - O
in - - O
response - - O
to - - O
multiple - - O
environmental - - O
inputs - - O
. - - O

Clb2 - - B-MUT
Cdc28 - - I-MUT
kinase - - I-MUT
is - - I-MUT
not - - O
required - - O
for - - O
the - - O
repression - - O
of - - O
MCB-binding - - O
factor - - B-MUT
transcriptional - - I-MUT
activity - - O
in - - O
G2 - - O
and - - O
M - - O
phase - - O
. - - O

Cbf3 - - B-MUT
contains - - O
three - - O
proteins - - O
, - - O
Cbf3a - - B-MUT
, - - O
Cbf3b - - B-MUT
and - - O
Cbf3c - - B-MUT
. - - O

The - - O
results - - O
of - - O
induced - - O
coexpression - - O
were - - O
also - - O
supported - - O
by - - O
rapid - - O
generation - - O
of - - O
FeLV - - O
recombinants - - O
when - - O
FeLV-C - - O
was - - O
used - - O
to - - O
infect - - O
the - - O
feline - - O
3201B - - O
cell - - O
line - - O
that - - O
constitutively - - O
expresses - - O
high - - O
levels - - O
of - - O
endogenous - - O
FeLV-specific - - O
mRNAs - - O
. - - O

COGLAB - - O
includes - - O
measures - - O
of - - O
preattentional - - O
, - - O
attentional - - O
, - - O
conceptual - - O
, - - O
and - - O
psychomotor - - O
performance - - O
. - - O

We - - O
discuss - - O
these - - O
results - - O
in - - O
terms - - O
of - - O
the - - O
influence - - O
that - - O
time - - O
and - - O
nutritional - - O
constraints - - O
have - - O
on - - O
odonate - - O
development - - O
patterns - - O
and - - O
fitness - - O
. - - O

Within - - O
each - - O
lobe - - O
, - - O
the - - O
PA - - O
dispersion - - O
was - - O
up - - O
to - - O
10 - - O
cmH2O - - O
at - - O
CFV - - O
of - - O
90 - - O
l - - O
min - - O
; - - O
when - - O
flow - - O
decreased - - O
, - - O
PA - - O
at - - O
all - - O
sites - - O
decreased - - O
, - - O
as - - O
did - - O
the - - O
intralobar - - O
dispersion - - O
. - - O

N - - O
. - - O
van - - O
Hoek - - O
, - - O
and - - O
M - - O
. - - O

Use - - O
of - - O
serum - - O
thyroglobulin - - B-MUT
determination - - O
in - - O
the - - O
follow-up - - O
of - - O
differentiated - - O
carcinomas - - O
of - - O
the - - O
thyroid - - O
. - - O

Large - - O
and - - O
small - - O
medullary - - O
lesions - - O
inhibited - - O
the - - O
occurrence - - O
of - - O
target - - O
fibres - - O
in - - O
the - - O
tenotomized - - O
muscles - - O
, - - O
the - - O
smallest - - O
one - - O
being - - O
neurolysis - - O
of - - O
the - - O
dorsal - - O
roots - - O
. - - O

No - - O
such - - O
benefits - - O
were - - O
seen - - O
for - - O
children - - O
with - - O
CD4+ - - B-MUT
counts - - O
below - - O
0 - - O
. - - O
2 - - O
x - - O
10 - - O
( - - O
9 - - O
) - - O
per - - O
liter - - O
at - - O
entry - - O
. - - O

Pyk2 - - B-MUT
phosphorylation - - O
increased - - O
upon - - O
adherence - - O
of - - O
FLG - - O
29 - - O
. - - O
1 - - O
cells - - O
to - - O
fibronectin - - B-MUT
and - - O
to - - O
ST2 - - O
stromal - - O
cells - - O
. - - O

Supplementing - - O
a - - O
soybean - - O
protein - - O
and - - O
sucrose-based - - O
diet - - O
with - - O
levels - - O
of - - O
2 - - O
. - - O
2 - - O
, - - O
11 - - O
, - - O
and - - O
55 - - O
ppm - - O
of - - O
the - - O
antibiotic - - O
, - - O
from - - O
the - - O
two - - O
sources - - O
each - - O
with - - O
two - - O
different - - O
purities - - O
, - - O
improved - - O
weight - - O
gain - - O
of - - O
chicks - - O
an - - O
average - - O
of - - O
23% - - O
and - - O
improved - - O
feed - - O
efficiency - - O
an - - O
average - - O
of - - O
13% - - O
at - - O
the - - O
higher - - O
levels - - O
( - - O
all - - O
P - - O
less - - O
than - - O
. - - O
01 - - O
) - - O
. - - O

Mutagenesis - - O
of - - O
IM1 - - B-MUT
enhances - - O
the - - O
ability - - O
of - - O
c-Fos - - B-MUT
to - - O
activate - - O
an - - O
AP1 - - B-MUT
bearing - - I-MUT
promoter - - I-MUT
. - - O

Hypothermia - - O
After - - O
Cardiac - - O
Arrest - - O
( - - O
HACA - - O
) - - O
Study - - O
Group - - O
. - - O

Intrathecal - - O
acetyl - - B-MUT
cholinesterase - - I-MUT
inhibitors - - O
produce - - O
analgesia - - O
that - - O
is - - O
synergistic - - O
with - - O
morphine - - O
and - - O
clonidine - - O
in - - O
rats - - O
. - - O

The - - O
bZP2 - - B-MUT
cDNA - - I-MUT
( - - I-MUT
115-1914 - - I-MUT
nt - - I-MUT
, - - I-MUT
1 - - I-MUT
. - - I-MUT
8 - - I-MUT
kb - - I-MUT
) - - I-MUT
, - - O
excluding - - O
sequences - - O
coding - - O
for - - O
N-terminal - - O
signal - - O
sequence - - O
and - - O
C-terminal - - O
transmembranelike - - O
domain - - O
, - - O
was - - O
PCR - - O
amplified - - O
and - - O
Sac1-Sal1 - - B-MUT
restricted - - I-MUT
fragment - - I-MUT
cloned - - O
in - - O
frame - - O
downstream - - O
of - - O
the - - O
T5 - - O
promoter - - O
under - - O
the - - O
lac - - B-MUT
operator - - I-MUT
control - - O
in - - O
a - - O
pQE-30 - - O
vector - - O
. - - O

Combining - - O
multiple - - O
laboratory - - O
studies - - O
may - - O
be - - O
of - - O
value - - O
in - - O
predetermining - - O
the - - O
eventual - - O
outcome - - O
in - - O
near-drowning - - O
. - - O

STUDY - - O
DESIGN - - O
. - - O

A - - O
tobacco - - O
homologue - - O
( - - O
trolC - - B-MUT
) - - O
of - - O
the - - O
rolC - - B-MUT
gene - - I-MUT
of - - I-MUT
the - - I-MUT
Agrobacterium - - I-MUT
rhizogenes - - I-MUT
Ri-plasmid - - I-MUT
was - - O
cloned - - O
and - - O
sequenced - - O
from - - O
Nicotiana - - O
tabacum - - O
L - - O
. - - O
cv - - O
. - - O

Sternocleidomastoid - - O
, - - O
neck - - O
or - - O
facial - - O
muscles - - O
wasting - - O
were - - O
also - - O
found - - O
in - - O
three - - O
cases - - O
. - - O

The - - O
first - - O
hypothesis - - O
was - - O
supported - - O
in - - O
the - - O
sense - - O
that - - O
stimulus - - O
differences - - O
might - - O
affect - - O
behaviour - - O
even - - O
without - - O
their - - O
successful - - O
attentive - - O
processing - - O
in - - O
normal - - O
participants - - O
. - - O

The - - O
prescription - - O
for - - O
apoplexy - - O
includes - - O
C1-7 - - O
, - - O
T1-9 - - O
and - - O
L2-4 - - O
. - - O

The - - O
expression - - O
of - - O
the - - O
putative - - O
operon - - O
bglPH - - B-MUT
of - - O
Bacillus - - O
subtilis - - O
was - - O
studied - - O
by - - O
using - - O
bglP'-lacZ - - B-MUT
transcriptional - - I-MUT
fusions - - I-MUT
. - - O

The - - O
correlation - - O
between - - O
PaCO2 - - O
and - - O
PtcO2 - - O
in - - O
RDS - - O
was - - O
insufficient - - O
to - - O
make - - O
clinical - - O
judgement - - O
. - - O

A - - O
series - - O
of - - O
amino - - O
terminal - - O
deletion - - O
mutants - - O
( - - O
d10 - - O
, - - O
d20 - - O
, - - O
d27 - - O
, - - O
d31 - - O
, - - O
d40 - - O
, - - O
d44 - - O
, - - O
and - - O
d73 - - O
) - - O
were - - O
compared - - O
for - - O
processing - - O
, - - O
cell - - O
surface - - O
expression - - O
, - - O
and - - O
maintenance - - O
of - - O
their - - O
biological - - O
attributes - - O
by - - O
recombinant - - O
expression - - O
of - - O
mutant - - O
genes - - O
using - - O
a - - O
plasmid - - O
vector - - O
( - - O
pcDL-SR - - O
alpha-296 - - O
) - - O
in - - O
CV-1 - - O
and - - O
HeLa - - O
cells - - O
. - - O

Cloning - - O
and - - O
characterization - - O
of - - O
human - - B-MUT
Lnk - - I-MUT
, - - O
an - - O
adaptor - - O
protein - - O
with - - O
pleckstrin - - B-MUT
homology - - O
and - - O
Src - - B-MUT
homology - - I-MUT
2 - - I-MUT
domains - - I-MUT
that - - O
can - - O
inhibit - - O
T - - O
cell - - O
activation - - O
. - - O

As - - O
a - - O
result - - O
, - - O
beta-apo-8'-carotenoic - - O
acid - - O
ethyl - - O
ester - - O
( - - O
apo-EE - - O
) - - O
was - - O
used - - O
as - - O
a - - O
reference - - O
standard - - O
in - - O
Experiments - - O
4 - - O
to - - O
6 - - O
. - - O

Nevertheless - - O
, - - O
in - - O
view - - O
of - - O
the - - O
potential - - O
transmission - - O
rates - - O
of - - O
HGV - - O
and - - O
the - - O
lack - - O
of - - O
effective - - O
immunization - - O
, - - O
HGV - - O
should - - O
be - - O
regarded - - O
as - - O
a - - O
potential - - O
occupational - - O
hazard - - O
for - - O
medical - - O
and - - O
dental - - O
staff - - O
. - - O

Disruption - - O
of - - O
any - - O
one - - O
of - - O
the - - O
four - - O
genes - - O
encoding - - O
the - - O
newly - - O
identified - - O
SRP - - B-MUT
proteins - - I-MUT
results - - O
in - - O
slow - - O
cell - - O
growth - - O
and - - O
inefficient - - O
protein - - O
translocation - - O
across - - O
the - - O
ER - - O
membrane - - O
. - - O

We - - O
derive - - O
joint - - O
probability - - O
density - - O
distributions - - O
for - - O
three - - O
key - - O
uncertain - - O
properties - - O
of - - O
the - - O
climate - - O
system - - O
, - - O
using - - O
an - - O
optimal - - O
fingerprinting - - O
approach - - O
to - - O
compare - - O
simulations - - O
of - - O
an - - O
intermediate - - O
complexity - - O
climate - - O
model - - O
with - - O
three - - O
distinct - - O
diagnostics - - O
of - - O
recent - - O
climate - - O
observations - - O
. - - O

An - - O
increase - - O
in - - O
the - - O
level - - O
of - - O
serum - - O
enzymes - - O
, - - O
such - - O
as - - O
aspartate - - B-MUT
transaminase - - I-MUT
, - - O
alkaline - - B-MUT
phosphatase - - I-MUT
, - - O
creatine - - B-MUT
phosphokinase - - I-MUT
, - - O
lactate - - B-MUT
dehydrogenase - - I-MUT
after - - O
D - - O
. - - O
russelli - - O
venom - - O
injection - - O
in - - O
albino - - O
rats - - O
is - - O
indicative - - O
of - - O
cell - - O
or - - O
tissue - - O
damage - - O
. - - O

Among - - O
a - - O
population - - O
of - - O
18 - - O
, - - O
175 - - O
children - - O
below - - O
7 - - O
years - - O
of - - O
age - - O
in - - O
medium - - O
sized - - O
towns - - O
and - - O
rural - - O
areas - - O
in - - O
south-western - - O
Germany - - O
552 - - O
( - - O
3 - - O
. - - O
03% - - O
) - - O
cases - - O
of - - O
croup - - O
were - - O
registered - - O
during - - O
a - - O
12 - - O
months - - O
period - - O
in - - O
1984-85 - - O
by - - O
their - - O
physicians - - O
. - - O

The - - O
7-day - - O
treatment - - O
resulted - - O
in - - O
a - - O
decrease - - O
in - - O
mitochondrial - - O
uptake - - O
of - - O
Rh123 - - O
and - - O
an - - O
increase - - O
in - - O
NAO - - O
uptake - - O
. - - O

Primer - - O
extension - - O
and - - O
mung - - B-MUT
bean - - I-MUT
and - - I-MUT
S1 - - I-MUT
nuclease - - I-MUT
mapping - - O
indicated - - O
multiple - - O
transcription - - O
initiation - - O
sites - - O
and - - O
were - - O
consistent - - O
with - - O
Northern - - O
analyses - - O
. - - O

GCN4 - - B-MUT
encodes - - O
a - - O
transcriptional - - O
activator - - O
of - - O
amino - - O
acid - - O
biosynthetic - - O
genes - - O
in - - O
Saccharomyces - - O
cerevisiae - - O
. - - O

The - - O
progress - - O
of - - O
morphological - - O
research - - O
on - - O
the - - O
parabrachial - - O
nucleus - - O
. - - O

The - - O
cysteine-rich - - O
region - - O
of - - O
raf-1 - - B-MUT
kinase - - I-MUT
contains - - O
zinc - - O
, - - O
translocates - - O
to - - O
liposomes - - O
, - - O
and - - O
is - - O
adjacent - - O
to - - O
a - - O
segment - - O
that - - O
binds - - O
GTP-ras - - B-MUT
. - - O

The - - O
CBF1 - - B-MUT
site - - I-MUT
within - - O
HS2 - - B-MUT
resides - - O
near - - O
sites - - O
for - - O
hematopoietic - - O
regulators - - O
such - - O
as - - O
GATA-1 - - B-MUT
, - - O
NF-E2 - - B-MUT
, - - O
and - - O
TAL1 - - B-MUT
. - - O

Here - - O
we - - O
provide - - O
the - - O
first - - O
evidence - - O
for - - O
the - - O
involvement - - O
of - - O
GCN1-GCN2 - - B-MUT
interaction - - O
in - - O
activation - - O
of - - O
GCN2 - - B-MUT
per - - O
se - - O
. - - O

The - - O
results - - O
of - - O
these - - O
experiments - - O
indicate - - O
that - - O
at - - O
least - - O
two - - O
upstream - - O
activator - - O
sequences - - O
( - - O
UAS - - O
) - - O
mediate - - O
maximum - - O
induction - - O
by - - O
galactose - - O
. - - O

In - - O
a - - O
second - - O
series - - O
of - - O
experiments - - O
, - - O
the - - O
efficacy - - O
of - - O
PDC - - O
HDC - - O
Ac - - O
was - - O
evaluated - - O
in - - O
both - - O
single - - O
and - - O
multiple - - O
dose - - O
regiments - - O
. - - O

Significant - - O
correlations - - O
existed - - O
between - - O
FEV1 - - O
and - - O
the - - O
corresponding - - O
values - - O
of - - O
Raw - - O
, - - O
MEF50 - - O
and - - O
MEF25 - - O
, - - O
although - - O
there - - O
were - - O
considerable - - O
individual - - O
differences - - O
between - - O
test - - O
results - - O
. - - O

The - - O
liver - - O
in - - O
the - - O
severely - - O
ill - - O
. - - O

20% - - O
of - - O
total - - O
HSL - - B-MUT
transcripts - - I-MUT
in - - O
human - - O
subcutaneous - - O
adipocytes - - O
. - - O

Western - - O
analyses - - O
with - - O
antisera - - O
raised - - O
against - - O
Lu-ECAM-1 - - B-MUT
peptides - - I-MUT
show - - O
that - - O
the - - O
N-terminal - - O
region - - O
of - - O
the - - O
predicted - - O
open - - O
reading - - O
frame - - O
is - - O
present - - O
only - - O
in - - O
the - - O
larger - - O
size - - O
proteins - - O
( - - O
i - - O
. - - O
e - - O
. - - O

Intrastriatal - - O
grafts - - O
of - - O
nigral - - O
and - - O
adrenal - - O
tissues - - O
have - - O
been - - O
found - - O
to - - O
be - - O
effective - - O
in - - O
alleviating - - O
many - - O
of - - O
the - - O
simple - - O
motor - - O
and - - O
sensorimotor - - O
deficits - - O
associated - - O
with - - O
lesions - - O
of - - O
the - - O
nigrostriatal - - O
dopamine - - O
system - - O
. - - O

In - - O
contrast - - O
, - - O
the - - O
action - - O
of - - O
GLP-1 - - B-MUT
at - - O
the - - O
CRE - - B-MUT
was - - O
not - - O
blocked - - O
by - - O
cotransfection - - O
with - - O
M1-CREB - - B-MUT
, - - O
an - - O
isoform - - O
that - - O
lacks - - O
a - - O
consensus - - O
serine - - O
residue - - O
serving - - O
as - - O
substrate - - O
for - - O
PKA-mediated - - O
phosphorylation - - O
. - - O

Post-operative - - O
functional - - O
outcome - - O
is - - O
related - - O
to - - O
pre-operative - - O
functional - - O
status - - O
. - - O

The - - O
cleavage - - O
of - - O
Fak - - B-MUT
by - - O
caspases - - B-MUT
may - - O
thus - - O
play - - O
an - - O
important - - O
role - - O
in - - O
the - - O
execution - - O
of - - O
the - - O
suicide - - O
program - - O
by - - O
disabling - - O
the - - O
anti-apoptotic - - O
function - - O
of - - O
Fak - - B-MUT
. - - O

As - - O
authorized - - O
by - - O
the - - O
World - - O
Health - - O
Organization - - O
29th - - O
Expert - - O
Committee - - O
on - - O
Biological - - O
Standardization - - O
, - - O
the - - O
preparation - - O
of - - O
human - - B-MUT
prolactin - - I-MUT
in - - O
ampoules - - O
coded - - O
75 - - O
504 - - O
has - - O
been - - O
established - - O
as - - O
the - - O
International - - O
Reference - - O
Preparation - - O
( - - O
IRP - - O
) - - O
of - - O
human - - O
prolactin - - B-MUT
for - - I-MUT
immunoassay - - O
. - - O

Many - - O
of - - O
these - - O
landfill - - O
operations - - O
were - - O
undertaken - - O
in - - O
the - - O
early - - O
1950s - - O
and - - O
1960s - - O
, - - O
when - - O
knowledge - - O
regarding - - O
the - - O
safe - - O
and - - O
prolonged - - O
containment - - O
of - - O
the - - O
waste - - O
buried - - O
was - - O
nonexistent - - O
or - - O
minimal - - O
at - - O
best - - O
. - - O

The - - O
SH2 - - B-MUT
and - - O
SH3 - - B-MUT
domains - - I-MUT
of - - O
pp60src - - B-MUT
direct - - O
stable - - O
association - - O
with - - O
tyrosine - - O
phosphorylated - - O
proteins - - O
p130 - - B-MUT
and - - O
p110 - - B-MUT
. - - O

The - - O
use - - O
of - - O
highly - - O
active - - O
antiretroviral - - O
therapy - - O
( - - O
HAART - - O
) - - O
has - - O
resulted - - O
in - - O
significant - - O
improvements - - O
in - - O
the - - O
treatment - - O
of - - O
HIV - - O
infection - - O
, - - O
including - - O
a - - O
decrease - - O
in - - O
the - - O
incidence - - O
and - - O
severity - - O
of - - O
several - - O
acquired - - O
immune - - O
deficiency - - O
syndrome - - O
( - - O
AIDS - - O
) - - O
-related - - O
malignancies - - O
. - - O

A - - O
particularly - - O
striking - - O
HpaII - - B-MUT
tiny - - O
fragment - - O
island - - O
, - - O
extending - - O
over - - O
nearly - - O
2 - - O
, - - O
000 - - O
base - - O
pairs - - O
, - - O
surrounds - - O
the - - O
USF2 - - B-MUT
translation - - I-MUT
initiation - - I-MUT
site - - I-MUT
. - - O

Our - - O
results - - O
implicate - - O
TGF-beta - - B-MUT
RII - - I-MUT
as - - O
a - - O
direct - - O
target - - O
of - - O
EWS-FLI1 - - B-MUT
. - - O

It - - O
was - - O
possible - - O
to - - O
classify - - O
the - - O
animals - - O
into - - O
high - - O
and - - O
low - - O
responders - - O
according - - O
to - - O
the - - O
pattern - - O
of - - O
humoral - - O
immune - - O
response - - O
. - - O

Requirements - - O
for - - O
the - - O
nuclear-cytoplasmic - - O
translocation - - O
of - - O
infected-cell - - B-MUT
protein - - I-MUT
0 - - I-MUT
of - - O
herpes - - O
simplex - - O
virus - - O
1 - - O
. - - O

Localization - - O
of - - O
67 - - O
exons - - O
on - - O
a - - O
YAC - - O
contig - - O
spanning - - O
1 - - O
. - - O
5 - - O
Mb - - O
around - - O
the - - O
multidrug - - B-MUT
resistance - - I-MUT
gene - - I-MUT
region - - I-MUT
of - - O
human - - O
chromosome - - O
7q21 - - O
. - - O
1 - - O
. - - O

The - - O
role - - O
of - - O
'scientific - - O
psychiatry' - - O
in - - O
understanding - - O
patients - - O
with - - O
chronic - - O
schizophrenia - - O
or - - O
severe - - O
personality - - O
disorder - - O
. - - O

The - - O
genes - - O
encoding - - O
( - - B-MUT
2Fe-2S - - I-MUT
) - - I-MUT
plant-like - - I-MUT
ferredoxins - - I-MUT
were - - O
studied - - O
in - - O
the - - O
widely - - O
used - - O
cyanobacterium - - O
Synechocystis - - O
PCC6803 - - O
. - - O

PURPOSE - - O
: - - O
The - - O
aim - - O
of - - O
this - - O
study - - O
was - - O
to - - O
evaluate - - O
the - - O
bony - - O
anchorage - - O
of - - O
a - - O
new - - O
implant - - O
( - - O
orderly - - O
wired - - O
surface - - O
effect - - O
with - - O
alloy - - O
Ti - - O
Al - - O
Va - - O
and - - O
ordered - - O
pores - - O
of - - O
488 - - O
mu - - O
) - - O
. - - O

Transfer - - B-MUT
RNA - - I-MUT
genes - - I-MUT
from - - I-MUT
Dictyostelium - - I-MUT
discoideum - - I-MUT
are - - O
frequently - - O
associated - - O
with - - O
repetitive - - O
elements - - O
and - - O
contain - - O
consensus - - O
boxes - - O
in - - O
their - - O
5' - - O
and - - O
3'-flanking - - O
regions - - O
. - - O

Ultrastructural - - O
studies - - O
of - - O
retinopathy - - O
of - - O
premature - - O
infants - - O
. - - O

The - - O
present - - O
studies - - O
compare - - O
the - - O
biochemical - - O
characteristics - - O
, - - O
Kanagawa - - O
hemolysin - - O
reactions - - O
, - - O
and - - O
plasmid - - O
profiles - - O
of - - O
13 - - O
patient - - O
and - - O
221 - - O
environmental - - O
isolates - - O
of - - O
the - - O
organism - - O
. - - O

A - - O
preliminary - - O
study - - O
of - - O
vincristine - - O
, - - O
methotrexate - - O
, - - O
and - - O
prednisolone - - O
( - - O
VM*P - - O
) - - O
combination - - O
chemotherapy - - O
for - - O
advanced - - O
adult - - O
non-Hodgkin's - - O
lymphoma - - O
. - - O

Accurate - - O
pathologic - - O
staging - - O
identifies - - O
patients - - O
who - - O
are - - O
potentially - - O
curable - - O
with - - O
radiotherapy - - O
. - - O

In - - O
addition - - O
, - - O
C - - B-MUT
EBP - - I-MUT
beta - - I-MUT
and - - I-MUT
C - - O
EBP - - B-MUT
gamma - - I-MUT
readily - - I-MUT
heterodimerize - - I-MUT
with - - O
each - - O
other - - O
as - - O
well - - O
as - - O
with - - O
C - - O
EBP - - O
alpha - - B-MUT
. - - I-MUT

Intraoperative - - O
measurement - - O
of - - O
activated - - O
partial - - O
thromboplastin - - B-MUT
time - - O
and - - O
prothrombin - - B-MUT
time - - O
with - - O
a - - O
new - - O
compact - - O
monitor - - O
. - - O

The - - O
pattern - - O
of - - O
RNase - - B-MUT
E - - I-MUT
digestion - - O
of - - O
finP305 - - B-MUT
RNA - - I-MUT
differed - - O
from - - O
FinP - - B-MUT
, - - O
and - - O
GST-FinO - - B-MUT
did - - O
not - - O
protect - - O
finP305 - - B-MUT
RNA - - I-MUT
from - - O
cleavage - - O
in - - O
vitro - - O
. - - O

During - - O
exercise - - O
K+ - - O
is - - O
released - - O
from - - O
contracting - - O
muscle - - O
and - - O
plasma - - O
K+ - - O
concentration - - O
rises - - O
. - - O

Second - - O
, - - O
the - - O
membrane - - O
expression - - O
of - - O
alpha - - O
and - - O
beta - - O
subunits - - O
was - - O
mimicked - - O
by - - O
cholesterol - - O
and - - O
17-ketocholesterol - - O
, - - O
both - - O
of - - O
which - - O
inhibit - - O
HMG-CoA - - B-MUT
reductase - - I-MUT
. - - O

In - - O
vitro - - O
affinity - - O
analyses - - O
demonstrated - - O
that - - O
recombinant - - O
130-kD - - O
protein - - O
directly - - O
interacts - - O
with - - O
ZO-1 - - B-MUT
and - - O
the - - O
cytoplasmic - - O
domain - - O
of - - O
occludin - - B-MUT
, - - O
but - - O
not - - O
with - - O
ZO-2 - - B-MUT
. - - O

Clinical - - O
differentiation - - O
of - - O
patients - - O
with - - O
mild - - O
diplegic - - O
cerebral - - O
palsy - - O
( - - O
CP - - O
) - - O
and - - O
idiopathic - - O
toe - - O
walking - - O
( - - O
ITW - - O
) - - O
can - - O
be - - O
difficult - - O
. - - O

Next - - O
, - - O
we - - O
stably - - O
overexpressed - - O
wild-type - - B-MUT
Shc - - I-MUT
or - - O
Y317F - - B-MUT
mutant - - I-MUT
Shc - - I-MUT
into - - O
HIRc - - O
cells - - O
. - - O

CONCLUSIONS - - O
: - - O
A - - O
comparison - - O
of - - O
the - - O
LysU - - B-MUT
crystal - - O
structure - - O
with - - O
the - - O
structures - - O
of - - O
seryl- - - B-MUT
and - - I-MUT
aspartyl-tRNA - - I-MUT
synthetases - - I-MUT
enables - - O
a - - O
conserved - - O
core - - O
to - - O
be - - O
identified - - O
. - - O

Quantitative - - O
analysis - - O
of - - O
the - - O
coronary - - O
stenosis - - O
was - - O
assessed - - O
before - - O
and - - O
after - - O
PTCA - - O
, - - O
and - - O
the - - O
dilatation - - O
resulted - - O
in - - O
an - - O
increase - - O
in - - O
minimal - - O
luminal - - O
cross-sectional - - O
area - - O
from - - O
1 - - O
. - - O
1 - - O
+ - - O
- - - O
0 - - O
. - - O
8 - - O
to - - O
2 - - O
. - - O
7 - - O
+ - - O
- - - O
1 - - O
. - - O
2 - - O
mm2 - - O
. - - O

Thirty-two - - O
rats - - O
were - - O
divided - - O
into - - O
four - - O
groups - - O
. - - O

Mice - - O
homozygous - - O
for - - O
the - - O
dlg - - B-MUT
mutation - - O
exhibit - - O
growth - - O
retardation - - O
in - - O
utero - - O
, - - O
have - - O
hypoplasia - - O
of - - O
the - - O
premaxilla - - O
and - - O
mandible - - O
, - - O
have - - O
a - - O
cleft - - O
secondary - - O
palate - - O
, - - O
and - - O
die - - O
perinatally - - O
. - - O

Here - - O
we - - O
focused - - O
on - - O
the - - O
role - - O
of - - O
the - - O
5' - - O
proximal - - O
regulatory - - O
cassette - - O
( - - O
-190 - - O
; - - O
+53 - - O
bp - - O
) - - O
of - - O
the - - O
rat - - B-MUT
enkephalin - - I-MUT
( - - O
rENK - - B-MUT
) - - O
gene - - O
in - - O
the - - O
developmental - - O
regulation - - O
of - - O
the - - O
enkephalin - - B-MUT
phenotype - - O
. - - O

The - - O
nucleotide - - O
sequence - - O
of - - O
the - - O
gene - - O
predicts - - O
a - - O
polypeptide - - O
of - - O
215 - - O
amino - - O
acids - - O
( - - O
25 - - O
. - - O
2 - - O
kDa - - O
) - - O
with - - O
two - - O
putative - - O
membrane-spanning - - O
domains - - O
. - - O

Quantum-statistical - - O
theory - - O
of - - O
high-field - - O
transport - - O
phenomena - - O
. - - O

Depletion - - O
of - - O
dopamine - - O
in - - O
the - - O
nucleus - - O
accumbens - - O
led - - O
to - - O
a - - O
dramatic - - O
shift - - O
in - - O
behavior - - O
in - - O
which - - O
there - - O
was - - O
a - - O
significant - - O
decrease - - O
in - - O
lever - - O
pressing - - O
but - - O
a - - O
significant - - O
increase - - O
in - - O
consumption - - O
of - - O
lab - - O
chow - - O
. - - O

The - - O
two - - O
genes - - O
code - - O
for - - O
polypeptides - - B-MUT
of - - I-MUT
420 - - I-MUT
amino - - I-MUT
acids - - I-MUT
( - - I-MUT
M - - I-MUT
. - - I-MUT
HgiCI - - I-MUT
) - - I-MUT
and - - O
345 - - B-MUT
amino - - I-MUT
acids - - I-MUT
( - - I-MUT
R - - I-MUT
. - - I-MUT
HgiCI - - I-MUT
) - - I-MUT
. - - O

Glucose-6-phosphate - - B-MUT
dehydrogenase - - I-MUT
( - - O
G-6-PD - - B-MUT
) - - O
deficiency - - O
in - - O
the - - O
newborn - - O
. - - O

Angiography - - O
of - - O
aneurysmal - - O
bone - - O
cyst - - O
. - - O

The - - O
two - - O
mouse - - O
lines - - O
carrying - - O
the - - O
unfragmented - - O
Hnf3g-lacZ - - B-MUT
YAC - - I-MUT
showed - - O
tissue-specific - - O
, - - O
copy - - O
number-dependent - - O
and - - O
position-independent - - O
expression - - O
, - - O
proving - - O
that - - O
170 - - O
kb - - O
of - - O
the - - O
Hnf3g - - B-MUT
locus - - O
contain - - O
all - - O
elements - - O
important - - O
in - - O
the - - O
regulation - - O
of - - O
Hnf3g - - B-MUT
. - - O

These - - O
results - - O
are - - O
the - - O
first - - O
to - - O
demonstrate - - O
the - - O
structural - - O
organization - - O
of - - O
a - - O
vertebrate - - O
gene - - O
encoding - - O
an - - O
integral - - O
membrane - - O
protein - - O
of - - O
the - - O
nuclear - - O
envelope - - O
that - - O
may - - O
be - - O
a - - O
member - - O
of - - O
a - - O
family - - O
of - - O
polypeptides - - O
conserved - - O
in - - O
evolution - - O
. - - O

Previous - - O
work - - O
has - - O
shown - - O
that - - O
spleen - - O
necrosis - - O
virus - - O
( - - O
SNV - - O
) - - O
long - - O
terminal - - O
repeats - - O
( - - O
LTRs - - O
) - - O
are - - O
associated - - O
with - - O
Rex - - O
Rex-responsive - - O
element-independent - - O
expression - - O
of - - O
bovine - - O
leukemia - - O
virus - - O
RNA - - O
and - - O
supports - - O
the - - O
hypothesis - - O
that - - O
SNV - - O
RNA - - O
contains - - O
a - - O
cis-acting - - O
element - - O
that - - O
interacts - - O
with - - O
cellular - - O
Rex-like - - B-MUT
proteins - - I-MUT
. - - I-MUT

After - - O
successful - - O
subtotal - - O
parathyroidectomy - - O
, - - O
evident - - O
by - - O
the - - O
decrease - - O
of - - O
serum - - O
iPTH - - B-MUT
levels - - O
, - - O
both - - O
the - - O
CL - - O
of - - O
group - - O
2 - - O
PMNs - - O
and - - O
the - - O
ability - - O
of - - O
group - - O
2 - - O
sera - - O
to - - O
induce - - O
augmented - - O
CL - - O
in - - O
normal - - O
PMNs - - O
decreased - - O
( - - O
p - - O
< - - O
0 - - O
. - - O
025 - - O
) - - O
. - - O

Current - - O
status - - O
of - - O
chemotherapy - - O
for - - O
Hodgkin's - - O
disease - - O
. - - O

AIMS - - O
METHODS - - O
: - - O
Reticuloendothelial - - O
system - - O
function - - O
, - - O
as - - O
assessed - - O
by - - O
clearance - - O
of - - O
radiolabelled - - O
bacteria - - O
, - - O
was - - O
evaluated - - O
in - - O
acute - - O
liver - - O
injury - - O
induced - - O
by - - O
D-galactosamine - - O
in - - O
rats - - O
, - - O
and - - O
compared - - O
with - - O
that - - O
after - - O
70% - - O
liver - - O
resection - - O
model - - O
. - - O

Lethal - - O
Tachmalcor - - O
( - - O
4- - - O
( - - O
3'-diethylamino-2'-hydroxypropyl - - O
) - - O
-ajmaline - - O
) - - O
poisoning - - O
in - - O
childhood - - O
. - - O

IgG - - B-MUT
levels - - O
of - - O
1 - - O
100 - - O
were - - O
present - - O
in - - O
only - - O
four - - O
out - - O
of - - O
ten - - O
samples - - O
obtained - - O
150 - - O
days - - O
after - - O
the - - O
clinical - - O
onset - - O
. - - O

RNase - - B-MUT
protection - - O
and - - O
primer - - O
extension - - O
assays - - O
confirmed - - O
that - - O
the - - O
5' - - O
non-coding - - O
exon - - O
is - - O
included - - O
in - - O
the - - O
DDT1 - - O
aFGF - - B-MUT
mRNA - - I-MUT
and - - O
that - - O
a - - O
major - - O
transcription - - O
start - - O
site - - O
is - - O
approximately - - O
136 - - O
bp - - O
upstream - - O
of - - O
the - - O
5' - - O
non-coding - - O
splice - - O
junction - - O
of - - O
this - - O
exon - - O
. - - O

Cytoskeletal - - O
polarization - - O
of - - O
T - - O
cells - - O
is - - O
regulated - - O
by - - O
an - - O
immunoreceptor - - O
tyrosine-based - - O
activation - - O
motif-dependent - - O
mechanism - - O
. - - O

Functional - - O
effects - - O
following - - O
subacute - - O
administration - - O
. - - O

( - - O
1988 - - O
) - - O
J - - O
. - - O

The - - O
effect - - O
of - - O
acetazolamide - - O
( - - O
ACZ - - O
) - - O
on - - O
HCO3- - - O
and - - O
Cl- - - O
activities - - O
in - - O
inner - - O
ear - - O
fluid - - O
was - - O
investigated - - O
by - - O
ion-selective - - O
microelectrode - - O
methods - - O
. - - O

Eukaryotic - - B-MUT
initiation - - I-MUT
factor - - I-MUT
3 - - I-MUT
( - - O
eIF3 - - B-MUT
) - - O
is - - O
a - - O
large - - O
multisubunit - - O
complex - - O
that - - O
stabilizes - - O
the - - O
ternary - - O
complex - - O
, - - O
eIF2 - - B-MUT
x - - O
GTP - - B-MUT
x - - O
tRNA - - B-MUT
( - - I-MUT
Met - - I-MUT
) - - I-MUT
i - - I-MUT
and - - O
promotes - - O
mRNA - - O
binding - - O
to - - O
the - - O
40 - - B-MUT
S - - I-MUT
ribosomal - - I-MUT
subunit - - I-MUT
. - - O
eIF3 - - B-MUT
also - - O
functions - - O
as - - O
a - - O
ribosome - - O
subunit - - O
anti-association - - O
factor - - O
. - - O

To - - O
investigate - - O
the - - O
effects - - O
of - - O
isotretinoin - - O
on - - O
HDL - - B-MUT
, - - O
we - - O
measured - - O
HDL-C - - B-MUT
, - - O
HDL - - B-MUT
phospholipids - - O
( - - O
HDL-PL - - B-MUT
) - - O
, - - O
apoprotein - - B-MUT
A1 - - I-MUT
( - - O
apo - - B-MUT
A-1 - - I-MUT
) - - O
, - - O
and - - O
HDL-C - - B-MUT
subfractions - - O
( - - O
HDL2-C - - B-MUT
and - - O
HDL3-C - - B-MUT
) - - O
in - - O
24 - - O
healthy - - O
, - - O
male - - O
patients - - O
receiving - - O
a - - O
16-week - - O
course - - O
of - - O
isotretinoin - - O
( - - O
1 - - O
. - - O
0 - - O
mg - - O
kg - - O
day - - O
) - - O
for - - O
treatment - - O
of - - O
severe - - O
acne - - O
vulgaris - - O
. - - O

The - - O
expression - - O
of - - O
the - - O
pilin - - B-MUT
gene - - I-MUT
, - - O
tcpA - - B-MUT
, - - O
is - - O
dependent - - O
upon - - O
ToxR - - B-MUT
and - - O
upon - - O
ToxT - - B-MUT
. - - O

These - - O
results - - O
indicate - - O
that - - O
patients - - O
who - - O
undergo - - O
postoperative - - O
irradiation - - O
for - - O
low - - O
grade - - O
spinal - - O
astrocytomas - - O
and - - O
localized - - O
spinal - - O
ependymomas - - O
achieve - - O
excellent - - O
survival - - O
. - - O

A - - O
one-week - - O
ulcer - - O
therapy - - O
with - - O
atropine - - O
and - - O
Vikalin - - O
( - - O
Roter - - O
) - - O
led - - O
to - - O
a - - O
significant - - O
( - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
01 - - O
) - - O
reduction - - O
of - - O
the - - O
nocturnal - - O
proteolytic - - O
activity - - O
. - - O

This - - O
GAP - - B-MUT
activity - - O
was - - O
observed - - O
in - - O
3T3-L1 - - O
adipocyte - - O
lysates - - O
, - - O
and - - O
was - - O
able - - O
to - - O
accelerate - - O
the - - O
hydrolysis - - O
of - - O
the - - O
[ - - O
alpha-32P - - O
] - - O
GTP - - O
bound - - O
to - - O
GST-Rab4 - - B-MUT
into - - O
[ - - O
alpha-32P - - O
] - - O
GDP - - O
. - - O

NF-kappa - - B-MUT
B - - I-MUT
Rel - - I-MUT
transcription - - I-MUT
factors - - I-MUT
participate - - I-MUT
in - - O
the - - O
activation - - O
of - - O
numerous - - O
genes - - O
involved - - O
in - - O
immune - - O
regulation - - O
inflammation - - O
including - - O
cytokines - - O
, - - O
cell - - O
surface - - O
receptors - - O
, - - O
adhesion - - O
molecules - - O
, - - O
and - - O
acute - - O
phase - - O
proteins - - O
. - - O

S - - O
. - - O
, - - O
Kim - - O
, - - O
S - - O
. - - O

The - - O
predicted - - O
protein - - O
, - - O
Seb1p - - B-MUT
, - - O
consists - - O
of - - O
82 - - O
amino - - O
acids - - O
and - - O
contains - - O
one - - O
potential - - O
membrane-spanning - - O
region - - O
at - - O
the - - O
C-terminus - - O
but - - O
no - - O
N-terminal - - O
signal - - O
sequence - - O
. - - O

Droperidol-induced - - O
extrapyramidal - - O
symptoms - - O
in - - O
an - - O
adolescent - - O
following - - O
strabismus - - O
surgery - - O
. - - O

Northern - - O
blot - - O
analysis - - O
revealed - - O
the - - O
expression - - O
of - - O
LIMK-1 - - B-MUT
mRNA - - I-MUT
predominantly - - O
in - - O
the - - O
brain - - O
and - - O
the - - O
expression - - O
of - - O
LIMK-2 - - B-MUT
mRNA - - I-MUT
in - - O
various - - O
tissues - - O
in - - O
the - - O
rat - - O
. - - O

Cyclin-dependent - - B-MUT
kinase-2 - - I-MUT
( - - O
Cdk2 - - B-MUT
) - - O
forms - - O
an - - O
inactive - - O
complex - - O
with - - O
cyclin - - B-MUT
D1 - - I-MUT
since - - O
Cdk2 - - B-MUT
associated - - O
with - - O
cyclin - - B-MUT
D1 - - I-MUT
is - - O
not - - O
phosphorylated - - O
by - - O
Cdk7-cyclin-H - - B-MUT
. - - O

The - - O
sixth - - O
nucleotide - - O
was - - O
bulged - - O
out - - O
to - - O
allow - - O
stacking - - O
of - - O
this - - O
U - - O
. - - O
G - - O
pair - - O
on - - O
the - - O
adjacent - - O
helical - - O
region - - O
. - - O

I - - O
propose - - O
that - - O
their - - O
gene - - O
products - - O
bind - - O
to - - O
the - - O
chromatin - - O
to - - O
establish - - O
or - - O
maintain - - O
a - - O
proper - - O
higher - - O
order - - O
structure - - O
as - - O
a - - O
prerequisite - - O
for - - O
a - - O
regulated - - O
gene - - O
expression - - O
. - - O

The - - O
invasive - - O
pattern - - O
of - - O
squamous - - O
cell - - O
carcinoma - - O
in - - O
the - - O
mandibular - - O
gingiva - - O
. - - O

Paraneoplastic - - O
rheumatic - - O
syndromes - - O
. - - O

The - - O
distribution - - O
of - - O
the - - O
various - - O
repeats - - O
suggests - - O
its - - O
organization - - O
is - - O
similar - - O
to - - O
the - - O
beta-heterochromatic - - O
regions - - O
near - - O
the - - O
base - - O
of - - O
the - - O
major - - O
chromosome - - O
arms - - O
. - - O

In - - O
the - - O
present - - O
report - - O
, - - O
66 - - O
hemochromatosis - - O
families - - O
yielding - - O
151 - - O
hemochromatosis - - O
chromosomes - - O
and - - O
182 - - O
normal - - O
chromosomes - - O
were - - O
RFLP-typed - - O
with - - O
a - - O
battery - - O
of - - O
probes - - O
, - - O
including - - O
two - - O
newly - - O
derived - - O
polymorphic - - O
markers - - O
from - - O
the - - O
6 - - O
. - - O
7 - - O
and - - O
HLA-F - - B-MUT
loci - - I-MUT
located - - O
150 - - O
and - - O
250 - - O
kb - - O
telomeric - - O
to - - O
HLA-A - - B-MUT
, - - O
respectively - - O
. - - O

The - - O
p34 - - B-MUT
. - - I-MUT
8 - - I-MUT
gene - - I-MUT
has - - O
a - - O
strong - - O
codon - - O
usage - - O
bias - - O
which - - O
is - - O
strikingly - - O
different - - O
from - - O
that - - O
of - - O
the - - O
polyhedrin - - B-MUT
gene - - I-MUT
. - - O

There - - O
was - - O
an - - O
increase - - O
in - - O
protein - - O
binding - - O
onto - - O
this - - O
element - - O
only - - O
after - - O
peptide - - O
treatment - - O
. - - O

The - - O
purposes - - O
of - - O
this - - O
study - - O
were - - O
1 - - O
) - - O
to - - O
examine - - O
the - - O
effect - - O
of - - O
high - - O
intensity - - O
, - - O
low - - O
frequency - - O
transcutaneous - - O
electrical - - O
nerve - - O
stimulation - - O
at - - O
auricular - - O
acupuncture - - O
points - - O
on - - O
experimental - - O
pain - - O
threshold - - O
measured - - O
at - - O
the - - O
wrist - - O
and - - O
2 - - O
) - - O
to - - O
determine - - O
the - - O
changes - - O
in - - O
effect - - O
over - - O
time - - O
. - - O

The - - O
chloramphenicol-resistance - - B-MUT
transposon - - I-MUT
Tn4451 - - B-MUT
undergoes - - O
precise - - O
conjugative - - O
deletion - - O
from - - O
its - - O
parent - - O
plasmid - - O
plP401 - - O
in - - O
Clostridium - - O
perfringens - - O
and - - O
precise - - O
spontaneous - - O
excision - - O
from - - O
multicopy - - O
plasmids - - O
in - - O
Escherichia - - O
coli - - O
. - - O

These - - O
temperature- - - O
and - - O
cold-sensitive - - O
strains - - O
were - - O
used - - O
to - - O
prepare - - O
extracts - - O
deficient - - O
in - - O
BRF1 - - B-MUT
activity - - O
and - - O
were - - O
tested - - O
for - - O
transcriptional - - O
activity - - O
by - - O
RNA - - B-MUT
polymerases - - I-MUT
I - - I-MUT
, - - I-MUT
II - - I-MUT
, - - I-MUT
and - - I-MUT
III - - I-MUT
in - - O
vitro - - O
. - - O

These - - O
data - - O
are - - O
consistent - - O
with - - O
a - - O
model - - O
in - - O
which - - O
GATA-5 - - B-MUT
performs - - O
a - - O
unique - - O
temporally - - O
and - - O
spatially - - O
restricted - - O
function - - O
in - - O
the - - O
embryonic - - O
heart - - O
and - - O
lung - - O
. - - O

Mesial - - O
temporal - - O
sclerosis - - O
. - - O

The - - O
Cili-2 - - B-MUT
sequences - - I-MUT
possess - - O
similarity - - O
to - - O
the - - O
RNaseH - - B-MUT
domain - - I-MUT
of - - O
Lian-Aa1 - - B-MUT
, - - O
a - - O
mosquito - - O
non-LTR - - O
retrotransposon - - O
. - - O

Whole - - O
bowel - - O
irrigation - - O
is - - O
a - - O
recently - - O
described - - O
technique - - O
to - - O
enhance - - O
the - - O
passage - - O
of - - O
drugs - - O
already - - O
beyond - - O
the - - O
pylorus - - O
. - - O

Experiments - - O
showed - - O
that - - O
temporary - - O
arrest - - O
of - - O
pulmonary - - O
circulation - - O
under - - O
conditions - - O
of - - O
extracorporeal - - O
circulation - - O
is - - O
attended - - O
by - - O
the - - O
development - - O
of - - O
ischemia - - O
of - - O
the - - O
respiratory - - O
pulmonary - - O
tissue - - O
. - - O

Heterogeneous - - B-MUT
nuclear - - I-MUT
ribonucleoprotein - - I-MUT
( - - I-MUT
hnRNP - - I-MUT
) - - I-MUT
core - - I-MUT
protein - - I-MUT
A1 - - I-MUT
is - - O
a - - O
major - - O
component - - O
of - - O
mammalian - - B-MUT
hnRNP - - I-MUT
40 - - I-MUT
S - - I-MUT
particles - - I-MUT
. - - O

Monkeys - - O
were - - O
evaluated - - O
before - - O
and - - O
after - - O
unilateral - - O
and - - O
serial - - O
bilateral - - O
removal - - O
of - - O
superior - - O
temporal - - O
cortex - - O
. - - O

Yeast - - B-MUT
U1 - - I-MUT
snRNP - - I-MUT
is - - O
considerably - - O
more - - O
complex - - O
than - - O
its - - O
metazoan - - O
counterpart - - O
, - - O
which - - O
suggests - - O
possible - - O
differences - - O
between - - O
yeast - - O
and - - O
metazoa - - O
in - - O
early - - O
splicing - - O
events - - O
. - - O

Plasma - - O
CCK - - B-MUT
levels - - O
were - - O
determined - - O
at - - O
regular - - O
intervals - - O
. - - O

In - - O
addition - - O
, - - O
stonin - - B-MUT
2 - - I-MUT
binds - - O
to - - O
the - - O
C2B - - B-MUT
domains - - I-MUT
of - - O
synaptotagmins - - B-MUT
I - - I-MUT
and - - I-MUT
II - - O
. - - O

12 - - O
healthy - - O
women - - O
( - - O
age - - O
18-38 - - O
years - - O
) - - O
were - - O
examined - - O
using - - O
the - - O
2-hour's - - O
method - - O
of - - O
passive - - O
leg - - O
rising - - O
( - - O
PLR - - O
) - - O
in - - O
follicular - - O
( - - O
FP - - O
) - - O
and - - O
luteal - - O
( - - O
LP - - O
) - - O
phases - - O
of - - O
normal - - O
ovulatory - - O
cycle - - O
. - - O

E1A - - B-MUT
represses - - O
apolipoprotein - - B-MUT
AI - - I-MUT
enhancer - - I-MUT
activity - - O
in - - O
liver - - O
cells - - O
through - - O
a - - O
pRb- - - O
and - - O
CBP-independent - - O
pathway - - O
. - - O

RESULTS - - O
: - - O
Circulating - - O
leptin - - B-MUT
concentrations - - O
in - - O
AN - - O
were - - O
3 - - O
. - - O
5+ - - O
-0 - - O
. - - O
5 - - O
versus - - O
7 - - O
. - - O
6+ - - O
-1 - - O
. - - O
2 - - O
ng - - O
ml - - O
in - - O
control - - O
subjects - - O
. - - O

In - - O
addition - - O
, - - O
two - - O
internal - - O
promoters - - O
, - - O
PmiaA - - B-MUT
and - - O
P1hfq - - B-MUT
were - - O
identified - - O
and - - O
mapped - - O
to - - O
201 - - O
and - - O
837 - - O
nucleotides - - O
upstream - - O
from - - O
the - - O
respective - - O
translation - - O
start - - O
sites - - O
. - - O

George - - O
T - - O
. - - O

Effects - - O
of - - O
alcoholism - - O
on - - O
the - - O
family - - O
. - - O

These - - O
results - - O
were - - O
superior - - O
to - - O
those - - O
in - - O
24 - - O
patients - - O
with - - O
conventional - - O
end-to-end - - O
sutures - - O
on - - O
clinical - - O
testing - - O
. - - O

These - - O
results - - O
indicate - - O
that - - O
virulence-associated - - O
genes - - O
and - - O
their - - O
overall - - O
chromosomal - - O
arrangement - - O
are - - O
relatively - - O
well - - O
conserved - - O
between - - O
B - - O
. - - O
henselae - - O
and - - O
other - - O
gram-negative - - O
bacteria - - O
such - - O
as - - O
A - - O
. - - O
tumefaciens - - O
. - - O

Effect - - O
of - - O
triftazin - - O
and - - O
aminazin - - O
on - - O
hippocampal - - O
bioelectric - - O
activity - - O
. - - O

TBPf - - O
is - - O
defined - - O
as - - O
a - - O
quotient - - O
of - - O
the - - O
difference - - O
of - - O
the - - O
first - - O
and - - O
the - - O
second - - O
measurement - - O
: - - O
TBPf - - O
= - - O
( - - O
P1 - - O
- - - O
P2 - - O
) - - O
( - - O
A1 - - O
- - - O
A2 - - O
) - - O
. - - O

Comparison - - O
of - - O
remnant-like - - O
lipoprotein - - O
particles - - O
in - - O
postmenopausal - - O
women - - O
with - - O
and - - O
without - - O
coronary - - O
artery - - O
disease - - O
and - - O
in - - O
men - - O
with - - O
coronary - - O
artery - - O
disease - - O
. - - O

One - - O
phage - - O
clone - - O
contains - - O
a - - O
junction - - O
between - - O
alpha - - O
satellite - - O
DNA - - O
and - - O
a - - O
novel - - O
low-copy - - O
repeated - - O
sequence - - O
. - - O

The - - O
yeast - - B-MUT
MMS2 - - I-MUT
gene - - I-MUT
was - - O
cloned - - O
by - - O
its - - O
ability - - O
to - - O
complement - - O
the - - O
methyl - - O
methanesulfonate - - O
sensitivity - - O
of - - O
the - - O
mms2-1 - - B-MUT
mutant - - I-MUT
and - - O
was - - O
later - - O
shown - - O
to - - O
be - - O
involved - - O
in - - O
DNA - - O
post-replication - - O
repair - - O
. - - O

Biopsies - - O
of - - O
the - - O
jejunal - - O
mucosa - - O
have - - O
shown - - O
abnormal - - O
enzyme - - O
activity - - O
or - - O
deficiencies - - O
in - - O
transport - - O
mechanisms - - O
. - - O

In - - O
the - - O
controls - - O
, - - O
it - - O
was - - O
found - - O
that - - O
all - - O
right-handed - - O
and - - O
10 - - O
out - - O
of - - O
14 - - O
left-handed - - O
control - - O
subjects - - O
showed - - O
a - - O
right - - O
VHF - - O
( - - O
i - - O
. - - O
e - - O
. - - O
, - - O
left - - O
hemisphere - - O
) - - O
advantage - - O
. - - O

Genes - - O
belonging - - O
to - - O
the - - O
ras - - B-MUT
superfamily - - I-MUT
encode - - O
low-molecular-weight - - B-MUT
GTP - - I-MUT
GDP-binding - - I-MUT
proteins - - I-MUT
that - - I-MUT
are - - O
highly - - O
conserved - - O
in - - O
wide - - O
variety - - O
of - - O
organisms - - O
. - - O

Four - - O
forms - - O
of - - O
salmonellosis - - O
were - - O
recognised - - O
in - - O
feedlots - - O
and - - O
during - - O
transport - - O
by - - O
sea - - O
: - - O
septicaemic - - O
, - - O
and - - O
acute - - O
, - - O
subacute - - O
and - - O
chronic - - O
enteric - - O
. - - O

A - - O
cDNA - - O
encoding - - O
a - - O
MYC-related - - B-MUT
DNA - - I-MUT
binding - - I-MUT
protein - - I-MUT
was - - O
isolated - - O
by - - O
DNA-ligand - - O
binding - - O
screening - - O
, - - O
using - - O
the - - O
67-bp - - O
region - - O
as - - O
a - - O
probe - - O
, - - O
and - - O
designated - - O
rd22BP1 - - B-MUT
. - - O

Two - - O
phosphopeptides - - O
, - - O
identified - - O
as - - O
RS- - - B-MUT
[ - - I-MUT
32P - - I-MUT
] - - I-MUT
SGASGLLTSEHHSR - - I-MUT
and - - O
S- - - B-MUT
[ - - I-MUT
32P - - I-MUT
] - - I-MUT
SGASGLLTSEHHSR - - I-MUT
, - - O
were - - O
obtained - - O
after - - O
stoichiometric - - O
phosphorylation - - O
and - - O
trypsinization - - O
of - - O
the - - O
peptide - - O
. - - O

DESIGN - - O
: - - O
Prospective - - O
cohort - - O
study - - O
with - - O
a - - O
20 - - O
y - - O
follow-up - - O
period - - O
, - - O
the - - O
First - - O
National - - O
Health - - O
and - - O
Examination - - O
Survey - - O
( - - O
NHANES - - O
1 - - O
) - - O
Epidemiologic - - O
Follow-up - - O
Study - - O
( - - O
NHEFS - - O
) - - O
. - - O

We - - O
present - - O
the - - O
preliminary - - O
results - - O
obtained - - O
on - - O
36 - - O
patients - - O
which - - O
were - - O
followed - - O
for - - O
a - - O
mean - - O
period - - O
of - - O
12 - - O
months - - O
. - - O

Moreover - - O
, - - O
expression - - O
of - - O
CBF1 - - B-MUT
in - - O
yeast - - O
was - - O
found - - O
to - - O
activate - - O
transcription - - O
of - - O
reporter - - O
genes - - O
containing - - O
the - - O
C-repeat - - B-MUT
DRE - - I-MUT
as - - I-MUT
an - - O
upstream - - O
activator - - O
sequence - - O
but - - O
not - - O
mutant - - O
versions - - O
of - - O
the - - O
DNA - - O
element - - O
. - - O

The - - O
computer-programmed - - O
cytocentrifuge - - O
is - - O
currently - - O
most - - O
popular - - O
. - - O

Levels - - O
of - - O
TSG-14 - - B-MUT
protein - - I-MUT
( - - O
also - - O
termed - - O
PTX-3 - - B-MUT
) - - O
become - - O
elevated - - O
in - - O
the - - O
serum - - O
of - - O
mice - - O
and - - O
humans - - O
after - - O
injection - - O
with - - O
bacterial - - O
lipopolysaccharide - - O
, - - O
but - - O
in - - O
contrast - - O
to - - O
conventional - - O
acute - - O
phase - - O
proteins - - O
, - - O
the - - O
bulk - - O
of - - O
TSG-14 - - B-MUT
synthesis - - O
in - - O
the - - O
intact - - O
organism - - O
occurs - - O
outside - - O
the - - O
liver - - O
. - - O

OBJECTIVE - - O
: - - O
To - - O
compare - - O
pregnancy - - O
complications - - O
in - - O
women - - O
having - - O
genetic - - O
amniocentesis - - O
at - - O
11-14 - - O
weeks - - O
versus - - O
those - - O
undergoing - - O
amniocentesis - - O
at - - O
16-19 - - O
weeks' - - O
gestation - - O
. - - O

These - - O
findings - - O
suggest - - O
that - - O
the - - O
F-wave - - O
may - - O
be - - O
elicited - - O
in - - O
motoneuron - - O
of - - O
different - - O
depolarization - - O
threshold - - O
but - - O
primarily - - O
in - - O
larger - - O
and - - O
faster - - O
nerve - - O
fibers - - O
, - - O
with - - O
a - - O
lower - - O
threshold - - O
of - - O
depolarization - - O
. - - O

Microcirculatory - - O
oxygenation - - O
and - - O
shunting - - O
in - - O
sepsis - - O
and - - O
shock - - O
. - - O

Thus - - O
, - - O
the - - O
characterization - - O
of - - O
the - - O
promoter - - O
region - - O
should - - O
help - - O
to - - O
define - - O
regulatory - - O
elements - - O
that - - O
control - - O
neuron-specific - - O
and - - O
developmental - - O
expression - - O
of - - O
the - - O
MAP1B - - B-MUT
gene - - I-MUT
. - - O

The - - O
induced - - O
respiratory - - O
burst - - O
was - - O
investigated - - O
by - - O
the - - O
intracellular - - O
oxidative - - O
transformation - - O
of - - O
dihydrorhodamine - - O
123 - - O
to - - O
the - - O
fluorescent - - O
dye - - O
rhodamine - - O
123 - - O
via - - O
flow - - O
cytometry - - O
. - - O

Transfection - - O
of - - O
non-deleted - - O
expression - - O
vector - - O
into - - O
NIH3T3 - - O
cells - - O
results - - O
in - - O
acquisition - - O
of - - O
focus-forming - - O
activity - - O
while - - O
a - - O
deleted - - O
form - - O
of - - O
expression - - O
vector - - O
fails - - O
to - - O
show - - O
this - - O
activity - - O
even - - O
in - - O
the - - O
presence - - O
of - - O
basic - - B-MUT
FGF - - I-MUT
. - - O

The - - O
results - - O
suggest - - O
that - - O
the - - O
bulbospinal - - O
micturition - - O
reflex - - O
evoked - - O
by - - O
bladder - - O
filling - - O
and - - O
L-dopa - - O
involves - - O
a - - O
descending - - O
pathway - - O
where - - O
transmission - - O
is - - O
partly - - O
mediated - - O
by - - O
spinal - - B-MUT
alpha - - I-MUT
1-adrenoceptors - - I-MUT
. - - O

Although - - O
isl-1 - - B-MUT
binds - - O
to - - O
both - - O
the - - O
insulin - - B-MUT
and - - O
amylin - - B-MUT
gene - - I-MUT
promoter - - I-MUT
elements - - I-MUT
in - - O
vitro - - O
, - - O
these - - O
sequences - - O
display - - O
marked - - O
differences - - O
in - - O
their - - O
relative - - O
transcriptional - - O
properties - - O
when - - O
ligated - - O
adjacent - - O
to - - O
a - - O
heterologous - - O
promoter - - O
and - - O
transfected - - O
into - - O
InR1 - - O
-G9 - - O
islet - - O
cells - - O
. - - O

RESULTS - - O
: - - O
The - - O
subjects - - O
in - - O
the - - O
augmented - - O
feedback - - O
group - - O
significantly - - O
reduced - - O
their - - O
peak - - O
vertical - - O
ground - - O
reaction - - O
force - - O
in - - O
both - - O
post-test - - O
conditions - - O
( - - O
2-minute - - O
post-test - - O
reduction - - O
, - - O
0 - - O
. - - O
85+ - - O
-0 - - O
. - - O
62 - - O
; - - O
1-week - - O
post-test - - O
reduction - - O
, - - O
0 - - O
. - - O
74+ - - O
-0 - - O
. - - O
58 - - O
) - - O
as - - O
compared - - O
to - - O
the - - O
sensory - - O
, - - O
control - - O
I - - O
, - - O
and - - O
control - - O
II - - O
feedback - - O
groups - - O
. - - O

Study - - O
of - - O
antinuclear - - B-MUT
autoantibodies - - I-MUT
by - - O
immunofluorescence - - O
technic - - O
in - - O
collagen - - B-MUT
diseases - - O
. - - O

PNT - - O
, - - O
ADD - - O
and - - O
BSS - - O
in - - O
the - - O
initial - - O
stage - - O
of - - O
kindling - - O
, - - O
kindling - - O
rate - - O
for - - O
the - - O
stage-3 - - O
and - - O
-5 - - O
seizures - - O
, - - O
seizure - - O
parameters - - O
at - - O
the - - O
first - - O
stage-3 - - O
and - - O
-5 - - O
were - - O
recorded - - O
and - - O
compared - - O
to - - O
the - - O
values - - O
of - - O
saline-treated - - O
, - - O
control - - O
group - - O
. - - O

Effects - - O
of - - O
negative - - O
pleural - - O
pressure - - O
on - - O
left - - O
ventricular - - O
hemodynamics - - O
. - - O

These - - O
data - - O
indicate - - O
that - - O
RNK-Met-1 - - B-MUT
is - - O
a - - O
serine - - B-MUT
protease - - I-MUT
with - - O
unique - - O
activity - - O
that - - O
is - - O
expressed - - O
in - - O
the - - O
granules - - O
of - - O
large - - O
granular - - O
lymphocytes - - O
. - - O

No - - O
effect - - O
of - - O
the - - O
intervention - - O
on - - O
depression - - O
scores - - O
was - - O
found - - O
. - - O

Ruddell - - O
, - - O
M - - O
. - - O

Rigid - - O
point - - O
feature - - O
registration - - O
using - - O
mutual - - O
information - - O
. - - O

Together - - O
, - - O
these - - O
results - - O
identify - - O
HPK1 - - B-MUT
as - - O
a - - O
new - - O
component - - O
of - - O
TCR - - B-MUT
signaling - - O
. - - O

Nine - - O
cases - - O
of - - O
GBS - - O
and - - O
five - - O
of - - O
TM - - O
reported - - O
to - - O
the - - O
active - - O
AFP - - O
surveillance - - O
were - - O
not - - O
found - - O
in - - O
the - - O
hospital - - O
searches - - O
. - - O

The - - O
B-oligomer - - O
of - - O
pertussis - - B-MUT
toxin - - I-MUT
deactivates - - O
CC - - B-MUT
chemokine - - I-MUT
receptor - - I-MUT
5 - - I-MUT
and - - O
blocks - - O
entry - - O
of - - O
M-tropic - - O
HIV-1 - - O
strains - - O
. - - O

The - - O
mass-specific - - O
resting - - O
minute - - O
ventilation - - O
( - - O
E - - O
) - - O
and - - O
the - - O
ventilatory - - O
equivalent - - O
( - - O
E - - O
( - - O
O - - O
( - - O
2 - - O
) - - O
) - - O
) - - O
were - - O
approximately - - O
the - - O
same - - O
at - - O
the - - O
two - - O
ages - - O
, - - O
with - - O
a - - O
breathing - - O
pattern - - O
significantly - - O
deeper - - O
and - - O
slower - - O
at - - O
day - - O
1 - - O
. - - O

Forty - - O
4-month - - O
old - - O
SD - - O
female - - O
rats - - O
were - - O
randomly - - O
divided - - O
into - - O
four - - O
groups - - O
, - - O
namely - - O
sham - - O
operation - - O
, - - O
bilateral - - O
ovariectomy - - O
, - - O
ovariectomy - - O
plus - - O
supplementary - - O
ethinyl - - O
estradiol - - O
( - - O
0 - - O
. - - O
2 - - O
microgram - - O
100 - - O
g - - O
B - - O
. - - O

The - - O
different - - O
holoenzyme - - B-MUT
RNA - - I-MUT
polymerases - - I-MUT
generated - - O
upon - - O
reconstituting - - O
these - - O
mutants - - O
independently - - O
with - - O
core - - B-MUT
RNA - - I-MUT
polymerase - - I-MUT
( - - O
alpha2beta - - B-MUT
beta' - - I-MUT
) - - O
have - - O
shown - - O
reduced - - O
transcriptional - - O
activity - - O
in - - O
comparison - - O
to - - O
the - - O
enzyme - - O
containing - - O
wild-type - - B-MUT
sigma - - I-MUT
factor - - I-MUT
. - - O

Thyrotropin-releasing - - O
hormone-induced - - O
contraction - - O
of - - O
urethral - - O
and - - O
vaginal - - O
muscle - - O
. - - O

Contacts - - O
between - - O
Bacillus - - O
subtilis - - O
catabolite - - O
regulatory - - O
protein - - O
CcpA - - B-MUT
and - - O
amyO - - B-MUT
target - - O
site - - O
. - - O

Thus - - O
, - - O
the - - O
tri-snRNP-specific - - B-MUT
27K - - I-MUT
protein - - I-MUT
could - - O
potentially - - O
be - - O
involved - - O
in - - O
SR - - B-MUT
protein-mediated - - O
protein - - O
protein - - O
interactions - - O
and - - O
, - - O
additionally - - O
, - - O
its - - O
phosphorylation - - O
state - - O
could - - O
modulate - - O
pre-mRNA - - O
splicing - - O
. - - O

Tcn1p - - B-MUT
Crz1p - - I-MUT
, - - I-MUT
a - - O
calcineurin-dependent - - O
transcription - - O
factor - - O
that - - O
differentially - - O
regulates - - O
gene - - O
expression - - O
in - - O
Saccharomyces - - O
cerevisiae - - O
. - - O

A - - O
comparison - - O
of - - O
the - - O
Flavobacterium - - O
glycosylasparaginase - - B-MUT
with - - O
a - - O
mammalian - - O
glycosylasparaginase - - B-MUT
revealed - - O
30% - - O
structural - - O
identity - - O
and - - O
60% - - O
overall - - O
similarity - - O
between - - O
the - - O
prokaryotic - - O
and - - O
eukaryotic - - O
forms - - O
of - - O
the - - O
enzyme - - O
. - - O

This - - O
region - - O
, - - O
however - - O
, - - O
contains - - O
a - - O
CCAATC - - O
box - - O
in - - O
the - - O
reverse - - O
complement - - O
and - - O
several - - O
GC - - O
boxes - - O
that - - O
are - - O
recognition - - O
sites - - O
for - - O
SP1 - - B-MUT
. - - O

Furthermore - - O
, - - O
the - - O
amount - - O
of - - O
tRNA - - B-MUT
( - - I-MUT
3Lys - - I-MUT
) - - I-MUT
that - - O
was - - O
placed - - O
onto - - O
viral - - O
RNA - - O
in - - O
mutated - - O
viruses - - O
was - - O
significantly - - O
less - - O
than - - O
that - - O
placed - - O
in - - O
the - - O
wild-type - - O
virus - - O
. - - O

All - - O
62 - - O
isolates - - O
were - - O
resistant - - O
to - - O
lincomycin - - O
, - - O
colistin - - O
, - - O
nystatin - - O
, - - O
amphotericin - - O
B - - O
, - - O
trimethoprim - - O
lactate - - O
, - - O
polymyxin - - O
B - - O
, - - O
and - - O
anisomycin - - O
. - - O

However - - O
, - - O
in - - O
a - - O
new - - O
experiment - - O
in - - O
which - - O
the - - O
deletion - - O
task - - O
was - - O
presented - - O
as - - O
a - - O
puppet - - O
game - - O
, - - O
and - - O
with - - O
pretraining - - O
and - - O
selection - - O
on - - O
vowel - - O
deletion - - O
, - - O
a - - O
significantly - - O
higher - - O
level - - O
of - - O
success - - O
was - - O
achieved - - O
by - - O
the - - O
children - - O
working - - O
with - - O
the - - O
CVCC - - O
material - - O
. - - O

These - - O
results - - O
indicate - - O
that - - O
significant - - O
pulmonary - - O
metabolism - - O
of - - O
5-HT - - O
followed - - O
by - - O
efflux - - O
of - - O
5-HIAA - - O
into - - O
venous - - O
output - - O
occurs - - O
during - - O
single-pass - - O
circulation - - O
. - - O

Thirty - - O
seven - - O
patients - - O
( - - O
amitriptyline - - O
n - - O
= - - O
16 - - O
, - - O
moclobemide - - O
n - - O
= - - O
21 - - O
) - - O
completed - - O
the - - O
six - - O
week - - O
protocol - - O
, - - O
which - - O
was - - O
conducted - - O
under - - O
double - - O
blind - - O
conditions - - O
. - - O

Evidence - - O
for - - O
the - - O
promoting - - O
role - - O
of - - O
the - - O
intra-uterine - - B-MUT
kinin - - I-MUT
release - - O
in - - O
the - - O
development - - O
of - - O
late - - O
hypertonic - - O
saline-induced - - O
abortion - - O
. - - O

Cross-linking - - O
FcalphaR - - B-MUT
on - - O
wt-ITAM - - B-MUT
or - - O
IIA-ITAM - - B-MUT
cells - - O
triggered - - O
equivalent - - O
PI - - O
3-kinase-dependent - - O
activation - - O
of - - O
PKBalpha - - B-MUT
. - - O

Characterization - - O
of - - O
a - - O
human - - B-MUT
alternatively - - I-MUT
spliced - - I-MUT
truncated - - I-MUT
reduced - - I-MUT
folate - - I-MUT
carrier - - I-MUT
increasing - - O
folate - - O
accumulation - - O
in - - O
parental - - O
leukemia - - O
cells - - O
. - - O

We - - O
conclude - - O
that - - O
cephalothin - - O
clearance - - O
of - - O
S - - O
. - - O
aureus - - O
from - - O
a - - O
site - - O
accessible - - O
to - - O
phagocytes - - O
was - - O
delayed - - O
when - - O
compared - - O
to - - O
a - - O
phagocyte-inaccessible - - O
site - - O
. - - O

Recently - - O
, - - O
we - - O
discovered - - O
that - - O
alanine - - O
substitutions - - O
of - - O
the - - O
active - - O
center - - O
cleft - - O
residues - - O
significantly - - O
impair - - O
the - - O
depurinating - - O
and - - O
ribosome - - O
inhibitory - - O
activity - - O
of - - O
PAP - - B-MUT
. - - O

The - - O
decrements - - O
in - - O
cerebrovascular - - O
resistance - - O
induced - - O
by - - O
hexamethonium - - O
, - - O
in - - O
mm - - O
Hg - - O
ml - - O
( - - O
-1 - - O
) - - O
. - - O
min - - O
( - - O
-1 - - O
) - - O
, - - O
were - - O
: - - O
under - - O
control - - O
. - - O

The - - O
resulting - - O
integrated - - O
physical - - O
, - - O
genetic - - O
, - - O
and - - O
cytogenetic - - O
map - - O
constitutes - - O
a - - O
resource - - O
for - - O
the - - O
characterization - - O
of - - O
genes - - O
that - - O
may - - O
be - - O
involved - - O
in - - O
the - - O
WAGR - - O
syndrome - - O
. - - O

Umweltchem - - O
. - - O

In - - O
Experiment - - O
2 - - O
, - - O
we - - O
again - - O
used - - O
classification - - O
, - - O
but - - O
the - - O
fixed - - O
standard - - O
75 - - O
was - - O
not - - O
at - - O
the - - O
center - - O
of - - O
the - - O
range - - O
of - - O
target - - O
numbers - - O
( - - O
20 - - O
, - - O
21 - - O
, - - O
. - - O
. - - O
. - - O

Leukemia - - O
in - - O
twins - - O
: - - O
world-wide - - O
review - - O
of - - O
clinical - - O
cases - - O
. - - O

The - - O
TUP1 - - B-MUT
gene - - I-MUT
was - - O
isolated - - O
in - - O
a - - O
screen - - O
for - - O
genes - - O
that - - O
regulate - - O
mating - - O
type - - O
( - - O
V - - O
. - - O
L - - O
. - - O

The - - O
Caenorhabditis - - B-MUT
elegans - - I-MUT
death - - I-MUT
susceptibility - - I-MUT
gene - - I-MUT
, - - O
ced-3 - - B-MUT
, - - O
has - - O
a - - O
number - - O
of - - O
homologs - - O
in - - O
vertebrate - - O
species - - O
, - - O
including - - O
interleukin-1 - - B-MUT
beta - - I-MUT
( - - I-MUT
IL-1 - - I-MUT
beta - - I-MUT
) - - I-MUT
-converting - - I-MUT
enzyme - - I-MUT
( - - O
ICE - - B-MUT
) - - O
, - - O
Ich-1long - - B-MUT
, - - O
and - - O
CPP32 - - B-MUT
. - - O

RPS14 - - B-MUT
introns - - O
3 - - O
and - - O
4 - - O
both - - O
contain - - O
Alu - - B-MUT
sequences - - I-MUT
. - - O

Transcription - - O
factors - - O
of - - O
the - - O
Stat - - B-MUT
family - - I-MUT
are - - O
controlled - - O
by - - O
protein - - B-MUT
kinases - - I-MUT
. - - O

A - - O
novel - - O
, - - O
testis-specific - - B-MUT
mRNA - - I-MUT
transcript - - I-MUT
encoding - - O
an - - O
NH2-terminal - - B-MUT
truncated - - I-MUT
nitric-oxide - - I-MUT
synthase - - I-MUT
. - - O
mRNA - - O
diversity - - O
represents - - O
a - - O
major - - O
theme - - O
of - - O
neuronal - - B-MUT
nitric-oxide - - I-MUT
synthase - - I-MUT
( - - O
nNOS - - B-MUT
) - - O
gene - - O
expression - - O
in - - O
somatic - - O
cells - - O
tissues - - O
. - - O

The - - O
isoform - - O
, - - O
designated - - O
HDAC9a - - B-MUT
, - - O
is - - O
132 - - O
aa - - O
shorter - - O
at - - O
the - - O
C - - O
terminus - - O
than - - O
HDAC9 - - B-MUT
. - - O

The - - O
ESEG's - - O
are - - O
a - - O
direct - - O
result - - O
of - - O
the - - O
NEXT - - O
study - - O
. - - O

Body - - O
temperature - - O
and - - O
overall - - O
conductance - - O
in - - O
the - - O
cold - - O
appear - - O
to - - O
be - - O
more - - O
variable - - O
in - - O
P - - O
. - - O
s - - O
. - - O
campbelli - - O
than - - O
in - - O
nominative - - O
sp - - O
. - - O

After - - O
6 - - O
months - - O
, - - O
definite - - O
improvement - - O
in - - O
strength - - O
occurred - - O
in - - O
4 - - O
of - - O
7 - - O
carnitine-treated - - O
patients - - O
and - - O
in - - O
none - - O
of - - O
7 - - O
controls - - O
. - - O

Fifty-seven - - O
patients - - O
aged - - O
< - - O
55 - - O
years - - O
with - - O
acute - - O
lymphoblastic - - O
leukemia - - O
( - - O
ALL - - O
) - - O
in - - O
second - - O
or - - O
third - - O
bone - - O
marrow - - O
( - - O
BM - - O
) - - O
relapse - - O
or - - O
refractory - - O
to - - O
first-line - - O
therapy - - O
were - - O
enrolled - - O
in - - O
an - - O
Italian - - O
cooperative - - O
study - - O
. - - O

After - - O
gamma-irradiation - - O
, - - O
the - - O
majority - - O
of - - O
F9 - - O
cells - - O
undergo - - O
apoptosis - - O
implying - - O
that - - O
wt-p53 - - B-MUT
likely - - O
triggers - - O
pro-apoptotic - - O
gene - - O
expression - - O
in - - O
DNA - - O
damaged - - O
cells - - O
. - - O

While - - O
fusion - - O
to - - O
the - - O
N-terminus - - O
required - - O
a - - O
linker - - O
to - - O
become - - O
surface - - O
accessible - - O
, - - O
both - - O
fusion - - O
to - - O
the - - O
N-terminus - - O
and - - O
to - - O
the - - O
C-terminus - - O
was - - O
compatible - - O
with - - O
particle - - O
assembly - - O
and - - O
preserved - - O
the - - O
native - - O
antigenicity - - O
and - - O
immunogenicity - - O
of - - O
HBcAg - - B-MUT
. - - O

Studies - - O
have - - O
substantiated - - O
the - - O
involvement - - O
of - - O
numerous - - O
loci - - O
on - - O
certain - - O
chromosomes - - O
; - - O
in - - O
excess - - O
of - - O
10 - - O
chromosomes - - O
are - - O
thought - - O
to - - O
be - - O
involved - - O
. - - O

Grade - - O
3 - - O
mucositis - - O
was - - O
reported - - O
in - - O
1 - - O
patient - - O
. - - O

Multiparous - - O
women - - O
presented - - O
higher - - O
BMI - - O
( - - O
P - - O
= - - O
0 - - O
. - - O
01 - - O
) - - O
and - - O
PBF - - O
( - - O
P - - O
= - - O
0 - - O
. - - O
03 - - O
) - - O
compared - - O
with - - O
primi- - - O
and - - O
nulliparous - - O
groups - - O
. - - O

Isolation - - O
by - - O
PCR - - O
of - - O
a - - O
cDNA - - O
clone - - O
from - - O
pea - - O
petals - - O
with - - O
similarity - - O
to - - O
petunia - - O
and - - O
wheat - - B-MUT
zinc - - I-MUT
finger - - I-MUT
proteins - - I-MUT
. - - O

Gastritis - - O
score - - O
was - - O
significantly - - O
lower - - O
in - - O
nodminus - - O
sign - - O
CagAminus - - O
signchildren - - O
than - - O
in - - O
nod+ - - O
CagAminus - - O
sign - - O
( - - O
p - - O
= - - O
. - - O
004 - - O
) - - O
, - - O
nodminus - - O
sign - - O
CagA+ - - O
( - - O
p - - O
= - - O
. - - O
002 - - O
) - - O
and - - O
nod+ - - O
CagA+ - - O
( - - O
p - - O
< - - O
. - - O
001 - - O
) - - O
, - - O
both - - O
in - - O
the - - O
antrum - - O
and - - O
corpus - - O
. - - O

We - - O
found - - O
no - - O
correlation - - O
between - - O
plasma - - O
COP - - O
and - - O
body - - O
weight - - O
at - - O
the - - O
same - - O
age - - O
( - - O
r2 - - O
= - - O
0 - - O
. - - O
05 - - O
, - - O
P - - O
= - - O
0 - - O
. - - O
155 - - O
) - - O
. - - O

The - - O
227-to-239 - - O
region - - O
blocked - - O
ADR1 - - B-MUT
activity - - O
independently - - O
of - - O
the - - O
TAD - - B-MUT
present - - O
on - - O
ADR1 - - B-MUT
, - - O
ADR1 - - B-MUT
DNA - - O
binding - - O
, - - O
and - - O
specific - - O
ADH2 - - B-MUT
promoter - - I-MUT
sequences - - I-MUT
. - - O

A - - O
polypeptide - - O
chain - - O
of - - O
34 - - O
residues - - O
of - - O
the - - O
deduced - - O
yeast - - O
amino - - O
acid - - O
sequence - - O
closely - - O
resembles - - O
a - - O
peptide - - O
sequence - - O
at - - O
the - - O
ADP - - O
binding - - O
site - - O
of - - O
bovine - - B-MUT
muscle - - I-MUT
pyruvate - - I-MUT
kinase - - I-MUT
. - - O

The - - O
enzymic - - O
hydrolysis - - O
of - - O
urea - - O
produces - - O
ammonia - - O
which - - O
causes - - O
a - - O
vivid - - O
yellow - - O
to - - O
purple - - O
colour - - O
change - - O
in - - O
the - - O
pH - - O
indicator - - O
. - - O

ZIOS - - O
was - - O
significantly - - O
more - - O
sensitive - - O
than - - O
all - - O
subsequent - - O
methods - - O
, - - O
and - - O
Ptc - - O
, - - O
O2 - - O
was - - O
significantly - - O
more - - O
sensitive - - O
than - - O
FEV1 - - O
. - - O

In - - O
contrast - - O
, - - O
the - - O
MAN - - O
showed - - O
a - - O
unimodal - - O
, - - O
skewed - - O
distribution - - O
, - - O
with - - O
a - - O
range - - O
from - - O
approximately - - O
1 - - O
to - - O
14 - - O
micron - - O
and - - O
a - - O
maximum - - O
at - - O
3-4 - - O
micron - - O
. - - O

Nuclear - - B-MUT
hormone - - I-MUT
receptors - - I-MUT
( - - O
NRs - - B-MUT
) - - O
are - - O
ligand-inducible - - O
transcription - - O
factors - - O
that - - O
mediate - - O
critical - - O
functions - - O
in - - O
many - - O
species - - O
. - - O

OBJECTIVES - - O
: - - O
The - - O
objective - - O
of - - O
this - - O
review - - O
was - - O
to - - O
assess - - O
the - - O
effects - - O
of - - O
prophylactic - - O
prostaglandin - - O
use - - O
in - - O
the - - O
third - - O
stage - - O
of - - O
labour - - O
. - - O

Ethylene - - O
is - - O
involved - - O
in - - O
endosperm - - O
rupture - - O
and - - O
high-level - - O
betaGLU - - B-MUT
I - - I-MUT
expression - - O
; - - O
but - - O
, - - O
it - - O
does - - O
not - - O
affect - - O
the - - O
spatial - - O
and - - O
temporal - - O
pattern - - O
of - - O
betaGLU - - B-MUT
I - - I-MUT
expression - - O
. - - O

The - - O
presence - - O
of - - O
visna-maedi - - O
in - - O
Italy - - O
is - - O
reported - - O
for - - O
the - - O
first - - O
time - - O
. - - O

Derivatives - - O
of - - O
fluorene - - O
. - - O

The - - O
normal - - O
cell - - O
cycle - - O
is - - O
regulated - - O
by - - O
several - - O
molecules - - O
, - - O
such - - O
as - - O
the - - O
tumor-suppressor - - B-MUT
protein - - I-MUT
pRb - - I-MUT
, - - O
the - - O
G1 - - B-MUT
cyclins - - I-MUT
, - - O
the - - O
cyclin-dependent - - B-MUT
kinases - - I-MUT
, - - O
and - - O
their - - O
inhibitors - - O
. - - O

Fast - - O
continuous - - O
expansion - - O
. - - O

In - - O
this - - O
paper - - O
, - - O
we - - O
demonstrate - - O
that - - O
binding - - O
of - - O
the - - O
GA-binding - - B-MUT
protein - - I-MUT
( - - O
GABP - - B-MUT
) - - O
to - - O
ets - - B-MUT
sequence - - I-MUT
motifs - - I-MUT
within - - O
each - - O
repeated - - O
unit - - O
is - - O
required - - O
for - - O
transcriptional - - O
activation - - O
of - - O
the - - O
COXIV - - B-MUT
promoter - - I-MUT
. - - O

( - - O
1997 - - O
) - - O
Science - - O
275 - - O
, - - O
1927-1930 - - O
) - - O
. - - O

No - - O
patient - - O
with - - O
bradyarrhythmia - - O
-related - - O
SCD - - O
had - - O
manifest - - O
atrioventricular - - O
block - - O
or - - O
bundle - - O
branch - - O
block - - O
. - - O

Overall - - O
, - - O
these - - O
findings - - O
demonstrate - - O
that - - O
mutations - - O
E768D - - O
and - - O
V804L - - O
are - - O
gain-of-function - - O
mutations - - O
that - - O
confer - - O
to - - O
the - - O
long - - B-MUT
RET - - I-MUT
isoform - - I-MUT
the - - O
capacity - - O
to - - O
exert - - O
a - - O
biological - - O
effect - - O
, - - O
although - - O
these - - O
mutations - - O
are - - O
more - - O
weakly - - O
activating - - O
than - - O
the - - O
MEN2A - - B-MUT
and - - O
MEN2B - - B-MUT
mutations - - O
. - - O

Several - - O
of - - O
the - - O
exon - - O
boundaries - - O
correspond - - O
to - - O
the - - O
boundaries - - O
of - - O
functional - - O
domains - - O
in - - O
the - - O
p55 - - B-MUT
protein - - I-MUT
. - - O

HS - - O
inducibility - - O
required - - O
the - - O
HSE - - B-MUT
which - - O
was - - O
bound - - O
by - - O
HS - - B-MUT
transcription - - I-MUT
factor-1 - - I-MUT
( - - I-MUT
HSF-1 - - I-MUT
) - - I-MUT
present - - O
in - - O
extracts - - O
prepared - - O
from - - O
cells - - O
exposed - - O
to - - O
HS - - O
. - - O

Comprehensive - - O
care - - O
of - - O
the - - O
patient - - O
exposed - - O
to - - O
a - - O
human - - O
teratogen - - O
may - - O
also - - O
include - - O
discussion - - O
of - - O
prenatal - - O
diagnostic - - O
procedures - - O
and - - O
other - - O
pregnancy - - O
management - - O
options - - O
. - - O

The - - O
avidin-biotin - - B-MUT
complex - - I-MUT
peroxidase - - I-MUT
( - - O
ABC-P - - B-MUT
) - - O
method - - O
was - - O
used - - O
to - - O
detect - - O
Mycobacterium - - O
bovis - - O
, - - O
and - - O
the - - O
results - - O
were - - O
compared - - O
with - - O
those - - O
obtained - - O
by - - O
the - - O
Ziehl-Neelsen - - O
( - - O
ZN - - O
) - - O
technique - - O
. - - O

Therefore - - O
, - - O
both - - O
the - - O
Chilean - - O
and - - O
the - - O
Japanese - - O
samples - - O
collected - - O
in - - O
high-risk - - O
areas - - O
showed - - O
higher - - O
mutagenic - - O
rates - - O
than - - O
the - - O
Japanese - - O
ones - - O
in - - O
a - - O
low-risk - - O
area - - O
, - - O
with - - O
a - - O
statistical - - O
significance - - O
( - - O
p - - O
< - - O
0 - - O
. - - O
001 - - O
) - - O
, - - O
chi-square - - O
test - - O
) - - O
. - - O

Counter-current - - O
heat - - O
exchange - - O
in - - O
the - - O
respiratory - - O
passages - - O
: - - O
effect - - O
on - - O
water - - O
and - - O
heat - - O
balance - - O
. - - O

Both - - O
mutant - - O
receptors - - O
were - - O
expressed - - O
on - - O
the - - O
cell - - O
surface - - O
and - - O
bound - - O
insulin - - B-MUT
normally - - O
, - - O
but - - O
showed - - O
markedly - - O
impaired - - O
autophosphorylation - - O
in - - O
response - - O
to - - O
insulin - - B-MUT
. - - O

Marked - - O
sedative - - O
activity - - O
was - - O
observed - - O
with - - O
9-methoxy-5-phenylpyrrolo - - O
[ - - O
2 - - O
, - - O
1-d - - O
] - - O
[ - - O
1 - - O
, - - O
5 - - O
] - - O
benzothiazepin-6 - - O
, - - O
6-dioxide - - O
( - - O
NF19 - - O
) - - O
and - - O
9-chloro-5-p-nitrophenylpyrrolo - - O
[ - - O
2 - - O
, - - O
1-d - - O
] - - O
[ - - O
1 - - O
, - - O
5 - - O
] - - O
benzothiazepin-6 - - O
, - - O
6-dioxide - - O
( - - O
NF20 - - O
) - - O
. - - O

A - - O
second - - O
, - - O
novel - - O
C - - B-MUT
subunit - - I-MUT
( - - O
CeCAT - - B-MUT
alpha' - - I-MUT
, - - O
374 - - O
residues - - O
) - - O
has - - O
a - - O
unique - - O
56-residue - - O
carboxyl-terminal - - O
region - - O
that - - O
is - - O
generated - - O
by - - O
the - - O
alternative - - O
splicing - - O
of - - O
the - - O
C - - B-MUT
pre-mRNA - - I-MUT
. - - O

The - - O
mouse - - O
extracellular - - B-MUT
signal-regulated - - I-MUT
kinase - - I-MUT
2 - - I-MUT
gene - - I-MUT
. - - O

Interaction - - O
of - - O
H-2Eb - - B-MUT
with - - O
an - - O
IAP - - B-MUT
retrotransposon - - I-MUT
in - - O
the - - O
A20 - - O
2J - - O
B - - O
cell - - O
lymphoma - - O
. - - O

The - - O
Lp - - B-MUT
mouse - - I-MUT
mutant - - I-MUT
provides - - O
a - - O
model - - O
for - - O
the - - O
severe - - O
human - - O
neural - - O
tube - - O
defect - - O
( - - O
NTD - - O
) - - O
, - - O
cranio-rachischisis - - O
. - - O

These - - O
effects - - O
were - - O
not - - O
seen - - O
with - - O
SHIP2 - - B-MUT
possessing - - O
a - - O
mutation - - O
in - - O
the - - O
SH2 - - B-MUT
domain - - I-MUT
( - - O
R47G - - B-MUT
) - - O
. - - O

We - - O
have - - O
identified - - O
and - - O
characterized - - O
a - - O
vitamin - - B-MUT
D - - I-MUT
response - - I-MUT
element - - I-MUT
( - - O
VDRE - - B-MUT
) - - O
in - - O
the - - O
promoter - - O
of - - O
c-fos - - B-MUT
. - - O

Plasma - - O
concentrations - - O
of - - O
atracurium - - O
and - - O
laudanosine - - O
were - - O
0 - - O
. - - O
73-3 - - O
. - - O
11 - - O
micrograms - - O
ml-1 - - O
and - - O
0 - - O
. - - O
48-8 - - O
. - - O
65 - - O
micrograms - - O
ml-1 - - O
, - - O
respectively - - O
; - - O
CSF - - O
concentration - - O
of - - O
laudanosine - - O
was - - O
70-440 - - O
ng - - O
ml-1 - - O
. - - O

These - - O
findings - - O
suggest - - O
that - - O
intraarterial - - O
neoadjuvant - - O
chemotherapy - - O
should - - O
be - - O
effective - - O
on - - O
advanced - - O
cervical - - O
cancer - - O
. - - O

Distinguishing - - O
roles - - O
of - - O
the - - O
membrane-cytoskeleton - - O
and - - O
cadherin - - B-MUT
mediated - - O
cell-cell - - O
adhesion - - O
in - - O
generating - - O
different - - O
Na+ - - B-MUT
, - - I-MUT
K - - I-MUT
( - - I-MUT
+ - - I-MUT
) - - I-MUT
-ATPase - - I-MUT
distributions - - O
in - - O
polarized - - O
epithelia - - O
. - - O

These - - O
results - - O
suggest - - O
that - - O
gluconeogenic - - O
genes - - O
are - - O
derepressed - - O
upon - - O
binding - - O
of - - O
Cat8p - - B-MUT
, - - O
whose - - O
synthesis - - O
depends - - O
on - - O
the - - O
release - - O
of - - O
Cat4p - - B-MUT
( - - O
Mig1p - - B-MUT
) - - O
from - - O
the - - O
CAT8 - - B-MUT
promoter - - I-MUT
. - - O

We - - O
failed - - O
to - - O
find - - O
these - - O
data - - O
to - - O
be - - O
useful - - O
in - - O
predicting - - O
the - - O
time - - O
of - - O
onset - - O
of - - O
initial - - O
seizures - - O
after - - O
acute - - O
ischemic - - O
stroke - - O
and - - O
recurrence - - O
. - - O

The - - O
interaction - - O
of - - O
AF-1 - - B-MUT
with - - O
proteins - - O
that - - O
regulate - - O
distinct - - O
steps - - O
of - - O
transcription - - O
may - - O
provide - - O
a - - O
mechanism - - O
for - - O
synergistic - - O
activation - - O
of - - O
gene - - O
expression - - O
by - - O
AF-1 - - B-MUT
. - - O

The - - O
N-terminal - - O
portion - - O
of - - O
Notch - - B-MUT
( - - I-MUT
IC - - I-MUT
) - - I-MUT
inhibited - - O
p50 - - B-MUT
DNA - - O
binding - - O
and - - O
interacted - - O
specifically - - O
with - - O
p50 - - B-MUT
subunit - - I-MUT
, - - O
not - - O
p65 - - B-MUT
of - - O
NF-kappaB - - B-MUT
. - - O

2 - - O
cases - - O
of - - O
type - - O
II - - O
tyrosinosis - - O
( - - O
Richner-Hanhart - - O
syndrome - - O
) - - O
. - - O

Expression - - O
of - - O
the - - O
human - - O
T - - B-MUT
cell - - I-MUT
receptor - - I-MUT
( - - I-MUT
TCR - - I-MUT
) - - I-MUT
alpha - - I-MUT
gene - - I-MUT
is - - O
regulated - - O
by - - O
a - - O
T - - O
cell-specific - - O
transcriptional - - O
enhancer - - O
that - - O
is - - O
located - - O
4 - - O
. - - O
5 - - O
kilobases - - O
( - - O
kb - - O
) - - O
3' - - O
to - - O
the - - O
C - - B-MUT
alpha - - I-MUT
gene - - I-MUT
segment - - I-MUT
. - - O

Each - - O
group - - O
received - - O
15 - - O
ml - - O
kg - - O
of - - O
either - - O
6% - - O
pentafraction - - O
, - - O
6% - - O
pentastarch - - O
, - - O
or - - O
plasma - - O
followed - - O
two - - O
hours - - O
later - - O
by - - O
1 - - O
. - - O
5 - - O
micrograms - - O
kg - - O
0 - - O
. - - O
5 - - O
hr - - O
E - - O
. - - O

Infectious - - O
mutant - - O
virus - - O
progeny - - O
was - - O
obtained - - O
only - - O
on - - O
complementing - - O
gK-expressing - - O
cells - - O
, - - O
suggesting - - O
that - - O
gK - - B-MUT
has - - O
an - - O
important - - O
function - - O
in - - O
the - - O
replication - - O
cycle - - O
. - - O

The - - O
amino - - O
acid - - O
sequence - - O
of - - O
the - - O
protein - - O
in - - O
the - - O
region - - O
of - - O
the - - O
specificity - - O
pocket - - O
is - - O
similar - - O
to - - O
that - - O
of - - O
S - - B-MUT
. - - I-MUT
griseus - - I-MUT
proteases - - I-MUT
A - - I-MUT
, - - I-MUT
B - - I-MUT
, - - I-MUT
and - - I-MUT
C - - I-MUT
. - - O

The - - O
prevalence - - O
and - - O
incidence - - O
of - - O
human - - O
immunodeficiency - - O
virus - - O
types - - O
1 - - O
and - - O
2 - - O
( - - O
HIV-1 - - O
, - - O
HIV-2 - - O
) - - O
, - - O
human - - O
T-lymphotropic - - O
virus - - O
types - - O
I - - O
and - - O
II - - O
( - - O
HTLV-I - - O
II - - O
) - - O
, - - O
and - - O
syphilitic - - O
infections - - O
and - - O
the - - O
association - - O
between - - O
these - - O
infections - - O
were - - O
determined - - O
in - - O
a - - O
cohort - - O
of - - O
police - - O
officers - - O
in - - O
Guinea-Bissau - - O
. - - O

As - - O
expected - - O
, - - O
the - - O
heparin - - O
did - - O
produce - - O
increased - - O
recalcification - - O
times - - O
and - - O
the - - O
development - - O
of - - O
occasional - - O
subcutaneous - - O
hematomas - - O
. - - O

The - - O
partial - - O
ORF - - O
was - - O
found - - O
to - - O
be - - O
identical - - O
to - - O
the - - O
C - - O
terminus - - O
of - - O
HrpJ2 - - B-MUT
. - - O

Expression - - O
of - - O
thiamin - - B-MUT
biosynthetic - - I-MUT
genes - - I-MUT
( - - O
thiCOGE - - B-MUT
) - - O
and - - O
production - - O
of - - O
symbiotic - - B-MUT
terminal - - I-MUT
oxidase - - I-MUT
cbb3 - - I-MUT
in - - O
Rhizobium - - O
etli - - O
. - - O

In - - O
this - - O
regard - - O
, - - O
we - - O
have - - O
recently - - O
observed - - O
that - - O
a - - O
constitutively - - O
active - - O
G - - B-MUT
protein-coupled - - I-MUT
receptor - - I-MUT
( - - O
GPCR - - B-MUT
) - - O
encoded - - O
by - - O
the - - O
Kaposi's - - O
sarcoma-associated - - O
herpes - - O
virus - - O
( - - O
KSHV - - O
) - - O
human - - O
herpes - - O
virus - - O
8 - - O
is - - O
oncogenic - - O
and - - O
stimulates - - O
angiogenesis - - O
by - - O
increasing - - O
the - - O
secretion - - O
of - - O
vascular - - O
endothelial - - B-MUT
growth - - I-MUT
factor - - I-MUT
( - - I-MUT
VEGF - - O
) - - B-MUT
, - - O
which - - O
is - - O
a - - O
key - - O
angiogenic - - O
stimulator - - O
and - - O
a - - O
critical - - O
mitogen - - O
for - - O
the - - O
development - - O
of - - O
Kaposi's - - O
sarcoma - - O
. - - O

Selected - - O
topics - - O
in - - O
laboratory - - O
animal - - O
medicine - - O
. - - O

II - - O
. - - O

These - - O
results - - O
suggest - - O
that - - O
leader-mRNA - - O
fusion - - O
in - - O
coronavirus - - O
transcription - - O
does - - O
not - - O
require - - O
direct - - O
RNA-RNA - - O
interaction - - O
between - - O
complementary - - O
sequences - - O
. - - O

These - - O
regions - - O
may - - O
be - - O
differentially - - O
involved - - O
in - - O
tissue-specificity - - O
, - - O
and - - O
or - - O
circadian - - O
regulation - - O
, - - O
of - - O
the - - O
human - - O
hPer1 - - B-MUT
gene - - I-MUT
transcription - - I-MUT
. - - O

Polyclonal - - O
antiserum - - O
generated - - O
to - - O
the - - O
fusion - - O
protein - - O
was - - O
capable - - O
of - - O
detecting - - O
42- - - O
and - - O
46-kilodalton - - O
polypeptides - - O
from - - O
virus - - O
particles - - O
; - - O
both - - O
polypeptides - - O
were - - O
also - - O
shown - - O
to - - O
contain - - O
HBsAg - - B-MUT
determinants - - I-MUT
. - - O

The - - O
LA - - O
50s - - O
derived - - O
from - - O
this - - O
combined - - O
data - - O
when - - O
compared - - O
with - - O
our - - O
earlier - - O
series - - O
from - - O
1965 - - O
to - - O
1970 - - O
also - - O
did - - O
not - - O
show - - O
a - - O
significant - - O
change - - O
in - - O
mortality - - O
. - - O

The - - O
amount - - O
of - - O
drained - - O
effusion - - O
was - - O
measured - - O
, - - O
and - - O
fluid - - O
was - - O
sent - - O
for - - O
diagnostic - - O
assessment - - O
. - - O

Since - - O
sildenafil - - O
came - - O
on - - O
the - - O
market - - O
, - - O
it - - O
seems - - O
that - - O
the - - O
place - - O
of - - O
MUSE - - O
is - - O
reduced - - O
because - - O
comparative - - O
studies - - O
give - - O
better - - O
results - - O
for - - O
sildenafil - - O
than - - O
MUSE - - O
( - - O
70% - - O
vs - - O
40% - - O
) - - O
and - - O
of - - O
course - - O
with - - O
a - - O
better - - O
acceptance - - O
. - - O

Asymptomatic - - O
bacteriospermia - - O
and - - O
fertility - - O
. - - O

There - - O
was - - O
no - - O
difference - - O
in - - O
plasma - - O
concentrations - - O
of - - O
PGI2 - - O
( - - O
figure - - O
4 - - O
) - - O
and - - O
TxA2 - - O
in - - O
patients - - O
with - - O
normal - - O
blood - - O
pressure - - O
, - - O
mild - - O
preeclampsia - - O
and - - O
hypotension - - O
, - - O
whereas - - O
in - - O
severe - - O
preeclampsia - - O
, - - O
the - - O
plasma - - O
concentration - - O
of - - O
PGI2 - - O
was - - O
significantly - - O
lower - - O
( - - O
p - - O
< - - O
0 - - O
. - - O
001 - - O
) - - O
and - - O
of - - O
TxA2 - - O
significantly - - O
higher - - O
( - - O
p - - O
< - - O
0 - - O
. - - O
001 - - O
) - - O
. - - O

Labial - - O
bar - - O
. - - O

Reperfusion - - O
with - - O
normal - - O
blood - - O
in - - O
the - - O
beating - - O
, - - O
working - - O
hearts - - O
caused - - O
extensive - - O
structural - - O
damage - - O
, - - O
reduced - - O
reflow - - O
, - - O
and - - O
failed - - O
to - - O
restore - - O
contractility - - O
in - - O
any - - O
instance - - O
( - - O
-27% - - O
systolic - - O
shortening - - O
, - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
05 - - O
) - - O
. - - O

By - - O
sequence - - O
comparison - - O
, - - O
42 - - O
blocks - - O
of - - O
homology - - O
are - - O
defined - - O
in - - O
the - - O
5'-terminal - - O
region - - O
, - - O
of - - O
which - - O
36 - - O
appear - - O
in - - O
the - - O
CpG - - O
island - - O
and - - O
contain - - O
numerous - - O
conserved - - O
CpG - - O
dinucleotides - - O
. - - O

GCD10 - - B-MUT
was - - O
first - - O
identified - - O
genetically - - O
as - - O
a - - O
translational - - O
repressor - - O
of - - O
GCN4 - - B-MUT
. - - O

Analysis - - O
of - - O
a - - O
Mac1p - - B-MUT
mutant - - I-MUT
, - - O
refractile - - O
for - - O
copper-dependent - - O
repression - - O
of - - O
the - - O
Cu - - B-MUT
( - - I-MUT
I - - I-MUT
) - - I-MUT
transport - - I-MUT
genes - - I-MUT
, - - O
showed - - O
an - - O
aberrant - - O
pattern - - O
of - - O
CUP1 - - B-MUT
expression - - O
and - - O
copper - - O
sensitivity - - O
. - - O

French - - O
, - - O
M - - O
. - - O

Stromelysin-1 - - B-MUT
, - - O
matrix - - B-MUT
metalloproteinase-3 - - I-MUT
( - - O
MMP-3 - - B-MUT
) - - O
, - - O
is - - O
an - - O
important - - O
endopeptidase - - B-MUT
selectively - - O
expressed - - O
by - - O
somatic - - O
cells - - O
in - - O
organ - - O
tissues - - O
. - - O

Ficat - - O
and - - O
Bizou's - - O
condylar - - O
depth - - O
index - - O
and - - O
the - - O
condylar-joint - - O
surface - - O
angle - - O
of - - O
Brattstrom - - O
are - - O
recommended - - O
as - - O
especially - - O
suitable - - O
methods - - O
of - - O
measurement - - O
. - - O

A - - O
soap - - O
and - - O
water - - O
( - - O
1 - - O
: - - O
1 - - O
, - - O
v - - O
v - - O
) - - O
solution - - O
effectively - - O
decontaminated - - O
powdered - - O
stratum - - O
corneum - - O
. - - O

Each - - O
repeat - - O
consists - - O
of - - O
12 - - O
nt - - O
, - - O
coding - - O
for - - O
the - - O
reiterated - - O
sequence - - O
, - - O
K - - B-MUT
NPAG - - I-MUT
. - - I-MUT

Purification - - O
of - - O
MvaT - - B-MUT
enriched - - O
for - - O
two - - O
polypeptides - - O
of - - O
approximate - - O
molecular - - O
mass - - O
15 - - O
kDa - - O
and - - O
16 - - O
kDa - - O
, - - O
designated - - O
P15 - - B-MUT
and - - O
P16 - - B-MUT
. - - O

The - - O
Asian - - O
mouse - - O
Mus - - O
castaneus - - O
is - - O
resistant - - O
to - - O
infection - - O
by - - O
the - - O
polytropic - - O
mink - - O
cell - - O
focus-inducing - - O
( - - O
MCF - - O
) - - O
subgroup - - O
of - - O
murine - - O
leukemia - - O
viruses - - O
( - - O
MuLVs - - O
) - - O
. - - O

AB004534 - - B-MUT
. - - O

The - - O
10 - - O
kDa - - O
polypeptide - - O
was - - O
phosphorylated - - O
in - - O
vitro - - O
by - - O
incubating - - O
wheat - - O
etioplast - - O
membranes - - O
with - - O
[ - - O
gamma - - O
32P - - O
] - - O
ATP - - O
. - - O

The - - O
RMRI - - O
was - - O
tested - - O
for - - O
interrater - - O
reliability - - O
using - - O
three - - O
simulated - - O
and - - O
10 - - O
actual - - O
patients - - O
. - - O

The - - O
rat - - O
incisor - - O
is - - O
an - - O
excellent - - O
model - - O
system - - O
in - - O
which - - O
to - - O
study - - O
amelgenesis - - O
. - - O

Haploid - - O
cells - - O
of - - O
mating - - O
type - - O
A - - O
of - - O
the - - O
basidiomycetous - - O
yeast - - O
Rhodosporidium - - O
toruloides - - O
secrete - - O
a - - O
mating - - O
pheromone - - O
, - - O
rhodotorucine - - B-MUT
A - - I-MUT
, - - O
which - - O
is - - O
an - - O
undecapeptide - - O
containing - - O
S-farnesyl - - O
cysteine - - O
at - - O
its - - O
carboxy - - O
terminus - - O
. - - O

The - - O
FBF - - O
questionnaire - - O
did - - O
not - - O
highlight - - O
a - - O
characteristic - - O
basic - - O
symptoms - - O
profile - - O
of - - O
schizoaffective - - O
disorder - - O
, - - O
when - - O
compared - - O
with - - O
bipolar - - O
affective - - O
disorder - - O
and - - O
schizophrenia - - O
. - - O

Magnetic - - O
trapping - - O
of - - O
spin-polarized - - O
atomic - - O
hydrogen - - O
. - - O

The - - O
transcription - - O
and - - O
alternative - - O
splicing - - O
of - - O
human - - B-MUT
ORL1 - - I-MUT
and - - O
GAIP - - B-MUT
are - - O
cell-type - - O
specific - - O
. - - O

In - - O
the - - O
single - - O
case - - O
the - - O
restoration - - O
of - - O
a - - O
structured - - O
daily - - O
routine - - O
represents - - O
the - - O
presupposition - - O
for - - O
a - - O
cognitive - - O
therapy - - O
. - - O

Exercise - - O
training - - O
has - - O
become - - O
increasingly - - O
important - - O
in - - O
the - - O
treatment - - O
of - - O
heart - - O
failure - - O
patients - - O
. - - O

BACKGROUND - - O
: - - O
Chronic - - O
alcohol - - O
consumption - - O
has - - O
been - - O
demonstrated - - O
to - - O
be - - O
deleterious - - O
to - - O
bone - - O
health - - O
. - - O

The - - O
similar - - O
phenotypes - - O
of - - O
bur6 - - B-MUT
and - - O
bur3 - - B-MUT
( - - O
mot1 - - B-MUT
) - - O
mutations - - O
suggest - - O
that - - O
Bur6p - - B-MUT
and - - O
Mot1p - - B-MUT
have - - O
related - - O
, - - O
but - - O
not - - O
identical - - O
, - - O
functions - - O
in - - O
modulating - - O
the - - O
activity - - O
of - - O
the - - O
general - - O
transcription - - O
machinery - - O
in - - O
vivo - - O
. - - O

Escherichia - - O
coli - - O
BL21 - - O
( - - O
DE3 - - O
) - - O
plysS - - O
, - - O
harbouring - - O
a - - O
recombinant - - O
plasmid - - O
containing - - O
the - - O
catalase-peroxidase - - B-MUT
gene - - I-MUT
, - - O
produced - - O
a - - O
large - - O
amount - - O
of - - O
proteins - - O
that - - O
co-migrated - - O
on - - O
SDS - - O
PAGE - - O
with - - O
the - - O
native - - O
enzyme - - O
. - - O

Uracil - - B-MUT
DNA - - I-MUT
glycosylase - - I-MUT
catalyzes - - O
the - - O
initial - - O
step - - O
in - - O
the - - O
repair - - O
pathway - - O
that - - O
removes - - O
potentially - - O
mutagenic - - O
uracil - - O
from - - O
duplex - - O
DNA - - O
. - - O

Disruption - - O
of - - O
re-replication - - O
control - - O
by - - O
overexpression - - O
of - - O
human - - B-MUT
ORC1 - - I-MUT
in - - O
fission - - O
yeast - - O
. - - O

Whereas - - O
Smad2 - - B-MUT
was - - O
rapidly - - O
phosphorylated - - O
by - - O
TGF-beta - - B-MUT
and - - O
involved - - O
in - - O
the - - O
initial - - O
activation - - O
of - - O
Agc - - B-MUT
expression - - O
in - - O
confluent - - O
cells - - O
, - - O
Smad2 - - B-MUT
activation - - O
was - - O
not - - O
required - - O
for - - O
maintaining - - O
the - - O
high - - O
level - - O
of - - O
Agc - - B-MUT
expression - - O
. - - O

DATA - - O
SOURCES - - O
: - - O
Epidemiologic - - O
studies - - O
, - - O
research - - O
studies - - O
, - - O
review - - O
articles - - O
, - - O
and - - O
government - - O
reports - - O
pertaining - - O
to - - O
epidemiology - - O
of - - O
lung - - O
cancer - - O
. - - O

Both - - O
alleles - - O
are - - O
functionally - - O
expressed - - O
and - - O
are - - O
distributed - - O
within - - O
CD4+ - - B-MUT
CD8+ - - I-MUT
T - - I-MUT
cell - - O
subsets - - O
. - - O

The - - O
Italian - - O
Lung - - O
Cancer - - O
Task - - O
Force - - O
( - - O
FONICAP - - O
) - - O
. - - O

These - - O
show - - O
that - - O
the - - O
collagen - - B-MUT
in - - O
this - - O
tissue - - O
is - - O
modified - - O
compared - - O
with - - O
that - - O
in - - O
tendon - - O
. - - O

Taken - - O
together - - O
, - - O
these - - O
data - - O
indicate - - O
that - - O
the - - O
VirD2 - - B-MUT
omega - - I-MUT
domain - - I-MUT
is - - O
important - - O
for - - O
efficient - - O
T-DNA - - O
integration - - O
. - - O

The - - O
spontaneous - - O
mutation - - O
blocking - - O
pca - - B-MUT
gene - - I-MUT
expression - - O
was - - O
located - - O
in - - O
the - - O
promoter - - O
for - - O
the - - O
pca - - B-MUT
operon - - I-MUT
. - - O

The - - O
binding - - O
specificity - - O
of - - O
this - - O
protein - - O
was - - O
compared - - O
to - - O
that - - O
of - - O
human - - B-MUT
E2F - - I-MUT
using - - O
a - - O
number - - O
of - - O
mutant - - B-MUT
E2F - - I-MUT
sites - - I-MUT
as - - O
competitors - - O
. - - O

These - - O
case - - O
reports - - O
provide - - O
further - - O
evidence - - O
that - - O
LiCO3 - - O
can - - O
be - - O
a - - O
useful - - O
medication - - O
in - - O
the - - O
treatment - - O
of - - O
aggressive - - O
behavior - - O
and - - O
affective - - O
instability - - O
after - - O
brain - - O
injury - - O
, - - O
but - - O
that - - O
it - - O
has - - O
significant - - O
potential - - O
for - - O
neurotoxicity - - O
in - - O
this - - O
population - - O
, - - O
particularly - - O
when - - O
used - - O
in - - O
conjunction - - O
with - - O
neuroleptic - - O
agents - - O
. - - O

We - - O
also - - O
isolated - - O
two - - O
alternatively - - O
spliced - - O
forms - - O
of - - O
human - - B-MUT
CD6 - - I-MUT
cDNA - - I-MUT
lacking - - O
sequences - - O
encoding - - O
membrane-proximal - - O
regions - - O
of - - O
the - - O
cytoplasmic - - O
domain - - O
which - - O
maintain - - O
the - - O
same - - O
reading - - O
frame - - O
as - - O
CD6-PB1 - - B-MUT
. - - O

Eight - - O
CAD - - O
patients - - O
who - - O
were - - O
matched - - O
to - - O
the - - O
treated - - O
patients - - O
for - - O
age - - O
( - - O
+ - - O
-3 - - O
years - - O
) - - O
, - - O
baseline - - O
low - - O
density - - B-MUT
lipoprotein - - I-MUT
( - - I-MUT
+ - - O
-5 - - O
mg - - O
dL - - O
) - - O
, - - O
and - - O
triglycerides - - O
( - - O
+ - - O
-50 - - O
mg - - O
dL - - O
) - - O
but - - O
who - - O
had - - O
never - - O
been - - O
treated - - O
with - - O
lipid-lowering - - O
drugs - - O
were - - O
selected - - O
as - - O
controls - - O
. - - O

Judge - - O
OKs - - O
docs' - - O
bid - - O
for - - O
Chicago - - O
hospital - - O
. - - O

The - - O
characterization - - O
of - - O
the - - O
promoter - - O
region - - O
indicated - - O
that - - O
three - - O
distinct - - O
regulatory - - O
elements - - O
corresponding - - O
to - - O
an - - O
AP-1 - - B-MUT
binding - - I-MUT
site - - I-MUT
( - - O
or - - O
TRE - - B-MUT
) - - O
, - - O
a - - O
PRDII - - B-MUT
kappaB - - I-MUT
domain - - I-MUT
, - - I-MUT
and - - O
a - - O
CAAT - - O
box - - O
are - - O
involved - - O
in - - O
the - - O
activation - - O
by - - O
pp60 - - O
( - - B-MUT
v- - - I-MUT
) - - I-MUT
src - - I-MUT
. - - I-MUT

The - - O
-64 - - O
-37 - - O
region - - O
interacted - - O
with - - O
purified - - O
Sp1 - - O
and - - B-MUT
an - - O
unidentified - - O
protein - - O
( - - O
s - - O
) - - O
, - - O
proximal - - O
regulatory - - B-MUT
factor - - I-MUT
( - - I-MUT
s - - I-MUT
) - - I-MUT
I - - I-MUT
( - - I-MUT
PRF-I - - O
) - - B-MUT
. - - O

Although - - O
most - - O
SH2-pTyr - - B-MUT
interactions - - O
occur - - O
between - - O
two - - O
different - - O
types - - O
of - - O
molecules - - O
, - - O
some - - O
appear - - O
to - - O
involve - - O
only - - O
a - - O
single - - O
molecular - - O
type - - O
. - - O

From - - O
an - - O
RNK-16 - - O
lambda-gt11 - - O
library - - O
, - - O
we - - O
have - - O
isolated - - O
and - - O
sequenced - - O
a - - O
novel - - O
cDNA - - O
rat - - B-MUT
NK - - I-MUT
cell - - I-MUT
protease - - I-MUT
1 - - I-MUT
( - - O
RNKP-1 - - B-MUT
) - - O
that - - O
has - - O
characteristics - - O
unique - - O
to - - O
serine - - B-MUT
proteases - - I-MUT
. - - O

Similarly - - O
, - - O
in - - O
mammalian - - O
cells - - O
PBP74 - - B-MUT
is - - O
synthesized - - O
as - - O
a - - O
pre-protein - - O
that - - O
requires - - O
membrane - - O
potential-dependent - - O
import - - O
into - - O
mitochondria - - O
for - - O
its - - O
maturation - - O
. - - O

The - - O
M - - B-MUT
reading - - I-MUT
frame - - I-MUT
differed - - O
from - - O
the - - O
reported - - O
sequence - - O
by - - O
a - - O
single - - O
nucleotide - - O
corresponding - - O
to - - O
a - - O
conservative - - O
lysine - - O
to - - O
arginine - - O
amino - - O
acid - - O
substitution - - O
near - - O
the - - O
carboxy-terminus - - O
conserved - - O
among - - O
the - - O
M - - B-MUT
proteins - - I-MUT
of - - O
paramyxoviruses - - O
. - - O

Occupational - - O
exposure - - O
to - - O
hepatitis - - O
B - - O
virus - - O
and - - O
human - - O
immunodeficiency - - O
virus - - O
: - - O
a - - O
comparative - - O
risk - - O
analysis - - O
. - - O

Although - - O
it - - O
is - - O
well - - O
known - - O
that - - O
calcium - - O
channel - - O
blockers - - O
can - - O
influence - - O
contraction - - O
of - - O
vascular - - O
smooth - - O
muscle - - O
, - - O
there - - O
is - - O
less - - O
knowledge - - O
on - - O
its - - O
effect - - O
on - - O
excitation - - O
contraction - - O
coupling - - O
in - - O
the - - O
endocrine - - O
glands - - O
and - - O
more - - O
specifically - - O
on - - O
insulin - - B-MUT
and - - O
glucagon - - O
release - - O
. - - O

There - - O
were - - O
no - - O
instances - - O
of - - O
major - - O
flap - - O
necrosis - - O
although - - O
two - - O
flaps - - O
showed - - O
tip - - O
ischaemia - - O
. - - O

Clinical - - O
applications - - O
of - - O
inhibition - - O
of - - O
beta-adrenergic - - B-MUT
receptors - - I-MUT
with - - O
propranolol - - O
. - - O

Improved - - O
methods - - O
have - - O
been - - O
developed - - O
for - - O
maintaining - - O
and - - O
breeding - - O
the - - O
neotropical - - O
short-tailed - - O
fruit - - O
bat - - O
, - - O
Carollia - - O
perspicillata - - O
, - - O
in - - O
an - - O
easily-reproduced - - O
, - - O
laboratory - - O
setting - - O
. - - O

The - - O
intensity - - O
of - - O
myocardial - - O
uptake - - O
of - - O
Tc-99m-PYP - - O
in - - O
patients - - O
with - - O
echocardiographic - - O
left - - O
ventricular - - O
hypertrophy - - O
and - - O
or - - O
highly - - O
refractile - - O
myocardial - - O
echoes - - O
, - - O
so-called - - O
granular - - O
sparkling - - O
appearance - - O
( - - O
GS - - O
) - - O
was - - O
slightly - - O
greater - - O
than - - O
that - - O
in - - O
patients - - O
with - - O
neither - - O
myocardial - - O
hypertrophy - - O
nor - - O
GS - - O
. - - O

The - - O
only - - O
predictor - - O
of - - O
response - - O
to - - O
tacrolimus - - O
was - - O
a - - O
previous - - O
response - - O
to - - O
cyclosporin - - O
and - - O
prednisone - - O
, - - O
either - - O
as - - O
a - - O
complete - - O
or - - O
partial - - O
remission - - O
( - - O
remission - - O
rate - - O
75% - - O
vs - - O
15 - - O
. - - O
3 - - O
; - - O
P - - O
= - - O
0 - - O
. - - O
036 - - O
) - - O
. - - O

Three - - O
group - - O
1 - - O
patients - - O
developed - - O
CMV - - O
disease - - O
; - - O
1 - - O
group - - O
2 - - O
patient - - O
developed - - O
CMV - - O
hepatitis - - O
. - - O

CAL - - O
gain - - O
amounted - - O
to - - O
4 - - O
. - - O
2+ - - O
-1 - - O
. - - O
3 - - O
mm - - O
, - - O
60% - - O
of - - O
the - - O
defects - - O
showing - - O
CAL - - O
gain - - O
> - - O
or - - O
= - - O
4 - - O
mm - - O
. - - O

After - - O
clofelin - - O
administration - - O
the - - O
autoregulation - - O
borders - - O
shifted - - O
to - - O
the - - O
right - - O
i - - O
. - - O
e - - O
. - - O
towards - - O
higher - - O
AP - - O
levels - - O
. - - O

Persistent - - O
acantholytic - - O
dermatosis - - O
with - - O
increased - - O
light - - O
sensitivity - - O
. - - O

In - - O
fact - - O
, - - O
SPT - - B-MUT
activity - - O
in - - O
the - - O
fly - - O
expressing - - O
epitope-tagged - - O
Lace - - B-MUT
was - - O
absorbed - - O
by - - O
epitope-specific - - O
antibody - - O
. - - O

The - - O
length - - O
scales - - O
of - - O
the - - O
turbulence - - O
were - - O
also - - O
estimated - - O
: - - O
at - - O
a - - O
Reynolds - - O
number - - O
near - - O
4 - - O
, - - O
000 - - O
the - - O
macroscale - - O
is - - O
about - - O
1 - - O
. - - O
25 - - O
mm - - O
, - - O
the - - O
Taylor - - O
microscale - - O
is - - O
about - - O
0 - - O
. - - O
85 - - O
mm - - O
, - - O
and - - O
the - - O
Kolmogoroff - - O
scale - - O
is - - O
near - - O
0 - - O
. - - O
075 - - O
mm - - O
. - - O

C - - O
. - - O

DESIGN - - O
: - - O
Prospective - - O
, - - O
randomized - - O
, - - O
double-blind - - O
, - - O
controlled - - O
trial - - O
. - - O

In - - O
this - - O
study - - O
, - - O
we - - O
investigated - - O
the - - O
signal - - O
transduction - - O
pathways - - O
that - - O
are - - O
involved - - O
in - - O
OM-induced - - O
LDLR - - B-MUT
transcription - - O
. - - O

The - - O
hexanucleotide - - B-MUT
5'-TGTCCT-3' - - I-MUT
, - - O
thought - - O
to - - O
be - - O
important - - O
for - - O
GRE - - B-MUT
activity - - O
, - - O
not - - O
only - - O
was - - O
found - - O
in - - O
this - - O
sequence - - O
and - - O
in - - O
the - - O
5'-flanking - - O
region - - O
, - - O
but - - O
also - - O
was - - O
present - - O
twice - - O
in - - O
the - - O
3' - - O
end - - O
of - - O
the - - O
gene - - O
that - - O
did - - O
not - - O
show - - O
specific - - O
receptor - - O
binding - - O
. - - O

The - - O
term - - O
endovascular - - O
papillary - - O
haemangioma - - O
is - - O
suggested - - O
. - - O

Mutations - - O
at - - O
the - - O
extreme - - O
C-terminus - - O
of - - O
EIAV - - B-MUT
Tat - - I-MUT
impaired - - O
both - - O
RNA - - O
binding - - O
and - - O
activation - - O
domain - - O
functions - - O
, - - O
suggesting - - O
effects - - O
on - - O
secondary - - O
or - - O
tertiary - - O
structure - - O
. - - O

Repeated - - O
efforts - - O
to - - O
isolate - - O
recombinant - - O
baculoviruses - - O
containing - - O
a - - O
wild-type - - B-MUT
kinase - - I-MUT
failed - - O
, - - O
whereas - - O
recombinants - - O
expressing - - O
a - - O
nonfunctional - - O
kinase - - B-MUT
with - - O
a - - O
catalytic - - O
domain - - B-MUT
II - - I-MUT
mutation - - O
were - - O
readily - - O
isolated - - O
. - - O

Elementary - - O
visual - - O
hallucinations - - O
in - - O
migraine - - O
and - - O
epilepsy - - O
. - - O

RT-PCR - - O
was - - O
performed - - O
using - - O
previously - - O
reported - - O
degenerate - - O
oligonucleotide - - O
primers - - O
to - - O
the - - O
ligand - - O
binding - - O
domain - - O
( - - O
LBD - - O
) - - O
of - - O
known - - O
beta - - B-MUT
integrin - - I-MUT
subunits - - I-MUT
and - - O
Bge - - B-MUT
cDNA - - I-MUT
. - - O

Chronic - - O
administration - - O
of - - O
sodium - - O
cyanate - - O
decreases - - O
O2 - - O
extraction - - O
ratio - - O
in - - O
dogs - - O
. - - O

Efficient - - O
phosphorylation - - O
of - - O
BRDG1 - - B-MUT
by - - O
Tec - - B-MUT
required - - O
the - - O
PH - - B-MUT
and - - O
SH2 - - B-MUT
domains - - I-MUT
as - - O
well - - O
as - - O
the - - O
kinase - - O
domain - - O
of - - O
the - - O
latter - - O
. - - O

Evidence-based - - O
care - - O
: - - O
a - - O
new - - O
formula - - O
for - - O
an - - O
old - - O
problem - - O
? - - O

With - - O
this - - O
GH - - B-MUT
and - - O
estrogen - - O
treatment - - O
regimen - - O
, - - O
most - - O
girls - - O
with - - O
TS - - O
can - - O
grow - - O
and - - O
develop - - O
much - - O
more - - O
in - - O
conformity - - O
with - - O
their - - O
healthy - - O
peers - - O
. - - O

After - - O
acclimation - - O
, - - O
resting - - O
supine - - O
and - - O
sitting - - O
DPB - - O
decreased - - O
( - - O
P - - O
less - - O
than - - O
0 - - O
. - - O
05 - - O
) - - O
by - - O
6 - - O
and - - O
9 - - O
mmHg - - O
, - - O
respectively - - O
. - - O

METHODS - - O
: - - O
DSF - - O
was - - O
instilled - - O
in - - O
one - - O
eye - - O
chosen - - O
at - - O
random - - O
and - - O
CF - - O
in - - O
the - - O
fellow - - O
eye - - O
of - - O
13 - - O
normal - - O
subjects - - O
and - - O
in - - O
13 - - O
patients - - O
with - - O
KCS - - O
. - - O

With - - O
regard - - O
to - - O
nonhematologic - - O
toxicities - - O
, - - O
diarrhea - - O
, - - O
infection - - O
and - - O
elevated - - O
serum - - B-MUT
alkaline - - I-MUT
phosphatase - - I-MUT
of - - O
grade - - O
3 - - O
or - - O
over - - O
were - - O
observed - - O
in - - O
2% - - O
of - - O
cycles - - O
, - - O
but - - O
were - - O
tolerable - - O
and - - O
reversible - - O
. - - O

Tests - - O
showed - - O
that - - O
an - - O
overall - - O
impression - - O
of - - O
the - - O
force - - O
applied - - O
could - - O
be - - O
obtained - - O
from - - O
a - - O
laboratory - - O
simulation - - O
, - - O
but - - O
that - - O
clearing - - O
cement - - O
and - - O
testing - - O
cement - - O
were - - O
not - - O
modelled - - O
by - - O
this - - O
method - - O
. - - O

These - - O
lesions - - O
were - - O
asymptomatic - - O
, - - O
but - - O
both - - O
were - - O
characterized - - O
clinically - - O
by - - O
central - - O
ulceration - - O
. - - O

In - - O
addition - - O
, - - O
double - - O
mutants - - O
with - - O
either - - O
dim1-delta - - B-MUT
or - - O
dim2-1 - - B-MUT
and - - O
the - - O
endocytosis - - O
mutants - - B-MUT
end4-1 - - I-MUT
or - - O
act1-1 - - B-MUT
displayed - - O
synthetic - - O
growth - - O
defects - - O
, - - O
indicating - - O
that - - O
the - - O
DIM - - B-MUT
gene - - I-MUT
products - - I-MUT
function - - O
in - - O
a - - O
common - - O
or - - O
parallel - - O
endocytic - - O
pathway - - O
. - - O

35 - - O
patients - - O
with - - O
acute - - O
arterial - - O
occlusions - - O
[ - - O
27 - - O
] - - O
and - - O
graft - - O
thromboses - - O
[ - - O
8 - - O
] - - O
, - - O
responsible - - O
for - - O
severe - - O
and - - O
recent - - O
ischemia - - O
, - - O
were - - O
treated - - O
by - - O
fibrinolytic - - O
therapy - - O
( - - O
Urokinase - - B-MUT
: - - O
1 - - O
000 - - O
units - - O
kg - - O
hour - - O
, - - O
and - - O
Lys - - O
Plasminogen - - O
) - - O
. - - B-MUT

Moreover - - O
, - - O
it - - O
is - - O
the - - O
assumptions - - O
behind - - O
steady-state - - O
O2 - - O
uptake - - O
that - - O
do - - O
not - - O
permit - - O
proper - - O
interpretation - - O
of - - O
energy - - O
expenditure - - O
during - - O
EPOC - - O
; - - O
1 - - O
l - - O
O2 - - O
not - - O
= - - O
20 - - O
. - - O
9 - - O
kJ - - O
. - - O

An - - O
examination - - O
of - - O
the - - O
properties - - O
of - - O
sequences - - O
surrounding - - O
ARS1 - - B-MUT
left - - O
open - - O
the - - O
possibility - - O
that - - O
ABFI - - B-MUT
enhances - - O
the - - O
initiation - - O
of - - O
DNA - - O
replication - - O
at - - O
ARS1 - - B-MUT
by - - O
transcriptional - - O
activation - - O
. - - O

The - - O
intron - - O
is - - O
capable - - O
of - - O
splicing - - O
despite - - O
the - - O
fact - - O
that - - O
both - - O
the - - O
EBS1 - - B-MUT
IBS1 - - I-MUT
and - - I-MUT
the - - O
EBS2 - - O
IBS2 - - B-MUT
sequence - - I-MUT
motifs - - I-MUT
, - - I-MUT
thought - - I-MUT
to - - O
be - - O
necessary - - O
for - - O
correct - - O
splicing - - O
, - - O
extend - - O
over - - O
5 - - O
instead - - O
of - - O
6 - - O
bp - - O
. - - O

From - - O
day - - O
10 - - O
, - - O
a - - O
significant - - O
increase - - O
in - - O
platelet - - O
count - - O
was - - O
observed - - O
in - - O
eight - - O
of - - O
the - - O
ten - - O
patients - - O
treated - - O
with - - O
heparin - - O
( - - O
p - - O
< - - O
0 - - O
. - - O
05 - - O
) - - O
, - - O
with - - O
return - - O
to - - O
the - - O
initial - - O
value - - O
after - - O
heparin - - O
cessation - - O
in - - O
six - - O
of - - O
the - - O
responders - - O
. - - O

The - - O
association - - O
of - - O
p255 - - B-MUT
with - - O
splicing - - O
complexes - - O
is - - O
suggested - - O
by - - O
the - - O
finding - - O
that - - O
mAb - - B-MUT
CC3 - - I-MUT
can - - O
inhibit - - O
in - - O
vitro - - O
splicing - - O
and - - O
immunoprecipitate - - O
pre-messenger - - O
RNA - - O
and - - O
splicing - - O
products - - O
. - - O

In - - O
rats - - O
anaesthetized - - O
with - - O
+-chloralose - - O
the - - O
changes - - O
in - - O
extracellular - - O
pH - - O
and - - O
K+ - - O
in - - O
spinal - - O
cord - - O
dorsal - - O
horn - - O
were - - O
studied - - O
using - - O
pH - - O
and - - O
K+ - - O
ion-selective - - O
electrodes - - O
. - - O

Rather - - O
, - - O
usp - - B-MUT
is - - O
required - - O
in - - O
late - - O
third - - O
instar - - O
larvae - - O
for - - O
appropriate - - O
developmental - - O
and - - O
transcriptional - - O
responses - - O
to - - O
the - - O
ecdysone - - O
pulse - - O
that - - O
triggers - - O
puparium - - O
formation - - O
. - - O

The - - O
majority - - O
of - - O
MRF - - O
units - - O
were - - O
behaviorally - - O
incongruent - - O
; - - O
in - - O
the - - O
most - - O
frequently - - O
observed - - O
case - - O
, - - O
their - - O
activity - - O
failed - - O
to - - O
change - - O
reliably - - O
when - - O
behavior - - O
habituated - - O
. - - O

There - - O
were - - O
no - - O
significant - - O
changes - - O
in - - O
either - - O
the - - O
fatty - - O
acid - - O
composition - - O
of - - O
biliary - - O
lecithin - - O
or - - O
in - - O
the - - O
bile - - O
acid - - O
composition - - O
of - - O
bile - - O
. - - O

In - - O
the - - O
present - - O
study - - O
, - - O
we - - O
sought - - O
to - - O
investigate - - O
whether - - O
constitutive - - B-MUT
NF-kappaB - - I-MUT
activity - - O
in - - O
chronically - - O
HIV-1-infected - - O
promonocytic - - O
U937 - - O
( - - O
U9-IIIB - - O
) - - O
and - - O
myeloblastic - - O
PLB-985 - - O
( - - O
PLB-IIIB - - O
) - - O
cells - - O
affects - - O
apoptotic - - O
signaling - - O
. - - O

Survey - - O
on - - O
antibody - - O
against - - O
egg - - O
drop - - O
syndrome-1976 - - O
virus - - O
among - - O
chicken - - O
flocks - - O
in - - O
Japan - - O
. - - O

We - - O
present - - O
evidence - - O
that - - O
the - - O
upstream - - O
open - - O
reading - - O
frame - - O
( - - O
uORF - - O
) - - O
represses - - O
the - - O
translation - - O
of - - O
the - - O
downstream - - O
major - - O
open - - O
reading - - O
frame - - O
( - - O
mORF - - O
) - - O
. - - O

In - - O
EEG - - O
only - - O
single - - O
slow - - O
waves - - O
above - - O
left - - O
temporal - - O
region - - O
were - - O
revealed - - O
. - - O

No - - O
increased - - O
tumor-related - - O
mortality - - O
was - - O
observed - - O
after - - O
a - - O
mean - - O
follow-up - - O
of - - O
44 - - O
months - - O
. - - O

In - - O
Rat-1a - - O
cells - - O
the - - O
expression - - O
of - - O
human - - B-MUT
c-jun - - I-MUT
mRNA - - I-MUT
was - - O
associated - - O
with - - O
the - - O
ability - - O
to - - O
clone - - O
in - - O
soft - - O
agarose - - O
and - - O
form - - O
tumors - - O
in - - O
nude - - O
mice - - O
. - - O

Carbonic - - B-MUT
anhydrase - - I-MUT
V - - I-MUT
( - - O
CA - - B-MUT
V - - I-MUT
) - - O
is - - O
expressed - - O
in - - O
mitochondrial - - O
matrix - - O
in - - O
liver - - O
and - - O
several - - O
other - - O
tissues - - O
. - - O

Metabolism - - O
of - - O
calcium - - O
and - - O
vitamin - - O
D3 - - O
in - - O
patients - - O
with - - O
acute - - O
tubulointerstitial - - O
nephritis - - O
: - - O
a - - O
study - - O
of - - O
41 - - O
patients - - O
with - - O
nephropathia - - O
epidemica - - O
. - - O

OBJECTIVES - - O
: - - O
The - - O
objective - - O
of - - O
this - - O
review - - O
was - - O
to - - O
compare - - O
the - - O
effectiveness - - O
, - - O
safety - - O
and - - O
acceptability - - O
of - - O
the - - O
diaphragm - - O
with - - O
and - - O
without - - O
spermicide - - O
. - - O

METHODS - - O
AND - - O
RESULTS - - O
: - - O
A - - O
64-year-old - - O
woman - - O
with - - O
confirmed - - O
AV - - O
nodal - - O
reentrant - - O
tachycardia - - O
underwent - - O
a - - O
successful - - O
"slow - - O
pathway" - - O
AV - - O
modification - - O
with - - O
a - - O
single - - O
radiofrequency - - O
application - - O
. - - O

In - - O
3 - - O
treatments - - O
the - - O
diet - - O
was - - O
supplemented - - O
with - - O
0 - - O
, - - O
100 - - O
and - - O
150 - - O
mg - - O
probiotic - - O
kg - - O
food - - O
. - - O

We - - O
show - - O
that - - O
stimulation - - O
of - - O
resting - - O
splenic - - O
B - - O
cells - - O
with - - O
CD40L-expressing - - O
Sf9 - - O
cells - - O
induces - - O
germ-line - - O
gamma - - B-MUT
1 - - I-MUT
and - - O
epsilon - - B-MUT
transcripts - - I-MUT
independently - - O
of - - O
cytokines - - O
. - - O

Routine - - O
blood - - O
examination - - O
showed - - O
leukocytosis - - O
, - - O
thrombocytopenia - - O
, - - O
positive - - O
CRP - - B-MUT
, - - O
and - - O
elevated - - O
myocardial - - O
enzymes - - O
. - - O

We - - O
propose - - O
that - - O
refeeding - - O
may - - O
be - - O
an - - O
important - - O
mechanism - - O
for - - O
activation - - O
of - - O
certain - - O
viral - - O
infections - - O
previously - - O
suppressed - - O
by - - O
famine - - O
. - - O

Survival - - O
after - - O
development - - O
of - - O
symptomatic - - O
infection - - O
( - - O
P-2 - - O
) - - O
did - - O
not - - O
differ - - O
by - - O
transmission - - O
mode - - O
. - - O

Most - - O
other - - O
end - - O
points - - O
were - - O
highly - - O
significant - - O
, - - O
and - - O
death - - O
, - - O
which - - O
was - - O
monitored - - O
across - - O
the - - O
U - - O
. - - O
S - - O
. - - O
program - - O
, - - O
was - - O
different - - O
with - - O
p - - O
< - - O
0 - - O
. - - O
0001 - - O
. - - O

Constipation - - O
is - - O
not - - O
a - - O
risk - - O
factor - - O
for - - O
hemorrhoids - - O
: - - O
a - - O
case-control - - O
study - - O
of - - O
potential - - O
etiological - - O
agents - - O
. - - O

Mutational - - O
analysis - - O
of - - O
chromosomal - - O
segment - - O
64AB - - O
, - - O
a - - O
region - - O
containing - - O
the - - O
glutamic - - B-MUT
acid - - I-MUT
decarboxylase - - I-MUT
gene - - I-MUT
. - - O

Substitution - - O
of - - O
the - - O
DR1 - - B-MUT
beta - - I-MUT
chain - - I-MUT
with - - O
H-2E - - B-MUT
beta - - I-MUT
k - - I-MUT
led - - O
to - - O
a - - O
dramatic - - O
loss - - O
of - - O
recognition - - O
; - - O
alpha - - O
chain - - O
substitution - - O
had - - O
a - - O
less - - O
marked - - O
effect - - O
. - - O

In - - O
contrast - - O
to - - O
the - - O
selective - - O
expression - - O
of - - O
the - - O
receptor - - O
, - - O
FL - - B-MUT
expression - - O
was - - O
detected - - O
in - - O
90-100% - - O
of - - O
the - - O
various - - O
cell - - O
types - - O
of - - O
leukemia - - O
cell - - O
lines - - O
from - - O
all - - O
hematopoietic - - O
cell - - O
lineages - - O
. - - O

Antibodies - - O
to - - O
the - - O
human - - B-MUT
PTS1R - - I-MUT
recognize - - O
this - - O
protein - - O
in - - O
human - - O
, - - O
monkey - - O
, - - O
rat - - O
, - - O
and - - O
hamster - - O
cells - - O
. - - O

The - - O
combination - - O
of - - O
Pitx2 - - B-MUT
and - - O
another - - O
homeodomain - - B-MUT
protein - - I-MUT
, - - O
Pit-1 - - B-MUT
, - - O
yielded - - O
a - - O
synergistic - - O
55-fold - - O
activation - - O
of - - O
the - - O
prolactin - - B-MUT
promoter - - I-MUT
in - - O
transfection - - O
assays - - O
. - - O

Consistent - - O
with - - O
the - - O
specificity - - O
observed - - O
for - - O
the - - O
interaction - - O
of - - O
DmCKIIalpha - - B-MUT
with - - O
these - - O
bHLH - - B-MUT
proteins - - I-MUT
, - - O
sequence - - O
alignment - - O
suggests - - O
that - - O
only - - O
m5 - - B-MUT
, - - O
m7 - - B-MUT
, - - O
and - - O
m8 - - B-MUT
contain - - O
a - - O
consensus - - O
site - - O
for - - O
phosphorylation - - O
by - - O
CKII - - B-MUT
within - - O
a - - O
subdomain - - O
unique - - O
to - - O
these - - O
three - - O
proteins - - O
. - - O

The - - O
transcription - - O
start - - O
point - - O
of - - O
the - - O
proximal - - O
promoter - - O
aligns - - O
to - - O
that - - O
of - - O
mouse - - B-MUT
promoter - - I-MUT
P3 - - I-MUT
and - - O
lies - - O
within - - O
a - - O
conserved - - O
region - - O
of - - O
sequence - - O
. - - O

METHODS - - O
: - - O
One - - O
hundred - - O
fourteen - - O
consecutive - - O
patients - - O
( - - O
mean - - O
age - - O
61 - - O
years - - O
) - - O
with - - O
focal - - O
pancreatic - - O
masses - - O
, - - O
detected - - O
on - - O
CT - - O
, - - O
underwent - - O
EUS-FNA - - O
by - - O
using - - O
a - - O
linear-array - - O
echoendoscope - - O
and - - O
22-gauge - - O
needles - - O
. - - O

The - - O
phosphorylation - - O
efficiency - - O
is - - O
improved - - O
by - - O
increasing - - O
the - - O
number - - O
of - - O
N-terminal - - O
arginine - - O
residues - - O
and - - O
by - - O
moving - - O
the - - O
arginyl - - O
cluster - - O
one - - O
residue - - O
further - - O
away - - O
from - - O
the - - O
serine - - O
, - - O
the - - O
nonapeptide - - B-MUT
( - - I-MUT
Arg - - I-MUT
) - - I-MUT
4-Ala-Ala-Ser-Val-Ala - - I-MUT
being - - O
the - - O
best - - O
substrate - - O
among - - O
all - - O
the - - O
short - - O
peptides - - O
tested - - O
( - - O
Km - - O
= - - O
15 - - O
microM - - O
) - - O
. - - O

Here - - O
is - - O
presented - - O
the - - O
monitoring - - O
of - - O
the - - O
accidental - - O
spill - - O
on - - O
vertical - - O
distribution - - O
of - - O
heavy - - O
metals - - O
in - - O
the - - O
estuarine - - O
sediments - - O
. - - O

A - - O
mutant - - O
in - - O
the - - O
AAV - - O
terminal - - O
resolution - - O
site - - O
( - - O
trs - - O
) - - O
was - - O
defective - - O
for - - O
DNA - - O
replication - - O
in - - O
the - - O
in - - O
vitro - - O
assay - - O
. - - O

Analysis - - O
of - - O
homologous - - O
DNA - - O
sequences - - O
within - - O
the - - O
first - - O
intron - - O
of - - O
the - - O
mouse - - B-MUT
and - - I-MUT
human - - I-MUT
mts1 - - I-MUT
genes - - I-MUT
: - - O
kB-like - - B-MUT
site - - I-MUT
and - - O
microsatellite - - O
DNA - - O
. - - O

The - - O
medium - - O
chains - - O
of - - O
these - - O
complexes - - O
, - - O
mu1 - - B-MUT
and - - O
mu2 - - B-MUT
, - - O
have - - O
been - - O
implicated - - O
in - - O
two - - O
types - - O
of - - O
interaction - - O
: - - O
assembly - - O
with - - O
the - - O
beta1 - - B-MUT
and - - I-MUT
beta2 - - I-MUT
chains - - I-MUT
of - - O
the - - O
corresponding - - O
complexes - - O
and - - O
recognition - - O
of - - O
tyrosine-based - - O
sorting - - O
signals - - O
. - - O

The - - O
promoter - - O
was - - O
stimulated - - O
8-20-fold - - O
by - - O
phorbol - - O
esters - - O
accounting - - O
for - - O
the - - O
previously - - O
observed - - O
transcriptional - - O
activation - - O
of - - O
protein - - B-MUT
kinase - - I-MUT
C - - I-MUT
beta - - I-MUT
. - - O

The - - O
rats - - O
were - - O
used - - O
for - - O
the - - O
study - - O
of - - O
the - - O
effects - - O
of - - O
sepsis - - O
on - - O
the - - O
utilization - - O
of - - O
exogenous - - O
fat - - O
emulsion - - O
. - - O

Its - - O
interaction - - O
with - - O
RFX5 - - B-MUT
and - - O
RFXAP - - B-MUT
is - - O
essential - - O
for - - O
binding - - O
of - - O
the - - O
RFX - - B-MUT
complex - - I-MUT
to - - O
MHC-II - - B-MUT
promoters - - I-MUT
. - - O

In - - O
CV-1 - - O
cells - - O
, - - O
cotransfection - - O
of - - O
the - - O
retinoid - - B-MUT
and - - I-MUT
estrogen - - I-MUT
receptors - - I-MUT
led - - O
to - - O
mutual - - O
inhibition - - O
of - - O
the - - O
other's - - O
activity - - O
, - - O
while - - O
an - - O
RA-dependent - - O
inhibition - - O
of - - O
ER - - B-MUT
activity - - O
was - - O
observed - - O
in - - O
breast - - O
cancer - - O
cells - - O
. - - O

Thirty - - O
minutes - - O
of - - O
supine - - O
restraint - - O
decreased - - O
DOPAC - - O
concentrations - - O
in - - O
the - - O
median - - O
eminence - - O
of - - O
female - - O
rats - - O
that - - O
were - - O
not - - O
exposed - - O
to - - O
ether - - O
, - - O
and - - O
brief - - O
exposure - - O
to - - O
ether - - O
enhanced - - O
this - - O
effect - - O
. - - O

Constrictive - - O
pericarditis - - O
and - - O
pleuropulmonary - - O
disease - - O
linked - - O
to - - O
ergot - - O
dopamine - - O
agonist - - O
therapy - - O
( - - O
cabergoline - - O
) - - O
for - - O
Parkinson's - - O
disease - - O
. - - O

The - - O
first - - O
follow-up - - O
was - - O
at - - O
a - - O
nearly - - O
constant - - O
interval - - O
of - - O
5 - - O
. - - O
1 - - O
years - - O
in - - O
Caerphilly - - O
and - - O
3 - - O
. - - O
2 - - O
years - - O
in - - O
Speedwell - - O
; - - O
251 - - O
major - - O
IHD - - O
events - - O
had - - O
occurred - - O
. - - O

A - - O
transgenic - - O
complementation - - O
assay - - O
was - - O
used - - O
to - - O
test - - O
whether - - O
NIa - - B-MUT
supplied - - O
in - - O
trans - - O
could - - O
rescue - - O
amplification-defective - - O
viral - - O
genomes - - O
encoding - - O
altered - - O
NIa - - B-MUT
proteins - - I-MUT
. - - O

Chirality-glass - - O
and - - O
spin-glass - - O
correlations - - O
in - - O
the - - O
two-dimensional - - O
random-bond - - O
XY - - O
model - - O
. - - O

Initial - - O
results - - O
indicate - - O
that - - O
this - - O
23S - - B-MUT
pre-rRNA - - I-MUT
is - - O
the - - O
same - - O
as - - O
the - - O
species - - O
detected - - O
on - - O
depletion - - O
of - - O
the - - O
small - - B-MUT
nucleolar - - I-MUT
RNA-associated - - I-MUT
proteins - - I-MUT
NOP1 - - B-MUT
and - - O
GAR1 - - B-MUT
and - - O
in - - O
an - - O
snr10 - - B-MUT
mutant - - I-MUT
strain - - O
. - - O

Complementary - - O
DNAs - - O
encompassing - - O
the - - O
coat - - B-MUT
protein - - I-MUT
coding - - O
and - - O
adjacent - - O
regions - - O
of - - O
Agropyron - - O
mosaic - - O
virus - - O
( - - O
AgMV - - O
) - - O
and - - O
Hordeum - - O
mosaic - - O
virus - - O
( - - O
HoMV - - O
) - - O
were - - O
cloned - - O
and - - O
sequenced - - O
. - - O

To - - O
understand - - O
further - - O
the - - O
expression - - O
and - - O
regulation - - O
of - - O
the - - O
V1aR - - B-MUT
, - - O
we - - O
now - - O
describe - - O
the - - O
genomic - - O
characteristics - - O
, - - O
tissue - - O
expression - - O
, - - O
chromosomal - - O
localization - - O
, - - O
and - - O
regional - - O
mapping - - O
of - - O
the - - O
human - - B-MUT
V1aR - - I-MUT
gene - - I-MUT
, - - O
AVPR1A - - B-MUT
. - - O

Vaccinia - - O
virus-expressed - - O
, - - O
purified - - O
full-length - - B-MUT
HPV-16 - - I-MUT
and - - I-MUT
BPV-1 - - I-MUT
E2 - - I-MUT
proteins - - I-MUT
bound - - O
a - - O
consensus - - O
E2 - - B-MUT
site - - I-MUT
with - - O
high - - O
specific - - O
affinities - - O
( - - O
Kd - - O
= - - O
approximately - - O
10 - - O
( - - O
-9 - - O
) - - O
M - - O
) - - O
and - - O
stimulated - - O
in - - O
vitro - - O
transcription - - O
up - - O
to - - O
six- - - O
to - - O
eightfold - - O
. - - O

Genes - - O
for - - O
ocs - - B-MUT
element - - I-MUT
binding - - I-MUT
factors - - I-MUT
( - - O
OBFs - - B-MUT
) - - O
, - - O
belonging - - O
to - - O
a - - O
specific - - O
class - - O
of - - O
basic-region - - B-MUT
leucine - - I-MUT
zipper - - I-MUT
( - - I-MUT
bZIP - - I-MUT
) - - I-MUT
transcription - - I-MUT
factors - - I-MUT
, - - O
have - - O
been - - O
isolated - - O
in - - O
a - - O
number - - O
of - - O
plants - - O
. - - O

Interestingly - - O
, - - O
highly - - O
charged - - O
residues - - O
were - - O
abundantly - - O
possessed - - O
in - - O
the - - O
carboxy-terminal - - O
part - - O
of - - O
the - - O
MDV2 - - B-MUT
UL10 - - I-MUT
protein - - I-MUT
. - - O

By - - O
using - - O
lambda - - O
gt11 - - O
expression - - O
cloning - - O
with - - O
oligonucleotides - - O
corresponding - - O
to - - O
the - - O
human - - O
immunodeficiency - - O
virus - - O
1 - - O
TATA - - O
element - - O
, - - O
we - - O
report - - O
the - - O
identification - - O
of - - O
a - - O
cellular - - O
protein - - O
with - - O
a - - O
calculated - - O
molecular - - O
mass - - O
of - - O
123 - - O
kDa - - O
that - - O
we - - O
designate - - O
TATA - - B-MUT
element - - I-MUT
modulatory - - I-MUT
factor - - I-MUT
( - - O
TMF - - B-MUT
) - - O
. - - O

We - - O
show - - O
here - - O
that - - O
RA - - O
and - - O
E1A - - B-MUT
induce - - O
phosphorylation - - O
of - - O
the - - O
E1A-associated - - B-MUT
300 - - I-MUT
kDa - - I-MUT
protein - - I-MUT
( - - O
p300 - - B-MUT
) - - O
during - - O
the - - O
differentiation - - O
of - - O
F9 - - O
cells - - O
. - - O

Pathophysiology - - O
of - - O
bone - - O
loss - - O
in - - O
castrated - - O
animals - - O
. - - O

A - - O
strong - - O
correlation - - O
exists - - O
between - - O
the - - O
numbers - - O
of - - O
CFU-GM - - O
transfused - - O
and - - O
the - - O
rate - - O
of - - O
granulocytes - - O
and - - O
platelets - - O
recovery - - O
. - - O

Because - - O
of - - O
serious - - O
infections - - O
( - - O
fever - - O
larger - - O
than - - O
or - - O
equal - - O
to - - O
101 - - O
degrees - - O
F - - O
. - - O
granulocytes - - O
less - - O
than - - O
1 - - O
, - - O
000 - - O
mm - - O
, - - O
3 - - O
and - - O
hospitalization - - O
) - - O
and - - O
1 - - O
drug - - O
death - - O
in - - O
the - - O
first - - O
4 - - O
patients - - O
, - - O
oral - - O
calcium - - O
leucovorin - - O
, - - O
20 - - O
to - - O
30 - - O
mg - - O
m2 - - O
orally - - O
, - - O
was - - O
given - - O
2 - - O
days - - O
after - - O
methotrexate - - O
in - - O
subsequent - - O
treatment - - O
cycles - - O
. - - O

Of - - O
the - - O
six - - O
cases - - O
of - - O
malignant - - O
polyposis - - O
, - - O
none - - O
were - - O
identified - - O
using - - O
CT - - O
, - - O
and - - O
only - - O
two - - O
were - - O
diagnosed - - O
by - - O
small - - O
bowel - - O
follow-through - - O
. - - O

Successful - - O
interaction - - O
of - - O
ARF - - B-MUT
and - - O
PKC-alpha - - B-MUT
with - - O
PLD1 - - B-MUT
was - - O
not - - O
achieved - - O
, - - O
but - - O
a - - O
C-terminal - - O
fragment - - O
of - - O
human - - B-MUT
PLD1 - - I-MUT
( - - O
denoted - - O
"D4" - - O
) - - O
interacted - - O
with - - O
the - - O
active - - O
mutant - - O
of - - O
RhoA - - B-MUT
, - - O
RhoAVal-14 - - B-MUT
. - - O

Repetitive - - O
sequences - - O
are - - O
present - - O
in - - O
at - - O
least - - O
three - - O
introns - - O
of - - O
the - - O
cytochrome - - B-MUT
P-450PBc2 - - I-MUT
gene - - I-MUT
, - - O
but - - O
not - - O
in - - O
exons - - O
or - - O
the - - O
5'-flanking - - O
region - - O
. - - O

( - - O
GUT - - O
) - - O
Sera - - O
of - - O
30 - - O
montoux - - O
negative - - O
healthy - - O
adults - - O
( - - O
age - - O
sex - - O
matched - - O
) - - O
were - - O
taken - - O
as - - O
control - - O
by - - O
detecting - - O
IgG - - O
anti - - B-MUT
bodies - - I-MUT
to - - I-MUT
A60 - - O
antigen - - B-MUT
. - - I-MUT

Using - - O
immunolocalization - - O
, - - O
we - - O
observe - - O
that - - O
ACE3 - - B-MUT
, - - O
a - - O
440-bp - - O
chorion - - O
element - - O
that - - O
contains - - O
information - - O
sufficient - - O
to - - O
drive - - O
amplification - - O
, - - O
directs - - O
DmORC - - O
localization - - O
in - - O
follicle - - O
cells - - O
. - - O

E2F - - B-MUT
activity - - O
is - - O
regulated - - O
in - - O
part - - O
by - - O
the - - O
retinoblastoma - - B-MUT
family - - I-MUT
of - - I-MUT
tumor - - I-MUT
suppressor - - I-MUT
proteins - - I-MUT
. - - O

The - - O
rate-decreasing - - O
effects - - O
of - - O
morphine - - O
and - - O
U50488 - - O
were - - O
reversed - - O
completely - - O
by - - O
a - - O
0 - - O
. - - O
01 - - O
and - - O
1 - - O
. - - O
0 - - O
mg - - O
kg - - O
dose - - O
of - - O
naloxone - - O
, - - O
respectively - - O
. - - O

Demonstration - - O
of - - O
fine - - O
structure - - O
of - - O
the - - O
guinea - - O
pig - - O
organ - - O
of - - O
Corti - - O
after - - O
electron - - O
microscopic - - O
silver - - O
staining - - O
. - - O

A - - O
cDNA - - O
encoding - - O
the - - O
NF-4FB - - B-MUT
enhancer - - I-MUT
binding - - I-MUT
protein - - I-MUT
has - - O
been - - O
cloned - - O
by - - O
screening - - O
a - - O
lambda - - O
gt11 - - O
cDNA - - O
library - - O
with - - O
a - - O
rabiolabelled - - O
oligonucleotide - - O
corresponding - - O
to - - O
the - - O
NF-4FB - - B-MUT
recognition - - I-MUT
sequence - - I-MUT
. - - O

The - - O
aim - - O
of - - O
the - - O
study - - O
was - - O
to - - O
correlate - - O
the - - O
responsiveness - - O
to - - O
bronchoprovocation - - O
with - - O
methacholine - - O
in - - O
subjects - - O
a - - O
with - - O
allergic - - O
rhinitis - - O
during - - O
and - - O
out - - O
of - - O
the - - O
pollen - - O
season - - O
with - - O
total - - O
serum - - O
IgE - - B-MUT
and - - O
blood - - O
eosinophils - - O
. - - O

The - - O
Siglecs - - B-MUT
are - - O
a - - O
subfamily - - O
of - - O
I-type - - B-MUT
lectins - - I-MUT
( - - O
immunoglobulin - - B-MUT
superfamily - - I-MUT
proteins - - I-MUT
that - - O
bind - - O
sugars - - O
) - - O
that - - O
specifically - - O
recognize - - O
sialic - - O
acids - - O
. - - O

The - - O
interaction - - O
between - - O
piroxicam - - O
and - - O
poloxamer - - O
was - - O
studied - - O
by - - O
x-ray - - O
diffractometry - - O
( - - O
XRD - - O
) - - O
, - - O
infrared - - O
( - - O
IR - - O
) - - O
spectroscopy - - O
and - - O
differential - - O
thermal - - O
analysis - - O
( - - O
DTA - - O
) - - O
with - - O
a - - O
solid - - O
dispersion - - O
, - - O
coprecipitate - - O
, - - O
or - - O
physical - - O
mixture - - O
. - - O

Immunelectrophoretic - - O
pattern - - O
of - - O
Wassermann - - O
reagin - - O
and - - O
comparison - - O
of - - O
the - - O
appearance - - O
time - - O
between - - O
RPCF - - B-MUT
and - - O
FTA - - B-MUT
antibodies - - I-MUT
. - - O

Reactive - - O
lymphoid - - O
hyperplasia - - O
was - - O
found - - O
in - - O
15 - - O
cases - - O
, - - O
2 - - O
cases - - O
had - - O
angiofollicular - - O
lymphoid - - O
hyperplasia - - O
or - - O
Castleman's - - O
disease - - O
, - - O
atypical - - O
lymphoid - - O
hyperplasia - - O
suggestive - - O
of - - O
malignant - - O
lymphoma - - O
was - - O
observed - - O
in - - O
3 - - O
cases - - O
, - - O
and - - O
malignant - - O
lymphoma - - O
was - - O
diagnosed - - O
in - - O
the - - O
remaining - - O
4 - - O
cases - - O
. - - O

In - - O
this - - O
report - - O
, - - O
we - - O
investigate - - O
the - - O
mechanism - - O
underlying - - O
Ras - - B-MUT
activation - - O
upon - - O
stimulation - - O
of - - O
these - - O
two - - O
types - - O
of - - O
receptors - - O
in - - O
hematopoietic - - O
cells - - O
. - - O

The - - O
distribution - - O
phase - - O
is - - O
followed - - O
by - - O
an - - O
elimination - - O
phase - - O
with - - O
a - - O
much - - O
longer - - O
half-life - - O
( - - O
mean - - O
value - - O
375 - - O
min - - O
) - - O
and - - O
a - - O
volume - - O
of - - O
distribution - - O
of - - O
approximately - - O
200-400 - - O
l - - O
. - - O

OKA - - O
and - - O
calyculin - - O
A - - O
do - - O
not - - O
decrease - - O
OCFRE - - B-MUT
DNA-protein - - O
interactions - - O
, - - O
suggesting - - O
that - - O
important - - O
protein-protein - - O
interactions - - O
are - - O
phosphatase - - O
regulated - - O
. - - O

In - - O
addition - - O
, - - O
media - - O
containing - - O
F - - B-MUT
beta - - I-MUT
alpha - - I-MUT
CG - - I-MUT
beta - - I-MUT
displayed - - I-MUT
high-affinity - - O
binding - - O
to - - O
both - - O
CG - - O
and - - B-MUT
FSH - - O
receptors - - B-MUT
. - - I-MUT

Antisense - - O
transcription - - O
of - - O
a - - O
murine - - B-MUT
FGFR-3 - - I-MUT
psuedogene - - I-MUT
during - - O
fetal - - O
developement - - O
. - - O

Within - - O
the - - O
Strep - - O
. - - O
mutans - - O
group - - O
there - - O
was - - O
a - - O
highly-significant - - O
difference - - O
between - - O
Strep - - O
. - - O
mutans - - O
Strep - - O
. - - O
cricetus - - O
( - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
01 - - O
) - - O
with - - O
respect - - O
to - - O
mean - - O
clump - - O
size - - O
. - - O

Here - - O
we - - O
review - - O
progress - - O
to - - O
date - - O
in - - O
this - - O
area - - O
. - - O

Both - - O
BG - - O
and - - O
IRI - - B-MUT
concentrations - - O
during - - O
the - - O
OGTT - - O
were - - O
the - - O
lowest - - O
in - - O
body - - O
builders - - O
, - - O
medium - - O
in - - O
controls - - O
, - - O
and - - O
the - - O
highest - - O
in - - O
obese - - O
men - - O
. - - O

Hypersplenism - - O
. - - O

We - - O
report - - O
the - - O
construction - - O
of - - O
an - - O
approximately - - O
1 - - O
. - - O
7-Mb - - O
sequence-ready - - O
YAC - - O
BAC - - O
clone - - O
contig - - O
of - - O
8p22-p23 - - O
. - - O

In - - O
the - - O
ePTFE - - O
specimens - - O
, - - O
tissue - - O
coverage - - O
had - - O
increased - - O
. - - O

A - - O
decrease - - O
of - - O
the - - O
lysozyme - - B-MUT
activity - - O
coincided - - O
with - - O
the - - O
clinical - - O
improvement - - O
of - - O
the - - O
bacterial - - O
meningitis - - O
. - - O

In - - O
this - - O
study - - O
, - - O
we - - O
elucidate - - O
signaling - - O
pathways - - O
induced - - O
by - - O
photodynamic - - O
therapy - - O
( - - O
PDT - - O
) - - O
with - - O
hypericin - - O
. - - O

In - - O
situ - - O
copper-phenanthroline - - O
footprinting - - O
of - - O
individual - - O
gel - - O
shift - - O
assembly - - O
intermediates - - O
shows - - O
that - - O
on - - O
the - - O
302-nucleotide - - O
G4oric - - O
, - - O
the - - O
first - - O
two - - O
SSB - - B-MUT
tetramers - - I-MUT
assemble - - O
at - - O
random - - O
, - - O
but - - O
the - - O
addition - - O
of - - O
more - - O
SSB - - B-MUT
tetramers - - I-MUT
results - - O
in - - O
formation - - O
of - - O
a - - O
unique - - O
structure - - O
. - - O

The - - O
distribution - - O
of - - O
patients - - O
was - - O
as - - O
follows - - O
: - - O
group - - O
1--complex - - O
gamma-therapy - - O
( - - O
55 - - O
cases - - O
) - - O
, - - O
group - - O
2--complex - - O
gamma-therapy - - O
plus - - O
iliac - - O
lymphadenectomy - - O
( - - O
50 - - O
cases - - O
) - - O
and - - O
group - - O
3--complex - - O
radiation - - O
treatment - - O
with - - O
megavolt - - O
bremsstrahlung - - O
beam - - O
from - - O
the - - O
luc - - O
type - - O
installation - - O
and - - O
iliac - - O
lymphadenectomy - - O
( - - O
50 - - O
cases - - O
) - - O
. - - O

Cellular - - B-MUT
Csk - - I-MUT
was - - O
associated - - O
with - - O
several - - O
phosphoproteins - - O
, - - O
some - - O
of - - O
which - - O
were - - O
interacting - - O
with - - O
the - - O
Csk - - B-MUT
SH2 - - B-MUT
domain - - I-MUT
. - - O

Previous - - O
studies - - O
characterized - - O
a - - O
cytokine-inducible - - O
, - - O
functional - - O
nuclear - - B-MUT
factor - - I-MUT
( - - I-MUT
NF - - I-MUT
) - - I-MUT
-kappaB - - I-MUT
consensus - - I-MUT
element - - I-MUT
in - - O
the - - O
immediate - - O
5' - - O
regulatory - - O
region - - O
of - - O
the - - O
MGSA - - B-MUT
GRO-alpha - - I-MUT
gene - - I-MUT
at - - I-MUT
-78 - - O
bp - - O
. - - O

Enhancer - - O
activity - - O
requires - - O
both - - O
the - - O
AP-1 - - B-MUT
site - - I-MUT
and - - O
these - - O
adjacent - - O
sequences - - O
. - - O

A - - O
significant - - O
association - - O
between - - O
a - - O
family - - O
history - - O
and - - O
a - - O
higher - - O
urinary - - O
pH - - O
was - - O
observed - - O
among - - O
the - - O
female - - O
calcium - - O
stone - - O
patients - - O
. - - O

Successful - - O
treatment - - O
of - - O
candidiasis - - O
with - - O
transfer - - O
factor - - O
. - - O

Disturbances - - O
of - - O
placental - - O
maturation - - O
, - - O
2 - - O
. - - O

Between - - O
acoR - - B-MUT
and - - O
acoXABC - - B-MUT
, - - O
two - - O
different - - O
types - - O
of - - O
sequences - - O
with - - O
dual - - O
rotational - - O
symmetry - - O
[ - - O
CAC- - - O
( - - O
N11 - - O
to - - O
N18 - - O
) - - O
-GTG - - O
and - - O
TGT- - - O
( - - O
N10 - - O
to - - O
N14 - - O
) - - O
-ACA - - O
] - - O
were - - O
found - - O
; - - O
these - - O
sequences - - O
are - - O
similar - - O
to - - O
NtrC - - B-MUT
and - - O
NifA - - B-MUT
upstream - - I-MUT
activator - - I-MUT
sequences - - I-MUT
, - - O
respectively - - O
. - - O

Workload - - O
, - - O
UAPs - - O
, - - O
and - - O
you - - O
. - - O

This - - O
unique - - O
location - - O
of - - O
cavernous - - O
malformation - - O
is - - O
associated - - O
with - - O
a - - O
risk - - O
of - - O
permanent - - O
loss - - O
of - - O
the - - O
vision - - O
. - - O

Results - - O
for - - O
men - - O
who - - O
drank - - O
up - - O
to - - O
two - - O
drinks - - O
per - - O
day - - O
suggest - - O
that - - O
if - - O
the - - O
dependence - - O
criteria - - O
were - - O
invalid - - O
, - - O
reductions - - O
in - - O
the - - O
prevalence - - O
of - - O
specific - - O
indicators - - O
of - - O
alcohol - - O
dependence - - O
would - - O
range - - O
from - - O
0 - - O
. - - O
3% - - O
to - - O
5 - - O
. - - O
2% - - O
. - - O

The - - O
complete - - O
response - - O
( - - O
CR - - O
) - - O
rate - - O
was - - O
34% - - O
in - - O
the - - O
CODE - - O
with - - O
rhG-CSF - - B-MUT
group - - O
and - - O
23% - - O
in - - O
the - - O
CODE - - O
alone - - O
group - - O
; - - O
the - - O
median - - O
survival - - O
was - - O
59 - - O
and - - O
32 - - O
weeks - - O
, - - O
respectively - - O
, - - O
in - - O
these - - O
groups - - O
( - - O
P - - O
= - - O
0 - - O
. - - O
004 - - O
) - - O
. - - O

The - - O
data - - O
further - - O
indicate - - O
that - - O
the - - O
IL-7R - - B-MUT
alpha - - I-MUT
chains - - I-MUT
are - - O
directly - - O
involved - - O
in - - O
the - - O
activation - - O
of - - O
JAKs - - B-MUT
and - - O
STATs - - B-MUT
and - - O
have - - O
a - - O
major - - O
role - - O
in - - O
proliferative - - O
signaling - - O
in - - O
precursor - - O
B - - O
cells - - O
. - - O

Chromatin - - O
repression - - O
of - - O
these - - O
replacement - - O
genes - - O
would - - O
be - - O
avoided - - O
, - - O
consistent - - O
with - - O
the - - O
high - - O
, - - O
constitutive - - O
expression - - O
of - - O
replacement - - O
H3 - - B-MUT
histone - - I-MUT
genes - - I-MUT
in - - O
plants - - O
. - - O

The - - O
mutants - - O
were - - O
obtained - - O
by - - O
substitution - - O
into - - O
a - - O
molecular - - O
clone - - O
of - - O
M-MuLV - - O
DNA - - O
by - - O
DNA - - O
from - - O
two - - O
acutely - - O
transforming - - O
viruses - - O
, - - O
Ableson - - O
MuLV - - O
( - - O
Ab-MuLV - - O
) - - O
and - - O
Moloney - - O
murine - - O
sarcoma - - O
virus - - O
( - - O
M-MSV - - O
) - - O
. - - O

Plasmids - - O
pAMS12 - - O
, - - O
pAMS13 - - O
and - - O
pAMS14 - - O
were - - O
transformed - - O
into - - O
a - - O
laboratory - - O
strain - - O
of - - O
Saccharomyces - - O
cerevisiae - - O
, - - O
whereas - - O
pAMS15 - - O
was - - O
stably - - O
introduced - - O
into - - O
two - - O
commercial - - O
wine - - O
yeast - - O
strains - - O
. - - O

Within - - O
Stage - - O
IA - - O
, - - O
141 - - O
patients - - O
had - - O
well - - O
differentiated - - O
tumor - - O
( - - O
G1 - - O
) - - O
, - - O
20 - - O
had - - O
moderately - - O
well - - O
differentiated - - O
tumor - - O
( - - O
G2 - - O
) - - O
, - - O
and - - O
12 - - O
patients - - O
had - - O
poorly - - O
differentiated - - O
( - - O
G3 - - O
) - - O
. - - O

Complete - - O
recovery - - O
of - - O
liver - - O
function - - O
after - - O
this - - O
surgery - - O
tended - - O
to - - O
be - - O
slow - - O
. - - O

USF - - B-MUT
synthesized - - O
in - - O
an - - O
in - - O
vitro - - O
transcription - - O
and - - O
translation - - O
system - - O
also - - O
binds - - O
to - - O
the - - O
ADH - - B-MUT
promoter - - I-MUT
as - - O
well - - O
as - - O
to - - O
the - - O
MLP - - O
. - - O

In - - O
lean - - O
mice - - O
, - - O
the - - O
fat - - O
water - - O
intensity - - O
ratio - - O
was - - O
about - - O
1 - - O
: - - O
4 - - O
, - - O
about - - O
half - - O
that - - O
in - - O
normal - - O
mice - - O
. - - O

MATERIAL - - O
AND - - O
METHODS - - O
: - - O
The - - O
authors - - O
analyzed - - O
41 - - O
persons - - O
formerly - - O
submitted - - O
to - - O
surgery - - O
( - - O
after - - O
8 - - O
years - - O
and - - O
4 - - O
months - - O
, - - O
as - - O
a - - O
mean - - O
) - - O
, - - O
31 - - O
to - - O
highly - - O
selective - - O
vagotomy - - O
, - - O
and - - O
10 - - O
to - - O
truncal - - O
or - - O
selective - - O
vagotomy - - O
plus - - O
gastroduodenal - - O
drainage - - O
. - - O

Ultimate - - O
strengthes - - O
seem - - O
to - - O
be - - O
reached - - O
for - - O
cast - - O
cobalt - - O
alloys - - O
, - - O
whereas - - O
titanium - - O
alloys - - O
, - - O
such - - O
as - - O
Ta - - O
6 - - O
V - - O
, - - O
present - - O
very - - O
high - - O
fatigue - - O
limit - - O
under - - O
corrosion - - O
. - - O

Low-grade - - O
gastric - - O
MALT - - O
lymphoma - - O
and - - O
helicobacter - - O
heilmannii - - O
( - - O
Gastrospirillum - - O
hominis - - O
. - - O

NOT4 - - B-MUT
interacts - - O
with - - O
NOT1 - - B-MUT
and - - O
NOT3 - - B-MUT
in - - O
the - - O
two-hybrid - - O
assay - - O
, - - O
and - - O
overexpression - - O
of - - O
NOT3 - - B-MUT
or - - O
NOT4 - - B-MUT
suppresses - - O
not1 - - B-MUT
and - - O
not2 - - B-MUT
mutations - - O
. - - O

Six - - O
patients - - O
with - - O
human - - O
T-cell - - O
lymphotropic - - O
virus - - O
type - - O
I - - O
( - - O
HTLV-I - - O
) - - O
-associated - - O
myelopathy - - O
( - - O
HAM - - O
) - - O
were - - O
studied - - O
by - - O
electrophysiologic - - O
methods - - O
. - - O

The - - O
naltrexone - - O
lofexidine - - O
combination - - O
was - - O
associated - - O
with - - O
a - - O
more - - O
rapid - - O
resolution - - O
of - - O
the - - O
opiate - - O
withdrawal - - O
syndrome - - O
than - - O
a - - O
7-day - - O
lofexidine-only - - O
treatment - - O
schedule - - O
, - - O
without - - O
substantial - - O
increases - - O
in - - O
withdrawal - - O
symptoms - - O
or - - O
hypotensive - - O
side-effects - - O
. - - O

PBSX - - O
is - - O
induced - - O
by - - O
agents - - O
which - - O
elicit - - O
the - - O
SOS - - O
response - - O
. - - O

Regulation - - O
of - - O
embryonic - - O
growth - - O
and - - O
lysosomal - - O
targeting - - O
by - - O
the - - O
imprinted - - O
Igf2 - - B-MUT
Mpr - - O
gene - - B-MUT
. - - O

Five - - O
control - - O
subjects - - O
with - - O
COPD - - O
, - - O
who - - O
performed - - O
the - - O
same - - O
sequence - - O
of - - O
tests - - O
without - - O
breathing - - O
30% - - O
O2 - - O
, - - O
showed - - O
no - - O
change - - O
in - - O
flow - - O
rates - - O
or - - O
density - - O
dependence - - O
. - - O

The - - O
protein - - O
was - - O
associated - - O
with - - O
purified - - O
vaccinia - - O
virus - - O
particles - - O
and - - O
with - - O
membranes - - O
of - - O
immature - - O
and - - O
mature - - O
virions - - O
that - - O
were - - O
visualized - - O
by - - O
electron - - O
microscopy - - O
of - - O
infected - - O
cells - - O
. - - O

Both - - O
factors - - O
demonstrated - - O
significant - - O
correlations - - O
with - - O
rCBF - - O
in - - O
the - - O
medial - - O
prefrontal - - O
cortex - - O
and - - O
frontal - - O
polar - - O
cortex - - O
while - - O
for - - O
each - - O
factor - - O
there - - O
were - - O
also - - O
unique - - O
patterns - - O
of - - O
correlations - - O
with - - O
posterior - - O
brain - - O
regions - - O
. - - O

Sudomoina - - O
, - - O
A - - O
. - - O

An - - O
exon - - O
that - - O
prevents - - O
transport - - O
of - - O
a - - O
mature - - O
mRNA - - O
. - - O

The - - O
results - - O
revealed - - O
increased - - O
blood - - O
lead - - O
level - - O
associated - - O
with - - O
decreased - - O
blood - - B-MUT
haemoglobin - - I-MUT
and - - O
increased - - O
urinary - - O
excretion - - O
of - - O
delta - - O
amino - - O
levulinic - - O
acid - - O
. - - O

An - - O
in - - O
vivo - - O
ZAP-70 - - B-MUT
substrate - - O
, - - O
SLP-76 - - B-MUT
, - - O
implicated - - O
in - - O
Erk - - B-MUT
activation - - O
, - - O
also - - O
became - - O
rapidly - - O
tyrosine-phosphorylated - - O
in - - O
Jurkat - - O
cells - - O
, - - O
but - - O
not - - O
in - - O
P116 - - O
cells - - O
, - - O
upon - - O
treatment - - O
with - - O
H2O2 - - O
. - - O

Promoter - - O
activity - - O
was - - O
dose-dependently - - O
inhibited - - O
by - - O
cotransfection - - O
with - - O
either - - O
ras - - B-MUT
or - - O
mos - - B-MUT
oncogenes - - I-MUT
, - - O
but - - O
oncogene - - O
inhibition - - O
was - - O
reversed - - O
and - - O
the - - O
overall - - O
activity - - O
increased - - O
when - - O
cells - - O
were - - O
treated - - O
with - - O
the - - O
MAP - - B-MUT
kinase - - I-MUT
kinase - - I-MUT
( - - O
MKK - - B-MUT
) - - O
inhibitor - - O
PD98059 - - O
. - - O

Bone - - O
and - - O
bones - - O
. - - O

In - - O
earlier - - O
studies - - O
we - - O
identified - - O
several - - O
regulatory - - O
elements - - O
that - - O
control - - O
transcriptional - - O
activation - - O
and - - O
aerobic - - O
repression - - O
of - - O
one - - O
of - - O
these - - O
genes - - O
, - - O
COX5b - - B-MUT
. - - O

Furthermore - - O
, - - O
we - - O
have - - O
identified - - O
a - - O
soluble - - O
form - - O
of - - O
ERp57 - - B-MUT
GRP58 - - I-MUT
by - - I-MUT
Western - - O
blotting - - O
and - - O
biosynthetic - - O
labeling - - O
. - - O

The - - O
models - - O
accurately - - O
localized - - O
the - - O
common - - O
boundaries - - O
between - - O
the - - O
PBB - - O
and - - O
CN - - O
. - - O

This - - O
experiment - - O
was - - O
conducted - - O
to - - O
determine - - O
if - - O
the - - O
sex - - O
or - - O
actual - - O
egg - - O
production - - O
was - - O
the - - O
important - - O
factor - - O
. - - O
( - - O
ABSTRACT - - O
TRUNCATED - - O
AT - - O
250 - - O
WORDS - - O
) - - O

Respiratory - - O
adaptation - - O
to - - O
chronic - - O
hypoxia - - O
in - - O
newborn - - O
rats - - O
. - - O

Collectively - - O
, - - O
these - - O
and - - O
previously - - O
published - - O
data - - O
suggest - - O
a - - O
model - - O
where - - O
NS1 - - B-MUT
recruits - - O
eIF4GI - - B-MUT
specifically - - O
to - - O
the - - O
5' - - O
untranslated - - O
region - - O
( - - O
5' - - O
UTR - - O
) - - O
of - - O
the - - O
viral - - O
mRNA - - O
, - - O
allowing - - O
for - - O
the - - O
preferential - - O
translation - - O
of - - O
the - - O
influenza - - O
virus - - O
messengers - - O
. - - O

Today - - O
there - - O
is - - O
no - - O
doubt - - O
that - - O
elevated - - O
plasma - - O
cholesterol - - O
levels - - O
should - - O
be - - O
lowered - - O
first - - O
by - - O
dietary - - O
modification - - O
even - - O
in - - O
early - - O
childhood - - O
, - - O
beginning - - O
at - - O
the - - O
age - - O
of - - O
two - - O
years - - O
. - - O

HEED - - B-MUT
was - - O
found - - O
to - - O
bind - - O
to - - O
MA - - B-MUT
protein - - I-MUT
in - - O
vitro - - O
, - - O
as - - O
efficiently - - O
as - - O
in - - O
vivo - - O
in - - O
yeast - - O
cells - - O
. - - O

Patients - - O
were - - O
randomly - - O
assigned - - O
to - - O
treatment - - O
with - - O
the - - O
ACE - - B-MUT
inhibitor - - O
perindopril - - O
( - - O
and - - O
the - - O
diuretic - - O
indapamide - - O
for - - O
those - - O
with - - O
no - - O
definite - - O
indication - - O
for - - O
or - - O
contraindication - - O
to - - O
treatment - - O
with - - O
a - - O
diuretic - - O
) - - O
or - - O
matching - - O
placebo - - O
( - - O
s - - O
) - - O
. - - O

I - - O
. - - O

Northern - - O
analysis - - O
of - - O
RNA - - O
samples - - O
isolated - - O
from - - O
ammonium-grown - - O
cultures - - O
of - - O
the - - O
ntcA - - B-MUT
mutant - - I-MUT
showed - - O
reduced - - O
amounts - - O
of - - O
glnA - - B-MUT
message - - I-MUT
and - - O
the - - O
absence - - O
of - - O
a - - O
1 - - O
. - - O
7-kb - - O
transcript - - O
. - - O

RVR - - B-MUT
'loss - - O
of - - O
function' - - O
studies - - O
by - - O
constitutive - - O
over-expression - - O
of - - O
a - - O
dominant - - O
negative - - O
RVR - - B-MUT
delta - - I-MUT
E - - I-MUT
resulted - - O
in - - O
increased - - O
levels - - O
of - - O
p21Cip1 - - B-MUT
Waf1 - - O
and - - B-MUT
myogenin - - O
mRNAs - - B-MUT
after - - I-MUT
serum - - O
withdrawal - - O
. - - O

Consistent - - O
with - - O
this - - O
, - - O
purified - - O
Dlk - - B-MUT
phosphorylated - - O
core - - O
histones - - B-MUT
H3 - - I-MUT
, - - O
H2A - - B-MUT
and - - O
H4 - - B-MUT
as - - O
exogenous - - O
substrates - - O
and - - O
endogenous - - O
histone - - B-MUT
H3 - - I-MUT
in - - O
kinase - - O
assays - - O
with - - O
nuclear - - O
extracts - - O
. - - O

The - - O
effects - - O
of - - O
taloximine - - O
and - - O
aminophylline - - O
on - - O
isolated - - O
human - - O
smooth - - O
muscle - - O
. - - O

In - - O
a - - O
highly - - O
select - - O
group - - O
of - - O
stable - - O
hypertensive - - O
patients - - O
, - - O
we - - O
have - - O
assessed - - O
the - - O
strength - - O
of - - O
association - - O
between - - O
various - - O
blood - - O
pressure - - O
measurements - - O
( - - O
24 - - O
h - - O
average - - O
automated - - O
ambulatory - - O
blood - - O
pressure - - O
, - - O
4 - - O
h - - O
automated - - O
ambulatory - - O
morning - - O
average - - O
blood - - O
pressure - - O
, - - O
multiple - - O
office - - O
visit - - O
average - - O
blood - - O
pressure - - O
, - - O
and - - O
a - - O
single - - O
office - - O
visit - - O
average - - O
blood - - O
pressure - - O
) - - O
and - - O
various - - O
echocardiographic - - O
indices - - O
of - - O
hypertensive - - O
cardiac - - O
target - - O
organ - - O
damage - - O
( - - O
left - - O
atrial - - O
diameter - - O
, - - O
left - - O
ventricular - - O
end - - O
diastolic - - O
diameter - - O
, - - O
posterior - - O
wall - - O
thickness - - O
, - - O
combined - - O
wall - - O
thickness - - O
, - - O
relative - - O
wall - - O
thickness - - O
, - - O
left - - O
ventricular - - O
mass - - O
and - - O
mass - - O
index - - O
, - - O
and - - O
combined - - O
wall - - O
thickness - - O
left - - O
ventricular - - O
diastolic - - O
diameter - - O
ratio - - O
) - - O
. - - O

The - - O
structural - - O
gene - - O
encoding - - O
the - - O
novel - - O
lantibiotic - - O
epilancin - - B-MUT
K7 - - I-MUT
from - - O
Staphylococcus - - O
epidermidis - - O
K7 - - O
was - - O
cloned - - O
and - - O
its - - O
nucleotide - - O
sequence - - O
was - - O
determined - - O
. - - O

Overexpression - - O
of - - O
H411 - - B-MUT
cDNA - - I-MUT
in - - O
the - - O
RAW - - O
264 - - O
. - - O
7 - - O
macrophage - - O
cell - - O
line - - O
promoted - - O
an - - O
increased - - O
growth - - O
rate - - O
, - - O
suggesting - - O
that - - O
expression - - O
of - - O
H411 - - B-MUT
is - - O
part - - O
of - - O
the - - O
proliferative - - O
cell - - O
response - - O
to - - O
LPS - - O
. - - O

Number - - O
and - - O
size - - O
of - - O
the - - O
myelin - - O
structures - - O
in - - O
the - - O
pneumocytes - - O
typ - - O
II - - O
increased - - O
simultaneously - - O
. - - O

cDNA - - O
and - - O
structural - - O
organization - - O
of - - O
the - - O
gene - - B-MUT
Pole1 - - I-MUT
for - - O
the - - O
mouse - - B-MUT
DNA - - I-MUT
polymerase - - I-MUT
epsilon - - I-MUT
catalytic - - I-MUT
subunit - - I-MUT
. - - O

A - - O
transcription - - O
factor - - O
exclusion - - O
assay - - O
was - - O
used - - O
to - - O
show - - O
that - - O
the - - O
PCF1 - - B-MUT
mutation - - I-MUT
affects - - O
two - - O
distinct - - O
stages - - O
in - - O
transcription - - O
: - - O
one - - O
prior - - O
to - - O
and - - O
one - - O
after - - O
stable - - O
complex - - O
formation - - O
; - - O
and - - O
that - - O
these - - O
effects - - O
are - - O
mediated - - O
by - - O
a - - O
component - - O
of - - O
the - - O
stable - - O
complex - - O
. - - O

Efficacy - - O
was - - O
determined - - O
by - - O
responses - - O
to - - O
question - - O
3 - - O
( - - O
ability - - O
to - - O
achieve - - O
an - - O
erection - - O
) - - O
and - - O
question - - O
4 - - O
( - - O
ability - - O
to - - O
maintain - - O
an - - O
erection - - O
) - - O
of - - O
the - - O
15-item - - O
International - - O
Index - - O
of - - O
Erectile - - O
Function - - O
( - - O
IIEF - - O
) - - O
. - - O

The - - O
1489-base - - O
pair - - O
EFIA - - B-MUT
cDNA - - O
encodes - - O
a - - O
322-amino - - O
acid - - O
protein - - O
which - - O
is - - O
nearly - - O
identical - - O
to - - O
two - - O
previously - - O
described - - O
human - - O
DNA - - O
binding - - O
proteins - - O
. - - O

PRL - - B-MUT
receptor - - I-MUT
also - - O
activates - - O
SHP-2 - - B-MUT
, - - O
a - - O
cytosolic - - B-MUT
tyrosine - - I-MUT
phosphatase - - I-MUT
. - - O

Thirty-one - - O
age-matched - - O
, - - O
conscious - - O
, - - O
virgin - - O
, - - O
male - - O
Sprague-Dawley - - O
rats - - O
and - - O
spontaneously - - O
hypertensive - - O
rats - - O
( - - O
SHRs - - O
) - - O
were - - O
individually - - O
injected - - O
with - - O
a - - O
single - - O
subcutaneous - - O
dose - - O
of - - O
85 - - O
mg - - O
kg - - O
dl-isoproterenol - - O
to - - O
determine - - O
the - - O
degree - - O
and - - O
time - - O
course - - O
of - - O
drug-induced - - O
cardiac - - O
failure - - O
and - - O
functional - - O
recovery - - O
. - - O

Termination - - O
of - - O
induced - - O
VT - - O
on - - O
the - - O
first - - O
attempt - - O
was - - O
comparable - - O
with - - O
BV - - O
pacing - - O
( - - O
87 - - O
. - - O
4% - - O
) - - O
versus - - O
RV - - O
pacing - - O
( - - O
89 - - O
. - - O
6% - - O
) - - O
. - - O

We - - O
mapped - - O
two - - O
overlapping - - O
expressed - - O
sequence - - O
tag - - O
clones - - O
within - - O
a - - O
genomic - - O
contig - - O
on - - O
human - - O
chromosome - - O
5 - - O
, - - O
band - - O
q31 - - O
. - - O

60 - - O
patients - - O
were - - O
entered - - O
into - - O
a - - O
randomised - - O
study - - O
comparing - - O
vindesine - - O
( - - O
3 - - O
mg - - O
m2 - - O
week - - O
) - - O
plus - - O
interferon-alpha - - O
2b - - O
( - - B-MUT
6 - - I-MUT
U - - O
m2 - - O
3 - - O
times - - O
per - - O
week - - O
) - - O
to - - O
vindesine - - O
alone - - O
or - - O
to - - O
interferon - - O
alone - - O
for - - O
the - - B-MUT
treatment - - O
of - - O
metastatic - - O
malignant - - O
melanoma - - O
. - - O

However - - O
, - - O
mutations - - O
in - - O
the - - O
HNF-4 - - B-MUT
binding - - I-MUT
site - - I-MUT
on - - O
element - - B-MUT
CIIB - - I-MUT
and - - O
inhibition - - O
of - - O
HNF-4 - - B-MUT
synthesis - - O
in - - O
HepG2 - - O
cells - - O
by - - O
antisense - - O
HNF-4 - - B-MUT
constructs - - I-MUT
decreased - - O
the - - O
apoCII - - B-MUT
promoter - - I-MUT
activity - - O
to - - O
25-40% - - O
of - - O
the - - O
control - - O
, - - O
indicating - - O
that - - O
HNF-4 - - B-MUT
is - - O
a - - O
positive - - O
regulator - - O
of - - O
the - - O
apoCII - - B-MUT
gene - - I-MUT
. - - O

Our - - O
results - - O
indicate - - O
that - - O
D - - B-MUT
( - - I-MUT
4 - - I-MUT
) - - I-MUT
and - - O
D - - B-MUT
( - - I-MUT
2L - - I-MUT
) - - I-MUT
receptors - - I-MUT
activate - - O
the - - O
ERK - - B-MUT
kinase - - I-MUT
cascade - - O
by - - O
first - - O
mobilizing - - O
signaling - - O
by - - O
the - - O
PDGF - - B-MUT
receptor - - I-MUT
, - - O
followed - - O
by - - O
the - - O
subsequent - - O
activation - - O
of - - O
ERK1 - - B-MUT
2 - - I-MUT
by - - I-MUT
pathways - - O
associated - - O
with - - O
this - - O
receptor - - O
tyrosine - - B-MUT
kinase - - I-MUT
. - - I-MUT

The - - O
effects - - O
of - - O
anabolic - - O
implants - - O
on - - O
rate - - O
, - - O
composition - - O
and - - O
energetic - - O
efficiency - - O
of - - O
growth - - O
were - - O
determined - - O
in - - O
steers - - O
fed - - O
diets - - O
varying - - O
in - - O
forage - - O
and - - O
grain - - O
content - - O
. - - O

The - - O
results - - O
of - - O
the - - O
lab - - O
and - - O
field - - O
tests - - O
yielded - - O
high - - O
levels - - O
of - - O
infestation - - O
in - - O
larvae - - O
with - - O
values - - O
ranging - - O
from - - O
90 - - O
to - - O
100% - - O
and - - O
from - - O
85 - - O
to - - O
95% - - O
, - - O
respectively - - O
. - - O

The - - O
FAS - - B-MUT
promoter - - I-MUT
was - - O
up-regulated - - O
by - - O
insulin - - B-MUT
through - - O
the - - O
proximal - - O
insulin - - B-MUT
response - - I-MUT
sequence - - I-MUT
containing - - O
an - - O
E-box - - O
motif - - O
at - - O
the - - O
-65-base - - O
pair - - O
position - - O
. - - O

In - - O
cell - - O
lines - - O
transformed - - O
by - - O
BCR - - B-MUT
ABL - - I-MUT
, - - I-MUT
CRKL - - O
was - - B-MUT
tyrosine - - O
phosphorylated - - O
, - - O
while - - O
CRK - - O
was - - B-MUT
not - - O
. - - O

The - - O
two-hybrid - - O
assay - - O
was - - O
then - - O
performed - - O
using - - O
full-length - - O
genes - - O
of - - O
CI - - B-MUT
, - - O
HC-Pro - - B-MUT
, - - O
P1 - - B-MUT
, - - O
P3 - - B-MUT
, - - O
and - - O
CP - - B-MUT
, - - O
but - - O
no - - O
heterologous - - O
interactions - - O
were - - O
detected - - O
. - - O

The - - O
nucleolin - - B-MUT
gene - - I-MUT
extends - - O
over - - O
9000 - - O
base-pairs - - O
and - - O
is - - O
split - - O
into - - O
14 - - O
exons - - O
that - - O
encode - - O
the - - O
706 - - O
amino - - O
acid - - O
residues - - O
of - - O
the - - O
protein - - O
. - - O

The - - O
absolute - - O
configuration - - O
at - - O
C-2 - - O
in - - O
monocrotalic - - O
acid - - O
. - - O

With - - O
the - - O
exception - - O
of - - O
mutants - - O
that - - O
remove - - O
the - - O
membrane - - O
anchor - - O
domain - - O
, - - O
all - - O
of - - O
the - - O
mutant - - O
glycoproteins - - O
retained - - O
the - - O
ability - - O
to - - O
cause - - O
fusion - - O
of - - O
CD4-bearing - - O
cells - - O
. - - O

We - - O
also - - O
present - - O
evidence - - O
that - - O
human - - B-MUT
HYAL1 - - I-MUT
is - - O
identical - - O
to - - O
an - - O
uncharacterized - - O
gene - - O
positionally - - O
cloned - - O
by - - O
others - - O
from - - O
chromosome - - O
3p21 - - O
. - - O
3 - - O
that - - O
is - - O
homozygously - - O
deleted - - O
in - - O
several - - O
small-cell - - O
lung - - O
carcinoma - - O
cell - - O
lines - - O
. - - O

Furthermore - - O
, - - O
strains - - O
with - - O
mutant - - B-MUT
RPM1 - - I-MUT
genes - - I-MUT
also - - O
accumulate - - O
precursor - - B-MUT
Rpm1r - - I-MUT
, - - O
suggesting - - O
that - - O
mutations - - O
in - - O
either - - O
gene - - O
can - - O
lead - - O
to - - O
similar - - O
biogenesis - - O
defects - - O
. - - O

Isolated - - O
Systolic - - O
Hypertension - - O
: - - O
An - - O
Update - - O
. - - O

STK - - O
RON-expressing - - O
Ba - - O
F3 - - O
pro-B - - O
cells - - O
( - - O
BaF - - O
STK - - O
) - - O
exhibited - - O
MSP-dependent - - O
growth - - O
, - - O
whereas - - O
STK - - O
RON-expressing - - O
mouse - - O
erythroleukaemia - - B-MUT
cells - - I-MUT
( - - O
MEL - - O
STK - - O
) - - O
displayed - - O
MSP-induced - - O
apoptosis - - O
. - - B-MUT

Also - - O
, - - O
the - - O
BALB - - B-MUT
c - - I-MUT
gene - - I-MUT
contains - - I-MUT
a - - O
single - - O
substitution - - O
in - - O
a - - O
conserved - - O
octamer - - O
sequence - - O
approximately - - O
equal - - O
to - - O
100 - - O
nucleotides - - O
upstream - - O
of - - O
the - - O
coding - - O
region - - O
, - - O
which - - O
could - - O
affect - - O
its - - O
expression - - O
. - - O

Immunological - - O
testing - - O
was - - O
performed - - O
on - - O
all - - O
brewery - - O
workers - - O
and - - O
some - - O
control - - O
volunteers - - O
using - - O
skin - - O
prick - - O
testing - - O
with - - O
hops - - O
, - - O
barley - - O
, - - O
and - - O
yeast - - O
antigens - - O
as - - O
well - - O
as - - O
other - - O
nonoccupational - - O
allergens - - O
, - - O
and - - O
by - - O
determining - - O
total - - O
serum - - B-MUT
IgE - - I-MUT
levels - - O
. - - O

Purified - - O
CarP - - B-MUT
binds - - O
in - - O
vitro - - O
to - - O
the - - O
carAB - - B-MUT
control - - I-MUT
region - - I-MUT
and - - O
protects - - O
against - - O
DNase - - B-MUT
I - - I-MUT
two - - O
approximately - - O
25 - - O
bp - - O
long - - O
stretches - - O
, - - O
one - - O
of - - O
which - - O
is - - O
located - - O
just - - O
downstream - - O
of - - O
the - - O
GATC - - B-MUT
sequence - - I-MUT
. - - O

An - - O
intact - - O
neurovascular - - O
supply - - O
is - - O
essential - - O
for - - O
the - - O
viability - - O
of - - O
a - - O
muscle - - O
flap - - O
. - - O

Prevention - - O
of - - O
maternal - - O
Rh - - O
sensitization - - O
: - - O
anti-Rh - - B-MUT
immune - - I-MUT
globulin - - I-MUT
. - - O

The - - O
pCMBS-reactive - - O
sulfhydryl - - O
groups - - O
were - - O
located - - O
exclusively - - O
in - - O
the - - O
exofacial - - O
half - - O
of - - O
the - - O
plasma - - O
membrane - - O
and - - O
, - - O
when - - O
presented - - O
in - - O
a - - O
helical - - O
model - - O
, - - O
lie - - O
along - - O
one - - O
side - - O
of - - O
the - - O
helices - - O
. - - O

These - - O
mutations - - O
alter - - O
two - - O
regions - - O
of - - O
GAL4 - - B-MUT
protein - - I-MUT
: - - O
the - - O
DNA - - O
binding - - O
domain - - O
, - - O
and - - O
the - - O
transcription - - O
activation - - O
domain - - O
. - - O

However - - O
, - - O
deletions - - O
of - - O
the - - O
C - - O
terminal - - O
11 - - O
or - - O
14 - - O
amino - - O
acids - - O
had - - O
more - - O
substantial - - O
effects - - O
. - - O

In - - O
the - - O
local - - O
geomagnetic - - O
field - - O
, - - O
the - - O
animals - - O
preferred - - O
the - - O
SE-sector - - O
. - - O

It - - O
contains - - O
a - - O
5'-noncoding - - O
region - - O
( - - O
NCR - - O
) - - O
of - - O
73 - - O
nucleotides - - O
, - - O
five - - O
open - - O
reading - - O
frames - - O
( - - O
ORFs - - O
1 - - O
to - - O
5 - - O
) - - O
which - - O
encode - - O
proteins - - O
with - - O
M - - O
( - - O
r - - O
) - - O
160 - - B-MUT
kDa - - I-MUT
RNA-dependent - - I-MUT
RNA - - I-MUT
polymerase - - I-MUT
( - - I-MUT
ORF1 - - I-MUT
) - - I-MUT
, - - O
26 - - B-MUT
kDa - - I-MUT
movement - - I-MUT
protein - - I-MUT
1 - - I-MUT
( - - I-MUT
ORF2 - - I-MUT
) - - I-MUT
, - - O
13 - - B-MUT
kDa - - I-MUT
movement - - I-MUT
protein - - I-MUT
2 - - I-MUT
( - - I-MUT
ORF3 - - I-MUT
) - - I-MUT
, - - O
10 - - B-MUT
kDa - - I-MUT
movement - - I-MUT
protein - - I-MUT
3 - - I-MUT
( - - I-MUT
ORF4 - - I-MUT
) - - I-MUT
, - - O
24 - - B-MUT
kDa - - I-MUT
coat - - I-MUT
protein - - I-MUT
( - - I-MUT
OFR5 - - I-MUT
) - - I-MUT
, - - O
and - - O
a - - O
3' - - O
NCR - - O
of - - O
76 - - O
nucleotides - - O
. - - O

Audiological - - O
findings - - O
in - - O
pregnancy - - O
. - - O

Hemodynamic - - O
assessment - - O
was - - O
obtained - - O
before - - O
and - - O
following - - O
administration - - O
of - - O
digoxin - - O
10 - - O
micrograms - - O
kg - - O
IV - - O
or - - O
dopamine - - O
, - - O
5 - - O
to - - O
12 - - O
micrograms - - O
kg - - O
min - - O
IV - - O
. - - O

Both - - O
groups - - O
were - - O
subjected - - O
to - - O
tests - - O
of - - O
delayed - - O
hypersensitivity - - O
with - - O
Candidin - - O
, - - O
Trycophytin - - O
and - - O
Tuberculin - - O
. - - O

Notably - - O
, - - O
these - - O
residues - - O
are - - O
located - - O
in - - O
different - - O
domains - - O
. - - O

The - - O
human - - O
U4 - - B-MUT
U6 - - I-MUT
snRNP - - I-MUT
contains - - I-MUT
60 - - O
and - - O
90kD - - O
proteins - - O
that - - O
are - - O
structurally - - O
homologous - - O
to - - O
the - - O
yeast - - O
splicing - - O
factors - - O
Prp4p - - O
and - - B-MUT
Prp3p - - O
. - - B-MUT

The - - O
diagnostic - - O
accuracy - - O
of - - O
serum - - O
PE-1 - - B-MUT
was - - O
0 - - O
. - - O
80 - - O
, - - O
and - - O
that - - O
of - - O
amylase - - B-MUT
0 - - O
. - - O
97 - - O
. - - O

Six - - O
healthy - - O
male - - O
subjects - - O
received - - O
single - - O
oral - - O
doses - - O
of - - O
regular - - O
release - - O
( - - O
RR - - O
) - - O
quinidine - - O
sulfate - - O
, - - O
sustained - - O
release - - O
( - - O
SR - - O
) - - O
quinidine - - O
bisulfate - - O
and - - O
the - - O
same - - O
dose - - O
of - - O
the - - O
SR - - O
product - - O
with - - O
food - - O
( - - O
SR-F - - O
) - - O
. - - O

We - - O
discuss - - O
the - - O
results - - O
in - - O
relation - - O
to - - O
previous - - O
systems - - O
for - - O
parcellating - - O
the - - O
posterior - - O
ectosylvian - - O
gyrus - - O
of - - O
the - - O
cat - - O
and - - O
consider - - O
the - - O
possibility - - O
that - - O
divisions - - O
of - - O
the - - O
feline - - O
posterior - - O
ectosylvian - - O
gyrus - - O
correspond - - O
directly - - O
to - - O
areas - - O
making - - O
up - - O
the - - O
superior - - O
temporal - - O
gyrus - - O
in - - O
primates - - O
. - - O

The - - O
results - - O
indicate - - O
that - - O
anthraquinone - - O
sennoside - - O
B - - O
and - - O
rhein - - O
are - - O
weakly - - O
genotoxic - - O
. - - O

Studies - - O
of - - O
biochemical - - O
and - - O
morphological - - O
changes - - O
( - - O
between - - O
normal - - O
and - - O
treated - - O
animals - - O
) - - O
show - - O
that - - O
chrysotile - - O
induces - - O
an - - O
increase - - O
in - - O
the - - O
lung - - O
free - - O
cell - - O
population - - O
and - - O
pulmonary - - O
surfactant - - O
levels - - O
. - - O

The - - O
motility - - O
of - - O
sperm - - O
, - - O
except - - O
for - - O
those - - O
adjacent - - O
to - - O
both - - O
electrodes - - O
, - - O
did - - O
not - - O
change - - O
after - - O
stimulation - - O
for - - O
60s - - O
, - - O
despite - - O
a - - O
high - - O
electrical - - O
energy - - O
. - - O

11-Aminoundecanoyl-SK-NH2 - - O
and - - O
11-aminoundecanoyl-SH-NH2 - - O
establish - - O
that - - O
a - - O
simple - - O
alkyl - - O
backbone - - O
can - - O
maintain - - O
an - - O
appropriate - - O
distance - - O
between - - O
three - - O
elements - - O
critical - - O
for - - O
recognition - - O
by - - O
the - - O
fungal - - O
enzyme's - - O
peptide-binding - - O
site - - O
: - - O
a - - O
simple - - O
omega-terminal - - O
amino - - O
group - - O
, - - O
a - - O
beta-hydroxyl - - O
, - - O
and - - O
an - - O
epsilon-amino - - O
group - - O
or - - O
an - - O
imidazole - - O
. - - O

Homo-oligomerisation - - O
and - - O
nuclear - - O
localisation - - O
of - - O
mouse - - B-MUT
histone - - I-MUT
deacetylase - - I-MUT
1 - - I-MUT
. - - O

Phorbol - - O
esters - - O
stimulated - - O
phosphorylation - - O
of - - O
CSK - - B-MUT
35H - - I-MUT
proteins - - I-MUT
, - - O
thus - - O
emphasizing - - O
that - - O
sequences - - O
isolated - - O
according - - O
to - - O
PKC - - B-MUT
binding - - O
activity - - O
in - - O
vitro - - O
are - - O
also - - O
PKC - - B-MUT
substrates - - O
in - - O
vivo - - O
. - - O

Serodiagnosis - - O
of - - O
ectromelia - - O
in - - O
laboratory - - O
mice - - O
. - - O

TBP - - B-MUT
can - - O
be - - O
phosphorylated - - O
in - - O
vitro - - O
by - - O
extracts - - O
of - - O
U937 - - O
cells - - O
or - - O
by - - O
bacterially - - O
expressed - - O
activated - - O
ERK2 - - B-MUT
; - - O
the - - O
phosphorylation - - O
sites - - O
were - - O
mapped - - O
to - - O
ERK - - B-MUT
kinase - - I-MUT
consensus - - I-MUT
sites - - I-MUT
in - - O
the - - O
TBP - - B-MUT
amino-terminal - - I-MUT
domain - - I-MUT
. - - O

Sodium-taurocholate-induced - - O
acute - - O
necrotizing - - O
pancreatitis - - O
does - - O
not - - O
affect - - O
jejunal - - O
oxygenation - - O
in - - O
pigs - - O
. - - O

Laser - - O
ablation - - O
has - - O
been - - O
employed - - O
as - - O
a - - O
therapeutic - - O
measure - - O
for - - O
chronic - - O
pulmonary - - O
emphysema - - O
. - - O

This - - O
differential - - O
sensitivity - - O
to - - O
DB - - O
, - - O
as - - O
measured - - O
by - - O
a - - O
lower - - O
concentration - - O
of - - O
DB - - O
which - - O
caused - - O
loss - - O
of - - O
righting - - O
in - - O
LS - - O
, - - O
was - - O
accompanied - - O
by - - O
an - - O
equal - - O
rate - - O
of - - O
water-soluble - - O
barbiturate - - O
brain - - O
distribution - - O
and - - O
elimination - - O
in - - O
the - - O
two - - O
lines - - O
. - - O

In - - O
the - - O
SPK - - O
and - - O
PTA - - O
category - - O
, - - O
anti-T-cell - - O
therapy - - O
significantly - - O
lowered - - O
the - - O
risk - - O
of - - O
graft - - O
loss - - O
. - - O

Smoking - - O
was - - O
regarded - - O
as - - O
the - - O
major - - O
contribution - - O
to - - O
pulmonary - - O
dysfunction - - O
. - - O

Deletion - - O
analysis - - O
showed - - O
that - - O
the - - O
-321 - - O
+41 - - O
sequence - - O
was - - O
sufficient - - O
for - - O
both - - O
the - - O
constitutive - - O
promoter - - O
activity - - O
and - - O
auto-activation - - O
and - - O
electrophoretic - - O
mobility - - O
shift - - O
assays - - O
identified - - O
the - - O
interaction - - O
of - - O
C - - O
EBPs - - B-MUT
and - - I-MUT
Sp1 - - I-MUT
to - - O
this - - B-MUT
region - - O
. - - O

A - - O
reduction - - O
of - - O
the - - O
aspartate - - B-MUT
aminotransferase - - I-MUT
activity - - O
was - - O
observed - - O
from - - O
800 - - O
mg - - O
kg - - O
b - - O
. - - O
w - - O
. - - O
d - - O
onwards - - O
. - - O

Through - - O
two - - O
novel - - O
mechanisms - - O
, - - O
Arf - - B-MUT
inhibits - - O
the - - O
oncoprotein - - B-MUT
Hdm2 - - I-MUT
, - - O
a - - O
negative - - O
regulator - - O
of - - O
p53 - - B-MUT
. - - O

Incidence - - O
correlated - - O
with - - O
the - - O
grade - - O
of - - O
oral - - O
hygiene - - O
und - - O
periodontal - - O
disease - - O
. - - O

On - - O
the - - O
basis - - O
of - - O
its - - O
bZIP - - B-MUT
structural - - O
homology - - O
, - - O
meq - - B-MUT
is - - O
perhaps - - O
the - - O
only - - O
member - - O
of - - O
the - - O
jun-fos - - B-MUT
gene - - I-MUT
family - - I-MUT
completely - - O
viral - - O
in - - O
origin - - O
. - - O

Although - - O
further - - O
studies - - O
are - - O
required - - O
to - - O
determine - - O
the - - O
precise - - O
role - - O
of - - O
PEBP2 - - B-MUT
in - - O
the - - O
GM-CSF - - B-MUT
promoter - - I-MUT
activity - - O
, - - O
the - - O
present - - O
findings - - O
suggested - - O
the - - O
importance - - O
of - - O
the - - O
relative - - O
ratio - - O
of - - O
different - - O
PEBP2 - - B-MUT
isoforms - - I-MUT
in - - O
regulating - - O
the - - O
levels - - O
of - - O
the - - O
promoter - - O
activity - - O
. - - O

FAK - - B-MUT
localizes - - O
to - - O
sites - - O
of - - O
transmembrane - - B-MUT
integrin - - I-MUT
receptor - - I-MUT
clustering - - O
and - - O
facilitates - - O
intracellular - - O
signaling - - O
events - - O
. - - O

In - - O
concert - - O
with - - O
the - - O
coactivator - - O
CREB - - B-MUT
binding - - I-MUT
protein - - I-MUT
p300 - - I-MUT
, - - I-MUT
which - - O
interacts - - O
with - - O
GABPalpha - - O
, - - B-MUT
the - - O
binding - - O
of - - O
GABPalpha - - O
and - - B-MUT
-beta - - I-MUT
to - - I-MUT
the - - O
dyad - - O
symmetry - - O
element - - O
controls - - O
the - - O
induction - - O
of - - O
IL-16 - - O
promoter - - B-MUT
in - - I-MUT
T - - O
cells - - O
. - - O

DNase - - B-MUT
I - - I-MUT
footprinting - - O
and - - O
electrophoretic - - O
mobility - - O
shift - - O
assays - - O
indicate - - O
that - - O
PBP - - B-MUT
binds - - O
to - - O
the - - O
half-site - - O
of - - O
each - - O
palindrome - - O
with - - O
the - - O
core - - B-MUT
recognition - - I-MUT
sequence - - I-MUT
TGGGAG - - I-MUT
. - - O

You - - O
make - - O
the - - O
diagnosis - - O
. - - O

In - - O
hemodialyzed - - O
patients - - O
( - - O
Epo - - B-MUT
and - - O
Non-Epo - - O
group - - O
) - - O
leptin - - B-MUT
levels - - O
were - - O
significantly - - O
higher - - O
when - - O
compared - - O
to - - O
CAPD - - O
patients - - O
( - - O
Epo - - B-MUT
and - - O
Non-Epo - - O
group - - O
, - - O
respectively - - O
) - - O
. - - O

Osteogenesis - - O
imperfecta - - O
. - - O

This - - O
region - - O
of - - O
60 - - O
amino - - O
acids - - O
may - - O
be - - O
involved - - O
in - - O
coiled-coil - - O
interactions - - O
similar - - O
to - - O
those - - O
that - - O
facilitate - - O
the - - O
filament - - O
formation - - O
in - - O
the - - O
rod - - O
region - - O
. - - O

Detection - - O
of - - O
hemophilia - - O
A - - O
carriers - - O
. - - O

DNase - - B-MUT
I - - I-MUT
footprinting - - O
and - - O
electrophoretic - - O
mobility - - O
shift - - O
analyses - - O
revealed - - O
two - - O
hepatocyte - - B-MUT
nuclear - - I-MUT
factor-1 - - I-MUT
( - - O
HNF1 - - B-MUT
) - - O
, - - O
three - - O
CCAAT - - B-MUT
enhancer-binding - - I-MUT
protein - - I-MUT
( - - I-MUT
C - - O
EBP - - B-MUT
) - - I-MUT
, - - I-MUT
and - - O
one - - O
consensus - - O
palindromic - - O
thyroid - - O
hormone - - O
response - - B-MUT
elements - - I-MUT
within - - I-MUT
the - - I-MUT
first - - O
215 - - O
base - - O
pairs - - O
( - - O
bp - - O
) - - O
of - - O
the - - O
promoter - - O
sequence - - O
of - - O
rat - - O
Std - - O
. - - B-MUT

GR63178A - - O
is - - O
a - - O
water-soluble - - O
analogue - - O
of - - O
mitoquidone - - O
, - - O
a - - O
pentacyclic - - O
pyrroloquinone - - O
. - - O

Identification - - O
of - - O
a - - O
proline-rich - - O
sequence - - O
in - - O
the - - O
CD2 - - B-MUT
cytoplasmic - - I-MUT
domain - - I-MUT
critical - - O
for - - O
regulation - - O
of - - O
integrin-mediated - - O
adhesion - - O
and - - O
activation - - O
of - - O
phosphoinositide - - B-MUT
3-kinase - - I-MUT
. - - O

16 - - O
women - - O
were - - O
treated - - O
with - - O
methadone - - O
to - - O
prevent - - O
withdrawal - - O
symptoms - - O
. - - O

Galphaq - - B-MUT
, - - O
Galpha12 - - B-MUT
, - - O
and - - O
Galpha13 - - B-MUT
, - - O
but - - O
not - - O
Galphai - - B-MUT
, - - O
activate - - O
SRF - - B-MUT
through - - O
RhoA - - B-MUT
. - - O

Fundus - - O
changes - - O
in - - O
( - - O
type - - O
II - - O
) - - O
mesangiocapillary - - O
glomerulonephritis - - O
simulating - - O
drusen - - O
: - - O
a - - O
histopathological - - O
report - - O
. - - O

The - - O
malate - - B-MUT
synthase - - I-MUT
gene - - I-MUT
, - - O
MLS1 - - B-MUT
, - - O
of - - O
the - - O
yeast - - O
Saccharomyces - - O
cerevisiae - - O
is - - O
transcriptionally - - O
regulated - - O
by - - O
the - - O
carbon - - O
source - - O
in - - O
the - - O
growth - - O
medium - - O
. - - O

OBJECTIVE - - O
: - - O
To - - O
follow-up - - O
prospectively - - O
patients - - O
with - - O
arthritis - - O
after - - O
infection - - O
with - - O
beta-haemolytic - - O
streptococci - - O
of - - O
Lancefield - - O
group - - O
A - - O
( - - O
beta - - O
HSA - - O
) - - O
, - - O
with - - O
emphasis - - O
on - - O
clinical - - O
characteristics - - O
and - - O
serological - - O
features - - O
. - - O

Gemfibrozil - - O
in - - O
hyperlipidaemic - - O
patients - - O
with - - O
peripheral - - O
arterial - - O
disease - - O
: - - O
some - - O
undiscovered - - O
actions - - O
. - - O

Mucin - - B-MUT
gene - - I-MUT
expression - - O
has - - O
been - - O
shown - - O
to - - O
be - - O
altered - - O
in - - O
many - - O
intestinal - - O
diseases - - O
and - - O
especially - - O
cancers - - O
of - - O
the - - O
gastrointestinal - - O
tract - - O
. - - O

The - - O
results - - O
support - - O
earlier - - O
reports - - O
that - - O
collagenase - - B-MUT
inhibitors - - O
are - - O
useful - - O
in - - O
controlling - - O
blister - - O
formation - - O
in - - O
recessive - - O
dystrophic - - O
epidermolysis - - O
bullosa - - O
. - - O

Framingham - - O
Type - - O
A - - O
behavior - - O
was - - O
positively - - O
associated - - O
with - - O
diastolic - - O
blood - - O
pressure - - O
( - - O
r - - O
= - - O
0 - - O
. - - O
17 - - O
, - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
05 - - O
) - - O
among - - O
the - - O
women - - O
. - - O

The - - O
neglect - - O
of - - O
Richards's - - O
theory - - O
demonstrates - - O
the - - O
range - - O
of - - O
factors - - O
, - - O
other - - O
than - - O
the - - O
strictly - - O
scientific - - O
, - - O
which - - O
can - - O
be - - O
important - - O
in - - O
determining - - O
the - - O
influence - - O
or - - O
otherwise - - O
of - - O
a - - O
psychological - - O
theory - - O
. - - O

C - - B-MUT
EBP - - I-MUT
beta - - I-MUT
V - - I-MUT
> - - I-MUT
A - - O
selectively - - O
binds - - O
only - - O
the - - O
subset - - O
of - - O
C - - O
EBP - - B-MUT
sites - - I-MUT
that - - I-MUT
are - - I-MUT
also - - O
DBP - - O
sites - - O
, - - B-MUT
both - - I-MUT
as - - O
oligonucleotides - - O
and - - O
within - - O
the - - O
natural - - O
contexts - - O
of - - O
the - - O
albumin - - O
and - - O
cholesterol - - B-MUT
hydroxylase - - O
promoters - - B-MUT
. - - I-MUT

The - - O
nucleotide - - O
( - - O
nt - - O
) - - O
sequences - - O
of - - O
the - - O
exons - - O
, - - O
exon - - O
intron - - O
boundaries - - O
and - - O
5'- - - O
and - - O
3'-untranslated - - O
regions - - O
were - - O
determined - - O
. - - O

The - - O
first - - O
algorithm - - O
, - - O
FOREPROJ - - O
, - - O
is - - O
a - - O
fast-forward - - O
projection - - O
algorithm - - O
that - - O
allows - - O
calculation - - O
of - - O
the - - O
3-D - - O
attenuation - - O
correction - - O
factors - - O
( - - O
ACF's - - O
) - - O
directly - - O
from - - O
a - - O
two-dimensional - - O
( - - O
2-D - - O
) - - O
transmission - - O
scan - - O
, - - O
without - - O
first - - O
reconstructing - - O
the - - O
attenuation - - O
map - - O
and - - O
then - - O
performing - - O
a - - O
3-D - - O
forward - - O
projection - - O
. - - O

The - - O
aim - - O
of - - O
this - - O
study - - O
was - - O
to - - O
assess - - O
the - - O
reproducibility - - O
of - - O
a - - O
number - - O
of - - O
simplified - - O
clearance - - O
methods - - O
using - - O
chromium-51 - - O
ethylenediamine - - O
tetraacetic - - O
acid - - O
( - - O
51Cr-EDTA - - O
) - - O
and - - O
to - - O
compare - - O
these - - O
with - - O
the - - O
multiple - - O
blood - - O
sample - - O
technique - - O
. - - O

Site-directed - - O
mutagenesis - - O
of - - O
CAR - - B-MUT
revealed - - O
that - - O
CAR - - B-MUT
residues - - I-MUT
Leu73 - - I-MUT
and - - I-MUT
Lys121 - - I-MUT
and - - I-MUT
or - - I-MUT
Lys123 - - I-MUT
are - - I-MUT
critical - - O
contact - - O
residues - - O
, - - O
with - - O
Tyr80 - - O
and - - O
Tyr83 - - O
being - - O
peripherally - - O
involved - - O
in - - O
the - - O
binding - - O
interaction - - O
with - - O
the - - O
Ad5 - - O
, - - O
Ad9 - - O
, - - O
Ad12 - - O
, - - O
and - - O
Ad41L - - O
fiber - - O
knobs - - O
. - - O

The - - O
Prolactin - - B-MUT
levels - - O
were - - O
within - - O
the - - O
physiological - - O
norms - - O
; - - O
the - - O
responses - - O
to - - O
TRH - - B-MUT
were - - O
normal - - O
, - - O
and - - O
elevated - - O
only - - O
in - - O
a - - O
few - - O
cases - - O
. - - O

To - - O
investigate - - O
the - - O
activity - - O
of - - O
TCF11 - - B-MUT
through - - O
this - - O
selected - - O
site - - O
, - - O
both - - O
alone - - O
and - - O
in - - O
the - - O
presence - - O
of - - O
MafG - - B-MUT
, - - O
we - - O
have - - O
used - - O
a - - O
transient - - O
transfection - - O
assay - - O
. - - O

Interleukin-1 - - B-MUT
levels - - O
remained - - O
low - - O
throughout - - O
the - - O
course - - O
. - - O

This - - O
dominant-negative - - O
effect - - O
of - - O
FRNK - - B-MUT
was - - O
reversed - - O
by - - O
a - - O
point - - O
mutation - - O
( - - O
Leu-1034 - - O
to - - O
Ser - - O
) - - O
which - - O
prevented - - O
FRNK - - B-MUT
localization - - O
to - - O
focal - - O
contact - - O
sites - - O
. - - O

In - - O
ten - - O
other - - O
experiments - - O
( - - O
5 - - O
experimental - - O
and - - O
5 - - O
control - - O
rats - - O
) - - O
99mTc-sulfur - - O
colloid - - O
was - - O
injected - - O
intravenously - - O
. - - O

Additionally - - O
, - - O
the - - O
mouse - - O
promoter - - O
contains - - O
22 - - O
copies - - O
of - - O
a - - O
CT - - B-MUT
dinucleotide - - I-MUT
repeat - - I-MUT
sequence - - I-MUT
located - - O
approximately - - O
155 - - O
bp - - O
5' - - O
to - - O
exon - - O
1 - - O
. - - O

Expression - - O
of - - O
various - - O
FAK - - B-MUT
mutants - - I-MUT
in - - O
the - - O
FAK- - - O
cells - - O
showed - - O
that - - O
FAK - - B-MUT
kinase - - I-MUT
activity - - O
, - - O
the - - O
Tyr-397 - - B-MUT
SH2 - - I-MUT
domain - - I-MUT
binding - - I-MUT
site - - I-MUT
, - - I-MUT
and - - O
the - - O
first - - O
proline-rich - - O
SH3 - - O
binding - - B-MUT
region - - I-MUT
in - - I-MUT
the - - O
FAK - - O
C-terminal - - B-MUT
domain - - I-MUT
were - - I-MUT
individually - - O
needed - - O
to - - O
promote - - O
full - - O
FAK-mediated - - O
FAK- - - O
cell - - O
migration - - O
to - - O
FN - - O
whereas - - B-MUT
direct - - O
paxillin - - O
binding - - B-MUT
to - - O
FAK - - O
was - - B-MUT
not - - O
required - - O
. - - O

In - - O
contrast - - O
, - - O
over-expression - - O
of - - O
RAR - - B-MUT
beta - - I-MUT
only - - O
poorly - - O
restored - - O
differentiation - - O
, - - O
although - - O
it - - O
could - - O
replace - - O
RAR - - B-MUT
gamma - - I-MUT
for - - O
the - - O
activation - - O
of - - O
target - - O
genes - - O
. - - O

CONCLUSION - - O
: - - O
Human - - O
preterm - - O
birth - - O
is - - O
associated - - O
with - - O
significantly - - O
lower - - O
progesterone - - O
17 - - O
beta-estradiol - - O
ratios - - O
than - - O
those - - O
of - - O
women - - O
with - - O
preterm - - O
labor - - O
delivered - - O
at - - O
term - - O
. - - O

Thus - - O
, - - O
two - - O
very - - O
different - - O
regulatory - - O
elements - - O
are - - O
used - - O
to - - O
mediate - - O
estrogen - - O
induction - - O
of - - O
related - - O
genes - - O
in - - O
chickens - - O
and - - O
amphibians - - O
. - - O

Specifically - - O
, - - O
by - - O
oligonucleotide-directed - - O
site-specific - - O
mutagenesis - - O
, - - O
we - - O
demonstrate - - O
that - - O
of - - O
10 - - O
cysteine - - O
residues - - O
in - - O
the - - O
ORF4 - - O
polypeptide - - O
, - - O
only - - O
C-421 - - O
and - - O
C-426 - - O
are - - O
essential - - O
for - - O
transactivator - - O
function - - O
and - - O
suggest - - O
that - - O
these - - O
cysteine - - O
residues - - O
may - - O
participate - - O
in - - O
critical - - O
protein-protein - - O
interactions - - O
rather - - O
than - - O
protein-nucleic - - O
acid - - O
interactions - - O
to - - O
mediate - - O
ORF4 - - O
inducibility - - O
. - - O

The - - O
ratio - - O
of - - O
P-31 - - O
NMR-S - - O
derived - - O
inorganic - - O
phosphates - - O
[ - - O
Pi - - O
] - - O
to - - O
phosphocreatine - - O
[ - - O
PCr - - O
] - - O
was - - O
significantly - - O
greater - - O
at - - O
rest - - O
in - - O
LVH - - O
baboons - - O
[ - - O
0 - - O
. - - O
53 - - O
+ - - O
- - - O
0 - - O
. - - O
06 - - O
versus - - O
controls - - O
= - - O
0 - - O
. - - O
41 - - O
+ - - O
- - - O
0 - - O
. - - O
17 - - O
; - - O
P - - O
less - - O
than - - O
0 - - O
. - - O
05 - - O
] - - O
. - - O

The - - O
effect - - O
of - - O
these - - O
cell - - O
cycle - - O
regulators - - O
is - - O
not - - O
specific - - O
to - - O
the - - O
rap1s - - B-MUT
or - - O
hmr - - B-MUT
delta - - I-MUT
A - - I-MUT
mutation - - I-MUT
, - - O
since - - O
swi6 - - B-MUT
, - - O
swi4 - - B-MUT
, - - O
and - - O
clb5 - - B-MUT
mutations - - I-MUT
also - - O
suppress - - O
mutations - - O
in - - O
SIR1 - - B-MUT
, - - O
another - - O
gene - - O
implicated - - O
in - - O
the - - O
establishment - - O
of - - O
silencing - - O
. - - O

Some - - O
of - - O
the - - O
peptide - - B-MUT
: - - I-MUT
MBP - - I-MUT
fusions - - I-MUT
were - - O
also - - O
analyzed - - O
using - - O
surface - - O
plasmon - - O
resonance - - O
. - - O

3 - - O
. - - O

METHODS - - O
: - - O
We - - O
studied - - O
the - - O
clinical - - O
benefit - - O
of - - O
depth-dependent - - O
RR - - O
, - - O
nonuniform - - O
AC - - O
using - - O
a - - O
scanning - - O
line - - O
source - - O
, - - O
and - - O
scatter - - O
correction - - O
( - - O
photon - - O
energy - - O
recovery - - O
[ - - O
PER - - O
] - - O
) - - O
compared - - O
with - - O
filtered - - O
backprojection - - O
alone - - O
. - - O

All - - O
89 - - O
participating - - O
household - - O
members - - O
were - - O
anti-HIV - - O
seronegative - - O
, - - O
and - - O
78 - - O
who - - O
were - - O
tested - - O
were - - O
serum - - B-MUT
p24 - - I-MUT
antigen - - I-MUT
negative - - O
. - - O

In - - O
contrast - - O
, - - O
a - - O
Maf-related - - B-MUT
protein - - I-MUT
, - - O
Nrl - - B-MUT
, - - O
completely - - O
mimicked - - O
c-Maf - - B-MUT
actions - - O
. - - O

TRAF2 - - B-MUT
is - - O
a - - O
potent - - O
activator - - O
of - - O
a - - O
95-kDa - - B-MUT
serine - - I-MUT
threonine - - I-MUT
kinase - - I-MUT
termed - - I-MUT
germinal - - O
center - - B-MUT
kinase - - I-MUT
related - - I-MUT
( - - I-MUT
GCKR - - O
, - - B-MUT
also - - O
referred - - O
to - - O
as - - O
KHS1 - - O
) - - B-MUT
, - - O
which - - O
signals - - O
activation - - O
of - - O
the - - O
SAPK - - O
pathway - - B-MUT
. - - O

Clinical - - O
and - - O
epidemiological - - O
characteristics - - O
of - - O
oral - - O
squamous - - O
cell - - O
carcinoma - - O
in - - O
women - - O
BACKGROUND - - O
: - - O
Squamous - - O
cell - - O
carcinoma - - O
( - - O
SCC - - O
) - - O
of - - O
the - - O
oral - - O
cavity - - O
occurs - - O
mainly - - O
in - - O
the - - O
male - - O
population - - O
. - - O

The - - O
TraD - - B-MUT
protein - - I-MUT
( - - I-MUT
83 - - I-MUT
, - - I-MUT
899 - - I-MUT
Da - - I-MUT
) - - I-MUT
contains - - O
three - - O
hydrophobic - - O
regions - - O
, - - O
of - - O
which - - O
two - - O
are - - O
located - - O
near - - O
the - - O
amino-terminal - - O
region - - O
. - - O

Responses - - O
to - - O
brainstem - - O
of - - O
nuclei - - O
medialis - - O
dorsalis - - O
, - - O
lateralis - - O
posterior - - O
were - - O
of - - O
considerably - - O
longer - - O
latency - - O
. - - O

Human - - O
ZFM1 - - B-MUT
protein - - I-MUT
is - - O
a - - O
transcriptional - - O
repressor - - O
that - - O
interacts - - O
with - - O
the - - O
transcription - - B-MUT
activation - - I-MUT
domain - - I-MUT
of - - I-MUT
stage-specific - - I-MUT
activator - - I-MUT
protein - - I-MUT
. - - O

Reaction - - O
times - - O
to - - O
tachistoscopically - - O
presented - - O
stimuli - - O
in - - O
diabetics - - O
. - - O

Following - - O
the - - O
satisfactory - - O
results - - O
and - - O
taking - - O
into - - O
account - - O
that - - O
the - - O
complications - - O
had - - O
reduced - - O
to - - O
a - - O
very - - O
low - - O
rate - - O
( - - O
in - - O
2 - - O
cases - - O
lead - - O
tip - - O
displacement - - O
and - - O
pouch - - O
haematoma - - O
occurred - - O
respectively - - O
) - - O
, - - O
the - - O
Authors - - O
consider - - O
the - - O
adopted - - O
method - - O
an - - O
useful - - O
approach - - O
for - - O
PMK - - O
implantation - - O
particularly - - O
when - - O
the - - O
use - - O
of - - O
the - - O
vena - - O
cephalica - - O
is - - O
deemed - - O
impossible - - O
. - - O

In - - O
patients - - O
with - - O
type - - O
IA - - O
maple - - O
syrup - - O
urine - - O
disease - - O
, - - O
the - - O
E1alpha - - B-MUT
subunit - - I-MUT
is - - O
affected - - O
, - - O
resulting - - O
in - - O
the - - O
loss - - O
of - - O
E1 - - B-MUT
and - - O
branched-chain - - B-MUT
ketoacid - - I-MUT
dehydrogenase - - I-MUT
catalytic - - O
activities - - O
. - - O

Postcoital - - O
contraception - - O
: - - O
a - - O
family - - O
planning - - O
study - - O
. - - O

These - - O
data - - O
indicate - - O
that - - O
the - - O
largest - - O
subunit - - O
of - - O
RNA - - B-MUT
polymerase - - I-MUT
II - - I-MUT
and - - O
TFIIB - - B-MUT
are - - O
important - - O
determinants - - O
of - - O
transcription - - O
start - - O
site - - O
selection - - O
in - - O
S - - O
. - - O
cerevisiae - - O
and - - O
suggest - - O
that - - O
this - - O
function - - O
might - - O
be - - O
conferred - - O
by - - O
interaction - - O
between - - O
these - - O
two - - O
proteins - - O
. - - O

Two - - O
patients - - O
with - - O
recurrent - - O
tumors - - O
had - - O
high - - O
S-phase - - O
fractions - - O
both - - O
on - - O
the - - O
first - - O
resected - - O
specimens - - O
and - - O
at - - O
the - - O
time - - O
of - - O
the - - O
second - - O
operation - - O
. - - O

SIN-1 - - O
had - - O
no - - O
influence - - O
on - - O
either - - O
the - - O
ischemic - - O
parameters - - O
in - - O
the - - O
surface - - O
electrocardiogram - - O
( - - O
ECG - - O
) - - O
or - - O
the - - O
intracoronary - - O
ECG - - O
. - - O

Human - - O
isoforms - - O
, - - O
designated - - O
1 - - O
to - - O
4 - - O
, - - O
differ - - O
from - - O
each - - O
other - - O
by - - O
the - - O
start - - O
codon - - O
used - - O
. - - O

No - - O
relevant - - O
changes - - O
in - - O
heart - - O
rate - - O
, - - O
body - - O
weight - - O
, - - O
and - - O
plasma - - O
levels - - O
of - - O
renin - - B-MUT
activity - - O
and - - O
aldosterone - - O
concentration - - O
were - - O
observed - - O
. - - O

The - - O
orf61 - - B-MUT
gene - - I-MUT
product - - I-MUT
, - - O
when - - O
expressed - - O
from - - O
an - - O
exogenous - - O
promoter - - O
, - - O
inhibited - - O
int-mediated - - O
integration - - O
at - - O
the - - O
chromosomal - - B-MUT
attB - - I-MUT
site - - I-MUT
. - - O

Surgical - - O
treatment - - O
of - - O
pathologic - - O
scars - - O
of - - O
myocardial - - O
infarct - - O
. - - O

Hybrid - - O
female - - O
mice - - O
( - - O
C57BL - - O
x - - O
CBA - - O
) - - O
were - - O
paired - - O
with - - O
breeder - - O
males - - O
( - - O
CD-1 - - O
) - - O
and - - O
LNG - - O
pellets - - O
were - - O
implanted - - O
on - - O
day - - O
0 - - O
, - - O
the - - O
day - - O
on - - O
which - - O
copulation - - O
plugs - - O
were - - O
found - - O
, - - O
or - - O
on - - O
day - - O
2 - - O
or - - O
day - - O
3 - - O
in - - O
the - - O
postcoital - - O
period - - O
. - - O

Temafloxacin - - O
400 - - O
mg - - O
b - - O
. - - O
i - - O
. - - O
d - - O
. - - O
administered - - O
orally - - O
for - - O
28 - - O
days - - O
represents - - O
a - - O
safe - - O
and - - O
effective - - O
treatment - - O
for - - O
chronic - - O
bacterial - - O
prostatitis - - O
. - - O

The - - O
currently - - O
proposed - - O
extended - - O
arch - - O
repair - - O
should - - O
be - - O
reserved - - O
for - - O
the - - O
small - - O
group - - O
of - - O
infants - - O
with - - O
transverse - - O
aortic - - O
arch - - O
to - - O
ascending - - O
aorta - - O
diameter - - O
ratios - - O
( - - O
arch - - O
indices - - O
) - - O
of - - O
less - - O
than - - O
0 - - O
. - - O
25 - - O
. - - O

Low - - O
MAO - - B-MUT
subjects - - O
showed - - O
a - - O
pattern - - O
of - - O
higher - - O
scores - - O
in - - O
KSP - - O
Impulsiveness - - O
, - - O
EPQ - - O
Neuroticism - - O
, - - O
and - - O
KSP - - O
Somatic - - O
Anxiety - - O
and - - O
Irritability - - O
and - - O
lower - - O
scores - - O
in - - O
KSP - - O
Socialization - - O
, - - O
in - - O
line - - O
with - - O
personality - - O
profiles - - O
found - - O
in - - O
alcoholics - - O
, - - O
psychopaths - - O
, - - O
and - - O
suicide - - O
attempters - - O
who - - O
also - - O
tend - - O
to - - O
have - - O
low - - O
platelet - - O
MAO - - B-MUT
activity - - O
. - - O

It - - O
brings - - O
about - - O
fatigue - - O
, - - O
negative - - O
moods - - O
, - - O
and - - O
impaired - - O
health - - O
, - - O
sleep - - O
, - - O
safety - - O
, - - O
and - - O
working - - O
capacity - - O
. - - O

Next - - O
, - - O
we - - O
show - - O
that - - O
two - - O
EMS-induced - - O
mutations - - O
, - - O
previously - - O
shown - - O
to - - O
interact - - O
genetically - - O
with - - O
zipper - - O
( - - O
Ebr - - B-MUT
) - - O
, - - O
disrupt - - O
the - - O
RhoA - - B-MUT
locus - - I-MUT
. - - O

HSF - - B-MUT
binds - - O
DNA - - O
as - - O
a - - O
trimer - - O
, - - O
and - - O
additional - - O
trimers - - O
can - - O
bind - - O
DNA - - O
co-operatively - - O
. - - O

Apart - - O
from - - O
antimicrobial - - O
properties - - O
, - - O
recent - - O
data - - O
indicate - - O
that - - O
PMN - - O
also - - O
exert - - O
anti-inflammatory - - O
effects - - O
by - - O
stimulation - - O
and - - O
release - - O
of - - O
cytokine - - O
antagonists - - O
such - - O
as - - O
interleukin-1 - - B-MUT
receptor - - I-MUT
antagonist - - I-MUT
( - - O
IL-1ra - - B-MUT
) - - O
. - - O

Mouse - - B-MUT
Impact - - I-MUT
is - - O
a - - O
paternally - - O
expressed - - O
gene - - O
encoding - - O
an - - O
evolutionarily - - O
conserved - - O
protein - - O
of - - O
unknown - - O
function - - O
. - - O

BACKGROUND - - O
: - - O
Mitosis - - O
is - - O
regulated - - O
by - - O
MPF - - B-MUT
( - - O
maturation - - B-MUT
promoting - - I-MUT
factor - - I-MUT
) - - O
, - - O
the - - O
active - - O
form - - O
of - - O
Cdc2 - - B-MUT
28-cyclin - - I-MUT
B - - I-MUT
complexes - - I-MUT
. - - I-MUT

We - - O
report - - O
an - - O
example - - O
of - - O
an - - O
MDV-transformed - - O
T-lymphoblastoid - - O
cell - - O
line - - O
( - - O
T9 - - O
) - - O
expressing - - O
high - - O
levels - - O
of - - O
a - - O
truncated - - B-MUT
C-MYB - - I-MUT
protein - - I-MUT
as - - O
a - - O
result - - O
of - - O
RAV - - O
integration - - O
within - - O
one - - O
c-myb - - B-MUT
allele - - I-MUT
. - - O

The - - O
interaction - - O
of - - O
caffeine - - O
, - - O
theophylline - - O
and - - O
theobromine - - O
with - - O
monoamine - - B-MUT
oxidase - - I-MUT
inhibitors - - O
. - - O

However - - O
, - - O
parallax - - O
measurements - - O
showed - - O
that - - O
at - - O
150K - - O
, - - O
collapse - - O
of - - O
Epon - - O
sections - - O
does - - O
not - - O
take - - O
place - - O
. - - O

To - - O
gain - - O
an - - O
understanding - - O
of - - O
the - - O
mGSTM2 - - B-MUT
regulation - - O
, - - O
we - - O
have - - O
also - - O
cloned - - O
and - - O
analyzed - - O
its - - O
promoter - - O
region - - O
. - - O

Mutations - - O
in - - O
three - - O
loci - - O
( - - O
SIC1 - - B-MUT
, - - O
SWI5 - - B-MUT
, - - O
and - - O
RIC3 - - B-MUT
) - - O
were - - O
identified - - O
. - - O

Therefore - - O
, - - O
mechanisms - - O
that - - O
control - - O
activation - - O
of - - O
the - - O
MAP - - B-MUT
kinase - - I-MUT
cascade - - I-MUT
temporally - - O
and - - O
spatially - - O
may - - O
be - - O
important - - O
for - - O
specification - - O
of - - O
cellular - - O
responses - - O
. - - O

None - - O
had - - O
a - - O
past - - O
history - - O
of - - O
opportunistic - - O
infections - - O
; - - O
neither - - O
did - - O
any - - O
have - - O
lymphopenia - - O
. - - O

EMSA - - O
competition - - O
experiments - - O
showed - - O
that - - O
mutations - - O
within - - O
the - - O
direct - - O
repeats - - O
failed - - O
to - - O
compete - - O
for - - O
binding - - O
of - - O
the - - O
nuclear - - O
proteins - - O
to - - O
labeled - - O
wild - - O
type - - O
oligonucleotide - - O
. - - O

In - - O
H4IIE - - O
rat - - O
hepatoma - - O
cells - - O
, - - O
glucocorticoids - - O
, - - O
retinoic - - O
acid - - O
and - - O
cyclic - - O
AMP - - O
( - - O
cAMP - - O
) - - O
increase - - O
PEPCK - - B-MUT
gene - - I-MUT
transcription - - O
whereas - - O
insulin - - B-MUT
and - - O
phorbol - - O
esters - - O
have - - O
the - - O
opposite - - O
effect - - O
. - - O

Until - - O
such - - O
investigations - - O
are - - O
performed - - O
, - - O
we - - O
conclude - - O
that - - O
the - - O
role - - O
for - - O
adjuvant - - O
treatment - - O
is - - O
questionable - - O
and - - O
that - - O
TME - - O
surgery - - O
is - - O
preferred - - O
as - - O
the - - O
treatment - - O
option - - O
for - - O
Stage - - O
T1-T3 - - O
rectal - - O
cancers - - O
. - - O

It - - O
was - - O
established - - O
that - - O
intrathecal - - O
or - - O
intraperitoneal - - O
PTFL - - O
, - - O
elevated - - O
the - - O
nociceptive - - O
threshold - - O
for - - O
mechanical - - O
stimuli - - O
in - - O
the - - O
formalin - - O
test - - O
in - - O
rats - - O
. - - O

The - - O
E1 - - B-MUT
nuclear - - I-MUT
transport - - I-MUT
motif - - I-MUT
is - - O
highly - - O
conserved - - O
in - - O
the - - O
animal - - O
and - - O
human - - O
papillomaviruses - - O
and - - O
is - - O
encoded - - O
in - - O
a - - O
similar - - O
region - - O
in - - O
the - - O
related - - O
E1 - - B-MUT
genes - - I-MUT
. - - O

Rapid - - O
evolution - - O
of - - O
the - - O
DNA-binding - - O
site - - O
in - - O
LAGLIDADG - - B-MUT
homing - - I-MUT
endonucleases - - I-MUT
. - - O

The - - O
gene - - O
is - - O
contained - - O
within - - O
a - - O
1 - - B-MUT
. - - I-MUT
8-kilobase - - I-MUT
AccI-EcoRI - - I-MUT
restriction - - I-MUT
fragment - - I-MUT
mapping - - O
at - - O
map - - O
coordinates - - O
0 - - O
. - - O
136 - - O
to - - O
0 - - O
. - - O
148 - - O
in - - O
the - - O
UL - - B-MUT
region - - I-MUT
of - - O
the - - O
EHV-1 - - O
genome - - O
and - - O
is - - O
transcribed - - O
from - - O
right - - O
to - - O
left - - O
. - - O

Alternatively - - O
processed - - O
isoforms - - O
of - - O
cellular - - B-MUT
nucleic - - I-MUT
acid-binding - - I-MUT
protein - - I-MUT
interact - - O
with - - O
a - - O
suppressor - - O
region - - O
of - - O
the - - O
human - - B-MUT
beta-myosin - - I-MUT
heavy - - I-MUT
chain - - I-MUT
gene - - I-MUT
. - - O

Improvement - - O
of - - O
the - - O
polypyrimidine - - O
tract - - O
also - - O
increased - - O
the - - O
splicing - - O
efficiency - - O
, - - O
but - - O
to - - O
a - - O
degree - - O
slightly - - O
less - - O
than - - O
that - - O
obtained - - O
with - - O
the - - O
branchpoint - - O
mutation - - O
. - - O

Thus - - O
, - - O
the - - O
predicted - - O
CD30v - - B-MUT
protein - - I-MUT
retains - - O
most - - O
of - - O
the - - O
cytoplasmic - - O
region - - O
, - - O
but - - O
lacks - - O
the - - O
extracellular - - O
and - - O
transmembrane - - O
domains - - O
. - - O

To - - O
evaluate - - O
whether - - O
the - - O
human - - O
gene - - O
is - - O
also - - O
a - - O
target - - O
of - - O
thyroid - - O
hormone - - O
we - - O
have - - O
searched - - O
for - - O
T3-responsive - - B-MUT
elements - - I-MUT
in - - O
NRGN - - B-MUT
cloned - - O
genomic - - O
fragments - - O
spanning - - O
the - - O
whole - - O
gene - - O
. - - O

Validity - - O
of - - O
immunohistology - - O
and - - O
in - - O
situ - - O
hybridization - - O
in - - O
the - - O
differential - - O
diagnosis - - O
of - - O
cytomegalovirus - - O
pneumonia - - O
and - - O
idiopathic - - O
interstitial - - O
pneumonia - - O
after - - O
allogenic - - O
bone - - O
marrow - - O
transplantation - - O
. - - O

This - - O
work - - O
, - - O
therefore - - O
, - - O
also - - O
emphasizes - - O
the - - O
importance - - O
of - - O
careful - - O
choice - - O
of - - O
oligonucleotide - - O
and - - O
cDNA - - O
probes - - O
to - - O
study - - O
PKC - - B-MUT
zeta - - I-MUT
mRNA - - I-MUT
. - - O

A - - O
prospective - - O
observational - - O
study - - O
was - - O
conducted - - O
to - - O
identify - - O
early - - O
indicators - - O
of - - O
acute - - O
dengue - - O
virus - - O
infection - - O
. - - O

The - - O
homeobox - - B-MUT
gene - - I-MUT
ATK1 - - I-MUT
of - - O
Arabidopsis - - O
thaliana - - O
is - - O
expressed - - O
in - - O
the - - O
shoot - - O
apex - - O
of - - O
the - - O
seedling - - O
and - - O
in - - O
flowers - - O
and - - O
inflorescence - - O
stems - - O
of - - O
mature - - O
plants - - O
. - - O

From - - O
the - - O
Icelandic - - O
Red - - O
Cross - - O
activities - - O
. - - O

Since - - O
glutathione - - B-MUT
peroxidase - - I-MUT
( - - O
GPX - - B-MUT
) - - O
and - - O
superoxide - - B-MUT
dismutase - - I-MUT
( - - O
SOD - - B-MUT
) - - O
play - - O
a - - O
significant - - O
role - - O
in - - O
erythrocyte - - O
antioxidative - - O
defence - - O
, - - O
it - - O
is - - O
very - - O
important - - O
to - - O
determine - - O
their - - O
activity - - O
in - - O
occupationally - - O
exposed - - O
workers - - O
. - - O

Oligosynaptic - - O
EPSP - - O
components - - O
were - - O
consistently - - O
modulated - - O
only - - O
in - - O
the - - O
superficial - - O
peroneal - - O
responses - - O
in - - O
flexor - - O
motoneurons - - O
, - - O
which - - O
exhibited - - O
enhanced - - O
amplitude - - O
during - - O
the - - O
flexion - - O
phase - - O
. - - O

Like - - O
the - - O
consensus - - B-MUT
mammalian - - I-MUT
LHbeta - - I-MUT
gene - - I-MUT
, - - O
the - - O
5'-flanking - - O
region - - O
of - - O
the - - O
gpLH - - B-MUT
CGbeta - - I-MUT
gene - - I-MUT
contains - - I-MUT
a - - O
single - - O
TATA - - O
sequence - - O
37 - - O
bp - - O
upstream - - O
of - - O
the - - O
translation - - O
start - - O
codon - - O
. - - O

Marrow - - O
cell - - O
necrosis - - O
in - - O
anorexia - - O
nervosa - - O
and - - O
involuntary - - O
starvation - - O
. - - O

Blood - - O
pressure - - O
in - - O
children - - O
. - - O

Because - - O
the - - O
hcf109 - - B-MUT
locus - - I-MUT
was - - O
mapped - - O
at - - O
a - - O
distance - - O
< - - O
0 - - O
. - - O
1 - - O
centimorgans - - O
from - - O
the - - O
phytochrome - - B-MUT
C - - I-MUT
gene - - I-MUT
, - - O
its - - O
molecular - - O
characterization - - O
by - - O
positional - - O
cloning - - O
is - - O
possible - - O
. - - O

Despite - - O
this - - O
there - - O
was - - O
no - - O
difference - - O
in - - O
the - - O
intubating - - O
conditions - - O
at - - O
one - - O
minute - - O
with - - O
25 - - O
excellent - - O
5 - - O
good - - O
in - - O
the - - O
suxamethonium - - O
group - - O
and - - O
27 - - O
excellent - - O
3 - - O
good - - O
in - - O
the - - O
rocuronium - - O
group - - O
. - - O

However - - O
, - - O
by - - O
an - - O
NS35-specific - - B-MUT
RNA - - I-MUT
capture - - O
assay - - O
, - - O
the - - O
multimers - - O
were - - O
shown - - O
to - - O
possess - - O
the - - O
RNA-binding - - O
activity - - O
previously - - O
demonstrated - - O
for - - O
NS35 - - B-MUT
. - - O

This - - O
molecule - - O
, - - O
wH22xeGFP - - B-MUT
, - - O
consists - - O
of - - O
the - - O
entire - - B-MUT
humanized - - I-MUT
anti-FcgammaRI - - I-MUT
mAb - - I-MUT
H22 - - B-MUT
with - - O
eGFP - - B-MUT
genetically - - O
fused - - O
to - - O
the - - O
C-terminal - - O
end - - O
of - - O
each - - O
CH3 - - B-MUT
domain - - I-MUT
. - - O
wH22xeGFP - - B-MUT
binds - - O
within - - O
the - - O
ligand-binding - - O
region - - O
by - - O
its - - O
Fc - - B-MUT
end - - O
, - - O
as - - O
well - - O
as - - O
outside - - O
the - - O
ligand-binding - - O
region - - O
by - - O
its - - O
Fab - - B-MUT
ends - - O
, - - O
thereby - - O
cross-linking - - O
FcgammaRI - - B-MUT
. - - O

In - - O
contrast - - O
, - - O
the - - O
distribution - - O
of - - O
endocytic - - O
markers - - O
is - - O
not - - O
affected - - O
. - - O

For - - O
example - - O
, - - O
introduction - - O
of - - O
immunogenic - - O
and - - O
purification - - O
tag - - O
sequences - - O
into - - O
the - - O
C-terminal - - O
coding - - O
region - - O
significantly - - O
decreased - - O
bop - - B-MUT
gene - - I-MUT
mRNA - - I-MUT
and - - O
protein - - O
accumulation - - O
. - - O

Together - - O
, - - O
these - - O
data - - O
suggest - - O
that - - O
the - - O
carboxyl - - O
terminus - - O
of - - O
CFTR - - B-MUT
contains - - O
a - - O
tyrosine-based - - O
internalization - - O
signal - - O
that - - O
interacts - - O
with - - O
the - - O
endocytic - - O
adaptor - - O
complex - - O
AP-2 - - B-MUT
to - - O
facilitate - - O
efficient - - O
entry - - O
of - - O
CFTR - - B-MUT
into - - O
clathrin-coated - - O
vesicles - - O
. - - O

After - - O
treatment - - O
with - - O
tunicamycin - - O
, - - O
the - - O
transfectants - - O
secreted - - O
unglycosylated - - O
18-kDa - - O
polypeptides - - O
which - - O
could - - O
also - - O
bind - - O
IgE - - B-MUT
. - - O

Fisher's - - O
exact - - O
test - - O
or - - O
Pearson's - - O
chi2 - - O
test - - O
were - - O
used - - O
for - - O
statistical - - O
analysis - - O
. - - O

RNP1 - - B-MUT
, - - O
a - - O
new - - O
ribonucleoprotein - - O
gene - - O
of - - O
the - - O
yeast - - O
Saccharomyces - - O
cerevisiae - - O
. - - O

RESULTS - - O
: - - O
Basal - - O
plasma - - B-MUT
IGF-I - - I-MUT
levels - - O
as - - O
well - - O
as - - O
body - - O
mass - - O
index - - O
( - - O
BMI - - O
) - - O
were - - O
lower - - O
in - - O
amenorrheic - - O
patients - - O
than - - O
in - - O
healthy - - O
controls - - O
. - - O

Studies - - O
on - - O
Coxsackie - - O
B - - O
Type - - O
5 - - O
virus - - O
infections - - O
. - - O

Polymerase - - O
chain - - O
reaction - - O
analysis - - O
of - - O
ETS1 - - B-MUT
cDNA - - I-MUT
identified - - O
several - - O
amplified - - O
products - - O
, - - O
indicating - - O
alternative - - O
splicing - - O
. - - O

Platelet-derived - - O
growth - - O
factor-dependent - - O
activation - - O
of - - O
phosphatidylinositol - - B-MUT
3-kinase - - I-MUT
is - - O
regulated - - O
by - - O
receptor - - O
binding - - O
of - - O
SH2-domain-containing - - B-MUT
proteins - - I-MUT
which - - O
influence - - O
Ras - - B-MUT
activity - - O
. - - O

APC-resistance - - O
was - - O
determined - - O
with - - O
a - - O
functional - - O
method - - O
with - - O
high - - O
sensitivity - - O
and - - O
specificity - - O
for - - O
the - - O
factor - - B-MUT
V - - I-MUT
Leiden - - O
mutation - - O
. - - O

The - - O
activity - - O
of - - O
the - - O
coat - - B-MUT
protein - - I-MUT
promoter - - I-MUT
of - - O
chloris - - O
striate - - O
mosaic - - O
virus - - O
is - - O
enhanced - - O
by - - O
its - - O
own - - O
and - - O
C1-C2 - - B-MUT
gene - - I-MUT
products - - I-MUT
. - - O

The - - O
ether - - O
phospholipid - - O
1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine - - O
( - - O
ET-18-OCH3 - - O
; - - O
edelfosine - - O
) - - O
is - - O
a - - O
potent - - O
inducer - - O
of - - O
apoptosis - - O
in - - O
human - - O
tumor - - O
cells - - O
. - - O

The - - O
factor - - O
structure - - O
of - - O
"schizotypal' - - O
traits - - O
: - - O
a - - O
large - - O
replication - - O
study - - O
. - - O

Resistance - - O
to - - O
the - - O
simulated - - O
physiologic - - O
environment - - O
was - - O
tested - - O
by - - O
measured - - O
retention - - O
of - - O
mechanical - - O
properties - - O
after - - O
immersion - - O
times - - O
in - - O
pseudo-extracellular - - O
fluid - - O
( - - O
PECF - - O
) - - O
at - - O
37 - - O
degrees - - O
C - - O
for - - O
as - - O
long - - O
as - - O
three - - O
years - - O
. - - O

In - - O
the - - O
absence - - O
of - - O
other - - O
stabilizers - - O
, - - O
increased - - O
sucrose - - O
can - - O
provide - - O
increased - - O
thermoresistance - - O
to - - O
the - - O
virus - - O
in - - O
2 - - O
. - - O
5% - - O
albumin - - B-MUT
. - - O

We - - O
found - - O
that - - O
lung - - O
cancer - - O
tissues - - O
of - - O
positive - - O
67Ga - - O
scan - - O
expressed - - O
TFR - - B-MUT
, - - O
but - - O
those - - O
of - - O
a - - O
negative - - O
scan - - O
did - - O
not - - O
. - - O

The - - O
results - - O
of - - O
replicase - - B-MUT
assays - - O
performed - - O
with - - O
mutant - - B-MUT
VP2 - - I-MUT
containing - - O
a - - O
deletion - - O
in - - O
its - - O
RNA-binding - - O
domain - - O
suggests - - O
that - - O
the - - O
essential - - O
role - - O
for - - O
VP2 - - B-MUT
in - - O
replication - - O
is - - O
linked - - O
to - - O
the - - O
protein's - - O
ability - - O
to - - O
bind - - O
the - - O
mRNA - - O
template - - O
for - - O
minus-strand - - O
synthesis - - O
. - - O

No - - O
significant - - O
differences - - O
were - - O
found - - O
between - - O
the - - O
TS - - O
and - - O
the - - O
PTS - - O
. - - O

Recurrent - - O
arterial - - O
thrombotic - - O
disease - - O
on - - O
young - - O
onset - - O
and - - O
protein - - B-MUT
S - - I-MUT
deficiency - - O
. - - O

Three - - O
mutants - - O
( - - O
pms1 - - B-MUT
, - - O
pms2 - - B-MUT
and - - O
pms3 - - B-MUT
) - - O
isolated - - O
earlier - - O
from - - O
MW104-1B - - O
were - - O
shown - - O
to - - O
correct - - O
in - - O
vitro - - O
constructed - - O
plasmids - - O
with - - O
defined - - O
DNA - - O
mismatches - - O
( - - O
G - - O
T - - O
, - - O
A - - O
C - - O
, - - O
G - - O
G - - O
, - - O
etc - - O
. - - O
) - - O
poorly - - O
( - - O
Kramer - - O
et - - O
al - - O
. - - O
, - - O
1989a - - O
) - - O
. - - O

Hemolytic - - O
jaundice - - O
due - - O
to - - O
G6PD - - B-MUT
deficiency - - O
causing - - O
kernicterus - - O
in - - O
a - - O
female - - O
newborn - - O
. - - O

The - - O
presence - - O
of - - O
locus-specific - - O
residues - - O
throughout - - O
the - - O
entire - - O
promoter - - O
region - - O
strongly - - O
suggests - - O
that - - O
the - - O
various - - O
HLA - - B-MUT
class - - I-MUT
I - - I-MUT
loci - - I-MUT
are - - O
differentially - - O
regulated - - O
. - - O

Copyright - - O
1998 - - O
Academic - - O
Press - - O
. - - O

Computer - - O
assisted - - O
mapping - - O
in - - O
quantitative - - O
analysis - - O
of - - O
cerebral - - O
positron - - O
emission - - O
tomograms - - O
. - - O

Animal - - O
studies - - O
showed - - O
that - - O
beam - - O
equalization - - O
significantly - - O
improved - - O
fluoroscopic - - O
and - - O
angiographic - - O
image - - O
quality - - O
. - - O

Maternal - - O
lactation - - O
. - - O

In - - O
mouse - - O
, - - O
Mmip1 - - B-MUT
( - - O
Mad - - B-MUT
member - - I-MUT
interacting - - I-MUT
protein - - I-MUT
1 - - I-MUT
) - - O
and - - O
Smc3 - - B-MUT
share - - O
99% - - O
sequence - - O
identity - - O
and - - O
are - - O
products - - O
of - - O
the - - O
same - - O
gene - - O
. - - O

Intracellular - - O
pH - - O
, - - O
H - - O
ion - - O
flux - - O
and - - O
H - - O
ion - - O
permeability - - O
coefficient - - O
in - - O
bullfrog - - O
toe - - O
muscle - - O
. - - O

The - - O
variability - - O
is - - O
most - - O
likely - - O
a - - O
result - - O
of - - O
alternative - - O
splicing - - O
of - - O
exons - - O
from - - O
the - - O
primary - - O
elastin - - B-MUT
transcripts - - I-MUT
. - - O

Identification - - O
of - - O
the - - O
plakoglobin-binding - - O
domain - - O
in - - O
desmoglein - - B-MUT
and - - O
its - - O
role - - O
in - - O
plaque - - O
assembly - - O
and - - O
intermediate - - O
filament - - O
anchorage - - O
. - - O

Analysis - - O
of - - O
the - - O
promoter - - O
sequence - - O
revealed - - O
the - - O
presence - - O
of - - O
a - - O
major - - O
transcriptional - - O
start - - O
site - - O
, - - O
a - - O
canonical - - O
TATA - - O
box - - O
and - - O
putative - - O
cis - - O
regulatory - - O
elements - - O
for - - O
pituitary - - O
specific - - O
expression - - O
as - - O
well - - O
as - - O
an - - O
E-responsive - - B-MUT
element - - I-MUT
. - - O

We - - O
previously - - O
showed - - O
that - - O
the - - O
upstream - - B-MUT
promoter - - I-MUT
element - - I-MUT
of - - O
the - - O
yeast - - B-MUT
RP39A - - I-MUT
gene - - I-MUT
consists - - O
of - - O
these - - O
identical - - O
sequence - - O
motifs - - O
. - - O

The - - O
roles - - O
of - - O
phorbol - - O
esters - - O
and - - O
cyclic - - O
AMP - - O
in - - O
mediating - - O
the - - O
GnRH - - B-MUT
response - - O
were - - O
also - - O
investigated - - O
. - - O

Clinical - - O
and - - O
haematological - - O
signs - - O
are - - O
not - - O
specific - - O
in - - O
this - - O
setting - - O
, - - O
and - - O
the - - O
diagnosis - - O
relies - - O
on - - O
histological - - O
features - - O
, - - O
mainly - - O
bone - - O
marrow - - O
examination - - O
. - - O

In - - O
conclusion - - O
, - - O
the - - O
disposition - - O
of - - O
venlafaxine - - O
and - - O
O-desmethylvenlafaxine - - O
is - - O
markedly - - O
altered - - O
in - - O
renal - - O
disease - - O
; - - O
therefore - - O
dosage - - O
adjustment - - O
is - - O
warranted - - O
for - - O
patients - - O
with - - O
creatinine - - O
clearance - - O
values - - O
below - - O
30 - - O
ml - - O
min - - O
. - - O

The - - O
prevalence - - O
of - - O
tobacco - - O
dependence - - O
diagnosed - - O
according - - O
to - - O
the - - O
ICD-10 - - O
criteria - - O
was - - O
higher - - O
in - - O
alcohol-dependent - - O
individuals - - O
( - - O
58 - - O
. - - O
1% - - O
) - - O
than - - O
in - - O
nondrinkers - - O
or - - O
social - - O
drinkers - - O
( - - O
12 - - O
. - - O
8% - - O
) - - O
. - - O

The - - O
carboxyl-terminal - - O
transactivation - - O
domain - - O
of - - O
heat - - B-MUT
shock - - I-MUT
factor - - I-MUT
1 - - I-MUT
is - - O
negatively - - O
regulated - - O
and - - O
stress - - O
responsive - - O
. - - O

Three - - O
new - - O
aromatase - - B-MUT
inhibitors - - O
have - - O
recently - - O
completed - - O
phase - - O
III - - O
evaluation - - O
as - - O
treatment - - O
of - - O
metastatic - - O
breast - - O
cancer - - O
in - - O
post-menopausal - - O
women - - O
whose - - O
disease - - O
has - - O
progressed - - O
despite - - O
tamoxifen - - O
therapy - - O
: - - O
anastrozole - - O
( - - O
ARIMIDEX - - O
, - - O
Zeneca - - O
) - - O
, - - O
letrozole - - O
( - - O
FEMARA - - O
, - - O
Novartis - - O
) - - O
and - - O
vorozole - - O
( - - O
RIVIZOR - - O
, - - O
Janssen - - O
) - - O
. - - O

The - - O
recognition - - O
specificity - - O
of - - O
the - - O
p55 - - B-MUT
PDZ - - B-MUT
domain - - I-MUT
appears - - O
to - - O
be - - O
unique - - O
, - - O
since - - O
the - - O
three - - O
PDZ - - B-MUT
domains - - I-MUT
of - - O
hDlg - - B-MUT
( - - O
human - - O
lymphocyte - - O
homologue - - O
of - - O
the - - O
Drosophila - - B-MUT
discs - - I-MUT
large - - I-MUT
tumor - - I-MUT
suppressor - - I-MUT
) - - O
do - - O
not - - O
bind - - O
the - - O
cytoplasmic - - O
domain - - O
of - - O
glycophorin - - B-MUT
C - - I-MUT
. - - O

Tolerance - - O
in - - O
renal - - O
transplantation - - O
after - - O
allogeneic - - O
bone - - O
marrow - - O
transplantation-6-year - - O
follow-up - - O
. - - O

The - - O
Fas - - B-MUT
receptor - - I-MUT
mediates - - O
a - - O
signalling - - O
cascade - - O
resulting - - O
in - - O
programmed - - O
cell - - O
death - - O
( - - O
apoptosis - - O
) - - O
within - - O
hours - - O
of - - O
receptor - - O
cross-linking - - O
. - - O

Moreover - - O
, - - O
it - - O
also - - O
discusses - - O
the - - O
effects - - O
of - - O
antihypertensive - - O
drugs - - O
currently - - O
regarded - - O
as - - O
first-choice - - O
agents - - O
, - - O
i - - O
. - - O
e - - O
. - - O
calcium - - O
antagonists - - O
and - - O
the - - O
angiotensin - - B-MUT
converting - - I-MUT
enzyme - - I-MUT
inhibitors - - O
, - - O
on - - O
intrarenal - - O
hemodynamics - - O
. - - O

Regulation - - O
of - - O
laminin - - B-MUT
beta2 - - I-MUT
chain - - I-MUT
gene - - I-MUT
expression - - O
in - - O
human - - O
cancer - - O
cell - - O
lines - - O
. - - O

Lesion - - O
diameters - - O
of - - O
greater - - O
than - - O
20 - - O
mm - - O
and - - O
the - - O
large - - O
sessile-type - - O
configurations - - O
were - - O
factors - - O
that - - O
were - - O
associated - - O
with - - O
incomplete - - O
removal - - O
. - - O

Effect - - O
of - - O
intraventricular - - O
administration - - O
of - - O
streptolysin - - B-MUT
O - - I-MUT
on - - O
the - - O
electroencephalogram - - O
of - - O
rabbits - - O
. - - O

Thus - - O
, - - O
diamide - - O
treatment - - O
of - - O
nuclear - - O
extracts - - O
strongly - - O
reduces - - O
the - - O
binding - - O
of - - O
NFI - - B-MUT
proteins - - I-MUT
, - - O
and - - O
the - - O
addition - - O
of - - O
higher - - O
concentrations - - O
of - - O
dithiothreitol - - O
to - - O
nuclear - - O
extracts - - O
from - - O
TG-treated - - O
cells - - O
restores - - O
NFI-DNA - - B-MUT
binding - - O
to - - O
levels - - O
in - - O
extracts - - O
from - - O
untreated - - O
cells - - O
. - - O

Subjects - - O
were - - O
16 - - O
male - - O
chronic - - O
schizophrenics - - O
consisting - - O
of - - O
8 - - O
DST - - O
suppressors - - O
and - - O
8 - - O
nonsuppressors - - O
. - - O

In - - O
these - - O
cells - - O
, - - O
E2 - - B-MUT
proteins - - I-MUT
had - - O
little - - O
or - - O
no - - O
stimulatory - - O
effect - - O
on - - O
the - - O
transcriptional - - O
activity - - O
of - - O
the - - O
HPV-11 - - B-MUT
enhancer-SV40 - - I-MUT
promoter - - I-MUT
. - - O

Constructs - - O
designed - - O
and - - O
expressed - - O
were - - O
E2L1 - - B-MUT
( - - I-MUT
1-98 - - I-MUT
) - - I-MUT
, - - O
E2L1 - - B-MUT
. - - I-MUT
H1 - - I-MUT
( - - I-MUT
1-128 - - I-MUT
) - - I-MUT
, - - O
E2L2 - - B-MUT
( - - I-MUT
120-233 - - I-MUT
) - - I-MUT
, - - O
E2H1 - - B-MUT
. - - I-MUT
L2 - - I-MUT
( - - I-MUT
98-233 - - I-MUT
) - - I-MUT
, - - O
and - - O
E2L1 - - B-MUT
. - - I-MUT
H1 - - I-MUT
. - - I-MUT
L2 - - I-MUT
( - - I-MUT
1-233 - - I-MUT
) - - I-MUT
, - - O
where - - O
numbers - - O
in - - O
parentheses - - O
give - - O
the - - O
amino - - O
acid - - O
sequence - - O
for - - O
the - - O
portions - - O
of - - O
the - - O
E2 - - B-MUT
component - - O
incorporated - - O
into - - O
a - - O
construct - - O
. - - O

633+ - - O
-258 - - O
aggregates - - O
ml - - O
at - - O
0 - - O
rpm - - O
; - - O
P - - O
< - - O
0 - - O
. - - O
001 - - O
) - - O
. - - O

Deglycosylation - - O
with - - O
endoglycosidase - - B-MUT
H - - I-MUT
showed - - O
that - - O
the - - O
mutant - - O
receptors - - O
had - - O
mainly - - O
high-mannose - - O
oligosaccharide - - O
chains - - O
. - - O

Pulmonary - - O
arterial - - O
pressure - - O
and - - O
structure - - O
in - - O
the - - O
patas - - O
monkey - - O
after - - O
prolonged - - O
administration - - O
of - - O
aminorex - - O
fumarate - - O
. - - O

This - - O
multiple-electrode - - O
array - - O
for - - O
round - - O
window - - O
cochlear - - O
implantation - - O
is - - O
a - - O
robust - - O
, - - O
reliable - - O
system - - O
for - - O
inserting - - O
20 - - O
mm - - O
along - - O
the - - O
scala - - O
tympani - - O
with - - O
a - - O
minimum - - O
of - - O
trauma - - O
and - - O
can - - O
provide - - O
for - - O
bipolar - - O
stimulation - - O
. - - O

Although - - O
there - - O
is - - O
little - - O
evidence - - O
that - - O
diet - - O
composition - - O
plays - - O
a - - O
clinically - - O
important - - O
role - - O
in - - O
the - - O
absorption - - O
or - - O
expenditure - - O
of - - O
energy - - O
, - - O
it - - O
does - - O
appear - - O
to - - O
play - - O
a - - O
role - - O
in - - O
food - - O
intake - - O
. - - O

This - - O
observation - - O
calls - - O
for - - O
careful - - O
monitoring - - O
of - - O
calcium - - O
and - - O
alkaline - - B-MUT
phosphatase - - I-MUT
values - - O
and - - O
possible - - O
adjustments - - O
of - - O
vitamin - - O
D - - O
intake - - O
when - - O
fortifiers - - O
are - - O
used - - O
for - - O
extended - - O
periods - - O
. - - O

Interference - - O
with - - O
rheumatoid - - B-MUT
factor - - I-MUT
was - - O
only - - O
observed - - O
in - - O
the - - O
ELISA - - O
enzygnost - - O
if - - O
sera - - O
were - - O
not - - O
pretreated - - O
with - - O
latex - - O
adsorbents - - O
. - - O

A - - O
comparison - - O
of - - O
the - - O
promoters - - O
for - - O
muMIP-1 - - B-MUT
beta - - I-MUT
and - - O
muMIP-1 - - B-MUT
alpha - - I-MUT
reveals - - O
a - - O
conserved - - O
CK-1 - - B-MUT
element - - I-MUT
, - - O
but - - O
transient - - O
expression - - O
studies - - O
in - - O
RAW - - O
264 - - O
. - - O
7 - - O
macrophages - - O
with - - O
proximal - - O
fragments - - O
of - - O
either - - O
the - - O
muMIP-1 - - B-MUT
beta - - I-MUT
or - - O
the - - O
muMIP-1 - - B-MUT
alpha - - I-MUT
5' - - I-MUT
promoter - - I-MUT
fused - - O
to - - O
a - - O
human - - B-MUT
growth - - I-MUT
hormone - - I-MUT
reporter - - I-MUT
gene - - I-MUT
link - - O
LPS-inducibility - - O
in - - O
both - - O
to - - O
promoter - - O
segments - - O
near - - O
to - - O
, - - O
but - - O
not - - O
identical - - O
with - - O
, - - O
the - - O
consensus - - B-MUT
CK-1 - - I-MUT
sequence - - I-MUT
. - - O

Cardiac - - O
markers - - O
troponin - - B-MUT
T - - I-MUT
, - - O
CK-MB - - B-MUT
mass - - O
and - - O
myoglobin - - B-MUT
were - - O
helpful - - O
in - - O
the - - O
differential - - O
diagnosis - - O
of - - O
chest - - O
pain - - O
, - - O
even - - O
when - - O
the - - O
ECG - - O
was - - O
unremarkable - - O
or - - O
nonspecific - - O
. - - O

We - - O
have - - O
determined - - O
that - - O
the - - O
mutants - - O
define - - O
two - - O
complementation - - O
groups - - O
, - - O
designated - - O
cgs1+ - - B-MUT
and - - O
cgs2+ - - B-MUT
( - - O
continues - - O
to - - O
grow - - O
in - - O
stationary - - O
) - - O
. - - O

The - - O
ectopic - - O
expression - - O
of - - O
Oct-3 - - B-MUT
4 - - I-MUT
in - - I-MUT
hybrid - - O
cells - - O
under - - O
a - - O
constitutive - - O
promoter - - O
is - - O
sufficient - - O
for - - O
transcriptional - - O
activation - - O
of - - O
an - - O
octamer-dependent - - O
promoter - - O
. - - O

The - - O
accumulation - - O
of - - O
both - - O
LHA4 - - B-MUT
and - - O
LHA2 - - B-MUT
mRNAs - - I-MUT
is - - O
induced - - O
by - - O
the - - O
addition - - O
of - - O
exogenous - - O
sugars - - O
and - - O
this - - O
induction - - O
appears - - O
to - - O
be - - O
dependent - - O
on - - O
sugar - - O
uptake - - O
and - - O
metabolism - - O
, - - O
because - - O
mannitol - - O
and - - O
3-O-methylglucose - - O
do - - O
not - - O
stimulate - - O
mRNA - - O
accumulation - - O
. - - O

A - - O
further - - O
study - - O
on - - O
plasminogen - - B-MUT
activator - - I-MUT
release - - O
by - - O
vasoactive - - O
agents - - O
in - - O
the - - O
isolated - - O
perfused - - O
dog - - O
leg - - O
. - - O

Distal - - O
lower - - O
motor - - O
neuron - - O
syndrome - - O
with - - O
high-titer - - O
serum - - B-MUT
IgM - - I-MUT
anti-GM1 - - I-MUT
antibodies - - I-MUT
: - - O
improvement - - O
following - - O
immunotherapy - - O
with - - O
monthly - - O
plasma - - O
exchange - - O
and - - O
intravenous - - O
cyclophosphamide - - O
. - - O

Spfkh1 - - B-MUT
is - - O
transcribed - - O
in - - O
one - - O
open - - O
reading - - O
frame - - O
that - - O
contains - - O
the - - O
DNA - - O
binding - - O
domain - - O
, - - O
nuclear - - O
localization - - O
signal - - O
and - - O
transactivation - - O
domain - - O
. - - O

Using - - O
appropriate - - O
synthetic - - B-MUT
HSE - - I-MUT
oligonucleotides - - I-MUT
, - - O
three - - O
types - - O
of - - O
clones - - O
with - - O
potential - - O
HSE - - B-MUT
binding - - I-MUT
domains - - I-MUT
were - - O
isolated - - O
from - - O
a - - O
tomato - - O
lambda - - O
gt11 - - O
expression - - O
library - - O
by - - O
DNA-ligand - - O
screening - - O
. - - O

The - - O
presence - - O
of - - O
such - - O
a - - O
putative - - O
RNA- - - O
binding - - O
domain - - O
suggests - - O
a - - O
mechanism - - O
for - - O
the - - O
observed - - O
autoregulation - - O
of - - O
bacteriophage - - O
T4 - - B-MUT
DNA - - I-MUT
polymerase - - I-MUT
synthesis - - O
by - - O
binding - - O
to - - O
its - - O
own - - O
mRNA - - O
. - - O

Glutathione - - B-MUT
S-transferase - - I-MUT
( - - O
GST - - B-MUT
) - - O
-E2F - - B-MUT
and - - O
GST-DP - - B-MUT
fusion - - I-MUT
proteins - - I-MUT
were - - O
found - - O
to - - O
cooperate - - O
in - - O
binding - - O
to - - O
the - - O
three - - O
E2F - - B-MUT
sites - - I-MUT
in - - O
the - - O
DNA - - B-MUT
polymerase - - I-MUT
alpha - - I-MUT
gene - - I-MUT
promoter - - I-MUT
in - - O
vitro - - O
. - - O

Influence - - O
of - - O
metoprolol - - O
treatment - - O
on - - O
sympatho-adrenal - - O
activation - - O
of - - O
fibrinolysis - - O
. - - O

Secondary - - O
cleavage - - O
of - - O
RT - - B-MUT
at - - O
Trp-595-Tyr-596 - - B-MUT
of - - I-MUT
Pol - - I-MUT
yields - - O
a - - O
truncated - - O
form - - O
lacking - - O
the - - O
C-terminal - - B-MUT
RNase - - I-MUT
H - - I-MUT
domain - - I-MUT
. - - O

Although - - O
p48 - - B-MUT
gene - - I-MUT
induction - - O
is - - O
dependent - - O
on - - O
STAT1 - - B-MUT
and - - O
JAK1 - - B-MUT
, - - O
activated - - O
STAT1 - - B-MUT
does - - O
not - - O
bind - - O
to - - O
GATE - - B-MUT
. - - O

The - - O
second - - O
method - - O
, - - O
the - - O
"macro" - - O
assay - - O
, - - O
has - - O
a - - O
sensitivity - - O
range - - O
of - - O
0 - - O
. - - O
03-5 - - O
. - - O
0 - - O
micrograms - - O
phosphorus - - O
with - - O
100-500 - - O
microliters - - O
HClO4 - - O
. - - O

In - - O
contrast - - O
, - - O
c-Src-derived - - B-MUT
construct - - I-MUT
( - - O
a-Src - - B-MUT
) - - O
, - - O
that - - O
was - - O
excluded - - O
from - - O
detergent-resistant - - O
membranes - - O
, - - O
could - - O
not - - O
restore - - O
the - - O
series - - O
of - - O
phagocytosis - - O
signaling - - O
. - - O

Ime1 - - B-MUT
plays - - O
a - - O
pivotal - - O
role - - O
in - - O
the - - O
initiation - - O
of - - O
meiosis - - O
in - - O
a - - O
alpha - - O
diploid - - O
cells - - O
of - - O
Saccharomyces - - O
cerevisiae - - O
. - - O

Concentrations - - O
of - - O
N - - O
( - - O
O3- - - O
) - - O
-N - - O
and - - O
N - - O
( - - O
H3- - - O
) - - O
-N - - O
at - - O
Deoprayag - - O
varied - - O
from - - O
0 - - O
. - - O
30 - - O
to - - O
0 - - O
. - - O
50 - - O
and - - O
0 - - O
. - - O
02 - - O
to - - O
0 - - O
. - - O
12 - - O
mg - - O
L - - O
, - - O
respectively - - O
, - - O
depending - - O
on - - O
season - - O
. - - O

To - - O
characterize - - O
this - - O
effect - - O
, - - O
we - - O
looked - - O
for - - O
targets - - O
of - - O
NS1 - - B-MUT
influenza - - I-MUT
virus - - I-MUT
protein - - I-MUT
among - - O
cellular - - O
translation - - O
factors - - O
. - - O

Innervation - - O
of - - O
the - - O
ventral - - O
diaphragm - - O
of - - O
the - - O
locust - - O
( - - O
Locusta - - O
migratoria - - O
) - - O
. - - O

In - - O
the - - O
37 - - O
patients - - O
without - - O
lung - - O
disease - - O
respiratory - - O
muscle - - O
weakness - - O
was - - O
accompanied - - O
by - - O
significant - - O
decreases - - O
in - - O
vital - - O
capacity - - O
, - - O
total - - O
lung - - O
capacity - - O
, - - O
and - - O
maximum - - O
voluntary - - O
ventilation - - O
; - - O
by - - O
significant - - O
increases - - O
in - - O
residual - - O
volume - - O
and - - O
arterial - - O
carbon - - O
dioxide - - O
tension - - O
( - - O
PaCO2 - - O
) - - O
; - - O
and - - O
greater - - O
likelihood - - O
of - - O
dependence - - O
on - - O
ventilators - - O
, - - O
atelectasis - - O
, - - O
and - - O
pneumonia - - O
. - - O

Of - - O
600 - - O
mediastinoscopies - - O
carried - - O
out - - O
from - - O
1966 - - O
to - - O
1973 - - O
, - - O
479 - - O
were - - O
performed - - O
to - - O
assess - - O
the - - O
operability - - O
of - - O
a - - O
pulmonary - - O
carcinoma - - O
. - - O

These - - O
data - - O
provide - - O
the - - O
molecular - - O
tools - - O
for - - O
the - - O
final - - O
identification - - O
of - - O
the - - O
MKS - - B-MUT
and - - O
the - - O
MUL - - B-MUT
genes - - I-MUT
. - - O

Compared - - O
to - - O
those - - O
with - - O
normal - - O
renal - - O
functions - - O
, - - O
these - - O
patients - - O
were - - O
older - - O
( - - O
P - - O
< - - O
or - - O
= - - O
0 - - O
. - - O
01 - - O
) - - O
, - - O
had - - O
significantly - - O
elevated - - O
blood - - O
pressures - - O
( - - O
P - - O
< - - O
0 - - O
. - - O
01 - - O
or - - O
P - - O
= - - O
0 - - O
. - - O
0001 - - O
) - - O
, - - O
and - - O
in - - O
the - - O
case - - O
of - - O
Type - - O
1 - - O
DM - - O
, - - O
with - - O
a - - O
higher - - O
body - - O
mass - - O
index - - O
( - - O
P - - O
= - - O
0 - - O
. - - O
0001 - - O
) - - O
and - - O
waist-hip - - O
ratio - - O
( - - O
P - - O
< - - O
0 - - O
. - - O
01 - - O
) - - O
. - - O

Implications - - O
in - - O
biomonitoring - - O
of - - O
the - - O
observed - - O
accumulation - - O
patterns - - O
, - - O
especially - - O
in - - O
the - - O
different - - O
tissues - - O
of - - O
Posidonia - - O
oceanica - - O
, - - O
are - - O
discussed - - O
. - - O

T-cell - - B-MUT
receptor - - I-MUT
beta - - I-MUT
( - - O
TCR - - B-MUT
beta - - I-MUT
) - - O
gene - - O
rearrangements - - O
occur - - O
in - - O
a - - O
third - - O
of - - O
early - - O
B-cell - - O
acute - - O
lymphoblastic - - O
leukemias - - O
( - - O
ALLs - - O
) - - O
. - - O

This - - O
study - - O
assesses - - O
the - - O
feasibility - - O
and - - O
toxicity - - O
of - - O
adoptive - - O
immunotherapy - - O
with - - O
tumor - - O
infiltrating - - O
lymphocytes - - O
and - - O
recombinant - - B-MUT
interleukin-2 - - I-MUT
in - - O
29 - - O
patients - - O
who - - O
underwent - - O
resection - - O
for - - O
stage - - O
III - - O
non-small-cell - - O
lung - - O
cancer - - O
. - - O

The - - O
MXR - - B-MUT
gene - - I-MUT
encodes - - O
a - - O
half-transporter - - O
and - - O
the - - O
absence - - O
of - - O
cytogenetic - - O
evidence - - O
of - - O
coamplification - - O
of - - O
other - - O
regions - - O
suggests - - O
that - - O
a - - O
partner - - O
may - - O
not - - O
be - - O
overexpressed - - O
, - - O
and - - O
instead - - O
the - - O
MXR - - B-MUT
half-transporter - - I-MUT
homodimerizes - - O
to - - O
mediate - - O
drug - - O
transport - - O
. - - O

We - - O
compared - - O
the - - O
parameters - - O
pleural - - B-MUT
adenosine - - I-MUT
deaminase - - I-MUT
( - - O
PADA - - B-MUT
, - - O
determined - - O
in - - O
405 - - O
patients - - O
) - - O
, - - O
the - - O
PADA - - B-MUT
serum - - I-MUT
ADA - - I-MUT
ratio - - I-MUT
( - - O
P - - O
SADA - - B-MUT
; - - I-MUT
276 - - I-MUT
cases - - O
) - - O
, - - O
pleural - - O
lysozyme - - O
( - - B-MUT
PLYS - - I-MUT
, - - O
276 - - B-MUT
cases - - O
) - - O
, - - O
the - - O
PLYS - - O
serum - - O
LYS - - B-MUT
ratio - - I-MUT
( - - I-MUT
P - - I-MUT
SLYS - - O
; - - O
276 - - B-MUT
cases - - I-MUT
) - - I-MUT
, - - O
and - - O
pleural - - O
interferon - - O
gamma - - O
( - - O
IFN - - B-MUT
, - - I-MUT
145 - - I-MUT
cases - - O
) - - B-MUT
regarding - - O
their - - O
ability - - O
to - - O
differentiate - - O
tuberculous - - O
pleural - - O
effusions - - O
from - - O
others - - O
. - - O

176 - - O
: - - O
787-792 - - O
, - - O
1992 - - O
; - - O
M - - O
. - - O

An - - O
immunologically - - O
related - - O
protein - - O
was - - O
detected - - O
in - - O
ribosome - - O
and - - O
membrane - - O
fractions - - O
of - - O
mitochondria - - O
from - - O
Saccharomyces - - O
cerevisiae - - O
. - - O

As - - O
the - - O
components - - O
of - - O
these - - O
complexes - - O
, - - O
at - - O
least - - O
five - - O
TRBPs - - B-MUT
( - - O
p30 - - B-MUT
, - - O
p37 - - B-MUT
, - - O
p46 - - B-MUT
, - - O
p50 - - B-MUT
, - - O
and - - O
p56 - - B-MUT
) - - O
showing - - O
specific - - O
binding - - O
to - - O
the - - O
TAR - - B-MUT
RNA - - I-MUT
were - - O
detected - - O
in - - O
the - - O
uv - - O
cross-linking - - O
assay - - O
. - - O

Acute - - O
stress - - O
in - - O
7 - - O
rats - - O
also - - O
increased - - O
the - - O
mean - - O
amount - - O
of - - O
IL-6 - - B-MUT
released - - O
in - - O
the - - O
urine - - O
by - - O
31 - - O
. - - O
5% - - O
from - - O
775 - - O
. - - O
9 - - O
+ - - O
- - - O
69 - - O
. - - O
2 - - O
to - - O
1 - - O
, - - O
021 - - O
. - - O
1 - - O
+ - - O
- - - O
93 - - O
. - - O
3 - - O
pg - - O
. - - O
ml - - O
. - - O

All - - O
of - - O
the - - O
basal - - O
TPN - - O
solutions - - O
were - - O
isonitrogenous - - O
and - - O
identical - - O
in - - O
nutrient - - O
composition - - O
, - - O
except - - O
for - - O
the - - O
difference - - O
in - - O
energy - - O
level - - O
, - - O
which - - O
was - - O
adjusted - - O
with - - O
glucose - - O
. - - O

We - - O
used - - O
stored - - O
plasma - - O
samples - - O
from - - O
409 - - O
patients - - O
in - - O
the - - O
National - - O
Institute - - O
of - - O
Neurological - - O
Diseases - - O
and - - O
Stroke - - O
( - - O
NINDS - - O
) - - O
tissue - - B-MUT
plasminogen - - I-MUT
activator - - I-MUT
( - - O
t-PA - - B-MUT
) - - O
Stroke - - O
Trial - - O
to - - O
examine - - O
the - - O
relationship - - O
between - - O
an - - O
apolipoprotein - - B-MUT
( - - I-MUT
Apo - - I-MUT
) - - I-MUT
E2 - - I-MUT
or - - O
an - - O
Apo - - B-MUT
E4 - - I-MUT
phenotype - - O
and - - O
a - - O
favorable - - O
outcome - - O
3 - - O
months - - O
after - - O
stroke - - O
, - - O
the - - O
risk - - O
of - - O
intracerebral - - O
hemorrhage - - O
, - - O
and - - O
the - - O
response - - O
to - - O
intravenous - - O
t-PA - - B-MUT
therapy - - O
. - - O

The - - O
introns - - O
are - - O
1 - - O
. - - O
6-1 - - O
. - - O
9 - - O
kbp - - O
long - - O
. - - O

Relations - - O
between - - O
adrenergic - - O
mechanisms - - O
and - - O
analgesic - - O
effects - - O
. - - O

Here - - O
we - - O
demonstrate - - O
that - - O
native - - B-MUT
MRCK - - I-MUT
exists - - O
in - - O
high-molecular-weight - - O
complexes - - O
. - - O

In - - O
vitro - - O
binding - - O
studies - - O
demonstrate - - O
that - - O
eIF-5A - - B-MUT
is - - O
required - - O
for - - O
efficient - - O
interaction - - O
of - - O
Rev-NES - - B-MUT
with - - O
CRM1 - - B-MUT
exportin1 - - I-MUT
and - - I-MUT
that - - O
eIF-5A - - O
interacts - - B-MUT
with - - O
the - - O
nucleoporins - - O
CAN - - O
nup214 - - B-MUT
, - - I-MUT
nup153 - - I-MUT
, - - O
nup98 - - B-MUT
, - - O
and - - B-MUT
nup62 - - O
. - - O

The - - O
antihypertensive - - O
effect - - O
of - - O
Estulic - - O
has - - O
been - - O
examined - - O
over - - O
a - - O
12-month - - O
period - - O
in - - O
101 - - O
hypertensive - - O
patients - - O
. - - O

The - - O
thrombolytic - - O
effects - - O
of - - O
native - - O
tissue-type - - B-MUT
plasminogen - - I-MUT
activator - - I-MUT
( - - O
AK-124 - - B-MUT
) - - O
on - - O
experimental - - O
canine - - O
coronary - - O
thrombosis - - O
. - - O

Both - - O
immunophilins - - B-MUT
may - - O
have - - O
important - - O
roles - - O
in - - O
receptor - - O
assembly - - O
and - - O
may - - O
represent - - O
a - - O
new - - O
category - - O
of - - O
ligand- - - O
and - - O
calcium-dependent - - O
modulators - - O
of - - O
protein - - O
function - - O
. - - O

Substitutions - - O
of - - O
region - - O
I - - O
with - - O
synthetic - - O
sequences - - O
showed - - O
that - - O
no - - O
specific - - O
sequence - - O
but - - O
rather - - O
repeats - - O
of - - O
three - - O
or - - O
more - - O
consecutive - - O
adenines - - O
or - - O
thymines - - O
, - - O
without - - O
interruption - - O
by - - O
guanine - - O
or - - O
cytosine - - O
, - - O
are - - O
required - - O
for - - O
the - - O
ARS - - B-MUT
activity - - O
. - - O

The - - O
coding - - O
region - - O
of - - O
2385 - - O
nucleotides - - O
corresponds - - O
to - - O
a - - O
polypeptide - - O
chain - - O
of - - O
795 - - O
amino - - O
acids - - O
, - - O
giving - - O
a - - O
molecular - - O
weight - - O
of - - O
91 - - O
, - - O
555 - - O
for - - O
the - - O
hsp108 - - B-MUT
protein - - I-MUT
. - - O

Both - - O
neural - - O
and - - O
hormonal - - O
pathways - - O
and - - O
both - - O
opiate - - O
and - - O
nonopiate - - O
substances - - O
play - - O
roles - - O
in - - O
the - - O
complex - - O
modulation - - O
of - - O
pain - - O
transmission - - O
. - - O

Sequence - - O
analysis - - O
suggests - - O
that - - O
TtrA - - B-MUT
contains - - O
a - - O
molybdopterin - - O
guanine - - O
dinucleotide - - O
cofactor - - O
and - - O
a - - O
[ - - O
4Fe-4S - - O
] - - O
cluster - - O
, - - O
that - - O
TtrB - - B-MUT
binds - - O
four - - O
[ - - O
4Fe-4S - - O
] - - O
clusters - - O
, - - O
and - - O
that - - O
TtrC - - B-MUT
is - - O
an - - O
integral - - O
membrane - - O
protein - - O
containing - - O
a - - O
quinol - - O
oxidation - - O
site - - O
. - - O

A - - O
tyrosine-based - - O
sorting - - O
signal - - O
in - - O
the - - O
beta2 - - B-MUT
integrin - - I-MUT
cytoplasmic - - I-MUT
domain - - I-MUT
mediates - - O
its - - O
recycling - - O
to - - O
the - - O
plasma - - O
membrane - - O
and - - O
is - - O
required - - O
for - - O
ligand-supported - - O
migration - - O
. - - O

The - - O
IE0 - - B-MUT
gene - - I-MUT
product - - O
also - - O
transactivated - - O
the - - O
IE1 - - B-MUT
promoter - - I-MUT
but - - O
did - - O
not - - O
affect - - O
expression - - O
from - - O
its - - O
own - - O
promoter - - O
. - - O

Variations - - O
of - - O
the - - O
timing - - O
of - - O
deflections - - O
in - - O
the - - O
His - - O
bundle - - O
recordings - - O
. - - O

The - - O
probability - - O
of - - O
treatment - - O
with - - O
lamotrigine - - O
being - - O
maintained - - O
for - - O
six - - O
months - - O
was - - O
86% - - O
, - - O
for - - O
twelve - - O
months - - O
61% - - O
and - - O
for - - O
three - - O
years - - O
31% - - O
. - - O

The - - O
ventilation - - O
did - - O
not - - O
increase - - O
when - - O
PACO2 - - O
was - - O
increased - - O
. - - O

The - - O
Arabidopsis - - B-MUT
FAD7 - - I-MUT
gene - - I-MUT
encodes - - O
a - - O
chloroplast - - B-MUT
omega-3 - - I-MUT
fatty - - I-MUT
acid - - I-MUT
desaturase - - I-MUT
that - - O
catalyzes - - O
the - - O
desaturation - - O
of - - O
lipid-linked - - O
dienoic - - O
fatty - - O
acids - - O
( - - O
18 - - O
: - - O
2 - - O
and - - O
16 - - O
: - - O
2 - - O
) - - O
. - - O

Transient - - O
overexpression - - O
of - - O
c-Jun - - B-MUT
induced - - O
tenascin-C - - B-MUT
expression - - O
in - - O
primary - - O
REF - - O
and - - O
in - - O
FR3T3 - - O
, - - O
an - - O
established - - O
fibroblast - - O
cell - - O
line - - O
. - - O

Dual - - O
roles - - O
of - - O
p82 - - B-MUT
, - - O
the - - O
clam - - O
CPEB - - B-MUT
homolog - - I-MUT
, - - O
in - - O
cytoplasmic - - O
polyadenylation - - O
and - - O
translational - - O
masking - - O
. - - O

Arterial - - O
radioactivity - - O
content - - O
after - - O
the - - O
intravenous - - O
administration - - O
of - - O
HMPAO - - O
in - - O
seven - - O
human - - O
subjects - - O
was - - O
analyzed - - O
. - - O

The - - O
alterations - - O
of - - O
5-HT - - O
and - - O
5-HIAA - - O
levels - - O
in - - O
several - - O
regions - - O
of - - O
the - - O
brain - - O
under - - O
the - - O
conditions - - O
examined - - O
may - - O
indicate - - O
that - - O
IDPN's - - O
neurotoxicity - - O
primarily - - O
affects - - O
5-HT-containing - - O
neurones - - O
. - - O

The - - O
recruitment - - O
of - - O
constitutively - - O
phosphorylated - - O
p185 - - B-MUT
( - - O
neu - - B-MUT
) - - O
and - - O
the - - O
activated - - O
mitogenic - - O
pathway - - O
proteins - - O
to - - O
this - - O
membrane-microfilament - - O
interaction - - O
site - - O
provides - - O
a - - O
physical - - O
model - - O
for - - O
integrating - - O
the - - O
assembly - - O
of - - O
the - - O
mitogenic - - O
pathway - - O
with - - O
the - - O
transmission - - O
of - - O
growth - - B-MUT
factor - - I-MUT
signal - - O
to - - O
the - - O
cytoskeleton - - O
. - - O

The - - O
outcome - - O
of - - O
the - - O
optimization - - O
of - - O
the - - O
seven-field - - O
plan - - O
prompted - - O
an - - O
investigation - - O
into - - O
the - - O
best - - O
results - - O
that - - O
could - - O
be - - O
achieved - - O
by - - O
an - - O
"ideal" - - O
conformal - - O
radiotherapy - - O
technique - - O
. - - O

The - - O
site-directed - - O
mutation - - O
of - - O
the - - O
kappa - - B-MUT
B - - I-MUT
motif - - I-MUT
in - - O
IL-6 - - B-MUT
CAT - - I-MUT
plasmid - - I-MUT
resulted - - O
in - - O
the - - O
complete - - O
abrogation - - O
of - - O
IL-6 - - O
promoter - - B-MUT
activity - - I-MUT
in - - O
these - - O
cells - - O
. - - O

METHODS - - O
: - - O
P-selectin - - B-MUT
expression - - O
of - - O
nonstimulated - - O
and - - O
ADP-stimulated - - O
platelets - - O
was - - O
flow - - O
cytometrically - - O
measured - - O
before - - O
the - - O
clopidogrel - - O
loading - - O
dose - - O
and - - O
on - - O
3 - - O
consecutive - - O
days - - O
in - - O
52 - - O
patients - - O
with - - O
coronary - - O
artery - - O
disease - - O
: - - O
21 - - O
patients - - O
in - - O
group - - O
1 - - O
received - - O
300 - - O
mg - - O
of - - O
clopidogrel - - O
after - - O
stent - - O
implantation - - O
and - - O
11 - - O
patients - - O
in - - O
group - - O
2 - - O
received - - O
the - - O
higher - - O
450-mg - - O
clopidogrel - - O
loading - - O
dose - - O
followed - - O
by - - O
a - - O
daily - - O
dose - - O
of - - O
75 - - O
mg - - O
of - - O
clopidogrel - - O
for - - O
both - - O
groups - - O
. - - O

The - - O
mouse - - B-MUT
beta - - I-MUT
2-syntrophin - - I-MUT
gene - - I-MUT
( - - O
> - - O
33 - - O
kilobases - - O
) - - O
contains - - O
seven - - O
exons - - O
, - - O
all - - O
of - - O
which - - O
have - - O
homologues - - O
at - - O
the - - O
corresponding - - O
position - - O
in - - O
the - - O
alpha - - B-MUT
1-syntrophin - - I-MUT
gene - - I-MUT
. - - O

Interestingly - - O
, - - O
the - - O
avirulent - - O
strain - - O
H37Ra - - O
showed - - O
weak - - O
hybridization - - O
with - - O
these - - O
two - - O
probes - - O
, - - O
suggesting - - O
that - - O
these - - O
genes - - O
might - - O
have - - O
been - - O
deleted - - O
in - - O
the - - O
avirulent - - O
strain - - O
or - - O
are - - O
present - - O
in - - O
limited - - O
copy - - O
numbers - - O
as - - O
opposed - - O
to - - O
those - - O
in - - O
the - - O
virulent - - O
strain - - O
H37Rv - - O
. - - O

In - - O
contrast - - O
to - - O
MPc3 - - B-MUT
, - - O
data - - O
indicate - - O
that - - O
the - - O
Pc - - B-MUT
protein - - I-MUT
M33 - - B-MUT
does - - O
not - - O
interact - - O
with - - O
AF9 - - B-MUT
. - - O

Expression - - O
of - - O
this - - O
protein - - O
in - - O
E - - O
. - - O
coli - - O
demonstrated - - O
that - - O
tyrosine - - O
was - - O
incorporated - - O
during - - O
suppression - - O
and - - O
that - - O
yeast - - B-MUT
cytoplasmic - - I-MUT
TyrRS - - I-MUT
activity - - O
was - - O
produced - - O
. - - O

Nucleotide - - O
sequence - - O
analysis - - O
of - - O
the - - O
Pseudomonas - - B-MUT
putida - - I-MUT
PpG7 - - I-MUT
salicylate - - I-MUT
hydroxylase - - I-MUT
gene - - I-MUT
( - - O
nahG - - B-MUT
) - - O
and - - O
its - - O
3'-flanking - - O
region - - O
. - - O

Taken - - O
together - - O
, - - O
our - - O
data - - O
suggest - - O
that - - O
PecS - - B-MUT
attenuates - - O
pelD - - B-MUT
and - - O
pelE - - B-MUT
expression - - O
rather - - O
than - - O
acting - - O
as - - O
a - - O
true - - O
repressor - - O
like - - O
KdgR - - B-MUT
. - - O

In - - O
several - - O
cell - - O
lines - - O
, - - O
mTOR - - B-MUT
or - - O
its - - O
downstream - - O
targets - - O
can - - O
be - - O
regulated - - O
by - - O
phosphatidylinositol - - B-MUT
( - - I-MUT
PI - - I-MUT
) - - I-MUT
3-kinase - - I-MUT
; - - O
protein - - B-MUT
kinases - - I-MUT
A - - I-MUT
, - - I-MUT
B - - I-MUT
, - - I-MUT
and - - I-MUT
C - - I-MUT
; - - O
heterotrimeric - - B-MUT
G-proteins - - I-MUT
; - - O
a - - O
PD98059-sensitive - - O
kinase - - B-MUT
or - - O
calcium - - O
; - - O
as - - O
well - - O
as - - O
by - - O
amino - - O
acids - - O
. - - O

Sequences - - O
downstream - - O
of - - O
the - - O
two - - O
human - - B-MUT
CA - - I-MUT
genes - - I-MUT
, - - O
possibly - - O
containing - - O
homologous - - O
enhancer - - O
elements - - O
, - - O
have - - O
not - - O
yet - - O
been - - O
reported - - O
. - - O

This - - O
establishes - - O
Rad3 - - B-MUT
Mec1 - - O
as - - B-MUT
the - - O
only - - O
conserved - - O
protein - - O
which - - O
is - - O
required - - O
for - - O
all - - O
the - - O
DNA - - O
structure - - O
checkpoints - - O
in - - O
both - - O
yeast - - O
model - - O
systems - - O
. - - O

However - - O
, - - O
plasmids - - O
carrying - - O
the - - O
yeast - - B-MUT
TyrRS - - I-MUT
gene - - I-MUT
could - - O
not - - O
be - - O
stably - - O
maintained - - O
in - - O
E - - O
. - - O
coli - - O
. - - O

16 - - O
percent - - O
, - - O
P - - O
< - - O
0 - - O
. - - O
001 - - O
) - - O
, - - O
and - - O
sustained - - O
normalization - - O
of - - O
serum - - B-MUT
alanine - - I-MUT
aminotransferase - - I-MUT
levels - - O
( - - O
41 - - O
percent - - O
vs - - O
. - - O

The - - O
sequence - - O
was - - O
determined - - O
of - - O
6493 - - O
nucleotides - - O
encompassing - - O
the - - O
bet - - B-MUT
genes - - I-MUT
of - - I-MUT
Escherichia - - I-MUT
coli - - I-MUT
which - - O
encode - - O
the - - O
osmoregulatory - - O
choline-glycine - - B-MUT
betaine - - I-MUT
pathway - - I-MUT
. - - O

135 - - O
students - - O
had - - O
a - - O
count - - O
of - - O
less - - O
than - - O
50 - - O
eggs - - O
10 - - O
ml - - O
. - - O
urine - - O
and - - O
56 - - O
had - - O
more - - O
than - - O
50 - - O
eggs - - O
10 - - O
ml - - O
. - - O

Based - - O
on - - O
the - - O
hypothesis - - O
that - - O
evolutionarily - - O
conserved - - O
regions - - O
are - - O
functionally - - O
important - - O
and - - O
likely - - O
to - - O
interact - - O
with - - O
coactivators - - O
, - - O
we - - O
compared - - O
the - - O
amino - - O
acid - - O
sequence - - O
of - - O
C - - B-MUT
EBPalpha - - I-MUT
from - - I-MUT
different - - O
species - - O
( - - O
frog - - O
to - - O
human - - O
) - - O
and - - O
identified - - O
four - - O
highly - - O
conserved - - O
regions - - O
( - - O
CR1-CR4 - - O
) - - B-MUT
within - - O
the - - O
transactivation - - O
domain - - O
. - - O

Evidence - - O
for - - O
a - - O
novel - - O
MAPKKK-independent - - O
pathway - - O
controlling - - O
the - - O
stress - - O
activated - - O
Sty1 - - B-MUT
Spc1 - - I-MUT
MAP - - I-MUT
kinase - - I-MUT
in - - I-MUT
fission - - O
yeast - - O
. - - O

A - - O
recombinant - - O
derivative - - O
harboring - - O
the - - O
pMJ101 - - O
replication - - O
region - - O
proved - - O
to - - O
be - - O
compatible - - O
with - - O
pJM1 - - O
, - - O
a - - O
plasmid - - O
containing - - O
the - - O
iron - - O
acquisition - - O
system - - O
required - - O
for - - O
the - - O
virulence - - O
of - - O
V - - O
. - - O
anguillarum - - O
775 - - O
, - - O
another - - O
important - - O
pathogen - - O
that - - O
causes - - O
vibriosis - - O
. - - O

Five - - O
of - - O
these - - O
have - - O
ocular - - O
or - - O
oculocutaneous - - O
albinism - - O
. - - O

NH3 - - O
and - - O
NO - - O
interaction - - O
with - - O
Si - - O
( - - O
100 - - O
) - - O
- - - O
( - - O
2 - - O
x - - O
1 - - O
) - - O
surfaces - - O
. - - O

Normal - - O
values - - O
for - - O
the - - O
peripheral - - O
blood - - O
and - - O
bone - - O
marrow - - O
of - - O
the - - O
grey - - O
( - - O
Armenian - - O
) - - O
hamster - - O
. - - O

Lipoprotein - - B-MUT
lipase - - I-MUT
( - - O
LPL - - B-MUT
) - - O
, - - O
a - - O
key - - O
enzyme - - O
in - - O
normal - - O
lipoprotein - - O
metabolism - - O
, - - O
has - - O
a - - O
complex - - O
pattern - - O
of - - O
regulation - - O
and - - O
tissue-specific - - O
expression - - O
. - - O

Protein - - O
electrophoresis - - O
showed - - O
decreased - - O
albumin - - B-MUT
levels - - O
in - - O
both - - O
groups - - O
, - - O
with - - O
lower - - O
values - - O
in - - O
G2 - - O
. - - O

A - - O
xylE - - B-MUT
transcriptional - - I-MUT
fusion - - I-MUT
to - - O
the - - O
putative - - O
mxbD - - B-MUT
promoter - - I-MUT
showed - - O
low-level - - O
expression - - O
in - - O
wild-type - - O
cells - - O
grown - - O
on - - O
one-carbon - - O
( - - O
C1 - - O
) - - O
compounds - - O
and - - O
no - - O
detectable - - O
expression - - O
in - - O
cells - - O
grown - - O
on - - O
succinate - - O
. - - O

The - - O
variable - - O
phenotype - - O
of - - O
the - - O
allotetraploids - - O
could - - O
not - - O
be - - O
explained - - O
by - - O
cytological - - O
abnormalities - - O
. - - O

The - - O
RNase - - B-MUT
MRP - - I-MUT
RNA - - I-MUT
gene - - I-MUT
was - - O
deleted - - O
by - - O
insertional - - O
replacement - - O
and - - O
found - - O
to - - O
be - - O
essential - - O
for - - O
cellular - - O
viability - - O
, - - O
indicating - - O
a - - O
critical - - O
nuclear - - O
role - - O
for - - O
RNase - - B-MUT
MRP - - I-MUT
. - - O

Studies - - O
on - - O
the - - O
method - - O
of - - O
size - - O
reduction - - O
of - - O
medicinal - - O
compounds - - O
. - - O

A - - O
human - - B-MUT
Raf-responsive - - I-MUT
zinc-finger - - I-MUT
protein - - I-MUT
that - - O
binds - - O
to - - O
divergent - - O
sequences - - O
. - - O

Copyright - - O
1999 - - O
Academic - - O
Press - - O
. - - O

One - - O
of - - O
these - - O
small - - B-MUT
inteins - - I-MUT
might - - O
be - - O
inactive - - O
or - - O
a - - O
"pseudo - - B-MUT
intein - - I-MUT
. - - I-MUT
" - - I-MUT
The - - O
results - - O
suggest - - O
a - - O
modular - - O
architecture - - O
for - - O
inteins - - B-MUT
, - - O
clarify - - O
their - - O
origin - - O
and - - O
relationship - - O
to - - O
other - - O
protein - - O
families - - O
, - - O
and - - O
extend - - O
recent - - O
experimental - - O
findings - - O
on - - O
the - - O
functional - - O
roles - - O
of - - O
intein - - B-MUT
N - - I-MUT
, - - I-MUT
C - - I-MUT
, - - I-MUT
and - - I-MUT
EN - - I-MUT
motifs - - I-MUT
. - - O

220 - - O
, - - O
263-273 - - O
) - - O
. - - O

As - - O
in - - O
S - - O
. - - O
cerevisiae - - O
, - - O
the - - O
sequence - - O
of - - O
rhp51+ - - B-MUT
showed - - O
two - - O
MluI - - B-MUT
cell-cycle - - I-MUT
boxes - - I-MUT
and - - O
a - - O
putative - - O
DNA - - O
damage-responsive - - O
element - - O
in - - O
its - - O
upstream - - O
region - - O
. - - O

There - - O
was - - O
no - - O
competition - - O
between - - O
activin - - B-MUT
A - - I-MUT
and - - O
OP-1 - - B-MUT
for - - O
availability - - O
of - - O
Smad4 - - B-MUT
, - - O
indicating - - O
that - - O
the - - O
concentration - - O
of - - O
this - - O
common - - O
signal - - O
transducer - - O
is - - O
not - - O
limiting - - O
for - - O
generating - - O
the - - O
observed - - O
biological - - O
responses - - O
. - - O

Intra-articular - - O
dislocation - - O
of - - O
the - - O
patella - - O
. - - O

Pneumothorax - - O
during - - O
laparoscopic - - O
dissection - - O
of - - O
the - - O
diaphragmatic - - O
hiatus - - O
. - - O

Dosage - - O
in - - O
both - - O
cases - - O
was - - O
0 - - O
. - - O
2 - - O
g - - O
m2 - - O
. - - O

Molecular - - O
cloning - - O
and - - O
functional - - O
characterization - - O
of - - O
murine - - B-MUT
sphingosine - - I-MUT
kinase - - I-MUT
. - - O

Processing - - O
of - - O
the - - O
polycistronic - - O
precursor - - O
requires - - O
nucleases - - B-MUT
also - - O
involved - - O
in - - O
rRNA - - B-MUT
processing - - O
, - - O
i - - O
. - - O
e - - O
. - - O
, - - O
Rnt1p - - B-MUT
and - - O
Rat1p - - B-MUT
. - - O

Hyperactivation - - O
of - - O
Cdc2 - - B-MUT
in - - O
fission - - O
yeast - - O
causes - - O
cells - - O
to - - O
undergo - - O
a - - O
lethal - - O
premature - - O
mitosis - - O
called - - O
mitotic - - O
catastrophe - - O
. - - O

Tissue-specific - - O
expression - - O
of - - O
the - - O
diazepam-binding - - B-MUT
inhibitor - - I-MUT
in - - O
Drosophila - - O
melanogaster - - O
: - - O
cloning - - O
, - - O
structure - - O
, - - O
and - - O
localization - - O
of - - O
the - - O
gene - - O
. - - O

Competition - - O
analysis - - O
by - - O
gel - - O
mobility - - O
shift - - O
electrophoresis - - O
indicates - - O
that - - O
this - - O
DNA-protein - - O
interaction - - O
is - - O
novel - - O
and - - O
not - - O
related - - O
to - - O
many - - O
transcription - - O
factors - - O
previously - - O
reported - - O
. - - O

Nevertheless - - O
, - - O
we - - O
demonstrate - - O
that - - O
the - - O
entire - - O
three-component - - O
yeast - - O
capping - - O
apparatus - - O
, - - O
consisting - - O
of - - O
RNA - - B-MUT
5'-triphosphatase - - I-MUT
( - - O
Cet1p - - B-MUT
) - - O
, - - O
RNA - - B-MUT
guanylyltransferase - - I-MUT
( - - O
Ceg1p - - B-MUT
) - - O
, - - O
and - - O
Abd1p - - B-MUT
could - - O
be - - O
replaced - - O
in - - O
vivo - - O
by - - O
the - - O
two-component - - O
mammalian - - O
apparatus - - O
consisting - - O
of - - O
a - - O
bifunctional - - O
triphosphatase-guanylyltransferase - - B-MUT
Mce1p - - I-MUT
and - - O
the - - O
methyltransferase - - B-MUT
Hcm1 - - I-MUT
( - - I-MUT
121-476 - - I-MUT
) - - I-MUT
p - - I-MUT
. - - O

We - - O
purified - - O
a - - O
Ca2+ - - B-MUT
calmodulin - - I-MUT
( - - I-MUT
CaM - - I-MUT
) - - I-MUT
-dependent - - I-MUT
protein - - I-MUT
kinase - - I-MUT
( - - I-MUT
CaM - - I-MUT
kinase - - I-MUT
) - - I-MUT
from - - I-MUT
the - - I-MUT
yeast - - I-MUT
Saccharomyces - - I-MUT
cerevisiae - - I-MUT
with - - I-MUT
properties - - O
similar - - O
to - - O
mammalian - - O
type - - B-MUT
II - - I-MUT
CaM - - I-MUT
kinases - - I-MUT
. - - I-MUT

The - - O
247-kDa - - O
complex - - O
appears - - O
to - - O
contain - - O
two - - O
distinct - - O
protein-DNA - - O
complexes - - O
of - - O
approximately - - O
232 - - O
and - - O
256 - - O
kDa - - O
and - - O
represents - - O
two - - O
proteins - - O
covalently - - O
cross-linked - - O
to - - O
a - - O
single - - O
DRE - - B-MUT
oligonucleotide - - O
, - - O
while - - O
the - - O
97 - - O
, - - O
105 - - O
, - - O
and - - O
115-kDa - - O
complexes - - O
represent - - O
single - - O
protein-DRE - - B-MUT
cross-links - - O
. - - O

Identification - - O
of - - O
a - - O
promoter-specific - - O
transactivation - - O
domain - - O
in - - O
the - - O
herpes - - B-MUT
simplex - - I-MUT
virus - - I-MUT
regulatory - - I-MUT
protein - - I-MUT
ICP4 - - I-MUT
. - - O

In - - O
insects - - O
, - - O
arylalkylamine - - B-MUT
N-acetyltransferases - - I-MUT
( - - O
AANATs - - B-MUT
) - - O
have - - O
been - - O
implicated - - O
in - - O
several - - O
physiological - - O
processes - - O
, - - O
including - - O
sclerotization - - O
, - - O
inactivation - - O
of - - O
certain - - O
neurotransmitters - - O
, - - O
and - - O
, - - O
similar - - O
to - - O
the - - O
function - - O
in - - O
vertebrates - - O
, - - O
catalysis - - O
of - - O
the - - O
rate-limiting - - O
step - - O
in - - O
melatonin - - O
biosynthesis - - O
. - - O

Eliminating - - O
any - - O
subset - - O
of - - O
ASCUS - - O
reduces - - O
the - - O
ASCUS - - O
SIL - - O
ratio - - O
but - - O
also - - O
significantly - - O
diminishes - - O
the - - O
sensitivity - - O
of - - O
the - - O
Papanicolaou - - O
test - - O
. - - O

The - - O
enteric - - O
route - - O
is - - O
the - - O
principal - - O
mode - - O
of - - O
transmission - - O
for - - O
hepatitis - - O
A - - O
, - - O
but - - O
maximal - - O
levels - - O
of - - O
hepatitis - - O
A - - O
virus - - O
excretion - - O
occur - - O
before - - O
the - - O
onset - - O
of - - O
jaundice - - O
. - - O

Km - - O
values - - O
for - - O
ammonium - - O
, - - O
2-oxoglutarate - - O
, - - O
NADH - - O
, - - O
glutamate - - O
and - - O
NAD+ - - O
were - - O
6 - - O
. - - O
5 - - O
, - - O
3 - - O
. - - O
5 - - O
, - - O
0 - - O
. - - O
06 - - O
, - - O
37 - - O
. - - O
1 - - O
and - - O
0 - - O
. - - O
046 - - O
mM - - O
, - - O
respectively - - O
. - - O

ROS - - B-MUT
x - - O
SRC - - B-MUT
( - - O
R - - B-MUT
) - - O
contains - - O
a - - O
16-amino-acid - - O
deletion - - O
that - - O
includes - - O
the - - O
3' - - O
half - - O
of - - O
the - - O
transmembrane - - O
domain - - O
of - - O
ros - - B-MUT
. - - O

Unlike - - O
the - - O
typical - - O
enhancer - - O
element - - O
, - - O
this - - O
region - - O
functions - - O
in - - O
an - - O
orientation-dependent - - O
manner - - O
. - - O

We - - O
present - - O
this - - O
case - - O
because - - O
of - - O
the - - O
rarity - - O
of - - O
left - - O
ventricular - - O
involvement - - O
associated - - O
with - - O
ARVD - - O
. - - O

We - - O
describe - - O
a - - O
novel - - O
zinc - - B-MUT
finger - - I-MUT
protein - - I-MUT
, - - O
dsRBP-ZFa - - B-MUT
, - - O
isolated - - O
by - - O
screening - - O
an - - O
expression - - O
library - - O
with - - O
dsRNA - - O
. - - O

With - - O
respect - - O
to - - O
effective - - O
diffusivity - - O
of - - O
platelets - - O
( - - O
De - - O
) - - O
and - - O
the - - O
surface - - O
reactivity - - O
constant - - O
( - - O
K - - O
) - - O
, - - O
less - - O
significant - - O
differences - - O
were - - O
found - - O
among - - O
artificial - - O
materials - - O
. - - O

Catch-up - - O
growth - - O
was - - O
observed - - O
only - - O
for - - O
a - - O
12-month - - O
period - - O
in - - O
4 - - O
children - - O
with - - O
a - - O
bone - - O
age - - O
of - - O
7 - - O
to - - O
8 - - O
years - - O
. - - O

Am - - O
. - - O

The - - O
frequency - - O
of - - O
PPNG - - O
strains - - O
increased - - O
from - - O
1 - - O
. - - O
7% - - O
in - - O
1981 - - O
to - - O
6 - - O
. - - O
7% - - O
in - - O
1985 - - O
. - - O

These - - O
results - - O
suggested - - O
that - - O
NfxB - - B-MUT
negatively - - O
autoregulates - - O
the - - O
expression - - O
of - - O
nfxB - - B-MUT
itself - - O
. - - O

An - - O
egg - - O
protein - - O
, - - O
lysozyme - - B-MUT
, - - O
is - - O
a - - O
still - - O
unlabeled - - O
additive - - O
currently - - O
used - - O
in - - O
cheese - - O
preparation - - O
. - - O

Component - - O
P100 - - O
was - - O
associated - - O
with - - O
a - - O
frontal - - O
negativity - - O
of - - O
similar - - O
latency - - O
favoring - - O
the - - O
hypothesis - - O
of - - O
a - - O
dipolar - - O
occipital - - O
generator - - O
. - - O

W - - O
. - - O

No - - O
direct - - O
repeats - - O
flank - - O
the - - O
pseudogene - - O
in - - O
the - - O
U2 - - B-MUT
4 - - I-MUT
locus - - I-MUT
. - - I-MUT

Crossover - - O
in - - O
the - - O
specific - - O
heat - - O
of - - O
dilute - - O
magnets - - O
induced - - O
by - - O
critical - - O
spin-wave - - O
dynamics - - O
. - - O

The - - O
effects - - O
on - - O
reflex - - O
latencies - - O
but - - O
not - - O
on - - O
paCO2 - - O
or - - O
pHa - - O
were - - O
blocked - - O
by - - O
naloxone - - O
( - - O
2 - - O
mg - - O
kg - - O
) - - O
, - - O
and - - O
were - - O
not - - O
present - - O
in - - O
morphine-tolerant - - O
animals - - O
. - - O

Pharmacologic - - O
doses - - O
of - - O
vitamin - - O
B6 - - O
administered - - O
to - - O
lactating - - O
women - - O
have - - O
been - - O
reported - - O
to - - O
suppress - - O
plasma - - B-MUT
prolactin - - I-MUT
. - - O

In - - O
Group - - O
V - - O
, - - O
the - - O
salvaged - - O
tissue - - O
was - - O
primarily - - O
subepicardial - - O
with - - O
virtually - - O
no - - O
lateral - - O
zone - - O
of - - O
salvaged - - O
tissue - - O
( - - O
ratio - - O
of - - O
salvaged - - O
subepicardium - - O
to - - O
salvaged - - O
subendocardium - - O
14 - - O
. - - O
8 - - O
+ - - O
- - - O
1 - - O
. - - O
9 - - O
to - - O
1 - - O
) - - O
. - - O

In - - O
a - - O
previous - - O
interim - - O
report - - O
we - - O
noted - - O
more - - O
prompt - - O
resolution - - O
of - - O
dermatomal - - O
signs - - O
and - - O
symptoms - - O
with - - O
acyclovir - - O
treatment - - O
. - - O

In - - O
cellular - - O
supernatant - - O
fraction - - O
, - - O
SHRSP - - O
showed - - O
a - - O
decrease - - O
of - - O
magnesium - - O
in - - O
many - - O
tissues - - O
and - - O
an - - O
elevation - - O
of - - O
the - - O
calcium - - O
to - - O
magnesium - - O
ratio - - O
when - - O
compared - - O
to - - O
age-matched - - O
WKY - - O
and - - O
SHRSR - - O
. - - O

Cloning - - O
of - - O
a - - O
human - - B-MUT
phosphoinositide - - I-MUT
3-kinase - - I-MUT
with - - O
a - - O
C2 - - B-MUT
domain - - I-MUT
that - - O
displays - - O
reduced - - O
sensitivity - - O
to - - O
the - - O
inhibitor - - O
wortmannin - - O
. - - O

Selective - - O
bronchial - - O
intubation - - O
in - - O
the - - O
management - - O
of - - O
unilateral - - O
pulmonary - - O
interstitial - - O
emphysema - - O
. - - O

Kidney - - O
weight - - O
and - - O
kidney-to-body - - O
weight - - O
ratio - - O
were - - O
significantly - - O
elevated - - O
at - - O
the - - O
highest - - O
dose - - O
level - - O
after - - O
10 - - O
weeks - - O
and - - O
at - - O
the - - O
two - - O
higher - - O
dose - - O
levels - - O
after - - O
15 - - O
weeks - - O
of - - O
exposure - - O
. - - O

However - - O
, - - O
inhibition - - O
of - - O
both - - O
the - - O
ERK - - B-MUT
RSK - - I-MUT
and - - I-MUT
the - - O
p38 - - O
MAPKAP - - B-MUT
kinase - - I-MUT
2 - - I-MUT
pathways - - I-MUT
completely - - I-MUT
abolished - - O
NGF-induced - - O
CREB - - O
Ser-133 - - O
phosphorylation - - B-MUT
. - - O

Malaria - - O
, - - O
anaemia - - O
, - - O
and - - O
HIV-1 - - O
transmission - - O
in - - O
central - - O
Africa - - O
. - - O

Association - - O
with - - O
HL-A - - B-MUT
W-27 - - I-MUT
. - - O

Endonuclease - - B-MUT
III - - I-MUT
( - - O
Nth - - B-MUT
) - - O
of - - O
Escherichia - - O
coli - - O
is - - O
a - - O
DNA - - B-MUT
glycosylase - - I-MUT
essential - - O
for - - O
the - - O
removal - - O
of - - O
oxidised - - O
pyrimidine - - O
base - - O
residues - - O
from - - O
DNA - - O
. - - O

This - - O
sequence - - O
, - - O
Thr-Gly-X-X-Gly-Asp-Gly-Lys-Ile-Phe - - B-MUT
, - - O
forms - - O
part - - O
of - - O
the - - O
B-loop - - B-MUT
and - - O
is - - O
conserved - - O
in - - O
a - - O
wide - - O
variety - - O
of - - O
organisms - - O
that - - O
include - - O
bacteria - - O
, - - O
algae - - O
and - - O
archeabacteria - - O
. - - O

Hierarchy - - O
of - - O
protein - - B-MUT
tyrosine - - I-MUT
kinases - - I-MUT
in - - O
interleukin-2 - - B-MUT
( - - O
IL-2 - - B-MUT
) - - O
signaling - - O
: - - O
activation - - O
of - - O
syk - - B-MUT
depends - - O
on - - O
Jak3 - - B-MUT
; - - O
however - - O
, - - O
neither - - O
Syk - - B-MUT
nor - - O
Lck - - B-MUT
is - - O
required - - O
for - - O
IL-2-mediated - - O
STAT - - B-MUT
activation - - O
. - - O

Multifunctional - - B-MUT
protein - - I-MUT
kinase - - I-MUT
( - - O
MFPK - - B-MUT
) - - O
phosphorylates - - O
ATP-citrate - - B-MUT
lyase - - I-MUT
on - - O
peptide - - B-MUT
B - - I-MUT
on - - O
two - - O
sites - - O
, - - O
BT - - O
and - - O
BS - - O
, - - O
on - - O
threonine - - O
and - - O
serine - - O
, - - O
respectively - - O
, - - O
inhibitor - - B-MUT
2 - - I-MUT
on - - O
a - - O
threonyl - - O
residue - - O
, - - O
and - - O
glycogen - - B-MUT
synthase - - I-MUT
at - - O
sites - - O
2 - - O
and - - O
3 - - O
. - - O

Prrp - - B-MUT
can - - O
also - - O
associate - - O
with - - O
the - - O
EVH1 - - B-MUT
domain - - I-MUT
of - - O
Mena - - B-MUT
, - - O
another - - O
microfilament-associated - - O
protein - - O
. - - O

The - - O
full - - O
length - - O
cDNA - - O
sequence - - O
of - - O
a - - O
Type - - B-MUT
I - - I-MUT
transforming - - I-MUT
growth - - I-MUT
factor-beta - - I-MUT
( - - I-MUT
TGF-beta - - I-MUT
) - - I-MUT
receptor - - I-MUT
has - - O
been - - O
isolated - - O
from - - O
the - - O
filarial - - O
parasitic - - O
nematode - - O
Brugia - - O
pahangi - - O
. - - O

The - - O
sample - - O
includes - - O
all - - O
the - - O
HIV-infected-patients - - O
continuously - - O
referred - - O
to - - O
the - - O
Outpatient - - O
Service - - O
of - - O
the - - O
Infectious - - O
Diseases - - O
dept - - O
. - - O
of - - O
Bologna's - - O
"Ospedale - - O
Maggiore" - - O
General - - O
Hospital - - O
during - - O
some - - O
five - - O
days - - O
( - - O
19-23rd - - O
, - - O
July - - O
1993 - - O
) - - O
. - - O

Angiography - - O
was - - O
performed - - O
following - - O
the - - O
rCBF - - O
study - - O
and - - O
the - - O
degree - - O
of - - O
vasospasm - - O
was - - O
measured - - O
on - - O
the - - O
angiograms - - O
. - - O

Furthermore - - O
, - - O
no - - O
transcripts - - O
of - - O
the - - O
same - - O
size - - O
and - - O
having - - O
the - - O
same - - O
developmental - - O
profile - - O
as - - O
those - - O
generated - - O
by - - O
the - - O
wild-type - - B-MUT
E10 - - I-MUT
fragment - - I-MUT
were - - O
identified - - O
by - - O
probes - - O
covering - - O
the - - O
remainder - - O
of - - O
the - - O
cloned - - O
region - - O
. - - O

We - - O
discuss - - O
the - - O
need - - O
to - - O
use - - O
animals - - O
older - - O
than - - O
3 - - O
months - - O
for - - O
the - - O
study - - O
of - - O
'adult' - - O
regeneration - - O
phenomena - - O
since - - O
3-month-old - - O
rats - - O
may - - O
be - - O
somewhat - - O
immature - - O
. - - O

Sequence - - O
analysis - - O
of - - O
reverse - - O
transcribed - - O
, - - O
amplified - - O
cDNA - - O
generated - - O
from - - O
total - - O
RNA - - O
isolated - - O
from - - O
transfected - - O
cells - - O
demonstrated - - O
the - - O
presence - - O
of - - O
abnormally - - O
spliced - - O
products - - O
containing - - O
13 - - O
and - - O
78 - - O
additional - - O
bases - - O
as - - O
well - - O
as - - O
the - - O
accumulation - - O
of - - O
unspliced - - O
mRNA - - O
. - - O

Furthermore - - O
, - - O
a - - O
p21X - - B-MUT
protein - - I-MUT
lacking - - O
the - - O
N-terminus - - O
of - - O
Rex1 - - B-MUT
was - - O
expressed - - O
at - - O
high - - O
levels - - O
; - - O
our - - O
data - - O
indicate - - O
that - - O
p21X - - B-MUT
is - - O
translated - - O
from - - O
the - - O
1 - - O
. - - O
6-kb - - O
mRNA - - O
which - - O
is - - O
derived - - O
primarily - - O
from - - O
deleted - - O
proviruses - - O
. - - O

Diet - - O
and - - O
atopic - - O
eczema - - O
. - - O

High - - O
values - - O
of - - O
both - - O
retinol - - O
and - - O
beta-carotene - - O
were - - O
found - - O
in - - O
full - - O
fat - - O
cheeses - - O
and - - O
whipping - - O
cream - - O
: - - O
from - - O
179 - - O
. - - O
0 - - O
( - - O
cheese - - O
, - - O
Edam-type - - O
) - - O
to - - O
318 - - O
. - - O
7 - - O
micrograms - - O
100 - - O
g - - O
( - - O
whipping - - O
cream - - O
) - - O
and - - O
from - - O
86 - - O
. - - O
7 - - O
( - - O
cheese - - O
, - - O
Edam-type - - O
) - - O
to - - O
186 - - O
. - - O
5 - - O
micrograms - - O
100 - - O
g - - O
( - - O
whipping - - O
cream - - O
) - - O
for - - O
all-trans - - O
retinol - - O
and - - O
total - - O
beta-carotene - - O
, - - O
respectively - - O
. - - O

Troubled - - O
CareNetwork - - O
gets - - O
pact - - O
from - - O
largest - - O
teacher - - O
union - - O
in - - O
Wis - - O
. - - O

OBJECTIVE - - O
: - - O
To - - O
evaluate - - O
the - - O
relationship - - O
between - - O
blood - - O
flow - - O
in - - O
the - - O
tumor - - O
assessed - - O
by - - O
color - - O
Doppler - - O
ultrasound - - O
, - - O
microvessel - - O
density - - O
, - - O
and - - O
vascular - - B-MUT
endothelial - - I-MUT
growth - - I-MUT
factor - - I-MUT
levels - - O
in - - O
endometrial - - O
carcinoma - - O
. - - O

Among - - O
mucus-secreting - - O
cells - - O
, - - O
the - - O
gastric - - O
gland - - O
mucous - - O
cells - - O
, - - O
Brunner's - - O
glands - - O
, - - O
accessory - - O
glands - - O
of - - O
pancreaticobiliary - - O
tract - - O
, - - O
and - - O
pancreatic - - O
ducts - - O
exhibiting - - O
gastric - - O
metaplasia - - O
are - - O
unique - - O
in - - O
that - - O
they - - O
express - - O
class - - B-MUT
III - - I-MUT
mucin - - I-MUT
identified - - O
by - - O
paradoxical - - O
Con - - B-MUT
A - - I-MUT
staining - - O
composed - - O
of - - O
periodate - - O
oxidation - - O
, - - O
sodium - - O
borohydride - - O
reduction - - O
, - - O
Con - - B-MUT
A - - I-MUT
, - - O
and - - O
horseradish - - B-MUT
peroxidase - - I-MUT
reaction - - O
. - - O

Elevated - - O
IOP - - O
developed - - O
in - - O
35 - - O
patients - - O
( - - O
44 - - O
eyes - - O
) - - O
during - - O
the - - O
study - - O
. - - O

To - - O
determine - - O
the - - O
function - - O
of - - O
VZV - - B-MUT
gK - - I-MUT
in - - O
virus - - O
growth - - O
, - - O
a - - O
series - - O
of - - O
gK - - B-MUT
deletion - - I-MUT
mutants - - I-MUT
were - - O
constructed - - O
with - - O
VZV - - O
cosmid - - O
DNA - - O
derived - - O
from - - O
the - - O
Oka - - O
strain - - O
. - - O

The - - O
effect - - O
of - - O
independent - - O
predictors - - O
on - - O
survival - - O
was - - O
examined - - O
in - - O
a - - O
Cox - - O
regression - - O
model - - O
with - - O
adjustment - - O
for - - O
existing - - O
illnesses - - O
. - - O

Ectopic - - O
ACTH - - B-MUT
syndrome - - O
and - - O
medullary - - O
thyroid - - O
carcinoma - - O
. - - O

We - - O
observed - - O
that - - O
dephosphorylation - - O
severely - - O
inhibits - - O
the - - O
DNA-binding - - O
ability - - O
of - - O
C - - B-MUT
EBP-delta - - I-MUT
and - - I-MUT
its - - O
transactivating - - O
potential - - O
increases - - O
in - - O
the - - O
presence - - O
of - - O
cellular - - O
phosphatase - - O
inhibitors - - B-MUT
, - - O
such - - O
as - - O
okadaic - - O
acid - - O
and - - O
sodium - - O
orthovanadate - - O
. - - O

Furthermore - - O
, - - O
phosphatidylinositol - - O
( - - O
3 - - O
, - - O
4 - - O
, - - O
5 - - O
) - - O
trisphosphate - - O
specifically - - O
stimulates - - O
the - - O
activity - - O
of - - O
ILK - - B-MUT
in - - O
vitro - - O
, - - O
and - - O
in - - O
addition - - O
, - - O
membrane - - O
targetted - - O
constitutively - - O
active - - O
Pi - - B-MUT
( - - I-MUT
3 - - I-MUT
) - - I-MUT
K - - I-MUT
activates - - O
ILK - - B-MUT
in - - O
vivo - - O
. - - O

49 - - O
, - - O
XXXXY - - O
chromosome - - O
anomaly - - O
: - - O
an - - O
unusual - - O
variant - - O
of - - O
Klinefelter's - - O
syndrome - - O
. - - O

Propafenone - - O
is - - O
well - - O
tolerated - - O
in - - O
the - - O
majority - - O
of - - O
young - - O
patients - - O
. - - O

Furthermore - - O
, - - O
our - - O
novel - - O
observation - - O
that - - O
expression - - O
of - - O
a - - O
highly - - O
activated - - O
FGFR3 - - B-MUT
kinase - - I-MUT
domain - - I-MUT
is - - O
able - - O
to - - O
morphologically - - O
transform - - O
fibroblasts - - O
suggests - - O
that - - O
dysregulation - - O
of - - O
FGFR3 - - B-MUT
has - - O
the - - O
potential - - O
to - - O
play - - O
a - - O
role - - O
in - - O
human - - O
neoplasia - - O
. - - O

Postdocs - - O
face - - O
hardship - - O
across - - O
mainland - - O
Europe - - O
. - - O

C - - B-MUT
EBP - - I-MUT
alpha - - I-MUT
also - - I-MUT
activates - - O
the - - O
promoter - - O
of - - O
the - - O
rat - - O
class-I - - B-MUT
ADH - - I-MUT
gene - - I-MUT
in - - I-MUT
a - - O
sequence-specific - - O
manner - - O
[ - - O
Potter - - O
et - - O
al - - O
. - - O
, - - O
Arch - - O
. - - O

An - - O
experimental - - O
long-term - - O
study - - O
. - - O

XYL1 - - B-MUT
was - - O
isolated - - O
as - - O
a - - O
highly - - O
expressed - - O
fusion - - O
clone - - O
from - - O
a - - O
'lacZ - - B-MUT
translational - - O
fusion - - O
library - - O
. - - O

Only - - O
transcripts - - O
specific - - O
for - - O
TSGF-2 - - B-MUT
are - - O
detected - - O
in - - O
ovary - - O
and - - O
testes - - O
tissues - - O
of - - O
adults - - O
as - - O
well - - O
as - - O
in - - O
puparia - - O
, - - O
while - - O
neither - - O
gene - - O
is - - O
expressed - - O
during - - O
the - - O
larval - - O
developmental - - O
stages - - O
. - - O

Using - - O
RACE - - O
techniques - - O
we - - O
have - - O
cloned - - O
and - - O
sequenced - - O
one - - O
of - - O
the - - O
hamster - - O
liver - - O
3-hydroxy-hexobarbital - - B-MUT
dehydrogenases - - I-MUT
which - - O
catalyze - - O
not - - O
only - - O
cyclic - - O
alcohols - - O
but - - O
also - - O
17beta-hydroxy-steroids - - O
and - - O
3alpha-hydroxysteroids - - O
. - - O

Currently - - O
, - - O
the - - O
clinical - - O
use - - O
of - - O
5-aminolaevulinic - - O
acid - - O
( - - O
ALA - - O
) - - O
induced - - O
protoporphyrin - - B-MUT
IX - - I-MUT
( - - O
PPIX - - B-MUT
) - - O
for - - O
photodynamic - - O
therapy - - O
( - - O
PDT - - O
) - - O
is - - O
limited - - O
by - - O
the - - O
maximum - - O
tolerated - - O
oral - - O
ALA - - O
dose - - O
( - - O
60 - - O
mg - - O
kg - - O
) - - O
. - - O

The - - O
presence - - O
of - - O
an - - O
unusual - - O
transcript - - O
possessing - - O
IVS2C - - B-MUT
beta - - I-MUT
1 - - I-MUT
at - - O
the - - O
5' - - O
terminus - - O
suggests - - O
that - - O
cleavage - - O
of - - O
its - - O
splice - - O
acceptor - - O
is - - O
inefficient - - O
or - - O
negatively - - O
regulated - - O
. - - O

We - - O
found - - O
sequences - - O
related - - O
to - - O
this - - O
insertion - - O
in - - O
wild-type - - O
strains - - O
of - - O
N - - O
. - - O
crassa - - O
and - - O
other - - O
Neurospora - - O
species - - O
. - - O

The - - O
altered - - O
amino - - O
acid - - O
residues - - O
of - - O
the - - O
seven - - O
mutant - - B-MUT
9ORF1 - - I-MUT
polypeptides - - I-MUT
clustered - - O
within - - O
three - - O
separate - - O
regions - - O
referred - - O
to - - O
as - - O
region - - O
I - - O
( - - O
residues - - O
34 - - O
to - - O
41 - - O
) - - O
, - - O
region - - O
II - - O
( - - O
residues - - O
89 - - O
to - - O
91 - - O
) - - O
, - - O
and - - O
C-terminal - - O
region - - O
III - - O
( - - O
residues - - O
122 - - O
to - - O
125 - - O
) - - O
. - - O

A - - O
one - - O
base - - O
pair - - O
mismatch - - O
within - - O
the - - O
corresponding - - O
region - - O
of - - O
the - - O
CYP3A4 - - B-MUT
gene - - I-MUT
was - - O
sufficient - - O
for - - O
a - - O
differential - - O
enhancer - - O
activity - - O
. - - O

The - - O
recombinant - - O
purified - - O
protein - - O
expressed - - O
in - - O
the - - O
baculovirus - - O
system - - O
had - - O
an - - O
approximate - - O
molecular - - O
size - - O
20 - - O
kDa - - O
with - - O
amino-terminal - - B-MUT
sequence - - I-MUT
of - - I-MUT
AVQGP - - I-MUT
. - - O

During - - O
the - - O
2h - - O
resuscitation - - O
period - - O
, - - O
extracellular - - O
aspartate - - O
and - - O
glutamate - - O
concentrations - - O
in - - O
the - - O
cerebral - - O
striatum - - O
were - - O
higher - - O
during - - O
hypoxaemic - - O
resuscitation - - O
( - - O
p - - O
= - - O
0 - - O
. - - O
044 - - O
and - - O
p - - O
= - - O
0 - - O
. - - O
055 - - O
, - - O
respectively - - O
) - - O
than - - O
during - - O
resuscitation - - O
with - - O
21% - - O
O2 - - O
or - - O
100% - - O
O2 - - O
, - - O
suggesting - - O
an - - O
unfavourable - - O
accumulation - - O
of - - O
potent - - O
excitotoxins - - O
during - - O
hypoxaemic - - O
resuscitation - - O
. - - O

When - - O
overexpressed - - O
in - - O
an - - O
appropriate - - O
cell - - O
line - - O
, - - O
TAN-1C - - B-MUT
prevented - - O
kappa - - O
B-dependent - - O
transactivation - - O
in - - O
transient - - O
reporter - - O
gene - - O
assays - - O
in - - O
a - - O
fashion - - O
similar - - O
to - - O
the - - O
structurally - - O
related - - O
protein - - O
, - - O
Bcl-3 - - B-MUT
. - - O

Ras-GRF1 - - B-MUT
transiently - - O
expressed - - O
with - - O
v-Src - - B-MUT
was - - O
tyrosine-phosphorylated - - O
and - - O
showed - - O
significant - - O
GEF - - B-MUT
activity - - O
toward - - O
Rac - - B-MUT
, - - O
but - - O
not - - O
Rho - - B-MUT
and - - O
Cdc42 - - B-MUT
, - - O
which - - O
was - - O
comparable - - O
with - - O
that - - O
induced - - O
by - - O
Gbetagamma - - B-MUT
. - - O

Protein - - O
films - - O
are - - O
distinctly - - O
different - - O
in - - O
mechanical - - O
profiles - - O
from - - O
those - - O
films - - O
made - - O
of - - O
other - - O
materials - - O
. - - O

The - - O
5' - - O
flanking - - O
region - - O
of - - O
the - - O
CD1 - - B-MUT
gene - - I-MUT
contained - - O
the - - O
binding - - O
motifs - - O
for - - O
two - - O
cytokine-inducible - - O
transcription - - O
factors - - O
, - - O
NF-IL2-A - - B-MUT
and - - O
NF-IL6 - - B-MUT
. - - O

This - - O
, - - O
together - - O
with - - O
the - - O
data - - O
obtained - - O
with - - O
haloperidol - - O
, - - O
suggests - - O
that - - O
a - - O
minimal - - O
increase - - O
in - - O
the - - O
firing - - O
rate - - O
of - - O
LC - - O
cells - - O
( - - O
+140% - - O
) - - O
is - - O
required - - O
before - - O
it - - O
could - - O
influence - - O
the - - O
turnover - - O
of - - O
NA - - O
, - - O
as - - O
measured - - O
by - - O
DOPAC - - O
changes - - O
. - - O

A - - O
. - - O

Replacement - - O
of - - O
the - - O
CRE - - B-MUT
with - - O
a - - O
second - - O
copy - - O
of - - O
the - - O
AP-1 - - B-MUT
site - - I-MUT
results - - O
in - - O
a - - O
level - - O
of - - O
transcriptional - - O
activity - - O
comparable - - O
with - - O
that - - O
of - - O
the - - O
wild-type - - O
sequence - - O
, - - O
but - - O
replacement - - O
of - - O
the - - O
AP-1 - - B-MUT
site - - I-MUT
with - - O
a - - O
CRE - - B-MUT
abolishes - - O
activity - - O
. - - O

Silencing - - O
can - - O
be - - O
restored - - O
by - - O
creation - - O
of - - O
a - - O
telomere - - O
at - - O
13 - - O
kb - - O
from - - O
the - - O
reporter - - O
construct - - O
, - - O
or - - O
by - - O
insertion - - O
of - - O
340 - - O
bp - - O
of - - O
yeast - - O
telomeric - - O
repeat - - O
sequence - - O
at - - O
this - - O
site - - O
without - - O
chromosomal - - O
truncation - - O
. - - O

In - - O
mammals - - O
, - - O
the - - O
transcriptional - - O
repressors - - O
in - - O
the - - O
Wnt - - B-MUT
pathway - - I-MUT
are - - O
not - - O
well - - O
defined - - O
. - - O

They - - O
were - - O
found - - O
to - - O
be - - O
seropositive - - O
for - - O
antibodies - - O
to - - O
hepatitis - - O
C - - O
virus - - O
by - - O
second-generation - - O
testing - - O
( - - O
RIBA - - O
2 - - O
, - - O
Ortho - - O
Diagnostic - - O
Systems - - O
Inc - - O
, - - O
Westwood - - O
, - - O
MA - - O
) - - O
. - - O

Replacing - - O
the - - O
aspartic - - O
acid - - O
with - - O
a - - O
lysine - - O
but - - O
not - - O
with - - O
an - - O
alanine - - O
or - - O
valine - - O
residue - - O
allowed - - O
formation - - O
of - - O
disulfide-linked - - O
dimers - - O
. - - O

Acute - - O
effects - - O
of - - O
LI - - O
160 - - O
( - - O
extract - - O
of - - O
Hypericum - - O
perforatum - - O
, - - O
St - - O
John's - - O
wort - - O
) - - O
and - - O
two - - O
of - - O
its - - O
constituents - - O
on - - O
neuroendocrine - - O
responses - - O
in - - O
the - - O
rat - - O
. - - O

Additional - - O
studies - - O
revealed - - O
that - - O
bovine - - B-MUT
brain - - I-MUT
Galpha - - I-MUT
( - - I-MUT
q - - I-MUT
11 - - I-MUT
) - - I-MUT
could - - I-MUT
also - - O
bind - - O
to - - O
an - - O
N-terminal - - O
construct - - O
of - - O
GRK2 - - O
, - - B-MUT
while - - O
no - - O
binding - - O
of - - O
Galpha - - O
( - - B-MUT
q - - I-MUT
11 - - I-MUT
) - - I-MUT
, - - I-MUT
Galpha - - I-MUT
( - - O
s - - B-MUT
) - - I-MUT
, - - I-MUT
Galpha - - I-MUT
( - - O
i - - B-MUT
) - - I-MUT
, - - I-MUT
or - - I-MUT
Galpha - - O
( - - O
12 - - B-MUT
13 - - I-MUT
) - - I-MUT
to - - I-MUT
comparable - - I-MUT
constructs - - I-MUT
of - - O
GRK5 - - O
or - - O
GRK6 - - O
was - - B-MUT
observed - - O
. - - B-MUT

Within - - O
this - - O
sequence - - O
the - - O
MSAS - - B-MUT
gene - - I-MUT
was - - O
identified - - O
as - - O
a - - O
5322-bp-long - - O
open - - O
reading - - O
frame - - O
coding - - O
for - - O
a - - O
protein - - O
of - - O
1774 - - O
amino - - O
acids - - O
and - - O
190 - - O
, - - O
731 - - O
Da - - O
molecular - - O
mass - - O
. - - O

These - - O
introns - - O
belong - - O
to - - O
the - - O
class - - O
of - - O
nuclear - - O
pre-mRNA - - O
introns - - O
and - - O
contain - - O
typical - - O
5'- - - O
and - - O
3'-consensus - - O
sequences - - O
, - - O
as - - O
well - - O
as - - O
unique - - O
features - - O
. - - O

Due - - O
to - - O
its - - O
relatively - - O
soluble - - O
chemical - - O
form - - O
, - - O
90Sr - - O
was - - O
rapidly - - O
translocated - - O
from - - O
lung - - O
to - - O
bone - - O
where - - O
a - - O
substantial - - O
portion - - O
was - - O
retained - - O
for - - O
a - - O
long - - O
period - - O
of - - O
time - - O
. - - O

Patients - - O
and - - O
their - - O
relatives - - O
must - - O
be - - O
informed - - O
about - - O
the - - O
available - - O
effective - - O
treatment - - O
possibilities - - O
and - - O
about - - O
the - - O
right - - O
moment - - O
for - - O
their - - O
application - - O
in - - O
an - - O
individual - - O
patient - - O
. - - O

Initially - - O
, - - O
we - - O
observed - - O
that - - O
unmutated - - O
p53 - - B-MUT
is - - O
strongly - - O
expressed - - O
in - - O
premalignant - - O
mammary - - O
glands - - O
and - - O
in - - O
mammary - - O
tumors - - O
derived - - O
from - - O
the - - O
MMTV-c-myc - - O
strain - - O
. - - O

Regional - - O
cerebral - - O
blood - - O
flow - - O
( - - O
rCBF - - O
) - - O
measurements - - O
and - - O
psychiatric - - O
ratings - - O
were - - O
performed - - O
on - - O
seven - - O
schizophrenic - - O
patients - - O
( - - O
mean - - O
age - - O
= - - O
41 - - O
. - - O
4 - - O
years - - O
) - - O
who - - O
had - - O
been - - O
examined - - O
18 - - O
years - - O
previously - - O
in - - O
a - - O
study - - O
that - - O
used - - O
similar - - O
psychiatric - - O
ratings - - O
and - - O
a - - O
comparable - - O
rCBF - - O
technique - - O
. - - O

The - - O
Dox-A2 - - B-MUT
ORF - - I-MUT
driven - - O
by - - O
the - - O
TDH3 - - B-MUT
promoter - - I-MUT
complemented - - O
the - - O
phenotype - - O
of - - O
a - - O
strain - - O
deleted - - O
for - - O
sun2 - - B-MUT
. - - O

Examples - - O
are - - O
using - - O
more - - O
subjects - - O
or - - O
an - - O
improved - - O
research - - O
design - - O
, - - O
developing - - O
consensus - - O
statements - - O
or - - O
using - - O
meta-analysis - - O
. - - O

Eight - - O
highly - - O
trained - - O
male - - O
kayakers - - O
were - - O
studied - - O
to - - O
determine - - O
the - - O
relationship - - O
between - - O
critical - - O
power - - O
( - - O
CP - - O
) - - O
and - - O
the - - O
onset - - O
of - - O
blood - - O
lactate - - O
accumulation - - O
( - - O
OBLA - - O
) - - O
. - - O

The - - O
presence - - O
of - - O
the - - O
foreign - - O
gene - - O
was - - O
confirmed - - O
by - - O
Southern - - O
analysis - - O
. - - O

We - - O
have - - O
isolated - - O
and - - O
functionally - - O
characterized - - O
the - - O
mouse - - O
gene - - O
for - - O
the - - O
C2 - - B-MUT
subunit - - I-MUT
of - - O
the - - O
20S - - B-MUT
proteasome - - I-MUT
. - - O

A - - O
fluoroimmunoassay - - O
for - - O
the - - O
determination - - O
of - - O
serum - - O
of - - O
plasma - - O
levels - - O
of - - O
propranolol - - O
was - - O
developed - - O
using - - O
antibodies - - O
to - - O
propranolol - - O
coupled - - O
to - - O
magnetizable - - O
solid-phase - - O
particles - - O
and - - O
fluorescein-labeled - - O
propranolol - - O
as - - O
tracer - - O
. - - O

A - - O
beta2 - - B-MUT
RARE - - I-MUT
reporter - - I-MUT
construct - - I-MUT
in - - O
which - - O
the - - O
methylation-susceptible - - O
cytosines - - O
in - - O
the - - O
sense - - O
strand - - O
were - - O
replaced - - O
by - - O
thymine - - O
displayed - - O
marked - - O
loss - - O
of - - O
activity - - O
in - - O
a - - O
replicated - - O
chromatin-dependent - - O
manner - - O
. - - O

I - - O
. - - O

Effect - - O
of - - O
indomethacin - - O
and - - O
prostaglandin - - O
F2 - - O
alpha - - O
on - - O
parturition - - O
in - - O
swine - - O
. - - O

The - - O
subjects - - O
received - - O
a - - O
single - - O
500 - - O
mg - - O
dose - - O
of - - O
acetaminophen - - O
i - - O
. - - O
v - - O
. - - O
and - - O
concentrations - - O
in - - O
plasma - - O
were - - O
measured - - O
for - - O
360 - - O
minutes - - O
and - - O
in - - O
urine - - O
for - - O
24 - - O
h - - O
in - - O
order - - O
to - - O
estimate - - O
the - - O
production - - O
of - - O
metabolites - - O
. - - O

The - - O
H-reflex - - O
recovery - - O
curve - - O
was - - O
obtained - - O
after - - O
stimulation - - O
of - - O
the - - O
median - - O
nerve - - O
at - - O
the - - O
elbow - - O
and - - O
recording - - O
from - - O
the - - O
flexor - - O
carpi - - O
radialis - - O
. - - O

The - - O
experimental - - O
results - - O
showed - - O
that - - O
the - - O
coagulation-electrooxidation - - O
process - - O
could - - O
efficiently - - O
remove - - O
the - - O
color - - O
and - - O
the - - O
COD - - O
from - - O
the - - O
simulated - - O
dye - - O
wastewater - - O
. - - O

The - - O
predicted - - O
L - - B-MUT
mRNA - - I-MUT
was - - O
6398 - - O
nucleotides - - O
long - - O
and - - O
contained - - O
a - - O
single - - O
open - - O
reading - - O
frame - - O
corresponding - - O
to - - O
an - - O
L - - B-MUT
protein - - I-MUT
encompassing - - I-MUT
2109 - - I-MUT
amino - - I-MUT
acids - - I-MUT
with - - O
a - - O
MW - - O
of - - O
241 - - O
, - - O
546 - - O
. - - O

The - - O
kinetics - - O
of - - O
kinase - - B-MUT
activity - - O
within - - O
these - - O
complexes - - O
compared - - O
to - - O
CheA - - B-MUT
alone - - O
indicate - - O
approximately - - O
a - - O
50% - - O
decrease - - O
in - - O
the - - O
KM - - O
for - - O
ATP - - O
and - - O
a - - O
100-fold - - O
increase - - O
in - - O
the - - O
Vmax - - O
. - - O

Thyrotropin-induced - - O
expression - - O
of - - O
a - - O
gene - - O
for - - O
a - - O
ribosomal - - O
protein - - O
related - - O
to - - O
the - - O
trk - - B-MUT
oncogene - - I-MUT
. - - O

Gap - - B-MUT
b3 - - I-MUT
consists - - O
of - - O
two - - O
polypeptide - - O
chains - - O
( - - O
Mr - - O
= - - O
110 - - O
, - - O
000 - - O
and - - O
30 - - O
, - - O
000 - - O
) - - O
, - - O
which - - O
seem - - O
to - - O
be - - O
proteolytic - - O
cleavage - - O
products - - O
connected - - O
by - - O
disulfide - - O
bonds - - O
from - - O
a - - O
precursor - - O
protein - - O
. - - O

The - - O
observed - - O
sequence - - O
variation - - O
disrupts - - O
the - - O
first - - O
ORF - - O
in - - O
many - - O
Y's - - B-MUT
while - - O
most - - O
of - - O
the - - O
second - - O
ORF - - O
including - - O
the - - O
putative - - O
helicase - - B-MUT
region - - I-MUT
is - - O
unaffected - - O
. - - O

Serum - - O
IgG - - B-MUT
was - - O
initially - - O
elevated - - O
in - - O
6 - - O
patients - - O
. - - O

The - - O
cleavage - - O
site - - O
between - - O
VPg - - B-MUT
and - - O
RNA - - B-MUT
dependent - - I-MUT
RNA - - I-MUT
polymerase - - I-MUT
was - - O
predicted - - O
to - - O
be - - O
E445-T446 - - O
based - - O
on - - O
the - - O
amino - - O
acid - - O
sequence - - O
analysis - - O
of - - O
the - - O
polyprotein - - O
from - - O
different - - O
sobemoviruses - - O
. - - O

Twenty-one - - O
percent - - O
of - - O
these - - O
patients - - O
had - - O
neurologic - - O
disease - - O
that - - O
appeared - - O
to - - O
be - - O
responsible - - O
for - - O
the - - O
tinnitus - - O
. - - O

The - - O
indoor - - O
radon - - O
concentration - - O
in - - O
the - - O
summer - - O
( - - O
1990 - - O
) - - O
period - - O
ranged - - O
between - - O
8 - - O
and - - O
81 - - O
Bq - - O
m-3 - - O
, - - O
while - - O
in - - O
the - - O
winter - - O
( - - O
1989-1990 - - O
) - - O
it - - O
ranged - - O
between - - O
20 - - O
and - - O
143 - - O
Bq - - O
m-3 - - O
for - - O
the - - O
first - - O
year - - O
of - - O
measurements - - O
or - - O
between - - O
8 - - O
and - - O
92 - - O
Bq - - O
m-3 - - O
in - - O
the - - O
summer - - O
( - - O
1991 - - O
) - - O
period - - O
and - - O
between - - O
12 - - O
and - - O
119 - - O
Bq - - O
m-3 - - O
in - - O
the - - O
winter - - O
( - - O
1990-1991 - - O
) - - O
for - - O
the - - O
second - - O
year - - O
of - - O
measurements - - O
. - - O

The - - O
model - - O
is - - O
able - - O
to - - O
anticipate - - O
why - - O
the - - O
effect - - O
of - - O
water - - O
fluoridation - - O
on - - O
caries - - O
prevalence - - O
is - - O
most - - O
pronounced - - O
when - - O
caries - - O
is - - O
diagnosed - - O
at - - O
cavity - - O
level - - O
. - - O

Coronary - - O
arteries--old - - O
and - - O
new - - O
. - - O

False - - O
positive - - O
PET - - O
FDG - - O
corresponded - - O
to - - O
lung - - O
infection - - O
, - - O
degenerative - - O
bone - - O
disease - - O
, - - O
and - - O
reconstruction - - O
artifact - - O
. - - O

These - - O
changes - - O
were - - O
the - - O
result - - O
of - - O
a - - O
decrease - - O
in - - O
afterload - - O
: - - O
mean - - O
aortic - - O
pressure - - O
fell - - O
from - - O
85 - - O
+ - - O
- - - O
11 - - O
. - - O
8 - - O
to - - O
68 - - O
+ - - O
- - - O
19 - - O
. - - O
6 - - O
mmHg - - O
( - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
01 - - O
) - - O
and - - O
systemic - - O
arterial - - O
resistance - - O
fell - - O
from - - O
2 - - O
886 - - O
+ - - O
- - - O
745 - - O
to - - O
2 - - O
010 - - O
+ - - O
- - - O
610 - - O
dynes - - O
cm-5 - - O
sec - - O
m-2 - - O
( - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
01 - - O
) - - O
. - - O

Furthermore - - O
, - - O
we - - O
showed - - O
that - - O
ERSF - - B-MUT
including - - O
NF-Y - - B-MUT
and - - O
ATF6alpha - - B-MUT
and - - I-MUT
or - - I-MUT
beta - - I-MUT
and - - I-MUT
capable - - O
of - - O
binding - - O
to - - O
ERSE - - O
is - - B-MUT
indeed - - O
formed - - O
when - - O
the - - O
cellular - - O
UPR - - O
is - - B-MUT
activated - - O
. - - O

Demographic - - O
and - - O
clinical - - O
data - - O
were - - O
compared - - O
with - - O
a - - O
control - - O
group - - O
of - - O
339 - - O
healthy - - O
age-matched - - O
women - - O
and - - O
with - - O
a - - O
sample - - O
of - - O
224 - - O
women - - O
with - - O
wrist - - O
fracture - - O
. - - O

The - - O
gene - - O
sequence - - O
also - - O
identified - - O
a - - O
340-nucleotide - - O
RNA - - O
in - - O
total - - O
yeast - - O
RNA - - O
and - - O
in - - O
purified - - O
RNase - - B-MUT
MRP - - I-MUT
enzyme - - I-MUT
preparations - - O
. - - O

Further - - O
observations - - O
on - - O
resorption - - O
in - - O
guinea - - O
pigs - - O
following - - O
injections - - O
of - - O
trypan - - O
blue - - O
. - - O

The - - O
murine - - B-MUT
MHC - - I-MUT
class - - I-MUT
I - - I-MUT
genes - - I-MUT
, - - O
H-2Dq - - B-MUT
and - - O
H-2Lq - - B-MUT
, - - O
are - - O
strikingly - - O
homologous - - O
to - - O
each - - O
other - - O
, - - O
H-2Ld - - B-MUT
, - - O
and - - O
two - - O
genes - - O
reported - - O
to - - O
encode - - O
tumor-specific - - B-MUT
antigens - - I-MUT
. - - O

The - - O
introduction - - O
of - - O
an - - O
acidic - - O
residue - - O
at - - O
the - - O
second - - O
site - - O
was - - O
essential - - O
for - - O
suppression - - O
of - - O
the - - O
Asn-285 - - O
mutation - - O
because - - O
Lys-220 - - O
and - - O
Gln-220 - - O
second-site - - O
mutants - - O
of - - O
the - - O
Asn-285 - - O
mutant - - O
showed - - O
very - - O
low - - O
tetracycline - - O
resistance - - O
. - - O
( - - O
ABSTRACT - - O
TRUNCATED - - O
AT - - O
250 - - O
WORDS - - O
) - - O

The - - O
effects - - O
of - - O
antithrombotic - - O
drugs - - O
in - - O
patients - - O
with - - O
left - - O
ventricular - - O
thrombi - - O
: - - O
assessment - - O
with - - O
indium-111 - - O
platelet - - O
imaging - - O
and - - O
two-dimensional - - O
echocardiography - - O
. - - O

To - - O
identify - - O
additional - - O
non-Sir - - B-MUT
factors - - I-MUT
that - - O
affect - - O
rDNA - - O
silencing - - O
, - - O
we - - O
performed - - O
a - - O
genetic - - O
screen - - O
designed - - O
to - - O
isolate - - O
mutations - - O
which - - O
alter - - O
the - - O
expression - - O
of - - O
reporter - - O
genes - - O
integrated - - O
within - - O
the - - O
rDNA - - O
. - - O

Blood - - O
flow - - O
velocity - - O
waveforms - - O
were - - O
recorded - - O
by - - O
pulsed - - O
Doppler - - O
examination - - O
of - - O
the - - O
fetal - - O
internal - - O
carotid - - O
and - - O
middle - - O
cerebral - - O
arteries - - O
using - - O
the - - O
established - - O
transabdominal - - O
route - - O
as - - O
well - - O
as - - O
a - - O
new - - O
transvaginal - - O
approach - - O
. - - O

The - - O
first - - O
85 - - O
nt - - O
upstream - - O
of - - O
the - - O
transcription - - O
initiation - - O
site - - O
of - - O
the - - O
mouse - - B-MUT
desmin - - I-MUT
gene - - I-MUT
, - - O
which - - O
contain - - O
an - - O
E - - O
box - - O
( - - O
E1 - - B-MUT
) - - O
, - - O
the - - O
binding - - O
site - - O
of - - O
the - - O
helix-loop-helix - - O
myogenic - - O
regulators - - O
, - - O
are - - O
sufficient - - O
to - - O
confer - - O
low - - O
level - - O
muscle-specific - - O
expression - - O
. - - O

The - - O
first - - O
involved - - O
complementation - - O
of - - O
a - - O
nonphotosynthetic - - O
mutant - - O
of - - O
Chlamydomonas - - O
, - - O
CC-2341 - - O
( - - O
ac-u-g-2 - - O
. - - O
3 - - O
) - - O
, - - O
which - - O
has - - O
a - - O
frameshift - - O
mutation - - O
in - - O
the - - O
psaB - - B-MUT
gene - - I-MUT
, - - O
and - - O
selection - - O
of - - O
photosynthetic - - O
transformants - - O
on - - O
minimal - - O
medium - - O
. - - O

Moreover - - O
, - - O
the - - O
second - - O
RCC1-like - - B-MUT
motif - - I-MUT
located - - O
at - - O
the - - O
amino-terminus - - O
of - - O
p619 - - B-MUT
stimulates - - O
guanine - - O
nucleotide - - O
exchange - - O
on - - O
ARF1 - - B-MUT
and - - O
on - - O
members - - O
of - - O
the - - O
related - - O
Rab - - B-MUT
proteins - - I-MUT
, - - O
but - - O
not - - O
on - - O
other - - O
small - - B-MUT
GTP - - I-MUT
binding - - I-MUT
proteins - - I-MUT
such - - O
as - - O
Ran - - B-MUT
or - - O
R-Ras2 - - B-MUT
TC21 - - O
. - - B-MUT

Subcloning - - O
of - - O
DNA - - O
fragments - - O
from - - O
the - - O
8 - - O
. - - O
5-kilobase - - O
( - - O
kb - - O
) - - O
insert - - O
of - - O
pAVO4 - - O
defined - - O
a - - O
4-kb - - O
DNA - - O
fragment - - O
which - - O
contained - - O
the - - O
functional - - B-MUT
FBP+ - - I-MUT
gene - - I-MUT
and - - O
its - - O
regulatory - - O
region - - O
. - - O

Spectroscopy - - O
of - - O
negative - - O
ions - - O
utilizing - - O
multiphoton - - O
detachment - - O
in - - O
a - - O
Raman - - O
coupling - - O
regime - - O
. - - O

Bandshift - - O
experiments - - O
demonstrate - - O
that - - O
BmHR3A - - B-MUT
binds - - O
specifically - - O
to - - O
RORE - - B-MUT
( - - O
Retinoic - - B-MUT
acid-related - - I-MUT
Orphan - - I-MUT
receptor - - I-MUT
Response - - I-MUT
Element - - I-MUT
) - - O
-like - - O
sequences - - O
in - - O
the - - O
promoters - - O
of - - O
both - - O
genes - - O
, - - O
thus - - O
suggesting - - O
a - - O
direct - - O
role - - O
for - - O
BmHR3A - - B-MUT
in - - O
regulating - - O
the - - O
expression - - O
of - - O
BmGATAbeta - - B-MUT
and - - O
ESP - - B-MUT
genes - - I-MUT
during - - O
vitellogenesis - - O
. - - O

Drugs - - O
that - - O
are - - O
transformed - - O
via - - O
phase - - O
II - - O
reactions - - O
usually - - O
do - - O
not - - O
require - - O
dosage - - O
adjustment - - O
. - - O

100 - - O
years - - O
of - - O
dentistry - - O
at - - O
the - - O
Friedrich - - O
Schiller - - O
University - - O
in - - O
Jena - - O
. - - O

Gamma - - B-MUT
glutamyl - - I-MUT
transpeptidase - - I-MUT
( - - O
GGTP - - B-MUT
) - - O
activity - - O
in - - O
the - - O
seminal - - O
fluid - - O
. - - O

In - - O
addition - - O
to - - O
that - - O
, - - O
she - - O
received - - O
hepatic - - O
intra-arterial - - O
infusion - - O
of - - O
levoforinate - - O
( - - O
l-LV - - O
) - - O
250 - - O
mg - - O
and - - O
5-fluorouracil - - O
( - - O
5-FU - - O
) - - O
500 - - O
mg - - O
for - - O
combined - - O
multiple - - O
hepatic - - O
metastases - - O
starting - - O
on - - O
postoperative - - O
day - - O
14 - - O
, - - O
and - - O
these - - O
medications - - O
were - - O
administered - - O
over - - O
48 - - O
hours - - O
once - - O
weekly - - O
by - - O
infuser - - O
pump - - O
. - - O

The - - O
morphological - - O
effects - - O
of - - O
two - - O
snake - - O
venoms - - O
, - - O
N - - O
. - - O
naja - - O
and - - O
A - - O
. - - O
piscivorus - - O
, - - O
and - - O
of - - O
the - - O
Direct - - B-MUT
Lytic - - I-MUT
Factor - - I-MUT
and - - O
Phospholipase-A - - B-MUT
, - - O
compounds - - O
purified - - O
from - - O
N - - O
. - - O
naja - - O
crude - - O
venom - - O
, - - O
were - - O
investigated - - O
on - - O
lung - - O
and - - O
cremaster - - O
vessels - - O
of - - O
rats - - O
. - - O

The - - O
regional - - O
blockade - - O
of - - O
H1R - - B-MUT
was - - O
observed - - O
mainly - - O
in - - O
the - - O
frontal - - O
, - - O
temporal - - O
and - - O
anterior - - O
cingulate - - O
cortices - - O
, - - O
and - - O
the - - O
intravenous - - O
administration - - O
of - - O
d-chlorpheniramine - - O
as - - O
a - - O
therapeutic - - O
dose - - O
( - - O
2 - - O
mg - - O
) - - O
blocked - - O
over - - O
60% - - O
of - - O
H1R - - B-MUT
in - - O
the - - O
frontal - - O
cortices - - O
. - - O

The - - O
frequency - - O
of - - O
positive - - O
anti-GM1 - - B-MUT
antibody - - I-MUT
titers - - O
in - - O
the - - O
Guillain-Barre - - O
syndrome - - O
patients - - O
with - - O
PEN - - O
19 - - O
isolates - - O
was - - O
higher - - O
than - - O
that - - O
in - - O
the - - O
Guillain-Barre - - O
syndrome - - O
and - - O
Fisher's - - O
syndrome - - O
patients - - O
without - - O
PEN - - O
19 - - O
isolates - - O
. - - O

TG-day - - O
and - - O
TG-night - - O
were - - O
19 - - O
. - - O
4 - - O
+ - - O
- - - O
6 - - O
. - - O
1% - - O
, - - O
26 - - O
. - - O
6 - - O
+ - - O
- - - O
5 - - O
. - - O
3% - - O
, - - O
( - - O
750 - - O
mm3 - - O
< - - O
T - - O
. - - O

We - - O
used - - O
deletion - - O
analysis - - O
and - - O
transfection - - O
assays - - O
with - - O
reporter - - O
gene - - O
constructs - - O
to - - O
examine - - O
the - - O
transcription - - O
control - - O
elements - - O
in - - O
the - - O
5' - - O
flanking - - O
region - - O
of - - O
the - - O
human - - B-MUT
EpoR - - I-MUT
gene - - I-MUT
. - - O

However - - O
, - - O
there - - O
were - - O
some - - O
properties - - O
of - - O
Rak - - B-MUT
that - - O
are - - O
distinct - - O
from - - O
Src-like - - B-MUT
kinases - - I-MUT
: - - O
( - - O
a - - O
) - - O
expression - - O
of - - O
Rak - - B-MUT
was - - O
predominantly - - O
in - - O
epithelial-derived - - O
cell - - O
lines - - O
and - - O
tissues - - O
, - - O
especially - - O
normal - - O
liver - - O
and - - O
kidney - - O
, - - O
and - - O
cell - - O
lines - - O
of - - O
breast - - O
and - - O
colon - - O
origin - - O
; - - O
( - - O
b - - O
) - - O
Rak - - B-MUT
does - - O
not - - O
harbor - - O
the - - O
NH2-terminal - - O
glycine - - O
essential - - O
for - - O
myristylation - - O
and - - O
membrane - - O
localization - - O
; - - O
and - - O
( - - O
c - - O
) - - O
Rak - - B-MUT
possesses - - O
a - - O
putative - - O
bipartite - - O
nuclear - - O
localization - - O
signal - - O
in - - O
the - - O
SH2 - - B-MUT
domain - - I-MUT
, - - O
and - - O
subcellular - - O
fractionation - - O
studies - - O
revealed - - O
that - - O
p54rak - - B-MUT
resides - - O
predominantly - - O
in - - O
the - - O
nucleus - - O
. - - O

The - - O
role - - O
of - - O
DNA - - O
rearrangement - - O
and - - O
alternative - - O
RNA - - O
processing - - O
in - - O
the - - O
expression - - O
of - - O
immunoglobulin - - B-MUT
delta - - I-MUT
genes - - I-MUT
. - - O

Genomic - - O
and - - O
functional - - O
characterization - - O
of - - O
the - - O
oas - - B-MUT
gene - - I-MUT
family - - I-MUT
encoding - - O
O-acetylserine - - B-MUT
( - - I-MUT
thiol - - I-MUT
) - - I-MUT
lyases - - I-MUT
, - - O
enzymes - - O
catalyzing - - O
the - - O
final - - O
step - - O
in - - O
cysteine - - O
biosynthesis - - O
in - - O
Arabidopsis - - O
thaliana - - O
. - - O

The - - O
results - - O
indicate - - O
that - - O
the - - O
open-section - - O
effect - - O
decreases - - O
the - - O
torsional - - O
stiffness - - O
and - - O
stress - - O
concentration - - O
effects - - O
decrease - - O
the - - O
torsional - - O
strength - - O
of - - O
a - - O
long - - O
bone - - O
with - - O
a - - O
longitudinal - - O
defect - - O
. - - O

Output - - O
of - - O
99mTcO-4 - - O
by - - O
the - - O
parotid - - O
gland - - O
closely - - O
mimicked - - O
fluctuations - - O
in - - O
parotid - - O
saliva - - O
flow - - O
rate - - O
. - - O

Evaluating - - O
dietary - - O
department - - O
management - - O
. - - O

A - - O
review - - O
of - - O
studies - - O
published - - O
between - - O
1983 - - O
and - - O
1995 - - O
shows - - O
that - - O
there - - O
are - - O
some - - O
common - - O
factors - - O
as - - O
regards - - O
the - - O
psychological - - O
distress - - O
and - - O
social - - O
and - - O
functional - - O
limitations - - O
this - - O
group - - O
of - - O
patients - - O
has - - O
to - - O
deal - - O
with - - O
. - - O

Plasma - - O
and - - O
bladder - - O
platinum - - O
concentration - - O
were - - O
measured - - O
following - - O
intravesical - - O
DDP - - O
, - - O
and - - O
also - - O
histopathological - - O
examination - - O
, - - O
urinalysis - - O
, - - O
complete - - O
blood - - O
count - - O
and - - O
blood - - O
chemistry - - O
were - - O
performed - - O
in - - O
order - - O
to - - O
know - - O
the - - O
toxicity - - O
of - - O
intravesical - - O
DDP - - O
. - - O

The - - O
cDNA - - O
sequence - - O
has - - O
an - - O
813-bp - - O
open - - O
reading - - O
frame - - O
( - - O
ORF - - O
) - - O
whose - - O
predicted - - O
amino - - O
acid - - O
sequence - - O
is - - O
97 - - O
. - - O
6% - - O
identical - - O
to - - O
the - - O
272 - - O
carboxy-terminal - - O
amino - - O
acids - - O
of - - O
the - - O
human - - B-MUT
ets-1 - - I-MUT
protein - - I-MUT
. - - O

Tetrad - - O
analysis - - O
and - - O
mitotic - - O
recombination - - O
experiments - - O
localized - - O
the - - O
PEP4 - - B-MUT
gene - - I-MUT
proximal - - O
to - - O
GAL4 - - B-MUT
on - - O
chromosome - - O
XVI - - O
. - - O

These - - O
results - - O
support - - O
the - - O
view - - O
that - - O
clonidine - - O
and - - O
6-OHDA - - O
, - - O
but - - O
not - - O
alpha-MD - - O
, - - O
have - - O
central - - O
pressor - - O
actions - - O
in - - O
the - - O
rat - - O
that - - O
oppose - - O
their - - O
antihypertensive - - O
action - - O
. - - O

Lauciello - - O
describes - - O
a - - O
technique - - O
for - - O
the - - O
placement - - O
of - - O
functionally - - O
generated - - O
amalgam - - O
stops - - O
as - - O
restorations - - O
within - - O
mandibular - - O
acrylic - - O
teeth - - O
. - - O

Here - - O
we - - O
present - - O
evidence - - O
that - - O
major - - B-MUT
IE - - I-MUT
proteins - - I-MUT
IE86 - - B-MUT
, - - O
IE72 - - B-MUT
, - - O
and - - O
IE55 - - B-MUT
are - - O
capable - - O
of - - O
trans-activating - - O
the - - O
HIV - - O
LTR - - O
in - - O
a - - O
T-cell - - O
line - - O
, - - O
HUT-78 - - O
. - - O

A - - O
phylogenetic - - O
analysis - - O
with - - O
the - - O
TK - - B-MUT
domains - - I-MUT
from - - O
these - - O
sequences - - O
and - - O
a - - O
fourth - - O
, - - O
from - - O
a - - O
novel - - O
scavenger - - B-MUT
RTK - - I-MUT
( - - O
all - - O
domains - - O
comprise - - O
the - - O
signature - - O
for - - O
the - - O
TK - - B-MUT
class - - I-MUT
II - - I-MUT
receptors - - I-MUT
) - - O
, - - O
showed - - O
that - - O
they - - O
are - - O
distantly - - O
related - - O
to - - O
the - - O
insulin - - B-MUT
and - - O
insulin-like - - B-MUT
receptors - - I-MUT
. - - O

Members - - O
of - - O
the - - O
myocyte-specific - - B-MUT
enhancer-binding - - I-MUT
factor - - I-MUT
2 - - I-MUT
( - - O
MEF2 - - B-MUT
) - - O
family - - O
of - - O
transcription - - O
factors - - O
bind - - O
a - - O
conserved - - O
A - - O
T-rich - - O
sequence - - O
in - - O
the - - O
control - - O
regions - - O
of - - O
numerous - - O
muscle-specific - - O
genes - - O
. - - O

We - - O
show - - O
that - - O
IL-6 - - B-MUT
activates - - O
JRE-IL6 - - B-MUT
through - - O
an - - O
H7-sensitive - - O
pathway - - O
that - - O
does - - O
not - - O
involve - - O
protein - - B-MUT
kinase - - I-MUT
C - - I-MUT
, - - O
cyclic - - B-MUT
AMP-dependent - - I-MUT
kinase - - I-MUT
, - - O
Ca - - B-MUT
( - - I-MUT
2+ - - I-MUT
) - - I-MUT
- - - I-MUT
or - - I-MUT
calmodulin-dependent - - I-MUT
kinases - - I-MUT
, - - O
Ras - - B-MUT
, - - O
Raf-1 - - B-MUT
, - - O
or - - O
NF-IL6 - - B-MUT
( - - O
C - - B-MUT
EBP - - I-MUT
beta - - I-MUT
) - - I-MUT
. - - O

Histological - - O
analysis - - O
showed - - O
that - - O
the - - O
neuronal - - O
loss - - O
in - - O
the - - O
DHED-treated - - O
group - - O
was - - O
notably - - O
reduced - - O
in - - O
the - - O
hippocampal - - O
area - - O
( - - O
CA1 - - O
) - - O
of - - O
ischemic - - O
rats - - O
and - - O
in - - O
the - - O
dentate - - O
gyrus - - O
and - - O
hippocampal - - O
area - - O
( - - O
CA1 - - O
and - - O
CA3 - - O
) - - O
of - - O
EC-lesioned - - O
rats - - O
compared - - O
with - - O
the - - O
nontreated - - O
group - - O
. - - O

Expression - - O
of - - O
the - - O
human - - B-MUT
papillomavirus - - I-MUT
type - - I-MUT
11 - - I-MUT
E5A - - I-MUT
protein - - I-MUT
from - - O
the - - O
E1E4 - - B-MUT
, - - I-MUT
E5 - - I-MUT
transcript - - I-MUT
. - - O

The - - O
next - - O
twenty - - O
years - - O
of - - O
prevention - - O
in - - O
Indian - - O
country - - O
: - - O
visionary - - O
, - - O
complex - - O
, - - O
and - - O
practical - - O
. - - O

The - - O
Jem - - B-MUT
peptide - - O
sequence - - O
shows - - O
a - - O
'leucine-zipper' - - O
dimerisation - - O
motif - - O
with - - O
limited - - O
homology - - O
to - - O
Fos - - B-MUT
Jun - - I-MUT
and - - I-MUT
ATF - - O
CREB - - B-MUT
proteins - - I-MUT
and - - I-MUT
several - - I-MUT
putative - - O
phosphorylation - - O
sites - - O
. - - O

We - - O
have - - O
utilized - - O
the - - O
human - - B-MUT
4F2 - - I-MUT
heavy - - I-MUT
chain - - I-MUT
( - - O
4F2HC - - B-MUT
) - - O
gene - - O
as - - O
a - - O
model - - O
system - - O
in - - O
studies - - O
designed - - O
to - - O
elucidate - - O
the - - O
molecular - - O
events - - O
involved - - O
in - - O
regulating - - O
inducible - - O
gene - - O
expression - - O
during - - O
normal - - O
human - - O
T-cell - - O
activation - - O
. - - O

We - - O
cloned - - O
the - - O
third - - O
human - - O
gene - - O
for - - O
the - - O
LD78 - - B-MUT
, - - O
termed - - O
LD78 - - B-MUT
gamma - - I-MUT
and - - O
the - - O
sequence - - O
analysis - - O
showed - - O
that - - O
it - - O
is - - O
a - - O
5'-truncated - - O
pseudogene - - O
. - - O

Moreover - - O
, - - O
the - - O
reconstitution - - O
of - - O
eUSF - - B-MUT
and - - O
TFIID-depleted - - O
transcription - - O
complexes - - O
with - - O
purified - - O
protein - - O
fractions - - O
demonstrate - - O
that - - O
not - - O
only - - O
TFIID - - B-MUT
but - - O
also - - O
eUSF - - B-MUT
essentially - - O
participates - - O
in - - O
complex - - O
formation - - O
even - - O
on - - O
H5 - - B-MUT
promoter - - I-MUT
mutations - - O
lacking - - O
the - - O
TATA-box - - O
. - - O

Histamine - - O
reactivity - - O
had - - O
returned - - O
to - - O
normal - - O
in - - O
half - - O
the - - O
workers - - O
who - - O
had - - O
left - - O
their - - O
original - - O
factories - - O
, - - O
but - - O
in - - O
only - - O
one - - O
worker - - O
who - - O
had - - O
moved - - O
within - - O
her - - O
original - - O
factory - - O
. - - O

BIAcore - - O
analysis - - O
gave - - O
a - - O
Kaff - - O
of - - O
4 - - O
. - - O
4 - - O
x - - O
10 - - O
( - - O
10 - - O
) - - O
M-1 - - O
for - - O
the - - O
binding - - O
of - - O
N-A3 - - B-MUT
to - - O
T84 - - B-MUT
. - - I-MUT
1 - - I-MUT
and - - O
2 - - O
. - - O
2 - - O
x - - O
10 - - O
( - - O
10 - - O
) - - O
M-1 - - O
for - - O
the - - O
binding - - O
of - - O
N-A3 - - B-MUT
to - - O
T84 - - B-MUT
. - - I-MUT
66 - - I-MUT
. - - O

Together - - O
these - - O
data - - O
imply - - O
that - - O
the - - O
HFV - - B-MUT
R - - I-MUT
region - - I-MUT
acts - - O
in - - O
the - - O
nucleus - - O
to - - O
modify - - O
the - - O
cytoplasmic - - O
fate - - O
of - - O
target - - B-MUT
HFV - - I-MUT
mRNA - - I-MUT
. - - O

Transcription - - O
factor - - O
recognition - - O
surface - - O
on - - O
the - - O
RNA - - B-MUT
polymerase - - I-MUT
alpha - - I-MUT
subunit - - I-MUT
is - - O
involved - - O
in - - O
contact - - O
with - - O
the - - O
DNA - - O
enhancer - - O
element - - O
. - - O

Rind - - O
et - - O
al - - O
. - - O
's - - O
study's - - O
main - - O
conclusions - - O
were - - O
not - - O
supported - - O
by - - O
the - - O
original - - O
data - - O
. - - O

Thus - - O
, - - O
transcriptional - - O
regulation - - O
, - - O
splicing - - O
, - - O
kinase - - O
interaction - - O
sites - - O
, - - O
and - - O
tyrosine - - O
phosphorylation - - O
of - - O
the - - O
LMP2A - - B-MUT
homologs - - I-MUT
have - - O
been - - O
conserved - - O
despite - - O
significant - - O
sequences - - O
heterogeneity - - O
in - - O
the - - O
preterminal - - O
repeat - - O
regions - - O
of - - O
these - - O
human - - O
and - - O
nonhuman - - O
primate - - O
EBVs - - O
. - - O

These - - O
results - - O
indicate - - O
the - - O
presence - - O
of - - O
TATA-unified - - O
transcription - - O
systems - - O
in - - O
contemporary - - O
eukaryotes - - O
and - - O
provide - - O
insight - - O
into - - O
the - - O
residual - - O
need - - O
for - - O
TBP - - B-MUT
by - - O
all - - O
three - - O
Pols - - B-MUT
in - - O
other - - O
eukaryotes - - O
despite - - O
a - - O
lack - - O
of - - O
TATA - - O
elements - - O
in - - O
their - - O
promoters - - O
. - - O

The - - O
Saccharomyces - - B-MUT
cerevisiae - - I-MUT
RAD30 - - I-MUT
gene - - I-MUT
, - - O
a - - O
homologue - - B-MUT
of - - I-MUT
Escherichia - - I-MUT
coli - - I-MUT
dinB - - I-MUT
and - - O
umuC - - B-MUT
, - - O
is - - O
DNA - - O
damage - - O
inducible - - O
and - - O
functions - - O
in - - O
a - - O
novel - - O
error-free - - O
postreplication - - O
repair - - O
mechanism - - O
. - - O

Right - - O
LHR - - O
( - - O
R-LHR - - O
) - - O
provided - - O
the - - O
best - - O
interobserver - - O
and - - O
intraobserver - - O
reproducibility - - O
. - - O

Two-Channel - - O
Kondo - - O
Lattice - - O
: - - O
An - - O
Incoherent - - O
Metal - - O
. - - O

A - - O
limiting - - O
factor - - O
were - - O
disturbances - - O
in - - O
the - - O
system - - O
of - - O
energy - - O
transport - - O
( - - O
creatine - - O
phosphate - - O
, - - O
creatine - - B-MUT
phosphokinase - - I-MUT
) - - O
and - - O
of - - O
the - - O
calcium - - O
pump - - O
( - - O
Ca++-ATPase - - B-MUT
of - - O
the - - O
sarcoplasmic - - O
reticulum - - O
, - - O
SPR - - O
) - - O
, - - O
which - - O
evidently - - O
led - - O
to - - O
a - - O
decrease - - O
of - - O
the - - O
inotropic - - O
properties - - O
of - - O
the - - O
myocardium - - O
at - - O
70% - - O
restriction - - O
of - - O
coronary - - O
blood - - O
flow - - O
. - - O

The - - O
IC50 - - O
values - - O
for - - O
rat - - O
and - - O
dog - - O
urinary - - O
bladder - - O
were - - O
3 - - O
. - - O
9 - - O
x - - O
10 - - O
( - - O
-6 - - O
) - - O
M - - O
and - - O
3 - - O
. - - O
8 - - O
x - - O
10 - - O
( - - O
-6 - - O
) - - O
M - - O
, - - O
respectively - - O
. - - O

It - - O
is - - O
shown - - O
that - - O
the - - O
( - - O
G+C - - O
) - - O
-rich - - O
element - - O
of - - O
the - - O
aldolase - - B-MUT
C - - I-MUT
promoter - - I-MUT
directs - - O
transcription - - O
in - - O
neuronal - - O
as - - O
well - - O
as - - O
in - - O
nonneuronal - - O
cells - - O
. - - O

During - - O
most - - O
of - - O
the - - O
cell - - O
cycle - - O
, - - O
separase - - B-MUT
is - - O
kept - - O
inactive - - O
by - - O
binding - - O
to - - O
an - - O
inhibitory - - O
protein - - O
called - - O
securin - - B-MUT
. - - O

A - - O
comparison - - O
of - - O
the - - O
nucleotide - - O
sequence - - O
of - - O
the - - O
p54 - - B-MUT
gene - - I-MUT
carried - - O
by - - O
two - - O
virulent - - O
ASFV - - O
strains - - O
( - - O
E70 - - O
and - - O
E75 - - O
) - - O
with - - O
that - - O
obtained - - O
from - - O
virus - - O
Ba71V - - O
showed - - O
100% - - O
similarity - - O
. - - O

The - - O
human - - B-MUT
immunodeficiency - - I-MUT
virus - - I-MUT
type-1 - - I-MUT
( - - I-MUT
HIV-1 - - I-MUT
) - - I-MUT
Tat - - I-MUT
protein - - I-MUT
regulates - - O
transcription - - O
by - - O
stimulating - - O
RNA - - B-MUT
polymerase - - I-MUT
processivity - - O
. - - O

Statistics - - O
of - - O
the - - O
past - - O
5 - - O
years - - O
. - - O

TB - - O
bone - - O
area - - O
( - - O
p - - O
< - - O
0 - - O
. - - O
001 - - O
) - - O
, - - O
height - - O
( - - O
p - - O
< - - O
0 - - O
. - - O
01 - - O
) - - O
, - - O
years - - O
in - - O
present - - O
colony - - O
( - - O
p - - O
= - - O
0 - - O
. - - O
03 - - O
) - - O
, - - O
and - - O
menses - - O
( - - O
p - - O
< - - O
0 - - O
. - - O
01 - - O
) - - O
predicted - - O
TB - - O
BMC - - O
. - - O

Cotransfection - - O
of - - O
the - - O
coactivator - - O
CREB-binding - - B-MUT
protein - - I-MUT
relieved - - O
the - - O
transcriptional - - O
repression - - O
of - - O
PPARalphawt - - B-MUT
by - - O
PPARalphatr - - B-MUT
, - - O
suggesting - - O
that - - O
the - - O
dominant - - O
negative - - O
effect - - O
of - - O
PPARalphatr - - B-MUT
might - - O
occur - - O
through - - O
competition - - O
for - - O
essential - - O
coactivators - - O
. - - O

Looming - - O
detectors - - O
in - - O
the - - O
human - - O
visual - - O
pathway - - O
. - - O

In - - O
contrast - - O
, - - O
exogenous - - B-MUT
PTHrP1-34 - - I-MUT
and - - I-MUT
1-86 - - I-MUT
peptides - - I-MUT
did - - O
not - - O
significantly - - O
affect - - O
IL-8 - - B-MUT
production - - O
; - - O
moreover - - O
, - - O
PTHrP-neutralizing - - B-MUT
antibodies - - I-MUT
did - - O
not - - O
inhibit - - O
the - - O
production - - O
of - - O
IL-8 - - B-MUT
by - - O
transfected - - O
PTHrP - - B-MUT
. - - O

All - - O
radiologists - - O
using - - O
the - - O
machine - - O
found - - O
that - - O
the - - O
reporting - - O
terminal - - O
was - - O
simple - - O
to - - O
operate - - O
, - - O
but - - O
found - - O
that - - O
reporting - - O
abnormalities - - O
caused - - O
an - - O
increased - - O
effort - - O
and - - O
took - - O
a - - O
longer - - O
time - - O
. - - O

Results - - O
: - - O
Transpulmonary - - O
passage - - O
of - - O
contrast - - O
occurred - - O
in - - O
sufficient - - O
amounts - - O
to - - O
enhance - - O
the - - O
intensity - - O
of - - O
the - - O
Doppler - - O
signal - - O
significantly - - O
, - - O
but - - O
the - - O
duration - - O
of - - O
this - - O
effect - - O
was - - O
short - - O
. - - O

Rams - - O
were - - O
weighed - - O
and - - O
testis - - O
size - - O
was - - O
estimated - - O
by - - O
orchimetry - - O
at - - O
each - - O
time - - O
period - - O
. - - O

Although - - O
the - - O
terminase - - B-MUT
apparently - - O
interacts - - O
with - - O
this - - O
gp20 - - B-MUT
portal - - I-MUT
peptide - - I-MUT
, - - O
polyclonal - - O
antibody - - O
against - - O
the - - O
portal - - O
peptide - - O
appears - - O
unable - - O
to - - O
access - - O
it - - O
in - - O
the - - O
native - - O
structure - - O
, - - O
suggesting - - O
intimate - - O
association - - O
of - - O
gp20 - - B-MUT
and - - O
gp17 - - B-MUT
possibly - - O
internalizes - - O
terminase - - B-MUT
regions - - I-MUT
within - - O
the - - O
portal - - O
in - - O
the - - O
packasome - - O
complex - - O
. - - O

Simulating - - O
the - - O
impact - - O
during - - O
human - - O
jumping - - O
by - - O
means - - O
of - - O
a - - O
4-degrees-of-freedom - - O
model - - O
. - - O

We - - O
report - - O
a - - O
prevalence - - O
study - - O
of - - O
the - - O
best - - O
visual - - O
acuity - - O
in - - O
the - - O
affected - - O
eye - - O
of - - O
100 - - O
selected - - O
patients - - O
with - - O
herpetic - - O
keratitis - - O
seen - - O
during - - O
a - - O
two-year - - O
period - - O
. - - O

The - - O
m7GpppN - - O
cap - - O
structure - - O
of - - O
eukaryotic - - O
mRNA - - O
is - - O
formed - - O
cotranscriptionally - - O
by - - O
the - - O
sequential - - O
action - - O
of - - O
three - - O
enzymes - - O
: - - O
RNA - - B-MUT
triphosphatase - - I-MUT
, - - O
RNA - - B-MUT
guanylyltransferase - - I-MUT
, - - O
and - - O
RNA - - B-MUT
( - - I-MUT
guanine-7 - - I-MUT
) - - I-MUT
-methyltransferase - - I-MUT
. - - O

R - - O
. - - O
, - - O
Fleischmann - - O
, - - O
R - - O
. - - O
, - - O
Venter - - O
, - - O
J - - O
. - - O

In - - O
addition - - O
, - - O
two-dimensional - - O
nuclear - - O
magnetic - - O
resonance - - O
studies - - O
with - - O
F17A - - O
, - - O
K13Q - - O
, - - O
F15Y - - O
and - - O
F27Y - - O
revealed - - O
that - - O
the - - O
mutants - - O
have - - O
the - - O
same - - O
overall - - O
structure - - O
as - - O
the - - O
wild-type - - B-MUT
CspB - - I-MUT
protein - - I-MUT
. - - O

The - - O
extraction - - O
recovery - - O
of - - O
Amphotericin - - O
B - - O
from - - O
the - - O
cerebrospinal - - O
fluid - - O
is - - O
higher - - O
than - - O
90% - - O
over - - O
the - - O
entire - - O
linear - - O
range - - O
. - - O

The - - O
plexiform - - O
neurofibroma - - O
and - - O
multiple - - O
localized - - O
neurofibromas - - O
are - - O
characteristic - - O
of - - O
NF1 - - B-MUT
. - - O

In - - O
addition - - O
, - - O
we - - O
find - - O
that - - O
E2F-1 - - B-MUT
can - - O
cause - - O
apoptosis - - O
in - - O
p53- - - B-MUT
- - - I-MUT
tumour - - I-MUT
cells - - O
and - - O
further - - O
p300 - - O
, - - B-MUT
which - - O
also - - O
functions - - O
as - - O
a - - O
co-activator - - O
for - - O
the - - O
E2F - - O
DP - - B-MUT
heterodimer - - I-MUT
, - - I-MUT
enhances - - I-MUT
the - - O
apoptotic - - O
activity - - O
of - - O
E2F-1 - - O
. - - O

Following - - O
retransfusion - - O
, - - O
the - - O
affected - - O
epithelial - - O
lining - - O
appeared - - O
greatly - - O
distended - - O
over - - O
the - - O
oedematous - - O
lamina - - O
propria - - O
, - - O
with - - O
almost - - O
complete - - O
loss - - O
of - - O
structural - - O
detail - - O
. - - O

Here - - O
we - - O
report - - O
that - - O
the - - O
proline-rich - - O
region - - O
of - - O
CAP - - B-MUT
is - - O
recognized - - O
by - - O
the - - O
SH3 - - B-MUT
domains - - I-MUT
of - - O
several - - O
proteins - - O
, - - O
including - - O
the - - O
yeast - - B-MUT
actin-associated - - I-MUT
protein - - I-MUT
Abp1p - - I-MUT
. - - O

Molecular - - O
cloning - - O
of - - O
a - - O
P-type - - B-MUT
ATPase - - I-MUT
gene - - I-MUT
from - - O
the - - O
cyanobacterium - - O
Synechocystis - - O
sp - - O
. - - O

The - - O
prognosis - - O
of - - O
seven - - O
patients - - O
who - - O
received - - O
ABSCT - - O
was - - O
significantly - - O
better - - O
than - - O
that - - O
of - - O
13 - - O
patients - - O
who - - O
received - - O
conventional - - O
therapy - - O
alone - - O
. - - O

In - - O
the - - O
work - - O
reported - - O
here - - O
, - - O
we - - O
used - - O
peptide - - O
mapping - - O
, - - O
mass - - O
spectrometry - - O
, - - O
and - - O
site-directed - - O
mutagenesis - - O
to - - O
identify - - O
two - - O
sets - - O
of - - O
pAP - - B-MUT
phosphorylation - - O
sites - - O
. - - O

The - - O
RAT3 - - B-MUT
gene - - I-MUT
encodes - - O
an - - O
1157-amino - - O
acid - - O
protein - - O
without - - O
similarity - - O
to - - O
other - - O
known - - O
proteins - - O
. - - O

The - - O
high - - O
conservation - - O
of - - O
the - - O
3' - - O
terminus - - O
suggests - - O
that - - O
this - - O
region - - O
directs - - O
the - - O
assembly - - O
of - - O
proteins - - O
required - - O
for - - O
the - - O
initiation - - O
of - - O
RNA - - O
replication - - O
. - - O

Sixteen - - O
patients - - O
were - - O
studied - - O
within - - O
24 - - O
hours - - O
of - - O
resuscitation - - O
and - - O
all - - O
showed - - O
depressed - - O
right - - O
ventricular - - O
ejection - - O
( - - O
RVEF - - O
) - - O
and - - O
or - - O
an - - O
increased - - O
end-diastolic - - O
volume - - O
( - - O
RVEDVI - - O
) - - O
. - - O

This - - O
is - - O
predicted - - O
to - - O
encode - - O
a - - O
315-residue - - O
protein - - O
containing - - O
seven - - O
hydrophobic - - O
helical - - O
regions - - O
and - - O
a - - O
17 - - O
amino - - O
acid - - O
motif - - O
characteristic - - O
of - - O
the - - O
R7G - - B-MUT
family - - I-MUT
of - - O
G-protein - - B-MUT
coupled - - I-MUT
membrane-bound - - I-MUT
receptors - - I-MUT
. - - O

In - - O
10 - - O
control - - O
sheep - - O
mean - - O
plasma - - O
TXB2 - - O
concentration - - O
increased - - O
from - - O
0 - - O
. - - O
39 - - O
ng - - O
ml - - O
prebypass - - O
to - - O
about - - O
1 - - O
. - - O
1 - - O
ng - - O
ml - - O
at - - O
8 - - O
and - - O
16 - - O
min - - O
of - - O
bypass - - O
. - - O

J - - O
. - - O

The - - O
distributed - - O
current - - O
density - - O
J - - O
is - - O
calculated - - O
within - - O
the - - O
volume - - O
defined - - O
by - - O
the - - O
motor - - O
unit - - O
. - - O

The - - O
PI3K_68D - - B-MUT
cDNA - - I-MUT
encodes - - O
a - - O
protein - - O
of - - O
210 - - O
kDa - - O
, - - O
which - - O
lacks - - O
sequences - - O
implicated - - O
in - - O
linking - - O
p110 - - O
PI - - B-MUT
3-kinases - - I-MUT
to - - O
p85 - - B-MUT
adaptor - - I-MUT
proteins - - I-MUT
, - - O
but - - O
contains - - O
an - - O
amino-terminal - - O
proline-rich - - O
sequence - - O
, - - O
which - - O
could - - O
bind - - O
to - - O
SH3 - - B-MUT
domains - - I-MUT
, - - O
and - - O
a - - O
carboxy-terminal - - O
C2 - - O
domain - - O
. - - O

Two - - O
mutations - - O
that - - O
affect - - O
larval - - B-MUT
cuticle - - I-MUT
protein - - I-MUT
gene - - I-MUT
expression - - O
in - - O
the - - O
2 - - O
3 - - O
variant - - O
Drosophila - - O
melanogaster - - O
strain - - O
were - - O
investigated - - O
. - - O

Nursing - - O
of - - O
patients - - O
with - - O
gynecological - - O
diseases - - O
. - - O

Prominent - - O
findings - - O
were - - O
chronic - - O
pancreatitis - - O
with - - O
acinar - - O
and - - O
ductal - - O
plugs - - O
, - - O
granulomatous - - O
and - - O
necrotizing - - O
peripancreatic - - O
steatitis - - O
, - - O
degenerative - - O
myopathy - - O
, - - O
testicular - - O
atrophy - - O
, - - O
candidiasis - - O
and - - O
bacterial - - O
necrotizing - - O
glossitis - - O
. - - O

Nipponbare - - O
as - - O
well - - O
as - - O
O - - O
. - - O
australiensis - - O
. - - O

We - - O
show - - O
that - - O
the - - O
Sm-binding - - B-MUT
site - - I-MUT
and - - O
stem-loop - - O
III - - O
structures - - O
are - - O
necessary - - O
for - - O
correct - - O
3'-end - - O
formation - - O
. - - O

Relief - - O
from - - O
autoinhibition - - O
and - - O
a - - O
subsequent - - O
10-60-fold - - O
increase - - O
in - - O
V - - O
( - - O
max - - O
) - - O
have - - O
been - - O
observed - - O
upon - - O
N-SH2 - - B-MUT
domain - - I-MUT
engagement - - O
by - - O
a - - O
specific - - O
phosphotyrosyl - - O
ligand - - O
or - - O
upon - - O
deletion - - O
of - - O
the - - O
SH2 - - B-MUT
domains - - I-MUT
to - - O
yield - - O
the - - O
catalytic - - O
PTPase - - B-MUT
domain - - I-MUT
. - - O

Viral - - O
cell-to-cell - - O
movement - - O
of - - O
PVX - - B-MUT
CP - - I-MUT
mutant - - I-MUT
was - - O
complemented - - O
in - - O
Nicotiana - - O
tabacum - - O
cv - - O
. - - O

The - - O
percentage - - O
RFR - - O
reduction - - O
at - - O
the - - O
end - - O
of - - O
CPB - - O
showed - - O
significant - - O
correlation - - O
with - - O
1 - - O
) - - O
CPB - - O
duration - - O
( - - O
r - - O
= - - O
0 - - O
. - - O
49 - - O
) - - O
, - - O
2 - - O
) - - O
oxygen - - O
flow - - O
rate - - O
index - - O
( - - O
OFRI - - O
) - - O
, - - O
i - - O
. - - O
e - - O
. - - O
flow - - O
min - - O
in - - O
the - - O
bubble - - O
oxygenator - - O
m2 - - O
bsa - - O
( - - O
r - - O
= - - O
0 - - O
. - - O
38 - - O
) - - O
, - - O
and - - O
3 - - O
) - - O
blood - - O
flow - - O
rate - - O
index - - O
( - - O
BFRI - - O
) - - O
, - - O
i - - O
. - - O
e - - O
. - - O
average - - O
volume - - O
of - - O
blood - - O
pumped - - O
through - - O
the - - O
heart-lung - - O
machine - - O
min - - O
CPB - - O
time - - O
m2 - - O
bsa - - O
( - - O
r - - O
= - - O
0 - - O
. - - O
51 - - O
) - - O
. - - O

Risk - - O
of - - O
HTLV - - O
infection - - O
in - - O
patients - - O
on - - O
haemodialysis - - O
. - - O

Unfolding - - O
can - - O
be - - O
described - - O
by - - O
a - - O
two-state - - O
process - - O
since - - O
a - - O
ratio - - O
of - - O
delta - - O
Hcalorimetric - - O
to - - O
delta - - O
Hvan't - - O
Hoff - - O
equals - - O
0 - - O
. - - O
96 - - O
. - - O

A - - O
proposal - - O
of - - O
50 - - O
performance - - O
indicators - - O
divided - - O
into - - O
five - - O
different - - O
groups - - O
is - - O
presented - - O
here - - O
, - - O
namely - - O
structural - - O
indicators - - O
, - - O
operational - - O
indicators - - O
, - - O
water - - O
and - - O
service - - O
quality - - O
indicators - - O
, - - O
personnel - - O
indicators - - O
and - - O
economic - - O
indicators - - O
. - - O

This - - O
study - - O
tested - - O
the - - O
hypothesis - - O
that - - O
sodium - - O
channel - - O
blocking - - O
drugs - - O
selectively - - O
prolong - - O
the - - O
late - - O
potential - - O
, - - O
or - - O
terminal - - O
low - - O
amplitude - - O
signal - - O
, - - O
portion - - O
of - - O
the - - O
signal-averaged - - O
QRS - - O
complex - - O
and - - O
that - - O
prolongation - - O
of - - O
the - - O
late - - O
potential - - O
would - - O
correlate - - O
with - - O
slowing - - O
of - - O
ventricular - - O
tachycardia - - O
. - - O

The - - O
in - - O
vitro - - O
activity - - O
of - - O
mecillinam - - O
and - - O
amoxicillin - - O
clavulanic - - O
acid - - O
against - - O
Escherichia - - O
coli - - O
strains - - O
producing - - O
beta-lactamases - - O
of - - B-MUT
the - - O
TEM-1 - - O
, - - B-MUT
Oxa-1 - - O
and - - B-MUT
chromosomal - - O
type - - O
were - - O
studied - - O
using - - O
the - - O
broth - - O
and - - O
agar - - O
dilution - - O
technique - - O
. - - O

The - - O
cop - - B-MUT
region - - I-MUT
also - - O
harbors - - O
a - - O
region - - O
of - - O
plasmid - - O
incompatibility - - O
, - - O
inc - - B-MUT
, - - O
encompassing - - O
a - - O
stem-loop - - O
structure - - O
, - - O
the - - O
repA - - B-MUT
promoter - - I-MUT
, - - O
Prep - - B-MUT
, - - O
as - - O
well - - O
as - - O
two - - O
distinct - - O
RepA - - B-MUT
binding - - I-MUT
sites - - I-MUT
, - - O
BD-1 - - B-MUT
and - - O
BD-2 - - B-MUT
. - - O

IL-12 - - B-MUT
production - - O
was - - O
correlated - - O
with - - O
C3a - - O
concentration - - O
measured - - O
at - - O
the - - O
outlet - - O
of - - O
hemodialyzer - - O
after - - O
15 - - O
min - - O
of - - O
dialysis - - O
( - - O
r - - O
= - - O
0 - - O
. - - O
69 - - O
, - - O
P - - O
< - - O
0 - - O
. - - O
01 - - O
) - - O
. - - O

Only - - O
two - - O
of - - O
27 - - O
participants - - O
( - - O
7 - - O
. - - O
4% - - O
) - - O
with - - O
definite - - O
POAG - - O
had - - O
been - - O
previously - - O
diagnosed - - O
and - - O
treated - - O
, - - O
and - - O
66 - - O
. - - O
7% - - O
of - - O
the - - O
previously - - O
undiagnosed - - O
had - - O
IOP - - O
less - - O
than - - O
22 - - O
mmHg - - O
. - - O

DNA - - O
sequence - - O
analysis - - O
reveals - - O
that - - O
the - - O
gene - - O
encodes - - O
a - - O
protein - - O
highly - - O
homologous - - O
to - - O
rat - - B-MUT
CRP1 - - I-MUT
. - - O

When - - O
cysteine - - O
is - - O
scanned - - O
through - - O
the - - O
helices - - O
, - - O
characteristic - - O
repeating - - O
patterns - - O
of - - O
solvent - - O
exposure - - O
and - - O
burial - - O
are - - O
observed - - O
. - - O

Recombinant - - O
expression - - O
of - - O
a - - O
chimeric - - O
EGFR - - B-MUT
ErbB-3 - - I-MUT
receptor - - I-MUT
in - - I-MUT
NIH - - O
3T3 - - O
fibroblasts - - O
allowed - - O
us - - O
to - - O
investigate - - O
cytoplasmic - - O
events - - O
associated - - O
with - - O
ErbB-3 - - O
signal - - B-MUT
transduction - - O
upon - - O
ligand - - O
activation - - O
. - - O

Replicating - - O
simian - - O
virus - - O
40 - - O
( - - O
SV40 - - O
) - - O
chromosomes - - O
were - - O
found - - O
to - - O
be - - O
similar - - O
to - - O
other - - O
eukaryotic - - O
chromosomes - - O
in - - O
that - - O
the - - O
rate - - O
and - - O
extent - - O
of - - O
micrococcal - - B-MUT
nuclease - - I-MUT
( - - O
MNase - - B-MUT
) - - O
digestion - - O
were - - O
greater - - O
with - - O
replicating - - O
than - - O
with - - O
nonreplicating - - O
mature - - O
SV40 - - O
chromatin - - O
. - - O

One - - O
gene - - O
appears - - O
ubiquitously - - O
expressed - - O
while - - O
the - - O
other - - O
is - - O
prominently - - O
expressed - - O
in - - O
muscle - - O
. - - O

Recurrence - - O
of - - O
oxalate - - O
deposition - - O
in - - O
a - - O
renal - - O
transplant - - O
during - - O
ciclosporin - - O
A - - O
therapy - - O
. - - O

As - - O
retinoic - - O
acid - - O
and - - O
thyroid - - O
hormone - - O
are - - O
frequently - - O
involved - - O
in - - O
developmental - - O
regulatory - - O
processes - - O
, - - O
it - - O
is - - O
possible - - O
that - - O
this - - O
element - - O
may - - O
be - - O
important - - O
in - - O
the - - O
process - - O
of - - O
islet - - O
cell - - O
differentiation - - O
. - - O

We - - O
have - - O
shown - - O
that - - O
the - - O
epidural - - O
( - - O
EPI - - O
) - - O
delivery - - O
of - - O
morphine - - O
encapsulated - - O
in - - O
multivesicular - - O
liposomes - - O
( - - O
DepoFoam - - O
drug - - O
delivery - - O
system - - O
) - - O
produces - - O
a - - O
sustained - - O
clearance - - O
of - - O
morphine - - O
and - - O
a - - O
prolonged - - O
analgesia - - O
. - - O

The - - O
results - - O
of - - O
these - - O
studies - - O
support - - O
a - - O
model - - O
in - - O
which - - O
VirB4 - - B-MUT
dimers - - I-MUT
or - - O
homomultimers - - O
contribute - - O
structural - - O
information - - O
for - - O
the - - O
assembly - - O
of - - O
a - - O
transenvelope - - O
channel - - O
competent - - O
for - - O
bidirectional - - O
DNA - - O
transfer - - O
, - - O
whereas - - O
an - - O
ATP-dependent - - O
activity - - O
is - - O
required - - O
for - - O
configuring - - O
this - - O
channel - - O
as - - O
a - - O
dedicated - - O
export - - O
machine - - O
. - - O

The - - O
C-terminal - - B-MUT
Cdk2 - - I-MUT
truncations - - O
, - - O
however - - O
, - - O
were - - O
non-functional - - O
in - - O
these - - O
strains - - O
and - - O
thus - - O
dependent - - O
for - - O
activity - - O
on - - O
the - - O
pho85 - - B-MUT
coding - - I-MUT
region - - I-MUT
which - - O
remained - - O
in - - O
the - - O
mutant - - B-MUT
pho85 - - I-MUT
: - - O
: - - O
HIS3 - - B-MUT
chromosomal - - I-MUT
locus - - I-MUT
. - - O

It - - O
is - - O
concluded - - O
that - - O
haloperidol - - O
selectively - - O
reduced - - O
the - - O
animal's - - O
capacity - - O
to - - O
'programme - - O
non-stimulus - - O
directed - - O
motor - - O
behaviour' - - O
. - - O

Sleep - - O
was - - O
determined - - O
again - - O
for - - O
an - - O
additional - - O
3 - - O
days - - O
and - - O
6 - - O
hours - - O
. - - O

Histochemical - - O
localization - - O
of - - O
GUS - - B-MUT
revealed - - O
promoter - - O
function - - O
in - - O
leaf - - O
epidermis - - O
, - - O
mesophyll - - O
and - - O
vascular - - O
bundles - - O
, - - O
in - - O
the - - O
cortex - - O
and - - O
vascular - - O
cylinder - - O
of - - O
the - - O
root - - O
. - - O

We - - O
show - - O
here - - O
that - - O
the - - O
in - - O
vitro - - O
transcription - - O
extract - - O
contains - - O
a - - O
binding - - O
activity - - O
that - - O
is - - O
specific - - O
for - - O
the - - O
initiator - - O
element - - O
and - - O
thus - - O
may - - O
participate - - O
in - - O
recruiting - - O
RNA - - B-MUT
polymerase - - I-MUT
II - - I-MUT
to - - O
the - - O
SL - - B-MUT
RNA - - I-MUT
gene - - I-MUT
promoter - - I-MUT
. - - O

The - - O
inserted - - O
region - - O
, - - O
which - - O
represents - - O
an - - O
intron - - O
in - - O
brain - - O
and - - O
muscle - - O
, - - O
is - - O
expressed - - O
in - - O
the - - O
tumor - - O
cell - - O
lines - - O
either - - O
as - - O
a - - O
"readthrough" - - O
form - - O
or - - O
with - - O
78 - - O
residues - - O
deleted - - O
from - - O
its - - O
5' - - O
end - - O
. - - O

Localization - - O
of - - O
the - - O
insertion - - O
locus - - O
in - - O
the - - O
yeast - - O
genome - - O
and - - O
complementation - - O
studies - - O
with - - O
the - - O
temperature-sensitive - - O
mutant - - O
indicate - - O
that - - O
the - - O
two - - O
mutations - - O
are - - O
allelic - - O
. - - O

The - - O
conditions - - O
for - - O
obtaining - - O
titanium - - O
dioxide - - O
from - - O
the - - O
substrates - - O
titanium - - O
tetrachloride - - O
and - - O
oxygen - - O
and - - O
applying - - O
this - - O
to - - O
a - - O
surgical - - O
stainless - - O
steel - - O
of - - O
the - - O
type - - O
316L - - O
by - - O
the - - O
plasma - - O
assisted - - O
chemical - - O
vapour - - O
deposition - - O
method - - O
have - - O
been - - O
determined - - O
. - - O

The - - O
growth - - O
defect - - O
of - - O
a - - O
reg1 - - B-MUT
reg2 - - B-MUT
double - - I-MUT
mutant - - I-MUT
is - - O
alleviated - - O
by - - O
a - - O
loss-of-function - - O
mutation - - O
in - - O
the - - O
SNF1-encoded - - B-MUT
protein - - I-MUT
kinase - - I-MUT
. - - O

When - - O
combined - - O
with - - O
serum - - O
ferritin - - B-MUT
and - - O
hemoglobin - - B-MUT
determinations - - O
, - - O
the - - O
serum - - O
transferrin - - B-MUT
receptor - - I-MUT
assay - - O
is - - O
a - - O
valuable - - O
addition - - O
in - - O
epidemiologic - - O
surveys - - O
because - - O
it - - O
provides - - O
a - - O
quantitative - - O
measure - - O
of - - O
functional - - O
iron - - O
deficiency - - O
and - - O
it - - O
distinguishes - - O
true - - O
IDA - - O
from - - O
the - - O
anemia - - O
of - - O
chronic - - O
disease - - O
. - - O

The - - O
MMPI-A - - O
( - - O
Butcher - - O
et - - O
al - - O
. - - O
, - - O
1992 - - O
) - - O
, - - O
like - - O
the - - O
older - - O
MMPI - - O
( - - O
Hathaway - - O
& - - O
McKinley - - O
, - - O
1983 - - O
) - - O
, - - O
distinguishes - - O
between - - O
anorexia - - O
and - - O
bulimia - - O
. - - O

In - - O
this - - O
study - - O
, - - O
to - - O
characterize - - O
the - - O
gene - - O
for - - O
protein - - B-MUT
Z - - I-MUT
, - - O
its - - O
organization - - O
and - - O
structure - - O
were - - O
determined - - O
by - - O
a - - O
combination - - O
of - - O
PCR - - O
amplification - - O
of - - O
leukocyte - - O
DNA - - O
and - - O
isolation - - O
of - - O
phage - - O
clones - - O
from - - O
a - - O
human - - O
genomic - - O
library - - O
. - - O

A - - O
genomic - - O
DNA - - O
clone - - O
encoding - - O
oryzacystatin - - B-MUT
( - - O
Oc - - B-MUT
) - - O
, - - O
a - - O
cysteine - - B-MUT
proteinase - - I-MUT
inhibitor - - I-MUT
( - - O
cystatin - - B-MUT
) - - O
of - - O
rice - - O
, - - O
was - - O
isolated - - O
from - - O
a - - O
lambda - - O
EMBL3 - - O
phage - - O
library - - O
constructed - - O
with - - O
Sau3AI - - B-MUT
partial - - O
digests - - O
of - - O
rice - - O
chromosomal - - O
DNA - - O
, - - O
by - - O
screening - - O
with - - O
an - - O
oc - - B-MUT
cDNA - - I-MUT
as - - O
a - - O
probe - - O
. - - O

Surprisingly - - O
, - - O
the - - O
RXR-specific - - O
ligand - - O
9-cis-retinoic - - O
acid - - O
induced - - O
binding - - O
of - - O
SRC-1 - - B-MUT
to - - O
the - - O
RXR - - B-MUT
component - - I-MUT
of - - O
the - - O
TRE-bound - - O
heterodimer - - O
. - - O

The - - O
average - - O
coefficients - - O
of - - O
correlation - - O
were - - O
0 - - O
. - - O
9998 - - O
and - - O
0 - - O
. - - O
9993 - - O
for - - O
the - - O
QMF - - O
and - - O
the - - O
QIT - - O
system - - O
, - - O
respectively - - O
. - - O

The - - O
results - - O
imply - - O
that - - O
kindling - - O
does - - O
not - - O
produce - - O
its - - O
facilitating - - O
effect - - O
on - - O
acquisition - - O
of - - O
HPC - - O
SS - - O
by - - O
removing - - O
a - - O
disruptive - - O
effect - - O
of - - O
the - - O
stimulation - - O
. - - O

When - - O
RNA - - O
encoding - - O
the - - O
tail - - O
domain - - O
of - - O
desmoglein - - B-MUT
was - - O
coinjected - - O
with - - O
plakoglobin - - B-MUT
RNA - - I-MUT
, - - O
both - - O
the - - O
dorsalizing - - O
effect - - O
and - - O
nuclear - - O
accumulation - - O
of - - O
plakoglobin - - B-MUT
were - - O
suppressed - - O
. - - O

Two - - O
related - - O
cDNAs - - O
were - - O
isolated - - O
that - - O
encode - - O
proteins - - O
that - - O
recognize - - O
the - - O
XMyoDa - - B-MUT
TATA - - I-MUT
motif - - I-MUT
. - - O

Fluorimetric - - O
determination - - O
of - - O
methylmercury - - O
as - - O
an - - O
ion-association - - O
complex - - O
with - - O
rhodamine - - O
B - - O
in - - O
the - - O
presence - - O
of - - O
iodide - - O
. - - O

Expression - - O
from - - O
this - - O
element - - O
is - - O
regulated - - O
by - - O
a - - O
heteromeric - - O
protein - - O
complex - - O
containing - - O
ubiquitous - - O
( - - O
i - - O
. - - O
e - - O
. - - O
the - - O
E2A- - - B-MUT
and - - O
HEB-encoded - - B-MUT
proteins - - I-MUT
) - - O
and - - O
islet-enriched - - O
members - - O
of - - O
the - - O
bHLH - - B-MUT
family - - I-MUT
. - - O

The - - O
electromyographically - - O
recorded - - O
responses - - O
consisted - - O
of - - O
an - - O
early - - O
R1 - - O
response - - O
in - - O
the - - O
orbicularis - - O
oculi - - O
muscle - - O
ipsilateral - - O
to - - O
the - - O
side - - O
of - - O
stimulation - - O
, - - O
a - - O
bilateral - - O
late - - O
response - - O
( - - O
ipsilateral - - O
R2 - - O
and - - O
contralateral - - O
Rc - - O
) - - O
and - - O
a - - O
third - - O
, - - O
R3 - - O
response - - O
, - - O
in - - O
the - - O
ipsilateral - - O
orbicularis - - O
oculi - - O
muscle - - O
. - - O

The - - O
amplification - - O
was - - O
achieved - - O
using - - O
two - - O
primers - - O
which - - O
correspond - - O
to - - O
TRH - - B-MUT
progenitor - - I-MUT
sequence - - I-MUT
( - - O
Lys - - B-MUT
Arg-Arg-Gln-His-Pro-Gly-Lys - - I-MUT
Arg-Arg - - I-MUT
) - - I-MUT
. - - I-MUT

Pilot - - O
study - - O
of - - O
blood - - O
coagulation - - O
in - - O
gout - - O
patients - - O
. - - O

The - - O
well-known - - O
Rel - - B-MUT
NF-kappaB - - I-MUT
family - - I-MUT
of - - I-MUT
vertebrate - - O
transcription - - O
factors - - O
comprises - - O
a - - O
number - - O
of - - O
structurally - - O
related - - O
, - - O
interacting - - O
proteins - - O
that - - O
bind - - O
DNA - - O
as - - O
dimers - - O
and - - O
whose - - O
activity - - O
is - - O
regulated - - O
by - - O
subcellular - - O
location - - O
. - - O

Contractile - - O
responses - - O
to - - O
norepinephrine - - O
, - - O
serotonin - - O
and - - O
potassium - - O
( - - O
K+ - - O
) - - O
and - - O
relaxant - - O
responses - - O
to - - O
isoproterenol - - O
and - - O
papaverine - - O
were - - O
studied - - O
in - - O
vitro - - O
with - - O
spirally - - O
cut - - O
thoracic - - O
aortic - - O
strips - - O
from - - O
aortic - - O
coarcted - - O
hypertensive - - O
rats - - O
( - - O
AHR - - O
) - - O
2 - - O
, - - O
6 - - O
, - - O
14 - - O
and - - O
28 - - O
days - - O
postoperatively - - O
and - - O
compared - - O
to - - O
time-matched - - O
, - - O
sham-operated - - O
normotensive - - O
controls - - O
. - - O

Tristetraprolin - - B-MUT
( - - O
TTP - - B-MUT
) - - O
is - - O
the - - O
prototype - - O
of - - O
a - - O
group - - O
of - - O
potential - - O
transcription - - O
factors - - O
that - - O
contain - - O
two - - O
or - - O
more - - O
unusual - - O
CCCH - - O
zinc - - O
fingers - - O
. - - O

These - - O
intron - - O
chimeras - - O
show - - O
that - - O
peripheral - - O
sequences - - O
and - - O
the - - O
elements - - O
that - - O
define - - O
the - - O
splice - - O
sites - - O
are - - O
adequate - - O
for - - O
self-splicing - - O
activity - - O
but - - O
that - - O
the - - O
central - - O
portions - - O
containing - - O
the - - O
catalytic - - O
cores - - O
of - - O
ai4 - - B-MUT
and - - O
bi4 - - B-MUT
are - - O
deficient - - O
; - - O
these - - O
cores - - O
are - - O
the - - O
likely - - O
targets - - O
of - - O
the - - O
splicing - - O
proteins - - O
. - - O

Km - - O
and - - O
Vmax - - O
for - - O
two - - O
substrates - - O
, - - O
src-related - - B-MUT
peptide - - I-MUT
and - - O
poly - - O
( - - O
Glu - - O
, - - O
Tyr - - O
) - - O
( - - O
4 - - O
: - - O
1 - - O
) - - O
, - - O
were - - O
2 - - O
. - - O
4 - - O
mM - - O
and - - O
2 - - O
. - - O
5 - - O
mumol - - O
min-1 - - O
mg-1 - - O
and - - O
0 - - O
. - - O
26 - - O
mM - - O
and - - O
1 - - O
. - - O
2 - - O
mumol - - O
min-1 - - O
mg-1 - - O
, - - O
respectively - - O
. - - O

Human - - B-MUT
ULK1 - - I-MUT
, - - O
a - - O
novel - - O
serine - - B-MUT
threonine - - I-MUT
kinase - - I-MUT
related - - I-MUT
to - - O
UNC-51 - - O
kinase - - B-MUT
of - - I-MUT
Caenorhabditis - - O
elegans - - O
: - - O
cDNA - - O
cloning - - O
, - - O
expression - - O
, - - O
and - - O
chromosomal - - O
assignment - - O
. - - O

Sulfhydryl - - O
titration - - O
with - - O
iodoacetamide - - O
, - - O
monitored - - O
by - - O
quantitating - - O
the - - O
residual - - O
thiols - - O
after - - O
reaction - - O
with - - O
a - - O
maleimide - - O
derivative - - O
of - - O
biotin - - O
, - - O
revealed - - O
a - - O
striking - - O
difference - - O
in - - O
the - - O
apparent - - O
pK - - O
( - - O
a - - O
) - - O
values - - O
of - - O
the - - O
cysteines - - O
at - - O
the - - O
two - - O
splice - - O
junctions - - O
. - - O

High - - O
plasma - - O
concentrations - - O
of - - O
soluble - - O
E-selectin - - B-MUT
were - - O
closely - - O
associated - - O
with - - O
multiple-organ - - O
dysfunction - - O
and - - O
death - - O
. - - O

In - - O
such - - O
a - - O
manner - - O
, - - O
activated - - O
PKR - - B-MUT
inhibits - - O
cell - - O
growth - - O
and - - O
induces - - O
apoptosis - - O
, - - O
whereas - - O
disruption - - O
of - - O
normal - - O
PKR - - B-MUT
signaling - - O
results - - O
in - - O
unregulated - - O
cell - - O
growth - - O
. - - O

When - - O
a - - O
tumour - - O
is - - O
present - - O
nipple - - O
discharge - - O
is - - O
of - - O
little - - O
importance - - O
for - - O
the - - O
diagnosis - - O
and - - O
treatment - - O
. - - O

When - - O
the - - O
CO2 - - O
content - - O
reached - - O
9 - - O
Vol% - - O
the - - O
animals - - O
became - - O
apathic - - O
and - - O
lost - - O
body - - O
weight - - O
. - - O

The - - O
results - - O
demonstrate - - O
that - - O
( - - O
i - - O
) - - O
no - - O
intact - - O
capsids - - O
were - - O
assembled - - O
when - - O
the - - O
full-length - - O
or - - O
a - - O
truncated - - O
( - - O
missing - - O
the - - O
C-terminal - - O
65 - - O
amino - - O
acids - - O
) - - O
UL80 - - B-MUT
. - - I-MUT
5 - - I-MUT
protein - - I-MUT
was - - O
tested - - O
; - - O
( - - O
ii - - O
) - - O
when - - O
the - - O
C-terminal - - O
65 - - O
amino - - O
acids - - O
of - - O
the - - O
UL80 - - B-MUT
. - - I-MUT
5 - - I-MUT
protein - - I-MUT
were - - O
replaced - - O
with - - O
the - - O
C-terminal - - O
25 - - O
amino - - O
acids - - O
of - - O
the - - O
UL26 - - B-MUT
. - - I-MUT
5 - - I-MUT
protein - - I-MUT
, - - O
intact - - O
capsids - - O
were - - O
made - - O
and - - O
direct - - O
interaction - - O
of - - O
the - - O
UL80 - - B-MUT
. - - I-MUT
5 - - I-MUT
protein - - I-MUT
with - - O
VP5 - - B-MUT
was - - O
detected - - O
; - - O
( - - O
iii - - O
) - - O
assembly - - O
of - - O
intact - - O
capsids - - O
was - - O
demonstrated - - O
when - - O
the - - O
sequence - - O
of - - O
the - - O
last - - O
12 - - O
amino - - O
acids - - O
of - - O
the - - O
UL80 - - B-MUT
. - - I-MUT
5 - - I-MUT
protein - - I-MUT
was - - O
changed - - O
from - - O
RRIFVA - - B-MUT
ALNKLE - - I-MUT
to - - O
RRIFVAAMMKLE - - B-MUT
; - - O
( - - O
iv - - O
) - - O
self-interaction - - O
of - - O
the - - O
scaffold - - O
proteins - - O
is - - O
mediated - - O
by - - O
sequences - - O
N - - O
terminal - - O
to - - O
the - - O
maturation - - O
cleavage - - O
site - - O
; - - O
and - - O
( - - O
v - - O
) - - O
the - - O
UL26 - - B-MUT
. - - I-MUT
5 - - I-MUT
and - - O
UL80 - - B-MUT
. - - I-MUT
5 - - I-MUT
proteins - - I-MUT
will - - O
not - - O
coassemble - - O
into - - O
scaffold - - O
structures - - O
. - - O

Anti-nucleolin - - B-MUT
mAb - - I-MUT
was - - O
used - - O
to - - O
confirm - - O
the - - O
antigenic - - O
properties - - O
of - - O
this - - O
p95 - - B-MUT
component - - I-MUT
. - - O

Sixty - - O
days - - O
after - - O
the - - O
intervention - - O
, - - O
twitch - - O
and - - O
tetanic - - O
tensions - - O
remained - - O
dependent - - O
upon - - O
the - - O
extracellular - - O
Ca2+ - - O
concentration - - O
( - - O
[ - - O
Ca - - O
] - - O
o - - O
) - - O
both - - O
in - - O
groups - - O
A - - O
and - - O
B - - O
. - - O

Methoxyflurane - - O
and - - O
renal - - O
function - - O
. - - O

In - - O
the - - O
present - - O
experiments - - O
, - - O
we - - O
investigate - - O
the - - O
role - - O
played - - O
by - - O
the - - O
temporal - - O
pattern - - O
of - - O
neural - - O
activity - - O
during - - O
the - - O
ontogeny - - O
of - - O
frequency - - O
tuning - - O
in - - O
the - - O
mouse - - O
central - - O
auditory - - O
system - - O
. - - O

Because - - O
the - - O
mutant - - O
defective - - O
in - - O
DNA - - O
binding - - O
also - - O
fails - - O
to - - O
stimulate - - O
Abf1 - - B-MUT
ARS1 - - B-MUT
DNA-binding - - O
activity - - O
, - - O
our - - O
results - - O
suggest - - O
that - - O
Cdc6 - - B-MUT
DNA-binding - - O
activity - - O
may - - O
play - - O
a - - O
pivotal - - O
role - - O
in - - O
the - - O
initiation - - O
of - - O
DNA - - O
replication - - O
. - - O

Transcriptional - - O
regulation - - O
of - - O
the - - O
vacuolar - - B-MUT
H - - I-MUT
( - - I-MUT
+ - - I-MUT
) - - I-MUT
-ATPase - - I-MUT
B2 - - I-MUT
subunit - - I-MUT
gene - - I-MUT
in - - O
differentiating - - O
THP-1 - - O
cells - - O
. - - O

Potential - - O
treatments - - O
include - - O
dobutamine - - O
, - - O
KATP - - O
channel - - O
activators - - O
, - - O
and - - O
21-aminosteroids - - O
. - - O

According - - O
to - - O
Sugiura's - - O
classification - - O
, - - O
they - - O
consisted - - O
of - - O
Type - - O
Ia - - O
in - - O
63% - - O
, - - O
Type - - O
Ib - - O
in - - O
11% - - O
, - - O
Type - - O
II - - O
in - - O
11% - - O
, - - O
and - - O
Type - - O
III - - O
in - - O
16% - - O
. - - O

METHODS - - O
: - - O
In - - O
the - - O
current - - O
study - - O
the - - O
authors - - O
reported - - O
on - - O
PPB - - O
cases - - O
from - - O
a - - O
national - - O
retrospective - - O
search - - O
performed - - O
in - - O
18 - - O
Italian - - O
Associations - - O
for - - O
Pediatric - - O
Hematology - - O
and - - O
Oncology - - O
centers - - O
. - - O

D - - O
. - - O

These - - O
results - - O
indicate - - O
that - - O
HIV-1 - - O
Gag - - B-MUT
sequences - - I-MUT
can - - O
influence - - O
the - - O
viral - - O
PR-mediated - - O
processing - - O
of - - O
the - - O
MuLV - - O
TM - - B-MUT
Env - - I-MUT
protein - - I-MUT
p15 - - B-MUT
( - - I-MUT
E - - I-MUT
) - - I-MUT
. - - O

Consistent - - O
with - - O
its - - O
role - - O
in - - O
p53 - - B-MUT
ubiquitination - - O
, - - O
mE6-AP - - B-MUT
was - - O
found - - O
both - - O
in - - O
the - - O
nucleus - - O
and - - O
cytosol - - O
, - - O
while - - O
Nedd-4 - - B-MUT
was - - O
found - - O
only - - O
in - - O
the - - O
cytosol - - O
. - - O

Tests - - O
of - - O
the - - O
method - - O
indicate - - O
( - - O
1 - - O
) - - O
the - - O
Mossbauer - - O
source - - O
can - - O
be - - O
placed - - O
on - - O
the - - O
basilar - - O
membrane - - O
without - - O
altering - - O
the - - O
signal-transmission - - O
properties - - O
of - - O
the - - O
cochlea - - O
, - - O
and - - O
( - - O
2 - - O
) - - O
the - - O
source - - O
adheres - - O
to - - O
the - - O
basilar - - O
membrane - - O
. - - O

When - - O
expressed - - O
alone - - O
in - - O
test - - O
cells - - O
, - - O
Atr-I - - B-MUT
is - - O
unable - - O
to - - O
bind - - O
TGF-beta - - B-MUT
, - - O
activin - - B-MUT
, - - O
or - - O
bone - - B-MUT
morphogenetic - - I-MUT
protein - - I-MUT
2 - - I-MUT
. - - O

One - - O
of - - O
these - - O
elements - - O
, - - O
the - - O
homeodomain-binding - - B-MUT
element - - I-MUT
, - - O
was - - O
identified - - O
to - - O
mediate - - O
negative - - O
regulation - - O
. - - O

The - - O
mutations - - O
did - - O
not - - O
affect - - O
the - - O
repression - - O
of - - O
CPA1 - - B-MUT
by - - O
arginine - - O
. - - O

Increasing - - O
the - - O
extracellular - - O
calcium - - O
concentration - - O
enhanced - - O
detrusor - - O
contractility - - O
in - - O
a - - O
dose-dependent - - O
manner - - O
in - - O
both - - O
control - - O
and - - O
obstructed - - O
bladders - - O
. - - O

These - - O
six - - O
districts - - O
have - - O
an - - O
area - - O
of - - O
34 - - O
, - - O
000 - - O
km2 - - O
and - - O
hold - - O
a - - O
population - - O
of - - O
30 - - O
million - - O
. - - O

Anti-hepatitis - - B-MUT
A - - I-MUT
virus - - O
( - - O
HAV - - O
) - - O
titer - - O
after - - O
vaccination - - O
was - - O
measured - - O
in - - O
83 - - O
HIV-positive - - O
and - - O
39 - - O
HIV-negative - - O
men - - O
. - - O

An - - O
endometrial - - O
luteal - - O
phase - - O
deficiency - - O
was - - O
detected - - O
in - - O
15 - - O
( - - O
30% - - O
) - - O
of - - O
aborting - - O
patients - - O
. - - O

These - - O
viruses - - O
depend - - O
on - - O
the - - O
host - - O
cell - - O
machinery - - O
for - - O
their - - O
existence - - O
, - - O
and - - O
interference - - O
with - - O
these - - O
processes - - O
typically - - O
interferes - - O
with - - O
other - - O
important - - O
host - - O
physiology - - O
. - - O

RNase - - B-MUT
protection - - O
analysis - - O
of - - O
two - - O
rRNA - - B-MUT
fragments - - I-MUT
whose - - O
genes - - O
are - - O
adjacent - - O
provided - - O
evidence - - O
for - - O
a - - O
polycistronic - - O
transcript - - O
containing - - O
sequences - - O
from - - O
both - - O
, - - O
as - - O
well - - O
as - - O
separate - - O
small - - O
RNAs - - O
. - - O

A - - O
38-year-old - - O
woman - - O
with - - O
ulcerative - - O
colitis - - O
subsequently - - O
developed - - O
sarcoidosis - - O
. - - O

Patients - - O
receiving - - O
VPA - - O
showed - - O
differences - - O
in - - O
attention - - O
, - - O
visuomotor - - O
performance - - O
, - - O
verbal - - O
span - - O
and - - O
sensory - - O
discrimination - - O
tasks - - O
at - - O
T1 - - O
, - - O
in - - O
visuomotor - - O
performance - - O
at - - O
T2 - - O
and - - O
in - - O
spatial - - O
span - - O
at - - O
T3 - - O
, - - O
whereas - - O
no - - O
differences - - O
were - - O
detected - - O
at - - O
T4 - - O
. - - O

Recently - - O
, - - O
an - - O
electrical-mechanical - - O
analog - - O
model - - O
of - - O
heat - - O
flow - - O
within - - O
the - - O
brain - - O
has - - O
been - - O
developed - - O
from - - O
which - - O
an - - O
expression - - O
for - - O
CBF - - O
has - - O
been - - O
derived - - O
: - - O
CBF - - O
= - - O
Cb - - O
( - - O
tau - - O
rho - - O
c - - O
) - - O
where - - O
tau - - O
is - - O
the - - O
thermal - - O
decay - - O
constant - - O
, - - O
rho - - O
is - - O
the - - O
density - - O
of - - O
blood - - O
, - - O
and - - O
c - - O
is - - O
its - - O
specific - - O
heat - - O
. - - O

It - - O
is - - O
suggested - - O
that - - O
a - - O
raised - - O
hydroxykynurenine - - O
hydroxyanthranilic - - O
acid - - O
ratio - - O
does - - O
not - - O
necessarily - - O
indicate - - O
vitamin - - O
B6 - - O
deficiency - - O
but - - O
may - - O
represent - - O
a - - O
nonspecific - - O
response - - O
of - - O
tryptophan - - O
metabolism - - O
to - - O
stress - - O
. - - O

"Complex - - O
partial" - - O
seizures - - O
. - - O

Acute - - O
feasibility - - O
and - - O
safety - - O
of - - O
a - - O
smoking - - O
reduction - - O
strategy - - O
for - - O
smokers - - O
with - - O
schizophrenia - - O
. - - O

RESULTS - - O
: - - O
A - - O
novel - - O
gene - - O
was - - O
cloned - - O
. - - O

To - - O
compare - - O
the - - O
PAX3 - - B-MUT
and - - O
putative - - O
PAX3-FKHR - - B-MUT
transactivation - - I-MUT
domains - - I-MUT
, - - O
we - - O
fused - - O
C-terminal - - O
test - - O
fragments - - O
to - - O
the - - O
heterologous - - O
GAL4 - - B-MUT
DNA-binding - - I-MUT
domain - - I-MUT
and - - O
tested - - O
activation - - O
of - - O
a - - O
reporter - - O
gene - - O
co-transfected - - O
into - - O
four - - O
cell - - O
types - - O
. - - O

A - - O
single - - O
amino - - O
acid - - O
change - - O
in - - O
the - - O
CPY - - B-MUT
vacuolar - - I-MUT
sorting - - I-MUT
signal - - I-MUT
prevents - - O
this - - O
interaction - - O
. - - O

Removal - - O
of - - O
PDMP - - O
from - - O
the - - O
cell - - O
medium - - O
resulted - - O
in - - O
reversal - - O
of - - O
the - - O
cell - - O
cycle - - O
changes - - O
, - - O
with - - O
cells - - O
re-entering - - O
the - - O
S - - O
phase - - O
. - - O

The - - O
phosphotransferase - - B-MUT
system - - O
( - - O
PTS - - O
) - - O
of - - O
Streptomyces - - O
coelicolor - - O
identification - - O
and - - O
biochemical - - O
analysis - - O
of - - O
a - - O
histidine - - B-MUT
phosphocarrier - - I-MUT
protein - - I-MUT
HPr - - B-MUT
encoded - - O
by - - O
the - - O
gene - - O
ptsH - - B-MUT
. - - O

One - - O
member - - O
of - - O
this - - O
family - - O
, - - O
RFX1 - - B-MUT
, - - O
is - - O
a - - O
transcription - - O
factor - - O
for - - O
a - - O
variety - - O
of - - O
viral - - O
and - - O
cellular - - O
genes - - O
. - - O

Evaluation - - O
of - - O
desmopressin - - O
for - - O
dental - - O
extractions - - O
in - - O
patients - - O
with - - O
hemostatic - - O
disorders - - O
. - - O

Combination - - O
of - - O
3 - - O
multiple - - O
primary - - O
malignant - - O
and - - O
benign - - O
tumors - - O
of - - O
the - - O
breasts - - O
and - - O
uterus - - O
. - - O

RESULTS - - O
: - - O
The - - O
standardised - - O
mortality - - O
ratio - - O
( - - O
SMR - - O
) - - O
for - - O
all - - O
malignant - - O
neoplasms - - O
was - - O
94 - - O
( - - O
95% - - O
CI - - O
74 - - O
to - - O
118 - - O
) - - O
. - - O

Erythrocyte - - O
AA - - O
in - - O
FO+EPO-supplemented - - O
infants - - O
remained - - O
low - - O
and - - O
below - - O
breast- - - O
and - - O
placebo - - O
formula-fed - - O
levels - - O
. - - O

A - - O
semiautomatic - - O
digital - - O
system - - O
( - - O
Videoplan - - O
2 - - O
) - - O
was - - O
used - - O
. - - O

On - - O
histologic - - O
examination - - O
the - - O
cuboidal - - O
epithelium - - O
of - - O
the - - O
mucous - - O
membrane - - O
was - - O
found - - O
to - - O
be - - O
changed - - O
into - - O
columnar - - O
epithelium - - O
, - - O
with - - O
uneven - - O
distribution - - O
of - - O
enlarged - - O
nuclei - - O
in - - O
the - - O
vacuolized - - O
cytoplasm - - O
. - - O

Swim-over - - O
: - - O
an - - O
alternative - - O
method - - O
for - - O
harvesting - - O
motile - - O
spermatozoa - - O
. - - O

The - - O
rat - - B-MUT
aldolase - - I-MUT
C - - I-MUT
gene - - I-MUT
encodes - - O
a - - O
glycolytic - - O
enzyme - - O
strongly - - O
expressed - - O
in - - O
adult - - O
brain - - O
. - - O

The - - O
human - - O
cDNA - - O
clone - - O
NFBD1 - - O
( - - O
previously - - O
designated - - O
KIAA0170 - - O
) - - O
encodes - - O
a - - O
novel - - O
protein - - O
( - - O
2089 - - O
amino - - O
acids - - O
in - - O
length - - O
; - - O
calculated - - O
molecular - - O
mass - - O
226 - - O
, - - O
440 - - O
D - - O
) - - O
with - - O
possible - - O
BRCT - - B-MUT
domains - - I-MUT
at - - O
its - - O
carboxy - - O
terminus - - O
( - - O
amino - - O
acid - - O
residues - - O
1894-2089 - - O
) - - O
. - - O

The - - O
effects - - O
of - - O
systemic - - O
glucose - - O
concentration - - O
on - - O
brain - - O
metabolism - - O
following - - O
repeated - - O
brain - - O
ischemia - - O
. - - O

Mechanism - - O
of - - O
interferon - - B-MUT
action - - O
: - - O
identification - - O
of - - O
essential - - O
positions - - O
within - - O
the - - O
novel - - O
15-base-pair - - B-MUT
KCS - - I-MUT
element - - I-MUT
required - - O
for - - O
transcriptional - - O
activation - - O
of - - O
the - - O
RNA-dependent - - B-MUT
protein - - I-MUT
kinase - - I-MUT
pkr - - I-MUT
gene - - I-MUT
. - - O

The - - O
strategies - - O
by - - O
which - - O
hepatitis - - O
B - - O
and - - O
hepatitis - - O
D - - O
can - - O
be - - O
diminished - - O
and - - O
eventually - - O
eliminated - - O
are - - O
: - - O
immunization - - O
, - - O
measures - - O
to - - O
prevent - - O
exposure - - O
to - - O
infective - - O
blood - - O
or - - O
blood - - O
derivatives - - O
and - - O
education - - O
( - - O
in - - O
particular - - O
awareness - - O
that - - O
hepatitis - - O
B - - O
is - - O
a - - O
sexually - - O
transmitted - - O
disease - - O
) - - O
. - - O

A - - O
single - - O
five - - O
minute - - O
period - - O
of - - O
rapid - - O
atrial - - O
pacing - - O
fails - - O
to - - O
limit - - O
infarct - - O
size - - O
in - - O
the - - O
in - - O
situ - - O
rabbit - - O
heart - - O
. - - O

Finally - - O
, - - O
three - - O
new - - O
missense - - O
mutations - - O
, - - O
E138V - - B-MUT
, - - O
R254G - - B-MUT
, - - O
and - - O
P362R - - B-MUT
, - - O
were - - O
identified - - O
in - - O
the - - O
human - - B-MUT
AC - - I-MUT
gene - - I-MUT
from - - O
FD - - O
patients - - O
. - - O

Although - - O
the - - O
spatial - - O
and - - O
temporal - - O
variability - - O
of - - O
LDF - - O
signals - - O
evoked - - O
by - - O
cerebrocortical - - O
microflow - - O
is - - O
in - - O
the - - O
same - - O
range - - O
as - - O
with - - O
other - - O
methods - - O
and - - O
in - - O
other - - O
organs - - O
, - - O
LDF - - O
cerebrocortical - - O
mapping - - O
is - - O
restricted - - O
by - - O
the - - O
large - - O
temporal - - O
and - - O
spatial - - O
heterogeneity - - O
of - - O
the - - O
cerebrocortical - - O
vasculature - - O
. - - O

Taken - - O
together - - O
, - - O
the - - O
results - - O
suggest - - O
that - - O
chlorphentermine - - O
may - - O
be - - O
capable - - O
of - - O
producing - - O
dual - - O
stimulus - - O
effects - - O
in - - O
animals - - O
. - - O

However - - O
, - - O
2 - - O
minimum - - O
alveolar - - O
concentration - - O
anesthesia - - O
did - - O
significantly - - O
decrease - - O
the - - O
calculated - - O
VE - - O
at - - O
a - - O
PCO2 - - O
of - - O
60 - - O
mmHg - - O
( - - O
from - - O
7 - - O
. - - O
4 - - O
+ - - O
- - - O
1 - - O
. - - O
2 - - O
to - - O
4 - - O
. - - O
0 - - O
+ - - O
- - - O
0 - - O
. - - O
6 - - O
l - - O
. - - O
min-1 - - O
) - - O
, - - O
indicating - - O
a - - O
rightward - - O
shift - - O
in - - O
the - - O
response - - O
relationship - - O
. - - O

Nuclease - - B-MUT
probing - - O
and - - O
structure-directed - - O
mutagenesis - - O
revealed - - O
that - - O
the - - O
105-nt - - B-MUT
TE - - I-MUT
( - - O
TE105 - - B-MUT
) - - O
forms - - O
a - - O
cruciform - - O
secondary - - O
structure - - O
containing - - O
four - - O
helices - - O
connected - - O
by - - O
single-stranded - - O
regions - - O
. - - O

These - - O
results - - O
suggested - - O
that - - O
the - - O
GG - - O
motifs - - O
contributed - - O
to - - O
the - - O
cell-specific - - O
transcription - - O
of - - O
the - - O
human - - B-MUT
insulin - - I-MUT
gene - - I-MUT
in - - O
association - - O
with - - O
the - - O
binding - - O
of - - O
the - - O
sequence-specific - - O
nuclear - - O
factor - - O
. - - O

To - - O
investigate - - O
the - - O
potential - - O
role - - O
of - - O
SP1 - - B-MUT
, - - O
we - - O
examined - - O
nuclear - - O
extracts - - O
from - - O
HCMV-infected - - O
cells - - O
. - - O

In - - O
contrast - - O
, - - O
the - - O
differentiation - - O
of - - O
neoplastically - - O
transformed - - O
cells - - O
does - - O
not - - O
repress - - O
mitogenic - - O
responsiveness - - O
or - - O
junB - - B-MUT
or - - O
c-fos - - B-MUT
inducibility - - O
. - - O

Of - - O
the - - O
drugs - - O
orally - - O
administered - - O
, - - O
WR-168643 - - O
was - - O
the - - O
best - - O
protector - - O
with - - O
a - - O
DMF - - O
of - - O
1 - - O
. - - O
51 - - O
. - - O

Here - - O
, - - O
we - - O
report - - O
that - - O
swa5-1 - - B-MUT
is - - O
a - - O
new - - O
temperature-sensitive - - O
allele - - O
of - - O
the - - O
clathrin - - B-MUT
heavy - - I-MUT
chain - - I-MUT
gene - - I-MUT
( - - O
chc1-5 - - B-MUT
) - - O
, - - O
which - - O
carries - - O
a - - O
frameshift - - O
mutation - - O
near - - O
the - - O
3' - - O
end - - O
of - - O
the - - O
CHC1 - - B-MUT
open - - O
reading - - O
frame - - O
. - - O

Artificial - - O
ventilation - - O
was - - O
conducted - - O
using - - O
a - - O
tidal - - O
volume - - O
of - - O
10 - - O
ml - - O
X - - O
kg-1 - - O
and - - O
a - - O
rate - - O
of - - O
10 - - O
to - - O
12 - - O
c - - O
X - - O
min-1 - - O
. - - O

Active - - O
complexes - - O
eluted - - O
at - - O
a - - O
higher - - O
molecular - - O
weight - - O
than - - O
inactive - - O
complexes - - O
, - - O
were - - O
relatively - - O
deficient - - O
in - - O
both - - O
p21 - - B-MUT
and - - O
p27 - - B-MUT
, - - O
and - - O
contained - - O
Cdk2 - - B-MUT
with - - O
increased - - O
threonine - - O
160 - - O
phosphorylation - - O
, - - O
consistent - - O
with - - O
a - - O
mechanism - - O
of - - O
activation - - O
of - - O
cyclin - - B-MUT
E-Cdk2 - - I-MUT
involving - - O
both - - O
reduced - - O
CDK - - B-MUT
inhibitor - - O
association - - O
and - - O
CDK-activating - - O
kinase-mediated - - O
phosphorylation - - O
of - - O
Cdk2 - - B-MUT
. - - O

Pancreaticoduodenal - - O
lymph - - O
node - - O
enlargement - - O
, - - O
regardless - - O
of - - O
cause - - O
, - - O
has - - O
been - - O
a - - O
source - - O
of - - O
imaging - - O
confusion - - O
because - - O
of - - O
its - - O
propensity - - O
to - - O
mimic - - O
pancreatic - - O
malignancy - - O
yet - - O
not - - O
cause - - O
biliary - - O
obstruction - - O
. - - O

The - - O
5'-flanking - - O
region - - O
, - - O
from - - O
nucleotide - - O
-837 - - O
to - - O
-336 - - O
, - - O
contains - - O
TATA - - O
and - - O
inverted - - O
CAAT - - O
boxes - - O
as - - O
well - - O
as - - O
GATA-1 - - B-MUT
SP1 - - O
erythroid-specific - - B-MUT
cis-acting - - O
regulatory - - O
elements - - O
. - - O

Mutation - - O
of - - O
KRKR - - B-MUT
to - - O
NGER - - B-MUT
retains - - O
MO15 - - B-MUT
in - - O
the - - O
cytoplasmic - - O
compartment - - O
, - - O
whilst - - O
the - - O
wild-type - - O
protein - - O
is - - O
detected - - O
exclusively - - O
in - - O
the - - O
nucleus - - O
. - - O

However - - O
, - - O
when - - O
combined - - O
with - - O
mitomycin - - O
C - - O
given - - O
with - - O
1 - - O
to - - O
5-days - - O
interval - - O
, - - O
the - - O
concurrent - - O
administration - - O
of - - O
SPG - - O
prolonged - - O
significantly - - O
the - - O
life-span - - O
of - - O
the - - O
tumor-bearing - - O
mice - - O
. - - O

The - - O
equilibrium - - O
phosphorus - - O
content - - O
( - - O
EPC0 - - O
) - - O
of - - O
surface - - O
soil - - O
was - - O
generally - - O
higher - - O
than - - O
the - - O
SRP - - O
content - - O
of - - O
drainage - - O
water - - O
, - - O
at - - O
one - - O
farm - - O
by - - O
1 - - O
order - - O
of - - O
magnitude - - O
. - - O

When - - O
blood - - O
samples - - O
of - - O
patients - - O
with - - O
hyperbilirubinemia - - O
were - - O
analyzed - - O
, - - O
direct - - O
measurement - - O
of - - O
ZPP - - O
by - - O
this - - O
fluorimeter - - O
yielded - - O
significantly - - O
higher - - O
levels - - O
than - - O
did - - O
an - - O
alternate - - O
extraction - - O
method - - O
. - - O

Transformation - - O
blocks - - O
differentiation-induced - - O
inhibition - - O
of - - O
serum - - B-MUT
response - - I-MUT
factor - - I-MUT
interactions - - O
with - - O
serum - - B-MUT
response - - I-MUT
elements - - I-MUT
. - - O

The - - O
monoexponential - - O
rate - - O
of - - O
clearance - - O
of - - O
tracer--obtained - - O
from - - O
the - - O
portion - - O
of - - O
the - - O
residue-detection - - O
curve - - O
reflecting - - O
metabolism - - O
of - - O
fatty - - O
acid - - O
incorporated - - O
into - - O
neutral - - O
lipids--correlated - - O
directly - - O
with - - O
induced - - O
changes - - O
in - - O
tension-time - - O
index - - O
after - - O
injections - - O
into - - O
the - - O
left - - O
atrium - - O
( - - O
r - - O
= - - O
0 - - O
. - - O
96 - - O
, - - O
n - - O
= - - O
12 - - O
) - - O
, - - O
right - - O
atrium - - O
( - - O
r - - O
= - - O
0 - - O
. - - O
86 - - O
, - - O
n - - O
= - - O
14 - - O
) - - O
, - - O
and - - O
ear - - O
vein - - O
( - - O
r - - O
= - - O
0 - - O
. - - O
93 - - O
, - - O
n - - O
= - - O
14 - - O
) - - O
. - - O

Using - - O
a - - O
previously - - O
published - - O
two-frequency - - O
( - - O
AC - - O
excitation - - O
) - - O
three-electrode - - O
method - - O
, - - O
the - - O
admittance - - O
locus - - O
plot - - O
( - - O
ALP - - O
) - - O
in - - O
the - - O
low-frequency - - O
region - - O
( - - O
< - - O
1000 - - O
Hz - - O
) - - O
has - - O
been - - O
shown - - O
to - - O
be - - O
very - - O
well - - O
approximated - - O
by - - O
a - - O
straight - - O
line - - O
and - - O
can - - O
be - - O
described - - O
with - - O
frequency-independent - - O
parameters - - O
; - - O
phase - - O
angle - - O
alpha - - O
pi - - O
2 - - O
, - - O
conductance - - O
at - - O
extrapolated - - O
zero - - O
frequency - - O
G0 - - O
= - - O
1 - - O
R0 - - O
, - - O
and - - O
ion - - O
relaxation - - O
time - - O
tau - - O
. - - O

A - - O
rather - - O
similar - - O
pattern - - O
of - - O
results - - O
was - - O
obtained - - O
with - - O
respect - - O
to - - O
LMP2B - - B-MUT
mRNA - - I-MUT
expression - - O
, - - O
such - - O
transcripts - - O
being - - O
detectable - - O
only - - O
in - - O
a - - O
subset - - O
of - - O
tumors - - O
, - - O
and - - O
then - - O
at - - O
apparently - - O
low - - O
levels - - O
. - - O

Temporal - - O
relationships - - O
and - - O
the - - O
development - - O
phase - - O
affected - - O
. - - O

To - - O
dissect - - O
these - - O
mechanisms - - O
, - - O
wild-type - - O
and - - O
mutant - - B-MUT
Raf-1 - - I-MUT
proteins - - I-MUT
were - - O
studied - - O
in - - O
an - - O
in - - O
vitro - - O
system - - O
with - - O
purified - - O
plasma - - O
membranes - - O
from - - O
v-Ras- - - O
and - - O
v-Src-transformed - - O
cells - - O
( - - O
transformed - - O
membranes - - O
) - - O
. - - O

The - - O
influence - - O
of - - O
p53 - - B-MUT
on - - O
cytokine-triggered - - O
Janus - - B-MUT
kinase-STAT - - I-MUT
signaling - - O
was - - O
investigated - - O
in - - O
human - - O
hepatoma - - O
Hep3B - - O
cell - - O
lines - - O
engineered - - O
to - - O
constitutively - - O
express - - O
the - - O
temperature-sensitive - - O
Val135 - - B-MUT
mutant - - I-MUT
of - - I-MUT
p53 - - I-MUT
. - - O

Anatomy - - O
of - - O
the - - O
uterine - - O
artery - - O
. - - O

Neurofibromatosis - - O
of - - O
the - - O
breast - - O
in - - O
a - - O
patient - - O
with - - O
Morbus - - O
von - - O
Recklinghausen - - O
. - - O

Endovascular - - O
aneurysm - - O
repair - - O
with - - O
the - - O
AneuRx - - O
stent-graft - - O
is - - O
safe - - O
, - - O
but - - O
is - - O
it - - O
effective - - O
? - - O

Vascular - - B-MUT
endothelial - - I-MUT
growth - - I-MUT
factor - - I-MUT
( - - O
VEGF - - B-MUT
) - - O
, - - O
a - - O
potent - - O
agonist - - O
secreted - - O
by - - O
virtually - - O
all - - O
cells - - O
, - - O
controls - - O
migration - - O
and - - O
division - - O
of - - O
vascular - - O
endothelial - - O
cells - - O
. - - O

This - - O
caused - - O
severe - - O
cortical - - O
damage - - O
and - - O
neuronal - - O
loss - - O
in - - O
hippocampus - - O
subfields - - O
CA1 - - O
, - - O
CA3 - - O
, - - O
and - - O
hilus - - O
. - - O

Only - - O
the - - O
3 - - O
. - - O
0-kb - - O
transcript - - O
was - - O
detected - - O
in - - O
adult - - O
tissues - - O
, - - O
where - - O
its - - O
expression - - O
was - - O
restricted - - O
almost - - O
exclusively - - O
to - - O
the - - O
central - - O
nervous - - O
system - - O
. - - O

A - - O
third - - O
prominent - - O
component - - O
of - - O
apparent - - O
molecular - - O
mass - - O
16 - - O
kDa - - O
displayed - - O
several - - O
properties - - O
, - - O
including - - O
ability - - O
to - - O
bind - - O
45Ca2+ - - O
, - - O
that - - O
are - - O
characteristic - - O
of - - O
the - - O
regulatory - - O
( - - O
B - - O
) - - O
subunit - - O
of - - O
mammalian - - B-MUT
calcineurin - - I-MUT
and - - O
was - - O
recognized - - O
by - - O
an - - O
antiserum - - O
raised - - O
against - - O
bovine - - B-MUT
calcineurin - - I-MUT
. - - O

Escalation - - O
to - - O
180 - - O
mg - - O
m2 - - O
was - - O
to - - O
be - - O
carried - - O
out - - O
if - - O
white - - O
blood - - O
cell - - O
nadir - - O
count - - O
was - - O
> - - O
2 - - O
. - - O
0 - - O
x - - O
10 - - O
( - - O
9 - - O
) - - O
l - - O
and - - O
platelet - - O
nadir - - O
count - - O
was - - O
> - - O
75 - - O
x - - O
10 - - O
( - - O
9 - - O
) - - O
l - - O
. - - O

Change - - O
in - - O
plasma - - B-MUT
cystyl - - I-MUT
aminopeptidase - - I-MUT
( - - O
oxytocinase - - B-MUT
) - - O
between - - O
30-34 - - O
weeks' - - O
gestation - - O
as - - O
a - - O
predictor - - O
of - - O
pregnancy-induced - - O
hypertension - - O
. - - O

Preflight - - O
, - - O
inflight - - O
, - - O
and - - O
postflight - - O
exercise - - O
response - - O
tests - - O
were - - O
conducted - - O
on - - O
the - - O
astronauts - - O
of - - O
the - - O
second - - O
Skylab - - O
mission - - O
( - - O
Skylab - - O
3 - - O
) - - O
as - - O
part - - O
of - - O
an - - O
evaluation - - O
of - - O
physiological - - O
adaptation - - O
to - - O
long-term - - O
weightlessness - - O
. - - O

When - - O
data - - O
were - - O
expressed - - O
in - - O
a - - O
cumulative - - O
manner - - O
, - - O
the - - O
response - - O
to - - O
intravenous - - O
adenosine - - O
3 - - O
mg - - O
, - - O
6 - - O
mg - - O
, - - O
9 - - O
mg - - O
and - - O
12 - - O
mg - - O
in - - O
the - - O
24 - - O
episodes - - O
of - - O
PSVT - - O
were - - O
5 - - O
episodes - - O
( - - O
21% - - O
) - - O
, - - O
16 - - O
episodes - - O
( - - O
67% - - O
) - - O
, - - O
20 - - O
episodes - - O
( - - O
83% - - O
) - - O
and - - O
20 - - O
episodes - - O
( - - O
83% - - O
) - - O
respectively - - O
. - - O

Letter - - O
: - - O
Aryl - - B-MUT
hydrocarbon - - I-MUT
hydroxylase - - I-MUT
and - - O
smoking - - O
. - - O

Measurements - - O
of - - O
activity - - O
with - - O
the - - O
radioprotective - - O
chamber - - O
VA-K-254 - - O
of - - O
the - - O
osimeter - - O
VA-J18 - - O
. - - O

Serial - - O
followup - - O
strength - - O
data - - O
for - - O
2 - - O
patients - - O
were - - O
compared - - O
to - - O
change - - O
in - - O
creatinine - - B-MUT
kinase - - I-MUT
( - - O
CK - - B-MUT
) - - O
levels - - O
. - - O

On - - O
the - - O
other - - O
hand - - O
, - - O
forced - - O
overexpression - - O
of - - O
the - - O
wild - - O
type - - O
, - - O
but - - O
not - - O
the - - O
kinase-inactivated - - O
mutant - - O
of - - O
nm23H1 - - B-MUT
, - - O
converted - - O
the - - O
GDP-bound - - O
forms - - O
of - - O
Rac1 - - B-MUT
, - - O
Cdc42 - - B-MUT
, - - O
and - - O
RhoA - - B-MUT
to - - O
their - - O
GTP-bound - - O
forms - - O
in - - O
vitro - - O
by - - O
its - - O
nucleoside - - B-MUT
diphosphate - - I-MUT
kinase - - I-MUT
activity - - O
, - - O
but - - O
nm23H1 - - B-MUT
alone - - O
apparently - - O
did - - O
not - - O
produce - - O
the - - O
GTP-bound - - O
form - - O
of - - O
these - - O
GTPases - - B-MUT
in - - O
vivo - - O
. - - O

Mobility - - O
and - - O
supershift - - O
assays - - O
demonstrated - - O
that - - O
upstream - - B-MUT
stimulatory - - I-MUT
factor - - I-MUT
( - - O
USF - - B-MUT
) - - O
and - - O
Sp1 - - B-MUT
bind - - O
to - - O
the - - O
former - - O
elements - - O
and - - O
competition - - O
experiments - - O
confirmed - - O
that - - O
CREB - - B-MUT
ATF - - O
and - - B-MUT
AP-1 - - O
bind - - B-MUT
to - - O
the - - O
CRE - - O
TRE - - B-MUT
element - - O
. - - B-MUT

The - - O
results - - O
showed - - O
that - - O
MIP - - O
, - - O
MMIF - - O
, - - O
FIC - - O
, - - O
Wimax - - O
, - - O
P0 - - O
. - - O
1 - - O
and - - O
minute - - O
ventilation - - O
( - - O
Vr - - O
) - - O
were - - O
significantly - - O
increased - - O
after - - O
administration - - O
of - - O
methylphenidatum - - O
and - - O
aminophylline - - O
. - - O

During - - O
BH - - O
the - - O
ventilator - - O
was - - O
disconnected - - O
and - - O
a - - O
bias - - O
flow - - O
of - - O
50% - - O
O2 - - O
at - - O
4-5 - - O
l - - O
min - - O
was - - O
delivered - - O
through - - O
the - - O
side - - O
ports - - O
of - - O
a - - O
small - - O
catheter - - O
whose - - O
tip - - O
was - - O
positioned - - O
1 - - O
cm - - O
cephalad - - O
of - - O
the - - O
carina - - O
. - - O

Growth - - B-MUT
factor - - I-MUT
stimulation - - O
of - - O
cells - - O
causes - - O
the - - O
phosphorylation - - O
of - - O
the - - O
c-Myc - - B-MUT
transcriptional - - I-MUT
activation - - I-MUT
domain - - I-MUT
at - - O
Ser62 - - O
within - - O
a - - O
proline-rich - - O
region - - O
that - - O
is - - O
highly - - O
conserved - - O
among - - O
members - - O
of - - O
the - - O
Myc - - B-MUT
family - - I-MUT
( - - O
Alvarez - - O
, - - O
E - - O
. - - O
, - - O
Northwood - - O
, - - O
I - - O
. - - O
C - - O
. - - O
, - - O
Gonzalez - - O
, - - O
F - - O
. - - O

In - - O
this - - O
report - - O
this - - O
technique - - O
was - - O
applied - - O
to - - O
human - - O
breast - - O
carcinoma - - O
MDA-MB231 - - O
cells - - O
overexpressing - - O
human - - B-MUT
MPG - - I-MUT
in - - O
order - - O
to - - O
assess - - O
whether - - O
up-regulation - - O
of - - O
the - - O
initial - - O
step - - O
in - - O
BER - - O
alters - - O
the - - O
activity - - O
of - - O
selected - - O
other - - O
BER - - O
( - - O
hOGG1 - - B-MUT
and - - O
APE - - B-MUT
ref-1 - - I-MUT
) - - I-MUT
or - - O
direct - - O
reversal - - O
( - - O
MGMT - - O
) - - B-MUT
repair - - O
activities - - O
. - - O

When - - O
BFDS - - O
was - - O
taken - - O
as - - O
the - - O
reference - - O
, - - O
W - - O
A - - O
Z - - O
scores - - O
showed - - O
consistent - - O
positive - - O
increments - - O
, - - O
from - - O
birth - - O
in - - O
girls - - O
and - - O
1 - - O
mo - - O
in - - O
boys - - O
. - - O

Plasmids - - O
for - - O
the - - O
cloning - - O
and - - O
expression - - O
of - - O
full-length - - O
double-stranded - - O
cDNAs - - O
under - - O
control - - O
of - - O
the - - O
SV40 - - B-MUT
early - - I-MUT
or - - I-MUT
late - - I-MUT
gene - - I-MUT
promoter - - I-MUT
. - - O

Regarding - - O
"the - - O
relation - - O
between - - O
sexual - - O
orientation - - O
and - - O
penile - - O
size - - O
, - - O
" - - O
by - - O
A - - O
. - - O

A - - O
total - - O
of - - O
281 - - O
patients - - O
were - - O
divided - - O
into - - O
groups - - O
according - - O
to - - O
their - - O
clinical - - O
diagnosis - - O
and - - O
were - - O
examined - - O
using - - O
capnography - - O
, - - O
spirometry - - O
and - - O
blood-gas - - O
analysis - - O
. - - O

A - - O
substantial - - O
fraction - - O
of - - O
Cbl - - B-MUT
was - - O
constitutively - - O
associated - - O
with - - O
Grb2 - - B-MUT
and - - O
this - - O
interaction - - O
was - - O
mediated - - O
by - - O
Grb2 - - B-MUT
SH3 - - I-MUT
domains - - I-MUT
. - - O

The - - O
AGM - - B-MUT
and - - I-MUT
NIH - - I-MUT
Swiss - - I-MUT
mouse - - I-MUT
CCR5 - - I-MUT
proteins - - I-MUT
are - - I-MUT
97 - - O
. - - O
7 - - O
to - - O
98 - - O
. - - O
3% - - O
and - - O
79 - - O
. - - O
8% - - O
identical - - O
to - - O
the - - O
human - - O
protein - - O
, - - O
respectively - - O
. - - O

Mutagenesis - - O
of - - O
the - - O
CDE - - B-MUT
CHR - - I-MUT
elements - - I-MUT
and - - I-MUT
Sp1 - - O
sites - - B-MUT
in - - I-MUT
this - - O
region - - O
, - - O
alone - - O
or - - O
in - - O
combination - - O
, - - O
reduced - - O
transcriptional - - O
activity - - O
by - - O
40-60% - - O
in - - O
asynchronously - - O
growing - - O
cells - - O
and - - O
abolished - - O
cell - - O
cycle - - O
periodicity - - O
in - - O
G2-M-synchronized - - O
cells - - O
. - - O

All - - O
our - - O
patients - - O
had - - O
polyps - - O
, - - O
23 - - O
( - - O
54% - - O
) - - O
had - - O
asthma - - O
, - - O
12 - - O
( - - O
27% - - O
) - - O
had - - O
aspirin - - O
sensitivity - - O
, - - O
20 - - O
( - - O
65% - - O
) - - O
had - - O
eosinophilia - - O
, - - O
and - - O
9 - - O
( - - O
69% - - O
) - - O
had - - O
increased - - O
total - - O
IgE - - B-MUT
levels - - O
. - - O

Differential - - O
activation - - O
of - - O
the - - O
extracellular - - B-MUT
signal-regulated - - I-MUT
kinase - - I-MUT
, - - O
Jun - - B-MUT
kinase - - I-MUT
and - - O
Janus - - B-MUT
kinase-Stat - - I-MUT
pathways - - O
by - - O
oncostatin - - O
M - - O
and - - O
basic - - B-MUT
fibroblast - - I-MUT
growth - - I-MUT
factor - - I-MUT
in - - O
AIDS-derived - - O
Kaposi's - - O
sarcoma - - O
cells - - O
. - - O

By - - O
contrast - - O
, - - O
PvirE - - B-MUT
or - - O
Plac - - B-MUT
promoter - - I-MUT
constructs - - I-MUT
yielded - - O
functional - - O
VirE2 - - B-MUT
only - - O
if - - O
virE1 - - B-MUT
was - - O
coexpressed - - O
with - - O
virE2 - - B-MUT
. - - O

PURPOSE - - O
: - - O
To - - O
introduce - - O
an - - O
image - - O
analysis - - O
of - - O
the - - O
cornea - - O
in - - O
photorefractive - - O
keratectomy - - O
( - - O
PRK - - O
) - - O
for - - O
preoperative - - O
and - - O
early - - O
postoperative - - O
determination - - O
of - - O
changes - - O
in - - O
the - - O
condition - - O
of - - O
the - - O
cornea - - O
. - - O

Normal - - O
alpha1 - - B-MUT
( - - I-MUT
I - - I-MUT
) - - I-MUT
collagen - - I-MUT
mRNA - - I-MUT
showed - - O
no - - O
significant - - O
reduction - - O
when - - O
AR - - O
or - - O
IR - - O
was - - O
expressed - - O
from - - O
the - - O
pHbetaAPr-1-neo - - O
vector - - O
and - - O
a - - O
small - - O
( - - O
10-20% - - O
) - - O
but - - O
significant - - O
reduction - - O
when - - O
either - - O
ribozyme - - B-MUT
was - - O
expressed - - O
from - - O
the - - O
pCI - - O
. - - O
neo - - O
vector - - O
. - - O

Patients - - O
with - - O
apparently - - O
minor - - O
CT - - O
abnormalities - - O
may - - O
have - - O
significant - - O
epidural - - O
disease - - O
. - - O

Diagnosis - - O
: - - O
progressive - - O
multifocal - - O
leukoencephalopathy - - O
. - - O

Transformed - - O
cell - - O
lines - - O
expressing - - O
solely - - O
E1a - - B-MUT
or - - O
E1a - - B-MUT
and - - O
E1b - - B-MUT
gene - - I-MUT
products - - I-MUT
derived - - O
from - - O
these - - O
viruses - - O
display - - O
enhanced - - O
anchorage-independent - - O
growth - - O
at - - O
37 - - O
degrees - - O
C - - O
versus - - O
32 - - O
degrees - - O
C - - O
and - - O
display - - O
a - - O
cytoskeletal - - O
architecture - - O
resembling - - O
untransformed - - O
fibroblastic - - O
CREF - - O
cells - - O
. - - O

The - - O
amino - - O
acid - - O
sequence - - O
of - - O
the - - O
S - - O
. - - O
aureus - - O
peptide - - O
carrying - - O
the - - O
phosphoryl - - O
group - - O
was - - O
found - - O
to - - O
be - - O
Gln-Val-Val-Ser-Thr-Phe-Met-Gly-Asn-Gly-Leu-Ala-Ile-Pro-His-Gly-Thr-Asp- - - B-MUT
Asp - - I-MUT
. - - O

PKC-gamma - - B-MUT
, - - O
which - - O
is - - O
not - - O
present - - O
in - - O
keratinocytes - - O
, - - O
also - - O
induces - - O
involucrin - - B-MUT
gene - - I-MUT
expression - - O
in - - O
a - - O
TPA-independent - - O
manner - - O
, - - O
when - - O
introduced - - O
into - - O
SVHK - - O
cells - - O
. - - O

The - - O
exogenous - - O
fos - - B-MUT
gene - - I-MUT
was - - O
rapidly - - O
induced - - O
to - - O
maximal - - O
levels - - O
within - - O
1-2 - - O
hr - - O
of - - O
estrogen - - O
addition - - O
. - - O

In - - O
addition - - O
, - - O
expected - - O
decreases - - O
in - - O
ATIC - - B-MUT
enzymatic - - O
function - - O
in - - O
ATIC-ALK-containing - - O
lymphomas - - O
may - - O
render - - O
these - - O
tumors - - O
more - - O
sensitive - - O
to - - O
antifolate - - O
drugs - - O
such - - O
as - - O
methotrexate - - O
. - - O

Examination - - O
of - - O
ANCA - - O
is - - O
not - - O
only - - O
a - - O
significant - - O
contribution - - O
towards - - O
a - - O
more - - O
accurate - - O
diagnosis - - O
of - - O
renal - - O
vasculitis - - O
, - - O
but - - O
also - - O
an - - O
indicator - - O
of - - O
the - - O
activity - - O
of - - O
the - - O
disease - - O
and - - O
thus - - O
of - - O
the - - O
effectiveness - - O
of - - O
immunosuppressive - - O
treatment - - O
. - - O

NaeI - - B-MUT
, - - O
a - - O
novel - - O
DNA - - B-MUT
endonuclease - - I-MUT
, - - O
shows - - O
topoisomerase - - B-MUT
and - - O
recombinase - - B-MUT
activities - - O
when - - O
a - - O
Lys - - O
residue - - O
is - - O
substituted - - O
for - - O
Leu - - O
43 - - O
. - - O

Expression - - O
of - - O
class - - B-MUT
IV - - I-MUT
ADH - - I-MUT
mRNA - - I-MUT
was - - O
detected - - O
in - - O
human - - O
stomach - - O
but - - O
not - - O
liver - - O
. - - O

Within - - O
the - - O
3' - - O
terminal - - O
50 - - O
nucleotides - - O
, - - O
the - - O
mouse - - B-MUT
mt - - I-MUT
12S - - I-MUT
rRNA - - I-MUT
contains - - O
a - - O
potential - - O
10 - - O
bp - - O
hairpin - - O
structure - - O
and - - O
a - - O
sequence - - O
of - - O
15 - - O
consecutive - - O
nucleotides - - O
common - - O
to - - O
the - - O
RNA - - O
of - - O
the - - O
small - - O
ribosomal - - O
subunit - - O
in - - O
all - - O
systems - - O
, - - O
but - - O
does - - O
not - - O
contain - - O
the - - O
mRNA - - O
binding - - O
site - - O
( - - O
ACCUCC - - B-MUT
) - - O
found - - O
in - - O
E - - O
. - - O
coli - - O
and - - O
corn - - O
chloroplast - - O
rRNAs - - O
. - - O

The - - O
second - - O
goal - - O
was - - O
to - - O
ascertain - - O
the - - O
somatotopic - - O
arrangement - - O
of - - O
the - - O
GPi - - O
in - - O
PD - - O
. - - O

In - - O
addition - - O
to - - O
its - - O
effect - - O
in - - O
augmenting - - O
the - - O
neutrophil - - O
response - - O
to - - O
eccentric - - O
exercise - - O
, - - O
vitamin - - O
E - - O
causes - - O
a - - O
greater - - O
increase - - O
in - - O
circulating - - O
creatine - - B-MUT
kinase - - I-MUT
activity - - O
, - - O
perhaps - - O
indicating - - O
increased - - O
skeletal - - O
muscle - - O
repair - - O
. - - O

The - - O
NR2 - - O
hybrid - - O
is - - O
a - - O
powerful - - O
tool - - O
for - - O
the - - O
mapping - - O
of - - O
new - - O
probes - - O
of - - O
this - - O
region - - O
, - - O
as - - O
well - - O
as - - O
for - - O
obtaining - - O
new - - O
informative - - O
probes - - O
specific - - O
for - - O
the - - O
deletion - - O
by - - O
subtractive - - O
cloning - - O
of - - O
the - - O
region - - O
. - - O

The - - O
sequence - - O
similarity - - O
has - - O
suggested - - O
that - - O
SCG10 - - B-MUT
and - - O
stathmin - - B-MUT
have - - O
been - - O
derived - - O
from - - O
structurally - - O
and - - O
evolutionarily - - O
related - - O
genes - - O
. - - O

PSI-G - - B-MUT
and - - O
PSI-K - - B-MUT
probably - - O
have - - O
evolved - - O
from - - O
a - - O
gene - - O
duplication - - O
of - - O
an - - O
ancestral - - O
gene - - O
. - - O

Each - - O
sample - - O
was - - O
analysed - - O
as - - O
soon - - O
as - - O
possible - - O
, - - O
and - - O
repeated - - O
15 - - O
, - - O
30 - - O
, - - O
60 - - O
and - - O
120 - - O
min - - O
after - - O
sampling - - O
. - - O

Chimaeric - - B-MUT
VP16-E2 - - I-MUT
molecules - - I-MUT
suggest - - O
that - - O
the - - O
epithelial - - O
specific - - O
transcriptional - - O
activation - - O
of - - O
the - - O
BPV-4 - - O
LCR - - O
promoter - - O
is - - O
mediated - - O
by - - O
the - - O
E2 - - B-MUT
transactivation - - I-MUT
domain - - I-MUT
. - - O

The - - O
pigment - - O
intensity - - O
of - - O
both - - O
melanized - - O
colonies - - O
and - - O
appressoria - - O
of - - O
CAL - - O
transformants - - O
was - - O
weaker - - O
than - - O
that - - O
of - - O
the - - O
wild - - O
type - - O
. - - O

Mutations - - O
in - - O
the - - O
alpha - - B-MUT
and - - I-MUT
sigma-70 - - I-MUT
subunits - - I-MUT
of - - I-MUT
RNA - - I-MUT
polymerase - - I-MUT
affect - - O
expression - - O
of - - O
the - - O
mer - - B-MUT
operon - - I-MUT
. - - O

Heterogeneity - - O
of - - O
human - - B-MUT
serum - - I-MUT
albumin - - I-MUT
. - - O

Total - - O
body - - O
irradiation - - O
was - - O
delivered - - O
according - - O
to - - O
a - - O
hyperfractionated - - O
scheme - - O
of - - O
12 - - O
fractions - - O
given - - O
three - - O
per - - O
day - - O
5 - - O
hr - - O
apart - - O
for - - O
4 - - O
days - - O
. - - O

This - - O
300 - - O
bp - - O
5'-upstream - - O
sequence - - O
of - - O
K3 - - B-MUT
keratin - - I-MUT
gene - - I-MUT
, - - O
which - - O
can - - O
function - - O
in - - O
vitro - - O
as - - O
a - - O
keratinocyte-specific - - O
promoter - - O
, - - O
contains - - O
two - - O
clusters - - O
of - - O
partially - - O
overlapping - - O
motifs - - O
, - - O
one - - O
with - - O
an - - O
NFkB - - B-MUT
consensus - - O
sequence - - O
and - - O
another - - O
with - - O
a - - O
GC - - O
box - - O
. - - O

The - - O
effect - - O
of - - O
feeding - - O
patterns - - O
on - - O
fat - - O
deposition - - O
in - - O
mice - - O
. - - O

A - - O
mutant - - O
form - - O
of - - O
Vps1p - - B-MUT
lacking - - O
the - - O
entire - - O
GTP-binding - - O
domain - - O
interfered - - O
with - - O
vacuolar - - O
protein - - O
sorting - - O
in - - O
wild-type - - O
cells - - O
. - - O

Both - - O
proprioceptive - - O
and - - O
electroreceptive - - O
units - - O
showed - - O
a - - O
progression - - O
of - - O
receptive - - O
fields - - O
from - - O
anterior - - O
to - - O
posterior - - O
body - - O
in - - O
the - - O
rostral - - O
to - - O
caudal - - O
direction - - O
along - - O
the - - O
length - - O
of - - O
DGR - - O
. - - O

Molecular - - O
identification - - O
of - - O
smg-4 - - B-MUT
, - - O
required - - O
for - - O
mRNA - - O
surveillance - - O
in - - O
C - - O
. - - O
elegans - - O
. - - O

Of - - O
these - - O
patients - - O
, - - O
46 - - O
, - - O
164 - - O
were - - O
placed - - O
on - - O
a - - O
waiting - - O
list - - O
for - - O
transplantation - - O
, - - O
23 - - O
, - - O
275 - - O
of - - O
whom - - O
received - - O
a - - O
first - - O
cadaveric - - O
transplant - - O
between - - O
1991 - - O
and - - O
1997 - - O
. - - O

Radiotherapy - - O
and - - O
early - - O
orchiectomy - - O
in - - O
stage - - O
D1 - - O
prostatic - - O
carcinoma - - O
. - - O

Interestingly - - O
, - - O
the - - O
RNA - - O
sequences - - O
selected - - O
by - - O
the - - O
mutated - - O
zinc - - B-MUT
knuckle - - I-MUT
9G8 - - I-MUT
variant - - I-MUT
are - - O
efficiently - - O
recognized - - O
by - - O
SRp20 - - B-MUT
, - - O
in - - O
agreement - - O
with - - O
the - - O
fact - - O
that - - O
the - - O
RBD - - O
of - - O
9G8 - - B-MUT
and - - O
SRp20 - - B-MUT
are - - O
similar - - O
. - - O

Krox-20 - - B-MUT
, - - O
a - - O
zinc - - O
finger - - O
gene - - O
, - - O
has - - O
a - - O
highly - - O
conserved - - O
pattern - - O
of - - O
expression - - O
in - - O
r3 - - B-MUT
and - - O
r5 - - B-MUT
and - - O
is - - O
functionally - - O
required - - O
for - - O
their - - O
maintenance - - O
in - - O
mouse - - O
embryos - - O
. - - O

These - - O
results - - O
illustrate - - O
an - - O
important - - O
role - - O
for - - O
La - - B-MUT
in - - O
RNA - - O
production - - O
by - - O
demonstrating - - O
its - - O
ability - - O
to - - O
clear - - O
the - - O
termination - - O
sites - - O
of - - O
class - - B-MUT
III - - I-MUT
templates - - I-MUT
, - - O
thereby - - O
promoting - - O
efficient - - O
use - - O
of - - O
transcription - - O
complexes - - O
by - - O
pol - - B-MUT
III - - I-MUT
. - - O

The - - O
cytosolic - - O
glutathione - - B-MUT
S-transferases - - I-MUT
( - - O
GSTs - - B-MUT
, - - O
EC - - O
2 - - O
. - - O
5 - - O
. - - O
1 - - O
. - - O
18 - - O
) - - O
are - - O
a - - O
superfamily - - O
of - - O
dimeric - - O
isoenzymes - - O
which - - O
catalyze - - O
the - - O
conjugation - - O
of - - O
electrophilic - - O
substrates - - O
with - - O
glutathione - - O
. - - O

The - - O
patient - - O
had - - O
developed - - O
left-sided - - O
low-frequency - - O
tremor - - O
and - - O
hemidystonia - - O
after - - O
a - - O
severe - - O
head - - O
trauma - - O
sustained - - O
at - - O
15 - - O
years - - O
of - - O
age - - O
. - - O

Full - - O
thyroid - - O
function - - O
testing - - O
was - - O
performed - - O
on - - O
600 - - O
randomly - - O
selected - - O
samples - - O
with - - O
normal - - O
TSH - - B-MUT
values - - O
and - - O
also - - O
on - - O
subjects - - O
with - - O
abnormal - - O
TSH - - B-MUT
levels - - O
. - - O

17 - - O
. - - O
5% - - O
of - - O
cycles - - O
) - - O
. - - O

The - - O
mei4+ - - B-MUT
gene - - I-MUT
of - - O
the - - O
fission - - O
yeast - - O
Schizosaccharomyces - - O
pombe - - O
was - - O
cloned - - O
by - - O
functional - - O
complementation - - O
. - - O

Molecular - - O
cloning - - O
and - - O
characterization - - O
of - - O
two - - O
genes - - B-MUT
encoding - - I-MUT
gp138 - - I-MUT
, - - O
a - - O
cell - - O
surface - - O
glycoprotein - - O
involved - - O
in - - O
the - - O
sexual - - O
cell - - O
fusion - - O
of - - O
Dictyostelium - - O
discoideum - - O
. - - O

Routinely - - O
collected - - O
, - - O
processed - - O
and - - O
stored - - O
breast - - O
cancer - - O
tissue - - O
blocks - - O
recovered - - O
from - - O
the - - O
archives - - O
of - - O
the - - O
Pathology - - O
laboratory - - O
in - - O
Dar - - O
es - - O
Salaam - - O
after - - O
storage - - O
of - - O
up - - O
to - - O
3 - - O
years - - O
were - - O
analysed - - O
by - - O
a - - O
flow - - O
cytometry - - O
for - - O
DNA - - O
ploidy - - O
and - - O
S-phase - - O
fraction - - O
. - - O

The - - O
daily - - O
administration - - O
of - - O
betamethasone - - O
for - - O
three - - O
weeks - - O
markedly - - O
reduced - - O
the - - O
absorption - - O
of - - O
calcium - - O
and - - O
phosphate - - O
as - - O
well - - O
as - - O
the - - O
growth - - O
rate - - O
. - - O

Overall - - O
prevalences - - O
of - - O
antibody - - O
were - - O
70 - - O
per - - O
cent - - O
in - - O
cattle - - O
, - - O
67 - - O
per - - O
cent - - O
in - - O
sheep - - O
and - - O
76 - - O
per - - O
cent - - O
in - - O
goats - - O
as - - O
assessed - - O
by - - O
an - - O
immunodiffusion - - O
test - - O
. - - O

So - - O
far - - O
15 - - O
children - - O
have - - O
been - - O
studied - - O
. - - O

Fluorescence - - O
in - - O
situ - - O
hybridization - - O
of - - O
metaphase - - O
spreads - - O
of - - O
chromosome - - O
8 - - O
, - - O
containing - - O
hybrid - - O
cell - - O
line - - O
706-B6 - - O
clone - - O
17 - - O
( - - O
CL-17 - - O
) - - O
with - - O
cosmid - - O
c101F1 - - O
, - - O
placed - - O
the - - O
9804 - - B-MUT
gene - - I-MUT
close - - O
to - - O
the - - O
telomere - - O
at - - O
8q24 - - O
. - - O
3 - - O
. - - O

Typical - - O
and - - O
atypical - - O
clinical - - O
features - - O
of - - O
this - - O
lacrimal - - O
sac - - O
cyst - - O
are - - O
emphasized - - O
. - - O

Recent - - O
studies - - O
have - - O
demonstrated - - O
that - - O
the - - O
activated - - O
GH - - B-MUT
receptor - - I-MUT
can - - O
stimulate - - O
Stat1 - - B-MUT
, - - O
a - - O
cytoplasmic - - O
transcription - - O
factor - - O
that - - O
becomes - - O
tyrosine - - O
phosphorylated - - O
and - - O
translocates - - O
to - - O
the - - O
nucleus - - O
, - - O
where - - O
it - - O
can - - O
interact - - O
with - - O
specific - - O
DNA - - O
sequences - - O
to - - O
modulate - - O
gene - - O
expression - - O
. - - O

Different - - O
sequence - - O
elements - - O
of - - O
both - - O
the - - O
retroviral - - O
vectors - - O
and - - O
the - - O
c-myc - - B-MUT
gene - - I-MUT
recombined - - O
during - - O
genesis - - O
of - - O
highly - - O
oncogenic - - O
retroviruses - - O
CMII - - O
, - - O
MC29 - - O
, - - O
or - - O
MH2 - - O
. - - O

The - - O
close - - O
proximity - - O
of - - O
the - - O
two - - O
neuropeptide - - B-MUT
Y - - I-MUT
receptor - - I-MUT
genes - - I-MUT
suggests - - O
that - - O
they - - O
have - - O
evolved - - O
from - - O
a - - O
gene - - O
duplication - - O
event - - O
with - - O
the - - O
small - - O
intron - - O
interrupting - - O
the - - O
coding - - O
sequence - - O
of - - O
the - - O
y1 - - B-MUT
gene - - I-MUT
being - - O
converted - - O
into - - O
a - - O
functional - - O
sequence - - O
within - - O
the - - O
y5 - - B-MUT
gene - - I-MUT
, - - O
while - - O
the - - O
reverse - - O
complementary - - O
sequence - - O
was - - O
utilized - - O
as - - O
an - - O
alternatively - - O
spliced - - O
5' - - O
exon - - O
for - - O
the - - O
y1 - - B-MUT
gene - - I-MUT
. - - O

Effect - - O
of - - O
2- - - O
( - - O
p-chlorophenyl - - O
) - - O
cyclopropylamine - - O
on - - O
5-hydroxyindole - - O
concentration - - O
and - - O
monoamine - - B-MUT
oxidase - - I-MUT
activity - - O
in - - O
rat - - O
brain - - O
. - - O

Mutations - - O
affecting - - O
only - - O
CD4 - - B-MUT
regulation - - O
mapped - - O
to - - O
residues - - O
previously - - O
shown - - O
to - - O
mediate - - O
the - - O
binding - - O
of - - O
Nef - - B-MUT
to - - O
this - - O
receptor - - O
, - - O
such - - O
as - - O
W57 - - O
and - - O
L58 - - O
, - - O
as - - O
well - - O
as - - O
to - - O
an - - O
AP-recruiting - - B-MUT
dileucine - - I-MUT
motif - - I-MUT
and - - O
to - - O
an - - O
acidic - - O
dipeptide - - O
in - - O
the - - O
C-terminal - - O
region - - O
of - - O
the - - O
protein - - O
. - - O

Furthermore - - O
, - - O
we - - O
notice - - O
two - - O
potential - - O
consensus - - O
motifs - - O
which - - O
are - - O
also - - O
found - - O
in - - O
corresponding - - O
positions - - O
in - - O
the - - O
genes - - O
for - - O
the - - O
nerve - - B-MUT
growth - - I-MUT
factor - - I-MUT
receptor - - I-MUT
and - - O
the - - O
68-kDa - - B-MUT
neurofilament - - I-MUT
protein - - I-MUT
. - - O

Pathogens - - O
( - - O
Staphylococcus - - O
aureus - - O
or - - O
Gram-negative - - O
bacilli - - O
) - - O
were - - O
isolated - - O
from - - O
only - - O
one - - O
member - - O
of - - O
staff - - O
in - - O
small - - O
numbers - - O
and - - O
irregularly - - O
and - - O
rarely - - O
in - - O
large - - O
numbers - - O
from - - O
patients - - O
. - - O

Mg-chelatase - - B-MUT
of - - O
tobacco - - O
: - - O
identification - - O
of - - O
a - - O
Chl - - B-MUT
D - - I-MUT
cDNA - - I-MUT
sequence - - I-MUT
encoding - - O
a - - O
third - - O
subunit - - O
, - - O
analysis - - O
of - - O
the - - O
interaction - - O
of - - O
the - - O
three - - O
subunits - - O
with - - O
the - - O
yeast - - O
two-hybrid - - O
system - - O
, - - O
and - - O
reconstitution - - O
of - - O
the - - O
enzyme - - O
activity - - O
by - - O
co-expression - - O
of - - O
recombinant - - B-MUT
CHL - - I-MUT
D - - I-MUT
, - - O
CHL - - B-MUT
H - - I-MUT
and - - O
CHL - - B-MUT
I - - I-MUT
. - - O

The - - O
nature - - O
of - - O
the - - O
process - - O
formed - - O
by - - O
the - - O
successive - - O
occurrences - - O
of - - O
this - - O
arrhythmia - - O
was - - O
studied - - O
in - - O
8 - - O
patients - - O
with - - O
a - - O
history - - O
of - - O
symptomatic - - O
paroxysmal - - O
AF - - O
. - - O

Interferon-alpha-induced - - O
gene - - O
expression - - O
: - - O
evidence - - O
for - - O
a - - O
selective - - O
effect - - O
of - - O
ouabain - - O
on - - O
activation - - O
of - - O
the - - O
ISGF3 - - B-MUT
transcription - - I-MUT
complex - - I-MUT
. - - O

Molecular - - O
and - - O
genetic - - O
analysis - - O
of - - O
the - - O
yeast - - B-MUT
early - - I-MUT
meiotic - - I-MUT
recombination - - I-MUT
genes - - I-MUT
REC102 - - I-MUT
and - - O
REC107 - - B-MUT
MER2 - - I-MUT
. - - I-MUT

Antibodies - - O
made - - O
against - - O
fusion - - O
protein - - O
produced - - O
by - - O
the - - O
DP1A - - B-MUT
clone - - O
reacted - - O
specifically - - O
with - - O
DP-I - - B-MUT
and - - I-MUT
-II - - I-MUT
on - - O
immunoblots - - O
. - - O

When - - O
voltage-operated - - O
Ca2+ - - O
channels - - O
( - - O
VOC - - O
) - - O
were - - O
blocked - - O
by - - O
nifedipine - - O
, - - O
midazolam - - O
, - - O
in - - O
concentrations - - O
more - - O
than - - O
1 - - O
microM - - O
, - - O
attenuated - - O
both - - O
phasic - - O
and - - O
tonic - - O
responses - - O
. - - O

Binding - - O
of - - O
U2 - - B-MUT
small - - I-MUT
nuclear - - I-MUT
ribonucleoprotein - - I-MUT
was - - O
partially - - O
inhibited - - O
. - - O

Hematology - - O
problem - - O
of - - O
the - - O
month - - O
: - - O
band - - O
or - - O
seg - - O
? - - O

Heme - - B-MUT
oxygenase - - I-MUT
1 - - I-MUT
is - - O
an - - O
essential - - O
enzyme - - O
in - - O
heme - - O
catabolism - - O
that - - O
cleaves - - O
heme - - O
to - - O
form - - O
biliverdin - - O
, - - O
iron - - O
, - - O
and - - O
carbon - - O
monoxide - - O
. - - O

The - - O
characteristic - - O
feature - - O
of - - O
liver - - O
and - - O
spleen - - O
MP - - O
function - - O
in - - O
patients - - O
with - - O
VHA - - O
associated - - O
with - - O
HBsAg - - B-MUT
carriership - - O
consisted - - O
in - - O
the - - O
lack - - O
of - - O
the - - O
compensatory - - O
reaction - - O
on - - O
the - - O
part - - O
of - - O
spleen - - O
MP - - O
, - - O
which - - O
was - - O
likely - - O
to - - O
be - - O
connected - - O
with - - O
overstrain - - O
of - - O
long - - O
standing - - O
and - - O
depletion - - O
of - - O
the - - O
MP - - O
system - - O
due - - O
to - - O
permanent - - O
antigenic - - O
stimulation - - O
of - - O
HBsAg - - B-MUT
. - - O

Since - - O
the - - O
RINX - - B-MUT
gene - - I-MUT
is - - O
likely - - O
an - - O
ortholog - - O
of - - O
the - - O
goldfish - - B-MUT
Vsx1 - - I-MUT
gene - - I-MUT
, - - O
it - - O
has - - O
been - - O
named - - O
VSX1 - - B-MUT
by - - O
the - - O
Human - - O
Gene - - O
Nomenclature - - O
Committee - - O
. - - O

The - - O
hepatitis - - B-MUT
A - - I-MUT
virus - - I-MUT
antibody - - I-MUT
( - - O
anti-HAV - - B-MUT
) - - O
in - - O
chronic - - O
diffuse - - O
liver - - O
diseases - - O
. - - O

Nature - - O
398 - - O
, - - O
828-830 - - O
) - - O
that - - O
the - - O
amino - - O
acid - - O
sequences - - O
of - - O
peptide - - O
fragments - - O
obtained - - O
from - - O
a - - O
polypeptide - - O
found - - O
in - - O
a - - O
complex - - O
of - - O
proteins - - O
that - - O
alters - - O
chromatin - - O
structure - - O
( - - O
ARC - - B-MUT
) - - O
are - - O
identical - - O
to - - O
portions - - O
of - - O
the - - O
deduced - - O
open - - O
reading - - O
frame - - O
of - - O
TIG-1 - - B-MUT
mRNA - - I-MUT
. - - O

Diazepam - - O
( - - O
3 - - O
mg - - O
kg - - O
) - - O
generalized - - O
to - - O
Ro - - O
11-6896 - - O
whereas - - O
the - - O
structurally - - O
related - - O
Ro - - O
5-4864 - - O
( - - O
3 - - O
mg - - O
kg - - O
and - - O
30 - - O
mg - - O
kg - - O
) - - O
did - - O
not - - O
. - - O

Additional - - O
factors - - O
such - - O
as - - O
advanced - - O
age - - O
, - - O
concomitant - - O
use - - O
of - - O
corticosteroids - - O
or - - O
anticoagulants - - O
, - - O
prior - - O
ulcer - - O
complications - - O
and - - O
co-morbid - - O
diseases - - O
may - - O
further - - O
increase - - O
the - - O
risk - - O
of - - O
bleeding - - O
. - - O

The - - O
magnitude - - O
of - - O
the - - O
early - - O
response - - O
was - - O
241 - - O
+ - - O
- - - O
51% - - O
in - - O
A - - O
( - - O
% - - O
baseline - - O
RL - - O
; - - O
mean - - O
+ - - O
- - - O
SE - - O
) - - O
, - - O
and - - O
significantly - - O
less - - O
in - - O
B - - O
( - - O
119 - - O
+ - - O
- - - O
7% - - O
) - - O
and - - O
C - - O
( - - O
131 - - O
+ - - O
- - - O
16% - - O
) - - O
( - - O
p - - O
< - - O
0 - - O
. - - O
01 - - O
) - - O
. - - O

In - - O
the - - O
eight - - O
patients - - O
with - - O
persistent - - O
generalized - - O
lymph-adenopathy - - O
( - - O
PGL - - O
) - - O
and - - O
nontender - - O
, - - O
nonenlarging - - O
nodes - - O
, - - O
pathologic - - O
analysis - - O
revealed - - O
lymphoid - - O
hyperplasia - - O
. - - O

We - - O
conclude - - O
that - - O
( - - O
a - - O
) - - O
the - - O
likelihood - - O
of - - O
detecting - - O
carcinoma - - O
or - - O
atypical - - O
hyperplasia - - O
exclusively - - O
in - - O
the - - O
adipose - - O
tissue - - O
component - - O
of - - O
grossly - - O
benign - - O
breast - - O
biopsies - - O
is - - O
extremely - - O
low - - O
, - - O
and - - O
( - - O
b - - O
) - - O
a - - O
possible - - O
cost-effective - - O
method - - O
of - - O
sampling - - O
grossly - - O
benign - - O
breast - - O
biopsies - - O
consists - - O
of - - O
initially - - O
submitting - - O
a - - O
maximum - - O
of - - O
10 - - O
blocks - - O
of - - O
fibrous - - O
parenchyma - - O
for - - O
each - - O
case - - O
, - - O
then - - O
examining - - O
the - - O
remaining - - O
tissue - - O
histologically - - O
only - - O
if - - O
carcinoma - - O
or - - O
atypical - - O
hyperplasia - - O
is - - O
found - - O
among - - O
these - - O
blocks - - O
. - - O

Simian - - O
parainfluenza - - O
virus - - O
5 - - O
( - - O
SV5 - - O
) - - O
is - - O
a - - O
prototype - - O
of - - O
the - - O
Paramyxoviridae - - O
family - - O
of - - O
nonsegmented - - O
negative-sense - - O
RNA - - O
viruses - - O
. - - O

Nephrotoxicity - - O
after - - O
orthotopic - - O
liver - - O
transplantation - - O
in - - O
cyclosporin - - O
A - - O
and - - O
FK - - O
506-treated - - O
patients - - O
. - - O

Despite - - O
considerable - - O
research - - O
, - - O
an - - O
explanation - - O
of - - O
this - - O
effect - - O
has - - O
been - - O
elusive - - O
. - - O

The - - O
standard - - O
principles - - O
of - - O
surgical - - O
management - - O
must - - O
be - - O
adhered - - O
to - - O
when - - O
using - - O
Sandostatin - - O
to - - O
treat - - O
patients - - O
with - - O
these - - O
disorders - - O
. - - O

Polycythemia-1973 - - O
. - - O

From - - O
two - - O
inhibitor - - O
scaffolds - - O
, - - O
we - - O
have - - O
identified - - O
potent - - O
and - - O
selective - - O
inhibitors - - O
for - - O
sensitized - - O
kinases - - B-MUT
from - - O
five - - O
distinct - - O
subfamilies - - O
. - - O

The - - O
purpose - - O
of - - O
this - - O
investigation - - O
was - - O
to - - O
study - - O
the - - O
morphological - - O
characteristics - - O
of - - O
the - - O
fibrous - - O
tissue - - O
capsule - - O
resulting - - O
from - - O
the - - O
implantation - - O
of - - O
aluminum - - O
calcium - - O
phosphate - - O
( - - O
ALCAP - - O
) - - O
and - - O
hydroxyapetite - - O
( - - O
HA - - O
) - - O
bioceramics - - O
. - - O

Biol - - O
. - - O

A - - O
distinct - - O
staining - - O
pattern - - O
for - - O
the - - O
N-utrophin - - B-MUT
was - - O
not - - O
detectable - - O
, - - O
although - - O
it - - O
was - - O
expected - - O
to - - O
localise - - O
at - - O
the - - O
actin - - B-MUT
stress - - O
fibers - - O
. - - O

The - - O
sequence - - O
of - - O
the - - O
repressor - - O
locus - - O
, - - O
c - - O
, - - O
of - - O
the - - O
Streptomyces - - O
temperate - - O
phage - - O
, - - O
phi - - O
C31 - - O
, - - O
was - - O
shown - - O
previously - - O
to - - O
contain - - O
an - - O
open - - O
reading - - O
frame - - O
encoding - - O
a - - O
74 - - O
kDa - - O
protein - - O
. - - O

Introductory - - O
remarks - - O
. - - O

Accumulated - - O
evidence - - O
indicates - - O
that - - O
, - - O
upon - - O
stimulation - - O
with - - O
interferon-gamma - - B-MUT
( - - O
IFN-gamma - - B-MUT
) - - O
, - - O
three - - O
beta-type - - O
subunits - - O
, - - O
designated - - O
LMP2 - - B-MUT
, - - O
LMP7 - - B-MUT
, - - O
and - - O
PSMB10 - - B-MUT
, - - O
are - - O
incorporated - - O
into - - O
the - - O
20S - - B-MUT
proteasome - - I-MUT
by - - O
displacing - - O
the - - O
housekeeping - - O
beta-type - - O
subunits - - O
designated - - O
PSMB6 - - B-MUT
, - - O
PSMB5 - - B-MUT
, - - O
and - - O
PSMB7 - - B-MUT
, - - O
respectively - - O
. - - O

The - - O
addition - - O
of - - O
zidovudine - - O
did - - O
not - - O
influence - - O
this - - O
transfer - - O
. - - O

The - - O
Dax-1 - - B-MUT
gene - - I-MUT
encodes - - O
a - - O
protein - - O
that - - O
is - - O
structurally - - O
related - - O
to - - O
members - - O
of - - O
the - - O
orphan - - B-MUT
nuclear - - I-MUT
receptor - - I-MUT
superfamily - - I-MUT
. - - O

Human - - B-MUT
AP-2rep - - I-MUT
repressed - - O
both - - O
reporter - - O
expression - - O
from - - O
a - - O
transiently - - O
transfected - - O
AP-2alpha - - B-MUT
promoter - - I-MUT
and - - O
the - - O
endogenous - - O
AP-2alpha - - B-MUT
gene - - I-MUT
and - - O
inversely - - O
was - - O
negatively - - O
regulated - - O
by - - O
AP-2alpha - - B-MUT
. - - O

The - - O
radial - - O
forearm - - O
flap - - O
is - - O
used - - O
most - - O
commonly - - O
, - - O
however - - O
the - - O
lateral - - O
arm - - O
flap - - O
may - - O
be - - O
the - - O
flap - - O
of - - O
choice - - O
in - - O
certain - - O
situations - - O
. - - O

Similarly - - O
, - - O
the - - O
N-terminal - - O
cytoplasmic - - O
domain - - O
of - - O
the - - O
latent - - B-MUT
membrane - - I-MUT
protein - - I-MUT
2A - - I-MUT
( - - O
LMP2A - - B-MUT
) - - O
of - - O
the - - O
Epstein-Barr - - O
virus - - O
( - - O
EBV - - O
) - - O
contains - - O
a - - O
single - - O
copy - - O
of - - O
the - - O
Tyr-X-X-Leu - - B-MUT
Ile-containing - - I-MUT
motif - - I-MUT
which - - I-MUT
could - - O
play - - O
a - - O
critical - - O
role - - O
in - - O
B - - O
cell - - O
transformation - - O
. - - O

The - - O
N-terminal - - O
small - - O
segment - - O
of - - O
yeast - - B-MUT
TAF145 - - I-MUT
( - - O
yTAF145 - - B-MUT
) - - O
binds - - O
to - - O
TBP - - B-MUT
and - - O
thereby - - O
inhibits - - O
TBP - - B-MUT
function - - O
. - - O

VEGF - - B-MUT
promoter - - I-MUT
activity - - O
in - - O
transient - - O
transfections - - O
was - - O
decreased - - O
by - - O
either - - O
pharmacological - - O
or - - O
genetic - - O
inhibition - - O
of - - O
EGFR - - B-MUT
, - - O
Ras - - B-MUT
, - - O
or - - O
phosphatidylinositol - - B-MUT
3'-kinase - - I-MUT
[ - - B-MUT
PI - - I-MUT
( - - I-MUT
3 - - I-MUT
) - - I-MUT
kinase - - I-MUT
] - - I-MUT
. - - O

A - - O
murine - - O
expressed - - O
sequence - - O
tag - - O
( - - O
EST - - O
) - - O
showing - - O
homology - - O
with - - O
erythropoietin - - B-MUT
receptor - - I-MUT
( - - O
EPOR - - B-MUT
) - - O
was - - O
identified - - O
in - - O
the - - O
EST - - O
database - - O
. - - O

The - - O
Schizosaccharomyces - - B-MUT
pombe - - I-MUT
rad1+ - - I-MUT
cell - - I-MUT
cycle - - I-MUT
checkpoint - - I-MUT
control - - I-MUT
gene - - I-MUT
is - - O
required - - O
for - - O
S-phase - - O
and - - O
G2 - - O
M - - O
arrest - - O
in - - O
response - - O
to - - O
both - - O
DNA - - O
damage - - O
and - - O
incomplete - - O
DNA - - O
replication - - O
. - - O

The - - O
mobility - - O
of - - O
the - - O
upper - - O
and - - O
lower - - O
premolars - - O
under - - O
load - - O
was - - O
investigated - - O
in - - O
relation - - O
to - - O
the - - O
interproximal - - O
contact - - O
and - - O
occlusal - - O
facets - - O
. - - O

32Pi - - O
labeling - - O
or - - O
isoelectric - - O
focusing - - O
analysis - - O
of - - O
eIF-2 - - B-MUT
alpha - - I-MUT
from - - O
conditional - - O
casein - - B-MUT
kinase - - I-MUT
II - - I-MUT
mutants - - I-MUT
indicated - - O
that - - O
phosphorylation - - O
of - - O
eIF-2 - - B-MUT
alpha - - I-MUT
is - - O
abolished - - O
or - - O
dephosphorylated - - O
forms - - O
of - - O
eIF-2 - - B-MUT
alpha - - I-MUT
are - - O
detected - - O
when - - O
these - - O
strains - - O
are - - O
grown - - O
at - - O
the - - O
restrictive - - O
growth - - O
conditions - - O
. - - O

Exons - - O
A1a - - O
and - - O
A1b - - O
are - - O
separated - - O
from - - O
each - - O
other - - O
by - - O
a - - O
124-nucleotide - - O
intron - - O
. - - O

Immunostaining - - O
of - - O
cells - - O
transfected - - O
with - - O
these - - O
constructs - - O
revealed - - O
that - - O
both - - O
the - - O
myristoylated - - O
and - - O
nonmyristoylated - - O
mutants - - O
were - - O
localized - - O
in - - O
nuclei - - O
, - - O
whereas - - O
wild-type - - B-MUT
PKC - - I-MUT
alpha - - I-MUT
was - - O
primarily - - O
cytoplasmic - - O
and - - O
perinuclear - - O
. - - O

Plasma - - B-MUT
lecithin - - I-MUT
cholesterol - - I-MUT
acyltransferase - - I-MUT
( - - I-MUT
LCAT - - O
) - - B-MUT
activity - - O
in - - O
multiple-organ - - O
donors - - O
: - - O
a - - O
predictor - - O
of - - O
allograft - - O
viability - - O
in - - O
clinical - - O
liver - - O
transplantation - - O
. - - O

Western - - O
blot - - O
analysis - - O
of - - O
various - - O
bovine - - O
tissues - - O
with - - O
human - - O
NMT - - B-MUT
peptide - - I-MUT
antibody - - I-MUT
indicated - - O
a - - O
common - - O
prominent - - O
immunoreactive - - O
band - - O
with - - O
an - - O
apparent - - O
molecular - - O
mass - - O
of - - O
48 - - O
. - - O
5-50 - - O
kDa - - O
in - - O
all - - O
tissues - - O
. - - O

These - - O
differences - - O
involve - - O
specific - - O
hydrogen-bonding - - O
interactions - - O
between - - O
the - - O
protein - - O
and - - O
DNA - - O
, - - O
including - - O
guanine - - O
N7 - - O
sites - - O
in - - O
the - - O
major - - O
groove - - O
of - - O
DNA - - O
, - - O
and - - O
alterations - - O
in - - O
DNA - - O
phosphodiester - - O
conformation - - O
induced - - O
by - - O
protein - - O
binding - - O
. - - O

Transient - - O
transfection - - O
assays - - O
showed - - O
that - - O
site - - O
A - - O
is - - O
necessary - - O
and - - O
sufficient - - O
for - - O
RXR - - B-MUT
alpha-mediated - - O
transactivation - - O
of - - O
the - - O
apoAI - - B-MUT
gene - - I-MUT
basal - - I-MUT
promoter - - I-MUT
in - - O
human - - O
hepatoma - - O
HepG2 - - O
cells - - O
in - - O
the - - O
presence - - O
of - - O
RA - - O
and - - O
that - - O
this - - O
transactivation - - O
is - - O
abolished - - O
by - - O
increasing - - O
amounts - - O
of - - O
cotransfected - - O
ARP-1 - - B-MUT
. - - O

This - - O
structure - - O
interconnects - - O
specific - - O
triplets - - O
of - - O
the - - O
basal - - O
bodies - - O
with - - O
the - - O
microtubular - - O
bundles - - O
that - - O
emerge - - O
from - - O
the - - O
basal - - O
apparatus - - O
. - - O

When - - O
this - - O
DNA - - O
fragment - - O
was - - O
placed - - O
upstream - - O
of - - O
the - - O
chloramphenicol - - B-MUT
acetyltransferase - - I-MUT
( - - O
CAT - - B-MUT
) - - O
reporter - - O
gene - - O
and - - O
transfected - - O
into - - O
a - - O
carp - - O
CF - - O
cell - - O
line - - O
, - - O
it - - O
could - - O
drive - - O
the - - O
synthesis - - O
of - - O
CAT - - B-MUT
enzyme - - I-MUT
16 - - O
times - - O
more - - O
efficiently - - O
than - - O
the - - O
promoterless - - O
pCAT-Basic - - B-MUT
. - - O

A - - O
single - - O
i - - O
. - - O
p - - O
. - - O
injection - - O
of - - O
d - - O
, - - O
l-baclofen - - O
10 - - O
mg - - O
kg - - O
both - - O
reduced - - O
noradrenaline - - O
( - - O
NA - - O
) - - O
biosynthesis - - O
in - - O
vivo - - O
( - - O
31% - - O
) - - O
and - - O
the - - O
endogenous - - O
concentration - - O
of - - O
normetanephrine - - O
( - - O
NMN - - O
) - - O
( - - O
32% - - O
) - - O
and - - O
increased - - O
NA - - O
levels - - O
( - - O
28% - - O
) - - O
. - - O

The - - O
case - - O
for - - O
neutrinos - - O
from - - O
SN - - O
1987A - - O
. - - O

The - - O
active - - O
site - - O
includes - - O
the - - O
acidic - - O
triad - - O
Asp53 - - O
( - - O
the - - O
site - - O
of - - O
phosphorylation - - O
) - - O
, - - O
Asp10 - - O
and - - O
Glu9 - - O
. - - O

Furthermore - - O
the - - O
median - - O
increase - - O
in - - O
cyclosporine - - O
DR - - O
C - - O
( - - O
SS - - O
trough - - O
) - - O
was - - O
18 - - O
l - - O
h-1 - - O
( - - O
-3 - - O
. - - O
1 - - O
to - - O
42 - - O
. - - O
1 - - O
l - - O
h-1 - - O
, - - O
interquartile - - O
range - - O
) - - O
. - - O

These - - O
results - - O
show - - O
that - - O
the - - O
CAAT-region - - O
is - - O
involved - - O
in - - O
upregulating - - O
the - - O
MDR1 - - B-MUT
promoter - - I-MUT
in - - O
HL60 - - O
VCR - - O
cells - - O
. - - O

The - - O
virus-associated - - O
VAI - - O
RNA - - O
of - - O
adenovirus - - O
is - - O
a - - O
small - - O
highly - - O
structured - - O
RNA - - O
that - - O
is - - O
required - - O
for - - O
the - - O
efficient - - O
translation - - O
of - - O
cellular - - O
and - - O
viral - - O
mRNAs - - O
at - - O
late - - O
times - - O
after - - O
infection - - O
. - - O

Hyperthyroidism - - O
. - - O

While - - O
interactions - - O
of - - O
WT - - B-MUT
and - - O
variant - - O
TGF-alpha - - B-MUT
with - - O
the - - O
ErbBs - - B-MUT
all - - O
result - - O
in - - O
ErbB2 - - B-MUT
activation - - O
, - - O
they - - O
produce - - O
different - - O
biological - - O
consequences - - O
, - - O
suggesting - - O
that - - O
the - - O
various - - O
TGF-alpha - - B-MUT
precursors - - I-MUT
differentially - - O
modulate - - O
ErbB - - B-MUT
signaling - - O
. - - O

By - - O
contrast - - O
, - - O
secretory - - B-MUT
HI - - I-MUT
antibodies - - I-MUT
were - - O
not - - O
demonstrated - - O
at - - O
the - - O
onset - - O
of - - O
illness - - O
in - - O
any - - O
of - - O
the - - O
patients - - O
, - - O
but - - O
their - - O
formation - - O
started - - O
early - - O
and - - O
the - - O
antibodies - - O
reached - - O
maximal - - O
levels - - O
about - - O
10 - - O
days - - O
after - - O
onset - - O
of - - O
illness - - O
. - - O

Mammalian - - B-MUT
ABPs - - I-MUT
and - - O
SHBGs - - B-MUT
bind - - O
sex - - O
steroids - - O
with - - O
high - - O
affinity - - O
, - - O
but - - O
some - - O
binding - - O
properties - - O
differ - - O
among - - O
species - - O
. - - O

PRDII-BF1-derived - - B-MUT
cDNAs - - I-MUT
did - - O
not - - O
result - - O
in - - O
stimulation - - O
of - - O
either - - O
basal - - O
or - - O
tat-induced - - O
activated - - O
gene - - O
expression - - O
. - - O

The - - O
rCBF - - O
ratio - - O
was - - O
mainly - - O
reduced - - O
in - - O
frontal - - O
lobes - - O
( - - O
65% - - O
) - - O
. - - O

We - - O
isolated - - O
several - - O
overlapping - - O
A-phage - - O
and - - O
cosmid - - O
clones - - O
that - - O
cover - - O
more - - O
than - - O
100 - - O
kb - - O
of - - O
human - - O
DNA - - O
and - - O
contained - - O
the - - O
entire - - O
VDR - - B-MUT
gene - - I-MUT
. - - O

The - - O
treatment - - O
group - - O
also - - O
showed - - O
in - - O
vivo - - O
T-cell - - O
activation - - O
with - - O
an - - O
initial - - O
lymphopenia - - O
followed - - O
by - - O
a - - O
rebound - - O
lymphocytosis - - O
and - - O
upregulation - - O
of - - O
the - - O
subset - - O
markers - - O
CD25 - - B-MUT
( - - O
interleukin - - B-MUT
2 - - I-MUT
receptor - - I-MUT
) - - O
and - - O
CD45RO - - B-MUT
( - - O
T-memory - - O
cells - - O
) - - O
. - - O

Selected - - O
parameters - - O
: - - O
heart - - O
rate - - O
( - - O
HR - - O
) - - O
, - - O
arterial - - O
blood - - O
pressure - - O
( - - O
ABP - - O
) - - O
and - - O
arterial - - O
O2 - - O
saturation - - O
( - - O
SaO2 - - O
) - - O
monitored - - O
by - - O
pulsoximetry - - O
were - - O
measured - - O
during - - O
the - - O
procedure - - O
. - - O

Persistent - - O
activation - - O
of - - O
mitogen-activated - - B-MUT
protein - - I-MUT
kinases - - I-MUT
p42 - - I-MUT
and - - O
p44 - - B-MUT
and - - O
ets-2 - - B-MUT
phosphorylation - - O
in - - O
response - - O
to - - O
colony-stimulating - - B-MUT
factor - - I-MUT
1 - - I-MUT
c-fms - - O
signaling - - B-MUT
. - - O

The - - O
psychologic - - O
factors - - O
associated - - O
wth - - O
serious - - O
illness - - O
, - - O
terminal - - O
prognoses - - O
, - - O
and - - O
dying - - O
complicate - - O
the - - O
scenario - - O
even - - O
more - - O
as - - O
compared - - O
with - - O
that - - O
of - - O
nonmalignant - - O
pain - - O
. - - O

It - - O
is - - O
transparent - - O
, - - O
cheap - - O
to - - O
be - - O
made - - O
, - - O
and - - O
easy - - O
to - - O
empty - - O
and - - O
was - - O
tested - - O
in - - O
118 - - O
animals - - O
for - - O
two - - O
and - - O
four - - O
weeks - - O
. - - O

Coenzyme - - B-MUT
Q10 - - I-MUT
: - - O
blood - - O
levels - - O
and - - O
metabolic - - O
demand - - O
. - - O

A - - O
drug - - O
with - - O
ISA - - O
"down - - O
regulates" - - O
beta - - B-MUT
receptors - - I-MUT
; - - O
thus - - O
, - - O
when - - O
the - - O
drug - - O
is - - O
withdrawn - - O
there - - O
is - - O
no - - O
post-beta-blocking - - O
drug - - O
hypersensitivity - - O
in - - O
contrast - - O
to - - O
agents - - O
without - - O
ISA - - O
. - - O

The - - O
workup - - O
included - - O
skin - - O
tests - - O
( - - O
up - - O
to - - O
1 - - O
microgram - - O
ml - - O
, - - O
Pharmacia - - O
) - - O
, - - O
measurement - - O
of - - O
specific - - O
serum - - O
IgE - - O
with - - B-MUT
RAST-CAP - - O
( - - O
Pharmacia - - O
) - - O
, - - O
and - - O
CAST - - O
with - - O
three - - O
concentrations - - O
of - - O
bee - - O
( - - O
Apis - - O
mellifera - - O
) - - O
and - - O
wasp - - O
( - - O
Vespula - - O
spec - - O
. - - O
) - - O
venom - - O
( - - O
Aquagen - - O
ALK - - O
) - - O
. - - O

A - - O
position-independent - - O
activation - - O
domain - - O
which - - O
contained - - O
conserved - - O
regions - - O
II - - O
and - - O
III - - O
was - - O
identified - - O
at - - O
the - - O
carboxyl - - O
terminus - - O
of - - O
the - - O
HNF-3 - - B-MUT
beta - - I-MUT
protein - - I-MUT
( - - O
amino - - O
acids - - O
361 - - O
to - - O
458 - - O
) - - O
. - - O

Mutations - - O
in - - O
genes - - O
encoding - - O
PR65 - - B-MUT
A - - I-MUT
subunits - - I-MUT
have - - I-MUT
been - - O
identified - - O
in - - O
several - - O
different - - O
human - - O
cancers - - O
and - - O
the - - O
PP2A - - O
inhibitor - - B-MUT
, - - O
termed - - O
fostriecin - - O
, - - O
is - - O
being - - O
tested - - O
as - - O
an - - O
anticancer - - O
drug - - O
. - - O

In - - O
contrast - - O
to - - O
the - - O
wild-type - - O
protein - - O
, - - O
expression - - O
of - - O
p45 - - B-MUT
NF-E2 - - I-MUT
lacking - - O
this - - O
activation - - O
domain - - O
in - - O
an - - O
NF-E2 - - B-MUT
null - - O
cell - - O
line - - O
fails - - O
to - - O
support - - O
enhancer-dependent - - O
transcription - - O
in - - O
transient - - O
assays - - O
. - - O

Similar - - O
clinical - - O
evaluation - - O
of - - O
an - - O
obligate - - O
carrier - - O
revealed - - O
no - - O
ocular - - O
abnormalities - - O
. - - O

The - - O
present - - O
study - - O
reports - - O
visual - - O
evoked - - O
potential - - O
responses - - O
to - - O
pattern - - O
reversal - - O
( - - O
VEP-P - - O
) - - O
in - - O
ten - - O
third - - O
trimester - - O
pregnant - - O
women - - O
and - - O
changes - - O
in - - O
latency - - O
of - - O
NPN - - O
complex - - O
when - - O
compared - - O
with - - O
these - - O
responses - - O
in - - O
the - - O
non - - O
pregnant - - O
state - - O
. - - O

Abrogation - - O
of - - O
p53 - - B-MUT
function - - O
by - - O
E6 - - B-MUT
resulted - - O
in - - O
an - - O
increase - - O
in - - O
the - - O
spontaneous - - O
mutation - - O
frequencies - - O
at - - O
the - - O
heterozygous - - O
thymidine - - B-MUT
kinase - - I-MUT
( - - O
TK - - B-MUT
) - - O
locus - - O
but - - O
not - - O
at - - O
the - - O
hemizygous - - O
hypoxanthine - - B-MUT
phosphoribosyl - - I-MUT
transferase - - I-MUT
( - - O
HPRT - - B-MUT
) - - O
locus - - O
. - - O

55 - - O
+ - - O
- - - O
11% - - O
) - - O
, - - O
all - - O
other - - O
parameters - - O
showed - - O
a - - O
significant - - O
increase - - O
: - - O
RS - - O
index - - O
5 - - O
. - - O
4 - - O
+ - - O
- - - O
1 - - O
. - - O
4 - - O
mVolt - - O
to - - O
6 - - O
. - - O
0 - - O
+ - - O
- - - O
1 - - O
. - - O
7 - - O
mVolt - - O
( - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
01 - - O
) - - O
; - - O
EDD - - O
6 - - O
. - - O
3 - - O
+ - - O
- - - O
0 - - O
. - - O
7 - - O
to - - O
6 - - O
. - - O
8 - - O
+ - - O
- - - O
0 - - O
. - - O
9 - - O
cm - - O
( - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
001 - - O
) - - O
; - - O
HV - - O
1017 - - O
+ - - O
- - - O
151 - - O
ml - - O
to - - O
1099 - - O
+ - - O
- - - O
261 - - O
ml - - O
( - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
01 - - O
) - - O
; - - O
EDV - - O
371 - - O
+ - - O
- - - O
131 - - O
ml - - O
to - - O
441 - - O
+ - - O
- - - O
175 - - O
ml - - O
( - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
001 - - O
) - - O
; - - O
RBV - - O
117 - - O
+ - - O
- - - O
57 - - O
ml - - O
to - - O
151 - - O
+ - - O
- - - O
77 - - O
ml - - O
( - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
001 - - O
) - - O
. - - O

Significant - - O
immunoglobulinuria - - O
developed - - O
prior - - O
to - - O
the - - O
development - - O
of - - O
azotemia - - O
, - - O
significantly - - O
decreased - - O
creatinine - - O
clearance - - O
, - - O
significant - - O
proteinuria - - O
( - - O
greater - - O
than - - O
or - - O
equal - - O
to - - O
3+ - - O
dipstick - - O
or - - O
greater - - O
than - - O
or - - O
equal - - O
to - - O
5 - - O
gm - - O
per - - O
24-hour - - O
urine - - O
collection - - O
) - - O
, - - O
or - - O
oliguria - - O
. - - O

ECM - - O
disruption - - O
in - - O
Lytechinus - - O
embryos - - O
caused - - O
a - - O
relative - - O
drop - - O
in - - O
USF - - B-MUT
RNA - - I-MUT
accumulation - - O
levels - - O
to - - O
approximately - - O
60% - - O
of - - O
control - - O
embryos - - O
, - - O
while - - O
LpS1 - - B-MUT
RNA - - I-MUT
accumulation - - O
levels - - O
dropped - - O
to - - O
less - - O
than - - O
5% - - O
. - - O

Deep - - O
tans - - O
were - - O
induced - - O
over - - O
the - - O
backs - - O
of - - O
volunteers - - O
with - - O
repeated - - O
exposure - - O
to - - O
longwave - - O
ultraviolet - - O
radiation - - O
( - - O
UV-A - - O
) - - O
. - - O

Significance - - O
of - - O
the - - O
pulmonary - - O
gas - - O
exchange - - O
reaction - - O
to - - O
physical - - O
loading - - O
in - - O
evaluating - - O
the - - O
effectiveness - - O
of - - O
mitral - - O
commissurotomy - - O
. - - O

It - - O
is - - O
shown - - O
that - - O
the - - O
displacement - - O
distribution - - O
measured - - O
by - - O
q-space - - O
MRI - - O
in - - O
both - - O
the - - O
large - - O
displacement - - O
( - - O
i - - O
. - - O
e - - O
. - - O
, - - O
large - - O
r - - O
) - - O
and - - O
the - - O
long-wavelength - - O
( - - O
i - - O
. - - O
e - - O
. - - O
, - - O
small - - O
q - - O
) - - O
limits - - O
is - - O
the - - O
same - - O
3D - - O
Gaussian - - O
displacement - - O
distribution - - O
assumed - - O
in - - O
DT-MRI - - O
. - - O

Electrophoretic - - O
mobility - - O
shift - - O
analysis - - O
indicates - - O
that - - O
NF-IL-6 - - B-MUT
, - - O
as - - O
well - - O
as - - O
other - - O
related - - O
members - - O
of - - O
this - - O
family - - O
, - - O
bind - - O
specifically - - O
to - - O
the - - O
NF-IL-6 - - B-MUT
site - - O
in - - O
the - - O
IL-8 - - B-MUT
promoter - - I-MUT
. - - O

The - - O
ICBF - - O
in - - O
the - - O
ischaemic - - O
cortex - - O
revealed - - O
a - - O
graded - - O
reduction - - O
from - - O
the - - O
ischaemic - - O
centre - - O
to - - O
the - - O
surrounding - - O
tissues - - O
. - - O

These - - O
changes - - O
at - - O
the - - O
site - - O
of - - O
injection - - O
consist - - O
of - - O
a - - O
focal - - O
abnormality - - O
characterized - - O
by - - O
a - - O
slight - - O
increase - - O
in - - O
signal - - O
intensity - - O
on - - O
T1 - - O
weighted - - O
images - - O
and - - O
markedly - - O
increased - - O
signal - - O
intensity - - O
on - - O
T2 - - O
weighted - - O
images - - O
. - - O

Copper - - O
treatments - - O
were - - O
assigned - - O
to - - O
simulate - - O
the - - O
different - - O
levels - - O
of - - O
copper - - O
intake - - O
that - - O
might - - O
result - - O
from - - O
differences - - O
in - - O
daily - - O
feed - - O
intake - - O
similar - - O
to - - O
the - - O
practice - - O
followed - - O
with - - O
commercial - - O
industry - - O
. - - O

3- - - O
( - - O
N-Alkyl-N-2-chloroethylaminomethyl - - O
) - - O
-5- - - O
or - - O
7-halogenobenzo - - O
[ - - O
b - - O
] - - O
thiophen - - O
hydrochlorides - - O
. - - O

Transcervical - - O
amnioinfusion - - O
. - - O

A - - O
computer - - O
program - - O
, - - O
ACCESS-IAQ - - O
, - - O
is - - O
developed - - O
to - - O
simulate - - O
the - - O
airflow - - O
pattern - - O
, - - O
the - - O
time - - O
history - - O
of - - O
the - - O
contaminant - - O
concentrations - - O
in - - O
the - - O
occupied - - O
zone - - O
, - - O
and - - O
the - - O
inhalation - - O
exposures - - O
. - - O

As - - O
with - - O
VP16 - - B-MUT
, - - O
the - - O
transactivation - - O
function - - O
of - - O
Luman - - B-MUT
is - - O
also - - O
regulated - - O
by - - O
HCF - - B-MUT
. - - O

Slowly - - O
adapting - - O
type - - B-MUT
I - - I-MUT
mechanoreceptor - - I-MUT
discharge - - O
as - - O
a - - O
function - - O
of - - O
dynamic - - O
force - - O
versus - - O
dynamic - - O
displacement - - O
of - - O
glabrous - - O
skin - - O
of - - O
raccoon - - O
and - - O
squirrel - - O
monkey - - O
hand - - O
. - - O

Hypomagnesemia - - O
was - - O
due - - O
to - - O
magnesium - - O
wasting - - O
by - - O
the - - O
kidney - - O
. - - O

Interestingly - - O
, - - O
although - - O
E - - B-MUT
domains - - I-MUT
of - - O
these - - O
two - - O
receptors - - O
are - - O
much - - O
less - - O
conserved - - O
, - - O
replacement - - O
of - - O
this - - O
domain - - O
in - - O
rtER - - B-MUT
by - - O
its - - O
human - - O
counterpart - - O
resulted - - O
in - - O
higher - - O
estradiol - - O
sensitivity - - O
but - - O
no - - O
increase - - O
in - - O
the - - O
magnitude - - O
of - - O
transactivation - - O
. - - O

Propranolol - - O
also - - O
effectively - - O
controlled - - O
her - - O
familial - - O
tremor - - O
. - - O

From - - O
sequence - - O
alignments - - O
with - - O
phylogenetically - - O
related - - O
viruses - - O
, - - O
including - - O
tymoviruses - - O
, - - O
we - - O
predicted - - O
that - - O
p223 - - B-MUT
contained - - O
a - - O
papain-like - - B-MUT
proteinase - - I-MUT
domain - - I-MUT
with - - O
a - - O
putative - - O
catalytic - - O
cysteine994 - - O
and - - O
histidine1075 - - O
. - - O

The - - O
distribution - - O
of - - O
their - - O
fibrinogen - - B-MUT
levels - - O
was - - O
Gaussian - - O
, - - O
but - - O
more - - O
wide-based - - O
than - - O
the - - O
distribution - - O
of - - O
our - - O
normal - - O
controls - - O
. - - O

The - - O
aim - - O
of - - O
this - - O
retrospective - - O
study - - O
was - - O
to - - O
demonstrate - - O
that - - O
in - - O
certain - - O
cases - - O
of - - O
expulsive - - O
choroidal - - O
hemorrhage - - O
( - - O
ECH - - O
) - - O
anatomical - - O
success - - O
and - - O
useful - - O
vision - - O
can - - O
be - - O
obtained - - O
with - - O
repeated - - O
vitreoretinal - - O
surgery - - O
. - - O

17 - - O
volunteer - - O
deaf - - O
Ss - - O
were - - O
compared - - O
with - - O
18 - - O
volunteer - - O
hearing - - O
Ss - - O
on - - O
the - - O
Stanford - - O
Hypnotic - - O
Clinical - - O
Scale - - O
( - - O
SHCS - - O
) - - O
of - - O
Morgan - - O
and - - O
J - - O
. - - O

1 - - O
The - - O
effects - - O
in - - O
normal - - O
subjects - - O
of - - O
a - - O
single - - O
oral - - O
dose - - O
of - - O
Motival - - O
( - - O
one - - O
tablet - - O
, - - O
containing - - O
fluphenazine - - O
0 - - O
. - - O
5 - - O
mg - - O
and - - O
nortriptyline - - O
10 - - O
mg - - O
) - - O
on - - O
the - - O
contingent - - O
negative - - O
variation - - O
( - - O
CNV - - O
) - - O
, - - O
reaction - - O
time - - O
, - - O
heart - - O
rate - - O
, - - O
blood - - O
pressure - - O
and - - O
self-rating - - O
scales - - O
for - - O
alertness - - O
, - - O
anxiety - - O
, - - O
tension - - O
, - - O
detachment - - O
and - - O
depression - - O
were - - O
compared - - O
with - - O
those - - O
of - - O
diazepam - - O
( - - O
5 - - O
mg - - O
and - - O
7 - - O
. - - O
5 - - O
mg - - O
) - - O
and - - O
placebo - - O
or - - O
propranolol - - O
( - - O
60 - - O
mg - - O
) - - O
. - - O

Summers - - O
, - - O
Virology - - O
89 - - O
: - - O
517-527 - - O
, - - O
1978 - - O
) - - O
. - - O

Lens - - B-MUT
aldose - - I-MUT
reductase - - I-MUT
in - - O
diabetic - - O
and - - O
galactosemic - - O
cataracts - - O
. - - O

This - - O
DNA - - O
motif - - O
represents - - O
a - - O
novel - - O
protein-binding - - O
sequence - - O
. - - O

The - - O
virus - - O
encodes - - O
a - - O
40-kDa - - O
protein - - O
, - - O
tax - - B-MUT
, - - O
that - - O
is - - O
important - - O
for - - O
the - - O
immortalization - - O
of - - O
T - - O
cells - - O
. - - O

[ - - B-MUT
Ala85 - - I-MUT
] - - I-MUT
Dk - - I-MUT
( - - I-MUT
69-85 - - I-MUT
) - - I-MUT
retains - - O
full - - O
biological - - O
activity - - O
. - - O

Platelet - - O
serotonin - - O
( - - O
5-HT - - O
) - - O
and - - O
5-HT - - B-MUT
releasing - - I-MUT
factor - - I-MUT
in - - O
plasma - - O
of - - O
migrainous - - O
patients - - O
. - - O

CONCLUSIONS - - O
: - - O
XCoe2 - - B-MUT
may - - O
play - - O
a - - O
pivotal - - O
role - - O
in - - O
the - - O
transcriptional - - O
cascade - - O
that - - O
specifies - - O
primary - - O
neurons - - O
in - - O
Xenopus - - O
embryos - - O
: - - O
by - - O
maintaining - - O
Delta-Notch - - O
signalling - - O
, - - O
XCoe2 - - B-MUT
stabilises - - O
the - - O
higher - - O
neural - - O
potential - - O
of - - O
selected - - O
progenitor - - O
cells - - O
that - - O
express - - O
X-ngnr-1 - - B-MUT
, - - O
ensuring - - O
the - - O
transition - - O
between - - O
neural - - O
competence - - O
and - - O
irreversible - - O
commitment - - O
to - - O
a - - O
neural - - O
fate - - O
; - - O
and - - O
it - - O
promotes - - O
neuronal - - O
differentiation - - O
by - - O
activating - - O
XNeuroD - - B-MUT
expression - - O
, - - O
directly - - O
or - - O
indirectly - - O
. - - O

Strontium-90 - - O
was - - O
inject - - O
i - - O
. - - O
v - - O
. - - O
into - - O
pregnant - - O
rats - - O
on - - O
day - - O
18 - - O
post - - O
conception - - O
( - - O
p - - O
. - - O
c - - O
. - - O
) - - O
. - - O

Iodine - - O
metabolism - - O
in - - O
chronic - - O
thyroiditis - - O
. - - O

However - - O
, - - O
with - - O
the - - O
alpha1 - - O
antagonist - - O
prazosin - - O
( - - O
5 - - O
x - - O
10 - - O
( - - O
-8 - - O
) - - O
-5 - - O
x - - O
10 - - O
( - - O
-7 - - O
) - - O
M - - O
) - - O
, - - O
no - - O
relaxation - - O
occurred - - O
. - - O

RESULTS - - O
: - - O
At - - O
latest - - O
examination - - O
, - - O
mean - - O
UPDRS - - O
II - - O
and - - O
III - - O
scores - - O
had - - O
improved - - O
by - - O
30% - - O
( - - O
on - - O
stimulation - - O
, - - O
off - - O
therapy - - O
) - - O
with - - O
mean - - O
50% - - O
reduction - - O
in - - O
daily - - O
off - - O
time - - O
. - - O

A - - O
phylogenetic - - O
analysis - - O
of - - O
the - - O
reverse - - B-MUT
transcriptase - - I-MUT
domain - - I-MUT
confirms - - O
our - - O
differential - - O
genetic - - O
assessment - - O
that - - O
Cyclops - - B-MUT
from - - O
pea - - O
is - - O
a - - O
novel - - O
element - - O
with - - O
no - - O
specific - - O
relationship - - O
to - - O
the - - O
previously - - O
described - - O
Gypsy-like - - B-MUT
elements - - I-MUT
from - - O
plants - - O
. - - O

Instead - - O
, - - O
it - - O
contained - - O
two - - O
tandem - - O
kappaB - - B-MUT
elements - - I-MUT
and - - O
a - - O
variant - - O
activating - - B-MUT
transcription - - I-MUT
factor - - I-MUT
cAMP - - I-MUT
response - - I-MUT
element - - I-MUT
site - - I-MUT
, - - O
which - - O
closely - - O
resembled - - O
sites - - O
in - - O
the - - O
E-selectin - - O
gene - - B-MUT
that - - I-MUT
are - - O
required - - O
for - - O
TNF-alpha- - - O
or - - O
LPS-inducible - - O
expression - - O
. - - O

Copyright - - O
2000 - - O
Academic - - O
Press - - O
. - - O

This - - O
paper - - O
describes - - O
the - - O
genomic - - O
organization - - O
of - - O
mouse - - O
gC1qBP - - B-MUT
and - - O
the - - O
characterization - - O
of - - O
its - - O
5' - - O
flanking - - O
region - - O
. - - O

PRL-1 - - B-MUT
is - - O
able - - O
to - - O
dephosphorylate - - O
phosphotyrosine - - O
substrates - - O
, - - O
and - - O
mutation - - O
of - - O
the - - O
active-site - - O
cysteine - - O
residue - - O
abolishes - - O
this - - O
activity - - O
. - - O

A - - O
Chinese - - O
( - - O
HK - - O
) - - O
SF-36 - - O
survey - - O
form - - O
was - - O
developed - - O
by - - O
an - - O
iterative - - O
translation - - O
process - - O
. - - O

Infarct - - O
regional - - O
ejection - - O
fraction - - O
improved - - O
by - - O
10 - - O
. - - O
1 - - O
+ - - O
- - - O
2 - - O
. - - O
1% - - O
between - - O
early - - O
and - - O
late - - O
studies - - O
when - - O
the - - O
infarct-related - - O
artery - - O
was - - O
patent - - O
and - - O
by - - O
4 - - O
. - - O
8 - - O
+ - - O
- - - O
1 - - O
. - - O
4% - - O
if - - O
it - - O
was - - O
occluded - - O
( - - O
p - - O
= - - O
0 - - O
. - - O
048 - - O
) - - O
; - - O
changes - - O
in - - O
global - - O
and - - O
noninfarct - - O
regional - - O
ejection - - O
fraction - - O
were - - O
similar - - O
irrespective - - O
of - - O
perfusion - - O
status - - O
. - - O

The - - O
activated - - O
glucocorticoid - - B-MUT
receptor - - I-MUT
forms - - O
a - - O
complex - - O
with - - O
Stat5 - - B-MUT
and - - O
enhances - - O
Stat5-mediated - - O
transcriptional - - O
induction - - O
. - - O

This - - O
partial - - O
transection - - O
could - - O
permit - - O
vasopressin - - B-MUT
to - - O
be - - O
secreted - - O
in - - O
response - - O
to - - O
a - - O
larger - - O
rise - - O
in - - O
plasma - - O
sodium - - O
concentration - - O
. - - O

This - - O
repressor - - O
is - - O
however - - O
unlikely - - O
to - - O
mediate - - O
spi - - B-MUT
2 - - I-MUT
. - - I-MUT
3 - - I-MUT
3' - - I-MUT
UTR - - I-MUT
silencer - - I-MUT
action - - O
since - - O
it - - O
was - - O
not - - O
detected - - O
in - - O
rat - - O
hepatocytes - - O
. - - O

Abstracts - - O
. - - O

The - - O
severity - - O
of - - O
pathologic - - O
changes - - O
increased - - O
with - - O
the - - O
magnitude - - O
of - - O
percussion - - O
. - - O

ANIMALS - - O
: - - O
Fifty - - O
dogs - - O
with - - O
naturally - - O
developing - - O
DM - - O
. - - O

Acute - - O
pancreatitis - - O
: - - O
a - - O
multisystem - - O
disease - - O
. - - O

Interestingly - - O
, - - O
the - - O
RXRalphaF318A - - B-MUT
constitutive - - O
activity - - O
generated - - O
within - - O
heterodimers - - O
in - - O
the - - O
presence - - O
of - - O
BMS614 - - O
requires - - O
the - - O
integrity - - O
of - - O
both - - O
RXR - - B-MUT
and - - O
RAR - - B-MUT
AF-2 - - B-MUT
domains - - I-MUT
. - - O

Fundamental - - O
and - - O
clinical - - O
evaluation - - O
of - - O
equilibrium - - O
dialysis--radioimmunoassay - - O
system - - O
for - - O
measurement - - O
of - - O
serum - - O
free - - O
thyroxine - - O
. - - O

The - - O
aims - - O
of - - O
this - - O
study - - O
were - - O
to - - O
determine - - O
and - - O
rank - - O
the - - O
frequency - - O
of - - O
self - - O
reported - - O
visual - - O
disability - - O
in - - O
daily - - O
tasks - - O
performed - - O
by - - O
glaucoma - - O
patients - - O
; - - O
to - - O
examine - - O
the - - O
interrelation - - O
between - - O
disabilities - - O
using - - O
factor - - O
analysis - - O
; - - O
to - - O
study - - O
the - - O
relation - - O
between - - O
perceived - - O
visual - - O
difficulty - - O
and - - O
a - - O
measure - - O
of - - O
the - - O
severity - - O
of - - O
visual - - O
field - - O
loss - - O
; - - O
to - - O
develop - - O
a - - O
glaucoma - - O
specific - - O
subgroup - - O
of - - O
questions - - O
; - - O
and - - O
examine - - O
the - - O
validity - - O
and - - O
reliability - - O
of - - O
this - - O
subgroup - - O
of - - O
questions - - O
. - - O

The - - O
amino-terminal - - O
third - - O
of - - O
the - - O
protein - - O
contains - - O
a - - O
high-mobility-group - - B-MUT
motif - - I-MUT
characteristic - - O
of - - O
DNA-binding - - O
proteins - - O
. - - O

In - - O
rlf2 - - B-MUT
mutants - - I-MUT
, - - O
telomeric - - O
chromatin - - O
is - - O
perturbed - - O
: - - O
Telomeric - - O
silencing - - O
is - - O
reduced - - O
and - - O
Rap1p - - B-MUT
localization - - O
is - - O
altered - - O
. - - O

Solution - - O
structure - - O
and - - O
mechanism - - O
of - - O
the - - O
MutT - - B-MUT
pyrophosphohydrolase - - I-MUT
. - - O

Among - - O
the - - O
H - - B-MUT
ACA - - I-MUT
snoRNAs - - I-MUT
associated - - I-MUT
with - - O
Gar1p - - O
, - - B-MUT
one - - O
can - - O
distinguish - - O
a - - O
large - - O
group - - O
of - - O
snoRNAs - - O
that - - B-MUT
are - - O
not - - O
essential - - O
in - - O
yeast - - O
and - - O
serve - - O
as - - O
guides - - O
for - - O
pseudouridine - - O
synthesis - - O
onto - - O
the - - O
pre-rRNA - - O
molecule - - B-MUT
. - - I-MUT

Against - - O
gram-positive - - O
organisms - - O
, - - O
E-4767 - - O
and - - O
E-5065 - - O
were - - O
, - - O
in - - O
general - - O
, - - O
eight- - - O
and - - O
fourfold - - O
more - - O
active - - O
than - - O
tosufloxacin - - O
, - - O
which - - O
is - - O
the - - O
most - - O
potent - - O
of - - O
the - - O
reference - - O
compounds - - O
. - - O

A - - O
significant - - O
degree - - O
of - - O
homology - - O
was - - O
also - - O
found - - O
among - - O
these - - O
genes - - O
and - - O
the - - O
Mtase - - B-MUT
gene - - I-MUT
of - - O
related - - O
phage - - O
SPR - - O
, - - O
which - - O
codes - - O
for - - O
an - - O
enzyme - - O
with - - O
different - - O
modification - - O
specificity - - O
. - - O

These - - O
results - - O
suggest - - O
that - - O
NZ-107 - - O
may - - O
be - - O
a - - O
useful - - O
drug - - O
for - - O
the - - O
treatment - - O
of - - O
bronchial - - O
asthma - - O
by - - O
reducing - - O
late-phase - - O
airway - - O
responses - - O
and - - O
airway - - O
hyperreactivity - - O
. - - O

RESULTS - - O
: - - O
Of - - O
the - - O
patients - - O
with - - O
IS - - O
, - - O
67% - - O
had - - O
significantly - - O
greater - - O
values - - O
of - - O
directional - - O
preponderance - - O
on - - O
the - - O
OVAR - - O
test - - O
( - - O
a - - O
measure - - O
of - - O
otolith - - O
system - - O
imbalance - - O
) - - O
compared - - O
with - - O
control - - O
subjects - - O
. - - O

Additional - - O
deletion - - O
mutations - - O
revealed - - O
a - - O
new - - O
, - - O
67-amino-acid - - O
functional - - O
domain - - O
within - - O
the - - O
proline-rich - - O
region - - O
of - - O
SLP-76 - - B-MUT
, - - O
which - - O
we - - O
have - - O
termed - - O
the - - O
P-1 - - B-MUT
domain - - I-MUT
. - - O

The - - O
deduced - - O
amino - - O
acid - - O
sequence - - O
has - - O
the - - O
greatest - - O
homology - - O
( - - O
61% - - O
) - - O
to - - O
the - - O
green - - B-MUT
alga - - I-MUT
Scenedemus - - I-MUT
obliquus - - I-MUT
plastocyanin - - I-MUT
. - - O

The - - O
viral - - O
LTR - - O
was - - O
used - - O
as - - O
the - - O
promoter - - O
. - - O

We - - O
also - - O
examined - - O
the - - O
relationship - - O
between - - O
the - - O
side - - O
of - - O
sinusitis - - O
and - - O
the - - O
cleft - - O
side - - O
in - - O
patients - - O
with - - O
unilateral - - O
cleft - - O
palate - - O
. - - O

When - - O
nifA - - B-MUT
mRNA - - I-MUT
5' - - O
start - - O
points - - O
were - - O
mapped - - O
by - - O
primer - - O
extension - - O
, - - O
both - - O
a - - O
minor - - O
upstream - - O
transcript - - O
( - - O
s - - O
) - - O
starting - - O
45 - - O
bp - - O
distal - - O
to - - O
the - - O
anaerobox - - O
and - - O
a - - O
major - - O
downstream - - O
transcript - - O
starting - - O
10 - - O
bp - - O
distal - - O
to - - O
the - - O
sigma - - B-MUT
54 - - I-MUT
box - - O
were - - O
observed - - O
. - - O

The - - O
sequence - - O
of - - O
monkey - - B-MUT
opsin - - I-MUT
closely - - O
resembles - - O
the - - O
human - - O
sequence - - O
at - - O
the - - O
nucleotide - - O
and - - O
the - - O
amino - - O
acid - - O
levels - - O
, - - O
with - - O
the - - O
latter - - O
having - - O
only - - O
7 - - O
differences - - O
out - - O
of - - O
348 - - O
residues - - O
. - - O

It - - O
is - - O
the - - O
oxidation - - O
peak - - O
of - - O
this - - O
product - - O
, - - O
arising - - O
in - - O
acidic - - O
media - - O
at - - O
0 - - O
. - - O
42 - - O
V - - O
, - - O
which - - O
was - - O
analysed - - O
using - - O
DPV - - O
, - - O
again - - O
following - - O
the - - O
accumulation - - O
of - - O
clenbuterol - - O
at - - O
the - - O
Nafion-modified - - O
CPE - - O
. - - O

Its - - O
potential - - O
as - - O
a - - O
diagnostic - - O
tool - - O
for - - O
epidemiological - - O
surveillance - - O
was - - O
assessed - - O
in - - O
comparison - - O
with - - O
three - - O
other - - O
diagnostic - - O
tests - - O
: - - O
stool - - O
examination - - O
, - - O
ELISA - - O
with - - O
soluble - - B-MUT
egg - - I-MUT
antigen - - I-MUT
( - - O
SEA - - B-MUT
) - - O
and - - O
the - - O
circumoval - - O
precipitin - - O
test - - O
( - - O
COPT - - O
) - - O
. - - O

Albumin - - B-MUT
expression - - O
is - - O
maintained - - O
in - - O
the - - O
liver - - O
by - - O
a - - O
combination - - O
of - - O
liver-enriched - - O
transcription - - O
factors - - O
such - - O
as - - O
CAAT - - B-MUT
enhancer-binding - - I-MUT
protein - - I-MUT
( - - I-MUT
C - - I-MUT
EBP - - I-MUT
) - - I-MUT
alpha - - I-MUT
and - - I-MUT
C - - O
EBPbeta - - B-MUT
. - - I-MUT

T2 - - O
cancers - - O
should - - O
not - - O
be - - O
excluded - - O
from - - O
the - - O
benefit - - O
of - - O
preoperative - - O
irradiation - - O
. - - O

Amounts - - O
of - - O
glucose - - O
infused - - O
during - - O
the - - O
last - - O
20 - - O
min - - O
of - - O
each - - O
2 - - O
hour - - O
insulin - - B-MUT
infusion - - O
were - - O
( - - O
at - - O
1 - - O
and - - O
10 - - O
m - - O
kg - - O
min - - O
respectively - - O
) - - O
: - - O
before - - O
treatment - - O
( - - O
K+ - - O
= - - O
2 - - O
. - - O
7 - - O
mmol - - O
l - - O
) - - O
: - - O
2 - - O
. - - O
4 - - O
and - - O
8 - - O
. - - O
4 - - O
mg - - O
kg - - O
min - - O
; - - O
after - - O
spironolactone - - O
( - - O
K+ - - O
= - - O
3 - - O
. - - O
9 - - O
mmol - - O
l - - O
) - - O
: - - O
3 - - O
. - - O
3 - - O
and - - O
15 - - O
. - - O
4 - - O
mg - - O
kg - - O
min - - O
; - - O
after - - O
indomethacine - - O
( - - O
K+ - - O
= - - O
3 - - O
. - - O
7 - - O
mmol - - O
l - - O
) - - O
: - - O
5 - - O
and - - O
19 - - O
mg - - O
kg - - O
min - - O
after - - O
stopping - - O
drugs - - O
( - - O
K+ - - O
= - - O
2 - - O
. - - O
9 - - O
mmol - - O
l - - O
) - - O
: - - O
2 - - O
. - - O
5 - - O
and - - O
5 - - O
. - - O
3 - - O
mg - - O
kg - - O
min - - O
. - - O

A - - O
gapped - - O
search - - O
with - - O
the - - O
C-terminal - - O
region - - O
of - - O
CDED - - B-MUT
LIOR - - I-MUT
revealed - - I-MUT
a - - O
36-41% - - O
similarity - - O
to - - O
several - - O
proteins - - O
related - - O
to - - O
signal - - O
transduction - - O
and - - O
cell - - O
replication - - O
, - - O
such - - O
as - - O
ORC1 - - O
and - - B-MUT
KSR - - O
. - - B-MUT

Circulating - - O
oxytocin - - B-MUT
in - - O
male - - O
guinea - - O
pigs - - O
affected - - O
by - - O
the - - O
female - - O
cohabitation - - O
and - - O
reproductive - - O
condition - - O
. - - O

Prophylactic - - O
lymph - - O
node - - O
dissection - - O
or - - O
radiation - - O
therapy - - O
to - - O
the - - O
nodal - - O
chain - - O
may - - O
decrease - - O
local - - O
recurrence - - O
but - - O
does - - O
not - - O
consistently - - O
affect - - O
overall - - O
survival - - O
. - - O

The - - O
COL7A1 - - B-MUT
gene - - I-MUT
, - - O
which - - O
encodes - - O
type - - B-MUT
VII - - I-MUT
collagen - - I-MUT
, - - O
has - - O
been - - O
implicated - - O
as - - O
a - - O
candidate - - O
gene - - O
for - - O
dominantly - - O
and - - O
recessively - - O
inherited - - O
forms - - O
of - - O
dystrophic - - O
epidermolysis - - O
bullosa - - O
. - - O

Cell - - O
factor-mediated - - O
regulatory - - O
interactions - - O
are - - O
involved - - O
in - - O
regulating - - O
the - - O
restricted - - O
expression - - O
of - - O
the - - O
HCMV - - B-MUT
major - - I-MUT
immediate-early - - I-MUT
( - - I-MUT
IE - - I-MUT
) - - I-MUT
gene - - I-MUT
( - - O
J - - O
. - - O

AIMS - - O
: - - O
To - - O
establish - - O
a - - O
baseline - - O
and - - O
intraindividual - - O
fluctuations - - O
of - - O
the - - O
tumour - - O
markers - - O
CEA - - B-MUT
, - - O
CA - - B-MUT
50 - - I-MUT
and - - O
CA - - B-MUT
242 - - I-MUT
in - - O
patients - - O
cured - - O
from - - O
colorectal - - O
cancer - - O
, - - O
and - - O
to - - O
test - - O
the - - O
hypothesis - - O
that - - O
serum - - O
concentrations - - O
and - - O
intraindividual - - O
fluctuations - - O
do - - O
not - - O
differ - - O
from - - O
the - - O
concentrations - - O
in - - O
cancer-free - - O
individuals - - O
. - - O

Effects - - O
of - - O
thromboxane - - B-MUT
synthetase - - I-MUT
inhibition - - O
on - - O
postburn - - O
mesenteric - - O
vascular - - O
resistance - - O
and - - O
the - - O
rate - - O
of - - O
bacterial - - O
translocation - - O
in - - O
a - - O
chronic - - O
porcine - - O
model - - O
. - - O

Formation - - O
of - - O
hyphae - - O
and - - O
chlamydospores - - O
by - - O
Cryptococcus - - O
laurentii - - O
. - - O

The - - O
transforming - - O
protein - - O
of - - O
Rous - - O
sarcoma - - O
virus - - O
, - - O
pp60v-src - - B-MUT
, - - O
and - - O
its - - O
normal - - O
cellular - - O
homolog - - O
, - - O
pp60c-src - - B-MUT
, - - O
differ - - O
not - - O
only - - O
in - - O
oncogenic - - O
potential - - O
but - - O
also - - O
in - - O
their - - O
subcellular - - O
localization - - O
and - - O
cytoskeletal - - O
binding - - O
ability - - O
. - - O
pp60v-src - - B-MUT
has - - O
been - - O
shown - - O
to - - O
stably - - O
associate - - O
with - - O
a - - O
detergent-insoluble - - O
cytoskeletal - - O
matrix - - O
, - - O
whereas - - O
pp60c-src - - B-MUT
does - - O
not - - O
. - - O

DNA - - O
from - - O
PCR - - O
was - - O
labeled - - O
and - - O
used - - O
to - - O
isolate - - O
several - - O
lambda - - O
gt11 - - O
cDNA - - O
clones - - O
, - - O
including - - O
one - - O
full-length - - O
one - - O
( - - O
Dd - - B-MUT
kinase-2 - - I-MUT
) - - O
. - - O

The - - O
importin - - B-MUT
alpha - - I-MUT
. - - I-MUT
beta - - I-MUT
heterodimer - - I-MUT
mediates - - O
nuclear - - O
import - - O
of - - O
proteins - - O
containing - - O
classical - - O
nuclear - - O
localization - - O
signals - - O
. - - O

Nineteen - - O
patients - - O
with - - O
non-visualized - - O
gallbladder - - O
with - - O
OCG - - O
subsequently - - O
had - - O
Tc-99m-PyG - - O
cholescintigraphy - - O
performed - - O
. - - O

The - - O
EC - - O
( - - O
50 - - O
) - - O
for - - O
suppression - - O
of - - O
long-term - - O
memory - - O
( - - O
the - - O
concentration - - O
decreasing - - O
memory - - O
by - - O
50% - - O
) - - O
of - - O
fear - - O
conditioning - - O
to - - O
context - - O
was - - O
2 - - O
. - - O
00% - - O
plus - - O
minus - - O
0 - - O
. - - O
01% - - O
( - - O
mean - - O
plus - - O
minus - - O
SEM - - O
) - - O
, - - O
and - - O
for - - O
fear - - O
conditioning - - O
to - - O
tone - - O
was - - O
3 - - O
. - - O
45% - - O
plus - - O
minus - - O
0 - - O
. - - O
26% - - O
, - - O
( - - O
P - - O
< - - O
0 - - O
. - - O
05 - - O
) - - O
. - - O

OBJECTIVE - - O
: - - O
Although - - O
the - - O
preponderance - - O
of - - O
findings - - O
offer - - O
support - - O
for - - O
transient - - O
( - - O
where - - O
is - - O
it - - O
? - - O
) - - O
as - - O
opposed - - O
to - - O
sustained - - O
( - - O
what - - O
is - - O
it - - O
? - - O
) - - O
deficit - - O
, - - O
a - - O
need - - O
remains - - O
for - - O
specific - - O
depiction - - O
of - - O
the - - O
deficit - - O
. - - O

E - - O
. - - O

Dietary - - O
supplement - - O
with - - O
fish - - O
oil - - O
and - - O
related - - O
n-3 - - O
EFAs - - O
has - - O
been - - O
used - - O
to - - O
study - - O
their - - O
antihypertensive - - O
property - - O
in - - O
animals - - O
and - - O
humans - - O
with - - O
borderline - - O
and - - O
essential - - O
hypertension - - O
. - - O

HCV - - O
infection - - O
acquired - - O
during - - O
or - - O
after - - O
BMT - - O
caused - - O
only - - O
mild - - O
acute - - O
hepatitis - - O
C - - O
, - - O
which - - O
progressed - - O
to - - O
chronic - - O
hepatitis - - O
C - - O
in - - O
one - - O
patient - - O
surviving - - O
10 - - O
years - - O
after - - O
BMT - - O
. - - O

Gel-shift - - O
assays - - O
with - - O
nuclear - - O
extracts - - O
and - - O
oligonucleotide - - O
sequences - - O
spanning - - O
the - - O
0 - - O
. - - O
125-kb - - O
promoter - - O
region - - O
detected - - O
an - - O
ETS-immunoreactive - - O
complex - - O
, - - O
present - - O
most - - O
abundantly - - O
in - - O
cells - - O
overexpressing - - O
HER2 - - B-MUT
, - - O
whose - - O
high-affinity - - O
binding - - O
depended - - O
on - - O
the - - O
GAGGAA - - B-MUT
response - - I-MUT
element - - I-MUT
. - - O

Northern - - O
analyses - - O
of - - O
RNAs - - O
from - - O
mouse - - O
tissues - - O
and - - O
cell - - O
lines - - O
indicated - - O
that - - O
p11 - - B-MUT
mRNA - - I-MUT
levels - - O
vary - - O
widely - - O
. - - O

Further - - O
research - - O
is - - O
required - - O
to - - O
better - - O
measure - - O
treatment - - O
effects - - O
, - - O
modification - - O
of - - O
MS - - O
natural - - O
history - - O
, - - O
and - - O
net - - O
societal - - O
costs - - O
of - - O
IFN - - B-MUT
beta-1b - - I-MUT
in - - O
RRMS - - O
. - - O

If - - O
delay - - O
has - - O
occurred - - O
between - - O
centrifugation - - O
and - - O
the - - O
measurement - - O
, - - O
causing - - O
substantial - - O
loss - - O
of - - O
CO2 - - O
, - - O
equilibration - - O
of - - O
the - - O
sample - - O
with - - O
a - - O
gas - - O
mixture - - O
corresponding - - O
to - - O
PCO2 - - O
= - - O
5 - - O
. - - O
3 - - O
kPa - - O
prior - - O
to - - O
the - - O
measurement - - O
is - - O
recommended - - O
. - - O

Magnetic - - O
resonance - - O
imaging - - O
in - - O
coccidioidal - - O
arthritis - - O
. - - O

For - - O
steers - - O
the - - O
urinary - - O
N - - O
values - - O
were - - O
403 - - O
and - - O
295 - - O
mg - - O
kg - - O
W0 - - O
. - - O
75 - - O
at - - O
200 - - O
and - - O
350 - - O
kg - - O
live - - O
weight - - O
respectively - - O
and - - O
total - - O
N - - O
excretion - - O
including - - O
faecal - - O
N - - O
was - - O
408 - - O
and - - O
320 - - O
mg - - O
kg - - O
W0 - - O
. - - O
75 - - O
. - - O

Data - - O
from - - O
the - - O
V-HeFT - - O
II - - O
show - - O
that - - O
at - - O
2-year - - O
follow-up - - O
, - - O
a - - O
progressive - - O
rise - - O
of - - O
plasma - - O
norepinephrine - - O
was - - O
observed - - O
in - - O
both - - O
treatment - - O
arms - - O
, - - O
suggesting - - O
that - - O
disease - - O
progresses - - O
despite - - O
treatment - - O
with - - O
either - - O
an - - O
angiotensin-converting - - B-MUT
enzyme - - I-MUT
inhibitor - - O
, - - O
enalapril - - O
, - - O
or - - O
vasodilator - - O
therapy - - O
with - - O
hydralazine - - O
isosorbide - - O
dinitrate - - O
. - - O

Diver - - O
respiratory - - O
responses - - O
to - - O
a - - O
tunable - - O
closed-circuit - - O
breathing - - O
apparatus - - O
. - - O

Phosphorylation - - O
of - - O
tyrosine - - O
residues - - O
in - - O
the - - O
kinase - - B-MUT
domain - - I-MUT
and - - O
juxtamembrane - - O
region - - O
regulates - - O
the - - O
biological - - O
and - - O
catalytic - - O
activities - - O
of - - O
Eph - - B-MUT
receptors - - I-MUT
. - - O

The - - O
indications - - O
for - - O
its - - O
use - - O
include - - O
every - - O
primary - - O
and - - O
secondary - - O
rhinoplasty - - O
candidate - - O
unless - - O
tip - - O
grafts - - O
are - - O
going - - O
to - - O
be - - O
under - - O
tension - - O
or - - O
if - - O
the - - O
deformity - - O
is - - O
minor - - O
. - - O

The - - O
effect - - O
of - - O
pure - - O
natural - - O
porcine - - B-MUT
secretin - - I-MUT
on - - O
endocrine - - O
and - - O
exocrine - - O
pancreatic - - O
secretion - - O
was - - O
studied - - O
in - - O
the - - O
totally - - O
isolated - - O
perfused - - O
porcine - - O
pancreas - - O
. - - O

Exogenous - - O
LHRH - - B-MUT
is - - O
also - - O
known - - O
to - - O
facilitate - - O
mating - - O
behavior - - O
in - - O
several - - O
species - - O
. - - O

CONCLUSION - - O
: - - O
Chronic - - O
administration - - O
of - - O
misoprostol - - O
may - - O
have - - O
caused - - O
a - - O
negative - - O
natriuretic - - O
effect - - O
in - - O
cirrhotic - - O
patients - - O
with - - O
ascites - - O
. - - O

The - - O
in - - O
vivo - - O
profile - - O
of - - O
ZFH-2 - - B-MUT
in - - O
the - - O
larval - - O
CNS - - O
shows - - O
intriguing - - O
overlap - - O
with - - O
DDC - - B-MUT
in - - O
specific - - O
serotonin - - O
and - - O
dopamine - - O
neurons - - O
. - - O

Using - - O
this - - O
reporter - - O
gene - - O
system - - O
, - - O
we - - O
previously - - O
showed - - O
that - - O
EPO-induced - - O
activation - - O
of - - O
the - - O
c-fos - - B-MUT
promoter - - I-MUT
can - - O
be - - O
detected - - O
rapidly - - O
and - - O
sensitively - - O
as - - O
an - - O
elevation - - O
of - - O
cellular - - B-MUT
luciferase - - I-MUT
activity - - O
. - - O

Demonstration - - O
of - - O
the - - O
agent - - O
was - - O
performed - - O
from - - O
the - - O
6th - - O
to - - O
the - - O
11th - - O
day - - O
p - - O
. - - O
i - - O
. - - O
by - - O
direct - - O
microscopic - - O
methods - - O
( - - O
Stamp - - O
and - - O
auramine - - O
staining - - O
, - - O
fluorescent - - O
antibody - - O
technique - - O
) - - O
; - - O
the - - O
Coxiella - - O
content - - O
was - - O
determined - - O
by - - O
titration - - O
in - - O
embryonated - - O
hen's - - O
eggs - - O
. - - O

These - - O
characteristic - - O
structural - - O
features - - O
were - - O
used - - O
to - - O
create - - O
the - - O
abbreviation - - O
AZF1 - - B-MUT
( - - O
Asparagine-rich - - B-MUT
Zinc - - I-MUT
Finger - - I-MUT
protein - - I-MUT
) - - O
. - - O

NMR - - O
of - - O
diffusing - - O
atoms - - O
in - - O
a - - O
periodic - - O
porous - - O
medium - - O
in - - O
the - - O
presence - - O
of - - O
a - - O
nonuniform - - O
magnetic - - O
field - - O
. - - O

Cost-effectiveness - - O
of - - O
interferon - - B-MUT
beta-1b - - I-MUT
in - - O
slowing - - O
multiple - - O
sclerosis - - O
disability - - O
progression - - O
. - - O

Pseudosubstrate - - O
( - - O
19-36 - - O
) - - O
, - - O
derived - - O
from - - O
the - - O
C-terminus - - O
of - - O
Ca-dependent - - B-MUT
PKC - - I-MUT
isotypes - - I-MUT
, - - O
inhibited - - O
beta-PKC - - B-MUT
but - - O
not - - O
nPKC - - B-MUT
activity - - O
using - - O
either - - O
Histone - - B-MUT
IIIS - - I-MUT
or - - O
peptide - - O
( - - O
19-31 - - O
) - - O
as - - O
substrate - - O
. - - O

Sensing - - O
with - - O
chemically - - O
and - - O
biologically - - O
modified - - O
carbon - - O
electrodes - - O
. - - O

Structure - - O
, - - O
promoter - - O
analysis - - O
and - - O
chromosomal - - O
assignment - - O
of - - O
the - - O
human - - B-MUT
APEX - - I-MUT
gene - - I-MUT
. - - O

Upon - - O
tyrosine - - O
phosphorylation - - O
at - - O
the - - O
ITIMs - - O
, - - O
these - - O
molecules - - O
recruit - - O
SH2 - - B-MUT
domain-containing - - O
phosphatases - - B-MUT
such - - O
as - - O
SH2-containing - - O
tyrosine - - B-MUT
phosphatase-1 - - I-MUT
and - - O
negatively - - O
regulate - - O
cell - - O
activity - - O
. - - O

Homologous - - O
recombination - - O
between - - O
the - - O
Autographa - - O
californica - - O
nuclear - - O
polyhedrosis - - O
virus - - O
( - - O
AcNPV - - O
) - - O
genome - - O
and - - O
a - - O
0 - - O
. - - O
6-kbp-long - - O
DNA - - O
fragment - - O
derived - - O
from - - O
the - - O
putative - - O
DNA - - B-MUT
helicase - - I-MUT
gene - - I-MUT
of - - I-MUT
Bombyx - - I-MUT
mori - - I-MUT
nuclear - - I-MUT
polyhedrosis - - I-MUT
virus - - I-MUT
generates - - O
eh2-AcNPV - - O
, - - O
an - - O
expanded-host-range - - O
AcNPV - - O
mutant - - O
( - - O
S - - O
. - - O

The - - O
transcriptional - - O
activities - - O
of - - O
the - - O
full-length - - O
promoter - - O
( - - O
-295 - - O
to - - O
+85 - - O
) - - O
and - - O
of - - O
three - - O
deletion - - O
constructs - - O
( - - O
-197 - - O
, - - O
-154 - - O
and - - O
-74 - - O
to - - O
+85 - - O
) - - O
were - - O
significantly - - O
down-regulated - - O
in - - O
resistant - - O
cells - - O
. - - O

Both - - O
variants - - O
display - - O
the - - O
seven-transmembrane - - O
topology - - O
that - - O
is - - O
typical - - O
for - - O
G - - B-MUT
protein-coupled - - I-MUT
receptors - - I-MUT
. - - O

This - - O
region - - O
does - - O
not - - O
contain - - O
an - - O
identifiable - - O
TATA - - O
element - - O
, - - O
indicating - - O
that - - O
transcription - - O
of - - O
the - - O
glutaminase - - B-MUT
gene - - I-MUT
is - - O
driven - - O
by - - O
a - - O
TATA-less - - O
promoter - - O
. - - O

Age - - O
> - - O
= - - O
50 - - O
years - - O
( - - O
odds - - O
ratio - - O
[ - - O
OR - - O
] - - O
, - - O
14 - - O
. - - O
1 - - O
) - - O
, - - O
BMI - - O
> - - O
= - - O
28 - - O
kg - - O
m - - O
( - - O
2 - - O
) - - O
( - - O
OR - - O
, - - O
5 - - O
. - - O
7 - - O
) - - O
, - - O
triglycerides - - O
> - - O
= - - O
1 - - O
. - - O
7 - - O
mmol - - O
L - - O
( - - O
OR - - O
, - - O
5 - - O
) - - O
, - - O
and - - O
alanine - - O
aminotransferase - - O
( - - O
ALT - - O
) - - O
> - - B-MUT
= - - I-MUT
2N - - O
( - - B-MUT
OR - - O
, - - O
4 - - O
. - - O
6 - - O
) - - O
were - - O
independently - - O
associated - - O
with - - O
septal - - O
fibrosis - - O
. - - O

XXI - - O
. - - O

They - - O
generated - - O
ca - - O
. - - O

Northern - - O
blot - - O
analyses - - O
demonstrate - - O
that - - O
3 - - O
. - - O
9- - - O
and - - O
5-kilobase - - O
mRNAs - - O
corresponding - - O
to - - O
the - - O
cDNA - - O
were - - O
present - - O
in - - O
all - - O
tissues - - O
examined - - O
, - - O
suggesting - - O
that - - O
the - - O
protein - - O
it - - O
encodes - - O
performs - - O
a - - O
housekeeping - - O
function - - O
. - - O

Furthermore - - O
, - - O
the - - O
DNA - - B-MUT
polymerase - - I-MUT
II - - I-MUT
complex - - I-MUT
was - - O
difficult - - O
to - - O
obtain - - O
from - - O
dpb2-1 - - B-MUT
mutant - - O
cells - - O
, - - O
suggesting - - O
that - - O
a - - O
stable - - O
DNA - - B-MUT
polymerase - - I-MUT
II - - I-MUT
complex - - I-MUT
requires - - O
DPB2 - - B-MUT
and - - O
is - - O
essential - - O
for - - O
chromosomal - - O
replication - - O
. - - O

Linking - - O
continuous - - O
community-based - - O
morbidity - - O
recording - - O
of - - O
influenza-like - - O
illness - - O
( - - O
ILI - - O
) - - O
with - - O
virological - - O
sampling - - O
has - - O
consistently - - O
proved - - O
its - - O
value - - O
as - - O
one - - O
of - - O
the - - O
earliest - - O
indicators - - O
of - - O
circulating - - O
influenza - - O
activity - - O
. - - O

Levels - - O
of - - O
the - - O
MEK - - B-MUT
inhibitor - - O
PD98059 - - O
that - - O
block - - O
EGF-induced - - O
mitogenesis - - O
and - - O
MAP - - B-MUT
kinase - - I-MUT
phosphorylation - - O
also - - O
abrogate - - O
EGF-induced - - O
focal - - O
adhesion - - O
disassembly - - O
and - - O
cell - - O
motility - - O
. - - O

IFI16 - - B-MUT
consists - - O
of - - O
ten - - O
exons - - O
and - - O
nine - - O
intervening - - O
introns - - O
spanning - - O
at - - O
least - - O
28 - - O
kilobases - - O
( - - O
kb - - O
) - - O
of - - O
DNA - - O
. - - O

Smoking - - O
history - - O
and - - O
awake - - O
oxygen - - O
saturation - - O
( - - O
SaO2 - - O
) - - O
was - - O
recorded - - O
in - - O
all - - O
of - - O
them - - O
. - - O

In - - O
a - - O
heterologous - - O
transcriptional - - O
system - - O
in - - O
which - - O
the - - O
upstream - - O
regions - - O
of - - O
oIFNtau - - B-MUT
were - - O
inserted - - O
in - - O
front - - O
of - - O
simian - - B-MUT
virus - - I-MUT
40 - - I-MUT
( - - I-MUT
SV40 - - I-MUT
) - - I-MUT
promoter - - I-MUT
, - - O
the - - O
regions - - O
between - - O
bases - - O
-654 - - O
and - - O
-555 - - O
were - - O
determined - - O
as - - O
being - - O
the - - O
enhancer - - O
region - - O
required - - O
for - - O
oIFNtau-SV40-CAT - - B-MUT
transactivation - - O
. - - O

The - - O
evidence - - O
presented - - O
here - - O
suggests - - O
that - - O
the - - O
p40 - - B-MUT
complex - - I-MUT
is - - O
a - - O
ribonucleoprotein - - O
complex - - O
containing - - O
L1Hs - - B-MUT
RNA - - I-MUT
( - - I-MUT
s - - I-MUT
) - - I-MUT
and - - O
that - - O
protein-protein - - O
interactions - - O
in - - O
which - - O
alpha-helix - - O
structures - - O
participate - - O
, - - O
for - - O
example - - O
coiled-coils - - O
, - - O
may - - O
occur - - O
in - - O
the - - O
complex - - O
. - - O

However - - O
, - - O
the - - O
elderly - - O
group - - O
showed - - O
significantly - - O
longer - - O
mean - - O
residence - - O
times - - O
( - - O
MRTs - - O
) - - O
and - - O
lower - - O
plasma - - O
clearance - - O
of - - O
lidocaine - - O
during - - O
the - - O
period - - O
compared - - O
with - - O
the - - O
adult - - O
group - - O
( - - O
P - - O
< - - O
. - - O
05 - - O
) - - O
. - - O

Two - - O
major - - O
and - - O
one - - O
minor - - O
transcription - - O
initiation - - O
sites - - O
were - - O
assigned - - O
to - - O
positions - - O
+1 - - O
and - - O
+24 - - O
and - - O
position - - O
+14 - - O
, - - O
respectively - - O
, - - O
by - - O
a - - O
combination - - O
of - - O
ribonuclease - - B-MUT
protection - - O
, - - O
primer - - O
extension - - O
, - - O
and - - O
5' - - O
RACE - - O
analyses - - O
. - - O

Taking - - O
into - - O
consideration - - O
weight - - O
and - - O
seasonal - - O
changes - - O
in - - O
bone - - O
mass - - O
, - - O
total - - O
( - - O
TBBMC - - O
) - - O
and - - O
regional - - O
body - - O
bone - - O
mineral - - O
content - - O
were - - O
measured - - O
in - - O
38 - - O
women - - O
treated - - O
with - - O
GnRH - - B-MUT
agonists - - O
for - - O
6 - - O
months - - O
for - - O
endometriosis - - O
or - - O
leiomyomata - - O
. - - O

Time - - O
to - - O
progression - - O
was - - O
6 - - O
months - - O
( - - O
5-7 - - O
months - - O
) - - O
with - - O
a - - O
median - - O
survival - - O
from - - O
registration - - O
of - - O
9 - - O
. - - O
6 - - O
months - - O
( - - O
95% - - O
CI - - O
8-12 - - O
months - - O
) - - O
. - - O

SCFFWD1 - - B-MUT
may - - O
be - - O
critical - - O
for - - O
tumor - - O
development - - O
and - - O
suppression - - O
through - - O
regulation - - O
of - - O
beta-catenin - - B-MUT
protein - - I-MUT
stability - - O
. - - O

In - - O
addition - - O
to - - O
the - - O
previously - - O
identified - - O
and - - O
characterized - - O
attenuator - - B-MUT
1 - - I-MUT
situated - - O
93 - - O
nucleotides - - O
downstream - - O
from - - O
the - - O
major - - O
late - - O
transcription - - O
start - - O
site - - O
, - - O
a - - O
second - - O
attenuator - - O
, - - O
attenuator - - B-MUT
2 - - I-MUT
, - - O
situated - - O
55 - - O
nucleotides - - O
downstream - - O
from - - O
it - - O
, - - O
has - - O
been - - O
identified - - O
. - - O

A - - O
long - - O
follow-up - - O
study - - O
revealed - - O
that - - O
convalescent - - O
stage - - O
children - - O
still - - O
have - - O
the - - O
potency - - O
to - - O
have - - O
an - - O
immediate - - O
type - - O
hypersensitivity - - O
reaction - - O
on - - O
exposure - - O
to - - O
mite - - O
antigen - - O
, - - O
with - - O
a - - O
high - - O
titer - - O
of - - O
mite - - B-MUT
specific - - I-MUT
IgE - - I-MUT
in - - O
their - - O
sera - - O
, - - O
but - - O
they - - O
are - - O
free - - O
from - - O
asthmatic - - O
attacks - - O
because - - O
of - - O
the - - O
reduction - - O
in - - O
the - - O
amount - - O
of - - O
mite - - O
antigen - - O
in - - O
the - - O
body - - O
, - - O
as - - O
shown - - O
by - - O
the - - O
reduction - - O
in - - O
the - - O
amount - - O
of - - O
mite - - B-MUT
specific - - I-MUT
IgG - - I-MUT
. - - O

These - - O
changes - - O
weren't - - O
so - - O
significant - - O
in - - O
the - - O
group - - O
of - - O
obese - - O
children - - O
who - - O
didn't - - O
lose - - O
weight - - O
. - - O

USA - - O
80 - - O
, - - O
3618-3622 - - O
) - - O
The - - O
two - - O
proteins - - O
show - - O
36% - - O
identities - - O
in - - O
their - - O
amino - - O
acid - - O
sequence - - O
, - - O
in - - O
an - - O
alignment - - O
requiring - - O
six - - O
gaps - - O
. - - O

After - - O
cells - - O
were - - O
stably - - O
transfected - - O
with - - O
CIITA - - B-MUT
, - - O
endogenous - - O
MHC - - B-MUT
class - - I-MUT
II - - I-MUT
genes - - I-MUT
were - - O
constitutively - - O
expressed - - O
, - - O
and - - O
MHC - - B-MUT
class - - I-MUT
II - - I-MUT
promoters - - I-MUT
, - - O
delivered - - O
by - - O
transfection - - O
, - - O
were - - O
actively - - O
transcribed - - O
in - - O
CIITA-expressing - - O
cells - - O
. - - O

POU-specific - - O
and - - O
POU-homeo - - B-MUT
domains - - I-MUT
of - - O
Oct3 - - B-MUT
were - - O
produced - - O
in - - O
Echerichia - - O
coli - - O
for - - O
characterization - - O
of - - O
DNA - - O
binding - - O
to - - O
the - - O
octamer - - O
sequence - - O
. - - O

Bullous - - O
angiolymphoid - - O
hyperplasia - - O
with - - O
eosinophilia - - O
. - - O

No - - O
title - - O
available - - O
. - - O

Regulation - - O
of - - O
urokinase - - B-MUT
plasminogen - - I-MUT
activator - - I-MUT
gene - - I-MUT
transcription - - O
in - - O
the - - O
RAW264 - - O
murine - - O
macrophage - - O
cell - - O
line - - O
by - - O
macrophage - - B-MUT
colony-stimulating - - I-MUT
factor - - I-MUT
( - - O
CSF-1 - - B-MUT
) - - O
is - - O
dependent - - O
upon - - O
the - - O
level - - O
of - - O
cell-surface - - O
receptor - - O
. - - O

Polyclonal - - O
antibodies - - O
against - - O
the - - O
N-terminal - - O
part - - O
( - - O
amino - - O
acids - - O
12-363 - - O
) - - O
and - - O
the - - O
C-terminal - - O
part - - O
( - - O
amino - - O
acids - - O
330-730 - - O
) - - O
of - - O
rainbow - - B-MUT
trout - - I-MUT
HIF-1alpha - - I-MUT
protein - - I-MUT
recognized - - O
rainbow - - B-MUT
trout - - I-MUT
and - - I-MUT
chinook - - I-MUT
salmon - - I-MUT
HIF-1alpha - - I-MUT
protein - - I-MUT
in - - O
Western - - O
blot - - O
analysis - - O
. - - O

It - - O
is - - O
thus - - O
one - - O
of - - O
the - - O
key - - O
enzymes - - O
involved - - O
in - - O
the - - O
triiodothyronine-mediated - - O
control - - O
of - - O
growth - - O
, - - O
differentiation - - O
and - - O
basal - - O
metabolism - - O
in - - O
vertebrates - - O
. - - O

Similarly - - O
, - - O
comparison - - O
of - - O
percentage - - O
reductions - - O
of - - O
heart - - O
rate - - O
at - - O
supine - - O
, - - O
sitting - - O
and - - O
exercise - - O
by - - O
repeated - - O
measure - - O
analysis - - O
showed - - O
the - - O
Malays - - O
to - - O
have - - O
significantly - - O
higher - - O
change - - O
compared - - O
to - - O
the - - O
Chinese - - O
( - - O
p - - O
= - - O
0 - - O
. - - O
040 - - O
) - - O
. - - O

To - - O
analyze - - O
the - - O
mechanism - - O
of - - O
fos - - B-MUT
jun - - O
activation - - B-MUT
by - - O
TCDD - - O
we - - O
have - - O
used - - O
electrophoretic - - O
mobility - - O
shift - - O
and - - O
transient - - O
expression - - O
assays - - O
of - - O
reporter - - O
gene - - O
constructs - - O
containing - - O
response - - O
elements - - O
for - - O
12-O-tetradecanoyl-phorbol-13-acetate - - O
( - - O
TRE - - O
) - - B-MUT
, - - O
serum - - O
( - - O
SRE - - O
) - - B-MUT
, - - O
cAMP - - O
( - - O
CRE - - O
) - - B-MUT
, - - O
and - - O
aromatic - - O
hydrocarbons - - O
( - - O
AhRE - - O
) - - O
from - - O
the - - O
fos - - O
and - - B-MUT
jun - - O
genes - - B-MUT
fused - - I-MUT
to - - O
the - - O
firefly - - O
luciferase - - B-MUT
gene - - I-MUT
under - - I-MUT
the - - O
control - - O
of - - O
the - - O
SV40 - - O
minimal - - B-MUT
promoter - - I-MUT
. - - I-MUT

The - - O
mysteries - - O
of - - O
geographic - - O
variability - - O
in - - O
nonmelanoma - - O
skin - - O
cancer - - O
incidence - - O
. - - O

The - - O
two - - O
different - - O
phosphoforms - - O
of - - O
STAT5 - - B-MUT
have - - O
identical - - O
in - - O
vitro - - O
DNA - - O
binding - - O
specificity - - O
and - - O
reactivity - - O
with - - O
tyrosine - - O
phosphopeptides - - O
, - - O
but - - O
differ - - O
in - - O
their - - O
cellular - - O
localization - - O
. - - O

Changes - - O
in - - O
tissue - - O
PCO2 - - O
were - - O
less - - O
dramatic - - O
and - - O
did - - O
not - - O
vary - - O
significantly - - O
from - - O
those - - O
recorded - - O
in - - O
venous - - O
blood - - O
. - - O

To - - O
improve - - O
test - - O
efficiency - - O
, - - O
we - - O
modified - - O
our - - O
previously - - O
introduced - - O
contrast - - O
color - - O
card - - O
test - - O
by - - O
including - - O
a - - O
patterned - - O
test - - O
stimulus - - O
and - - O
reducing - - O
the - - O
number - - O
of - - O
stimuli - - O
in - - O
both - - O
experimental - - O
phases - - O
. - - O

Sequence - - O
comparisons - - O
of - - O
prokaryotic - - B-MUT
RCR - - I-MUT
initiators - - I-MUT
has - - O
revealed - - O
a - - O
set - - O
of - - O
three - - O
common - - O
motifs - - O
, - - O
two - - O
of - - O
which - - O
, - - O
a - - O
putative - - O
metal - - O
coordination - - O
site - - O
and - - O
a - - O
downstream - - O
active-site - - O
tyrosine - - O
motif - - O
, - - O
could - - O
be - - O
tentatively - - O
identified - - O
in - - O
parvoviral - - B-MUT
replicator - - I-MUT
proteins - - I-MUT
. - - O

An - - O
even - - O
greater - - O
inflammatory - - O
response - - O
was - - O
observed - - O
after - - O
intratracheal - - O
instillation - - O
of - - O
ufCB - - O
, - - O
but - - O
not - - O
after - - O
CB - - O
instillation - - O
. - - O

Validity - - O
of - - O
NIR - - O
spectroscopy - - O
for - - O
quantitatively - - O
measuring - - O
muscle - - O
oxidative - - O
metabolic - - O
rate - - O
in - - O
exercise - - O
. - - O

Ten - - O
males - - O
performed - - O
both - - O
test - - O
conditions - - O
and - - O
oxygen - - O
uptake - - O
VO2 - - O
, - - O
heart - - O
rate - - O
, - - O
minute - - O
ventilation - - O
VE - - O
, - - O
perceived - - O
exertion - - O
and - - O
spinal - - O
shrinkage - - O
were - - O
recorded - - O
. - - O

A - - O
major - - O
mechanism - - O
whereby - - O
steroid - - B-MUT
hydroxylase - - I-MUT
gene - - I-MUT
transcription - - O
is - - O
regulated - - O
in - - O
the - - O
adrenal - - O
cortex - - O
requires - - O
the - - O
pituitary - - O
peptide - - O
hormone - - O
, - - O
ACTH - - B-MUT
, - - O
which - - O
acts - - O
via - - O
cAMP - - O
. - - O

AF - - B-MUT
showed - - O
a - - O
mixed - - O
nuclear - - O
cytoplasmic - - O
pattern - - O
of - - O
expression - - O
in - - O
the - - O
epithelial - - O
, - - O
endothelial - - O
, - - O
and - - O
stromal - - O
component - - O
of - - O
the - - O
normal - - O
breast - - O
and - - O
benign - - O
lesions - - O
, - - O
whereas - - O
an - - O
impressive - - O
loss - - O
of - - O
AF - - O
expression - - B-MUT
was - - O
noted - - O
in - - O
in - - O
situ - - O
and - - O
invasive - - O
breast - - O
cancer - - O
and - - O
tumoral - - O
stroma - - O
. - - O

Based - - O
on - - O
213 - - O
determinations - - O
, - - O
the - - O
control - - O
mean - - O
serum - - B-MUT
CPK - - I-MUT
activity - - O
was - - O
262 - - O
+ - - O
- - - O
113 - - O
I - - O
. - - O
U - - O
. - - O
liter - - O
. - - O

In - - O
vivo - - O
, - - O
selective - - O
activation - - O
of - - O
SAPKs - - B-MUT
stimulates - - O
formation - - O
of - - O
the - - O
ternary - - O
complex - - O
containing - - O
Elk-1 - - B-MUT
, - - O
serum - - B-MUT
response - - I-MUT
factor - - I-MUT
and - - O
the - - O
serum - - B-MUT
response - - I-MUT
element - - I-MUT
, - - O
and - - O
enhances - - O
Elk-1-dependent - - O
transcription - - O
. - - O

At - - O
all - - O
time-points - - O
, - - O
most - - O
patients - - O
( - - O
> - - O
= - - O
87% - - O
) - - O
were - - O
receiving - - O
irbesartan - - O
HCTZ - - O
alone - - O
. - - O

A - - O
leucine - - O
zipper - - O
domain - - O
of - - O
the - - O
suppressor - - B-MUT
of - - I-MUT
Hairy-wing - - I-MUT
protein - - I-MUT
mediates - - O
its - - O
repressive - - O
effect - - O
on - - O
enhancer - - O
function - - O
. - - O

Analysis - - O
of - - O
the - - O
inferred - - O
1 - - B-MUT
, - - I-MUT
859-residue - - I-MUT
ama-1 - - I-MUT
product - - I-MUT
showed - - O
considerable - - O
identity - - O
with - - O
the - - O
largest - - O
subunit - - O
of - - O
RNAP - - B-MUT
II - - I-MUT
from - - O
other - - O
organisms - - O
, - - O
including - - O
the - - O
presence - - O
of - - O
a - - O
zinc - - O
finger - - O
motif - - O
near - - O
the - - O
amino - - O
terminus - - O
, - - O
and - - O
a - - O
carboxyl-terminal - - O
domain - - O
of - - O
42 - - O
tandemly - - O
reiterated - - O
heptamers - - O
with - - O
the - - O
consensus - - O
Tyr - - O
Ser - - O
Pro - - O
Thr - - O
Ser - - O
Pro - - O
Ser - - O
. - - O

The - - O
two - - O
contiguous - - O
IGF2 - - B-MUT
( - - O
human - - B-MUT
insulin-like - - I-MUT
growth - - I-MUT
factor - - I-MUT
II - - I-MUT
) - - O
and - - O
H19 - - B-MUT
genes - - I-MUT
are - - O
reciprocally - - O
imprinted - - O
in - - O
both - - O
human - - O
and - - O
mouse - - O
. - - O

The - - O
requirement - - O
of - - O
3' - - O
complementarity - - O
for - - O
a - - O
ligation - - O
reaction - - O
is - - O
reaffirmed - - O
by - - O
results - - O
from - - O
1 - - O
nt - - O
insertions - - O
on - - O
either - - O
the - - O
3'- - - O
or - - O
5'-side - - O
of - - O
the - - O
nick - - O
. - - O

In - - O
serum-stimulated - - O
cells - - O
, - - O
the - - O
binding - - O
of - - O
NF-Y - - B-MUT
CBF - - I-MUT
to - - I-MUT
TKC1 - - O
increased - - B-MUT
gradually - - O
, - - O
reaching - - O
a - - O
plateau - - O
at - - O
the - - O
S - - O
phase - - O
. - - O

Data - - O
are - - O
presented - - O
hinting - - O
that - - O
the - - O
15 - - O
beta-hydroxy- - - O
, - - O
metabolite - - O
of - - O
CPA - - O
may - - O
actually - - O
be - - O
the - - O
biologically - - O
active - - O
agent - - O
. - - O

A - - O
sharp - - O
outbreak - - O
of - - O
influenza - - O
A - - O
occurred - - O
on - - O
the - - O
base - - O
during - - O
February - - O
that - - O
was - - O
due - - O
to - - O
an - - O
A - - O
Texas - - O
1 - - O
77-like - - O
virus - - O
, - - O
a - - O
variant - - O
of - - O
the - - O
A - - O
Victoria - - O
3 - - O
75 - - O
prototpye - - O
. - - O

One - - O
missense - - O
allele - - O
( - - O
P236S - - B-MUT
) - - O
with - - O
complete - - O
loss - - O
of - - O
function - - O
at - - O
30 - - O
degreesC - - O
and - - O
four - - O
missense - - O
alleles - - O
( - - O
L173F - - B-MUT
, - - O
E225K - - B-MUT
, - - O
S269L - - B-MUT
and - - O
E274K - - B-MUT
) - - O
that - - O
conferred - - O
a - - O
temperature - - O
sensitive - - O
phenotype - - O
were - - O
identified - - O
. - - O

Similar - - O
results - - O
were - - O
obtained - - O
with - - O
xylitol - - O
, - - O
an - - O
activator - - O
of - - O
the - - O
pentose - - O
phosphate - - O
pathway - - O
. - - O

Pentane - - O
and - - O
ethane - - O
, - - O
which - - O
arise - - O
during - - O
lipid - - O
peroxidation - - O
in - - O
vivo - - O
, - - O
were - - O
measured - - O
by - - O
gas - - O
chromatography - - O
in - - O
breath - - O
samples - - O
of - - O
rats - - O
fed - - O
for - - O
8 - - O
weeks - - O
a - - O
vitamin - - O
E-deficient - - O
diet - - O
to - - O
which - - O
had - - O
been - - O
added - - O
0 - - O
, - - O
11 - - O
, - - O
or - - O
40 - - O
IU - - O
vitamin - - O
E - - O
acetate - - O
per - - O
kg - - O
. - - O

Here - - O
we - - O
have - - O
determined - - O
the - - O
nucleotide - - O
sequence - - O
of - - O
3 - - O
. - - O
5 - - O
kb - - O
from - - O
the - - O
3' - - O
end - - O
of - - O
delta - - B-MUT
gag - - I-MUT
to - - O
the - - O
3' - - O
end - - O
of - - O
molecularly - - O
cloned - - O
proviral - - O
MH2 - - O
DNA - - O
, - - O
in - - O
order - - O
to - - O
elucidate - - O
the - - O
genetic - - O
structure - - O
of - - O
the - - O
virus - - O
and - - O
to - - O
compare - - O
it - - O
with - - O
other - - O
mht - - B-MUT
- - - O
and - - O
myc-containing - - O
oncogenic - - O
viruses - - O
as - - O
well - - O
as - - O
with - - O
the - - O
chicken - - B-MUT
proto-myc - - I-MUT
gene - - I-MUT
. - - O

Concurrent - - O
with - - O
ligand-dependent - - O
uptake - - O
, - - O
we - - O
now - - O
show - - O
that - - O
the - - O
receptor - - O
undergoes - - O
ligand-induced - - O
ubiquitination - - O
, - - O
suggesting - - O
that - - O
receptor - - O
ubiquitination - - O
may - - O
function - - O
in - - O
the - - O
ligand-dependent - - O
endocytosis - - O
of - - O
the - - O
a-factor - - B-MUT
receptor - - I-MUT
as - - O
well - - O
as - - O
in - - O
its - - O
constitutive - - O
endocytosis - - O
. - - O

Cleavage - - O
and - - O
DNA - - O
joining - - O
reactions - - O
, - - O
carried - - O
out - - O
by - - O
human - - B-MUT
immunodeficiency - - I-MUT
virus - - I-MUT
type - - I-MUT
1 - - I-MUT
( - - I-MUT
HIV-1 - - I-MUT
) - - I-MUT
integrase - - I-MUT
, - - O
are - - O
necessary - - O
to - - O
effect - - O
the - - O
covalent - - O
insertion - - O
of - - O
HIV-1 - - O
DNA - - O
into - - O
the - - O
host - - O
genome - - O
. - - O

Immunoprecipitation - - O
experiments - - O
using - - O
DokR-specific - - B-MUT
antibodies - - I-MUT
revealed - - O
an - - O
interaction - - O
between - - O
endogenous - - B-MUT
DokR - - I-MUT
and - - O
a - - O
150-kDa - - O
protein - - O
that - - O
is - - O
tyrosine-phosphorylated - - O
in - - O
EGF-stimulated - - O
BaF - - O
3 - - O
cells - - O
. - - O

The - - O
requirement - - O
for - - O
proteolytic - - O
activity - - O
of - - O
both - - O
FVIIa - - B-MUT
and - - O
FXa - - B-MUT
suggests - - O
that - - O
protease-activated - - O
receptors - - O
may - - O
be - - O
involved - - O
. - - O

The - - O
weight-bearing - - O
surface - - O
of - - O
the - - O
PE - - O
head - - O
became - - O
smoother - - O
with - - O
time - - O
after - - O
THA - - O
, - - O
and - - O
the - - O
friction - - O
coefficient - - O
did - - O
not - - O
differ - - O
significantly - - O
from - - O
that - - O
of - - O
an - - O
unused - - O
PE - - O
head - - O
. - - O

Collaborative - - O
study - - O
of - - O
Japanese - - O
Pharmacopoeia - - O
Heparin - - O
Sodium - - O
Reference - - O
Standard - - O
. - - O

The - - O
cDNA - - O
corresponding - - O
to - - O
the - - O
FPS1 - - B-MUT
gene - - I-MUT
was - - O
isolated - - O
by - - O
functional - - O
complementation - - O
of - - O
a - - O
mutant - - O
yeast - - O
strain - - O
defective - - O
in - - O
FPS - - B-MUT
activity - - O
( - - O
Delourme - - O
, - - O
D - - O
. - - O
, - - O
Lacroute - - O
, - - O
F - - O
. - - O
, - - O
and - - O
Karst - - O
, - - O
F - - O
. - - O

Pharmacokinetic - - O
parameters - - O
were - - O
similar - - O
to - - O
values - - O
given - - O
in - - O
the - - O
literature - - O
for - - O
intravenous - - O
( - - O
IV - - O
) - - O
or - - O
intraarterial - - O
( - - O
IA - - O
) - - O
bolus - - O
MMC - - O
injections - - O
( - - O
Tmax - - O
= - - O
7 - - O
. - - O
0 - - O
min - - O
following - - O
the - - O
beginning - - O
of - - O
MMC - - O
infusion - - O
, - - O
Vss - - O
= - - O
0 - - O
. - - O
57 - - O
1 - - O
kg - - O
, - - O
C1 - - O
= - - O
8 - - O
. - - O
9 - - O
ml - - O
min - - O
. - - O
kg - - O
, - - O
T1 - - O
2 - - O
alpha - - O
= - - O
8 - - O
. - - O
3 - - O
min - - O
, - - O
T1 - - O
2 - - O
beta - - O
= - - O
58 - - O
. - - O
6 - - O
min - - O
) - - O
. - - O

In - - O
the - - O
present - - O
study - - O
, - - O
we - - O
demonstrate - - O
that - - O
expression - - O
of - - O
TD-IkappaBalpha - - B-MUT
blocked - - O
phorbol - - O
myristate - - O
acetate-phytohemagglutinin - - B-MUT
or - - O
tumor - - B-MUT
necrosis - - I-MUT
factor - - I-MUT
alpha-induced - - O
IkappaBalpha - - B-MUT
gene - - I-MUT
transcription - - O
and - - O
abolished - - O
NF-kappaB - - B-MUT
DNA - - O
binding - - O
activity - - O
, - - O
due - - O
to - - O
the - - O
continued - - O
cytoplasmic - - O
sequestration - - O
of - - O
RelA - - B-MUT
( - - I-MUT
p65 - - I-MUT
) - - I-MUT
by - - O
TD-IkappaBalpha - - B-MUT
. - - O

A - - O
second - - O
promoter - - O
activity - - O
was - - O
identified - - O
in - - O
the - - O
region - - O
between - - O
the - - O
two - - O
major - - O
transcriptional - - O
start - - O
sites - - O
. - - O

Unique - - O
to - - O
this - - O
system - - O
, - - O
the - - O
activity - - O
of - - O
TraR - - B-MUT
is - - O
negatively - - O
modulated - - O
by - - O
an - - O
antiactivator - - O
called - - O
TraM - - B-MUT
. - - O

Direct - - O
and - - O
inverted - - O
repeat - - O
elements - - O
of - - O
10 - - O
, - - O
11 - - O
, - - O
16 - - O
, - - O
19 - - O
, - - O
and - - O
22 - - O
nucleotides - - O
( - - O
nt - - O
) - - O
flank - - O
the - - O
promoter - - O
site - - O
. - - O

Single - - O
tooth - - O
replacement - - O
with - - O
the - - O
aid - - O
of - - O
the - - O
ITI - - O
( - - O
International - - O
Team - - O
fur - - O
Implantologie - - O
) - - O
type - - O
F - - O
hollow-cylinder - - O
implant - - O
. - - O

Interestingly - - O
, - - O
the - - O
positions - - O
of - - O
these - - O
introns - - O
have - - O
been - - O
conserved - - O
in - - O
comparison - - O
with - - O
the - - O
genes - - O
of - - O
two - - O
other - - O
transglutaminase-like - - O
activities - - O
described - - O
in - - O
the - - O
literature - - O
, - - O
but - - O
the - - O
TGM1 - - B-MUT
gene - - I-MUT
is - - O
by - - O
far - - O
the - - O
smallest - - O
characterized - - O
to - - O
date - - O
because - - O
its - - O
introns - - O
are - - O
relatively - - O
smaller - - O
. - - O

Studies - - O
on - - O
swine - - O
enteroviruses - - O
. - - O

In - - O
addition - - O
, - - O
anti-phosphotyrosine - - B-MUT
antibodies - - I-MUT
immunoprecipitated - - O
80K-H - - B-MUT
from - - O
cell - - O
lysates - - O
of - - O
FGF-stimulated - - O
but - - O
not - - O
from - - O
control - - O
fibroblasts - - O
. - - O

Splice - - O
variations - - O
in - - O
genes - - O
coding - - O
for - - O
the - - O
transmembrane - - B-MUT
FGF - - I-MUT
receptor - - I-MUT
( - - O
FGFR - - B-MUT
) - - O
result - - O
in - - O
isoforms - - O
that - - O
vary - - O
in - - O
the - - O
ectodomain - - O
, - - O
intracellular - - O
juxtamembrane - - O
domain - - O
, - - O
and - - O
the - - O
intracellular - - B-MUT
kinase - - I-MUT
domain - - I-MUT
. - - O

The - - O
efficacy - - O
of - - O
quantitative - - O
and - - O
qualitative - - O
chloride - - O
titrators - - O
in - - O
the - - O
estimation - - O
of - - O
human - - O
salt - - O
intake - - O
. - - O

During - - O
the - - O
period - - O
from - - O
May - - O
to - - O
August - - O
, - - O
1978 - - O
, - - O
an - - O
epidemic - - O
of - - O
hand - - O
, - - O
foot - - O
and - - O
mouth - - O
disease - - O
( - - O
HFMD - - O
) - - O
occurred - - O
in - - O
Gifu - - O
prefecture - - O
. - - O

The - - O
design - - O
principle - - O
based - - O
on - - O
a - - O
uniform - - O
vibration - - O
mode - - O
is - - O
presented - - O
. - - O

The - - O
enzymatic - - O
response - - O
of - - O
neutrophils - - O
and - - O
monocytes - - O
was - - O
similar - - O
although - - O
the - - O
magnitude - - O
of - - O
the - - O
NADPH - - B-MUT
oxidase - - I-MUT
activity - - O
was - - O
significantly - - O
higher - - O
in - - O
neutrophils - - O
than - - O
in - - O
monocytes - - O
. - - O

These - - O
results - - O
suggest - - O
that - - O
beta-1 - - B-MUT
may - - O
act - - O
as - - O
a - - O
tissue-specific - - O
, - - O
trans-acting - - O
regulator - - O
of - - O
the - - O
expression - - O
of - - O
the - - O
beta-zein - - B-MUT
gene - - I-MUT
in - - O
developing - - O
maize - - O
endosperm - - O
. - - O

Thus - - O
, - - O
through - - O
a - - O
change - - O
in - - O
conformation - - O
upon - - O
repair - - O
of - - O
the - - O
6RG - - O
lesion - - O
, - - O
MGMT - - B-MUT
switches - - O
from - - O
a - - O
DNA - - O
repair - - O
factor - - O
to - - O
a - - O
transcription - - O
regulator - - O
( - - O
R-MGMT - - B-MUT
) - - O
, - - O
enabling - - O
the - - O
cell - - O
to - - O
sense - - O
as - - O
well - - O
as - - O
respond - - O
to - - O
mutagens - - O
. - - O

Mothers - - O
with - - O
severe - - O
anatomical - - O
abnormalities - - O
, - - O
who - - O
are - - O
HIV - - O
positive - - O
, - - O
have - - O
active - - O
TB - - O
or - - O
whose - - O
children - - O
have - - O
inherited - - O
mono- - - O
or - - O
disaccharide - - O
intolerances - - O
should - - O
not - - O
breastfeed - - O
. - - O

Metal - - O
coordination - - O
compounds - - O
of - - O
thiabendazole - - O
. - - O

The - - O
responsiveness - - O
of - - O
visual - - O
cortex - - O
( - - O
VC - - O
) - - O
and - - O
superior - - O
colliculus - - O
( - - O
SC - - O
) - - O
was - - O
simultaneously - - O
compared - - O
following - - O
conditioning - - O
"ON" - - O
or - - O
"OFF" - - O
stimulation - - O
, - - O
in - - O
the - - O
rabbit - - O
. - - O

Existence - - O
and - - O
uniqueness - - O
of - - O
solutions - - O
of - - O
the - - O
appropriate - - O
boundary - - O
value - - O
problems - - O
are - - O
established - - O
, - - O
in - - O
the - - O
case - - O
of - - O
small - - O
permeability - - O
coefficients - - O
and - - O
transport - - O
rates - - O
, - - O
or - - O
large - - O
diffusion - - O
coefficients - - O
and - - O
small - - O
resistance - - O
to - - O
flow - - O
constants - - O
. - - O

The - - O
neurohypophysial - - O
vasopressin - - B-MUT
and - - O
oxytocin - - B-MUT
content - - O
was - - O
bioassayed - - O
by - - O
pressor - - O
effect - - O
following - - O
Dekanski - - O
or - - O
milk-ejection - - O
activity - - O
in - - O
vitro - - O
following - - O
van - - O
Dongen - - O
and - - O
Hays - - O
, - - O
respectively - - O
. - - O

MK-927 - - O
: - - O
a - - O
topically - - O
active - - O
ocular - - O
hypotensive - - O
carbonic - - B-MUT
anhydrase - - I-MUT
inhibitor - - O
. - - O

Because - - O
of - - O
differences - - O
in - - O
patient - - O
characteristics - - O
, - - O
control - - O
measurements - - O
were - - O
obtained - - O
from - - O
normal - - O
muscle - - O
in - - O
all - - O
patients - - O
. - - O

We - - O
have - - O
cloned - - O
the - - O
single-copy - - O
gene - - O
for - - O
the - - O
trans - - B-MUT
-spliceosomal - - I-MUT
U5 - - I-MUT
snRNA - - I-MUT
from - - O
the - - O
trypanosomatid - - O
species - - O
Leptomonas - - O
seymouri - - O
, - - O
using - - O
U5 - - B-MUT
RNA - - I-MUT
affinity - - O
selection - - O
and - - O
cDNA - - O
cloning - - O
. - - O

In - - O
these - - O
experiments - - O
we - - O
begin - - O
to - - O
study - - O
the - - O
potential - - O
functions - - O
of - - O
the - - O
alpha - - B-MUT
7 - - I-MUT
cytoplasmic - - I-MUT
domain - - I-MUT
by - - O
analyzing - - O
homologies - - O
between - - O
the - - O
rat - - O
and - - O
human - - O
sequences - - O
, - - O
by - - O
immunologic - - O
studies - - O
using - - O
an - - O
anti-cytoplasmic - - O
domain - - O
antiserum - - O
, - - O
and - - O
by - - O
identifying - - O
two - - O
alternate - - O
forms - - O
. - - O

The - - O
Mauriceville - - O
and - - O
Varkud - - O
mitochondrial - - O
plasmids - - O
are - - O
closely - - O
related - - O
, - - O
closed-circular - - O
DNAs - - O
( - - O
3 - - O
. - - O
6 - - O
and - - O
3 - - O
. - - O
7 - - O
kb - - O
, - - O
respectively - - O
) - - O
that - - O
have - - O
characteristics - - O
of - - O
mtDNA - - O
introns - - O
and - - O
retroid - - O
elements - - O
. - - O

RESULTS - - O
: - - O
The - - O
target - - O
dose - - O
was - - O
comparable - - O
in - - O
the - - O
3D-CRT - - O
and - - O
IMRT - - O
plans - - O
, - - O
although - - O
improvements - - O
were - - O
seen - - O
when - - O
seven - - O
and - - O
nine - - O
IMRT - - O
fields - - O
were - - O
used - - O
. - - O

[ - - O
Pulmonary - - O
vascular - - O
resistance - - O
( - - O
PVR - - O
) - - O
during - - O
10% - - O
O2-PVR - - O
during - - O
21% - - O
O2 - - O
PVR - - O
during - - O
21% - - O
O2 - - O
] - - O
x - - O
100 - - O
was - - O
termed - - O
as - - O
hypoxic - - O
pulmonary - - O
vasoconstriction - - O
( - - O
HPV - - O
) - - O
. - - O

This - - O
analysis - - O
revealed - - O
an - - O
intact - - O
gene - - O
( - - O
arg4 - - B-MUT
) - - O
showing - - O
a - - O
high - - O
degree - - O
of - - O
homology - - O
with - - O
the - - O
Saccharomyces - - B-MUT
cerevisiae - - I-MUT
CPA2 - - I-MUT
gene - - I-MUT
encoding - - O
the - - O
large - - O
subunit - - O
of - - O
carbamoyl-phosphate - - B-MUT
synthetase - - I-MUT
( - - O
CPS-A - - B-MUT
) - - O
. - - O

Diminished - - O
forearm - - O
arteriolar - - O
dilator - - O
capacity - - O
produced - - O
by - - O
mineralocorticoid-induced - - O
salt - - O
retention - - O
in - - O
man - - O
. - - O

The - - O
effects - - O
of - - O
dominant - - O
interfering - - O
forms - - O
of - - O
the - - O
JNK - - B-MUT
p38 - - I-MUT
signaling - - I-MUT
pathway - - O
demonstrate - - O
that - - O
activation - - O
of - - O
these - - O
kinases - - O
is - - O
critical - - O
for - - O
cytokine-induced - - O
E-selectin - - O
gene - - B-MUT
expression - - I-MUT
. - - O

During - - O
flexion - - O
whiplash - - O
, - - O
the - - O
torque - - O
at - - O
the - - O
occipital - - O
condyle - - O
reverses - - O
its - - O
direction - - O
at - - O
about - - O
25 - - O
ms - - O
after - - O
impact - - O
. - - O

Mutations - - O
of - - O
the - - O
RET - - B-MUT
gene - - I-MUT
, - - O
encoding - - O
a - - O
receptor - - B-MUT
tyrosine - - I-MUT
kinase - - I-MUT
, - - O
have - - O
been - - O
associated - - O
with - - O
the - - O
inherited - - O
cancer - - O
syndromes - - O
MEN - - O
2A - - O
and - - O
MEN - - O
2B - - O
. - - O

Analyses - - O
revealed - - O
that - - O
scale - - O
matters - - O
above - - O
and - - O
beyond - - O
the - - O
effect - - O
of - - O
quadrat - - O
area - - O
. - - O

The - - O
topology - - O
and - - O
chain - - O
folding - - O
of - - O
the - - O
beta - - O
subunits - - O
in - - O
the - - O
artifactual - - O
beta - - O
60 - - O
capsid - - O
are - - O
similar - - O
to - - O
the - - O
native - - B-MUT
alpha - - I-MUT
3 - - I-MUT
beta - - I-MUT
60 - - I-MUT
enzyme - - I-MUT
. - - O

Northern - - O
blot - - O
analysis - - O
, - - O
using - - O
the - - O
Ltp4-specific - - O
probe - - O
, - - O
indicated - - O
that - - O
Xanthomonas - - O
campestris - - O
pv - - O
. - - O
translucens - - O
induced - - O
an - - O
increase - - O
over - - O
basal - - O
levels - - O
of - - O
Ltp4 - - B-MUT
mRNA - - I-MUT
, - - O
while - - O
Pseudomonas - - O
syringae - - O
pv - - O
. - - O
japonica - - O
caused - - O
a - - O
decrease - - O
. - - O

Together - - O
, - - O
these - - O
data - - O
identify - - O
ERK2 - - B-MUT
as - - O
a - - O
specific - - O
and - - O
direct - - O
target - - O
of - - O
HePTP - - B-MUT
and - - O
are - - O
consistent - - O
with - - O
a - - O
model - - O
in - - O
which - - O
HePTP - - B-MUT
negatively - - O
regulates - - O
ERK2 - - B-MUT
activity - - O
as - - O
part - - O
of - - O
a - - O
feedback - - O
mechanism - - O
. - - O

UV - - O
cross-linking - - O
experiments - - O
demonstrated - - O
that - - O
HSV - - O
infection - - O
caused - - O
enhanced - - O
binding - - O
of - - O
protein - - O
factors - - O
, - - O
including - - O
the - - O
64-kDa - - B-MUT
component - - I-MUT
of - - I-MUT
cleavage - - I-MUT
stimulation - - I-MUT
factor - - I-MUT
( - - O
CstF - - B-MUT
) - - O
, - - O
to - - O
poly - - O
( - - O
A - - O
) - - O
site - - O
RNAs - - O
from - - O
virus - - O
genes - - O
of - - O
all - - O
temporal - - O
classes - - O
and - - O
that - - O
this - - O
enhanced - - O
binding - - O
required - - O
expression - - O
of - - O
IE63 - - B-MUT
. - - O

However - - O
, - - O
little - - O
was - - O
understood - - O
about - - O
the - - O
normal - - O
function - - O
of - - O
CREB-2 - - B-MUT
in - - O
mammalian - - O
development - - O
or - - O
organ - - O
physiology - - O
. - - O

Follow-up - - O
study - - O
showed - - O
85% - - O
of - - O
these - - O
patients - - O
with - - O
effectiveness - - O
. - - O

In - - O
order - - O
to - - O
gain - - O
deeper - - O
insight - - O
into - - O
the - - O
role - - O
of - - O
the - - O
amino-terminal - - O
domain - - O
of - - O
the - - O
p24 - - B-MUT
( - - I-MUT
CA - - I-MUT
) - - I-MUT
protein - - O
during - - O
viral - - O
replication - - O
, - - O
eight - - O
highly - - O
conserved - - O
proline - - O
residues - - O
known - - O
to - - O
promote - - O
turns - - O
and - - O
to - - O
terminate - - O
alpha-helices - - O
within - - O
the - - O
p24 - - B-MUT
tertiary - - O
structure - - O
were - - O
replaced - - O
by - - O
a - - O
leucine - - O
residue - - O
( - - O
P-position-L - - O
) - - O
. - - O

However - - O
, - - O
when - - O
directed - - O
to - - O
the - - O
nucleosome - - O
by - - O
fusion - - O
to - - O
core - - B-MUT
histone - - I-MUT
H2A - - I-MUT
or - - O
H2B - - B-MUT
, - - O
the - - O
non-histone - - O
tail - - O
forms - - O
an - - O
MCB - - O
that - - O
appears - - O
identical - - O
to - - O
that - - O
of - - O
the - - O
endogenous - - O
protein - - O
. - - O

A - - O
novel - - O
growth-related - - O
nuclear - - O
protein - - O
binds - - O
and - - O
inhibits - - O
rat - - O
aldolase - - B-MUT
B - - I-MUT
gene - - I-MUT
promoter - - O
. - - O

The - - O
investigation - - O
was - - O
apt - - O
at - - O
studying - - O
the - - O
relationship - - O
between - - O
urinary - - O
metabolites - - O
of - - O
serotonin - - O
and - - O
catecholamine - - O
( - - O
5-HIAA - - O
and - - O
VMA - - O
) - - O
, - - O
T-cells - - O
( - - O
OKT3+ - - B-MUT
) - - O
, - - O
T-helper - - O
( - - O
OKT4+ - - B-MUT
) - - O
, - - O
T-suppressor - - O
( - - O
OKT8+ - - B-MUT
) - - O
and - - O
B-cells - - O
( - - O
EAC-rosette - - O
forming - - O
cells - - O
) - - O
in - - O
normal - - O
( - - O
10 - - O
subjects - - O
, - - O
1 - - O
female - - O
, - - O
9 - - O
male - - O
, - - O
age - - O
21 - - O
+ - - O
- - - O
5 - - O
years - - O
) - - O
and - - O
stress - - O
administered - - O
subjects - - O
( - - O
20 - - O
subjects - - O
, - - O
3 - - O
female - - O
, - - O
17 - - O
male - - O
, - - O
age - - O
20 - - O
+ - - O
- - - O
4 - - O
years - - O
) - - O
. - - O

During - - O
the - - O
following - - O
pregnancy - - O
ultrasonographic - - O
studies - - O
of - - O
the - - O
male - - O
fetus - - O
in - - O
the - - O
16th - - O
week - - O
of - - O
gestation - - O
revealed - - O
severe - - O
micrognathia - - O
, - - O
short - - O
and - - O
wide - - O
thumbs - - O
, - - O
and - - O
big - - O
toes - - O
, - - O
and - - O
bowed - - O
tibiae - - O
. - - O

Bacteriostatic - - O
and - - O
bacteriacidal - - O
activity - - O
of - - O
hydroxy-9 - - O
ellipticine - - O
in - - O
vitro - - O
. - - O

A - - O
cDNA - - O
clone - - O
was - - O
isolated - - O
from - - O
a - - O
chicken - - O
embryo - - O
cDNA - - O
library - - O
employing - - O
a - - O
PCR-generated - - O
radiolabeled - - O
probe - - O
specific - - O
for - - O
the - - O
U3 - - B-MUT
region - - I-MUT
of - - O
the - - O
Rous - - O
sarcoma - - O
virus - - O
LTR - - O
. - - O

Finally - - O
, - - O
there - - O
are - - O
a - - O
growing - - O
number - - O
of - - O
arguments - - O
favouring - - O
the - - O
use - - O
of - - O
ACE - - B-MUT
inhibitors - - O
very - - O
early - - O
in - - O
patients - - O
with - - O
diabetes - - O
mellitus - - O
. - - O

5 - - O
micrograms - - O
l - - O
was - - O
detected - - O
in - - O
urine - - O
from - - O
some - - O
non-occupationally - - O
exposed - - O
persons - - O
. - - O

Lipiodol - - O
was - - O
covalently - - O
conjugated - - O
with - - O
EDTB - - O
. - - O

Transfection - - O
of - - O
HepG2 - - O
and - - O
SK-N-MC - - O
cells - - O
with - - O
constructs - - O
deleted - - O
of - - O
additional - - O
5'-flanking - - O
fragments - - O
permitted - - O
the - - O
definition - - O
of - - O
a - - O
minimal - - O
200 - - O
bp - - O
promoter - - O
fragment - - O
containing - - O
the - - O
pseudo-TATA - - O
box - - O
and - - O
two - - O
putative - - O
SP1-binding - - B-MUT
sites - - I-MUT
. - - O

Comparison - - O
of - - O
cDNA - - O
and - - O
genomic - - O
sequences - - O
shows - - O
that - - O
the - - O
ZNF189 - - B-MUT
gene - - I-MUT
spans - - O
approximately - - O
11 - - O
kb - - O
and - - O
is - - O
organized - - O
into - - O
at - - O
least - - O
four - - O
exons - - O
, - - O
the - - O
large - - O
3'-end - - O
exon - - O
coding - - O
for - - O
the - - O
complete - - O
zinc - - O
finger - - O
domain - - O
and - - O
the - - O
3' - - O
untranslated - - O
region - - O
. - - O

86 - - O
: - - O
3199-3203 - - O
) - - O
or - - O
G1 - - O
to - - O
S - - O
phase - - O
( - - O
Reilly - - O
, - - O
C - - O
. - - O

Mutations - - O
truncating - - O
as - - O
many - - O
as - - O
143 - - O
C-terminal - - O
residues - - O
from - - O
the - - O
transcriptional - - O
activator - - O
encoded - - O
by - - O
the - - O
areA - - B-MUT
gene - - I-MUT
, - - O
mediating - - O
nitrogen - - O
metabolite - - O
repression - - O
in - - O
Aspergillus - - O
nidulans - - O
, - - O
do - - O
not - - O
significantly - - O
reduce - - O
the - - O
ability - - O
of - - O
the - - O
areA - - B-MUT
product - - I-MUT
to - - O
activate - - O
expression - - O
of - - O
most - - O
genes - - O
under - - O
areA - - B-MUT
control - - O
. - - O

However - - O
, - - O
we - - O
identified - - O
a - - O
gene - - O
between - - O
the - - O
MDV2 - - B-MUT
UL54 - - I-MUT
and - - O
UL55 - - B-MUT
genes - - I-MUT
with - - O
homology - - O
to - - O
the - - O
first - - O
ORF - - O
( - - O
ORF-1 - - B-MUT
) - - O
of - - O
equine - - O
herpesvirus - - O
type - - O
1 - - O
and - - O
corresponding - - O
gene - - O
identified - - O
in - - O
pseudorabies - - O
virus - - O
. - - O

Using - - O
lectin-affinity - - O
chromatography - - O
, - - O
discordance - - O
between - - O
the - - O
pattern - - O
of - - O
O-glycosylation - - O
of - - O
SSBP - - B-MUT
and - - O
DSBP - - B-MUT
was - - O
demonstrated - - O
. - - O

The - - O
first - - O
case - - O
of - - O
HCV - - O
seroconversion - - O
in - - O
Portugal - - O
after - - O
the - - O
introduction - - O
of - - O
HCV - - O
NAT - - O
screening - - O
. - - O

Analysis - - O
of - - O
hematopoietic - - B-MUT
growth - - I-MUT
factor - - I-MUT
prescriptions - - O
in - - O
19 - - O
french - - O
cancer - - O
centers - - O
. - - O

The - - O
mechanism - - O
underlying - - O
such - - O
analgesia - - O
has - - O
been - - O
suggested - - O
to - - O
involve - - O
the - - O
interaction - - O
between - - O
the - - O
two - - O
separate - - O
but - - O
interconnected - - O
motivational - - O
systems - - O
"defense" - - O
and - - O
"pain - - O
. - - O
" - - O
To - - O
determine - - O
the - - O
developmental - - O
course - - O
of - - O
defense - - O
and - - O
nociception - - O
, - - O
these - - O
processes - - O
were - - O
analyzed - - O
during - - O
early - - O
ontogeny - - O
in - - O
rats - - O
. - - O

By - - O
in - - O
vitro - - O
immunoprecipitations - - O
and - - O
gel - - O
shift - - O
assays - - O
, - - O
we - - O
identified - - O
two - - O
classes - - O
of - - O
high - - O
affinity - - O
Engrailed-binding - - B-MUT
sites - - I-MUT
upstream - - O
of - - O
each - - O
of - - O
the - - O
two - - O
polyhomeotic - - O
transcription - - O
units - - O
. - - O

From - - O
our - - O
ultrastructural - - O
and - - O
biochemical - - O
studies - - O
, - - O
it - - O
is - - O
evident - - O
that - - O
Type - - O
II - - O
pneumocytes - - O
are - - O
an - - O
early - - O
target - - O
of - - O
radiation - - O
and - - O
the - - O
release - - O
of - - O
surfactant - - O
into - - O
the - - O
alveolus - - O
shortly - - O
after - - O
exposure - - O
persists - - O
for - - O
days - - O
and - - O
weeks - - O
. - - O

METHODS - - O
: - - O
Experiments - - O
testing - - O
the - - O
new - - O
catheter - - O
and - - O
comparing - - O
it - - O
to - - O
the - - O
existing - - O
catheter - - O
included - - O
: - - O
( - - O
1 - - O
) - - O
measurement - - O
of - - O
the - - O
laser - - O
output - - O
beam - - O
sizes - - O
and - - O
divergences - - O
; - - O
( - - O
2 - - O
) - - O
evaluation - - O
of - - O
particulate - - O
matter - - O
generation - - O
during - - O
ablation - - O
of - - O
atherosclerotic - - O
tissue - - O
; - - O
( - - O
3 - - O
) - - O
measurement - - O
of - - O
ablation - - O
hole - - O
sizes - - O
and - - O
tissue - - O
penetration - - O
rates - - O
; - - O
( - - O
4 - - O
) - - O
histopathologic - - O
examination - - O
of - - O
laser-induced - - O
in - - O
vivo - - O
vessel - - O
wall - - O
injury - - O
. - - O

Treatment - - O
of - - O
suppurative - - O
peritonitis - - O
. - - O

In - - O
Experiment - - O
2 - - O
scopolamine - - O
hydrobromide - - O
, - - O
0 - - O
. - - O
5 - - O
and - - O
1 - - O
. - - O
0 - - O
mg - - O
kg - - O
i - - O
. - - O
p - - O
. - - O
, - - O
was - - O
administered - - O
1 - - O
h - - O
before - - O
each - - O
electrical - - O
stimulation - - O
until - - O
each - - O
rat - - O
showed - - O
the - - O
stage-3 - - O
seizure - - O
. - - O

In - - O
the - - O
clinical - - O
study - - O
, - - O
the - - O
defect - - O
size - - O
shown - - O
by - - O
BMIPP - - O
imaging - - O
was - - O
greater - - O
in - - O
anterior - - O
than - - O
in - - O
inferior - - O
infarcts - - O
( - - O
p - - O
< - - O
0 - - O
. - - O
001 - - O
) - - O
and - - O
correlated - - O
well - - O
with - - O
the - - O
risk - - O
area - - O
revealed - - O
by - - O
contrast - - O
ventriculography - - O
( - - O
r - - O
= - - O
0 - - O
. - - O
80 - - O
, - - O
p - - O
< - - O
0 - - O
. - - O
0001 - - O
) - - O
CONCLUSION - - O
: - - O
The - - O
above - - O
preliminary - - O
data - - O
, - - O
admittedly - - O
from - - O
a - - O
small - - O
group - - O
of - - O
patients - - O
, - - O
suggest - - O
that - - O
tomographic - - O
BMIPP - - O
imaging - - O
provides - - O
an - - O
accurate - - O
quantification - - O
of - - O
defect - - O
size - - O
by - - O
means - - O
of - - O
a - - O
simple - - O
threshold - - O
technique - - O
and - - O
, - - O
in - - O
the - - O
subacute - - O
phase - - O
, - - O
permits - - O
determination - - O
of - - O
the - - O
amount - - O
of - - O
myocardium - - O
at - - O
risk - - O
after - - O
acute - - O
myocardial - - O
infarction - - O
. - - O

Nucleotide - - O
sequence - - O
analysis - - O
of - - O
the - - O
HA - - B-MUT
gene - - I-MUT
in - - O
these - - O
two - - O
mutants - - O
confirmed - - O
the - - O
HA- - - B-MUT
phenotype - - O
. - - O

Characterization - - O
of - - O
FIII - - B-MUT
YY1 - - O
, - - B-MUT
a - - O
Xenopus - - O
laevis - - O
conserved - - O
zinc-finger - - O
protein - - O
binding - - O
to - - O
the - - O
first - - O
exon - - O
of - - O
L1 - - O
and - - B-MUT
L14 - - O
ribosomal - - B-MUT
protein - - I-MUT
genes - - I-MUT
. - - I-MUT

This - - O
binary - - O
repeat - - O
contains - - O
repetitive - - O
DNA - - O
elements - - O
that - - O
include - - O
LINES - - O
, - - O
SINES - - O
, - - O
medium - - O
reiteration - - O
frequency - - O
repeats - - O
, - - O
and - - O
a - - O
transposon-like - - O
element - - O
. - - O

Corticosteroid-mediated - - O
transcriptional - - O
inhibition - - O
was - - O
greater - - O
for - - O
MR - - B-MUT
GR - - I-MUT
in - - I-MUT
combination - - O
than - - O
for - - O
MR - - O
or - - B-MUT
GR - - O
alone - - B-MUT
. - - O

The - - O
other - - O
model - - O
was - - O
a - - O
continuous - - O
exponential - - O
plus - - O
constant - - O
of - - O
the - - O
form - - O
La- - - O
= - - O
a - - O
+ - - O
b - - O
[ - - O
exp - - O
( - - O
cVO2 - - O
) - - O
] - - O
. - - O

DESIGN--A - - O
randomised - - O
study - - O
was - - O
conducted - - O
in - - O
all - - O
women - - O
aged - - O
50-70 - - O
years - - O
who - - O
were - - O
eligible - - O
for - - O
breast - - O
cancer - - O
screening - - O
and - - O
living - - O
in - - O
the - - O
city - - O
of - - O
Utrecht - - O
. - - O

Interestingly - - O
, - - O
dTFIIA-L - - B-MUT
S - - I-MUT
is - - I-MUT
also - - O
able - - O
to - - O
significantly - - O
enhance - - O
transcriptional - - O
activation - - O
by - - O
upstream - - O
transcription - - O
factors - - O
including - - O
Sp1 - - O
, - - B-MUT
VP16 - - O
, - - B-MUT
and - - O
NTF-1 - - O
. - - B-MUT

A - - O
"Level - - O
A" - - O
in - - O
vitro - - O
in - - O
vivo - - O
correlation - - O
was - - O
established - - O
for - - O
a - - O
sustained - - O
release - - O
theophylline - - O
( - - O
CAS - - O
58-55-9 - - O
) - - O
preparation - - O
( - - O
Bronchoretard - - O
) - - O
under - - O
investigation - - O
. - - O

The - - O
most - - O
frequent - - O
risk - - O
factor - - O
for - - O
ischaemic - - O
was - - O
hypertension - - O
. - - O

Prostate-specific - - B-MUT
antigen - - I-MUT
( - - O
PSA - - B-MUT
) - - O
promoter-driven - - O
androgen-inducible - - O
expression - - O
of - - O
sodium - - B-MUT
iodide - - I-MUT
symporter - - I-MUT
in - - O
prostate - - O
cancer - - O
cell - - O
lines - - O
. - - O

In - - O
addition - - O
, - - O
npm3 - - B-MUT
, - - O
which - - O
is - - O
usually - - O
coactivated - - O
with - - O
fgf8 - - B-MUT
by - - O
MMTV - - O
insertion - - O
, - - O
was - - O
not - - O
up-regulated - - O
by - - O
androgens - - O
in - - O
SC-3 - - O
cells - - O
. - - O

Prostaglandin - - O
synthesis - - O
inhibitors - - O
have - - O
been - - O
shown - - O
to - - O
delay - - O
healing - - O
of - - O
bone - - O
and - - O
this - - O
has - - O
led - - O
to - - O
limitations - - O
on - - O
their - - O
use - - O
clinically - - O
in - - O
some - - O
situations - - O
. - - O

Here - - O
we - - O
show - - O
that - - O
independent - - O
of - - O
uncertainties - - O
in - - O
the - - O
models - - O
, - - O
terrestrial - - O
planets - - O
with - - O
dense - - O
atmosphere - - O
like - - O
Venus - - O
can - - O
evolve - - O
into - - O
one - - O
of - - O
only - - O
four - - O
possible - - O
rotation - - O
states - - O
. - - O

Elimination - - O
of - - O
ETH1 - - B-MUT
in - - O
apn1 - - B-MUT
strains - - O
also - - O
increased - - O
spontaneous - - O
mutation - - O
rates - - O
9- - - O
or - - O
31-fold - - O
compared - - O
to - - O
the - - O
wild - - O
type - - O
as - - O
determined - - O
by - - O
reversion - - O
to - - O
adenine - - O
or - - O
lysine - - O
prototrophy - - O
, - - O
respectively - - O
. - - O

In - - O
flies - - O
, - - O
the - - O
dShc - - B-MUT
protein - - I-MUT
physically - - O
associates - - O
with - - O
the - - O
activated - - O
Drosophila - - B-MUT
epidermal - - I-MUT
growth - - I-MUT
factor - - I-MUT
receptor - - I-MUT
homolog - - I-MUT
( - - O
DER - - B-MUT
) - - O
and - - O
is - - O
inducibly - - O
phosphorylated - - O
on - - O
tyrosine - - O
by - - O
DER - - B-MUT
. - - O

FEV1 - - O
did - - O
not - - O
fall - - O
significantly - - O
in - - O
patients - - O
without - - O
acute - - O
or - - O
chronic - - O
GVHD - - O
and - - O
recovered - - O
earlier - - O
than - - O
in - - O
patients - - O
without - - O
posttransplant - - O
pulmonary - - O
infection - - O
. - - O

Helicobacter - - O
pylori - - O
and - - O
stomach - - O
diseases - - O
: - - O
from - - O
clinical - - O
point - - O
of - - O
view - - O

Its - - O
cognate - - O
binding - - O
protein - - O
, - - O
REST - - B-MUT
NRSF - - I-MUT
, - - I-MUT
is - - O
an - - O
essential - - O
transcription - - O
factor - - O
; - - O
its - - O
null - - O
mutations - - O
result - - O
in - - O
embryonic - - O
lethality - - O
, - - O
and - - O
its - - O
dominant - - O
negative - - O
mutants - - O
produce - - O
aberrant - - O
expression - - O
of - - O
neuron-specific - - O
genes - - O
. - - O

These - - O
two - - O
repeat - - O
motifs - - O
are - - O
organized - - O
in - - O
an - - O
extremely - - O
well-ordered - - O
pattern - - O
in - - O
each - - O
domain - - O
, - - O
which - - O
suggests - - O
that - - O
SbHRGP3 - - B-MUT
belongs - - O
to - - O
a - - O
new - - O
group - - O
of - - O
proteins - - O
having - - O
the - - O
repeat - - O
motifs - - O
of - - O
two - - O
distinct - - O
groups - - O
of - - O
dicot - - B-MUT
extensins - - I-MUT
. - - O

Here - - O
, - - O
we - - O
show - - O
that - - O
the - - O
zinc - - B-MUT
finger - - I-MUT
protein - - I-MUT
Gis1 - - I-MUT
acts - - O
as - - O
a - - O
dosage-dependent - - O
suppressor - - O
of - - O
the - - O
rim15Delta - - B-MUT
defect - - O
in - - O
nutrient - - O
limitation-induced - - O
transcriptional - - O
derepression - - O
of - - O
SSA3 - - B-MUT
. - - O

Rho - - B-MUT
GDP - - I-MUT
GTP - - I-MUT
exchange - - I-MUT
inhibitor - - I-MUT
, - - I-MUT
Rho - - O
GDI - - B-MUT
, - - I-MUT
comigrated - - O
with - - O
Rac2 - - O
and - - B-MUT
RhoA - - O
, - - B-MUT
but - - O
not - - O
Rac1 - - O
. - - B-MUT

Angina - - O
haemorrhagica - - O
bullosa - - O
causing - - O
respiratory - - O
obstruction - - O
postoperatively - - O
. - - O

In - - O
this - - O
study - - O
, - - O
we - - O
have - - O
cloned - - O
the - - O
5'-flanking - - O
region - - O
of - - O
the - - O
human - - B-MUT
nidogen - - I-MUT
gene - - I-MUT
. - - O

Phagocytosis - - O
of - - O
tubercle - - O
bacilli - - O
by - - O
macrophages - - O
. - - O

Acad - - O
. - - O

A - - O
mutant - - O
( - - O
residues - - O
1-332 - - O
) - - O
showed - - O
complete - - O
Ca2+ - - O
CaM-dependent - - O
activity - - O
. - - O

A - - O
statistically - - O
significant - - O
improvement - - O
due - - O
to - - O
the - - O
administration - - O
of - - O
Bromergon - - O
was - - O
observed - - O
in - - O
symptoms - - O
associated - - O
with - - O
overreactiveness - - O
to - - O
normal - - O
prolactin - - B-MUT
levels - - O
, - - O
i - - O
. - - O
e - - O
. - - O
abdominal - - O
tension - - O
, - - O
edema - - O
, - - O
weight - - O
gain - - O
and - - O
breast - - O
tenderness - - O
. - - O

Structural - - O
organization - - O
and - - O
developmental - - O
expression - - O
pattern - - O
of - - O
the - - O
mouse - - B-MUT
WD-repeat - - I-MUT
gene - - I-MUT
DMR-N9 - - I-MUT
immediately - - O
upstream - - O
of - - O
the - - O
myotonic - - B-MUT
dystrophy - - I-MUT
locus - - I-MUT
. - - O

Visual - - O
averaged - - O
evoked - - O
responses - - O
and - - O
platelet - - B-MUT
monoamine - - I-MUT
oxidase - - I-MUT
in - - O
patients - - O
suffering - - O
from - - O
alcoholism - - O
. - - O

Notice - - O
of - - O
retraction - - O
. - - O

Anisotropic - - O
heat - - O
transport - - O
in - - O
the - - O
octylcyanobiphenyl - - O
( - - O
8CB - - O
) - - O
liquid - - O
crystal - - O
. - - O

In - - O
this - - O
study - - O
, - - O
evidence - - O
is - - O
presented - - O
that - - O
temporally - - O
and - - O
spatially - - O
specific - - O
mef2 - - B-MUT
expression - - O
is - - O
controlled - - O
by - - O
a - - O
complex - - O
array - - O
of - - O
cis-acting - - O
regulatory - - O
modules - - O
that - - O
are - - O
responsive - - O
to - - O
different - - O
genetic - - O
signals - - O
. - - O

BACKGROUND - - O
: - - O
We - - O
hypothesized - - O
that - - O
the - - O
postoperative - - O
serum - - O
level - - O
of - - O
TA90-IC - - B-MUT
, - - O
an - - O
immune - - O
complex - - O
of - - O
a - - O
90-kDa - - O
tumor-associated - - O
antigen - - O
and - - O
its - - O
antibody - - O
, - - O
might - - O
have - - O
a - - O
significant - - O
correlation - - O
with - - O
recurrence - - O
and - - O
survival - - O
in - - O
patients - - O
with - - O
thick - - O
primary - - O
melanomas - - O
. - - O

Tolerance - - O
test - - O
of - - O
HB - - O
419 - - O
in - - O
animal - - O
experiments - - O
. - - O

The - - O
present - - O
data - - O
also - - O
demonstrate - - O
that - - O
ectopic - - O
expression - - O
of - - O
blr1 - - B-MUT
increased - - O
JNK - - B-MUT
SAPK - - I-MUT
activity - - I-MUT
, - - O
but - - O
JNK - - O
SAPK - - B-MUT
activation - - I-MUT
was - - B-MUT
not - - O
needed - - O
for - - O
accelerated - - O
RA-induced - - O
differentiation - - O
and - - O
growth - - O
arrest - - O
. - - O

Structure - - O
of - - O
the - - O
EMAPII - - B-MUT
domain - - I-MUT
of - - O
human - - B-MUT
aminoacyl-tRNA - - I-MUT
synthetase - - I-MUT
complex - - I-MUT
reveals - - O
evolutionary - - O
dimer - - O
mimicry - - O
. - - O

To - - O
identify - - O
nuclear - - O
regulatory - - O
factors - - O
, - - O
we - - O
have - - O
located - - O
and - - O
functionally - - O
characterized - - O
the - - O
CCR5 - - B-MUT
gene - - I-MUT
promoter - - I-MUT
. - - O

Effects - - O
of - - O
estradiol - - O
on - - O
worm - - O
burden - - O
and - - O
peripheral - - O
leukocytes - - O
in - - O
Parastrongylus - - O
malaysiensis-infected - - O
rats - - O
. - - O

The - - O
protein - - O
expressed - - O
by - - O
F2771 - - B-MUT
cDNA - - I-MUT
in - - O
transfected - - O
COS - - O
cells - - O
is - - O
localized - - O
in - - O
the - - O
cytoplasm - - O
. - - O

No - - O
mutations - - O
were - - O
found - - O
in - - O
follicular - - O
adenomas - - O
. - - O

Pax-3 - - B-MUT
is - - O
a - - O
paired-type - - B-MUT
homeobox - - I-MUT
gene - - I-MUT
that - - O
is - - O
specifically - - O
expressed - - O
in - - O
the - - O
dorsal - - O
and - - O
posterior - - O
neural - - O
tube - - O
. - - O

The - - O
present - - O
study - - O
sought - - O
to - - O
develop - - O
an - - O
equation - - O
to - - O
estimate - - O
VO2peak - - O
in - - O
peripheral - - O
arterial - - O
occlusive - - O
disease - - O
( - - O
PAOD - - O
) - - O
patients - - O
with - - O
intermittent - - O
claudication - - O
and - - O
to - - O
determine - - O
independent - - O
predictors - - O
of - - O
VO2peak - - O
in - - O
this - - O
population - - O
. - - O

The - - O
predominant - - O
sensitizing - - O
allergens - - O
in - - O
Swedish - - O
asthmatic - - O
children - - O
are - - O
furred - - O
pet - - O
animals - - O
. - - O

There - - O
were - - O
45 - - O
to - - O
56 - - O
nt - - O
differences - - O
between - - O
the - - O
virulent - - O
and - - O
avirulent - - O
groups - - O
while - - O
there - - O
were - - O
6 - - O
to - - O
14 - - O
nt - - O
differences - - O
among - - O
four - - O
avirulent - - O
strains - - O
. - - O

These - - O
data - - O
demonstrate - - O
that - - O
DMVA - - O
does - - O
not - - O
cause - - O
more - - O
myocardial - - O
trauma - - O
than - - O
CPB - - O
when - - O
used - - O
to - - O
provide - - O
resuscitative - - O
circulatory - - O
support - - O
. - - O

This - - O
night-day - - O
oscillation - - O
is - - O
driven - - O
by - - O
the - - O
endogenous - - O
clock - - O
( - - O
located - - O
in - - O
the - - O
suprachiasmatic - - O
nucleus - - O
, - - O
SCN - - O
) - - O
. - - O

Magnetically - - O
induced - - O
optical - - O
self-pulsing - - O
in - - O
a - - O
nonlinear - - O
resonator - - O
. - - O

Furthermore - - O
, - - O
transfection - - O
of - - O
cells - - O
with - - O
the - - O
spacer-RING - - O
domain - - O
alone - - O
suppressed - - O
the - - O
antiapoptotic - - O
function - - O
of - - O
the - - O
N-terminal - - O
BIR - - O
domain - - O
of - - O
c-IAP1 - - B-MUT
and - - O
induced - - O
apoptosis - - O
. - - O

Factors - - O
associated - - O
with - - O
intrafamilial - - O
transmission - - O
of - - O
hepatitis - - O
B - - O
virus - - O
infection - - O
in - - O
Korea - - O
. - - O

N-terminal - - O
sequence - - O
analysis - - O
and - - O
NMR - - O
measurements - - O
revealed - - O
that - - O
this - - O
fragment - - O
originates - - O
from - - O
the - - O
C-terminal - - O
80 - - O
residues - - O
of - - O
MBF1 - - B-MUT
and - - O
form - - O
a - - O
well - - O
structured - - O
C-terminal - - O
domain - - O
of - - O
MBF1 - - B-MUT
, - - O
MBF1CTD - - B-MUT
. - - O

Involvement - - O
of - - O
early - - B-MUT
growth - - I-MUT
response - - I-MUT
factor - - I-MUT
Egr-1 - - I-MUT
in - - O
apolipoprotein - - B-MUT
AI - - I-MUT
gene - - I-MUT
transcription - - O
. - - O

Eight - - O
rabbits - - O
were - - O
exposed - - O
to - - O
0 - - O
. - - O
7 - - O
+ - - O
- - - O
0 - - O
. - - O
4 - - O
mg - - O
m3 - - O
Co2+ - - O
as - - O
CoCl2 - - O
and - - O
1 - - O
. - - O
2 - - O
+ - - O
- - - O
0 - - O
. - - O
7 - - O
mg - - O
m3 - - O
Cr3+ - - O
as - - O
Cr - - O
( - - O
NO3 - - O
) - - O
3 - - O
( - - O
group - - O
Co - - O
+ - - O
Cr - - O
) - - O
, - - O
eight - - O
to - - O
0 - - O
. - - O
6 - - O
+ - - O
- - - O
0 - - O
. - - O
5 - - O
mg - - O
m3 - - O
Co2+ - - O
( - - O
group - - O
Co - - O
) - - O
, - - O
and - - O
eight - - O
to - - O
filtered - - O
air - - O
( - - O
control - - O
group - - O
) - - O
, - - O
for - - O
4 - - O
months - - O
, - - O
5 - - O
days - - O
week - - O
, - - O
and - - O
6 - - O
hr - - O
day - - O
. - - O

From - - O
life-table - - O
analyses - - O
of - - O
these - - O
patients - - O
, - - O
we - - O
estimated - - O
that - - O
the - - O
incidence - - O
of - - O
secondary - - O
chondrosarcoma - - O
in - - O
patients - - O
who - - O
have - - O
Ollier - - O
disease - - O
is - - O
about - - O
25 - - O
per - - O
cent - - O
at - - O
the - - O
age - - O
of - - O
forty - - O
years - - O
, - - O
and - - O
that - - O
malignant - - O
degeneration - - O
is - - O
almost - - O
a - - O
certainty - - O
in - - O
patients - - O
who - - O
have - - O
Maffucci - - O
syndrome - - O
. - - O

Reagent - - O
strips - - O
are - - O
frequently - - O
used - - O
in - - O
the - - O
practice - - O
of - - O
laboratory - - O
medicine - - O
as - - O
well - - O
as - - O
outside - - O
the - - O
professional - - O
laboratories - - O
. - - O

Having - - O
an - - O
LRR - - B-MUT
domain - - I-MUT
and - - O
an - - O
SH3-binding - - B-MUT
domain - - I-MUT
, - - O
Acan125 - - B-MUT
and - - O
the - - O
C - - O
. - - O
elegans - - O
homologue - - O
define - - O
a - - O
novel - - O
family - - O
of - - O
bifunctional - - O
binding - - O
proteins - - O
. - - O

The - - O
newly - - O
recognised - - O
skeletogenital - - O
syndrome - - O
. - - O

Valuing - - O
families - - O
: - - O
social - - O
work - - O
practice - - O
with - - O
families - - O
from - - O
a - - O
strengths - - O
perspective - - O
. - - O

The - - O
Psc2 - - B-MUT
cDNA - - I-MUT
contained - - O
an - - O
open - - O
reading - - O
frame - - O
homologous - - O
to - - O
CP2 - - B-MUT
family - - I-MUT
proteins - - I-MUT
. - - O

These - - O
data - - O
show - - O
that - - O
PTH - - B-MUT
and - - O
cAMP - - O
can - - O
repress - - O
collagen - - B-MUT
promoter - - I-MUT
activity - - O
in - - O
calvariae - - O
from - - O
transgenic - - O
mice - - O
, - - O
suggesting - - O
that - - O
the - - O
alpha - - B-MUT
1 - - I-MUT
( - - I-MUT
I - - I-MUT
) - - I-MUT
collagen - - I-MUT
promoter - - I-MUT
may - - O
contain - - O
cis - - O
elements - - O
down-stream - - O
of - - O
-2 - - O
. - - O
3 - - O
kilobases - - O
that - - O
mediate - - O
PTH - - B-MUT
and - - O
cAMP - - O
repression - - O
of - - O
collagen - - B-MUT
gene - - I-MUT
expression - - O
in - - O
bone - - O
. - - O

Mean - - O
corpuscular - - B-MUT
hemoglobin - - I-MUT
concentrations - - O
remained - - O
normal - - O
for - - O
48 - - O
h - - O
and - - O
then - - O
decreased - - O
in - - O
both - - O
groups - - O
, - - O
the - - O
CO2 - - O
group - - O
showing - - O
the - - O
larger - - O
decrease - - O
. - - O

The - - O
aim - - O
of - - O
our - - O
study - - O
was - - O
to - - O
evaluate - - O
the - - O
level - - O
of - - O
oxidative - - O
stress - - O
in - - O
healthy - - O
controls - - O
( - - O
CTL - - O
) - - O
compared - - O
with - - O
CRF - - O
and - - O
HD - - O
patients - - O
before - - O
( - - O
pre-HD - - O
) - - O
and - - O
after - - O
( - - O
post-HD - - O
) - - O
the - - O
dialysis - - O
session - - O
, - - O
carried - - O
out - - O
on - - O
a - - O
high - - O
biocompatible - - O
polyacrylonitrile - - O
membrane - - O
AN69 - - O
. - - O

Effects - - O
of - - O
methiothepin - - O
and - - O
lysergic - - O
acid - - O
diethylamide - - O
on - - O
serotonin - - O
release - - O
in - - O
vitro - - O
and - - O
serotonin - - O
synthesis - - O
in - - O
vivo - - O
: - - O
possible - - O
relation - - O
to - - O
serotonin - - B-MUT
autoreceptor - - I-MUT
function - - O
. - - O

Rabbit - - O
eyes - - O
were - - O
removed - - O
and - - O
held - - O
in - - O
temperature-regulated - - O
chambers - - O
and - - O
irrigated - - O
with - - O
saline - - O
. - - O

In - - O
contrast - - O
to - - O
the - - O
myoD - - B-MUT
promoter - - I-MUT
, - - O
the - - O
myoD - - B-MUT
enhancer - - I-MUT
shows - - O
striking - - O
conservation - - O
between - - O
humans - - O
and - - O
mice - - O
both - - O
in - - O
its - - O
sequence - - O
and - - O
its - - O
distal - - O
position - - O
. - - O

Serum - - B-MUT
beta - - I-MUT
2-microglobulin - - I-MUT
levels - - O
( - - O
beta-2-M - - B-MUT
) - - O
were - - O
studied - - O
in - - O
150 - - O
drug - - O
addicts - - O
, - - O
50 - - O
of - - O
them - - O
asymptomatic - - O
carriers - - O
of - - O
anti - - B-MUT
HIV-1 - - I-MUT
antibodies - - I-MUT
, - - O
50 - - O
symptomatic - - O
carriers - - O
with - - O
persistent - - O
generalized - - O
lymphadenopathy - - O
( - - O
P - - O
. - - O
G - - O
. - - O
L - - O
. - - O
) - - O
and - - O
50 - - O
serum - - O
negative - - O
patients - - O
who - - O
had - - O
been - - O
living - - O
in - - O
a - - O
closed - - O
community - - O
for - - O
at - - O
least - - O
2 - - O
years - - O
. - - O

During - - O
challenge - - O
, - - O
rebiopsy - - O
was - - O
done - - O
when - - O
reticulin - - B-MUT
antibodies - - I-MUT
turned - - O
positive - - O
( - - O
mean - - O
0 - - O
. - - O
6 - - O
years - - O
, - - O
range - - O
0 - - O
. - - O
2-2 - - O
. - - O
0 - - O
) - - O
or - - O
at - - O
the - - O
end - - O
of - - O
the - - O
two - - O
year - - O
study - - O
. - - O

The - - O
Bacillus - - B-MUT
subtilis - - I-MUT
phage - - I-MUT
phi - - I-MUT
105 - - I-MUT
repressor - - I-MUT
, - - O
a - - O
lambda - - B-MUT
repressor-like - - O
transcriptional - - O
regulatory - - O
protein - - B-MUT
, - - O
was - - O
overproduced - - O
in - - O
Escherichia - - O
coli - - O
and - - O
purified - - O
to - - O
near - - O
homogeneity - - O
in - - O
order - - O
to - - O
examine - - O
its - - O
in - - O
vitro - - O
DNA-binding - - O
properties - - O
. - - O

The - - O
present - - O
study - - O
examined - - O
the - - O
dependence - - O
of - - O
difference - - O
tone - - O
level - - O
[ - - O
L - - O
( - - O
f2-f1 - - O
) - - O
] - - O
on - - O
the - - O
following - - O
parameters - - O
of - - O
the - - O
two-tone - - O
input - - O
: - - O
f1 - - O
, - - O
f2 - - O
f1 - - O
( - - O
f2 - - O
greater - - O
than - - O
f1 - - O
) - - O
, - - O
L1 - - O
, - - O
L2 - - O
, - - O
and - - O
L1 - - O
= - - O
L2 - - O
. - - O

We - - O
now - - O
show - - O
that - - O
regulation - - O
of - - O
flaN - - B-MUT
transcription - - O
in - - O
vivo - - O
depends - - O
on - - O
a - - O
sigma - - B-MUT
54 - - I-MUT
promoter - - I-MUT
and - - O
two - - O
ftr - - B-MUT
elements - - I-MUT
located - - O
downstream - - O
of - - O
the - - O
transcription - - O
start - - O
site - - O
at - - O
+86 - - O
( - - O
ftr2 - - B-MUT
) - - O
and - - O
+120 - - O
( - - O
ftr3 - - B-MUT
) - - O
. - - O

Subsequently - - O
, - - O
we - - O
show - - O
that - - O
the - - O
reexpression - - O
of - - O
the - - O
r-PTPeta - - B-MUT
gene - - I-MUT
in - - O
highly - - O
malignant - - O
rat - - O
thyroid - - O
cells - - O
transformed - - O
by - - O
retroviruses - - O
carrying - - O
the - - O
v-mos - - B-MUT
and - - O
v-ras-Ki - - B-MUT
oncogenes - - I-MUT
suppresses - - O
their - - O
malignant - - O
phenotype - - O
. - - O

Synovial - - O
cysts - - O
of - - O
the - - O
hip - - O
joint - - O
. - - O

In - - O
vitro - - O
binding - - O
studies - - O
using - - O
GST - - B-MUT
fusion - - O
proteins - - O
and - - O
yeast - - O
extracts - - O
defined - - O
distinct - - O
binding - - O
sites - - O
on - - O
yAP180A - - B-MUT
for - - O
Pan1p - - B-MUT
and - - O
clathrin - - B-MUT
. - - O
yAP180 - - B-MUT
proteins - - I-MUT
and - - O
Pan1p - - B-MUT
, - - O
like - - O
actin - - B-MUT
, - - O
localize - - O
to - - O
peripheral - - O
patches - - O
along - - O
the - - O
plasma - - O
membrane - - O
. - - O

The - - O
availability - - O
of - - O
potent - - O
regulatory - - O
DNA - - O
cassettes - - O
harboring - - O
the - - O
murine - - B-MUT
D1A - - I-MUT
gene - - I-MUT
promoter - - I-MUT
could - - O
aid - - O
testing - - O
the - - O
neuronal-specific - - O
expression - - O
of - - O
transgenes - - O
in - - O
vivo - - O
. - - O

Autoradiographic - - O
localisation - - O
of - - O
its - - O
cellular - - O
distribution - - O
in - - O
the - - O
kidney - - O
. - - O

Syndromes - - O
of - - O
abnormal - - O
fat - - O
redistribution - - O
and - - O
metabolic - - O
complications - - O
in - - O
HIV-infected - - O
patients - - O
. - - O

We - - O
have - - O
identified - - O
in - - O
the - - O
5' - - O
untranslated - - O
region - - O
of - - O
the - - O
Drosophila - - B-MUT
copia - - I-MUT
retrotransposon - - I-MUT
, - - O
3' - - O
to - - O
the - - O
left - - O
LTR - - O
, - - O
a - - O
sequence - - O
for - - O
transcriptional - - O
regulation - - O
by - - O
homeoproteins - - O
. - - O

Effects - - O
of - - O
estrogen - - O
and - - O
glucocorticoids - - O
on - - O
the - - O
adrenal - - O
development - - O
of - - O
the - - O
fetus - - O
. - - O

A - - O
concentration - - O
of - - O
12 - - O
. - - O
5 - - O
ppm - - O
SO2 - - O
induced - - O
a - - O
decrease - - O
from - - O
baseline - - O
values - - O
of - - O
approximately - - O
80% - - O
in - - O
mean - - O
MCA - - O
and - - O
of - - O
roughly - - O
70% - - O
in - - O
mean - - O
CBF - - O
. - - O

CM - - O
reduced - - O
the - - O
nuclear - - O
binding - - O
activity - - O
of - - O
transcription - - B-MUT
factor - - I-MUT
AP-1 - - I-MUT
. - - O

The - - O
SUP44 - - B-MUT
suppressor - - I-MUT
mutation - - I-MUT
occurs - - O
near - - O
a - - O
region - - O
of - - O
the - - O
protein - - O
that - - O
corresponds - - O
to - - O
the - - O
known - - O
positions - - O
of - - O
alterations - - O
in - - O
E - - B-MUT
. - - I-MUT
coli - - I-MUT
S5 - - I-MUT
ram - - I-MUT
mutations - - I-MUT
. - - O

The - - O
DNA - - O
sequence - - O
encodes - - O
a - - O
protein - - O
of - - O
1520 - - O
amino - - O
acids - - O
with - - O
sequence - - O
homology - - O
to - - O
the - - O
human - - B-MUT
c-abl - - I-MUT
proto-oncogene - - I-MUT
product - - I-MUT
, - - O
beginning - - O
at - - O
the - - O
amino - - O
terminus - - O
and - - O
extending - - O
656 - - O
amino - - O
acids - - O
through - - O
the - - O
region - - O
essential - - O
for - - O
tyrosine - - B-MUT
kinase - - I-MUT
activity - - O
. - - O

The - - O
expression - - O
pattern - - O
of - - O
GL2 - - B-MUT
, - - O
as - - O
demonstrated - - O
by - - O
in - - O
situ - - O
hybridization - - O
, - - O
indicated - - O
that - - O
the - - O
gene - - O
is - - O
expressed - - O
in - - O
trichome - - O
progenitor - - O
cells - - O
and - - O
at - - O
stages - - O
associated - - O
with - - O
trichome - - O
development - - O
. - - O

The - - O
amount - - O
of - - O
these - - O
factors - - O
was - - O
reduced - - O
in - - O
GEO - - O
cells - - O
in - - O
which - - O
the - - O
u-PAR - - B-MUT
gene - - I-MUT
is - - O
only - - O
weakly - - O
transcriptionally - - O
activated - - O
. - - O

Homozygous - - O
mutant - - O
mice - - O
, - - O
designated - - O
Cux - - B-MUT
CDPDeltaCR1 - - I-MUT
, - - I-MUT
display - - O
a - - O
phenotype - - O
characterized - - O
by - - O
curly - - O
vibrissae - - O
and - - O
wavy - - O
hair - - O
. - - O

In - - O
the - - O
3' - - O
flanking - - O
region - - O
of - - O
the - - O
27 - - B-MUT
kDa - - I-MUT
zein - - I-MUT
gene - - I-MUT
, - - O
several - - O
AATAAA-like - - O
sequences - - O
and - - O
a - - O
sequence - - O
resembling - - O
the - - O
mammalian - - O
GT-rich - - O
sequence - - O
are - - O
present - - O
around - - O
the - - O
polyadenylation - - O
sites - - O
. - - O

Furthermore - - O
it - - O
was - - O
suggested - - O
that - - O
FK506 - - O
plasma - - O
levels - - O
were - - O
concerned - - O
with - - O
the - - O
appearance - - O
of - - O
side - - O
effect - - O
. - - O

CONCLUSION - - O
: - - O
SPT - - O
is - - O
more - - O
useful - - O
than - - O
WST - - O
in - - O
differentiating - - O
patients - - O
predisposed - - O
to - - O
aspiration - - O
. - - O

The - - O
qualitative - - O
concentrations - - O
of - - O
HCG - - B-MUT
had - - O
a - - O
sensitivity - - O
of - - O
37 - - O
. - - O
5% - - O
and - - O
a - - O
specificity - - O
of - - O
100% - - O
. - - O

Mapping - - O
of - - O
RNA- - - O
temperature-sensitive - - B-MUT
mutants - - I-MUT
of - - I-MUT
Sindbis - - I-MUT
virus - - I-MUT
: - - I-MUT
complementation - - I-MUT
group - - I-MUT
F - - I-MUT
mutants - - I-MUT
have - - O
lesions - - O
in - - O
nsP4 - - B-MUT
. - - O

In - - O
addition - - O
to - - O
a - - O
previously - - O
characterized - - O
promoter - - O
( - - O
P1 - - B-MUT
) - - O
, - - O
we - - O
now - - O
show - - O
the - - O
existence - - O
of - - O
a - - O
second - - O
promoter - - O
for - - O
the - - O
human - - B-MUT
IL-5Ralpha - - I-MUT
gene - - I-MUT
. - - O

Allergenic - - O
activity - - O
of - - O
allergen - - O
extract - - O
Ambrosia - - O
elatior - - O
( - - O
AE - - O
) - - O
was - - O
tested - - O
in - - O
fifteen - - O
volunteers - - O
extremely - - O
sensitive - - O
to - - O
the - - O
allergen - - O
. - - O

This - - O
approach - - O
was - - O
examined - - O
utilizing - - O
the - - O
fetal - - O
protein - - O
, - - O
HGB - - B-MUT
F - - I-MUT
. - - O

Data - - O
were - - O
processed - - O
with - - O
a - - O
semi-automatic - - O
computer - - O
program - - O
which - - O
develops - - O
an - - O
averaged-volume - - O
curve - - O
from - - O
an - - O
assigned - - O
LV - - O
region-of-interest - - O
. - - O

The - - O
mouse - - B-MUT
M-lysozyme - - I-MUT
downstream - - I-MUT
enhancer - - I-MUT
has - - O
been - - O
previously - - O
characterized - - O
on - - O
several - - O
levels - - O
of - - O
gene - - O
regulation - - O
. - - O

This - - O
complex - - O
interacts - - O
at - - O
the - - O
GTPase - - B-MUT
domain - - I-MUT
in - - O
the - - O
large - - B-MUT
subunit - - I-MUT
rRNA - - I-MUT
, - - O
overlapping - - O
the - - O
binding - - O
site - - O
of - - O
the - - O
protein - - B-MUT
L11-like - - I-MUT
eukaryotic - - I-MUT
counterpart - - I-MUT
( - - O
Saccharomyces - - B-MUT
cerevisiae - - I-MUT
protein - - I-MUT
L15 - - I-MUT
and - - O
mammalian - - B-MUT
protein - - I-MUT
L12 - - I-MUT
) - - O
. - - O

Each - - O
patient - - O
had - - O
measurable - - O
LH - - B-MUT
and - - O
FSH - - B-MUT
levels - - O
, - - O
with - - O
pulsed - - O
nocturnal - - O
secretion - - O
, - - O
and - - O
pubertal - - O
LH - - B-MUT
and - - O
FSH - - B-MUT
responses - - O
to - - O
LRH - - B-MUT
. - - O

Using - - O
one - - O
of - - O
the - - O
six - - O
fragments - - O
( - - O
CPK3-8 - - B-MUT
) - - O
, - - O
we - - O
isolated - - O
a - - O
2022 - - B-MUT
bp - - I-MUT
cDNA - - I-MUT
( - - I-MUT
VrCDPK-1 - - I-MUT
) - - I-MUT
from - - O
a - - O
Vigna - - O
radiata - - O
lambda - - O
gt11 - - O
library - - O
. - - O

TIEG - - B-MUT
expression - - O
in - - O
hFOB - - O
cells - - O
was - - O
highly - - O
induced - - O
by - - O
TGF-beta - - B-MUT
and - - O
bone - - B-MUT
morphogenetic - - I-MUT
protein-2 - - I-MUT
( - - O
BMP-2 - - B-MUT
) - - O
, - - O
with - - O
a - - O
moderate - - O
induction - - O
by - - O
epidermal - - B-MUT
growth - - I-MUT
factor - - I-MUT
( - - O
EGF - - B-MUT
) - - O
, - - O
but - - O
no - - O
induction - - O
by - - O
other - - O
growth - - O
factors - - O
cytokines - - O
was - - O
observed - - O
. - - O

Introduction - - O
of - - O
v-fms - - B-MUT
into - - O
a - - O
CSF-1 - - B-MUT
dependent - - O
murine - - O
macrophage - - O
cell - - O
line - - O
induced - - O
factor - - O
independence - - O
and - - O
tumorigenicity - - O
by - - O
a - - O
nonautocrine - - O
mechanism - - O
. - - O

Eighteen - - O
patients - - O
were - - O
untreated - - O
, - - O
and - - O
8 - - O
had - - O
been - - O
given - - O
previous - - O
treatment - - O
with - - O
depot - - O
testosterone - - O
100 - - O
mg - - O
intramuscularly - - O
every - - O
2-3 - - O
weeks - - O
for - - O
an - - O
average - - O
duration - - O
of - - O
4 - - O
. - - O
7 - - O
years - - O
. - - O

We - - O
tried - - O
amphotericin - - O
B - - O
( - - O
AmB - - O
) - - O
, - - O
and - - O
remission - - O
of - - O
the - - O
tumor - - O
was - - O
obtained - - O
. - - O

Isolation - - O
of - - O
T - - O
. - - O
gambiense - - O
strains - - O
in - - O
Zaire - - O
and - - O
their - - O
adaptation - - O
to - - O
laboratory - - O
animals - - O
. - - O

The - - O
mRNA - - O
identified - - O
in - - O
both - - O
human - - O
and - - O
rat - - O
cells - - O
with - - O
the - - O
human - - B-MUT
clathrin - - I-MUT
clone - - O
revealed - - O
transcripts - - O
of - - O
approximately - - O
6 - - O
. - - O
5 - - O
kb - - O
, - - O
which - - O
is - - O
consistent - - O
with - - O
the - - O
predicted - - O
180 - - O
kDa - - O
molecular - - O
weight - - O
of - - O
the - - O
clathrin - - B-MUT
heavy - - I-MUT
chain - - I-MUT
. - - O

Survival - - O
of - - O
111 - - O
Indium-labelled - - O
autologous - - O
platelets - - O
was - - O
studied - - O
in - - O
2 - - O
patients - - O
after - - O
correction - - O
of - - O
platelet - - O
count - - O
and - - O
was - - O
still - - O
found - - O
shortened - - O
. - - O

Analysis - - O
of - - O
mCTR - - B-MUT
mRNAs - - I-MUT
has - - O
revealed - - O
that - - O
the - - O
three - - O
alternative - - O
promoters - - O
give - - O
rise - - O
to - - O
at - - O
least - - O
seven - - O
mCTR - - B-MUT
isoforms - - I-MUT
in - - O
the - - O
5' - - O
region - - O
of - - O
the - - O
gene - - O
and - - O
generate - - O
5'-untranslated - - O
regions - - O
of - - O
very - - O
different - - O
lengths - - O
. - - O

The - - O
overall - - O
incidence - - O
of - - O
SIDS - - O
was - - O
1 - - O
. - - O
43 - - O
per - - O
1 - - O
, - - O
000 - - O
live - - O
births - - O
. - - O

A - - O
method - - O
for - - O
the - - O
simultaneous - - O
determination - - O
of - - O
de - - O
( - - O
N-methyl - - O
) - - O
-N-ethyl-8 - - O
, - - O
9 - - O
-anhydroerythromycin - - O
A - - O
6 - - O
, - - O
9-hemiacetal - - O
( - - O
EM523 - - O
, - - O
I - - O
) - - O
and - - O
its - - O
three - - O
metabolites - - O
in - - O
human - - O
plasma - - O
and - - O
urine - - O
has - - O
been - - O
developed - - O
using - - O
high-performance - - O
liquid - - O
chromatography - - O
( - - O
HPLC - - O
) - - O
with - - O
chemiluminescence - - O
( - - O
CL - - O
) - - O
detection - - O
. - - O

Expression - - O
of - - O
the - - O
CYP11A1 - - B-MUT
gene - - I-MUT
is - - O
increased - - O
by - - O
hormones - - O
, - - O
such - - O
as - - O
adrenocorticotropin - - B-MUT
and - - O
luteinizing - - B-MUT
hormone - - I-MUT
, - - O
as - - O
well - - O
as - - O
by - - O
a - - O
number - - O
of - - O
growth - - B-MUT
factors - - I-MUT
, - - O
suggesting - - O
that - - O
its - - O
promoter - - O
may - - O
contain - - O
regulatory - - O
elements - - O
that - - O
respond - - O
to - - O
multiple - - O
signal - - O
transduction - - O
pathways - - O
. - - O

Deletion - - O
analysis - - O
of - - O
the - - O
ICL1 - - B-MUT
promoter - - I-MUT
led - - O
to - - O
the - - O
identification - - O
of - - O
an - - O
upstream - - O
activating - - O
sequence - - O
element - - O
, - - O
UASICL1 - - B-MUT
( - - O
5' - - B-MUT
CATTCATCCG - - I-MUT
3' - - I-MUT
) - - O
, - - O
necessary - - O
and - - O
sufficient - - O
for - - O
conferring - - O
carbon - - O
source-dependent - - O
regulation - - O
on - - O
a - - O
heterologous - - O
reporter - - O
gene - - O
. - - O

Cotransfections - - O
with - - O
ATF-2 - - B-MUT
and - - O
HNF-4 - - B-MUT
expression - - O
plasmids - - O
resulted - - O
in - - O
additive - - O
transactivation - - O
of - - O
the - - O
apoCIII - - B-MUT
promoter - - I-MUT
. - - O

Precision - - O
measurement - - O
of - - O
the - - O
pion - - O
mass - - O
difference - - O
m - - O
pi - - O
--m - - O
pi - - O
0 - - O
. - - O

Once - - O
NGF - - B-MUT
administration - - O
is - - O
proven - - O
effective - - O
it - - O
will - - O
be - - O
possible - - O
to - - O
develop - - O
alternative - - O
ways - - O
of - - O
NGF - - B-MUT
administration - - O
. - - O

Environmental - - O
factors - - O
were - - O
more - - O
important - - O
in - - O
the - - O
older - - O
cohorts - - O
( - - O
perhaps - - O
because - - O
of - - O
less - - O
reliable - - O
recall - - O
) - - O
. - - O

Two-dimensional - - O
gel - - O
electrophoresis - - O
of - - O
anti-p59fyn - - B-MUT
immunoprecipitates - - O
obtained - - O
from - - O
non-transformed - - O
resting - - O
human - - O
T - - O
lymphocytes - - O
resulted - - O
in - - O
the - - O
identification - - O
of - - O
an - - O
oligomeric - - O
protein - - O
complex - - O
which - - O
is - - O
constitutively - - O
formed - - O
between - - O
Fyn - - B-MUT
and - - O
several - - O
additional - - O
phosphoproteins - - O
( - - O
pp43 - - B-MUT
, - - O
pp72 - - B-MUT
, - - O
pp85 - - B-MUT
, - - O
the - - O
protein - - B-MUT
tyrosine - - I-MUT
kinase - - I-MUT
Pyk2 - - B-MUT
, - - O
as - - O
well - - O
as - - O
the - - O
two - - O
recently - - O
cloned - - O
adaptor - - O
proteins - - O
, - - O
SKAP55 - - B-MUT
and - - O
SLAP-130 - - B-MUT
) - - O
. - - O

Sequence - - O
analysis - - O
of - - O
the - - O
zebrafish - - B-MUT
egr1 - - I-MUT
coding - - I-MUT
region - - I-MUT
revealed - - O
a - - O
high - - O
level - - O
of - - O
homology - - O
to - - O
the - - O
mouse - - O
, - - O
rat - - O
, - - O
and - - O
human - - B-MUT
Egr1 - - I-MUT
genes - - I-MUT
with - - O
the - - O
notable - - O
exception - - O
of - - O
a - - O
polymorphic - - O
, - - O
triplet - - O
nucleotide - - O
repeat - - O
sequence - - O
in - - O
the - - O
region - - O
coding - - O
for - - O
the - - O
amino - - O
terminus - - O
of - - O
the - - O
Egr1 - - B-MUT
protein - - I-MUT
. - - O

Pseudocontact - - O
shifts - - O
arise - - O
from - - O
the - - O
isotropic - - O
reorientational - - O
average - - O
of - - O
the - - O
dipolar - - O
coupling - - O
between - - O
unpaired - - O
electron - - O
and - - O
nuclei - - O
, - - O
in - - O
the - - O
presence - - O
of - - O
magnetic - - O
susceptibility - - O
anisotropy - - O
. - - O

However - - O
, - - O
no - - O
studies - - O
have - - O
been - - O
conducted - - O
to - - O
further - - O
investigate - - O
this - - O
potentially - - O
hazardous - - O
effect - - O
of - - O
lidocaine - - O
. - - O

On - - O
the - - O
basis - - O
of - - O
these - - O
unique - - O
properties - - O
, - - O
the - - O
newly - - O
characterized - - O
hemagglutinin - - B-MUT
has - - O
been - - O
termed - - O
Limulus - - B-MUT
18K - - I-MUT
agglutination-aggregation - - I-MUT
factor - - I-MUT
( - - O
18K-LAF - - B-MUT
) - - O
. - - O

Products - - O
of - - O
immune - - O
cells - - O
such - - O
as - - O
transfer - - B-MUT
factor - - I-MUT
and - - O
lymphokines - - O
form - - O
the - - O
third - - O
and - - O
possibly - - O
most - - O
important - - O
group - - O
of - - O
immune-stimulating - - O
agents - - O
. - - O

Its - - O
clearance - - O
has - - O
been - - O
found - - O
to - - O
be - - O
decreased - - O
( - - O
typically - - O
by - - O
around - - O
25% - - O
, - - O
but - - O
often - - O
by - - O
far - - O
more - - O
) - - O
by - - O
erythromycin - - O
, - - O
troleandomycin - - O
( - - O
triacetyloleandomycin - - O
) - - O
, - - O
roxithromycin - - O
, - - O
enoxacin - - O
, - - O
ciprofloxacin - - O
, - - O
pefloxacin - - O
, - - O
norfloxacin - - O
, - - O
ofloxacin - - O
, - - O
fluoroquinolone - - O
T-3262 - - O
, - - O
pipemidic - - O
acid - - O
, - - O
cimetidine - - O
, - - O
etintidine - - O
, - - O
propranolol - - O
, - - O
verapamil - - O
, - - O
diltiazem - - O
, - - O
nifedipine - - O
, - - O
furosemide - - O
( - - O
frusemide - - O
) - - O
, - - O
at - - O
least - - O
some - - O
anovulent - - O
agents - - O
, - - O
viloxazine - - O
, - - O
allopurinol - - O
, - - O
ticlopidine - - O
, - - O
idrocilamide - - O
, - - O
thiabendazole - - O
, - - O
disulfiram - - O
, - - O
influenza- - - O
and - - O
BCG-vaccination - - O
, - - O
interferon - - B-MUT
, - - O
and - - O
caffeine - - O
( - - O
half-life - - O
increase - - O
) - - O
. - - O

Of - - O
110 - - O
previously - - O
untreated - - O
patients - - O
who - - O
had - - O
entered - - O
the - - O
study - - O
of - - O
protocol - - O
TCL821 - - O
, - - O
96 - - O
were - - O
evaluable - - O
. - - O

Grippers - - O
with - - O
integrated - - O
piezoresistive - - O
force - - O
sensors - - O
and - - O
with - - O
attached - - O
strain - - O
gauges - - O
have - - O
been - - O
reported - - O
. - - O

Advanced - - O
adenoma - - O
was - - O
defined - - O
as - - O
an - - O
adenoma - - O
larger - - O
than - - O
10 - - O
mm - - O
or - - O
an - - O
adenoma - - O
of - - O
any - - O
size - - O
with - - O
villous - - O
component - - O
, - - O
high-grade - - O
dysplasia - - O
or - - O
invasive - - O
carcinoma - - O
. - - O

Here - - O
, - - O
we - - O
identified - - O
three - - O
cis-elements - - O
required - - O
for - - O
replication - - O
within - - O
the - - O
200 - - O
bp - - O
promoter - - O
, - - O
using - - O
autonomously - - O
replicating - - O
plasmids - - O
carrying - - O
various - - O
mutations - - O
and - - O
deletions - - O
. - - O

Oligonucleotides - - O
, - - O
designed - - O
on - - O
the - - O
basis - - O
of - - O
conserved - - O
flanking - - O
amino - - O
acid - - O
sequence - - O
segments - - O
within - - O
the - - O
catalytic - - O
domain - - O
of - - O
eukaryotic - - B-MUT
protein - - I-MUT
kinase - - I-MUT
C - - I-MUT
( - - B-MUT
PKC - - I-MUT
) - - I-MUT
proteins - - I-MUT
, - - O
were - - O
used - - O
as - - O
primers - - O
for - - O
polymerase - - O
chain - - O
reactions - - O
to - - O
amplify - - O
a - - O
427-bp - - O
chromosomal - - O
DNA - - O
fragment - - O
from - - O
the - - O
filamentous - - O
fungus - - O
Trichoderma - - O
reesei - - O
. - - O

Potentially - - O
load-insensitive - - O
measures - - O
of - - O
ventricular - - O
performance - - O
were - - O
therefore - - O
evaluated - - O
in - - O
10 - - O
open- - - O
and - - O
closed-chested - - O
, - - O
anesthetized - - O
rabbits - - O
. - - O

Two - - O
patients - - O
were - - O
treated - - O
successfully - - O
with - - O
a - - O
combination - - O
of - - O
metronidazole - - O
( - - O
a - - O
tissue - - O
amoebicide - - O
) - - O
and - - O
diloxanide - - O
( - - O
a - - O
lumenal - - O
amoebicide - - O
) - - O
. - - O

The - - O
interindividual - - O
variability - - O
of - - O
the - - O
parameters - - O
is - - O
taken - - O
into - - O
consideration - - O
by - - O
interactively - - O
determining - - O
the - - O
threshold - - O
levels - - O
. - - O

Merlie - - O
, - - O
Cold - - O
Spring - - O
Harbor - - O
Symp - - O
. - - O

Late - - O
complications - - O
of - - O
catheterisation - - O
for - - O
intravenous - - O
nutrition - - O
[ - - O
letter - - O
] - - O
. - - O

Toward - - O
this - - O
end - - O
, - - O
we - - O
prepared - - O
synthetic - - O
proteins - - O
with - - O
either - - O
the - - O
catalytic - - O
domain - - O
of - - O
FAP-1 - - B-MUT
( - - I-MUT
C-terminal - - I-MUT
399 - - I-MUT
amino - - I-MUT
acids - - I-MUT
) - - I-MUT
or - - O
its - - O
inactive - - O
form - - O
( - - O
Cys2408-- - - O
> - - O
Ser - - O
) - - O
fused - - O
to - - O
glutathione-S-transferase - - B-MUT
( - - O
GST - - B-MUT
) - - O
. - - O

To - - O
investigate - - O
the - - O
mechanisms - - O
involved - - O
in - - O
the - - O
transcriptional - - O
control - - O
of - - O
retinoid - - B-MUT
X - - I-MUT
receptor - - I-MUT
( - - O
RXR - - B-MUT
) - - O
gene - - O
expression - - O
, - - O
the - - O
5'-flanking - - O
region - - O
of - - O
the - - O
human - - B-MUT
RXRgamma2 - - I-MUT
isoform - - I-MUT
was - - O
characterized - - O
. - - O

The - - O
E1 - - B-MUT
gene - - I-MUT
is - - O
located - - O
within - - O
the - - O
first - - O
intron - - O
of - - O
the - - O
gene - - O
for - - O
RCC1 - - B-MUT
, - - O
a - - O
protein - - O
that - - O
regulates - - O
onset - - O
of - - O
mitosis - - O
. - - O

Young - - O
CD-1 - - O
mice - - O
, - - O
4 - - O
days - - O
old - - O
, - - O
exposed - - O
to - - O
0 - - O
. - - O
1% - - O
nicotine - - O
sulfate - - O
on - - O
gestational - - O
days - - O
6-20 - - O
were - - O
compared - - O
with - - O
untreated - - O
pups - - O
of - - O
the - - O
same - - O
age - - O
to - - O
determine - - O
its - - O
effect - - O
on - - O
the - - O
development - - O
of - - O
mandibular - - O
first - - O
molars - - O
. - - O

Here - - O
we - - O
demonstrate - - O
that - - O
AML1a - - B-MUT
, - - O
which - - O
solely - - O
has - - O
no - - O
effects - - O
as - - O
a - - O
transcriptional - - O
regulator - - O
, - - O
dominantly - - O
suppresses - - O
transcriptional - - O
activation - - O
by - - O
AML1b - - B-MUT
, - - O
and - - O
that - - O
AML1a - - B-MUT
exhibits - - O
the - - O
higher - - O
affinity - - O
for - - O
DNA-binding - - O
than - - O
AML1b - - B-MUT
. - - O

During - - O
the - - O
past - - O
4 - - O
years - - O
, - - O
a - - O
purposeful - - O
search - - O
was - - O
made - - O
for - - O
electrocardiograms - - O
with - - O
documented - - O
reversible - - O
QRS - - O
changes - - O
associated - - O
with - - O
all - - O
acute - - O
injury - - O
pattern - - O
. - - O

Four - - O
patients - - O
( - - O
group - - O
1 - - O
) - - O
had - - O
type - - O
I - - O
basement - - O
membrane - - O
nephropathy - - O
, - - O
characterized - - O
by - - O
marked - - O
thickening - - O
and - - O
lamellation - - O
of - - O
the - - O
basement - - O
membrane - - O
in - - O
a - - O
pattern - - O
resembling - - O
that - - O
of - - O
Alport's - - O
syndrome - - O
. - - O

A - - O
genetic - - O
screen - - O
in - - O
yeast - - O
has - - O
allowed - - O
us - - O
to - - O
identify - - O
a - - O
novel - - O
transcriptional - - O
factor - - O
binding - - O
to - - O
the - - O
GlRE - - B-MUT
, - - O
i - - O
. - - O
e - - O
. - - O
the - - O
chicken - - B-MUT
ovalbumin - - I-MUT
upstream - - I-MUT
promoter-transcription - - I-MUT
factor - - I-MUT
II - - I-MUT
( - - O
COUP-TFII - - B-MUT
) - - O
. - - O

SAPK - - B-MUT
JNK - - I-MUT
activation - - I-MUT
was - - O
completely - - O
abolished - - O
in - - O
the - - O
absence - - O
of - - O
MKK7 - - O
, - - B-MUT
even - - O
though - - O
expression - - O
of - - O
MKK4 - - O
was - - B-MUT
strongly - - O
upregulated - - O
in - - O
mkk7 - - O
( - - B-MUT
- - - I-MUT
- - - I-MUT
) - - I-MUT
mast - - I-MUT
cell - - I-MUT
lines - - O
, - - O
and - - O
phosphorylation - - O
of - - O
MKK4 - - O
occurred - - O
normally - - B-MUT
in - - O
response - - O
to - - O
multiple - - O
stress - - O
stimuli - - O
. - - O

In - - O
a - - O
PC12 - - O
cell - - O
mutant - - O
that - - O
is - - O
deficient - - O
in - - O
protein - - B-MUT
kinase - - I-MUT
A - - I-MUT
activity - - O
( - - O
AB - - O
. - - O
11 - - O
) - - O
, - - O
all - - O
three - - O
differentiating - - O
agents - - O
were - - O
unable - - O
to - - O
down-regulate - - O
nrg-1 - - B-MUT
mRNA - - I-MUT
. - - O

Thus - - O
, - - O
the - - O
active-site - - O
mutation - - O
prevents - - O
the - - O
wild-type - - O
processing - - O
of - - O
the - - O
N-glycosylated - - O
73-kDa - - O
precursor - - O
of - - O
PrB - - B-MUT
to - - O
the - - O
41 - - B-MUT
. - - I-MUT
5 - - I-MUT
kDa - - I-MUT
pro-PrB - - I-MUT
in - - O
the - - O
endoplasmic - - O
reticulum - - O
. - - O

99mTc-HMPAO - - O
was - - O
distributed - - O
in - - O
the - - O
territories - - O
of - - O
the - - O
ACA - - O
and - - O
MCA - - O
in - - O
the - - O
two - - O
patients - - O
who - - O
were - - O
treated - - O
with - - O
intraarterial - - O
infusion - - O
of - - O
papaverine - - O
from - - O
the - - O
C4 - - O
segment - - O
, - - O
but - - O
was - - O
distributed - - O
only - - O
to - - O
the - - O
territory - - O
of - - O
the - - O
ACA - - O
in - - O
four - - O
patients - - O
who - - O
were - - O
treated - - O
with - - O
intraarterial - - O
infusion - - O
of - - O
papaverine - - O
from - - O
the - - O
C1 - - O
segment - - O
at - - O
1 - - O
ml - - O
min - - O
. - - O

The - - O
diabetic - - O
state - - O
was - - O
characterized - - O
by - - O
mild - - O
insulin - - B-MUT
deficiency - - O
, - - O
plasma - - O
levels - - O
being - - O
73% - - O
of - - O
controls - - O
, - - O
and - - O
mild - - O
hyperglycemia - - O
, - - O
with - - O
nonfasting - - O
plasma - - O
glucose - - O
levels - - O
of - - O
1 - - O
. - - O
5 - - O
times - - O
normal - - O
. - - O

Acquired - - O
antithrombin - - B-MUT
deficiency - - O
in - - O
sepsis - - O
. - - O

Thrombolytic - - O
therapy - - O
in - - O
spontaneous - - O
coronary - - O
artery - - O
dissection - - O
. - - O

Structural - - O
studies - - O
have - - O
shown - - O
that - - O
class - - B-MUT
I - - I-MUT
major - - I-MUT
histocompatibility - - I-MUT
complex - - I-MUT
( - - O
MHC - - B-MUT
) - - O
-restricted - - O
peptide-specific - - B-MUT
T - - I-MUT
cell - - I-MUT
receptor - - I-MUT
( - - I-MUT
TCR - - I-MUT
) - - I-MUT
-alpha - - I-MUT
betas - - I-MUT
make - - I-MUT
multiple - - O
contacts - - O
with - - O
the - - O
alpha1 - - O
and - - O
alpha2 - - O
helices - - O
of - - O
the - - O
MHC - - O
, - - B-MUT
but - - O
it - - O
is - - O
unclear - - O
which - - O
or - - O
how - - O
many - - O
of - - O
these - - O
interactions - - O
contribute - - O
to - - O
functional - - O
binding - - O
. - - O

The - - O
bearing - - O
of - - O
season - - O
and - - O
sequence - - O
of - - O
calving - - O
on - - O
frequency - - O
of - - O
male - - O
, - - O
female - - O
and - - O
total - - O
calvings - - O
in - - O
Hariana - - O
cows - - O
. - - O

Histological - - O
evaluation - - O
revealed - - O
a - - O
more - - O
than - - O
twofold - - O
increase - - O
in - - O
the - - O
number - - O
of - - O
interepithelial - - O
mononuclear - - O
cells - - O
( - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
005 - - O
) - - O
, - - O
while - - O
the - - O
number - - O
of - - O
epithelial - - O
cells - - O
100 - - O
microns - - O
of - - O
villous - - O
mucosa - - O
and - - O
the - - O
mean - - O
height - - O
of - - O
the - - O
epithelial - - O
cells - - O
were - - O
comparable - - O
in - - O
both - - O
groups - - O
. - - O

8% - - O
( - - O
95% - - O
CI - - O
, - - O
21 - - O
. - - O
3-44 - - O
. - - O
3% - - O
) - - O
. - - O

The - - O
responsive - - O
region - - O
of - - O
the - - O
alpha - - B-MUT
2 - - I-MUT
( - - I-MUT
V - - I-MUT
) - - I-MUT
collagen - - I-MUT
gene - - I-MUT
was - - O
localized - - O
to - - O
a - - O
fragment - - O
including - - O
100 - - O
bp - - O
of - - O
basal - - O
promoter - - O
and - - O
150 - - O
bp - - O
of - - O
exon - - O
1 - - O
sequences - - O
, - - O
which - - O
contained - - O
two - - O
CRE-like - - B-MUT
elements - - I-MUT
. - - O

Various - - O
mutant - - B-MUT
HN - - I-MUT
genes - - I-MUT
were - - O
constructed - - O
to - - O
examine - - O
the - - O
role - - O
of - - O
residues - - O
flanking - - O
the - - O
signal-anchor - - O
domain - - O
, - - O
including - - O
the - - O
cytoplasmic - - O
tail - - O
, - - O
on - - O
assembly - - O
and - - O
intracellular - - O
transport - - O
of - - O
the - - O
HN - - B-MUT
glycoprotein - - I-MUT
. - - O

A - - O
model - - O
with - - O
age - - O
and - - O
weight - - O
described - - O
the - - O
best - - O
fit - - O
for - - O
TBBMD - - O
, - - O
whereas - - O
age - - O
, - - O
weight - - O
, - - O
and - - O
height - - O
described - - O
the - - O
best - - O
fit - - O
for - - O
total - - O
body - - O
TBBMC - - O
. - - O

In - - O
view - - O
of - - O
the - - O
short - - O
t1 - - O
2 - - O
, - - O
we - - O
used - - O
three - - O
doses - - O
day - - O
. - - O

These - - O
findings - - O
suggest - - O
a - - O
novel - - O
ankyrin-independent - - O
role - - O
for - - O
LAD-1 - - B-MUT
related - - O
to - - O
FGFR - - B-MUT
signaling - - O
. - - O

To - - O
facilitate - - O
the - - O
investigation - - O
of - - O
parameters - - O
that - - O
govern - - O
selective - - O
export - - O
in - - O
adenovirus-infected - - O
cells - - O
, - - O
we - - O
constructed - - O
a - - O
marked - - O
human - - O
beta-actin - - B-MUT
minigene - - I-MUT
under - - O
the - - O
control - - O
of - - O
the - - O
glucocorticoid-inducible - - B-MUT
enhancer-promoter - - I-MUT
of - - O
mouse - - O
mammary - - O
tumor - - O
virus - - O
and - - O
introduced - - O
it - - O
into - - O
the - - O
left - - O
end - - O
of - - O
the - - O
adenovirus - - O
type - - O
5 - - O
( - - O
Ad5 - - O
) - - O
genome - - O
. - - O

In - - O
the - - O
latter - - O
category - - O
particular - - O
emphasis - - O
is - - O
being - - O
placed - - O
on - - O
new - - O
anthracycline - - O
analogues - - O
of - - O
doxorubicin - - O
and - - O
analogues - - O
of - - O
cisplatinum - - O
diammine - - O
dichloride - - O
. - - O

A - - O
human - - B-MUT
SPT3-TAFII31-GCN5-L - - I-MUT
acetylase - - I-MUT
complex - - I-MUT
distinct - - O
from - - O
transcription - - B-MUT
factor - - I-MUT
IID - - I-MUT
. - - O

It - - O
is - - O
possible - - O
that - - O
cyclic - - O
variations - - O
in - - O
heme - - O
turnover - - O
are - - O
related - - O
to - - O
changes - - O
in - - O
erythrocyte - - O
characteristics - - O
during - - O
the - - O
progesterone - - O
phase - - O
. - - O

We - - O
report - - O
here - - O
the - - O
identification - - O
of - - O
a - - O
cDNA - - O
that - - O
encodes - - O
a - - O
new - - O
member - - O
of - - O
the - - O
GTPase-activating - - B-MUT
protein - - I-MUT
( - - O
GAP - - B-MUT
) - - O
family - - O
of - - O
GTPase - - B-MUT
regulators - - O
. - - O

In - - O
addition - - O
, - - O
CaMig1 - - B-MUT
formed - - O
specific - - O
complexes - - O
with - - O
the - - O
URS1 - - B-MUT
region - - I-MUT
of - - O
the - - O
S - - B-MUT
. - - I-MUT
cerevisiae - - I-MUT
FBP1 - - I-MUT
gene - - I-MUT
. - - O

New - - O
beta-blocking - - O
drugs - - O
have - - O
been - - O
introduced - - O
which - - O
may - - O
prove - - O
beneficial - - O
in - - O
certain - - O
clinical - - O
situations - - O
since - - O
they - - O
exert - - O
more - - O
selective - - O
blockade - - O
of - - O
the - - O
cardiac - - B-MUT
receptors - - I-MUT
( - - O
beta1 - - B-MUT
) - - O
as - - O
opposed - - O
to - - O
smooth - - B-MUT
muscle - - I-MUT
receptors - - I-MUT
( - - O
beta2 - - B-MUT
) - - O
. - - O

The - - O
nucleotide - - O
sequence - - O
alignment - - O
between - - O
mouse - - O
and - - O
human - - B-MUT
CA - - I-MUT
IV - - I-MUT
shows - - O
69% - - O
identity - - O
in - - O
the - - O
coding - - O
region - - O
and - - O
all - - O
of - - O
the - - O
exon-intron - - O
boundaries - - O
are - - O
conserved - - O
, - - O
as - - O
are - - O
the - - O
sizes - - O
of - - O
the - - O
introns - - O
. - - O

The - - O
transcription - - O
factor - - O
Sp1 - - B-MUT
bound - - O
to - - O
eight - - O
sites - - O
, - - O
as - - O
demonstrated - - O
by - - O
footprinting - - O
assays - - O
and - - O
gel - - O
shift - - O
analysis - - O
with - - O
purified - - O
Sp1 - - B-MUT
. - - O

Thus - - O
, - - O
a - - O
negative - - O
test - - O
is - - O
compatible - - O
with - - O
low - - O
disease - - O
activity - - O
and - - O
or - - O
efficacy - - O
of - - O
calcium - - O
antagonist - - O
treatment - - O
. - - O

Structural - - O
changes - - O
in - - O
the - - O
C-terminus - - O
of - - O
Ca2+-bound - - O
rat - - B-MUT
S100B - - I-MUT
( - - O
beta - - B-MUT
beta - - I-MUT
) - - O
upon - - O
binding - - O
to - - O
a - - O
peptide - - O
derived - - O
from - - O
the - - O
C-terminal - - O
regulatory - - O
domain - - O
of - - O
p53 - - B-MUT
. - - O

Rapid - - O
detection - - O
of - - O
radioisotopically - - O
contaminated - - O
test - - O
serum - - O
before - - O
radioassay - - O
of - - O
vitamin - - O
B12 - - O
. - - O

These - - O
disorders - - O
include - - O
low-back - - O
pain - - O
, - - O
saddle - - O
anesthesia - - O
, - - O
bilateral - - O
sciatica - - O
, - - O
then - - O
motor - - O
weakness - - O
of - - O
the - - O
lower - - O
extremities - - O
or - - O
chronic - - O
paraplegia - - O
and - - O
, - - O
bladder - - O
dysfunction - - O
. - - O

Weight - - O
loss - - O
reduces - - O
arterial - - O
pressure - - O
by - - O
a - - O
decrease - - O
in - - O
intravascular - - O
volume - - O
and - - O
cardiac - - O
output - - O
associated - - O
with - - O
a - - O
fall - - O
in - - O
sympathetic - - O
activity - - O
. - - O

A - - O
promising - - O
new - - O
cement - - O
, - - O
4-META - - O
MMA-TBB - - O
opaque - - O
resin - - O
, - - O
has - - O
shown - - O
remarkable - - O
adhesive - - O
properties - - O
as - - O
a - - O
bone - - O
cement - - O
in - - O
vivo - - O
. - - O

The - - O
first - - O
symptoms - - O
of - - O
enzootic - - O
calcinosis - - O
were - - O
noted - - O
in - - O
March - - O
1998 - - O
, - - O
when - - O
some - - O
of - - O
the - - O
cows - - O
developed - - O
locomotor - - O
abnormalities - - O
. - - O

Temperature-shift - - O
experiments - - O
using - - O
synchronously - - O
grown - - O
cells - - O
of - - O
a - - O
delta - - B-MUT
top1 - - I-MUT
top2 - - B-MUT
temperature-sensitive - - I-MUT
( - - I-MUT
ts - - I-MUT
) - - I-MUT
double - - I-MUT
mutant - - I-MUT
and - - O
its - - O
isogenic - - O
top2 - - B-MUT
ts - - O
strain - - O
show - - O
that - - O
, - - O
whereas - - O
mitotic - - O
blocks - - O
can - - O
prevent - - O
killing - - O
of - - O
the - - O
top2 - - B-MUT
ts - - I-MUT
mutant - - I-MUT
at - - O
a - - O
nonpermissive - - O
temperature - - O
, - - O
the - - O
same - - O
treatments - - O
are - - O
ineffective - - O
in - - O
preventing - - O
cell - - O
death - - O
of - - O
the - - O
delta - - B-MUT
top1 - - I-MUT
top2 - - B-MUT
ts - - I-MUT
double - - I-MUT
mutant - - I-MUT
. - - O

These - - O
results - - O
indicate - - O
that - - O
TGF-betaf - - B-MUT
potentiates - - O
the - - O
c-fos - - B-MUT
SRE - - B-MUT
activated - - O
by - - O
PKC - - B-MUT
through - - O
the - - O
SRF - - B-MUT
binding - - I-MUT
site - - I-MUT
. - - O

By - - O
using - - O
a - - O
DNA - - O
sequence - - O
selected - - O
for - - O
its - - O
ability - - O
to - - O
bind - - O
recombinant - - B-MUT
BCL-6 - - I-MUT
in - - O
vitro - - O
, - - O
we - - O
show - - O
here - - O
that - - O
BCL-6 - - B-MUT
is - - O
present - - O
in - - O
DNA-binding - - O
complexes - - O
in - - O
nuclear - - O
extracts - - O
from - - O
various - - O
B-cell - - O
lines - - O
. - - O

Here - - O
we - - O
demonstrate - - O
that - - O
the - - O
protein - - O
product - - O
of - - O
the - - O
ref-1 - - B-MUT
gene - - I-MUT
stimulates - - O
the - - O
DNA - - O
binding - - O
activity - - O
of - - O
Fos-Jun - - B-MUT
heterodimers - - I-MUT
, - - O
Jun-Jun - - B-MUT
homodimers - - I-MUT
and - - O
Hela - - O
cell - - O
AP-1 - - B-MUT
proteins - - I-MUT
as - - O
well - - O
as - - O
that - - O
of - - O
several - - O
other - - O
transcription - - O
factors - - O
including - - O
NF-kappa - - B-MUT
B - - I-MUT
, - - O
Myb - - B-MUT
and - - O
members - - O
of - - O
the - - O
ATF - - B-MUT
CREB - - I-MUT
family - - I-MUT
. - - I-MUT

The - - O
data - - O
obtained - - O
up - - O
to - - O
now - - O
only - - O
suggest - - O
the - - O
future - - O
potentiality - - O
of - - O
Bestatin - - O
treatment - - O
for - - O
these - - O
types - - O
of - - O
malignancy - - O
. - - O

The - - O
results - - O
supported - - O
the - - O
therapeutic - - O
principle - - O
of - - O
TCM - - O
: - - O
Treating - - O
patients - - O
according - - O
to - - O
their - - O
pathophysiological - - O
patterns - - O
. - - O

Ki-ras4BVal-12 - - B-MUT
transfectant - - O
cells - - O
expressed - - O
2-fold - - O
elevated - - O
protein - - O
levels - - O
of - - O
the - - O
lysosomal - - B-MUT
cysteine - - I-MUT
protease - - I-MUT
cathepsin - - I-MUT
B - - I-MUT
but - - O
did - - O
not - - O
up-regulate - - O
cathepsin - - B-MUT
B - - I-MUT
mRNA - - I-MUT
expression - - O
. - - O

Fgd3 - - B-MUT
and - - O
FGD1 - - B-MUT
share - - O
a - - O
high - - O
degree - - O
of - - O
sequence - - O
identity - - O
that - - O
spans - - O
> - - O
560 - - O
contiguous - - O
amino - - O
acid - - O
residues - - O
. - - O

Conformational - - O
studies - - O
combining - - O
secondary - - O
structure - - O
predictions - - O
, - - O
CD - - O
and - - O
NMR - - O
spectroscopy - - O
together - - O
with - - O
ELISA - - O
assays - - O
, - - O
showed - - O
that - - O
the - - O
greater - - O
is - - O
the - - O
propensity - - O
of - - O
the - - O
epitope - - O
for - - O
helix - - O
formation - - O
the - - O
higher - - O
is - - O
the - - O
recognition - - O
by - - O
anti-K159 - - B-MUT
. - - O

Spores - - O
from - - O
Rhizopus - - O
stolonifer - - O
were - - O
suspended - - O
in - - O
distilled - - O
water - - O
( - - O
1 - - O
x - - O
10 - - O
( - - O
6 - - O
) - - O
spores - - O
mL - - O
) - - O
and - - O
used - - O
as - - O
starter - - O
. - - O

Gene - - B-MUT
1 - - I-MUT
has - - O
been - - O
completely - - O
sequenced - - O
. - - O

BACKGROUND - - O
AND - - O
OBJECTIVES - - O
: - - O
The - - O
sexually - - O
transmitted - - O
diseases - - O
( - - O
STD - - O
) - - O
control - - O
program - - O
for - - O
female - - O
sex - - O
workers - - O
( - - O
FSW - - O
) - - O
in - - O
Lima - - O
, - - O
Peru - - O
, - - O
provided - - O
periodic - - O
serological - - O
tests - - O
for - - O
syphilis - - O
and - - O
cervical - - O
smears - - O
for - - O
gonococci - - O
, - - O
but - - O
not - - O
medication - - O
for - - O
STD - - O
or - - O
condoms - - O
. - - O

Ciprofloxacin - - O
: - - O
an - - O
overview - - O
of - - O
adverse - - O
experiences - - O
. - - O

Persistence - - O
of - - O
toxaphene - - O
in - - O
treated - - O
lakes - - O
. - - O

Nevertheless - - O
cryopreservation - - O
of - - O
spermatozoa - - O
in - - O
a - - O
medium - - O
containing - - O
neither - - O
SP - - O
nor - - O
biological - - O
substances - - O
could - - O
offer - - O
an - - O
acceptable - - O
cryoprotection - - O
of - - O
spermatozoa - - O
to - - O
be - - O
used - - O
in - - O
assisted - - O
fertilization - - O
procedures - - O
, - - O
especially - - O
for - - O
intracytoplasmic - - O
sperm - - O
injection - - O
. - - O

Comparison - - O
of - - O
three - - O
different - - O
preparations - - O
of - - O
disodium - - O
cromoglycate - - O
in - - O
the - - O
prevention - - O
of - - O
exercise-induced - - O
bronchospasm - - O
: - - O
a - - O
double-blind - - O
study - - O
. - - O

Fenoldopam - - O
, - - O
a - - O
dopamine - - B-MUT
receptor - - I-MUT
agonist - - O
, - - O
has - - O
been - - O
shown - - O
, - - O
in - - O
animal - - O
experiments - - O
, - - O
to - - O
improve - - O
renal - - O
perfusion - - O
. - - O

Escherichia - - O
coli - - O
JRG582 - - O
is - - O
an - - O
ampD - - B-MUT
ampE - - B-MUT
deletion - - O
derivative - - O
of - - O
strain - - O
HfrH - - O
and - - O
accordingly - - O
it - - O
is - - O
derepressed - - O
for - - O
expression - - O
of - - O
the - - O
cloned - - O
inducible - - O
beta-lactamase - - B-MUT
gene - - I-MUT
of - - O
Citrobacter - - O
freundii - - O
, - - O
carried - - O
on - - O
plasmid - - O
pNU305 - - O
. - - O

Guinea - - O
pigs - - O
weighing - - O
300 - - O
approximately - - O
350 - - O
g - - O
were - - O
used - - O
. - - O

Alginate - - B-MUT
biosynthesis - - O
is - - O
controlled - - O
by - - O
a - - O
complex - - O
regulatory - - O
mechanism - - O
. - - O

In - - O
visible - - O
tumours - - O
the - - O
best - - O
results - - O
were - - O
obtained - - O
with - - O
FB - - O
( - - O
85% - - O
) - - O
while - - O
TBN - - O
was - - O
positive - - O
in - - O
65% - - O
. - - O

Molecules - - O
of - - O
NH3 - - O
are - - O
capable - - O
of - - O
emitting - - O
stimulated - - O
radiation - - O
( - - O
MASER - - O
) - - O
. - - O

A - - O
simplified - - O
thin-layer - - O
chromatographic - - O
determination - - O
of - - O
hippuric - - O
acid - - O
and - - O
methylhippuric - - O
acids - - O
. - - O

Mutations - - O
in - - O
the - - O
nuclear - - B-MUT
gene - - I-MUT
CBP1 - - I-MUT
of - - I-MUT
Saccharomyces - - I-MUT
cerevisiae - - I-MUT
result - - O
in - - O
degradation - - O
of - - O
mitochondrially - - B-MUT
encoded - - I-MUT
cytochrome - - I-MUT
b - - I-MUT
( - - O
cob - - B-MUT
) - - O
RNA - - O
; - - O
thus - - O
, - - O
the - - O
cells - - O
are - - O
unable - - O
to - - O
respire - - O
. - - O

Radiative - - O
corrections - - O
to - - O
beta - - O
decay - - O
and - - O
the - - O
possibility - - O
of - - O
a - - O
fourth - - O
generation - - O
. - - O

Results - - O
support - - O
the - - O
hypothesis - - O
that - - O
endogenous - - B-MUT
corticotropin-releasing - - I-MUT
factor - - I-MUT
, - - O
perhaps - - O
acting - - O
at - - O
a - - O
peripheral - - O
binding - - O
site - - O
, - - O
suppresses - - O
the - - O
active - - O
behavioral - - O
response - - O
characteristic - - O
of - - O
pups - - O
during - - O
the - - O
early - - O
phase - - O
of - - O
isolation - - O
in - - O
novel - - O
surroundings - - O
. - - O

TFEC - - B-MUT
, - - O
a - - O
basic - - B-MUT
helix-loop-helix - - I-MUT
protein - - I-MUT
, - - O
forms - - O
heterodimers - - O
with - - O
TFE3 - - B-MUT
and - - O
inhibits - - O
TFE3-dependent - - O
transcription - - O
activation - - O
. - - O

Ly-49 - - B-MUT
is - - O
a - - O
family - - B-MUT
type - - I-MUT
II - - I-MUT
transmembrane - - I-MUT
proteins - - I-MUT
encoded - - O
by - - O
a - - O
gene - - O
cluster - - O
on - - O
murine - - O
chromosome - - O
6 - - O
. - - O

Our - - O
results - - O
suggest - - O
that - - O
the - - O
crucial - - O
role - - O
of - - O
the - - O
mutations - - O
activating - - O
v-erbA - - B-MUT
as - - O
an - - O
oncogene - - O
is - - O
to - - O
'freeze' - - O
c-ErbA - - B-MUT
TRalpha - - O
in - - B-MUT
its - - O
non-liganded - - O
, - - O
repressive - - O
conformation - - O
and - - O
to - - O
facilitate - - O
its - - O
overexpression - - O
. - - O

All - - O
were - - O
experienced - - O
hearing - - O
aid - - O
users - - O
who - - O
wore - - O
linear - - O
Class - - O
D - - O
instruments - - O
with - - O
input - - O
compression - - O
limiting - - O
at - - O
the - - O
time - - O
of - - O
their - - O
enrollment - - O
in - - O
this - - O
study - - O
. - - O

Adenyl - - B-MUT
cyclase - - I-MUT
activity - - O
of - - O
gastric - - O
mucosa - - O
in - - O
patients - - O
with - - O
duodenal - - O
ulcer - - O
before - - O
and - - O
after - - O
treatment - - O
. - - O

In - - O
whole - - O
sardine - - O
, - - O
domoic - - O
acid - - O
was - - O
detected - - O
in - - O
levels - - O
exceeding - - O
sometimes - - O
the - - O
regulatory - - O
limit - - O
. - - O

Comparison - - O
of - - O
beta - - B-MUT
2-microglobulin - - I-MUT
removal - - O
using - - O
the - - O
same - - O
polysulphone - - O
membrane - - O
for - - O
haemodialysis - - O
and - - O
haemofiltration - - O
shows - - O
that - - O
beta - - B-MUT
2-microglobulin - - I-MUT
is - - O
more - - O
effectively - - O
removed - - O
by - - O
convection - - O
than - - O
by - - O
diffusion - - O
when - - O
both - - O
treatment - - O
modes - - O
are - - O
matched - - O
for - - O
blood - - O
flow - - O
and - - O
urea - - O
clearance - - O
. - - O

The - - O
mice - - O
are - - O
phenotypically - - O
normal - - O
and - - O
do - - O
not - - O
develop - - O
spontaneous - - O
tumors - - O
at - - O
an - - O
early - - O
age - - O
, - - O
in - - O
contrast - - O
to - - O
knock-out - - O
( - - O
p53 - - B-MUT
( - - I-MUT
- - - I-MUT
- - - I-MUT
) - - I-MUT
) - - I-MUT
strains - - O
with - - O
a - - O
defective - - O
p53 - - O
gene - - B-MUT
. - - I-MUT

At - - O
this - - O
timepoint - - O
, - - O
many - - O
leucocytes - - O
in - - O
the - - O
ME - - O
and - - O
ET - - O
mucosa - - O
had - - O
incorporated - - O
BrdU - - O
( - - O
between - - O
15 - - O
and - - O
25% - - O
within - - O
the - - O
subsets - - O
) - - O
. - - O

The - - O
cost - - O
per - - O
test - - O
is - - O
less - - O
than - - O
those - - O
for - - O
CC - - O
, - - O
kEIA - - O
and - - O
PACE2 - - O
. - - O

Effect - - O
of - - O
succimer - - O
on - - O
the - - O
intensity - - O
of - - O
tricarboxylic - - B-MUT
acid - - I-MUT
dehydrogenase - - I-MUT
reactions - - O
in - - O
the - - O
brain - - O
of - - O
rats - - O
poisoned - - O
with - - O
mercuric - - O
chloride - - O
. - - O

Our - - O
results - - O
suggest - - O
that - - O
the - - O
C-terminal - - O
region - - O
of - - O
Crk - - B-MUT
contains - - O
negative - - O
regulatory - - O
elements - - O
important - - O
for - - O
both - - O
Abl - - B-MUT
and - - O
FAK - - B-MUT
dependent - - O
signal - - O
pathways - - O
, - - O
and - - O
offers - - O
a - - O
paradigm - - O
for - - O
an - - O
autoinhibitory - - O
region - - O
in - - O
the - - O
SH3 - - B-MUT
linker - - O
C-terminal - - O
SH3 - - O
domain - - B-MUT
. - - O

Adriamycin - - O
: - - O
comparison - - O
of - - O
a - - O
5-week - - O
schedule - - O
with - - O
a - - O
3-week - - O
schedule - - O
in - - O
the - - O
treatment - - O
of - - O
breast - - O
cancer - - O
. - - O

In - - O
contrast - - O
, - - O
mutations - - O
affecting - - O
the - - O
other - - O
two - - O
Nim1p-related - - B-MUT
kinases - - I-MUT
in - - O
S - - O
. - - O
cerevisiae - - O
, - - O
Hsl1p - - B-MUT
and - - O
Kcc4p - - B-MUT
, - - O
produce - - O
no - - O
detectable - - O
effect - - O
on - - O
septin - - B-MUT
organization - - O
. - - O

A - - O
Drosophila - - B-MUT
shc - - I-MUT
gene - - I-MUT
product - - I-MUT
is - - O
implicated - - O
in - - O
signaling - - O
by - - O
the - - O
DER - - B-MUT
receptor - - I-MUT
tyrosine - - I-MUT
kinase - - I-MUT
. - - O

Group - - O
psychometric - - O
functions - - O
for - - O
listeners - - O
with - - O
hearing - - O
loss - - O
do - - O
not - - O
show - - O
a - - O
decrease - - O
in - - O
performance - - O
at - - O
the - - O
largest - - O
values - - O
of - - O
delta - - O
f - - O
included - - O
in - - O
this - - O
study - - O
. - - O

Thus - - O
, - - O
blocks - - O
in - - O
the - - O
RARalpha-specific - - O
pathway - - O
of - - O
retinoid-induced - - O
differentiation - - O
may - - O
be - - O
bypassed - - O
during - - O
retinoid - - O
induction - - O
of - - O
FR-beta - - B-MUT
expression - - O
. - - O

Once - - O
the - - O
proliferation - - O
of - - O
fibroblasts - - O
and - - O
collagen - - B-MUT
synthesis - - O
had - - O
led - - O
to - - O
an - - O
increase - - O
of - - O
mechanical - - O
strength - - O
, - - O
no - - O
negative - - O
effect - - O
on - - O
wound - - O
healing - - O
could - - O
be - - O
detected - - O
applying - - O
the - - O
same - - O
chemotherapeutic - - O
agents - - O
. - - O

In - - O
10 - - O
pentobarbitalized - - O
dogs - - O
, - - O
plasma - - O
viscosity - - O
( - - O
Ep - - O
) - - O
was - - O
raised - - O
fourfold - - O
while - - O
apparent - - O
blood - - O
viscosity - - O
( - - O
Ea - - O
) - - O
increased - - O
about - - O
twofold - - O
by - - O
two - - O
steps - - O
of - - O
exchange - - O
transfusion - - O
of - - O
200 - - O
ml - - O
of - - O
plasma - - O
with - - O
plasma - - O
containing - - O
high - - O
molecular - - O
weight - - O
dextran - - O
( - - O
mol - - O
wt - - O
500 - - O
, - - O
000 - - O
, - - O
20% - - O
wt - - O
vol - - O
) - - O
. - - O

Hospital - - O
hit - - O
for - - O
hiring - - O
AHERF - - O
physicians - - O
. - - O

After - - O
overtraining - - O
on - - O
the - - O
original - - O
discrimination - - O
, - - O
the - - O
controls - - O
showed - - O
the - - O
normal - - O
difficulty - - O
in - - O
learning - - O
the - - O
first - - O
reversal - - O
. - - O

Interestingly - - O
, - - O
the - - O
activity - - O
of - - O
IkappaB - - B-MUT
kinase - - I-MUT
( - - O
IKK-beta - - B-MUT
) - - O
, - - O
which - - O
plays - - O
an - - O
essential - - O
role - - O
in - - O
NF-kappaB - - B-MUT
activation - - O
through - - O
IkappaB - - B-MUT
phosphorylation - - O
, - - O
was - - O
largely - - O
enhanced - - O
in - - O
paclitaxel-treated - - O
cells - - O
, - - O
detected - - O
as - - O
IkappaBalpha - - B-MUT
phosphorylation - - O
. - - O

We - - O
evaluated - - O
regional - - O
right - - O
ventricular - - O
wall - - O
motion - - O
during - - O
systole - - O
in - - O
patients - - O
with - - O
surgically - - O
repaired - - O
tetralogy - - O
of - - O
Fallot - - O
( - - O
TOF - - O
) - - O
using - - O
color - - O
kinesis - - O
imaging - - O
. - - O

The - - O
effect - - O
of - - O
Rho - - B-MUT
on - - O
AP-1 - - B-MUT
is - - O
independent - - O
of - - O
the - - O
mitogen-activated - - B-MUT
protein - - I-MUT
kinase - - I-MUT
pathway - - I-MUT
, - - O
as - - O
a - - O
dominant-negative - - B-MUT
MEK - - I-MUT
and - - O
a - - O
MEK - - B-MUT
inhibitor - - O
( - - O
PD98059 - - O
) - - O
did - - O
not - - O
affect - - O
Rho-induced - - B-MUT
AP-1 - - I-MUT
activity - - O
. - - O

The - - O
mortality - - O
rate - - O
and - - O
histopathological - - O
features - - O
of - - O
Nocardia - - O
asteroides - - O
and - - O
Nocardia - - O
brasiliensis - - O
infections - - O
in - - O
congenitally - - O
athymic - - O
( - - O
nude - - O
) - - O
mice - - O
of - - O
ICR - - O
and - - O
C3H - - O
eB - - O
origins - - O
were - - O
quite - - O
different - - O
from - - O
what - - O
we - - O
found - - O
for - - O
Swiss - - O
white - - O
mice - - O
and - - O
other - - O
inbred - - O
mouse - - O
strains - - O
( - - O
namely - - O
, - - O
C57 - - O
BL - - O
6J - - O
, - - O
New - - O
Zealand - - O
Black - - O
, - - O
BALB - - O
c - - O
, - - O
CBA - - O
LAC - - O
, - - O
and - - O
C3H - - O
eB - - O
) - - O
. - - O

Influence - - O
of - - O
oil - - O
emulsions - - O
and - - O
diphenyl - - O
on - - O
post-harvest - - O
physiconutritional - - O
changes - - O
in - - O
Kagzi - - O
limes - - O
( - - O
Citrus - - O
aurantifolia - - O
) - - O
was - - O
studied - - O
. - - O

IFN-stimulated - - B-MUT
gene - - I-MUT
factor-3 - - I-MUT
and - - O
STAT1 - - B-MUT
homodimers - - I-MUT
formed - - O
and - - O
bound - - O
an - - O
IFN-stimulated - - B-MUT
response - - I-MUT
element - - I-MUT
( - - O
ISRE - - B-MUT
) - - O
and - - O
gamma-activated - - B-MUT
sequence - - I-MUT
( - - O
GAS - - B-MUT
) - - O
element - - O
, - - O
respectively - - O
. - - O

Re - - O
: - - O
A - - O
modified - - O
method - - O
for - - O
the - - O
in - - O
vivo - - O
labeling - - O
of - - O
red - - O
blood - - O
cells - - O
with - - O
Tc-99m - - O
. - - O

ORF - - B-MUT
M1 - - I-MUT
has - - O
striking - - O
homology - - O
to - - O
poxvirus - - O
serpins - - B-MUT
, - - O
while - - O
ORF - - B-MUT
M11 - - I-MUT
encodes - - O
a - - O
potential - - O
homolog - - O
of - - O
Bcl-2-like - - B-MUT
molecules - - I-MUT
encoded - - O
by - - O
other - - O
gammaherpesviruses - - O
( - - O
gene - - B-MUT
16 - - I-MUT
of - - O
HVS - - O
and - - O
KSHV - - O
and - - O
the - - O
BHRF1 - - B-MUT
gene - - I-MUT
of - - O
EBV - - O
) - - O
. - - O

A - - O
short - - O
sequence - - O
surrounding - - O
the - - O
major - - O
JNK - - B-MUT
phosphorylation - - O
site - - O
of - - O
c-Jun - - B-MUT
is - - O
conserved - - O
in - - O
c-Fos - - B-MUT
and - - O
is - - O
part - - O
of - - O
its - - O
activation - - O
domain - - O
, - - O
suggesting - - O
that - - O
c-Fos - - B-MUT
may - - O
be - - O
similarly - - O
regulated - - O
. - - O

Two - - O
hundred - - O
sixty-four - - O
patients - - O
scheduled - - O
for - - O
DCBM - - O
were - - O
randomized - - O
to - - O
receive - - O
intravenously - - O
geG - - O
0 - - O
. - - O
25 - - O
mg - - O
( - - O
geG-25 - - O
) - - O
, - - O
or - - O
geG - - O
0 - - O
. - - O
5 - - O
mg - - O
( - - O
geG-50 - - O
) - - O
, - - O
or - - O
HBB - - O
20 - - O
mg - - O
as - - O
hypotonic - - O
agent - - O
. - - O

Estrogen - - O
replacement - - O
, - - O
either - - O
as - - O
17 - - O
beta-estradiol - - O
or - - O
beta-estradiol-3-benzoate - - O
via - - O
subcutaneous - - O
Silastic - - O
capsules - - O
, - - O
was - - O
associated - - O
with - - O
elevated - - O
rates - - O
of - - O
heat - - O
production - - O
and - - O
dry - - O
heat - - O
loss - - O
relative - - O
to - - O
untreated - - O
ovariectomized - - O
controls - - O
. - - O

Sodium - - O
restriction - - O
in - - O
cardiac - - O
failure - - O
. - - O

Rapamycin - - O
( - - O
FRAP - - B-MUT
mTOR - - O
inhibitor - - B-MUT
) - - O
blocked - - O
4E-BP1 - - O
phosphorylation - - B-MUT
causing - - O
a - - O
predominance - - O
of - - O
the - - O
alpha - - O
( - - O
hypophosphorylated - - O
) - - O
band - - O
. - - O

CONTEXT - - O
: - - O
ThinPrep - - O
, - - O
AutoPap - - O
, - - O
and - - O
Papnet - - O
are - - O
3 - - O
new - - O
technologies - - O
that - - O
increase - - O
the - - O
sensitivity - - O
and - - O
cost - - O
of - - O
cervical - - O
cancer - - O
screening - - O
. - - O

A - - O
unique - - O
leucine-proline - - B-MUT
repeat - - I-MUT
element - - I-MUT
found - - O
N-terminal - - O
to - - O
the - - O
DNA-binding - - O
domain - - O
of - - O
EmBP-1 - - B-MUT
does - - O
not - - O
appear - - O
to - - O
play - - O
a - - O
role - - O
in - - O
DNA-binding - - O
or - - O
dimerization - - O
. - - O

Endosonography - - O
accurately - - O
assessed - - O
tumor - - O
extension - - O
in - - O
two - - O
T2 - - O
tumors - - O
, - - O
14 - - O
T3 - - O
tumors - - O
, - - O
and - - O
seven - - O
T4 - - O
tumors - - O
. - - O

The - - O
PDE4A-subfamily-specific - - B-MUT
linker - - I-MUT
region - - I-MUT
LR1 - - B-MUT
, - - O
which - - O
joins - - O
UCR1 - - B-MUT
and - - O
UCR2 - - B-MUT
, - - O
is - - O
encoded - - O
by - - O
two - - O
exons - - O
, - - O
whereas - - O
LR2 - - B-MUT
, - - O
which - - O
joins - - O
UCR2 - - B-MUT
to - - O
the - - O
catalytic - - O
unit - - O
, - - O
is - - O
encoded - - O
by - - O
a - - O
single - - O
exon - - O
. - - O

Range - - O
behavior - - O
of - - O
Hereford - - O
, - - O
Hereford - - O
x - - O
Holstein - - O
and - - O
Holstein - - O
non-lactating - - O
heifers - - O
. - - O

Forty-eight - - O
pigs - - O
were - - O
removed - - O
from - - O
sows - - O
at - - O
1 - - O
d - - O
of - - O
age - - O
and - - O
randomly - - O
assigned - - O
to - - O
one - - O
of - - O
three - - O
treatments - - O
: - - O
1 - - O
) - - O
control - - O
with - - O
lactose - - O
as - - O
the - - O
carbohydrate - - O
source - - O
, - - O
2 - - O
) - - O
lactose - - O
replaced - - O
( - - O
gram - - O
for - - O
gram - - O
) - - O
with - - O
CSS - - O
( - - O
dextrose - - O
equivalent - - O
[ - - O
DE - - O
] - - O
-20 - - O
) - - O
, - - O
and - - O
3 - - O
) - - O
lactose - - O
replaced - - O
with - - O
DE-42 - - O
. - - O

Oxidative - - O
degradation - - O
of - - O
adrenaline - - O
solutions - - O
: - - O
study - - O
of - - O
the - - O
intermediate - - O
stages - - O
and - - O
their - - O
analytic - - O
value - - O
for - - O
the - - O
control - - O
of - - O
this - - O
solute - - O
. - - O

Forskolin - - O
treatment - - O
( - - O
10 - - O
microM - - O
) - - O
of - - O
the - - O
transfected - - O
cells - - O
for - - O
3--6 - - O
h - - O
maximally - - O
induced - - O
luciferase - - B-MUT
threefold - - O
. - - O

We - - O
have - - O
used - - O
these - - O
modified - - O
assay - - O
conditions - - O
to - - O
extend - - O
studies - - O
on - - O
the - - O
transposition - - O
pathway - - O
. - - O

Thirty - - O
Class - - O
I - - O
and - - O
Class - - O
II - - O
recessions - - O
in - - O
30 - - O
patients - - O
were - - O
treated - - O
with - - O
a - - O
modified - - O
subepithelial - - O
connective - - O
tissue - - O
graft - - O
procedure - - O
. - - O

Two - - O
classes - - O
of - - O
inactive - - O
receptors - - O
were - - O
identified - - O
: - - O
one - - O
in - - O
which - - O
both - - O
transcriptional - - O
activation - - O
and - - O
dimerization - - O
were - - O
compromised - - O
and - - O
a - - O
second - - O
in - - O
which - - O
only - - O
transcriptional - - O
activation - - O
was - - O
abolished - - O
. - - O

The - - O
results - - O
also - - O
imply - - O
that - - O
the - - O
absence - - O
of - - O
perforin - - B-MUT
expression - - O
in - - O
non-cytotoxic - - O
cells - - O
may - - O
be - - O
due - - O
to - - O
the - - O
suppression - - O
of - - O
the - - O
induction - - O
of - - O
the - - O
killer-cell-specific - - O
trans-acting - - O
factor - - O
NF-P2 - - B-MUT
. - - O

Vibrio - - O
cholerae - - O
O139 - - O
in - - O
Calcutta - - O
. - - O

A - - O
brief - - O
account - - O
of - - O
the - - O
1988 - - O
seminar - - O
in - - O
Shanghai - - O
on - - O
viral - - O
hepatitis - - O
A - - O
. - - O

To - - O
characterize - - O
the - - O
expression - - O
of - - O
this - - O
DNA - - B-MUT
repair - - I-MUT
enzyme - - I-MUT
, - - O
we - - O
have - - O
isolated - - O
the - - O
corresponding - - O
genomic - - O
clone - - O
. - - O

Serum - - B-MUT
gamma - - I-MUT
glutamyltransferase - - I-MUT
in - - O
the - - O
diagnosis - - O
of - - O
liver - - O
disease - - O
in - - O
cattle - - O
. - - O

Snail - - O
mortality - - O
did - - O
not - - O
differ - - O
among - - O
the - - O
various - - O
treatment - - O
conditions - - O
. - - O

The - - O
effect - - O
of - - O
a - - O
constant - - O
magnetic - - O
field - - O
on - - O
the - - O
phagocytic - - O
activity - - O
of - - O
Paramecia - - O
. - - O

However - - O
, - - O
one - - O
CAK-phosphorylated - - O
phosphopeptide - - O
comigrates - - O
with - - O
a - - O
Cdc2-phosphorylated - - O
phosphopeptide - - O
previously - - O
shown - - O
to - - O
be - - O
mitosis-specific - - O
, - - O
suggesting - - O
that - - O
, - - O
in - - O
vitro - - O
, - - O
CAK - - B-MUT
is - - O
able - - O
to - - O
phosphorylate - - O
at - - O
least - - O
one - - O
site - - O
that - - O
is - - O
also - - O
phosphorylated - - O
in - - O
vivo - - O
. - - O

The - - O
5-year - - O
overall - - O
survival - - O
( - - O
OS - - O
) - - O
and - - O
progression-free - - O
survival - - O
( - - O
PFS - - O
) - - O
rates - - O
were - - O
58 - - O
. - - O
9% - - O
and - - O
55 - - O
. - - O
4% - - O
for - - O
arm - - O
A - - O
and - - O
44 - - O
. - - O
5% - - O
and - - O
41 - - O
. - - O
3% - - O
for - - O
arm - - O
B - - O
( - - O
P - - O
= - - O
. - - O
007 - - O
and - - O
P - - O
= - - O
. - - O
02 - - O
) - - O
, - - O
respectively - - O
. - - O

The - - O
JTc - - O
delta - - O
among - - O
the - - O
three - - O
groups - - O
did - - O
not - - O
differ - - O
as - - O
well - - O
: - - O
JTc - - O
delta - - O
of - - O
the - - O
VT - - O
group - - O
was - - O
70 - - O
ms - - O
+ - - O
- - - O
30 - - O
ms - - O
, - - O
the - - O
JTc - - O
delta - - O
of - - O
the - - O
PVC - - O
group - - O
was - - O
60 - - O
msec - - O
+ - - O
- - - O
25 - - O
msec - - O
, - - O
and - - O
the - - O
JTc - - O
delta - - O
of - - O
the - - O
control - - O
group - - O
was - - O
70 - - O
ms - - O
+ - - O
- - - O
30 - - O
ms - - O
. - - O

Overall - - O
least-squares - - O
means - - O
for - - O
uncooked - - O
and - - O
cooked - - O
longissimus - - O
muscle - - O
and - - O
subcutaneous - - O
fat - - O
were - - O
63 - - O
. - - O
32 - - O
, - - O
80 - - O
. - - O
27 - - O
and - - O
98 - - O
. - - O
90 - - O
mg - - O
of - - O
cholesterol - - O
100 - - O
g - - O
of - - O
tissue - - O
, - - O
respectively - - O
. - - O

Sequence - - O
analysis - - O
of - - O
the - - O
isolated - - O
genomic - - O
clone - - O
revealed - - O
that - - O
the - - O
DNA - - O
binding - - O
domain - - O
of - - O
this - - O
orphan - - B-MUT
receptor - - I-MUT
is - - O
most - - O
homologous - - O
to - - O
the - - O
human - - B-MUT
TR2 - - I-MUT
receptor - - I-MUT
. - - O

Interestingly - - O
, - - O
this - - O
amino-terminal - - O
determinant - - O
appears - - O
not - - O
to - - O
reside - - O
in - - O
the - - O
HSV-alpha - - O
TIF - - B-MUT
, - - O
which - - O
displays - - O
no - - O
independent - - O
amino-terminal - - O
activity - - O
. - - O

UVA-induced - - O
melanocytic - - O
lesions - - O
. - - O

PFK-A - - B-MUT
mRNA - - O
was - - O
more - - O
abundantly - - O
expressed - - O
in - - O
all - - O
tissues - - O
than - - O
were - - O
the - - O
PFK-B - - B-MUT
and - - O
PFK-C - - B-MUT
genes - - I-MUT
. - - O

The - - O
hybrid - - O
viruses - - O
were - - O
found - - O
to - - O
accumulate - - O
to - - O
high - - O
levels - - O
in - - O
infected - - O
plants - - O
, - - O
to - - O
form - - O
stable - - O
virions - - O
, - - O
and - - O
to - - O
be - - O
mechanically - - O
transmissible - - O
. - - O

The - - O
ORs - - O
of - - O
GC - - O
, - - O
adjusted - - O
for - - O
age - - O
and - - O
sex - - O
, - - O
varied - - O
from - - O
17 - - O
. - - O
1 - - O
, - - O
for - - O
those - - O
with - - O
baseline - - O
diagnoses - - O
of - - O
superficial - - O
intestinal - - O
metaplasia - - O
( - - O
IM - - O
) - - O
, - - O
to - - O
29 - - O
. - - O
3 - - O
, - - O
for - - O
those - - O
with - - O
deep - - O
IM - - O
or - - O
mild - - O
dysplasia - - O
( - - O
DYS - - O
) - - O
or - - O
IM - - O
with - - O
glandular - - O
atrophy - - O
and - - O
neck - - O
hyperplasia - - O
, - - O
to - - O
104 - - O
. - - O
2 - - O
, - - O
for - - O
those - - O
with - - O
moderate - - O
or - - O
severe - - O
DYS - - O
, - - O
as - - O
compared - - O
with - - O
subjects - - O
with - - O
superficial - - O
gastritis - - O
( - - O
SG - - O
) - - O
or - - O
chronic - - O
atrophic - - O
gastritis - - O
( - - O
CAG - - O
) - - O
at - - O
baseline - - O
. - - O

Lesions - - O
were - - O
made - - O
by - - O
pressure - - O
injection - - O
of - - O
kainic - - O
acid - - O
into - - O
the - - O
SOC - - O
through - - O
a - - O
stereotaxically - - O
positioned - - O
glass - - O
micropipette - - O
. - - O

Analysis - - O
of - - O
the - - O
intact - - O
hGH - - B-MUT
gene - - I-MUT
or - - O
hGH - - B-MUT
5'-flanking - - I-MUT
DNA - - I-MUT
( - - I-MUT
5'-FR - - I-MUT
) - - I-MUT
coupled - - O
to - - O
the - - O
hGh - - B-MUT
cDNA - - I-MUT
or - - O
chloramphenicol - - B-MUT
acetyltransferase - - I-MUT
or - - O
luciferase - - B-MUT
genes - - I-MUT
, - - O
indicated - - O
that - - O
cAMP - - O
primarily - - O
stimulated - - O
hGH - - B-MUT
promoter - - I-MUT
activity - - O
. - - O

Chemical - - O
histologic - - O
and - - O
immunologic - - O
responses - - O
in - - O
rats - - O
to - - O
CC1-4 - - O
by - - O
different - - O
routes - - O
of - - O
administration - - O
. - - O

Clone - - O
39 - - O
was - - O
a - - O
homolog - - O
of - - O
CONSTANS - - B-MUT
, - - O
which - - O
is - - O
a - - O
gene - - O
involved - - O
in - - O
controlling - - O
the - - O
flowering - - O
time - - O
in - - O
Arabidopsis - - O
. - - O

Here - - O
we - - O
describe - - O
the - - O
identification - - O
and - - O
characterization - - O
of - - O
several - - O
Sp100 - - B-MUT
splice - - I-MUT
variant - - I-MUT
proteins - - I-MUT
and - - O
support - - O
their - - O
existence - - O
by - - O
elucidation - - O
of - - O
the - - O
3'-end - - O
of - - O
the - - O
Sp100 - - B-MUT
gene - - I-MUT
. - - O

Although - - O
linker - - O
regions - - O
in - - O
transcription - - O
factors - - O
are - - O
known - - O
to - - O
modulate - - O
DNA - - O
binding - - O
specificity - - O
, - - O
our - - O
studies - - O
suggest - - O
that - - O
the - - O
human - - B-MUT
HSF1 - - I-MUT
linker - - O
plays - - O
no - - O
role - - O
in - - O
determining - - O
HSF1 - - B-MUT
binding - - O
preferences - - O
in - - O
vivo - - O
but - - O
is - - O
a - - O
critical - - O
determinant - - O
in - - O
regulating - - O
the - - O
HSF1 - - B-MUT
monomer-trimer - - I-MUT
equilibrium - - O
. - - O

They - - O
also - - O
negatively - - O
modulate - - O
the - - O
PI - - B-MUT
3-kinase - - I-MUT
catalytic - - O
activity - - O
but - - O
to - - O
different - - O
extents - - O
, - - O
dependent - - O
on - - O
the - - O
unique - - O
N-terminal - - O
structure - - O
of - - O
each - - O
isoform - - O
. - - O

We - - O
conclude - - O
that - - O
the - - O
'morning - - O
dip' - - O
observed - - O
in - - O
asthmatic - - O
patients - - O
cannot - - O
simply - - O
be - - O
explained - - O
by - - O
changes - - O
in - - O
cell - - O
receptor - - O
number - - O
or - - O
affinity - - O
, - - O
as - - O
our - - O
results - - O
suggest - - O
that - - O
both - - O
groups - - O
have - - O
intact - - O
beta-adrenoceptor - - B-MUT
function - - O
. - - O

In - - O
contrast - - O
, - - O
the - - O
PPSF - - O
+ - - O
DBP - - O
side - - O
showed - - O
large - - O
amounts - - O
of - - O
bone - - O
formation - - O
, - - O
and - - O
bone - - O
almost - - O
covered - - O
the - - O
implant - - O
. - - O

Clinicopathologic - - O
studies - - O
in - - O
feminizing - - O
tumors - - O
of - - O
the - - O
ovary - - O
. - - O

A - - O
case - - O
of - - O
a - - O
dense - - O
epidermoid - - O
cyst - - O
of - - O
the - - O
suprasellar - - O
cistern - - O
is - - O
presented - - O
. - - O

The - - O
divergence - - O
in - - O
primary - - O
structure - - O
between - - O
the - - O
sheep - - O
CRF1 - - B-MUT
and - - O
the - - O
other - - O
mammalian - - B-MUT
CRF1s - - I-MUT
is - - O
primarily - - O
localized - - O
to - - O
the - - O
extracellular - - O
amino - - O
terminal - - O
domain - - O
of - - O
the - - O
receptor - - O
( - - O
18 - - O
of - - O
22 - - O
divergent - - O
residues - - O
, - - O
ovine - - O
vs - - O
human - - B-MUT
CRF1 - - I-MUT
) - - O
. - - O

Localization - - O
of - - O
the - - O
cytokine - - B-MUT
response - - I-MUT
element - - I-MUT
by - - O
5'-deletion - - O
analysis - - O
and - - O
site-directed - - O
mutagenesis - - O
revealed - - O
a - - O
cis-acting - - O
binding - - O
site - - O
for - - O
activated - - O
STAT - - B-MUT
complexes - - I-MUT
. - - O

Comparison - - O
of - - O
human - - B-MUT
and - - I-MUT
murine - - I-MUT
blk - - I-MUT
sequences - - I-MUT
indicated - - O
that - - O
they - - O
share - - O
86% - - O
amino - - O
acid - - O
identity - - O
, - - O
the - - O
most - - O
conserved - - O
region - - O
being - - O
the - - O
catalytic - - O
domain - - O
( - - O
93% - - O
identity - - O
) - - O
. - - O

An - - O
experiment - - O
on - - O
the - - O
return-of-fear - - O
( - - O
ROF - - O
) - - O
was - - O
carried - - O
out - - O
on - - O
40 - - O
snake- - - O
or - - O
spider-phobic - - O
subjects - - O
in - - O
order - - O
to - - O
determine - - O
whether - - O
an - - O
arousing - - O
event - - O
that - - O
occurs - - O
shortly - - O
before - - O
retest - - O
influences - - O
the - - O
magnitude - - O
of - - O
the - - O
ROF - - O
. - - O

Members - - O
of - - O
the - - O
Ras - - B-MUT
subfamily - - I-MUT
of - - O
small - - B-MUT
GTP-binding - - I-MUT
proteins - - I-MUT
have - - O
been - - O
shown - - O
to - - O
be - - O
promiscuous - - O
towards - - O
a - - O
variety - - O
of - - O
putative - - O
effector - - O
molecules - - O
such - - O
as - - O
the - - O
protein - - B-MUT
kinase - - I-MUT
c-Raf - - I-MUT
and - - O
the - - O
Ral-specific - - B-MUT
guanine - - I-MUT
nucleotide - - I-MUT
exchange - - I-MUT
factor - - I-MUT
( - - O
Ral-GEF - - B-MUT
) - - O
. - - O

Targeted - - O
disruption - - O
of - - O
the - - O
OGG1 - - B-MUT
gene - - I-MUT
in - - O
yeast - - O
revealed - - O
a - - O
second - - O
OG - - B-MUT
glycosylase - - I-MUT
lyase - - I-MUT
protein - - I-MUT
, - - I-MUT
tentatively - - O
named - - O
Ogg2 - - O
, - - B-MUT
which - - O
differs - - O
from - - O
Ogg1 - - O
in - - B-MUT
that - - O
it - - O
preferentially - - O
acts - - O
on - - O
OG - - O
: - - O
G - - O
. - - O

Characterization - - O
of - - O
the - - O
regulatory - - O
regions - - O
of - - O
the - - O
human - - B-MUT
aromatase - - I-MUT
( - - O
P450arom - - B-MUT
) - - O
gene - - O
involved - - O
in - - O
placenta-specific - - O
expression - - O
. - - O

Ectopic - - O
expression - - O
of - - O
Apo-3 - - B-MUT
in - - O
HEK293 - - O
or - - O
HeLa - - O
cells - - O
induced - - O
marked - - O
apoptosis - - O
. - - O

Here - - O
we - - O
report - - O
the - - O
complete - - O
6-kilobase - - O
cDNA - - O
sequence - - O
coding - - O
for - - O
a - - O
chain - - O
of - - O
1775 - - O
amino - - O
acids - - O
, - - O
as - - O
well - - O
as - - O
the - - O
genomic - - O
structure - - O
. - - O

Regulation - - O
of - - O
RhoA - - B-MUT
is - - O
required - - O
to - - O
maintain - - O
adhesion - - O
in - - O
stationary - - O
cells - - O
, - - O
but - - O
is - - O
also - - O
critical - - O
for - - O
cell - - O
spreading - - O
and - - O
migration - - O
[ - - O
3 - - O
] - - O
. - - O

Prolonged - - O
heavy - - O
work - - O
effected - - O
an - - O
increase - - O
of - - O
10 - - O
. - - O
3 - - O
plus - - O
or - - O
minus - - O
0 - - O
. - - O
9 - - O
mmHg - - O
in - - O
in - - O
vivo - - O
P50 - - O
( - - O
7 - - O
. - - O
30 - - O
PH-v - - O
, - - O
41 - - O
degrees - - O
C-v - - O
, - - O
and - - O
45 - - O
Pv-CO2 - - O
) - - O
; - - O
due - - O
entirely - - O
to - - O
the - - O
additive - - O
effects - - O
of - - O
increased - - O
venous - - O
temperature - - O
and - - O
[ - - O
H+ - - O
] - - O
. - - O

DNase - - B-MUT
I - - I-MUT
footprinting - - O
of - - O
the - - O
proximal - - O
promoter - - O
revealed - - O
four - - O
regions - - O
of - - O
protection - - O
. - - O

Atmospheric - - O
benzene - - O
, - - O
urinary - - O
muconic - - O
acid - - O
( - - O
tt-MA - - O
) - - O
and - - O
leukocyte - - B-MUT
alkaline - - I-MUT
phosphatase - - I-MUT
activity - - O
( - - O
LAPA - - O
) - - O
were - - O
evaluated - - O
among - - O
66 - - O
car - - O
mechanics - - O
, - - O
34 - - O
road - - O
tanker - - O
drivers - - O
, - - O
and - - O
28 - - O
nonexposed - - O
workers - - O
. - - O

These - - O
results - - O
indicate - - O
that - - O
residue - - O
266 - - O
serves - - O
as - - O
a - - O
"protein - - O
sensor" - - O
of - - O
altered - - O
minor - - O
groove - - O
interactions - - O
and - - O
identifies - - O
which - - O
base - - O
pair - - O
interactions - - O
are - - O
altered - - O
by - - O
these - - O
lesions - - O
. - - O

Supraventricular - - O
arrhythmias--digoxin - - O
and - - O
quinidine - - O
revisited - - O
. - - O

In - - O
the - - O
present - - O
study - - O
, - - O
we - - O
have - - O
investigated - - O
the - - O
functional - - O
role - - O
of - - O
the - - O
other - - O
MAP - - B-MUT
kinases - - I-MUT
in - - O
PDGF-mediated - - O
cellular - - O
responses - - O
. - - O

Differentiating - - O
among - - O
renal - - O
stones - - O
. - - O

Biological - - O
action - - O
and - - O
kinetics - - O
of - - O
the - - O
elimination - - O
of - - O
tritium - - O
oxide - - O
in - - O
dogs - - O
. - - O

Chordoma - - O
of - - O
the - - O
spinal - - O
cord - - O
in - - O
a - - O
F344 - - O
rat - - O
. - - O

Does - - O
afferent - - O
loop - - O
syndrome - - O
exist - - O
? - - O
It - - O
is - - O
the - - O
author's - - O
opinion - - O
that - - O
diagnosis - - O
of - - O
the - - O
"adducent - - O
loop - - O
syndrome" - - O
is - - O
unlikely - - O
to - - O
be - - O
correct - - O
in - - O
patients - - O
subjected - - O
to - - O
Billroth-II - - O
gastrectomy - - O
. - - O

The - - O
active - - O
derivatives - - O
of - - O
the - - O
present - - O
series - - O
were - - O
also - - O
tested - - O
for - - O
their - - O
analgesic - - O
activity - - O
against - - O
aconitine-induced - - O
writhing - - O
in - - O
albino - - O
mice - - O
and - - O
ulcerogenic - - O
activity - - O
in - - O
albino - - O
rats - - O
. - - O

Disruption - - O
of - - O
the - - O
HOG1 - - B-MUT
and - - O
PBS2 - - B-MUT
genes - - I-MUT
leads - - O
to - - O
a - - O
dramatic - - O
decrease - - O
of - - O
the - - O
HSP12 - - B-MUT
inducibility - - O
in - - O
osmostressed - - O
cells - - O
, - - O
whereas - - O
overproduction - - O
of - - O
Hog1 - - B-MUT
produces - - O
a - - O
fivefold - - O
increase - - O
in - - O
wild-type - - O
induced - - O
levels - - O
upon - - O
a - - O
shift - - O
to - - O
a - - O
high - - O
salt - - O
concentration - - O
. - - O

Human - - B-MUT
Duo - - I-MUT
contains - - O
a - - O
guanine - - B-MUT
nucleotide - - I-MUT
exchange - - I-MUT
factor - - I-MUT
( - - O
GEF - - B-MUT
) - - O
domain - - O
that - - O
is - - O
likely - - O
to - - O
be - - O
rac1-specific - - O
, - - O
a - - O
pleckstrin - - B-MUT
homology - - I-MUT
( - - O
PH - - B-MUT
) - - O
domain - - O
and - - O
spectrin-like - - B-MUT
repeat - - I-MUT
units - - I-MUT
. - - O

The - - O
relations - - O
between - - O
type - - O
A - - O
behavior - - O
, - - O
clinically - - O
relevant - - O
behavior - - O
, - - O
academic - - O
achievement - - O
, - - O
and - - O
IQ - - O
in - - O
children - - O
. - - O

The - - O
results - - O
suggest - - O
that - - O
the - - O
greater - - O
estrogenic - - O
influence - - O
associated - - O
with - - O
the - - O
ethinyl - - O
estradiol-containing - - O
OC - - O
resulted - - O
in - - O
inhibition - - O
of - - O
coronary - - O
artery - - O
atherosclerosis - - O
despite - - O
a - - O
pronounced - - O
progestin-induced - - O
lowering - - O
of - - O
plasma - - O
HDL - - O
cholesterol - - O
concentration - - O
and - - O
, - - O
further - - O
, - - O
that - - O
hormonal - - O
balance - - O
may - - O
have - - O
a - - O
marked - - O
influence - - O
on - - O
the - - O
relationship - - O
between - - O
plasma - - O
lipids - - O
and - - O
atherogenesis - - O
. - - O

In - - O
this - - O
study - - O
, - - O
we - - O
describe - - O
a - - O
mammalian - - O
cell-free - - O
transcription - - O
system - - O
reconstituted - - O
with - - O
only - - O
recombinant - - O
proteins - - O
and - - O
epitope-tagged - - O
multiprotein - - O
complexes - - O
. - - O

We - - O
specially - - O
devised - - O
3 - - O
types - - O
of - - O
turbo - - O
pumps - - O
, - - O
a - - O
centrifugal - - O
pump - - O
( - - O
CFP - - O
) - - O
, - - O
a - - O
mixed - - O
flow - - O
pump - - O
( - - O
MFP - - O
) - - O
, - - O
and - - O
an - - O
axial - - O
flow - - O
pump - - O
( - - O
AFP - - O
) - - O
, - - O
and - - O
analyzed - - O
their - - O
in - - O
vitro - - O
performance - - O
. - - O

Physical - - O
analysis - - O
maps - - O
SAL6 - - B-MUT
to - - O
chromosome - - O
XVI - - O
between - - O
TPK2 - - B-MUT
and - - O
spt14 - - B-MUT
. - - O

Calcium - - O
and - - O
phosphorus - - O
metabolism - - O
in - - O
chronic - - O
uremia - - O
. - - O

Role - - O
of - - O
the - - O
3' - - O
untranslated - - O
region - - O
of - - O
baculovirus - - B-MUT
p10 - - I-MUT
mRNA - - I-MUT
in - - O
high-level - - O
expression - - O
of - - O
foreign - - O
genes - - O
. - - O

The - - O
three - - O
isoforms - - O
purified - - O
with - - O
anti-FLAG - - B-MUT
antibody - - I-MUT
affinity - - O
column - - O
transferred - - O
sulfate - - O
to - - O
heparan - - O
sulfate - - O
and - - O
heparin - - O
but - - O
not - - O
to - - O
other - - O
glycosaminoglycans - - O
. - - O

Cloning - - O
and - - O
expression - - O
of - - O
a - - O
specific - - O
human - - B-MUT
alpha - - I-MUT
1 - - I-MUT
, - - I-MUT
2-mannosidase - - I-MUT
that - - O
trims - - O
Man9GlcNAc2 - - O
to - - O
Man8GlcNAc2 - - O
isomer - - O
B - - O
during - - O
N-glycan - - O
biosynthesis - - O
. - - O

Higher - - O
fasting - - O
serum - - O
gastrin - - B-MUT
concentration - - O
( - - O
102 - - O
. - - O
0 - - O
+ - - O
- - - O
21 - - O
. - - O
1 - - O
vs - - O
63 - - O
. - - O
3 - - O
+ - - O
- - - O
8 - - O
. - - O
3 - - O
ng - - O
. - - O
l-1 - - O
) - - O
, - - O
and - - O
greater - - O
postprandial - - O
gastrin - - O
release - - O
( - - B-MUT
AUC0-120 - - O
: - - O
16690 - - O
+ - - O
- - - O
2648 - - O
vs - - O
10654 - - O
+ - - O
- - - O
1283 - - O
ng - - O
. - - O
l-1 - - O
min - - O
) - - O
were - - O
observed - - O
after - - O
VTP-HM - - O
than - - O
after - - O
VTP-Cas - - O
. - - O

Second - - O
, - - O
the - - O
transcription - - B-MUT
factor - - I-MUT
Gal-ER - - I-MUT
was - - O
rendered - - O
more - - O
potent - - O
and - - O
less - - O
susceptible - - O
to - - O
cell - - O
type-specific - - O
variation - - O
by - - O
fusing - - O
the - - O
strong - - O
activating - - O
domain - - O
of - - O
the - - O
herpesvirus - - B-MUT
protein - - I-MUT
VP16 - - I-MUT
onto - - O
its - - O
C - - O
terminus - - O
. - - O

A - - O
progressive - - O
growth - - O
of - - O
blood - - O
erythrocyte - - O
membrane - - O
injury - - O
has - - O
been - - O
demonstrated - - O
after - - O
rats - - O
were - - O
exposed - - O
to - - O
gamma-irradiaton - - O
at - - O
a - - O
dose - - O
of - - O
100 - - O
to - - O
500 - - O
Gy - - O
. - - O

VDR - - B-MUT
RXR - - I-MUT
bound - - I-MUT
well - - O
to - - O
the - - O
VDREs - - O
and - - B-MUT
to - - O
DR4 - - O
and - - B-MUT
DR5 - - O
using - - B-MUT
the - - O
electrophoretic - - O
mobility - - O
shift - - O
assay - - O
. - - O

We - - O
describe - - O
a - - O
case - - O
of - - O
acetaminophen - - O
overdose - - O
that - - O
was - - O
treated - - O
with - - O
both - - O
hemodialysis - - O
( - - O
HD - - O
) - - O
and - - O
NAC - - O
due - - O
to - - O
severe - - O
intoxication - - O
and - - O
slow - - O
drug - - O
clearance - - O
. - - O

Acad - - O
. - - O

The - - O
amplitudes - - O
of - - O
DPOAE - - O
also - - O
recovered - - O
to - - O
a - - O
greater - - O
extent - - O
and - - O
outer - - O
hair - - O
cell - - O
losses - - O
were - - O
less - - O
severe - - O
in - - O
the - - O
R-PIA-treated - - O
ears - - O
. - - O

Furthermore - - O
, - - O
beta - - B-MUT
2-adrenoceptor - - I-MUT
sensitivity - - O
appears - - O
to - - O
be - - O
unaltered - - O
in - - O
BHT - - O
. - - O

Fifty-eight - - O
RMI's - - O
occurred - - O
in - - O
the - - O
placebo - - O
group - - O
as - - O
compared - - O
to - - O
only - - O
twenty - - O
in - - O
the - - O
AC - - O
group - - O
( - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
01 - - O
) - - O
. - - O

Nodal - - O
domains - - O
are - - O
regions - - O
where - - O
a - - O
function - - O
has - - O
definite - - O
sign - - O
. - - O

HYPOTHESIS - - O
: - - O
The - - O
aim - - O
of - - O
this - - O
study - - O
was - - O
to - - O
investigate - - O
the - - O
oxidative - - O
susceptibility - - O
of - - O
apolipoprotein - - B-MUT
B-containing - - I-MUT
lipoproteins - - I-MUT
and - - O
antioxidant - - O
status - - O
in - - O
patients - - O
with - - O
acute - - O
coronary - - O
syndromes - - O
and - - O
chronic - - O
stable - - O
angina - - O
pectoris - - O
. - - O

Cost-effectiveness - - O
analysis - - O
provides - - O
a - - O
rational - - O
means - - O
of - - O
allocating - - O
limited - - O
health - - O
care - - O
resources - - O
by - - O
allowing - - O
the - - O
comparison - - O
of - - O
the - - O
costs - - O
of - - O
lipid-lowering - - O
therapy - - O
, - - O
in - - O
particular - - O
, - - O
therapy - - O
with - - O
beta-hydroxy-beta-methylglutaryl-CoA - - B-MUT
( - - I-MUT
coenzyme - - I-MUT
A - - I-MUT
) - - I-MUT
reductase - - I-MUT
inhibitors - - O
( - - O
statins - - O
) - - O
, - - O
with - - O
the - - O
costs - - O
of - - O
atherosclerosis - - O
that - - O
could - - O
be - - O
prevented - - O
by - - O
lowering - - O
cholesterol - - O
. - - O

Further - - O
, - - O
Ser - - O
Thr - - O
phosphorylation - - O
of - - O
downstream - - O
molecules - - O
Akt - - O
and - - B-MUT
p70 - - O
S6 - - B-MUT
kinase - - I-MUT
was - - I-MUT
inhibited - - O
. - - O

The - - O
cloning - - O
of - - O
PTR2 - - B-MUT
represents - - O
the - - O
first - - O
example - - O
of - - O
the - - O
molecular - - O
genetic - - O
characterization - - O
of - - O
a - - O
eucaryotic - - O
peptide - - O
transport - - O
gene - - O
. - - O

These - - O
include - - O
the - - O
CACCC - - O
and - - O
CAAT - - O
motifs - - O
. - - O

Sixty-nine - - O
( - - O
44% - - O
) - - O
patients - - O
were - - O
administered - - O
250 - - O
MBq - - O
( - - O
7 - - O
mCi - - O
) - - O
99Tcm-tetrofosmin - - O
at - - O
rest - - O
followed - - O
4 - - O
h - - O
later - - O
by - - O
750 - - O
MBq - - O
( - - O
21 - - O
mCi - - O
) - - O
during - - O
stress - - O
( - - O
the - - O
1 - - O
day - - O
protocol - - O
) - - O
, - - O
whereas - - O
88 - - O
( - - O
56% - - O
) - - O
patients - - O
had - - O
rest - - O
and - - O
stress - - O
imaging - - O
studies - - O
on - - O
two - - O
separate - - O
days - - O
, - - O
receiving - - O
a - - O
500 - - O
MBq - - O
( - - O
14 - - O
mCi - - O
) - - O
dose - - O
of - - O
99Tcm-tetrofosmin - - O
on - - O
each - - O
occasion - - O
( - - O
the - - O
2 - - O
day - - O
protocol - - O
) - - O
. - - O

Liver - - O
microsomes - - O
of - - O
the - - O
shag - - O
showed - - O
smaller - - O
than - - O
8% - - O
of - - O
the - - O
epoxide - - B-MUT
hydrase - - I-MUT
activity - - O
and - - O
smaller - - O
than - - O
14% - - O
of - - O
the - - O
hydroxylating - - O
capacity - - O
of - - O
liver - - O
microsomes - - O
from - - O
the - - O
rat - - O
. - - O

Deletion - - O
analysis - - O
of - - O
rOC - - B-MUT
promoter-chloramphenicol - - I-MUT
acetyltransferase - - I-MUT
constructs - - I-MUT
demonstrates - - O
that - - O
an - - O
AML-1-binding - - B-MUT
sequence - - I-MUT
within - - O
the - - O
proximal - - O
promoter - - O
( - - O
-138 - - O
to - - O
-130 - - O
nt - - O
) - - O
contributes - - O
to - - O
75% - - O
of - - O
the - - O
level - - O
of - - O
osteocalcin - - B-MUT
gene - - I-MUT
expression - - O
. - - O

Recently - - O
, - - O
it - - O
was - - O
shown - - O
that - - O
purified - - O
RAG1 - - B-MUT
2 - - I-MUT
proteins - - I-MUT
can - - I-MUT
cleave - - O
DNA - - O
hairpins - - O
in - - O
vitro - - O
, - - O
but - - O
the - - O
same - - O
activity - - O
was - - O
also - - O
described - - O
for - - O
a - - O
protein - - O
complex - - O
of - - O
the - - O
DNA - - O
repair - - B-MUT
proteins - - I-MUT
Nbs1 - - I-MUT
Mre11 - - I-MUT
Rad50 - - I-MUT
. - - I-MUT

Finally - - O
, - - O
the - - O
stability - - O
of - - O
the - - O
nucleotide - - O
binding - - O
function - - O
of - - O
the - - O
two - - O
proteins - - O
is - - O
similar - - O
as - - O
assessed - - O
by - - O
sensitivity - - O
to - - O
urea - - O
. - - O

Our - - O
studies - - O
extend - - O
these - - O
findings - - O
and - - O
show - - O
that - - O
the - - O
E2 - - B-MUT
transactivation - - I-MUT
gene - - I-MUT
is - - O
expressed - - O
from - - O
multiple - - O
promoters - - O
. - - O

Expression - - O
of - - O
a - - O
hybrid - - O
protein - - O
containing - - O
the - - O
cytoplasmic - - O
C-terminal - - O
half - - O
of - - O
UhpB - - B-MUT
fused - - O
to - - O
glutathione - - B-MUT
S-transferase - - I-MUT
( - - O
GST - - B-MUT
) - - O
also - - O
interfered - - O
with - - O
Uhp - - B-MUT
signaling - - O
. - - O

Morphological - - O
and - - O
functional - - O
alterations - - O
noted - - O
after - - O
baboon - - O
renal - - O
allotransplantation - - O
. - - O

The - - O
sequence - - O
of - - O
the - - O
HIR1 - - B-MUT
gene - - I-MUT
predicts - - O
an - - O
88-kDa - - O
protein - - O
with - - O
three - - O
repeats - - O
of - - O
a - - O
motif - - O
found - - O
in - - O
the - - O
G - - B-MUT
beta - - I-MUT
subunit - - I-MUT
of - - O
retinal - - B-MUT
transducin - - I-MUT
and - - O
in - - O
a - - O
yeast - - O
transcriptional - - O
repressor - - O
, - - O
Tup1 - - B-MUT
. - - O

65-kilodalton - - O
protein - - O
phosphorylated - - O
by - - O
interleukin - - B-MUT
2 - - I-MUT
stimulation - - O
bears - - O
two - - O
putative - - O
actin-binding - - B-MUT
sites - - I-MUT
and - - O
two - - O
calcium-binding - - O
sites - - O
. - - O

The - - O
murine - - B-MUT
mutation - - I-MUT
dominant - - I-MUT
white - - I-MUT
spotting - - I-MUT
( - - O
W - - B-MUT
) - - O
is - - O
in - - O
the - - O
proto-oncogene - - O
, - - O
c-kit - - B-MUT
. - - O

Protein - - B-MUT
kinase - - I-MUT
C - - I-MUT
( - - O
PKC - - B-MUT
) - - O
, - - O
a - - O
widely-distributed - - O
enzyme - - O
implicated - - O
in - - O
the - - O
regulation - - O
of - - O
many - - O
physiological - - O
processes - - O
, - - O
consists - - O
of - - O
a - - O
family - - O
of - - O
at - - O
least - - O
twelve - - O
isoenzymes - - O
which - - O
differ - - O
in - - O
tissue - - O
distribution - - O
, - - O
subcellular - - O
localization - - O
, - - O
regulatory - - O
properties - - O
, - - O
etc - - O
. - - O

Therefore - - O
, - - O
the - - O
rbcL-rbcS - - B-MUT
locus - - I-MUT
seems - - O
to - - O
be - - O
barely - - O
expressed - - O
under - - O
a - - O
standard - - O
condition - - O
for - - O
photoautotrophic - - O
growth - - O
. - - O

In - - O
particular - - O
, - - O
the - - O
S1' - - B-MUT
specificity - - I-MUT
site - - I-MUT
is - - O
a - - O
deep - - O
and - - O
highly - - O
hydrophobic - - O
cavity - - O
. - - O

Pigs - - O
were - - O
switched - - O
from - - O
the - - O
growing - - O
to - - O
the - - O
finishing - - O
diet - - O
at - - O
57 - - O
and - - O
61 - - O
kg - - O
in - - O
Exp - - O
. - - O

In - - O
broken - - O
L-cell - - O
membranes - - O
expressing - - O
wild - - B-MUT
type - - I-MUT
or - - I-MUT
mutant - - I-MUT
M6P - - I-MUT
IGF - - I-MUT
II - - I-MUT
receptors - - I-MUT
, - - I-MUT
30 - - O
nM - - O
IGF - - O
II - - B-MUT
also - - I-MUT
failed - - O
to - - O
affect - - O
the - - O
pertussis - - O
toxin - - B-MUT
substrate - - I-MUT
activity - - O
. - - O

NF-HB - - B-MUT
( - - O
BSAP - - B-MUT
) - - O
is - - O
a - - O
repressor - - O
of - - O
the - - O
murine - - B-MUT
immunoglobulin - - I-MUT
heavy-chain - - I-MUT
3' - - I-MUT
alpha - - I-MUT
enhancer - - I-MUT
at - - O
early - - O
stages - - O
of - - O
B-cell - - O
differentiation - - O
. - - O

We - - O
found - - O
that - - O
RhoA - - B-MUT
can - - O
initiate - - O
a - - O
linear - - O
kinase - - O
cascade - - O
leading - - O
to - - O
the - - O
activation - - O
of - - O
ERK6 - - B-MUT
( - - O
p38 - - B-MUT
gamma - - I-MUT
) - - O
, - - O
a - - O
recently - - O
identified - - O
member - - O
of - - O
the - - O
p38 - - B-MUT
family - - I-MUT
of - - O
MAPKs - - B-MUT
. - - O

Granulocyte - - B-MUT
colony-stimulating - - I-MUT
factor - - I-MUT
( - - O
G-CSF - - B-MUT
) - - O
administration - - O
in - - O
vivo - - O
has - - O
been - - O
shown - - O
to - - O
improve - - O
the - - O
defence - - O
mechanisms - - O
against - - O
infection - - O
by - - O
different - - O
microbes - - O
. - - O

Exposure - - O
to - - O
higher - - O
TPA - - B-MUT
concentrations - - O
decreased - - O
the - - O
content - - O
of - - O
these - - O
transcripts - - O
. - - O

100 - - O
and - - O
14 - - O
p - - O
. - - O

GN101 - - O
, - - O
YC819-9 - - O
, - - O
and - - O
SB3 - - O
. - - O

Another - - O
common - - O
mutation - - O
involved - - O
amino - - O
acids - - O
that - - O
are - - O
thought - - O
to - - O
make - - O
specific - - O
contacts - - O
with - - O
DNA - - O
. - - O

Patients - - O
were - - O
assessed - - O
for - - O
cardiac - - O
MIBG - - O
uptake - - O
, - - O
circulating - - O
norepinephrine - - O
concentration - - O
, - - O
LVEF - - O
, - - O
peak - - O
Vo2 - - O
, - - O
x-ray - - O
cardiothoracic - - O
ratio - - O
, - - O
M-mode - - O
echographic - - O
end-diastolic - - O
diameter - - O
and - - O
right-sided - - O
heart - - O
catheterization - - O
parameters - - O
. - - O

Comparison - - O
of - - O
the - - O
sequences - - O
of - - O
attP - - B-MUT
, - - O
attB - - B-MUT
and - - O
bacteria-prophage - - O
junctions - - O
attL - - B-MUT
and - - O
attR - - B-MUT
showed - - O
a - - O
26 - - O
bp - - O
common - - O
core - - O
sequence - - O
, - - O
where - - O
recombination - - O
takes - - O
place - - O
, - - O
near - - O
the - - O
5' - - O
end - - O
of - - O
the - - O
integrase - - B-MUT
gene - - I-MUT
. - - O

This - - O
revealed - - O
a - - O
minimum - - O
of - - O
six - - O
novel - - O
OSBP-related - - B-MUT
proteins - - I-MUT
, - - O
designated - - O
ORP-1 - - B-MUT
to - - O
ORP-6 - - B-MUT
. - - O

Hp - - O
positive - - O
relatives - - O
of - - O
gastric - - O
cancer - - O
had - - O
a - - O
markedly - - O
higher - - O
prevalence - - O
of - - O
atrophy - - O
than - - O
those - - O
with - - O
Hp - - O
negativity - - O
without - - O
cancer - - O
relatives - - O
( - - O
29 - - O
vs - - O
. - - O

A - - O
. - - O
, - - O
Swift - - O
, - - O
A - - O
. - - O

We - - O
have - - O
been - - O
studying - - O
the - - O
interaction - - O
of - - O
the - - O
oncogenic - - O
human - - O
polyomavirus - - O
BK - - O
( - - O
BKV - - O
) - - O
with - - O
the - - O
tumor-suppressor - - B-MUT
protein - - I-MUT
p53 - - I-MUT
to - - O
understand - - O
the - - O
biology - - O
of - - O
this - - O
virus - - O
as - - O
well - - O
as - - O
to - - O
understand - - O
the - - O
basic - - O
mechanisms - - O
of - - O
p53 - - B-MUT
transactivation - - O
. - - O

The - - O
pJR - - O
vectors - - O
differ - - O
among - - O
them - - O
in - - O
: - - O
( - - O
a - - O
) - - O
the - - O
selectable - - O
marker - - O
( - - O
Saccharomyces - - O
cerevisiae - - O
LEU - - B-MUT
2 - - I-MUT
gene - - I-MUT
, - - O
which - - O
complements - - O
S - - B-MUT
. - - I-MUT
pombe - - I-MUT
leu1- - - I-MUT
gene - - I-MUT
and - - O
S - - O
. - - O
pombe - - O
ura4+ - - B-MUT
and - - O
his3+ - - B-MUT
genes - - I-MUT
) - - O
; - - O
( - - O
b - - O
) - - O
the - - O
thiamine-repressible - - O
nmt1 - - B-MUT
promoter - - I-MUT
( - - O
3X - - O
, - - O
41X - - O
and - - O
81X - - O
with - - O
extremely - - O
high - - O
, - - O
moderate - - O
or - - O
low - - O
transcription - - O
efficiency - - O
, - - O
respectively - - O
) - - O
; - - O
and - - O
( - - O
c - - O
) - - O
the - - O
multiple - - O
cloning - - O
site - - O
( - - O
two - - O
multiple - - O
cloning - - O
sites - - O
, - - O
with - - O
12 - - O
restriction - - O
sites - - O
each - - O
) - - O
. - - O

This - - O
report - - O
substantiates - - O
that - - O
at - - O
least - - O
two - - O
of - - O
the - - O
18 - - O
kDa - - O
hsps - - B-MUT
in - - O
maize - - O
are - - O
products - - O
of - - O
different - - O
but - - O
related - - O
genes - - O
. - - O

The - - O
novel - - O
hematopoietic - - B-MUT
growth - - I-MUT
factor - - I-MUT
FLT3 - - I-MUT
ligand - - I-MUT
( - - O
FL - - B-MUT
) - - O
is - - O
the - - O
cognate - - O
ligand - - O
for - - O
the - - O
FLT3 - - B-MUT
, - - O
tyrosine - - B-MUT
kinase - - I-MUT
receptor - - I-MUT
( - - O
R - - B-MUT
) - - O
, - - O
also - - O
referred - - O
to - - O
as - - O
FLK-2 - - B-MUT
and - - O
STK-1 - - B-MUT
. - - O

The - - O
mucosal - - O
defence - - O
capacity - - O
against - - O
proteolytic - - O
leukocyte - - O
enzymes - - O
. - - O

The - - O
Mif1 - - B-MUT
5' - - I-MUT
flanking - - I-MUT
region - - I-MUT
contains - - O
a - - O
functional - - O
ER - - B-MUT
stress-responsive - - I-MUT
element - - I-MUT
which - - O
is - - O
sufficient - - O
for - - O
induction - - O
by - - O
tunicamycin - - O
. - - O

After - - O
infection - - O
of - - O
293 - - O
cells - - O
( - - O
which - - O
provide - - O
complementary - - O
E1a-E1b - - B-MUT
functions - - O
) - - O
, - - O
both - - O
viruses - - O
directed - - O
equal - - O
amounts - - O
of - - O
P - - B-MUT
C-specific - - I-MUT
mRNA - - I-MUT
transcription - - I-MUT
. - - O

This - - O
prospective - - O
study - - O
compared - - O
the - - O
measured - - O
energy - - O
expenditures - - O
of - - O
30 - - O
patients - - O
using - - O
indirect - - O
calorimetry - - O
with - - O
their - - O
predicted - - O
basal - - O
energy - - O
expenditure - - O
according - - O
to - - O
the - - O
Harris-Benedict - - O
equation - - O
, - - O
or - - O
their - - O
calculated - - O
energy - - O
expenditure - - O
derived - - O
from - - O
basal - - O
energy - - O
expenditure - - O
times - - O
, - - O
an - - O
activity - - O
factor - - O
, - - O
and - - O
a - - O
stress - - O
factor - - O
. - - O

To - - O
determine - - O
what - - O
role - - O
eIF4E - - B-MUT
might - - O
play - - O
in - - O
c-myc - - B-MUT
expression - - O
, - - O
the - - O
c-myc - - B-MUT
5' - - I-MUT
untranslated - - I-MUT
region - - I-MUT
( - - I-MUT
UTR - - I-MUT
) - - I-MUT
was - - O
fused - - O
in-frame - - O
to - - O
CAT - - B-MUT
reporters - - I-MUT
, - - O
and - - O
several - - O
more - - O
derivative - - O
constructs - - O
were - - O
made - - O
. - - O

Such - - O
a - - O
change - - O
may - - O
involve - - O
increased - - O
mammary - - O
utilization - - O
of - - O
pre-formed - - O
long-chain - - O
fatty - - O
acid - - O
and - - O
increased - - O
metabolism - - O
of - - O
glucose - - O
via - - O
glycolysis - - O
. - - O

Unaided - - O
attempts - - O
to - - O
quit - - O
smoking - - O
are - - O
generally - - O
unsuccessful - - O
. - - O

Mycotoxins - - B-MUT
in - - O
feeds - - O
and - - O
foods - - O
. - - O

The - - O
experiments - - O
show - - O
that - - O
it - - O
is - - O
the - - O
micromilieu - - O
of - - O
the - - O
alveoli - - O
and - - O
the - - O
condition - - O
of - - O
the - - O
AM - - O
( - - O
certain - - O
physiological - - O
activation - - O
states - - O
, - - O
such - - O
as - - O
phagocytic - - O
activity - - O
) - - O
that - - O
essentially - - O
determine - - O
the - - O
degree - - O
of - - O
recovery - - O
. - - O

Comparative - - O
studies - - O
of - - O
the - - O
antithrombin - - B-MUT
III - - I-MUT
level - - O
and - - O
plasminogen - - B-MUT
activator - - I-MUT
activity - - O
in - - O
patients - - O
with - - O
thrombophlebitis - - O
. - - O

Thus - - O
, - - O
YMIP - - B-MUT
is - - O
a - - O
functional - - O
homolog - - O
of - - O
RMIP - - B-MUT
and - - O
represents - - O
a - - O
new - - O
component - - O
of - - O
the - - O
yeast - - O
mitochondrial - - O
import - - O
machinery - - O
. - - O

METHODS - - O
: - - O
Forty-nine - - O
cases - - O
with - - O
intrahepatic - - O
multiple - - O
nodules - - O
of - - O
HCC - - O
, - - O
by - - O
gross - - O
examination - - O
, - - O
among - - O
184 - - O
consecutive - - O
resected - - O
HCCs - - O
were - - O
examined - - O
clinicopathologically - - O
. - - O

Influence - - O
of - - O
cigarette - - O
smoking - - O
on - - O
some - - O
blood - - O
coagulation - - O
tests - - O
. - - O

During - - O
the - - O
program's - - O
use - - O
at - - O
the - - O
RSNA - - O
meeting - - O
, - - O
the - - O
program - - O
selected - - O
the - - O
correct - - O
diagnosis - - O
in - - O
the - - O
top - - O
five - - O
22% - - O
of - - O
the - - O
time - - O
. - - O

Mutation - - O
of - - O
Enh4 - - B-MUT
, - - O
an - - O
essential - - O
GT-IIC-like - - B-MUT
enhanson - - I-MUT
in - - O
the - - O
context - - O
of - - O
the - - O
intact - - O
enhancer - - O
, - - O
abolishes - - O
silencer - - O
activity - - O
, - - O
and - - O
multimerized - - O
GT-IIC - - B-MUT
enhansons - - I-MUT
mimic - - O
the - - O
intact - - O
CSEn - - B-MUT
enhancer - - I-MUT
silencer - - I-MUT
activities - - I-MUT
in - - O
BeWo - - O
and - - O
GC - - O
cells - - O
, - - O
respectively - - O
. - - O

The - - O
complete - - O
gene - - O
organization - - O
was - - O
obtained - - O
by - - O
combining - - O
the - - O
results - - O
of - - O
the - - O
sequence - - O
of - - O
these - - O
clones - - O
and - - O
those - - O
of - - O
the - - O
characterization - - O
of - - O
polymerase - - B-MUT
chain - - O
reaction-amplified - - O
genomic - - O
segments - - O
. - - O

The - - O
dopamine - - B-MUT
D4 - - I-MUT
receptor - - I-MUT
as - - O
well - - O
as - - O
many - - O
other - - O
catecholaminergic - - B-MUT
receptors - - I-MUT
contain - - O
several - - O
putative - - O
SH3 - - B-MUT
binding - - I-MUT
domains - - I-MUT
. - - O

These - - O
data - - O
indicate - - O
that - - O
activation - - O
of - - O
these - - O
enzymes - - O
is - - O
not - - O
sufficient - - O
for - - O
the - - O
acute - - O
stimulation - - O
of - - O
glucose - - O
transport - - O
. - - O

EXAFS - - O
measurements - - O
around - - O
the - - O
Ge-K - - O
edge - - O
have - - O
been - - O
carried - - O
out - - O
for - - O
liquid - - O
Ge-Si - - O
alloys - - O
for - - O
the - - O
first - - O
time - - O
to - - O
investigate - - O
the - - O
local - - O
structure - - O
around - - O
a - - O
Ge - - O
atom - - O
. - - O

We - - O
used - - O
the - - O
Toshiba - - O
IIDR - - O
system - - O
, - - O
which - - O
is - - O
composed - - O
of - - O
an - - O
X-ray - - O
TV - - O
system - - O
and - - O
a - - O
digital - - O
image - - O
managing - - O
circuit - - O
. - - O

Dissociable - - O
effects - - O
of - - O
lidocaine - - O
inactivation - - O
of - - O
the - - O
rostral - - O
and - - O
caudal - - O
basolateral - - O
amygdala - - O
on - - O
the - - O
maintenance - - O
and - - O
reinstatement - - O
of - - O
cocaine-seeking - - O
behavior - - O
in - - O
rats - - O
. - - O

Spontaneous - - O
degradation - - O
of - - O
atracurium - - O
in - - O
plasma - - O
is - - O
the - - O
major - - O
route - - O
of - - O
elimination - - O
in - - O
man - - O
and - - O
contributes - - O
to - - O
a - - O
short - - O
elimination - - O
half-life - - O
( - - O
approximatively - - O
20 - - O
min - - O
) - - O
. - - O

Wild-type - - B-MUT
AT1A - - I-MUT
receptors - - I-MUT
, - - O
expressed - - O
in - - O
Chinese - - O
hamster - - O
ovary - - O
cells - - O
, - - O
rapidly - - O
internalized - - O
after - - O
Ang - - B-MUT
II - - I-MUT
stimulation - - O
[ - - O
t1 - - O
2 - - O
2 - - O
. - - O
3 - - O
min - - O
; - - O
maximal - - O
level - - O
of - - O
internalization - - O
( - - O
Ymax - - O
) - - O
78 - - O
. - - O
2% - - O
] - - O
, - - O
as - - O
did - - O
mutant - - O
receptors - - O
carrying - - O
single - - O
acidic - - O
substitutions - - O
( - - O
T332E - - O
, - - O
t1 - - O
2 - - O
2 - - O
. - - O
7 - - O
min - - O
, - - O
Ymax - - O
76 - - O
. - - O
3% - - O
; - - O
S335D - - O
, - - O
t1 - - O
2 - - O
2 - - O
. - - O
4 - - O
min - - O
, - - O
Ymax - - O
76 - - O
. - - O
7% - - O
; - - O
T336E - - O
, - - O
t1 - - O
2 - - O
2 - - O
. - - O
5 - - O
min - - O
, - - O
Ymax - - O
78 - - O
. - - O
2% - - O
; - - O
S338D - - O
, - - O
t1 - - O
2 - - O
2 - - O
. - - O
6 - - O
min - - O
, - - O
Ymax - - O
78 - - O
. - - O
4% - - O
) - - O
. - - O

Almost - - O
complete - - O
sequence - - O
identity - - O
was - - O
found - - O
between - - O
the - - O
3' - - O
end - - O
of - - O
the - - O
DXS6673E - - B-MUT
gene - - I-MUT
and - - O
two - - O
expressed - - O
sequence - - O
tags - - O
( - - O
ESTs - - O
) - - O
and - - O
between - - O
the - - O
5' - - O
end - - O
of - - O
the - - O
DXS6673E - - B-MUT
gene - - I-MUT
and - - O
a - - O
third - - O
EST - - O
. - - O

1 - - O
. - - O

The - - O
rate-limiting - - O
step - - O
for - - O
telomerase - - B-MUT
activity - - O
seems - - O
to - - O
be - - O
the - - O
expression - - O
of - - O
the - - O
catalytic - - O
subunit - - O
of - - O
the - - O
enzyme - - O
, - - O
encoded - - O
by - - O
the - - O
human - - B-MUT
telomerase - - I-MUT
reverse - - I-MUT
transcriptase - - I-MUT
( - - O
hTERT - - B-MUT
) - - O
gene - - O
. - - O

Characterization - - O
of - - O
the - - O
5'-flanking - - O
region - - O
of - - O
the - - O
human - - B-MUT
multidrug - - I-MUT
resistance - - I-MUT
protein - - I-MUT
2 - - I-MUT
( - - O
MRP2 - - B-MUT
) - - O
gene - - O
and - - O
its - - O
regulation - - O
in - - O
comparison - - O
withthe - - O
multidrug - - B-MUT
resistance - - I-MUT
protein - - I-MUT
3 - - I-MUT
( - - O
MRP3 - - B-MUT
) - - O
gene - - O
. - - O

Epstein-Barr - - B-MUT
virus - - I-MUT
( - - I-MUT
EBV - - I-MUT
) - - I-MUT
latent - - I-MUT
membrane - - I-MUT
protein - - I-MUT
1 - - I-MUT
( - - O
LMP1 - - B-MUT
) - - O
is - - O
essential - - O
for - - O
EBV-mediated - - O
transformation - - O
of - - O
primary - - O
B - - O
lymphocytes - - O
. - - O

Regulation - - O
of - - O
parathyroid - - B-MUT
hormone-related - - I-MUT
protein - - I-MUT
( - - O
PTHrP - - B-MUT
) - - O
gene - - O
expression - - O
. - - O

Taken - - O
together - - O
, - - O
our - - O
data - - O
suggest - - O
that - - O
the - - O
antagonistic - - O
effects - - O
of - - O
CRP - - B-MUT
and - - O
KdgR - - B-MUT
on - - O
the - - O
expression - - O
of - - O
the - - O
pectinolysis - - B-MUT
genes - - I-MUT
occur - - O
by - - O
different - - O
mechanisms - - O
, - - O
including - - O
direct - - O
competition - - O
between - - O
the - - O
two - - O
regulators - - O
or - - O
between - - O
the - - O
repressor - - O
and - - O
RNA - - B-MUT
polymerase - - I-MUT
for - - O
the - - O
occupation - - O
of - - O
a - - O
common - - O
DNA - - O
region - - O
on - - O
the - - O
target - - O
genes - - O
. - - O

In - - O
a - - O
gntR - - B-MUT
deletion - - I-MUT
mutant - - I-MUT
, - - O
the - - O
expression - - O
of - - O
a - - O
chromosomal - - B-MUT
gntT - - I-MUT
: - - I-MUT
: - - I-MUT
lacZ - - I-MUT
fusion - - I-MUT
is - - O
both - - O
high - - O
and - - O
constitutive - - O
, - - O
confirming - - O
that - - O
GntR - - B-MUT
is - - O
the - - O
negative - - O
regulator - - O
of - - O
gntT - - B-MUT
. - - O

Consistent - - O
with - - O
the - - O
protein - - O
expression - - O
data - - O
, - - O
V - - B-MUT
beta - - I-MUT
8 - - I-MUT
. - - I-MUT
3 - - I-MUT
gene - - I-MUT
transcripts - - I-MUT
were - - O
found - - O
only - - O
in - - O
the - - O
transgenic - - O
lines - - O
with - - O
the - - O
wild-type - - O
promoter - - O
. - - O

These - - O
synergistic - - O
effects - - O
were - - O
strongly - - O
Jem-1 - - B-MUT
dose-dependent - - O
. - - O

Their - - O
afterglows - - O
are - - O
brighter - - O
than - - O
supernovae - - O
and - - O
therefore - - O
are - - O
called - - O
hypernovae - - O
. - - O

AMDA - - O
white - - O
paper - - O
identifies - - O
ways - - O
to - - O
improve - - O
pharmaceutical - - O
care - - O
in - - O
SNFs - - O
. - - O

Compensatory - - O
renal - - O
hypertrophy - - O
in - - O
parabiotic - - O
rats - - O
. - - O

Story - - O
of - - O
a - - O
hospital - - O
that - - O
filmed - - O
its - - O
employee - - O
orientation - - O
program - - O
. - - O

An - - O
activation-responsive - - O
element - - O
in - - O
single - - B-MUT
C - - I-MUT
motif-1 - - I-MUT
lymphotactin - - O
promoter - - B-MUT
is - - O
a - - O
site - - O
of - - O
constitutive - - O
and - - O
inducible - - O
DNA-protein - - O
interactions - - O
involving - - O
nuclear - - O
factor - - O
of - - O
activated - - O
T - - O
cell - - O
. - - O

TNF - - O
Treatment - - O
of - - O
cell - - O
activated - - O
the - - O
p38 - - B-MUT
MAP - - I-MUT
kinase - - I-MUT
pathway - - O
, - - O
as - - O
revealed - - O
by - - O
increased - - O
phosphorylation - - O
of - - O
p38 - - B-MUT
MAP - - I-MUT
kinase - - I-MUT
itself - - O
, - - O
activation - - O
of - - O
the - - O
substrate - - O
protein - - O
MAPKAP - - B-MUT
kinase-2 - - I-MUT
, - - O
and - - O
culminating - - O
in - - O
the - - O
phosphorylation - - O
of - - O
the - - O
heat - - B-MUT
shock - - I-MUT
protein - - I-MUT
27 - - I-MUT
( - - O
hsp27 - - B-MUT
) - - O
. - - O

Nernst--Planck - - O
analog - - O
equations - - O
and - - O
stationary - - O
state - - O
membrane - - O
electric - - O
potentials - - O
. - - O

Two - - O
of - - O
the - - O
three - - O
groups - - O
were - - O
administered - - O
dauricine - - O
, - - O
as - - O
a - - O
new - - O
calcium - - O
channel - - O
blocker - - O
, - - O
and - - O
verapamil - - O
, - - O
as - - O
a - - O
generally - - O
recognized - - O
calcium - - O
channel - - O
blocker - - O
, - - O
respectively - - O
, - - O
from - - O
15 - - O
minutes - - O
pre-bypass - - O
to - - O
the - - O
end - - O
of - - O
the - - O
bypass - - O
procedure - - O
( - - O
a - - O
period - - O
of - - O
95 - - O
minutes - - O
) - - O
. - - O

Contrary - - O
to - - O
1 - - O
, - - O
8-dihydroxy-9-anthrone - - O
, - - O
1 - - O
, - - O
8 - - O
, - - O
9-triacetoxyanthracene - - O
and - - O
1 - - O
, - - O
8-diacetoxy-9-anthrone - - O
are - - O
effective - - O
against - - O
psoriatic - - O
lesions - - O
without - - O
accompanying - - O
inflammations - - O
of - - O
the - - O
skin - - O
. - - O

We - - O
have - - O
isolated - - O
and - - O
sequenced - - O
the - - O
gene - - O
encoding - - O
the - - O
human - - B-MUT
U1-70K - - I-MUT
snRNP - - I-MUT
protein - - I-MUT
. - - O

Underlying - - O
the - - O
clustering - - O
of - - O
these - - O
risk - - O
variables - - O
were - - O
three - - O
factors - - O
. - - O

We - - O
found - - O
that - - O
the - - O
gene - - O
segment - - O
containing - - O
the - - O
mu - - B-MUT
m - - I-MUT
poly - - I-MUT
( - - I-MUT
A - - I-MUT
) - - I-MUT
signals - - I-MUT
, - - O
along - - O
with - - O
536 - - O
bp - - O
of - - O
downstream - - O
flanking - - O
sequence - - O
, - - O
acted - - O
as - - O
a - - O
transcription - - O
terminator - - O
in - - O
both - - O
myeloma - - O
cells - - O
and - - O
L - - O
cell - - O
fibroblasts - - O
. - - O

These - - O
results - - O
continue - - O
to - - O
support - - O
the - - O
hypothesis - - O
that - - O
HS2 - - B-MUT
, - - O
HS3 - - B-MUT
, - - O
and - - O
HS4 - - B-MUT
act - - O
as - - O
a - - O
single - - O
, - - O
integral - - O
unit - - O
to - - O
regulate - - O
human - - B-MUT
globin - - I-MUT
gene - - I-MUT
transcription - - O
as - - O
a - - O
holocomplex - - O
, - - O
but - - O
they - - O
can - - O
also - - O
be - - O
interpreted - - O
to - - O
say - - O
that - - O
formation - - O
of - - O
a - - O
DNase - - B-MUT
I - - I-MUT
hypersensitive - - O
holocomplex - - O
alone - - O
is - - O
not - - O
sufficient - - O
for - - O
mediating - - O
high-level - - O
globin - - B-MUT
gene - - I-MUT
transcription - - O
. - - O

Ischemia - - O
and - - O
reperfusion - - O
markedly - - O
increased - - O
the - - O
release - - O
of - - O
6-keto-PGF1 - - B-MUT
alpha - - I-MUT
and - - O
TXB2 - - B-MUT
. - - O

Prenatal - - O
exposure - - O
to - - O
the - - O
fungicide - - O
dinocap - - O
causes - - O
behavioral - - O
torticollis - - O
, - - O
ballooning - - O
and - - O
cleft - - O
palate - - O
in - - O
mice - - O
, - - O
but - - O
not - - O
rats - - O
or - - O
hamsters - - O
. - - O

Calibration - - O
and - - O
a - - O
correction - - O
of - - O
blood - - O
O2 - - O
content - - O
measured - - O
by - - O
Po2 - - O
and - - O
CO - - O
saturation - - O
. - - O

In - - O
addition - - O
, - - O
we - - O
observe - - O
that - - O
the - - O
hUBF-promoter - - B-MUT
interaction - - O
is - - O
highly - - O
sensitive - - O
to - - O
the - - O
antagonistic - - O
effects - - O
of - - O
cisplatin-DNA - - O
adducts - - O
. - - O

Using - - O
the - - O
two-hybrid - - O
system - - O
, - - O
we - - O
show - - O
that - - O
nonprenylated - - O
Rac1 - - B-MUT
interacts - - O
very - - O
weakly - - O
with - - O
Rho-GDI - - B-MUT
, - - O
pointing - - O
to - - O
the - - O
predominant - - O
role - - O
of - - O
protein-isoprene - - O
interaction - - O
in - - O
complex - - O
formation - - O
. - - O

Tele-Talk - - O
has - - O
the - - O
extra - - O
capability - - O
of - - O
operating - - O
in - - O
live - - O
conference - - O
situations - - O
using - - O
microphone - - O
input - - O
. - - O

This - - O
open - - O
reading - - O
frame - - O
was - - O
confirmed - - O
the - - O
correct - - O
one - - O
by - - O
direct - - O
amino-terminal - - O
sequence - - O
analysis - - O
of - - O
the - - O
overproduced - - O
msgB - - B-MUT
gene - - I-MUT
product - - I-MUT
. - - O

Neither - - O
ethanol - - O
regimen - - O
impaired - - O
spontaneous - - O
alternation - - O
, - - O
but - - O
the - - O
4 - - O
g - - O
ethanol - - O
. - - O
kg-1 - - O
x - - O
day-1 - - O
regimen - - O
increased - - O
the - - O
percent - - O
completed - - O
trials - - O
. - - O

Site-directed - - O
mutagenesis - - O
of - - O
the - - O
traI - - B-MUT
structural - - I-MUT
gene - - I-MUT
and - - O
application - - O
of - - O
purified - - O
mutant - - O
TraI - - B-MUT
proteins - - I-MUT
for - - O
in - - O
vitro - - O
assays - - O
served - - O
to - - O
evaluate - - O
the - - O
functional - - O
importance - - O
of - - O
conserved - - O
amino - - O
acid - - O
residues - - O
. - - O

This - - O
indicates - - O
that - - O
the - - O
mechanism - - O
by - - O
which - - O
CX - - O
blocks - - O
rapid - - O
degradation - - O
of - - O
tubulin - - B-MUT
mRNA - - I-MUT
in - - O
vivo - - O
is - - O
not - - O
simply - - O
by - - O
preventing - - O
its - - O
translation - - O
and - - O
suggests - - O
the - - O
involvement - - O
of - - O
an - - O
altered - - O
trans-factor - - O
. - - O

By - - O
using - - O
space-discrete - - O
continuous - - O
metapopulation - - O
dynamic - - O
models - - O
and - - O
computer - - O
simulations - - O
, - - O
we - - O
show - - O
that - - O
there - - O
can - - O
be - - O
two - - O
principally - - O
different - - O
regimes - - O
of - - O
metapopulation - - O
dynamics - - O
. - - O

Activated - - O
areas - - O
have - - O
been - - O
identified - - O
by - - O
means - - O
of - - O
cross-correlation - - O
analysis - - O
. - - O

The - - O
protein - - O
product - - O
of - - O
orfD - - B-MUT
, - - O
which - - O
is - - O
probably - - O
a - - O
new - - O
tra - - B-MUT
gene - - I-MUT
( - - O
named - - O
traX - - B-MUT
) - - O
, - - O
contains - - O
65% - - O
hydrophobic - - O
amino - - O
acids - - O
, - - O
especially - - O
rich - - O
in - - O
alanine - - O
and - - O
leucine - - O
. - - O

Members - - O
of - - O
the - - O
titin - - B-MUT
myosin - - O
light - - B-MUT
chain - - I-MUT
kinase - - I-MUT
family - - I-MUT
play - - O
an - - O
essential - - O
role - - O
in - - O
the - - O
organization - - O
of - - O
the - - O
actin - - O
myosin - - O
cytoskeleton - - O
, - - O
especially - - O
in - - O
sarcomere - - O
assembly - - O
and - - O
function - - O
. - - O

Purified - - O
Hsk1 - - B-MUT
phosphorylates - - O
the - - O
Cdc19 - - B-MUT
( - - O
Mcm2 - - B-MUT
) - - O
subunit - - O
of - - O
the - - O
six-member - - B-MUT
minichromosome - - I-MUT
maintenance - - I-MUT
protein - - I-MUT
complex - - I-MUT
purified - - O
from - - O
fission - - O
yeast - - O
. - - O

In - - O
these - - O
vectors - - O
the - - O
chimeric - - O
long - - O
terminal - - O
repeat - - O
( - - O
chLTR - - O
) - - O
drives - - O
the - - O
expression - - O
of - - O
the - - O
chloramphenicol - - B-MUT
acetyl - - I-MUT
transferase - - I-MUT
( - - O
CAT - - B-MUT
) - - O
reporter - - O
gene - - O
that - - O
is - - O
followed - - O
by - - O
an - - O
internal - - O
SV40 - - O
virus - - O
early - - O
region - - O
promoter - - O
linked - - O
to - - O
the - - O
neomycin - - B-MUT
phosphotransferase - - I-MUT
II - - I-MUT
( - - O
NEO - - B-MUT
) - - O
gene - - O
. - - O

A - - O
second - - O
peptide - - O
( - - O
amino - - O
acids - - O
58-77 - - O
) - - O
also - - O
antagonized - - O
p21-activity - - O
, - - O
but - - O
this - - O
peptide - - O
did - - O
not - - O
affect - - O
the - - O
ability - - O
of - - O
p21 - - B-MUT
to - - O
interact - - O
with - - O
cyclin - - B-MUT
E - - I-MUT
Cdk2 - - I-MUT
. - - I-MUT

Some - - O
reflexions - - O
apropos - - O
of - - O
a - - O
personal - - O
statistical - - O
study - - O
of - - O
513 - - O
arterial - - O
embolisms - - O
. - - O

Mutational - - O
analysis - - O
of - - O
mRNA - - B-MUT
capping - - I-MUT
enzyme - - I-MUT
identifies - - O
amino - - O
acids - - O
involved - - O
in - - O
GTP - - O
binding - - O
, - - O
enzyme-guanylate - - O
formation - - O
, - - O
and - - O
GMP - - O
transfer - - O
to - - O
RNA - - O
. - - O

Preferential - - O
heterodimeric - - O
parallel - - O
coiled-coil - - O
formation - - O
by - - O
synthetic - - B-MUT
Max - - I-MUT
and - - O
c-Myc - - B-MUT
leucine - - I-MUT
zippers - - I-MUT
: - - O
a - - O
description - - O
of - - O
putative - - O
electrostatic - - O
interactions - - O
responsible - - O
for - - O
the - - O
specificity - - O
of - - O
heterodimerization - - O
. - - O

For - - O
oral - - O
administration - - O
, - - O
AUC0-infinity - - O
was - - O
58 - - O
. - - O
47 - - O
+ - - O
- - - O
16 - - O
. - - O
37 - - O
microg - - O
x - - O
h - - O
ml - - O
, - - O
t1 - - O
2beta - - O
was - - O
18 - - O
. - - O
39 - - O
+ - - O
- - - O
0 - - O
. - - O
06 - - O
hours - - O
, - - O
maximum - - O
concentration - - O
( - - O
Cmax - - O
) - - O
was - - O
2 - - O
. - - O
12 - - O
+ - - O
- - - O
00 - - O
. - - O
51 - - O
microg - - O
ml - - O
, - - O
time - - O
to - - O
Cmax - - O
was - - O
2 - - O
. - - O
20 - - O
+ - - O
- - - O
2 - - O
. - - O
17 - - O
hours - - O
, - - O
mean - - O
absorption - - O
time - - O
was - - O
2 - - O
. - - O
09 - - O
+ - - O
- - - O
0 - - O
. - - O
51 - - O
hours - - O
, - - O
and - - O
bioavailability - - O
was - - O
42 - - O
+ - - O
- - - O
0 - - O
. - - O
42% - - O
. - - O

Unlike - - O
p59v-rel - - B-MUT
, - - O
which - - O
is - - O
a - - O
nuclear - - O
protein - - O
in - - O
CEF - - O
, - - O
indirect - - O
immunofluorescence - - O
showed - - O
that - - O
p68c-rel - - B-MUT
in - - O
JD214c-rel - - O
infected - - O
CEF - - O
is - - O
located - - O
exclusively - - O
in - - O
the - - O
cytoplasm - - O
of - - O
these - - O
cells - - O
, - - O
even - - O
though - - O
the - - O
sequence - - O
of - - O
p68c-rel - - B-MUT
showed - - O
that - - O
it - - O
contains - - O
a - - O
nuclear - - O
localizing - - O
sequence - - O
identical - - O
to - - O
the - - O
one - - O
previously - - O
identified - - O
in - - O
p59v-rel - - B-MUT
. - - O

In - - O
addition - - O
, - - O
depletion - - O
of - - O
Oct-1 - - B-MUT
from - - O
the - - O
nuclear - - O
extract - - O
by - - O
using - - O
Oct-1-specific - - O
antiserum - - O
or - - O
a - - O
sequence-specific - - O
DNA - - O
affinity - - O
resin - - O
decreased - - O
in - - O
vitro - - O
transcription - - O
from - - O
the - - O
wild-type - - O
MMTV - - O
promoter - - O
to - - O
a - - O
level - - O
identical - - O
to - - O
that - - O
obtained - - O
from - - O
a - - O
promoter - - O
in - - O
which - - O
all - - O
three - - O
octamer-related - - O
sequences - - O
were - - O
mutated - - O
. - - O

Bacterially - - O
expressed - - O
protein - - O
, - - O
as - - O
well - - O
as - - O
the - - O
in - - O
vitro - - O
reticulocyte - - O
lysate - - O
translation - - O
product - - O
, - - O
comigrated - - O
with - - O
the - - O
purified - - O
37-kDa - - O
protein - - O
on - - O
sodium - - O
dodecyl - - O
sulfate-polyacrylamide - - O
gels - - O
. - - O

Although - - O
diagnostic - - O
laparoscopy - - O
is - - O
still - - O
considered - - O
the - - O
standard - - O
reference - - O
in - - O
the - - O
diagnosis - - O
of - - O
ectopic - - O
pregnancy - - O
( - - O
EP - - O
) - - O
, - - O
use - - O
of - - O
high-resolution - - O
endovaginal - - O
sonography - - O
, - - O
in - - O
conjunction - - O
with - - O
qualitative - - O
serum - - O
assays - - O
of - - O
the - - O
beta - - O
subunit - - O
of - - O
human - - B-MUT
chorionic - - I-MUT
gonadotropin - - I-MUT
( - - O
beta-hCG - - B-MUT
) - - O
, - - O
allows - - O
detection - - O
of - - O
earlier - - O
and - - O
smaller - - O
EPs - - O
. - - O

Proprotein - - O
processing - - O
occurs - - O
intracellularly - - O
. - - O

In - - O
this - - O
report - - O
, - - O
almost - - O
6 - - O
kb - - O
of - - O
DNA - - O
sequence - - O
is - - O
presented - - O
, - - O
including - - O
1251 - - O
bp - - O
5' - - O
to - - O
the - - O
gene - - O
, - - O
over - - O
4 - - O
kb - - O
of - - O
exon - - O
and - - O
exon-intron - - O
junctions - - O
, - - O
and - - O
583 - - O
bp - - O
3' - - O
to - - O
the - - O
gene - - O
. - - O

Patients - - O
with - - O
low - - O
probability - - O
of - - O
having - - O
aluminum - - O
overload - - O
( - - O
serum - - O
iron - - O
levels - - O
< - - O
40 - - O
micrograms - - O
L - - O
and - - O
DAI - - O
< - - O
150 - - O
micrograms - - O
L - - O
) - - O
had - - O
significantly - - O
higher - - O
values - - O
of - - O
serum - - O
iron - - O
, - - O
iron - - O
transferrin - - O
saturation - - O
, - - B-MUT
and - - O
serum - - O
ferritin - - O
levels - - B-MUT
compared - - I-MUT
with - - O
those - - O
patients - - O
with - - O
a - - O
high - - O
probability - - O
of - - O
having - - O
aluminum - - O
overload - - O
( - - O
serum - - O
aluminum - - O
levels - - O
> - - O
40 - - O
micrograms - - O
L - - O
and - - O
DAI - - O
> - - O
150 - - O
micrograms - - O
L - - O
) - - O
. - - O

It - - O
has - - O
a - - O
grave - - O
prognosis - - O
with - - O
> - - O
70% - - O
mortality - - O
in - - O
3 - - O
months - - O
, - - O
despite - - O
mechanical - - O
ventilation - - O
. - - O

In - - O
calves - - O
receiving - - O
milk-substitute - - O
diets - - O
containing - - O
80-260 - - O
g - - O
DM - - O
kg - - O
, - - O
milk - - O
intakes - - O
were - - O
reduced - - O
by - - O
up - - O
to - - O
30% - - O
on - - O
the - - O
1st - - O
day - - O
that - - O
calves - - O
were - - O
fed - - O
once - - O
daily - - O
instead - - O
of - - O
twice - - O
daily - - O
. - - O

Our - - O
results - - O
suggest - - O
that - - O
Lrp - - B-MUT
binds - - O
a - - O
central - - O
palindromic - - O
site - - O
, - - O
interacting - - O
predominantly - - O
with - - O
the - - O
major - - O
groove - - O
of - - O
its - - O
DNA - - O
target - - O
, - - O
and - - O
that - - O
additional - - O
dimers - - O
bind - - O
to - - O
flanking - - O
sites - - O
to - - O
form - - O
a - - O
nucleoprotein - - O
activation - - O
complex - - O
. - - O

In - - O
vitro - - O
expression - - O
levels - - O
of - - O
the - - O
different - - O
plasmids - - O
differed - - O
by - - O
as - - O
much - - O
as - - O
tenfold - - O
. - - O

It - - O
could - - O
also - - O
inhibit - - O
C1q-dependent - - O
haemolysis - - O
of - - O
both - - O
IgG- - - O
and - - O
IgM-sensitized - - O
erythrocytes - - O
. - - O

After - - O
resection - - O
of - - O
the - - O
proximal - - O
fragment - - O
, - - O
all - - O
scaphoid - - O
contact - - O
area - - O
and - - O
pressure - - O
was - - O
born - - O
by - - O
the - - O
distal - - O
scaphoid - - O
fragment - - O
. - - O

OBJECTIVE - - O
: - - O
To - - O
investigate - - O
the - - O
association - - O
between - - O
complete - - O
congenital - - O
heart - - O
block - - O
( - - O
CCHB - - O
) - - O
in - - O
the - - O
fetus - - O
and - - O
adult - - O
disease - - O
. - - O

Polypyrimidine - - O
and - - O
ssDNA - - O
binding - - O
by - - O
the - - O
isolated - - O
VH - - B-MUT
domain - - I-MUT
of - - O
immunization-induced - - O
anti-Z-DNA - - B-MUT
Ab - - I-MUT
resembles - - O
the - - O
activity - - O
of - - O
natural - - O
autoantibodies - - O
and - - O
suggests - - O
that - - O
VH-dependent - - O
binding - - O
to - - O
a - - O
ligand - - O
mimicked - - O
by - - O
polypyrimidines - - O
may - - O
play - - O
a - - O
role - - O
in - - O
B - - O
cell - - O
selection - - O
before - - O
immunization - - O
with - - O
Z-DNA - - O
. - - O

Likewise - - O
, - - O
rad6-delta - - B-MUT
reduces - - O
silencing - - O
of - - O
the - - O
telomere-located - - B-MUT
RNAP - - I-MUT
II-transcribed - - I-MUT
genes - - I-MUT
URA3 - - I-MUT
and - - O
ADE2 - - B-MUT
. - - O

In - - O
this - - O
report - - O
we - - O
studied - - O
the - - O
role - - O
of - - O
protein-tyrosine - - B-MUT
phosphatase - - I-MUT
SHP-2 - - B-MUT
in - - O
ErbB-mediated - - O
activation - - O
of - - O
mitogen-activated - - B-MUT
protein - - I-MUT
kinase - - I-MUT
( - - O
MAPK - - B-MUT
) - - O
by - - O
overexpressing - - O
SHP-2 - - B-MUT
mutants - - I-MUT
in - - O
COS-7 - - O
cells - - O
. - - O

I - - O
hypothesize - - O
that - - O
white - - B-MUT
gene - - I-MUT
expression - - O
from - - O
P - - O
[ - - O
en - - O
] - - O
is - - O
repressed - - O
by - - O
the - - O
formation - - O
of - - O
a - - O
protein - - O
complex - - O
which - - O
is - - O
initiated - - O
at - - O
the - - O
engrailed - - B-MUT
PS - - I-MUT
sites - - I-MUT
and - - O
also - - O
requires - - O
interactions - - O
with - - O
flanking - - O
genomic - - O
DNA - - O
. - - O

Ninety-four - - O
percent - - O
of - - O
the - - O
EPs - - O
were - - O
tubal - - O
, - - O
and - - O
90% - - O
of - - O
the - - O
tubes - - O
exhibited - - O
some - - O
pathologic - - O
changes - - O
, - - O
including - - O
chronic - - O
salpingitis - - O
( - - O
49 - - O
. - - O
5% - - O
) - - O
and - - O
follicular - - O
salpingitis - - O
( - - O
10% - - O
) - - O
, - - O
among - - O
others - - O
. - - O

A - - O
comparison - - O
of - - O
the - - O
clinical - - O
profile - - O
of - - O
cavernous - - O
malformations - - O
with - - O
and - - O
without - - O
associated - - O
venous - - O
malformations - - O
. - - O

These - - O
genes - - O
encode - - O
a - - O
tryptophanyl - - B-MUT
tRNA - - I-MUT
, - - O
the - - O
protein - - B-MUT
translocase - - I-MUT
component - - O
SecE - - B-MUT
, - - O
the - - O
antiterminator - - B-MUT
protein - - I-MUT
NusG - - I-MUT
, - - O
and - - O
the - - O
ribosomal - - B-MUT
proteins - - I-MUT
L11 - - I-MUT
and - - I-MUT
L1 - - I-MUT
in - - O
addition - - O
to - - O
PkwR - - B-MUT
, - - O
a - - O
putative - - O
regulatory - - O
protein - - O
of - - O
the - - O
LacI-GalR - - B-MUT
family - - I-MUT
. - - O

The - - O
Caenorhabditis - - B-MUT
elegans - - I-MUT
vitellogenin - - I-MUT
genes - - I-MUT
are - - O
subject - - O
to - - O
sex- - - O
, - - O
stage- - - O
, - - O
and - - O
tissue-specific - - O
regulation - - O
: - - O
they - - O
are - - O
expressed - - O
solely - - O
in - - O
the - - O
adult - - O
hermaphrodite - - O
intestine - - O
. - - O

For - - O
colostral - - O
milk - - O
there - - O
was - - O
a - - O
significant - - O
correlation - - O
of - - O
vitamin - - O
K1 - - O
to - - O
cholesterol - - O
( - - O
r - - O
= - - O
0 - - O
. - - O
62 - - O
) - - O
but - - O
not - - O
to - - O
total - - O
lipid - - O
or - - O
phospholipid - - O
suggesting - - O
a - - O
role - - O
for - - O
cholesterol - - O
in - - O
the - - O
secretion - - O
of - - O
vitamin - - O
K1 - - O
into - - O
colostral - - O
milk - - O
. - - O

Hypercalcemia - - O
associated - - O
with - - O
elevated - - O
serum - - B-MUT
PTH - - I-MUT
concentration - - O
indicating - - O
primary - - O
hyperparathyroidism - - O
was - - O
found - - O
in - - O
7 - - O
BC - - O
patients - - O
( - - O
7% - - O
) - - O
and - - O
in - - O
none - - O
of - - O
healthy - - O
women - - O
or - - O
patients - - O
with - - O
thyroid - - O
cancer - - O
. - - O

Effect - - O
of - - O
heat - - O
treatments - - O
on - - O
the - - O
meltability - - O
of - - O
cheeses - - O
. - - O

Epidemiologic - - O
evidence - - O
indicates - - O
that - - O
estrogen - - O
replacement - - O
therapy - - O
after - - O
menopause - - O
increases - - O
breast - - O
cancer - - O
risk - - O
. - - O

In - - O
8 - - O
healthy - - O
volunteers - - O
there - - O
were - - O
no - - O
significant - - O
differences - - O
in - - O
AUC - - O
, - - O
peak - - O
plasma - - O
concentrations - - O
or - - O
time - - O
to - - O
peak - - O
concentration - - O
when - - O
OXC - - O
was - - O
administered - - O
either - - O
with - - O
or - - O
without - - O
ERY - - O
. - - O

Salient - - O
applications - - O
of - - O
PB-PK - - O
modeling - - O
to - - O
toxicological - - O
problems - - O
are - - O
illustrated - - O
with - - O
examples - - O
. - - O

Determination - - O
of - - O
20 - - O
alpha-hydroxy-9 - - O
beta - - O
, - - O
10 - - O
alpha-pregna-4 - - O
, - - O
6-dien-3-one - - O
in - - O
plasma - - O
by - - O
selected - - O
ion - - O
monitoring - - O
. - - O

Metabolic - - O
labeling - - O
studies - - O
in - - O
S - - O
. - - O
cerevisiae - - O
and - - O
co-expression - - O
of - - O
nmt72p - - B-MUT
with - - O
several - - O
protein - - O
substrates - - O
of - - O
Nmt1p - - B-MUT
in - - O
Escherichia - - O
coli - - O
indicate - - O
that - - O
the - - O
Leu99-- - - O
> - - O
Pro - - O
substitution - - O
causes - - O
a - - O
reduction - - O
in - - O
the - - O
acylation - - O
of - - O
some - - O
but - - O
not - - O
all - - O
protein - - O
substrates - - O
. - - O

G-CSF - - B-MUT
activates - - O
multiple - - O
signaling - - O
molecules - - O
, - - O
including - - O
the - - O
JAK1 - - B-MUT
and - - O
JAK2 - - B-MUT
kinases - - I-MUT
and - - O
the - - O
STAT - - B-MUT
transcription - - O
factors - - O
. - - O

Schooling - - O
is - - O
found - - O
to - - O
be - - O
related - - O
to - - O
good - - O
health - - O
even - - O
after - - O
controlling - - O
for - - O
differences - - O
in - - O
observable - - O
health - - O
inputs - - O
. - - O

The - - O
reason - - O
that - - O
nitrous - - O
oxide - - O
does - - O
not - - O
produce - - O
hydroxyl - - O
radicals - - O
readily - - O
might - - O
be - - O
that - - O
the - - O
one-electron - - O
reduction - - O
proceeds - - O
through - - O
an - - O
N2O- - - O
intermediate - - O
which - - O
is - - O
energetically - - O
very - - O
unfavourable - - O
: - - O
EO - - O
( - - O
N2O - - O
N2O- - - O
) - - O
= - - O
-1 - - O
. - - O
1 - - O
V - - O
. - - O

Parkinsonian - - O
patients - - O
had - - O
a - - O
significantly - - O
lower - - O
prevalence - - O
of - - O
alcohol - - O
use - - O
. - - O

There - - O
was - - O
evidence - - O
of - - O
attenuated - - O
regression - - O
slopes - - O
relating - - O
recalled - - O
to - - O
observed - - O
portion - - O
sizes - - O
for - - O
4 - - O
of - - O
the - - O
10 - - O
food - - O
groups - - O
; - - O
adjusted - - O
r2 - - O
values - - O
for - - O
the - - O
recalled - - O
portion - - O
sizes - - O
ranged - - O
from - - O
0 - - O
. - - O
02 - - O
to - - O
0 - - O
. - - O
94 - - O
. - - O

Retroviral - - B-MUT
nucleocapsid - - I-MUT
proteins - - I-MUT
( - - O
NCPs - - B-MUT
) - - O
are - - O
CCHC-type - - B-MUT
zinc - - I-MUT
finger - - I-MUT
proteins - - I-MUT
that - - O
mediate - - O
virion - - O
RNA - - O
binding - - O
activities - - O
associated - - O
with - - O
retrovirus - - O
assembly - - O
and - - O
genomic - - O
RNA - - O
encapsidation - - O
. - - O

Binding - - O
of - - O
serum - - B-MUT
response - - I-MUT
factor - - I-MUT
to - - O
CArG - - B-MUT
box - - I-MUT
sequences - - I-MUT
is - - O
necessary - - O
but - - O
not - - O
sufficient - - O
to - - O
restrict - - O
gene - - O
expression - - O
to - - O
arterial - - O
smooth - - O
muscle - - O
cells - - O
. - - O

Acquired - - O
bile - - O
duct - - O
blockage - - O
: - - O
entry - - O
of - - O
hepatobiliary - - O
agent - - O
into - - O
an - - O
intrahepatic - - O
abscess - - O
. - - O

The - - O
patients - - O
were - - O
divided - - O
into - - O
3 - - O
subgroups - - O
: - - O
1 - - O
) - - O
13 - - O
N+ - - O
patients - - O
with - - O
multiple - - O
hot - - O
spots - - O
( - - O
greater - - O
than - - O
2 - - O
) - - O
( - - O
N+ - - O
IM - - O
) - - O
; - - O
2 - - O
) - - O
24 - - O
N+ - - O
patients - - O
with - - O
single - - O
hot - - O
spots - - O
( - - O
less - - O
than - - O
or - - O
equal - - O
to - - O
2 - - O
) - - O
( - - O
N+ - - O
IS - - O
) - - O
; - - O
3 - - O
) - - O
12 - - O
N- - - O
patients - - O
with - - O
single - - O
hot - - O
spots - - O
( - - O
less - - O
than - - O
or - - O
equal - - O
to - - O
2 - - O
) - - O
( - - O
N- - - O
IS - - O
) - - O
. - - O

Carbon - - O
catabolite - - O
repression - - O
of - - O
the - - O
gnt - - B-MUT
operon - - I-MUT
of - - I-MUT
Bacillus - - I-MUT
subtilis - - I-MUT
is - - O
mediated - - O
by - - O
the - - O
catabolite - - O
control - - O
protein - - O
CcpA - - B-MUT
and - - O
by - - O
HPr - - B-MUT
, - - O
a - - O
phosphocarrier - - O
protein - - O
of - - O
the - - O
phosphotransferase - - B-MUT
system - - I-MUT
. - - O

The - - O
frequency - - O
of - - O
integrations - - O
that - - O
led - - O
to - - O
transcription - - O
of - - O
the - - O
lacZ - - B-MUT
gene - - I-MUT
was - - O
estimated - - O
to - - O
be - - O
0 - - O
. - - O
5% - - O
of - - O
all - - O
integrations - - O
, - - O
of - - O
which - - O
14% - - O
were - - O
downregulated - - O
on - - O
differentiation - - O
of - - O
32D - - O
cells - - O
towards - - O
neutrophils - - O
. - - O

Interferon-alpha - - B-MUT
treatment - - O
of - - O
posttransplant - - O
lymphoproliferative - - O
disorder - - O
in - - O
recipients - - O
of - - O
solid - - O
organ - - O
transplants - - O
. - - O

ATP-dependent - - O
assembly - - O
of - - O
a - - O
ternary - - O
complex - - O
consisting - - O
of - - O
a - - O
DNA - - O
mismatch - - O
and - - O
the - - O
yeast - - B-MUT
MSH2-MSH6 - - I-MUT
and - - O
MLH1-PMS1 - - B-MUT
protein - - I-MUT
complexes - - I-MUT
. - - O

Since - - O
1967 - - O
at - - O
the - - O
times - - O
of - - O
their - - O
biennial - - O
ABCC - - O
RERF - - O
radiological - - O
examinations - - O
, - - O
all - - O
Adult - - O
Health - - O
Study - - O
( - - O
AHS - - O
) - - O
subjects - - O
have - - O
been - - O
interviewed - - O
to - - O
determine - - O
the - - O
exposures - - O
to - - O
medical - - O
x-rays - - O
they - - O
experienced - - O
in - - O
institutions - - O
other - - O
than - - O
RERF - - O
in - - O
order - - O
to - - O
estimate - - O
the - - O
numbers - - O
of - - O
examinations - - O
and - - O
corresponding - - O
doses - - O
which - - O
they - - O
received - - O
. - - O

We - - O
have - - O
determined - - O
that - - O
these - - O
nicks - - O
occur - - O
in - - O
both - - O
the - - O
wild-type - - O
and - - O
the - - O
mutant - - O
sites - - O
. - - O

The - - O
tumor - - O
suppressor - - O
and - - O
transcriptional - - O
factor - - O
p53 - - B-MUT
is - - O
a - - O
phosphorylated - - O
protein - - O
. - - O

Treatment - - O
of - - O
PCC4 - - O
. - - O
aza1R - - O
cells - - O
with - - O
an - - O
RAR-selective - - O
agonist - - O
also - - O
repressed - - O
the - - O
expression - - O
of - - O
EC-1 - - B-MUT
mRNA - - I-MUT
while - - O
treatment - - O
with - - O
an - - O
RXR-selective - - O
agonist - - O
reduced - - O
EC-1 - - B-MUT
expression - - O
slightly - - O
. - - O

By - - O
comparing - - O
the - - O
abundances - - O
of - - O
many - - O
yeast - - O
transcripts - - O
in - - O
isogenic - - O
wild-type - - O
and - - O
paf1 - - B-MUT
mutant - - I-MUT
strains - - O
, - - O
we - - O
have - - O
identified - - O
genes - - O
whose - - O
expression - - O
is - - O
affected - - O
by - - O
PAF1 - - B-MUT
. - - O

The - - O
physical - - O
characteristics - - O
of - - O
these - - O
calls - - O
vary - - O
among - - O
species - - O
of - - O
bat - - O
, - - O
and - - O
variations - - O
also - - O
exist - - O
in - - O
the - - O
timing - - O
and - - O
patterns - - O
of - - O
respiratory - - O
muscle - - O
recruitment - - O
during - - O
echolocation - - O
. - - O

Most - - O
important - - O
, - - O
infection - - O
of - - O
the - - O
cells - - O
with - - O
an - - O
adenoviral - - O
construct - - O
expressing - - O
this - - O
mutant - - O
inhibited - - O
the - - O
induction - - O
of - - O
VEGF - - B-MUT
mRNA - - I-MUT
under - - O
conditions - - O
that - - O
mimic - - O
hypoxia - - O
. - - O

A - - O
constitutive - - O
allele - - O
of - - O
GPA2 - - B-MUT
could - - O
stimulate - - O
growth - - O
of - - O
a - - O
strain - - O
lacking - - O
both - - O
RAS - - B-MUT
genes - - I-MUT
. - - O

The - - O
end-stage - - O
or - - O
involutional - - O
phase - - O
of - - O
proliferative - - O
diabetic - - O
retinopathy - - O
may - - O
result - - O
in - - O
stabilization - - O
of - - O
vision - - O
for - - O
long - - O
periods - - O
of - - O
time - - O
. - - O

We - - O
have - - O
previously - - O
reported - - O
that - - O
expression - - O
of - - O
a - - O
tumour - - O
derived - - O
brk - - B-MUT
cDNA - - I-MUT
in - - O
mouse - - O
embryonic - - O
fibroblasts - - O
and - - O
human - - O
mammary - - O
epithelial - - O
cells - - O
supports - - O
anchorage - - O
independent - - O
growth - - O
, - - O
and - - O
in - - O
the - - O
latter - - O
potentiates - - O
the - - O
mitogenic - - O
response - - O
to - - O
epidermal - - B-MUT
growth - - I-MUT
factor - - I-MUT
. - - O

A - - O
total - - O
of - - O
26 - - O
BCG - - O
strains - - O
, - - O
out - - O
of - - O
them - - O
10 - - O
Czechoslovak - - O
strains - - O
( - - O
2 - - O
lyophilized - - O
cultures - - O
of - - O
BCG - - O
of - - O
different - - O
batch - - O
, - - O
6 - - O
strains - - O
isolated - - O
from - - O
abscesses - - O
of - - O
children - - O
after - - O
BCG-vaccination - - O
and - - O
2 - - O
strains - - O
from - - O
fatal - - O
cases - - O
after - - O
BCG-vaccination - - O
) - - O
and - - O
16 - - O
strains - - O
obtained - - O
from - - O
foreign - - O
laboratories - - O
, - - O
were - - O
used - - O
. - - O

The - - O
myeloproliferative - - O
sarcoma - - O
virus - - O
( - - O
MPSV - - O
) - - O
was - - O
derived - - O
by - - O
passage - - O
of - - O
Moloney - - O
sarcoma - - O
virus - - O
( - - O
Mo-MuSV - - O
) - - O
in - - O
adult - - O
mice - - O
. - - O

Re - - O
: - - O
"Assessing - - O
the - - O
direction - - O
of - - O
causality - - O
in - - O
cross-sectional - - O
studies" - - O
. - - O

Standard - - O
curve - - O
correlation - - O
coefficients - - O
of - - O
0 - - O
. - - O
995 - - O
or - - O
greater - - O
were - - O
obtained - - O
during - - O
validation - - O
experiments - - O
and - - O
analysis - - O
of - - O
study - - O
samples - - O
. - - O

Echosismography - - O
enables - - O
to - - O
improve - - O
the - - O
diagnosis - - O
when - - O
compared - - O
with - - O
classical - - O
sonography - - O
in - - O
about - - O
20% - - O
of - - O
cases - - O
. - - O

The - - O
serine - - B-MUT
threonine - - I-MUT
kinase - - I-MUT
Raf-1 - - I-MUT
functions - - I-MUT
downstream - - O
of - - O
Rats - - O
in - - B-MUT
a - - O
signal - - O
transduction - - O
cascade - - O
which - - O
transmits - - O
mitogenic - - O
stimuli - - O
from - - O
the - - O
plasma - - O
membrane - - O
to - - O
the - - O
nucleus - - O
. - - O

Furthermore - - O
, - - O
the - - O
over-replication - - O
phenotype - - O
produced - - O
by - - O
this - - O
mutant - - B-MUT
p65cdc18 - - I-MUT
is - - O
resistant - - O
to - - O
increased - - O
mitotic - - O
cyclin - - B-MUT
CDK - - I-MUT
activity - - I-MUT
, - - O
a - - O
known - - O
inhibitor - - O
of - - O
over-replication - - O
. - - O

Benefits - - O
of - - O
obtaining - - O
board - - O
certification - - O
in - - O
pharmacotherapy - - O
. - - O

For - - O
various - - O
dog - - O
vessels - - O
in - - O
vivo - - O
, - - O
Q - - O
Dk - - O
ranged - - O
from - - O
0 - - O
. - - O
15 - - O
to - - O
47 - - O
X - - O
10 - - O
( - - O
5 - - O
) - - O
Torr - - O
cm2 - - O
. - - O

Plate - - O
luting - - O
, - - O
a - - O
technique - - O
that - - O
uses - - O
polymethylmethacrylate - - O
( - - O
PMMA - - O
) - - O
interposed - - O
between - - O
the - - O
plate - - O
and - - O
the - - O
bone - - O
, - - O
as - - O
well - - O
as - - O
between - - O
the - - O
screw - - O
heads - - O
and - - O
the - - O
plate - - O
, - - O
to - - O
improve - - O
the - - O
stability - - O
of - - O
internal - - O
fixation - - O
was - - O
tested - - O
in - - O
vitro - - O
using - - O
20 - - O
paired - - O
equine - - O
third - - O
metacarpal - - O
bones - - O
with - - O
mid-diaphyseal - - O
osteotomies - - O
plated - - O
with - - O
six-hole - - O
broad - - O
ASIF - - O
compression - - O
plates - - O
. - - O

Our - - O
study - - O
was - - O
designed - - O
to - - O
investigate - - O
the - - O
effect - - O
of - - O
MMF - - O
on - - O
in - - O
vivo - - O
bone - - O
mineral - - O
metabolism - - O
. - - O

These - - O
data - - O
suggest - - O
that - - O
these - - O
sequences - - O
located - - O
immediately - - O
3' - - O
to - - O
the - - O
breakpoint - - O
of - - O
the - - O
HPFH-3 - - B-MUT
deletion - - I-MUT
, - - O
exhibit - - O
both - - O
the - - O
structure - - O
and - - O
the - - O
function - - O
of - - O
an - - O
enhancer - - O
, - - O
and - - O
can - - O
modify - - O
the - - O
developmental - - O
specificity - - O
of - - O
the - - O
fetal - - B-MUT
gamma-globin - - I-MUT
genes - - I-MUT
, - - O
resulting - - O
in - - O
their - - O
continued - - O
expression - - O
during - - O
adult - - O
life - - O
. - - O

CONCLUSIONS - - O
: - - O
While - - O
INR - - O
correction - - O
may - - O
be - - O
achieved - - O
by - - O
all - - O
the - - O
above - - O
methods - - O
, - - O
that - - O
relating - - O
log - - O
reference - - O
INR - - O
to - - O
log - - O
local - - O
prothrombin - - B-MUT
time - - O
by - - O
linear - - O
regression - - O
analysis - - O
is - - O
the - - O
simplest - - O
to - - O
perform - - O
. - - O

Sensory - - O
kindling - - O
: - - O
implications - - O
for - - O
development - - O
of - - O
sensory - - O
prostheses - - O
. - - O

A - - O
rapid - - O
fluorimetric - - O
procedure - - O
for - - O
the - - O
determination - - O
of - - O
the - - O
fungicide - - O
5-fluorocytosine - - O
in - - O
serum - - O
is - - O
described - - O
. - - O

In - - O
this - - O
study - - O
, - - O
we - - O
examine - - O
the - - O
effects - - O
of - - O
Msx2 - - B-MUT
expression - - O
on - - O
OC - - B-MUT
promoter - - I-MUT
activation - - O
( - - O
luciferase - - B-MUT
reporter - - I-MUT
) - - O
by - - O
FGF2 - - B-MUT
FSK - - I-MUT
and - - I-MUT
calcitriol - - O
in - - O
MC3T3-E1 - - O
osteoblasts - - O
. - - O

Human - - B-MUT
neuronal - - I-MUT
Elav-like - - I-MUT
proteins - - I-MUT
contain - - O
three - - O
RNP-type - - B-MUT
RNA - - I-MUT
recognition - - I-MUT
motifs - - I-MUT
( - - O
RRMs - - B-MUT
) - - O
. - - O

Liquid - - O
chromatographic - - O
method - - O
for - - O
analysis - - O
of - - O
all-rac-alpha-tocopheryl - - O
acetate - - O
and - - O
retinyl - - O
palmitate - - O
in - - O
milk-based - - O
infant - - O
formula - - O
using - - O
matrix - - O
solid-phase - - O
dispersion - - O
. - - O

Interestingly - - O
, - - O
internal - - O
and - - O
5' - - O
deletions - - O
revealed - - O
tha - - O
the - - O
distal - - O
promoter - - O
was - - O
not - - O
required - - O
for - - O
full - - O
transcriptional - - O
activity - - O
and - - O
that - - O
the - - O
first - - O
631 - - O
base - - O
pairs - - O
of - - O
WNT-5A - - B-MUT
harbored - - O
the - - O
strongest - - O
promoter - - O
activity - - O
. - - O

Truncated - - O
forms - - O
of - - O
a - - O
novel - - O
yeast - - O
protein - - O
suppress - - O
the - - O
lethality - - O
of - - O
a - - O
G - - B-MUT
protein - - I-MUT
alpha - - I-MUT
subunit - - I-MUT
deficiency - - O
by - - O
interacting - - O
with - - O
the - - O
beta - - O
subunit - - O
. - - O

Thus - - O
, - - O
BALB - - O
c - - O
mice - - O
appear - - O
to - - O
be - - O
the - - O
most - - O
appropriate - - O
strain - - O
of - - O
mice - - O
to - - O
perform - - O
studies - - O
on - - O
the - - O
possible - - O
connection - - O
between - - O
infection - - O
with - - O
T - - O
. - - O
canis - - O
and - - O
allergic - - O
asthma - - O
. - - O

These - - O
studies - - O
demonstrate - - O
that - - O
site-specific - - O
recognition - - O
of - - O
the - - O
bxd - - B-MUT
PRE - - I-MUT
by - - O
d - - O
( - - O
GA - - O
) - - O
( - - O
n - - O
) - - O
repeat - - O
binding - - O
activities - - O
mediates - - O
PcG-dependent - - O
silencing - - O
. - - O

We - - O
studied - - O
the - - O
effect - - O
of - - O
skinfold - - O
thickness - - O
on - - O
the - - O
correlation - - O
between - - O
serum - - O
total - - O
bilirubin - - O
level - - O
and - - O
transcutaneous - - O
bilirubin - - O
( - - O
TcB - - O
) - - O
readings - - O
. - - O

Binding - - O
affinities - - O
of - - O
these - - O
recombinant - - O
phages - - O
as - - O
determined - - O
by - - O
the - - O
retention - - O
of - - O
these - - O
phages - - O
by - - O
a - - O
His-tag - - O
immobilized - - O
gp17 - - B-MUT
column - - O
, - - O
and - - O
by - - O
co-immunoprecipitation - - O
with - - O
purified - - O
terminase - - B-MUT
supported - - O
the - - O
specific - - O
nature - - O
of - - O
the - - O
portal - - B-MUT
protein - - I-MUT
and - - O
terminase - - B-MUT
interaction - - I-MUT
sites - - I-MUT
. - - O

During - - O
the - - O
following - - O
9 - - O
1 - - O
2 - - O
years - - O
three - - O
sequential - - O
liver - - O
biopsies - - O
were - - O
performed - - O
. - - O

Toward - - O
absolute - - O
methods - - O
in - - O
clinical - - O
chemistry - - O
: - - O
application - - O
of - - O
mass - - O
fragmentography - - O
to - - O
high-accuracy - - O
analyses - - O
. - - O

Psychiatric - - O
disorders - - O
in - - O
children - - O
and - - O
adolescents - - O
carry - - O
considerable - - O
morbidity - - O
, - - O
impede - - O
development - - O
, - - O
and - - O
carry - - O
a - - O
significant - - O
mortality - - O
by - - O
suicide - - O
. - - O

Functional - - O
characterization - - O
of - - O
a - - O
fraction - - O
identified - - O
by - - O
its - - O
activity - - O
in - - O
a - - O
second - - O
template - - O
rescue - - O
assay - - O
. - - O

Here - - O
, - - O
we - - O
describe - - O
the - - O
isolation - - O
of - - O
MdPin1 - - B-MUT
, - - O
a - - O
Pin1 - - B-MUT
homologue - - O
from - - O
the - - O
plant - - O
species - - O
apple - - O
( - - O
Malus - - O
domestica - - O
) - - O
and - - O
show - - O
that - - O
it - - O
has - - O
the - - O
same - - O
phosphorylation-specific - - O
substrate - - O
specificity - - O
and - - O
can - - O
be - - O
inhibited - - O
by - - O
juglone - - O
in - - O
vitro - - O
, - - O
as - - O
is - - O
the - - O
case - - O
for - - O
Pin1 - - B-MUT
. - - O

Commun - - O
. - - O

Teratological - - O
study - - O
of - - O
etoperidone - - O
in - - O
the - - O
rat - - O
and - - O
rabbit - - O
. - - O

( - - O
3 - - O
) - - O
This - - O
effect - - O
occurs - - O
without - - O
removing - - O
TRs - - B-MUT
from - - O
the - - O
TRE - - B-MUT
. - - O

A - - O
Y - - B-MUT
. - - I-MUT
lipolytica - - I-MUT
Kar2p - - I-MUT
mutant - - I-MUT
was - - O
isolated - - O
that - - O
restored - - O
interaction - - O
with - - O
an - - O
Sls1p - - B-MUT
mutant - - I-MUT
, - - O
suggesting - - O
that - - O
the - - O
interaction - - O
with - - O
Sls1p - - B-MUT
could - - O
be - - O
nucleotide - - O
and - - O
or - - O
conformation - - O
dependent - - O
. - - O

Nine - - O
animals - - O
served - - O
as - - O
control - - O
animals - - O
, - - O
whereas - - O
20 - - O
animals - - O
received - - O
a - - O
focal - - O
arachnoid - - O
scar - - O
at - - O
C1-C2 - - O
, - - O
which - - O
was - - O
produced - - O
by - - O
placement - - O
of - - O
a - - O
kaolin-soaked - - O
fibrin - - B-MUT
sponge - - O
on - - O
the - - O
posterior - - O
surface - - O
of - - O
the - - O
spinal - - O
cord - - O
. - - O

High - - O
ATP - - O
GTP - - O
ratios - - O
promoted - - O
initiation - - O
of - - O
RNA - - O
primer - - O
synthesis - - O
at - - O
3'-dCTTT - - O
sites - - B-MUT
, - - I-MUT
whereas - - O
low - - O
ATP - - O
GTP - - O
ratios - - O
promoted - - O
initiation - - O
at - - O
3'-dCCC - - O
sites - - O
. - - B-MUT

Two - - O
predominant - - O
effects - - O
were - - O
noted - - O
: - - O
( - - O
i - - O
) - - O
the - - O
Xaa - - O
residue - - O
in - - O
the - - O
dual - - B-MUT
phosphorylation - - I-MUT
motif - - I-MUT
Thr-Xaa-Tyr - - I-MUT
as - - O
well - - O
as - - O
the - - O
length - - O
of - - O
L12 - - O
influence - - O
p38 - - B-MUT
substrate - - O
specificity - - O
, - - O
and - - O
( - - O
ii - - O
) - - O
the - - O
length - - O
of - - O
L12 - - O
plays - - O
a - - O
major - - O
role - - O
in - - O
controlling - - O
autophosphorylation - - O
. - - O

This - - O
L-myc - - B-MUT
sequence - - I-MUT
is - - O
amplified - - O
10-20-fold - - O
in - - O
four - - O
SCLC - - O
cell - - O
line - - O
DNAs - - O
and - - O
in - - O
one - - O
SCLC - - O
tumour - - O
specimen - - O
taken - - O
directly - - O
from - - O
a - - O
patient - - O
. - - O

We - - O
have - - O
previously - - O
reported - - O
reduced - - O
levels - - O
of - - O
choline - - B-MUT
acetyltransferase - - I-MUT
activity - - O
in - - O
the - - O
cerebral - - O
cortex - - O
of - - O
patients - - O
who - - O
died - - O
after - - O
a - - O
head - - O
injury - - O
, - - O
demonstrating - - O
that - - O
there - - O
is - - O
a - - O
loss - - O
of - - O
cortical - - O
cholinergic - - O
innervation - - O
. - - O

Significant - - O
increases - - O
in - - O
mean - - O
serum - - O
E2 - - O
concentration - - O
( - - O
100 - - O
to - - O
150 - - O
pg - - O
ml - - O
) - - O
were - - O
noted - - O
at - - O
6 - - O
and - - O
8 - - O
hours - - O
after - - O
administration - - O
on - - O
day - - O
1 - - O
and - - O
at - - O
8 - - O
hours - - O
on - - O
day - - O
4 - - O
. - - O

Paleoceanographic - - O
data - - O
from - - O
the - - O
Laurentian - - O
Fan - - O
, - - O
used - - O
as - - O
a - - O
proxy - - O
for - - O
sea - - O
surface - - O
temperature - - O
, - - O
reveal - - O
that - - O
surface - - O
slope - - O
waters - - O
north - - O
of - - O
the - - O
Gulf - - O
Stream - - O
experienced - - O
warming - - O
during - - O
the - - O
Little - - O
Ice - - O
Age - - O
of - - O
the - - O
16th - - O
to - - O
19th - - O
centuries - - O
and - - O
support - - O
the - - O
notion - - O
of - - O
an - - O
NAO-driven - - O
coupled - - O
system - - O
. - - O

Six - - O
putative - - O
MDV - - O
genome - - O
products - - O
, - - O
including - - O
one - - O
Rep - - B-MUT
and - - O
five - - O
non-Rep - - O
proteins - - O
, - - O
show - - O
high - - O
( - - O
70 - - O
. - - O
4-90 - - O
. - - O
9% - - O
) - - O
amino - - O
acid - - O
identity - - O
to - - O
the - - O
corresponding - - O
six - - O
FBNYV - - B-MUT
proteins - - I-MUT
, - - O
whereas - - O
two - - O
other - - O
Rep - - B-MUT
proteins - - I-MUT
encoded - - O
by - - O
MDV-C2 - - B-MUT
and - - O
C3 - - B-MUT
are - - O
82 - - O
. - - O
3% - - O
and - - O
73 - - O
. - - O
0% - - O
identical - - O
to - - O
those - - O
encoded - - O
by - - O
SCSV-C2 - - B-MUT
and - - O
C6 - - B-MUT
, - - O
respectively - - O
. - - O

We - - O
investigated - - O
the - - O
smoking - - O
habits - - O
of - - O
relapsers - - O
1 - - O
year - - O
after - - O
quitting - - O
in - - O
a - - O
smoking - - O
cessation - - O
trial - - O
using - - O
nicotine - - O
or - - O
placebo - - O
patches - - O
. - - O

While - - O
determination - - O
of - - O
the - - O
protein - - O
content - - O
of - - O
the - - O
formulae - - O
gave - - O
no - - O
valid - - O
information - - O
, - - O
RAST - - O
EAST - - O
inhibition - - O
was - - O
highest - - O
for - - O
cow's - - O
milk - - O
, - - O
followed - - O
by - - O
the - - O
partially - - O
hydrolysed - - O
whey - - O
formula - - O
, - - O
partially - - O
hydrolysed - - O
whey - - O
casein - - O
formula - - O
, - - O
soy - - O
pork - - O
collagen - - B-MUT
formula - - I-MUT
, - - I-MUT
and - - I-MUT
the - - O
amino - - O
acid - - O
formula - - O
. - - O

Transcriptional - - O
regulation - - O
of - - O
SUP35 - - B-MUT
and - - O
SUP45 - - B-MUT
in - - I-MUT
Saccharomyces - - I-MUT
cerevisiae - - I-MUT
. - - O

The - - O
clinical - - O
relevance - - O
of - - O
these - - O
findings - - O
is - - O
strengthened - - O
by - - O
the - - O
observation - - O
that - - O
similar - - O
results - - O
were - - O
obtained - - O
when - - O
P - - O
. - - O
HCl - - O
was - - O
given - - O
by - - O
the - - O
intravenous - - O
route - - O
. - - O

RESULTS - - O
: - - O
Looking - - O
at - - O
the - - O
question - - O
of - - O
its - - O
benefits - - O
, - - O
we - - O
were - - O
unable - - O
to - - O
find - - O
any - - O
methodologically - - O
sound - - O
studies - - O
that - - O
have - - O
shown - - O
efficacy - - O
for - - O
EMDR - - O
in - - O
eating - - O
disorders - - O
, - - O
or - - O
, - - O
indeed - - O
, - - O
any - - O
psychiatric - - O
disorder - - O
. - - O

The - - O
2 - - O
kb - - O
of - - O
5'-flanking - - O
region - - O
and - - O
the - - O
1 - - O
. - - O
1 - - O
kb - - O
of - - O
the - - O
entire - - O
sGTH - - B-MUT
alpha - - I-MUT
subunit - - I-MUT
coding - - O
region - - O
were - - O
sequenced - - O
from - - O
the - - O
genomic - - O
clone - - O
, - - O
sGTH - - B-MUT
alpha-G1 - - I-MUT
. - - O

Here - - O
, - - O
we - - O
describe - - O
the - - O
isolation - - O
of - - O
bovine - - B-MUT
and - - I-MUT
rat - - I-MUT
GHF-1 - - I-MUT
cDNA - - I-MUT
clones - - O
. - - O

These - - O
data - - O
demonstrate - - O
that - - O
paxillin - - B-MUT
localizes - - O
to - - O
focal - - O
adhesions - - O
independent - - O
of - - O
interactions - - O
with - - O
vinculin - - B-MUT
and - - O
or - - O
FAK - - O
, - - B-MUT
and - - O
represents - - O
the - - O
first - - O
definitive - - O
demonstration - - O
of - - O
LIM - - O
domains - - B-MUT
functioning - - I-MUT
as - - O
a - - O
primary - - O
determinant - - O
of - - O
protein - - O
subcellular - - O
localization - - O
to - - O
focal - - O
adhesions - - O
. - - O

Systematic - - O
functional - - O
analysis - - O
of - - O
V1a - - B-MUT
V2 - - I-MUT
hybrid - - I-MUT
receptors - - I-MUT
showed - - I-MUT
that - - O
the - - O
second - - O
intracellular - - O
loop - - O
of - - O
the - - O
V1a - - O
receptor - - B-MUT
is - - I-MUT
required - - O
and - - O
sufficient - - O
for - - O
efficient - - O
coupling - - O
to - - O
Gq - - O
11 - - B-MUT
, - - I-MUT
whereas - - I-MUT
the - - O
third - - O
intracellular - - O
loop - - O
of - - O
the - - O
V2 - - O
receptor - - O
is - - B-MUT
required - - I-MUT
and - - O
sufficient - - O
for - - O
coupling - - O
to - - O
Gs - - O
. - - O

Both - - O
NUP98-HOXA9 - - B-MUT
chimeras - - I-MUT
transformed - - O
NIH - - O
3T3 - - O
fibroblasts - - O
, - - O
and - - O
this - - O
transformation - - O
required - - O
the - - O
HOXA9 - - B-MUT
domains - - I-MUT
for - - O
DNA - - O
binding - - O
and - - O
PBX - - B-MUT
interaction - - O
. - - O

KFC - - B-MUT
, - - O
a - - O
Ste20-like - - B-MUT
kinase - - I-MUT
with - - O
mitogenic - - O
potential - - O
and - - O
capability - - O
to - - O
activate - - O
the - - O
SAPK - - B-MUT
JNK - - I-MUT
pathway - - I-MUT
. - - I-MUT

One - - O
RNA - - O
construct - - O
which - - O
consisted - - O
of - - O
112 - - O
nucleotides - - O
( - - O
nt - - O
) - - O
from - - O
nt - - O
639 - - O
to - - O
nt - - O
750 - - O
formed - - O
a - - O
heterodimeric - - O
complex - - O
with - - O
the - - O
RNA - - O
which - - O
consisted - - O
of - - O
200 - - O
nucleotides - - O
from - - O
nt - - O
551 - - O
to - - O
nt - - O
750 - - O
. - - O

Cytogenetic - - O
analysis - - O
of - - O
LOH - - O
mutants - - O
by - - O
chromosome - - O
painting - - O
indicated - - O
a - - O
mosaic - - O
of - - O
chromosomal - - O
aberrations - - O
involving - - O
chromosome - - O
17 - - O
, - - O
in - - O
which - - O
partial - - O
chromosome - - O
deletions - - O
, - - O
amplifications - - O
, - - O
and - - O
multiple - - O
translocations - - O
appeared - - O
heterogeneously - - O
in - - O
a - - O
single - - O
mutant - - O
. - - O

In - - O
addition - - O
, - - O
a - - O
potent - - O
splicing - - O
enhancer - - O
sequence - - O
isolated - - O
in - - O
the - - O
selection - - O
specifically - - O
binds - - O
a - - O
20-kDa - - B-MUT
SR - - I-MUT
protein - - I-MUT
. - - O

A - - O
dose-dependent - - O
fall - - O
in - - O
GABA - - O
content - - O
was - - O
observed - - O
; - - O
GABA - - O
decrease - - O
was - - O
evident - - O
15 - - O
min - - O
after - - O
the - - O
administration - - O
, - - O
reached - - O
its - - O
nadir - - O
at - - O
60 - - O
min - - O
and - - O
disappeared - - O
at - - O
120 - - O
minutes - - O
. - - O

Within - - O
their - - O
polypeptide - - O
chain - - O
, - - O
they - - O
all - - O
contain - - O
those - - O
conserved - - O
features - - O
that - - O
define - - O
a - - O
plant - - O
CDPK - - B-MUT
; - - O
kinase - - B-MUT
catalytic - - I-MUT
sequences - - I-MUT
are - - O
linked - - O
to - - O
a - - O
calmodulin-like - - B-MUT
regulatory - - I-MUT
domain - - I-MUT
through - - O
a - - O
junction - - O
region - - O
. - - O

RESULTS - - O
: - - O
The - - O
parameters - - O
SF2 - - O
and - - O
plating - - O
efficiency - - O
were - - O
stable - - O
throughout - - O
the - - O
4-year - - O
test - - O
period - - O
. - - O

Involvement - - O
of - - O
AP-2 - - B-MUT
in - - O
regulation - - O
of - - O
the - - O
R-FABP - - B-MUT
gene - - I-MUT
in - - O
the - - O
developing - - O
chick - - O
retina - - O
. - - O

Two - - O
studies - - O
assessed - - O
two - - O
types - - O
of - - O
reliability - - O
of - - O
the - - O
student - - O
Jenkins - - O
Activity - - O
Survey - - O
( - - O
JAS - - O
; - - O
a - - O
questionnaire - - O
measure - - O
of - - O
Type - - O
A - - O
behavior - - O
) - - O
. - - O

Two-way - - O
analysis - - O
of - - O
variance - - O
was - - O
used - - O
to - - O
determine - - O
whether - - O
composite - - O
knowledge - - O
score - - O
differed - - O
among - - O
patient - - O
groups - - O
. - - O

We - - O
have - - O
shown - - O
previously - - O
that - - O
in - - O
contrast - - O
to - - O
other - - O
extracellular - - O
matrix - - O
molecules - - O
pepsin-solubilized - - O
collagen - - B-MUT
VI - - I-MUT
( - - O
CVI - - B-MUT
) - - O
can - - O
stimulate - - O
DNA - - O
synthesis - - O
of - - O
various - - O
mesenchymal - - O
cell - - O
types - - O
, - - O
apparently - - O
independent - - O
of - - O
integrin-mediated - - O
signal - - O
transduction - - O
. - - O

Isolation - - O
and - - O
characterization - - O
of - - O
a - - O
cDNA - - O
encoding - - O
a - - O
putative - - O
cytokine - - O
which - - O
is - - O
induced - - O
by - - O
stimulation - - O
via - - O
the - - O
CD2 - - B-MUT
structure - - I-MUT
on - - O
human - - O
T - - O
lymphocytes - - O
. - - O

In - - O
the - - O
studies - - O
reported - - O
here - - O
, - - O
the - - O
5'-flanking - - O
region - - O
of - - O
the - - O
human - - B-MUT
gp130 - - I-MUT
gene - - I-MUT
was - - O
isolated - - O
and - - O
the - - O
transcription - - O
initiation - - O
sites - - O
were - - O
mapped - - O
. - - O

Preimmune - - B-MUT
IgG - - I-MUT
, - - O
anti-GalT - - B-MUT
Fab - - I-MUT
fragments - - I-MUT
, - - O
irrelevant - - O
polymers - - O
and - - O
monomeric - - O
N-acetylglucosamine - - O
had - - O
no - - O
effect - - O
. - - O

Cloning - - O
and - - O
characterization - - O
of - - O
a - - O
cDNA - - O
encoding - - O
a - - O
bacteriophage-type - - B-MUT
RNA - - I-MUT
polymerase - - I-MUT
from - - O
the - - O
higher - - O
plant - - O
Chenopodium - - O
album - - O
. - - O

Female - - O
but - - O
not - - O
male - - O
mortalities - - O
were - - O
significantly - - O
higher - - O
for - - O
cake-fed - - O
rats - - O
than - - O
for - - O
those - - O
fed - - O
diet - - O
41B - - O
. - - O

Genomic - - O
DNA - - O
hybridization - - O
suggests - - O
that - - O
SpSHR2 - - B-MUT
is - - O
a - - O
single-copy - - O
gene - - O
in - - O
the - - O
S - - O
. - - O
purpuratus - - O
genome - - O
. - - O

Its - - O
transcription - - O
in - - O
vitro - - O
by - - O
pol - - B-MUT
III - - I-MUT
requires - - O
the - - O
same - - O
factors - - O
as - - O
the - - O
U6 - - B-MUT
gene - - I-MUT
with - - O
the - - O
major - - O
exception - - O
that - - O
the - - O
modified - - O
TATA-box - - O
of - - O
this - - O
construct - - O
only - - O
interacts - - O
with - - O
a - - O
TATA-binding - - B-MUT
protein - - I-MUT
( - - O
TBP - - B-MUT
) - - O
mutant - - O
( - - O
TBP-DR2 - - B-MUT
) - - O
but - - O
not - - O
with - - O
TBP - - B-MUT
wild-type - - I-MUT
( - - O
TBPwt - - B-MUT
) - - O
. - - O

How - - O
do - - O
graduates - - O
of - - O
different - - O
types - - O
of - - O
programs - - O
perform - - O
on - - O
state - - O
boards - - O
? - - O

Interdomain - - O
signaling - - O
in - - O
a - - O
two-domain - - O
fragment - - O
of - - O
the - - O
human - - B-MUT
glucocorticoid - - I-MUT
receptor - - I-MUT
. - - O

Teratological - - O
studies - - O
on - - O
SF-837 - - O
. - - O

Our - - O
laboratory - - O
and - - O
others - - O
have - - O
shown - - O
alternative - - O
splicing - - O
of - - O
up - - O
to - - O
ten - - O
exons - - O
at - - O
a - - O
discrete - - O
extracellular - - O
site - - O
to - - O
be - - O
primarily - - O
responsible - - O
for - - O
the - - O
generation - - O
of - - O
CD44 - - B-MUT
variant - - I-MUT
( - - O
CD44v - - B-MUT
) - - O
isoforms - - O
. - - O

She - - O
has - - O
since - - O
developed - - O
a - - O
positive - - O
anti-cardiolipin - - B-MUT
antibody - - I-MUT
but - - O
does - - O
not - - O
meet - - O
diagnostic - - O
criteria - - O
for - - O
systemic - - O
lupus - - O
erythematosis - - O
. - - O
Conclusion - - O
: - - O
The - - O
presence - - O
of - - O
known - - O
autoimmune - - O
disease - - O
in - - O
a - - O
woman - - O
with - - O
POF - - O
should - - O
not - - O
dissuade - - O
the - - O
clinician - - O
from - - O
evaluating - - O
for - - O
a - - O
potential - - O
genetic - - O
cause - - O
. - - O

Forced - - O
expression - - O
of - - O
BZAP45 - - B-MUT
strongly - - O
stimulates - - O
H4 - - B-MUT
promoter - - I-MUT
( - - O
nt - - O
-215 - - O
to - - O
-1 - - O
) - - O
CAT - - B-MUT
reporter - - I-MUT
gene - - I-MUT
activity - - I-MUT
. - - O

This - - O
up-grading - - O
of - - O
the - - O
final - - O
score - - O
by - - O
the - - O
CA - - O
component - - O
is - - O
greater - - O
( - - O
3-8% - - O
) - - O
in - - O
the - - O
less - - O
able - - O
students - - O
with - - O
scores - - O
below - - O
the - - O
mean - - O
level - - O
. - - O

The - - O
ORF - - O
was - - O
analyzed - - O
for - - O
secondary - - O
structural - - O
features - - O
, - - O
and - - O
the - - O
sequence - - O
data - - O
bases - - O
were - - O
searched - - O
for - - O
homologies - - O
. - - O

The - - O
[ - - O
18F - - O
] - - O
FMISO - - O
TMRR - - O
is - - O
a - - O
simple - - O
and - - O
clinically - - O
useful - - O
index - - O
for - - O
detecting - - O
tumour - - O
hypoxia - - O
in - - O
NPC - - O
. - - O

The - - O
transcripts - - O
were - - O
equally - - O
active - - O
with - - O
or - - O
without - - O
a - - O
5' - - O
methylated - - O
capstructure - - O
as - - O
expected - - O
, - - O
since - - O
EMCV-RNA - - O
is - - O
one - - O
of - - O
the - - O
mRNAs - - O
capable - - O
of - - O
internal - - O
initiation - - O
. - - O

Patients - - O
were - - O
divided - - O
into - - O
two - - O
group - - O
; - - O
Control - - O
group - - O
A - - O
in - - O
which - - O
a - - O
hot-water - - O
circulating - - O
system - - O
was - - O
used - - O
and - - O
group - - O
B - - O
in - - O
which - - O
a - - O
transtracheal - - O
heating - - O
and - - O
humidification - - O
system - - O
by - - O
ANAMED - - O
HUMITUBE - - O
was - - O
used - - O
, - - O
during - - O
gastric - - O
cancer - - O
operation - - O
. - - O

The - - O
equilibrium - - O
dissociation - - O
binding - - O
constant - - O
for - - O
the - - O
interaction - - O
of - - O
TnrA - - B-MUT
with - - O
the - - O
nrgAB - - B-MUT
promoter - - I-MUT
fragment - - I-MUT
was - - O
7 - - O
. - - O
7 - - O
nM - - O
under - - O
the - - O
conditions - - O
used - - O
here - - O
. - - O

Tissue-specific - - O
expression - - O
of - - O
the - - O
tmy-1 - - B-MUT
gene - - I-MUT
was - - O
determined - - O
by - - O
microinjection - - O
of - - O
a - - O
promoter - - B-MUT
lacZ - - I-MUT
fusion - - I-MUT
gene - - I-MUT
and - - I-MUT
with - - O
immunohistochemistry - - O
by - - O
using - - O
affinity-purified - - O
tissue-specific - - O
anti-tropomyosins - - B-MUT
. - - I-MUT

Radiolabeled - - O
recombinant - - B-MUT
TARC - - I-MUT
specifically - - O
bound - - O
to - - O
T - - O
cell - - O
lines - - O
and - - O
peripheral - - O
T - - O
cells - - O
but - - O
not - - O
to - - O
monocytes - - O
or - - O
granulocytes - - O
. - - O

Intravenous - - O
versus - - O
oral - - O
administration - - O
of - - O
amitriptyline - - O
in - - O
patients - - O
with - - O
major - - O
depression - - O
. - - O

One - - O
enigmatic - - O
aspect - - O
of - - O
GATA - - B-MUT
factor - - I-MUT
expression - - O
is - - O
that - - O
several - - O
GATA - - B-MUT
proteins - - I-MUT
, - - O
which - - O
ostensibly - - O
share - - O
the - - O
same - - O
DNA-binding - - O
site - - O
specificity - - O
, - - O
are - - O
coexpressed - - O
in - - O
erythroid - - O
cells - - O
. - - O

Calcitriol - - O
therapy - - O
was - - O
associated - - O
with - - O
a - - O
decrease - - O
in - - O
serum - - O
iPTH - - B-MUT
levels - - O
( - - O
701 - - O
+ - - O
- - - O
103 - - O
. - - O
9 - - O
vs - - O
. - - O

In - - O
most - - O
subjects - - O
, - - O
markers - - O
of - - O
bone - - O
formation - - O
and - - O
resorption - - O
were - - O
normal - - O
. - - O

Nevertheless - - O
, - - O
inactivation - - O
of - - O
the - - O
cyclin - - B-MUT
E-Cdk2 - - I-MUT
complex - - I-MUT
in - - O
response - - O
to - - O
mitogen - - O
starvation - - O
occurs - - O
normally - - O
in - - O
MEFs - - O
that - - O
have - - O
a - - O
homozygous - - O
deletion - - O
of - - O
the - - O
p27 - - B-MUT
gene - - I-MUT
. - - O

Moreover - - O
, - - O
this - - O
enhancement - - O
of - - O
transcriptional - - O
activation - - O
by - - O
COUP-TFI - - B-MUT
requires - - O
specifically - - O
the - - O
AF-1 - - B-MUT
transactivation - - O
function - - O
of - - O
ER - - B-MUT
and - - O
can - - O
be - - O
observed - - O
in - - O
the - - O
presence - - O
of - - O
E2 - - O
or - - O
4-hydroxytamoxifen - - O
but - - O
not - - O
ICI - - O
164384 - - O
. - - O

A - - O
pharmacokinetic - - O
study - - O
of - - O
apalcillin - - O
was - - O
performed - - O
in - - O
12 - - O
patients - - O
in - - O
an - - O
intensive-care - - O
unit - - O
. - - O

Autoimmune - - O
manipulation - - O
aids - - O
juvenile - - O
diabetes - - O
management - - O
. - - O

Effect - - O
of - - O
indoramin - - O
in - - O
small - - O
doses - - O
on - - O
the - - O
central - - O
vasomotor - - O
loci - - O
has - - O
been - - O
studied - - O
in - - O
chloralose - - O
anesthetized - - O
cats - - O
by - - O
localizing - - O
it - - O
to - - O
the - - O
central - - O
sites - - O
. - - O

We - - O
also - - O
demonstrate - - O
that - - O
the - - O
spo20 - - B-MUT
( - - I-MUT
+ - - I-MUT
) - - I-MUT
gene - - I-MUT
product - - I-MUT
is - - O
structurally - - O
homologous - - O
to - - O
Saccharomyces - - B-MUT
cerevisiae - - I-MUT
Sec14 - - I-MUT
, - - O
the - - O
major - - O
phosphatidylinositol - - O
transfer - - O
protein - - O
of - - O
budding - - O
yeast - - O
. - - O

Baseline - - O
electrocorticography - - O
over - - O
the - - O
surface - - O
of - - O
the - - O
temporal - - O
lobe - - O
and - - O
depth - - O
electrode - - O
recordings - - O
in - - O
the - - O
amygdala - - O
and - - O
hippocampus - - O
were - - O
obtained - - O
, - - O
followed - - O
by - - O
10 - - O
min - - O
of - - O
recording - - O
before - - O
and - - O
after - - O
the - - O
i - - O
. - - O
v - - O
. - - O
administration - - O
of - - O
both - - O
alfentanil - - O
50 - - O
microg - - O
kg - - O
and - - O
fentanyl - - O
10 - - O
microg - - O
kg - - O
. - - O

Although - - O
elevated - - O
serum - - O
levels - - O
of - - O
antibodies - - O
to - - O
the - - O
nicotinic - - B-MUT
acetylcholine - - I-MUT
receptor - - I-MUT
( - - O
nAChR - - B-MUT
) - - O
have - - O
been - - O
reported - - O
in - - O
neuroleptic - - O
treated - - O
patients - - O
with - - O
tardive - - O
dyskinesia - - O
, - - O
such - - O
antibodies - - O
have - - O
not - - O
been - - O
determined - - O
in - - O
comparable - - O
nondyskinetic - - O
patients - - O
. - - O

VII - - O
. - - O

Recently - - O
, - - O
a - - O
mutation - - O
in - - O
the - - O
amino-terminus - - O
of - - O
IB1 - - B-MUT
was - - O
associated - - O
with - - O
diabetes - - O
. - - O

In - - O
budding - - O
yeast - - O
, - - O
the - - O
protein - - O
Skp1p - - B-MUT
, - - O
the - - O
cullin-family - - B-MUT
member - - I-MUT
Cdc53p - - B-MUT
, - - O
and - - O
the - - O
F-box - - B-MUT
WD-repeat - - I-MUT
protein - - I-MUT
Cdc4p - - I-MUT
form - - B-MUT
the - - O
SCFCdc4p - - O
ubiquitin - - B-MUT
ligase - - B-MUT
complex - - B-MUT
, - - I-MUT
which - - O
targets - - O
the - - O
cyclin-dependent - - O
kinase - - B-MUT
( - - I-MUT
Cdk - - O
) - - B-MUT
inhibitor - - O
Sic1p - - O
for - - B-MUT
proteolysis - - O
[ - - O
3 - - O
] - - O
[ - - O
4 - - O
] - - O
[ - - O
5 - - O
] - - O
[ - - O
6 - - O
] - - O
[ - - O
7 - - O
] - - O
[ - - O
8 - - O
] - - O
. - - O

We - - O
show - - O
that - - O
p73 - - B-MUT
can - - O
transcriptionally - - O
inhibit - - O
a - - O
number - - O
of - - O
cellular - - O
and - - O
viral - - O
promoters - - O
. - - O

Induced - - O
expression - - O
of - - O
Rnd3 - - B-MUT
is - - O
associated - - O
with - - O
transformation - - O
of - - O
polarized - - O
epithelial - - O
cells - - O
by - - O
the - - O
Raf-MEK-extracellular - - B-MUT
signal-regulated - - I-MUT
kinase - - I-MUT
pathway - - I-MUT
. - - O

How - - O
does - - O
a - - O
nurse - - O
go - - O
about - - O
maintaining - - O
her - - O
level - - O
of - - O
competence - - O
when - - O
she - - O
is - - O
one - - O
of - - O
the - - O
few - - O
local - - O
practitioners - - O
in - - O
her - - O
field - - O
? - - O
Vancouver - - O
sex - - O
therapist - - O
Bianca - - O
Rucker - - O
is - - O
doing - - O
it - - O
by - - O
cultivating - - O
a - - O
network - - O
of - - O
colleagues - - O
and - - O
mentors - - O
in - - O
related - - O
fields - - O
both - - O
at - - O
home - - O
and - - O
across - - O
the - - O
continent - - O
. - - O

In - - O
addition - - O
, - - O
benzocaine - - O
and - - O
2-phenoxyethanol - - O
depressed - - O
complement - - O
activity - - O
and - - O
phagocytosis - - O
, - - O
while - - O
MS222 - - O
and - - O
quinaldine - - O
sulphate - - O
did - - O
not - - O
. - - O

( - - O
1992 - - O
) - - O
J - - O
. - - O

Expression - - O
of - - O
neuronal - - O
traits - - O
in - - O
pancreatic - - O
beta - - O
cells - - O
. - - O

All - - O
four - - O
domains - - O
were - - O
linked - - O
via - - O
proline-threonine-rich - - O
peptides - - O
. - - O

Both - - O
genes - - O
comprise - - O
three - - O
exons - - O
, - - O
two - - O
introns - - O
and - - O
an - - O
unusually - - O
long - - O
3'-untranslated - - O
region - - O
( - - O
3 - - O
. - - O
2 - - O
kilobase - - O
pairs - - O
) - - O
, - - O
specificying - - O
a - - O
mRNA - - O
of - - O
approximately - - O
4 - - O
. - - O
1 - - O
kilobases - - O
. - - O

Convulsive - - O
seizure - - O
during - - O
a - - O
treatment - - O
with - - O
interferon - - B-MUT
alpha - - I-MUT
for - - O
chronic - - O
viral - - O
hepatitis - - O
C - - O
. - - O

The - - O
ratio - - O
of - - O
the - - O
activity - - O
of - - O
arogenate - - B-MUT
dehydrogenase - - I-MUT
to - - O
that - - O
of - - O
prephenate - - B-MUT
dehydrogenase - - I-MUT
( - - O
approximately - - O
3 - - O
: - - O
1 - - O
) - - O
remained - - O
constant - - O
throughout - - O
purification - - O
, - - O
and - - O
the - - O
two - - O
activities - - O
were - - O
therefore - - O
inseparable - - O
. - - O

Pathogenetic - - O
relationships - - O
between - - O
renal - - O
tubular - - O
acidosis - - O
and - - O
sodium - - O
metabolism - - O
alterations - - O
in - - O
liver - - O
cirrhosis - - O
. - - O

At - - O
the - - O
end - - O
of - - O
the - - O
experiment - - O
the - - O
urinary - - O
porphyrin - - B-MUT
excretion - - O
and - - O
the - - O
porphyrin - - B-MUT
content - - O
in - - O
lijver - - O
and - - O
skin - - O
were - - O
diminished - - O
in - - O
HCB-CQ-treated - - O
animals - - O
by - - O
about - - O
50% - - O
compared - - O
to - - O
the - - O
HCB - - O
controls - - O
. - - O

YAC - - O
and - - O
cosmid - - O
contigs - - O
spanning - - O
the - - O
Batten - - B-MUT
disease - - I-MUT
( - - I-MUT
CLN3 - - I-MUT
) - - I-MUT
region - - I-MUT
at - - O
16p12 - - O
. - - O
1-p11 - - O
. - - O
2 - - O
. - - O

Hu-Met-1 - - B-MUT
mRNA - - I-MUT
expression - - O
in - - O
a - - O
small - - O
number - - O
of - - O
human - - O
T - - O
cell - - O
tumor - - O
lines - - O
did - - O
not - - O
correlate - - O
with - - O
any - - O
particular - - O
phenotype - - O
or - - O
stage - - O
of - - O
development - - O
. - - O

Identification - - O
of - - O
dynein - - B-MUT
heavy - - I-MUT
chain - - I-MUT
genes - - I-MUT
expressed - - O
in - - O
human - - O
and - - O
mouse - - O
testis - - O
: - - O
chromosomal - - O
localization - - O
of - - O
an - - O
axonemal - - B-MUT
dynein - - I-MUT
gene - - I-MUT
. - - O

The - - O
granules - - O
grew - - O
as - - O
the - - O
melted - - O
material - - O
immersed - - O
into - - O
the - - O
void - - O
space - - O
among - - O
the - - O
adhered - - O
particles - - O
. - - O

We - - O
conclude - - O
that - - O
administration - - O
of - - O
the - - O
calcium - - O
antagonist - - O
Verapamil - - O
is - - O
of - - O
no - - O
additional - - O
value - - O
in - - O
tocolytic - - O
treatment - - O
with - - O
beta-mimetics - - O
. - - O

The - - O
method - - O
was - - O
adapted - - O
for - - O
the - - O
determination - - O
of - - O
nadolol - - O
racemate - - O
A - - O
by - - O
a - - O
change - - O
in - - O
mobile - - O
phase - - O
composition - - O
. - - O

Examples - - O
of - - O
its - - O
use - - O
in - - O
the - - O
intensive - - O
therapy - - O
unit - - O
are - - O
described - - O
. - - O

At - - O
physiological - - O
doses - - O
, - - O
either - - O
insulin-like - - B-MUT
growth - - I-MUT
factor - - I-MUT
I - - I-MUT
( - - O
IGF-I - - B-MUT
) - - O
or - - O
insulin - - B-MUT
turned - - O
out - - O
to - - O
be - - O
as - - O
potent - - O
as - - O
dibutyryl - - O
cAMP - - O
( - - O
dbcAMP - - O
) - - O
in - - O
increasing - - O
UCP1 - - B-MUT
gene - - I-MUT
transcription - - O
rate - - O
( - - O
1 - - O
h - - O
) - - O
and - - O
also - - O
UCP1 - - B-MUT
mRNA - - I-MUT
accumulation - - O
( - - O
3 - - O
h - - O
) - - O
, - - O
their - - O
maximal - - O
effect - - O
( - - O
15-fold - - O
increase - - O
) - - O
reached - - O
upon - - O
treatment - - O
for - - O
24 - - O
h - - O
. - - O

However - - O
, - - O
the - - O
increase - - O
in - - O
biliary - - O
excretion - - O
did - - O
not - - O
compensate - - O
for - - O
the - - O
reduced - - O
elimination - - O
of - - O
bretylium - - O
and - - O
hexylsalicylic - - O
acid - - O
via - - O
the - - O
kidney - - O
. - - O

Therefore - - O
, - - O
the - - O
positive - - O
cAMP - - O
control - - O
of - - O
the - - O
hypoxic - - O
SRP1 - - B-MUT
and - - O
HEM13 - - B-MUT
genes - - I-MUT
was - - O
uncoupled - - O
from - - O
the - - O
HOG - - O
pathway - - O
. - - O

Auditory - - O
threshold - - O
shifts - - O
, - - O
as - - O
measured - - O
by - - O
the - - O
auditory - - O
evoked - - O
brainstem - - O
response - - O
, - - O
were - - O
measured - - O
at - - O
2 - - O
, - - O
4 - - O
, - - O
8 - - O
, - - O
12 - - O
, - - O
16 - - O
, - - O
20 - - O
and - - O
24 - - O
kHz - - O
. - - O

The - - O
hybridizing - - O
clone - - O
of - - O
V - - O
. - - O
vulnificus - - O
chromosomal - - O
DNA - - O
complemented - - O
a - - O
V - - B-MUT
. - - I-MUT
cholerae - - I-MUT
fur - - I-MUT
mutant - - I-MUT
. - - O

Furthermore - - O
, - - O
RING1 - - B-MUT
overexpression - - O
results - - O
in - - O
enhanced - - O
expression - - O
of - - O
the - - O
proto-oncogenes - - O
c-jun - - B-MUT
and - - O
c-fos - - B-MUT
. - - O

TPTA - - O
produced - - O
brain - - O
congestion - - O
, - - O
and - - O
hepatic - - O
and - - O
pulmonary - - O
petechial - - O
and - - O
generalized - - O
hemorrhages - - O
. - - O

A - - O
patient - - O
with - - O
an - - O
infected - - O
wound - - O
or - - O
one - - O
on - - O
a - - O
primary - - O
area - - O
( - - O
hands - - O
, - - O
feet - - O
, - - O
face - - O
, - - O
or - - O
perineum - - O
) - - O
may - - O
have - - O
to - - O
be - - O
hospitalized - - O
to - - O
ensure - - O
proper - - O
care - - O
. - - O

STUDY - - O
DESIGN - - O
: - - O
Fine - - O
needle - - O
aspiration - - O
cytologic - - O
smears - - O
from - - O
21 - - O
cases - - O
of - - O
invasive - - O
lobular - - O
carcinoma - - O
( - - O
ILC - - O
) - - O
of - - O
breast - - O
were - - O
subjected - - O
to - - O
detailed - - O
cytomorphologic - - O
analysis - - O
. - - O

Detection - - O
of - - O
exercise-induced - - O
asynergy - - O
by - - O
M-mode - - O
echocardiography - - O
. - - O

Twenty-one - - O
ELISA-positive - - O
sera - - O
were - - O
tested - - O
and - - O
confirmed - - O
positive - - O
by - - O
plaque - - O
reduction - - O
neutralization - - O
testing - - O
. - - O

We - - O
have - - O
reviewed - - O
the - - O
experience - - O
of - - O
a - - O
major - - O
MMT - - O
general - - O
practice - - O
with - - O
hepatitis - - O
C - - O
virus - - O
( - - O
HCV - - O
) - - O
infection - - O
from - - O
1991 - - O
to - - O
1995 - - O
. - - O

An - - O
intralobar - - O
change - - O
in - - O
temperature - - O
above - - O
or - - O
below - - O
36 - - O
degrees - - O
C - - O
decreases - - O
only - - O
the - - O
lobar - - O
bronchial - - O
blood - - O
flow - - O
and - - O
does - - O
not - - O
influence - - O
blood - - O
flow - - O
to - - O
other - - O
nearby - - O
tissues - - O
including - - O
those - - O
vascularized - - O
by - - O
the - - O
bronchial - - O
circulation - - O
. - - O

The - - O
cloned - - O
HindIII - - B-MUT
fragment - - I-MUT
, - - O
which - - O
was - - O
shown - - O
by - - O
DNA - - O
sequence - - O
analysis - - O
to - - O
encode - - O
the - - O
N-terminal - - O
half - - O
of - - O
the - - O
B - - B-MUT
. - - I-MUT
subtilis - - I-MUT
IF2 - - I-MUT
protein - - I-MUT
and - - O
0 - - O
. - - O
2 - - O
kb - - O
of - - O
upstream - - O
flanking - - O
sequence - - O
, - - O
was - - O
utilized - - O
as - - O
a - - O
homologous - - O
probe - - O
to - - O
clone - - O
an - - O
overlapping - - O
2 - - B-MUT
. - - I-MUT
76-kb - - I-MUT
ClaI - - I-MUT
chromosomal - - I-MUT
fragment - - I-MUT
containing - - O
the - - O
entire - - B-MUT
IF2 - - I-MUT
structural - - I-MUT
gene - - I-MUT
. - - O

The - - O
5'flanking - - O
region - - O
is - - O
highly - - O
GC - - O
rich - - O
, - - O
with - - O
multiple - - O
CpG - - O
doublets - - O
, - - O
and - - O
contains - - O
multiple - - O
binding - - O
sites - - O
for - - O
Sp1 - - B-MUT
. - - O

HTLV-1 - - O
decreases - - O
Th2 - - O
type - - O
of - - O
immune - - O
response - - O
in - - O
patients - - O
with - - O
strongyloidiasis - - O
. - - O

The - - O
gene - - O
product - - O
of - - O
cotS - - B-MUT
was - - O
confirmed - - O
to - - O
be - - O
identical - - O
to - - O
Cot40-2 - - B-MUT
by - - O
SDS-PAGE - - O
and - - O
immunoblotting - - O
from - - O
Escherichia - - O
coli - - O
transformed - - O
with - - O
a - - O
plasmid - - O
containing - - O
the - - O
cotS - - B-MUT
region - - I-MUT
. - - O

All - - O
four - - O
of - - O
the - - O
genes - - O
have - - O
a - - O
similar - - O
structure - - O
, - - O
with - - O
the - - O
receptor - - O
protein - - O
encoded - - O
in - - O
a - - O
single - - O
exon - - O
. - - O

During - - O
surgery - - O
bone - - O
cysts - - O
were - - O
excised - - O
and - - O
filled - - O
by - - O
bone - - O
grafts - - O
. - - O

Presentation - - O
of - - O
a - - O
horse - - B-MUT
cytochrome - - I-MUT
c - - I-MUT
peptide - - I-MUT
by - - O
multiple - - O
H-2b - - B-MUT
class - - I-MUT
I - - I-MUT
major - - I-MUT
histocompatibility - - I-MUT
complex - - I-MUT
( - - O
MHC - - B-MUT
) - - O
molecules - - O
to - - O
C57BL - - O
6- - - O
and - - O
bm1-derived - - O
cytotoxic - - O
T - - O
lymphocytes - - O
: - - O
presence - - O
of - - O
a - - O
single - - O
MHC - - O
anchor - - B-MUT
residue - - I-MUT
may - - I-MUT
confer - - O
efficient - - O
peptide-specific - - O
CTL - - O
recognition - - O
. - - O

The - - O
major - - O
myosin-binding - - B-MUT
domain - - I-MUT
of - - O
skeletal - - B-MUT
muscle - - I-MUT
MyBP-C - - I-MUT
( - - O
C - - B-MUT
protein - - I-MUT
) - - O
resides - - O
in - - O
the - - O
COOH-terminal - - O
, - - O
immunoglobulin - - B-MUT
C2 - - B-MUT
motif - - I-MUT
. - - O

The - - O
differences - - O
in - - O
the - - O
CPIgG - - B-MUT
, - - O
CRP - - B-MUT
, - - O
and - - O
fibrinogen - - B-MUT
levels - - O
in - - O
patients - - O
who - - O
were - - O
diagnosed - - O
with - - O
ACS - - O
versus - - O
those - - O
who - - O
were - - O
not - - O
( - - O
non-ACS - - O
) - - O
were - - O
evaluated - - O
. - - O

FTF - - B-MUT
is - - O
also - - O
abundantly - - O
expressed - - O
in - - O
the - - O
pancreas - - O
and - - O
may - - O
exert - - O
differentiation - - O
functions - - O
in - - O
endodermal - - O
sublineages - - O
, - - O
similar - - O
to - - O
SF-1 - - B-MUT
in - - O
steroidogenic - - O
tissues - - O
. - - O

The - - O
2 - - O
cDNAs - - O
differed - - O
in - - O
the - - O
length - - O
of - - O
their - - O
respective - - O
3' - - O
untranslated - - O
regions - - O
, - - O
of - - O
577 - - O
bp - - O
in - - O
Cp - - B-MUT
. - - I-MUT
F6 - - I-MUT
and - - O
72 - - O
bp - - O
in - - O
Cp - - B-MUT
. - - I-MUT
F10 - - I-MUT
, - - O
in - - O
both - - O
of - - O
which - - O
a - - O
putative - - O
polyadenylation - - O
signal - - O
was - - O
identified - - O
. - - O

Iron - - O
and - - O
folate - - O
deficiency - - O
in - - O
pregnancy - - O
. - - O

In - - O
the - - O
first - - O
part - - O
of - - O
our - - O
study - - O
, - - O
the - - O
highest - - O
mutagenicity - - O
was - - O
revealed - - O
by - - O
TA98 - - O
strain - - O
without - - O
enzymatic - - O
activation - - O
, - - O
suggesting - - O
a - - O
direct-acting - - O
mutagenicity - - O
prevalence - - O
in - - O
diesel - - O
particulate - - O
. - - O

However - - O
, - - O
excretion - - O
of - - O
6-keto-prostaglandin - - O
F1 - - O
alpha - - O
was - - O
further - - O
reduced - - O
in - - O
the - - O
smokers - - O
who - - O
used - - O
oral - - O
contraceptives - - O
( - - O
133 - - O
+ - - O
- - - O
20 - - O
to - - O
86 - - O
+ - - O
- - - O
9 - - O
ng - - O
gm - - O
of - - O
creatinine - - O
, - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
05 - - O
) - - O
. - - O

R-wave - - O
voltage - - O
in - - O
the - - O
right - - O
precordial - - O
leads - - O
in - - O
anthracycline - - O
cardiomyopathy - - O
: - - O
a - - O
clinical - - O
study - - O
. - - O

A - - O
single - - O
NMSC - - O
was - - O
present - - O
in - - O
69 - - O
. - - O
4% - - O
, - - O
two - - O
in - - O
16% - - O
, - - O
three - - O
in - - O
6 - - O
. - - O
4% - - O
, - - O
four - - O
in - - O
3 - - O
. - - O
5% - - O
, - - O
five - - O
to - - O
nine - - O
in - - O
4 - - O
. - - O
2% - - O
, - - O
and - - O
0 - - O
. - - O
5% - - O
had - - O
ten - - O
or - - O
more - - O
. - - O

To - - O
overcome - - O
this - - O
problem - - O
, - - O
we - - O
have - - O
overexpressed - - O
Kex2p - - B-MUT
using - - O
the - - O
baculovirus - - O
insect - - O
cell - - O
expression - - O
system - - O
. - - O

Basal - - O
promoter - - O
activity - - O
is - - O
enhanced - - O
by - - O
a - - O
functional - - O
M1 - - B-MUT
domain - - I-MUT
in - - O
LHR-expressing - - O
mouse - - O
Leydig - - O
tumor - - O
cells - - O
( - - O
MLTC - - O
) - - O
but - - O
not - - O
in - - O
non-expressing - - O
CHO - - O
cells - - O
. - - O

In - - O
contrast - - O
, - - O
no - - O
change - - O
was - - O
detected - - O
in - - O
the - - O
phenotype - - O
of - - O
'unstressed' - - O
clones - - O
, - - O
with - - O
respect - - O
to - - O
any - - O
of - - O
the - - O
following - - O
parameters - - O
: - - O
proliferation - - O
rate - - O
in - - O
monolayer - - O
, - - O
serum-dependence - - O
for - - O
proliferation - - O
or - - O
survival - - O
, - - O
tumorigenicity - - O
, - - O
cellular - - O
morphology - - O
, - - O
or - - O
tissue-specific - - O
differentiation - - O
markers - - O
. - - O

In - - O
vitro - - O
penetration - - O
tests - - O
of - - O
human - - O
sperm - - O
into - - O
cervical - - O
mucus - - O
were - - O
introduced - - O
in - - O
order - - O
to - - O
study - - O
the - - O
interaction - - O
between - - O
sperm - - O
and - - O
cervical - - O
mucus - - O
. - - O

The - - O
concentration - - O
of - - O
PGI2 - - O
on - - O
the - - O
newly-formed - - O
luminal - - O
surface - - O
remained - - O
low - - O
. - - O

The - - O
most - - O
important - - O
risk - - O
factors - - O
are - - O
: - - O
1 - - O
) - - O
genetic - - O
; - - O
2 - - O
) - - O
Epstein-Barr - - O
virus - - O
( - - O
infectious - - O
mononucleosis - - O
) - - O
; - - O
3 - - O
) - - O
congenital - - O
and - - O
acquired - - O
immunodeficiency - - O
; - - O
4 - - O
) - - O
occupational - - O
exposure - - O
( - - O
the - - O
wood - - O
industry - - O
) - - O
. - - O

Urinary - - O
urate - - O
excretion - - O
, - - O
urate - - O
clearance - - O
, - - O
and - - O
fractional - - O
excretion - - O
of - - O
urate - - O
all - - O
increased - - O
significantly - - O
during - - O
water - - O
immersion - - O
, - - O
and - - O
decreased - - O
in - - O
the - - O
hour - - O
following - - O
water - - O
immersion - - O
. - - O

Statistically - - O
significant - - O
effects - - O
were - - O
noted - - O
at - - O
doses - - O
which - - O
did - - O
not - - O
appear - - O
to - - O
be - - O
maternally - - O
toxic - - O
. - - O

Recently - - O
, - - O
a - - O
human - - B-MUT
transcription - - I-MUT
elongation - - I-MUT
factor - - I-MUT
P-TEFb - - I-MUT
, - - O
consisting - - O
of - - O
CDK9 - - B-MUT
kinase - - I-MUT
, - - O
cyclin - - B-MUT
T - - I-MUT
and - - O
other - - O
associated - - O
factors - - O
, - - O
has - - O
been - - O
shown - - O
to - - O
interact - - O
with - - O
Tat - - B-MUT
to - - O
restore - - O
Tat - - B-MUT
activation - - O
in - - O
HeLa - - O
nuclear - - O
extract - - O
depleted - - O
of - - O
P-TEFb - - B-MUT
. - - O

Following - - O
the - - O
injection - - O
of - - O
PGF2 - - B-MUT
alpha - - I-MUT
, - - O
heifers - - O
were - - O
observed - - O
visually - - O
for - - O
signs - - O
of - - O
estrus - - O
at - - O
0730 - - O
and - - O
1630 - - O
( - - O
45 - - O
min - - O
each - - O
) - - O
. - - O

ECP - - B-MUT
and - - O
tryptase - - B-MUT
levels - - O
in - - O
serum - - O
were - - O
measured - - O
before - - O
and - - O
after - - O
the - - O
last - - O
oral - - O
challenge - - O
. - - O

The - - O
combination - - O
of - - O
F1 - - O
and - - O
F2 - - O
which - - O
was - - O
the - - O
best - - O
predictor - - O
of - - O
CHD - - O
in - - O
this - - O
population - - O
( - - O
G1 - - O
) - - O
might - - O
be - - O
interpreted - - O
as - - O
reflecting - - O
trunk - - O
adiposity - - O
mainly - - O
abdominal - - O
. - - O

Other - - O
therapies - - O
are - - O
also - - O
available - - O
, - - O
including - - O
hypertonic - - O
saline - - O
solution - - O
, - - O
THAM - - O
( - - O
Tris-hydroxy-methyl-aminomethane - - O
) - - O
buffer - - O
, - - O
and - - O
high-dose - - O
barbiturates - - O
. - - O

Mean+ - - O
-SD - - O
serum - - O
VEGF - - B-MUT
concentrations - - I-MUT
were - - O
significantly - - O
higher - - O
( - - O
P - - O
< - - O
0 - - O
. - - O
001 - - O
) - - O
in - - O
women - - O
with - - O
PCO - - O
and - - O
PCOS - - O
( - - O
3 - - O
. - - O
4+ - - O
-0 - - O
. - - O
7 - - O
and - - O
3 - - O
. - - O
2+ - - O
-0 - - O
. - - O
66 - - O
ng - - O
ml - - O
respectively - - O
) - - O
compared - - O
with - - O
women - - O
with - - O
normal - - O
ovaries - - O
( - - O
2 - - O
. - - O
3+ - - O
-0 - - O
. - - O
5 - - O
ng - - O
ml - - O
) - - O
. - - O

During - - O
V-A - - O
bypass - - O
, - - O
hemodynamics - - O
were - - O
stable - - O
. - - O

However - - O
, - - O
a - - O
zinc-depleted - - O
enzyme - - O
was - - O
obtained - - O
after - - O
prolonged - - O
dialysis - - O
against - - O
the - - O
specific - - O
chelating - - O
agent - - O
1 - - O
, - - O
10-phenanthroline - - O
. - - O

This - - O
indicates - - O
that - - O
lipid - - O
peroxidation - - O
may - - O
be - - O
involved - - O
in - - O
the - - O
development - - O
of - - O
senile - - O
cataract - - O
and - - O
, - - O
as - - O
a - - O
direct - - O
consequence - - O
of - - O
retinal - - O
damage - - O
, - - O
also - - O
in - - O
the - - O
pathogenesis - - O
of - - O
cataract - - O
in - - O
diabetes - - O
and - - O
in - - O
severe - - O
myopia - - O
. - - O

Major - - O
clinical - - O
symptoms - - O
of - - O
the - - O
disease - - O
were - - O
defined - - O
in - - O
this - - O
group - - O
of - - O
patients - - O
. - - O

The - - O
effect - - O
of - - O
dietary - - O
zinc - - O
deficiency - - O
on - - O
the - - O
mossy - - O
fiber - - O
zinc - - O
content - - O
of - - O
the - - O
rat - - O
hippocampus - - O
. - - O

To - - O
investigate - - O
the - - O
functions - - O
of - - O
GE - - O
, - - O
IG - - O
, - - O
and - - O
GS - - O
sequences - - O
in - - O
transcription - - O
, - - O
we - - O
constructed - - O
plasmids - - O
containing - - O
cDNAs - - O
of - - O
the - - O
full-length - - O
SV5 - - O
genome - - O
in - - O
which - - O
the - - O
gene - - O
junction - - O
sequences - - O
( - - O
GE - - O
, - - O
IG - - O
, - - O
and - - O
GS - - O
sequences - - O
) - - O
located - - O
between - - O
the - - O
hemagglutinin-neuraminidase - - B-MUT
( - - O
HN - - B-MUT
) - - O
and - - O
the - - O
polymerase - - B-MUT
( - - I-MUT
L - - I-MUT
) - - I-MUT
genes - - I-MUT
were - - O
replaced - - O
with - - O
the - - O
counterpart - - O
sequences - - O
from - - O
other - - O
gene - - O
junctions - - O
. - - O

Effect - - O
of - - O
tracheal - - O
insufflation - - O
of - - O
deferoxamine - - O
on - - O
acute - - O
ozone - - O
toxicity - - O
in - - O
rats - - O
. - - O

nos-1 - - B-MUT
and - - O
nos-2 - - B-MUT
, - - O
two - - O
genes - - O
related - - O
to - - O
Drosophila - - B-MUT
nanos - - I-MUT
, - - O
regulate - - O
primordial - - O
germ - - O
cell - - O
development - - O
and - - O
survival - - O
in - - O
Caenorhabditis - - O
elegans - - O
. - - O

The - - O
addition - - O
of - - O
an - - O
equimolar - - O
complex - - O
of - - O
the - - O
fourth - - O
and - - O
seventh - - O
largest - - O
subunits - - O
, - - O
purified - - O
from - - O
pol - - B-MUT
II - - I-MUT
holoenzyme - - I-MUT
by - - O
ion-exchange - - O
chromatography - - O
in - - O
the - - O
presence - - O
of - - O
urea - - O
, - - O
restored - - O
promoter-directed - - O
initiation - - O
activity - - O
to - - O
pol - - B-MUT
II - - I-MUT
delta - - I-MUT
4 - - I-MUT
7 - - I-MUT
. - - I-MUT

We - - O
propose - - O
that - - O
TFOs - - O
represent - - O
a - - O
therapeutic - - O
potential - - O
to - - O
specifically - - O
diminish - - O
the - - O
expression - - O
of - - O
c-sis - - B-MUT
PDGF-B - - I-MUT
proto-oncogene - - I-MUT
in - - I-MUT
various - - O
pathologic - - O
settings - - O
where - - O
constitutive - - O
expression - - O
of - - O
this - - O
gene - - O
has - - O
been - - O
observed - - O
. - - O

We - - O
found - - O
that - - O
the - - O
3'-end-adjacent - - O
sequence - - O
CA - - O
( - - O
N - - O
) - - O
3-10AGTNNAA - - O
, - - O
conserved - - O
in - - O
plant - - O
Pol - - B-MUT
II-specific - - I-MUT
U - - I-MUT
snRNA - - I-MUT
genes - - I-MUT
, - - O
is - - O
essential - - O
for - - O
the - - O
3'-end - - O
formation - - O
of - - O
U2 - - B-MUT
transcripts - - I-MUT
and - - O
, - - O
similar - - O
to - - O
the - - O
vertebrate - - O
3' - - O
box - - O
, - - O
is - - O
highly - - O
tolerant - - O
to - - O
mutation - - O
. - - O

The - - O
effectiveness - - O
of - - O
the - - O
haemodialysate - - O
Solcoseryl - - O
for - - O
second-intention - - O
wound - - O
healing - - O
in - - O
horses - - O
and - - O
ponies - - O
. - - O

In - - O
addition - - O
, - - O
the - - O
gcd1-101 - - B-MUT
mutation - - I-MUT
suppressed - - O
the - - O
low - - O
translational - - O
efficiency - - O
of - - O
GCN4-lacZ - - B-MUT
mRNA - - I-MUT
observed - - O
in - - O
gcn2- - - B-MUT
and - - O
gcn3- - - B-MUT
cells - - O
. - - O

In - - O
this - - O
report - - O
, - - O
we - - O
describe - - O
the - - O
characterization - - O
of - - O
two - - O
early - - O
class - - B-MUT
II - - I-MUT
flagellar - - I-MUT
genes - - I-MUT
contained - - O
in - - O
the - - O
orfX-fliP - - B-MUT
locus - - I-MUT
. - - O

The - - O
effect - - O
of - - O
the - - O
fatty - - B-MUT
acid - - I-MUT
cyclo-oxygenase - - I-MUT
inhibitor - - O
indomethacin - - O
on - - O
cerebral - - O
blood - - O
flow - - O
( - - O
CBF - - O
) - - O
and - - O
the - - O
metabolic - - O
rate - - O
for - - O
oxygen - - O
( - - O
CMRO2 - - O
) - - O
was - - O
studied - - O
in - - O
paralyzed - - O
and - - O
artificially - - O
ventilated - - O
rats - - O
. - - O

From - - O
February - - O
1991 - - O
to - - O
August - - O
1997 - - O
, - - O
124 - - O
patients - - O
with - - O
endometrial - - O
carcinoma - - O
were - - O
treated - - O
postoperatively - - O
with - - O
high-dose-rate - - O
vaginal - - O
vault - - O
brachytherapy - - O
as - - O
the - - O
only - - O
adjuvant - - O
treatment - - O
. - - O

Contingency - - O
contracting - - O
between - - O
clients - - O
and - - O
their - - O
parents - - O
caregivers - - O
was - - O
used - - O
to - - O
specify - - O
consequences - - O
for - - O
daily - - O
self-monitoring - - O
, - - O
reduced - - O
caloric - - O
intake - - O
, - - O
weight - - O
loss - - O
, - - O
and - - O
exercise - - O
. - - O

The - - O
ParaSight-F - - O
test - - O
alone - - O
was - - O
used - - O
to - - O
monitor - - O
serum - - O
antigen - - O
levels - - O
after - - O
treatment - - O
in - - O
24 - - O
patients - - O
. - - O

The - - O
expressed - - O
G1-G2 - - B-MUT
bound - - O
to - - O
both - - O
hyaluronan - - O
and - - O
link - - B-MUT
protein - - I-MUT
indicating - - O
that - - O
the - - O
immunoglobulin-fold - - B-MUT
motif - - I-MUT
and - - O
proteoglycan - - O
tandem - - O
repeat - - O
loops - - O
of - - O
the - - O
G1 - - B-MUT
domain - - I-MUT
were - - O
correctly - - O
folded - - O
. - - O

Among - - O
genes - - O
induced - - O
by - - O
added - - O
pMesogenin1 - - B-MUT
is - - O
Xwnt-8 - - B-MUT
, - - O
a - - O
signaling - - O
factor - - O
that - - O
induces - - O
a - - O
similar - - O
repertoire - - O
of - - O
marker - - O
genes - - O
and - - O
a - - O
similar - - O
cellular - - O
phenotype - - O
. - - O

A - - O
phylogenetic - - O
tree - - O
of - - O
members - - O
of - - O
the - - O
T2 - - B-MUT
S-RNase - - I-MUT
superfamily - - I-MUT
in - - I-MUT
plants - - O
was - - O
obtained - - O
. - - O

Characterization - - O
of - - O
the - - O
promoter - - O
for - - O
the - - O
human - - B-MUT
85 - - I-MUT
kDa - - I-MUT
cytosolic - - I-MUT
phospholipase - - I-MUT
A2 - - I-MUT
gene - - I-MUT
. - - O

Gtx - - B-MUT
mRNA - - I-MUT
accumulates - - O
in - - O
parallel - - O
with - - O
the - - O
RNAs - - O
encoding - - O
the - - O
major - - O
structural - - O
proteins - - O
of - - O
myelin - - O
, - - O
myelin - - B-MUT
basic - - I-MUT
protein - - I-MUT
( - - O
MBP - - B-MUT
) - - O
, - - O
and - - O
proteolipid - - B-MUT
protein - - I-MUT
( - - O
PLP - - B-MUT
) - - O
during - - O
postnatal - - O
brain - - O
development - - O
; - - O
Gtx - - B-MUT
mRNA - - I-MUT
decreases - - O
in - - O
parallel - - O
with - - O
MBP - - B-MUT
and - - O
PLP - - B-MUT
mRNAs - - I-MUT
in - - O
the - - O
brains - - O
of - - O
myelin-deficient - - O
rats - - O
, - - O
which - - O
have - - O
a - - O
point - - O
mutation - - O
in - - O
the - - O
PLP - - B-MUT
gene - - I-MUT
. - - O

Two - - O
separate - - O
NF1-binding - - B-MUT
loci - - I-MUT
were - - O
also - - O
found - - O
in - - O
the - - O
equivalent - - O
IE68 - - B-MUT
gene - - I-MUT
of - - O
HCMV - - O
( - - O
Towne - - O
) - - O
DNA - - O
, - - O
but - - O
in - - O
this - - O
case - - O
the - - O
DNA - - O
sequence - - O
and - - O
competition - - O
filter - - O
binding - - O
experiments - - O
indicated - - O
a - - O
maximum - - O
of - - O
only - - O
four - - O
to - - O
five - - O
consensus - - O
binding - - O
sites - - O
encompassing - - O
the - - O
promoter-enhancer - - O
region - - O
. - - O

The - - O
second - - O
patient - - O
had - - O
received - - O
pituitary-derived - - B-MUT
growth - - I-MUT
hormone - - I-MUT
for - - O
treatment - - O
of - - O
growth - - B-MUT
hormone - - I-MUT
deficiency - - O
, - - O
secondary - - O
to - - O
a - - O
third - - O
ventricle - - O
teratoma - - O
, - - O
exised - - O
13 - - O
yr - - O
earlier - - O
. - - O

The - - O
shift - - O
in - - O
the - - O
earliest - - O
activation - - O
site - - O
after - - O
administration - - O
of - - O
esmolol - - O
was - - O
compared - - O
with - - O
the - - O
shift - - O
after - - O
RFA - - O
. - - O
The - - O
heart - - O
rate - - O
at - - O
rest - - O
and - - O
in - - O
drug-free - - O
state - - O
ranged - - O
between - - O
95 - - O
and - - O
125 - - O
beats - - O
min - - O
( - - O
mean - - O
99 - - O
+ - - O
- - - O
14 - - O
beats - - O
min - - O
) - - O
. - - O

The - - O
hypertension - - O
with - - O
elevated - - O
PRA - - O
, - - O
however - - O
, - - O
was - - O
resistant - - O
to - - O
the - - O
angiotensin - - B-MUT
II - - I-MUT
( - - O
AII - - B-MUT
) - - O
analog - - O
[ - - O
Sar1 - - O
, - - O
Ile8 - - O
] - - O
ALL - - O
. - - O

Eight - - O
patients - - O
with - - O
ARC - - O
and - - O
renal - - O
failure - - O
were - - O
recently - - O
evaluated - - O
. - - O

The - - O
Escherichia - - B-MUT
coli - - I-MUT
tet-repressor - - I-MUT
( - - O
TetR - - B-MUT
) - - O
operator - - O
system - - O
was - - O
used - - O
to - - O
develop - - O
a - - O
variation - - O
of - - O
the - - O
yeast - - O
two-hybrid - - O
assay - - O
in - - O
which - - O
disruptions - - O
of - - O
protein-protein - - O
interactions - - O
can - - O
be - - O
identified - - O
by - - O
a - - O
positive - - O
selection - - O
. - - O

Western - - O
blotting - - O
( - - O
immunoblotting - - O
) - - O
with - - O
an - - O
antiserum - - O
to - - O
a - - O
partial - - O
SOD - - B-MUT
expressed - - O
in - - O
Escherichia - - O
coli - - O
revealed - - O
two - - O
proteins - - O
with - - O
estimated - - O
molecular - - O
masses - - O
of - - O
19 - - O
and - - O
29 - - O
kDa - - O
. - - O

D - - O
. - - O

Determination - - O
of - - O
an - - O
RNA - - O
structure - - O
involved - - O
in - - O
splicing - - O
inhibition - - O
of - - O
a - - O
muscle-specific - - O
exon - - O
. - - O

The - - O
authors - - O
report - - O
the - - O
clinicopathologic - - O
findings - - O
in - - O
four - - O
cases - - O
of - - O
adult - - O
women - - O
with - - O
rhabdomyosarcomas - - O
that - - O
originated - - O
in - - O
the - - O
endometrium - - O
or - - O
cervix - - O
, - - O
or - - O
both - - O
. - - O

A - - O
total - - O
of - - O
112 - - O
patients - - O
received - - O
anistreplase - - O
and - - O
119 - - O
received - - O
heparin - - O
within - - O
a - - O
mean - - O
period - - O
of - - O
188 - - O
+ - - O
- - - O
62 - - O
min - - O
following - - O
the - - O
onset - - O
of - - O
symptoms - - O
. - - O

Unlike - - O
wild-type - - B-MUT
p53 - - I-MUT
, - - O
the - - O
delta - - B-MUT
proAE - - I-MUT
mutant - - I-MUT
cDNA - - I-MUT
can - - O
be - - O
stably - - O
expressed - - O
in - - O
tumor - - O
derived - - O
cell - - O
lines - - O
with - - O
few - - O
immediate - - O
detrimental - - O
effects - - O
. - - O

The - - O
complete - - O
exon-intron - - O
structure - - O
of - - O
the - - O
156-kb - - B-MUT
human - - I-MUT
gene - - I-MUT
NFKB1 - - I-MUT
, - - O
which - - O
encodes - - O
the - - O
p105 - - B-MUT
and - - O
p50 - - B-MUT
proteins - - I-MUT
of - - O
transcription - - O
factors - - O
NF-kappa - - B-MUT
B - - I-MUT
and - - O
I - - B-MUT
kappa - - I-MUT
B-gamma - - I-MUT
: - - O
implications - - O
for - - O
NF-kappa - - O
B-mediated - - O
signal - - O
transduction - - O
. - - O

The - - O
platelet - - O
adhesion - - O
rate - - O
on - - O
these - - O
layers - - O
were - - O
tested - - O
concerning - - O
the - - O
valuation - - O
of - - O
the - - O
haemocompatibility - - O
of - - O
the - - O
basic-polymers - - O
polyurethane - - O
( - - O
PUR - - O
) - - O
, - - O
polyvinylchloride - - O
( - - O
PVC - - O
) - - O
, - - O
and - - O
polystyrene - - O
( - - O
PS - - O
) - - O
in - - O
two - - O
different - - O
worked - - O
test - - O
chambers - - O
. - - O

Influence - - O
of - - O
compression - - O
therapy - - O
on - - O
symptoms - - O
following - - O
soft - - O
tissue - - O
injury - - O
from - - O
maximal - - O
eccentric - - O
exercise - - O
. - - O

To - - O
test - - O
promotor - - O
function - - O
, - - O
chimeric - - O
genes - - O
were - - O
constructed - - O
linking - - O
fragments - - O
of - - O
chicken - - O
IGF-I - - B-MUT
5'-flanking - - O
DNA - - O
to - - O
a - - O
promoterless - - O
reporter - - O
plasmid - - O
. - - O

Here - - O
, - - O
we - - O
identify - - O
Rsc3 - - B-MUT
and - - O
Rsc30 - - B-MUT
as - - O
novel - - O
components - - O
of - - O
the - - O
essential - - O
yeast - - B-MUT
remodeler - - I-MUT
RSC - - I-MUT
complex - - I-MUT
. - - O

Urinary - - O
LTE4 - - O
increased - - O
after - - O
both - - O
challenges - - O
the - - O
rise - - O
being - - O
higher - - O
following - - O
oral - - O
as - - O
compared - - O
to - - O
inhalation - - O
provocation - - O
( - - O
p - - O
= - - O
0 - - O
. - - O
0001 - - O
) - - O
. - - O

The - - O
subepicardial - - O
lymphatic - - O
capillaries - - O
were - - O
ramified - - O
and - - O
anastomosed - - O
with - - O
each - - O
other - - O
to - - O
form - - O
a - - O
relatively - - O
dense - - O
network - - O
which - - O
extended - - O
over - - O
the - - O
entire - - O
surface - - O
of - - O
both - - O
ventricles - - O
. - - O

Recombination - - O
and - - O
transcription - - O
of - - O
the - - O
endogenous - - B-MUT
Ig - - I-MUT
heavy - - I-MUT
chain - - I-MUT
locus - - I-MUT
is - - O
effected - - O
by - - O
the - - O
Ig - - B-MUT
heavy - - I-MUT
chain - - I-MUT
intronic - - I-MUT
enhancer - - I-MUT
core - - I-MUT
region - - I-MUT
in - - O
the - - O
absence - - O
of - - O
the - - O
matrix - - O
attachment - - O
regions - - O
. - - O

These - - O
results - - O
strongly - - O
suggest - - O
that - - O
locally-applied - - O
TTC - - O
in - - O
combination - - O
with - - O
FDBA - - O
enhances - - O
new - - O
bone - - O
formation - - O
in - - O
experimental - - O
alveolar - - O
bone - - O
defects - - O
. - - O

To - - O
confirm - - O
the - - O
GapIII - - B-MUT
protein - - I-MUT
activity - - O
, - - O
constructs - - O
containing - - O
different - - O
GapIII-GRD - - B-MUT
domains - - I-MUT
were - - O
transformed - - O
into - - O
iral - - O
mutant - - O
yeast - - O
to - - O
determine - - O
their - - O
relative - - O
ability - - O
to - - O
replace - - O
IRA1 - - B-MUT
functionally - - O
. - - O

The - - O
clinical - - O
tolerance - - O
and - - O
pharmacokinetics - - O
of - - O
FCE - - O
22101 - - O
( - - O
sodium - - O
( - - O
5R - - O
, - - O
6S - - O
) - - O
-6- - - O
[ - - O
( - - O
1R - - O
) - - O
-hydroxyethyl - - O
] - - O
-2-carbamoyloxymethyl-2-penem-3-carboxylate - - O
) - - O
, - - O
a - - O
new - - O
penem - - O
antibiotic - - O
, - - O
have - - O
been - - O
studied - - O
after - - O
giving - - O
a - - O
single - - O
i - - O
. - - O
v - - O
. - - O
dose - - O
of - - O
4 - - O
mg - - O
. - - O
kg-1 - - O
to - - O
ten - - O
healthy - - O
male - - O
volunteers - - O
. - - O

RESULTS - - O
: - - O
Acetabular - - O
index - - O
returned - - O
to - - O
normal - - O
gradually - - O
as - - O
the - - O
time - - O
went - - O
by - - O
and - - O
significantly - - O
within - - O
one - - O
year - - O
after - - O
the - - O
reduction - - O
of - - O
developmental - - O
dislocation - - O
of - - O
the - - O
hip - - O
. - - O

Growth - - B-MUT
factor - - I-MUT
stimulation - - O
rapidly - - O
induces - - O
a - - O
reversible - - O
change - - O
in - - O
the - - O
electrophoretic - - O
mobility - - O
of - - O
the - - O
ternary - - O
complex - - O
, - - O
accompanied - - O
by - - O
increased - - O
phosphorylation - - O
of - - O
the - - O
Elk-1 - - B-MUT
C-terminal - - I-MUT
region - - I-MUT
and - - O
by - - O
the - - O
activation - - O
of - - O
a - - O
42 - - B-MUT
kd - - I-MUT
cellular - - I-MUT
Elk-1 - - I-MUT
kinase - - I-MUT
. - - O

Inhibition - - O
of - - O
erythromycin - - O
synthesis - - O
by - - O
disruption - - O
of - - O
malonyl-coenzyme - - B-MUT
A - - I-MUT
decarboxylase - - I-MUT
gene - - I-MUT
eryM - - B-MUT
in - - O
Saccharopolyspora - - O
erythraea - - O
. - - O

This - - O
experimental - - O
design - - O
was - - O
used - - O
to - - O
determine - - O
the - - O
effect - - O
of - - O
displacement - - O
of - - O
the - - O
alpha - - B-MUT
4-2 - - I-MUT
binding - - I-MUT
site - - I-MUT
on - - O
the - - O
repression - - O
of - - O
alpha - - B-MUT
4 - - I-MUT
gene - - I-MUT
transcription - - O
by - - O
ICP4 - - B-MUT
. - - O

We - - O
analyzed - - O
data - - O
from - - O
56 - - O
patients - - O
with - - O
Systemic - - O
Lupus - - O
Erythematosus - - O
( - - O
SLE - - O
) - - O
in - - O
whom - - O
renal - - O
biopsies - - O
were - - O
done - - O
systematically - - O
. - - O

We - - O
have - - O
screened - - O
the - - O
elastin - - B-MUT
gene - - I-MUT
for - - O
mutations - - O
responsible - - O
for - - O
supravalvular - - O
aortic - - O
stenosis - - O
( - - O
SVAS - - O
) - - O
in - - O
two - - O
large - - O
, - - O
independently - - O
collected - - O
families - - O
with - - O
isolated - - O
( - - O
nonsyndromic - - O
) - - O
SVAS - - O
. - - O

In - - O
NASCIS - - O
III - - O
, - - O
a - - O
randomization - - O
imbalance - - O
occurred - - O
that - - O
allocated - - O
a - - O
disproportionate - - O
number - - O
of - - O
patients - - O
with - - O
no - - O
motor - - O
deficit - - O
( - - O
and - - O
therefore - - O
no - - O
chance - - O
for - - O
recovery - - O
) - - O
to - - O
the - - O
lower - - O
dose - - O
control - - O
group - - O
. - - O

Southern - - O
blotting - - O
and - - O
single - - O
strand - - O
conformation - - O
polymorphism - - O
analyses - - O
did - - O
not - - O
show - - O
tumor-specific - - O
alterations - - O
of - - O
this - - O
gene - - O
in - - O
gliomas - - O
and - - O
RT-PCR - - O
studies - - O
showed - - O
expression - - O
in - - O
glioma - - O
cell - - O
lines - - O
, - - O
suggesting - - O
that - - O
ANOVA - - B-MUT
is - - O
not - - O
the - - O
chromosome - - O
19q - - O
glioma - - O
tumor - - O
suppressor - - O
gene - - O
. - - O

The - - O
backbone - - O
dynamics - - O
of - - O
residues - - O
located - - O
in - - O
the - - O
folded - - O
part - - O
of - - O
CRP2 - - B-MUT
( - - O
LIM2 - - B-MUT
) - - O
R122A - - B-MUT
have - - O
been - - O
characterized - - O
by - - O
proton-detected - - O
( - - O
15 - - O
) - - O
N - - O
NMR - - O
spectroscopy - - O
. - - O

In - - O
protocol - - O
2 - - O
, - - O
eight - - O
different - - O
subjects - - O
performed - - O
Con - - O
and - - O
Ecc - - O
arm - - O
curls - - O
to - - O
fatigue - - O
, - - O
followed - - O
by - - O
postexercise - - O
muscle - - O
ischemia - - O
, - - O
by - - O
using - - O
the - - O
same - - O
resistance - - O
as - - O
in - - O
protocol - - O
1 - - O
. - - O

This - - O
study - - O
examined - - O
the - - O
role - - O
of - - O
cholesteryl - - O
ester - - O
transfer - - O
( - - O
CET - - O
) - - O
, - - O
cholesteryl - - B-MUT
ester - - I-MUT
transfer - - I-MUT
protein - - I-MUT
( - - O
CETP - - B-MUT
) - - O
activity - - O
, - - O
and - - O
phospholipid - - B-MUT
transfer - - I-MUT
protein - - I-MUT
( - - O
PLTP - - B-MUT
) - - O
activity - - O
in - - O
the - - O
increased - - O
prevalence - - O
of - - O
coronary - - O
artery - - O
calcification - - O
( - - O
CAC - - O
) - - O
in - - O
diabetic - - O
subjects - - O
compared - - O
with - - O
nondiabetic - - O
subjects - - O
and - - O
in - - O
the - - O
loss - - O
of - - O
the - - O
sex - - O
difference - - O
in - - O
CAC - - O
in - - O
diabetes - - O
. - - O

Collectively - - O
, - - O
these - - O
results - - O
show - - O
that - - O
the - - O
differential - - O
utilization - - O
of - - O
Staf - - B-MUT
zinc - - I-MUT
finger - - I-MUT
1 - - I-MUT
represents - - O
a - - O
new - - O
, - - O
critical - - O
determinant - - O
of - - O
the - - O
transcriptional - - O
activation - - O
mechanism - - O
for - - O
the - - O
Xenopus - - B-MUT
tRNA - - I-MUT
( - - I-MUT
Sec - - I-MUT
) - - I-MUT
and - - O
human - - B-MUT
U6 - - I-MUT
snRNA - - I-MUT
genes - - I-MUT
. - - O

The - - O
corresponding - - O
gene - - O
was - - O
identified - - O
in - - O
the - - O
GenBankTM - - O
data - - O
base - - O
by - - O
sequence - - O
alignment - - O
and - - O
termed - - O
RPS30A - - B-MUT
. - - O

Southern - - O
blot - - O
analysis - - O
of - - O
endonuclease-digested - - O
genomic - - O
DNA - - O
from - - O
primary - - O
chick - - O
embryo - - O
fibroblasts - - O
( - - O
CEF - - O
) - - O
suggested - - O
that - - O
MEK2 - - B-MUT
is - - O
a - - O
single-copy - - O
gene - - O
in - - O
this - - O
vertebrate - - O
species - - O
. - - O

The - - O
members - - O
of - - O
the - - O
Myb - - B-MUT
family - - I-MUT
of - - I-MUT
transcription - - I-MUT
factors - - I-MUT
are - - O
defined - - O
by - - O
homology - - O
in - - O
the - - O
DNA-binding - - O
domain - - O
; - - O
all - - O
bind - - O
the - - O
Myb-binding - - B-MUT
site - - I-MUT
( - - O
MBS - - B-MUT
) - - O
sequence - - O
( - - O
YG - - B-MUT
( - - I-MUT
A - - I-MUT
G - - I-MUT
) - - I-MUT
C - - I-MUT
( - - I-MUT
A - - I-MUT
C - - I-MUT
G - - I-MUT
) - - I-MUT
GTT - - I-MUT
( - - I-MUT
G - - I-MUT
A - - I-MUT
) - - I-MUT
) - - I-MUT
. - - I-MUT

The - - O
predominant - - O
binding - - O
activity - - O
was - - O
not - - O
Ets-1 - - B-MUT
but - - O
rather - - O
two - - O
independent - - O
DNA-protein - - O
complexes - - O
that - - O
comigrated - - O
in - - O
mobility - - O
shift - - O
assays - - O
. - - O

( - - O
i - - O
) - - O
Complete - - O
Grb10 - - B-MUT
expression - - O
from - - O
cDNA - - O
with - - O
an - - O
ecdysone-regulated - - O
transient - - O
expression - - O
system - - O
stimulated - - O
PDGF-BB- - - O
, - - O
IGF-I - - B-MUT
, - - O
and - - O
insulin- - - O
but - - O
not - - O
epidermal - - B-MUT
growth - - I-MUT
factor - - I-MUT
( - - O
EGF - - B-MUT
) - - O
-induced - - O
DNA - - O
synthesis - - O
in - - O
an - - O
ecdysone - - O
dose-responsive - - O
fashion - - O
. - - O

Chronic - - O
E-B - - O
virus - - O
infection - - O
terminated - - O
in - - O
malignant - - O
lymphoma - - O
: - - O
a - - O
case - - O
report - - O
. - - O

High - - O
plasma - - B-MUT
AVP - - I-MUT
levels - - O
observed - - O
in - - O
the - - O
two - - O
cases - - O
suggest - - O
that - - O
SSRIs - - O
stimulate - - O
AVP - - B-MUT
secretion - - O
, - - O
thereby - - O
causing - - O
SIADH - - O
. - - O

These - - O
data - - O
indicate - - O
a - - O
functional - - O
role - - O
for - - O
U1 - - B-MUT
in - - O
NRS-mediated - - O
splicing - - O
inhibition - - O
. - - O

Based - - O
on - - O
subcellular - - O
fractionation - - O
, - - O
the - - O
47-kDa - - B-MUT
P-CIP2 - - I-MUT
protein - - I-MUT
is - - O
mostly - - O
cytosolic - - O
. - - O

Role - - O
of - - O
c-myc - - B-MUT
in - - O
simian - - O
virus - - O
40 - - O
large - - O
tumor - - O
antigen-induced - - O
DNA - - O
synthesis - - O
in - - O
quiescent - - O
3T3-L1 - - O
mouse - - O
fibroblasts - - O
. - - O

Binding - - O
of - - O
cell - - O
type-specific - - O
nuclear - - O
proteins - - O
to - - O
the - - O
5'-flanking - - O
region - - O
of - - O
maize - - B-MUT
C4 - - I-MUT
phosphoenolpyruvate - - I-MUT
carboxylase - - I-MUT
gene - - I-MUT
confers - - O
its - - O
differential - - O
transcription - - O
in - - O
mesophyll - - O
cells - - O
. - - O

With - - O
histology - - O
and - - O
Evans - - O
blue - - O
injections - - O
, - - O
blood-brain - - O
barrier - - O
alterations - - O
were - - O
seen - - O
as - - O
early - - O
as - - O
4 - - O
days - - O
after - - O
a - - O
dose - - O
of - - O
50 - - O
Gy - - O
. - - O

The - - O
identity - - O
between - - O
hnRNPs - - B-MUT
H - - I-MUT
and - - O
H' - - B-MUT
is - - O
96% - - O
, - - O
between - - O
H - - B-MUT
and - - O
F - - B-MUT
78% - - O
, - - O
and - - O
between - - O
H' - - B-MUT
and - - O
F - - B-MUT
75% - - O
, - - O
respectively - - O
. - - O

Jkappa - - B-MUT
DNA-binding - - I-MUT
sites - - I-MUT
were - - O
not - - O
required - - O
for - - O
this - - O
activation - - O
, - - O
and - - O
a - - O
mutant - - B-MUT
EBNA-3C - - I-MUT
protein - - I-MUT
unable - - O
to - - O
bind - - O
Jkappa - - B-MUT
activated - - O
transcription - - O
as - - O
efficiently - - O
as - - O
wild-type - - B-MUT
EBNA-3C - - I-MUT
, - - O
indicating - - O
that - - O
EBNA-3C - - B-MUT
can - - O
regulate - - O
transcription - - O
through - - O
a - - O
mechanism - - O
that - - O
is - - O
independent - - O
of - - O
Jkappa - - B-MUT
. - - O

As - - O
pH - - O
and - - O
Hb - - B-MUT
can - - O
also - - O
affect - - O
mixed - - O
venous - - O
CO2 - - O
content - - O
, - - O
the - - O
effect - - O
on - - O
Q - - O
was - - O
also - - O
assessed - - O
. - - O

Upon - - O
UV - - O
damage - - O
, - - O
Crb2 - - B-MUT
is - - O
transiently - - O
modified - - O
, - - O
probably - - O
phosphorylated - - O
, - - O
with - - O
a - - O
similar - - O
timing - - O
of - - O
phosphorylation - - O
in - - O
Chk1 - - B-MUT
kinase - - I-MUT
, - - O
which - - O
is - - O
reported - - O
to - - O
restrain - - O
Cdc2 - - B-MUT
activation - - O
. - - O

CONCLUSION - - O
: - - O
This - - O
retrospective - - O
analysis - - O
does - - O
not - - O
confirm - - O
the - - O
efficacy - - O
of - - O
one - - O
course - - O
of - - O
simultaneous - - O
Mitomycin-C - - O
and - - O
5-fluorouracil - - O
, - - O
at - - O
least - - O
in - - O
association - - O
with - - O
full-dose - - O
radiotherapy - - O
incorporating - - O
Iridium-192 - - O
boost - - O
. - - O

Furthermore - - O
, - - O
ICER - - B-MUT
negatively - - O
autoregulates - - O
the - - O
alternative - - O
promoter - - O
, - - O
thus - - O
generating - - O
a - - O
feedback - - O
loop - - O
. - - O

Consistent - - O
with - - O
this - - O
similarity - - O
, - - O
the - - O
cdc28-P8 - - B-MUT
mutant - - I-MUT
accumulates - - O
unspliced - - O
precursors - - O
at - - O
the - - O
restrictive - - O
temperature - - O
. - - O

Cotransfection - - O
of - - O
Ets-2 - - B-MUT
and - - O
p44 - - B-MUT
mitogen-activated - - B-MUT
protein - - I-MUT
( - - I-MUT
MAP - - I-MUT
) - - I-MUT
kinase - - I-MUT
expression - - O
vectors - - O
strongly - - O
potentiated - - O
HB-EGF - - B-MUT
promoter - - I-MUT
activation - - O
in - - O
response - - O
to - - O
deltaRaf-1 - - B-MUT
: - - I-MUT
ER - - I-MUT
. - - O

A - - O
reduction - - O
in - - O
blood - - O
pressure - - O
was - - O
only - - O
observed - - O
at - - O
the - - O
end - - O
of - - O
the - - O
study - - O
, - - O
from - - O
142 - - O
+ - - O
- - - O
17 - - O
86 - - O
. - - O
6 - - O
+ - - O
- - - O
9 - - O
. - - O
1 - - O
to - - O
139 - - O
+ - - O
- - - O
13 - - O
82 - - O
. - - O
9 - - O
+ - - O
- - - O
8 - - O
. - - O
9 - - O
mmHg - - O
( - - O
P - - O
less - - O
than - - O
0 - - O
. - - O
05 - - O
for - - O
DBP - - O
) - - O
. - - O

With - - O
chemical - - O
shift - - O
imaging - - O
, - - O
the - - O
signal - - O
intensity - - O
decreased - - O
on - - O
the - - O
out-of-phase - - O
images - - O
in - - O
six - - O
of - - O
seven - - O
( - - O
86% - - O
) - - O
patients - - O
with - - O
APA - - O
and - - O
in - - O
eight - - O
of - - O
nine - - O
( - - O
89% - - O
) - - O
patients - - O
with - - O
BAH - - O
. - - O

Creatine - - B-MUT
kinase - - I-MUT
release - - O
after - - O
hepatic - - O
artery - - O
embolization - - O
in - - O
patients - - O
with - - O
carcinoid - - O
tumors - - O
. - - O

BACKGROUND - - O
: - - O
Ischemic - - O
heart - - O
disease - - O
is - - O
the - - O
primary - - O
cause - - O
of - - O
morbidity - - O
and - - O
mortality - - O
among - - O
diabetics - - O
, - - O
especially - - O
those - - O
who - - O
became - - O
ill - - O
at - - O
a - - O
young - - O
age - - O
. - - O

SRE - - O
activity - - O
is - - O
dependent - - O
upon - - O
the - - O
activation - - O
by - - O
phosphorylation - - O
of - - O
a - - O
ternary - - O
complex - - O
factor - - O
; - - O
included - - O
among - - O
the - - O
ternary - - O
complex - - O
factors - - O
is - - O
Elk-1 - - B-MUT
. - - O

Significantly - - O
, - - O
two - - O
proximal - - O
GATA-1-binding - - B-MUT
sites - - I-MUT
( - - O
-118 - - O
-113 - - O
and - - O
-98 - - O
-93 - - O
) - - O
and - - O
a - - O
region - - O
located - - O
within - - O
-518 - - O
to - - O
-315bp - - O
of - - O
the - - O
mouse - - O
ALAS2 - - O
promoter - - B-MUT
were - - I-MUT
essential - - I-MUT
for - - O
transcriptional - - O
activation - - O
during - - O
chemically - - O
induced - - O
differentiation - - O
of - - O
MEL - - O
cells - - O
, - - O
implying - - O
their - - O
importance - - O
in - - O
conferring - - O
erythroid - - O
specificity - - O
to - - O
the - - O
ALAS2 - - O
transcriptional - - O
activation - - B-MUT
. - - O

The - - O
p73pct1 - - B-MUT
p85cdc10 - - I-MUT
complex - - I-MUT
binds - - I-MUT
both - - O
in - - O
vitro - - O
and - - O
in - - O
vivo - - O
to - - O
MCB - - O
but - - B-MUT
not - - O
SCB - - O
or - - B-MUT
E2F - - O
sites - - B-MUT
. - - I-MUT

Transient - - O
expression - - O
of - - O
VSF-1 - - B-MUT
in - - O
protoplasts - - O
stimulated - - O
vs-1 - - B-MUT
dependent - - O
activation - - O
of - - O
the - - O
-76 - - B-MUT
grp1 - - I-MUT
. - - I-MUT
8 - - I-MUT
minimal - - I-MUT
promoter - - I-MUT
. - - I-MUT

To - - O
analyze - - O
the - - O
VH - - B-MUT
regions - - I-MUT
of - - O
polyreactive - - O
antibodies - - O
, - - O
with - - O
particular - - O
attention - - O
at - - O
their - - O
somatically - - O
mutated - - O
status - - O
, - - O
we - - O
generated - - O
five - - O
IgG - - B-MUT
( - - O
three - - O
IgG1 - - B-MUT
and - - O
two - - O
IgG3 - - B-MUT
) - - O
mAb - - O
( - - O
using - - O
B - - O
cells - - O
from - - O
a - - O
healthy - - O
subject - - O
, - - O
a - - O
patient - - O
with - - O
insulin-dependent - - O
diabetes - - O
mellitus - - O
and - - O
a - - O
patient - - O
with - - O
SLE - - O
) - - O
, - - O
which - - O
bound - - O
with - - O
various - - O
efficiencies - - O
a - - O
number - - O
of - - O
different - - O
self - - O
and - - O
foreign - - O
Ag - - O
. - - O

Non-complement-dependent - - O
sperm-immobilizing - - O
activity - - O
was - - O
also - - O
detected - - O
in - - O
the - - O
cervical - - O
mucus - - O
of - - O
several - - O
patients - - O
. - - O

The - - O
c-myc - - B-MUT
TGF-alpha - - I-MUT
HCCs - - I-MUT
were - - O
also - - O
characterized - - O
by - - O
a - - O
particularly - - O
strong - - O
expression - - O
of - - O
TGF-alpha - - O
and - - B-MUT
very - - O
low - - O
apoptotic - - O
index - - O
in - - O
contrast - - O
to - - O
high - - O
levels - - O
of - - O
apoptosis - - O
in - - O
peritumorous - - O
tissues - - O
and - - O
c-myc - - O
HCCs - - B-MUT
. - - O

The - - O
primary - - O
structure - - O
of - - O
each - - O
of - - O
the - - O
three - - O
proteins - - O
has - - O
about - - O
70% - - O
homology - - O
with - - O
that - - O
of - - O
mouse - - B-MUT
contrapsin - - I-MUT
, - - O
in - - O
contrast - - O
to - - O
43-46% - - O
homology - - O
with - - O
that - - O
of - - O
rat - - B-MUT
alpha - - I-MUT
1-protease - - I-MUT
inhibitor - - O
. - - O

Linear - - O
extrapolation - - O
is - - O
used - - O
below - - O
the - - O
experimental - - O
data - - O
range - - O
to - - O
establish - - O
an - - O
upper - - O
bound - - O
on - - O
carcinogenic - - O
risk - - O
at - - O
low - - O
doses - - O
. - - O

This - - O
study - - O
was - - O
performed - - O
to - - O
assess - - O
the - - O
role - - O
of - - O
additional - - O
diagnostic - - O
laparoscopy - - O
in - - O
the - - O
preoperative - - O
staging - - O
of - - O
patients - - O
with - - O
adenocarcinoma - - O
of - - O
the - - O
esophagus - - O
, - - O
gastric - - O
cancer - - O
and - - O
pancreatic - - O
cancer - - O
prior - - O
to - - O
intended - - O
curative - - O
surgery - - O
. - - O

Treatment - - O
of - - O
N18TG-2 - - O
cells - - O
with - - O
a - - O
demethylating - - O
agent - - O
, - - O
5-aza-deoxycytidine - - O
, - - O
resulted - - O
in - - O
an - - O
expression - - O
of - - O
mlt - - B-MUT
1 - - I-MUT
, - - O
indicating - - O
that - - O
the - - O
repression - - O
of - - O
mlt - - B-MUT
1 - - I-MUT
is - - O
attributable - - O
to - - O
methylation - - O
Thus - - O
, - - O
mlt - - B-MUT
1 - - I-MUT
is - - O
a - - O
novel - - O
target - - O
gene - - O
that - - O
is - - O
silenced - - O
by - - O
methylation - - O
during - - O
liver - - O
tumorigenesis - - O
initiated - - O
by - - O
SV40 - - B-MUT
T - - I-MUT
antigen - - I-MUT
. - - O

Of - - O
these - - O
carriers - - O
149 - - O
were - - O
diagnosed - - O
to - - O
be - - O
asymptomatic - - O
clinically - - O
, - - O
biochemically - - O
and - - O
echographically - - O
. - - O

Animals - - O
were - - O
put - - O
to - - O
death - - O
8 - - O
weeks - - O
later - - O
and - - O
the - - O
grafts - - O
were - - O
sterilely - - O
explanted - - O
and - - O
analyzed - - O
via - - O
microbiologic - - O
culture - - O
and - - O
standard - - O
histologic - - O
procedures - - O
for - - O
evidence - - O
of - - O
infection - - O
. - - O

A - - O
13 - - O
base-pair - - O
oligonucleotide - - O
spanning - - O
nucleotides - - O
+80 - - O
to - - O
+92 - - O
of - - O
the - - O
5 - - B-MUT
S - - I-MUT
RNA - - I-MUT
gene - - I-MUT
retained - - O
specific - - O
and - - O
high-affinity - - O
binding - - O
, - - O
although - - O
the - - O
latter - - O
was - - O
reduced - - O
sixfold - - O
relative - - O
to - - O
longer - - O
DNA - - O
fragments - - O
. - - O

( - - O
1986 - - O
) - - O
method - - O
of - - O
separation - - O
of - - O
Cryptosporidium - - O
spp - - O
. - - O
oocysts - - O
from - - O
feces - - O
by - - O
using - - O
a - - O
percoll - - O
discontinuous - - O
density - - O
gradient - - O
appeared - - O
a - - O
method - - O
of - - O
choice - - O
for - - O
obtaining - - O
large - - O
numbers - - O
of - - O
oocysts - - O
of - - O
C - - O
. - - O
parvum - - O
free - - O
of - - O
fecal - - O
contamination - - O
. - - O

The - - O
deduced - - O
protein - - O
sequence - - O
is - - O
characterized - - O
by - - O
a - - O
putative - - O
16-residue - - O
amino-terminal - - O
signal - - O
peptide - - O
that - - O
is - - O
cleaved - - O
, - - O
resulting - - O
in - - O
a - - O
239-residue - - O
polypeptide - - O
. - - O

The - - O
relationships - - O
between - - O
the - - O
partial - - O
pressures - - O
of - - O
O2 - - O
and - - O
CO2 - - O
as - - O
well - - O
as - - O
between - - O
their - - O
gradients - - O
, - - O
become - - O
stronger - - O
with - - O
the - - O
increase - - O
of - - O
the - - O
ventilation-perfusion - - O
ratio - - O
. - - O

Two - - O
promoters - - O
were - - O
identified - - O
by - - O
S1 - - B-MUT
nuclease - - I-MUT
mapping - - O
: - - O
P1 - - O
, - - O
which - - O
lies - - O
about - - O
72 - - O
bp - - O
upstream - - O
from - - O
the - - O
structural - - O
gene - - O
; - - O
and - - O
P2 - - O
, - - O
which - - O
lies - - O
about - - O
35 - - O
bp - - O
upstream - - O
. - - O

Multiple - - O
regression - - O
analyses - - O
revealed - - O
that - - O
WAIS-R - - O
factor - - O
scores - - O
Verbal - - O
Comprehension - - O
and - - O
Freedom - - O
from - - O
Distractibility - - O
accounted - - O
for - - O
up - - O
to - - O
42% - - O
of - - O
the - - O
variance - - O
in - - O
WMS-R - - O
and - - O
CVLT - - O
indices - - O
. - - O

The - - O
second - - O
transcriptional - - O
unit - - O
, - - O
designated - - O
UL26 - - B-MUT
. - - I-MUT
5 - - I-MUT
, - - O
predicted - - O
to - - O
specify - - O
a - - O
protein - - O
of - - O
329 - - O
amino - - O
acids - - O
, - - O
encodes - - O
the - - O
family - - B-MUT
35 - - I-MUT
proteins - - I-MUT
; - - O
it - - O
is - - O
transcribed - - O
by - - O
an - - O
mRNA - - O
which - - O
initiates - - O
at - - O
approximately - - O
nucleotide - - O
+1000 - - O
of - - O
the - - O
UL26 - - B-MUT
transcription - - O
initiation - - O
site - - O
and - - O
is - - O
translated - - O
from - - O
the - - O
methionine - - O
initiation - - O
codon - - O
located - - O
at - - O
position - - O
+1099 - - O
of - - O
the - - O
UL26 - - B-MUT
transcriptional - - I-MUT
unit - - I-MUT
. - - O

The - - O
MSY2 - - B-MUT
associated - - O
kinase - - B-MUT
is - - O
not - - O
casein - - B-MUT
kinase - - I-MUT
2 - - I-MUT
, - - O
the - - O
kinase - - B-MUT
believed - - O
to - - O
phosphorylate - - O
mRNP3+4 - - B-MUT
in - - O
oocytes - - O
, - - O
but - - O
a - - O
yet - - O
unidentified - - O
kinase - - B-MUT
. - - O

( - - O
1997 - - O
) - - O
Nature - - O
387 - - O
, - - O
370-376 - - O
) - - O
] - - O
, - - O
we - - O
suggest - - O
that - - O
the - - O
metal - - O
fluoride - - O
ions - - O
replaced - - O
phosphate - - O
at - - O
the - - O
two - - O
ATP-binding - - O
sites - - O
of - - O
the - - O
iron - - O
protein - - O
, - - O
Kp2 - - B-MUT
. - - O

Only - - O
one - - O
gene - - O
, - - O
fibronectin - - B-MUT
( - - O
FN - - B-MUT
) - - O
, - - O
was - - O
highly - - O
overexpressed - - O
( - - O
> - - O
60-fold - - O
) - - O
in - - O
LNCaP-r - - O
cells - - O
, - - O
consistent - - O
with - - O
previously - - O
reported - - O
overexpression - - O
of - - O
FN - - B-MUT
in - - O
prostate - - O
cancer - - O
. - - O

The - - O
former - - O
procedure - - O
is - - O
economical - - O
but - - O
complicated - - O
, - - O
whereas - - O
the - - O
latter - - O
is - - O
simple - - O
and - - O
labour-saving - - O
, - - O
but - - O
a - - O
special - - O
ultrafiltration - - O
tube - - O
is - - O
required - - O
. - - O

Rat - - B-MUT
kidney - - I-MUT
carboxylesterase - - I-MUT
. - - O

This - - O
suggests - - O
roles - - O
for - - O
both - - O
the - - O
CE1 - - B-MUT
and - - O
CE2 - - B-MUT
elements - - O
in - - O
regulating - - O
Hoxb1 - - B-MUT
gene - - I-MUT
expression - - O
during - - O
development - - O
. - - O

The - - O
human - - B-MUT
insulin-like - - I-MUT
growth - - I-MUT
factor - - I-MUT
II - - I-MUT
( - - O
IGF-II - - B-MUT
) - - O
gene - - O
contains - - O
four - - O
promoters - - O
( - - O
P1 - - O
, - - O
P2 - - O
, - - O
P3 - - O
and - - O
P4 - - O
) - - O
. - - O

The - - O
symptoms - - O
and - - O
objective - - O
findings - - O
were - - O
caused - - O
by - - O
a - - O
malignant - - O
lymphoma - - O
, - - O
and - - O
the - - O
diagnosis - - O
was - - O
established - - O
from - - O
a - - O
drill - - O
biopsy - - O
. - - O

The - - O
cis-acting - - O
element - - O
, - - O
identified - - O
as - - O
CACGTGACCCG - - B-MUT
, - - O
is - - O
located - - O
34 - - O
bp - - O
upstream - - O
from - - O
the - - O
transcription - - O
initiation - - O
site - - O
, - - O
and - - O
contains - - O
the - - O
core - - O
sequence - - O
of - - O
the - - O
upstream - - O
promoter - - O
sequence - - O
of - - O
Ad2MLP - - O
. - - O

Two - - O
techniques - - O
based - - O
on - - O
assay - - O
coefficients - - O
of - - O
variation - - O
were - - O
employed - - O
to - - O
characterize - - O
a - - O
normal - - O
circadian - - O
pattern - - O
of - - O
cortisol - - O
. - - O

This - - O
interaction - - O
is - - O
mediated - - O
by - - O
the - - O
SH2 - - B-MUT
domain - - I-MUT
of - - O
Crk - - B-MUT
and - - O
can - - O
be - - O
inhibited - - O
with - - O
a - - O
phosphopeptide - - O
containing - - O
the - - O
Crk-SH2 - - B-MUT
binding - - I-MUT
motif - - I-MUT
. - - O

The - - O
differences - - O
among - - O
subgenera - - O
of - - O
the - - O
genus - - O
Dermacentor - - O
are - - O
more - - O
significant - - O
. - - O

Luteinizing - - B-MUT
hormone-releasing - - I-MUT
hormone - - I-MUT
analog - - O
therapy - - O
of - - O
uterine - - O
fibroid - - O
: - - O
analysis - - O
of - - O
results - - O
obtained - - O
with - - O
buserelin - - O
administered - - O
intranasally - - O
and - - O
goserelin - - O
administered - - O
subcutaneously - - O
as - - O
a - - O
monthly - - O
depot - - O
. - - O

Proteins - - O
known - - O
to - - O
bind - - O
the - - O
PEPCK - - B-MUT
CRE - - B-MUT
include - - O
the - - O
CRE-binding - - B-MUT
protein - - I-MUT
( - - O
CREB - - B-MUT
) - - O
and - - O
members - - O
of - - O
the - - O
CCAAT - - B-MUT
enhancer-binding - - I-MUT
protein - - I-MUT
( - - I-MUT
C - - O
EBP - - B-MUT
) - - I-MUT
family - - I-MUT
. - - O

RESULTS - - O
: - - O
Statistically - - O
significant - - O
differences - - O
were - - O
obtained - - O
between - - O
group - - O
I - - O
and - - O
II - - O
concerning - - O
the - - O
number - - O
of - - O
patients - - O
in - - O
whom - - O
induced - - O
atrial - - O
fibrillation - - O
with - - O
conduction - - O
by - - O
the - - O
accessory - - O
pathway - - O
and - - O
RR - - O
< - - O
or - - O
= - - O
250 - - O
msec - - O
was - - O
found - - O
( - - O
0 - - O
vs - - O
6 - - O
, - - O
p - - O
= - - O
0 - - O
. - - O
0045 - - O
) - - O
. - - O

Other - - O
hemostatic - - O
values - - O
evaluated - - O
were - - O
activated - - O
partial - - O
thromboplastin - - B-MUT
times - - O
, - - O
prothrombin - - B-MUT
times - - O
, - - O
thrombin - - B-MUT
times - - O
, - - O
fibrinogen - - B-MUT
, - - O
platelet - - O
counts - - O
, - - O
and - - O
fibrin - - B-MUT
fibrinogen - - I-MUT
degradation - - I-MUT
products - - O
. - - O

The - - O
human - - O
gene - - O
fragment - - O
ligated - - O
to - - O
the - - O
minimal - - O
rat - - O
liver - - O
glucokinase - - B-MUT
promoter - - O
was - - O
shown - - O
to - - O
work - - O
as - - O
an - - O
enhancer - - O
in - - O
the - - O
hepatocyte - - O
transfection - - O
system - - O
. - - O

Esophageal - - O
brush - - O
cytological - - O
screening - - O
was - - O
undertaken - - O
and - - O
blood - - O
concentrations - - O
of - - O
micronutrients - - O
( - - O
vitamin - - O
A - - O
, - - O
E - - O
, - - O
B12 - - O
, - - O
folic - - O
acid - - O
and - - O
methionine - - O
) - - O
determined - - O
from - - O
adults - - O
at - - O
risk - - O
for - - O
esophageal - - O
carcinoma - - O
( - - O
EC - - O
) - - O
in - - O
Transkei - - O
and - - O
Ciskei - - O
, - - O
Southern - - O
Africa - - O
. - - O

The - - O
large - - O
fluxes - - O
of - - O
239+240Pu - - O
might - - O
be - - O
attributed - - O
to - - O
episodic - - O
lateral - - O
transport - - O
of - - O
particles - - O
that - - O
flow - - O
down - - O
the - - O
continental - - O
slope - - O
with - - O
the - - O
nepheloid - - O
layer - - O
which - - O
was - - O
considered - - O
to - - O
be - - O
significant - - O
for - - O
239+240Pu - - O
transport - - O
on - - O
the - - O
continental - - O
slope - - O
in - - O
the - - O
East - - O
China - - O
Sea - - O
. - - O

In - - O
only - - O
two - - O
patients - - O
were - - O
we - - O
able - - O
to - - O
demonstrate - - O
changes - - O
suggestive - - O
of - - O
pulmonary - - O
metastases - - O
any - - O
earlier - - O
with - - O
a - - O
99mTc-EHDP - - O
scan - - O
than - - O
with - - O
chest - - O
radiographs - - O
and - - O
one - - O
of - - O
these - - O
resolved - - O
spontaneously - - O
. - - O

A - - O
chimeric - - B-MUT
VP16-Tat - - I-MUT
construct - - I-MUT
containing - - O
the - - O
leucine - - O
mutations - - O
showed - - O
no - - O
increased - - O
AP-1 - - B-MUT
responsiveness - - O
in - - O
comparison - - O
with - - O
that - - O
of - - O
the - - O
VP16 - - B-MUT
activation - - I-MUT
domain - - I-MUT
alone - - O
. - - O

An - - O
examination - - O
of - - O
the - - O
role - - O
of - - O
the - - O
carboxyl - - O
terminus - - O
in - - O
regulating - - O
NGFI-B - - B-MUT
transcriptional - - O
activity - - O
revealed - - O
that - - O
, - - O
in - - O
accordance - - O
with - - O
other - - O
nuclear - - O
receptors - - O
, - - O
mutants - - O
lacking - - O
portions - - O
of - - O
the - - O
carboxyl - - O
terminus - - O
had - - O
greatly - - O
decreased - - O
activity - - O
. - - O

They - - O
were - - O
then - - O
subjected - - O
to - - O
whole-body - - O
heat - - O
stress - - O
( - - O
water-perfused - - O
suits - - O
) - - O
, - - O
and - - O
the - - O
3 - - O
minutes - - O
of - - O
LBNP - - O
was - - O
repeated - - O
. - - O

Preservatives - - O
are - - O
an - - O
important - - O
component - - O
of - - O
ophthalmic - - O
preparations - - O
, - - O
providing - - O
antimicrobial - - O
activity - - O
in - - O
the - - O
bottle - - O
and - - O
preventing - - O
decomposition - - O
of - - O
active - - O
drug - - O
. - - O

Vaccinia - - O
virus - - O
( - - O
VV - - O
) - - O
is - - O
a - - O
potent - - O
immunogen - - O
, - - O
but - - O
the - - O
nature - - O
of - - O
VV - - O
proteins - - O
involved - - O
in - - O
the - - O
activation - - O
of - - O
the - - O
immune - - O
response - - O
of - - O
the - - O
host - - O
is - - O
not - - O
yet - - O
known - - O
. - - O

Beta - - B-MUT
1 - - I-MUT
integrin- - - I-MUT
and - - O
proteoglycan-mediated - - O
stimulation - - O
of - - O
T - - O
lymphoma - - O
cell - - O
adhesion - - O
and - - O
mitogen-activated - - B-MUT
protein - - I-MUT
kinase - - I-MUT
signaling - - O
by - - O
thrombospondin-1 - - B-MUT
and - - O
thrombospondin-1 - - B-MUT
peptides - - I-MUT
. - - O

In - - O
addition - - O
, - - O
an - - O
mck1 - - B-MUT
mds1 - - B-MUT
mrk1 - - B-MUT
triple - - O
disruptant - - O
was - - O
viable - - O
. - - O

Evaluation - - O
of - - O
antiepileptic - - O
drug - - O
effect - - O
on - - O
membrane - - O
fluidity - - O
. - - O

One - - O
defective - - O
RNA - - O
with - - O
a - - O
large - - O
deletion - - O
in - - O
the - - O
p70 - - B-MUT
coding - - I-MUT
region - - I-MUT
was - - O
able - - O
to - - O
replicate - - O
efficiently - - O
, - - O
both - - O
when - - O
inoculated - - O
with - - O
the - - O
helper - - O
genome - - O
and - - O
when - - O
inoculated - - O
with - - O
a - - O
second - - O
complementing - - O
defective - - O
RNA - - O
that - - O
supplied - - O
a - - O
wild-type - - B-MUT
p70 - - I-MUT
. - - O

In - - O
contrast - - O
, - - O
H-NS - - B-MUT
negative - - O
regulation - - O
operated - - O
only - - O
in - - O
the - - O
absence - - O
of - - O
Fur - - B-MUT
. - - O

Although - - O
the - - O
molecular - - O
mechanisms - - O
involved - - O
in - - O
this - - O
regulation - - O
are - - O
currently - - O
being - - O
elucidated - - O
, - - O
very - - O
little - - O
is - - O
known - - O
about - - O
the - - O
trans-acting - - O
factors - - O
that - - O
allow - - O
expression - - O
of - - O
the - - O
nitrate - - B-MUT
and - - I-MUT
nitrite - - I-MUT
reductase - - I-MUT
genes - - I-MUT
which - - O
code - - O
for - - O
the - - O
first - - O
enzymes - - O
in - - O
the - - O
pathway - - O
. - - O

The - - O
sequence - - O
up - - O
to - - O
-267 - - O
bp - - O
relative - - O
to - - O
the - - O
transcription - - O
start - - O
site - - O
was - - O
sufficient - - O
to - - O
enhance - - O
reporter - - O
gene - - O
expression - - O
depending - - O
on - - O
the - - O
mesodermal - - O
differentiation - - O
of - - O
P19 - - O
cells - - O
. - - O

In - - O
this - - O
article - - O
, - - O
the - - O
clinical - - O
actions - - O
of - - O
the - - O
principal - - O
dopamine - - B-MUT
receptor - - I-MUT
stimulating - - O
agents - - O
( - - O
apomorphine - - O
and - - O
its - - O
derivatives - - O
; - - O
piribedil - - O
, - - O
rye-ergot - - O
derivatives - - O
) - - O
are - - O
discussed - - O
on - - O
the - - O
basis - - O
of - - O
their - - O
biochemical - - O
and - - O
pharmacological - - O
properties - - O
. - - O

To - - O
address - - O
these - - O
questions - - O
, - - O
a - - O
recombinant - - B-MUT
FRAP - - I-MUT
mTOR - - I-MUT
protein - - I-MUT
and - - I-MUT
a - - O
FRAP - - O
mTOR - - B-MUT
immunoprecipitate - - I-MUT
were - - I-MUT
utilized - - O
in - - O
in - - O
vitro - - O
kinase - - O
assays - - O
to - - B-MUT
phosphorylate - - O
4E-BP1 - - O
. - - O

Here - - O
we - - O
report - - O
the - - O
cloning - - O
, - - O
expression - - O
, - - O
and - - O
biochemical - - O
characterization - - O
of - - O
the - - O
32-kDa - - O
subunit - - O
of - - O
human - - O
( - - O
h - - O
) - - O
TFIID - - B-MUT
, - - O
termed - - O
hTAFII32 - - B-MUT
. - - O

The - - O
Scm - - B-MUT
and - - O
ph - - B-MUT
proteins - - O
share - - O
a - - O
homology - - O
domain - - O
with - - O
38% - - O
identity - - O
over - - O
a - - O
length - - O
of - - O
65 - - O
amino - - O
acids - - O
, - - O
termed - - O
the - - O
SPM - - B-MUT
domain - - I-MUT
, - - O
that - - O
is - - O
located - - O
at - - O
their - - O
respective - - O
C - - O
termini - - O
. - - O

Clb - - B-MUT
Cdc28 - - I-MUT
kinases - - I-MUT
promote - - I-MUT
nuclear - - O
export - - O
of - - O
the - - O
replication - - O
initiator - - B-MUT
proteins - - I-MUT
Mcm2-7 - - I-MUT
. - - I-MUT

This - - O
repression - - O
was - - O
reversed - - O
agonists - - O
of - - O
either - - O
receptor - - O
demonstrating - - O
a - - O
functional - - O
interaction - - O
between - - O
NCoR - - B-MUT
and - - O
PPARalpha - - B-MUT
. - - I-MUT
RXRalpha - - I-MUT
heterodimeric - - I-MUT
complexes - - I-MUT
in - - O
mammalian - - O
cells - - O
. - - O

When - - O
the - - O
degree - - O
of - - O
exercise - - O
was - - O
maximal - - O
, - - O
mPAP - - O
was - - O
maintained - - O
, - - O
SVI - - O
decreased - - O
, - - O
HR - - O
was - - O
unchanged - - O
, - - O
and - - O
CO - - O
and - - O
VO2 - - O
decreased - - O
. - - O

Thus - - O
, - - O
the - - O
association - - O
of - - O
PS1 - - B-MUT
fragments - - I-MUT
may - - O
be - - O
maintained - - O
during - - O
cycles - - O
of - - O
phosphorylation - - O
dephosphorylation - - O
of - - O
the - - O
PS1 - - O
CTF - - B-MUT
. - - I-MUT

Microcomputer - - O
management - - O
of - - O
chronic - - O
hepatitis - - O
B - - O
virus - - O
asymptomatic - - O
patients - - O
. - - O

Four - - O
casein - - B-MUT
kinase - - I-MUT
I - - I-MUT
isoforms - - I-MUT
are - - O
differentially - - O
partitioned - - O
between - - O
nucleus - - O
and - - O
cytoplasm - - O
. - - O

Furthermore - - O
, - - O
the - - O
validity - - O
of - - O
this - - O
new - - O
subset - - O
of - - O
questions - - O
was - - O
shown - - O
to - - O
be - - O
significant - - O
( - - O
r - - O
= - - O
0 - - O
. - - O
037 - - O
, - - O
p - - O
< - - O
0 - - O
. - - O
05 - - O
) - - O
for - - O
the - - O
correlation - - O
between - - O
a - - O
measure - - O
of - - O
the - - O
severity - - O
of - - O
binocular - - O
visual - - O
field - - O
loss - - O
and - - O
the - - O
mean - - O
score - - O
of - - O
the - - O
variables - - O
used - - O
in - - O
the - - O
glaucoma - - O
specific - - O
subgroup - - O
of - - O
questions - - O
. - - O

FASEB - - O
Federal - - O
Funding - - O
Consensus - - O
Conference - - O
FY - - O
2000 - - O
. - - O

Azithromycin - - O
is - - O
a - - O
new - - O
generation - - O
macrolide - - O
antibiotic - - O
with - - O
unusual - - O
and - - O
favorable - - O
pharmacokinetics - - O
, - - O
and - - O
seems - - O
to - - O
be - - O
a - - O
very - - O
promising - - O
agent - - O
for - - O
innovative - - O
anti-H - - O
. - - O
pylori - - O
regimens - - O
. - - O

Based - - O
on - - O
this - - O
analysis - - O
, - - O
we - - O
propose - - O
that - - O
the - - O
interactions - - O
of - - O
Sos - - B-MUT
with - - O
the - - O
switch - - O
1 - - O
and - - O
switch - - O
2 - - O
regions - - O
of - - O
Ras - - B-MUT
have - - O
distinct - - O
functional - - O
consequences - - O
: - - O
the - - O
interaction - - O
with - - O
switch - - O
2 - - O
mediates - - O
the - - O
anchoring - - O
of - - O
Ras - - B-MUT
to - - O
Sos - - B-MUT
, - - O
whereas - - O
the - - O
interaction - - O
with - - O
switch - - O
1 - - O
leads - - O
to - - O
disruption - - O
of - - O
the - - O
nucleotide-binding - - O
site - - O
and - - O
GDP - - O
dissociation - - O
. - - O

Peroxisome - - B-MUT
proliferator-activated - - I-MUT
receptors - - I-MUT
( - - O
PPARs - - B-MUT
) - - O
and - - O
retinoid - - B-MUT
X - - I-MUT
receptors - - I-MUT
( - - O
RXRs - - B-MUT
) - - O
are - - O
nuclear - - O
hormone - - O
receptors - - O
that - - O
are - - O
activated - - O
by - - O
fatty - - O
acids - - O
and - - O
9-cis-retinoic - - O
acid - - O
, - - O
respectively - - O
. - - O

Chenodeoxycholic - - O
acid - - O
( - - O
cheno - - O
) - - O
and - - O
ursodeoxycholic - - O
acid - - O
( - - O
urso - - O
) - - O
dissolve - - O
cholesterol - - O
gallstones - - O
in - - O
man - - O
. - - O

The - - O
second - - O
part - - O
of - - O
this - - O
paper - - O
shows - - O
some - - O
medical - - O
applications - - O
of - - O
these - - O
two - - O
aspects - - O
of - - O
NMR - - O
, - - O
with - - O
help - - O
of - - O
some - - O
examples - - O
, - - O
taken - - O
from - - O
the - - O
literature - - O
, - - O
according - - O
to - - O
what - - O
is - - O
concerned - - O
with - - O
endocrinology - - O
. - - O

However - - O
, - - O
D8 - - B-MUT
binding - - O
was - - O
observed - - O
by - - O
nuclease - - B-MUT
protection - - O
with - - O
lactotroph- - - O
as - - O
well - - O
as - - O
somatotroph-like - - B-MUT
cell - - I-MUT
nuclear - - I-MUT
protein - - I-MUT
. - - O

These - - O
findings - - O
suggest - - O
that - - O
direct - - O
cDNA - - O
mapping - - O
using - - O
fluorescence - - O
in - - O
situ - - O
hybridization - - O
provides - - O
an - - O
accurate - - O
and - - O
rapid - - O
approach - - O
to - - O
the - - O
definition - - O
of - - O
a - - O
transcribed - - O
map - - O
of - - O
the - - O
human - - O
genome - - O
. - - O

The - - O
significance - - O
of - - O
the - - O
phenolphthalein - - B-MUT
sulphatase - - I-MUT
test - - O
for - - O
the - - O
differentiation - - O
and - - O
identification - - O
of - - O
Nocardia - - O
species - - O
. - - O

These - - O
results - - O
indicate - - O
that - - O
T - - O
. - - O
C - - O
. - - O
, - - O
LDL-C - - B-MUT
. - - O
, - - O
HDL-C - - B-MUT
. - - O
, - - O
HDL2-C - - B-MUT
. - - O
, - - O
apo - - B-MUT
B - - I-MUT
, - - O
apo - - B-MUT
A-I - - I-MUT
B - - I-MUT
ratio - - I-MUT
and - - O
apo - - O
A-II - - B-MUT
B - - I-MUT
ratio - - I-MUT
are - - I-MUT
predictive - - O
risk - - O
factors - - O
of - - O
the - - O
coronary - - O
heart - - O
disease - - O
. - - O

This - - O
last - - O
includes - - O
tissue - - O
O2 - - O
transfer - - O
( - - O
Ft' - - O
) - - O
and - - O
mitochondrial - - O
O2 - - O
utilization - - O
( - - O
Fm' - - O
) - - O
. - - O

To - - O
identify - - O
cis-acting - - O
elements - - O
that - - O
target - - O
c-myc - - B-MUT
mRNA - - I-MUT
for - - O
downregulation - - O
during - - O
myogenesis - - O
, - - O
we - - O
stably - - O
transfected - - O
C2C12 - - O
cells - - O
with - - O
mutant - - B-MUT
myc - - I-MUT
genes - - I-MUT
or - - O
chimeric - - O
genes - - O
in - - O
which - - O
various - - O
myc - - B-MUT
sequences - - I-MUT
were - - O
fused - - O
to - - O
the - - O
human - - B-MUT
beta-globin - - I-MUT
gene - - I-MUT
or - - O
to - - O
the - - O
bacterial - - B-MUT
chloramphenicol - - I-MUT
acetyltransferase - - I-MUT
( - - O
CAT - - B-MUT
) - - O
gene - - O
. - - O

We - - O
report - - O
here - - O
that - - O
in - - O
cultured - - O
Jurkat - - O
T - - O
cells - - O
, - - O
Cbl - - B-MUT
is - - O
coprecipitated - - O
with - - O
antibody - - O
against - - O
the - - O
adapter - - B-MUT
protein - - I-MUT
Grb2 - - I-MUT
. - - O

These - - O
findings - - O
and - - O
the - - O
differential - - O
tissue - - O
distribution - - O
of - - O
p54 - - B-MUT
suggest - - O
that - - O
this - - O
novel - - O
SR - - B-MUT
protein - - I-MUT
may - - O
participate - - O
in - - O
regulation - - O
of - - O
alternative - - O
splicing - - O
in - - O
a - - O
tissue- - - O
and - - O
substrate-dependent - - O
manner - - O
. - - O

Nine - - O
cats - - O
received - - O
PMEA - - O
at - - O
a - - O
dosage - - O
of - - O
10 - - O
mg - - O
kg - - O
body - - O
weight - - O
, - - O
nine - - O
cats - - O
received - - O
FPMPA - - O
at - - O
a - - O
dosage - - O
of - - O
25 - - O
mg - - O
kg - - O
body - - O
weight - - O
. - - O

Mutational - - O
studies - - O
revealed - - O
that - - O
it - - O
was - - O
the - - O
homeodomain - - B-MUT
binding - - I-MUT
site - - I-MUT
II - - I-MUT
sequence - - I-MUT
that - - O
was - - O
required - - O
for - - O
this - - O
regulation - - O
. - - O

BACKGROUND - - O
: - - O
Left - - O
ventricular - - O
hypertrophy - - O
is - - O
a - - O
heterogeneous - - O
disorder - - O
with - - O
distinct - - O
morphologies - - O
. - - O

Proliferative - - O
vasculopathy - - O
and - - O
cutaneous - - O
hemorrhages - - O
in - - O
porcine - - O
neonates - - O
infected - - O
with - - O
the - - O
porcine - - O
reproductive - - O
and - - O
respiratory - - O
syndrome - - O
virus - - O
. - - O

Additionally - - O
, - - O
MIP-2A - - B-MUT
antagonizes - - O
cell - - O
growth - - O
regulatory - - O
role - - O
of - - O
MBP-1 - - B-MUT
. - - O

We - - O
also - - O
reported - - O
the - - O
identification - - O
of - - O
three - - O
corresponding - - O
alternative - - O
first - - O
exons - - O
and - - O
an - - O
intronic - - O
promoter - - O
in - - O
the - - O
human - - B-MUT
PDE5A - - I-MUT
gene - - I-MUT
. - - O

METHODS - - O
AND - - O
RESULTS - - O
: - - O
Studies - - O
were - - O
undertaken - - O
in - - O
9 - - O
isolated - - O
guinea - - O
pig - - O
hearts - - O
, - - O
which - - O
demonstrated - - O
reverse - - O
use-dependent - - O
prolongation - - O
of - - O
cardiac - - O
repolarization - - O
by - - O
100 - - O
nmol - - O
L - - O
domperidone - - O
. - - O

In - - O
the - - O
point - - O
mutant - - O
we - - O
observed - - O
normal - - O
repair - - O
of - - O
endonuclease - - B-MUT
III - - I-MUT
site - - I-MUT
( - - O
i - - O
. - - O
e - - O
. - - O
as - - O
wild - - O
type - - O
) - - O
, - - O
but - - O
no - - O
removal - - O
of - - O
CPDs - - O
at - - O
the - - O
MAT - - B-MUT
alpha - - I-MUT
and - - O
HML - - B-MUT
alpha - - I-MUT
loci - - I-MUT
. - - O

The - - O
amino-terminal - - O
half - - O
of - - O
1a - - B-MUT
is - - O
a - - O
distant - - O
homolog - - B-MUT
of - - I-MUT
alphavirus - - I-MUT
nonstructural - - I-MUT
protein - - I-MUT
nsP1 - - I-MUT
, - - O
which - - O
has - - O
been - - O
implicated - - O
in - - O
capping - - O
viral - - O
RNAs - - O
. - - O

Two - - O
putative - - O
Rev - - B-MUT
proteins - - I-MUT
with - - O
apparent - - O
molecular - - O
masses - - O
of - - O
18 - - O
and - - O
16 - - O
kDa - - O
were - - O
expressed - - O
by - - O
p2 - - O
2 - - O
and - - O
p176 - - O
, - - O
while - - O
p20 - - O
expressed - - O
only - - O
a - - O
16-kDa - - O
species - - O
. - - O

These - - O
analyses - - O
re-open - - O
the - - O
question - - O
whether - - O
all - - O
the - - O
CesA - - B-MUT
genes - - I-MUT
encode - - O
cellulose - - B-MUT
synthases - - I-MUT
or - - O
whether - - O
some - - O
of - - O
the - - O
sub-class - - O
members - - O
may - - O
encode - - O
other - - O
non-cellulosic - - B-MUT
( - - I-MUT
1-- - - I-MUT
> - - I-MUT
4 - - I-MUT
) - - I-MUT
beta-glycan - - I-MUT
synthases - - I-MUT
in - - O
plants - - O
. - - O

E - - O
50 - - O
, - - O
843 - - O
( - - O
1994 - - O
) - - O
] - - O
. - - O

In - - O
this - - O
situation - - O
the - - O
convlusion - - O
threshold - - O
for - - O
the - - O
8 - - O
substances - - O
is - - O
as - - O
follows - - O
: - - O
pethidine - - O
20 - - O
mg - - O
. - - O
kg-1 - - O
I - - O
. - - O
V - - O
. - - O
, - - O
piritramide - - O
30 - - O
, - - O
morphine - - O
180 - - O
, - - O
phenoperidine - - O
4 - - O
, - - O
R - - O
39 - - O
209 - - O
5 - - O
, - - O
fentanyl - - O
4 - - O
, - - O
sufentanil - - O
4 - - O
and - - O
R - - O
34 - - O
995 - - O
10 - - O
mg - - O
. - - O
kg-1 - - O
I - - O
. - - O
V - - O
. - - O

Vibrio - - O
fluvialis - - O
( - - O
group - - O
F - - O
vibrio - - O
) - - O
in - - O
Maharashtra - - O
. - - O

To - - O
assess - - O
the - - O
ability - - O
of - - O
the - - O
atria - - O
to - - O
maintain - - O
elevated - - O
plasma - - O
concentrations - - O
of - - O
atrial - - B-MUT
natriuretic - - I-MUT
peptide - - I-MUT
( - - O
ANP - - B-MUT
) - - O
, - - O
the - - O
temporal - - O
changes - - O
in - - O
plasma - - B-MUT
ANP - - I-MUT
concentrations - - O
were - - O
studied - - O
in - - O
seven - - O
chloralose-anaesthetized - - O
dogs - - O
during - - O
4 - - O
h - - O
of - - O
sustained - - O
rapid - - O
cardiac - - O
pacing - - O
. - - O

Our - - O
results - - O
show - - O
that - - O
the - - O
temperature-sensitive - - B-MUT
rad54-3 - - I-MUT
allele - - I-MUT
blocks - - O
mitotic - - O
recombination - - O
between - - O
tandemly - - O
repeated - - O
DYZ3 - - B-MUT
satellite - - I-MUT
sequences - - I-MUT
and - - O
significantly - - O
stabilizes - - O
a - - O
human - - B-MUT
DYZ5 - - I-MUT
satellite-containing - - O
YAC - - O
clone - - O
. - - O

Again - - O
residue - - O
Glu-381 - - O
of - - O
beta - - O
was - - O
notably - - O
reduced - - O
and - - O
no - - O
missing - - O
residue - - O
from - - O
the - - O
epsilon - - B-MUT
peptide - - I-MUT
could - - O
be - - O
identified - - O
, - - O
but - - O
the - - O
peptide - - O
sequence - - O
limited - - O
the - - O
possible - - O
choices - - O
to - - O
Ser-106 - - O
, - - O
Ser-107 - - O
, - - O
or - - O
Ser-108 - - O
. - - O

Differential - - O
expression - - O
and - - O
regulation - - O
by - - O
20-hydroxyecdysone - - O
of - - O
mosquito - - O
ultraspiracle - - O
isoforms - - O
. - - O

Nucleotide - - O
sequences - - O
between - - O
the - - O
env - - B-MUT
gene - - I-MUT
and - - O
the - - O
LTR - - O
of - - O
SFV-1 - - O
were - - O
determined - - O
. - - O

As - - O
a - - O
part - - O
of - - O
a - - O
large - - O
examination - - O
, - - O
total - - O
and - - O
free - - O
serum - - O
cholesterol - - O
, - - O
total - - O
lipid - - O
and - - O
triglyceride - - O
levels - - O
were - - O
determined - - O
. - - O

Only - - O
two - - O
patients - - O
( - - O
0 - - O
. - - O
3% - - O
) - - O
had - - O
a - - O
CA - - O
125 - - O
response - - O
at - - O
the - - O
time - - O
of - - O
clinical - - O
progression - - O
. - - O

The - - O
alterations - - O
in - - O
differentiation - - O
of - - O
osteoprogenitor - - O
cells - - O
, - - O
together - - O
with - - O
the - - O
failure - - O
of - - O
mineralization - - O
, - - O
resulted - - O
in - - O
significantly - - O
lower - - O
rates - - O
of - - O
bone - - O
formation - - O
( - - O
as - - O
measured - - O
by - - O
fluorochrome - - O
labeling - - O
) - - O
in - - O
the - - O
magnesium-deficient - - O
rats - - O
. - - O

Radionuclide - - O
study - - O
and - - O
endomyocardial - - O
biopsy - - O
revealed - - O
remarkable - - O
degeneration - - O
of - - O
myocardium - - O
. - - O

ICA - - O
in - - O
the - - O
reference - - O
solution - - O
was - - O
characterised - - O
by - - O
LC - - O
and - - O
time-of-flight - - O
( - - O
TOF - - O
) - - O
MS - - O
and - - O
quantified - - O
by - - O
LC - - O
chemiluminescent - - O
nitrogen - - O
detection - - O
( - - O
LC-CLND - - O
) - - O
. - - O

In - - O
contrast - - O
, - - O
similar - - O
rates - - O
of - - O
B - - O
. - - O
sphaericus - - O
products - - O
, - - O
ABG-6184 - - O
technical - - O
powder - - O
and - - O
BSP-2 - - O
flowable - - O
concentrate - - O
, - - O
produced - - O
no - - O
significant - - O
reduction - - O
. - - O

The - - O
aspirate - - O
from - - O
a - - O
parathyroid - - O
cyst - - O
was - - O
watery - - O
clear - - O
and - - O
contained - - O
high - - O
amount - - O
of - - O
parathyroid - - B-MUT
hormone - - I-MUT
. - - O

The - - O
number - - O
of - - O
fecal - - O
pellets - - O
ingested - - O
peaked - - O
at - - O
5 - - O
to - - O
6 - - O
weeks - - O
old - - O
( - - O
13 - - O
pellets - - O
day - - O
) - - O
and - - O
gradually - - O
decreased - - O
, - - O
thereafter - - O
( - - O
2 - - O
. - - O
1 - - O
pellets - - O
at - - O
78 - - O
weeks - - O
old - - O
, - - O
1 - - O
. - - O
5 - - O
pellets - - O
at - - O
104 - - O
weeks - - O
old - - O
) - - O
. - - O

Our - - O
results - - O
indicate - - O
that - - O
Shh - - B-MUT
can - - O
drive - - O
continued - - O
cycling - - O
in - - O
immature - - O
, - - O
proliferating - - O
CGNPs - - O
. - - O

The - - O
roxithromycin - - O
doses - - O
that - - O
were - - O
chosen - - O
for - - O
these - - O
studies - - O
were - - O
less - - O
than - - O
achievable - - O
blood - - O
levels - - O
. - - O

Urease - - B-MUT
activity - - O
, - - O
judged - - O
as - - O
the - - O
amount - - O
of - - O
ammonia - - O
production - - O
from - - O
urea - - O
, - - O
could - - O
be - - O
measured - - O
at - - O
25 - - O
ng - - O
per - - O
tube - - O
( - - O
S - - O
N - - O
= - - O
1 - - O
. - - O
5 - - O
) - - O
with - - O
Jack - - O
bean - - B-MUT
meal - - I-MUT
urease - - I-MUT
. - - I-MUT

These - - O
data - - O
confirm - - O
the - - O
existence - - O
of - - O
hyperlipemic - - O
abdominal - - O
crisis - - O
as - - O
a - - O
distinct - - O
entity - - O
and - - O
testify - - O
to - - O
the - - O
importance - - O
of - - O
recognizing - - O
this - - O
syndrome - - O
in - - O
order - - O
to - - O
avoid - - O
the - - O
occurrence - - O
of - - O
acute - - O
pancreatitis - - O
and - - O
the - - O
performance - - O
of - - O
unnecessary - - O
and - - O
potentially - - O
harmful - - O
surgery - - O
. - - O

Using - - O
reference - - O
probes - - O
as - - O
internal - - O
standards - - O
, - - O
we - - O
show - - O
that - - O
the - - O
ost - - B-MUT
transcription - - I-MUT
unit - - I-MUT
is - - O
located - - O
within - - O
the - - O
cytogenetic - - O
band - - O
interval - - O
89A1 - - O
, - - O
2 - - O
on - - O
the - - O
right - - O
arm - - O
of - - O
the - - O
third - - O
chromosome - - O
, - - O
and - - O
that - - O
it - - O
exerts - - O
diagnostic - - O
segmentation - - O
gene - - O
expression - - O
patterns - - O
in - - O
the - - O
embryo - - O
. - - O

The - - O
proteasome - - O
is - - O
a - - O
large - - O
complex - - O
consisting - - O
of - - O
two - - O
multisubunit - - O
structures - - O
, - - O
the - - O
20S - - B-MUT
and - - O
19S - - B-MUT
( - - I-MUT
PA700 - - I-MUT
) - - I-MUT
or - - O
P28 - - B-MUT
complexes - - I-MUT
, - - O
that - - O
combine - - O
to - - O
form - - O
the - - O
26S - - B-MUT
particles - - I-MUT
. - - O

The - - O
amino - - O
acid - - O
sequences - - O
of - - O
the - - O
predicted - - O
RfbA - - B-MUT
and - - O
RfbB - - B-MUT
homologs - - I-MUT
showed - - O
identities - - O
of - - O
75 - - O
. - - O
7% - - O
( - - O
87 - - O
. - - O
9% - - O
total - - O
similarity - - O
) - - O
and - - O
78 - - O
. - - O
0% - - O
( - - O
86 - - O
. - - O
5% - - O
total - - O
similarity - - O
) - - O
, - - O
respectively - - O
. - - O

The - - O
UBA - - B-MUT
domains - - I-MUT
of - - O
RAD23 - - B-MUT
and - - O
DDI1 - - B-MUT
are - - O
required - - O
for - - O
these - - O
interactions - - O
. - - O

Intracellular - - O
recordings - - O
were - - O
performed - - O
on - - O
the - - O
optic - - O
tectum - - O
of - - O
the - - O
carp - - O
in - - O
vitro - - O
. - - O

RESULTS - - O
: - - O
Nodular - - O
opacities - - O
, - - O
mainly - - O
centrilobular - - O
in - - O
distribution - - O
, - - O
were - - O
the - - O
most - - O
common - - O
finding - - O
, - - O
seen - - O
in - - O
21 - - O
( - - O
72% - - O
) - - O
and - - O
15 - - O
( - - O
65% - - O
) - - O
of - - O
patients - - O
with - - O
MTB - - O
and - - O
NTMB - - O
, - - O
respectively - - O
. - - O

The - - O
results - - O
strengthen - - O
the - - O
conclusion - - O
that - - O
predominantly - - O
dynamic - - O
activity - - O
increases - - O
the - - O
G4 - - B-MUT
content - - O
of - - O
mature - - O
innervated - - O
fast - - O
muscles - - O
. - - O

Green - - O
pepper - - O
significantly - - O
inhibited - - O
N-nitrosothiazolidine-carboxylic - - O
acid - - O
formation - - O
relative - - O
to - - O
ascorbic - - O
acid - - O
alone - - O
. - - O

Serum - - O
ferritin - - B-MUT
concentration - - O
and - - O
bone - - O
marrow - - O
iron - - O
stores - - O
. - - O

The - - O
mechanism - - O
of - - O
ligand-activated - - O
estrogen - - B-MUT
receptor - - I-MUT
alpha - - I-MUT
( - - O
ERalpha - - B-MUT
) - - O
-dependent - - O
activation - - O
of - - O
gene - - O
expression - - O
through - - O
the - - O
SRE - - B-MUT
was - - O
determined - - O
by - - O
mutational - - O
analysis - - O
of - - O
the - - O
promoter - - O
, - - O
analysis - - O
of - - O
mitogen-activated - - B-MUT
protein - - I-MUT
kinase - - I-MUT
( - - O
MAPK - - B-MUT
) - - O
pathway - - O
activation - - O
by - - O
E2 - - B-MUT
, - - O
and - - O
transforming - - B-MUT
growth - - I-MUT
factor - - I-MUT
alpha - - I-MUT
( - - O
TGF-alpha - - B-MUT
) - - O
as - - O
a - - O
positive - - O
control - - O
. - - O

Risk - - O
of - - O
infection - - O
in - - O
the - - O
treatment - - O
of - - O
fractures - - O
. - - O

The - - O
large - - O
subfamily - - O
of - - O
receptor - - B-MUT
tyrosine - - I-MUT
kinases - - I-MUT
( - - O
RTKs - - B-MUT
) - - O
for - - O
which - - O
EPH - - B-MUT
is - - O
the - - O
prototype - - O
have - - O
likely - - O
roles - - O
in - - O
intercellular - - O
communication - - O
during - - O
normal - - O
mammalian - - O
development - - O
, - - O
but - - O
the - - O
biochemical - - O
signalling - - O
pathways - - O
utilised - - O
by - - O
this - - O
family - - O
are - - O
poorly - - O
characterised - - O
. - - O

Analysis - - O
of - - O
RAR - - B-MUT
alpha - - I-MUT
mutants - - I-MUT
in - - O
transfection - - O
studies - - O
reveals - - O
that - - O
the - - O
DNA - - O
binding - - O
domain - - O
is - - O
sufficient - - O
for - - O
inhibition - - O
of - - O
BZLF1 - - B-MUT
activity - - O
. - - O

At - - O
both - - O
companies - - O
sites - - O
Salmonella - - O
enteritidis - - O
and - - O
Salmonella - - O
typhimurium - - O
Tr104 - - O
were - - O
also - - O
isolated - - O
occasionally - - O
from - - O
various - - O
locations - - O
. - - O

Comparison - - O
of - - O
the - - O
proportion - - O
of - - O
nonsynonymous - - O
( - - O
pN - - O
) - - O
and - - O
synonymous - - O
( - - O
pS - - O
) - - O
substitutions - - O
occurring - - O
per - - O
site - - O
within - - O
tamarin - - B-MUT
variable - - I-MUT
region - - I-MUT
genes - - I-MUT
demonstrated - - O
a - - O
reduction - - O
in - - O
pN - - O
in - - O
the - - O
framework - - O
regions - - O
compared - - O
with - - O
pN - - O
in - - O
the - - O
presumed - - O
MHC - - B-MUT
contact - - I-MUT
regions - - I-MUT
( - - O
CDR1 - - B-MUT
and - - O
CDR2 - - B-MUT
) - - O
. - - O

Tracheal - - O
transsection - - O
combined - - O
with - - O
hilar - - O
ligation - - O
( - - O
TL&PL - - O
) - - O
effected - - O
a - - O
reduction - - O
of - - O
19 - - O
. - - O
9% - - O
( - - O
n - - O
. - - O
s - - O
. - - O
) - - O
. - - O

Papers - - O
of - - O
the - - O
Society - - O
for - - O
Clinical - - O
Vascular - - O
Surgery - - O
. - - O

The - - O
COOH-terminal - - O
region - - O
of - - O
the - - O
transcripts - - O
contained - - O
fifteen - - O
triplet - - O
repeats - - O
( - - O
GCT - - O
; - - O
alanine - - O
) - - O
at - - O
nucleotide - - O
465 - - O
to - - O
509 - - O
, - - O
which - - O
is - - O
significantly - - O
expanded - - O
compared - - O
to - - O
the - - O
rat - - B-MUT
RL14 - - I-MUT
. - - O

Dual - - O
radionuclide - - O
subtraction - - O
imaging - - O
of - - O
the - - O
spleen - - O
using - - O
67Ga - - O
citrate - - O
and - - O
99mTc - - O
is - - O
useful - - O
in - - O
further - - O
delineating - - O
lesions - - O
that - - O
are - - O
identified - - O
on - - O
either - - O
a - - O
routine - - O
radiogallium - - O
survey - - O
or - - O
on - - O
a - - O
conventional - - O
sulfur - - O
colloid - - O
liver-spleen - - O
image - - O
. - - O

Gene - - O
constructs - - O
consisting - - O
of - - O
human - - B-MUT
growth - - I-MUT
hormone - - I-MUT
( - - O
hGH - - B-MUT
) - - O
gene - - O
driven - - O
by - - O
promoter - - O
regulatory - - O
sequence - - O
of - - O
mouse - - O
metallothionein - - B-MUT
( - - I-MUT
mMT - - O
) - - B-MUT
, - - O
viral - - O
thymidine - - B-MUT
kinase - - I-MUT
( - - I-MUT
vTK - - O
) - - B-MUT
, - - O
rat - - O
cholecystokinin - - B-MUT
( - - I-MUT
rCCK - - O
) - - B-MUT
, - - O
or - - O
chicken - - O
beta-actin - - B-MUT
( - - I-MUT
cBA - - O
) - - B-MUT
gene - - O
were - - O
injected - - O
into - - O
the - - O
cytoplasm - - O
of - - O
fertilized - - O
medaka - - O
eggs - - O
via - - O
the - - O
micropyle - - O
. - - O

DNase - - B-MUT
I - - I-MUT
footprinting - - O
analysis - - O
indicated - - O
that - - O
DREF - - B-MUT
binds - - O
to - - O
the - - O
24-bp - - O
DRE - - B-MUT
region - - O
of - - O
the - - O
DNA - - B-MUT
polymerase - - I-MUT
alpha - - I-MUT
gene - - I-MUT
in - - O
which - - O
8-bp - - O
palindromic - - O
sequences - - O
are - - O
centered - - O
. - - O

This - - O
study - - O
was - - O
carried - - O
out - - O
to - - O
analyze - - O
PRL - - B-MUT
secretion - - O
in - - O
metastatic - - O
prostate - - O
cancer - - O
patients - - O
both - - O
at - - O
basal - - O
conditions - - O
and - - O
in - - O
response - - O
to - - O
L-Dopa - - O
and - - O
metoclopramide - - O
, - - O
which - - O
represents - - O
the - - O
most - - O
classical - - O
inhibitory - - O
and - - O
stimulatory - - O
tests - - O
for - - O
PRL - - B-MUT
secretion - - O
, - - O
respectively - - O
. - - O

Expression - - O
of - - O
PTPRO - - B-MUT
was - - O
also - - O
observed - - O
in - - O
human - - B-MUT
CD34+ - - I-MUT
bone - - O
marrow - - O
cells - - O
and - - O
5-FU-treated - - O
murine - - O
primitive - - O
stem - - O
cells - - O
. - - O

A - - O
3-yr - - O
retrospective - - O
review - - O
is - - O
effective - - O
and - - O
detects - - O
94% - - O
of - - O
the - - O
undercalls - - O
. - - O

The - - O
partial - - O
farm - - O
budget - - O
highlighted - - O
the - - O
importance - - O
of - - O
reducing - - O
sub-clinical - - O
lesions - - O
in - - O
a - - O
feedlot - - O
. - - O

Additional - - O
exonuclease - - B-MUT
III - - I-MUT
protection - - O
was - - O
observed - - O
beyond - - O
the - - O
core - - O
region - - O
on - - O
both - - O
the - - O
5' - - O
and - - O
3' - - O
sides - - O
, - - O
suggesting - - O
that - - O
E1 - - B-MUT
interacted - - O
with - - O
more - - O
distal - - O
sequences - - O
as - - O
well - - O
. - - O

Serum - - O
antibodies - - O
were - - O
detected - - O
in - - O
at - - O
least - - O
95% - - O
of - - O
the - - O
infected - - O
guinea - - O
pigs - - O
between - - O
4-30 - - O
WPI - - O
and - - O
rats - - O
between - - O
3-16 - - O
WPI - - O
. - - O

Physiol - - O
. - - O

Two - - O
experiments - - O
were - - O
conducted - - O
to - - O
study - - O
the - - O
vacuous - - O
jaw - - O
movements - - O
induced - - O
in - - O
rats - - O
by - - O
acute - - O
administration - - O
of - - O
the - - O
monoamine-depleting - - O
agent - - O
reserpine - - O
. - - O

Impaction - - O
of - - O
gastrostomy - - O
tube - - O
in - - O
the - - O
abdominal - - O
wall - - O
. - - O

However - - O
, - - O
during - - O
our - - O
work - - O
with - - O
a - - O
replication-deficient - - O
virus - - O
expressing - - O
the - - O
ASF - - B-MUT
SF2 - - O
splicing - - B-MUT
factor - - I-MUT
from - - O
a - - O
progesterone - - O
antagonist-inducible - - O
gene - - O
cassette - - O
, - - O
we - - O
discovered - - O
that - - O
ASF - - O
SF2 - - B-MUT
was - - O
expressed - - B-MUT
at - - O
a - - O
significant - - O
level - - O
in - - O
the - - O
293 - - O
producer - - O
cell - - O
line - - O
, - - O
even - - O
in - - O
the - - O
absence - - O
of - - O
inducer - - O
. - - O

Molecular - - O
cloning - - O
of - - O
mouse - - B-MUT
glycolate - - I-MUT
oxidase - - I-MUT
. - - O

E2 - - O
treatments - - O
elevated - - O
hen - - O
plasma - - O
TG - - O
7 - - O
. - - O
2X - - O
, - - O
PL - - O
5 - - O
. - - O
1X - - O
, - - O
and - - O
C - - O
7 - - O
. - - O
2X - - O
; - - O
and - - O
pullet - - O
plasma - - O
TG - - O
6 - - O
. - - O
8X - - O
, - - O
PL - - O
3 - - O
. - - O
7X - - O
, - - O
and - - O
C - - O
2 - - O
. - - O
5X - - O
. - - O

The - - O
MVV-value - - O
is - - O
under - - O
the - - O
predicted - - O
level - - O
in - - O
the - - O
case - - O
of - - O
67-76 - - O
percent - - O
. - - O

Using - - O
the - - O
rap1t - - B-MUT
alleles - - I-MUT
to - - O
generate - - O
wild-type - - O
cells - - O
differing - - O
only - - O
in - - O
telomere - - O
tract - - O
lengths - - O
, - - O
we - - O
also - - O
show - - O
that - - O
telomere - - O
position - - O
effects - - O
are - - O
highly - - O
sensitive - - O
to - - O
changes - - O
in - - O
the - - O
size - - O
( - - O
or - - O
structure - - O
) - - O
of - - O
the - - O
telomeric - - O
tract - - O
. - - O

Two - - O
protease-resistant - - O
fragments - - O
spanning - - O
the - - O
N- - - O
and - - O
C-terminal - - O
halves - - O
of - - O
the - - O
nuclease - - B-MUT
were - - O
identified - - O
using - - O
different - - O
proteases - - B-MUT
which - - O
cleave - - O
the - - O
protein - - O
in - - O
the - - O
same - - O
region - - O
. - - O

Dorsal - - O
root - - O
ganglia - - O
neuron-specific - - O
promoter - - O
activity - - O
of - - O
the - - O
rabbit - - B-MUT
beta-galactoside - - I-MUT
alpha1 - - I-MUT
, - - I-MUT
2-fucosyltransferase - - I-MUT
gene - - I-MUT
. - - O

Peroxisome - - B-MUT
proliferator-activated - - I-MUT
receptors - - I-MUT
( - - O
PPAR - - B-MUT
) - - O
modulate - - O
transcription - - O
by - - O
binding - - O
to - - O
specific - - O
peroxisome - - B-MUT
proliferator-response - - I-MUT
elements - - I-MUT
( - - O
PPRE - - B-MUT
) - - O
through - - O
heterodimerization - - O
with - - O
the - - O
9-cis - - B-MUT
retinoic - - I-MUT
acid - - I-MUT
receptor - - I-MUT
( - - O
RXR - - B-MUT
) - - O
. - - O

A - - O
prospectively - - O
gated - - O
2D - - O
axial - - O
sequence - - O
with - - O
velocity - - O
encoding - - O
in - - O
the - - O
craniocaudal - - O
direction - - O
in - - O
the - - O
cervical - - O
region - - O
was - - O
set - - O
at - - O
a - - O
velocity - - O
of - - O
+ - - O
- - - O
10 - - O
cm - - O
s - - O
. - - O

Alterations - - O
of - - O
the - - O
5q23-q31 - - O
interval - - O
are - - O
frequently - - O
observed - - O
in - - O
myelodysplasia - - O
and - - O
myeloid - - O
leukemia - - O
. - - O

Mechanistically - - O
, - - O
the - - O
presence - - O
of - - O
the - - O
GRR - - O
appears - - O
to - - O
stop - - O
further - - O
degradation - - O
of - - O
p50 - - B-MUT
and - - O
to - - O
stabilize - - O
the - - O
molecule - - O
. - - O

Suppressive - - O
therapy - - O
for - - O
thyroid - - O
nodules - - O
. - - O

Therefore - - O
, - - O
in - - O
order - - O
to - - O
search - - O
for - - O
the - - O
latent - - O
genes - - O
, - - O
we - - O
used - - O
allotype-specific - - O
oligonucleotides - - O
for - - O
b5 - - B-MUT
, - - O
b6 - - B-MUT
and - - O
b9 - - B-MUT
to - - O
probe - - O
DNAs - - O
from - - O
both - - O
normal - - O
and - - O
T - - O
. - - O
brucei-infected - - O
rabbits - - O
by - - O
Southern - - O
blotting - - O
. - - O

A - - O
high-frequency - - O
restriction - - O
fragment - - O
length - - O
polymorphism - - O
was - - O
evident - - O
in - - O
the - - O
DNA - - O
from - - O
29 - - O
unrelated - - O
individuals - - O
using - - O
the - - O
enzyme - - O
BglII - - B-MUT
. - - O

RPA190 - - B-MUT
encodes - - O
a - - O
polypeptide - - O
chain - - O
of - - O
186 - - O
, - - O
270 - - O
daltons - - O
in - - O
a - - O
large - - O
uninterrupted - - O
reading - - O
frame - - O
. - - O

The - - O
arginyl - - O
peptide - - O
bonds - - O
that - - O
are - - O
cleaved - - O
in - - O
the - - O
conversion - - O
of - - O
human - - B-MUT
factor - - I-MUT
IX - - I-MUT
to - - O
factor - - B-MUT
IXa - - I-MUT
by - - O
factor - - B-MUT
XIa - - I-MUT
were - - O
identified - - O
as - - O
Arg145-Ala146 - - O
and - - O
Arg180-Val181 - - O
. - - O

Synthetic - - O
oligonucleotides - - O
representing - - O
the - - O
19 - - O
bp - - O
repeat - - O
unit - - O
strongly - - O
reduced - - O
the - - O
activity - - O
of - - O
the - - O
IE1 - - B-MUT
2 - - I-MUT
enhancer - - I-MUT
promoter - - I-MUT
in - - I-MUT
cotransfection - - I-MUT
assays - - O
after - - O
transient - - O
expression - - O
. - - O

Toxicities - - O
included - - O
: - - O
nausea - - O
vomiting - - O
( - - O
69% - - O
) - - O
, - - O
headache - - O
( - - O
25% - - O
) - - O
, - - O
chills - - O
( - - O
69% - - O
) - - O
, - - O
pain - - O
at - - O
tumor - - O
sites - - O
( - - O
63% - - O
) - - O
, - - O
hypotension - - O
( - - O
31% - - O
) - - O
, - - O
and - - O
hypertension - - O
( - - O
38% - - O
) - - O
. - - O

Despite - - O
the - - O
existence - - O
of - - O
30 - - O
cysteine - - O
residues - - O
, - - O
carboxymethylation - - O
prevented - - O
the - - O
formation - - O
of - - O
most - - O
if - - O
not - - O
all - - O
disulfide - - O
bonds - - O
that - - O
otherwise - - O
occurred - - O
when - - O
the - - O
cells - - O
were - - O
sonicated - - O
. - - O

A - - O
control - - O
group - - O
of - - O
nine - - O
women - - O
( - - O
age - - O
23-40 - - O
years - - O
) - - O
on - - O
oral - - O
contraceptives - - O
( - - O
Nordette-28 - - O
) - - O
was - - O
also - - O
studied - - O
four - - O
times - - O
during - - O
a - - O
pill - - O
cycle - - O
. - - O

This - - O
motif - - O
has - - O
been - - O
shown - - O
to - - O
mediate - - O
protein - - O
interactions - - O
in - - O
the - - O
case - - O
of - - O
ankyrin - - B-MUT
as - - O
well - - O
as - - O
several - - O
other - - O
repeat-bearing - - O
proteins - - O
. - - O

The - - O
coating - - O
materials - - O
were - - O
poloxamine - - O
904 - - O
, - - O
poloxamine - - O
908 - - O
, - - O
poloxamine - - O
1508 - - O
, - - O
poloxamer - - O
338 - - O
, - - O
and - - O
Brij - - O
35 - - O
. - - O

In - - O
addition - - O
, - - O
there - - O
was - - O
a - - O
significant - - O
increase - - O
in - - O
postdexamethasone - - O
cortical - - O
concentrations - - O
with - - O
age - - O
( - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
01 - - O
; - - O
r - - O
= - - O
0 - - O
. - - O
31 - - O
) - - O
. - - O

Mycobacterium - - O
avium-intracellulare - - O
complex - - O
infections - - O
in - - O
the - - O
acquired - - O
immunodeficiency - - O
syndrome - - O
. - - O

Recent - - O
application - - O
of - - O
recombinant - - O
canarypox - - O
ALVAC - - O
HIV-1 - - O
vectors - - O
as - - O
vaccine - - O
immunogens - - O
in - - O
HIV-1 - - O
, - - O
-noninfected - - O
volunteers - - O
has - - O
produced - - O
CTL - - O
responses - - O
in - - O
a - - O
significant - - O
number - - O
of - - O
vaccinees - - O
. - - O

The - - O
purpose - - O
of - - O
this - - O
study - - O
was - - O
to - - O
evaluate - - O
simplified - - O
methods - - O
for - - O
estimation - - O
of - - O
Technetium - - O
Tc - - O
99m - - O
( - - O
99mTc - - O
) - - O
-pentetate - - O
and - - O
orthoiodohippurate - - O
I - - O
131 - - O
( - - O
131I-OIH - - O
) - - O
plasma - - O
clearance - - O
in - - O
dogs - - O
and - - O
cats - - O
with - - O
1 - - O
and - - O
2 - - O
blood - - O
samples - - O
. - - O

Hovenitin - - O
I - - O
and - - O
( - - O
+ - - O
) - - O
-ampelopsin - - O
, - - O
both - - O
of - - O
which - - O
were - - O
principal - - O
ingredients - - O
of - - O
the - - O
active - - O
fractions - - O
from - - O
this - - O
natural - - O
medicine - - O
, - - O
were - - O
found - - O
to - - O
show - - O
an - - O
inhibitory - - O
activity - - O
on - - O
the - - O
ethanol-induced - - O
muscle - - O
relaxation - - O
in - - O
rats - - O
. - - O

This - - O
paper - - O
brings - - O
together - - O
data - - O
, - - O
obtained - - O
from - - O
a - - O
variety - - O
of - - O
sources - - O
, - - O
on - - O
the - - O
extent - - O
of - - O
prescription - - O
and - - O
use - - O
of - - O
psychotropic - - O
drugs - - O
in - - O
the - - O
late - - O
1960s - - O
and - - O
early - - O
1970s - - O
. - - O

This - - O
observation - - O
suggests - - O
that - - O
the - - O
methyl-directed - - O
repair - - O
system - - O
utilizes - - O
the - - O
proximal - - O
d - - O
( - - O
GATC - - O
) - - O
sequence - - O
to - - O
direct - - O
correction - - O
. - - O

Elements - - O
that - - O
are - - O
fundamental - - O
to - - O
the - - O
safety - - O
evaluation - - O
of - - O
flavor - - O
ingredients - - O
include - - O
exposure - - O
, - - O
structural - - O
analogy - - O
, - - O
metabolism - - O
, - - O
pharmacokinetics - - O
and - - O
toxicology - - O
. - - O

This - - O
repression - - O
does - - O
not - - O
require - - O
the - - O
PU - - B-MUT
. - - I-MUT
1 - - I-MUT
transactivation - - O
or - - O
PEST - - B-MUT
domains - - I-MUT
and - - O
cannot - - O
be - - O
reversed - - O
by - - O
p300 - - B-MUT
expression - - O
. - - O

Possible - - O
roles - - O
of - - O
RAD5 - - B-MUT
putative - - O
ATPase - - B-MUT
DNA - - I-MUT
helicase - - I-MUT
activity - - I-MUT
in - - O
DNA - - O
repair - - O
and - - O
in - - O
the - - O
maintenance - - O
of - - O
wild-type - - O
rates - - O
of - - O
instability - - O
of - - O
simple - - O
repetitive - - O
sequences - - O
are - - O
discussed - - O
. - - O

Factors - - O
influencing - - O
the - - O
bond - - O
strength - - O
between - - O
glass - - O
polyalkenoate - - O
( - - O
ionomer - - O
) - - O
cements - - O
and - - O
dentine - - O
. - - O

CDC31 - - B-MUT
is - - O
required - - O
for - - O
SPB - - O
duplication - - O
and - - O
encodes - - O
a - - O
calmodulin-like - - B-MUT
protein - - I-MUT
that - - O
is - - O
most - - O
closely - - O
related - - O
to - - O
caltractin - - O
centrin - - O
, - - O
a - - O
protein - - O
associated - - O
with - - O
the - - O
Chlamydomonas - - O
basal - - O
body - - O
. - - O

The - - O
occurrence - - O
of - - O
multiple - - O
malignancy - - O
was - - O
studied - - O
in - - O
674 - - O
patients - - O
with - - O
hematologic - - O
malignancies - - O
who - - O
were - - O
admitted - - O
to - - O
this - - O
department - - O
during - - O
the - - O
past - - O
10 - - O
years - - O
. - - O

RESULTS - - O
: - - O
Of - - O
the - - O
24 - - O
patients - - O
, - - O
6 - - O
had - - O
Grade - - O
1 - - O
pneumonitis - - O
, - - O
and - - O
13 - - O
had - - O
Grade - - O
2 - - O
pneumonitis - - O
. - - O

The - - O
effect - - O
of - - O
ethanol - - O
on - - O
human - - O
sensorimotor - - O
reactivity - - O
was - - O
assessed - - O
by - - O
examining - - O
the - - O
acoustic - - O
startle - - O
response - - O
. - - O

Corneal - - O
scrapping - - O
and - - O
deep - - O
stromal - - O
biopsy - - O
were - - O
obtained - - O
and - - O
stained - - O
for - - O
microscopic - - O
evaluation - - O
with - - O
periodic - - O
acid-Schiff - - O
, - - O
Giemsa - - O
, - - O
and - - O
Gomori's - - O
methenamine - - O
silver - - O
stains - - O
. - - O

A - - O
bovine - - O
abomasum - - O
lambda - - O
gt11 - - O
cDNA - - O
library - - O
was - - O
screened - - O
with - - O
a - - O
monoclonal - - O
antibody - - O
raised - - O
against - - O
the - - O
rabbit - - B-MUT
H - - I-MUT
, - - I-MUT
K-ATPase - - I-MUT
beta - - I-MUT
subunit - - I-MUT
. - - O

All - - O
pigs - - O
had - - O
significant - - O
regional - - O
LV - - O
dysfunction - - O
and - - O
reduced - - O
LV - - O
ejection - - O
fraction - - O
( - - O
41+ - - O
-11% - - O
) - - O
. - - O

After - - O
MOPP - - O
therapy - - O
, - - O
complete - - O
remission - - O
of - - O
Hodgkin's - - O
disease - - O
was - - O
accompanied - - O
by - - O
normalization - - O
of - - O
the - - O
glucocerebrosidase - - B-MUT
level - - O
and - - O
disappearance - - O
of - - O
Gaucher's - - O
cells - - O
. - - O

67 - - O
393 - - O
bp - - O
of - - O
contiguous - - O
DNA - - O
located - - O
between - - O
markers - - O
cdc18 - - B-MUT
and - - O
cdc14 - - B-MUT
on - - O
the - - O
right - - O
arm - - O
of - - O
fission - - O
yeast - - O
chromosome - - O
II - - O
has - - O
been - - O
sequenced - - O
as - - O
part - - O
of - - O
the - - O
European - - O
Union - - O
Schizosaccharomyces - - O
pombe - - O
genome - - O
sequencing - - O
project - - O
. - - O

Optical - - O
CD - - O
, - - O
and - - O
spectral - - O
and - - O
activity - - O
analyses - - O
were - - O
used - - O
to - - O
examine - - O
reactivity - - O
of - - O
HO - - B-MUT
isozymes - - I-MUT
with - - O
NO - - O
species - - O
produced - - O
by - - O
NO - - O
donors - - O
. - - O

Neither - - O
gene - - O
possesses - - O
a - - O
distinct - - O
transcriptional - - O
start - - O
site - - O
as - - O
shown - - O
by - - O
nuclease - - B-MUT
S1 - - I-MUT
analysis - - O
. - - O

Treatment - - O
was - - O
well-tolerated - - O
. - - O

Deletion - - O
analyses - - O
of - - O
the - - O
construct - - O
revealed - - O
that - - O
the - - O
transcription - - O
of - - O
BOXF1 - - B-MUT
gene - - I-MUT
is - - O
regulated - - O
by - - O
BOX - - B-MUT
DNA - - I-MUT
, - - O
preferentially - - O
in - - O
undifferentiated - - O
EC - - O
cells - - O
versus - - O
differentiated - - O
cells - - O
. - - O

Fluid - - O
( - - O
AVLF - - O
) - - O
31 - - O
. - - O

Optimal - - O
monitoring - - O
of - - O
ODA - - O
remains - - O
undefined - - O
. - - O

Ig-alpha - - B-MUT
and - - O
Ig-beta - - B-MUT
contain - - O
extended - - O
cytoplasmic - - O
structure - - O
( - - O
61 - - O
and - - O
48 - - O
amino - - O
acids - - O
, - - O
respectively - - O
) - - O
and - - O
associate - - O
with - - O
cytoplasmic - - O
effectors - - O
indicating - - O
that - - O
they - - O
are - - O
directly - - O
involved - - O
in - - O
signal - - O
transduction - - O
. - - O

Topics - - O
reviewed - - O
here - - O
include - - O
: - - O
data - - O
supporting - - O
the - - O
association - - O
of - - O
myositis - - O
with - - O
cancer - - O
and - - O
the - - O
appropriate - - O
evaluations - - O
for - - O
malignancy - - O
in - - O
a - - O
myositis - - O
patient - - O
; - - O
an - - O
approach - - O
to - - O
the - - O
assessment - - O
of - - O
patients - - O
with - - O
dermatomyositis - - O
sine - - O
myositis - - O
; - - O
the - - O
usefulness - - O
of - - O
the - - O
clinicopathological - - O
and - - O
serological - - O
classifications - - O
; - - O
a - - O
discussion - - O
of - - O
whether - - O
childhood - - O
and - - O
adult - - O
myositis - - O
are - - O
the - - O
same - - O
or - - O
different - - O
entities - - O
; - - O
a - - O
review - - O
of - - O
those - - O
prognostic - - O
factors - - O
to - - O
consider - - O
in - - O
the - - O
clinical - - O
management - - O
of - - O
myositis - - O
patients - - O
; - - O
current - - O
approaches - - O
and - - O
their - - O
limitations - - O
for - - O
assessing - - O
disease - - O
activity - - O
and - - O
damage - - O
. - - O

Examination - - O
of - - O
the - - O
sequence - - O
of - - O
the - - O
Punta - - B-MUT
Toro - - I-MUT
M - - I-MUT
gene - - I-MUT
product - - I-MUT
reveals - - O
the - - O
presence - - O
of - - O
multiple - - O
hydrophobic - - O
sequences - - O
including - - O
a - - O
19-amino - - B-MUT
acid - - I-MUT
, - - I-MUT
carboxy-proximal - - I-MUT
, - - I-MUT
hydrophobic - - I-MUT
region - - I-MUT
( - - I-MUT
G2 - - I-MUT
) - - I-MUT
. - - O

In - - O
angiodysplasia - - O
, - - O
ectatic - - O
vessels - - O
in - - O
the - - O
mucosa - - O
appeared - - O
to - - O
contain - - O
less - - O
collagen - - B-MUT
type - - I-MUT
IV - - I-MUT
than - - O
similarly - - O
sized - - O
vessels - - O
in - - O
the - - O
submucosa - - O
, - - O
and - - O
perforating - - O
vessels - - O
appeared - - O
in - - O
many - - O
cases - - O
to - - O
lose - - O
staining - - O
at - - O
the - - O
level - - O
of - - O
the - - O
muscularis - - O
mucosae - - O
. - - O

RESULTS - - O
: - - O
Total - - O
IgE - - B-MUT
levels - - O
showed - - O
a - - O
tendency - - O
to - - O
diminish - - O
. - - O

In - - O
ischemic - - O
and - - O
hypoxic - - O
hypoxia - - O
, - - O
a - - O
strong - - O
correlation - - O
was - - O
found - - O
between - - O
cyt - - O
a - - O
, - - O
a3 - - O
oxidation - - O
level - - O
and - - O
VO2 - - O
in - - O
both - - O
ischemic - - O
and - - O
hypoxic - - O
hypoxia - - O
( - - O
r2 - - O
= - - O
. - - O
90 - - O
and - - O
. - - O
87 - - O
, - - O
respectively - - O
) - - O
. - - O

The - - O
sequence - - O
of - - O
the - - O
putative - - O
RBP1 - - B-MUT
protein - - I-MUT
contains - - O
two - - O
copies - - O
of - - O
an - - O
RNA - - O
recognition - - O
motif - - O
, - - O
two - - O
glutamine - - O
stretches - - O
, - - O
an - - O
asparagine-rich - - O
region - - O
, - - O
a - - O
methionine-rich - - O
region - - O
, - - O
and - - O
two - - O
long - - O
potential - - O
alpha-helixes - - O
. - - O

In - - O
a - - O
group - - O
of - - O
13 - - O
patients - - O
with - - O
obliterative - - O
arteriopathies - - O
of - - O
the - - O
lower - - O
limbs - - O
the - - O
plasma - - O
levels - - O
of - - O
thrombomodulin - - B-MUT
( - - O
TM - - B-MUT
) - - O
, - - O
betathromboglobulin - - B-MUT
( - - O
beta-TG - - B-MUT
) - - O
, - - O
D-dimer - - B-MUT
( - - O
DD - - B-MUT
) - - O
and - - O
plasminogen - - B-MUT
activator-inhibitor - - I-MUT
( - - O
pAI-1 - - B-MUT
) - - O
were - - O
measured - - O
, - - O
and - - O
compared - - O
to - - O
the - - O
values - - O
obtained - - O
from - - O
10 - - O
healthy - - O
volunteers - - O
. - - O

Research - - O
was - - O
carried - - O
out - - O
on - - O
the - - O
rheumatoid - - B-MUT
factors - - I-MUT
in - - O
the - - O
serum - - O
of - - O
917 - - O
patients - - O
by - - O
means - - O
of - - O
two - - O
tests - - O
( - - O
one - - O
using - - O
polystyrene - - O
and - - O
one - - O
with - - O
erythrocytes - - O
) - - O
and - - O
the - - O
results - - O
obtained - - O
were - - O
compared - - O
using - - O
a - - O
method - - O
of - - O
reference - - O
. - - O

A - - O
new - - O
semi-automatic - - O
method - - O
for - - O
quantifying - - O
regional - - O
cerebral - - O
uptake - - O
of - - O
99m - - O
technetium-hexamethylpropylene - - O
amine - - O
oxime - - O
( - - O
99mTc-HMPAO - - O
) - - O
was - - O
used - - O
to - - O
assess - - O
single - - O
photon - - O
emission - - O
tomograms - - O
from - - O
5 - - O
normal - - O
subjects - - O
, - - O
14 - - O
patients - - O
with - - O
Alzheimer's - - O
disease - - O
, - - O
14 - - O
patients - - O
with - - O
dementia - - O
of - - O
frontal - - O
lobe - - O
type - - O
and - - O
4 - - O
patients - - O
with - - O
dementia - - O
with - - O
motor - - O
neurone - - O
disease - - O
. - - O

However - - O
, - - O
alterations - - O
in - - O
electrostatic - - O
and - - O
hydrophobic - - O
interactions - - O
created - - O
by - - O
the - - O
three - - O
amino - - O
acid - - O
substitutions - - O
prevent - - O
the - - O
conformational - - O
change - - O
in - - O
the - - O
enzyme - - O
usually - - O
produced - - O
by - - O
calmodulin - - B-MUT
binding - - O
. - - O

The - - O
products - - O
of - - O
the - - O
Saccharomyces - - B-MUT
cerevisiae - - I-MUT
CIN1 - - I-MUT
, - - O
CIN2 - - B-MUT
and - - O
CIN4 - - B-MUT
genes - - I-MUT
participate - - O
in - - O
a - - O
nonessential - - O
pathway - - O
required - - O
for - - O
normal - - O
microtubule - - O
function - - O
. - - O

This - - O
study - - O
indicates - - O
that - - O
this - - O
dose-intense - - O
regimen - - O
can - - O
be - - O
safely - - O
administered - - O
, - - O
even - - O
with - - O
the - - O
use - - O
of - - O
purged - - O
marrow - - O
, - - O
with - - O
an - - O
acceptable - - O
toxicity - - O
profile - - O
. - - O

Transcription - - O
initiation - - O
sites - - O
of - - O
the - - O
rat - - B-MUT
II - - I-MUT
beta- - - I-MUT
, - - I-MUT
III - - I-MUT
beta - - I-MUT
, - - I-MUT
and - - I-MUT
O - - I-MUT
beta-globin - - I-MUT
genes - - I-MUT
were - - O
determined - - O
to - - O
be - - O
52 - - O
base - - O
pairs - - O
( - - O
bp - - O
) - - O
5'-upstream - - O
of - - O
the - - O
translation - - O
initiation - - O
codon - - O
( - - O
ATG - - O
) - - O
, - - O
in - - O
each - - O
gene - - O
by - - O
primer - - O
extension - - O
analysis - - O
. - - O

Transabdominal - - O
repair - - O
of - - O
type - - O
IV - - O
thoraco-abdominal - - O
aortic - - O
aneurysms - - O
. - - O

RESULTS - - O
: - - O
The - - O
main - - O
effect - - O
of - - O
muscle - - O
pain - - O
, - - O
compared - - O
to - - O
non-painful - - O
stimulation - - O
, - - O
was - - O
a - - O
significant - - O
and - - O
long-lasting - - O
increase - - O
of - - O
delta - - O
( - - O
1-3 - - O
Hz - - O
) - - O
power - - O
and - - O
an - - O
alpha-1 - - O
( - - O
9-11 - - O
Hz - - O
) - - O
power - - O
increase - - O
over - - O
the - - O
contralateral - - O
parietal - - O
locus - - O
. - - O

Here - - O
we - - O
present - - O
evidence - - O
that - - O
the - - O
distal - - O
half - - O
( - - O
Stem - - O
2 - - O
) - - O
of - - O
the - - O
conserved - - O
base-paired - - O
stem - - O
structure - - O
found - - O
in - - O
all - - O
hY - - B-MUT
RNAs - - I-MUT
also - - O
plays - - O
a - - O
critical - - O
role - - O
in - - O
the - - O
export - - O
process - - O
. - - O

While - - O
the - - O
examiner - - O
observed - - O
the - - O
interior - - O
of - - O
the - - O
eye - - O
with - - O
indirect - - O
ophthalmoscopy - - O
, - - O
the - - O
point - - O
source - - O
of - - O
light - - O
from - - O
the - - O
fiberoptic - - O
light - - O
pipe - - O
was - - O
moved - - O
along - - O
the - - O
margins - - O
of - - O
the - - O
episcleral - - O
plaque - - O
. - - O

In - - O
contrast - - O
to - - O
some - - O
results - - O
previously - - O
published - - O
for - - O
a - - O
very - - O
close - - O
sequence - - O
variant - - O
( - - O
see - - O
ref - - O
. - - O

S1 - - B-MUT
nuclease - - I-MUT
analysis - - O
of - - O
RNA - - O
from - - O
chemically - - O
induced - - O
B95-8 - - O
cells - - O
and - - O
from - - O
Vero - - O
cells - - O
cotransfected - - O
with - - O
NotI - - B-MUT
repeat - - I-MUT
promoter-CAT - - I-MUT
and - - O
Z - - B-MUT
showed - - O
that - - O
Z - - B-MUT
transactivation - - O
increased - - O
the - - O
level - - O
of - - O
correctly - - O
initiated - - O
, - - O
stable - - O
RNA - - O
transcripts - - O
. - - O

The - - O
nifJ - - B-MUT
and - - O
nifH - - B-MUT
promoters - - I-MUT
of - - I-MUT
Klebsiella - - I-MUT
pneumoniae - - I-MUT
are - - O
divergently - - O
transcribed - - O
sigma - - B-MUT
54-dependent - - I-MUT
promoters - - I-MUT
that - - O
are - - O
positively - - O
activated - - O
by - - O
the - - O
NifA - - B-MUT
protein - - I-MUT
. - - O

Both - - O
toxins - - O
in - - O
a - - O
dose - - O
10-fold - - O
surpassimg - - O
the - - O
maximum - - O
permissible - - O
concentration - - O
increased - - O
activity - - O
of - - O
glutathione - - B-MUT
peroxidase - - I-MUT
in - - O
brain - - O
tissue - - O
; - - O
moreover - - O
, - - O
toluene - - O
increased - - O
chemiluminescence - - O
intensity - - O
, - - O
which - - O
attested - - O
to - - O
activation - - O
of - - O
free - - O
radical - - O
processes - - O
. - - O

To - - O
this - - O
end - - O
, - - O
we - - O
analyzed - - O
the - - O
phosphorylation - - O
status - - O
of - - O
a - - O
universal - - O
tyrosine - - B-MUT
kinase - - I-MUT
substrate - - O
, - - O
the - - O
transforming - - O
Shc - - B-MUT
adapter - - I-MUT
protein - - I-MUT
, - - O
in - - O
fibroblasts - - O
expressing - - O
the - - O
viral - - O
oncogene - - O
. - - O

Partial - - O
characterization - - O
of - - O
the - - O
active - - O
site - - O
human - - B-MUT
platelet - - I-MUT
cAMP - - I-MUT
phosphodiesterase - - I-MUT
, - - O
PDE3A - - B-MUT
, - - O
by - - O
site-directed - - O
mutagenesis - - O
. - - O

The - - O
region - - O
between - - O
DXS52 - - B-MUT
and - - O
Factor - - B-MUT
VIII - - I-MUT
gene - - I-MUT
in - - O
the - - O
human - - O
Xq28 - - O
chromosomal - - O
band - - O
contains - - O
a - - O
G+C-rich - - O
isochore - - O
to - - O
which - - O
many - - O
genes - - O
have - - O
been - - O
mapped - - O
. - - O

Biochemical - - O
characterization - - O
of - - O
valosin-containing - - B-MUT
protein - - I-MUT
, - - O
a - - O
protein - - B-MUT
tyrosine - - I-MUT
kinase - - I-MUT
substrate - - O
in - - O
hematopoietic - - O
cells - - O
. - - O

The - - O
latency - - O
time - - O
for - - O
the - - O
lactate - - O
concentration - - O
to - - O
reach - - O
the - - O
top - - O
values - - O
was - - O
reduced - - O
by - - O
aerobic - - O
training - - O
( - - O
T2 - - O
) - - O
. - - O

We - - O
also - - O
provide - - O
evidence - - O
that - - O
gar2 - - B-MUT
is - - O
phosphorylated - - O
in - - O
vitro - - O
by - - O
a - - O
p13 - - B-MUT
( - - O
suc1 - - B-MUT
) - - O
-Sepharose-bound - - O
kinase - - B-MUT
from - - O
Schizosaccharomyces - - O
pombe - - O
extracts - - O
that - - O
displays - - O
cell - - O
cycle-regulated - - O
activity - - O
similar - - O
to - - O
that - - O
of - - O
the - - O
p34 - - B-MUT
( - - O
cdc2 - - B-MUT
( - - O
kinase - - O
. - - O

Our - - O
results - - O
support - - O
a - - O
model - - O
where - - O
both - - O
E2F- - - O
and - - O
CDE-mediated - - O
repression - - O
, - - O
acting - - O
at - - O
different - - O
stages - - O
in - - O
the - - O
cell - - O
cycle - - O
, - - O
are - - O
dependent - - O
on - - O
promoter-specific - - O
CHR - - B-MUT
elements - - I-MUT
. - - O

Indeed - - O
, - - O
significant - - O
level - - O
of - - O
CAT - - B-MUT
activity - - O
was - - O
observed - - O
in - - O
human - - O
lung - - O
adenocarcinoma - - O
( - - O
A549-1 - - O
) - - O
cells - - O
which - - O
had - - O
been - - O
incubated - - O
with - - O
a - - O
complex - - O
of - - O
T7 - - B-MUT
RNA - - I-MUT
polymerase - - I-MUT
, - - O
pT7-EMC-CAT - - B-MUT
DNA - - I-MUT
and - - O
DC-chol - - O
cationic - - O
liposomes - - O
. - - O

CONCLUSIONS - - O
. - - O

Preceptorship - - O
of - - O
CNS - - O
students - - O
: - - O
an - - O
exploratory - - O
study - - O
. - - O

The - - O
difference - - O
of - - O
hardness - - O
over - - O
time - - O
of - - O
composite - - O
specimens - - O
was - - O
measured - - O
using - - O
Knoop - - O
hardness - - O
measurements - - O
taken - - O
at - - O
the - - O
top - - O
and - - O
bottom - - O
surfaces - - O
of - - O
resin - - O
specimens - - O
made - - O
in - - O
a - - O
Teflon - - O
mold - - O
the - - O
same - - O
dimensions - - O
as - - O
the - - O
cavity - - O
prepared - - O
in - - O
dentin - - B-MUT
. - - O

An - - O
alternatively - - O
spliced - - O
MAdCAM-1 - - B-MUT
variant - - O
was - - O
identified - - O
that - - O
lacks - - O
exon - - O
4 - - O
encoding - - O
the - - O
mucin - - B-MUT
domain - - O
, - - O
and - - O
may - - O
mediate - - O
leukocyte - - O
adhesion - - O
to - - O
LPAM-1 - - B-MUT
without - - O
adhesion - - O
to - - O
the - - O
alternate - - O
receptor - - O
, - - O
L-selectin - - B-MUT
. - - O

The - - O
hypothesis - - O
of - - O
Geisler - - O
( - - O
Brain - - O
Res - - O
. - - O

EM - - O
analysis - - O
demonstrated - - O
that - - O
only - - O
one - - O
Rep-DNA - - B-MUT
complex - - I-MUT
was - - O
formed - - O
on - - O
ch-19 - - O
target - - O
DNA - - O
. - - O

Epithelial - - O
nerve - - O
fiber - - O
defects - - O
included - - O
absence - - O
or - - O
distorted - - O
architecture - - O
of - - O
the - - O
basal - - O
epithelial - - O
plexus - - O
and - - O
intra-epithelial - - O
terminals - - O
. - - O

In - - O
an - - O
effort - - O
to - - O
contribute - - O
to - - O
the - - O
transcript - - O
map - - O
of - - O
human - - O
chromosome - - O
21 - - O
and - - O
the - - O
understanding - - O
of - - O
the - - O
pathophysiology - - O
of - - O
trisomy - - O
21 - - O
, - - O
we - - O
have - - O
used - - O
exon - - O
trapping - - O
to - - O
identify - - O
fragments - - O
of - - O
chromosome - - O
21 - - O
genes - - O
. - - O

We - - O
previously - - O
demonstrated - - O
that - - O
acute - - O
expression - - O
of - - O
the - - O
bovine - - O
papillomavirus - - O
type - - O
1 - - O
( - - O
BPV1 - - O
) - - O
E2 - - B-MUT
protein - - I-MUT
in - - O
HeLa - - O
and - - O
HT-3 - - O
cervical - - O
carcinoma - - O
cell - - O
lines - - O
greatly - - O
reduced - - O
cellular - - O
proliferation - - O
by - - O
imposing - - O
a - - O
specific - - O
G1 - - O
S - - O
phase - - O
growth - - O
arrest - - O
. - - O

The - - O
mean - - O
plasma - - O
sodium - - O
concentration - - O
which - - O
was - - O
135 - - O
. - - O
95 - - O
( - - O
+ - - O
- - - O
SD - - O
4 - - O
. - - O
14 - - O
) - - O
mEq - - O
kg - - O
before - - O
diuretic - - O
treatment - - O
was - - O
significantly - - O
decreased - - O
during - - O
treatment - - O
to - - O
129 - - O
. - - O
19 - - O
( - - O
+ - - O
- - - O
SD - - O
2 - - O
. - - O
77 - - O
) - - O
mEq - - O
kg - - O
, - - O
P - - O
less - - O
than - - O
0 - - O
. - - O
001 - - O
. - - O

In - - O
insulin-responsive - - O
cells - - O
, - - O
Akt - - B-MUT
phosphorylates - - O
and - - O
inactivates - - O
the - - O
serine - - B-MUT
threonine - - I-MUT
kinase - - I-MUT
glycogen - - I-MUT
synthase - - B-MUT
kinase-3 - - I-MUT
( - - I-MUT
GSK-3 - - O
) - - B-MUT
. - - O

Cyclin - - B-MUT
D1-associated - - I-MUT
kinase - - I-MUT
activity - - O
and - - O
protein - - O
levels - - O
were - - O
increased - - O
in - - O
mammary - - O
tumors - - O
from - - O
murine - - B-MUT
mammary - - I-MUT
tumor - - I-MUT
virus-pp60 - - I-MUT
( - - I-MUT
c-src527F - - I-MUT
) - - I-MUT
transgenic - - O
mice - - O
. - - O

We - - O
conducted - - O
a - - O
prospective - - O
, - - O
randomized - - O
controlled - - O
trial - - O
of - - O
metoprolol - - O
, - - O
a - - O
selective - - O
beta-blocker - - O
for - - O
prevention - - O
of - - O
gastrointestinal - - O
bleeding - - O
from - - O
portal - - O
hypertension - - O
in - - O
29 - - O
non-selected - - O
patients - - O
with - - O
liver - - O
disease - - O
and - - O
previous - - O
gastrointestinal - - O
bleeding - - O
. - - O

[ - - O
Treatment - - O
of - - O
early - - O
T1 - - O
small - - O
T2N - - O
breast - - O
cancers - - O
. - - O

Mutation - - O
analysis - - O
demonstrates - - O
that - - O
the - - O
motif - - O
TCCCCT - - B-MUT
is - - O
critical - - O
for - - O
PyRo1 - - B-MUT
interaction - - O
. - - O

Cdc2 - - B-MUT
co-precipitates - - O
with - - O
Pch1 - - B-MUT
in - - O
S - - O
. - - O
pombe - - O
cell - - O
lysates - - O
, - - O
although - - O
Cdc2 - - B-MUT
may - - O
not - - O
be - - O
the - - O
major - - O
catalytic - - O
partner - - O
of - - O
a - - O
Pch1 - - B-MUT
kinase - - I-MUT
in - - O
vivo - - O
. - - O

This - - O
paper - - O
presents - - O
the - - O
reasons - - O
why - - O
countries - - O
to - - O
which - - O
Chagas - - O
disease - - O
is - - O
endemic - - O
should - - O
carry - - O
out - - O
the - - O
relevant - - O
research - - O
themselves - - O
. - - O

Copyright - - O
2000 - - O
Academic - - O
Press - - O
. - - O

Despite - - O
significant - - O
lethality - - O
and - - O
cardiovascular - - O
dysfunction - - O
, - - O
in - - O
the - - O
septic - - O
group - - O
on - - O
Days - - O
1 - - O
and - - O
2 - - O
, - - O
septic - - O
versus - - O
control - - O
animals - - O
had - - O
no - - O
significant - - O
differences - - O
in - - O
mean - - O
metabolic - - O
cart - - O
measured - - O
( - - O
Vo2DIR - - O
, - - O
ml - - O
kg - - O
min - - O
; - - O
Day - - O
1 - - O
: - - O
11 - - O
. - - O
9 - - O
versus - - O
12 - - O
. - - O
4 - - O
, - - O
p - - O
= - - O
0 - - O
. - - O
81 - - O
; - - O
Day - - O
2 - - O
: - - O
14 - - O
. - - O
2 - - O
versus - - O
13 - - O
. - - O
5 - - O
, - - O
p - - O
= - - O
0 - - O
. - - O
72 - - O
, - - O
respectively - - O
) - - O
and - - O
intravascular - - O
catheter - - O
calculated - - O
( - - O
Vo2INDIR - - O
, - - O
ml - - O
kg - - O
min - - O
; - - O
Day - - O
1 - - O
: - - O
11 - - O
. - - O
2 - - O
versus - - O
11 - - O
. - - O
2 - - O
, - - O
p - - O
= - - O
0 - - O
. - - O
99 - - O
; - - O
Day - - O
2 - - O
: - - O
12 - - O
. - - O
8 - - O
versus - - O
15 - - O
. - - O
4 - - O
, - - O
p - - O
= - - O
0 - - O
. - - O
49 - - O
, - - O
respectively - - O
) - - O
. - - O

This - - O
would - - O
have - - O
had - - O
the - - O
effect - - O
of - - O
positioning - - O
the - - O
genes - - O
currently - - O
on - - O
the - - O
long - - O
arm - - O
adjacent - - O
to - - O
the - - O
centromeric - - O
heterochromatin - - O
, - - O
perhaps - - O
resulting - - O
in - - O
a - - O
"position - - O
effect" - - O
on - - O
transcription - - O
of - - O
these - - O
genes - - O
. - - O

T1-weighted - - O
MRI - - O
on - - O
the - - O
49th - - O
postoperative - - O
day - - O
demonstrated - - O
bilateral - - O
and - - O
symmetrical - - O
hyperintense - - O
lesions - - O
in - - O
the - - O
globus - - O
pallidus - - O
. - - O

The - - O
side-to-side - - O
difference - - O
was - - O
statistically - - O
significant - - O
at - - O
EXT - - O
30 - - O
degrees - - O
s - - O
and - - O
60 - - O
degrees - - O
s - - O
( - - O
p - - O
< - - O
0 - - O
. - - O
05 - - O
) - - O
. - - O

Formalin - - O
activated - - O
both - - O
SNO - - O
NS - - O
and - - O
NnS - - O
neurones - - O
, - - O
but - - O
, - - O
when - - O
they - - O
responded - - O
, - - O
NS - - O
neurones - - O
( - - O
n - - O
= - - O
5 - - O
) - - O
showed - - O
only - - O
the - - O
first - - O
phase - - O
of - - O
activity - - O
while - - O
NnS - - O
neurones - - O
showed - - O
either - - O
one - - O
( - - O
n - - O
= - - O
13 - - O
) - - O
or - - O
two - - O
phases - - O
( - - O
n - - O
= - - O
6 - - O
) - - O
. - - O

The - - O
IgG - - B-MUT
subclass - - O
profile - - O
of - - O
untreated - - O
coeliac - - O
disease - - O
was - - O
found - - O
to - - O
be - - O
the - - O
same - - O
as - - O
in - - O
healthy - - O
controls - - O
( - - O
IgG1 - - B-MUT
approximately - - O
IgG2 - - B-MUT
> - - O
IgG3 - - B-MUT
> - - O
IgG4 - - B-MUT
) - - O
, - - O
with - - O
only - - O
the - - O
magnitude - - O
of - - O
the - - O
individual - - O
subclass - - O
responses - - O
being - - O
increased - - O
in - - O
coeliac - - O
patients - - O
. - - O

1 - - O
. - - O

An - - O
8-h - - O
exposure - - O
to - - O
10 - - O
mg - - O
DMEA - - O
m3 - - O
corresponds - - O
to - - O
a - - O
postexposure - - O
plasma - - O
concentration - - O
and - - O
2-h - - O
postexposure - - O
urinary - - O
excretion - - O
of - - O
4 - - O
. - - O
9 - - O
mumol - - O
l - - O
and - - O
75 - - O
mmol - - O
mol - - O
creatinine - - O
, - - O
respectively - - O
. - - O

Sequence - - O
analysis - - O
of - - O
this - - O
region - - O
revealed - - O
three - - O
eight-bp - - O
repetitive - - O
elements - - O
, - - O
the - - O
deletion - - O
of - - O
which - - O
restored - - O
wild-type - - O
levels - - O
of - - O
luciferase - - B-MUT
activity - - O
to - - O
the - - O
-916-bp - - O
reporter - - O
plasmid - - O
. - - O

The - - O
radiation - - O
burden - - O
associated - - O
with - - O
the - - O
majority - - O
of - - O
examinations - - O
in - - O
nuclear - - O
medicine - - O
expressed - - O
as - - O
the - - O
effective - - O
dose - - O
is - - O
comparable - - O
with - - O
the - - O
radiation - - O
burden - - O
of - - O
radiodiagnostic - - O
examinations - - O
, - - O
only - - O
after - - O
administration - - O
of - - O
preparations - - O
with - - O
131I - - O
, - - O
201Tl - - O
, - - O
67Ga - - O
and - - O
111In - - O
it - - O
is - - O
markedly - - O
higher - - O
. - - O

Here - - O
, - - O
we - - O
describe - - O
directional - - O
chromosome - - O
walking - - O
studies - - O
starting - - O
from - - O
D8S260 - - B-MUT
as - - O
well - - O
as - - O
D8S285 - - B-MUT
. - - O

RUSH-1 - - B-MUT
beta - - I-MUT
is - - O
a - - O
95-kDa - - O
truncated - - O
version - - O
of - - O
RUSH-1 - - B-MUT
alpha - - I-MUT
that - - O
results - - O
from - - O
alternative - - O
splicing - - O
of - - O
a - - O
57-bp - - O
exon - - O
as - - O
confirmed - - O
by - - O
genomic - - O
cloning - - O
. - - O

Reduction - - O
in - - O
dosage - - O
restored - - O
normal - - O
taste - - O
sense - - O
in - - O
all - - O
three - - O
, - - O
but - - O
in - - O
two - - O
the - - O
drug - - O
had - - O
to - - O
be - - O
discontinued - - O
because - - O
of - - O
persisting - - O
high - - O
transaminase - - B-MUT
levels - - O
. - - O

Thus - - O
analysis - - O
indicated - - O
no - - O
reliable - - O
evidence - - O
that - - O
conscious - - O
presleep - - O
suggestions - - O
become - - O
incorporated - - O
into - - O
dream - - O
content - - O
. - - O

Thus - - O
, - - O
our - - O
studies - - O
suggest - - O
that - - O
pV-mediated - - O
activation - - O
of - - O
HIV-1 - - B-MUT
LTR - - I-MUT
activity - - O
is - - O
controlled - - O
by - - O
the - - O
nuclear - - O
translocation - - O
of - - O
the - - O
NF-kappaB - - B-MUT
transcription - - I-MUT
factor - - I-MUT
, - - O
which - - O
is - - O
mediated - - O
by - - O
IkappaBalpha - - B-MUT
serine - - O
phosphorylation - - O
and - - O
degradation - - O
, - - O
but - - O
also - - O
by - - O
a - - O
still - - O
undefined - - O
NF-kappaB-independent - - O
pathway - - O
. - - O

Acute - - O
appearance - - O
of - - O
hemiparesis - - O
or - - O
hemiplegia - - O
with - - O
initial - - O
marked - - O
spasticity - - O
was - - O
observed - - O
in - - O
8 - - O
stroke - - O
patients - - O
. - - O

Schlegel - - O
, - - O
J - - O
. - - O

Analysis - - O
of - - O
one - - O
cDNA - - O
revealed - - O
an - - O
unusual - - O
splicing - - O
event - - O
involving - - O
EZH1 - - B-MUT
and - - O
a - - O
tandemly - - O
linked - - O
gene - - O
GPR2 - - B-MUT
and - - O
suggests - - O
a - - O
potential - - O
mechanism - - O
for - - O
modifying - - O
the - - O
EZH1 - - B-MUT
protein - - I-MUT
in - - O
the - - O
conserved - - O
C-terminal - - O
domain - - O
. - - O

We - - O
analysed - - O
two - - O
regions - - O
involved - - O
in - - O
preS2 - - B-MUT
S - - O
gene - - B-MUT
transcription - - I-MUT
of - - O
the - - O
HBV - - O
adw - - O
subtype - - O
: - - O
the - - O
diverged - - O
TATA - - O
box - - O
and - - O
a - - O
putative - - O
initiator - - O
element - - O
. - - O

Effect - - O
of - - O
chronic - - O
undernutrition - - O
on - - O
susceptibility - - O
to - - O
cold - - O
stress - - O
in - - O
young - - O
adult - - O
and - - O
aged - - O
rats - - O
. - - O

During - - O
this - - O
time - - O
, - - O
the - - O
patients - - O
all - - O
had - - O
the - - O
characteristic - - O
plasma - - O
thyroid - - O
hormone - - O
changes - - O
associated - - O
with - - O
amiodarone - - O
therapy - - O
, - - O
i - - O
. - - O
e - - O
. - - O
increased - - O
T4 - - O
, - - O
free - - O
T4 - - O
, - - O
and - - O
rT3 - - O
and - - O
decreased - - O
T3 - - O
, - - O
while - - O
remaining - - O
clinically - - O
euthyroid - - O
. - - O

Normal - - O
rates - - O
of - - O
weight - - O
gain - - O
were - - O
seen - - O
once - - O
absorbed - - O
energy - - O
intakes - - O
reached - - O
100-110% - - O
of - - O
requirements - - O
. - - O

The - - O
C18 - - O
: - - O
1 - - O
: - - O
C10 - - O
value - - O
is - - O
a - - O
convenient - - O
measure - - O
of - - O
these - - O
changes - - O
and - - O
can - - O
be - - O
determined - - O
more - - O
rapidly - - O
than - - O
determining - - O
all - - O
the - - O
lower - - O
fatty - - O
acids - - O
. - - O

The - - O
cytoprotective - - O
and - - O
antiulcer - - O
activities - - O
of - - O
the - - O
antacid - - O
magaldrate - - O
( - - O
ES - - O
Riopan - - O
) - - O
as - - O
well - - O
as - - O
its - - O
effects - - O
on - - O
gastric - - O
mucosal - - O
blood - - O
flow - - O
and - - O
mucus - - O
secretions - - O
, - - O
were - - O
determined - - O
in - - O
the - - O
rat - - O
. - - O

Retinal - - O
changes - - O
in - - O
pigmentary - - O
retinopathy - - O
in - - O
children - - O
. - - O

The - - O
overall - - O
prevalence - - O
of - - O
psoriasis - - O
was - - O
4 - - O
. - - O
79% - - O
in - - O
men - - O
and - - O
4 - - O
. - - O
85% - - O
in - - O
women - - O
. - - O

When - - O
introduced - - O
into - - O
recJ+ - - B-MUT
strains - - O
, - - O
srjA - - B-MUT
mutations - - O
conferred - - O
hyperrecombinational - - O
and - - O
hyper-UVr - - O
phenotypes - - O
. - - O

Previous - - O
studies - - O
showed - - O
that - - O
mutations - - O
in - - O
the - - O
6K - - O
protein - - O
led - - O
to - - O
the - - O
slow - - O
release - - O
of - - O
aberrant - - O
, - - O
multi-cored - - O
infectious - - O
virions - - O
. - - O

Performance - - O
on - - O
two - - O
verbal - - O
measures-the - - O
National - - O
Adult - - O
Reading - - O
Test-Revised - - O
( - - O
NART-R - - O
) - - O
and - - O
the - - O
Vocabulary - - O
subtest - - O
from - - O
the - - O
Wechsler - - O
Adult - - O
Intelligence - - O
Scale-Revised - - O
( - - O
WAIS-R - - O
) - - O
-showed - - O
strong - - O
correlations - - O
with - - O
level - - O
of - - O
education - - O
. - - O

The - - O
influence - - O
of - - O
Epstein-Barr - - O
virus - - O
seropositivity - - O
on - - O
the - - O
efficacy - - O
of - - O
intravenous - - O
immune - - B-MUT
globulin - - I-MUT
in - - O
children - - O
with - - O
immune - - O
thrombocytopenic - - O
purpura - - O
. - - O

Malaria - - O
had - - O
diminished - - O
significantly - - O
by - - O
the - - O
early - - O
1940s - - O
, - - O
and - - O
this - - O
paper - - O
queries - - O
whether - - O
that - - O
reduction - - O
was - - O
due - - O
to - - O
the - - O
control - - O
projects - - O
of - - O
the - - O
thirties - - O
, - - O
and - - O
, - - O
if - - O
so - - O
, - - O
whether - - O
such - - O
projects - - O
should - - O
be - - O
a - - O
model - - O
for - - O
the - - O
current - - O
developing - - O
world - - O
, - - O
where - - O
malaria - - O
is - - O
a - - O
growing - - O
problem - - O
today - - O
. - - O

Plasma - - O
renin - - B-MUT
activity - - O
did - - O
not - - O
change - - O
in - - O
response - - O
to - - O
head-up - - O
tilt - - O
or - - O
isoprenaline - - O
infusion - - O
in - - O
the - - O
patients - - O
. - - O

On - - O
the - - O
role - - O
of - - O
transferrin - - B-MUT
in - - O
the - - O
uptake - - O
of - - O
gallium - - O
by - - O
tumor - - O
cells - - O
. - - O

Spatial - - O
accuracy - - O
of - - O
primary - - O
and - - O
secondary - - O
memory-guided - - O
saccades - - O
in - - O
schizophrenic - - O
patients - - O
. - - O

A - - O
16-year - - O
follow-up - - O
study - - O
of - - O
69 - - O
paraplegics - - O
with - - O
complete - - O
lesions - - O
from - - O
T1-L3 - - O
is - - O
presented - - O
. - - O

Combination - - O
of - - O
a - - O
Shwachman - - O
syndrome - - O
and - - O
a - - O
complex - - O
granulocyte - - O
function - - O
disorder - - O
in - - O
a - - O
girl - - O
. - - O

This - - O
shows - - O
that - - O
in - - O
situations - - O
of - - O
separated - - O
breaks - - O
, - - O
NHEJ - - O
deficiency - - O
leads - - O
to - - O
genomic - - O
rearrangements - - O
, - - O
in - - O
agreement - - O
with - - O
chromosomal - - O
studies - - O
. - - O

Interestingly - - O
, - - O
the - - O
IR5 - - B-MUT
ORF - - I-MUT
of - - O
EHV-1 - - O
possesses - - O
a - - O
sequence - - O
of - - O
13 - - O
amino - - O
acids - - O
( - - O
CAYWCCLGHAFAC - - B-MUT
) - - O
that - - O
is - - O
a - - O
perfect - - O
match - - O
to - - O
the - - O
consensus - - O
zinc - - O
finger - - O
motif - - O
( - - O
C-X2-4-C-X2-15-C - - B-MUT
H-X2-4-C - - I-MUT
H - - I-MUT
) - - I-MUT
. - - I-MUT

Mutating - - O
a - - O
potential - - O
cleavage - - O
site - - O
located - - O
N-terminal - - O
to - - O
the - - O
protease - - B-MUT
domain - - I-MUT
, - - I-MUT
Gln2526-Asp2527 - - I-MUT
, - - O
diminished - - O
processing - - O
. - - O

The - - O
German - - O
Society - - O
of - - O
Pediatric - - O
Oncology - - O
in - - O
1981 - - O
initiated - - O
the - - O
Cooperative - - O
Ewing's - - O
Sarcoma - - O
Study - - O
( - - O
CESS - - O
81 - - O
) - - O
using - - O
a - - O
four-drug - - O
combination - - O
of - - O
chemotherapy - - O
prior - - O
to - - O
definitive - - O
local - - O
control - - O
with - - O
surgery - - O
and - - O
or - - O
radiation - - O
. - - O

An - - O
RME1-independent - - O
pathway - - O
for - - O
sporulation - - O
control - - O
in - - O
Saccharomyces - - O
cerevisiae - - O
acts - - O
through - - O
IME1 - - B-MUT
transcript - - I-MUT
accumulation - - O
. - - O

Reversal - - O
of - - O
the - - O
increase - - O
in - - O
apomorphine-induced - - O
stereotypy - - O
and - - O
aggression - - O
in - - O
REM - - O
sleep - - O
deprived - - O
rats - - O
by - - O
dopamine - - O
agonist - - O
pretreatments - - O
. - - O

The - - O
effect - - O
of - - O
osmotic - - O
flow - - O
on - - O
the - - O
distribution - - O
of - - O
horseradish - - B-MUT
peroxidase - - I-MUT
within - - O
the - - O
intercellular - - O
spaces - - O
of - - O
toad - - O
bladder - - O
epithelium - - O
. - - O

There - - O
was - - O
no - - O
evident - - O
inciting - - O
agent - - O
of - - O
the - - O
disease - - O
. - - O

A - - O
three-phased - - O
analysis - - O
of - - O
treatment - - O
plans - - O
for - - O
45 - - O
patients - - O
was - - O
undertaken - - O
. - - O

M - - O
. - - O
, - - O
and - - O
D - - O
. - - O

Here - - O
we - - O
show - - O
that - - O
a - - O
novel - - O
isoform - - O
of - - O
Rapl - - B-MUT
GTPase-activating - - I-MUT
protein - - I-MUT
, - - O
called - - O
rap1GAPII - - B-MUT
, - - O
binds - - O
specifically - - O
to - - O
the - - O
alpha-subunits - - O
of - - O
the - - O
G - - B-MUT
( - - I-MUT
i - - I-MUT
) - - I-MUT
family - - I-MUT
of - - O
heterotrimeric - - B-MUT
G-proteins - - I-MUT
. - - O

The - - O
kappa - - O
coefficient - - O
of - - O
agreement - - O
between - - O
the - - O
Patho - - O
Dx - - O
Kit - - O
and - - O
the - - O
standard - - O
method - - O
was - - O
0 - - O
. - - O
958 - - O
. - - O

Transient - - O
transfection - - O
assays - - O
using - - O
reporter - - O
gene - - O
constructs - - O
containing - - O
various - - O
lengths - - O
of - - O
the - - O
5' - - B-MUT
mdr1b - - I-MUT
sequences - - I-MUT
revealed - - O
that - - O
the - - O
sequence - - O
located - - O
between-247 - - O
to - - O
-126 - - O
bp - - O
was - - O
important - - O
for - - O
the - - O
expression - - O
of - - O
the - - O
reporter - - O
gene - - O
in - - O
many - - O
different - - O
cell - - O
lines - - O
. - - O

It - - O
is - - O
concluded - - O
that - - O
opiate - - B-MUT
receptors - - I-MUT
bordering - - O
the - - O
fourth - - O
cerebral - - O
ventricle - - O
mediate - - O
the - - O
cardiovascular - - O
and - - O
hypnotic - - O
action - - O
of - - O
fentanyl - - O
. - - O

A - - O
number - - O
of - - O
serological - - O
tests - - O
measuring - - O
the - - O
presence - - O
of - - O
Helicobacter - - O
pylori-specific - - O
serum - - O
immunoglobulin - - B-MUT
G - - I-MUT
( - - O
IgG - - B-MUT
) - - O
are - - O
now - - O
commercially - - O
available - - O
. - - O

BACKGROUND - - O
: - - O
Delineation - - O
of - - O
the - - O
morphologic - - O
aspects - - O
of - - O
age-related - - O
macular - - O
degeneration - - O
( - - O
ARMD - - O
) - - O
is - - O
helpful - - O
in - - O
correlation - - O
with - - O
the - - O
clinical - - O
features - - O
and - - O
may - - O
contribute - - O
to - - O
understanding - - O
the - - O
pathogenesis - - O
. - - O

Twenty-three - - O
sequence-tagged - - O
sites - - O
( - - O
STSs - - O
) - - O
were - - O
mapped - - O
within - - O
the - - O
contig - - O
, - - O
a - - O
density - - O
of - - O
approximately - - O
1 - - O
per - - O
200 - - O
kb - - O
. - - O

RT-PCR - - O
and - - O
in - - O
situ - - O
hybridization - - O
analyses - - O
of - - O
a - - O
time - - O
course - - O
of - - O
juvenile - - O
testis - - O
development - - O
indicate - - O
that - - O
Spo11 - - B-MUT
expression - - O
begins - - O
in - - O
early - - O
meiotic - - O
Prophase - - O
I - - O
, - - O
prior - - O
to - - O
the - - O
pachytene - - O
stage - - O
, - - O
with - - O
increasing - - O
accumulation - - O
of - - O
mRNA - - O
through - - O
the - - O
pachytene - - O
stage - - O
. - - O

However - - O
, - - O
the - - O
beta5L - - B-MUT
splice - - I-MUT
variant - - I-MUT
was - - O
found - - O
only - - O
in - - O
the - - O
retina - - O
. - - O

The - - O
P-wr - - B-MUT
and - - O
P-rr - - B-MUT
cDNA - - I-MUT
sequences - - I-MUT
are - - O
very - - O
similar - - O
in - - O
their - - O
5' - - O
regions - - O
. - - O

By - - O
site-specific - - O
mutagenesis - - O
, - - O
we - - O
also - - O
show - - O
that - - O
individual - - O
ICP27 - - B-MUT
C-terminal - - I-MUT
amino - - I-MUT
acid - - I-MUT
residues - - I-MUT
that - - O
are - - O
positionally - - O
conserved - - O
in - - O
ICP27 - - B-MUT
homologs - - I-MUT
in - - O
other - - O
herpesviruses - - O
( - - O
D-357 - - O
, - - O
E-358 - - O
, - - O
H-479 - - O
, - - O
C-400 - - O
, - - O
C-483 - - O
, - - O
and - - O
C-488 - - O
) - - O
are - - O
critical - - O
for - - O
trans-regulatory - - O
activity - - O
. - - O

Electronic - - O
structure - - O
of - - O
a - - O
buried - - O
NiSi2 - - O
or - - O
CoSi2 - - O
layer - - O
in - - O
bulk - - O
Si - - O
. - - O

Six - - O
tandem - - O
repeats - - O
of - - O
the - - O
P - - B-MUT
element - - I-MUT
linked - - O
to - - O
the - - O
SV40 - - B-MUT
promoter - - I-MUT
responded - - O
to - - O
phorbol - - O
12-myristate - - O
13-acetate - - O
, - - O
while - - O
that - - O
of - - O
other - - O
elements - - O
did - - O
not - - O
. - - O

The - - O
pWP-19 - - B-MUT
also - - O
encodes - - O
the - - O
AAV - - O
inverted - - O
terminal - - O
repeats - - O
for - - O
integration - - O
and - - O
replication - - O
and - - O
the - - O
herpes - - O
virus - - O
thymidine - - B-MUT
kinase - - I-MUT
promoter-driven - - O
gene - - O
for - - O
neomycin - - O
resistance - - O
( - - O
neoR - - B-MUT
) - - O
. - - O

Binding - - O
site - - O
selection - - O
using - - O
in - - O
vitro-synthesized - - O
proteins - - O
reveals - - O
that - - O
the - - O
ROR - - B-MUT
alpha - - I-MUT
1 - - I-MUT
and - - O
ROR - - B-MUT
alpha - - I-MUT
2 - - I-MUT
isoforms - - I-MUT
bind - - O
DNA - - O
as - - O
monomers - - O
to - - O
hormone - - B-MUT
response - - I-MUT
elements - - I-MUT
composed - - O
of - - O
a - - O
6-bp - - O
AT-rich - - O
sequence - - O
preceding - - O
a - - O
half-site - - O
core - - B-MUT
motif - - I-MUT
PuGGTCA - - I-MUT
( - - O
RORE - - B-MUT
) - - O
. - - O

Genotoxic - - O
activity - - O
of - - O
a - - O
tobacco-specific - - O
nitrosamine - - O
. - - O

Our - - O
findings - - O
also - - O
provide - - O
the - - O
basis - - O
for - - O
the - - O
development - - O
of - - O
assays - - O
to - - O
screen - - O
for - - O
the - - O
ligands - - O
to - - O
testis - - B-MUT
receptor - - I-MUT
2 - - I-MUT
and - - O
hERR1 - - B-MUT
. - - O

The - - O
response - - O
chain - - O
in - - O
each - - O
component - - O
was - - O
maintained - - O
by - - O
food - - O
presentation - - O
under - - O
a - - O
fixed-ratio - - O
schedule - - O
. - - O

Signaling - - O
from - - O
the - - O
small - - B-MUT
GTP-binding - - I-MUT
proteins - - I-MUT
Rac1 - - I-MUT
and - - O
Cdc42 - - B-MUT
to - - O
the - - O
c-Jun - - B-MUT
N-terminal - - I-MUT
kinase - - I-MUT
stress-activated - - I-MUT
protein - - I-MUT
kinase - - I-MUT
pathway - - I-MUT
. - - O

METHODS - - O
: - - O
We - - O
retrospectively - - O
reviewed - - O
242 - - O
adult - - O
cadaveric - - O
renal - - O
transplant - - O
recipients - - O
treated - - O
between - - O
11 - - O
91 - - O
and - - O
5 - - O
97 - - O
. - - O

UV - - O
cross-linking - - O
experiments - - O
show - - O
that - - O
TEP - - B-MUT
has - - O
an - - O
apparent - - O
molecular - - O
mass - - O
of - - O
approximately - - O
65 - - O
kDa - - O
. - - O

Elevated - - O
expression - - O
of - - O
a - - O
previously - - O
uncharacterized - - O
gene - - O
, - - O
SPP381 - - B-MUT
, - - O
efficiently - - O
suppresses - - O
the - - O
growth - - O
and - - O
splicing - - O
defects - - O
of - - O
a - - O
temperature-sensitive - - O
( - - O
Ts - - O
) - - O
mutant - - B-MUT
prp38-1 - - I-MUT
. - - O

Based - - O
on - - O
a - - O
type - - O
I - - O
error - - O
of - - O
0 - - O
. - - O
05 - - O
, - - O
our - - O
study - - O
had - - O
a - - O
power - - O
greater - - O
than - - O
or - - O
equal - - O
to - - O
75% - - O
to - - O
detect - - O
group - - O
differences - - O
in - - O
treatment - - O
effect - - O
of - - O
greater - - O
than - - O
or - - O
equal - - O
to - - O
15% - - O
to - - O
20% - - O
. - - O

Expression - - O
of - - O
activated - - O
Cdc42 - - B-MUT
results - - O
in - - O
the - - O
translocation - - O
of - - O
PKClambda - - B-MUT
from - - O
the - - O
nucleus - - O
into - - O
the - - O
cytosol - - O
, - - O
and - - O
Cdc42 - - B-MUT
and - - O
PKClambda - - B-MUT
colocalize - - O
at - - O
the - - O
plasma - - O
membrane - - O
and - - O
in - - O
the - - O
cytoplasm - - O
. - - O

NPT - - B-MUT
II - - I-MUT
synthesis - - O
, - - O
measured - - O
by - - O
agar - - O
plate - - O
assays - - O
of - - O
kanamycin - - O
resistance - - O
and - - O
by - - O
immunoprecipitation - - O
of - - O
the - - O
NPT - - B-MUT
II - - I-MUT
protein - - I-MUT
, - - O
was - - O
repressed - - O
in - - O
the - - O
presence - - O
of - - O
cysteine - - O
and - - O
derepressed - - O
in - - O
its - - O
absence - - O
. - - O

Also - - O
like - - O
the - - O
thrombin - - B-MUT
receptor - - I-MUT
, - - O
PAR2 - - B-MUT
can - - O
be - - O
activated - - O
by - - O
the - - O
hexapeptide - - O
corresponding - - O
to - - O
its - - O
tethered - - O
ligand - - O
sequence - - O
independent - - O
of - - O
receptor - - O
cleavage - - O
. - - O

The - - O
5' - - O
region - - O
of - - O
ADH5 - - B-MUT
contains - - O
consensus - - O
binding - - O
sites - - O
for - - O
the - - O
transcriptional - - O
regulatory - - O
proteins - - O
, - - O
Sp1 - - B-MUT
, - - O
AP2 - - B-MUT
, - - O
LF-A1 - - B-MUT
, - - O
NF-1 - - B-MUT
, - - O
NF-A2 - - B-MUT
, - - O
and - - O
NF-E1 - - B-MUT
. - - O

Tumor - - B-MUT
necrosis - - I-MUT
factor - - I-MUT
signaling - - O
to - - O
stress-activated - - B-MUT
protein - - I-MUT
kinase - - I-MUT
( - - O
SAPK - - B-MUT
) - - O
Jun - - B-MUT
NH2-terminal - - I-MUT
kinase - - I-MUT
( - - I-MUT
JNK - - O
) - - B-MUT
and - - O
p38 - - O
. - - B-MUT

The - - O
class - - B-MUT
II - - I-MUT
Escherichia - - I-MUT
coli - - I-MUT
alanine - - I-MUT
tRNA - - I-MUT
synthetase - - I-MUT
aminoacylates - - I-MUT
RNA - - I-MUT
miniduplexes - - I-MUT
, - - O
which - - O
reconstruct - - O
the - - O
acceptor - - O
end - - O
of - - O
alanine - - B-MUT
tRNA - - I-MUT
with - - O
the - - O
critical - - O
G3 - - O
: - - O
U70 - - O
base - - O
pair - - O
. - - O

Breast-fed - - O
newborn - - O
infants - - O
synthesize - - O
n-6 - - O
long-chain - - O
polyunsaturated - - O
fatty - - O
acids - - O
already - - O
during - - O
the - - O
first - - O
week - - O
of - - O
life - - O
, - - O
but - - O
the - - O
contribution - - O
of - - O
endogenous - - O
synthesis - - O
to - - O
the - - O
total - - O
plasma - - O
long-chain - - O
polyunsaturated - - O
pool - - O
is - - O
small - - O
. - - O

Elevation - - O
of - - O
intracellular - - O
Ca - - O
( - - O
2+ - - O
) - - O
levels - - O
are - - O
also - - O
involved - - O
because - - O
treatment - - O
with - - O
receptor-associated - - O
protein - - O
, - - O
nifedipine - - O
, - - O
MK801 - - O
, - - O
removal - - O
of - - O
Ca - - O
( - - O
2+ - - O
) - - O
from - - O
the - - O
medium - - O
and - - O
dantrolene - - O
all - - O
served - - O
to - - O
inhibit - - O
calcium - - O
elevation - - O
and - - O
attenuate - - O
the - - O
activation - - O
of - - O
CREB - - B-MUT
. - - O

Ten - - O
days - - O
of - - O
cefadroxil - - O
therapy - - O
was - - O
used - - O
to - - O
treat - - O
44 - - O
children - - O
with - - O
urinary - - O
tract - - O
infection - - O
and - - O
CRP - - B-MUT
values - - O
greater - - O
than - - O
or - - O
equal - - O
to - - O
28 - - O
microgram - - O
ml - - O
( - - O
CRP-positive - - O
group - - O
) - - O
. - - O

Studies - - O
on - - O
the - - O
life - - O
cycle - - O
of - - O
Haplorchis - - O
pumilio - - O
( - - O
Looss - - O
, - - O
1896 - - O
) - - O
Looss - - O
, - - O
1899 - - O
with - - O
morphological - - O
redescription - - O
of - - O
larval - - O
and - - O
adult - - O
stages - - O
. - - O

R - - O
. - - O

The - - O
amino - - O
acid - - O
sequence - - O
alignment - - O
of - - O
TC - - B-MUT
II - - I-MUT
with - - O
that - - O
of - - O
other - - O
Cbl - - B-MUT
binding - - I-MUT
proteins - - I-MUT
( - - O
rat - - B-MUT
intrinsic - - I-MUT
factor - - I-MUT
, - - O
human - - B-MUT
transcobalamin - - I-MUT
I - - I-MUT
and - - O
porcine - - B-MUT
haptocorrin - - I-MUT
) - - O
revealed - - O
only - - O
33% - - O
overall - - O
homology - - O
. - - O

Temperature - - O
dependence - - O
of - - O
the - - O
sublattice - - O
spontaneous - - O
magnetization - - O
of - - O
YBa2Cu3O6 - - O
. - - O

A - - O
reassessment - - O
of - - O
the - - O
prevalence - - O
data - - O
was - - O
carried - - O
out - - O
in - - O
the - - O
southern - - O
province - - O
of - - O
Uusimaa - - O
and - - O
in - - O
the - - O
western - - O
province - - O
of - - O
Vaasa - - O
, - - O
the - - O
prevalence - - O
day - - O
being - - O
January - - O
1 - - O
, - - O
1979 - - O
. - - O

New - - O
technologies - - O
in - - O
diagnosis - - O
and - - O
classification - - O
of - - O
malignancy - - O
. - - O

Me - - O
( - - O
2 - - O
) - - O
SO-induced - - O
neuronal - - O
differentiation - - O
of - - O
N1E-115 - - O
neuroblastoma - - O
cells - - O
increased - - O
both - - O
the - - O
expression - - O
of - - O
the - - O
endogenous - - B-MUT
Ntr-1 - - I-MUT
gene - - I-MUT
and - - O
reporter - - O
genes - - O
driven - - O
by - - O
NTR-1 - - B-MUT
promoter - - I-MUT
sequences - - I-MUT
by - - O
3-4-fold - - O
. - - O

This - - O
phenomenon - - O
may - - O
be - - O
regarded - - O
as - - O
a - - O
variant - - O
of - - O
selective - - O
individual - - O
cell - - O
death - - O
, - - O
currently - - O
referred - - O
to - - O
as - - O
apoptosis - - O
, - - O
which - - O
has - - O
not - - O
been - - O
previously - - O
reported - - O
in - - O
a - - O
case - - O
of - - O
embryonal - - O
rhabdomyosarcoma - - O
. - - O

The - - O
E6 - - B-MUT
E7 - - I-MUT
promoter - - I-MUT
of - - I-MUT
all - - O
genital - - O
human - - O
papillomaviruses - - O
is - - O
responsible - - O
for - - O
expression - - O
of - - O
the - - O
viral - - O
transforming - - B-MUT
genes - - I-MUT
. - - I-MUT

The - - O
effect - - O
of - - O
calcitonin - - B-MUT
, - - O
a - - O
large - - O
amount - - O
of - - O
calcium - - O
given - - O
orally - - O
, - - O
pentagastrin - - O
and - - O
glucagon - - O
on - - O
plasma - - O
47Ca - - O
radioactivity - - O
curves - - O
in - - O
subjects - - O
pretreated - - O
with - - O
47Ca - - O
was - - O
examined - - O
. - - O

CO2 - - O
assimilation - - O
by - - O
chloroplasts - - O
illuminated - - O
on - - O
filter - - O
paper - - O
. - - O

Comparative - - O
analysis - - O
of - - O
various - - O
techniques - - O
of - - O
prostatic - - O
drainage - - O
in - - O
patients - - O
with - - O
chronic - - O
obstructive - - O
prostatitis - - O
The - - O
efficacy - - O
of - - O
prostatic - - O
drainage - - O
using - - O
transurethral - - O
vacuum - - O
aspiration - - O
( - - O
Introl-4 - - O
unit - - O
) - - O
and - - O
transrectal - - O
pneumovibromassage - - O
( - - O
PVM-R-01 - - O
) - - O
was - - O
compared - - O
in - - O
1511 - - O
patients - - O
with - - O
chronic - - O
obstructive - - O
prostatitis - - O
. - - O

As - - O
the - - O
rate - - O
of - - O
protein - - O
synthesis - - O
decreases - - O
during - - O
late - - O
embryogenesis - - O
, - - O
levels - - O
of - - O
SEC-1 - - B-MUT
and - - O
its - - O
cognate - - O
mRNA - - O
decline - - O
precipitously - - O
. - - O

The - - O
presence - - O
of - - O
type - - O
I - - O
hypersensitivity - - O
in - - O
a - - O
subgroup - - O
of - - O
aspergillomas - - O
suggests - - O
an - - O
immunoallergic - - O
component - - O
to - - O
this - - O
disease - - O
which - - O
could - - O
contribute - - O
to - - O
a - - O
chronic - - O
inflammatory - - O
response - - O
to - - O
Aspergillus - - O
in - - O
some - - O
aspergillomas - - O
. - - O

No - - O
TATA - - O
or - - O
Inr - - B-MUT
sequence - - I-MUT
was - - O
found - - O
. - - O

In - - O
the - - O
current - - O
study - - O
, - - O
the - - O
roles - - O
of - - O
two - - O
putative - - O
cis-acting - - O
elements - - O
within - - O
the - - O
-73 - - O
to - - O
+44 - - O
region - - O
in - - O
basal - - O
exon - - O
2 - - O
promoter - - O
activity - - O
were - - O
evaluated - - O
using - - O
mutagenesis - - O
and - - O
nuclear - - O
protein-DNA - - O
binding - - O
assays - - O
. - - O

Radionuclide - - O
angiography - - O
and - - O
static - - O
whole - - O
body - - O
imaging - - O
performed - - O
with - - O
technetium-99m-labeled - - O
particulates - - O
can - - O
clearly - - O
demonstrate - - O
differential - - O
shunting - - O
in - - O
patients - - O
with - - O
patent - - O
ductus - - O
arteriosus - - O
( - - O
PDA - - O
) - - O
with - - O
Eisenmenger - - O
physiology - - O
. - - O

The - - O
evolution - - O
of - - O
the - - O
CCR5 - - B-MUT
cis-regulatory - - I-MUT
region - - I-MUT
versus - - O
the - - O
open - - O
reading - - O
frame - - O
as - - O
well - - O
as - - O
among - - O
different - - O
domains - - O
of - - O
the - - O
open - - O
reading - - O
frame - - O
differed - - O
from - - O
one - - O
another - - O
. - - O

PURPOSE - - O
: - - O
A - - O
two-generation - - O
consanguineous - - O
Pakistani - - O
family - - O
with - - O
autosomal - - O
recessive - - O
Leber - - O
congenital - - O
amaurosis - - O
( - - O
LCA - - O
, - - O
MIM - - O
204 - - O
, - - O
000 - - O
) - - O
and - - O
keratoconus - - O
was - - O
identified - - O
. - - O

Gene - - O
and - - O
pseudogene - - O
of - - O
the - - O
mouse - - O
cation-dependent - - O
mannose - - B-MUT
6-phosphate - - I-MUT
receptor - - I-MUT
. - - O

L-735 - - O
, - - O
524 - - O
free - - O
base - - O
or - - O
sulfate - - O
salt - - O
was - - O
administered - - O
orally - - O
as - - O
suspension - - O
, - - O
solution - - O
or - - O
in - - O
solid - - O
dosage - - O
forms - - O
to - - O
fasted - - O
or - - O
fed - - O
Beagle - - O
dogs - - O
. - - O

The - - O
results - - O
strongly - - O
support - - O
the - - O
notion - - O
that - - O
the - - O
OBF1-binding - - B-MUT
sites - - I-MUT
and - - O
the - - O
OBF1 - - B-MUT
protein - - I-MUT
are - - O
important - - O
for - - O
normal - - O
ARS - - B-MUT
function - - O
as - - O
an - - O
origin - - O
of - - O
replication - - O
. - - O

Moreover - - O
, - - O
in - - O
one - - O
patient - - O
with - - O
a - - O
sarcoma - - O
who - - O
underwent - - O
a - - O
leg-sparing - - O
procedure - - O
, - - O
no - - O
sciatic - - O
nerve - - O
enlargement - - O
was - - O
seen - - O
postoperatively - - O
. - - O

The - - O
GHR - - B-MUT
mRNA - - I-MUT
: - - O
GHBP - - B-MUT
mRNA - - I-MUT
ratio - - O
was - - O
1 - - O
. - - O
1 - - O
+ - - O
- - - O
0 - - O
. - - O
12 - - O
and - - O
remained - - O
unchanged - - O
during - - O
differentiation - - O
. - - O

D - - O
. - - O

After - - O
tilting - - O
, - - O
systolic - - O
blood - - O
pressure - - O
fell - - O
an - - O
average - - O
of - - O
17% - - O
in - - O
patients - - O
who - - O
cramped - - O
infrequently - - O
( - - O
p - - O
= - - O
0 - - O
. - - O
0031 - - O
) - - O
but - - O
only - - O
10% - - O
in - - O
frequently - - O
cramping - - O
patients - - O
. - - O

The - - O
tissue - - O
specificity - - O
of - - O
gene - - O
expression - - O
was - - O
identical - - O
to - - O
that - - O
described - - O
previously - - O
for - - O
the - - O
CaMV - - B-MUT
35S - - I-MUT
domain - - I-MUT
B - - I-MUT
enhancer - - I-MUT
element - - I-MUT
. - - O

Substitution - - O
of - - O
the - - O
Ser-Thr - - O
sites - - O
with - - O
the - - O
phosphomimetic - - O
Asp - - O
generated - - O
a - - O
constitutively - - O
active - - O
form - - O
of - - O
IRF-3 - - B-MUT
that - - O
functioned - - O
as - - O
a - - O
very - - O
strong - - O
activator - - O
of - - O
promoters - - O
containing - - O
PRDI-PRDIII - - B-MUT
or - - O
ISRE - - B-MUT
regulatory - - I-MUT
elements - - I-MUT
. - - O

Palindromic - - O
rheumatism - - O
. - - O

Precipitation - - O
using - - O
GST - - B-MUT
fusion - - I-MUT
proteins - - I-MUT
containing - - O
Fyn - - B-MUT
SH2 - - B-MUT
, - - O
SH3 - - B-MUT
, - - O
and - - O
SH2 - - B-MUT
SH3 - - I-MUT
domains - - I-MUT
revealed - - I-MUT
that - - O
PI - - O
3-kinase - - B-MUT
bound - - I-MUT
principally - - O
to - - O
the - - O
SH3 - - O
domain - - B-MUT
of - - I-MUT
Fyn - - O
. - - B-MUT

Five - - O
of - - O
the - - O
Aeromonas - - O
strains - - O
and - - O
one - - O
of - - O
V - - O
cholerae - - O
non-O1 - - O
were - - O
positive - - O
for - - O
enterotoxin - - B-MUT
activity - - O
. - - O

Northern - - O
blot - - O
analysis - - O
of - - O
total - - O
cellular - - O
RNA - - O
indicated - - O
that - - O
xylP - - B-MUT
encodes - - O
a - - O
1 - - O
. - - O
3-kb - - O
transcript - - O
which - - O
is - - O
induced - - O
by - - O
xylan - - O
. - - O

Effects - - O
of - - O
spatial - - O
and - - O
temporal - - O
smoothing - - O
on - - O
stimulated - - O
brillouin - - O
scattering - - O
in - - O
the - - O
independent-hot-spot - - O
model - - O
limit - - O
The - - O
influence - - O
of - - O
laser - - O
beam - - O
smoothing - - O
on - - O
stimulated - - O
Brillouin - - O
backscattering - - O
( - - O
SBBS - - O
) - - O
is - - O
studied - - O
analytically - - O
in - - O
the - - O
limit - - O
of - - O
the - - O
independent - - O
hot - - O
spot - - O
model - - O
. - - O

A - - O
second - - O
domain - - O
, - - O
located - - O
in - - O
the - - O
C-terminal - - O
437 - - O
amino - - O
acids - - O
of - - O
IE1 - - B-MUT
, - - O
is - - O
required - - O
for - - O
inhibitory - - O
and - - O
DNA-binding - - O
activities - - O
. - - O

Mean - - O
( - - O
+ - - O
- - - O
SE - - O
) - - O
measurements - - O
of - - O
clearance - - O
( - - O
24 - - O
. - - O
5 - - O
+ - - O
- - - O
2 - - O
. - - O
06 - - O
v - - O
26 - - O
. - - O
5 - - O
+ - - O
- - - O
2 - - O
. - - O
05 - - O
mL - - O
min - - O
m2 - - O
) - - O
, - - O
half-life - - O
( - - O
5 - - O
. - - O
7 - - O
+ - - O
- - - O
0 - - O
. - - O
5 - - O
v - - O
6 - - O
. - - O
4 - - O
+ - - O
- - - O
0 - - O
. - - O
5 - - O
hours - - O
) - - O
, - - O
and - - O
volume - - O
of - - O
distribution - - O
( - - O
12 - - O
. - - O
4 - - O
+ - - O
- - - O
1 - - O
. - - O
1 - - O
v - - O
13 - - O
. - - O
7 - - O
+ - - O
- - - O
1 - - O
. - - O
6 - - O
L - - O
m2 - - O
) - - O
were - - O
not - - O
significantly - - O
different - - O
in - - O
patients - - O
with - - O
jaundice - - O
when - - O
compared - - O
with - - O
controls - - O
. - - O

Immunity - - O
acquired - - O
by - - O
mice - - O
during - - O
I - - O
. - - O
scapularis - - O
nymphal - - O
activity - - O
in - - O
early - - O
summer - - O
may - - O
exclude - - O
a - - O
large - - O
proportion - - O
of - - O
the - - O
mouse - - O
population - - O
from - - O
maintaining - - O
E - - O
. - - O
phagocytophila - - O
during - - O
the - - O
period - - O
of - - O
larval - - O
activity - - O
later - - O
in - - O
the - - O
season - - O
. - - O

To - - O
evaluate - - O
the - - O
gas - - O
chromatographic - - O
electron - - O
capture - - O
detection - - O
method - - O
described - - O
earlier - - O
, - - O
23 - - O
plasma - - O
samples - - O
have - - O
been - - O
analysed - - O
by - - O
both - - O
techniques - - O
. - - O

Despite - - O
abundant - - O
expression - - O
of - - O
NtmybAS - - B-MUT
transcripts - - I-MUT
in - - O
mature - - O
pollen - - O
, - - O
gPAL1 - - B-MUT
transcripts - - I-MUT
were - - O
not - - O
detectable - - O
in - - O
pollen - - O
. - - O

Moreover - - O
, - - O
Lck - - B-MUT
was - - O
reversibly - - O
co-immunoprecipitated - - O
with - - O
p95Vav - - B-MUT
, - - O
and - - O
the - - O
stoichiometry - - O
of - - O
binding - - O
increased - - O
in - - O
anti-CD3-treated - - O
Jurkat - - O
cells - - O
. - - O

The - - O
muscles - - O
from - - O
the - - O
ischemic - - O
group - - O
had - - O
significantly - - O
lower - - O
( - - O
P - - O
less - - O
than - - O
. - - O
05 - - O
) - - O
values - - O
for - - O
capillary - - O
density - - O
and - - O
capillary - - O
to - - O
fiber - - O
ratio - - O
and - - O
significantly - - O
higher - - O
intercapillary - - O
distance - - O
than - - O
those - - O
from - - O
the - - O
normal - - O
group - - O
. - - O

For - - O
this - - O
purpose - - O
, - - O
we - - O
used - - O
a - - O
series - - O
of - - O
plasmid - - O
constructs - - O
encoding - - O
different - - O
forms - - O
of - - O
the - - O
envelope - - B-MUT
glycoprotein - - I-MUT
E - - I-MUT
of - - I-MUT
the - - I-MUT
flavivirus - - I-MUT
tick-borne - - I-MUT
encephalitis - - I-MUT
virus - - I-MUT
. - - O

We - - O
constructed - - O
a - - O
yeast - - O
reporter - - O
strain - - O
containing - - O
the - - O
lacZ - - B-MUT
gene - - I-MUT
under - - O
the - - O
control - - O
of - - O
the - - O
CYC1 - - B-MUT
promoter - - I-MUT
associated - - O
with - - O
three - - O
copies - - O
of - - O
TRE-1 - - B-MUT
. - - O

Differences - - O
in - - O
profiles - - O
of - - O
viscosity - - O
variables - - O
between - - O
subgroups - - O
of - - O
EAD - - O
in - - O
RA - - O
patients - - O
were - - O
observed - - O
. - - O

Male - - O
contraception - - O
: - - O
ideas - - O
for - - O
the - - O
future - - O
. - - O

Fifteen - - O
light - - O
for - - O
dates - - O
infants - - O
and - - O
their - - O
placentae - - O
were - - O
compared - - O
to - - O
15 - - O
well-grown - - O
infants - - O
and - - O
their - - O
placentae - - O
. - - O

Although - - O
it - - O
has - - O
two - - O
potential - - O
binding - - O
sites - - O
, - - O
the - - O
purified - - O
MerR - - B-MUT
homodimer - - I-MUT
binds - - O
only - - O
one - - O
Hg - - O
( - - O
II - - O
) - - O
ion - - O
, - - O
employing - - O
Cys82 - - O
from - - O
one - - O
monomer - - O
and - - O
Cys117 - - O
and - - O
Cys126 - - O
from - - O
the - - O
other - - O
. - - O

The - - O
envelope - - B-MUT
glycoproteins - - I-MUT
of - - I-MUT
Rous - - I-MUT
sarcoma - - I-MUT
virus - - I-MUT
( - - I-MUT
RSV - - I-MUT
) - - I-MUT
, - - O
gp85 - - B-MUT
and - - O
gp37 - - B-MUT
, - - O
are - - O
anchored - - O
in - - O
the - - O
membrane - - O
by - - O
a - - O
27-amino - - O
acid - - O
, - - O
hydrophobic - - O
domain - - O
that - - O
lies - - O
adjacent - - O
to - - O
a - - O
22-amino - - O
acid - - O
, - - O
cytoplasmic - - O
domain - - O
at - - O
the - - O
carboxy - - O
terminus - - O
of - - O
gp37 - - B-MUT
. - - O

HupI - - B-MUT
showed - - O
strong - - O
identity - - O
to - - O
rubredoxin - - B-MUT
and - - O
rubredoxin-like - - B-MUT
proteins - - I-MUT
from - - O
many - - O
other - - O
bacteria - - O
. - - O

The - - O
already - - O
elevated - - O
prolactin - - B-MUT
levels - - O
in - - O
nursing - - O
women - - O
were - - O
not - - O
influenced - - O
by - - O
chronic - - O
oestradiol - - O
administration - - O
. - - O

Osteocalcin - - B-MUT
( - - O
serum - - B-MUT
bone-Gla - - I-MUT
protein - - I-MUT
, - - O
sBGP - - B-MUT
) - - O
, - - O
serum - - B-MUT
alkaline - - I-MUT
phosphatase - - I-MUT
( - - O
sAP - - B-MUT
) - - O
and - - O
urinary - - O
hydroxyproline - - O
creatinine - - O
ratio - - O
( - - O
uOH-Prol - - O
creatinine - - O
) - - O
have - - O
been - - O
measured - - O
in - - O
21 - - O
patients - - O
with - - O
primary - - O
hyperparathyroidism - - O
( - - O
PHPT - - O
) - - O
and - - O
in - - O
nine - - O
patients - - O
with - - O
hypercalcaemia - - O
of - - O
malignancy - - O
( - - O
HM - - O
) - - O
. - - O

During - - O
the - - O
conditioning - - O
procedure - - O
, - - O
the - - O
C-fiber - - O
reflex - - O
was - - O
facilitated - - O
( - - O
wind-up - - O
) - - O
in - - O
a - - O
stimulus-dependent - - O
fashion - - O
in - - O
intact - - O
, - - O
anesthetized - - O
animals - - O
during - - O
the - - O
application - - O
of - - O
the - - O
first - - O
seven - - O
conditioning - - O
stimuli - - O
; - - O
thereafter - - O
, - - O
the - - O
magnitude - - O
of - - O
the - - O
responses - - O
reached - - O
a - - O
plateau - - O
and - - O
then - - O
decreased - - O
. - - O

In - - O
35 - - O
of - - O
those - - O
patients - - O
DD - - O
was - - O
measured - - O
also - - O
with - - O
microlatex - - O
tests--Tinaquant - - O
and - - O
BC - - O
d-dimer - - O
. - - O

The - - O
purpose - - O
of - - O
this - - O
article - - O
is - - O
to - - O
discuss - - O
the - - O
factors - - O
involved - - O
in - - O
the - - O
selection - - O
of - - O
antibodies - - O
, - - O
radionuclides - - O
and - - O
labeling - - O
methods - - O
in - - O
the - - O
development - - O
of - - O
radioimmunotherapy - - O
( - - O
RIT - - O
) - - O
for - - O
non-Hodgkin's - - O
lymphoma - - O
( - - O
NHL - - O
) - - O
from - - O
a - - O
single - - O
clinical - - O
study - - O
site - - O
through - - O
multicenter - - O
trials - - O
and - - O
commercialization - - O
. - - O

For - - O
patients - - O
with - - O
recurrent - - O
or - - O
metastatic - - O
disease - - O
, - - O
the - - O
data - - O
suggest - - O
that - - O
I-131 - - O
MIBG - - O
scintigraphy - - O
is - - O
the - - O
examination - - O
of - - O
choice - - O
. - - O

In - - O
contrast - - O
, - - O
the - - O
Anabaena - - O
strain - - O
7120 - - O
leuA - - B-MUT
gene - - O
did - - O
not - - O
complement - - O
the - - O
nifV - - B-MUT
mutation - - I-MUT
of - - O
R229I - - O
efficiently - - O
. - - O

Y15170 - - B-MUT
( - - O
Surf-2 - - B-MUT
, - - O
Surf-4 - - B-MUT
) - - O
, - - O
Y15171 - - B-MUT
( - - O
Surf-3 - - B-MUT
, - - O
Surf-1 - - B-MUT
, - - O
Surf-6 - - B-MUT
) - - O
, - - O
and - - O
Y15172 - - B-MUT
( - - O
Surf-5 - - B-MUT
. - - O
) - - O
] - - O

Yusuf - - O
Dawood - - O
Docrat - - O
L - - O
. - - O
R - - O
. - - O
C - - O
. - - O
P - - O
. - - O

A - - O
total - - O
of - - O
576 - - O
1-day-old - - O
Ross - - O
broiler - - O
chicks - - O
were - - O
housed - - O
in - - O
six - - O
treatment - - O
groups - - O
[ - - O
six - - O
replicates - - O
of - - O
16 - - O
each - - O
; - - O
control - - O
, - - O
CLI - - O
( - - O
15 - - O
g - - O
kg - - O
( - - O
-1 - - O
) - - O
diet - - O
) - - O
, - - O
50 - - O
parts - - O
per - - O
billion - - O
( - - O
ppb - - O
) - - O
AF - - O
, - - O
50 - - O
ppb - - O
AF - - O
plus - - O
CLI - - O
, - - O
100 - - O
ppb - - O
AF - - O
, - - O
100 - - O
ppb - - O
AF - - O
plus - - O
CLI - - O
] - - O
for - - O
42 - - O
days - - O
. - - O

Anti-HBc - - B-MUT
production - - O
of - - O
PBMC - - O
was - - O
enhanced - - O
remarkably - - O
in - - O
this - - O
case - - O
. - - O

The - - O
RNA-binding - - O
and - - O
RNA-DNA - - B-MUT
helicase - - I-MUT
activities - - O
of - - O
the - - O
Escherichia - - B-MUT
coli - - I-MUT
transcription - - I-MUT
termination - - I-MUT
factor - - I-MUT
rho - - I-MUT
have - - O
been - - O
investigated - - O
using - - O
natural - - O
RNA - - O
molecules - - O
that - - O
are - - O
255 - - O
and - - O
391 - - O
nucleotide - - O
residues - - O
in - - O
length - - O
and - - O
that - - O
contain - - O
the - - O
trp - - B-MUT
t' - - I-MUT
rho-dependent - - I-MUT
termination - - I-MUT
sequence - - I-MUT
of - - O
E - - O
. - - O
coli - - O
. - - O

Effects - - O
of - - O
chronic - - O
descending - - O
tractotomy - - O
on - - O
the - - O
response - - O
patterns - - O
of - - O
neurons - - O
in - - O
the - - O
trigeminal - - O
nuclei - - O
principalis - - O
and - - O
oralis - - O
. - - O

Short - - O
therapy - - O
with - - O
omeprazole - - O
20 - - O
mg - - O
b - - O
. - - O
i - - O
. - - O
d - - O
. - - O
, - - O
clarithromycin - - O
500 - - O
mg - - O
b - - O
. - - O
i - - O
. - - O
d - - O
. - - O
, - - O
and - - O
CBS - - O
120 - - O
mg - - O
q - - O
. - - O
i - - O
. - - O
d - - O
. - - O
is - - O
a - - O
safe - - O
, - - O
well - - O
tolerated - - O
combination - - O
that - - O
achieves - - O
a - - O
80 - - O
. - - O
6% - - O
eradication - - O
rate - - O
of - - O
H - - O
. - - O
pylori - - O
and - - O
duodenal - - O
ulcer - - O
healing - - O
rates - - O
as - - O
good - - O
as - - O
those - - O
achieved - - O
by - - O
omeprazole - - O
20 - - O
mg - - O
d - - O
when - - O
given - - O
for - - O
4 - - O
wk - - O
. - - O

Using - - O
adenoviral - - O
transfer - - O
of - - O
IkappaBalpha - - B-MUT
( - - O
IkappaBalpha - - B-MUT
overexpression - - O
) - - O
, - - O
the - - O
production - - O
of - - O
TNF-alpha - - B-MUT
induced - - O
by - - O
whole - - O
GBS - - O
was - - O
inhibited - - O
by - - O
only - - O
20% - - O
. - - O

In - - O
the - - O
present - - O
study - - O
, - - O
we - - O
have - - O
isolated - - O
and - - O
sequenced - - O
several - - O
p15E - - B-MUT
cDNA - - I-MUT
gene - - I-MUT
fragments - - I-MUT
amplified - - O
by - - O
means - - O
of - - O
polymerase - - B-MUT
chain - - O
reaction - - O
( - - O
PCR - - O
) - - O
from - - O
parental - - O
( - - O
P815 - - O
) - - O
and - - O
xenogenized - - O
( - - O
P815 - - O
DTIC - - O
) - - O
tumour - - O
cells - - O
. - - O

Documentation - - O
of - - O
a - - O
successful - - O
intrauterine - - O
fertilization - - O
with - - O
delivery - - O
of - - O
a - - O
term - - O
baby - - O
supports - - O
the - - O
theoretical - - O
feasibility - - O
of - - O
the - - O
EP - - O
; - - O
however - - O
, - - O
anovulation - - O
incurred - - O
by - - O
our - - O
procedure - - O
appears - - O
to - - O
be - - O
the - - O
major - - O
drawback - - O
. - - O

4 - - O
. - - O
26 - - O
+ - - O
- - - O
1 - - O
. - - O
54 - - O
mmol - - O
l - - O
, - - O
P - - O
< - - O
0 - - O
. - - O
01 - - O
) - - O
, - - O
and - - O
systolic - - O
BP - - O
responses - - O
to - - O
intravenous - - O
norepinephrine - - O
and - - O
angiotensin - - O
II - - O
were - - B-MUT
significantly - - I-MUT
higher - - O
on - - O
glibenclamide - - O
than - - O
on - - O
metformin - - O
( - - O
P - - O
< - - O
0 - - O
. - - O
02 - - O
and - - O
P - - O
< - - O
0 - - O
. - - O
05 - - O
, - - O
respectively - - O
) - - O
. - - O

Experimental - - O
chlorpromazine - - O
cataracts - - O
. - - O

Interactions - - O
between - - O
adrenergics - - O
, - - O
adrenolytics - - O
and - - O
monoamine - - B-MUT
oxidase - - I-MUT
inhibitors - - O
. - - O

Leukocyte - - O
cultures - - O
, - - O
prepared - - O
from - - O
blood - - O
drawn - - O
from - - O
these - - O
18 - - O
children - - O
at - - O
6 - - O
months - - O
of - - O
age - - O
, - - O
produced - - O
lower - - O
yields - - O
of - - O
IFN - - B-MUT
than - - O
those - - O
of - - O
the - - O
remaining - - O
53 - - O
children - - O
, - - O
when - - O
stimulated - - O
with - - O
adenovirus - - O
( - - O
P - - O
< - - O
0 - - O
. - - O
001 - - O
) - - O
, - - O
coronavirus - - O
( - - O
P - - O
< - - O
0 - - O
. - - O
001 - - O
) - - O
or - - O
rhinovirus - - O
( - - O
P - - O
= - - O
0 - - O
. - - O
002 - - O
) - - O
. - - O

Using - - O
the - - O
yeast - - O
two-hybrid - - O
system - - O
to - - O
screen - - O
for - - O
proteins - - O
which - - O
interact - - O
with - - O
Tax1 - - B-MUT
, - - O
we - - O
isolated - - O
the - - O
B - - O
subunit - - O
of - - O
the - - O
CCAAT - - B-MUT
binding - - I-MUT
protein - - I-MUT
NF-Y - - B-MUT
from - - O
a - - O
HeLa - - O
cDNA - - O
library - - O
. - - O

Amisulpride - - O
400 - - O
mg - - O
had - - O
several - - O
adverse - - O
effects - - O
on - - O
psychomotor - - O
and - - O
, - - O
although - - O
less - - O
severe - - O
, - - O
on - - O
cognitive - - O
performance - - O
on - - O
the - - O
fifth - - O
day - - O
only - - O
. - - O

The - - O
pharmacokinetic - - O
profiles - - O
of - - O
digoxin - - O
and - - O
warfarin - - O
were - - O
not - - O
altered - - O
by - - O
the - - O
simultaneous - - O
and - - O
continued - - O
administration - - O
of - - O
sevelamer - - O
. - - O

Band-shift - - O
assays - - O
and - - O
DNase - - B-MUT
I - - I-MUT
footprinting - - O
experiments - - O
using - - O
purified - - O
42 - - O
kDa - - O
repressor - - O
isoform - - O
confirmed - - O
that - - O
CIRs - - B-MUT
5 - - I-MUT
and - - I-MUT
6 - - I-MUT
were - - O
indeed - - O
the - - O
targets - - O
for - - O
binding - - O
of - - O
this - - O
protein - - O
. - - O

Immediate-early - - O
transcription - - O
from - - O
the - - O
channel - - O
catfish - - O
virus - - O
genome - - O
: - - O
characterization - - O
of - - O
two - - O
immediate-early - - B-MUT
transcripts - - I-MUT
. - - O

The - - O
average - - O
backscatter - - O
coefficient - - O
was - - O
six - - O
time - - O
larger - - O
in - - O
regions - - O
of - - O
infarct - - O
studied - - O
8--10 - - O
weeks - - O
after - - O
occlusion - - O
than - - O
that - - O
in - - O
regions - - O
of - - O
infarct - - O
studied - - O
5--6 - - O
weeks - - O
after - - O
occlusion - - O
. - - O

INTERVENTIONS - - O
: - - O
Study - - O
patients - - O
were - - O
randomly - - O
divided - - O
into - - O
four - - O
parallel - - O
groups - - O
to - - O
receive - - O
either - - O
terbinafine - - O
250 - - O
mg - - O
a - - O
day - - O
for - - O
12 - - O
or - - O
16 - - O
weeks - - O
( - - O
groups - - O
T12 - - O
and - - O
T16 - - O
) - - O
or - - O
itraconazole - - O
400 - - O
mg - - O
a - - O
day - - O
for - - O
1 - - O
week - - O
in - - O
every - - O
4 - - O
weeks - - O
for - - O
12 - - O
or - - O
16 - - O
weeks - - O
( - - O
groups - - O
I3 - - O
and - - O
I4 - - O
) - - O
. - - O

However - - O
, - - O
limited - - O
comparisons - - O
reveal - - O
domains - - O
in - - O
the - - O
NH2 - - O
and - - O
COOH - - O
termini - - O
that - - O
have - - O
a - - O
high - - O
degree - - O
of - - O
similarity - - O
suggesting - - O
functional - - O
conservation - - O
. - - O

Interaction - - O
of - - O
HRI - - B-MUT
with - - O
Hsc70 - - B-MUT
was - - O
required - - O
for - - O
the - - O
transformation - - O
of - - O
HRI - - B-MUT
, - - O
as - - O
the - - O
Hsc70 - - B-MUT
antagonist - - O
clofibric - - O
acid - - O
inhibited - - O
the - - O
folding - - O
of - - O
HRI - - B-MUT
into - - O
a - - O
mature-competent - - O
conformation - - O
. - - O

The - - O
levels - - O
of - - O
transactivation - - O
are - - O
correlated - - O
with - - O
the - - O
respective - - O
binding - - O
affinities - - O
of - - O
the - - O
response - - O
elements - - O
( - - O
IRper-1 - - B-MUT
> - - O
DR-4 - - B-MUT
> - - O
IRhsp-1 - - B-MUT
) - - O
. - - O

Long-term - - O
results - - O
with - - O
MACOP-B - - O
and - - O
radiation - - O
therapy - - O
for - - O
aggressive - - O
lymphomas - - O
BACKGROUND - - O
: - - O
Long-term - - O
results - - O
are - - O
needed - - O
to - - O
evaluate - - O
chemotherapy - - O
regimens - - O
and - - O
prognostic - - O
factors - - O
in - - O
non-Hodgkin's - - O
lymphomas - - O
( - - O
NHL - - O
) - - O
. - - O

In - - O
analyses - - O
with - - O
control - - O
for - - O
multiple - - O
variables - - O
, - - O
relative - - O
risk - - O
for - - O
microalbuminuria - - O
( - - O
urinary - - O
albumin - - B-MUT
excretion - - O
, - - O
20-199 - - O
microg - - O
min - - O
) - - O
in - - O
men - - O
and - - O
women - - O
was - - O
2 - - O
. - - O
51 - - O
and - - O
1 - - O
. - - O
62 - - O
, - - O
respectively - - O
, - - O
with - - O
18 - - O
mm - - O
Hg - - O
higher - - O
( - - O
1 - - O
SD - - O
) - - O
systolic - - O
blood - - O
pressure - - O
; - - O
2 - - O
. - - O
25 - - O
and - - O
2 - - O
. - - O
10 - - O
, - - O
respectively - - O
, - - O
with - - O
1 - - O
. - - O
0-mmol - - O
L - - O
( - - O
40 - - O
mg - - O
dL - - O
) - - O
higher - - O
plasma - - O
cholesterol - - O
level - - O
; - - O
1 - - O
. - - O
99 - - O
and - - O
1 - - O
. - - O
91 - - O
, - - O
respectively - - O
, - - O
for - - O
smokers - - O
vs - - O
nonsmokers - - O
; - - O
and - - O
1 - - O
. - - O
83 - - O
and - - O
1 - - O
. - - O
33 - - O
, - - O
respectively - - O
, - - O
with - - O
4 - - O
kg - - O
m2 - - O
higher - - O
body - - O
mass - - O
index - - O
. - - O

Solving - - O
an - - O
age - - O
old - - O
problem - - O
. - - O

DNA - - O
sequencing - - O
of - - O
a - - O
17-kb - - O
segment - - O
encompassing - - O
a - - O
gammaherpesvirus - - O
divergent - - O
locus - - O
( - - O
DL-B - - O
) - - O
between - - O
ORF11 - - O
and - - O
ORF17 - - O
revealed - - O
the - - O
presence - - O
of - - O
nine - - O
viral - - O
ORFs - - O
with - - O
predicted - - O
gene - - O
products - - O
related - - O
to - - O
cellular - - O
proteins - - O
. - - O

Here - - O
we - - O
describe - - O
the - - O
cloning - - O
, - - O
tissue-specific - - O
expression - - O
pattern - - O
, - - O
and - - O
functional - - O
characterization - - O
of - - O
two - - O
novel - - O
TEF-1 - - B-MUT
isoforms - - I-MUT
, - - O
TEF-1beta - - B-MUT
and - - O
TEF-1gamma - - B-MUT
. - - O

The - - O
RFLP - - O
patterns - - O
of - - O
the - - O
isolates - - O
from - - O
six - - O
of - - O
these - - O
patients - - O
remained - - O
essentially - - O
unchanged - - O
( - - O
two - - O
strains - - O
showed - - O
one - - O
additional - - O
band - - O
) - - O
despite - - O
the - - O
development - - O
of - - O
drug - - O
resistance - - O
. - - O

Max - - B-MUT
: - - O
functional - - O
domains - - O
and - - O
interaction - - O
with - - O
c-Myc - - B-MUT
. - - O

Conversely - - O
, - - O
treatment - - O
of - - O
human - - B-MUT
protein-tyrosine - - I-MUT
phosphatase - - I-MUT
alpha-overexpressing - - O
cells - - O
with - - O
phenylarsine - - O
oxide - - O
led - - O
to - - O
a - - O
loss - - O
of - - O
the - - O
constitutive - - O
NF-kappa - - B-MUT
B - - I-MUT
activity - - O
. - - O

2 - - O
cases - - O
of - - O
toxic - - O
lymphomononucleosis - - O
. - - O

Studies - - O
on - - O
the - - O
pathogenicity - - O
of - - O
ECHO - - O
9 - - O
( - - O
HILL - - O
) - - O
virus - - O
and - - O
its - - O
mutants - - O
for - - O
suckling - - O
mice - - O
. - - O

1 - - O
, - - O
among - - O
which - - O
nine - - O
have - - O
been - - O
cloned - - O
and - - O
two - - O
( - - O
potentially - - O
functional - - O
) - - O
sequenced - - O
. - - O

Using - - O
immunogold - - O
electron - - O
microscopy - - O
, - - O
we - - O
found - - O
that - - O
p58 - - B-MUT
p45 - - I-MUT
and - - I-MUT
p54 - - O
are - - B-MUT
localized - - O
on - - O
both - - O
sides - - O
of - - O
the - - O
nuclear - - O
pore - - O
complex - - O
, - - O
like - - O
p62 - - O
. - - B-MUT

HEF1 - - B-MUT
, - - O
p130 - - B-MUT
( - - I-MUT
Cas - - I-MUT
) - - I-MUT
, - - O
and - - O
Efs - - B-MUT
Sin - - I-MUT
constitute - - I-MUT
a - - O
family - - O
of - - O
multidomain - - O
docking - - O
proteins - - O
that - - O
have - - O
been - - O
implicated - - O
in - - O
coordinating - - O
the - - O
regulation - - O
of - - O
cell - - O
adhesion - - O
. - - O

Role - - O
of - - O
biocenosis - - O
in - - O
the - - O
manifestation - - O
of - - O
Shigella - - O
virulence - - O
. - - O

Among - - O
mammalian - - B-MUT
HSFs - - I-MUT
, - - O
HSF1 - - B-MUT
has - - O
been - - O
shown - - O
to - - O
be - - O
important - - O
for - - O
regulation - - O
of - - O
the - - O
heat-induced - - B-MUT
stress - - I-MUT
gene - - I-MUT
expression - - O
, - - O
whereas - - O
the - - O
function - - O
of - - O
HSF2 - - B-MUT
in - - O
stress - - O
response - - O
is - - O
unclear - - O
. - - O

In - - O
all - - O
cells - - O
, - - O
the - - O
accumulation - - O
of - - O
high - - O
Dsg - - B-MUT
protein - - I-MUT
levels - - O
required - - O
calcium - - O
and - - O
was - - O
not - - O
observed - - O
in - - O
low - - O
calcium - - O
( - - O
0 - - O
. - - O
05-0 - - O
. - - O
07 - - O
mM - - O
) - - O
media - - O
. - - O

Point - - O
mutations - - O
that - - O
suppressed - - O
the - - O
in - - O
vitro - - O
binding - - O
of - - O
NF-Y - - B-MUT
to - - O
the - - O
internal - - O
palindromic - - O
arm - - O
reduced - - O
the - - O
activity - - O
of - - O
the - - O
resident - - O
P4 - - B-MUT
promoter - - I-MUT
, - - O
while - - O
those - - O
preventing - - O
complex - - O
formation - - O
with - - O
USF - - B-MUT
did - - O
not - - O
, - - O
as - - O
determined - - O
by - - O
transient - - O
expression - - O
assays - - O
using - - O
the - - O
luciferase - - B-MUT
reporter - - O
gene - - O
. - - O

Two - - O
specific - - O
DNA-protein - - O
complexes - - O
were - - O
identified - - O
in - - O
gel - - O
retardation - - O
assays - - O
using - - O
HeLa - - O
cell - - O
nuclear - - O
extracts - - O
and - - O
an - - O
oligonucleotide - - O
probe - - O
spanning - - O
the - - O
footprinted - - O
region - - O
. - - O

We - - O
present - - O
a - - O
case - - O
of - - O
type - - O
II - - O
hyperbetalipoproteinemia - - O
in - - O
a - - O
patient - - O
whose - - O
diagnosis - - O
had - - O
been - - O
previously - - O
unrecognized - - O
, - - O
and - - O
who - - O
had - - O
previously - - O
been - - O
misdiagnosed - - O
with - - O
rheumatoid - - O
arthritis - - O
and - - O
later - - O
gout - - O
. - - O

We - - O
found - - O
that - - O
the - - O
SOCS - - B-MUT
box - - I-MUT
interacted - - O
with - - O
Cullin-2 - - B-MUT
and - - O
promoted - - O
ubiquitination - - O
of - - O
TEL-JAK2 - - B-MUT
. - - O

TPA - - O
and - - O
TGF-beta - - B-MUT
1 - - I-MUT
did - - O
not - - O
markedly - - O
affect - - O
the - - O
activities - - O
of - - O
the - - O
72-kDa - - O
enzyme - - O
. - - O

The - - O
remaining - - O
six - - O
patients - - O
had - - O
slightly - - O
decreased - - O
( - - O
n - - O
= - - O
3 - - O
) - - O
or - - O
normal - - O
( - - O
n - - O
= - - O
3 - - O
) - - O
seminal - - O
parameters - - O
. - - O

AMY-1 - - B-MUT
was - - O
localized - - O
in - - O
the - - O
cytoplasm - - O
in - - O
cells - - O
expressing - - O
c-myc - - B-MUT
at - - O
low - - O
levels - - O
, - - O
but - - O
in - - O
the - - O
nucleus - - O
in - - O
the - - O
cells - - O
of - - O
a - - O
high - - O
c-myc - - B-MUT
expression - - O
in - - O
transiently - - O
transfected - - O
cells - - O
. - - O

Methysergide - - O
is - - O
a - - O
serotonin - - O
antagonist - - O
and - - O
has - - O
been - - O
demonstrated - - O
to - - O
reduce - - O
wound - - O
blood - - O
flow - - O
and - - O
edema - - O
formation - - O
. - - O

Imposed - - O
angular - - O
displacements - - O
of - - O
monkey's - - O
wrist - - O
produce - - O
three - - O
major - - O
peaks - - O
of - - O
activity - - O
( - - O
terms - - O
M1 - - O
, - - O
M2 - - O
, - - O
and - - O
M3 - - O
peaks - - O
) - - O
in - - O
the - - O
averaged - - O
gross - - O
EMG - - O
activity - - O
ot - - O
the - - O
stretched - - O
muscles - - O
. - - O

Because - - O
the - - O
adrenergic - - O
nervous - - O
system - - O
influences - - O
cardiac - - O
arrhythmias - - O
and - - O
myocardial - - O
infarction - - O
can - - O
directly - - O
affect - - O
sympathetic - - O
innervation - - O
in - - O
the - - O
heart - - O
, - - O
we - - O
investigated - - O
the - - O
role - - O
of - - O
the - - O
sympathetic - - O
nervous - - O
system - - O
on - - O
reentry - - O
in - - O
the - - O
canine - - O
heart - - O
4 - - O
days - - O
after - - O
infarction - - O
. - - O

Though - - O
the - - O
BACTEC - - O
9000 - - O
MB - - O
system - - O
is - - O
recommended - - O
for - - O
respiratory - - O
specimens - - O
, - - O
we - - O
demonstrated - - O
that - - O
it - - O
can - - O
be - - O
successfully - - O
used - - O
also - - O
for - - O
recovery - - O
of - - O
mycobacteria - - O
from - - O
clinical - - O
specimens - - O
from - - O
various - - O
extrapulmonary - - O
sites - - O
. - - O

HL - - O
02 - - O
type - - O
oculomotor - - O
stimulator - - O
. - - O

OBJECTIVE - - O
: - - O
This - - O
meta-analysis - - O
of - - O
67 - - O
controlled - - O
trials - - O
was - - O
performed - - O
to - - O
quantify - - O
the - - O
cholesterol-lowering - - O
effect - - O
of - - O
major - - O
dietary - - O
fibers - - O
. - - O

Among - - O
these - - O
are - - O
: - - O
( - - O
1 - - O
) - - O
Is - - O
there - - O
sufficient - - O
understanding - - O
of - - O
family - - O
pathophysiology - - O
, - - O
of - - O
the - - O
sensitivity - - O
and - - O
specificity - - O
of - - O
diagnostic - - O
techniques - - O
and - - O
of - - O
the - - O
safety - - O
and - - O
efficacy - - O
of - - O
therapeutic - - O
modalities - - O
to - - O
make - - O
true - - O
family - - O
health - - O
care - - O
possible - - O
? - - O
( - - O
2 - - O
) - - O
If - - O
this - - O
type - - O
of - - O
care - - O
is - - O
possible - - O
, - - O
how - - O
are - - O
the - - O
needs - - O
of - - O
the - - O
family - - O
and - - O
its - - O
individual - - O
members - - O
met - - O
, - - O
or - - O
value - - O
judgements - - O
made - - O
about - - O
their - - O
relative - - O
importance - - O
? - - O
and - - O
( - - O
3 - - O
) - - O
What - - O
are - - O
the - - O
consequences - - O
for - - O
the - - O
health - - O
care - - O
delivery - - O
system - - O
of - - O
this - - O
type - - O
of - - O
care - - O
? - - O
An - - O
extensive - - O
literature - - O
review - - O
is - - O
used - - O
in - - O
an - - O
attempt - - O
to - - O
answer - - O
these - - O
queries - - O
, - - O
from - - O
which - - O
questions - - O
for - - O
further - - O
study - - O
are - - O
posed - - O
. - - O

These - - O
studies - - O
suggest - - O
an - - O
additional - - O
component - - O
or - - O
cellular - - O
environment - - O
is - - O
required - - O
for - - O
SPRK - - B-MUT
activation - - O
by - - O
Cdc42 - - B-MUT
. - - O

The - - O
response - - O
of - - O
serum - - B-MUT
GH - - I-MUT
to - - O
arginine - - O
infusion - - O
was - - O
normal - - O
, - - O
while - - O
that - - O
to - - O
insulin-induced - - O
hypoglycemia - - O
was - - O
poor - - O
. - - O

Convulsive - - O
status - - O
epilepticus - - O
after - - O
infusion - - O
of - - O
cisplatin - - O
. - - O

NDRF - - B-MUT
NeuroD2 - - I-MUT
was - - I-MUT
co-precipitated - - O
with - - O
PKN - - O
from - - B-MUT
the - - O
lysate - - O
of - - O
COS-7 - - O
cells - - O
transfected - - O
with - - O
both - - O
expression - - O
constructs - - O
for - - O
NDRF - - O
NeuroD2 - - B-MUT
and - - I-MUT
PKN - - I-MUT
. - - O

Effect - - O
of - - O
trauma - - O
on - - O
plasma - - B-MUT
glucagon - - I-MUT
and - - O
insulin - - B-MUT
concentrations - - O
in - - O
sheep - - O
. - - O

While - - O
blood - - O
pressure - - O
and - - O
noradrenergic - - O
activity - - O
, - - O
assessed - - O
as - - O
changes - - O
in - - O
the - - O
plasma - - O
levels - - O
and - - O
urinary - - O
excretion - - O
of - - O
norepinephrine - - O
, - - O
remained - - O
unaffected - - O
in - - O
the - - O
Pl - - O
group - - O
, - - O
a - - O
significant - - O
drop - - O
in - - O
the - - O
supine - - O
systolic - - O
and - - O
diastolic - - O
blood - - O
pressures - - O
, - - O
as - - O
well - - O
as - - O
in - - O
the - - O
resting - - O
venous - - O
norepinephrine - - O
level - - O
and - - O
in - - O
urinary - - O
norepinephrine - - O
excretion - - O
was - - O
found - - O
after - - O
the - - O
first - - O
month - - O
of - - O
dF - - O
administration - - O
. - - O

In - - O
vitro - - O
protein - - O
retention - - O
experiments - - O
in - - O
which - - O
Hsp90 - - B-MUT
heterocomplexes - - I-MUT
were - - O
precipitated - - O
resulted - - O
in - - O
coprecipitation - - O
of - - O
Cns1 - - B-MUT
. - - O

We - - O
have - - O
identified - - O
two - - O
functional - - O
elements - - O
, - - O
both - - O
located - - O
downstream - - O
from - - O
the - - O
TATA - - O
motif - - O
, - - O
that - - O
control - - O
Id4 - - B-MUT
promoter - - I-MUT
activity - - O
. - - O

Four - - O
of - - O
these - - O
five - - O
subjects - - O
also - - O
performed - - O
mixed - - O
sequences - - O
under - - O
conditional - - O
control - - O
of - - O
the - - O
words - - O
( - - O
e - - O
. - - O
g - - O
. - - O
, - - O
A1----B2----A3----B4----A5 - - O
and - - O
its - - O
reversal - - O
) - - O
, - - O
verifying - - O
that - - O
the - - O
stimuli - - O
which - - O
occupied - - O
the - - O
same - - O
position - - O
in - - O
each - - O
sequence - - O
were - - O
members - - O
of - - O
the - - O
same - - O
class - - O
. - - O

This - - O
inhibitory - - O
domain - - O
has - - O
been - - O
deleted - - O
in - - O
all - - O
naturally - - O
occurring - - O
AHC - - B-MUT
deletion - - I-MUT
mutants - - I-MUT
described - - O
to - - O
date - - O
. - - O

Zhu - - O
, - - O
V - - O
. - - O

The - - O
xylose - - B-MUT
isomerase-encoding - - I-MUT
gene - - I-MUT
( - - O
xylA - - B-MUT
) - - O
of - - O
Clostridium - - O
thermosaccharolyticum - - O
: - - O
cloning - - O
, - - O
sequencing - - O
and - - O
phylogeny - - O
of - - O
XylA - - B-MUT
enzymes - - I-MUT
. - - O

Two - - O
disulphide - - O
bridges - - O
, - - O
which - - O
are - - O
conserved - - O
in - - O
all - - O
spermadhesin - - O
molecules - - O
and - - O
many - - O
CUB - - B-MUT
domains - - I-MUT
, - - O
crosslink - - O
loop - - O
LA - - O
and - - O
strand - - O
beta - - O
4 - - O
and - - O
loops - - O
LE - - O
and - - O
LG - - O
, - - O
respectively - - O
, - - O
at - - O
opposite - - O
edges - - O
of - - O
the - - O
same - - O
face - - O
of - - O
the - - O
domain - - O
. - - O

A - - O
. - - O

Etiopathogenetic - - O
and - - O
therapeutic - - O
problems - - O
in - - O
acute - - O
orbital - - O
inflammation - - O
. - - O

Detection - - O
of - - O
anti-lymphocyte - - O
antibodies - - O
using - - O
the - - O
immunoperoxidase - - B-MUT
antiglobulin - - B-MUT
technic - - O
. - - O

Remarkably - - O
, - - O
both - - O
TTD-A - - O
and - - O
XP-D - - O
defects - - O
are - - O
associated - - O
with - - O
subunits - - O
of - - O
TFIIH - - B-MUT
, - - O
a - - O
basal - - O
transcription - - O
factor - - O
with - - O
a - - O
second - - O
function - - O
in - - O
DNA - - O
repair - - O
. - - O

Monotherapy - - O
with - - O
ceftazidime - - O
was - - O
clinically - - O
and - - O
bacteriologically - - O
as - - O
effective - - O
as - - O
a - - O
combination - - O
therapy - - O
with - - O
cefazolin - - O
and - - O
tobramycin - - O
. - - O

The - - O
skp1+ - - B-MUT
gene - - I-MUT
is - - O
not - - O
essential - - O
. - - O

Sequence - - O
analysis - - O
of - - O
the - - O
sMtCK - - B-MUT
genomic - - I-MUT
upstream - - I-MUT
sequences - - I-MUT
reveals - - O
a - - O
typical - - O
TATAA - - O
box - - O
within - - O
the - - O
80 - - O
base - - O
pairs - - O
( - - O
bp - - O
) - - O
that - - O
, - - O
by - - O
transfection - - O
experiments - - O
, - - O
are - - O
sufficient - - O
to - - O
promote - - O
expression - - O
of - - O
chimeric - - O
plasmids - - O
with - - O
the - - O
chloramphenicol - - B-MUT
acetyltransferase - - I-MUT
reporter - - I-MUT
. - - O

To - - O
evaluate - - O
the - - O
effects - - O
of - - O
propranolol - - O
on - - O
myocardial - - O
metabolism - - O
after - - O
coronary - - O
reperfusion - - O
, - - O
serial - - O
measurements - - O
of - - O
myocardial - - B-MUT
creatine - - I-MUT
kinase - - I-MUT
( - - O
CK - - B-MUT
) - - O
and - - O
calcium - - O
( - - O
Ca - - O
) - - O
contents - - O
and - - O
CK - - B-MUT
and - - O
lactic - - O
acid - - O
( - - O
LA - - O
) - - O
concentrations - - O
in - - O
coronary - - O
sinus - - O
blood - - O
were - - O
carried - - O
out - - O
in - - O
33 - - O
open-chest - - O
dogs - - O
. - - O

Titration - - O
of - - O
the - - O
human - - O
and - - O
porcine - - O
proteins - - O
with - - O
2-nitro-5-thiosulfabenzoate - - O
indicates - - O
that - - O
membrane - - B-MUT
dipeptidase - - I-MUT
additionally - - O
possesses - - O
two - - O
intrachain - - O
disulfide - - O
bonds - - O
. - - O

The - - O
first - - O
identification - - O
of - - O
the - - O
active - - B-MUT
37LRP - - I-MUT
p40 - - I-MUT
gene - - I-MUT
presented - - I-MUT
in - - O
this - - O
study - - O
is - - O
a - - O
critical - - O
step - - O
toward - - O
the - - O
isolation - - O
of - - O
the - - O
corresponding - - O
human - - O
gene - - O
and - - O
the - - O
understanding - - O
of - - O
the - - O
molecular - - O
mechanisms - - O
involved - - O
in - - O
the - - O
up-regulation - - O
of - - O
its - - O
expression - - O
during - - O
tumor - - O
invasion - - O
and - - O
metastasis - - O
. - - O

Analyses - - O
of - - O
additional - - O
tumors - - O
induced - - O
in - - O
mice - - O
from - - O
two - - O
reciprocal - - O
crosses - - O
, - - O
A - - O
J - - O
x - - O
C3H - - O
HeJ - - O
F1 - - O
( - - O
hereafter - - O
called - - O
AC3F1 - - O
) - - O
and - - O
C3H - - O
HeJ - - O
x - - O
A - - O
J - - O
F1 - - O
( - - O
hereafter - - O
called - - O
C3AF1 - - O
) - - O
, - - O
provided - - O
evidence - - O
for - - O
the - - O
inactivation - - O
of - - O
one - - O
allele - - O
of - - O
the - - O
putative - - O
chromosome - - O
4 - - O
tumor - - O
suppressor - - O
gene - - O
by - - O
parental - - O
imprinting - - O
. - - O

On - - O
the - - O
other - - O
hand - - O
, - - O
if - - O
the - - O
measured - - O
angle - - O
ANB - - O
is - - O
smaller - - O
than - - O
the - - O
calculated - - O
angle - - O
, - - O
the - - O
skeletal - - O
relation - - O
is - - O
Class - - O
III - - O
. - - O

Venkatesan - - O
, - - O
and - - O
D - - O
. - - O

The - - O
lack - - O
of - - O
the - - O
C2 - - B-MUT
domain - - I-MUT
of - - O
the - - O
Ca - - B-MUT
( - - I-MUT
2+ - - I-MUT
) - - I-MUT
-dependent - - I-MUT
PKCs - - I-MUT
and - - O
the - - O
presence - - O
of - - O
a - - O
unique - - O
NH2-terminal - - O
sequence - - O
with - - O
a - - O
potential - - O
signal - - O
peptide - - O
and - - O
a - - O
transmembrane - - O
domain - - O
suggest - - O
that - - O
PKC - - B-MUT
mu - - I-MUT
is - - O
a - - O
novel - - O
member - - O
of - - O
the - - O
subgroup - - O
of - - O
atypical - - O
PKCs - - B-MUT
. - - O

However - - O
, - - O
whether - - O
or - - O
not - - O
nonsense - - O
codon - - O
recognition - - O
within - - O
TPI - - B-MUT
transcripts - - I-MUT
takes - - O
place - - O
prior - - O
to - - O
or - - O
after - - O
splicing - - O
remained - - O
unresolved - - O
. - - O

18F - - O
and - - O
85Sr - - O
scintimetry - - O
in - - O
the - - O
study - - O
of - - O
primary - - O
arthropathies - - O
. - - O

Separation - - O
of - - O
ninhydrin-positive - - O
compounds - - O
in - - O
urine - - O
by - - O
the - - O
combined - - O
methods - - O
of - - O
medium-tension - - O
intophoresis - - O
and - - O
partition - - O
chromatography - - O
. - - O

Molecular - - O
analysis - - O
of - - O
the - - O
pRA2 - - O
partitioning - - O
region - - O
: - - O
ParB - - B-MUT
autoregulates - - O
parAB - - B-MUT
transcription - - O
and - - O
forms - - O
a - - O
nucleoprotein - - O
complex - - O
with - - O
the - - O
plasmid - - O
partition - - O
site - - O
, - - O
parS - - B-MUT
. - - O

The - - O
5' - - O
untranslated - - O
and - - O
coding - - O
regions - - O
are - - O
contained - - O
within - - O
12 - - O
exons - - O
, - - O
with - - O
the - - O
translation - - O
start - - O
site - - O
located - - O
within - - O
the - - O
first - - O
exon - - O
. - - O

A - - O
mutation - - O
in - - O
the - - O
C - - O
domain - - O
of - - O
Rb - - B-MUT
, - - O
L901Q - - O
, - - O
has - - O
been - - O
identified - - O
that - - O
completely - - O
abolishes - - O
cdk4 - - B-MUT
D1 - - I-MUT
phosphorylation - - I-MUT
of - - O
the - - O
isolated - - O
C - - O
domain - - O
. - - O

Specific - - O
clotting - - O
factor - - O
assays - - O
showed - - O
an - - O
isolated - - O
deficiency - - O
of - - O
factor - - B-MUT
X - - I-MUT
ranging - - O
from - - O
7 - - O
to - - O
12 - - O
per - - O
cent - - O
on - - O
three - - O
determinations - - O
. - - O

Thus - - O
RV - - O
O2 - - O
demand - - O
fell - - O
when - - O
RC - - O
O2 - - O
supply - - O
was - - O
reduced - - O
, - - O
although - - O
a - - O
flow - - O
reserve - - O
was - - O
available - - O
. - - O

These - - O
data - - O
should - - O
be - - O
useful - - O
in - - O
developing - - O
reagents - - O
for - - O
heterozygote - - O
detection - - O
and - - O
prenatal - - O
diagnosis - - O
of - - O
11 - - B-MUT
beta-hydroxylase - - I-MUT
deficiency - - O
, - - O
the - - O
second - - O
most - - O
frequent - - O
cause - - O
of - - O
congenital - - O
adrenal - - O
hyperplasia - - O
. - - O

These - - O
exons - - O
, - - O
further - - O
identified - - O
as - - O
exons - - O
9 - - O
, - - O
10 - - O
, - - O
and - - O
11 - - O
, - - O
together - - O
encode - - O
the - - O
37 - - O
amino - - O
acid - - O
residues - - O
present - - O
in - - O
alpha - - B-MUT
s1-casein - - I-MUT
variant - - I-MUT
A - - I-MUT
but - - O
missing - - O
in - - O
variant - - O
F - - O
. - - O

Since - - O
1970 - - O
the - - O
frequency - - O
of - - O
potassium-induced - - O
ulceration - - O
has - - O
been - - O
low--3 - - O
cases - - O
per - - O
100 - - O
000 - - O
patient-years - - O
of - - O
slow-release - - O
tablet - - O
use - - O
. - - O

Examination - - O
of - - O
neurohumoral - - O
factors - - O
revealed - - O
a - - O
hyperactive - - O
sympathetic - - O
nervous - - O
system - - O
and - - O
an - - O
increase - - O
in - - O
plasma - - O
renin - - B-MUT
activity - - O
. - - O

We - - O
have - - O
used - - O
a - - O
full-length - - O
cDNA - - O
clone - - O
of - - O
a - - O
mouse - - O
hepatitis - - O
virus - - O
strain - - O
A59 - - O
defective - - O
interfering - - O
( - - O
DI - - O
) - - O
RNA - - O
, - - O
pMIDI-C - - O
, - - O
and - - O
cassette - - O
mutagenesis - - O
to - - O
study - - O
the - - O
mechanism - - O
of - - O
coronavirus - - O
subgenomic - - O
mRNA - - O
synthesis - - O
. - - O

This - - O
investigation - - O
was - - O
undertaken - - O
to - - O
determine - - O
whether - - O
consuming - - O
several - - O
small - - O
feedings - - O
of - - O
preexercise - - O
carbohydrate - - O
( - - O
CHO - - O
) - - O
, - - O
rather - - O
than - - O
a - - O
single - - O
bolus - - O
, - - O
would - - O
affect - - O
blood - - O
glucose - - O
and - - O
insulin - - B-MUT
responses - - O
during - - O
rest - - O
and - - O
exercise - - O
. - - O

A - - O
triple - - O
Ser-- - - O
> - - O
Ala - - O
mutant - - O
form - - O
of - - O
yeast - - O
eIF-2 - - B-MUT
alpha - - I-MUT
was - - O
found - - O
to - - O
be - - O
no - - O
longer - - O
phosphorylated - - O
by - - O
either - - O
of - - O
the - - O
yeast - - O
( - - O
or - - O
mammalian - - O
) - - O
casein - - B-MUT
kinase - - I-MUT
activities - - O
in - - O
vitro - - O
. - - O

HexA71 - - B-MUT
negatively - - O
affects - - O
RpoS - - B-MUT
, - - O
as - - O
the - - O
levels - - O
of - - O
this - - O
alternative - - O
sigma - - B-MUT
factor - - I-MUT
are - - O
higher - - O
in - - O
the - - O
HexA- - - B-MUT
mutant - - I-MUT
than - - O
in - - O
the - - O
HexA+ - - B-MUT
strain - - O
. - - O

Site-directed - - O
mutagenesis - - O
of - - O
binding - - O
sites - - O
for - - O
the - - O
repressor - - B-MUT
proteins - - I-MUT
BP1 - - I-MUT
and - - O
BP2 - - B-MUT
in - - O
the - - O
upstream - - O
portion - - O
of - - O
the - - O
beta - - B-MUT
globin - - I-MUT
gene - - I-MUT
flanking - - I-MUT
region - - I-MUT
led - - O
to - - O
a - - O
4-6 - - O
fold - - O
increase - - O
in - - O
promoter - - O
activity - - O
. - - O

To - - O
study - - O
a - - O
possible - - O
functional - - O
role - - O
of - - O
this - - O
putative - - O
chicken - - O
ICS - - B-MUT
, - - O
an - - O
oligonucleotide - - O
spanning - - O
the - - O
upstream - - O
sequences - - O
of - - O
the - - O
BF-IV - - B-MUT
gene - - I-MUT
( - - O
-174 - - O
-194 - - O
) - - O
was - - O
cloned - - O
singly - - O
or - - O
in - - O
multiple - - O
copies - - O
before - - O
the - - O
herpes - - O
TK - - O
promoter - - B-MUT
controlling - - I-MUT
the - - O
chloramphenicol - - O
acetyl - - B-MUT
transferase - - I-MUT
( - - I-MUT
CAT - - O
) - - B-MUT
gene - - O
( - - O
pBLCAT2 - - O
) - - O
. - - O

The - - O
results - - O
suggested - - O
that - - O
, - - O
depending - - O
upon - - O
the - - O
cell - - O
type - - O
, - - O
gene - - O
cotransfer - - O
using - - O
aminoglycoside - - O
resistance - - O
as - - O
a - - O
selectable - - O
marker - - O
may - - O
seriously - - O
perturb - - O
important - - O
cellular - - O
control - - O
mechanisms - - O
such - - O
as - - O
the - - O
PKC - - B-MUT
pathway - - O
leading - - O
to - - O
activation - - O
of - - O
gene - - O
expression - - O
. - - O

Pulmonary - - O
embolectomy - - O
and - - O
lung - - O
transplantation - - O
are - - O
the - - O
main - - O
indications - - O
for - - O
the - - O
use - - O
of - - O
heart-lung-machine - - O
. - - O

With - - O
the - - O
increasing - - O
use - - O
of - - O
ACE - - B-MUT
inhibitors - - O
, - - O
the - - O
incidence - - O
of - - O
rare - - O
adverse - - O
effects - - O
such - - O
as - - O
potentially - - O
lethal - - O
pancreatitis - - O
is - - O
likely - - O
to - - O
increase - - O
. - - O

Staphylococcus - - O
aureus - - O
and - - O
CNS - - O
showed - - O
high - - O
or - - O
moderate - - O
resistance - - O
rates - - O
to - - O
methicillin - - O
( - - O
DMPPC - - O
) - - O
. - - O

No - - O
significant - - O
differences - - O
were - - O
found - - O
in - - O
relation - - O
to - - O
Type - - O
A - - O
behaviour - - O
and - - O
beta-adrenoceptor - - B-MUT
blockade - - O
. - - O

The - - O
genome - - O
of - - O
Thogoto - - O
virus - - O
comprises - - O
six - - O
segments - - O
of - - O
single-stranded - - O
, - - O
negative - - O
sense - - O
RNA - - O
. - - O

Overexpression - - O
of - - O
EFG1 - - B-MUT
in - - O
C - - O
. - - O
albicans - - O
leads - - O
to - - O
enhanced - - O
filamentous - - O
growth - - O
in - - O
the - - O
form - - O
of - - O
extended - - O
pseudohyphae - - O
in - - O
liquid - - O
and - - O
on - - O
solid - - O
media - - O
. - - O

The - - O
26S - - B-MUT
rRNA - - I-MUT
binding - - I-MUT
ribosomal - - I-MUT
protein - - I-MUT
equivalent - - O
to - - O
bacterial - - B-MUT
protein - - I-MUT
L11 - - I-MUT
is - - O
encoded - - O
by - - O
unspliced - - O
duplicated - - O
genes - - O
in - - O
Saccharomyces - - O
cerevisiae - - O
. - - O

An - - O
unexpected - - O
finding - - O
was - - O
the - - O
presence - - O
at - - O
position - - O
-403 - - O
to - - O
-385 - - O
of - - O
a - - O
putative - - O
dioxin - - B-MUT
responsive - - I-MUT
element - - I-MUT
, - - O
a - - O
sequence - - O
found - - O
to - - O
be - - O
responsible - - O
for - - O
the - - O
induction - - O
of - - O
transcription - - O
of - - O
the - - O
cytochrome - - B-MUT
P450IA1 - - I-MUT
gene - - I-MUT
( - - O
CYPIA1 - - B-MUT
) - - O
and - - O
other - - O
genes - - O
involved - - O
in - - O
detoxification - - O
activation - - O
of - - O
polycyclic - - O
aromatic - - O
hydrocarbons - - O
. - - O

Hypertonic - - O
glucose - - O
administered - - O
intrajejunally - - O
in - - O
Heidenhain - - O
pouch - - O
dogs - - O
resulted - - O
in - - O
an - - O
equal - - O
inhibition - - O
of - - O
pentagastrin-induced - - O
acid - - O
secretion - - O
from - - O
the - - O
pouch - - O
and - - O
the - - O
main - - O
stomach - - O
, - - O
whereas - - O
hypertonic - - O
saline - - O
had - - O
no - - O
effect - - O
. - - O

APOE-epsilon4 - - B-MUT
count - - O
predicts - - O
age - - O
when - - O
prevalence - - O
of - - O
AD - - O
increases - - O
, - - O
then - - O
declines - - O
: - - O
the - - O
Cache - - O
County - - O
Study - - O
. - - O

In - - O
contrast - - O
, - - O
resensitization - - O
of - - O
a - - O
sequestration-impaired - - O
beta2AR - - B-MUT
mutant - - I-MUT
( - - I-MUT
Y326A - - I-MUT
) - - I-MUT
was - - O
reestablished - - O
following - - O
the - - O
overexpression - - O
of - - O
either - - O
GRK2 - - B-MUT
or - - O
beta-arrestin - - B-MUT
1 - - I-MUT
. - - O

In - - O
contrast - - O
to - - O
hemodynamic - - O
and - - O
histopathological - - O
predictors - - O
of - - O
survival - - O
, - - O
vWF - - O
: - - O
Ag - - O
does - - O
not - - O
require - - O
invasive - - O
techniques - - O
to - - O
be - - O
determined - - O
. - - O

Despite - - O
supraphysiologic - - O
E2 - - O
concentrations - - O
, - - O
however - - O
, - - O
cervical - - O
mucus - - O
scores - - O
were - - O
significantly - - O
reduced - - O
in - - O
the - - O
CC-treated - - O
group - - O
( - - O
P - - O
less - - O
than - - O
0 - - O
. - - O
01 - - O
) - - O
. - - O

Oscillatory - - O
exchange - - O
of - - O
atoms - - O
between - - O
traps - - O
containing - - O
Bose - - O
condensates - - O
. - - O

Patients - - O
with - - O
a - - O
secondary - - O
cardiac - - O
event - - O
had - - O
more - - O
common - - O
Type - - O
A - - O
behavior - - O
patterns - - O
and - - O
higher - - O
Bortner - - O
scores - - O
than - - O
patients - - O
without - - O
a - - O
secondary - - O
cardiac - - O
event - - O
. - - O

McCann - - O
III - - O
, - - O
F - - O
. - - O

A - - O
deproteinization - - O
procedure - - O
was - - O
coupled - - O
with - - O
a - - O
reversed-phase - - O
HPLC - - O
separation - - O
using - - O
a - - O
250x4 - - O
. - - O
6 - - O
mm - - O
I - - O
. - - O
D - - O
. - - O

Recently - - O
, - - O
a - - O
distantly - - O
related - - O
UmuC-homolog - - B-MUT
, - - O
DinB - - B-MUT
, - - O
has - - O
also - - O
been - - O
identified - - O
in - - O
E - - O
. - - O
coli - - O
. - - O

Molecular - - O
cloning - - O
of - - O
human - - O
cDNA - - O
encoding - - O
a - - O
novel - - O
beta1 - - B-MUT
, - - I-MUT
6-N-acetylglucosaminyltransferase - - I-MUT
forming - - O
core - - O
2 - - O
and - - O
core - - O
4 - - O
. - - O

On - - O
the - - O
constituents - - O
of - - O
Dryopteris - - O
polylepis - - O
. - - O

The - - O
basal - - O
promoter - - O
elements - - O
of - - O
murine - - B-MUT
cytochrome - - I-MUT
c - - I-MUT
oxidase - - I-MUT
subunit - - I-MUT
IV - - I-MUT
gene - - I-MUT
consist - - O
of - - O
tandemly - - O
duplicated - - O
ets - - B-MUT
motifs - - I-MUT
that - - O
bind - - O
to - - O
GABP-related - - B-MUT
transcription - - I-MUT
factors - - I-MUT
. - - O

The - - O
alcoholic - - O
patient - - O
, - - O
his - - O
work - - O
and - - O
the - - O
subjectivity - - O
of - - O
the - - O
period - - O
. - - O

Expression - - O
of - - O
SREBP-1a - - B-MUT
stimulated - - O
StAR - - B-MUT
promoter - - I-MUT
activity - - O
in - - O
the - - O
context - - O
of - - O
COS-1 - - O
cells - - O
and - - O
human - - O
granulosa-lutein - - O
cells - - O
. - - O

Serum - - O
levels - - O
of - - O
albumin - - B-MUT
, - - O
globulin - - B-MUT
, - - O
and - - O
coagulation - - B-MUT
protein - - I-MUT
activity - - O
were - - O
measured - - O
preshock - - O
, - - O
postshock - - O
, - - O
and - - O
daily - - O
for - - O
3 - - O
days - - O
; - - O
skin - - O
lymph - - O
levels - - O
were - - O
measured - - O
on - - O
Day - - O
3 - - O
. - - O

In - - O
10 - - O
patients - - O
with - - O
subacute - - O
cardiac - - O
tamponade - - O
, - - O
pulmonary - - O
wedge - - O
pressure - - O
( - - O
PWP - - O
) - - O
, - - O
RAP - - O
, - - O
and - - O
IPP - - O
were - - O
measured - - O
along - - O
with - - O
indexes - - O
of - - O
systolic - - O
function - - O
. - - O

The - - O
Drosophila - - O
clathrin - - B-MUT
heavy - - I-MUT
chain - - I-MUT
gene - - O
: - - O
clathrin - - B-MUT
function - - O
is - - O
essential - - O
in - - O
a - - O
multicellular - - O
organism - - O
. - - O

Experimental - - O
studies - - O
on - - O
virus - - O
excretion - - O
and - - O
non-arthropod - - O
transmission - - O
. - - O

Fregnac - - O
, - - O
M - - O
. - - O

However - - O
, - - O
after - - O
repeated - - O
infections - - O
, - - O
hypobiotic - - O
larvae - - O
were - - O
numerous - - O
. - - O

After - - O
28 - - O
days - - O
of - - O
haloperidol - - O
treatment - - O
, - - O
similar - - O
changes - - O
were - - O
observed - - O
for - - O
delta - - O
, - - O
together - - O
with - - O
an - - O
increase - - O
of - - O
alpha - - O
1 - - O
, - - O
and - - O
a - - O
decrease - - O
of - - O
fast - - O
beta - - O
. - - O

Incidences - - O
of - - O
nonfatal - - O
stroke - - O
, - - O
myocardial - - O
infarction - - O
, - - O
angina - - O
pectoris - - O
und - - O
left - - O
ventricular - - O
hypertrophy - - O
could - - O
also - - O
be - - O
lowered - - O
. - - O

Kidney - - O
length - - O
did - - O
not - - O
significantly - - O
differ - - O
between - - O
right - - O
and - - O
left - - O
, - - O
however - - O
, - - O
kidney - - O
width - - O
, - - O
cortical - - O
thickness - - O
and - - O
size - - O
did - - O
( - - O
p - - O
< - - O
0 - - O
. - - O
05 - - O
) - - O
. - - O

These - - O
findings - - O
suggest - - O
that - - O
late - - O
MYO - - O
M - - O
is - - O
more - - O
useful - - O
than - - O
washout - - O
rate - - O
to - - O
assess - - O
the - - O
effect - - O
of - - O
treatment - - O
on - - O
heart - - O
failure - - O
due - - O
to - - O
DCM - - O
. - - O

Rarely - - O
, - - O
patients - - O
with - - O
locally - - O
advanced - - O
, - - O
uncontrollable - - O
, - - O
non-metastatic - - O
prostatic - - O
cancer - - O
enjoy - - O
prolonged - - O
survival - - O
. - - O

Cells - - O
differentiate - - O
in - - O
response - - O
to - - O
various - - O
extracellular - - O
stimuli - - O
. - - O

The - - O
pathogenesis - - O
of - - O
Limited - - O
Joint - - O
Mobility - - O
( - - O
LJM - - O
) - - O
in - - O
diabetes - - O
is - - O
unknown - - O
, - - O
but - - O
the - - O
abnormality - - O
is - - O
said - - O
to - - O
be - - O
associated - - O
with - - O
an - - O
increased - - O
incidence - - O
of - - O
microangiopathy - - O
. - - O

Radiolabeled - - O
biantennary - - O
N-glycans - - O
synthesized - - O
by - - O
Pro - - B-MUT
( - - I-MUT
- - - I-MUT
) - - I-MUT
5Lec20 - - I-MUT
were - - O
proportionately - - O
less - - O
ricin-bound - - O
than - - O
similar - - O
species - - O
from - - O
parental - - O
CHO - - O
cells - - O
, - - O
and - - O
Lec20 - - O
cell - - O
extracts - - O
had - - O
a - - O
markedly - - O
reduced - - O
ability - - O
to - - O
transfer - - O
Gal - - O
to - - O
GlcNAc-terminating - - O
acceptors - - O
. - - O

In - - O
Saccharomyces - - O
cerevisiae - - O
the - - O
cAMP-dependent - - B-MUT
kinases - - I-MUT
( - - O
PKAs - - B-MUT
) - - O
promote - - O
cytoplasmic - - O
growth - - O
and - - O
modulate - - O
the - - O
growth-regulated - - O
mechanism - - O
triggering - - O
the - - O
begin - - O
of - - O
DNA - - O
synthesis - - O
. - - O

In - - O
marked - - O
contrast - - O
to - - O
AgfA - - B-MUT
, - - O
none - - O
of - - O
the - - O
chimeric - - B-MUT
SefA - - I-MUT
proteins - - I-MUT
were - - O
expressed - - O
or - - O
assembled - - O
into - - O
fimbriae - - O
. - - O

Kinetic - - O
experiments - - O
revealed - - O
that - - O
within - - O
10 - - O
min - - O
this - - O
radiolabeled - - O
precursor - - O
protein - - O
was - - O
converted - - O
in - - O
HL-60 - - O
cells - - O
into - - O
an - - O
Mr - - O
approximately - - O
150 - - O
, - - O
000 - - O
chondroitin - - O
sulfate - - O
proteoglycan - - O
intermediate - - O
. - - O

Heparin - - O
had - - O
no - - O
effect - - O
on - - O
rAC-st - - B-MUT
myosin - - I-MUT
light - - I-MUT
chain - - I-MUT
phosphatase - - I-MUT
activity - - O
, - - O
while - - O
the - - O
B - - O
subunit-containing - - O
forms - - O
were - - O
stimulated - - O
2-3-fold - - O
. - - O

Randomly - - O
selected - - O
300 - - O
children - - O
aged - - O
3 - - O
months-3 - - O
yr - - O
were - - O
analysed - - O
over - - O
a - - O
period - - O
of - - O
one - - O
year - - O
for - - O
estimating - - O
prevalence - - O
of - - O
nutritional - - O
anaemia - - O
. - - O

Studies - - O
using - - O
the - - O
yeast - - O
two-hybrid - - O
system - - O
also - - O
did - - O
not - - O
provide - - O
evidence - - O
for - - O
the - - O
formation - - O
of - - O
a - - O
VDR-TR - - B-MUT
protein-protein - - O
interaction - - O
. - - O

The - - O
frequency - - O
of - - O
lactase - - B-MUT
phenotypes - - I-MUT
in - - O
Aymara - - O
children - - O
. - - O

( - - O
iii - - O
) - - O
In - - O
these - - O
cells - - O
, - - O
PKCbeta - - B-MUT
plays - - O
a - - O
unique - - O
Ras-independent - - O
role - - O
in - - O
mediating - - O
insulin - - B-MUT
but - - O
not - - O
EGF - - B-MUT
or - - O
other - - O
growth - - B-MUT
factor - - I-MUT
mitogenic - - O
signals - - O
. - - O

Chem - - O
. - - O

Adenylosuccinate - - B-MUT
synthetase - - I-MUT
( - - O
IMP - - O
: - - O
L-aspartate - - B-MUT
ligase - - I-MUT
( - - O
GDP - - O
) - - O
, - - O
EC - - O
6 - - O
. - - O
3 - - O
. - - O
4 - - O
. - - O
4 - - O
) - - O
plays - - O
an - - O
important - - O
role - - O
in - - O
purine - - O
biosynthesis - - O
catalyzing - - O
the - - O
GTP-dependent - - O
conversion - - O
of - - O
IMP - - O
to - - O
AMP - - O
. - - O

Glucocorticoid - - O
induced - - O
hypertension - - O
has - - O
been - - O
regarded - - O
as - - O
independent - - O
of - - O
sodium - - O
( - - O
Na - - O
) - - O
, - - O
in - - O
contrast - - O
to - - O
mineralocorticoid - - O
induced - - O
hypertension - - O
, - - O
which - - O
is - - O
Na+-dependent - - O
. - - O

These - - O
experiments - - O
delineate - - O
a - - O
186-bp - - O
, - - O
EBNA-2-responsive - - O
cell - - O
DNA - - O
fragment - - O
and - - O
provide - - O
firm - - O
evidence - - O
that - - O
EBNA-2 - - B-MUT
transactivates - - O
transcription - - O
of - - O
cell - - O
genes - - O
. - - O

Northern - - O
blot - - O
analysis - - O
demonstrated - - O
that - - O
the - - O
STORP - - B-MUT
gene - - I-MUT
has - - O
a - - O
ubiquitous - - O
pattern - - O
of - - O
expression - - O
similar - - O
to - - O
that - - O
of - - O
the - - O
PML - - B-MUT
gene - - I-MUT
. - - O

These - - O
data - - O
provide - - O
strong - - O
evidence - - O
that - - O
E2F - - B-MUT
or - - O
an - - O
E2F-related - - B-MUT
transcription - - I-MUT
factor - - I-MUT
is - - O
involved - - O
in - - O
the - - O
regulation - - O
of - - O
nonmuscle - - B-MUT
myosin - - I-MUT
expression - - O
. - - O

In - - O
Saccharomyces - - O
cerevisiae - - O
, - - O
entry - - O
into - - O
mitosis - - O
requires - - O
activation - - O
of - - O
the - - O
cyclin-dependent - - B-MUT
kinase - - I-MUT
Cdc28 - - I-MUT
in - - O
its - - O
cyclin - - B-MUT
B - - I-MUT
( - - O
Clb - - B-MUT
) - - O
-associated - - O
form - - O
. - - O

Similar - - O
data - - O
were - - O
also - - O
obtained - - O
when - - O
either - - O
dominant - - B-MUT
negative - - I-MUT
EGFR-CD533 - - I-MUT
or - - O
dominant - - B-MUT
negative - - I-MUT
Ras - - I-MUT
N17 - - I-MUT
were - - O
used - - O
to - - O
block - - O
MAPK - - B-MUT
activation - - O
. - - O

HANYS - - O
criticizes - - O
laparoscopic - - O
gall - - O
bladder - - O
guidelines - - O
. - - O

By - - O
far-Western - - O
analysis - - O
and - - O
coimmunoprecipitation - - O
studies - - O
, - - O
we - - O
demonstrate - - O
that - - O
ZNF74 - - B-MUT
interacts - - O
, - - O
via - - O
its - - O
zinc - - O
finger - - O
domain - - O
, - - O
with - - O
the - - O
hyperphosphorylated - - O
largest - - O
subunit - - O
of - - O
RNA - - B-MUT
polymerase - - I-MUT
II - - I-MUT
( - - O
pol - - B-MUT
IIo - - I-MUT
) - - O
but - - O
not - - O
with - - O
the - - O
hypophosphorylated - - O
form - - O
. - - O

The - - O
examination - - O
must - - O
include - - O
T1 - - O
and - - O
T2 - - O
sequences - - O
and - - O
scans - - O
in - - O
three - - O
planes - - O
. - - O

Genetic - - O
and - - O
biochemical - - O
evidence - - O
suggests - - O
that - - O
v-Crk - - B-MUT
can - - O
induce - - O
transformation - - O
of - - O
chicken - - O
embryo - - O
fibroblasts - - O
by - - O
influencing - - O
the - - O
activity - - O
of - - O
cellular - - O
proteins - - O
involved - - O
in - - O
growth - - O
regulation - - O
. - - O

Heating - - O
cells - - O
to - - O
43 - - O
degrees - - O
C - - O
decreased - - O
the - - O
amount - - O
of - - O
newly - - O
synthesized - - O
rRNA - - B-MUT
to - - O
less - - O
than - - O
5% - - O
of - - O
the - - O
control - - O
level - - O
and - - O
led - - O
to - - O
greater - - O
than - - O
95% - - O
inhibition - - O
of - - O
transcription - - O
termination - - O
at - - O
a - - O
region - - O
355 - - O
to - - O
362 - - O
nucleotides - - O
downstream - - O
of - - O
the - - O
3' - - O
end - - O
of - - O
28S - - B-MUT
rRNA - - I-MUT
, - - O
with - - O
readthrough - - O
continuing - - O
into - - O
the - - O
next - - O
transcription - - O
unit - - O
. - - O

Intravesical - - O
chemotherapy - - O
. - - O

Antibodies - - O
affinity-purified - - O
using - - O
the - - O
bacterially - - O
expressed - - O
recombinant - - O
protein - - O
recognized - - O
the - - O
56K - - B-MUT
autoantigen - - I-MUT
in - - O
a - - O
HeLa - - O
cell - - O
extract - - O
. - - O
cDNA - - O
sequencing - - O
revealed - - O
that - - O
the - - O
56K - - B-MUT
cDNA - - I-MUT
shares - - O
a - - O
high - - O
degree - - O
of - - O
homology - - O
in - - O
both - - O
nucleotide - - O
( - - O
87% - - O
) - - O
and - - O
amino - - O
acid - - O
sequence - - O
( - - O
92 - - O
. - - O
5% - - O
) - - O
with - - O
bovine - - B-MUT
annexin - - I-MUT
XI - - I-MUT
, - - O
indicating - - O
that - - O
the - - O
56K - - B-MUT
cDNA - - I-MUT
encodes - - O
the - - O
human - - B-MUT
homologue - - I-MUT
of - - I-MUT
annexin - - I-MUT
XI - - I-MUT
, - - O
a - - O
member - - O
of - - O
the - - O
Ca - - B-MUT
( - - I-MUT
2+ - - I-MUT
) - - I-MUT
-dependent - - I-MUT
phospholipid - - I-MUT
binding - - I-MUT
protein - - I-MUT
family - - I-MUT
. - - O

Protein - - B-MUT
cHMGI - - I-MUT
binds - - O
preferentially - - O
to - - O
AT-rich - - O
DNA - - O
with - - O
a - - O
half-saturation - - O
value - - O
of - - O
1 - - O
. - - O
1 - - O
nM - - O
. - - O

Total - - O
VO2 - - O
was - - O
decreased - - O
in - - O
both - - O
groups - - O
during - - O
severe - - O
hypoxia - - O
but - - O
limb - - O
VO2 - - O
was - - O
maintained - - O
in - - O
the - - O
beta-block - - O
group - - O
. - - O
beta-Block - - O
prevented - - O
the - - O
fall - - O
in - - O
total - - O
and - - O
limb - - O
peripheral - - O
resistance - - O
seen - - O
in - - O
severe - - O
hypoxia - - O
but - - O
did - - O
not - - O
alter - - O
the - - O
consistently - - O
more - - O
efficient - - O
utilization - - O
of - - O
total - - O
O2 - - O
delivery - - O
shown - - O
by - - O
the - - O
limb - - O
in - - O
comparison - - O
to - - O
the - - O
whole - - O
body - - O
by - - O
higher - - O
O2 - - O
extraction - - O
ratios - - O
and - - O
lower - - O
venous - - O
O2 - - O
pressure - - O
. - - O
beta-Vasodilator - - B-MUT
receptors - - I-MUT
evidently - - O
played - - O
an - - O
active - - O
part - - O
in - - O
the - - O
vasodilatation - - O
seen - - O
during - - O
severe - - O
hypoxia - - O
. - - O

SPECT - - O
examination - - O
of - - O
the - - O
TMJ - - O
using - - O
99m - - O
Tc-MDP - - O
was - - O
performed - - O
in - - O
43 - - O
patients - - O
with - - O
arthrographically - - O
proven - - O
anterior - - O
dislocation - - O
of - - O
the - - O
disc - - O
and - - O
in - - O
30 - - O
normals - - O
. - - O

J - - O
. - - O

The - - O
size - - O
of - - O
the - - O
group - - O
allocated - - O
to - - O
the - - O
good - - O
compliance - - O
category - - O
by - - O
the - - O
use - - O
of - - O
the - - O
digoxin - - O
marker - - O
was - - O
equivalent - - O
in - - O
size - - O
to - - O
a - - O
group - - O
of - - O
patients - - O
who - - O
had - - O
returned - - O
less - - O
than - - O
15% - - O
of - - O
their - - O
prescribed - - O
dose - - O
or - - O
reported - - O
a - - O
deviation - - O
of - - O
less - - O
than - - O
6% - - O
from - - O
their - - O
prescription - - O
. - - O

In - - O
the - - O
mouse - - O
, - - O
CtBP1 - - B-MUT
is - - O
expressed - - O
from - - O
embryo - - O
to - - O
adult - - O
, - - O
but - - O
CtBP2 - - B-MUT
is - - O
mainly - - O
expressed - - O
during - - O
embryogenesis - - O
. - - O

Intracranial - - O
arachnoid - - O
cyst - - O
of - - O
the - - O
middle - - O
fossa - - O
demonstrated - - O
by - - O
positive - - O
99mTc - - O
brainscintigraphy - - O
. - - O

Rat - - B-MUT
liver - - I-MUT
catalase - - I-MUT
is - - O
sorted - - O
to - - O
peroxisomes - - O
by - - O
its - - O
C-terminal - - O
tripeptide - - O
Ala-Asn-Leu - - B-MUT
, - - O
not - - O
by - - O
the - - O
internal - - B-MUT
Ser-Lys-Leu - - I-MUT
motif - - I-MUT
. - - O

Evidence - - O
for - - O
a - - O
role - - O
of - - O
endogenous - - B-MUT
corticotropin-releasing - - I-MUT
factor - - I-MUT
in - - O
cold - - O
, - - O
ether - - O
, - - O
immobilization - - O
, - - O
and - - O
traumatic - - O
stress - - O
. - - O

The - - O
encoded - - O
amino - - O
acid - - O
sequences - - O
in - - O
the - - O
full-length - - O
bovine - - O
and - - O
porcine - - O
cDNAs - - O
were - - O
identical - - O
, - - O
consisting - - O
of - - O
209 - - O
amino - - O
acid - - O
residues - - O
, - - O
and - - O
were - - O
nearly - - O
the - - O
same - - O
as - - O
the - - O
published - - O
sequence - - O
determined - - O
by - - O
Edman - - O
degradation - - O
. - - O

The - - O
4 - - O
days - - O
dexamethasone - - O
suppression - - O
test - - O
showed - - O
more - - O
than - - O
80% - - O
suppression - - O
of - - O
dehydroepiandrosterone-sulphate - - O
and - - O
a - - O
variable - - O
( - - O
40-60% - - O
) - - O
reduction - - O
of - - O
testosterone - - O
and - - O
androstenedione - - O
levels - - O
. - - O

Dd - - B-MUT
PK1 - - I-MUT
RNA - - I-MUT
decreases - - O
after - - O
6 - - O
h - - O
of - - O
starvation - - O
to - - O
re-accumulate - - O
once - - O
the - - O
cells - - O
have - - O
aggregated - - O
. - - O

She - - O
also - - O
had - - O
slight - - O
weakness - - O
of - - O
the - - O
upper - - O
extremities - - O
. - - O

Redistribution - - O
of - - O
mannosidase - - B-MUT
I - - I-MUT
was - - O
also - - O
observed - - O
in - - O
cells - - O
incubated - - O
at - - O
15 - - O
degrees - - O
C - - O
. - - O

In - - O
some - - O
cases - - O
, - - O
the - - O
aberrant - - O
methylation - - O
of - - O
CpGs - - O
within - - O
5' - - O
regulatory - - O
regions - - O
has - - O
led - - O
to - - O
suppression - - O
of - - O
gene - - O
activity - - O
. - - O

The - - O
second - - O
transcript - - O
, - - O
rhis4l - - B-MUT
, - - O
is - - O
bicistronic - - O
. - - O

Current - - O
status - - O
and - - O
future - - O
perspectives - - O
. - - O

In - - O
support - - O
of - - O
this - - O
interpretation - - O
we - - O
demonstrate - - O
that - - O
MQ9b - - B-MUT
binds - - O
strongly - - O
5 - - O
of - - O
17 - - O
motif-positive - - O
, - - O
pathogen-derived - - O
synthetic - - O
peptides - - O
. - - O

Human - - O
expressed - - O
sequence - - O
tag - - O
clones - - O
were - - O
identified - - O
by - - O
sequence - - O
similarity - - O
to - - O
mammalian - - B-MUT
and - - I-MUT
yeast - - I-MUT
oligosaccharide-processing - - I-MUT
mannosidases - - I-MUT
, - - O
and - - O
the - - O
full-length - - O
coding - - O
region - - O
of - - O
the - - O
putative - - O
mannosidase - - B-MUT
homolog - - I-MUT
was - - O
isolated - - O
by - - O
a - - O
combination - - O
of - - O
5'-rapid - - O
amplification - - O
of - - O
cDNA - - O
ends - - O
and - - O
direct - - O
polymerase - - B-MUT
chain - - O
reaction - - O
from - - O
human - - O
placental - - O
cDNA - - O
. - - O

Irradiation - - O
of - - O
human - - O
blood - - O
platelets - - O
with - - O
UV-A - - O
in - - O
vitro - - O
impairs - - O
their - - O
ability - - O
to - - O
aggregate - - O
after - - O
challenge - - O
with - - O
collagen - - B-MUT
. - - O

Exploration - - O
on - - O
the - - O
effects - - O
of - - O
activating - - O
blood - - O
circulation - - O
to - - O
remove - - O
blood - - O
stasis - - O
on - - O
barrier - - O
action - - O
of - - O
gastric - - O
wall - - O
in - - O
chronic - - O
atrophic - - O
gastritis - - O

Diagnosis - - O
of - - O
FHCS - - O
has - - O
been - - O
weighed - - O
upon - - O
laparoscopic - - O
findings - - O
. - - O

Because - - O
all - - O
PDGFbetaR - - B-MUT
fusions - - I-MUT
described - - O
thus - - O
far - - O
result - - O
in - - O
splicing - - O
to - - O
a - - O
common - - O
exon - - O
of - - O
this - - O
gene - - O
, - - O
we - - O
performed - - O
5'-rapid - - O
amplification - - O
of - - O
cDNA - - O
ends - - O
PCR - - O
on - - O
patient - - O
RNA - - O
. - - O

Here - - O
we - - O
have - - O
investigated - - O
the - - O
structural - - O
requirements - - O
and - - O
consequences - - O
of - - O
regulatory - - O
phosphorylation - - O
for - - O
the - - O
interaction - - O
between - - O
c-Jun - - B-MUT
and - - O
JNK - - B-MUT
in - - O
vivo - - O
. - - O

To - - O
determine - - O
whether - - O
mononuclear - - O
cell - - O
secretory - - O
products - - O
contribute - - O
to - - O
the - - O
changes - - O
in - - O
bone - - O
turnover - - O
that - - O
characterize - - O
the - - O
development - - O
of - - O
postmenopausal - - O
osteoporosis - - O
, - - O
we - - O
evaluated - - O
the - - O
effects - - O
of - - O
oophorectomy - - O
and - - O
subsequent - - O
estrogen - - O
replacement - - O
on - - O
the - - O
spontaneous - - O
secretion - - O
of - - O
interleukin - - B-MUT
1 - - I-MUT
( - - O
IL-1 - - B-MUT
) - - O
and - - O
tumor - - B-MUT
necrosis - - I-MUT
factor - - I-MUT
alpha - - I-MUT
( - - O
TNF-alpha - - B-MUT
) - - O
and - - O
on - - O
the - - O
phytohemagglutinin - - O
A-induced - - O
secretion - - O
of - - O
granulocyte-macrophage - - B-MUT
colony-stimulating - - I-MUT
factor - - I-MUT
( - - O
GM-CSF - - B-MUT
) - - O
from - - O
peripheral - - O
blood - - O
mononuclear - - O
cells - - O
. - - O

METHODS - - O
: - - O
A - - O
structured - - O
interview - - O
was - - O
undertaken - - O
at - - O
the - - O
time - - O
of - - O
initial - - O
consultation - - O
and - - O
at - - O
subsequent - - O
1-year - - O
intervals - - O
regarding - - O
type - - O
of - - O
BHS - - O
, - - O
frequency - - O
of - - O
spells - - O
, - - O
associated - - O
phenomenon - - O
, - - O
sequelae - - O
, - - O
family - - O
history - - O
, - - O
and - - O
age - - O
at - - O
termination - - O
of - - O
spells - - O
. - - O

Selective - - O
macrophage - - O
inhibition - - O
abolishes - - O
warfarin-induced - - O
reduction - - O
of - - O
metastasis - - O
. - - O

The - - O
human - - O
cDNA - - O
was - - O
used - - O
to - - O
demonstrate - - O
that - - O
tumor - - B-MUT
necrosis - - I-MUT
factor-alpha - - I-MUT
could - - O
rapidly - - O
stimulate - - O
MARCKS - - B-MUT
gene - - I-MUT
transcription - - O
in - - O
the - - O
human - - O
promyelocytic - - O
leukemia - - O
cell - - O
line - - O
HL60 - - O
. - - O

We - - O
have - - O
therefore - - O
studied - - O
the - - O
molecular - - O
mechanisms - - O
of - - O
TGF-beta1 - - B-MUT
action - - O
on - - O
thyroglobulin - - B-MUT
( - - O
TG - - B-MUT
) - - O
gene - - O
expression - - O
by - - O
focusing - - O
our - - O
attention - - O
on - - O
TGF-beta1 - - B-MUT
regulation - - O
of - - O
thyroid-specific - - O
transcription - - O
factors - - O
. - - O

The - - O
predicted - - O
receptor - - O
structure - - O
includes - - O
a - - O
cysteine-rich - - O
extracellular - - O
domain - - O
, - - O
a - - O
single - - O
hydrophobic - - O
transmembrane - - O
domain - - O
, - - O
and - - O
a - - O
predicted - - O
cytoplasmic - - B-MUT
serine - - I-MUT
threonine - - I-MUT
kinase - - I-MUT
domain - - I-MUT
. - - I-MUT

DESIGN - - O
: - - O
A - - O
retrospective - - O
chart - - O
review - - O
of - - O
9 - - O
, - - O
322 - - O
patients - - O
undergoing - - O
surgical - - O
procedures - - O
in - - O
the - - O
period - - O
January - - O
1993 - - O
to - - O
December - - O
1998 - - O
. - - O

Genetic - - O
and - - O
molecular - - O
complexity - - O
of - - O
the - - O
position - - O
effect - - O
variegation - - O
modifier - - O
mod - - B-MUT
( - - I-MUT
mdg4 - - I-MUT
) - - I-MUT
in - - O
Drosophila - - O
. - - O
mod - - B-MUT
( - - I-MUT
mdg4 - - I-MUT
) - - I-MUT
, - - O
also - - O
known - - O
as - - O
E - - B-MUT
( - - I-MUT
var - - I-MUT
) - - I-MUT
3-93D - - I-MUT
, - - O
is - - O
involved - - O
in - - O
a - - O
variety - - O
of - - O
processes - - O
, - - O
such - - O
as - - O
gene - - O
silencing - - O
in - - O
position - - O
effect - - O
variegation - - O
( - - O
PEV - - O
) - - O
, - - O
the - - O
control - - O
of - - O
gypsy - - B-MUT
insulator - - I-MUT
sequences - - I-MUT
, - - O
regulation - - O
of - - O
homeotic - - B-MUT
gene - - I-MUT
expression - - O
, - - O
and - - O
programmed - - O
cell - - O
death - - O
. - - O

Studies - - O
of - - O
lipoproteins - - O
should - - O
, - - O
however - - O
, - - O
be - - O
made - - O
in - - O
children - - O
from - - O
families - - O
known - - O
to - - O
have - - O
FH - - O
or - - O
early - - O
coronary - - O
heart - - O
disease - - O
. - - O

U4 - - B-MUT
U6 - - I-MUT
snRNP - - I-MUT
is - - I-MUT
one - - O
of - - O
four - - O
essential - - O
small - - O
nuclear - - B-MUT
ribonucleoprotein - - I-MUT
( - - I-MUT
snRNP - - I-MUT
) - - I-MUT
particles - - I-MUT
( - - I-MUT
U1 - - I-MUT
, - - I-MUT
U2 - - I-MUT
, - - I-MUT
U5 - - I-MUT
and - - I-MUT
U4 - - I-MUT
U6 - - I-MUT
) - - I-MUT
present - - I-MUT
in - - O
the - - O
spliceosome - - O
. - - O

Eight - - O
of - - O
the - - O
non-acceptable - - O
inlays - - O
onlays - - O
and - - O
five - - O
of - - O
the - - O
direct - - O
restorations - - O
were - - O
replaced - - O
, - - O
while - - O
the - - O
other - - O
ones - - O
were - - O
repaired - - O
with - - O
resin - - O
composite - - O
. - - O

Before - - O
this - - O
date - - O
, - - O
the - - O
drug - - O
directly - - O
inhibits - - O
fetal - - O
weight - - O
gain - - O
, - - O
whereas - - O
the - - O
sensitivity - - O
of - - O
the - - O
placenta - - O
is - - O
only - - O
transient - - O
at - - O
day - - O
16 - - O
resulting - - O
in - - O
maximum - - O
weight - - O
decrease - - O
of - - O
this - - O
organ - - O
24 - - O
h - - O
later - - O
. - - O

When - - O
cotransfected - - O
in - - O
fibroblasts - - O
with - - O
a - - O
C - - B-MUT
EBP - - I-MUT
alpha - - I-MUT
expression - - I-MUT
vector - - O
, - - O
reporter - - O
gene - - O
expression - - O
increased - - O
3-fold - - O
only - - O
in - - O
the - - O
wild-type - - O
constructs - - O
. - - O

This - - O
utilization - - O
of - - O
an - - O
intronic - - O
polyadenylation - - O
site - - O
without - - O
alternative - - O
exon - - O
usage - - O
is - - O
comparable - - O
to - - O
the - - O
mechanism - - O
whereby - - O
both - - O
secreted - - O
and - - O
membrane-bound - - O
forms - - O
of - - O
the - - O
immunoglobulin - - B-MUT
mu - - I-MUT
heavy - - I-MUT
chain - - I-MUT
are - - O
made - - O
from - - O
a - - O
single - - O
genetic - - O
locus - - O
. - - O

The - - O
characterized - - O
Y' - - B-MUT
repeated - - I-MUT
sequence - - I-MUT
families - - I-MUT
provide - - O
an - - O
experimental - - O
system - - O
in - - O
which - - O
repeated - - O
sequence - - O
interactions - - O
and - - O
subsequent - - O
evolution - - O
can - - O
be - - O
studied - - O
. - - O

Also - - O
discussed - - O
is - - O
the - - O
possibility - - O
of - - O
a - - O
combined - - O
genetic - - O
and - - O
environmental - - O
etiology - - O
. - - O

In - - O
these - - O
constructs - - O
, - - O
GUS - - B-MUT
expression - - O
was - - O
driven - - O
by - - O
promoter - - O
regions - - O
derived - - O
from - - O
the - - O
Arabidopsis - - B-MUT
alcohol - - I-MUT
dehydrogenase - - I-MUT
( - - O
Adh1 - - B-MUT
) - - O
, - - O
maize - - B-MUT
ubiquitin - - I-MUT
( - - O
Ubi1 - - B-MUT
) - - O
, - - O
rice - - B-MUT
actin - - I-MUT
( - - O
Act1 - - B-MUT
) - - O
and - - O
CaMV - - B-MUT
35S - - I-MUT
genes - - I-MUT
. - - O

The - - O
films - - O
were - - O
analyzed - - O
using - - O
a - - O
scanning - - O
helium-neon - - O
laser - - O
densitometer - - O
with - - O
a - - O
small - - O
aperture - - O
of - - O
5-10 - - O
microns - - O
. - - O

While - - O
no - - O
obvious - - O
transmembrane - - O
regions - - O
were - - O
identified - - O
, - - O
several - - O
short - - O
hydrophobic - - O
amino - - O
acid - - O
stretches - - O
were - - O
found - - O
to - - O
be - - O
localized - - O
in - - O
and - - O
around - - O
the - - O
Pro - - B-MUT
II - - I-MUT
region - - I-MUT
, - - O
and - - O
these - - O
may - - O
be - - O
responsible - - O
for - - O
attachment - - O
of - - O
precursors - - O
to - - O
membranes - - O
. - - O

In - - O
addition - - O
, - - O
carp - - B-MUT
JAK1 - - I-MUT
shows - - O
higher - - O
sequence - - O
homology - - O
to - - O
mammalian - - B-MUT
JAK1 - - I-MUT
in - - O
both - - O
the - - O
kinase-like - - B-MUT
( - - O
JH2 - - B-MUT
) - - O
and - - O
kinase - - B-MUT
( - - O
JH1 - - B-MUT
) - - O
domains - - O
( - - O
approximately - - O
70% - - O
identity - - O
) - - O
. - - O

U73 - - B-MUT
contains - - O
C - - O
, - - O
D - - O
and - - O
D' - - O
boxes - - O
and - - O
a - - O
12-nucleotide - - O
antisense - - O
complementarity - - O
to - - O
the - - O
28S - - B-MUT
ribosomal - - I-MUT
RNA - - I-MUT
. - - O

This - - O
paper - - O
gives - - O
an - - O
overview - - O
of - - O
the - - O
global - - O
pattern - - O
of - - O
casualties - - O
in - - O
earthquakes - - O
which - - O
occurred - - O
during - - O
the - - O
30-month - - O
period - - O
from - - O
1 - - O
September - - O
1993 - - O
to - - O
29 - - O
February - - O
1996 - - O
. - - O

By - - O
contrast - - O
, - - O
deletion - - O
of - - O
this - - O
Ras-binding - - B-MUT
site - - I-MUT
did - - O
not - - O
diminish - - O
activation - - O
of - - O
Raf-1 - - B-MUT
kinase - - I-MUT
by - - O
Src - - B-MUT
, - - O
implying - - O
that - - O
Src - - B-MUT
and - - O
Ras - - B-MUT
can - - O
activate - - O
Raf-1 - - B-MUT
through - - O
independent - - O
mechanisms - - O
. - - O

The - - O
clinical - - O
picture - - O
and - - O
laboratory - - O
parameters - - O
were - - O
consistent - - O
with - - O
a - - O
serum - - O
sickness - - O
reaction - - O
. - - O

The - - O
Stat5b - - B-MUT
mRNA - - I-MUT
has - - O
a - - O
size - - O
of - - O
5 - - O
. - - O
6 - - O
kb - - O
and - - O
encodes - - O
a - - O
protein - - O
of - - O
786 - - O
amino - - O
acids - - O
. - - O

Expression - - O
of - - O
the - - O
wt1 - - B-MUT
gene - - I-MUT
via - - O
transient - - O
transfection - - O
in - - O
COS-1 - - O
cells - - O
revealed - - O
a - - O
52 - - O
kDa - - O
protein - - O
which - - O
was - - O
immunoprecipitated - - O
by - - O
both - - O
the - - O
N-terminal- - - O
and - - O
C-terminal-specific - - O
antisera - - O
. - - O

Cotransfection - - O
of - - O
either - - O
construct - - O
with - - O
plasmids - - O
encoding - - O
PKI - - B-MUT
( - - I-MUT
1-31 - - I-MUT
) - - I-MUT
inhibits - - O
cAMP-stimulated - - O
but - - O
not - - O
basal- - - O
or - - O
phorbol - - O
ester-stimulated - - O
expression - - O
. - - O

Sequence - - O
analysis - - O
showed - - O
that - - O
the - - O
5'-flanking - - O
region - - O
upstream - - O
to - - O
the - - O
ATG - - O
codon - - O
did - - O
not - - O
contain - - O
a - - O
conventional - - O
TATA - - O
box - - O
. - - O

Tensile - - O
bond - - O
strengths - - O
between - - O
resin - - O
composite - - O
and - - O
bovine - - B-MUT
dentin - - I-MUT
using - - O
dentin - - B-MUT
adhesive - - O
systems - - O
( - - O
Clearfil - - O
Liner - - O
Bond - - O
II - - O
: - - O
LB - - O
II - - O
; - - O
Scotchbond - - O
Multi-Purpose - - O
: - - O
MP - - O
) - - O
bonding - - O
systems - - O
showed - - O
a - - O
large - - O
scatter - - O
among - - O
students - - O
and - - O
dentists - - O
. - - O

Regression - - O
analyses - - O
showed - - O
that - - O
SOREMP - - O
dream - - O
occurrences - - O
were - - O
significantly - - O
related - - O
to - - O
the - - O
amount - - O
of - - O
REM - - O
sleep - - O
, - - O
while - - O
NREMP - - O
dream - - O
occurrences - - O
were - - O
related - - O
to - - O
arousals - - O
from - - O
NREM - - O
sleep - - O
. - - O

At - - O
the - - O
end - - O
of - - O
each - - O
day - - O
of - - O
migration - - O
the - - O
pulmonary - - O
hemolymph - - O
PO2 - - O
decreased - - O
by - - O
1-2 - - O
. - - O
5 - - O
kPa - - O
, - - O
but - - O
the - - O
hemocyanin - - O
remained - - O
saturated - - O
with - - O
O2 - - O
and - - O
the - - O
venous - - O
reserve - - O
was - - O
largely - - O
unchanged - - O
( - - O
O2 - - O
> - - O
0 - - O
. - - O
4 - - O
mmol - - O
x - - O
l - - O
( - - O
-1 - - O
) - - O
) - - O
. - - O

Prominent - - O
protein - - B-MUT
kinase - - I-MUT
cascades - - I-MUT
are - - O
those - - O
that - - O
activate - - O
mitogen-activated - - B-MUT
protein - - I-MUT
( - - I-MUT
MAP - - I-MUT
) - - I-MUT
kinases - - I-MUT
. - - O

A - - O
constitutive - - O
mutant - - O
form - - O
with - - O
a - - O
single - - O
substitution - - O
( - - O
V88A - - O
) - - O
in - - O
the - - O
amino-terminal - - O
( - - O
response - - O
regulator - - O
) - - O
region - - O
was - - O
used - - O
. - - O

Substitution - - O
of - - O
a - - O
threonine - - O
residue - - O
by - - O
an - - O
alanine - - O
residue - - O
at - - O
position - - O
-2 - - O
( - - O
P2 - - O
) - - O
of - - O
this - - O
cleavage - - O
site - - O
abolished - - O
cleavage - - O
, - - O
whereas - - O
substitution - - O
of - - O
a - - O
tyrosine - - O
residue - - O
by - - O
a - - O
phenylalanine - - O
residue - - O
at - - O
amino - - O
acid - - O
position - - O
-1 - - O
( - - O
P1 - - O
) - - O
of - - O
the - - O
cleavage - - O
site - - O
did - - O
not - - O
influence - - O
processing - - O
. - - O

In - - O
previous - - O
work - - O
( - - O
E - - O
. - - O

In - - O
the - - O
SPP2 - - O
screening - - O
test - - O
, - - O
a - - O
few - - O
plates - - O
were - - O
not - - O
seen - - O
in - - O
both - - O
groups - - O
. - - O

Hydrocortisone - - O
caused - - O
lymphopenia - - O
and - - O
inhibited - - O
the - - O
blastogenic - - O
response - - O
of - - O
peripheral - - O
blood - - O
lymphocytes - - O
to - - O
phytohemagglutinin - - B-MUT
and - - O
concanavalin - - B-MUT
A - - I-MUT
mitogens - - O
. - - O

A - - O
deletion - - O
series - - O
of - - O
the - - O
5' - - O
flanking - - O
region - - O
was - - O
created - - O
from - - O
position - - O
-1329 - - O
to - - O
-74 - - O
relative - - O
to - - O
the - - O
transcriptional - - O
initiation - - O
site - - O
and - - O
similarly - - O
examined - - O
in - - O
transgenic - - O
tobacco - - O
. - - O

A - - O
subset - - O
of - - O
these - - O
DMP1 - - B-MUT
recognition - - I-MUT
sequences - - I-MUT
containing - - O
a - - O
GGA - - O
trinucleotide - - O
core - - O
can - - O
also - - O
function - - O
as - - O
Ets-responsive - - B-MUT
elements - - I-MUT
. - - O

Ab-MLV - - O
strains - - O
expressing - - O
P70 - - B-MUT
S2 - - I-MUT
failed - - I-MUT
to - - O
transform - - O
NIH - - O
3T3 - - O
cells - - O
and - - O
demonstrated - - O
a - - O
greatly - - O
reduced - - O
capacity - - O
to - - O
mediate - - O
signaling - - O
events - - O
associated - - O
with - - O
the - - O
Ras-dependent - - O
mitogen-activated - - B-MUT
protein - - I-MUT
( - - I-MUT
MAP - - I-MUT
) - - I-MUT
kinase - - I-MUT
pathway - - I-MUT
. - - O

The - - O
promoter - - O
activity - - O
of - - O
the - - O
gene - - B-MUT
encoding - - I-MUT
Alzheimer - - I-MUT
beta-amyloid - - I-MUT
precursor - - I-MUT
protein - - I-MUT
( - - O
APP - - B-MUT
) - - O
is - - O
regulated - - O
by - - O
two - - O
blocks - - O
of - - O
upstream - - O
sequences - - O
. - - O

High-affinity - - O
site-specific - - O
DNA - - O
binding - - O
by - - O
POU - - B-MUT
domain - - I-MUT
transcription - - O
factors - - O
requires - - O
both - - O
the - - O
POU-specific - - O
and - - O
the - - O
POU-homeodomain - - B-MUT
. - - O

These - - O
utilisation - - O
data - - O
imply - - O
annual - - O
drug - - O
costs - - O
in - - O
the - - O
range - - O
of - - O
$US - - O
480 - - O
, - - O
000 - - O
to - - O
$US - - O
3 - - O
, - - O
600 - - O
, - - O
000 - - O
for - - O
TNF - - B-MUT
antagonists - - O
for - - O
RA - - O
per - - O
1 - - O
million - - O
population - - O
. - - O

Prognosis - - O
in - - O
Bowen's - - O
disease - - O
localized - - O
to - - O
the - - O
ano-genital - - O
region - - O
. - - O

Nucleotide - - O
sequence - - O
analysis - - O
revealed - - O
that - - O
TAR-binding - - B-MUT
protein - - I-MUT
is - - O
very - - O
similar - - O
to - - O
the - - O
CREB2 - - B-MUT
protein - - I-MUT
. - - O

Hepatitis - - O
B - - O
vaccination - - O
strategy - - O
for - - O
health-care - - O
workers - - O
in - - O
a - - O
country - - O
of - - O
intermediate - - O
hepatitis - - O
B - - O
endemicity - - O
. - - O

So - - O
far - - O
no - - O
problems - - O
with - - O
multiply - - O
resistant - - O
strains - - O
have - - O
developed - - O
. - - O

These - - O
observed - - O
drug - - O
interactions - - O
, - - O
plus - - O
the - - O
known - - O
effect - - O
of - - O
probenecid - - O
to - - O
block - - O
secretion - - O
of - - O
PZA - - O
, - - O
have - - O
to - - O
be - - O
considered - - O
in - - O
evaluating - - O
the - - O
effect - - O
of - - O
the - - O
two - - O
drugs - - O
given - - O
together - - O
, - - O
compared - - O
to - - O
the - - O
effect - - O
of - - O
each - - O
drug - - O
given - - O
separately - - O
. - - O

A - - O
385 - - B-MUT
bp - - I-MUT
Glucocorticoid - - I-MUT
Response - - I-MUT
Unit - - I-MUT
( - - O
GRU - - B-MUT
) - - O
was - - O
identified - - O
whose - - O
glucocorticoid - - O
induction - - O
was - - O
enhanced - - O
by - - O
dibutyryl-cAMP - - O
and - - O
reduced - - O
by - - O
phorbol - - O
esters - - O
. - - O

The - - O
Novacor - - O
Left - - O
Ventricular - - O
Assist - - O
System - - O
( - - O
LVAS - - O
) - - O
( - - O
Novacor - - O
Corp - - O
, - - O
Oakland - - O
, - - O
CA - - O
) - - O
was - - O
initially - - O
console-based - - O
and - - O
has - - O
been - - O
available - - O
since - - O
1993 - - O
in - - O
a - - O
wearable - - O
configuration - - O
. - - O

In - - O
the - - O
absence - - O
of - - O
Mg2+ - - O
, - - O
a - - O
hydrophobic - - O
exonuclease - - B-MUT
site - - I-MUT
dominates - - O
over - - O
the - - O
polymerase - - B-MUT
site - - I-MUT
for - - O
possession - - O
of - - O
the - - O
primer - - O
terminus - - O
. - - O

Both - - O
carbachol - - O
( - - O
100 - - O
microM - - O
) - - O
and - - O
EGF - - B-MUT
( - - O
10 - - O
nM - - O
) - - O
induced - - O
Ras - - B-MUT
activation - - O
. - - O

Statistics - - O
for - - O
nurse - - O
managers--3 - - O
. - - O

These - - O
results - - O
suggest - - O
that - - O
low - - O
concentrations - - O
of - - O
IL-1 - - B-MUT
beta - - I-MUT
may - - O
be - - O
useful - - O
for - - O
nonsurgical - - O
treatment - - O
of - - O
human - - O
vitreous - - O
hemorrhage - - O
. - - O

Results - - O
of - - O
the - - O
official - - O
inspection - - O
of - - O
the - - O
commercial - - O
anti-inflammatory - - O
enzyme - - O
preparations - - O
containing - - O
chymotrypsin - - B-MUT
and - - O
trypsin - - B-MUT
by - - O
means - - O
of - - O
modified - - O
NF - - O
13 - - O
methods - - O
. - - O

T - - O
cell - - O
leukemia-associated - - O
human - - O
Notch - - O
translocation-associated - - O
Notch - - O
homologue - - B-MUT
has - - I-MUT
I - - O
kappa - - O
B-like - - O
activity - - O
and - - O
physically - - O
interacts - - O
with - - O
nuclear - - O
factor-kappa - - B-MUT
B - - I-MUT
proteins - - I-MUT
in - - I-MUT
T - - O
cells - - O
. - - O

A - - O
stratified - - O
random - - O
sample - - O
of - - O
20 - - O
active - - O
employees - - O
from - - O
a - - O
cohort - - O
of - - O
phenoxy - - O
herbicide - - O
workers - - O
was - - O
selected - - O
in - - O
1995 - - O
for - - O
determining - - O
PCDD - - O
and - - O
PCDF - - O
congeners - - O
in - - O
blood - - O
lipids - - O
to - - O
assess - - O
the - - O
extent - - O
of - - O
past - - O
PCDD - - O
and - - O
PCDF - - O
exposure - - O
in - - O
this - - O
cohort - - O
and - - O
whether - - O
that - - O
exposure - - O
might - - O
explain - - O
site-specific - - O
cancer - - O
findings - - O
in - - O
the - - O
total - - O
cohort - - O
. - - O

A - - O
point - - O
mutation - - O
in - - O
Galphao - - B-MUT
and - - O
Galphai1 - - B-MUT
blocks - - O
interaction - - O
with - - O
regulator - - O
of - - O
G - - B-MUT
protein - - I-MUT
signaling - - O
proteins - - O
. - - O

Linear - - O
regression - - O
analysis - - O
was - - O
performed - - O
and - - O
the - - O
following - - O
result - - O
was - - O
obtained - - O
: - - O
clearance - - O
( - - O
HMPAO - - O
) - - O
= - - O
0 - - O
. - - O
07 - - O
+ - - O
0 - - O
. - - O
43 - - O
. - - O
rCBF - - O
with - - O
a - - O
high - - O
significance - - O
( - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
001 - - O
) - - O
. - - O

Copyright - - O
2001 - - O
Academic - - O
Press - - O
. - - O

Conformational - - O
changes - - O
of - - O
the - - O
ferric - - O
uptake - - O
regulation - - O
protein - - O
upon - - O
metal - - O
activation - - O
and - - O
DNA - - O
binding - - O
; - - O
first - - O
evidence - - O
of - - O
structural - - O
homologies - - O
with - - O
the - - O
diphtheria - - B-MUT
toxin - - I-MUT
repressor - - I-MUT
. - - O

The - - O
genome - - O
organization - - O
of - - O
the - - O
mite-transmitted - - O
wheat - - O
streak - - O
mosaic - - O
virus - - O
( - - O
WSMV - - O
) - - O
appears - - O
to - - O
parallel - - O
that - - O
of - - O
members - - O
of - - O
the - - O
Potyviridae - - O
with - - O
monopartite - - O
genomes - - O
, - - O
but - - O
there - - O
are - - O
substantial - - O
amino - - O
acid - - O
dissimilarities - - O
with - - O
other - - O
potyviral - - O
polyproteins - - O
. - - O

Acupuncture - - O
effect - - O
on - - O
deep - - O
receptors - - O
was - - O
not - - O
limited - - O
to - - O
one - - O
point - - O
but - - O
within - - O
a - - O
certain - - O
area - - O
, - - O
namely - - O
distant - - O
effect - - O
existed - - O
. - - O

Cbl - - B-MUT
constitutively - - O
interacts - - O
with - - O
the - - O
SH3 - - B-MUT
domains - - I-MUT
of - - O
Grb2 - - B-MUT
, - - O
with - - O
a - - O
preference - - O
for - - O
the - - O
amino-terminal - - O
domain - - O
, - - O
and - - O
is - - O
in - - O
this - - O
way - - O
recruited - - O
to - - O
Shc - - B-MUT
upon - - O
BCR - - B-MUT
stimulation - - O
. - - O

Colorectal - - O
carcinoma - - O
: - - O
therapeutic - - O
approach - - O
in - - O
patients - - O
already - - O
treated - - O
with - - O
metastasis - - O
resection - - O
. - - O

The - - O
frequency - - O
of - - O
previous - - O
transfusion - - O
in - - O
chronic - - O
hepatitis - - O
, - - O
cirrhosis - - O
and - - O
hepatocellular - - O
carcinoma - - O
of - - O
type - - O
NANB - - O
was - - O
42 - - O
. - - O
8 - - O
, - - O
37 - - O
. - - O
1 - - O
and - - O
15 - - O
. - - O
1% - - O
, - - O
respectively - - O
, - - O
whereas - - O
the - - O
incidence - - O
of - - O
early - - O
posttransfusion - - O
hepatitis - - O
was - - O
8 - - O
. - - O
5 - - O
, - - O
8 - - O
. - - O
6 - - O
and - - O
7 - - O
. - - O
5% - - O
, - - O
respectively - - O
. - - O
in - - O
chronic - - O
liver - - O
diseases - - O
with - - O
a - - O
history - - O
of - - O
jaundice - - O
and - - O
or - - O
hepatitis - - O
, - - O
previous - - O
transfusions - - O
are - - O
more - - O
frequently - - O
associated - - O
with - - O
type - - O
NANB - - O
than - - O
with - - O
type - - O
B - - O
disease - - O
. - - O

Distribution - - O
and - - O
changing - - O
morphological - - O
course - - O
. - - O

Bacteriol - - O
. - - O

By - - O
creating - - O
Pax-6-BSAP - - B-MUT
fusion - - I-MUT
proteins - - I-MUT
, - - O
we - - O
were - - O
able - - O
to - - O
identify - - O
a - - O
short - - O
amino - - O
acid - - O
stretch - - O
in - - O
the - - O
N-terminal - - O
part - - O
of - - O
the - - O
paired - - O
domain - - O
which - - O
is - - O
responsible - - O
for - - O
these - - O
differences - - O
in - - O
DNA-binding - - O
specificity - - O
. - - O

This - - O
computerized - - O
list - - O
was - - O
linked - - O
to - - O
the - - O
central - - O
files - - O
of - - O
the - - O
Massachusetts - - O
Cancer - - O
Registry - - O
and - - O
cases - - O
diagnosed - - O
between - - O
1982 - - O
and - - O
1988 - - O
were - - O
identified - - O
. - - O

Significance - - O
of - - O
delta-aminolevulinic - - O
acid - - O
analysis - - O
in - - O
clinical - - O
tests - - O
. - - O

Following - - O
iv - - O
injection - - O
of - - O
0 - - O
. - - O
5 - - O
g - - O
galactose - - O
per - - O
kg - - O
body - - O
weight - - O
, - - O
together - - O
with - - O
2 - - O
mu - - O
Ci - - O
generally - - O
14C-labelled - - O
galactose - - O
, - - O
14CO2 - - O
is - - O
collected - - O
in - - O
regular - - O
intervals - - O
during - - O
one - - O
hour - - O
. - - O

A - - O
clinically - - O
useful - - O
diagnostic - - O
method - - O
has - - O
been - - O
developed - - O
for - - O
detecting - - O
and - - O
quantitating - - O
periods - - O
of - - O
apnea - - O
in - - O
pediatric - - O
patients - - O
. - - O

A - - O
value - - O
of - - O
1 - - O
. - - O
1 - - O
l - - O
kg - - O
was - - O
used - - O
for - - O
V - - O
in - - O
calculating - - O
all - - O
single - - O
sample - - O
estimates - - O
of - - O
clearance - - O
( - - O
CL - - O
) - - O
, - - O
and - - O
a - - O
value - - O
of - - O
4 - - O
. - - O
3 - - O
l - - O
kg - - O
was - - O
used - - O
to - - O
calculate - - O
single - - O
sample - - O
estimates - - O
of - - O
clearance - - O
of - - O
plasma - - O
unbound - - O
drug - - O
( - - O
CLunb - - O
) - - O
. - - O

The - - O
catenins - - B-MUT
bind - - O
to - - O
APC - - B-MUT
and - - O
E-cadherin - - B-MUT
in - - O
a - - O
similar - - O
fashion - - O
, - - O
but - - O
APC - - B-MUT
and - - O
E-cadherin - - B-MUT
do - - O
not - - O
associate - - O
with - - O
each - - O
other - - O
either - - O
in - - O
the - - O
presence - - O
or - - O
absence - - O
of - - O
catenins - - B-MUT
. - - O

The - - O
rhaB - - B-MUT
transcription - - I-MUT
start - - I-MUT
site - - I-MUT
was - - O
mapped - - O
to - - O
-24 - - O
relative - - O
to - - O
the - - O
start - - O
of - - O
translation - - O
. - - O

Despite - - O
the - - O
activation - - O
of - - O
these - - O
intracellular - - O
signaling - - O
molecules - - O
, - - O
PDGF - - B-MUT
beta - - I-MUT
receptor - - I-MUT
activation - - O
elicited - - O
no - - O
detectable - - O
effect - - O
on - - O
cell - - O
proliferation - - O
or - - O
differentiation - - O
. - - O

A - - O
fusion - - O
protein - - O
composed - - O
of - - O
beta-galactosidase - - B-MUT
and - - O
full-length - - B-MUT
Ahr - - I-MUT
translocates - - O
from - - O
the - - O
cytoplasm - - O
to - - O
the - - O
nucleus - - O
in - - O
a - - O
ligand-dependent - - O
manner - - O
. - - O

In - - O
strains - - O
lacking - - O
tup11 - - B-MUT
and - - O
tup12 - - B-MUT
, - - O
the - - O
atf1-pcr1 - - B-MUT
transcriptional - - I-MUT
activator - - I-MUT
continues - - O
to - - O
play - - O
a - - O
central - - O
role - - O
in - - O
fbp1-lacZ - - B-MUT
expression - - O
; - - O
however - - O
, - - O
spc1 - - B-MUT
MAPK - - I-MUT
phosphorylation - - O
of - - O
atf1 - - B-MUT
is - - O
no - - O
longer - - O
essential - - O
for - - O
its - - O
activation - - O
. - - O

In - - O
contrast - - O
to - - O
full-length - - B-MUT
E2F-3 - - I-MUT
, - - O
which - - O
is - - O
expressed - - O
only - - O
at - - O
the - - O
G1 - - O
S - - O
boundary - - O
, - - O
E2F-3B - - O
is - - B-MUT
detected - - O
throughout - - O
the - - O
cell - - O
cycle - - O
with - - O
peak - - O
levels - - O
in - - O
GO - - O
where - - O
it - - O
is - - O
associated - - O
with - - O
Rb - - O
. - - O

A - - O
5 - - B-MUT
. - - I-MUT
8S-like - - I-MUT
structure - - I-MUT
is - - O
present - - O
within - - O
the - - O
5'-terminal - - O
region - - O
of - - O
all - - O
three - - O
fungal - - B-MUT
mitochondrial - - I-MUT
LSU - - I-MUT
rRNAs - - I-MUT
; - - O
in - - O
contrast - - O
, - - O
no - - O
4 - - B-MUT
. - - I-MUT
5S-like - - I-MUT
structure - - I-MUT
is - - O
evident - - O
at - - O
the - - O
3' - - O
end - - O
of - - O
these - - O
molecules - - O
. - - O

Phenotypic - - O
changes - - O
induced - - O
by - - O
wild - - B-MUT
type - - I-MUT
and - - I-MUT
variant - - I-MUT
c-src - - I-MUT
genes - - I-MUT
carrying - - O
C-terminal - - O
sequence - - O
alterations - - O
. - - O

These - - O
results - - O
suggest - - O
that - - O
members - - O
of - - O
the - - O
ATF - - B-MUT
family - - I-MUT
are - - O
involved - - O
in - - O
mediating - - O
the - - O
transcriptional - - O
regulation - - O
of - - O
the - - O
KGF - - B-MUT
gene - - I-MUT
in - - O
response - - O
to - - O
extracellular - - O
stimuli - - O
via - - O
a - - O
novel - - O
CRE - - B-MUT
regulatory - - I-MUT
element - - I-MUT
. - - O

Unusual - - O
two-domain - - B-MUT
arginine - - I-MUT
kinases - - I-MUT
( - - O
AKs - - B-MUT
) - - O
arose - - O
independently - - O
at - - O
least - - O
two - - O
times - - O
during - - O
molecular - - O
evolution - - O
of - - O
phosphagen - - B-MUT
kinases - - I-MUT
: - - O
AKs - - B-MUT
from - - O
the - - O
primitive - - O
sea - - O
anemone - - O
Anthopleurura - - O
japonicus - - O
and - - O
from - - O
the - - O
clam - - O
Pseudocardium - - O
sachalinensis - - O
. - - O

Stable - - O
expression - - O
of - - O
the - - O
chimeric - - O
alpha - - O
i - - O
( - - O
54 - - O
) - - O
s - - O
polypeptide - - O
in - - O
Chinese - - O
hamster - - O
ovary - - O
( - - O
CHO - - O
) - - O
cells - - O
constitutively - - O
increased - - O
both - - O
cAMP - - O
synthesis - - O
and - - O
cAMP-dependent - - O
protein - - B-MUT
kinase - - I-MUT
activity - - I-MUT
. - - O

Ca2+ - - O
decreased - - O
Zn2+ - - O
binding - - O
in - - O
S100 - - B-MUT
beta - - I-MUT
but - - O
it - - O
did - - O
not - - O
influence - - O
binding - - O
to - - O
MRP14 - - B-MUT
, - - O
suggesting - - O
that - - O
the - - O
Zn2+ - - O
binding - - O
site - - O
was - - O
distinct - - O
from - - O
and - - O
independent - - O
of - - O
the - - O
two - - O
Ca2+ - - O
binding - - O
domains - - O
. - - O

However - - O
, - - O
rapamycin - - O
inhibited - - O
proliferation - - O
of - - O
Ba - - O
F3-EpoRgp55 - - O
but - - O
not - - O
of - - O
MEL - - O
cells - - O
despite - - O
inhibition - - O
of - - O
p70 - - O
S6 - - B-MUT
kinase - - I-MUT
activity - - I-MUT
in - - O
both - - O
cells - - O
. - - O

Further - - O
, - - O
the - - O
PIP2 - - O
content - - O
of - - O
the - - O
85-90 - - O
kDa - - O
protein - - O
appeared - - O
to - - O
decrease - - O
with - - O
CSF-1 - - B-MUT
treatment - - O
. - - O

Experimental - - O
ischemic - - O
heart - - O
disease - - O
induced - - O
by - - O
thromboxane - - B-MUT
A2 - - I-MUT
in - - O
rabbits - - O
. - - O

This - - O
spindle - - O
defect - - O
of - - O
pds1 - - B-MUT
mutants - - I-MUT
results - - O
from - - O
a - - O
temperature-sensitive - - O
step - - O
that - - O
occurs - - O
around - - O
the - - O
G1 - - O
S - - O
boundary - - O
about - - O
the - - O
time - - O
of - - O
spindle - - O
assembly - - O
. - - O

The - - O
discordant - - O
behaviour - - O
in - - O
weakly - - O
infected - - O
mice - - O
was - - O
due - - O
to - - O
the - - O
occurrence - - O
in - - O
some - - O
animals - - O
of - - O
a - - O
second - - O
phase - - O
of - - O
more - - O
rapid - - O
increase - - O
of - - O
the - - O
parasitemia - - O
. - - O

Behcet's - - O
syndrome - - O
. - - O

Serum - - O
lipids - - O
and - - O
lipoproteins - - O
of - - O
29 - - O
insulin - - B-MUT
dependent - - O
diabetic - - O
children - - O
have - - O
been - - O
determined - - O
and - - O
related - - O
to - - O
the - - O
metabolic - - O
status - - O
of - - O
the - - O
patients - - O
. - - O

Since - - O
general - - B-MUT
regulatory - - I-MUT
factor - - I-MUT
I - - I-MUT
( - - O
GRFI - - B-MUT
) - - O
repressor - - B-MUT
activator - - I-MUT
site - - I-MUT
binding - - I-MUT
protein - - I-MUT
1 - - I-MUT
( - - I-MUT
RAP1 - - I-MUT
) - - O
translation - - B-MUT
upstream - - O
factor - - B-MUT
( - - I-MUT
TUF - - I-MUT
) - - I-MUT
is - - O
believed - - B-MUT
to - - O
be - - O
an - - O
activator - - O
of - - O
MAT - - O
alpha - - O
expression - - O
, - - B-MUT
we - - I-MUT
examined - - O
whether - - O
PYK1 - - O
, - - O
which - - O
is - - B-MUT
known - - O
to - - O
be - - O
regulated - - O
by - - O
GRFI - - O
RAP1 - - O
TUF - - O
, - - B-MUT
is - - I-MUT
also - - I-MUT
affected - - I-MUT
by - - I-MUT
the - - O
gal11 - - O
mutation - - O
. - - O

In - - O
both - - O
groups - - O
there - - O
were - - O
5 - - O
management - - O
failure - - O
of - - O
therapy - - O
, - - O
so - - O
that - - O
alternative - - O
medication - - O
or - - O
a - - O
cesarean - - O
section - - O
lead - - O
to - - O
delivery - - O
. - - O

LHbeta - - B-MUT
is - - O
expressed - - O
in - - O
pituitary - - O
gonadotrope - - O
cells - - O
and - - O
CGbeta - - B-MUT
is - - O
expressed - - O
in - - O
placental - - O
trophoblast - - O
cells - - O
. - - O

Williams - - O
, - - O
2 - - O
August - - O
1977 - - O
. - - O

These - - O
results - - O
suggest - - O
that - - O
, - - O
in - - O
this - - O
experimental - - O
model - - O
, - - O
ACE - - B-MUT
inhibitors - - O
limit - - O
the - - O
arrhythmias - - O
following - - O
ischemia-reperfusion - - O
and - - O
free - - O
radical - - O
scavenging - - O
action - - O
of - - O
these - - O
drugs - - O
does - - O
not - - O
have - - O
a - - O
major - - O
contributory - - O
role - - O
in - - O
their - - O
protective - - O
effect - - O
. - - O

Skin - - O
cancers - - O
, - - O
followed - - O
by - - O
gastrointestinal - - O
tract - - O
and - - O
male - - O
genital - - O
system - - O
affected - - O
mostly - - O
older - - O
age - - O
patients - - O
. - - O

ICAM-1 - - B-MUT
has - - O
been - - O
suggested - - O
a - - O
predictor - - O
of - - O
the - - O
onset - - O
of - - O
GO - - O
. - - O

CONCLUSIONS - - O
: - - O
EBCT - - O
technology - - O
allows - - O
minimally - - O
invasive - - O
evaluation - - O
of - - O
intramyocardial - - O
microcirculatory - - O
function - - O
and - - O
permits - - O
assessment - - O
of - - O
microvascular - - O
BV - - O
distribution - - O
in - - O
different - - O
functional - - O
components - - O
. - - O

( - - O
2 - - O
) - - O
The - - O
inappropriateness - - O
of - - O
adaptive - - O
segmentation - - O
for - - O
the - - O
isolation - - O
of - - O
spikes - - O
and - - O
sharp - - O
waves - - O
, - - O
which - - O
had - - O
been - - O
anticipated - - O
in - - O
view - - O
of - - O
the - - O
short - - O
duration - - O
of - - O
such - - O
transients - - O
in - - O
relation - - O
to - - O
the - - O
length - - O
of - - O
the - - O
window - - O
( - - O
1 - - O
. - - O
2 - - O
sec - - O
) - - O
used - - O
for - - O
the - - O
autocorrelation - - O
functions - - O
employed - - O
in - - O
the - - O
segmentation - - O
algorithm - - O
, - - O
was - - O
confirmed - - O
. - - O

The - - O
acids - - O
were - - O
obtained - - O
by - - O
hydrolysis - - O
of - - O
the - - O
corresponding - - O
esters - - O
, - - O
and - - O
their - - O
anti-inflammatory - - O
activity - - O
was - - O
tested - - O
. - - O

All - - O
six - - O
genes - - O
were - - O
cloned - - O
and - - O
characterised - - O
. - - O

Autotransplantation - - O
of - - O
a - - O
vein - - O
segment - - O
with - - O
valve - - O
in - - O
the - - O
treatment - - O
of - - O
deep - - O
vein - - O
valvular - - O
insufficiency - - O
of - - O
the - - O
lower - - O
extremity - - O
. - - O

The - - O
mean - - O
body - - O
mass - - O
index - - O
( - - O
BMI - - O
) - - O
was - - O
31 - - O
. - - O
8 - - O
+ - - O
- - - O
6 - - O
. - - O
3 - - O
kg - - O
m2 - - O
and - - O
28 - - O
. - - O
5 - - O
+ - - O
- - - O
6 - - O
. - - O
3 - - O
kg - - O
m2 - - O
in - - O
women - - O
and - - O
men - - O
, - - O
respectively - - O
. - - O

CONCLUSION - - O
: - - O
In - - O
women - - O
who - - O
want - - O
or - - O
require - - O
conservative - - O
management - - O
of - - O
grade - - O
4 - - O
prolapse - - O
and - - O
are - - O
unable - - O
to - - O
retain - - O
a - - O
single - - O
pessary - - O
, - - O
the - - O
placement - - O
of - - O
two - - O
pessaries - - O
often - - O
will - - O
be - - O
successful - - O
. - - O

JCAHO - - O
asks - - O
for - - O
hospitals' - - O
patience - - O
. - - O

This - - O
interaction - - O
is - - O
reciprocal - - O
, - - O
since - - O
C - - B-MUT
EBP - - I-MUT
dimer - - I-MUT
binding - - I-MUT
to - - O
a - - O
strong - - O
C - - O
EBP - - B-MUT
site - - I-MUT
leads - - I-MUT
to - - I-MUT
enhanced - - O
CREB-1 - - O
recruitment - - O
to - - B-MUT
ATF - - O
CREB - - O
sites - - B-MUT
that - - I-MUT
are - - I-MUT
weakly - - I-MUT
bound - - O
by - - O
CREB - - O
. - - O

Possible - - O
relationship - - O
between - - O
hyperinsulinemia - - O
and - - O
glomerular - - O
hypertrophy - - O
in - - O
nephrosclerosis - - O
. - - O

Mutations - - O
in - - O
the - - O
alpha-amanitin - - B-MUT
conserved - - O
domain - - O
of - - O
the - - O
largest - - O
subunit - - O
of - - O
yeast - - B-MUT
RNA - - I-MUT
polymerase - - I-MUT
III - - I-MUT
affect - - O
pausing - - O
, - - O
RNA - - O
cleavage - - O
and - - O
transcriptional - - O
transitions - - O
. - - O

Since - - O
very - - O
recent - - O
scanning-deletion - - O
analysis - - O
indicates - - O
that - - O
there - - O
is - - O
a - - O
critical - - O
region - - O
for - - O
activity - - O
near - - O
Cys-118 - - O
and - - O
that - - O
Cys-118 - - O
is - - O
necessary - - O
for - - O
maximal - - O
activity - - O
, - - O
we - - O
conclude - - O
that - - O
the - - O
Cys-118 - - O
residue - - O
is - - O
necessary - - O
for - - O
proper - - O
glycosylation - - O
and - - O
maximal - - O
biologic - - O
activity - - O
of - - O
GM-CSF - - B-MUT
. - - O

1972 - - O
. - - O

The - - O
findings - - O
suggest - - O
that - - O
, - - O
although - - O
iodine - - O
deficiency - - O
is - - O
the - - O
most - - O
probable - - O
cause - - O
of - - O
goiter - - O
among - - O
immigrants - - O
of - - O
the - - O
1928 - - O
cohort - - O
, - - O
where - - O
the - - O
native - - O
population - - O
is - - O
concerned - - O
( - - O
both - - O
men - - O
and - - O
women - - O
) - - O
, - - O
some - - O
other - - O
goitrogenic - - O
factor - - O
( - - O
s - - O
) - - O
must - - O
be - - O
involved - - O
. - - O

"Let - - O
the - - O
hundred - - O
flowers - - O
bloom" - - O
. - - O

Fragments - - O
and - - O
analogs - - O
of - - O
the - - O
hormone - - O
ACTH - - B-MUT
were - - O
previously - - O
shown - - O
to - - O
have - - O
beneficial - - O
effect - - O
on - - O
the - - O
outcome - - O
of - - O
head - - O
injury - - O
, - - O
while - - O
elevated - - O
levels - - O
of - - O
corticosterone - - O
( - - O
CS - - O
) - - O
exacerbate - - O
it - - O
. - - O

Cardiac - - O
taurine - - O
levels - - O
and - - O
sarcolemmal - - O
calcium - - O
binding - - O
activity - - O
in - - O
furazolidone-induced - - O
cardiomyopathy - - O
. - - O

This - - O
is - - O
concluded - - O
from - - O
the - - O
isolation - - O
of - - O
cDNAs - - O
from - - O
spinach - - O
( - - O
Spinacia - - O
oleracea - - O
) - - O
and - - O
barley - - O
( - - O
Hordeum - - O
vulgare - - O
cv - - O
. - - O

Over-expression - - O
of - - O
Azf1p - - B-MUT
in - - O
the - - O
yeast - - O
cell - - O
does - - O
not - - O
influence - - O
the - - O
expression - - O
level - - O
of - - O
the - - O
mitochondrial - - B-MUT
transcription - - I-MUT
factor - - I-MUT
Mtf1p - - I-MUT
, - - O
indicating - - O
that - - O
the - - O
influence - - O
of - - O
Azf1p - - B-MUT
on - - O
the - - O
suppression - - O
of - - O
the - - O
special - - O
mitochondrial - - B-MUT
RNA - - I-MUT
polymerase - - I-MUT
mutant - - I-MUT
is - - O
an - - O
indirect - - O
one - - O
. - - O

Treatment - - O
with - - O
MK-801 - - O
induced - - O
a - - O
burst - - O
suppression - - O
in - - O
the - - O
EEG - - O
and - - O
a - - O
transient - - O
drop - - O
( - - O
11 - - O
. - - O
4 - - O
+ - - O
- - - O
6 - - O
. - - O
5 - - O
mm - - O
Hg - - O
) - - O
in - - O
the - - O
mean - - O
arterial - - O
pressure - - O
. - - O

We - - O
have - - O
also - - O
found - - O
that - - O
the - - O
in - - O
vitro - - O
interaction - - O
between - - O
the - - O
SV40 - - O
octamer - - O
motif - - O
and - - O
the - - O
lymphoid - - B-MUT
cell-specific - - I-MUT
protein - - I-MUT
oct-B2 - - I-MUT
was - - O
negatively - - O
modulated - - O
by - - O
a - - O
component - - O
present - - O
in - - O
the - - O
nuclear - - O
extracts - - O
from - - O
several - - O
lymphoid - - O
cell - - O
lines - - O
. - - O

The - - O
appearance - - O
of - - O
dyskinetic - - O
movement - - O
disorders - - O
in - - O
humans - - O
following - - O
the - - O
chronic - - O
use - - O
of - - O
levodopa - - O
or - - O
amphetamine - - O
may - - O
be - - O
a - - O
manifestation - - O
of - - O
similarly - - O
increased - - O
dopamine - - B-MUT
receptor - - I-MUT
site - - I-MUT
sensitivity - - O
within - - O
the - - O
striatum - - O
. - - O

The - - O
obtained - - O
results - - O
were - - O
compared - - O
with - - O
control - - O
group - - O
( - - O
10 - - O
female - - O
volunteers - - O
) - - O
. - - O

DNA-STAT - - B-MUT
complexes - - I-MUT
were - - O
detected - - O
in - - O
all - - O
Bcr - - O
Abl-transformed - - O
cell - - O
lines - - O
and - - O
they - - O
were - - O
supershifted - - O
by - - O
antibodies - - O
against - - O
STAT1 - - O
and - - B-MUT
STAT5 - - O
. - - B-MUT

But - - O
the - - O
application - - O
solutions - - O
of - - O
instrument - - O
disinfectants - - O
should - - O
not - - O
be - - O
used - - O
longer - - O
than - - O
one - - O
day - - O
. - - O

Four - - O
CsA-treated - - O
patients - - O
developed - - O
persistently - - O
elevated - - O
UAER - - O
> - - O
30 - - O
mg - - O
24 - - O
h - - O
( - - O
n - - O
= - - O
3 - - O
with - - O
microalbuminuria - - O
) - - O
, - - O
whereas - - O
all - - O
the - - O
17 - - O
placebo-treated - - O
patients - - O
had - - O
normal - - O
UAER - - O
( - - O
< - - O
30 - - O
mg - - O
24 - - O
h - - O
) - - O
after - - O
7 - - O
years - - O
of - - O
follow-up - - O
. - - O

This - - O
brief - - O
review - - O
analyses - - O
these - - O
interactions - - O
and - - O
defines - - O
clinical - - O
settings - - O
where - - O
antibiotic-induced - - O
endotoxin - - B-MUT
release - - O
may - - O
prove - - O
to - - O
be - - O
clinically - - O
relevant - - O
. - - O

These - - O
studies - - O
serve - - O
as - - O
the - - O
basis - - O
for - - O
the - - O
further - - O
characterization - - O
of - - O
the - - O
regulatory - - O
mechanism - - O
of - - O
aromatase - - B-MUT
expression - - O
in - - O
human - - O
breast - - O
cancer - - O
and - - O
ASCs - - O
. - - O

However - - O
, - - O
a - - O
similar - - O
mutation - - O
of - - O
a - - O
leucine - - O
residue - - O
to - - O
arginine - - O
at - - O
position - - O
422 - - O
showed - - O
no - - O
alteration - - O
of - - O
heterodimerization - - O
, - - O
DNA - - O
binding - - O
, - - O
or - - O
transcriptional - - O
activation - - O
. - - O

Studies - - O
carried - - O
out - - O
with - - O
the - - O
Glossina - - O
morsitans - - O
colony - - O
of - - O
Lisbon - - O
. - - O

Steal - - O
is - - O
a - - O
pathophysiological - - O
process - - O
in - - O
which - - O
increased - - O
blood - - O
flow - - O
through - - O
a - - O
low-resistance - - O
vascular - - O
bed - - O
is - - O
sufficient - - O
to - - O
divert - - O
flow - - O
away - - O
from - - O
a - - O
region - - O
of - - O
the - - O
central - - O
nervous - - O
system - - O
. - - O

Cross-reaction - - O
between - - O
a - - O
monoclonal - - O
antibody - - O
and - - O
two - - O
alpha - - B-MUT
beta - - I-MUT
T - - I-MUT
cell - - I-MUT
receptors - - I-MUT
. - - O

The - - O
coordinate - - O
increase - - O
in - - O
cyclin - - B-MUT
D1 - - I-MUT
and - - O
p21 - - B-MUT
had - - O
the - - O
effect - - O
of - - O
decreasing - - O
the - - O
specific - - O
but - - O
not - - O
absolute - - O
activity - - O
of - - O
cyclin - - B-MUT
D1 - - I-MUT
cdk4 - - I-MUT
. - - I-MUT
p53 - - O
was - - B-MUT
not - - O
involved - - O
since - - O
CSF-1 - - O
induction - - B-MUT
of - - O
p21 - - O
was - - B-MUT
unaffected - - O
by - - O
dominant-negative - - O
p53 - - B-MUT
expression - - I-MUT
. - - O

We - - O
show - - O
that - - O
stabilization - - O
of - - O
the - - O
hairpin - - O
reduced - - O
the - - O
amount - - O
of - - O
tRNA - - O
primer - - O
that - - O
is - - O
annealed - - O
to - - O
the - - O
PBS - - O
. - - O

Our - - O
findings - - O
support - - O
the - - O
view - - O
of - - O
a - - O
multifactorial - - O
genesis - - O
of - - O
the - - O
cardiac - - O
involvement - - O
in - - O
uremic - - O
patients - - O
. - - O

Myocardial - - O
antioxidant - - O
enzymes - - O
, - - O
catalase - - B-MUT
, - - O
glutathione - - B-MUT
peroxidase - - I-MUT
and - - O
superoxide - - B-MUT
dismutase - - I-MUT
, - - O
in - - O
the - - O
MCT-treated - - O
rats - - O
were - - O
not - - O
different - - O
compared - - O
to - - O
control - - O
rats - - O
. - - O

Dietetics - - O
of - - O
childhood- - - O
and - - O
juvenile - - O
diabetes - - O
. - - O

AP - - O
was - - O
induced - - O
by - - O
intraductal - - O
infusion - - O
of - - O
two - - O
different - - O
concentrations - - O
of - - O
glycodeoxycholic - - O
acid - - O
( - - O
GDOC - - O
17 - - O
mmol - - O
and - - O
34 - - O
mmol - - O
) - - O
. - - O

Penicillinase - - B-MUT
production - - O
in - - O
Staphylococcus - - O
aureus - - O
strains - - O
of - - O
clinical - - O
importance - - O
. - - O

The - - O
PC-based - - O
RTPS - - O
is - - O
designed - - O
to - - O
run - - O
in - - O
the - - O
Microsoft - - O
Windows - - O
3 - - O
. - - O
11 - - O
environment - - O
( - - O
and - - O
later - - O
versions - - O
) - - O
, - - O
for - - O
computers - - O
equipped - - O
with - - O
486 - - O
or - - O
Pentium - - O
processors - - O
. - - O

Our - - O
data - - O
show - - O
also - - O
that - - O
phagocytic - - O
killing - - O
of - - O
meningococci - - O
is - - O
probably - - O
a - - O
more - - O
consistent - - O
assay - - O
than - - O
antibody - - O
titer - - O
levels - - O
for - - O
antimeningococcal - - O
immunity - - O
, - - O
especially - - O
in - - O
LCC-deficient - - O
patients - - O
. - - O

Human - - O
synovial - - O
fluid - - O
: - - O
detection - - O
of - - O
a - - O
new - - O
component - - O
. - - O

Desmethylferrochloroquine - - O
1a - - O
and - - O
didesmethylferrochloroquine - - O
2 - - O
would - - O
be - - O
more - - O
potent - - O
against - - O
schizontocides - - O
than - - O
CQ - - O
in - - O
vitro - - O
against - - O
two - - O
strains - - O
( - - O
HB3 - - O
and - - O
Dd2 - - O
) - - O
of - - O
Plasmodium - - O
falciparum - - O
. - - O

Furthermore - - O
, - - O
this - - O
study - - O
looks - - O
at - - O
the - - O
impact - - O
of - - O
synthesis - - O
conditions - - O
on - - O
block - - O
length - - O
and - - O
crystallinity - - O
, - - O
and - - O
the - - O
impact - - O
of - - O
the - - O
blocking - - O
on - - O
both - - O
, - - O
crystallinity - - O
and - - O
solubility - - O
of - - O
the - - O
polymers - - O
. - - O

The - - O
carboxy - - O
terminus - - O
of - - O
Mbp1 - - B-MUT
is - - O
sufficient - - O
for - - O
interaction - - O
with - - O
Swi6 - - B-MUT
, - - O
and - - O
the - - O
carboxy - - O
terminus - - O
of - - O
Swi6 - - B-MUT
is - - O
required - - O
for - - O
interaction - - O
with - - O
Mbp1 - - B-MUT
. - - O

10 - - O
long-term - - O
hemodialysis - - O
patients - - O
had - - O
immediate - - O
and - - O
redistribution - - O
thallium-201 - - O
myocardial - - O
imaging - - O
performed - - O
after - - O
a - - O
course - - O
of - - O
hemodialysis - - O
. - - O

However - - O
, - - O
L-plastin - - B-MUT
has - - O
been - - O
found - - O
in - - O
many - - O
types - - O
of - - O
malignant - - O
human - - O
cells - - O
of - - O
non-hemopoietic - - O
origin - - O
suggesting - - O
that - - O
its - - O
expression - - O
is - - O
induced - - O
accompanying - - O
tumorigenesis - - O
in - - O
solid - - O
tissues - - O
. - - O

Neither - - O
is - - O
it - - O
a - - O
major - - O
cause - - O
of - - O
rehydration-induced - - O
renal - - O
Na - - O
retention - - O
. - - O

Gel - - O
mobility - - O
shift - - O
and - - O
super-shift - - O
assays - - O
using - - O
liver - - O
nuclear - - O
extracts - - O
from - - O
either - - O
rat - - O
liver - - O
or - - O
DDT1MF-2 - - O
cells - - O
demonstrated - - O
that - - O
the - - O
CRE - - B-MUT
in - - O
the - - O
alpha - - B-MUT
1B-AR - - I-MUT
gene - - I-MUT
bound - - O
CRE - - B-MUT
binding - - I-MUT
protein - - I-MUT
. - - O

Therefore - - O
, - - O
analogs - - O
of - - O
vitamin - - O
D3 - - O
have - - O
been - - O
investigated - - O
in - - O
a - - O
number - - O
of - - O
trials - - O
showing - - O
improvement - - O
of - - O
psoriasis - - O
. - - O

A - - O
larger - - O
region - - O
upstream - - O
of - - O
human - - B-MUT
CMV - - I-MUT
dbp - - I-MUT
also - - O
mediated - - O
replication - - O
in - - O
transient - - O
assays - - O
. - - O

There - - O
is - - O
no - - O
TATA - - O
box - - O
appropriately - - O
spaced - - O
upstream - - O
from - - O
the - - O
transcription - - O
initiation - - O
site - - O
. - - O

Using - - O
this - - O
method - - O
, - - O
we - - O
were - - O
able - - O
to - - O
select - - O
strong - - O
enhancer-type - - O
activation - - O
domains - - O
from - - O
the - - O
immediate - - B-MUT
early - - I-MUT
regions - - I-MUT
of - - O
two - - O
herpesviruses - - O
, - - O
namely - - O
pseudorabies - - O
virus - - O
and - - O
bovine - - O
herpesvirus - - O
1 - - O
. - - O

An - - O
association - - O
was - - O
demonstrated - - O
between - - O
the - - O
expression - - O
of - - O
aberrantly - - O
and - - O
or - - O
alternatively - - O
spliced - - O
mdm2 - - O
mRNAs - - B-MUT
and - - I-MUT
a - - O
lack - - O
of - - O
progesterone - - O
receptor - - B-MUT
. - - I-MUT

The - - O
differentiation - - O
and - - O
maintenance - - O
of - - O
a - - O
neurotransmitter - - O
phenotype - - O
is - - O
guided - - O
by - - O
the - - O
interaction - - O
of - - O
exogenous - - O
cues - - O
with - - O
intrinsic - - O
genetic - - O
machinery - - O
. - - O

Data - - O
supported - - O
the - - O
brevity - - O
of - - O
the - - O
WISC-III - - O
short - - O
form - - O
and - - O
the - - O
criterion-related - - O
validity - - O
of - - O
both - - O
the - - O
K-FAST - - O
and - - O
and - - O
Kaufman - - O
Short - - O
Neuropsychological - - O
Assessment - - O
Procedure - - O
( - - O
K-SNAP - - O
) - - O
. - - O

In - - O
contrast - - O
, - - O
rats - - O
receiving - - O
U74500A - - O
( - - O
2 - - O
mg - - O
kg - - O
i - - O
. - - O
v - - O
. - - O
infusion - - O
commencing - - O
30 - - O
min - - O
prior - - O
to - - O
revascularisation - - O
) - - O
exhibited - - O
enhanced - - O
GMBF - - O
throughout - - O
reperfusion - - O
[ - - O
PI - - O
10 - - O
min - - O
: - - O
3 - - O
. - - O
26 - - O
( - - O
2 - - O
. - - O
56-3 - - O
. - - O
63 - - O
) - - O
; - - O
120 - - O
min - - O
: - - O
2 - - O
. - - O
03 - - O
( - - O
1 - - O
. - - O
73-2 - - O
. - - O
25 - - O
) - - O
; - - O
240 - - O
min - - O
: - - O
2 - - O
. - - O
13 - - O
( - - O
1 - - O
. - - O
75-2 - - O
. - - O
44 - - O
) - - O
, - - O
p - - O
< - - O
0 - - O
. - - O
01 - - O
vs - - O
. - - O
controls - - O
and - - O
normals - - O
] - - O
with - - O
complete - - O
muscle - - O
salvage - - O
[ - - O
GMV - - O
100% - - O
in - - O
all - - O
reperfused - - O
muscles - - O
, - - O
p - - O
< - - O
0 - - O
. - - O
01 - - O
vs - - O
. - - O
controls - - O
, - - O
not - - O
significant - - O
( - - O
NS - - O
) - - O
vs - - O
. - - O
normals - - O
and - - O
6 - - O
h - - O
ischaemia - - O
] - - O
. - - O
( - - O
ABSTRACT - - O
TRUNCATED - - O
AT - - O
250 - - O
WORDS - - O
) - - O

Phosphotyrosyl - - B-MUT
peptides - - I-MUT
block - - O
Stat3-mediated - - O
DNA-binding - - O
activity - - O
, - - O
gene - - O
regulation - - O
and - - O
cell - - O
transformation - - O
. - - O

The - - O
therapy - - O
time - - O
to - - O
deliver - - O
the - - O
NCS - - O
therapeutic - - O
dose - - O
of - - O
10000 - - O
RBE-cGy - - O
, - - O
is - - O
27 - - O
times - - O
longer - - O
when - - O
157Gd - - O
is - - O
used - - O
instead - - O
of - - O
10B - - O
. - - O

G-CSF - - B-MUT
( - - O
480 - - O
micrograms - - O
subcutaneously - - O
( - - O
s - - O
. - - O
c - - O
. - - O
) - - O
) - - O
were - - O
used - - O
in - - O
55 - - O
and - - O
GM-CSF - - B-MUT
( - - O
400 - - O
micrograms - - O
s - - O
. - - O
c - - O
. - - O
) - - O
in - - O
28 - - O
chemotherapeutic - - O
cycles - - O
. - - O

A - - O
significant - - O
relationship - - O
existed - - O
during - - O
the - - O
evolution - - O
of - - O
the - - O
disease - - O
between - - O
CRS - - O
BW - - O
and - - O
gas - - O
exchange - - O
parameters - - O
( - - O
FIO2 - - O
and - - O
a - - O
AO2 - - O
ratio - - O
) - - O
( - - O
P - - O
less - - O
than - - O
0 - - O
. - - O
01 - - O
) - - O
, - - O
but - - O
gas - - O
exchange - - O
improved - - O
earlier - - O
than - - O
lung - - O
mechanics - - O
. - - O

Specific - - O
IgE - - B-MUT
levels - - O
decreased - - O
slightly - - O
, - - O
but - - O
always - - O
remained - - O
within - - O
the - - O
pathological - - O
range - - O
. - - O

Mutating - - O
the - - O
E-box - - O
in - - O
the - - O
context - - O
of - - O
the - - O
3'-flanking - - O
region - - O
confirmed - - O
that - - O
it - - O
contributes - - O
to - - O
the - - O
enhancement - - O
of - - O
transcriptional - - O
activity - - O
of - - O
the - - O
alpha1 - - B-MUT
( - - I-MUT
I - - I-MUT
) - - I-MUT
collagen - - I-MUT
gene - - I-MUT
promoter - - I-MUT
. - - O

The - - O
study - - O
was - - O
repeated - - O
after - - O
administration - - O
of - - O
oral - - O
amiodarone - - O
, - - O
50 - - O
mg - - O
kg - - O
day - - O
for - - O
2 - - O
days - - O
in - - O
8 - - O
divided - - O
doses - - O
( - - O
mean - - O
dose - - O
6 - - O
. - - O
9 - - O
+ - - O
- - - O
0 - - O
. - - O
4 - - O
g - - O
) - - O
. - - O

VII - - O
. - - O

Ischemic - - O
heart - - O
disease - - O
, - - O
age - - O
of - - O
more - - O
than - - O
75 - - O
years - - O
, - - O
and - - O
the - - O
fact - - O
that - - O
the - - O
patient - - O
was - - O
a - - O
woman - - O
were - - O
independent - - O
predictors - - O
of - - O
poor - - O
cardiac - - O
function - - O
. - - O

To - - O
determine - - O
if - - O
the - - O
NF - - B-MUT
( - - I-MUT
H - - I-MUT
) - - I-MUT
promoter - - I-MUT
can - - O
be - - O
activated - - O
in - - O
a - - O
tissue - - O
specific - - O
manner - - O
during - - O
development - - O
transgenic - - O
mice - - O
containing - - O
the - - O
promoter - - O
region - - O
linked - - O
to - - O
a - - O
beta-galactosidase - - B-MUT
reporter - - I-MUT
gene - - I-MUT
were - - O
generated - - O
. - - O

Serum - - B-MUT
IgE - - I-MUT
levels - - O
in - - O
Tauranga - - O
children - - O
. - - O

Renal - - O
excretion - - O
of - - O
sulphadimidine - - O
in - - O
normal - - O
and - - O
uraemic - - O
subjects - - O
. - - O

It - - O
is - - O
considered - - O
that - - O
the - - O
recurrent - - O
annular - - O
erythema - - O
is - - O
a - - O
specific - - O
skin - - O
manifestation - - O
of - - O
SjS - - O
with - - O
anti - - B-MUT
SS-A - - I-MUT
SS-B - - I-MUT
antibodies - - I-MUT
. - - I-MUT

Changes - - O
of - - O
thirtynine - - O
serum - - O
protein - - O
components - - O
following - - O
surgical - - O
stress - - O
. - - O

The - - O
TAF - - O
factor - - O
appears - - O
to - - O
be - - O
particularly - - O
significant - - O
in - - O
OCD - - O
. - - O

A - - O
developmentally - - O
regulated - - O
4 - - O
. - - O
6 - - O
kb - - O
mRNA - - O
is - - O
recognized - - O
on - - O
Northern - - O
blots - - O
of - - O
oocyte - - O
RNA - - O
using - - O
the - - O
X - - O
. - - O
laevis - - O
cDNA - - O
. - - O

Cell - - O
. - - O

Reperfusion - - O
caused - - O
a - - O
transient - - O
reduction - - O
in - - O
lactate - - O
production - - O
and - - O
a - - O
significant - - O
increase - - O
in - - O
LDH - - B-MUT
release - - O
. - - O

Secondary - - O
pancreatic - - O
involvement - - O
of - - O
mycosis - - O
fungoides - - O
detected - - O
by - - O
a - - O
clinically - - O
palpable - - O
mass - - O
. - - O

The - - O
relationship - - O
between - - O
primary - - O
malignant - - O
lymphoma - - O
of - - O
the - - O
thyroid - - O
and - - O
chronic - - O
thyroiditis - - O
is - - O
discussed - - O
. - - O

Finally - - O
, - - O
antibody - - O
binding - - O
to - - O
site - - O
IIIa - - O
on - - O
the - - O
hCG-ectodomain - - B-MUT
complex - - I-MUT
was - - O
also - - O
hindered - - O
by - - O
an - - O
anti-peptide - - B-MUT
mAb - - I-MUT
directed - - O
against - - O
a - - O
peptide - - O
encoded - - O
by - - O
the - - O
eighth - - O
exon - - O
( - - O
pE - - O
x - - O
8 - - O
) - - O
of - - O
the - - O
LHR - - B-MUT
. - - O

Identical - - O
c-erbB3 - - B-MUT
transcripts - - I-MUT
are - - O
expressed - - O
in - - O
normal - - O
human - - O
placental - - O
tissues - - O
. - - O

T-cell - - O
hybridomas - - O
, - - O
thymocytes - - O
, - - O
and - - O
T - - O
cells - - O
can - - O
be - - O
induced - - O
to - - O
undergo - - O
apoptotic - - O
cell - - O
death - - O
by - - O
activation - - O
through - - O
the - - O
T-cell - - B-MUT
receptor - - I-MUT
. - - O

These - - O
data - - O
demonstrate - - O
the - - O
presence - - O
of - - O
a - - O
single - - O
binding - - O
site - - O
for - - O
vinculin - - B-MUT
, - - O
and - - O
at - - O
least - - O
two - - O
binding - - O
sites - - O
for - - O
FAK - - B-MUT
that - - O
are - - O
separated - - O
by - - O
an - - O
intervening - - O
stretch - - O
of - - O
100 - - O
amino - - O
acids - - O
. - - O

As - - O
stands - - O
shifted - - O
in - - O
dominance - - O
from - - O
pine - - O
to - - O
fir - - O
with - - O
age - - O
, - - O
subalpine - - O
fir - - O
appeared - - O
to - - O
maintain - - O
gradually - - O
increasing - - O
rates - - O
of - - O
whole-forest - - O
productivity - - O
until - - O
stands - - O
were - - O
approximately - - O
400 - - O
years - - O
old - - O
. - - O

We - - O
have - - O
identified - - O
and - - O
characterized - - O
the - - O
structure - - O
of - - O
the - - O
Spec1 - - B-MUT
gene - - I-MUT
in - - O
the - - O
sea - - O
urchin - - O
Strongylocentrotus - - O
purpuratus - - O
. - - O

The - - O
cDNA - - O
contained - - O
an - - O
open - - O
reading - - O
frame - - O
of - - O
1392 - - O
bp - - O
that - - O
predicted - - O
a - - O
protein - - O
of - - O
464 - - O
amino - - O
acids - - O
and - - O
a - - O
molecular - - O
mass - - O
of - - O
52 - - O
kDa - - O
; - - O
this - - O
protein - - O
has - - O
97% - - O
identity - - O
to - - O
rat - - B-MUT
liver - - I-MUT
glucokinase - - I-MUT
. - - O

The - - O
real - - O
challenge - - O
for - - O
the - - O
future - - O
will - - O
be - - O
the - - O
management - - O
of - - O
patients - - O
who - - O
do - - O
not - - O
respond - - O
to - - O
first-line - - O
treatment - - O
. - - O

This - - O
study - - O
was - - O
designed - - O
to - - O
assess - - O
and - - O
compare - - O
the - - O
ability - - O
of - - O
three - - O
different - - O
forms - - O
of - - O
DSG - - O
to - - O
block - - O
EIB - - O
. - - O

In - - O
the - - O
whole - - O
group - - O
of - - O
infected - - O
children - - O
, - - O
an - - O
age-specific - - O
z - - O
score - - O
< - - O
-2 - - O
for - - O
weight - - O
and - - O
for - - O
FFM - - O
was - - O
significantly - - O
associated - - O
with - - O
an - - O
increased - - O
risk - - O
of - - O
death - - O
[ - - O
relative - - O
risk - - O
( - - O
95% - - O
CI - - O
) - - O
= - - O
11 - - O
. - - O
4 - - O
( - - O
3 - - O
. - - O
1 - - O
, - - O
41 - - O
. - - O
0 - - O
) - - O
and - - O
5 - - O
. - - O
1 - - O
( - - O
1 - - O
. - - O
5 - - O
, - - O
18 - - O
. - - O
2 - - O
) - - O
, - - O
respectively - - O
] - - O
; - - O
when - - O
only - - O
children - - O
with - - O
more - - O
severe - - O
disease - - O
were - - O
considered - - O
, - - O
only - - O
z - - O
score - - O
for - - O
weight - - O
was - - O
significantly - - O
associated - - O
with - - O
an - - O
increased - - O
risk - - O
[ - - O
4 - - O
. - - O
6 - - O
( - - O
1 - - O
. - - O
4 - - O
, - - O
14 - - O
. - - O
9 - - O
) - - O
] - - O
. - - O

His - - O
carnitine - - B-MUT
palmitoyltransferase - - I-MUT
( - - I-MUT
CPT - - I-MUT
) - - I-MUT
I - - I-MUT
and - - I-MUT
II - - I-MUT
activities - - O
were - - O
0 - - O
. - - O
06 - - O
and - - O
0 - - O
. - - O
12 - - O
nmol - - O
min - - O
mg - - O
protein - - O
, - - O
as - - O
compared - - O
with - - O
a - - O
mean - - O
value - - O
of - - O
0 - - O
. - - O
22 - - O
+ - - O
- - - O
0 - - O
. - - O
14 - - O
and - - O
0 - - O
. - - O
27 - - O
+ - - O
- - - O
0 - - O
. - - O
07 - - O
nmol - - O
min - - O
mg - - O
protein - - O
, - - O
respectively - - O
, - - O
in - - O
control - - O
subjects - - O
. - - O

However - - O
, - - O
neu - - B-MUT
differentiation - - O
factor-induced - - O
heterodimers - - O
of - - O
ErbB2 - - B-MUT
and - - O
ErbB4 - - B-MUT
activated - - O
Stat5 - - B-MUT
. - - O

Coexpression - - O
of - - O
the - - O
p120 - - B-MUT
( - - I-MUT
ctn - - I-MUT
) - - I-MUT
protein - - I-MUT
with - - O
an - - O
N-terminal - - O
deletion - - O
, - - O
which - - O
eliminates - - O
some - - O
potential - - O
tyrosine - - O
phosphorylation - - O
sites - - O
, - - O
or - - O
the - - O
protein - - O
with - - O
a - - O
single - - O
amino - - O
acid - - O
substitution - - O
( - - O
tyrosine - - O
at - - O
217 - - O
to - - O
phenylalanine - - O
) - - O
resulted - - O
in - - O
an - - O
increase - - O
in - - O
the - - O
aggregation - - O
of - - O
v-Src-transformed - - O
EL - - O
and - - O
EalphaCL - - O
cells - - O
. - - O

In - - O
a - - O
control - - O
group - - O
both - - O
common - - O
carotid - - O
arteries - - O
( - - O
CCA - - O
) - - O
were - - O
ligated - - O
. - - O

Thus - - O
, - - O
it - - O
was - - O
confirmed - - O
that - - O
the - - O
sodium - - O
lauryl - - O
sulfate - - O
method - - O
of - - O
estimating - - O
hemoglobin - - B-MUT
concentration - - O
is - - O
an - - O
appropriate - - O
alternative - - O
to - - O
the - - O
cyanmethemoglobin - - O
method - - O
and - - O
avoids - - O
the - - O
generation - - O
of - - O
toxic - - O
wastes - - O
. - - O

CTF1alpha - - B-MUT
, - - O
expressed - - O
in - - O
Escherichia - - O
coli - - O
, - - O
showed - - O
specific - - O
binding - - O
to - - O
the - - O
palindrome - - O
2 - - O
DNA - - O
fragment - - O
but - - O
not - - O
to - - O
palindrome - - O
1 - - O
or - - O
mutant - - O
palindrome - - O
2 - - O
DNA - - O
fragments - - O
, - - O
suggesting - - O
specific - - O
binding - - O
of - - O
CTF1alpha - - B-MUT
to - - O
palindrome - - O
2 - - O
. - - O

BACKGROUND - - O
: - - O
The - - O
effectiveness - - O
of - - O
monoamine - - B-MUT
oxidase - - I-MUT
inhibitors - - O
( - - O
MAOIs - - O
) - - O
in - - O
tricyclic - - O
resistant - - O
depression - - O
has - - O
received - - O
surprisingly - - O
little - - O
systematic - - O
study - - O
. - - O

Monospecific - - O
antibodies - - O
, - - O
eluted - - O
from - - O
the - - O
beta-galactosidase - - B-MUT
fusion - - O
protein - - O
of - - O
either - - O
clone - - O
reacted - - O
with - - O
the - - O
U1 - - B-MUT
snRNP-specific - - I-MUT
A - - I-MUT
antigen - - I-MUT
. - - O

However - - O
, - - O
at - - O
18 - - O
months - - O
of - - O
age - - O
, - - O
significantly - - O
higher - - O
levels - - O
of - - O
IgG1 - - B-MUT
( - - O
P - - O
less - - O
than - - O
0 - - O
. - - O
05 - - O
) - - O
and - - O
of - - O
IgG4 - - B-MUT
( - - O
P - - O
less - - O
than - - O
0 - - O
. - - O
01 - - O
) - - O
were - - O
found - - O
in - - O
infants - - O
with - - O
an - - O
elevated - - O
IgE - - B-MUT
( - - O
greater - - O
than - - O
or - - O
equal - - O
to - - O
8 - - O
. - - O
0 - - O
kU - - O
l - - O
) - - O
than - - O
in - - O
those - - O
with - - O
a - - O
lower - - O
level - - O
. - - O

RNA - - O
gel - - O
retardation - - O
and - - O
competition - - O
analyses - - O
indicate - - O
that - - O
TRP-185 - - B-MUT
binding - - O
is - - O
strongly - - O
dependent - - O
on - - O
the - - O
TAR - - B-MUT
RNA - - I-MUT
loop - - I-MUT
sequences - - I-MUT
. - - O

Transcript - - O
analysis - - O
reveals - - O
that - - O
lethal - - O
B - - B-MUT
block - - I-MUT
substitutions - - O
reduce - - O
U6 - - B-MUT
RNA - - I-MUT
synthesis - - O
at - - O
least - - O
10-fold - - O
in - - O
vivo - - O
and - - O
20-fold - - O
in - - O
vitro - - O
. - - O

KEY - - O
WORDS - - O
: - - O
Melaleuca - - O
; - - O
Lake - - O
Okeechobee - - O
; - - O
Littoral - - O
zone - - O
; - - O
Water - - O
level - - O
; - - O
Regulation - - O
schedule - - O

The - - O
primers - - O
were - - O
degenerate - - O
sets - - O
of - - O
oligonucleotides - - O
derived - - O
from - - O
known - - O
amino - - O
acid - - O
sequences - - O
of - - O
the - - O
PBAN - - B-MUT
precursor - - I-MUT
. - - O

Therefore - - O
, - - O
the - - O
results - - O
indicate - - O
that - - O
repeated - - O
exposure - - O
to - - O
amphetamine - - O
or - - O
apomorphine - - O
overcomes - - O
the - - O
context-dependent - - O
component - - O
of - - O
sensitization - - O
of - - O
amphetamine- - - O
or - - O
apomorphine-induced - - O
stereotyped - - O
behavior - - O
. - - O

An - - O
end-to-end - - O
pancreaticojejunostomy - - O
using - - O
a - - O
mechanical - - O
purse-string - - O
device - - O
. - - O

Because - - O
the - - O
CAP - - O
measures - - O
variables - - O
predictive - - O
of - - O
abusive - - O
behavior - - O
, - - O
a - - O
substantial - - O
relationship - - O
was - - O
expected - - O
between - - O
the - - O
CAP - - O
and - - O
the - - O
MHI - - O
Loss - - O
of - - O
Behavioral - - O
Emotional - - O
Control - - O
scale - - O
. - - O

Soft-x-ray - - O
lasing - - O
at - - O
32 - - O
. - - O
6 - - O
nm - - O
in - - O
Ne-like - - O
Ti - - O
ions - - O
driven - - O
by - - O
40 - - O
J - - O
of - - O
energy - - O
from - - O
two - - O
650-ps - - O
laser - - O
pulses - - O
. - - O

After - - O
measuring - - O
baseline - - O
Vmca - - O
at - - O
a - - O
partial - - O
pressure - - O
of - - O
carbon - - O
dioxide - - O
in - - O
arterial - - O
blood - - O
( - - O
PaCO2 - - O
) - - O
of - - O
37 - - O
. - - O
7 - - O
+ - - O
- - - O
4 - - O
. - - O
5 - - O
mmHg - - O
( - - O
mean - - O
+ - - O
- - - O
SD - - O
) - - O
, - - O
measurements - - O
were - - O
repeated - - O
at - - O
a - - O
PaCO - - O
of - - O
44 - - O
. - - O
2 - - O
+ - - O
- - - O
3 - - O
. - - O
8 - - O
mmHg - - O
, - - O
and - - O
the - - O
carbon - - O
dioxide - - O
reactivity - - O
( - - O
absolute - - O
value - - O
: - - O
cm - - O
x - - O
s - - O
( - - O
-1 - - O
) - - O
x - - O
mmHg - - O
( - - O
-1 - - O
) - - O
; - - O
relative - - O
value - - O
: - - O
percentage - - O
of - - O
baseline - - O
Vmca - - O
mmHg - - O
) - - O
was - - O
calculated - - O
. - - O

Isoelectric - - O
focusing - - O
of - - O
tryptic - - O
peptides - - O
generated - - O
from - - O
MHC-B - - B-MUT
phosphorylated - - O
with - - O
cdc2 - - B-MUT
kinase - - I-MUT
revealed - - O
one - - O
major - - O
phosphopeptide - - O
that - - O
was - - O
purified - - O
by - - O
reverse-phase - - O
high - - O
performance - - O
liquid - - O
chromatography - - O
and - - O
sequenced - - O
. - - O

Such - - O
an - - O
interaction - - O
could - - O
be - - O
detected - - O
using - - O
a - - O
GST-POU - - B-MUT
fusion - - I-MUT
protein - - I-MUT
bound - - O
to - - O
glutathione-agarose - - O
beads - - O
. - - O

Molecular - - O
cloning - - O
of - - O
mouse - - B-MUT
thioredoxin - - I-MUT
reductases - - I-MUT
. - - O

Factors - - O
that - - O
showed - - O
significant - - O
correlation - - O
to - - O
elevated - - O
CIC's - - O
in - - O
the - - O
highly - - O
elevated - - O
portion - - O
of - - O
our - - O
CIC - - O
population - - O
were - - O
poor - - O
NIH - - O
score - - O
, - - O
increased - - O
patient - - O
age - - O
, - - O
low - - O
peak - - O
expiratory - - O
flow - - O
rate - - O
, - - O
and - - O
elevated - - O
total - - O
serum - - B-MUT
IgG - - I-MUT
. - - O

There - - O
are - - O
many - - O
different - - O
proposals - - O
for - - O
the - - O
statistical - - O
analysis - - O
of - - O
data - - O
to - - O
determine - - O
early - - O
onset - - O
of - - O
action - - O
. - - O

A - - O
chaotropic - - O
detergent - - O
, - - O
0 - - O
. - - O
1% - - O
Nonidet - - O
P-40 - - O
, - - O
also - - O
abolished - - O
the - - O
interaction - - O
, - - O
further - - O
supporting - - O
the - - O
hydrophobic - - O
nature - - O
of - - O
the - - O
interaction - - O
. - - O

Thus - - O
, - - O
the - - O
inhibition - - O
of - - O
pepsin - - B-MUT
in - - O
human - - O
gastric - - O
juice - - O
does - - O
not - - O
appear - - O
to - - O
have - - O
a - - O
major - - O
influence - - O
on - - O
the - - O
healing - - O
of - - O
duodenal - - O
ulcer - - O
. - - O

Restarting - - O
time - - O
was - - O
not - - O
affected - - O
by - - O
magnesium - - O
cardioplegia - - O
. - - O

These - - O
cell - - O
lines - - O
displayed - - O
methylation - - O
of - - O
the - - O
CpG - - O
island - - O
surrounding - - O
the - - O
first - - O
exon - - O
of - - O
p16INK4A - - B-MUT
and - - O
expressed - - O
abundant - - O
levels - - O
of - - O
a - - O
nontranslated - - O
mRNA - - O
containing - - O
an - - O
alternative - - O
first - - O
exon - - O
( - - O
E1 - - B-MUT
beta - - I-MUT
) - - O
, - - O
as - - O
did - - O
all - - O
other - - O
cell - - O
lines - - O
in - - O
which - - O
the - - O
p16INK4A - - B-MUT
locus - - I-MUT
was - - O
not - - O
deleted - - O
. - - O

In - - O
reconstitution - - O
experiments - - O
, - - O
we - - O
first - - O
showed - - O
that - - O
expression - - O
in - - O
the - - O
RAW - - O
264 - - O
. - - O
7 - - O
cell - - O
line - - O
of - - O
C-terminal - - B-MUT
Src - - I-MUT
kinase - - I-MUT
( - - O
Csk - - B-MUT
) - - O
inhibited - - O
and - - O
that - - O
of - - O
a - - O
membrane-anchored - - O
, - - O
gain-of-function - - O
Csk - - B-MUT
abolished - - O
the - - O
Fc - - O
gamma - - O
R-mediated - - O
signaling - - O
that - - O
leads - - O
to - - O
phagocytosis - - O
in - - O
a - - O
kinase-dependent - - O
manner - - O
. - - O

These - - O
mutants - - O
were - - O
tested - - O
for - - O
ability - - O
to - - O
bind - - O
each - - O
of - - O
the - - O
Site - - B-MUT
II - - I-MUT
cognate - - I-MUT
proteins - - I-MUT
, - - O
and - - O
subsequently - - O
evaluated - - O
for - - O
ability - - O
to - - O
confer - - O
H4 - - B-MUT
transcriptional - - O
activity - - O
using - - O
chimeric - - O
H4 - - B-MUT
promoter - - O
CAT - - O
fusion - - B-MUT
constructs - - O
in - - O
different - - O
cell - - O
types - - O
. - - O

The - - O
determination - - O
of - - O
the - - O
double - - O
bounds - - O
in - - O
blood - - O
serum - - O
lipids - - O
by - - O
titration - - O
with - - O
ozone - - O
: - - O
the - - O
pathophysiology - - O
and - - O
diagnostic - - O
significance - - O
In - - O
this - - O
article - - O
the - - O
method - - O
of - - O
definition - - O
of - - O
double - - O
binders - - O
in - - O
lipids - - O
of - - O
blood - - O
serum - - O
in - - O
patients - - O
with - - O
different - - O
diseases - - O
basically - - O
atherosclerosis - - O
and - - O
ischemic - - O
heart - - O
disease - - O
, - - O
with - - O
use - - O
titration - - O
by - - O
ozone - - O
is - - O
given - - O
. - - O

On - - O
the - - O
other - - O
hand - - O
, - - O
neither - - O
phosphate - - O
buffered - - O
saline - - O
injection - - O
into - - O
the - - O
ES - - O
nor - - O
primary - - O
KLH - - B-MUT
challenges - - O
of - - O
the - - O
ES - - O
were - - O
capable - - O
of - - O
elevating - - O
the - - O
threshold - - O
level - - O
and - - O
changing - - O
the - - O
latency - - O
. - - O

Viral - - O
and - - O
atypical - - O
pathogens - - O
as - - O
causes - - O
of - - O
type - - O
1 - - O
acute - - O
exacerbations - - O
of - - O
chronic - - O
bronchitis - - O
. - - O

Thus - - O
, - - O
depending - - O
on - - O
their - - O
location - - O
, - - O
psoralen - - B-MUT
cross-links - - O
affected - - O
different - - O
steps - - O
in - - O
the - - O
initiation - - O
process - - O
. - - O

The - - O
5' - - O
end - - O
of - - O
the - - O
genomic - - O
RNA - - O
of - - O
rubella - - O
virus - - O
( - - O
RUB - - O
) - - O
contains - - O
a - - O
14-nucleotide - - O
( - - O
nt - - O
) - - O
single-stranded - - O
leader - - O
( - - O
ss-leader - - O
) - - O
followed - - O
by - - O
a - - O
stem-and-loop - - O
structure - - O
[ - - O
5' - - O
( - - O
+ - - O
) - - O
SL - - O
] - - O
( - - O
nt - - O
15 - - O
to - - O
65 - - O
) - - O
, - - O
the - - O
complement - - O
of - - O
which - - O
at - - O
the - - O
3' - - O
end - - O
of - - O
the - - O
minus-strand - - O
RNA - - O
[ - - O
3' - - O
( - - O
- - - O
) - - O
SL - - O
] - - O
has - - O
been - - O
proposed - - O
to - - O
function - - O
as - - O
a - - O
promoter - - O
for - - O
synthesis - - O
of - - O
genomic - - O
plus - - O
strands - - O
. - - O

We - - O
examined - - O
behavioral - - O
alterations - - O
in - - O
the - - O
brown - - O
cockroach - - O
, - - O
Periplaneta - - O
brunnea - - O
, - - O
infected - - O
with - - O
the - - O
acanthocephalan - - O
, - - O
Moniliformis - - O
moniliformis - - O
. - - O

The - - O
prominent - - O
lesions - - O
were - - O
confined - - O
to - - O
the - - O
cerebral - - O
surface - - O
layer - - O
and - - O
leptomeningeal - - O
tissue - - O
including - - O
the - - O
arachnoid - - O
vessels - - O
, - - O
which - - O
were - - O
all - - O
bathed - - O
in - - O
the - - O
cerebrospinal - - O
fluid - - O
, - - O
suggesting - - O
that - - O
some - - O
necrotizing - - O
toxins - - O
had - - O
been - - O
secreted - - O
into - - O
the - - O
fluid - - O
by - - O
the - - O
B - - O
. - - O
cereus - - O
. - - O

A - - O
decrease - - O
in - - O
insulin-induced - - O
receptor - - B-MUT
kinase - - I-MUT
activity - - O
was - - O
observed - - O
for - - O
solubilized - - O
chimeric - - O
receptors - - O
. - - O

BYV - - O
, - - O
citrus - - O
tristeza - - O
virus - - O
( - - O
CTV - - O
) - - O
, - - O
beet - - O
yellow - - O
stunt - - O
virus - - O
( - - O
BYSV - - O
) - - O
and - - O
carnation - - O
necrotic - - O
fleck - - O
virus - - O
templates - - O
produced - - O
1 - - O
kb - - O
amplification - - O
products - - O
, - - O
which - - O
were - - O
shown - - O
by - - O
sequencing - - O
to - - O
represent - - O
fragments - - O
of - - O
the - - O
respective - - O
HSP70 - - B-MUT
genes - - I-MUT
. - - O

At - - O
the - - O
same - - O
time - - O
, - - O
the - - O
results - - O
indicate - - O
that - - O
p53 - - B-MUT
plays - - O
a - - O
defensive - - O
role - - O
against - - O
HBV - - O
by - - O
transcriptionally - - O
repressing - - O
the - - O
HBV - - B-MUT
core - - I-MUT
promoter - - I-MUT
through - - O
liver-specific - - B-MUT
enhancer - - I-MUT
II - - I-MUT
and - - O
HBx - - B-MUT
is - - O
required - - O
to - - O
counteract - - O
this - - O
inhibitory - - O
function - - O
of - - O
p53 - - B-MUT
. - - O

The - - O
vaccine - - O
used - - O
was - - O
known - - O
to - - O
be - - O
immunogenic - - O
for - - O
older - - O
children - - O
and - - O
adults - - O
. - - O

The - - O
first - - O
group - - O
of - - O
sequential - - O
BMB - - O
showed - - O
a - - O
significant - - O
progress - - O
to - - O
myelofibrosis - - O
in - - O
so-called - - O
"Chronic - - O
Megakaryocytic-Granulocytic - - O
Myelosis"--CMGM- - - O
, - - O
which - - O
corresponds - - O
to - - O
Agnogenic - - O
Myeloid - - O
Metaplasia-AMM-in - - O
72 - - O
. - - O
4% - - O
( - - O
21 - - O
29 - - O
patients - - O
) - - O
, - - O
as - - O
well - - O
as - - O
in - - O
CML - - O
with - - O
megakaryocytic - - O
increase-CML - - O
. - - O
MI-in - - O
39 - - O
. - - O
2% - - O
( - - O
20 - - O
51 - - O
) - - O
. - - O

Our - - O
results - - O
indicate - - O
that - - O
V3 - - B-MUT
peptides - - O
from - - O
all - - O
major - - O
clades - - O
of - - O
HIV-1 - - O
carried - - O
by - - O
HIV-2 - - B-MUT
gag - - I-MUT
can - - O
be - - O
used - - O
as - - O
a - - O
potential - - O
HIV - - O
AIDS - - O
vaccine - - O
. - - O

The - - O
stereoselectivity - - O
of - - O
drug - - O
action - - O
. - - O

Thrombophlebitis - - O
and - - O
pulmonary - - O
embolism - - O
in - - O
congenital - - O
factor - - B-MUT
XII - - I-MUT
deficiency - - O
. - - O

Guidelines - - O
for - - O
performing - - O
a - - O
routine - - O
spiral - - O
assay - - O
are - - O
presented - - O
, - - O
and - - O
alternative - - O
test - - O
methods - - O
intended - - O
to - - O
overcome - - O
a - - O
variety - - O
of - - O
technical - - O
difficulties - - O
( - - O
such - - O
as - - O
restricted - - O
sample - - O
availability - - O
, - - O
sample - - O
viscosity - - O
or - - O
volatility - - O
, - - O
etc - - O
. - - O
) - - O
are - - O
recommended - - O
. - - O

A - - O
further - - O
subdivision - - O
of - - O
Category - - O
pN1 - - O
into - - O
pN1a - - O
( - - O
metastasis - - O
in - - O
single - - O
node - - O
) - - O
and - - O
pN1b - - O
( - - O
two - - O
or - - O
more - - O
nodes - - O
) - - O
is - - O
recommended - - O
. - - O

In - - O
contrast - - O
, - - O
the - - O
CRE - - B-MUT
of - - O
the - - O
human - - B-MUT
c-fos - - I-MUT
promoter - - I-MUT
located - - O
at - - O
-60 - - O
was - - O
weakly - - O
induced - - O
by - - O
cAMP - - O
and - - O
E1a - - B-MUT
in - - O
both - - O
HeLa - - O
and - - O
PC12 - - O
cells - - O
. - - O

The - - O
RAD6 - - B-MUT
UBC2 - - I-MUT
gene - - I-MUT
from - - I-MUT
Saccharomyces - - O
cerevisiae - - O
encodes - - O
a - - O
ubiquitin-conjugating - - O
enzyme - - B-MUT
involved - - I-MUT
in - - O
DNA - - O
repair - - O
, - - O
induced - - O
mutagenesis - - O
, - - O
and - - O
sporulation - - O
. - - O

Deletion - - O
of - - O
a - - O
53-bp - - O
early - - O
promoter - - O
region - - O
containing - - O
the - - O
transcription - - O
start - - O
site - - O
and - - O
a - - O
putative - - O
TATA - - O
box - - O
completely - - O
abolishes - - O
the - - O
ability - - O
of - - O
upstream - - O
elements - - O
to - - O
drive - - O
transcription - - O
of - - O
the - - O
luciferase - - B-MUT
cDNA - - I-MUT
. - - O

However - - O
, - - O
the - - O
few - - O
studies - - O
that - - O
address - - O
antimicrobial - - O
prophylaxis - - O
in - - O
bone - - O
marrow - - O
transplantation - - O
have - - O
not - - O
always - - O
shown - - O
a - - O
survival - - O
benefit - - O
. - - O

Transcriptional - - O
control - - O
of - - O
a - - O
nuclear - - O
gene - - O
encoding - - O
a - - O
mitochondrial - - O
fatty - - O
acid - - O
oxidation - - O
enzyme - - O
in - - O
transgenic - - O
mice - - O
: - - O
role - - O
for - - O
nuclear - - O
receptors - - O
in - - O
cardiac - - O
and - - O
brown - - O
adipose - - O
expression - - O
. - - O

Insulin - - B-MUT
stimulation - - O
promoted - - O
the - - O
association - - O
of - - O
mIRS3 - - B-MUT
with - - O
p85 - - B-MUT
, - - O
SHP2 - - B-MUT
, - - O
Nck - - B-MUT
, - - O
and - - O
Shc - - B-MUT
. - - O

Experience - - O
with - - O
the - - O
tensor - - O
fasciae - - O
latae - - O
free - - O
flap - - O
. - - O

In - - O
particular - - O
, - - O
71 - - O
and - - O
69% - - O
amino - - O
acid - - O
sequence - - O
similarities - - O
were - - O
identified - - O
with - - O
hsp70 - - B-MUT
of - - I-MUT
Escherichia - - I-MUT
coli - - I-MUT
and - - I-MUT
Bacillus - - I-MUT
megaterium - - I-MUT
, - - O
respectively - - O
. - - O

Thirty - - O
cadaver - - O
brains - - O
were - - O
examined - - O
under - - O
X - - O
6 - - O
to - - O
16 - - O
magnification - - O
in - - O
order - - O
to - - O
define - - O
the - - O
microsurgical - - O
anatomy - - O
of - - O
the - - O
pineal - - O
region - - O
, - - O
particularly - - O
the - - O
relationship - - O
of - - O
the - - O
pineal - - O
body - - O
, - - O
posterior - - O
cerebral - - O
artery - - O
, - - O
superior - - O
cerebellar - - O
artery - - O
, - - O
vein - - O
of - - O
Galen - - O
, - - O
basal - - O
vein - - O
of - - O
Rosenthal - - O
, - - O
internal - - O
cerebral - - O
vein - - O
, - - O
straight - - O
sinus - - O
, - - O
bridging - - O
vein - - O
, - - O
the - - O
size - - O
of - - O
the - - O
tentorial - - O
notch - - O
, - - O
and - - O
the - - O
third - - O
and - - O
the - - O
fourth - - O
cranial - - O
nerves - - O
. - - O

Increased - - O
erythropoietin - - B-MUT
synthesis - - O
in - - O
patients - - O
with - - O
COLD - - O
or - - O
left - - O
heart - - O
failure - - O
is - - O
related - - O
to - - O
alterations - - O
in - - O
renal - - O
haemodynamics - - O
. - - O

Unlike - - O
ARF - - B-MUT
, - - O
the - - O
ARP - - B-MUT
immunoreactivity - - O
was - - O
detected - - O
in - - O
plasma - - O
membranes - - O
but - - O
not - - O
in - - O
cytosol - - O
of - - O
fractionated - - O
3T3-L1 - - O
cells - - O
. - - O

The - - O
deduced - - O
amino - - O
acid - - O
sequence - - O
of - - O
destrin - - B-MUT
is - - O
165 - - O
residues - - O
long - - O
and - - O
is - - O
very - - O
similar - - O
( - - O
71% - - O
identical - - O
) - - O
to - - O
that - - O
of - - O
cofilin - - B-MUT
, - - O
a - - O
widely - - O
distributed - - O
, - - O
pH-sensitive - - O
actin-modulating - - O
protein - - O
. - - O

Effects - - O
of - - O
chronic - - O
metaraminol - - O
treatment - - O
on - - O
the - - O
sympathetic - - O
activity - - O
of - - O
intact - - O
and - - O
adrenal - - O
demedullated - - O
rats - - O
kept - - O
in - - O
warm - - O
or - - O
cold - - O
environments - - O
. - - O

Bepridil - - O
, - - O
a - - O
calcium - - O
antagonist - - O
with - - O
a - - O
half-life - - O
of - - O
approximately - - O
42 - - O
hours - - O
, - - O
was - - O
compared - - O
with - - O
placebo - - O
in - - O
a - - O
double-blind - - O
, - - O
randomized - - O
, - - O
crossover - - O
trial - - O
. - - O

Involvement - - O
of - - O
AP1 - - B-MUT
and - - O
PEA3 - - B-MUT
binding - - I-MUT
sites - - I-MUT
in - - O
the - - O
regulation - - O
of - - O
murine - - B-MUT
tissue - - I-MUT
inhibitor - - I-MUT
of - - I-MUT
metalloproteinases-1 - - I-MUT
( - - O
TIMP-1 - - B-MUT
) - - O
transcription - - O
. - - O

Alternative - - O
processing - - O
of - - O
the - - O
tryptophanyl-tRNA - - B-MUT
synthetase - - I-MUT
mRNA - - I-MUT
from - - O
interferon-treated - - O
human - - O
cells - - O
. - - O

Oligonucleotide - - O
competitors - - O
were - - O
used - - O
to - - O
evaluate - - O
the - - O
accessibility - - O
of - - O
the - - O
TATA-binding - - O
site - - O
in - - O
TIF-IB - - B-MUT
, - - O
TFIID - - B-MUT
, - - O
and - - O
TFIIIB - - B-MUT
. - - O

The - - O
East - - O
African - - O
dik-dik - - O
antelope - - O
represents - - O
a - - O
miniature - - O
model - - O
ruminant - - O
for - - O
comparative - - O
studies - - O
. - - O

Three - - O
patients - - O
had - - O
well- - - O
, - - O
6 - - O
patients - - O
had - - O
moderately- - - O
, - - O
and - - O
5 - - O
patients - - O
had - - O
poorly-differentiated - - O
adenocarcinoma - - O
of - - O
the - - O
prostate - - O
. - - O

The - - O
"28 - - O
percent" - - O
Venturi - - O
mask - - O
in - - O
obstructive - - O
airway - - O
disease - - O
. - - O

Human - - B-MUT
LAF-4 - - I-MUT
readily - - O
hybridized - - O
with - - O
genes - - O
in - - O
mouse - - O
and - - O
chicken - - O
, - - O
thus - - O
showing - - O
that - - O
this - - O
gene - - O
family - - O
has - - O
been - - O
highly - - O
conserved - - O
during - - O
vertebrate - - O
evolution - - O
. - - O

Northern - - O
analysis - - O
, - - O
to - - O
search - - O
for - - O
a - - O
pcbAB - - B-MUT
transcript - - I-MUT
, - - O
showed - - O
no - - O
distinct - - O
transcript - - O
and - - O
indicated - - O
severely - - O
degraded - - O
mRNA - - O
. - - O

RESULTS - - O
: - - O
In - - O
an - - O
18 - - O
moth - - O
period - - O
and - - O
out - - O
of - - O
a - - O
total - - O
of - - O
284 - - O
positive - - O
blood - - O
cultures - - O
( - - O
154 - - O
significant - - O
isolations - - O
) - - O
14 - - O
episodes - - O
of - - O
bacteremia - - O
by - - O
M - - O
. - - O
tuberculosis - - O
were - - O
studied - - O
in - - O
12 - - O
prison - - O
patients - - O
coinfected - - O
by - - O
the - - O
human - - O
immunodeficiency - - O
virus - - O
with - - O
associated - - O
severe - - O
immunosuppression - - O
( - - O
mean - - O
of - - O
CD4 - - B-MUT
= - - O
0 - - O
. - - O
068 - - O
x - - O
10 - - O
( - - O
9 - - O
) - - O
l - - O
) - - O
. - - O

Morphologic - - O
variables - - O
included - - O
cancer - - O
volume - - O
, - - O
histologic - - O
grade - - O
, - - O
capsular - - O
penetration - - O
, - - O
seminal - - O
vesicle - - O
invasion - - O
, - - O
and - - O
lymph - - O
node - - O
metastasis - - O
. - - O

The - - O
genes - - O
encoding - - O
the - - O
transcription - - B-MUT
factor - - I-MUT
yTAFII60 - - I-MUT
, - - O
the - - O
G4p1 - - B-MUT
protein - - I-MUT
and - - O
a - - O
putative - - O
glucose - - B-MUT
transporter - - I-MUT
are - - O
contained - - O
in - - O
a - - O
12 - - O
. - - O
3 - - O
kb - - O
DNA - - O
fragment - - O
on - - O
the - - O
left - - O
arm - - O
of - - O
Saccharomyces - - O
cerevisiae - - O
chromosome - - O
VII - - O
. - - O

Evaluation - - O
of - - O
the - - O
new - - O
Gravigard - - O
IUCD - - O
inserter - - O
. - - O

In - - O
the - - O
presence - - O
of - - O
the - - O
in - - O
vivo - - O
reducing - - O
system - - O
( - - O
thioredoxin - - B-MUT
, - - O
thioredoxin - - B-MUT
reductase - - I-MUT
, - - O
and - - O
NADPH - - O
) - - O
, - - O
however - - O
, - - O
each - - O
of - - O
these - - O
mutants - - O
catalyzed - - O
the - - O
formation - - O
of - - O
only - - O
0 - - O
. - - O
6-0 - - O
. - - O
8 - - O
dCTPs - - O
per - - O
mole - - O
of - - O
enzyme - - O
. - - O

Not - - O
Available - - O

Functional - - O
and - - O
regulatory - - O
analysis - - O
of - - O
the - - O
two - - O
copies - - O
of - - O
the - - O
fixNOQP - - B-MUT
operon - - I-MUT
of - - O
Rhizobium - - O
leguminosarum - - O
strain - - O
VF39 - - O
. - - O

The - - O
9 - - O
; - - O
22 - - O
chromosomal - - O
translocation - - O
characteristic - - O
of - - O
CML - - O
results - - O
in - - O
a - - O
fused - - B-MUT
bcr - - I-MUT
abl - - I-MUT
gene - - I-MUT
and - - I-MUT
an - - O
abnormal - - O
fusion - - O
protein - - O
, - - O
p210bcr - - O
abl - - B-MUT
. - - I-MUT

We - - O
have - - O
measured - - O
the - - O
MBF - - O
on - - O
incisors - - O
and - - O
its - - O
direction - - O
in - - O
three - - O
dimensions - - O
for - - O
different - - O
jaw - - O
openings - - O
in - - O
ten - - O
subjects - - O
. - - O

RNAs - - O
are - - O
not - - O
only - - O
essential - - O
components - - O
of - - O
both - - O
ribosomal - - O
subunits - - O
but - - O
also - - O
transiently - - O
interacting - - O
factors - - O
during - - O
particle - - O
formation - - O
. - - O

Subcellular - - O
localizations - - O
of - - O
the - - O
wild-type - - B-MUT
CBFbeta - - I-MUT
and - - O
the - - O
CBFbeta-SMMHC - - B-MUT
fusion - - I-MUT
protein - - I-MUT
were - - O
determined - - O
by - - O
immunofluorescence - - O
of - - O
NIH - - O
3T3 - - O
cells - - O
that - - O
overexpress - - O
wild-type - - O
or - - O
fusion - - O
protein - - O
. - - O

In - - O
conclusion - - O
, - - O
IgM - - B-MUT
class - - O
CIC - - O
is - - O
the - - O
predominant - - O
CIC - - O
in - - O
acute - - O
hepatitis - - O
A - - O
and - - O
correlated - - O
with - - O
disease - - O
activity - - O
. - - O

Echinostomiasis - - O
is - - O
aggravated - - O
by - - O
socioeconomic - - O
factors - - O
such - - O
as - - O
poverty - - O
, - - O
malnutrition - - O
, - - O
an - - O
explosively - - O
growing - - O
free-food - - O
market - - O
, - - O
a - - O
lack - - O
of - - O
supervised - - O
food - - O
inspection - - O
, - - O
poor - - O
or - - O
insufficient - - O
sanitation - - O
, - - O
other - - O
helminthiases - - O
, - - O
and - - O
declining - - O
economic - - O
conditions - - O
. - - O

We - - O
further - - O
demonstrate - - O
that - - O
the - - O
Stress-Activated-Protein-Kinase - - B-MUT
( - - O
SAPK - - B-MUT
) - - O
target - - O
sites - - O
of - - O
ATF2 - - B-MUT
, - - O
Thr69 - - O
and - - O
Thr71 - - O
are - - O
not - - O
required - - O
for - - O
the - - O
formation - - O
of - - O
the - - O
p300 - - B-MUT
CBP-ATF2 - - I-MUT
multiprotein - - I-MUT
complex - - O
. - - O

Patch - - O
test - - O
results - - O
obtained - - O
with - - O
corticosteroid - - O
allergic - - O
patients - - O
tested - - O
with - - O
a - - O
large - - O
corticosteroid - - O
series - - O
validated - - O
the - - O
earlier - - O
classification - - O
of - - O
corticosteroid - - O
molecules - - O
in - - O
four - - O
groups - - O
of - - O
cross-reacting - - O
molecules - - O
: - - O
i - - O
. - - O
e - - O
. - - O
, - - O
group - - O
A - - O
( - - O
hydrocortisone - - O
type - - O
) - - O
, - - O
group - - O
B - - O
( - - O
acetonides - - O
) - - O
, - - O
group - - O
C - - O
( - - O
betamethasone - - O
type-non - - O
esterified - - O
) - - O
and - - O
group - - O
D - - O
( - - O
esters - - O
) - - O
. - - O

Mae - - O
West - - O
and - - O
the - - O
doctor - - O
shortage - - O
. - - O

Oncogenic - - O
capacity - - O
of - - O
the - - O
E2F1 - - B-MUT
gene - - I-MUT
. - - O

Thus - - O
, - - O
Sir - - B-MUT
proteins - - I-MUT
from - - O
K - - O
. - - O
lactis - - O
have - - O
roles - - O
in - - O
both - - O
silencing - - O
and - - O
telomere - - O
length - - O
maintenance - - O
, - - O
reflecting - - O
conserved - - O
functional - - O
themes - - O
. - - O

The - - O
p55 - - B-MUT
mRNA - - I-MUT
is - - O
undetectable - - O
in - - O
non-EBV-infected - - O
B- - - O
and - - O
T-cell - - O
lines - - O
or - - O
in - - O
a - - O
myelomonocytic - - O
cell - - O
line - - O
( - - O
U937 - - O
) - - O
. - - O

Histone - - O
acetylation - - O
levels - - O
in - - O
cells - - O
result - - O
from - - O
a - - O
dynamic - - O
equilibrium - - O
between - - O
competing - - O
histone - - B-MUT
acetylases - - I-MUT
and - - O
deacetylases - - B-MUT
. - - O

In - - O
Experiments - - O
1 - - O
and - - O
2 - - O
, - - O
infants - - O
, - - O
like - - O
adults - - O
, - - O
initially - - O
categorized - - O
novel - - O
objects - - O
on - - O
the - - O
basis - - O
of - - O
physical - - O
appearance - - O
, - - O
but - - O
only - - O
if - - O
trained - - O
with - - O
multiple - - O
exemplars - - O
, - - O
after - - O
delays - - O
of - - O
1 - - O
and - - O
7 - - O
days - - O
. - - O

Successful - - O
use - - O
of - - O
transureteroureterostomy - - O
to - - O
salvage - - O
ureterosigmoidostomy - - O
after - - O
anastomotic - - O
failure - - O
. - - O

SRF-deficient - - O
embryos - - O
( - - O
Srf - - B-MUT
- - - O
- - - O
) - - O
have - - O
a - - O
severe - - O
gastrulation - - O
defect - - O
and - - O
do - - O
not - - O
develop - - O
to - - O
term - - O
. - - O

Four - - O
full-thickness - - O
skin - - O
incisions - - O
were - - O
made - - O
in - - O
the - - O
back - - O
of - - O
10 - - O
female - - O
pigs - - O
that - - O
treated - - O
twice - - O
a - - O
day - - O
for - - O
14 - - O
days - - O
with - - O
2 - - O
ml - - O
of - - O
epidermal - - B-MUT
growth - - I-MUT
factor - - I-MUT
( - - O
300 - - O
ng - - O
ml - - O
) - - O
or - - O
2 - - O
ml - - O
of - - O
Ringer's - - O
lactate - - O
solution - - O
in - - O
a - - O
single-blind - - O
, - - O
randomized - - O
fashion - - O
. - - O

Various - - O
companies - - O
produce - - O
this - - O
type - - O
of - - O
lens - - O
. - - O

In - - O
mammalian - - O
tissue - - O
culture - - O
cells - - O
, - - O
overexpression - - O
of - - O
any - - O
of - - O
the - - O
four - - O
mouse - - O
deltex - - O
homologs - - O
suppressed - - O
the - - O
transcriptional - - O
activity - - O
of - - O
E47 - - B-MUT
, - - O
a - - O
basic - - B-MUT
helix-loop-helix - - I-MUT
( - - I-MUT
bHLH - - I-MUT
) - - I-MUT
protein - - I-MUT
, - - O
in - - O
a - - O
manner - - O
similar - - O
to - - O
suppression - - O
by - - O
an - - O
activated - - O
form - - O
of - - O
human - - B-MUT
Notch1 - - I-MUT
or - - O
human - - B-MUT
DTX1 - - I-MUT
. - - O

However - - O
, - - O
kidneys - - O
perfused - - O
for - - O
72 - - O
hr - - O
demonstrated - - O
more - - O
similar - - O
renal - - O
functions - - O
when - - O
tested - - O
by - - O
either - - O
IMPK - - O
or - - O
IBPK - - O
. - - O

Patients - - O
with - - O
antibody - - O
peaks - - O
, - - O
defined - - O
as - - O
fivefold - - O
or - - O
higher - - O
increase - - O
in - - O
antibody - - O
titer - - O
compared - - O
to - - O
the - - O
lowest - - O
antibody - - O
titer - - O
over - - O
the - - O
course - - O
of - - O
GBS - - O
, - - O
had - - O
higher - - O
disability - - O
scores - - O
during - - O
the - - O
first - - O
two - - O
weeks - - O
of - - O
GBS - - O
and - - O
a - - O
worse - - O
clinical - - O
outcome - - O
( - - O
anti-GM1 - - B-MUT
IgG - - I-MUT
and - - O
anti-GD1a - - B-MUT
IgM - - I-MUT
antibody - - I-MUT
peaks - - O
) - - O
and - - O
axonal - - O
damage - - O
( - - O
anti-GD1a - - B-MUT
IgM - - I-MUT
antibody - - I-MUT
peaks - - O
) - - O
, - - O
compared - - O
to - - O
patients - - O
without - - O
peak - - O
antibody - - O
titers - - O
. - - O

This - - O
core - - O
sequence - - O
, - - O
along - - O
with - - O
additional - - O
nonspecific - - O
downstream - - O
nucleotides - - O
, - - O
is - - O
sufficient - - O
for - - O
partial - - O
suppression - - O
of - - O
spliceosome - - O
assembly - - O
and - - O
splicing - - O
of - - O
BPV-1 - - O
pre-mRNAs - - O
. - - O

CONCLUSIONS - - O
: - - O
Turbutest - - O
is - - O
a - - O
valuable - - O
tool - - O
in - - O
asthmatic - - O
patients' - - O
training - - O
, - - O
allowing - - O
identification - - O
and - - O
improvement - - O
of - - O
an - - O
inadequate - - O
inhalation - - O
technique - - O
with - - O
Turbuhaler - - O
. - - O

Inhibition - - O
of - - O
the - - O
Raf-1 - - B-MUT
target - - I-MUT
ERK - - B-MUT
kinase - - I-MUT
( - - O
MEK - - B-MUT
) - - O
either - - O
attenuated - - O
or - - O
abolished - - O
Rp-cAMPS- - - O
and - - O
PKI-induced - - O
ERK - - B-MUT
activation - - O
, - - O
caldesmon - - B-MUT
phosphorylation - - O
, - - O
and - - O
stress - - O
fiber - - O
formation - - O
. - - O

METHODS - - O
: - - O
T2*-weighted - - O
, - - O
three-dimensional - - O
gradient-echo - - O
images - - O
were - - O
acquired - - O
by - - O
exploiting - - O
the - - O
magnetic - - O
susceptibility - - O
difference - - O
between - - O
oxygenated - - O
and - - O
deoxygenated - - O
hemoglobin - - B-MUT
in - - O
the - - O
vasculature - - O
and - - O
microvasculature - - O
. - - O

In - - O
a - - O
second - - O
experiment - - O
involving - - O
an - - O
18-h - - O
lung - - O
clearance - - O
assay - - O
, - - O
we - - O
used - - O
the - - O
mAb - - O
3 - - O
. - - O
2 - - O
. - - O
3 - - O
to - - O
deplete - - O
rats - - O
of - - O
LGL - - O
NK - - O
cells - - O
with - - O
the - - O
following - - O
rationale - - O
: - - O
if - - O
LGL - - O
NK - - O
cells - - O
are - - O
necessary - - O
to - - O
mediate - - O
an - - O
event - - O
, - - O
then - - O
in - - O
their - - O
absence - - O
, - - O
that - - O
event - - O
should - - O
not - - O
occur - - O
. - - O

The - - O
rci - - B-MUT
gene - - I-MUT
was - - O
fused - - O
with - - O
lacZ - - B-MUT
and - - O
its - - O
gene - - O
product - - O
was - - O
identified - - O
by - - O
Western - - O
blot - - O
analysis - - O
. - - O

Thus - - O
, - - O
multiple - - O
myogenic - - O
factors - - O
that - - O
vary - - O
qualitatively - - O
and - - O
quantitatively - - O
may - - O
be - - O
responsible - - O
for - - O
the - - O
different - - O
and - - O
complex - - O
modulatory - - O
programs - - O
of - - O
actin - - B-MUT
gene - - I-MUT
expression - - O
observed - - O
during - - O
in - - O
vivo - - O
muscle - - O
differentiation - - O
. - - O

Variety - - O
of - - O
cows - - O
and - - O
sires - - O
according - - O
to - - O
types - - O
of - - O
dermatoglyphics - - O
( - - O
patterns - - O
) - - O
of - - O
the - - O
nose-labial - - O
mirror - - O
of - - O
cattle - - O
. - - O

Many - - O
cells - - O
were - - O
negative - - O
for - - O
endothelial-cell - - O
markers - - O
, - - O
and - - O
they - - O
reacted - - O
with - - O
a - - O
monoclonal - - O
antibody - - O
against - - O
muscle - - O
actin - - B-MUT
. - - O

We - - O
studied - - O
the - - O
role - - O
of - - O
prostaglandins - - O
in - - O
acid-induced - - O
esophagitis - - O
and - - O
the - - O
associated - - O
LES - - O
hypotension - - O
by - - O
simultaneous - - O
treatment - - O
of - - O
some - - O
animals - - O
with - - O
indomethacin - - O
( - - O
150 - - O
micrograms - - O
kg - - O
intravenous - - O
) - - O
, - - O
a - - O
specific - - O
inhibitor - - O
of - - O
prostaglandin - - O
synthesis - - O
, - - O
either - - O
during - - O
production - - O
of - - O
esophagitis - - O
or - - O
during - - O
recovery - - O
. - - O

Of - - O
these - - O
sites - - O
, - - O
PEA3 - - B-MUT
and - - O
STAT - - B-MUT
contributed - - O
specifically - - O
to - - O
induction - - O
by - - O
v-src - - B-MUT
, - - O
whereas - - O
the - - O
remaining - - O
elements - - O
were - - O
also - - O
involved - - O
in - - O
induction - - O
by - - O
the - - O
phorbol - - O
ester - - O
phorbol - - O
myristate - - O
acetate - - O
( - - O
PMA - - O
) - - O
. - - O

There - - O
were - - O
significant - - O
differences - - O
( - - O
p - - O
< - - O
0 - - O
. - - O
05 - - O
) - - O
between - - O
the - - O
fracture - - O
and - - O
nonfracture - - O
groups - - O
in - - O
the - - O
total - - O
femur - - O
BMD - - O
( - - O
13% - - O
) - - O
, - - O
trabecular - - O
BMD - - O
in - - O
the - - O
distal - - O
radius - - O
( - - O
4% - - O
) - - O
, - - O
and - - O
the - - O
fractal - - O
dimension - - O
in - - O
the - - O
radiographs - - O
( - - O
FD2 - - O
) - - O
( - - O
3% - - O
) - - O
. - - O

An - - O
ASSEMBLER - - O
routine - - O
for - - O
on-line - - O
graphic - - O
display - - O
and - - O
averaging - - O
of - - O
data - - O
acquired - - O
on - - O
a - - O
personal - - O
microcomputer - - O
. - - O

The - - O
exodomain - - O
alone - - O
has - - O
the - - O
high - - O
affinity - - O
hormone - - O
binding - - O
site - - O
but - - O
is - - O
not - - O
capable - - O
of - - O
generating - - O
hormonal - - O
signal - - O
. - - O

We - - O
therefore - - O
applied - - O
a - - O
radiolabelled - - O
serumalbumin - - O
method - - O
to - - O
determine - - O
blood - - O
volume - - O
after - - O
haemodilution - - O
with - - O
crosslinked - - O
or - - O
conjugated - - O
haemoglobin - - B-MUT
, - - O
in - - O
comparison - - O
with - - O
a - - O
reference - - O
solution - - O
of - - O
hydroxyethyl - - O
starch - - O
( - - O
HES - - O
) - - O
. - - O

The - - O
average - - O
birth - - O
mass - - O
of - - O
these - - O
newborns - - O
was - - O
3491 - - O
. - - O
9 - - O
+ - - O
- - - O
2 - - O
SD - - O
780 - - O
. - - O
5 - - O
g - - O
and - - O
that - - O
in - - O
the - - O
control - - O
group - - O
3 - - O
, - - O
767 - - O
. - - O
5 - - O
+ - - O
- - - O
2 - - O
SD - - O
824 - - O
. - - O
2 - - O
g - - O
( - - O
P - - O
less - - O
than - - O
0 - - O
. - - O
05 - - O
) - - O
. - - O

The - - O
effect - - O
of - - O
iron - - O
intake - - O
on - - O
59Fe - - O
absorption - - O
throughout - - O
pregnancy - - O
, - - O
and - - O
on - - O
maternal - - O
and - - O
fetal - - O
Fe - - O
status - - O
towards - - O
the - - O
end - - O
of - - O
pregnancy - - O
, - - O
was - - O
investigated - - O
in - - O
rats - - O
. - - O

This - - O
exon - - O
, - - O
here - - O
named - - O
exon - - O
0 - - O
, - - O
contained - - O
the - - O
entire - - O
5' - - O
untranslated - - O
region - - O
and - - O
the - - O
N-terminal - - O
signal - - O
sequence - - O
of - - O
the - - O
polypeptide - - O
. - - O

Expression - - O
of - - O
herpes - - B-MUT
simplex - - I-MUT
virus - - I-MUT
beta - - I-MUT
and - - I-MUT
gamma - - I-MUT
genes - - I-MUT
integrated - - O
in - - O
mammalian - - O
cells - - O
and - - O
their - - O
induction - - O
by - - O
an - - O
alpha - - B-MUT
gene - - I-MUT
product - - I-MUT
. - - O

A - - O
. - - O
, - - O
Slatkin - - O
, - - O
D - - O
. - - O

Analysis - - O
of - - O
the - - O
rate - - O
constants - - O
indicated - - O
that - - O
the - - O
isomerization - - O
rate - - O
k12 - - O
was - - O
approximately - - O
equal - - O
to - - O
the - - O
apparent - - O
degradation - - O
rate - - O
of - - O
the - - O
delta - - O
3 - - O
ester - - O
kdeg - - O
, - - O
and - - O
slower - - O
than - - O
the - - O
hydrolysis - - O
rate - - O
of - - O
the - - O
delta - - O
2 - - O
ester - - O
k24 - - O
. - - O

The - - O
human - - B-MUT
ABCG1 - - I-MUT
gene - - I-MUT
encodes - - O
a - - O
member - - O
of - - O
the - - O
ATP-binding - - B-MUT
cassette - - I-MUT
( - - O
ABC - - B-MUT
) - - O
superfamily - - O
of - - O
transporter - - B-MUT
proteins - - I-MUT
and - - O
is - - O
highly - - O
induced - - O
when - - O
macrophages - - O
are - - O
incubated - - O
with - - O
oxysterols - - O
. - - O

Yap1p - - B-MUT
is - - O
constitutively - - O
nuclear - - O
in - - O
a - - O
crm1 - - B-MUT
mutant - - I-MUT
, - - O
and - - O
Crm1p - - B-MUT
binds - - O
to - - O
a - - O
nuclear - - O
export - - O
sequence - - O
( - - O
NES - - O
) - - O
-like - - O
sequence - - O
in - - O
Yap1p - - B-MUT
in - - O
the - - O
presence - - O
of - - O
RanGTP - - B-MUT
. - - O

Clinical - - O
chemistry - - O
. - - O

Hematopoietic - - O
system - - O
in - - O
streptococcal - - O
allergy - - O
. - - O

However - - O
, - - O
using - - O
ATL-16T - - O
nuclear - - O
extract - - O
, - - O
we - - O
demonstrated - - O
that - - O
GATA-4 - - B-MUT
is - - O
the - - O
only - - O
GATA-binding - - B-MUT
protein - - I-MUT
that - - O
forms - - O
specific - - O
DNA-protein - - O
complex - - O
with - - O
the - - O
-70 - - B-MUT
GATA - - I-MUT
site - - I-MUT
. - - O

We - - O
suppose - - O
that - - O
this - - O
injection - - O
speed - - O
( - - O
0 - - O
. - - O
1-0 - - O
. - - O
2 - - O
ml - - O
. - - O
s-1 - - O
) - - O
is - - O
suitable - - O
for - - O
spinal - - O
anesthesia - - O
. - - O

Toluene - - O
is - - O
the - - O
chemical - - O
most - - O
frequently - - O
present - - O
in - - O
cases - - O
involving - - O
volatile - - O
solvents - - O
. - - O

Thus - - O
, - - O
we - - O
have - - O
produced - - O
lipoyl - - O
domain - - O
constructs - - O
that - - O
can - - O
be - - O
employed - - O
in - - O
sorting - - O
the - - O
specific - - O
roles - - O
of - - O
E2L1 - - B-MUT
and - - O
E2L2 - - B-MUT
in - - O
facilitating - - O
catalytic - - O
and - - O
regulatory - - O
processes - - O
. - - O

Transfecting - - O
the - - O
cloned - - O
bovine - - O
PBR - - B-MUT
IBP - - O
cDNA - - B-MUT
into - - O
COS-7 - - O
cells - - O
resulted - - O
in - - O
an - - O
11-fold - - O
increase - - O
in - - O
the - - O
density - - O
of - - O
high - - O
affinity - - O
[ - - O
3H - - O
] - - O
PK - - O
11195 - - O
binding - - O
sites - - O
which - - O
had - - O
only - - O
low - - O
affinity - - O
for - - O
Ro5-4864 - - O
. - - O

Digestion - - O
of - - O
NF-IL6 - - B-MUT
with - - O
endoprotease - - B-MUT
Asp-N - - I-MUT
produced - - O
a - - O
domain - - O
smaller - - O
than - - O
the - - O
TCD - - B-MUT
( - - O
NF-IL6 - - B-MUT
bZIP - - I-MUT
domains - - I-MUT
( - - O
NFBD - - B-MUT
) - - O
( - - O
272-345 - - O
) - - O
) - - O
, - - O
a - - O
domain - - O
identified - - O
either - - O
in - - O
the - - O
absence - - O
or - - O
the - - O
presence - - O
of - - O
DNA - - O
. - - O

A - - O
combination - - O
of - - O
comparative - - O
sequence - - O
analysis - - O
and - - O
thermodynamic - - O
methods - - O
reveals - - O
the - - O
conservation - - O
of - - O
tertiary - - O
structure - - O
elements - - O
in - - O
the - - O
5' - - O
untranslated - - O
region - - O
( - - O
UTR - - O
) - - O
of - - O
human - - O
enteroviruses - - O
and - - O
rhinoviruses - - O
. - - O

Hypothalamic - - O
control - - O
of - - O
coronary - - O
circulation - - O
in - - O
the - - O
dog - - O
. - - O

Intensification - - O
of - - O
human - - O
myocardial - - O
contractile - - O
activity - - O
as - - O
affected - - O
by - - O
blood - - O
serum - - O
. - - O

These - - O
results - - O
demonstrate - - O
that - - O
although - - O
PI2 - - O
and - - O
PI3 - - O
viruses - - O
belong - - O
to - - O
the - - O
same - - O
parainfluenza - - O
virus - - O
genus - - O
, - - O
these - - O
viruses - - O
show - - O
marked - - O
differences - - O
with - - O
respect - - O
to - - O
functional - - O
requirements - - O
for - - O
the - - O
cytoplasmic - - O
tail - - O
of - - O
the - - O
F - - B-MUT
glycoprotein - - I-MUT
. - - O

The - - O
human - - B-MUT
cytomegalovirus - - I-MUT
( - - I-MUT
HCMV - - I-MUT
) - - I-MUT
major - - I-MUT
immediate-early - - I-MUT
protein - - I-MUT
IE2 - - I-MUT
is - - O
a - - O
nuclear - - B-MUT
phosphoprotein - - I-MUT
that - - O
is - - O
believed - - O
to - - O
be - - O
a - - O
key - - O
regulator - - O
in - - O
both - - O
lytic - - O
and - - O
latent - - O
infections - - O
. - - O

The - - O
highest - - O
prevalence - - O
of - - O
reported - - O
pet - - O
allergy - - O
, - - O
chronic - - O
cough - - O
, - - O
wheeze - - O
, - - O
attacks - - O
of - - O
shortness - - O
of - - O
breath - - O
with - - O
wheezing - - O
, - - O
and - - O
doctor-diagnosed - - O
asthma - - O
was - - O
found - - O
in - - O
children - - O
who - - O
had - - O
pets - - O
in - - O
the - - O
past - - O
but - - O
not - - O
anymore - - O
. - - O

MEASUREMENTS - - O
AND - - O
MAIN - - O
RESULTS - - O
: - - O
Lung - - O
elastance - - O
( - - O
EL - - O
) - - O
and - - O
resistance - - O
( - - O
RL - - O
) - - O
were - - O
calculated - - O
from - - O
measurements - - O
of - - O
airway - - O
pressure - - O
, - - O
esophageal - - O
pressure - - O
, - - O
and - - O
airway - - O
flow - - O
in - - O
five - - O
anesthetized - - O
, - - O
paralyzed - - O
dogs - - O
during - - O
sinusoidal - - O
forcing - - O
at - - O
a - - O
constant - - O
mean - - O
airway - - O
pressure - - O
of - - O
10 - - O
cmH2O - - O
in - - O
a - - O
wide - - O
range - - O
of - - O
breathing - - O
frequencies - - O
( - - O
0 - - O
. - - O
2 - - O
to - - O
1 - - O
. - - O
0 - - O
Hz - - O
in - - O
intervals - - O
of - - O
0 - - O
. - - O
2 - - O
) - - O
and - - O
tidal - - O
volumes - - O
( - - O
50 - - O
, - - O
100 - - O
, - - O
200 - - O
, - - O
and - - O
to - - O
300 - - O
mL - - O
) - - O
. - - O

The - - O
mean - - O
power - - O
( - - O
in - - O
mu - - O
W - - O
) - - O
required - - O
to - - O
produce - - O
the - - O
observed - - O
flow - - O
rate - - O
was - - O
estimated - - O
at - - O
each - - O
outflow - - O
pressure - - O
as - - O
the - - O
product - - O
of - - O
the - - O
flow - - O
rate - - O
and - - O
the - - O
pressure - - O
across - - O
the - - O
lymphatic - - O
vessel - - O
. - - O

A - - O
mutational - - O
analysis - - O
has - - O
resolved - - O
a - - O
region - - O
of - - O
seven - - O
amino - - O
acids - - O
( - - O
amino - - O
acids - - O
26-32 - - O
) - - O
in - - O
the - - O
N-terminus - - O
of - - O
Bob1 - - B-MUT
that - - O
are - - O
important - - O
for - - O
contacting - - O
the - - O
DNA - - O
binding - - O
POU - - B-MUT
domain - - I-MUT
of - - O
Oct-1 - - B-MUT
or - - O
Oct-2 - - B-MUT
. - - O

Ethylene - - O
glycol - - O
and - - O
diethylene - - O
glycol - - O
were - - O
each - - O
administered - - O
once - - O
weekly - - O
subcutaneously - - O
to - - O
groups - - O
of - - O
100 - - O
female - - O
NMRI - - O
mice - - O
at - - O
3 - - O
dosages - - O
( - - O
30 - - O
; - - O
10 - - O
und - - O
3 - - O
mg - - O
single - - O
dose - - O
per - - O
mouse - - O
) - - O
. - - O

These - - O
findings - - O
show - - O
that - - O
EBP50 - - B-MUT
is - - O
a - - O
physiologically - - O
relevant - - O
ezrin - - B-MUT
binding - - I-MUT
protein - - I-MUT
. - - O

METHODS - - O
: - - O
Sixteen - - O
pigs - - O
were - - O
assigned - - O
randomly - - O
to - - O
control - - O
and - - O
shock - - O
groups - - O
. - - O

Because - - O
endogenous - - O
HSF - - B-MUT
DNA-binding - - O
activity - - O
is - - O
low - - O
and - - O
anti-hHSF1 - - B-MUT
antibody - - I-MUT
does - - O
not - - O
recognize - - O
Xenopus - - B-MUT
HSF - - I-MUT
, - - O
we - - O
employed - - O
this - - O
system - - O
for - - O
mapping - - O
regions - - O
in - - O
hHSF1 - - B-MUT
that - - O
are - - O
required - - O
for - - O
the - - O
maintenance - - O
of - - O
the - - O
monomeric - - O
state - - O
. - - O

On - - O
the - - O
comparison - - O
of - - O
correlated - - O
proportions - - O
for - - O
clustered - - O
data - - O
. - - O

No - - O
significant - - O
correlations - - O
of - - O
peak - - O
VO2 - - O
were - - O
observed - - O
between - - O
the - - O
3 - - O
tests - - O
. - - O

We - - O
discuss - - O
these - - O
results - - O
with - - O
respect - - O
to - - O
the - - O
transcriptional - - O
induction - - O
of - - O
the - - O
HNF-3 - - B-MUT
alpha - - I-MUT
gene - - I-MUT
in - - O
respiratory - - O
epithelium - - O
during - - O
embryogenesis - - O
. - - O

We - - O
were - - O
interested - - O
in - - O
studying - - O
the - - O
relationship - - O
between - - O
the - - O
circadian - - O
rhythm - - O
in - - O
body - - O
temperature - - O
and - - O
24-h - - O
variations - - O
in - - O
plasma - - O
concentrations - - O
of - - O
iron - - O
, - - O
zinc - - O
, - - O
circulating - - O
leukocyte - - O
counts - - O
, - - O
and - - O
plasma - - O
interleukin - - B-MUT
1 - - I-MUT
( - - O
IL-1 - - B-MUT
) - - O
activity - - O
. - - O

Activation - - O
was - - O
biphasic - - O
; - - O
peaking - - O
at - - O
5-10 - - O
min - - O
and - - O
24 - - O
h - - O
after - - O
treatment - - O
. - - O

Three - - O
cysteine - - O
and - - O
four - - O
tryptophan - - O
residues - - O
, - - O
previously - - O
identified - - O
as - - O
conserved - - O
amongst - - O
nitrous-oxide - - B-MUT
reductases - - I-MUT
, - - O
are - - O
found - - O
in - - O
the - - O
Paracoccus - - O
enzyme - - O
. - - O

Animal - - O
age - - O
and - - O
sex - - O
had - - O
no - - O
significant - - O
effects - - O
on - - O
CSF - - O
composition - - O
, - - O
but - - O
serum - - O
IgG - - B-MUT
concentration - - O
increased - - O
with - - O
age - - O
. - - O

These - - O
studies - - O
point - - O
to - - O
the - - O
involvement - - O
of - - O
the - - O
MAP - - B-MUT
kinase - - I-MUT
pathway - - O
in - - O
the - - O
activation - - O
of - - O
monocytic - - O
cells - - O
during - - O
transmigration - - O
to - - O
inflammatory - - O
sites - - O
. - - O

This - - O
gene - - O
encodes - - O
a - - O
putative - - O
transcription - - O
factor - - O
with - - O
regions - - O
of - - O
homology - - O
to - - O
several - - O
other - - O
proteins - - O
including - - O
the - - O
zinc - - O
fingers - - O
and - - O
other - - O
domains - - O
of - - O
the - - O
Drosophila - - B-MUT
trithorax - - I-MUT
gene - - I-MUT
product - - I-MUT
, - - O
and - - O
the - - O
"AT-hook" - - B-MUT
DNA-binding - - I-MUT
motif - - I-MUT
of - - O
high - - B-MUT
mobility - - I-MUT
group - - I-MUT
proteins - - I-MUT
. - - O

High - - O
trough - - O
serum - - O
TOB - - O
concentrations - - O
were - - O
associated - - O
with - - O
death - - O
and - - O
very - - O
low - - O
levels - - O
with - - O
recovery - - O
. - - O

Baseline - - O
MBF - - O
in - - O
females - - O
was - - O
significantly - - O
( - - O
P - - O
< - - O
0 - - O
. - - O
001 - - O
) - - O
higher - - O
than - - O
in - - O
males - - O
. - - O

Delayed - - O
or - - O
paradoxically - - O
emptying - - O
regions - - O
of - - O
the - - O
left - - O
ventricle - - O
were - - O
detected - - O
by - - O
a - - O
relatively - - O
new - - O
nuclear - - O
technique--phase - - O
imaging - - O
. - - O

To - - O
clarify - - O
whether - - O
seizure-offset - - O
patterns - - O
are - - O
reliable - - O
in - - O
predicting - - O
seizure - - O
outcome - - O
, - - O
we - - O
studied - - O
SEEG - - O
ECoG - - O
in - - O
a - - O
similar - - O
group - - O
of - - O
patients - - O
with - - O
temporal - - O
lobe - - O
epilepsy - - O
( - - O
TLE - - O
) - - O
. - - O

The - - O
11 - - O
; - - O
22 - - O
chromosomal - - O
translocation - - O
specifically - - O
linked - - O
to - - O
Ewing - - O
sarcoma - - O
and - - O
primitive - - O
neuroectodermal - - O
tumor - - O
results - - O
in - - O
a - - O
chimeric - - O
molecule - - O
fusing - - O
the - - O
amino-terminal-encoding - - O
portion - - O
of - - O
the - - O
EWS - - B-MUT
gene - - I-MUT
to - - O
the - - O
carboxyl-terminal - - O
DNA-binding - - O
domain - - O
encoded - - O
by - - O
the - - O
FLI1 - - B-MUT
gene - - I-MUT
. - - O

Immediately - - O
after - - O
surgery - - O
, - - O
dialysate - - O
PGE2 - - O
and - - O
adenosine - - O
concentrations - - O
were - - O
3 - - O
. - - O
7 - - O
+ - - O
- - - O
0 - - O
. - - O
7 - - O
and - - O
296 - - O
+ - - O
- - - O
127 - - O
nM - - O
, - - O
respectively - - O
. - - O

We - - O
randomly - - O
assigned - - O
1 - - O
, - - O
219 - - O
subjects - - O
to - - O
receive - - O
either - - O
the - - O
standard - - O
three-times-weekly - - O
( - - O
TIW - - O
) - - O
interferon - - B-MUT
alfa-2b - - I-MUT
dose - - O
( - - O
3 - - O
MIU - - O
) - - O
or - - O
the - - O
once-weekly - - O
( - - O
QW - - O
) - - O
peginterferon - - O
alfa-2b - - O
( - - O
0 - - O
. - - O
5 - - O
, - - O
1 - - O
. - - O
0 - - O
, - - O
or - - O
1 - - O
. - - O
5 - - O
microg - - O
kg - - O
) - - O
. - - O

We - - O
show - - O
that - - O
CBF-A - - B-MUT
and - - O
CBF-C - - B-MUT
interact - - O
with - - O
each - - O
other - - O
to - - O
form - - O
a - - O
CBF-A-CBF-C - - B-MUT
complex - - I-MUT
and - - O
that - - O
CBF-B - - B-MUT
does - - O
not - - O
interact - - O
with - - O
CBF-A - - B-MUT
or - - O
CBF-C - - B-MUT
individually - - O
but - - O
that - - O
it - - O
associates - - O
with - - O
the - - O
CBF-A-CBF-C - - B-MUT
complex - - I-MUT
. - - O

Protein - - B-MUT
S - - I-MUT
levels - - O
were - - O
virtually - - O
undetectable - - O
at - - O
the - - O
time - - O
of - - O
admission - - O
and - - O
failed - - O
to - - O
respond - - O
to - - O
infusions - - O
of - - O
fresh - - O
frozen - - O
plasma - - O
, - - O
despite - - O
correction - - O
of - - O
other - - O
procoagulant - - O
and - - O
anticoagulant - - O
factors - - O
. - - O

Low-grade - - O
glioma - - O
. - - O

While - - O
Pt - - B-MUT
; - - I-MUT
cycH - - I-MUT
; - - I-MUT
1 - - I-MUT
and - - O
Os - - B-MUT
; - - I-MUT
cycH - - I-MUT
; - - I-MUT
1 - - I-MUT
were - - O
expressed - - O
in - - O
all - - O
tissues - - O
examined - - O
, - - O
the - - O
transcripts - - O
accumulated - - O
abundantly - - O
in - - O
dividing - - O
cells - - O
. - - O

In - - O
patients - - O
in - - O
group - - O
A - - O
( - - O
"normal" - - O
CI - - O
) - - O
, - - O
the - - O
CI - - O
, - - O
heart - - O
rate - - O
and - - O
the - - O
mean - - O
circumferential - - O
fiber - - O
shortening - - O
velocity - - O
( - - O
mVCF - - O
) - - O
were - - O
normal - - O
, - - O
but - - O
the - - O
TPR - - O
was - - O
increased - - O
significantly - - O
. - - O

The - - O
other - - O
patients - - O
continued - - O
the - - O
trial - - O
with - - O
single - - O
daily - - O
doses - - O
of - - O
monotherapy - - O
. - - O

Our - - O
results - - O
suggest - - O
that - - O
proteasome - - O
inhibition - - O
leads - - O
to - - O
upregulation - - O
of - - O
specific - - O
members - - O
of - - O
transcription - - O
factor - - O
families - - O
controlling - - O
cellular - - O
stress - - O
response - - O
and - - O
proliferation - - O
. - - O

Potency - - O
of - - O
enflurane - - O
in - - O
dogs - - O
: - - O
comparison - - O
with - - O
halothane - - O
and - - O
isoflurane - - O
. - - O

Oxfendazole - - O
, - - O
which - - O
was - - O
active - - O
for - - O
the - - O
shortest - - O
time - - O
( - - O
about - - O
65 - - O
days - - O
) - - O
from - - O
the - - O
start - - O
of - - O
grazing - - O
( - - O
May - - O
1 - - O
) - - O
, - - O
produced - - O
a - - O
78 - - O
. - - O
1 - - O
per - - O
cent - - O
reduction - - O
in - - O
Ostertagia - - O
species - - O
and - - O
an - - O
84 - - O
. - - O
4 - - O
per - - O
cent - - O
reduction - - O
in - - O
D - - O
viviparus - - O
. - - O

METHODS - - O
: - - O
93 - - O
female - - O
and - - O
43 - - O
male - - O
patients - - O
undergoing - - O
thyroid - - O
surgery - - O
were - - O
stratified - - O
according - - O
to - - O
gender - - O
and - - O
then - - O
randomised - - O
to - - O
receive - - O
double-blind - - O
one - - O
of - - O
four - - O
antiemetic - - O
regimes - - O
: - - O
50 - - O
mg - - O
dolasetron - - O
given - - O
orally - - O
45 - - O
minutes - - O
prior - - O
to - - O
induction - - O
of - - O
anaesthesia - - O
( - - O
group - - O
I - - O
) - - O
, - - O
12 - - O
. - - O
5 - - O
mg - - O
dolasetron - - O
given - - O
intravenously - - O
during - - O
induction - - O
of - - O
anaesthesia - - O
( - - O
group - - O
II - - O
) - - O
, - - O
1 - - O
. - - O
25 - - O
mg - - O
DHB - - B-MUT
given - - O
intravenously - - O
during - - O
induction - - O
of - - O
anaesthesia - - O
( - - O
group - - O
III - - O
) - - O
or - - O
placebo - - O
( - - O
group - - O
IV - - O
) - - O
. - - O

The - - O
specific - - O
interaction - - O
between - - O
a - - O
defined - - O
structural - - O
element - - O
of - - O
the - - O
human - - O
immunodeficiency - - O
virus - - O
mRNA - - O
( - - O
RRE - - B-MUT
, - - O
the - - O
Rev - - B-MUT
response - - I-MUT
element - - I-MUT
) - - O
and - - O
the - - O
virus-encoded - - B-MUT
protein - - I-MUT
Rev - - I-MUT
has - - O
been - - O
implicated - - O
in - - O
the - - O
regulation - - O
of - - O
the - - O
export - - O
of - - O
unspliced - - O
or - - O
singly - - O
spliced - - O
mRNA - - O
from - - O
the - - O
nucleus - - O
to - - O
the - - O
cytoplasm - - O
. - - O

These - - O
cells - - O
were - - O
able - - O
to - - O
present - - O
influenza - - O
virus - - O
particles - - O
to - - O
HLA-DR1-restricted - - O
T - - O
cell - - O
clones - - O
. - - O

The - - O
4 - - O
degrees - - O
stimuli - - O
were - - O
found - - O
to - - O
elicit - - O
scalp - - O
distributions - - O
for - - O
the - - O
pattern - - O
reversal - - O
P100 - - O
and - - O
the - - O
pattern - - O
onset - - O
C1 - - O
consistent - - O
with - - O
striate - - O
and - - O
extrastriate - - O
visual - - O
cortical - - O
origins - - O
respectively - - O
. - - O

In - - O
conclusion - - O
, - - O
these - - O
observations - - O
demonstrated - - O
that - - O
stratification - - O
of - - O
acute - - O
MI - - O
patients - - O
by - - O
plasma - - O
ANF - - B-MUT
level - - O
is - - O
a - - O
useful - - O
non-invasive - - O
method - - O
for - - O
predicting - - O
prognosis - - O
and - - O
for - - O
identifying - - O
individuals - - O
at - - O
high - - O
risk - - O
of - - O
cardiac - - O
death - - O
. - - O

Heat-inducible - - O
CAT - - B-MUT
activity - - O
was - - O
detectable - - O
when - - O
additional - - O
sequences - - O
from - - O
the - - O
native - - O
promoter - - O
containing - - O
three - - O
CCAAT - - O
boxes - - O
and - - O
a - - O
single - - O
HSE - - B-MUT
were - - O
present - - O
in - - O
the - - O
constructions - - O
. - - O

Characterization - - O
of - - O
a - - O
Xenopus - - B-MUT
laevis - - I-MUT
CXC - - I-MUT
chemokine - - I-MUT
receptor - - I-MUT
4 - - I-MUT
: - - O
implications - - O
for - - O
hematopoietic - - O
cell - - O
development - - O
in - - O
the - - O
vertebrate - - O
embryo - - O
. - - O

The - - O
effect - - O
of - - O
crude - - O
oil - - O
spillage - - O
on - - O
growth - - O
, - - O
productivity - - O
and - - O
nutrient - - O
uptake - - O
of - - O
maize - - O
( - - O
Zea - - O
mays - - O
L - - O
. - - O
) - - O
was - - O
assessed - - O
in - - O
a - - O
pot - - O
experiment - - O
using - - O
an - - O
Evwreni - - O
manifold - - O
sample - - O
of - - O
a - - O
petroleum - - O
development - - O
company - - O
, - - O
which - - O
had - - O
a - - O
specific - - O
gravity - - O
of - - O
0 - - O
. - - O
8778 - - O
. - - O

Moreover - - O
, - - O
the - - O
hypoxia-induced - - O
expression - - O
of - - O
the - - O
endogenous - - O
Epo - - B-MUT
gene - - I-MUT
was - - O
significantly - - O
inhibited - - O
in - - O
Hep3B - - O
cells - - O
stably - - O
transfected - - O
with - - O
HNF-4 - - B-MUT
delta - - I-MUT
C - - I-MUT
. - - O

The - - O
subjects - - O
were - - O
shown - - O
to - - O
be - - O
capable - - O
of - - O
assessing - - O
integrally - - O
the - - O
value - - O
of - - O
accelerations - - O
and - - O
estimating - - O
it - - O
with - - O
an - - O
error - - O
of - - O
0 - - O
. - - O
1-0 - - O
. - - O
12 - - O
g - - O
. - - O

Two - - O
XPG - - B-MUT
regions - - I-MUT
with - - O
putative - - O
NLS - - O
[ - - O
amino - - O
acid - - O
( - - O
AA - - O
) - - O
coordinates - - O
: - - O
NLS-B - - O
( - - O
AA - - O
1057-1074 - - O
) - - O
and - - O
NLS-C - - O
( - - O
AA - - O
1171-1185 - - O
) - - O
] - - O
were - - O
each - - O
shown - - O
to - - O
independently - - O
localize - - O
the - - O
beta-gal - - B-MUT
extensively - - O
( - - O
> - - O
80% - - O
) - - O
to - - O
the - - O
nucleus - - O
of - - O
HeLa - - O
cells - - O
. - - O

Although - - O
metabolized - - O
by - - O
the - - O
cytochrome - - B-MUT
P-450 - - I-MUT
( - - O
CYP - - B-MUT
) - - O
system - - O
, - - O
venlafaxine - - O
inhibits - - O
CYP - - B-MUT
2D6 - - I-MUT
and - - I-MUT
3A4 - - I-MUT
to - - O
a - - O
far - - O
lesser - - O
extent - - O
than - - O
do - - O
the - - O
SSRIs - - O
. - - O

Signaling - - O
by - - O
tyrosine - - B-MUT
kinases - - I-MUT
involves - - O
direct - - O
associations - - O
between - - O
proteins - - O
with - - O
Src - - B-MUT
homology - - I-MUT
2 - - I-MUT
( - - O
SH2 - - B-MUT
) - - O
domains - - O
and - - O
sites - - O
of - - O
tyrosine - - O
phosphorylation - - O
. - - O

In - - O
addition - - O
, - - O
and - - O
in - - O
support - - O
of - - O
a - - O
mediating - - O
role - - O
of - - O
STATs - - B-MUT
in - - O
the - - O
activation - - O
of - - O
the - - O
p21 - - B-MUT
promoter - - I-MUT
, - - O
overexpression - - O
of - - O
Stat3 - - B-MUT
potentiated - - O
the - - O
cytokine - - O
effect - - O
on - - O
the - - O
p21 - - B-MUT
promoter - - I-MUT
; - - O
whereas - - O
a - - O
dominant - - B-MUT
negative - - I-MUT
Stat3 - - I-MUT
, - - O
or - - O
a - - O
mutation - - O
of - - O
the - - O
STAT - - B-MUT
response - - I-MUT
element - - I-MUT
on - - O
the - - O
promoter - - O
, - - O
significantly - - O
reduced - - O
the - - O
cytokine - - O
effect - - O
. - - O

Extramedullary - - O
relapse - - O
in - - O
childhood - - O
leukemia - - O
. - - O

Testing - - O
for - - O
serum - - B-MUT
IgM - - I-MUT
binding - - O
to - - O
GM1 - - O
ganglioside - - O
in - - O
clinical - - O
practice - - O
. - - O

Using - - O
GST-PKR - - B-MUT
fusion - - I-MUT
chromatography - - O
, - - O
direct - - O
physical - - O
interaction - - O
between - - O
the - - O
mouse - - O
and - - O
human - - B-MUT
PKR - - I-MUT
homologs - - I-MUT
was - - O
established - - O
. - - O

In - - O
contrast - - O
, - - O
the - - O
deduced - - O
amino - - O
acid - - O
sequence - - O
of - - O
a - - O
second - - O
family - - O
( - - O
ART5 - - B-MUT
) - - O
of - - O
transferases - - B-MUT
, - - O
cloned - - O
from - - O
murine - - O
lymphoma - - O
cells - - O
and - - O
expressed - - O
in - - O
high - - O
abundance - - O
in - - O
testis - - O
, - - O
displays - - O
a - - O
hydrophobic - - O
amino - - O
terminus - - O
, - - O
consistent - - O
with - - O
a - - O
signal - - O
sequence - - O
, - - O
but - - O
lacks - - O
a - - O
hydrophobic - - O
signal - - O
sequence - - O
at - - O
its - - O
carboxyl - - O
terminus - - O
, - - O
suggesting - - O
that - - O
the - - O
protein - - O
is - - O
destined - - O
for - - O
export - - O
. - - O

Sp1's - - O
role - - O
in - - O
transactivation - - O
of - - O
the - - O
pgp2 - - B-MUT
mdr1b - - I-MUT
promoter - - I-MUT
was - - I-MUT
tested - - O
in - - O
Drosophila - - O
Schneider - - O
cells - - O
. - - O

Prostaglandins - - O
and - - O
gallstones - - O
. - - O

Studies - - O
were - - O
performed - - O
on - - O
several - - O
superficial - - O
veins - - O
from - - O
the - - O
rabbit - - O
face - - O
to - - O
examine - - O
the - - O
relationship - - O
between - - O
beta - - B-MUT
adrenoceptor - - I-MUT
subtype - - I-MUT
distribution - - O
, - - O
intrinsic - - O
myogenic - - O
tone - - O
and - - O
sympathetic - - O
nerve - - O
innervation - - O
. - - O

Several - - O
lines - - O
of - - O
evidence - - O
demonstrate - - O
that - - O
this - - O
growth - - O
inhibition - - O
requires - - O
active - - O
PKA - - B-MUT
subunits - - I-MUT
and - - O
cAMP - - O
: - - O
( - - O
i - - O
) - - O
this - - O
phenotype - - O
is - - O
dependent - - O
on - - O
cAMP - - O
since - - O
it - - O
is - - O
not - - O
seen - - O
in - - O
a - - O
strain - - O
lacking - - O
adenylyl - - B-MUT
cyclase - - I-MUT
activity - - O
, - - O
but - - O
the - - O
growth - - O
rate - - O
of - - O
these - - O
transformants - - O
is - - O
slower - - O
when - - O
exogenous - - O
cAMP - - O
is - - O
added - - O
; - - O
( - - O
ii - - O
) - - O
normal - - O
growth - - O
occurs - - O
when - - O
wild-type - - O
RI - - B-MUT
cDNA - - O
is - - O
replaced - - O
by - - O
a - - O
mutant - - B-MUT
RI - - I-MUT
cDNA - - I-MUT
encoding - - O
a - - O
RI - - B-MUT
protein - - I-MUT
with - - O
reduced - - O
cAMP - - O
binding - - O
; - - O
and - - O
( - - O
iii - - O
) - - O
the - - O
growth-inhibited - - O
phenotype - - O
of - - O
the - - O
transformed - - O
BL21 - - O
( - - O
DE3 - - O
) - - O
cells - - O
requires - - O
soluble - - O
, - - O
active - - O
C - - B-MUT
alpha - - I-MUT
protein - - I-MUT
. - - O

In - - O
this - - O
paper - - O
, - - O
we - - O
have - - O
analyzed - - O
the - - O
structure - - O
of - - O
human - - O
gene - - O
for - - O
Gx - - B-MUT
alpha - - I-MUT
, - - O
which - - O
spans - - O
more - - O
than - - O
60 - - O
kilobases - - O
. - - O

The - - O
author - - O
analyzes - - O
extensive - - O
own - - O
data - - O
based - - O
on - - O
study - - O
into - - O
particular - - O
features - - O
of - - O
cardiovascular - - O
disorders - - O
in - - O
chronic - - O
renal - - O
impairement - - O
with - - O
making - - O
use - - O
of - - O
modern - - O
diagnostic - - O
tools - - O
. - - O

Nuclear - - B-MUT
protein - - I-MUT
phosphatase - - I-MUT
2A - - I-MUT
dephosphorylates - - O
protein - - B-MUT
kinase - - I-MUT
A-phosphorylated - - O
CREB - - B-MUT
and - - O
regulates - - O
CREB - - B-MUT
transcriptional - - O
stimulation - - O
. - - O

Antileukoproteinase - - B-MUT
( - - O
ALP - - B-MUT
) - - O
is - - O
a - - O
low - - O
mol - - O
wt - - O
mucosal - - O
secretory - - O
protein - - O
which - - O
, - - O
in - - O
human - - O
tissues - - O
, - - O
inhibits - - O
the - - O
activities - - O
of - - O
the - - O
neutral - - O
serine - - B-MUT
lysosomal - - I-MUT
proteinases - - I-MUT
elastase - - B-MUT
and - - O
cathepsin-G - - B-MUT
. - - O

No - - O
dominant - - O
clinical - - O
factor - - O
of - - O
risk - - O
was - - O
found - - O
, - - O
but - - O
multiple - - O
regression - - O
analysis - - O
identified - - O
age - - O
, - - O
body - - O
surface - - O
area - - O
, - - O
valve - - O
size - - O
, - - O
shop - - O
order - - O
fracture - - O
rate - - O
, - - O
and - - O
manufacturing - - O
period - - O
as - - O
risk - - O
factors - - O
for - - O
OSF - - O
. - - O

It - - O
is - - O
useful - - O
as - - O
an - - O
adjunct - - O
to - - O
mammography - - O
in - - O
those - - O
patients - - O
with - - O
radiographically - - O
dense - - O
breasts - - O
for - - O
the - - O
characterization - - O
of - - O
palpable - - O
masses - - O
. - - O

There - - O
was - - O
however - - O
, - - O
no - - O
significant - - O
difference - - O
in - - O
the - - O
prevalence - - O
of - - O
chronic - - O
respiratory - - O
symptoms - - O
between - - O
animal - - O
food - - O
workers - - O
with - - O
positive - - O
and - - O
negative - - O
skin - - O
tests - - O
to - - O
house - - O
dust - - O
or - - O
to - - O
fish - - O
flour - - O
or - - O
among - - O
those - - O
with - - O
increased - - O
or - - O
normal - - O
IgE - - B-MUT
( - - O
except - - O
for - - O
dyspnea - - O
) - - O
. - - O

This - - O
protein - - O
with - - O
a - - O
hydrophobic - - O
amino - - O
terminus - - O
appears - - O
to - - O
be - - O
a - - O
secreted - - O
protein - - O
. - - O

Initial - - O
estimates - - O
indicate - - O
that - - O
27 - - O
, - - O
193 - - O
people - - O
are - - O
either - - O
in - - O
receipt - - O
of - - O
or - - O
in - - O
need - - O
of - - O
mental - - O
handicap - - O
services - - O
. - - O

Significance - - O
of - - O
the - - O
biopsy - - O
site - - O
of - - O
the - - O
latissimus - - O
dorsi - - O
muscle - - O
for - - O
fiber - - O
typing - - O
. - - O

Our - - O
mapping - - O
results - - O
did - - O
not - - O
suggest - - O
involvement - - O
of - - O
this - - O
gene - - O
in - - O
previously - - O
mapped - - O
genetic - - O
disorders - - O
or - - O
in - - O
known - - O
neoplasia-associated - - O
translocation - - O
breakpoints - - O
. - - O

OBJECTIVE - - O
: - - O
This - - O
study - - O
was - - O
designed - - O
to - - O
analyze - - O
the - - O
common - - O
cause - - O
of - - O
asthenopia - - O
, - - O
mixed - - O
astigmatism - - O
. - - O

The - - O
5-year - - O
OS - - O
for - - O
stage - - O
IIIB - - O
was - - O
30 - - O
. - - O
9% - - O
, - - O
compared - - O
to - - O
7 - - O
. - - O
8% - - O
for - - O
stage - - O
IV - - O
. - - O

The - - O
simultaneous - - O
recording - - O
of - - O
electrical - - O
activity - - O
from - - O
the - - O
surface - - O
electrocardiogram - - O
, - - O
right - - O
ventricular - - O
apex - - O
, - - O
His - - O
bundle - - O
, - - O
high - - O
right - - O
atrium - - O
, - - O
coronary - - O
sinus - - O
, - - O
with - - O
or - - O
without - - O
a - - O
roving - - O
mapping - - O
catheter - - O
, - - O
enables - - O
us - - O
to - - O
precisely - - O
map - - O
the - - O
electrical - - O
activation - - O
sequence - - O
in - - O
the - - O
heart - - O
. - - O

As - - O
with - - O
the - - O
murine - - B-MUT
and - - I-MUT
human - - I-MUT
mb-1 - - I-MUT
genes - - I-MUT
, - - O
the - - O
5' - - O
region - - O
of - - O
the - - O
bovine - - B-MUT
mb-1 - - I-MUT
gene - - I-MUT
lacked - - O
a - - O
TATA - - O
box - - O
. - - O

Sequence - - O
analyses - - O
of - - O
sos2 - - B-MUT
mutant - - I-MUT
alleles - - I-MUT
reveal - - O
that - - O
both - - O
the - - O
N-terminal - - O
catalytic - - O
domain - - O
and - - O
the - - O
C-terminal - - O
regulatory - - O
domain - - O
of - - O
SOS2 - - B-MUT
are - - O
functionally - - O
essential - - O
. - - O

Furthermore - - O
, - - O
analysis - - O
of - - O
the - - O
E2 - - B-MUT
proteins - - I-MUT
present - - O
in - - O
various - - O
cell - - O
lines - - O
harboring - - O
specific - - O
BPV-1 - - O
mutants - - O
, - - O
including - - O
the - - O
2558 - - B-MUT
acceptor - - I-MUT
mutant - - I-MUT
, - - O
proves - - O
that - - O
alternate - - O
modes - - O
of - - O
E2 - - B-MUT
expression - - O
exist - - O
. - - O

When - - O
statistically - - O
analyzed - - O
in - - O
various - - O
subgroupings - - O
, - - O
the - - O
obtained - - O
average - - O
sedimentation - - O
coefficients - - O
and - - O
polydispersity - - O
profiles - - O
supported - - O
the - - O
following - - O
conclusions - - O
: - - O
( - - O
a - - O
) - - O
loss - - O
of - - O
proteoglycan - - O
aggregation - - O
and - - O
sedimentability - - O
is - - O
confirmed - - O
to - - O
be - - O
a - - O
primary - - O
sign - - O
of - - O
cartilage - - O
matrix - - O
degradation - - O
; - - O
( - - O
b - - O
) - - O
higher - - O
S - - O
values - - O
for - - O
proteoglycans - - O
of - - O
the - - O
high - - O
weight - - O
( - - O
HW - - O
) - - O
-bearing - - O
areas - - O
and - - O
lower - - O
values - - O
for - - O
those - - O
of - - O
the - - O
low - - O
weight - - O
( - - O
LW - - O
) - - O
-bearing - - O
areas - - O
were - - O
a - - O
typical - - O
finding - - O
in - - O
normal - - O
cartilage - - O
samples - - O
; - - O
( - - O
c - - O
) - - O
inversion - - O
of - - O
this - - O
pattern - - O
was - - O
indicative - - O
of - - O
matrix - - O
degradation - - O
, - - O
suggesting - - O
that - - O
the - - O
HW - - O
regions - - O
are - - O
more - - O
affected - - O
than - - O
the - - O
LW-bearing - - O
areas - - O
; - - O
( - - O
d - - O
) - - O
the - - O
average - - O
S - - O
value - - O
distribution - - O
across - - O
cartilage - - O
thickness - - O
tended - - O
to - - O
resemble - - O
the - - O
corresponding - - O
proteoglycan - - O
content - - O
versus - - O
distance - - O
from - - O
articular - - O
surface - - O
; - - O
and - - O
( - - O
e - - O
) - - O
the - - O
deepest - - O
cartilage - - O
layer - - O
had - - O
, - - O
in - - O
most - - O
cases - - O
, - - O
the - - O
smallest - - O
amount - - O
of - - O
aggregates - - O
while - - O
the - - O
highest - - O
average - - O
sedimentability - - O
was - - O
observed - - O
at - - O
the - - O
middle - - O
zone - - O
of - - O
the - - O
normal - - O
samples - - O
. - - O

Cyclins - - B-MUT
are - - O
one - - O
of - - O
the - - O
pivotal - - O
determinants - - O
regulating - - O
cell - - O
cycle - - O
progression - - O
. - - O

A - - O
centromere - - O
in - - O
S - - O
. - - O
cerevisiae - - O
consists - - O
of - - O
a - - O
region - - O
of - - O
DNA - - O
, - - O
approximately - - O
150 - - O
bp - - O
in - - O
length - - O
, - - O
containing - - O
three - - O
important - - O
sequence - - O
elements - - O
, - - O
which - - O
are - - O
folded - - O
with - - O
proteins - - O
into - - O
a - - O
specific - - O
conformation - - O
in - - O
the - - O
chromatin - - O
( - - O
the - - O
yeast - - O
kinetochore - - O
) - - O
. - - O

The - - O
first - - O
146 - - O
consecutive - - O
patients - - O
treated - - O
with - - O
EVL - - O
during - - O
the - - O
period - - O
from - - O
August - - O
, - - O
1986 - - O
to - - O
July - - O
, - - O
1989 - - O
are - - O
reported - - O
. - - O

Two - - O
scintigraphic - - O
methods - - O
, - - O
resting - - O
dipyridamole - - O
and - - O
exercise - - O
thallium-201 - - O
myocardial - - O
perfusion - - O
imaging - - O
, - - O
to - - O
detect - - O
and - - O
localize - - O
coronary - - O
artery - - O
stenosis - - O
were - - O
compared - - O
in - - O
32 - - O
patients - - O
suffering - - O
from - - O
coronary - - O
artery - - O
disease - - O
. - - O

In - - O
all - - O
sessions - - O
under - - O
IFN - - B-MUT
, - - O
the - - O
latency - - O
of - - O
the - - O
P100 - - O
component - - O
of - - O
the - - O
VEP - - O
was - - O
shortened - - O
as - - O
compared - - O
to - - O
baseline - - O
conditions - - O
. - - O

CONCLUSIONS - - O
: - - O
Our - - O
meta-analysis - - O
of - - O
randomized - - O
controlled - - O
trials - - O
of - - O
HRT - - O
noted - - O
a - - O
statistically - - O
significant - - O
reduction - - O
in - - O
nonvertebral - - O
fractures - - O
. - - O

Prevention - - O
of - - O
transfusion - - O
reactions - - O
by - - O
the - - O
use - - O
of - - O
saline - - O
washed - - O
red - - O
blood - - O
cells - - O
. - - O

In - - O
human - - O
proliferative - - O
cells - - O
, - - O
the - - O
NADP-dependent - - O
ME - - B-MUT
activity - - O
is - - O
poorly - - O
expressed - - O
and - - O
barely - - O
inducible - - O
by - - O
thyroid - - O
hormones - - O
. - - O

The - - O
delta - - B-MUT
srb10 - - I-MUT
mutation - - I-MUT
also - - O
influenced - - O
on - - O
the - - O
transcript - - O
levels - - O
of - - O
meiosis-inducing - - O
genes - - O
called - - O
IME1 - - B-MUT
and - - O
IME2 - - B-MUT
: - - O
the - - O
mutation - - O
elevated - - O
the - - O
transcript - - O
level - - O
of - - O
IME1 - - B-MUT
but - - O
reduced - - O
that - - O
of - - O
IME2 - - B-MUT
, - - O
resulting - - O
in - - O
partial - - O
defects - - O
in - - O
premeiotic - - O
DNA - - O
synthesis - - O
and - - O
meiosis - - O
. - - O

After - - O
screening - - O
the - - O
Berkeley - - O
Drosophila - - O
Genome - - O
Project - - O
database - - O
with - - O
sequences - - O
from - - O
a - - O
recently - - O
characterized - - O
Leu-rich - - B-MUT
repeats-containing - - I-MUT
G - - I-MUT
protein-coupled - - I-MUT
receptor - - I-MUT
( - - O
LGR - - B-MUT
) - - O
from - - O
Drosophila - - O
( - - O
DLGR-1 - - B-MUT
) - - O
, - - O
we - - O
identified - - O
a - - O
second - - O
gene - - O
for - - O
a - - O
different - - O
LGR - - B-MUT
( - - O
DLGR-2 - - B-MUT
) - - O
and - - O
cloned - - O
its - - O
cDNA - - O
. - - O

Takahashi - - O
, - - O
H - - O
. - - O

The - - O
telomerase - - B-MUT
RNA-protein - - I-MUT
complex - - I-MUT
responsible - - O
for - - O
maintenance - - O
of - - O
telomeric - - O
DNA - - O
at - - O
chromosome - - O
ends - - O
, - - O
is - - O
usually - - O
inactive - - O
in - - O
most - - O
primary - - O
somatic - - O
human - - O
cells - - O
, - - O
but - - O
is - - O
specifically - - O
activated - - O
with - - O
in - - O
vitro - - O
immortalization - - O
and - - O
during - - O
tumorigenesis - - O
. - - O

Sequence - - O
analysis - - O
of - - O
these - - O
genes - - O
and - - O
their - - O
surrounding - - O
sequences - - O
are - - O
presented - - O
and - - O
compared - - O
with - - O
other - - O
known - - O
tRNA - - O
genes - - O
from - - O
plant - - O
mitochondria - - O
. - - O

Interferon - - B-MUT
type - - I-MUT
I - - I-MUT
in - - O
protective - - O
body - - O
reactions - - O
in - - O
an - - O
experimental - - O
Klebsiella - - O
infection - - O
. - - O

In - - O
addition - - O
, - - O
the - - O
consensus - - O
amino - - O
acid - - O
motif - - O
for - - O
serine - - B-MUT
threonine - - I-MUT
receptor - - I-MUT
kinases - - I-MUT
was - - O
also - - O
present - - O
. - - O

However - - O
, - - O
despite - - O
its - - O
relationship - - O
to - - O
the - - O
TR - - B-MUT
, - - O
Rev-Erb - - B-MUT
bound - - O
poorly - - O
to - - O
TR - - B-MUT
binding - - I-MUT
sites - - I-MUT
. - - O

These - - O
data - - O
suggest - - O
that - - O
the - - O
G-protein - - B-MUT
gene - - I-MUT
family - - I-MUT
may - - O
be - - O
distributed - - O
over - - O
at - - O
least - - O
two - - O
human - - O
chromosomes - - O
. - - O

Radioimmunoassay - - O
of - - O
serum - - O
creatine - - B-MUT
kinase - - I-MUT
B - - I-MUT
isoenzyme - - I-MUT
in - - O
the - - O
diagnosis - - O
of - - O
acute - - O
myocardial - - O
infarction - - O
. - - O

Two - - O
potential - - O
regulatory - - O
sequences - - O
for - - O
DNA - - O
binding - - O
proteins - - O
were - - O
found - - O
in - - O
the - - O
non-coding - - O
5' - - O
region - - O
: - - O
a - - O
HAP2 - - B-MUT
HAP3 - - I-MUT
consensus - - I-MUT
recognition - - I-MUT
sequence - - I-MUT
at - - I-MUT
nucleotide-154 - - O
and - - O
a - - O
BAF1 - - O
consensus - - B-MUT
recognition - - I-MUT
sequence - - I-MUT
at - - I-MUT
nucleotide-136 - - O
. - - O

Transfection - - O
experiments - - O
using - - O
preformed - - O
triplexes - - O
with - - O
a - - O
reporter - - O
plasmid - - O
containing - - O
the - - O
collagen - - B-MUT
promoter - - I-MUT
sequence - - I-MUT
showed - - O
significant - - O
inhibition - - O
of - - O
transcription - - O
when - - O
compared - - O
with - - O
a - - O
control - - O
phosphorothioate - - O
ODN - - O
. - - O

The - - O
nucleotide - - O
sequences - - O
at - - O
the - - O
5' - - O
and - - O
3' - - O
ends - - O
of - - O
these - - O
introns - - O
are - - O
characteristic - - O
of - - O
spliced - - O
transcripts - - O
from - - O
eukaryotic - - O
protein-encoding - - O
genes - - O
, - - O
with - - O
one - - O
significant - - O
difference - - O
; - - O
i - - O
. - - O
e - - O
. - - O
, - - O
the - - O
5' - - O
end - - O
of - - O
the - - O
LAT - - B-MUT
intron - - I-MUT
is - - O
GC - - O
instead - - O
of - - O
the - - O
consensus - - O
sequence - - O
GT - - O
. - - O

Human - - O
T-cell - - O
leukemia - - O
virus - - O
type - - O
I - - O
Tax - - B-MUT
activation - - O
of - - O
NF-kappa - - B-MUT
B - - I-MUT
Rel - - I-MUT
involves - - I-MUT
phosphorylation - - O
and - - O
degradation - - O
of - - O
I - - O
kappa - - B-MUT
B - - I-MUT
alpha - - I-MUT
and - - I-MUT
RelA - - O
( - - B-MUT
p65 - - O
) - - B-MUT
-mediated - - O
induction - - O
of - - O
the - - O
c-rel - - O
gene - - B-MUT
. - - I-MUT

Before - - O
birth - - O
, - - O
there - - O
were - - O
a - - O
few - - O
perivascular - - O
adrenergic - - O
nerves - - O
and - - O
correspondingly - - O
low - - O
ovarian - - O
NE - - O
levels - - O
. - - O

Habituation - - O
of - - O
completely - - O
isolated - - O
neurons - - O
of - - O
the - - O
edible - - O
snail - - O
to - - O
electrical - - O
stimulation - - O
. - - O

A - - O
synergistic - - O
effect - - O
on - - O
HCK - - B-MUT
promoter - - I-MUT
activity - - O
was - - O
observed - - O
at - - O
high - - O
concentrations - - O
of - - O
Sp1 - - B-MUT
. - - O

Further - - O
characterization - - O
of - - O
these - - O
putative - - O
Hoxa-1 - - B-MUT
target - - I-MUT
genes - - I-MUT
will - - O
aid - - O
in - - O
delineating - - O
the - - O
functions - - O
of - - O
the - - O
Hoxa-1 - - B-MUT
protein - - I-MUT
in - - O
the - - O
differentiation - - O
processes - - O
which - - O
occur - - O
during - - O
embryogenesis - - O
. - - O

The - - O
ANB1 - - B-MUT
locus - - I-MUT
of - - O
Saccharomyces - - O
cerevisiae - - O
encodes - - O
the - - O
protein - - B-MUT
synthesis - - I-MUT
initiation - - I-MUT
factor - - I-MUT
eIF-4D - - I-MUT
. - - O

No - - O
serious - - O
side - - O
effects - - O
were - - O
observed - - O
. - - O

Although - - O
the - - O
risk - - O
of - - O
malformation - - O
in - - O
children - - O
born - - O
after - - O
ICSI - - O
is - - O
not - - O
increased - - O
there - - O
is - - O
an - - O
increased - - O
risk - - O
to - - O
transmit - - O
genetic - - O
abnormalities - - O
in - - O
case - - O
of - - O
NOA - - O
( - - O
such - - O
as - - O
the - - O
rate - - O
of - - O
sex - - O
chromosome - - O
, - - O
or - - O
microdeletions - - O
of - - O
the - - O
Y - - O
chromosome - - O
) - - O
and - - O
in - - O
case - - O
of - - O
congenital - - O
OA - - O
( - - O
mutations - - O
of - - O
the - - O
cystic - - B-MUT
fibrosis - - I-MUT
gene - - I-MUT
) - - O
. - - O

Mg2+ - - O
and - - O
Mn2+ - - O
compete - - O
for - - O
binding - - O
sites - - O
, - - O
with - - O
the - - O
former - - O
having - - O
lower - - O
affinity - - O
. - - O

Promoter - - O
activities - - O
were - - O
estimated - - O
using - - O
beta-glucuronidase - - B-MUT
and - - O
neomycin - - B-MUT
phosphotransferase - - I-MUT
II - - I-MUT
reporter - - I-MUT
gene - - I-MUT
systems - - I-MUT
. - - O

Timing - - O
of - - O
symptoms - - O
and - - O
oocyst - - O
excretion - - O
in - - O
human - - O
cryptosporidiosis - - O
. - - O

In - - O
vivo - - O
association - - O
between - - O
Shb-SH3 - - B-MUT
domain - - I-MUT
proteins - - O
v-Src - - B-MUT
and - - O
Eps8 - - B-MUT
was - - O
detected - - O
by - - O
coimmunoprecipitation - - O
. - - O

The - - O
first - - O
gene - - O
codes - - O
for - - O
a - - O
protein - - O
containing - - O
11 - - O
cystein - - O
residues - - O
in - - O
an - - O
arrangement - - O
typical - - O
for - - O
Fe - - B-MUT
S - - I-MUT
proteins - - I-MUT
. - - I-MUT

In - - O
7 - - O
of - - O
9 - - O
cases - - O
, - - O
the - - O
enhancer - - O
is - - O
fused - - O
to - - O
the - - O
c-myc - - B-MUT
bearing - - I-MUT
sequences - - I-MUT
of - - O
chromosome - - O
8 - - O
. - - O

The - - O
critical - - O
mutations - - O
were - - O
likely - - O
to - - O
have - - O
been - - O
multiple - - O
and - - O
dispersed - - O
, - - O
including - - O
elongation - - O
of - - O
the - - O
TM - - B-MUT
and - - O
Nef - - B-MUT
coding - - I-MUT
sequences - - I-MUT
; - - O
changes - - O
in - - O
RNA - - O
splice - - O
donor - - O
and - - O
acceptor - - O
sites - - O
, - - O
TATA - - O
box - - O
sites - - O
, - - O
and - - O
Sp1 - - B-MUT
sites - - I-MUT
; - - O
multiple - - O
changes - - O
in - - O
the - - O
V2 - - B-MUT
region - - I-MUT
of - - O
SU - - B-MUT
, - - O
including - - O
a - - O
consensus - - O
neutralization - - O
epitope - - O
; - - O
and - - O
five - - O
new - - O
N-linked - - O
glycosylation - - O
sites - - O
in - - O
SU - - B-MUT
. - - O

These - - O
patients - - O
failed - - O
to - - O
respond - - O
to - - O
intravenous - - O
cyclophosphamide - - O
and - - O
steroids - - O
and - - O
were - - O
then - - O
changed - - O
to - - O
receive - - O
oral - - O
cyclosporine - - O
A - - O
, - - O
at - - O
a - - O
dose - - O
of - - O
5 - - O
mg - - O
kg - - O
day - - O
. - - O

The - - O
yeast - - O
enzyme - - O
was - - O
6-fold - - O
slower - - O
than - - O
the - - O
mammalian - - O
enzymes - - O
, - - O
which - - O
made - - O
it - - O
amenable - - O
to - - O
pre-steady-state - - O
stopped-flow - - O
spectroscopic - - O
kinetic - - O
analysis - - O
at - - O
30 - - O
degrees - - O
C - - O
and - - O
pH - - O
6 - - O
. - - O
0 - - O
. - - O

Each - - O
immunoprecipitate - - O
contained - - O
a - - O
complex - - O
of - - O
N1 - - B-MUT
( - - I-MUT
deltaEC - - I-MUT
) - - I-MUT
and - - O
CBF1 - - B-MUT
. - - O

In - - O
vitro - - O
evaluation - - O
of - - O
the - - O
mucolytic - - O
action - - O
of - - O
urea - - O
. - - O

The - - O
hBRAG - - B-MUT
gene - - I-MUT
was - - O
localized - - O
to - - O
the - - O
long - - O
arm - - O
of - - O
chromosome - - O
10 - - O
( - - O
10q26 - - O
) - - O
. - - O

Dopamine - - B-MUT
receptor - - I-MUT
blockade - - O
and - - O
the - - O
neuroleptics - - O
, - - O
a - - O
crystallographic - - O
study - - O
. - - O

Expression - - O
was - - O
cell - - O
cycle - - O
controlled - - O
, - - O
with - - O
steady-state - - O
RNA - - O
levels - - O
significantly - - O
higher - - O
in - - O
growth-arrested - - O
than - - O
in - - O
growth-stimulated - - O
cells - - O
. - - O

Pharmacologic - - O
aspects - - O
of - - O
neonatal - - O
hyperbilirubinemia - - O
. - - O

Of - - O
the - - O
21 - - O
quadrants - - O
positive - - O
in - - O
the - - O
controls - - O
, - - O
17 - - O
were - - O
correlated - - O
with - - O
previously - - O
detected - - O
jaw - - O
pathoses - - O
. - - O

In - - O
15 - - O
ventilator-dependent - - O
, - - O
SB - - O
, - - O
and - - O
actively - - O
expiring - - O
patients - - O
, - - O
we - - O
found - - O
that - - O
the - - O
difference - - O
PEEP - - O
( - - O
i - - O
) - - O
, - - O
dyn - - O
- - - O
Pga - - O
, - - O
total - - O
decay - - O
( - - O
mean - - O
+ - - O
- - - O
SD - - O
, - - O
5 - - O
. - - O
7 - - O
+ - - O
- - - O
1 - - O
. - - O
9 - - O
cm - - O
H - - O
( - - O
2 - - O
) - - O
O - - O
) - - O
was - - O
quite - - O
similar - - O
to - - O
PEEP - - O
( - - O
i - - O
) - - O
, - - O
dyn - - O
ref - - O
( - - O
5 - - O
. - - O
3 - - O
+ - - O
- - - O
1 - - O
. - - O
9 - - O
cm - - O
H - - O
( - - O
2 - - O
) - - O
O - - O
) - - O
. - - O

Perfusion - - O
technique - - O
for - - O
perfusion-assisted - - O
direct - - O
coronary - - O
artery - - O
bypass - - O
( - - O
PADCAB - - O
) - - O
. - - O

By - - O
contrast - - O
, - - O
kidneys - - O
from - - O
rats - - O
with - - O
chronic - - O
metabolic - - O
acidosis - - O
produced - - O
significantly - - O
more - - O
NH3 - - O
than - - O
both - - O
these - - O
groups - - O
( - - O
2 - - O
. - - O
73 - - O
+ - - O
- - - O
0 - - O
. - - O
29 - - O
mumol - - O
X - - O
min-1 - - O
X - - O
g-1 - - O
) - - O
. - - O

This - - O
phosphorylation - - O
can - - O
be - - O
catalyzed - - O
by - - O
a - - O
break-ended - - O
double-stranded - - O
DNA-activated - - O
protein - - B-MUT
kinase - - I-MUT
activity - - O
from - - O
the - - O
sea - - O
urchin - - O
nucleus - - O
in - - O
vitro - - O
. - - O

In - - O
addition - - O
, - - O
we - - O
also - - O
show - - O
that - - O
cdk7 - - B-MUT
may - - O
phosphorylate - - O
the - - O
carboxy-terminal - - O
domain - - O
( - - O
CTD - - O
) - - O
of - - O
RNA - - B-MUT
pol - - I-MUT
II - - I-MUT
in - - O
the - - O
absence - - O
of - - O
promoter - - O
opening - - O
. - - O

Delayed - - O
gallbladder - - O
visualization - - O
and - - O
reduction - - O
in - - O
ejection - - O
fraction - - O
were - - O
sensitive - - O
but - - O
nonspecific - - O
indicators - - O
of - - O
biliary - - O
disease - - O
. - - O

Managing - - O
vertigo - - O
and - - O
vertigo - - O
syndromes - - O
in - - O
the - - O
elderly - - O

After - - O
base-line - - O
CBF - - O
was - - O
established - - O
, - - O
hexamethonium - - O
bromide - - O
( - - O
2 - - O
mg - - O
kg - - O
iv - - O
) - - O
, - - O
ipratropium - - O
bromide - - O
( - - O
0 - - O
. - - O
5 - - O
microgram - - O
kg - - O
iv - - O
) - - O
, - - O
indomethacin - - O
( - - O
2 - - O
mg - - O
kg - - O
iv - - O
) - - O
, - - O
or - - O
intravenous - - O
0 - - O
. - - O
9% - - O
saline - - O
was - - O
administered - - O
. - - O

Mean - - O
intake - - O
of - - O
vitamin - - O
A - - O
amounted - - O
to - - O
1 - - O
. - - O
1 - - O
and - - O
0 - - O
. - - O
9 - - O
mg - - O
RE - - O
day - - O
for - - O
men - - O
and - - O
women - - O
, - - O
respectively - - O
; - - O
the - - O
contributions - - O
of - - O
meat - - O
, - - O
fats - - O
and - - O
oils - - O
, - - O
vegetables - - O
and - - O
dairy - - O
products - - O
to - - O
total - - O
intake - - O
were - - O
35% - - O
, - - O
24% - - O
, - - O
16% - - O
, - - O
and - - O
16% - - O
, - - O
respectively - - O
. - - O

The - - O
risk - - O
for - - O
these - - O
complications - - O
is - - O
increased - - O
by - - O
the - - O
following - - O
factors - - O
: - - O
multiple - - O
gestation - - O
, - - O
the - - O
combination - - O
of - - O
magnesium - - O
sulfate - - O
and - - O
beta-adrenergic - - O
agonist - - O
, - - O
and - - O
the - - O
use - - O
of - - O
adrenocortico-steroids - - O
to - - O
hasten - - O
fetal - - O
pulmonary - - O
maturity - - O
. - - O

Human - - B-MUT
rIL-3 - - I-MUT
expressed - - O
in - - O
COS7 - - O
cells - - O
has - - O
multipotential - - O
CSF - - B-MUT
activity - - O
in - - O
semisolid - - O
cultures - - O
of - - O
bone - - O
marrow - - O
cells - - O
, - - O
and - - O
selectively - - O
induced - - O
the - - O
proliferation - - O
of - - O
My-10+ - - O
marrow - - O
or - - O
cord - - O
blood - - O
cells - - O
in - - O
liquid - - O
cultures - - O
. - - O

EBER1 - - B-MUT
mRNA - - I-MUT
, - - O
a - - O
consistent - - O
marker - - O
of - - O
viral - - O
latency - - O
, - - O
was - - O
positive - - O
in - - O
all - - O
PEL - - O
cases - - O
, - - O
although - - O
at - - O
lower - - O
levels - - O
than - - O
in - - O
the - - O
non-PEL - - O
controls - - O
due - - O
to - - O
EBER1 - - B-MUT
expression - - O
by - - O
only - - O
a - - O
variable - - O
subset - - O
of - - O
lymphoma - - O
cells - - O
. - - O

We - - O
used - - O
two - - O
approaches - - O
to - - O
ascertain - - O
whether - - O
CDP - - B-MUT
cut - - I-MUT
serves - - I-MUT
as - - O
a - - O
repressor - - O
of - - O
gp91-phox - - O
gene - - B-MUT
expression - - I-MUT
. - - O

Interestingly - - O
, - - O
one - - O
IRF - - B-MUT
binding - - I-MUT
site - - I-MUT
was - - O
found - - O
within - - O
the - - O
IRF-2 - - B-MUT
promoter - - I-MUT
, - - O
and - - O
expression - - O
of - - O
the - - O
IRF-2 - - B-MUT
gene - - I-MUT
was - - O
affected - - O
by - - O
both - - O
transient - - O
and - - O
stable - - O
IRF-1 - - B-MUT
expression - - O
. - - O

The - - O
domains - - O
involved - - O
in - - O
superactivation - - O
appear - - O
to - - O
be - - O
a - - O
subset - - O
of - - O
those - - O
necessary - - O
to - - O
achieve - - O
synergistic - - O
activation - - O
. - - O

Effects - - O
of - - O
posteroventral - - O
pallidotomy - - O
on - - O
Parkinson's - - O
disease - - O
. - - O

We - - O
also - - O
demonstrate - - O
that - - O
preformed - - O
triplexes - - O
are - - O
quite - - O
stable - - O
when - - O
precipitated - - O
with - - O
ethanol - - O
and - - O
resuspended - - O
in - - O
water - - O
. - - O

Furthermore - - O
, - - O
both - - O
rhHR23 - - B-MUT
proteins - - I-MUT
function - - O
in - - O
a - - O
defined - - O
NER - - O
system - - O
reconstituted - - O
with - - O
purified - - O
proteins - - O
, - - O
indicating - - O
direct - - O
involvement - - O
of - - O
hHR23 - - B-MUT
proteins - - I-MUT
in - - O
the - - O
DNA - - O
repair - - O
reaction - - O
via - - O
interaction - - O
with - - O
XPC - - B-MUT
. - - O

2 - - O
. - - O

All - - O
patients - - O
were - - O
evaluable - - O
for - - O
toxicity - - O
and - - O
9 - - O
for - - O
response - - O
. - - O

It - - O
was - - O
found - - O
that - - O
increase - - O
in - - O
the - - O
RH - - O
level - - O
boosts - - O
the - - O
current - - O
values - - O
by - - O
2-3 - - O
orders - - O
of - - O
magnitude - - O
; - - O
contrariwise - - O
, - - O
the - - O
voltage - - O
values - - O
rise - - O
by - - O
about - - O
three - - O
times - - O
with - - O
drop - - O
in - - O
the - - O
RH - - O
. - - O

Both - - O
verapamil - - O
and - - O
propranolol - - O
can - - O
exhibit - - O
additive - - O
effects - - O
with - - O
adenosine - - O
in - - O
prolonging - - O
AV - - O
nodal - - O
conduction - - O
time - - O
; - - O
however - - O
, - - O
only - - O
verapamil - - O
can - - O
reduce - - O
the - - O
dose - - O
of - - O
adenosine - - O
required - - O
to - - O
produce - - O
AV - - O
nodal - - O
block - - O
. - - O

The - - O
extents - - O
of - - O
phosphorylation - - O
of - - O
Ser44 - - O
and - - O
Ser64 - - O
were - - O
1 - - O
: - - O
1 - - O
, - - O
whereas - - O
those - - O
of - - O
the - - O
four - - O
minor - - O
sites - - O
all - - O
together - - O
were - - O
< - - O
30% - - O
of - - O
the - - O
major - - O
one - - O
. - - O

DNA - - O
blot - - O
hybridization - - O
suggests - - O
that - - O
the - - O
rat - - O
genome - - O
may - - O
contain - - O
more - - O
than - - O
one - - O
gene - - O
encoding - - O
PtdIns - - B-MUT
transfer - - I-MUT
protein - - I-MUT
. - - O

The - - O
deduced - - O
protein - - O
sequence - - O
was - - O
88% - - O
homologous - - O
to - - O
that - - O
of - - O
hNUC - - B-MUT
I - - I-MUT
, - - O
isolated - - O
from - - O
human - - O
osteosarcoma - - O
cells - - O
. - - O

The - - O
experimental - - O
end - - O
points - - O
were - - O
the - - O
time - - O
required - - O
for - - O
treated - - O
tumors - - O
to - - O
reach - - O
3 - - O
times - - O
their - - O
treatment - - O
size - - O
, - - O
the - - O
survival - - O
of - - O
stem - - O
cells - - O
in - - O
the - - O
duodenal - - O
crypts - - O
, - - O
and - - O
the - - O
breathing - - O
rate - - O
measured - - O
early - - O
( - - O
19-23 - - O
weeks - - O
) - - O
and - - O
late - - O
( - - O
41-46 - - O
weeks - - O
) - - O
after - - O
treatment - - O
. - - O

Recruitment - - O
of - - O
an - - O
RNA - - B-MUT
polymerase - - I-MUT
II - - I-MUT
complex - - I-MUT
is - - O
mediated - - O
by - - O
the - - O
constitutive - - O
activation - - O
domain - - O
in - - O
CREB - - B-MUT
, - - O
independently - - O
of - - O
CREB - - B-MUT
phosphorylation - - O
. - - O

The - - O
potential - - O
for - - O
highly - - O
reactive - - O
nanoparticles - - O
( - - O
RNP - - O
) - - O
to - - O
absorb - - O
destructively - - O
, - - O
i - - O
. - - O
e - - O
. - - O
to - - O
neutralize - - O
highly - - O
toxic - - O
substances - - O
such - - O
as - - O
the - - O
warfare - - O
agents - - O
GA - - O
, - - O
GB - - O
, - - O
HD - - O
and - - O
VX - - O
, - - O
has - - O
been - - O
demonstrated - - O
in - - O
the - - O
laboratory - - O
. - - O

The - - O
procedure - - O
is - - O
less - - O
aggressive - - O
and - - O
painful - - O
than - - O
sternotomy - - O
. - - O

Treatment - - O
of - - O
keratinocytes - - O
expressing - - O
a - - O
normal - - O
epidermal - - B-MUT
growth - - I-MUT
factor - - I-MUT
receptor - - I-MUT
( - - O
EGFR - - B-MUT
) - - O
with - - O
TGFalpha - - B-MUT
or - - O
epidermal - - B-MUT
growth - - I-MUT
factor - - I-MUT
for - - O
5 - - O
min - - O
induced - - O
PKCdelta - - B-MUT
tyrosine - - O
phosphorylation - - O
. - - O

SV - - O
increased - - O
less - - O
in - - O
SHR - - O
, - - O
mainly - - O
reflecting - - O
the - - O
reduced - - O
diastolic - - O
compliance - - O
of - - O
the - - O
hypertrophied - - O
SHR - - O
left - - O
ventricle - - O
and - - O
the - - O
consequent - - O
rightward - - O
shift - - O
of - - O
its - - O
Frank-Starling - - O
curve - - O
. - - O

The - - O
first - - O
transfusion - - O
resulted - - O
in - - O
a - - O
platelet - - O
increment - - O
to - - O
32 - - O
Gpt - - O
l - - O
( - - O
CCI - - O
11 - - O
) - - O
. - - O

We - - O
also - - O
mapped - - O
a - - O
3'-polyadenylation - - O
site - - O
504bp - - O
downstream - - O
of - - O
the - - O
TGA - - O
stop - - O
codon - - O
, - - O
consistent - - O
with - - O
the - - O
2 - - O
. - - O
5kb - - O
transcript - - O
size - - O
. - - O

265 - - O
, - - O
1102-1110 - - O
) - - O
. - - O

As - - O
an - - O
oral - - O
, - - O
nontoxic - - O
compound - - O
with - - O
a - - O
mechanism - - O
of - - O
action - - O
distinct - - O
from - - O
that - - O
of - - O
ABL - - B-MUT
tyrosine - - I-MUT
kinase - - I-MUT
inhibition - - O
, - - O
FTI - - O
SCH66336 - - O
shows - - O
promise - - O
for - - O
the - - O
treatment - - O
of - - O
BCR - - O
ABL-induced - - O
leukemia - - O
. - - O

REM - - O
sleep - - O
deprivation - - O
was - - O
performed - - O
using - - O
the - - O
platform - - O
technique - - O
. - - O

Genomic - - O
locus - - O
of - - O
chCTCF - - B-MUT
contains - - O
a - - O
GC-rich - - O
untranslated - - O
exon - - O
separated - - O
from - - O
seven - - O
coding - - O
exons - - O
by - - O
a - - O
long - - O
intron - - O
. - - O

Primary - - O
and - - O
secondary - - O
structural - - O
elements - - O
required - - O
for - - O
synthesis - - O
of - - O
barley - - O
yellow - - O
dwarf - - O
virus - - O
subgenomic - - O
RNA1 - - O
. - - O

Heparin - - O
( - - O
100 - - O
Ucenter - - O
dotkg - - O
( - - O
minus - - O
sign1 - - O
) - - O
center - - O
dotday - - O
( - - O
minus - - O
sign1 - - O
) - - O
) - - O
was - - O
injected - - O
subcutaneously - - O
to - - O
the - - O
rats - - O
in - - O
H - - O
group - - O
while - - O
normal - - O
saline - - O
to - - O
those - - O
in - - O
N - - O
group - - O
once - - O
a - - O
day - - O
. - - O

Deletion - - O
and - - O
site-directed - - O
mutagenesis - - O
localized - - O
a - - O
novel - - O
SF-1 - - B-MUT
regulatory - - I-MUT
element - - I-MUT
( - - O
TCA - - B-MUT
GGGCCA - - I-MUT
; - - O
-137 - - O
to - - O
-129 - - O
) - - O
adjacent - - O
to - - O
a - - O
variant - - O
cAMP-response - - B-MUT
element - - I-MUT
( - - O
CRE - - B-MUT
; - - O
-120 - - O
to - - O
-114 - - O
) - - O
. - - O

If - - O
we - - O
apply - - O
the - - O
finding - - O
of - - O
non-visualization - - O
of - - O
the - - O
GB - - O
at - - O
4 - - O
h - - O
post - - O
injection - - O
as - - O
the - - O
criterion - - O
for - - O
the - - O
diagnosis - - O
of - - O
AC - - O
, - - O
the - - O
diagnostic - - O
accuracy - - O
was - - O
only - - O
40 - - O
. - - O
7% - - O
( - - O
11 - - O
27 - - O
) - - O
. - - O

Regional - - O
insertional - - O
mutagenesis - - O
of - - O
specific - - O
genes - - O
on - - O
the - - O
CIC5F11 - - B-MUT
CIC2B9 - - I-MUT
locus - - I-MUT
of - - I-MUT
Arabidopsis - - O
thaliana - - O
chromosome - - O
5 - - O
using - - O
the - - O
Ac - - O
Ds - - B-MUT
transposon - - I-MUT
in - - I-MUT
combination - - I-MUT
with - - O
the - - O
cDNA - - O
scanning - - O
method - - O
. - - O

Two - - O
remotely - - O
situated - - O
exons - - O
within - - O
the - - O
complement - - B-MUT
C3 - - I-MUT
gene - - O
locus - - O
encode - - O
an - - O
alternate - - O
5' - - O
end - - O
and - - O
proximal - - O
ORF - - O
under - - O
the - - O
control - - O
of - - O
a - - O
bidirectional - - O
promoter - - O
. - - O

Three - - O
of - - O
the - - O
short - - O
ORFs - - O
in - - O
the - - O
central - - O
region - - O
of - - O
BIV - - O
have - - O
been - - O
identified - - O
by - - O
location - - O
and - - O
structural - - O
similarity - - O
to - - O
the - - O
nonstructural - - O
regulatory - - O
genes - - O
( - - O
vif - - O
, - - B-MUT
tat - - O
, - - B-MUT
and - - O
rev - - O
) - - B-MUT
of - - O
other - - O
lentiviruses - - O
; - - O
we - - O
also - - O
discovered - - O
two - - O
unique - - O
ORFs - - O
, - - O
termed - - O
W - - O
and - - B-MUT
Y - - O
, - - B-MUT
which - - O
may - - O
serve - - O
as - - O
exons - - O
for - - O
novel - - O
genes - - O
. - - O

This - - O
dependence - - O
, - - O
however - - O
, - - O
can - - O
be - - O
overcome - - O
to - - O
a - - O
large - - O
extent - - O
by - - O
dividing - - O
min - - O
LVdP - - O
dt - - O
by - - O
mean - - O
aortic - - O
pressure - - O
. - - O

A - - O
randomized - - O
clinical - - O
trial - - O
in - - O
sixty-two - - O
adult - - O
patients - - O
suffering - - O
from - - O
typhoid - - O
fever - - O
, - - O
proved - - O
by - - O
blood - - O
and - - O
marrow - - O
culture - - O
, - - O
showed - - O
that - - O
amoxycillin - - O
in - - O
a - - O
dosage - - O
schedule - - O
of - - O
1 - - O
g - - O
8-hourly - - O
orally - - O
for - - O
fourteen - - O
days - - O
was - - O
better - - O
than - - O
chloramphenicol - - O
with - - O
regard - - O
to - - O
clinical - - O
and - - O
temperature - - O
response - - O
and - - O
in - - O
respect - - O
of - - O
carriers - - O
and - - O
relapse - - O
rates - - O
. - - O

The - - O
systolic - - O
pressure - - O
gradient - - O
( - - O
SPG - - O
) - - O
between - - O
the - - O
left - - O
ventricle - - O
( - - O
LV - - O
) - - O
and - - O
left - - O
atrium - - O
( - - O
LA - - O
) - - O
was - - O
obtained - - O
from - - O
high-fidelity - - O
pressure - - O
transducers - - O
. - - O

Serum - - B-MUT
PTH - - I-MUT
tended - - O
to - - O
increase - - O
in - - O
the - - O
WL - - O
group - - O
but - - O
not - - O
in - - O
the - - O
WM - - O
group - - O
( - - O
P - - O
< - - O
0 - - O
. - - O
06 - - O
) - - O
. - - O

When - - O
multiple - - O
copies - - O
of - - O
the - - O
IL-1 - - B-MUT
beta - - I-MUT
NF-kappa - - B-MUT
B - - I-MUT
site - - I-MUT
were - - O
linked - - O
to - - O
an - - O
enhancerless - - O
simian - - O
virus - - O
40 - - O
promoter - - O
, - - O
this - - O
element - - O
was - - O
able - - O
to - - O
mediate - - O
phorbol - - O
ester- - - O
or - - O
lipopolysaccharide-inducible - - O
gene - - O
expression - - O
. - - O

The - - O
ability - - O
of - - O
BCL-6 - - B-MUT
to - - O
function - - O
as - - O
a - - O
transcriptional - - O
repressor - - O
may - - O
contribute - - O
to - - O
its - - O
ability - - O
to - - O
transform - - O
B - - O
lymphocytes - - O
in - - O
diffuse - - O
large - - O
cell - - O
lymphoma - - O
. - - O

Recipients - - O
with - - O
acute - - O
leukaemia - - O
in - - O
first - - O
remission - - O
or - - O
chronic - - O
myeloid - - O
leukaemia - - O
in - - O
first - - O
chronic - - O
phase - - O
were - - O
analysed - - O
as - - O
good - - O
risk - - O
, - - O
and - - O
those - - O
beyond - - O
these - - O
stages - - O
, - - O
as - - O
poor - - O
risk - - O
patients - - O
. - - O

It - - O
can - - O
also - - O
be - - O
used - - O
to - - O
examine - - O
various - - O
laryngeal - - O
parameters - - O
obtained - - O
from - - O
videotaped - - O
endoscopic - - O
and - - O
stroboscopic - - O
examinations - - O
. - - O

Chemotherapy - - O
of - - O
metastasizing - - O
breast - - O
cancer - - O
. - - O

Diagnostic - - O
value - - O
of - - O
serum - - B-MUT
myoglobin - - I-MUT
in - - O
cases - - O
of - - O
neuromuscular - - O
disease - - O
. - - O

We - - O
found - - O
the - - O
following - - O
: - - O
Specific - - O
mutations - - O
affected - - O
the - - O
precise - - O
carbohydrate - - O
structure - - O
and - - O
folding - - O
of - - O
the - - O
HA - - B-MUT
trimer - - I-MUT
. - - O

The - - O
patients - - O
undergoing - - O
VTLB - - O
had - - O
significantly - - O
shorter - - O
operative - - O
times - - O
( - - O
VTLB - - O
, - - O
100 - - O
. - - O
2 - - O
+ - - O
- - - O
27 - - O
. - - O
2 - - O
min - - O
. - - O
vs - - O
OLB - - O
, - - O
119 - - O
. - - O
8 - - O
+ - - O
- - - O
42 - - O
. - - O
6 - - O
min - - O
; - - O
p - - O
< - - O
0 - - O
. - - O
01 - - O
) - - O
and - - O
less - - O
blood - - O
loss - - O
( - - O
VTLB - - O
, - - O
4 - - O
. - - O
7 - - O
+ - - O
- - - O
14 - - O
. - - O
6 - - O
ml - - O
vs - - O
OLB - - O
, - - O
65 - - O
. - - O
7 - - O
+ - - O
- - - O
77 - - O
. - - O
0 - - O
ml - - O
; - - O
p - - O
< - - O
0 - - O
. - - O
001 - - O
) - - O
. - - O

The - - O
'Newcastle' - - O
model - - O
, - - O
which - - O
is - - O
based - - O
on - - O
Hotelling's - - O
T2 - - O
statistic - - O
, - - O
proved - - O
to - - O
be - - O
more - - O
sensitive - - O
and - - O
diagnosed - - O
a - - O
systematic - - O
displacement - - O
for - - O
three - - O
prostate - - O
patients - - O
. - - O

Validation - - O
of - - O
automated - - O
systems--system - - O
definition - - O
. - - O

Radioligand - - O
binding - - O
was - - O
indistinguishable - - O
for - - O
both - - O
transiently - - O
expressed - - O
constructs - - O
. - - O

A - - O
22K - - O
polypeptide - - O
was - - O
detected - - O
as - - O
a - - O
translation - - O
product - - O
of - - O
late - - O
RNA - - O
that - - O
hybridized - - O
to - - O
this - - O
DNA - - O
fragment - - O
. - - O

Gastrointestinal - - O
manifestations - - O
of - - O
systemic - - O
sclerosis - - O
. - - O

Transient - - O
transfection - - O
experiments - - O
revealed - - O
that - - O
Pax-8 - - B-MUT
isoforms - - I-MUT
a - - I-MUT
and - - I-MUT
b - - I-MUT
, - - O
but - - O
not - - O
c - - O
and - - O
d - - O
, - - O
strongly - - O
stimulate - - O
transcription - - O
from - - O
a - - O
promoter - - O
containing - - O
six - - O
copies - - O
of - - O
a - - O
paired-domain - - B-MUT
recognition - - I-MUT
sequence - - I-MUT
. - - O

Low-selenium - - O
diet - - O
has - - O
a - - O
human - - O
unfavourable - - O
impact - - O
. - - O

In - - O
DNase - - B-MUT
I - - I-MUT
footprinting - - O
protection - - O
analysis - - O
, - - O
both - - O
SFRE - - B-MUT
and - - O
ERE - - B-MUT
regions - - I-MUT
were - - O
protected - - O
by - - O
glutathione - - B-MUT
S-transferase-ERRalpha1 - - I-MUT
fusion - - I-MUT
protein - - I-MUT
. - - O

In - - O
the - - O
BF - - O
ECT - - O
group - - O
the-age - - O
based - - O
dose - - O
would - - O
have - - O
been - - O
similarly - - O
dependent - - O
on - - O
the - - O
initial - - O
seizure - - O
threshold - - O
level - - O
. - - O

CONCLUSIONS - - O
: - - O
The - - O
mechanism - - O
of - - O
MIRI - - O
is - - O
Qi - - O
deficiency - - O
and - - O
blood - - O
stasis - - O
in - - O
TCM - - O
, - - O
its - - O
treating - - O
principles - - O
should - - O
be - - O
promoting - - O
Qi - - O
and - - O
removing - - O
the - - O
blood - - O
stasis - - O
. - - O

Instead - - O
, - - O
mRNA - - O
of - - O
2 - - O
. - - O
0 - - O
and - - O
2 - - O
. - - O
8 - - O
kb - - O
are - - O
detected - - O
in - - O
varying - - O
abundance - - O
. - - O

Transcription - - O
from - - O
adenovirus - - B-MUT
E2-early - - I-MUT
promoter - - I-MUT
is - - O
controlled - - O
by - - O
a - - O
unique - - O
array - - O
of - - O
four - - O
cis-acting - - O
elements - - O
which - - O
include - - O
an - - O
atypical - - O
TBP - - B-MUT
site - - I-MUT
, - - O
two - - O
E2F - - B-MUT
sites - - I-MUT
present - - O
in - - O
an - - O
inverted - - O
orientation - - O
relative - - O
to - - O
each - - O
other - - O
, - - O
and - - O
an - - O
ATF - - B-MUT
site - - I-MUT
. - - O

Three - - O
women - - O
have - - O
had - - O
abnormal - - O
endocervical - - O
follow - - O
up - - O
cytology - - O
suggestive - - O
of - - O
residual - - O
disease - - O
. - - O

Clone - - O
pSRc200 - - O
hybrid - - O
selected - - O
an - - O
mRNA - - O
that - - O
on - - O
cell-free - - O
translation - - O
produced - - O
a - - O
38-kDa - - O
polypeptide - - O
. - - O

More - - O
generally - - O
, - - O
Ets1 - - B-MUT
and - - O
Ets2 - - B-MUT
could - - O
regulate - - O
transcription - - O
of - - O
cellular - - O
genes - - O
. - - O

The - - O
cdr1 - - B-MUT
sequence - - I-MUT
includes - - O
an - - O
additional - - O
237 - - O
amino - - O
acids - - O
of - - O
the - - O
contiguous - - O
fragment - - O
and - - O
encodes - - O
a - - O
product - - O
of - - O
predicted - - O
Mr - - O
67 - - O
, - - O
000 - - O
. - - O

In - - O
14 - - O
cases - - O
, - - O
isolates - - O
were - - O
biotyped - - O
yielding - - O
eight - - O
with - - O
biotype - - O
II - - O
, - - O
four - - O
with - - O
biotype - - O
III - - O
, - - O
and - - O
one - - O
each - - O
with - - O
biotypes - - O
IV - - O
and - - O
V - - O
. - - O

In - - O
one - - O
, - - O
exploratory - - O
behavior - - O
( - - O
assessed - - O
by - - O
hole - - O
pokes - - O
) - - O
and - - O
locomotion - - O
were - - O
assessed - - O
during - - O
a - - O
10-min - - O
test - - O
session - - O
. - - O

Sequence - - O
analysis - - O
of - - O
these - - O
regions - - O
showed - - O
a - - O
CAAT - - O
box - - O
upstream - - O
of - - O
exon - - O
1a - - O
and - - O
high - - O
G-C - - O
content - - O
regions - - O
within - - O
both - - O
P1 - - B-MUT
and - - O
P2 - - B-MUT
. - - O

Both - - O
reduced - - O
spontaneous - - O
locomotor - - O
activity - - O
in - - O
mice - - O
, - - O
protected - - O
them - - O
from - - O
death - - O
from - - O
amphetamine - - O
induced - - O
toxicity - - O
, - - O
prolonged - - O
hexobarbitone - - O
sleeping - - O
time - - O
and - - O
caused - - O
a - - O
depletion - - O
of - - O
catecholamines - - O
from - - O
various - - O
organs - - O
of - - O
the - - O
rat - - O
. - - O

This - - O
construct - - O
, - - O
termed - - O
pDeltaCREC - - B-MUT
EBP - - I-MUT
, - - I-MUT
binds - - O
C - - O
EBPalpha - - B-MUT
and - - I-MUT
beta - - I-MUT
but - - I-MUT
not - - I-MUT
CREB - - O
, - - O
yet - - B-MUT
it - - O
confers - - O
a - - O
nearly - - O
complete - - O
glucocorticoid - - O
response - - O
when - - O
transiently - - O
transfected - - O
into - - O
H4IIE - - O
rat - - O
hepatoma - - O
cells - - O
. - - O

The - - O
region - - O
containing - - O
both - - O
serines - - O
is - - O
homologous - - O
to - - O
the - - O
N-terminal - - O
destruction - - O
box - - O
of - - O
IkappaBalpha - - B-MUT
, - - I-MUT
-beta - - I-MUT
, - - I-MUT
and - - I-MUT
-epsilon - - I-MUT
. - - O

Echinococcus - - O
granulosus - - O
was - - O
diagnosed - - O
by - - O
fine-needle - - O
aspiration - - O
cytology - - O
of - - O
a - - O
lung - - O
cyst - - O
in - - O
a - - O
6-yr-old - - O
white - - O
female - - O
in - - O
central - - O
Missouri - - O
. - - O

Herein - - O
, - - O
we - - O
show - - O
that - - O
Smad3 - - B-MUT
physically - - O
interacts - - O
with - - O
the - - O
HMG - - B-MUT
box - - I-MUT
domain - - I-MUT
of - - O
LEF1 - - B-MUT
and - - O
that - - O
TGFbeta - - B-MUT
and - - O
Wnt - - B-MUT
pathways - - I-MUT
synergize - - O
to - - O
activate - - O
transcription - - O
of - - O
the - - O
Xenopus - - B-MUT
homeobox - - I-MUT
gene - - I-MUT
twin - - B-MUT
( - - O
Xtwn - - B-MUT
) - - O
. - - O

The - - O
association - - O
of - - O
clopamide - - O
and - - O
hydergine - - O
( - - O
Brinedine - - O
) - - O
in - - O
the - - O
treatment - - O
of - - O
the - - O
vasculo-renal - - O
syndromes - - O
of - - O
pregnancy - - O
. - - O

Thromboelastography - - O
is - - O
a - - O
test - - O
that - - O
could - - O
potentially - - O
correlate - - O
with - - O
the - - O
degree - - O
of - - O
anticoagulation - - O
produced - - O
by - - O
low - - O
molecular - - O
weight - - O
heparin - - O
. - - O

Using - - O
the - - O
postural - - O
and - - O
force - - O
data - - O
as - - O
input - - O
to - - O
a - - O
3-D - - O
biomechanical - - O
model - - O
, - - O
the - - O
lumbosacral - - O
spinal - - O
compression - - O
was - - O
calculated - - O
. - - O

Within - - O
12 - - O
hours - - O
after - - O
MR - - O
tomography - - O
the - - O
patients - - O
were - - O
surgically - - O
explored - - O
, - - O
biopsied - - O
and - - O
if - - O
necessary - - O
orchiectomised - - O
. - - O

The - - O
human - - O
protein - - O
sequence - - O
exhibits - - O
a - - O
putative - - O
DNA-binding - - O
domain - - O
similar - - O
to - - O
that - - O
seen - - O
in - - O
rat - - B-MUT
HBP1 - - I-MUT
and - - O
shows - - O
homology - - O
with - - O
the - - O
activation - - O
and - - O
repressor - - O
domains - - O
previously - - O
demonstrated - - O
in - - O
the - - O
rat - - O
protein - - O
. - - O

These - - O
results - - O
demonstrate - - O
that - - O
EKLF - - B-MUT
provides - - O
a - - O
crucial - - O
transactivation - - O
function - - O
for - - O
globin - - B-MUT
expression - - O
and - - O
further - - O
reinforce - - O
the - - O
idea - - O
that - - O
EKLF - - B-MUT
is - - O
an - - O
important - - O
regulator - - O
of - - O
CACCC - - O
element-directed - - O
transcription - - O
in - - O
erythroid - - O
cells - - O
. - - O

Although - - O
the - - O
DSK2-1 - - B-MUT
mutation - - I-MUT
alters - - O
a - - O
conserved - - O
residue - - O
in - - O
the - - O
Dsk2p - - B-MUT
ubiquitin-like - - B-MUT
domain - - I-MUT
, - - O
we - - O
detect - - O
no - - O
differences - - O
in - - O
Dsk2p - - B-MUT
or - - O
Cdc31p - - B-MUT
stability - - O
. - - O

Characteristics - - O
of - - O
lipase - - B-MUT
activity - - O
. - - O

The - - O
complete - - O
cDNA - - O
sequence - - O
of - - O
human - - B-MUT
betaV - - I-MUT
spectrin - - I-MUT
is - - O
available - - O
from - - O
GenBank - - O
( - - O
TM - - O
) - - O
as - - O
accession - - O
number - - O
. - - O

Although - - O
the - - O
effects - - O
of - - O
the - - O
calcium - - O
supplement - - O
or - - O
calcium - - O
antagonist - - O
alone - - O
were - - O
significant - - O
, - - O
such - - O
hypotensive - - O
responses - - O
were - - O
not - - O
optimal - - O
or - - O
predictable - - O
or - - O
clearly - - O
dose-dependent - - O
. - - O

At - - O
a - - O
PaCO2 - - O
of - - O
40 - - O
mmHg - - O
, - - O
baseline - - O
brain - - O
pHi - - O
measured - - O
7 - - O
. - - O
03 - - O
+ - - O
- - - O
0 - - O
. - - O
04 - - O
, - - O
while - - O
regional - - O
cortical - - O
blood - - O
flow - - O
was - - O
47 - - O
. - - O
0 - - O
+ - - O
- - - O
4 - - O
. - - O
3 - - O
ml - - O
. - - O
100 - - O
g-1 - - O
. - - O
min-1 - - O
. - - O

In - - O
contrast - - O
, - - O
the - - O
neu - - B-MUT
proto-oncogene - - I-MUT
did - - O
not - - O
show - - O
kinase - - O
activity - - O
or - - O
transforming - - O
properties - - O
when - - O
expressed - - O
at - - O
similar - - O
levels - - O
in - - O
NIH - - O
3T3 - - O
cells - - O
. - - O
( - - O
ABSTRACT - - O
TRUNCATED - - O
AT - - O
250 - - O
WORDS - - O
) - - O

The - - O
CVA16 - - B-MUT
. - - I-MUT
4 - - I-MUT
proteolipid - - I-MUT
transcript - - I-MUT
is - - O
the - - O
most - - O
prevalent - - O
of - - O
the - - O
two - - O
proteolipid - - O
messages - - O
in - - O
expanding - - O
ovules - - O
harvested - - O
10 - - O
d - - O
post-anthesis - - O
. - - O

Furthermore - - O
, - - O
interactions - - O
were - - O
identified - - O
between - - O
endogenous - - B-MUT
E-cadherin - - I-MUT
and - - O
the - - O
chimera - - O
containing - - O
the - - O
E-cadherin - - B-MUT
extracellular - - I-MUT
domain - - I-MUT
and - - O
the - - O
desmoglein - - B-MUT
1 - - I-MUT
intracellular - - I-MUT
domain - - I-MUT
providing - - O
in - - O
vivo - - O
evidence - - O
for - - O
previously - - O
predicted - - O
lateral - - O
interactions - - O
of - - O
E-cadherin - - B-MUT
extracellular - - I-MUT
domains - - I-MUT
. - - O

No - - O
UOxase - - B-MUT
mRNA - - I-MUT
was - - O
detected - - O
in - - O
11 - - O
nonhepatic - - O
tissues - - O
of - - O
rat - - O
, - - O
suggesting - - O
tissue - - O
specificity - - O
of - - O
expression - - O
of - - O
this - - O
UOxase - - B-MUT
gene - - I-MUT
. - - O

CONCLUSION - - O
: - - O
We - - O
were - - O
unable - - O
to - - O
identify - - O
features - - O
of - - O
disease - - O
likely - - O
to - - O
be - - O
associated - - O
with - - O
a - - O
clinically - - O
useful - - O
response - - O
to - - O
inhaled - - O
NO - - O
therapy - - O
using - - O
the - - O
parameters - - O
studied - - O
. - - O

High - - O
levels - - O
of - - O
IC - - O
coincided - - O
with - - O
relative - - O
hypocomplementemia - - O
. - - O

The - - O
CAPLC1 - - B-MUT
protein - - I-MUT
also - - O
exhibited - - O
several - - O
unique - - O
features - - O
, - - O
including - - O
a - - O
novel - - O
stretch - - O
of - - O
18-19 - - O
amino - - O
acid - - O
residues - - O
within - - O
the - - O
X - - B-MUT
domain - - I-MUT
and - - O
an - - O
unusually - - O
long - - O
N-terminus - - O
which - - O
did - - O
not - - O
contain - - O
a - - O
recognizable - - O
EF-hand - - B-MUT
Ca - - I-MUT
( - - I-MUT
2+ - - I-MUT
) - - I-MUT
-binding - - I-MUT
domain - - I-MUT
. - - O

Besides - - O
the - - O
characterization - - O
and - - O
discussion - - O
of - - O
the - - O
experimental - - O
setup - - O
used - - O
, - - O
the - - O
rate - - O
constants - - O
obtained - - O
are - - O
discussed - - O
and - - O
compared - - O
with - - O
estimated - - O
values - - O
. - - O

We - - O
consider - - O
that - - O
DIL-CP - - O
is - - O
a - - O
safe - - O
and - - O
excellent - - O
CP - - O
in - - O
CABG - - O
surgery - - O
and - - O
we - - O
are - - O
now - - O
utilizing - - O
this - - O
CP - - O
in - - O
all - - O
patients - - O
requiring - - O
CABG - - O
surgery - - O
. - - O

Isolation - - O
of - - O
a - - O
temperature-sensitive - - O
mutant - - O
with - - O
an - - O
altered - - O
tRNA - - B-MUT
nucleotidyltransferase - - I-MUT
and - - O
cloning - - O
of - - O
the - - O
gene - - B-MUT
encoding - - I-MUT
tRNA - - I-MUT
nucleotidyltransferase - - I-MUT
in - - I-MUT
the - - I-MUT
yeast - - I-MUT
Saccharomyces - - I-MUT
cerevisiae - - I-MUT
. - - O

Measurement - - O
of - - O
open-loop - - O
responses - - O
to - - O
electrical - - O
stimulation - - O
in - - O
olfactory - - O
bulb - - O
of - - O
cat - - O
. - - O

Finally - - O
, - - O
we - - O
present - - O
evidence - - O
that - - O
fimbrin - - B-MUT
is - - O
a - - O
third - - O
distinct - - O
plastin - - B-MUT
isoform - - I-MUT
which - - O
is - - O
specifically - - O
expressed - - O
at - - O
high - - O
levels - - O
in - - O
the - - O
small - - O
intestine - - O
. - - O

The - - O
UV - - O
absorption - - O
spectrum - - O
revealed - - O
a - - O
shoulder - - O
at - - O
250 - - O
nm - - O
, - - O
characteristic - - O
of - - O
CysS-Cd - - O
( - - O
II - - O
) - - O
ligand-to-metal - - O
charge-transfer - - O
transitions - - O
, - - O
and - - O
the - - O
difference - - O
absorption - - O
coefficient - - O
after - - O
acidification - - O
( - - O
delta - - O
epsilon - - O
248 - - O
, - - O
24 - - O
mM-1 - - O
cm-1 - - O
) - - O
indicated - - O
the - - O
presence - - O
of - - O
a - - O
Cd - - O
( - - O
Cys-S - - O
) - - O
4 - - O
center - - O
. - - O

Growth - - B-MUT
hormone - - I-MUT
and - - O
insulin-like - - B-MUT
growth - - I-MUT
factor - - I-MUT
I - - I-MUT
receptors - - I-MUT
in - - O
the - - O
temporomandibular - - O
joint - - O
of - - O
the - - O
rat - - O
. - - O

Adverse - - O
foetal - - O
outcome - - O
in - - O
specific - - O
IgM - - B-MUT
positive - - O
Chlamydia - - O
trachomatis - - O
infection - - O
in - - O
pregnancy - - O
. - - O

On - - O
the - - O
basis - - O
of - - O
size - - O
, - - O
the - - O
CRS - - B-MUT
sequence - - I-MUT
to - - O
which - - O
it - - O
binds - - O
, - - O
and - - O
its - - O
tentative - - O
identification - - O
as - - O
a - - O
zinc - - B-MUT
finger - - I-MUT
protein - - I-MUT
, - - O
Adx - - B-MUT
factor - - I-MUT
has - - O
been - - O
identified - - O
as - - O
a - - O
Kruppel-like - - B-MUT
zinc - - I-MUT
finger - - I-MUT
protein - - I-MUT
( - - O
a - - O
mouse - - B-MUT
ZBP-89 - - I-MUT
homologue - - I-MUT
) - - O
. - - O

STP1 - - B-MUT
is - - O
an - - O
unessential - - O
yeast - - O
gene - - O
involved - - O
in - - O
the - - O
removal - - O
of - - O
intervening - - O
sequences - - O
from - - O
some - - O
, - - O
but - - O
not - - O
all - - O
, - - O
families - - O
of - - O
intervening - - O
sequence-containing - - O
pre-tRNAs - - O
. - - O

The - - O
downstream - - O
, - - O
TATA-less - - O
promoter - - O
has - - O
high - - O
G+C - - O
content - - O
, - - O
and - - O
exon - - O
1b - - O
predominates - - O
among - - O
abundantly - - O
expressed - - O
mRNA - - O
species - - O
. - - O

Both - - O
P5CDh - - B-MUT
cDNA - - I-MUT
clones - - O
detect - - O
a - - O
single - - O
3 - - O
. - - O
2-kb - - O
transcript - - O
on - - O
Northern - - O
blots - - O
of - - O
multiple - - O
human - - O
tissues - - O
, - - O
indicating - - O
the - - O
long - - O
cDNA - - O
containing - - O
the - - O
3'-untranslated - - O
intron - - O
represents - - O
the - - O
predominant - - O
transcript - - O
. - - O

Although - - O
there - - O
are - - O
no - - O
octamer - - O
elements - - O
in - - O
the - - O
adenovirus - - O
genome - - O
that - - O
are - - O
known - - O
to - - O
be - - O
important - - O
for - - O
transcription - - O
, - - O
there - - O
are - - O
octamer - - O
elements - - O
in - - O
the - - O
viral - - O
terminal - - O
repeat - - O
sequences - - O
. - - O

Carcinoembryonic - - B-MUT
antigen - - I-MUT
( - - O
CEA - - B-MUT
) - - O
procedures - - O
and - - O
clinical - - O
evaluation - - O
. - - O
pp - - O
. - - O

Functional - - O
recognition - - O
of - - O
5' - - O
splice - - O
site - - O
by - - O
U4 - - B-MUT
U6 - - I-MUT
. - - I-MUT
U5 - - I-MUT
tri-snRNP - - I-MUT
defines - - I-MUT
a - - O
novel - - O
ATP-dependent - - O
step - - O
in - - O
early - - O
spliceosome - - O
assembly - - O
. - - O

Acylation - - O
with - - O
the - - O
palmitate - - O
analog - - O
was - - O
prevented - - O
when - - O
Gly-2 - - O
was - - O
mutated - - O
to - - O
alanine - - O
, - - O
implying - - O
that - - O
N-myristylation - - O
is - - O
required - - O
for - - O
palmitylation - - O
, - - O
and - - O
when - - O
either - - O
Cys-3 - - O
or - - O
Cys-6 - - O
was - - O
mutated - - O
to - - O
serine - - O
. - - O

Follow-up - - O
controls - - O
of - - O
luteinizing - - B-MUT
hormone - - I-MUT
( - - O
LH - - B-MUT
) - - O
, - - O
follicle - - B-MUT
stimulating - - I-MUT
hormone - - I-MUT
( - - O
FSH - - B-MUT
) - - O
, - - O
prolactin - - B-MUT
( - - O
HPRL - - B-MUT
) - - O
, - - O
oestradiol - - O
( - - O
E2 - - O
) - - O
, - - O
progesterone - - O
( - - O
P - - O
) - - O
and - - O
testosterone - - O
( - - O
T - - O
) - - O
in - - O
the - - O
catabolic - - O
and - - O
healing - - O
phase - - O
of - - O
burn - - O
disease - - O
. - - O

Confirming - - O
measures - - O
made - - O
by - - O
nurses - - O
and - - O
additionally - - O
, - - O
ABPM - - O
for - - O
women - - O
, - - O
seem - - O
to - - O
lessen - - O
this - - O
effect - - O
. - - O

The - - O
gene - - B-MUT
cat-86 - - I-MUT
, - - O
specifying - - O
chloramphenicol-inducible - - B-MUT
chloramphenicol - - I-MUT
acetyltransferase - - I-MUT
, - - O
is - - O
located - - O
on - - O
the - - O
1 - - O
. - - O
1-kilobase - - O
cloned - - O
DNA - - O
. - - O

Effects - - O
of - - O
perceptual - - O
salience - - O
on - - O
the - - O
matrix - - O
task - - O
performance - - O
of - - O
four- - - O
and - - O
six-year-old - - O
children - - O
. - - O

UDP-GlcNAc - - B-MUT
: - - O
alpha-6-D-mannoside - - B-MUT
beta-1 - - I-MUT
, - - I-MUT
2-N-acetylglucosaminyltransferase - - I-MUT
II - - I-MUT
( - - O
GnT - - B-MUT
II - - I-MUT
; - - O
EC - - B-MUT
2 - - I-MUT
. - - I-MUT
4 - - I-MUT
. - - I-MUT
1 - - I-MUT
. - - I-MUT
143 - - I-MUT
) - - O
is - - O
essential - - O
for - - O
the - - O
normal - - O
assembly - - O
of - - O
complex - - O
Asn-linked - - O
glycans - - O
. - - O

The - - O
MET4 - - B-MUT
gene - - O
was - - O
cloned - - O
, - - O
and - - O
its - - O
sequence - - O
reveals - - O
that - - O
it - - O
encodes - - O
a - - O
protein - - O
related - - O
to - - O
the - - O
family - - O
of - - O
the - - O
bZIP - - B-MUT
transcriptional - - I-MUT
activators - - I-MUT
. - - O

This - - O
region - - O
of - - O
hsp90 - - B-MUT
mediates - - O
ATP-independent - - O
chaperone - - B-MUT
activity - - O
, - - O
overlaps - - O
the - - O
hsp90 - - B-MUT
dimerization - - I-MUT
domain - - I-MUT
, - - O
and - - O
includes - - O
structural - - O
elements - - O
important - - O
for - - O
steroid - - B-MUT
receptor - - I-MUT
interaction - - O
. - - O

The - - O
novel - - O
Notch - - B-MUT
homologue - - I-MUT
mouse - - B-MUT
Notch - - I-MUT
3 - - I-MUT
lacks - - O
specific - - O
epidermal - - B-MUT
growth - - I-MUT
factor-repeats - - I-MUT
and - - O
is - - O
expressed - - O
in - - O
proliferating - - O
neuroepithelium - - O
. - - O

GGS1 - - B-MUT
is - - O
the - - O
same - - O
gene - - O
as - - O
TPS1 - - B-MUT
which - - O
was - - O
identified - - O
as - - O
encoding - - O
a - - O
subunit - - O
of - - O
the - - O
trehalose-6-phosphate - - B-MUT
synthase - - I-MUT
phosphatase - - I-MUT
complex - - I-MUT
and - - I-MUT
it - - O
is - - O
allelic - - O
to - - O
the - - O
fdp1 - - O
, - - B-MUT
byp1 - - O
, - - B-MUT
glc6 - - O
and - - B-MUT
cif1 - - O
mutations - - O
. - - O

Structure - - O
and - - O
expression - - O
of - - O
the - - O
alternative - - O
sigma - - O
factor - - O
, - - O
RpoN - - B-MUT
, - - O
in - - O
Rhodobacter - - O
capsulatus - - O
; - - O
physiological - - O
relevance - - O
of - - O
an - - O
autoactivated - - O
nifU2-rpoN - - B-MUT
superoperon - - O
. - - O

Pneumonia - - O
in - - O
children - - O
. - - O

Statement - - O
on - - O
the - - O
development - - O
of - - O
guidelines - - O
for - - O
the - - O
prevention - - O
of - - O
AIDS - - O
transmission - - O
in - - O
the - - O
workplace - - O
. - - O

M-Ras - - B-MUT
interacted - - O
poorly - - O
in - - O
a - - O
yeast - - O
two-hybrid - - O
assay - - O
with - - O
multiple - - O
Ras - - B-MUT
effectors - - O
, - - O
including - - O
c-Raf-1 - - B-MUT
, - - O
A-Raf - - B-MUT
, - - O
B-Raf - - B-MUT
, - - O
phosphoinositol-3 - - B-MUT
kinase - - I-MUT
delta - - I-MUT
, - - O
RalGDS - - B-MUT
, - - O
and - - O
Rin1 - - B-MUT
. - - O

Isolation - - O
and - - O
characterization - - O
of - - O
SRF - - B-MUT
accessory - - I-MUT
proteins - - I-MUT
. - - O

The - - O
3 - - O
. - - O
3-fold - - O
higher - - O
expression - - O
in - - O
the - - O
fetal - - O
heart - - O
than - - O
in - - O
the - - O
adult - - O
heart - - O
suggests - - O
that - - O
HFHZ - - B-MUT
mRNA - - I-MUT
is - - O
downregulated - - O
in - - O
the - - O
process - - O
of - - O
development - - O
. - - O

On - - O
an - - O
antithrombin - - O
unit - - O
basis - - O
, - - O
CY - - O
216 - - O
and - - O
CY - - O
222 - - O
were - - O
equivalent - - O
and - - O
more - - O
potent - - O
than - - O
UH - - O
. - - O

Marked - - O
racial - - O
variation - - O
in - - O
birthweight - - O
percentiles - - O
by - - O
gestational - - O
age - - O
was - - O
evident - - O
. - - O

2 - - O
- - - O
Chemical - - O
occlusion - - O
of - - O
vas - - O
is - - O
quite - - O
effective - - O
in - - O
producing - - O
a - - O
block - - O
in - - O
the - - O
vas - - O
deferens - - O
of - - O
dogs - - O
. - - O

SPA - - O
from - - O
PAG - - O
sites - - O
was - - O
associated - - O
with - - O
aversion - - O
. - - O

The - - O
observation - - O
of - - O
late - - O
effects - - O
after - - O
irradiations - - O
or - - O
after - - O
space - - O
flights - - O
show - - O
the - - O
difficulties - - O
encountered - - O
in - - O
assessing - - O
radiative - - O
risks - - O
during - - O
long - - O
duration - - O
space - - O
flights - - O
. - - O

TEMTU - - O
and - - O
DPTU - - O
were - - O
the - - O
most - - O
potent - - O
teratogens - - O
. - - O

An - - O
intravenous - - O
drip - - O
infusion - - O
of - - O
AMK - - O
in - - O
adequate - - O
dosage - - O
would - - O
be - - O
beneficial - - O
to - - O
use - - O
against - - O
some - - O
infectious - - O
diseases - - O
of - - O
otorhinolaryngologic - - O
field - - O
. - - O

Antithrombin - - B-MUT
III - - I-MUT
deficiency - - O
: - - O
when - - O
substitute - - O
, - - O
when - - O
heparin - - O
? - - O
Thrombosis - - O
ABC - - O
, - - O
3 - - O
: - - O
The - - O
role - - O
of - - O
antithrombin - - B-MUT
III - - I-MUT
. - - O

Identification - - O
of - - O
Ets- - - B-MUT
and - - I-MUT
notch-related - - I-MUT
subunits - - I-MUT
in - - O
GA - - B-MUT
binding - - I-MUT
protein - - I-MUT
. - - O

40 - - O
patients - - O
with - - O
chronic - - O
osteomyelitis - - O
were - - O
treated - - O
per - - O
os - - O
with - - O
the - - O
bactericidal - - O
beta-lactam-antibiotic - - O
cephalexin - - O
during - - O
3 - - O
to - - O
60 - - O
weeks - - O
. - - O

It - - O
was - - O
concluded - - O
that - - O
both - - O
of - - O
these - - O
surgical - - O
procedures - - O
were - - O
as - - O
effective - - O
as - - O
pinealectomy - - O
in - - O
reversing - - O
the - - O
pineal-induced - - O
alterations - - O
in - - O
the - - O
reproductive - - O
physiology - - O
of - - O
the - - O
blind-anosmic - - O
female - - O
rat - - O
. - - O

Is - - O
nisoldipine - - O
capable - - O
of - - O
reducing - - O
left - - O
ventricular - - O
preload - - O
? - - O
In - - O
ten - - O
anesthetized - - O
pigs - - O
, - - O
nisoldipine - - O
( - - O
2-4 - - O
micrograms - - O
X - - O
kg-1 - - O
X - - O
min-1 - - O
) - - O
, - - O
a - - O
calcium - - O
channel - - O
blocker - - O
structurally - - O
related - - O
to - - O
nifedipine - - O
, - - O
reduced - - O
left - - O
ventricular - - O
systolic - - O
pressure - - O
( - - O
40% - - O
) - - O
and - - O
systemic - - O
vascular - - O
resistance - - O
( - - O
35% - - O
) - - O
, - - O
whereas - - O
maxLVdP - - O
dt - - O
decreased - - O
by - - O
20% - - O
and - - O
cardiac - - O
output - - O
was - - O
unchanged - - O
. - - O

In - - O
a - - O
reconstituted - - O
human - - O
DNA - - O
repair - - O
system - - O
containing - - O
DNA - - B-MUT
polymerase - - I-MUT
beta - - I-MUT
and - - O
DNA - - B-MUT
ligase - - I-MUT
III-XRCC1 - - I-MUT
, - - O
accurate - - O
rejoining - - O
of - - O
a - - O
3' - - O
mismatched - - O
base - - O
residue - - O
at - - O
a - - O
single-strand - - O
break - - O
is - - O
dependent - - O
on - - O
addition - - O
of - - O
the - - O
exonuclease - - B-MUT
. - - O

Soluble - - O
FasR - - B-MUT
ligand-binding - - O
domain - - O
: - - O
high-yield - - O
production - - O
of - - O
active - - O
fusion - - O
and - - O
non-fusion - - O
recombinant - - O
proteins - - O
using - - O
the - - O
baculovirus - - O
insect - - O
cell - - O
system - - O
. - - O

Furthermore - - O
, - - O
co-expression - - O
of - - O
both - - O
p46 - - B-MUT
and - - O
p54 - - B-MUT
subunits - - I-MUT
markedly - - O
altered - - O
the - - O
subcellular - - O
distribution - - O
of - - O
p46 - - B-MUT
; - - O
co-expressed - - O
p46 - - B-MUT
was - - O
transported - - O
into - - O
the - - O
nucleus - - O
as - - O
efficiently - - O
as - - O
p54 - - B-MUT
. - - O

Evaluation - - O
of - - O
myocardial - - O
perfusion - - O
by - - O
99mTc-tetrofosmin - - O
SPECT - - O
before - - O
and - - O
after - - O
emergent - - O
percutaneous - - O
transluminal - - O
coronary - - O
angioplasty - - O
for - - O
acute - - O
myocardial - - O
infarction - - O
. - - O

These - - O
results - - O
support - - O
a - - O
model - - O
in - - O
which - - O
p53 - - B-MUT
protein - - I-MUT
contributes - - O
to - - O
the - - O
maintenance - - O
of - - O
genomic - - O
integrity - - O
through - - O
recombinational - - O
repair - - O
. - - O

Posttranslational - - O
regulation - - O
of - - O
Ty1 - - B-MUT
retrotransposition - - O
by - - O
mitogen-activated - - B-MUT
protein - - I-MUT
kinase - - I-MUT
Fus3 - - I-MUT
. - - O

Finally - - O
, - - O
we - - O
determined - - O
the - - O
genomic - - O
organization - - O
of - - O
the - - O
human - - B-MUT
TrxR2 - - I-MUT
gene - - I-MUT
, - - O
which - - O
consists - - O
of - - O
18 - - O
exons - - O
spanning - - O
about - - O
67 - - O
kb - - O
, - - O
and - - O
its - - O
chromosomal - - O
localization - - O
at - - O
position - - O
22q11 - - O
. - - O
2 - - O
. - - O

The - - O
5' - - O
flanking - - O
region - - O
contains - - O
potential - - O
binding - - O
sites - - O
for - - O
TATA-binding - - B-MUT
protein - - I-MUT
, - - O
Sp1 - - B-MUT
, - - O
nuclear - - B-MUT
factor - - I-MUT
1 - - I-MUT
( - - O
NF1 - - B-MUT
) - - O
, - - O
CAAT-box - - B-MUT
binding - - I-MUT
protein - - I-MUT
( - - O
C - - B-MUT
EBP - - I-MUT
) - - I-MUT
, - - O
hepatocyte - - O
nuclear - - B-MUT
factors - - I-MUT
1 - - I-MUT
and - - I-MUT
5 - - I-MUT
( - - I-MUT
HNF1 - - O
, - - B-MUT
HNF5 - - O
) - - B-MUT
and - - O
activator - - O
proteins - - B-MUT
1 - - I-MUT
and - - I-MUT
2 - - I-MUT
( - - I-MUT
AP1 - - O
, - - B-MUT
AP2 - - O
) - - B-MUT
. - - O

The - - O
most - - O
likely - - O
explanation - - O
for - - O
this - - O
is - - O
that - - O
gold - - O
principally - - O
accumulates - - O
in - - O
the - - O
Kupffer - - O
cells - - O
and - - O
renal - - O
cortex - - O
and - - O
these - - O
cells - - O
do - - O
not - - O
express - - O
Type - - B-MUT
I - - I-MUT
deiodinase - - I-MUT
. - - O

The - - O
importance - - O
of - - O
this - - O
new - - O
epidemiological - - O
profile - - O
of - - O
schistosomiasis - - O
in - - O
the - - O
State - - O
of - - O
Pernambuco - - O
relies - - O
on - - O
the - - O
fact - - O
that - - O
it - - O
can - - O
be - - O
related - - O
with - - O
the - - O
drastic - - O
human - - O
interference - - O
on - - O
the - - O
environment - - O
. - - O

All - - O
nuclear - - O
receptors - - O
have - - O
several - - O
well-characterized - - O
structural - - O
domains - - O
, - - O
including - - O
a - - O
conserved - - O
DNA-binding - - O
domain - - O
, - - O
and - - O
a - - O
ligand - - O
binding - - O
domain - - O
at - - O
the - - O
carboxyl - - O
terminus - - O
of - - O
the - - O
receptor - - O
. - - O

New - - O
alkaloids - - O
from - - O
bark - - O
of - - O
Erythrophleum - - O
ivorense - - O
. - - O

In - - O
order - - O
to - - O
investigate - - O
to - - O
what - - O
extent - - O
this - - O
interaction - - O
might - - O
contribute - - O
to - - O
tumor - - O
induction - - O
by - - O
the - - O
virus - - O
, - - O
we - - O
have - - O
introduced - - O
two - - O
different - - O
point - - O
mutations - - O
within - - O
the - - O
putative - - O
pRb-binding - - B-MUT
sequence - - I-MUT
of - - O
large - - B-MUT
T - - I-MUT
antigen - - I-MUT
, - - O
and - - O
as - - O
a - - O
preliminary - - O
to - - O
in - - O
vivo - - O
experiments - - O
we - - O
have - - O
studied - - O
their - - O
effects - - O
in - - O
vitro - - O
on - - O
some - - O
biological - - O
activities - - O
relevant - - O
to - - O
tumor - - O
induction - - O
. - - O

However - - O
, - - O
calphostin - - O
C - - O
, - - O
a - - O
specific - - O
inhibitor - - O
of - - O
PKC - - B-MUT
, - - O
abolished - - O
the - - O
TPA-induced - - O
increase - - O
in - - O
CFI - - B-MUT
mRNA - - I-MUT
levels - - O
. - - O

An - - O
intravenous - - O
preparation - - O
of - - O
doxycycline - - O
( - - O
DOTC - - O
, - - O
Vibramycin - - O
'Pfizer' - - O
) - - O
, - - O
a - - O
long-lasting - - O
tetracycline - - O
, - - O
was - - O
administered - - O
mainly - - O
by - - O
drip - - O
infusion - - O
for - - O
a - - O
series - - O
of - - O
study - - O
in - - O
the - - O
pediatrics - - O
field - - O
, - - O
and - - O
the - - O
results - - O
were - - O
as - - O
follows - - O
: - - O
1 - - O
) - - O
DOTC - - O
( - - O
100 - - O
mg - - O
) - - O
was - - O
dissolved - - O
in - - O
a - - O
100 - - O
ml - - O
of - - O
glucose - - O
solution - - O
and - - O
2--3 - - O
mg - - O
kg - - O
was - - O
administered - - O
intravenously - - O
. - - O

Cytomegalovirus - - O
, - - O
Chlamydia - - O
pneumoniae - - O
, - - O
and - - O
Helicobacter - - O
pylori - - O
IgG - - B-MUT
antibodies - - I-MUT
and - - O
restenosis - - O
after - - O
stent - - O
implantation - - O
: - - O
an - - O
angiographic - - O
and - - O
intravascular - - O
ultrasound - - O
study - - O
. - - O

The - - O
mechanism - - O
by - - O
which - - O
E2-C - - B-MUT
represses - - O
E2-dependent - - B-MUT
enhancer - - I-MUT
activity - - O
most - - O
likely - - O
involves - - O
competition - - O
with - - O
E2 - - B-MUT
for - - O
binding - - O
to - - O
a - - O
common - - O
transcriptional - - O
regulatory - - O
site - - O
. - - O
( - - O
ABSTRACT - - O
TRUNCATED - - O
AT - - O
400 - - O
WORDS - - O
) - - O

Upon - - O
serum - - O
withdrawal - - O
at - - O
the - - O
permissive - - O
temperature - - O
, - - O
p53-mediated - - O
apoptosis - - O
was - - O
induced - - O
in - - O
50 - - O
to - - O
60% - - O
of - - O
the - - O
cells - - O
. - - O

A - - O
needs - - O
assessment - - O
of - - O
these - - O
families - - O
was - - O
also - - O
done - - O
. - - O

Recording - - O
of - - O
the - - O
digital - - O
sphygmic - - O
activity - - O
in - - O
the - - O
lower - - O
extremities - - O
with - - O
the - - O
photoplethysmographic - - O
and - - O
strain-gauge - - O
methods - - O
. - - O

No - - O
positive - - O
family - - O
history - - O
was - - O
obtained - - O
. - - O

In - - O
this - - O
paper - - O
we - - O
describe - - O
properties - - O
of - - O
the - - O
cdc10-C4 - - B-MUT
mutant - - I-MUT
of - - I-MUT
the - - I-MUT
fission - - I-MUT
yeast - - I-MUT
Schizosaccharomyces - - I-MUT
pombe - - I-MUT
. - - O

Consistent - - O
with - - O
ErbB-2 - - B-MUT
being - - O
a - - O
shared - - O
receptor - - O
subunit - - O
, - - O
its - - O
tyrosine - - O
phosphorylation - - O
was - - O
increased - - O
by - - O
both - - O
heterologous - - O
ligands - - O
and - - O
it - - O
mediated - - O
a - - O
trans-inhibitory - - O
effect - - O
of - - O
NDF - - B-MUT
on - - O
EGF - - B-MUT
binding - - O
. - - O

This - - O
conformer - - O
features - - O
a - - O
Type - - O
I - - O
beta-turn - - O
and - - O
has - - O
extensive - - O
hydrophobic - - O
contacts - - O
with - - O
the - - O
FKBP12 - - B-MUT
binding - - O
surface - - O
. - - O

Endocytosis - - O
and - - O
vacuolar - - O
degradation - - O
of - - O
the - - O
plasma - - O
membrane-localized - - O
Pdr5 - - B-MUT
ATP-binding - - I-MUT
cassette - - I-MUT
multidrug - - I-MUT
transporter - - I-MUT
in - - O
Saccharomyces - - O
cerevisiae - - O
. - - O

Of - - O
7 - - O
patients - - O
treated - - O
with - - O
cyclophosphamide - - O
, - - O
hexamethylmelamine - - O
, - - O
adriamycin - - O
and - - O
cisplatin - - O
( - - O
CHAP-5 - - O
) - - O
, - - O
6 - - O
had - - O
measurable - - O
disease - - O
, - - O
of - - O
whom - - O
5 - - O
yielded - - O
a - - O
response - - O
( - - O
2 - - O
complete - - O
responses - - O
for - - O
19+ - - O
and - - O
40 - - O
months - - O
and - - O
3 - - O
partial - - O
responses - - O
for - - O
4 - - O
, - - O
7 - - O
and - - O
8 - - O
months - - O
) - - O
. - - O

Morphometrical - - O
quantification - - O
of - - O
brain - - O
edema - - O
related - - O
to - - O
experimental - - O
multiple - - O
micro-infarcts - - O
in - - O
mice - - O
: - - O
assessment - - O
of - - O
neurotropin - - O
effect - - O
. - - O

The - - O
degree - - O
of - - O
lung - - O
destruction - - O
, - - O
reflected - - O
by - - O
interstitial - - O
hemorrhage - - O
was - - O
assessed - - O
by - - O
measuring - - O
hemoglobin - - B-MUT
content - - O
in - - O
the - - O
fluid - - O
of - - O
the - - O
lavaged - - O
lungs - - O
. - - O

To - - O
elucidate - - O
the - - O
functional - - O
significance - - O
of - - O
Fyn - - B-MUT
in - - O
the - - O
expression - - O
of - - O
viral - - O
promoters - - O
, - - O
we - - O
transfected - - O
a - - O
Fyn-expression - - O
vector - - O
together - - O
with - - O
a - - O
reporter - - O
plasmid - - O
containing - - O
the - - O
chloramphenicol - - B-MUT
acetyltransferase - - I-MUT
gene - - I-MUT
driven - - O
by - - O
HIV - - B-MUT
LTR - - I-MUT
into - - O
a - - O
human - - O
T - - O
cell - - O
line - - O
, - - O
Jurkat - - O
. - - O

They - - O
consist - - O
of - - O
at - - O
least - - O
two - - O
separable - - O
components - - O
, - - O
one - - O
heat - - O
stable - - O
and - - O
the - - O
other - - O
heat - - O
labile - - O
. - - O

Polymyxin - - O
B - - O
was - - O
given - - O
intravenously - - O
for - - O
1 - - O
week - - O
postburn - - O
in - - O
doses - - O
designed - - O
to - - O
neutralize - - O
circulating - - O
endotoxemia - - O
. - - O

These - - O
data - - O
are - - O
consistent - - O
with - - O
the - - O
idea - - O
that - - O
the - - O
neuron-specific - - B-MUT
SCG10 - - I-MUT
gene - - I-MUT
evolved - - O
by - - O
duplication - - O
and - - O
modification - - O
of - - O
the - - O
more - - O
broadly - - O
expressed - - O
stathmin - - B-MUT
Lap18 - - I-MUT
gene - - I-MUT
. - - I-MUT

We - - O
studied - - O
GSH-Px - - B-MUT
enzyme - - I-MUT
activity - - O
in - - O
serum - - O
after - - O
acute - - O
myocardial - - O
infarction - - O
( - - O
AMI - - O
) - - O
and - - O
unstable - - O
angina - - O
pectoris - - O
( - - O
UAP - - O
) - - O
. - - O

The - - O
N-terminal - - O
115 - - O
amino - - O
acids - - O
correspond - - O
to - - O
a - - O
putative - - O
DNA-binding - - O
domain - - O
and - - O
show - - O
significant - - O
sequence - - O
similarity - - O
with - - O
other - - O
cloned - - O
IFN - - B-MUT
response - - I-MUT
factors - - I-MUT
( - - O
IRF-1 - - B-MUT
and - - O
IRF-2 - - B-MUT
) - - O
. - - O

OBJECTIVE - - O
: - - O
The - - O
study - - O
was - - O
designed - - O
to - - O
investigate - - O
the - - O
frequency - - O
of - - O
alterations - - O
in - - O
serum - - O
creatinine - - O
in - - O
patients - - O
with - - O
psoriasis - - O
receiving - - O
5 - - O
mg - - O
kg - - O
day - - O
of - - O
cyclosporine - - O
. - - O

Thirty - - O
isolates - - O
of - - O
Haemophilus - - O
influenzae - - O
type - - O
b - - O
were - - O
obtained - - O
during - - O
an - - O
outbreak - - O
of - - O
invasive - - O
H - - O
. - - O
influenzae - - O
type - - O
b - - O
disease - - O
and - - O
were - - O
classified - - O
by - - O
the - - O
electrophoretic - - O
profile - - O
of - - O
their - - O
lipopolysaccharide - - O
( - - O
LPS - - O
) - - O
. - - O

A - - O
combination - - O
of - - O
cisplatin - - O
and - - O
5-fluorouracil - - O
, - - O
both - - O
administered - - O
4 - - O
days - - O
continuously - - O
as - - O
infusion - - O
, - - O
was - - O
assessed - - O
in - - O
advanced - - O
head - - O
and - - O
neck - - O
cancer - - O
. - - O

NE - - B-MUT
and - - O
PR3 - - B-MUT
assist - - O
in - - O
the - - O
destruction - - O
of - - O
phagocytosed - - O
microorganisms - - O
, - - O
cleave - - O
the - - O
important - - O
connective-tissue - - B-MUT
protein - - I-MUT
elastin - - I-MUT
, - - O
and - - O
generate - - O
chemotactic - - O
activities - - O
by - - O
forming - - O
alpha - - B-MUT
1-proteinase - - I-MUT
inhibitor - - I-MUT
complexes - - I-MUT
and - - O
elastin - - B-MUT
peptides - - I-MUT
. - - O

They - - O
suggest - - O
that - - O
decreased - - O
steady-state - - O
levels - - O
of - - O
IME1 - - B-MUT
and - - O
IME2 - - B-MUT
mRNA - - I-MUT
were - - O
not - - O
merely - - O
the - - O
result - - O
of - - O
non-specific - - O
adverse - - O
affects - - O
on - - O
nucleic - - O
acid - - O
metabolism - - O
caused - - O
by - - O
the - - O
yvh1 - - B-MUT
disruption - - O
. - - O

Blood - - O
levels - - O
of - - O
melatonin - - O
, - - O
serotonin - - O
, - - O
cortisol - - O
, - - O
and - - O
prolactin - - B-MUT
in - - O
relation - - O
to - - O
the - - O
circadian - - O
rhythm - - O
of - - O
platelet - - O
serotonin - - O
uptake - - O
. - - O

Induction - - O
of - - O
correctly - - O
spliced - - O
germline - - O
transcripts - - O
is - - O
necessary - - O
to - - O
target - - O
a - - O
switch - - O
region - - O
for - - O
recombination - - O
and - - O
switching - - O
. - - O

A - - O
narrow - - O
zone - - O
of - - O
myelin-axonal - - O
dissociation - - O
was - - O
also - - O
observed - - O
. - - O

Tranilast - - O
in - - O
the - - O
Therapy - - O
of - - O
Coronary - - O
Artery - - O
Disease - - O
. - - O

Analysis - - O
of - - O
this - - O
sequence - - O
combined - - O
with - - O
that - - O
previously - - O
reported - - O
for - - O
the - - O
5'-flanking - - O
region - - O
directly - - O
proximal - - O
to - - O
the - - O
start - - O
of - - O
transcription - - O
revealed - - O
several - - O
putative - - O
regulatory - - O
sequences - - O
. - - O

Polyadenylation - - O
of - - O
B4 - - B-MUT
RNA - - I-MUT
, - - O
which - - O
occurs - - O
very - - O
early - - O
during - - O
maturation - - O
, - - O
is - - O
limited - - O
to - - O
150 - - O
residues - - O
, - - O
and - - O
it - - O
is - - O
this - - O
number - - O
that - - O
is - - O
required - - O
for - - O
polysomal - - O
recruitment - - O
. - - O

In - - O
comparison - - O
of - - O
cDNA - - O
and - - O
genomic - - O
sequences - - O
four - - O
RNA - - O
editing - - O
events - - O
were - - O
found - - O
in - - O
both - - O
atp9 - - B-MUT
genes - - I-MUT
. - - O

We - - O
show - - O
that - - O
these - - O
three - - O
gain-of-function - - O
mutants - - O
differ - - O
considerably - - O
in - - O
their - - O
ability - - O
to - - O
bypass - - O
the - - O
sex - - O
determination - - O
signal - - O
, - - O
with - - O
SxlM4 - - B-MUT
being - - O
the - - O
strongest - - O
and - - O
SxlM1 - - B-MUT
the - - O
weakest - - O
. - - O

Overlapping - - O
cDNA - - O
clones - - O
were - - O
isolated - - O
and - - O
sequenced - - O
. - - O

Of - - O
270 - - O
patients - - O
with - - O
well-defined - - O
drug - - O
reactions - - O
, - - O
190 - - O
( - - O
70 - - O
per - - O
cent - - O
) - - O
gave - - O
a - - O
positive - - O
response - - O
to - - O
the - - O
mast - - O
cell - - O
test - - O
. - - O

( - - O
2 - - O
) - - O
Diffusion - - O
limitation - - O
in - - O
the - - O
heterogeneous - - O
model - - O
sets - - O
in - - O
at - - O
a - - O
lower - - O
O2 - - O
requirement - - O
value - - O
, - - O
and - - O
increases - - O
more - - O
gradually - - O
with - - O
increasing - - O
O2 - - O
requirement - - O
, - - O
than - - O
in - - O
the - - O
corresponding - - O
homogeneous - - O
models - - O
with - - O
the - - O
same - - O
average - - O
cylinder - - O
diameter - - O
. - - O

BACKGROUND - - O
: - - O
There - - O
is - - O
increasing - - O
interest - - O
on - - O
the - - O
part - - O
of - - O
investigators - - O
and - - O
the - - O
public - - O
at - - O
large - - O
in - - O
finding - - O
ways - - O
to - - O
study - - O
and - - O
improve - - O
treatments - - O
for - - O
the - - O
seriously - - O
mentally - - O
ill - - O
without - - O
exposing - - O
such - - O
individuals - - O
to - - O
unnecessary - - O
risks - - O
. - - O

In - - O
mammals - - O
, - - O
the - - O
Rb - - B-MUT
protein - - I-MUT
interacts - - O
specifically - - O
with - - O
D-type - - B-MUT
cyclins - - I-MUT
and - - O
regulates - - O
cell - - O
proliferation - - O
by - - O
binding - - O
and - - O
inhibiting - - O
E2F - - B-MUT
transcription - - I-MUT
factors - - I-MUT
. - - O

The - - O
data - - O
imply - - O
that - - O
JAK - - B-MUT
STAT - - I-MUT
signaling - - I-MUT
has - - O
a - - O
role - - O
in - - O
EBV-associated - - O
malignancies - - O
. - - O

Against - - O
200 - - O
strains - - O
of - - O
methicillin-resistant - - O
Staphylococcus - - O
aureus - - O
( - - O
MRSA - - O
) - - O
isolated - - O
from - - O
1990 - - O
to - - O
1991 - - O
, - - O
minimum - - O
inhibitory - - O
concentrations - - O
( - - O
MICs - - O
) - - O
of - - O
a - - O
total - - O
of - - O
15 - - O
antibacterial - - O
agents - - O
including - - O
arbekacin - - O
( - - O
ABK - - O
) - - O
were - - O
determined - - O
. - - O

The - - O
perioperative - - O
mortality - - O
of - - O
all - - O
patients - - O
was - - O
1 - - O
. - - O
9% - - O
, - - O
the - - O
mortality - - O
of - - O
patients - - O
older - - O
than - - O
70 - - O
years - - O
was - - O
4 - - O
. - - O
3% - - O
. - - O

We - - O
determined - - O
whether - - O
a - - O
single - - O
injection - - O
of - - O
slow-release - - O
estradiol-17beta - - O
( - - O
SRE2 - - O
) - - O
would - - O
induce - - O
pseudopregnancy - - O
in - - O
gilts - - O
and - - O
whether - - O
PGF2alpha - - O
would - - O
regress - - O
the - - O
corpora - - O
lutea - - O
( - - O
CL - - O
) - - O
of - - O
pseudopregnancy - - O
. - - O

Fecal - - O
samples - - O
were - - O
collected - - O
at - - O
the - - O
beginning - - O
and - - O
end - - O
of - - O
each - - O
trial - - O
period - - O
and - - O
were - - O
analyzed - - O
for - - O
gastrointestinal - - O
nematode - - O
eggs - - O
and - - O
Giardia - - O
cyst - - O
. - - O

Analysis - - O
for - - O
DNA-protein - - O
interactions - - O
by - - O
in - - O
vitro - - O
DNase-I - - B-MUT
footprinting - - O
identified - - O
a - - O
broad - - O
region - - O
of - - O
protection - - O
extending - - O
from - - O
nt - - O
-12 - - O
to - - O
+38 - - O
. - - O

Using - - O
himA - - B-MUT
mutants - - I-MUT
, - - O
we - - O
confirmed - - O
that - - O
IHF - - B-MUT
plays - - O
a - - O
role - - O
in - - O
the - - O
molybdate-dependent - - O
regulation - - O
of - - O
dmsA-lacZ - - B-MUT
expression - - O
in - - O
vivo - - O
. - - O

A - - O
heterologous - - O
promoter - - O
construct - - O
containing - - O
three - - O
repeats - - O
of - - O
a - - O
consensus - - O
Sp1 - - B-MUT
site - - I-MUT
, - - O
cloned - - O
upstream - - O
of - - O
a - - O
single - - O
copy - - O
of - - O
the - - O
ZII - - B-MUT
( - - O
CREB - - B-MUT
AP1 - - I-MUT
) - - I-MUT
element - - O
from - - O
the - - O
BZLF1 - - O
promoter - - B-MUT
linked - - I-MUT
to - - O
the - - O
beta-globin - - O
TATA - - B-MUT
box - - O
, - - O
exhibited - - O
phorbol - - O
ester - - O
inducibility - - O
. - - O

Early-onset - - O
scleral - - O
necrosis - - O
after - - O
iodine - - O
I - - O
125 - - O
plaque - - O
radiotherapy - - O
for - - O
ciliochoroidal - - O
melanoma - - O
. - - O

Treatment - - O
and - - O
care - - O
of - - O
adult - - O
diabetes - - O
mellitus - - O
without - - O
coma - - O
. - - O

Identification - - O
and - - O
structure - - O
of - - O
the - - O
Marek's - - B-MUT
disease - - I-MUT
virus - - I-MUT
serotype - - I-MUT
2 - - I-MUT
glycoprotein - - I-MUT
M - - I-MUT
gene - - I-MUT
: - - O
comparison - - O
with - - O
glycoprotein - - B-MUT
M - - I-MUT
genes - - I-MUT
of - - O
Herpesviridae - - O
family - - O
. - - O

Dimerization - - O
of - - O
Myf-5 - - B-MUT
with - - O
the - - O
ubiquitously - - O
expressed - - O
bHLH - - B-MUT
protein - - I-MUT
E12 - - B-MUT
not - - O
only - - O
increases - - O
the - - O
affinity - - O
for - - O
DNA - - O
but - - O
also - - O
stimulates - - O
transactivation - - O
independently - - O
of - - O
DNA - - O
binding - - O
. - - O

Myocardial - - O
perfusion - - O
was - - O
evaluated - - O
using - - O
the - - O
enhanced - - O
gray - - O
level - - O
after - - O
contrast - - O
injection - - O
, - - O
and - - O
the - - O
level - - O
was - - O
compared - - O
with - - O
the - - O
morphology - - O
and - - O
degree - - O
of - - O
collateral - - O
development - - O
. - - O

Changes - - O
in - - O
body - - O
weight - - O
and - - O
agonistic - - O
behavior - - O
were - - O
also - - O
recorded - - O
. - - O

The - - O
mechanisms - - O
that - - O
govern - - O
the - - O
activation - - O
or - - O
suppression - - O
of - - O
the - - O
CD8 - - B-MUT
gene - - I-MUT
are - - O
likely - - O
to - - O
be - - O
central - - O
to - - O
the - - O
T - - O
cell - - O
development - - O
program - - O
. - - O

A - - O
segmental - - O
analysis - - O
of - - O
the - - O
key - - O
regions - - O
of - - O
HLA-DR1 - - B-MUT
that - - O
control - - O
T - - O
cell - - O
allorecognition - - O
was - - O
performed - - O
by - - O
using - - O
a - - O
series - - O
of - - O
transfected - - O
cell - - O
lines - - O
expressing - - O
the - - O
products - - O
of - - O
recombinant - - B-MUT
DRB - - I-MUT
H-2Eb - - I-MUT
genes - - I-MUT
, - - I-MUT
paired - - O
with - - O
either - - O
DR - - O
alpha - - B-MUT
or - - I-MUT
H-2E - - O
alpha - - B-MUT
. - - I-MUT

Effects - - O
of - - O
methylene - - O
chloride - - O
, - - O
trichloroethane - - O
, - - O
trichloroethylene - - O
, - - O
tetrachloroethylene - - O
and - - O
toluene - - O
on - - O
the - - O
development - - O
of - - O
chick - - O
embryos - - O
. - - O

To - - O
assess - - O
more - - O
specific - - O
PKA-dependent - - O
mediation - - O
of - - O
LH's - - B-MUT
contribution - - O
to - - O
combined - - O
hormonal - - O
drive - - O
, - - O
the - - O
LDL - - B-MUT
receptor - - I-MUT
( - - I-MUT
-1076 - - I-MUT
to - - I-MUT
+11 - - I-MUT
bp - - I-MUT
) - - I-MUT
reporter - - I-MUT
plasmid - - O
was - - O
cotransfected - - O
with - - O
a - - O
full-sequence - - B-MUT
rabbit - - I-MUT
muscle - - I-MUT
protein - - I-MUT
kinase - - I-MUT
inhibitor - - I-MUT
( - - O
PKI - - B-MUT
) - - O
minigene - - O
driven - - O
constitutively - - O
by - - O
a - - O
Rous - - O
sarcoma - - O
virus - - O
promoter - - O
. - - O

A - - O
full-length - - B-MUT
human - - I-MUT
pim-1 - - I-MUT
cDNA - - I-MUT
was - - O
subcloned - - O
into - - O
the - - O
bacterial - - O
vector - - O
pGEX-2T - - O
and - - O
the - - O
Pim-1 - - B-MUT
protein - - I-MUT
expressed - - O
as - - O
a - - O
fusion - - O
product - - O
with - - O
bacterial - - B-MUT
glutathione - - I-MUT
S-transferase - - I-MUT
( - - O
GST - - B-MUT
) - - O
. - - O

Although - - O
L-threo-dihydroxyphenylserine - - O
( - - O
DOPS - - O
) - - O
, - - O
an - - O
artificial - - O
norepinephrine - - O
( - - O
NE - - O
) - - O
precursor - - O
, - - O
did - - O
not - - O
change - - O
immobility - - O
in - - O
intact - - O
mice - - O
, - - O
DOPS - - O
significantly - - O
reduced - - O
immobility - - O
in - - O
mice - - O
pretreated - - O
with - - O
the - - O
selective - - O
NE - - O
neurotoxin - - O
DSP4 - - O
. - - O

Circulating - - O
thrombomodulin - - B-MUT
: - - O
current - - O
knowledge - - O
and - - O
future - - O
prospects - - O
. - - O

Six - - O
hours - - O
after - - O
the - - O
last - - O
administration - - O
, - - O
uterus - - O
of - - O
Gf - - O
and - - O
Cv - - O
mice - - O
were - - O
weight - - O
337 - - O
. - - O
6 - - O
mg% - - O
and - - O
423 - - O
. - - O
5 - - O
mg% - - O
respectively - - O
, - - O
the - - O
difference - - O
was - - O
statistically - - O
significant - - O
( - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
01 - - O
) - - O
. - - O

In - - O
contrast - - O
to - - O
the - - O
situation - - O
in - - O
mammalian - - O
cells - - O
, - - O
prolonged - - O
exposure - - O
of - - O
the - - O
agonist - - O
( - - O
24 - - O
h - - O
) - - O
does - - O
not - - O
result - - O
in - - O
down - - O
regulation - - O
of - - O
the - - O
remaining - - O
70% - - O
of - - O
the - - O
receptors - - O
. - - O

The - - O
mitochondrial - - B-MUT
regulatory - - I-MUT
region - - I-MUT
( - - O
mrr - - B-MUT
) - - O
located - - O
between - - O
the - - O
tRNAPhe - - B-MUT
and - - O
tRNAPro - - B-MUT
genes - - I-MUT
of - - O
mitochondrial - - O
DNA - - O
( - - O
mtDNA - - O
) - - O
is - - O
essential - - O
for - - O
regulation - - O
of - - O
replication - - O
and - - O
transcription - - O
of - - O
the - - O
mitochondrial - - O
genome - - O
. - - O

In - - O
order - - O
to - - O
examine - - O
the - - O
potential - - O
role - - O
of - - O
transcriptional - - O
silencing - - O
during - - O
productive - - O
HSV-1 - - O
infection - - O
, - - O
recombinant - - O
viruses - - O
were - - O
generated - - O
in - - O
which - - O
wild-type - - B-MUT
or - - I-MUT
mutant - - I-MUT
ICP34 - - I-MUT
. - - I-MUT
5 - - I-MUT
promoters - - I-MUT
controlling - - O
the - - O
expression - - O
of - - O
a - - O
chloramphenicol - - B-MUT
acetyltransferase - - I-MUT
reporter - - I-MUT
gene - - I-MUT
were - - O
inserted - - O
into - - O
the - - O
thymidine - - B-MUT
kinase - - I-MUT
gene - - I-MUT
of - - O
the - - O
viral - - O
genome - - O
. - - O

The - - O
gene - - O
structure - - O
of - - O
Elk1 - - B-MUT
spans - - O
15 - - O
. - - O
2 - - O
kb - - O
and - - O
consists - - O
of - - O
seven - - O
exons - - O
and - - O
six - - O
introns - - O
. - - O

The - - O
structure - - O
of - - O
digiprogenin - - O
. - - O

We - - O
have - - O
isolated - - O
and - - O
characterised - - O
a - - O
differentially-regulated - - O
gene - - O
family - - O
in - - O
the - - O
protozoan - - O
parasite - - O
Leishmania - - O
major - - O
. - - O

The - - O
quantitative - - O
determination - - O
of - - O
HBSAG--a - - O
valuable - - O
aid - - O
in - - O
evaluating - - O
the - - O
infectiousness - - O
of - - O
hepatitis - - O
B - - O
virus - - O
carriers - - O
. - - O

We - - O
could - - O
demonstrate - - O
the - - O
involvement - - O
of - - O
cAMP-dependent - - B-MUT
protein - - I-MUT
kinase - - I-MUT
( - - O
PKA - - B-MUT
) - - O
in - - O
the - - O
phosphorylation - - O
of - - O
CDC25Mm - - B-MUT
in - - O
fibroblasts - - O
overexpressing - - O
this - - O
RasGEF - - B-MUT
as - - O
well - - O
as - - O
in - - O
mouse - - O
brain - - O
synaptosomal - - O
membranes - - O
. - - O

Saccharomyces - - O
cerevisiae - - O
activates - - O
a - - O
regulatory - - O
network - - O
called - - O
"general - - O
control" - - O
that - - O
provides - - O
the - - O
cell - - O
with - - O
sufficient - - O
amounts - - O
of - - O
protein - - O
precursors - - O
during - - O
amino - - O
acid - - O
starvation - - O
. - - O

The - - O
cardiac - - B-MUT
myosin - - I-MUT
light - - I-MUT
chain-2 - - I-MUT
( - - O
MLC-2 - - B-MUT
) - - O
gene - - O
promoter - - O
contains - - O
several - - O
positive - - O
and - - O
negative - - O
cis-acting - - O
sequences - - O
that - - O
are - - O
involved - - O
in - - O
the - - O
regulation - - O
of - - O
its - - O
expression - - O
. - - O

No - - O
apparent - - O
clinical - - O
signs - - O
indicative - - O
of - - O
systemic - - O
toxicity - - O
were - - O
observed - - O
in - - O
the - - O
F0 - - O
and - - O
F1 - - O
animals - - O
of - - O
either - - O
sex - - O
. - - O

CONCLUSION - - O
: - - O
Our - - O
findings - - O
suggest - - O
that - - O
endometriosis - - O
increases - - O
soluble - - O
CD23 - - B-MUT
levels - - O
, - - O
which - - O
can - - O
be - - O
suppressed - - O
with - - O
either - - O
danazol - - O
or - - O
leuprolide - - O
acetate - - O
injection - - O
. - - O

Diagnosis - - O
of - - O
unilateral - - O
renal - - O
artery - - O
lesions - - O
after - - O
captopril - - O
administration - - O
. - - O

Insulin-regulated - - O
events - - O
, - - O
however - - O
, - - O
occur - - O
in - - O
all - - O
cells - - O
. - - O

The - - O
major - - O
urinary - - O
metabolites - - O
were - - O
3- - - O
( - - O
3-carboxyphenyl - - O
) - - O
-5-hydroxymethyl-2-oxazolidinone - - O
and - - O
a - - O
glucuronide - - O
of - - O
toloxatone - - O
. - - O

This - - O
suggested - - O
that - - O
baboon - - B-MUT
liver - - I-MUT
class - - I-MUT
I - - I-MUT
ADH - - I-MUT
is - - O
of - - O
the - - O
same - - O
ancestral - - O
lineage - - O
as - - O
the - - O
human - - B-MUT
ADH-beta - - I-MUT
. - - O

Nine - - O
DNA - - O
fragments - - O
that - - O
were - - O
specifically - - O
recognized - - O
and - - O
bound - - O
by - - O
histidine-tagged - - O
AdpA - - B-MUT
were - - O
isolated - - O
by - - O
cycles - - O
of - - O
a - - O
gel - - O
mobility - - O
shift-PCR - - O
method - - O
. - - O

We - - O
conclude - - O
that - - O
pancreatic - - B-MUT
polypeptide - - I-MUT
and - - O
motilin - - B-MUT
responses - - O
to - - O
a - - O
meal - - O
are - - O
different - - O
in - - O
encopretic - - O
children - - O
than - - O
in - - O
children - - O
in - - O
the - - O
control - - O
group - - O
. - - O

The - - O
zta - - B-MUT
transactivator - - I-MUT
involved - - O
in - - O
induction - - O
of - - O
lytic - - O
cycle - - O
gene - - O
expression - - O
in - - O
Epstein-Barr - - O
virus-infected - - O
lymphocytes - - O
binds - - O
to - - O
both - - O
AP-1 - - B-MUT
and - - O
ZRE - - B-MUT
sites - - I-MUT
in - - O
target - - O
promoter - - O
and - - O
enhancer - - O
regions - - O
. - - O

The - - O
pen - - O
can - - O
heal - - O
. - - O

The - - O
nuclear - - O
proteins - - O
encoded - - O
by - - O
the - - O
c-fos - - B-MUT
and - - O
c-jun - - B-MUT
protooncogenes - - I-MUT
are - - O
expressed - - O
during - - O
the - - O
proliferation - - O
period - - O
of - - O
osteoblast - - O
phenotype - - O
development - - O
. - - O

The - - O
effect - - O
of - - O
the - - O
thromboxane - - B-MUT
A2 - - I-MUT
( - - I-MUT
TXA2 - - I-MUT
) - - I-MUT
prostaglandin - - I-MUT
endoperoxide - - I-MUT
receptor - - I-MUT
antagonist - - I-MUT
, - - O
SQ - - O
29 - - O
, - - O
548 - - O
on - - O
pacing-induced - - O
ischemia - - O
was - - O
determined - - O
in - - O
anesthetized - - O
open-chest - - O
dogs - - O
. - - O

Strontium - - O
nitrate - - O
mixed - - O
with - - O
glycolic - - O
acid - - O
, - - O
in - - O
comparison - - O
with - - O
glycolic - - O
acid - - O
alone - - O
, - - O
markedly - - O
( - - O
p - - O
< - - O
0 - - O
. - - O
01 - - O
) - - O
shortened - - O
the - - O
duration - - O
of - - O
the - - O
irritation - - O
sensation - - O
from - - O
24 - - O
. - - O
4+ - - O
-4 - - O
. - - O
1 - - O
( - - O
mean+ - - O
-SEM - - O
) - - O
min - - O
to - - O
8 - - O
. - - O
9+ - - O
-3 - - O
. - - O
7 - - O
( - - O
mean+ - - O
-SEM - - O
) - - O
min - - O
, - - O
and - - O
significantly - - O
( - - O
p - - O
< - - O
0 - - O
. - - O
05 - - O
) - - O
reduced - - O
the - - O
mean - - O
magnitude - - O
of - - O
the - - O
irritation - - O
sensation - - O
at - - O
all - - O
time - - O
points - - O
( - - O
overall - - O
) - - O
. - - O

Two - - O
differentially - - O
expressed - - O
LNX - - B-MUT
messages - - I-MUT
encode - - O
overlapping - - O
proteins - - O
with - - O
predicted - - O
molecular - - O
masses - - O
of - - O
80 - - B-MUT
kDa - - I-MUT
( - - I-MUT
LNX - - I-MUT
) - - I-MUT
and - - O
70 - - B-MUT
kDa - - I-MUT
( - - I-MUT
LNX-b - - I-MUT
) - - I-MUT
. - - O

Recessive - - O
lethal - - O
mutations - - O
were - - O
isolated - - O
based - - O
upon - - O
failure - - O
to - - O
complement - - O
the - - O
recessive - - O
lethality - - O
of - - O
Df - - O
( - - O
3L - - O
) - - O
RR2 - - O
, - - O
a - - O
deletion - - O
of - - O
the - - O
DRE - - B-MUT
region - - I-MUT
that - - O
removes - - O
16-18 - - O
polytene - - O
chromosome - - O
bands - - O
. - - O

Therefore - - O
, - - O
the - - O
molecular - - O
mechanisms - - O
of - - O
the - - O
estrogen - - O
action - - O
that - - O
govern - - O
the - - O
lactoferrin - - B-MUT
gene - - I-MUT
expression - - O
differ - - O
between - - O
mouse - - O
and - - O
human - - O
. - - O

The - - O
program - - O
has - - O
been - - O
written - - O
in - - O
a - - O
generic - - O
BASIC - - O
in - - O
order - - O
to - - O
make - - O
the - - O
procedure - - O
user-friendly - - O
. - - O

SPECT - - O
is - - O
an - - O
important - - O
aid - - O
in - - O
the - - O
diagnosis - - O
of - - O
AIDS - - O
dementia - - O
complex - - O
and - - O
contributes - - O
to - - O
the - - O
understanding - - O
of - - O
the - - O
pathophysiological - - O
mechanisms - - O
of - - O
this - - O
disorder - - O
. - - O

Small - - B-MUT
Maf - - I-MUT
proteins - - I-MUT
heterodimerize - - O
with - - O
Fos - - B-MUT
and - - O
may - - O
act - - O
as - - O
competitive - - O
repressors - - O
of - - O
the - - O
NF-E2 - - B-MUT
transcription - - I-MUT
factor - - I-MUT
. - - O

These - - O
and - - O
other - - O
data - - O
presented - - O
suggest - - O
that - - O
TAg - - B-MUT
're-models' - - O
host - - O
cell - - O
transcription - - O
factors - - O
that - - O
are - - O
used - - O
early - - O
in - - O
viral - - O
infection - - O
, - - O
and - - O
thereby - - O
mimics - - O
an - - O
event - - O
that - - O
naturally - - O
occurs - - O
during - - O
transformation - - O
. - - O

One - - O
P1 - - O
genomic - - O
clone - - O
and - - O
six - - O
subsequent - - O
plasmid - - O
subclones - - O
were - - O
isolated - - O
and - - O
analyzed - - O
for - - O
the - - O
exon-intron - - O
organization - - O
of - - O
the - - O
Ctpct - - B-MUT
gene - - I-MUT
. - - O

A - - O
second - - O
study - - O
group - - O
, - - O
with - - O
intact - - O
cardiac - - O
innervation - - O
, - - O
consisted - - O
of - - O
19 - - O
patients - - O
with - - O
stable - - O
angina - - O
pectoris - - O
class - - O
I - - O
to - - O
III - - O
. - - O

Mature - - O
mRNA - - O
for - - O
cytosolic - - B-MUT
phosphoenolpyruvate - - I-MUT
carboxykinase - - I-MUT
of - - I-MUT
the - - I-MUT
chicken - - I-MUT
is - - O
2 - - O
. - - O
8 - - O
kilobases - - O
in - - O
length - - O
, - - O
similar - - O
to - - O
that - - O
previously - - O
noted - - O
for - - O
mRNA - - O
coding - - O
for - - O
the - - O
same - - O
enzyme - - O
in - - O
the - - O
rat - - O
. - - O

No - - O
significant - - O
differences - - O
could - - O
be - - O
seen - - O
in - - O
response - - O
rates - - O
according - - O
to - - O
the - - O
concentration - - O
of - - O
estrogen - - B-MUT
receptors - - I-MUT
or - - O
presence - - O
of - - O
progesteron - - B-MUT
receptors - - I-MUT
in - - O
this - - O
group - - O
of - - O
patients - - O
. - - O

Surface-coil - - O
experiments - - O
on - - O
phantoms - - O
and - - O
on - - O
human - - O
calf - - O
muscles - - O
in - - O
vivo - - O
are - - O
presented - - O
. - - O

Six - - O
patients - - O
with - - O
glomerulonephritis - - O
in - - O
association - - O
with - - O
a - - O
ventriculovascular - - O
shunt - - O
were - - O
treated - - O
with - - O
three - - O
basic - - O
modes - - O
of - - O
therapy - - O
. - - O

The - - O
results - - O
obtained - - O
tend - - O
to - - O
prove - - O
that - - O
the - - O
reticuloendothelial - - O
system - - O
mainly - - O
participated - - O
in - - O
beryllium - - O
retention - - O
. - - O

Molecular - - O
characterization - - O
of - - O
the - - O
50- - - O
and - - O
57-kDa - - O
subunits - - O
of - - O
the - - O
bovine - - B-MUT
vacuolar - - I-MUT
proton - - I-MUT
pump - - I-MUT
. - - O

One - - O
hundred - - O
twenty - - O
units - - O
of - - O
deglycerolized - - O
red - - O
blood - - O
cells - - O
, - - O
some - - O
with - - O
glycerol - - O
added - - O
so - - O
as - - O
to - - O
exceed - - O
an - - O
acceptable - - O
1% - - O
glycerol - - O
content - - O
, - - O
had - - O
measurements - - O
made - - O
of - - O
the - - O
post-wash - - O
supernatant - - O
fluid - - O
by - - O
refractive - - O
index - - O
and - - O
osmometry - - O
. - - O

The - - O
E-box - - O
sequence - - O
in - - O
the - - O
SE2 - - B-MUT
fragment - - I-MUT
of - - O
the - - O
transferrin - - B-MUT
promoter - - I-MUT
was - - O
CATCTG - - O
and - - O
was - - O
similar - - O
in - - O
gel - - O
shifts - - O
to - - O
the - - O
consensus - - O
E-box - - O
elements - - O
( - - O
CANNTG - - O
) - - O
previously - - O
characterized - - O
. - - O

Although - - O
human - - O
infections - - O
with - - O
bacteraemia - - O
due - - O
to - - O
Pasteurella - - O
multocida - - O
are - - O
not - - O
uncommon - - O
, - - O
endocarditis - - O
associated - - O
with - - O
P - - O
. - - O
haemolytica - - O
is - - O
rare - - O
. - - O

OBJECTIVE - - O
: - - O
To - - O
determine - - O
the - - O
association - - O
of - - O
depressive - - O
symptoms - - O
with - - O
HIV-related - - O
mortality - - O
and - - O
decline - - O
in - - O
CD4 - - B-MUT
lymphocyte - - O
counts - - O
among - - O
women - - O
with - - O
HIV - - O
. - - O

Complex - - O
repetitive - - O
discharges - - O
were - - O
observed - - O
in - - O
muscles - - O
of - - O
mdx - - O
mice - - O
but - - O
no - - O
complex - - O
repetitive - - O
discharges - - O
or - - O
other - - O
abnormalities - - O
were - - O
observed - - O
in - - O
muscles - - O
of - - O
normal - - O
control - - O
mice - - O
. - - O

Positive - - O
CRP - - B-MUT
test - - O
were - - O
seen - - O
. - - O

RA-treatment - - O
of - - O
these - - O
transfectants - - O
induced - - O
morphologic - - O
and - - O
immunophenotypic - - O
maturation - - O
, - - O
changes - - O
in - - O
RA-regulated - - O
genes - - O
, - - O
and - - O
a - - O
G1 - - O
cell - - O
cycle - - O
arrest - - O
in - - O
a - - O
manner - - O
similar - - O
to - - O
parental - - O
NT2 - - O
D1 - - O
cells - - O
. - - O

Surprisingly - - O
, - - O
TFIIIC - - B-MUT
alpha - - I-MUT
has - - O
no - - O
homology - - O
to - - O
any - - O
of - - O
the - - O
yeast - - B-MUT
TFIIIC - - I-MUT
subunits - - I-MUT
already - - O
cloned - - O
, - - O
suggesting - - O
a - - O
significant - - O
degree - - O
of - - O
evolutionary - - O
divergence - - O
for - - O
RNA - - B-MUT
polymerase - - I-MUT
III - - I-MUT
factors - - I-MUT
. - - O

When - - O
used - - O
subcutaneously - - O
or - - O
intravenously - - O
in - - O
maximum - - O
tolerated - - O
doses - - O
the - - O
antibiotic - - O
inhibited - - O
the - - O
development - - O
of - - O
lymphadenosis - - O
NK - - O
Li - - O
by - - O
90 - - O
and - - O
70 - - O
per - - O
cent - - O
respectively - - O
. - - O

The - - O
sequence-specific - - O
interaction - - O
of - - O
nuclear - - B-MUT
factor - - I-MUT
HiNF-D - - I-MUT
with - - O
this - - O
key - - O
proximal - - O
promoter - - O
element - - O
of - - O
the - - O
H4-FO108 - - B-MUT
gene - - I-MUT
is - - O
cell - - O
cycle - - O
regulated - - O
in - - O
normal - - O
diploid - - O
cells - - O
( - - O
J - - O
. - - O

Only - - O
after - - O
a - - O
pretreatment - - O
aimed - - O
at - - O
increasing - - O
its - - O
oxide - - O
surface - - O
layer - - O
was - - O
titanium - - O
powder - - O
found - - O
to - - O
accelerate - - O
the - - O
precipitation - - O
from - - O
solutions - - O
containing - - O
2 - - O
mmol - - O
L - - O
CaCl2 - - O
, - - O
2 - - O
mmol - - O
L - - O
KH2PO4 - - O
, - - O
50 - - O
mmol - - O
L - - O
Hepes - - O
, - - O
pH - - O
7 - - O
. - - O
2 - - O
, - - O
and - - O
to - - O
induce - - O
precipitation - - O
from - - O
metastable - - O
solutions - - O
containing - - O
1 - - O
. - - O
2 - - O
mmol - - O
L - - O
CaCl2 - - O
, - - O
1 - - O
. - - O
2 - - O
mmol - - O
L - - O
KH2PO4 - - O
, - - O
50 - - O
mmol - - O
L - - O
Hepes - - O
, - - O
pH - - O
7 - - O
. - - O
2 - - O
, - - O
at - - O
37 - - O
degrees - - O
C - - O
. - - O

The - - O
approach - - O
derives - - O
from - - O
a - - O
recently - - O
described - - O
strategy - - O
for - - O
making - - O
recombinants - - O
from - - O
five - - O
overlapping - - O
EBV - - O
cosmid-cloned - - O
DNAs - - O
( - - O
B - - O
. - - O

Using - - O
homology - - O
cloning - - O
techniques - - O
, - - O
we - - O
identified - - O
a - - O
mouse - - O
homologue - - O
of - - O
E - - B-MUT
( - - I-MUT
Pc - - I-MUT
) - - I-MUT
, - - O
termed - - O
Epc1 - - B-MUT
, - - O
a - - O
yeast - - O
protein - - O
that - - O
we - - O
name - - O
EPL1 - - B-MUT
, - - O
and - - O
as - - O
well - - O
as - - O
additional - - O
ESTs - - O
from - - O
Caenorhabditis - - O
elegans - - O
, - - O
mice - - O
and - - O
humans - - O
. - - O

The - - O
promoter - - O
of - - O
the - - O
rat - - B-MUT
pgp2 - - I-MUT
mdr1b - - I-MUT
gene - - I-MUT
has - - I-MUT
a - - O
GC-rich - - O
region - - O
( - - O
pgp2GC - - O
) - - B-MUT
that - - O
is - - O
highly - - O
conserved - - O
in - - O
mdr - - O
genes - - B-MUT
and - - I-MUT
contains - - O
an - - O
consensus - - O
Sp1 - - O
site - - B-MUT
. - - I-MUT

Natural - - O
and - - O
induced - - O
malarias - - O
in - - O
western - - O
hemisphere - - O
monkeys - - O
. - - O

Detection - - O
of - - O
congenital - - O
hypothyroidism - - O
in - - O
26 - - O
, - - O
282 - - O
newborn - - O
infants - - O
. - - O

A - - O
polymorphic - - O
bipartite - - O
motif - - O
signals - - O
nuclear - - O
targeting - - O
of - - O
early - - O
auxin-inducible - - O
proteins - - O
related - - O
to - - O
PS-IAA4 - - B-MUT
from - - I-MUT
pea - - I-MUT
( - - I-MUT
Pisum - - I-MUT
sativum - - I-MUT
) - - I-MUT
. - - O

A - - O
two - - O
phase - - O
slug - - O
flow - - O
tubular - - O
heat - - O
exchanger - - O
was - - O
used - - O
for - - O
the - - O
thermal - - O
inactivation - - O
of - - O
Listeria - - O
monocytogenes - - O
in - - O
natural - - O
infected - - O
milk - - O
from - - O
seven - - O
cows - - O
. - - O

Granisetron - - O
, - - O
but - - O
not - - O
saline - - O
, - - O
abolished - - O
vomiting - - O
and - - O
nausea - - O
when - - O
given - - O
as - - O
intervention - - O
after - - O
this - - O
combined - - O
emetic - - O
regimen - - O
. - - O

Specific - - O
and - - O
heritable - - O
genetic - - O
interference - - O
by - - O
double-stranded - - O
RNA - - O
in - - O
Arabidopsis - - O
thaliana - - O
. - - O

Upstream - - O
of - - O
-37 - - O
, - - O
the - - O
5' - - O
untranslated - - O
sequences - - O
of - - O
the - - O
isolates - - O
differ - - O
in - - O
both - - O
length - - O
and - - O
sequence - - O
. - - O

Lysine-ketoglutarate - - B-MUT
reductase - - I-MUT
and - - O
saccharopine - - B-MUT
dehydrogenase - - I-MUT
from - - O
Arabidopsis - - O
thaliana - - O
: - - O
nucleotide - - O
sequence - - O
and - - O
characterization - - O
. - - O

To - - O
test - - O
the - - O
feasibility - - O
of - - O
using - - O
liposomes - - O
to - - O
deliver - - O
therapeutic - - O
agents - - O
to - - O
the - - O
lungs - - O
, - - O
the - - O
effect - - O
of - - O
liposome-encapsulated - - O
superoxide - - B-MUT
dismutase - - I-MUT
( - - O
SOD - - B-MUT
) - - O
or - - O
catalase - - B-MUT
on - - O
pulmonary - - O
oxygen - - O
toxicity - - O
was - - O
studied - - O
in - - O
rats - - O
. - - O

3 - - O
activities - - O
of - - O
the - - O
factor - - B-MUT
II - - I-MUT
molecule - - O
in - - O
the - - O
newborn - - O
infant - - O
at - - O
term - - O
. - - O

There - - O
was - - O
no - - O
evidence - - O
of - - O
linkage - - O
disequilibrium - - O
between - - O
the - - O
polymorphic - - O
site - - O
in - - O
the - - O
B - - O
cell - - O
specific - - O
promoter - - O
and - - O
those - - O
in - - O
the - - O
3' - - O
UTR - - O
. - - O

Patients - - O
with - - O
lesions - - O
affecting - - O
the - - O
PRC - - O
but - - O
sparing - - O
the - - O
PHC - - O
, - - O
and - - O
patients - - O
with - - O
lesions - - O
affecting - - O
both - - O
PRC - - O
and - - O
PHC - - O
, - - O
performed - - O
an - - O
oculomotor - - O
delayed - - O
response - - O
task - - O
with - - O
unpredictably - - O
varied - - O
memory - - O
delays - - O
of - - O
up - - O
to - - O
30 - - O
s - - O
. - - O

Relaxation - - O
of - - O
catch - - O
in - - O
a - - O
molluscan - - O
smooth - - O
muscle - - O
. - - O

Chinese - - O
Spring - - O
( - - O
CS - - O
) - - O
carrying - - O
the - - O
Q - - B-MUT
gene - - I-MUT
to - - O
those - - O
of - - O
a - - O
chromosome - - O
deletion - - O
line - - O
of - - O
CS - - O
, - - O
namely - - O
, - - O
q5 - - O
, - - O
which - - O
lacks - - O
15% - - O
of - - O
5AL - - O
including - - O
the - - O
Q - - B-MUT
gene - - I-MUT
. - - O

The - - O
resulting - - O
R - - B-MUT
protein - - I-MUT
terminates - - O
five - - O
codons - - O
downstream - - O
of - - O
the - - O
frameshift - - O
site - - O
at - - O
the - - O
V - - B-MUT
protein - - I-MUT
stop - - O
codon - - O
. - - O

Here - - O
we - - O
report - - O
that - - O
expression - - O
of - - O
the - - O
I-POU - - B-MUT
tI-POU - - I-MUT
message - - I-MUT
is - - I-MUT
maximal - - O
late - - O
in - - O
the - - O
embryonic - - O
phase - - O
of - - O
Drosophila - - O
development - - O
, - - O
and - - O
I-POU - - O
is - - B-MUT
the - - O
preferred - - O
splice - - O
variant - - O
. - - O

Perilunar - - O
luxation--an - - O
unusual - - O
injury - - O
demanding - - O
immediate - - O
and - - O
correct - - O
treatment - - O
. - - O

Insulin-like - - B-MUT
growth - - I-MUT
factor-binding - - I-MUT
protein-2 - - I-MUT
( - - O
IGF-BP-2 - - B-MUT
) - - O
transcription - - O
in - - O
rat - - O
liver - - O
varies - - O
with - - O
developmental - - O
age - - O
and - - O
fasting - - O
. - - O

In - - O
recent - - O
years - - O
, - - O
successful - - O
physiological - - O
models - - O
have - - O
been - - O
developed - - O
for - - O
a - - O
variety - - O
of - - O
volatile - - O
and - - O
nonvolatile - - O
chemicals - - O
, - - O
and - - O
their - - O
ability - - O
to - - O
perform - - O
the - - O
extrapolations - - O
needed - - O
in - - O
risk - - O
assessment - - O
has - - O
been - - O
demonstrated - - O
. - - O

These - - O
data - - O
indicate - - O
that - - O
the - - O
third - - O
intracellular - - O
loop - - O
of - - O
the - - O
rat - - B-MUT
GnRH-R - - I-MUT
is - - O
involved - - O
in - - O
receptor - - B-MUT
G - - I-MUT
( - - I-MUT
q - - I-MUT
11 - - I-MUT
) - - I-MUT
protein - - I-MUT
coupling - - I-MUT
and - - O
or - - O
selectivity - - O
, - - O
and - - O
in - - O
the - - O
GGH - - O
( - - O
3 - - O
) - - O
1' - - O
cell - - O
line - - O
, - - O
this - - O
loop - - O
is - - O
also - - O
involved - - O
in - - O
signal - - O
transduction - - O
mediated - - O
through - - O
the - - O
Gs - - O
protein - - O
pathway - - B-MUT
. - - I-MUT

Administration - - O
of - - O
growth - - B-MUT
hormone - - I-MUT
leads - - O
to - - O
faster - - O
growth - - O
, - - O
but - - O
also - - O
faster - - O
bone - - O
maturation - - O
. - - O

Evidence - - O
from - - O
the - - O
structure - - O
of - - O
a - - O
number - - O
of - - O
cDNA - - O
clones - - O
, - - O
as - - O
well - - O
as - - O
S1 - - B-MUT
nuclease - - I-MUT
and - - O
primer - - O
extension - - O
studies - - O
supports - - O
the - - O
hypothesis - - O
that - - O
the - - O
PTHrP - - B-MUT
gene - - I-MUT
contains - - O
at - - O
least - - O
two - - O
mRNA - - O
transcription - - O
start - - O
points - - O
that - - O
define - - O
two - - O
putative - - O
regulatory - - O
domains - - O
. - - O

Since - - O
proteins - - O
containing - - O
TPR - - B-MUT
elements - - I-MUT
are - - O
typically - - O
involved - - O
in - - O
multiple - - O
protein-protein - - O
interactions - - O
, - - O
we - - O
suggest - - O
that - - O
the - - O
102kD - - O
protein - - O
interacts - - O
within - - O
the - - O
tri-snRNP - - B-MUT
with - - O
both - - O
the - - O
U5 - - B-MUT
and - - I-MUT
U4 - - I-MUT
U6 - - I-MUT
snRNPs - - I-MUT
, - - I-MUT
thus - - O
bridging - - O
the - - O
two - - O
particles - - O
. - - O

The - - O
comparison - - O
of - - O
the - - O
expression - - O
patterns - - O
of - - O
the - - O
known - - O
Kv4 - - B-MUT
family - - I-MUT
members - - I-MUT
shows - - O
subtype - - O
specificity - - O
with - - O
significant - - O
overlaps - - O
. - - O

Some - - O
strains - - O
of - - O
A - - O
. - - O
parasiticus - - O
produced - - O
all - - O
four - - O
aflatoxins - - B-MUT
B1 - - I-MUT
B2 - - I-MUT
G1 - - I-MUT
G2 - - I-MUT
, - - O
while - - O
the - - O
other - - O
ones - - O
produced - - O
AF - - B-MUT
B1 - - I-MUT
+ - - O
G1 - - B-MUT
only - - O
, - - O
with - - O
concentrations - - O
of - - O
aflatoxins - - B-MUT
from - - O
0 - - O
. - - O
1 - - O
to - - O
450 - - O
mg - - O
kg - - O
. - - O

We - - O
have - - O
tested - - O
this - - O
possibility - - O
by - - O
constructing - - O
a - - O
consecutive - - O
series - - O
of - - O
cysteine - - O
substitutions - - O
in - - O
the - - O
Neu - - B-MUT
juxtamembrane - - I-MUT
domain - - I-MUT
in - - O
order - - O
to - - O
force - - O
dimerization - - O
along - - O
a - - O
series - - O
of - - O
interreceptor - - O
faces - - O
. - - O

4 - - O
. - - O

We - - O
have - - O
examined - - O
the - - O
ability - - O
of - - O
various - - O
NF-kappa - - B-MUT
B - - I-MUT
subunits - - I-MUT
to - - O
bind - - O
to - - O
, - - O
and - - O
activate - - O
transcription - - O
from - - O
, - - O
the - - O
IL-8 - - B-MUT
promoter - - I-MUT
. - - O

In - - O
another - - O
study - - O
, - - O
intravenous - - O
administration - - O
of - - O
devazepide - - O
, - - O
a - - O
specific - - O
cholecystokinin-A - - B-MUT
receptor - - I-MUT
antagonist - - O
, - - O
at - - O
a - - O
dose - - O
of - - O
0 - - O
. - - O
1 - - O
mg - - O
kg - - O
hr - - O
was - - O
begun - - O
15 - - O
min - - O
before - - O
postprandial - - O
saline - - O
intake - - O
and - - O
continued - - O
for - - O
1 - - O
hr - - O
. - - O

In - - O
the - - O
icosahaedral - - O
MVMi - - O
capsid - - O
, - - O
this - - O
sequence - - O
forms - - O
the - - O
carboxy - - O
end - - O
of - - O
the - - O
amphipathic - - O
beta-strand - - B-MUT
I - - I-MUT
( - - O
betaI - - B-MUT
) - - O
, - - O
and - - O
all - - O
its - - O
basic - - O
residues - - O
are - - O
contiguously - - O
positioned - - O
at - - O
the - - O
face - - O
that - - O
in - - O
the - - O
unassembled - - O
subunit - - O
would - - O
be - - O
exposed - - O
to - - O
solvent - - O
. - - O

UAS1 - - B-MUT
is - - O
the - - O
binding - - O
site - - O
for - - O
the - - O
transcriptional - - O
regulator - - O
Adr1p - - B-MUT
. - - O

Both - - O
receptors - - O
utilize - - O
protein - - B-MUT
tyrosine - - I-MUT
kinases - - I-MUT
( - - O
PTKs - - B-MUT
) - - O
for - - O
the - - O
phosphorylation - - O
of - - O
various - - O
signaling - - O
molecules - - O
, - - O
a - - O
process - - O
that - - O
is - - O
critical - - O
for - - O
the - - O
function - - O
of - - O
both - - O
receptors - - O
. - - O

Because - - O
the - - O
Pit-1 - - B-MUT
sites - - I-MUT
in - - O
the - - O
hGH-N - - B-MUT
gene - - I-MUT
promoter - - I-MUT
are - - O
insufficient - - O
for - - O
such - - O
gene - - O
activation - - O
in - - O
vivo - - O
, - - O
these - - O
data - - O
suggested - - O
a - - O
unique - - O
chromatin-mediated - - O
developmental - - O
role - - O
for - - O
Pit-1 - - B-MUT
in - - O
the - - O
hGH - - B-MUT
LCR - - I-MUT
. - - O

Optical-absorption - - O
spectra - - O
, - - O
crystal-field - - O
energy - - O
levels - - O
, - - O
and - - O
transition - - O
line - - O
strengths - - O
of - - O
holmium - - O
in - - O
trigonal - - O
Na3 - - O
[ - - O
Ho - - O
( - - O
C4H4O5 - - O
) - - O
3 - - O
] - - O
[ - - O
sdot - - O
] - - O
2NaClO4 - - O
[ - - O
sdot - - O
] - - O
6H2O - - O
. - - O

During - - O
organogenesis - - O
, - - O
HFH-8 - - B-MUT
expression - - O
is - - O
found - - O
in - - O
the - - O
splanchnic - - O
mesoderm - - O
in - - O
close - - O
apposition - - O
of - - O
the - - O
gut - - O
endoderm - - O
, - - O
suggesting - - O
a - - O
role - - O
in - - O
mesenchymal-epithelial - - O
induction - - O
of - - O
lung - - O
and - - O
gut - - O
morphogenesis - - O
. - - O

Atrial - - O
fibrillation - - O
and - - O
the - - O
autonomic - - O
nervous - - O
system - - O
. - - O

The - - O
IgA - - B-MUT
deficiency - - O
is - - O
combined - - O
with - - O
the - - O
IgE - - B-MUT
one - - O
. - - O

Our - - O
results - - O
suggest - - O
that - - O
Anu2p - - B-MUT
is - - O
the - - O
yeast - - B-MUT
homologue - - I-MUT
of - - I-MUT
mammalian - - I-MUT
epsilon-COP - - I-MUT
and - - O
the - - O
abrupt - - O
accumulation - - O
of - - O
the - - O
ER - - O
membrane - - O
caused - - O
by - - O
a - - O
blockage - - O
of - - O
the - - O
early - - O
protein - - O
transport - - O
pathway - - O
leads - - O
to - - O
alteration - - O
of - - O
nuclear - - O
morphology - - O
of - - O
the - - O
budding - - O
yeast - - O
cells - - O
. - - O

The - - O
penicillin - - B-MUT
binding - - I-MUT
proteins - - I-MUT
( - - O
PBPs - - B-MUT
) - - O
synthesize - - O
and - - O
remodel - - O
peptidoglycan - - O
, - - O
the - - O
structural - - O
component - - O
of - - O
the - - O
bacterial - - O
cell - - O
wall - - O
. - - O

Effect - - O
of - - O
hyperglycemia - - O
on - - O
pain - - O
threshold - - O
in - - O
alloxan-diabetic - - O
rats - - O
. - - O

The - - O
juxtamembrane - - O
region - - O
of - - O
the - - O
insulin - - B-MUT
receptor - - I-MUT
( - - I-MUT
IR - - I-MUT
) - - I-MUT
beta-subunit - - I-MUT
contains - - O
an - - O
unphosphorylated - - O
tyrosyl - - O
residue - - O
( - - O
Tyr960 - - O
) - - O
that - - O
is - - O
essential - - O
for - - O
insulin-stimulated - - O
tyrosyl - - O
phosphorylation - - O
of - - O
some - - O
endogenous - - O
substrates - - O
and - - O
certain - - O
biological - - O
responses - - O
( - - O
White - - O
, - - O
M - - O
. - - O
F - - O
. - - O
, - - O
Livingston - - O
, - - O
J - - O
. - - O
N - - O
. - - O
, - - O
Backer - - O
, - - O
J - - O
. - - O
M - - O
. - - O
, - - O
Lauris - - O
, - - O
V - - O
. - - O
, - - O
Dull - - O
, - - O
T - - O
. - - O
J - - O
. - - O
, - - O
Ullrich - - O
, - - O
A - - O
. - - O
, - - O
and - - O
Kahn - - O
, - - O
C - - O
. - - O
R - - O
. - - O

Using - - O
an - - O
ELISA - - O
, - - O
we - - O
found - - O
that - - O
surfactant - - B-MUT
protein - - I-MUT
A - - I-MUT
( - - O
SP-A - - B-MUT
) - - O
was - - O
markedly - - O
elevated - - O
in - - O
the - - O
pneumonia - - O
patients - - O
. - - O

Resistance - - O
ratios - - O
for - - O
the - - O
other - - O
field - - O
strains - - O
obtained - - O
by - - O
comparison - - O
with - - O
the - - O
R5 - - O
strain - - O
ranged - - O
from - - O
24 - - O
. - - O
5 - - O
to - - O
239 - - O
for - - O
topical - - O
application - - O
and - - O
from - - O
1 - - O
. - - O
2 - - O
to - - O
9 - - O
. - - O
8 - - O
for - - O
the - - O
glass - - O
jar - - O
method - - O
. - - O

Among - - O
the - - O
v-myc - - B-MUT
codons - - O
, - - O
the - - O
first - - O
5 - - O
are - - O
derived - - O
from - - O
the - - O
noncoding - - O
5' - - O
terminus - - O
of - - O
the - - O
second - - O
c-myc - - B-MUT
exon - - O
, - - O
and - - O
412 - - O
codons - - O
correspond - - O
to - - O
the - - O
c-myc - - B-MUT
coding - - O
region - - O
. - - O

A - - O
cDNA - - O
for - - O
a - - O
newly - - O
discovered - - O
pseudogene - - O
, - - O
closely - - O
related - - O
to - - O
the - - O
mouse - - B-MUT
mast - - I-MUT
cell - - I-MUT
chymases - - I-MUT
was - - O
isolated - - O
by - - O
polymerase - - B-MUT
chain - - O
reaction - - O
amplification - - O
from - - O
a - - O
mouse - - O
connective - - O
tissue-like - - O
mast - - O
cell - - O
line - - O
. - - O

Their - - O
circadian - - O
responses - - O
to - - O
both - - O
photic - - O
and - - O
non-photic - - O
cues - - O
were - - O
then - - O
tested - - O
. - - O

Expression - - O
of - - O
the - - O
mouse - - B-MUT
TSH - - I-MUT
beta - - I-MUT
gene - - I-MUT
, - - O
therefore - - O
, - - O
gives - - O
rise - - O
to - - O
multiple - - O
mRNAs - - O
, - - O
each - - O
with - - O
a - - O
unique - - O
5'-untranslated - - O
region - - O
. - - O

The - - O
nucleotide - - O
sequences - - O
of - - O
these - - O
genes - - O
differ - - O
at - - O
only - - O
nine - - O
positions - - O
, - - O
resulting - - O
in - - O
three - - O
amino - - O
acid - - O
differences - - O
. - - O

Thromboplastic - - O
and - - O
fibrynolytic - - O
activity - - O
of - - O
the - - O
blood - - O
after - - O
administration - - O
of - - O
intralipid - - O
in - - O
men - - O
with - - O
history - - O
of - - O
myocardial - - O
infarction - - O
up - - O
to - - O
45 - - O
year - - O
of - - O
life - - O
. - - O

Many - - O
factors - - O
do - - O
influence - - O
the - - O
educational - - O
outcome - - O
in - - O
students - - O
and - - O
large - - O
statistical - - O
power - - O
( - - O
such - - O
as - - O
meta - - O
analysis - - O
) - - O
should - - O
be - - O
helpful - - O
to - - O
eliminate - - O
many - - O
souces - - O
of - - O
error - - O
. - - O

Most - - O
of - - O
the - - O
expressed - - O
human - - B-MUT
E3 - - I-MUT
polypeptides - - I-MUT
( - - O
five - - O
bands - - O
) - - O
were - - O
found - - O
in - - O
the - - O
insoluble - - O
pellet - - O
while - - O
primarily - - O
full-length - - B-MUT
mature - - I-MUT
E3 - - I-MUT
was - - O
found - - O
in - - O
the - - O
soluble - - O
fraction - - O
. - - O

We - - O
show - - O
that - - O
a - - O
protein - - O
, - - O
UBC9 - - B-MUT
, - - O
interacts - - O
specifically - - O
with - - O
TEL - - B-MUT
in - - O
vitro - - O
and - - O
in - - O
vivo - - O
. - - O

Thus - - O
, - - O
this - - O
reading - - O
frame - - O
was - - O
concluded - - O
to - - O
encode - - O
the - - O
precursor - - O
of - - O
mitochondrial - - B-MUT
fumarase - - I-MUT
. - - O

By - - O
contrast - - O
, - - O
all - - O
proteins - - O
initiated - - O
with - - O
a - - O
methionine - - O
placed - - O
one - - O
residue - - O
upstream - - O
of - - O
the - - O
natural - - O
N - - O
terminus - - O
of - - O
PR - - B-MUT
failed - - O
to - - O
show - - O
specific - - O
proteolysis - - O
. - - O

In - - O
this - - O
paper - - O
, - - O
characterization - - O
is - - O
given - - O
of - - O
clinical - - O
and - - O
biochemical - - O
features - - O
of - - O
VH - - O
B - - O
course - - O
against - - O
the - - O
background - - O
of - - O
narcomania - - O
. - - O

The - - O
statistical - - O
significance - - O
of - - O
the - - O
prognosis - - O
factors - - O
was - - O
studied - - O
by - - O
uni- - - O
and - - O
multivariative - - O
methods - - O
, - - O
according - - O
to - - O
the - - O
model - - O
of - - O
Cox - - O
, - - O
with - - O
the - - O
help - - O
of - - O
an - - O
IMB - - O
computer - - O
. - - O

Current - - O
evidence - - O
for - - O
this - - O
type - - O
of - - O
DNA - - O
supercoiling-dependent - - O
transcriptional - - O
coupling - - O
, - - O
based - - O
largely - - O
on - - O
the - - O
in - - O
vivo - - O
activities - - O
of - - O
promoters - - O
contained - - O
in - - O
engineered - - O
DNA - - O
constructs - - O
, - - O
suggests - - O
that - - O
the - - O
transcription - - O
complex - - O
must - - O
be - - O
physically - - O
hindered - - O
to - - O
generate - - O
DNA - - O
supercoils - - O
and - - O
to - - O
prevent - - O
their - - O
diffusion - - O
throughout - - O
the - - O
DNA - - O
duplex - - O
. - - O

With - - O
the - - O
help - - O
of - - O
a - - O
nomogram - - O
one - - O
can - - O
read - - O
off - - O
the - - O
refraction - - O
, - - O
when - - O
axis - - O
length - - O
and - - O
corneal - - O
curvature - - O
are - - O
known - - O
. - - O

A - - O
subset - - O
of - - O
patients - - O
( - - O
n - - O
= - - O
30 - - O
) - - O
underwent - - O
multichannel - - O
pressure - - O
flow - - O
studies - - O
, - - O
which - - O
demonstrated - - O
that - - O
transrectal - - O
HIFU - - O
reduces - - O
bladder - - O
outflow - - O
obstruction - - O
. - - O

Two - - O
of - - O
seven - - O
initiation - - O
sites - - O
were - - O
flanked - - O
by - - O
a - - O
sequence - - O
homologous - - O
to - - O
the - - O
consensus - - O
promoter - - O
motif - - O
that - - O
includes - - O
the - - O
CRTA - - O
motif - - O
( - - O
where - - O
R - - O
is - - O
A - - O
or - - O
G - - O
) - - O
of - - O
the - - O
rice - - O
mitochondrion - - O
. - - O

Recent - - O
molecular - - O
analysis - - O
has - - O
revealed - - O
that - - O
the - - O
S - - B-MUT
locus - - I-MUT
is - - O
highly - - O
polymorphic - - O
and - - O
contains - - O
several - - O
genes - - O
, - - O
i - - O
. - - O
e - - O
. - - O
, - - O
SLG - - B-MUT
, - - O
SRK - - B-MUT
, - - O
the - - O
as-yet-unidentified - - O
pollen - - B-MUT
S - - I-MUT
gene - - I-MUT
( - - I-MUT
s - - I-MUT
) - - I-MUT
, - - O
and - - O
other - - O
linked - - O
genes - - O
. - - O

The - - O
major - - O
type - - O
involves - - O
activator - - O
proteins - - O
that - - O
bind - - O
to - - O
DNA - - O
adjacent - - O
to - - O
where - - O
the - - O
RNA - - B-MUT
polymerase - - I-MUT
( - - O
RNAP - - B-MUT
) - - O
holoenzyme - - O
binds - - O
, - - O
usually - - O
assisting - - O
in - - O
recruitment - - O
of - - O
the - - O
RNAP - - B-MUT
to - - O
the - - O
promoter - - O
. - - O

The - - O
sub-acute - - O
inhalation - - O
toxicity - - O
of - - O
furfural - - O
was - - O
studied - - O
in - - O
Syrian - - O
golden - - O
hamsters - - O
. - - O

Gel - - O
retardation - - O
assays - - O
combined - - O
with - - O
DNase - - B-MUT
I - - I-MUT
footprinting - - O
and - - O
diethyl - - O
pyrocarbonate - - O
interference - - O
showed - - O
that - - O
a - - O
nuclear - - O
factor - - O
from - - O
differentiated - - O
C2 - - O
myotubes - - O
and - - O
BC3H1 - - O
myocytes - - O
recognized - - O
a - - O
conserved - - O
A - - O
+ - - O
T-rich - - O
sequence - - O
within - - O
the - - O
peripheral - - O
activating - - O
region - - O
. - - O

The - - O
application - - O
of - - O
these - - O
instruments - - O
allows - - O
occlusion - - O
of - - O
the - - O
ascending - - O
aorta - - O
traversed - - O
by - - O
the - - O
perfusion - - O
cannula - - O
inserted - - O
directly - - O
or - - O
through - - O
the - - O
apex - - O
of - - O
the - - O
heart - - O
as - - O
well - - O
as - - O
simultaneous - - O
left - - O
ventricular - - O
venting - - O
. - - O

Chronic - - O
renal - - O
failure - - O
patients - - O
essentially - - O
die - - O
from - - O
cardiovascular - - O
causes - - O
, - - O
and - - O
the - - O
frequency - - O
of - - O
malignant - - O
disease - - O
responsible - - O
for - - O
death - - O
is - - O
estimated - - O
to - - O
be - - O
10% - - O
. - - O

In - - O
the - - O
formalin - - O
test - - O
, - - O
however - - O
, - - O
naloxone - - O
attenuated - - O
morphine - - O
analgesia - - O
at - - O
the - - O
lower - - O
doses - - O
( - - O
0 - - O
. - - O
1 - - O
and - - O
0 - - O
. - - O
3 - - O
mg - - O
kg - - O
) - - O
and - - O
potentiated - - O
morphine - - O
analgesia - - O
at - - O
the - - O
highest - - O
dose - - O
( - - O
10 - - O
mg - - O
kg - - O
) - - O
. - - O

5 - - O
( - - O
Sunset - - O
Yellow - - O
FCF - - O
) - - O
were - - O
determined - - O
using - - O
liquid - - O
chromatography - - O
mass - - O
spectrometry - - O
( - - O
LC - - O
MS - - O
) - - O
with - - O
electrospray - - O
ionization - - O
. - - O

The - - O
present - - O
results - - O
demonstrate - - O
that - - O
rats - - O
with - - O
relatively - - O
small - - O
remnants - - O
of - - O
one - - O
olfactory - - O
bulb - - O
can - - O
perform - - O
a - - O
variety - - O
of - - O
odor - - O
detection - - O
and - - O
discrimination - - O
tasks - - O
as - - O
well - - O
or - - O
nearly - - O
as - - O
well - - O
as - - O
controls - - O
. - - O

Most - - O
patients - - O
preferred - - O
tablets - - O
to - - O
injection - - O
both - - O
on - - O
day - - O
1 - - O
( - - O
313 - - O
v - - O
200 - - O
) - - O
and - - O
at - - O
follow - - O
up - - O
( - - O
373 - - O
v - - O
104 - - O
) - - O
. - - O

Two - - O
of - - O
these - - O
six - - O
cases - - O
showed - - O
mucosal - - O
spread - - O
without - - O
stromal - - O
invasion - - O
( - - O
type - - O
A - - O
) - - O
; - - O
the - - O
remaining - - O
four - - O
cases - - O
presented - - O
a - - O
direct - - O
extension - - O
( - - O
type - - O
B - - O
) - - O
from - - O
muscle-invasive - - O
carcinomas - - O
of - - O
the - - O
bladder - - O
. - - O

IV - - O
. - - O

Competitive - - O
mobility - - O
shift - - O
assays - - O
using - - O
either - - O
alphaT3-1 - - O
nuclear - - O
extract - - O
or - - O
recombinant - - B-MUT
SF-1 - - I-MUT
protein - - I-MUT
clearly - - O
indicated - - O
that - - O
SF-1 - - B-MUT
is - - O
able - - O
to - - O
interact - - O
specifically - - O
with - - O
this - - O
GSE - - B-MUT
element - - I-MUT
positioned - - O
at - - O
-134 - - O
. - - O

A - - O
liquid - - O
chromatographic - - O
method - - O
is - - O
described - - O
for - - O
analysis - - O
of - - O
beta-carotene - - O
in - - O
medical - - O
food - - O
. - - O

Animals - - O
that - - O
received - - O
DSP-4 - - O
were - - O
significantly - - O
retarded - - O
in - - O
motor - - O
recovery - - O
compared - - O
with - - O
the - - O
saline - - O
group - - O
. - - O

Site-directed - - O
mutagenesis - - O
of - - O
the - - O
R2 - - B-MUT
protein - - I-MUT
was - - O
used - - O
to - - O
provide - - O
evidence - - O
that - - O
this - - O
motif - - O
is - - O
also - - O
part - - O
of - - O
the - - O
active - - O
site - - O
of - - O
the - - O
endonuclease - - B-MUT
encoded - - O
by - - O
this - - O
element - - O
. - - O

We - - O
determined - - O
whether - - O
the - - O
human - - B-MUT
StAR - - I-MUT
promoter - - I-MUT
is - - O
responsive - - O
to - - O
sterol - - B-MUT
regulatory - - I-MUT
element-binding - - I-MUT
proteins - - I-MUT
( - - O
SREBPs - - B-MUT
) - - O
. - - O

We - - O
show - - O
that - - O
other - - O
cdc33 - - B-MUT
mutants - - I-MUT
also - - O
arrest - - O
in - - O
G1 - - O
. - - O

The - - O
network - - O
evolution - - O
was - - O
interpreted - - O
by - - O
an - - O
approach - - O
based - - O
on - - O
the - - O
Flory - - O
model - - O
. - - O

In - - O
addition - - O
, - - O
the - - O
ketamine-treated - - O
rats - - O
had - - O
more - - O
neurons - - O
and - - O
glial - - O
cells - - O
surrounding - - O
the - - O
ventricles - - O
. - - O

RESULTS - - O
: - - O
In - - O
this - - O
group - - O
of - - O
patients - - O
, - - O
male - - O
gender - - O
( - - O
P - - O
= - - O
0 - - O
. - - O

The - - O
results - - O
presented - - O
suggest - - O
that - - O
TIQ - - O
reduces - - O
the - - O
turnover - - O
rate - - O
of - - O
the - - O
nigrostriatal - - O
dopamine - - O
neurons - - O
after - - O
repeated - - O
administration - - O
for - - O
a - - O
long - - O
period - - O
in - - O
mice - - O
. - - O

And - - O
the - - O
natural - - O
barriers - - O
? - - O

In - - O
experiments - - O
with - - O
the - - O
D1 - - B-MUT
antagonist - - O
SCH - - O
23390 - - O
, - - O
buprenorphine-induced - - O
depression - - O
was - - O
consistently - - O
blocked - - O
, - - O
but - - O
facilitation - - O
was - - O
unaffected - - O
. - - O

Each - - O
individual - - O
shot - - O
25 - - O
bullets - - O
in - - O
about - - O
5 - - O
minutes - - O
, - - O
at - - O
an - - O
intensity - - O
level - - O
calculated - - O
at - - O
163 - - O
dB - - O
. - - O

Positioning - - O
this - - O
uORF - - O
, - - O
together - - O
with - - O
its - - O
accompanying - - O
Kozak - - O
sequences - - O
, - - O
between - - O
a - - O
heterologous - - O
promoter - - O
from - - O
SV40 - - O
and - - O
a - - O
CAT - - B-MUT
reporter - - I-MUT
gene - - I-MUT
resulted - - O
in - - O
marked - - O
inhibition - - O
of - - O
CAT - - B-MUT
protein - - I-MUT
production - - O
without - - O
a - - O
decrease - - O
in - - O
CAT - - B-MUT
mRNA - - I-MUT
. - - O

Morphine - - O
injected - - O
into - - O
the - - O
lateral - - O
ventricle - - O
of - - O
the - - O
rat - - O
produced - - O
unilateral - - O
analgesia - - O
in - - O
the - - O
formalin - - O
test - - O
, - - O
which - - O
involves - - O
continuous - - O
, - - O
moderate - - O
pain - - O
. - - O

The - - O
subjects - - O
from - - O
the - - O
two - - O
regions - - O
with - - O
a - - O
higher - - O
pollution - - O
level - - O
had - - O
lower - - O
FVC - - O
and - - O
FEV1 - - O
values - - O
than - - O
those - - O
from - - O
the - - O
Viskovo - - O
region - - O
. - - O

Specific - - O
hyperimmune - - B-MUT
globulins - - I-MUT
to - - O
pathogens - - O
such - - O
as - - O
Haemophilus - - O
influenzae - - O
and - - O
Streptococcus - - O
pneumoniae - - O
have - - O
also - - O
been - - O
studied - - O
. - - O

From - - O
day - - O
30 - - O
after - - O
turnout - - O
, - - O
the - - O
PFB-group - - O
had - - O
significantly - - O
lower - - O
serum - - B-MUT
pepsinogen - - I-MUT
levels - - O
, - - O
which - - O
reflects - - O
the - - O
low - - O
degree - - O
of - - O
abomasal - - O
damage - - O
in - - O
these - - O
animals - - O
. - - O

This - - O
technique - - O
has - - O
a - - O
sensitivity - - O
and - - O
a - - O
specificity - - O
of - - O
almost - - O
100% - - O
, - - O
and - - O
is - - O
currently - - O
the - - O
best - - O
way - - O
to - - O
diagnose - - O
nodal - - O
involvement - - O
, - - O
apart - - O
from - - O
laparotomy - - O
. - - O

At - - O
the - - O
C-terminus - - O
of - - O
the - - O
protein - - O
is - - O
a - - O
domain - - O
that - - O
contains - - O
sequences - - O
very - - O
similar - - O
to - - O
those - - O
found - - O
in - - O
the - - O
breakpoint - - O
cluster - - O
region - - O
gene - - O
product - - O
, - - O
n-chimerin - - B-MUT
, - - O
and - - O
rho - - B-MUT
GAP - - I-MUT
, - - O
all - - O
of - - O
which - - O
have - - O
been - - O
shown - - O
to - - O
possess - - O
intrinsic - - O
GAP - - B-MUT
activity - - O
on - - O
small - - B-MUT
GTPases - - I-MUT
. - - O

Skin - - O
and - - O
bowel - - O
TPO2 - - O
varied - - O
with - - O
DO2 - - O
and - - O
each - - O
other - - O
( - - O
P - - O
< - - O
0 - - O
. - - O
05 - - O
) - - O
. - - O

In - - O
order - - O
to - - O
identify - - O
and - - O
classify - - O
the - - O
basic - - O
CT - - O
appearances - - O
of - - O
interstitial - - O
pneumonia - - O
, - - O
radiologic - - O
-pathologic - - O
correlative - - O
study - - O
was - - O
performed - - O
using - - O
inflated - - O
and - - O
fixed - - O
lungs - - O
from - - O
autopsy - - O
and - - O
surgery - - O
. - - O

Thrombotic - - O
thrombocytopenic - - O
purpura - - O
in - - O
systemic - - O
lupus - - O
erythematosus - - O
. - - O

The - - O
expression - - O
analysis - - O
of - - O
the - - O
KlHIS4 - - B-MUT
gene - - I-MUT
under - - O
phosphate - - O
starvation - - O
or - - O
high - - O
adenine - - O
supply - - O
shows - - O
that - - O
factors - - O
, - - O
such - - O
as - - O
Bas1 - - B-MUT
or - - O
Bas2 - - B-MUT
, - - O
involved - - O
in - - O
the - - O
basal - - O
control - - O
may - - O
also - - O
operate - - O
in - - O
a - - O
different - - O
way - - O
in - - O
K - - O
. - - O
lactis - - O
. - - O

Local - - O
graft - - O
irradiation - - O
as - - O
an - - O
adjunct - - O
to - - O
pharmacologic - - O
immunosuppression - - O
. - - O

The - - O
US - - O
National - - O
Institute - - O
on - - O
Alcohol - - O
Abuse - - O
and - - O
Alcoholism - - O
( - - O
NIAAA - - O
) - - O
recognizes - - O
two - - O
forms - - O
of - - O
problematic - - O
drinking - - O
: - - O
'willful - - O
alcohol - - O
abuse' - - O
, - - O
a - - O
behavioural - - O
problem - - O
, - - O
and - - O
'alcohol - - O
dependence' - - O
, - - O
a - - O
true - - O
medical - - O
disorder - - O
, - - O
which - - O
includes - - O
a - - O
genetic - - O
component - - O
, - - O
that - - O
can - - O
be - - O
scientifically - - O
understood - - O
and - - O
medically - - O
treated - - O
. - - O

Oleate - - O
induced - - O
steady-state - - O
levels - - O
of - - O
M-CPT - - B-MUT
I - - I-MUT
mRNA - - I-MUT
4 - - O
. - - O
5-fold - - O
. - - O

A - - O
MEK-specific - - O
inhibitor - - O
( - - O
PD098059 - - O
) - - O
( - - O
Dudley - - O
, - - O
D - - O
. - - O

Homozygous - - O
null - - O
embryos - - O
also - - O
displayed - - O
abnormalities - - O
in - - O
heart - - O
development - - O
, - - O
consistent - - O
with - - O
the - - O
conclusion - - O
that - - O
Tek - - B-MUT
is - - O
necessary - - O
for - - O
endocardial - - O
myocardial - - O
interactions - - O
during - - O
development - - O
. - - O

Of - - O
major - - O
concern - - O
to - - O
food - - O
processors - - O
is - - O
the - - O
inadvertent - - O
cross-contact - - O
of - - O
food - - O
products - - O
with - - O
allergenic - - O
residues - - O
, - - O
which - - O
could - - O
result - - O
in - - O
potentially - - O
life-threatening - - O
reactions - - O
in - - O
those - - O
with - - O
a - - O
food - - O
allergy - - O
. - - O

No - - O
homologs - - O
of - - O
other - - O
members - - O
of - - O
the - - O
Surfeit - - B-MUT
gene - - I-MUT
cluster - - I-MUT
were - - O
detected - - O
in - - O
close - - O
proximity - - O
to - - O
the - - O
D - - B-MUT
. - - I-MUT
melanogaster - - I-MUT
Surf-3 - - I-MUT
rpL7a - - I-MUT
gene - - I-MUT
. - - I-MUT
( - - I-MUT
ABSTRACT - - I-MUT
TRUNCATED - - I-MUT
AT - - O
250 - - O
WORDS - - O
) - - O

Dopamine - - O
caused - - O
a - - O
prominent - - O
potassium - - O
efflux - - O
measured - - O
as - - O
86Rb+ - - O
efflux - - O
from - - O
control - - O
glands - - O
, - - O
but - - O
was - - O
without - - O
effect - - O
in - - O
denervated - - O
glands - - O
. - - O

DATA - - O
SYNTHESIS - - O
: - - O
Intracoronary - - O
ultrasound - - O
has - - O
been - - O
shown - - O
to - - O
improve - - O
upon - - O
demonstrated - - O
weaknesses - - O
of - - O
coronary - - O
angiography - - O
. - - O

These - - O
mutants - - O
grow - - O
normally - - O
in - - O
3T6 - - O
mouse - - O
fibroblast - - O
cells - - O
, - - O
and - - O
they - - O
do - - O
not - - O
complement - - O
the - - O
wild-type - - O
virus - - O
in - - O
coinfection - - O
experiments - - O
of - - O
C2 - - O
myoblasts - - O
. - - O

Serial - - O
levels - - O
of - - O
troponin - - B-MUT
T - - I-MUT
and - - O
the - - O
activity - - O
of - - O
CK-MB - - B-MUT
were - - O
measured - - O
6 - - O
, - - O
12 - - O
, - - O
24 - - O
and - - O
48 - - O
h - - O
after - - O
aortic - - O
unclamping - - O
. - - O

We - - O
also - - O
show - - O
that - - O
activation - - O
of - - O
protein - - B-MUT
kinase - - I-MUT
A - - I-MUT
( - - O
PKA - - B-MUT
) - - O
signaling - - O
is - - O
sufficient - - O
to - - O
down-regulate - - O
caveolin-1 - - B-MUT
protein - - I-MUT
expression - - O
and - - O
promoter - - O
activity - - O
. - - O

As - - O
expected - - O
, - - O
glycosylation - - O
of - - O
Env - - B-MUT
produced - - O
from - - O
mutants - - O
was - - O
affected - - O
but - - O
, - - O
irrespective - - O
of - - O
the - - O
glycosylation - - O
phenotype - - O
, - - O
( - - O
i - - O
) - - O
similar - - O
quantities - - O
of - - O
Env - - B-MUT
were - - O
synthesized - - O
, - - O
( - - O
ii - - O
) - - O
the - - O
immunoreactivity - - O
of - - O
V3 - - O
was - - O
similar - - O
, - - O
( - - O
iii - - O
) - - O
gp160 - - B-MUT
was - - O
efficiently - - O
cleaved - - O
into - - O
gp120 - - B-MUT
and - - O
gp41 - - B-MUT
, - - O
( - - O
vi - - O
) - - O
Env - - B-MUT
was - - O
exposed - - O
at - - O
the - - O
cell - - O
membrane - - O
, - - O
( - - O
v - - O
) - - O
secreted - - O
gp120 - - B-MUT
bound - - O
CD4 - - B-MUT
, - - O
and - - O
( - - O
vi - - O
) - - O
membrane - - O
gp41 - - B-MUT
was - - O
able - - O
to - - O
induce - - O
membrane - - O
fusion - - O
with - - O
CD4+ - - B-MUT
cells - - O
. - - O

Significantly - - O
, - - O
the - - O
polymerase - - O
chain - - O
reaction - - O
results - - O
demonstrated - - O
that - - O
gene - - B-MUT
IV - - I-MUT
transcripts - - I-MUT
were - - O
associated - - O
with - - O
hepatic - - O
polysome - - O
fractions - - O
, - - O
indicating - - O
their - - O
active - - O
utilization - - O
in - - O
this - - O
tissue - - O
. - - O

Stability - - O
of - - O
pyrimethamine - - O
in - - O
a - - O
liquid - - O
dosage - - O
formulation - - O
stored - - O
for - - O
three - - O
months - - O
. - - O

On - - O
transition - - O
from - - O
high - - O
to - - O
low - - O
voltage - - O
there - - O
was - - O
a - - O
significant - - O
fall - - O
in - - O
arterial - - O
pressure - - O
( - - O
7% - - O
) - - O
and - - O
an - - O
increase - - O
in - - O
flow - - O
( - - O
19-38% - - O
) - - O
to - - O
areas - - O
of - - O
the - - O
brain - - O
corresponding - - O
to - - O
the - - O
arborization - - O
of - - O
the - - O
reticular - - O
formation - - O
, - - O
i - - O
. - - O
e - - O
. - - O
excluding - - O
the - - O
cerebrum - - O
and - - O
cerebellum - - O
. - - O

The - - O
results - - O
indicate - - O
that - - O
the - - O
pooling - - O
requirements - - O
are - - O
task - - O
dependent - - O
. - - O

Also - - O
, - - O
the - - O
anti-inflammatory - - O
activities - - O
of - - O
an - - O
aqueous - - O
extract - - O
of - - O
Buddleia - - O
cordata - - O
and - - O
its - - O
principal - - O
glycoside - - O
linarin - - O
were - - O
evaluated - - O
. - - O

The - - O
possible - - O
mechanisms - - O
underlying - - O
differences - - O
in - - O
post-tetanic - - O
effects - - O
from - - O
muscle - - O
and - - O
cutaneous - - O
afferents - - O
in - - O
adults - - O
and - - O
neonates - - O
are - - O
discussed - - O
. - - O

For - - O
immunological - - O
methods - - O
, - - O
identification - - O
of - - O
such - - O
antigens - - O
with - - O
intermolecular - - O
variability - - O
, - - O
e - - O
. - - O
g - - O
. - - O
, - - O
the - - O
structural - - O
aescin - - O
analogs - - O
, - - O
is - - O
of - - O
unknown - - O
validity - - O
. - - O

This - - O
report - - O
provides - - O
further - - O
evidence - - O
for - - O
the - - O
riMLF - - O
in - - O
the - - O
control - - O
of - - O
downgaze - - O
, - - O
and - - O
a - - O
synkinesis - - O
is - - O
postulated - - O
for - - O
the - - O
development - - O
of - - O
the - - O
convergence - - O
retraction - - O
nystagmus - - O
. - - O

Abnormal - - O
calcium - - O
metabolism - - O
in - - O
normocalcaemic - - O
sarcoidosis - - O
[ - - O
letter - - O
] - - O
. - - O

All - - O
patients - - O
diagnosed - - O
of - - O
H - - O
. - - O
influenza - - O
type - - O
b - - O
meningitis - - O
were - - O
less - - O
than - - O
3 - - O
years - - O
old - - O
. - - O

This - - O
lack - - O
of - - O
correlation - - O
may - - O
be - - O
due - - O
to - - O
variations - - O
in - - O
the - - O
metabolic - - O
activity - - O
of - - O
the - - O
endometriotic - - O
implants - - O
present - - O
at - - O
different - - O
stages - - O
of - - O
the - - O
disease - - O
. - - O

Patients - - O
with - - O
acute - - O
myocardial - - O
infarction - - O
had - - O
higher - - O
plasma - - O
concentrations - - O
of - - O
neutrophil - - B-MUT
elastase - - I-MUT
and - - O
the - - O
non-peroxide - - O
diene - - O
conjugated - - O
isomer - - O
of - - O
linoleic - - O
acid - - O
than - - O
normal - - O
volunteers - - O
or - - O
patients - - O
with - - O
stable - - O
ischaemic - - O
heart - - O
disease - - O
. - - O

A - - O
probe - - O
evoked - - O
potentials - - O
procedure - - O
was - - O
used - - O
to - - O
assess - - O
the - - O
relative - - O
engagement - - O
of - - O
both - - O
cerebral - - O
hemispheres - - O
during - - O
a - - O
language - - O
task - - O
in - - O
the - - O
following - - O
four - - O
groups - - O
of - - O
dextral - - O
adults - - O
: - - O
left - - O
hemisphere - - O
( - - O
LH - - O
) - - O
-damaged - - O
aphasics - - O
recovering - - O
from - - O
stroke - - O
, - - O
dysarthrics - - O
, - - O
right - - O
hemisphere - - O
( - - O
RH - - O
) - - O
-damaged - - O
nonaphasic - - O
patients - - O
, - - O
and - - O
normal - - O
control - - O
subjects - - O
. - - O

On - - O
Day - - O
8 - - O
, - - O
the - - O
CIDR-B - - O
was - - O
removed - - O
and - - O
500 - - O
micrograms - - O
cloprostenol - - O
injected - - O
, - - O
IM - - O
. - - O

Plasma - - O
glucose - - O
, - - O
immunoreactive - - B-MUT
insulin - - I-MUT
( - - O
IRI - - B-MUT
) - - O
, - - O
C-peptide - - B-MUT
, - - O
glucagon - - B-MUT
, - - O
and - - O
GLP-1 - - B-MUT
levels - - O
at - - O
each - - O
time - - O
point - - O
during - - O
OGTT - - O
were - - O
measured - - O
. - - O

The - - O
Drosophila - - B-MUT
insulin - - I-MUT
receptor - - I-MUT
homolog - - I-MUT
: - - O
a - - O
gene - - O
essential - - O
for - - O
embryonic - - O
development - - O
encodes - - O
two - - O
receptor - - O
isoforms - - O
with - - O
different - - O
signaling - - O
potential - - O
. - - O

Internal - - O
modes - - O
of - - O
a - - O
soliton - - O
. - - O

Vitrectomy - - O
was - - O
still - - O
a - - O
significant - - O
risk - - O
factor - - O
when - - O
macular - - O
holes - - O
were - - O
excluded - - O
. - - O

The - - O
absolute - - O
concentrations - - O
of - - O
alpha - - B-MUT
2-plasmin - - I-MUT
inhibitor - - O
, - - O
alpha - - B-MUT
2-macroglobulin - - I-MUT
, - - O
and - - O
antithrombin - - B-MUT
III - - I-MUT
increased - - O
with - - O
exercise - - O
( - - O
all - - O
P - - O
less - - O
than - - O
0 - - O
. - - O
005 - - O
) - - O
, - - O
but - - O
when - - O
concentrations - - O
were - - O
corrected - - O
for - - O
acute - - O
shifts - - O
of - - O
plasma - - O
water - - O
during - - O
exercise - - O
, - - O
the - - O
quantity - - O
of - - O
these - - O
inhibitors - - O
actually - - O
decreased - - O
( - - O
all - - O
P - - O
less - - O
than - - O
0 - - O
. - - O
005 - - O
) - - O
. - - O

In - - O
Rat - - O
1a - - O
cells - - O
, - - O
m1R - - B-MUT
stimulation - - O
of - - O
phospholipase - - B-MUT
C - - I-MUT
beta - - I-MUT
and - - O
the - - O
marked - - O
rise - - O
in - - O
intracellular - - O
calcium - - O
stimulated - - O
cyclic - - O
AMP - - O
( - - O
cAMP - - O
) - - O
synthesis - - O
, - - O
resulting - - O
in - - O
the - - O
activation - - O
of - - O
protein - - B-MUT
kinase - - I-MUT
A - - O
. - - O

Electron - - O
microscopic - - O
and - - O
enzymatic - - O
analyses - - O
revealed - - O
that - - O
the - - O
A118 - - O
genome - - O
is - - O
a - - O
linear - - O
, - - O
circularly - - O
permuted - - O
, - - O
terminally - - O
redundant - - O
collection - - O
of - - O
double-stranded - - O
DNA - - O
molecules - - O
. - - O

Vbeta - - B-MUT
segments - - I-MUT
are - - O
appended - - O
to - - O
DJbeta - - B-MUT
rearrangements - - I-MUT
, - - O
with - - O
little - - O
or - - O
no - - O
direct - - O
Vbeta - - B-MUT
to - - O
Jbeta - - B-MUT
joining - - O
, - - O
despite - - O
12 - - O
23 - - O
compatibility - - O
of - - O
Vbeta - - O
23-RSSs - - B-MUT
and - - I-MUT
Jbeta12-RSSs - - O
. - - B-MUT

Immunophenotyping - - O
in - - O
four - - O
cases - - O
, - - O
demonstrated - - O
non-B - - O
, - - O
non-T - - O
cell - - O
origin - - O
in - - O
three - - O
and - - O
pre-B - - O
cell - - O
origin - - O
in - - O
one - - O
. - - O

Of - - O
254 - - O
children - - O
with - - O
neuroblastoma - - O
treated - - O
at - - O
St - - O
. - - O

SAMPLE - - O
POPULATION - - O
: - - O
MCB - - O
from - - O
7 - - O
racing - - O
Greyhounds - - O
euthanatized - - O
for - - O
reasons - - O
unrelated - - O
to - - O
MCB - - O
abnormalities - - O
. - - O

Wild-type - - O
protein - - O
bound - - O
azido-ATP - - O
well - - O
, - - O
but - - O
mutants - - O
with - - O
substitutions - - O
in - - O
the - - O
consensus - - O
amino - - O
acids - - O
were - - O
unable - - O
to - - O
bind - - O
azido-ATP - - O
. - - O

The - - O
UAS - - B-MUT
of - - O
the - - O
AAC2 - - B-MUT
gene - - I-MUT
contains - - O
at - - O
least - - O
two - - O
distinct - - O
motifs - - O
for - - O
DNA-binding - - B-MUT
transcriptional - - I-MUT
activators - - I-MUT
, - - O
including - - O
one - - O
which - - O
is - - O
identical - - O
with - - O
the - - O
core - - O
HAP2 - - B-MUT
3 - - I-MUT
4 - - I-MUT
binding - - I-MUT
motif - - I-MUT
, - - I-MUT
and - - I-MUT
a - - O
second - - O
one - - O
with - - O
the - - O
ABF1 - - O
consensus - - O
binding - - B-MUT
sequence - - I-MUT
. - - I-MUT

At - - O
temperatures - - O
permissive - - O
for - - O
transformation - - O
, - - O
6m2 - - O
cells - - O
contain - - O
P58gag - - B-MUT
produced - - O
from - - O
the - - O
4 - - O
. - - O
0-kilobase - - O
( - - O
kb - - O
) - - O
viral - - O
RNA - - O
genome - - O
and - - O
P85gag-mos - - B-MUT
translated - - O
from - - O
a - - O
3 - - O
. - - O
5-kb - - O
spliced - - O
mRNA - - O
. - - O

The - - O
reconstituted - - O
RNA - - B-MUT
polymerases - - I-MUT
containing - - O
the - - O
mutant - - O
alpha - - O
subunits - - O
were - - O
examined - - O
for - - O
their - - O
response - - O
to - - O
transcription - - O
activation - - O
by - - O
cAMP-CRP - - B-MUT
and - - O
the - - O
rrnBP1 - - B-MUT
UP - - I-MUT
element - - I-MUT
. - - O

2001 - - O
. - - O

In - - O
short-term - - O
cotransfections - - O
, - - O
a - - O
pFRTK-CAT - - B-MUT
target - - O
containing - - O
EBNA-1-binding - - B-MUT
sites - - I-MUT
from - - O
the - - O
EBV - - O
origin - - O
of - - O
plasmid - - O
replication - - O
, - - O
ori-P - - B-MUT
, - - O
was - - O
transactivated - - O
by - - O
a - - O
carboxy-terminal - - B-MUT
EBNA-1 - - I-MUT
construction - - I-MUT
( - - O
amino - - O
acids - - O
450 - - O
to - - O
641 - - O
) - - O
that - - O
also - - O
carried - - O
a - - O
c-myc - - B-MUT
nuclear - - I-MUT
localization - - I-MUT
signal - - I-MUT
. - - O

The - - O
atp - - B-MUT
1 - - I-MUT
and - - O
atp - - B-MUT
2 - - I-MUT
types - - O
of - - O
cDNA - - O
sequences - - O
were - - O
the - - O
most - - O
redundant - - O
among - - O
the - - O
28 - - O
different - - O
isoperoxidases - - B-MUT
identified - - O
among - - O
about - - O
200 - - O
peroxidase - - B-MUT
encoding - - I-MUT
ESTs - - I-MUT
. - - O

REV - - O
I - - O
: - - O
All - - O
vessels - - O
up - - O
to - - O
50% - - O
stenosed - - O
have - - O
a - - O
patent - - O
graft - - O
. - - O

One - - O
is - - O
to - - O
act - - O
within - - O
the - - O
visceral - - O
endoderm - - O
to - - O
promote - - O
proper - - O
streak - - O
morphogenesis - - O
. - - O

Interestingly - - O
, - - O
the - - O
activated - - O
PDGF - - B-MUT
beta-receptor - - I-MUT
was - - O
found - - O
not - - O
to - - O
bind - - O
Crk - - B-MUT
proteins - - I-MUT
. - - O

The - - O
transverse - - O
magnetization - - O
decays - - O
mentioned - - O
above - - O
exhibited - - O
two - - O
components - - O
, - - O
a - - O
T2 - - O
fast - - O
( - - O
T2f - - O
) - - O
and - - O
a - - O
T2 - - O
slow - - O
( - - O
T2s - - O
) - - O
component - - O
. - - O

The - - O
deduced - - O
96-residue - - O
amino - - O
acid - - O
coding - - O
sequence - - O
of - - O
the - - O
murine - - O
HMG-I - - B-MUT
( - - I-MUT
Y - - I-MUT
) - - I-MUT
cDNA - - O
is - - O
very - - O
similar - - O
to - - O
the - - O
reported - - O
amino - - O
acid - - O
sequence - - O
of - - O
human - - O
HMG-I - - B-MUT
, - - O
except - - O
that - - O
it - - O
lacks - - O
11 - - O
internal - - O
amino - - O
acids - - O
reported - - O
in - - O
the - - O
human - - O
protein - - O
. - - O

Furthermore - - O
, - - O
SB203580 - - O
inhibited - - O
LPS-induced - - O
activation - - O
of - - O
Sp1 - - B-MUT
, - - O
as - - O
well - - O
as - - O
the - - O
promoter - - O
activity - - O
in - - O
cells - - O
transfected - - O
with - - O
a - - O
plasmid - - O
containing - - O
the - - O
Sp1 - - B-MUT
consensus - - O
sequence - - O
. - - O

It - - O
is - - O
now - - O
recognized - - O
that - - O
essentially - - O
all - - O
eukaryotic - - O
and - - O
prokaryotic - - O
genes - - O
whose - - O
5'-flanking - - O
regions - - O
are - - O
known - - O
and - - O
that - - O
encode - - O
barbiturate-inducible - - O
proteins - - O
contain - - O
the - - O
Barbie - - B-MUT
box - - I-MUT
element - - I-MUT
. - - O

The - - O
effects - - O
of - - O
mean - - O
luminance - - O
were - - O
also - - O
measured - - O
and - - O
a - - O
general - - O
expression - - O
that - - O
would - - O
take - - O
them - - O
into - - O
account - - O
was - - O
derived - - O
. - - O

The - - O
structural - - O
study - - O
of - - O
peptides - - O
belonging - - O
to - - O
the - - O
terminal - - O
domains - - O
of - - O
histone - - B-MUT
H1 - - I-MUT
can - - O
be - - O
considered - - O
as - - O
a - - O
step - - O
toward - - O
the - - O
understanding - - O
of - - O
the - - O
function - - O
of - - O
H1 - - B-MUT
in - - O
chromatin - - O
. - - O

3 - - O
. - - O

Clear - - O
and - - O
evidenced-based - - O
information - - O
should - - O
be - - O
provided - - O
to - - O
patients - - O
as - - O
to - - O
the - - O
means - - O
of - - O
prevention - - O
with - - O
special - - O
attention - - O
to - - O
individual - - O
risk - - O
groups - - O
such - - O
as - - O
IV - - O
drug - - O
abusers - - O
. - - O

The - - O
eating - - O
and - - O
drinking - - O
patterns - - O
of - - O
pygmy - - O
goats - - O
fed - - O
ad - - O
lib - - O
and - - O
kept - - O
on - - O
a - - O
12 - - O
h - - O
light - - O
12 - - O
h - - O
dark - - O
cycle - - O
were - - O
recorded - - O
and - - O
analyzed - - O
. - - O

Chaotic - - O
electron - - O
dynamics - - O
around - - O
a - - O
single - - O
elliptically - - O
shaped - - O
antidot - - O
. - - O

In - - O
the - - O
present - - O
study - - O
we - - O
demonstrated - - O
a - - O
unique - - O
mechanism - - O
of - - O
action - - O
of - - O
8-Cl-cAMP - - O
in - - O
the - - O
regulation - - O
of - - O
these - - O
kinase - - B-MUT
isozymes - - I-MUT
in - - O
HL-60 - - O
human - - O
promyelocytic - - O
leukemia - - O
cells - - O
. - - O

The - - O
comparisons - - O
revealed - - O
that - - O
female - - O
homicide-suicide - - O
perpetrators - - O
were - - O
more - - O
likely - - O
than - - O
female - - O
homicide-suicide - - O
victims - - O
to - - O
live - - O
in - - O
mobile - - O
homes - - O
, - - O
kill - - O
their - - O
lover - - O
or - - O
ex-lover - - O
, - - O
have - - O
their - - O
crime - - O
accidentally - - O
discovered - - O
, - - O
leave - - O
a - - O
suicide - - O
note - - O
, - - O
kill - - O
on - - O
a - - O
weekend - - O
, - - O
and - - O
be - - O
depressed - - O
, - - O
but - - O
are - - O
less - - O
likely - - O
than - - O
female - - O
homicide-suicide - - O
victims - - O
to - - O
live - - O
with - - O
a - - O
spouse - - O
. - - O

Efficacy - - O
and - - O
safety - - O
of - - O
aspirin - - O
in - - O
the - - O
long-term - - O
management - - O
of - - O
atherothrombosis - - O
. - - O

Northern - - O
( - - O
RNA - - O
) - - O
blot - - O
analyses - - O
indicated - - O
that - - O
the - - O
cdh - - B-MUT
genes - - I-MUT
encoding - - O
the - - O
five - - O
subunits - - O
and - - O
an - - O
open - - O
reading - - O
frame - - O
( - - O
ORF1 - - O
) - - O
with - - O
unknown - - O
function - - O
are - - O
cotranscribed - - O
during - - O
growth - - O
on - - O
acetate - - O
. - - O

Prospects - - O
for - - O
controlled-delivery - - O
systems - - O
. - - O

Mycoplasma - - O
hominis - - O
infections - - O
are - - O
easily - - O
missed - - O
because - - O
conventional - - O
methods - - O
for - - O
bacterial - - O
detection - - O
may - - O
fail - - O
. - - O

Finally - - O
, - - O
in - - O
situ - - O
RNA - - O
hybridization - - O
studies - - O
revealed - - O
a - - O
very - - O
specific - - O
pattern - - O
of - - O
EphA8 - - B-MUT
gene - - I-MUT
expression - - O
restricted - - O
to - - O
the - - O
rostral - - O
region - - O
of - - O
midbrain - - O
tectum - - O
during - - O
embryonic - - O
development - - O
. - - O

The - - O
1 - - O
. - - O
7 - - O
kb - - O
cloned - - O
fragment - - O
was - - O
sequenced - - O
and - - O
shown - - O
to - - O
contain - - O
the - - O
entire - - O
fliA - - B-MUT
gene - - I-MUT
. - - O

The - - O
results - - O
indicate - - O
that - - O
the - - O
carbon-perfused - - O
areas - - O
and - - O
MBF - - O
in - - O
the - - O
liver - - O
, - - O
renal - - O
cortex - - O
, - - O
spleen - - O
, - - O
and - - O
small - - O
intestinal - - O
serosa - - O
( - - O
only - - O
MBF - - O
) - - O
increased - - O
significantly - - O
5 - - O
h - - O
after - - O
CLP - - O
. - - O

Since - - O
RCC1p - - B-MUT
acts - - O
as - - O
GNRP - - B-MUT
for - - O
Ran - - B-MUT
, - - O
a - - O
small - - B-MUT
nuclear - - I-MUT
GTPase - - I-MUT
of - - O
the - - O
ras - - B-MUT
superfamily - - I-MUT
, - - O
we - - O
have - - O
identified - - O
two - - O
homologs - - O
of - - O
Ran - - B-MUT
in - - O
S - - O
. - - O
cerevisiae - - O
( - - O
CNR1 - - B-MUT
and - - O
CNR2 - - B-MUT
) - - O
. - - O

These - - O
mutant - - O
proteins - - O
retained - - O
the - - O
ability - - O
to - - O
competitively - - O
inhibit - - O
kappa - - O
B-mediated - - O
transcriptional - - O
activation - - O
of - - O
the - - O
human - - O
immunodeficiency - - O
virus - - O
long - - O
terminal - - O
repeat - - O
but - - O
failed - - O
to - - O
efficiently - - O
transform - - O
chicken - - O
lymphoid - - O
cells - - O
both - - O
in - - O
vitro - - O
and - - O
in - - O
vivo - - O
. - - O

A - - O
patient - - O
of - - O
Group - - O
B - - O
had - - O
severe - - O
athetoid - - O
CP - - O
with - - O
spasticity - - O
, - - O
being - - O
unable - - O
to - - O
right - - O
his - - O
trunk - - O
and - - O
neck - - O
. - - O

Mapping - - O
of - - O
the - - O
human - - B-MUT
Voltage-Dependent - - I-MUT
Anion - - I-MUT
Channel - - I-MUT
isoforms - - I-MUT
1 - - I-MUT
and - - I-MUT
2 - - I-MUT
reconsidered - - O
. - - O

The - - O
Functional - - O
Independence - - O
Measure - - O
: - - O
a - - O
comparative - - O
study - - O
of - - O
clinician - - O
and - - O
self - - O
ratings - - O
. - - O

The - - O
combination - - O
of - - O
MISO - - O
and - - O
WR-2721 - - O
gave - - O
an - - O
intermediate - - O
response - - O
compared - - O
with - - O
either - - O
drug - - O
used - - O
alone - - O
, - - O
resulting - - O
in - - O
some - - O
sensitization - - O
with - - O
single - - O
doses - - O
and - - O
an - - O
overall - - O
protection - - O
with - - O
repeated - - O
small - - O
doses - - O
. - - O

To - - O
determine - - O
whether - - O
P35 - - B-MUT
could - - O
activate - - O
the - - O
39k - - O
promoter - - O
in - - O
the - - O
absence - - O
of - - O
IE1 - - B-MUT
, - - O
the - - O
p35 - - B-MUT
open - - O
reading - - O
frame - - O
was - - O
cloned - - O
under - - O
the - - O
control - - O
of - - O
the - - O
ie1 - - B-MUT
promoter - - I-MUT
. - - O

A - - O
previous - - O
report - - O
described - - O
that - - O
a - - O
548-bp - - B-MUT
BglII-SmaI - - I-MUT
fragment - - I-MUT
has - - O
an - - O
SSO - - O
activity - - O
( - - O
ori2 - - O
; - - O
Kataoka - - O
et - - O
al - - O
. - - O
, - - O
Mol - - O
. - - O

In - - O
summary - - O
, - - O
the - - O
segments - - O
of - - O
C3 - - B-MUT
represented - - O
by - - O
amino - - O
acid - - O
residues - - O
1082-1118 - - O
, - - O
1117-1155 - - O
, - - O
1234-1294 - - O
and - - O
1312-1404 - - O
accommodate - - O
C3 - - B-MUT
( - - I-MUT
D - - I-MUT
) - - I-MUT
epitopes - - I-MUT
that - - O
are - - O
expressed - - O
by - - O
erythrocyte-bound - - O
C3 - - B-MUT
fragments - - I-MUT
, - - O
but - - O
not - - O
by - - O
the - - O
corresponding - - O
fluid-phase - - O
fragment - - O
, - - O
whereas - - O
the - - O
segments - - O
spanning - - O
residues - - O
973-1026 - - O
and - - O
1477-1510 - - O
contain - - O
C3 - - B-MUT
( - - I-MUT
D - - I-MUT
) - - I-MUT
epitopes - - I-MUT
that - - O
are - - O
exposed - - O
exclusively - - O
in - - O
denatured - - O
C3 - - B-MUT
and - - O
therefore - - O
hidden - - O
in - - O
physiological - - O
fragments - - O
of - - O
the - - O
protein - - O
. - - O

Thus - - O
, - - O
TRAF2 - - B-MUT
initiates - - O
SAPK - - B-MUT
and - - O
p38 - - B-MUT
activation - - O
by - - O
binding - - O
two - - O
proximal - - O
protein - - B-MUT
kinases - - I-MUT
: - - O
GCK - - B-MUT
and - - O
RIP - - B-MUT
. - - O

Of - - O
the - - O
43 - - O
infants - - O
with - - O
a - - O
( - - O
probable - - O
) - - O
loss - - O
18 - - O
were - - O
examined - - O
again - - O
at - - O
3 - - O
months - - O
corrected - - O
age - - O
. - - O

3 - - O
cases - - O
. - - O

The - - O
52-protein - - O
subunit - - O
of - - O
T4 - - B-MUT
DNA - - I-MUT
topoisomerase - - I-MUT
is - - O
homologous - - O
to - - O
the - - O
gyrA-protein - - B-MUT
of - - O
gyrase - - B-MUT
. - - O

Intensive - - O
synthesis - - O
of - - O
PNA - - B-MUT
in - - O
the - - O
cells - - O
of - - O
microvascular - - O
wall - - O
evidenced - - O
of - - O
their - - O
high - - O
functional - - O
activity - - O
, - - O
and - - O
the - - O
synthesis - - O
of - - O
DNA - - O
in - - O
them - - O
showed - - O
their - - O
ability - - O
for - - O
proliferation - - O
, - - O
i - - O
. - - O
g - - O
. - - O
--for - - O
growth - - O
. - - O

In - - O
a - - O
randomized - - O
study - - O
on - - O
150 - - O
patients - - O
( - - O
ASA - - O
1 - - O
) - - O
undergoing - - O
induction - - O
of - - O
anaesthesia - - O
, - - O
the - - O
effects - - O
of - - O
Fentanyl - - O
( - - O
0 - - O
. - - O
1 - - O
mg - - O
) - - O
, - - O
the - - O
combination - - O
of - - O
Fentanyl - - O
( - - O
0 - - O
. - - O
1 - - O
mg - - O
) - - O
and - - O
Droperidol - - O
( - - O
5 - - O
mg - - O
) - - O
( - - O
Innovar - - O
, - - O
Thalamonal - - O
) - - O
and - - O
Atropine - - O
( - - O
0 - - O
. - - O
01 - - O
mg - - O
kg - - O
b - - O
. - - O
w - - O
. - - O
) - - O
alone - - O
on - - O
cardiocirculatory - - O
parameters - - O
were - - O
studied - - O
. - - O

Since - - O
the - - O
ETS - - B-MUT
domain - - I-MUT
, - - O
which - - O
is - - O
localized - - O
in - - O
the - - O
carboxy - - O
terminal - - O
region - - O
of - - O
the - - O
encoded - - O
protein - - O
, - - O
is - - O
95% - - O
and - - O
96% - - O
identical - - O
to - - O
that - - O
of - - O
PEA3 - - B-MUT
and - - O
ER81 - - B-MUT
, - - O
respectively - - O
, - - O
we - - O
named - - O
this - - O
new - - O
member - - O
'Ets - - B-MUT
Related - - I-MUT
Molecule - - I-MUT
PEA3-like' - - I-MUT
( - - O
ERM - - B-MUT
) - - O
. - - O

Relative - - O
to - - O
coherent - - O
control - - O
words - - O
( - - O
e - - O
. - - O
g - - O
. - - O
, - - O
quick - - O
) - - O
, - - O
these - - O
discourse-dependent - - O
semantic - - O
anomalies - - O
elicited - - O
a - - O
large - - O
N400 - - O
effect - - O
that - - O
began - - O
at - - O
about - - O
200 - - O
to - - O
250 - - O
msec - - O
after - - O
word - - O
onset - - O
. - - O

The - - O
second - - O
primary - - O
mutant - - O
contained - - O
a - - O
proline-to-leucine - - O
change - - O
at - - O
position - - O
243 - - O
( - - O
P243L - - O
) - - O
. - - O

The - - O
fast - - O
real-time - - O
digital - - O
processing - - O
of - - O
the - - O
N2 - - O
and - - O
flow - - O
signals - - O
incorporated - - O
filtering - - O
, - - O
delay - - O
compensation - - O
, - - O
and - - O
corrections - - O
for - - O
the - - O
effects - - O
of - - O
changes - - O
in - - O
gas - - O
composition - - O
and - - O
temperature - - O
. - - O

In - - O
patients - - O
with - - O
myalgia - - O
, - - O
Raynaud's - - O
syndrome - - O
, - - O
skin - - O
vasculitis - - O
and - - O
vascular - - O
diseases - - O
WFAg - - B-MUT
concentrations - - O
were - - O
higher - - O
than - - O
in - - O
patients - - O
without - - O
them - - O
. - - O

The - - O
Y - - O
. - - O
lipolytica - - O
genomic - - O
POT1 - - B-MUT
gene - - O
was - - O
disrupted - - O
by - - O
replacing - - O
120 - - O
bp - - O
of - - O
its - - O
coding - - O
sequence - - O
with - - O
2 - - O
. - - O
7 - - O
kbp - - O
of - - O
DNA - - O
including - - O
the - - O
Y - - O
. - - O
lipolytica - - O
LEU2 - - B-MUT
gene - - I-MUT
. - - O

Activated - - O
PKR - - B-MUT
may - - O
exist - - O
as - - O
a - - O
dimer - - O
and - - O
phosphorylates - - O
the - - O
eukaryotic - - B-MUT
translation - - I-MUT
initiation - - I-MUT
factor - - I-MUT
2 - - I-MUT
alpha - - I-MUT
subunit - - I-MUT
( - - O
cIF-2 - - B-MUT
alpha - - I-MUT
) - - O
to - - O
inhibit - - O
polypeptide - - O
chain - - O
initiation - - O
. - - O

After - - O
24 - - O
hour - - O
incubation - - O
, - - O
total - - O
cell-associated - - O
IL-1Ra - - B-MUT
and - - O
IL-1 - - B-MUT
beta - - I-MUT
were - - O
measured - - O
by - - O
specific - - O
radioimmunoassay - - O
. - - O

SGPT - - B-MUT
, - - O
SGOT - - B-MUT
, - - O
and - - O
alkaline - - B-MUT
phosphatase - - I-MUT
concentrations - - O
were - - O
essentially - - O
normal - - O
in - - O
all - - O
subjects - - O
. - - O

Weak - - O
allergenicity - - O
of - - O
recombinant - - B-MUT
hirudin - - I-MUT
CGP - - I-MUT
39393 - - I-MUT
( - - O
REVASC - - O
) - - O
in - - O
immunocompetent - - O
volunteers - - O
. - - O

The - - O
DNA - - O
sequencing - - O
of - - O
the - - O
recombinant - - O
clones - - O
revealed - - O
the - - O
expression - - O
of - - O
RXR - - B-MUT
alpha - - I-MUT
and - - O
RXR - - B-MUT
beta - - I-MUT
. - - O

TBARS - - O
levels - - O
, - - O
oxygen-radical - - O
absorbing - - O
capacity - - O
assay - - O
and - - O
AFR - - O
release - - O
assessed - - O
by - - O
electron - - O
paramagnetic - - O
resonance - - O
( - - O
EPR - - O
) - - O
were - - O
used - - O
to - - O
explore - - O
the - - O
existence - - O
of - - O
oxidative - - O
stress - - O
in - - O
diabetes - - O
. - - O

METHODS - - O
: - - O
A - - O
population - - O
survey - - O
was - - O
undertaken - - O
in - - O
10 - - O
, - - O
148 - - O
individuals - - O
to - - O
measure - - O
the - - O
prevalence - - O
and - - O
identify - - O
the - - O
causes - - O
of - - O
blindness - - O
in - - O
Lebanon - - O
. - - O

A - - O
73 - - B-MUT
bp - - I-MUT
fragment - - I-MUT
( - - I-MUT
X1 - - I-MUT
region - - I-MUT
) - - I-MUT
of - - O
the - - O
PRB-1b - - B-MUT
promoter - - I-MUT
, - - O
located - - O
between - - O
positions - - O
-213 - - O
and - - O
-141 - - O
, - - O
was - - O
sufficient - - O
to - - O
confer - - O
ethylene - - O
responsiveness - - O
to - - O
the - - O
reporter - - O
gene - - O
. - - O

More - - O
recently - - O
, - - O
however - - O
, - - O
a - - O
number - - O
of - - O
developments - - O
such - - O
as - - O
the - - O
successful - - O
use - - O
of - - O
the - - O
inhaled - - O
steroid - - O
budesonide - - O
and - - O
oral - - O
dexamethasone - - O
have - - O
reinforced - - O
the - - O
argument - - O
for - - O
using - - O
steroids - - O
. - - O

Comparison - - O
with - - O
a - - O
recently - - O
described - - O
c-sis - - B-MUT
cDNA - - I-MUT
clone - - I-MUT
( - - O
Collins - - O
et - - O
al - - O
. - - O
, - - O
Nature - - O
316 - - O
, - - O
748-750 - - O
( - - O
1985 - - O
) - - O
) - - O
revealed - - O
that - - O
the - - O
1 - - O
. - - O
9 - - O
kbp - - O
DNA - - O
region - - O
contained - - O
a - - O
large - - O
5' - - B-MUT
c-sis - - I-MUT
exon - - I-MUT
of - - O
at - - O
least - - O
1050 - - O
bp - - O
. - - O

This - - O
cluster - - O
consisted - - O
of - - O
four - - O
apparently - - O
unrelated - - O
ESTs - - O
and - - O
two - - O
genes - - O
, - - O
pregnancy-associated - - B-MUT
plasma - - I-MUT
protein-A - - I-MUT
( - - O
PAPP-A - - B-MUT
) - - O
and - - O
a - - O
novel - - O
gene - - O
( - - O
tentatively - - O
named - - O
EST-YD1 - - B-MUT
) - - O
. - - O

The - - O
revertant - - O
TATA - - O
boxes - - O
accelerated - - O
the - - O
kinetics - - O
of - - O
HIV - - O
replication - - O
when - - O
present - - O
in - - O
the - - O
context - - O
of - - O
an - - O
LTR - - O
containing - - O
a - - O
Sp1 - - B-MUT
mutation - - O
( - - O
deletion - - O
or - - O
site - - O
specific - - O
) - - O
; - - O
no - - O
effect - - O
was - - O
observed - - O
on - - O
the - - O
infectivity - - O
of - - O
wild-type - - O
HIV - - O
. - - O

Higher - - O
CYP3A23 - - B-MUT
basal - - O
activity - - O
appears - - O
to - - O
be - - O
due - - O
to - - O
an - - O
E-box - - O
in - - O
3A23SiteA - - B-MUT
that - - O
interacts - - O
with - - O
USF1 - - B-MUT
, - - O
a - - O
ubiquitous - - O
bHLH - - B-MUT
leucine - - I-MUT
zipper - - I-MUT
transcription - - I-MUT
factor - - I-MUT
. - - I-MUT

Transcription - - O
factor - - O
binding - - O
sites - - O
downstream - - O
of - - O
the - - O
human - - O
immunodeficiency - - O
virus - - O
type - - O
1 - - O
transcription - - O
start - - O
site - - O
are - - O
important - - O
for - - O
virus - - O
infectivity - - O
. - - O

Results - - O
from - - O
our - - O
and - - O
other - - O
laboratories - - O
have - - O
suggested - - O
that - - O
UCN-01 - - O
induces - - O
preferential - - O
G1-phase - - O
accumulation - - O
in - - O
several - - O
human - - O
tumor - - O
cell - - O
lines - - O
tested - - O
. - - O

To - - O
understand - - O
the - - O
basis - - O
for - - O
the - - O
increased - - O
cell - - O
surface - - O
stability - - O
compared - - O
with - - O
wild-type - - O
peptide - - O
and - - O
to - - O
understand - - O
the - - O
differences - - O
in - - O
T - - O
cell - - O
recognition - - O
between - - O
I1Y - - B-MUT
and - - O
I1F - - B-MUT
, - - O
we - - O
determined - - O
the - - O
x-ray - - O
crystal - - O
structures - - O
of - - O
the - - O
two - - O
class - - B-MUT
I - - I-MUT
MHC-peptide - - I-MUT
complexes - - I-MUT
. - - O

AgMNPV - - O
and - - O
Orgyia - - O
pseudotsugata - - O
MNPV - - O
( - - O
OpMNPV - - O
) - - O
are - - O
similar - - O
in - - O
terms - - O
of - - O
promoter - - O
structure - - O
and - - O
polyhedrin - - B-MUT
primary - - I-MUT
sequence - - I-MUT
, - - O
and - - O
the - - O
polyhedrin - - B-MUT
gene - - I-MUT
of - - O
both - - O
viruses - - O
is - - O
transcribed - - O
in - - O
the - - O
anti-clockwise - - O
direction - - O
in - - O
relation - - O
to - - O
their - - O
physical - - O
maps - - O
. - - O

Stress - - O
effects - - O
on - - O
affiliation - - O
preferences - - O
among - - O
subjects - - O
possessing - - O
the - - O
type - - O
A - - O
coronary-prone - - O
behavior - - O
pattern - - O
. - - O

The - - O
performance - - O
of - - O
pH-sensitive - - O
particles - - O
is - - O
attributed - - O
to - - O
their - - O
ability - - O
to - - O
release - - O
the - - O
drug - - O
selectively - - O
in - - O
the - - O
upper - - O
part - - O
of - - O
the - - O
intestine - - O
in - - O
a - - O
molecular - - O
or - - O
amorphous - - O
form - - O
. - - O

Chlamydia - - O
and - - O
cervical - - O
cancer - - O
: - - O
a - - O
real - - O
association - - O
? - - O

From - - O
250 - - O
g - - O
of - - O
cells - - O
, - - O
we - - O
isolated - - O
1 - - O
mg - - O
of - - O
PDH - - B-MUT
complex - - I-MUT
with - - O
a - - O
specific - - O
activity - - O
of - - O
12 - - O
. - - O
6 - - O
U - - O
mg - - O
of - - O
protein - - O
. - - O

Progression - - O
after - - O
first-line - - O
chemotherapy - - O
was - - O
associated - - O
with - - O
significantly - - O
worse - - O
survival - - O
for - - O
patients - - O
with - - O
metastasis - - O
. - - O

The - - O
histopathology - - O
and - - O
neovascularization - - O
did - - O
not - - O
appreciably - - O
differ - - O
between - - O
xenograft - - O
tumors - - O
derived - - O
from - - O
FGF4 - - B-MUT
over-expressing - - O
versus - - O
control - - O
transfectants - - O
. - - O

ORF - - O
2 - - O
potentially - - O
encoded - - O
a - - O
hydrophobic - - O
protein - - O
of - - O
29 - - O
, - - O
705 - - O
Da - - O
with - - O
six - - O
potential - - O
membrane-spanning - - O
regions - - O
. - - O

Genomic - - O
structure - - O
and - - O
chromosomal - - O
location - - O
of - - O
the - - O
mouse - - B-MUT
pre-T-cell - - I-MUT
receptor - - I-MUT
alpha - - I-MUT
gene - - I-MUT
. - - O

When - - O
the - - O
entire - - O
diet - - O
consisted - - O
of - - O
SBF - - O
, - - O
voluntary - - O
feed - - O
intake - - O
was - - O
reduced - - O
, - - O
indicating - - O
that - - O
SBF - - O
should - - O
not - - O
be - - O
fed - - O
to - - O
ponies - - O
as - - O
the - - O
sole - - O
dietary - - O
ingredient - - O
. - - O

The - - O
authors - - O
made - - O
an - - O
analysis - - O
of - - O
social-economical - - O
conditions - - O
limiting - - O
the - - O
possibilities - - O
of - - O
rendering - - O
cardiosurgical - - O
care - - O
to - - O
children - - O
. - - O

Therefore - - O
, - - O
it - - O
is - - O
hoped - - O
that - - O
by - - O
defining - - O
the - - O
transcriptional - - O
control - - O
of - - O
the - - O
L7 - - B-MUT
gene - - I-MUT
insights - - O
into - - O
the - - O
mechanisms - - O
that - - O
control - - O
functional - - O
fate - - O
and - - O
organization - - O
in - - O
the - - O
nervous - - O
system - - O
can - - O
be - - O
gained - - O
. - - O

We - - O
showed - - O
previously - - O
that - - O
a - - O
fusion - - O
protein - - O
( - - O
GAL4-p40 - - B-MUT
) - - O
containing - - O
the - - O
DNA-binding - - O
domain - - O
of - - O
GAL4 - - B-MUT
and - - O
sequences - - O
of - - O
chicken - - B-MUT
l - - I-MUT
kappa - - I-MUT
B-alpha - - I-MUT
( - - O
p40 - - B-MUT
) - - O
inhibits - - O
growth - - O
in - - O
the - - O
yeast - - O
Saccharomyces - - O
cerevisiae - - O
. - - O

Activation - - O
of - - O
the - - O
SH2-containing - - B-MUT
protein - - I-MUT
tyrosine - - I-MUT
phosphatase - - I-MUT
, - - O
SH-PTP2 - - B-MUT
, - - O
by - - O
phosphotyrosine-containing - - O
peptides - - O
derived - - O
from - - O
insulin - - B-MUT
receptor - - I-MUT
substrate-1 - - I-MUT
. - - O

We - - O
thus - - O
conclude - - O
that - - O
the - - O
NFAT - - B-MUT
RIR - - I-MUT
plays - - O
an - - O
essential - - O
dual - - O
role - - O
in - - O
DNA - - O
recognition - - O
and - - O
cooperative - - O
binding - - O
to - - O
AP-1 - - B-MUT
family - - I-MUT
transcription - - I-MUT
factors - - I-MUT
. - - O

Atheroma - - O
appears - - O
as - - O
a - - O
very - - O
low - - O
signal - - O
intensity - - O
area - - O
on - - O
2-dimensional - - O
time-of-flight - - O
( - - O
TOF - - O
) - - O
magnetic - - O
resonance - - O
( - - O
MR - - O
) - - O
images - - O
, - - O
and - - O
its - - O
components - - O
have - - O
various - - O
signal - - O
intensities - - O
on - - O
spin-echo - - O
( - - O
SE - - O
) - - O
images - - O
. - - O

After - - O
that - - O
report - - O
, - - O
carboxypeptidase - - B-MUT
D - - I-MUT
( - - O
CPD - - B-MUT
) - - O
was - - O
subsequently - - O
purified - - O
from - - O
bovine - - O
pituitary - - O
and - - O
characterized - - O
as - - O
a - - O
novel - - O
carboxypeptidase - - B-MUT
E - - I-MUT
( - - O
CPE - - B-MUT
) - - O
-like - - O
enzyme - - O
, - - O
with - - O
many - - O
characteristics - - O
in - - O
common - - O
with - - O
duck - - O
gp180 - - B-MUT
( - - O
Song - - O
, - - O
L - - O
. - - O
, - - O
Fricker - - O
, - - O
L - - O
. - - O
D - - O
. - - O
, - - O
1995 - - O
. - - O

Proteinuria--selected - - O
physiopathological - - O
and - - O
clinical - - O
problems - - O
. - - O

Although - - O
popular - - O
this - - O
hypothesis - - O
is - - O
far - - O
from - - O
explaining - - O
all - - O
the - - O
clinical - - O
facts - - O
, - - O
namely - - O
that - - O
rigidity - - O
is - - O
equal - - O
in - - O
extensor - - O
and - - O
flexor - - O
, - - O
proximal - - O
and - - O
distal - - O
muscles - - O
. - - O

In - - O
patients - - O
with - - O
osteomyelitis - - O
and - - O
joint - - O
empyema - - O
( - - O
n - - O
= - - O
48 - - O
) - - O
PMN - - B-MUT
elastase - - I-MUT
had - - O
a - - O
sensitivity - - O
of - - O
77% - - O
, - - O
which - - O
was - - O
only - - O
exceeded - - O
by - - O
that - - O
of - - O
the - - O
unspecific - - O
erythrocyte - - O
sedimentation - - O
rate - - O
( - - O
sensitivity - - O
89% - - O
) - - O
. - - O

Cytoplasmic - - B-MUT
dynein - - I-MUT
is - - O
a - - O
multisubunit - - O
, - - O
microtubule-dependent - - O
mechanochemical - - O
enzyme - - O
that - - O
has - - O
been - - O
proposed - - O
to - - O
function - - O
in - - O
a - - O
variety - - O
of - - O
intracellular - - O
movements - - O
, - - O
including - - O
minus-end-directed - - O
transport - - O
of - - O
organelles - - O
. - - O

The - - O
authors - - O
undertook - - O
a - - O
retrospective - - O
analysis - - O
of - - O
pathology - - O
with - - O
quantification - - O
of - - O
the - - O
percentage - - O
of - - O
papillary - - O
serous - - O
component - - O
( - - O
% - - O
PSC - - O
) - - O
and - - O
p53 - - B-MUT
expression - - O
. - - O

The - - O
maximum - - O
induction - - O
of - - O
ACC-oxidase - - B-MUT
transcripts - - I-MUT
occurred - - O
at - - O
about - - O
6 - - O
h - - O
after - - O
excision - - O
, - - O
while - - O
the - - O
maximum - - O
enzyme - - O
activity - - O
was - - O
observed - - O
at - - O
24 - - O
h - - O
. - - O

TPO - - B-MUT
by - - O
itself - - O
did - - O
not - - O
activate - - O
ERK1 - - B-MUT
, - - O
ERK2 - - B-MUT
and - - O
protein - - B-MUT
kinase - - I-MUT
C - - I-MUT
( - - O
PKC - - B-MUT
) - - O
, - - O
whereas - - O
TPO - - B-MUT
directly - - O
enhanced - - O
the - - O
PKC-dependent - - O
activation - - O
of - - O
ERKs - - B-MUT
induced - - O
by - - O
other - - O
agonists - - O
including - - O
thrombin - - B-MUT
and - - O
phorbol - - O
esters - - O
, - - O
without - - O
affecting - - O
the - - O
PKC - - B-MUT
activation - - O
by - - O
those - - O
agonists - - O
. - - O

Except - - O
for - - O
nonperfusion - - O
of - - O
neurosensory - - O
retinal - - O
vessels - - O
at - - O
a - - O
light - - O
dose - - O
of - - O
150 - - O
J - - O
cm2 - - O
, - - O
no - - O
other - - O
adverse - - O
events - - O
were - - O
of - - O
concern - - O
. - - O

The - - O
complement - - B-MUT
C3a - - I-MUT
anaphylatoxin - - I-MUT
receptor - - I-MUT
( - - O
C3aR - - B-MUT
) - - O
is - - O
a - - O
seven-transmembrane - - B-MUT
G-protein - - I-MUT
coupled - - I-MUT
chemoattractant - - I-MUT
receptor - - I-MUT
that - - O
on - - O
binding - - O
the - - O
C3a - - B-MUT
peptide - - I-MUT
ligand - - I-MUT
mediates - - O
numerous - - O
cellular - - O
responses - - O
, - - O
including - - O
histamine - - O
release - - O
from - - O
mast - - O
cells - - O
. - - O
smooth - - O
muscle - - O
contraction - - O
, - - O
and - - O
the - - O
directed - - O
migration - - O
of - - O
eosinophils - - O
. - - O

With - - O
constructs - - O
containing - - O
the - - O
binding - - O
site - - O
of - - O
one - - O
gene - - O
fused - - O
to - - O
the - - O
promoter - - O
of - - O
the - - O
other - - O
, - - O
we - - O
demonstrated - - O
that - - O
the - - O
positional - - O
requirements - - O
are - - O
a - - O
function - - O
of - - O
the - - O
specific - - O
binding - - O
site - - O
, - - O
not - - O
the - - O
promoter - - O
. - - O

These - - O
results - - O
indicate - - O
that - - O
CSFHU - - B-MUT
can - - O
increase - - O
neutrophil - - O
counts - - O
by - - O
increasing - - O
the - - O
number - - O
and - - O
maturity - - O
of - - O
the - - O
marrow - - O
neutrophil - - O
precursors - - O
in - - O
some - - O
types - - O
of - - O
childhood - - O
chronic - - O
neutropenia - - O
. - - O

Initial - - O
experience - - O
with - - O
a - - O
serotonin - - O
agonist - - O
. - - O

( - - O
1998 - - O
) - - O
FASEB - - O
J - - O
. - - O

Lung - - O
prostacyclin - - O
production - - O
may - - O
be - - O
related - - O
to - - O
flow - - O
. - - O

Nucleotide - - O
sequence - - O
analysis - - O
of - - O
R - - B-MUT
has - - O
revealed - - O
similarities - - O
to - - O
the - - O
R1 - - O
plasmid - - O
found - - O
in - - O
some - - O
South - - O
American - - O
maize - - O
races - - O
with - - O
RU - - O
cytoplasm - - O
, - - O
to - - O
the - - O
M1 - - O
plasmid - - O
found - - O
in - - O
one - - O
source - - O
of - - O
Zea - - O
luxurians - - O
teosinte - - O
, - - O
to - - O
the - - O
atp9 - - B-MUT
mitochondrial - - I-MUT
gene - - I-MUT
and - - O
its - - O
3' - - O
flanking - - O
sequence - - O
, - - O
and - - O
also - - O
to - - O
a - - O
region - - O
3' - - O
to - - O
the - - O
orf221 - - B-MUT
gene - - I-MUT
. - - O

The - - O
P13 - - O
and - - O
N22 - - O
of - - O
ppSEPs - - O
had - - O
phase - - O
reversal - - O
relationship - - O
with - - O
the - - O
P2 - - O
and - - O
N2 - - O
recorded - - O
from - - O
the - - O
PES - - O
, - - O
respectively - - O
. - - O

Three - - O
classes - - O
of - - O
test - - O
objects - - O
were - - O
considered - - O
: - - O
( - - O
1 - - O
) - - O
a - - O
multicompartment - - O
test - - O
object - - O
for - - O
31P - - O
MRS - - O
measurements - - O
performed - - O
with - - O
slice-selective - - O
sequences - - O
; - - O
( - - O
2 - - O
) - - O
a - - O
two-compartment - - O
test - - O
object - - O
for - - O
volume-selection - - O
1H - - O
MRS - - O
; - - O
and - - O
( - - O
3 - - O
) - - O
two-compartment - - O
test - - O
objects - - O
for - - O
assessing - - O
the - - O
performance - - O
of - - O
experimental - - O
systems - - O
using - - O
ISIS - - O
as - - O
volume - - O
localization - - O
sequence - - O
in - - O
31P - - O
MRS - - O
. - - O

Purified - - O
spleen - - O
GAP - - B-MUT
accelerated - - O
hydrolysis - - O
of - - O
GTP - - O
bound - - O
to - - O
recombinant - - B-MUT
ARF1 - - I-MUT
, - - O
ARF3 - - B-MUT
, - - O
ARF5 - - B-MUT
, - - O
and - - O
ARF6 - - B-MUT
; - - O
no - - O
effect - - O
of - - O
NH2-terminal - - O
myristoylation - - O
was - - O
observed - - O
. - - O

Specifically - - O
, - - O
recombination - - O
at - - O
HMR - - B-MUT
was - - O
used - - O
to - - O
produce - - O
rings - - O
that - - O
lacked - - O
the - - O
E - - B-MUT
and - - I-MUT
I - - I-MUT
silencers - - I-MUT
. - - O

Twenty - - O
patients - - O
aged - - O
45 - - O
or - - O
older - - O
with - - O
the - - O
diagnosis - - O
of - - O
endogenous - - O
depression - - O
were - - O
evaluated - - O
in - - O
terms - - O
of - - O
safety - - O
and - - O
efficacy - - O
in - - O
their - - O
response - - O
to - - O
multiple - - O
monitored - - O
electroconvulsive - - O
therapy - - O
( - - O
MMECT - - O
) - - O
versus - - O
single - - O
electroconvulsive - - O
therapy - - O
( - - O
SECT - - O
) - - O
. - - O

Despite - - O
the - - O
reported - - O
detrimental - - O
effects - - O
on - - O
CNS - - O
development - - O
, - - O
a - - O
number - - O
of - - O
animal - - O
studies - - O
have - - O
shown - - O
that - - O
pretreatment - - O
with - - O
corticosteroids - - O
nevertheless - - O
protect - - O
the - - O
brain - - O
from - - O
hypoxia-ischemic - - O
injury - - O
; - - O
however - - O
, - - O
clinically - - O
such - - O
treatment - - O
is - - O
no - - O
longer - - O
favored - - O
. - - O

V - - O
. - - O

No - - O
previous - - O
studies - - O
have - - O
determined - - O
the - - O
pharmaco-dynamics - - O
of - - O
intravenous - - O
procainamide - - O
when - - O
administered - - O
in - - O
a - - O
dose - - O
of - - O
15 - - O
mg - - O
kg - - O
and - - O
at - - O
a - - O
rate - - O
of - - O
50 - - O
mg - - O
min - - O
, - - O
as - - O
is - - O
common - - O
practice - - O
during - - O
electropharmacologic - - O
testing - - O
. - - O

The - - O
objective - - O
of - - O
this - - O
study - - O
was - - O
to - - O
examine - - O
the - - O
influence - - O
of - - O
HHCA - - O
and - - O
other - - O
serological - - O
factors - - O
upon - - O
the - - O
development - - O
of - - O
VGS - - O
. - - O

Separate - - O
experiments - - O
measured - - O
AIB - - O
and - - O
86RbCl - - O
uptake - - O
in - - O
36B-10 - - O
cells - - O
in - - O
vitro - - O
1 - - O
and - - O
2 - - O
days - - O
following - - O
20 - - O
Gy - - O
irradiation - - O
to - - O
assess - - O
whether - - O
this - - O
radiation - - O
dose - - O
reduced - - O
the - - O
capacity - - O
of - - O
tumor - - O
cells - - O
to - - O
trap - - O
AIB - - O
or - - O
Rb+ - - O
. - - O

Hydropathy - - O
analysis - - O
of - - O
KCC1 - - B-MUT
indicates - - O
structural - - O
homology - - O
to - - O
NKCC - - B-MUT
, - - O
including - - O
12 - - O
transmembrane - - O
domains - - O
, - - O
a - - O
large - - O
extracellular - - O
loop - - O
with - - O
potential - - O
N-linked - - O
glycosylation - - O
sites - - O
, - - O
and - - O
cytoplasmic - - O
N- - - O
and - - O
C-terminal - - O
regions - - O
. - - O

Liver - - O
injuries - - O
. - - O

Furthermore - - O
, - - O
experiments - - O
with - - O
32D - - O
temperature-sensitive - - O
p53 - - B-MUT
cells - - O
indicate - - O
that - - O
aberrant - - O
tal-1 - - B-MUT
expression - - O
at - - O
the - - O
permissive - - O
temperature - - O
does - - O
not - - O
exert - - O
a - - O
proliferative - - O
effect - - O
but - - O
causes - - O
p53-mediated - - O
apoptosis - - O
, - - O
i - - O
. - - O
e - - O
. - - O
, - - O
the - - O
tal-1 - - B-MUT
proliferative - - O
effect - - O
depends - - O
on - - O
the - - O
integrity - - O
of - - O
the - - O
cell - - O
cycle - - O
checkpoints - - O
of - - O
the - - O
host - - O
cell - - O
, - - O
as - - O
observed - - O
for - - O
c-myc - - B-MUT
and - - O
other - - O
oncogenes - - O
. - - O
tal-1 - - B-MUT
mutant - - I-MUT
experiments - - O
indicate - - O
that - - O
ectopic - - O
tal-1 - - B-MUT
effects - - O
are - - O
mediated - - O
by - - O
both - - O
the - - O
DNA-binding - - O
and - - O
the - - O
heterodimerization - - O
domains - - O
, - - O
while - - O
the - - O
N-terminally - - B-MUT
truncated - - I-MUT
tal-1 - - I-MUT
variant - - I-MUT
( - - O
M3 - - B-MUT
) - - O
expressed - - O
in - - O
T-ALL - - O
malignant - - O
cells - - O
mimics - - O
the - - O
effects - - O
of - - O
the - - O
wild-type - - O
protein - - O
. - - O

However - - O
, - - O
each - - O
promoter - - O
activated - - O
by - - O
IEP86 - - B-MUT
was - - O
synergistically - - O
affected - - O
by - - O
the - - O
addition - - O
of - - O
IEP72 - - B-MUT
. - - O

Computer - - O
software - - O
assisted - - O
ordering - - O
( - - O
CSAO - - O
) - - O
was - - O
developed - - O
to - - O
integrate - - O
PN - - O
Ca - - O
: - - O
P - - O
solubility - - O
with - - O
clinical - - O
data - - O
to - - O
improve - - O
parenteral - - O
Ca - - O
and - - O
P - - O
administration - - O
. - - O

In - - O
adulthood - - O
these - - O
rats - - O
were - - O
hyperactive - - O
and - - O
learned - - O
the - - O
active - - O
avoidance - - O
response - - O
later - - O
than - - O
the - - O
controls - - O
. - - O

Activation - - O
of - - O
PKA - - B-MUT
by - - O
8-bromo-cyclic - - O
AMP - - O
or - - O
forskolin - - O
, - - O
and - - O
inhibition - - O
of - - O
PKC - - B-MUT
by - - O
calphostin - - O
C - - O
, - - O
resulted - - O
in - - O
a - - O
significant - - O
decrease - - O
in - - O
3TP - - B-MUT
activity - - O
as - - O
well - - O
as - - O
in - - O
vitro - - O
ERK - - B-MUT
kinase - - I-MUT
activity - - O
in - - O
CRAC - - O
. - - O

When - - O
tested - - O
with - - O
wild-type - - O
( - - O
DBA - - O
2 - - O
) - - O
p16 - - O
, - - B-MUT
both - - O
A134C - - O
and - - O
G232A - - O
BALB - - O
c-specific - - O
variants - - O
of - - O
p16 - - O
were - - O
inefficient - - B-MUT
in - - O
their - - O
ability - - O
to - - O
inhibit - - O
the - - O
activity - - O
of - - O
cyclin - - O
D2 - - O
CDK4 - - B-MUT
in - - I-MUT
kinase - - I-MUT
assays - - I-MUT
with - - O
retinoblastoma - - O
protein - - O
, - - O
suggesting - - B-MUT
this - - I-MUT
defective - - O
, - - O
inherited - - O
allele - - O
plays - - O
an - - O
important - - O
role - - O
in - - O
the - - O
genetic - - O
susceptibility - - O
of - - O
BALB - - O
c - - O
mice - - O
for - - O
plasmacytoma - - O
induction - - O
and - - O
that - - O
p16 - - O
( - - O
INK4a - - O
) - - O
is - - B-MUT
a - - I-MUT
strong - - I-MUT
candidate - - I-MUT
for - - O
the - - O
Pctr1 - - O
locus - - O
. - - O

We - - O
previously - - O
delineated - - O
a - - O
region - - O
in - - O
the - - O
fatty-acid - - B-MUT
synthase - - I-MUT
promoter - - I-MUT
, - - O
which - - O
was - - O
responsible - - O
for - - O
obesity-related - - O
overexpression - - O
of - - O
the - - O
fatty-acid - - B-MUT
synthase - - I-MUT
( - - O
FAS - - B-MUT
) - - O
gene - - O
, - - O
by - - O
negatively - - O
regulating - - O
the - - O
activity - - O
of - - O
the - - O
downstream - - O
promoter - - O
in - - O
lean - - O
but - - O
not - - O
obese - - O
rat - - O
fat - - O
cells - - O
. - - O

DESIGN - - O
: - - O
A - - O
cross-sectional - - O
study - - O
. - - O

Therefore - - O
, - - O
in - - O
a - - O
large - - O
animal - - O
model - - O
of - - O
permanent - - O
focal - - O
ischemia - - O
in - - O
which - - O
transfusion - - O
starts - - O
30 - - O
min - - O
after - - O
ischemia - - O
, - - O
tetrameric - - O
cross-linked - - O
hemoglobin - - B-MUT
transfusion - - O
can - - O
augment - - O
oxygen - - O
transport - - O
to - - O
the - - O
ischemic - - O
cortex - - O
, - - O
but - - O
the - - O
increase - - O
can - - O
be - - O
delayed - - O
and - - O
not - - O
necessarily - - O
provide - - O
protection - - O
. - - O

One - - O
such - - O
element - - O
, - - O
1P - - B-MUT
, - - O
was - - O
employed - - O
to - - O
clone - - O
from - - O
a - - O
rat - - O
pituitary - - O
cDNA - - O
expression - - O
library - - O
a - - O
novel - - O
417-amino - - B-MUT
acid - - I-MUT
WD - - I-MUT
protein - - I-MUT
, - - O
designated - - O
PREB - - B-MUT
( - - I-MUT
PRL - - I-MUT
regulatory - - I-MUT
element - - I-MUT
binding - - I-MUT
) - - I-MUT
protein - - I-MUT
. - - O

Thus - - O
, - - O
a - - O
critical - - O
question - - O
is - - O
how - - O
HOX - - B-MUT
proteins - - I-MUT
select - - O
the - - O
correct - - O
sets - - O
of - - O
target - - O
genes - - O
in - - O
vivo - - O
. - - O

Two - - O
homologues - - O
of - - O
the - - O
rhombotin - - B-MUT
gene - - I-MUT
have - - O
now - - O
been - - O
isolated - - O
. - - O

Thus - - O
, - - O
the - - O
human - - B-MUT
D1A - - I-MUT
gene - - I-MUT
belongs - - O
to - - O
the - - O
category - - O
of - - O
tissue-specific - - O
, - - O
regulated - - O
genes - - O
that - - O
have - - O
housekeeping-type - - O
promoters - - O
. - - O

As - - O
PP2A - - B-MUT
exerts - - O
a - - O
range - - O
of - - O
cellular - - O
functions - - O
including - - O
cell - - O
cycle - - O
regulation - - O
and - - O
cell - - O
fate - - O
determination - - O
, - - O
we - - O
were - - O
surprised - - O
to - - O
find - - O
that - - O
these - - O
embryos - - O
develop - - O
normally - - O
until - - O
postimplantation - - O
, - - O
around - - O
embryonic - - O
day - - O
5 - - O
. - - O
5 - - O
6 - - O
. - - O
0 - - O
. - - O

The - - O
femoral - - O
artery - - O
vein - - O
and - - O
the - - O
soleus - - O
and - - O
gastrocnemius - - O
muscles - - O
were - - O
examined - - O
in - - O
healthy - - O
human - - O
male - - O
volunteers - - O
. - - O

We - - O
also - - O
show - - O
that - - O
zygotically - - O
activated - - O
Xretpos - - O
transcripts - - O
are - - O
restricted - - O
to - - O
ventro-posterior - - O
specific - - O
regions - - O
and - - O
induced - - O
by - - O
UV-irradiation - - O
and - - O
BMP-4 - - B-MUT
overexpression - - O
in - - O
cycloheximide-dependent - - O
way - - O
. - - O
genesis - - O
26 - - O
: - - O
198-207 - - O
, - - O
2000 - - O
. - - O

All - - O
runners - - O
drank - - O
a - - O
total - - O
of - - O
1 - - O
. - - O
4 - - O
L - - O
of - - O
water - - O
during - - O
the - - O
race - - O
. - - O

An - - O
abundant - - O
1 - - O
. - - O
1-kb - - O
virion-sense - - O
polyadenylated - - O
RNA - - O
and - - O
four - - O
complementary-sense - - O
polyadenylated - - O
RNAs - - O
of - - O
1 - - O
. - - O
7 - - O
, - - O
1 - - O
. - - O
5 - - O
, - - O
1 - - O
. - - O
3 - - O
, - - O
and - - O
0 - - O
. - - O
7 - - O
kb - - O
have - - O
been - - O
identified - - O
by - - O
northern - - O
blot - - O
hybridization - - O
, - - O
confirming - - O
the - - O
bidirectional - - O
transcription - - O
strategy - - O
implied - - O
by - - O
the - - O
arrangement - - O
of - - O
ORFs - - O
. - - O

A - - O
case - - O
of - - O
manifest - - O
latent - - O
nystagmus - - O
of - - O
late - - O
onset - - O
in - - O
a - - O
13-year-old - - O
girl - - O
is - - O
reported - - O
. - - O

Tightly - - O
ordered - - O
proteasomal - - O
degradation - - O
of - - O
proteins - - O
critical - - O
for - - O
cell - - O
cycle - - O
control - - O
implies - - O
a - - O
role - - O
of - - O
the - - O
proteasome - - O
in - - O
maintaining - - O
cell - - O
proliferation - - O
and - - O
cell - - O
survival - - O
. - - O

We - - O
found - - O
in - - O
the - - O
control - - O
subjects - - O
rCBF - - O
increases - - O
in - - O
regions - - O
associated - - O
with - - O
the - - O
meso-striatal - - O
and - - O
meso-corticolimbic - - O
circuits - - O
in - - O
response - - O
to - - O
both - - O
monetary - - O
reward - - O
and - - O
nonmonetary - - O
reinforcement - - O
. - - O

The - - O
TA - - O
muscle - - O
was - - O
fatigued - - O
by - - O
four - - O
forms - - O
of - - O
repeated - - O
isometric - - O
contractions - - O
: - - O
( - - O
1 - - O
) - - O
maximal - - O
voluntary - - O
contractions - - O
( - - O
MVC - - O
) - - O
, - - O
( - - O
2 - - O
) - - O
MVC - - O
with - - O
circulation - - O
occluded - - O
, - - O
( - - O
3 - - O
) - - O
electrically - - O
evoked - - O
contractions - - O
with - - O
20 - - O
Hz - - O
supramaximal - - O
voltage - - O
stimulation - - O
and - - O
( - - O
4 - - O
) - - O
electrically - - O
evoked - - O
contractions - - O
with - - O
circulation - - O
occluded - - O
. - - O

Growth - - O
of - - O
tracheal - - O
anastomoses - - O
in - - O
growing - - O
animals - - O
. - - O

The - - O
human - - O
immunodeficiency - - O
virus - - O
type - - O
1 - - O
( - - O
HIV-1 - - O
) - - O
preferentially - - O
infects - - O
CD4+ - - B-MUT
T - - O
lymphocytes - - O
and - - O
may - - O
exist - - O
as - - O
a - - O
latent - - O
provirus - - O
within - - O
these - - O
cells - - O
for - - O
extended - - O
periods - - O
. - - O

However - - O
, - - O
it - - O
is - - O
only - - O
one-half - - O
and - - O
one-third - - O
the - - O
size - - O
of - - O
the - - O
proteolipids - - O
from - - O
M - - O
. - - O
thermoautotrophicum - - O
and - - O
M - - O
. - - O
jannaschii - - O
, - - O
respectively - - O
. - - O
ahaK - - B-MUT
is - - O
expressed - - O
in - - O
Escherichia - - O
coli - - O
, - - O
and - - O
it - - O
is - - O
incorporated - - O
into - - O
the - - O
cytoplasmic - - O
membrane - - O
despite - - O
the - - O
different - - O
chemical - - O
natures - - O
of - - O
lipids - - O
from - - O
archaea - - O
and - - O
bacteria - - O
. - - O

Calves - - O
fed - - O
MCT-milk - - O
had - - O
significantly - - O
lower - - O
blood - - O
cholesterol - - O
than - - O
calves - - O
fed - - O
T- - - O
or - - O
SBO-milk - - O
. - - O

It - - O
is - - O
mainly - - O
transcribed - - O
in - - O
neural - - O
structures - - O
and - - O
in - - O
developing - - O
organs - - O
characterized - - O
by - - O
epithelial-mesenchymal - - O
interactions - - O
. - - O

Although - - O
the - - O
extracellular - - O
domain - - O
of - - O
the - - O
TSH-R - - B-MUT
is - - O
sufficient - - O
for - - O
high - - O
affinity - - O
binding - - O
of - - O
TSH - - B-MUT
, - - O
we - - O
conclude - - O
that - - O
the - - O
hyt - - O
mutation - - O
in - - O
the - - O
fourth - - O
transmembrane - - O
domain - - O
eliminates - - O
TSH - - B-MUT
binding - - O
. - - O

Pseudomonas - - O
aeruginosa - - O
strains - - O
infecting - - O
patients - - O
with - - O
cystic - - O
fibrosis - - O
( - - O
CF - - O
) - - O
acquire - - O
a - - O
mucoid - - O
phenotype - - O
due - - O
to - - O
overproduction - - O
of - - O
alginate - - O
. - - O

All - - O
the - - O
women - - O
received - - O
13 - - O
. - - O
5 - - O
mg - - O
plain - - O
bupivacaine - - O
via - - O
subarachnoid - - O
injection - - O
at - - O
the - - O
L2-3 - - O
interspace - - O
. - - O

The - - O
level - - O
of - - O
subclinical - - O
infection - - O
was - - O
75% - - O
among - - O
seropositive - - O
dogs - - O
. - - O

The - - O
susceptibility - - O
of - - O
the - - O
PPNG - - O
strains - - O
to - - O
clinically - - O
relevant - - O
antibiotics - - O
varied - - O
with - - O
the - - O
plasmid - - O
pattern - - O
; - - O
this - - O
stresses - - O
the - - O
necessity - - O
of - - O
permanent - - O
surveillance - - O
of - - O
gonococcal - - O
infections - - O
and - - O
of - - O
regular - - O
evaluation - - O
of - - O
the - - O
recommendations - - O
for - - O
antimicrobial - - O
treatment - - O
. - - O

Benztropine - - O
for - - O
venlafaxine-induced - - O
night - - O
sweats - - O
. - - O

( - - O
1992 - - O
) - - O
Genomics - - O
12 - - O
, - - O
58-62 - - O
) - - O
. - - O

The - - O
future - - O
of - - O
research - - O
with - - O
interferon - - B-MUT
may - - O
be - - O
divided - - O
into - - O
three - - O
areas - - O
: - - O
Efforts - - O
must - - O
be - - O
made - - O
to - - O
determine - - O
how - - O
best - - O
to - - O
translate - - O
the - - O
in - - O
vitro - - O
synergy - - O
into - - O
clinically - - O
meaningful - - O
terms - - O
; - - O
in - - O
order - - O
to - - O
exploit - - O
the - - O
fullest - - O
potential - - O
of - - O
IFN - - B-MUT
, - - O
research - - O
is - - O
moving - - O
toward - - O
using - - O
this - - O
agent - - O
earlier - - O
in - - O
disease - - O
either - - O
as - - O
an - - O
adjuvant - - O
after - - O
tumor - - O
debulking - - O
or - - O
after - - O
initial - - O
diagnosis - - O
; - - O
the - - O
medical - - O
community - - O
must - - O
rethink - - O
the - - O
natural - - O
history - - O
of - - O
some - - O
diseases - - O
, - - O
because - - O
the - - O
fullest - - O
potential - - O
of - - O
the - - O
biologic - - O
agents - - O
will - - O
most - - O
likely - - O
manifest - - O
itself - - O
when - - O
these - - O
agents - - O
are - - O
used - - O
together - - O
. - - O

Proteasomes - - B-MUT
are - - O
the - - O
multisubunit - - O
protease - - B-MUT
involved - - O
in - - O
the - - O
generation - - O
of - - O
peptides - - O
presented - - O
by - - O
MHC - - B-MUT
class - - I-MUT
I - - I-MUT
molecules - - I-MUT
. - - O

Degenerate - - O
primers - - O
homologous - - O
to - - O
highly - - O
conserved - - O
regions - - O
of - - O
known - - O
CYP3A - - B-MUT
sequences - - I-MUT
were - - O
used - - O
for - - O
initial - - O
RT-PCRs - - O
. - - O

IFN-gamma - - B-MUT
was - - O
elevated - - O
during - - O
active - - O
TB - - O
when - - O
compared - - O
with - - O
healthy - - O
controls - - O
, - - O
declining - - O
during - - O
and - - O
after - - O
treatment - - O
. - - O

Within - - O
the - - O
human - - O
enhancer - - O
, - - O
these - - O
two - - O
sites - - O
are - - O
located - - O
within - - O
the - - O
previously - - O
defined - - O
DNase - - B-MUT
I - - I-MUT
footprints - - I-MUT
, - - O
NFAT-1 - - B-MUT
and - - O
NFIL-2B - - B-MUT
, - - O
respectively - - O
. - - O

Analysis - - O
of - - O
SRE - - O
oligonucleotide - - O
gel - - O
mobility - - O
shift - - O
assays - - O
with - - O
nuclear - - O
extracts - - O
from - - O
Sertoli - - O
cells - - O
demonstrated - - O
the - - O
presence - - O
of - - O
both - - O
the - - O
SRF - - B-MUT
and - - O
the - - O
ubiquitously - - O
expressed - - O
bHLH - - B-MUT
protein - - I-MUT
E12 - - B-MUT
E47 - - I-MUT
. - - I-MUT

These - - O
results - - O
lead - - O
us - - O
to - - O
hypothesize - - O
that - - O
a - - O
single - - O
multisubunit - - B-MUT
TFIID - - I-MUT
protein - - I-MUT
supports - - O
transcriptional - - O
stimulation - - O
by - - O
diverse - - O
activation - - O
domains - - O
and - - O
from - - O
a - - O
TATA-less - - O
promoter - - O
. - - O

Tumor - - O
stages - - O
were - - O
IIB - - O
( - - O
T3 - - O
N0 - - O
) - - O
in - - O
52% - - O
, - - O
IIIA - - O
in - - O
15% - - O
, - - O
and - - O
IIIB - - O
in - - O
27% - - O
of - - O
patients - - O
. - - O

The - - O
ZnF20 - - B-MUT
cDNA - - I-MUT
hybridized - - O
to - - O
multiple - - O
transcripts - - O
in - - O
a - - O
thyroid - - O
cancer - - O
cell - - O
line - - O
( - - O
8 - - O
. - - O
0 - - O
, - - O
4 - - O
. - - O
5 - - O
and - - O
2 - - O
kb - - O
) - - O
that - - O
increased - - O
after - - O
cycloheximide - - O
treatment - - O
and - - O
decayed - - O
< - - O
2 - - O
h - - O
after - - O
addition - - O
of - - O
actinomycin - - O
D - - O
. - - O

This - - O
fragment - - O
contained - - O
the - - O
C-terminal - - O
47 - - O
nucleotides - - O
of - - O
leuB - - B-MUT
, - - O
encoding - - O
3-isopropylmalate - - B-MUT
dehydrogenase - - I-MUT
; - - O
asd - - B-MUT
, - - O
encoding - - O
aspartate-beta-semialdehyde - - B-MUT
dehydrogenase - - I-MUT
( - - O
Asd - - B-MUT
) - - O
; - - O
and - - O
orfA - - O
, - - O
whose - - O
product - - O
showed - - O
similarity - - O
to - - O
the - - O
Asd - - B-MUT
proteins - - I-MUT
from - - I-MUT
Vibrio - - I-MUT
spp - - I-MUT
. - - O

Sp1 - - B-MUT
can - - O
activate - - O
transcription - - O
through - - O
immunoglobulin - - B-MUT
kappa-chain - - I-MUT
enhancer - - I-MUT
or - - O
P-selectin - - B-MUT
promoter - - I-MUT
NF-kappaB - - B-MUT
sites - - I-MUT
. - - O
p50 - - B-MUT
homodimers - - I-MUT
replace - - O
Sp1 - - B-MUT
from - - O
the - - O
P-selectin - - B-MUT
promoter - - I-MUT
by - - O
binding - - O
site - - O
competition - - O
and - - O
thereby - - O
either - - O
inhibit - - O
basal - - O
Sp1-driven - - O
expression - - O
or - - O
, - - O
in - - O
concert - - O
with - - O
Bcl-3 - - B-MUT
, - - O
stimulate - - O
expression - - O
. - - O

Results - - O
of - - O
two-hybrid - - O
assays - - O
and - - O
electrophoretic - - O
mobility - - O
shift - - O
assays - - O
strongly - - O
suggest - - O
that - - O
all - - O
HD-Zip - - B-MUT
proteins - - I-MUT
of - - O
families - - O
I - - O
and - - O
II - - O
can - - O
form - - O
homodimers - - O
and - - O
also - - O
heterodimers - - O
with - - O
all - - O
HD-Zip - - B-MUT
proteins - - I-MUT
of - - O
the - - O
same - - O
family - - O
. - - O

Nine - - O
new - - O
naphthalene - - O
related - - O
compounds - - O
( - - O
I - - O
, - - O
IV - - O
, - - O
V - - O
, - - O
VII-XII - - O
) - - O
together - - O
with - - O
four - - O
known - - O
compounds - - O
( - - O
II - - O
, - - O
III - - O
, - - O
VI - - O
, - - O
XIII - - O
) - - O
were - - O
isolated - - O
from - - O
the - - O
root - - O
bark - - O
of - - O
Oroxylum - - O
indicum - - O
Vent - - O
. - - O

Simian - - O
immunodeficiency - - O
virus - - O
( - - O
SIV - - O
) - - O
is - - O
a - - O
lentivirus - - O
with - - O
morphological - - O
and - - O
antigenic - - O
similarities - - O
to - - O
human - - O
immunodeficiency - - O
virus - - O
, - - O
the - - O
causative - - O
agent - - O
of - - O
acquired - - O
immunodeficiency - - O
syndrome - - O
( - - O
AIDS - - O
) - - O
of - - O
humans - - O
. - - O

This - - O
sequence - - O
possessed - - O
homology - - O
with - - O
a - - O
methylation-sensitive - - O
promoter - - O
element - - O
, - - O
Enh2 - - B-MUT
, - - O
present - - O
in - - O
the - - O
LTR - - O
of - - O
mouse - - O
intractisternal - - O
A-particles - - O
. - - O

The - - O
p36 - - B-MUT
gene - - I-MUT
is - - O
at - - O
least - - O
22 - - O
kb - - O
in - - O
length - - O
and - - O
has - - O
a - - O
coding - - O
sequence - - O
of - - O
approximately - - O
1 - - O
kb - - O
, - - O
representing - - O
only - - O
4 - - O
. - - O
5% - - O
of - - O
the - - O
gene - - O
. - - O
( - - O
ABSTRACT - - O
TRUNCATED - - O
AT - - O
250 - - O
WORDS - - O
) - - O

Members - - O
of - - O
the - - O
mitogen - - B-MUT
activated - - I-MUT
protein - - I-MUT
( - - I-MUT
MAP - - I-MUT
) - - I-MUT
kinase - - I-MUT
family - - I-MUT
, - - O
extracellular - - B-MUT
signal-regulated - - I-MUT
kinase - - I-MUT
, - - O
stress-activated - - B-MUT
protein - - I-MUT
kinase-1 - - I-MUT
c-Jun - - I-MUT
NH2-terminal - - I-MUT
kinase - - I-MUT
, - - I-MUT
and - - O
p38 - - O
, - - B-MUT
are - - O
central - - O
elements - - O
that - - O
transduce - - O
the - - O
signal - - O
generated - - O
by - - O
growth - - O
factors - - B-MUT
, - - I-MUT
cytokines - - O
, - - O
and - - O
stressing - - O
agents - - O
. - - O

To - - O
assess - - O
the - - O
function - - O
( - - O
s - - O
) - - O
of - - O
E74 - - B-MUT
during - - O
metamorphosis - - O
, - - O
we - - O
have - - O
isolated - - O
and - - O
characterized - - O
recessive - - O
loss-of-function - - O
mutations - - O
specific - - O
to - - O
each - - O
transcription - - O
unit - - O
. - - O

Fifty-four - - O
patients - - O
were - - O
divided - - O
into - - O
groups - - O
according - - O
to - - O
their - - O
clinical - - O
presentation - - O
; - - O
seven - - O
asymptomatic - - O
volunteers - - O
, - - O
20 - - O
patients - - O
with - - O
duodenal-gastric - - O
reflux - - O
gastropathy - - O
( - - O
DRG - - O
) - - O
, - - O
16 - - O
patients - - O
with - - O
recurrent - - O
ulcers - - O
of - - O
the - - O
duodenal - - O
bulb - - O
( - - O
RUD - - O
) - - O
, - - O
and - - O
11 - - O
patients - - O
with - - O
Moynihan's - - O
disease - - O
. - - O

If - - O
this - - O
is - - O
unavailable - - O
, - - O
then - - O
Supramid - - O
has - - O
a - - O
proven - - O
record - - O
for - - O
good - - O
tissue - - O
compatibility - - O
and - - O
resistance - - O
to - - O
infection - - O
. - - O

Recently - - O
, - - O
our - - O
laboratory - - O
developed - - O
a - - O
screen - - O
that - - O
identified - - O
five - - O
multicopy - - O
suppressors - - O
that - - O
can - - O
rescue - - O
lethal - - O
strains - - O
of - - O
clathrin - - B-MUT
heavy - - O
chain-deficient - - O
yeast - - O
( - - O
Chc - - B-MUT
- - - I-MUT
scd1-i - - I-MUT
) - - O
to - - O
viability - - O
. - - O

In - - O
19 - - O
patients - - O
vagotomy - - O
not - - O
only - - O
curbed - - O
the - - O
bleeding - - O
but - - O
provided - - O
definitive - - O
therapy - - O
( - - O
Visick - - O
I-II - - O
) - - O
; - - O
4 - - O
patients - - O
died - - O
( - - O
mortality - - O
rate - - O
16% - - O
) - - O
. - - O

Saunders - - O
Company - - O
. - - O

Cytokine-induced - - O
NF-kappa - - B-MUT
B - - I-MUT
DNA - - O
binding - - O
activity - - O
, - - O
RelA - - B-MUT
nuclear - - O
translocation - - O
, - - O
I - - B-MUT
kappa - - I-MUT
B - - I-MUT
alpha - - I-MUT
degradation - - O
, - - O
I - - B-MUT
kappa - - I-MUT
B - - I-MUT
serine - - O
32 - - O
phosphorylation - - O
, - - O
and - - O
I - - B-MUT
kappa - - I-MUT
B - - I-MUT
kinase - - I-MUT
( - - O
IKK - - B-MUT
) - - O
activity - - O
were - - O
blocked - - O
by - - O
curcumin - - O
treatment - - O
. - - O

HPLC - - O
phosphopeptide - - O
mapping - - O
, - - O
amino - - O
acid - - O
sequencing - - O
, - - O
and - - O
site-directed - - O
mutagenesis - - O
determined - - O
that - - O
NCLK - - B-MUT
phosphorylates - - O
Ser - - O
( - - O
67 - - O
) - - O
of - - O
I-1 - - B-MUT
. - - O

Identification - - O
of - - O
a - - O
consensus - - O
cyclin-dependent - - B-MUT
kinase - - I-MUT
phosphorylation - - I-MUT
site - - I-MUT
unique - - O
to - - O
the - - O
nuclear - - O
form - - O
of - - O
human - - B-MUT
deoxyuridine - - I-MUT
triphosphate - - I-MUT
nucleotidohydrolase - - I-MUT
. - - O

OBJECTIVES - - O
: - - O
To - - O
assess - - O
the - - O
ability - - O
of - - O
pretreatment - - O
and - - O
post-treatment - - O
prostate-specific - - B-MUT
antigen - - I-MUT
( - - O
PSA - - B-MUT
) - - O
measurements - - O
, - - O
clinical - - O
tumor - - O
stage - - O
, - - O
tumor - - O
grade - - O
, - - O
Gleason - - O
sum - - O
, - - O
race - - O
, - - O
age - - O
, - - O
and - - O
radiation - - O
dose - - O
to - - O
predict - - O
the - - O
recurrence - - O
of - - O
prostate - - O
cancer - - O
following - - O
external - - O
beam - - O
radiation - - O
therapy - - O
( - - O
XRT - - O
) - - O
since - - O
the - - O
introduction - - O
of - - O
PSA - - B-MUT
as - - O
a - - O
tumor - - O
marker - - O
at - - O
one - - O
tertiary - - O
care - - O
center - - O
. - - O

Taken - - O
together - - O
, - - O
our - - O
data - - O
indicate - - O
that - - O
multiple - - O
survival - - O
pathways - - O
are - - O
triggered - - O
via - - O
this - - O
receptor - - O
, - - O
whereas - - O
NF-kappaB - - B-MUT
Rel - - O
and - - B-MUT
PI-3K - - O
are - - B-MUT
crucial - - O
for - - O
CD40-induced - - O
proliferation - - O
. - - O

The - - O
activity - - O
of - - O
Rac1 - - B-MUT
leads - - O
to - - O
STAT3 - - B-MUT
translocation - - O
to - - O
the - - O
nucleus - - O
coincident - - O
with - - O
STAT3-dependent - - O
gene - - O
expression - - O
. - - O

In - - O
vivo - - O
dimethyl - - O
sulfate - - O
footprinting - - O
of - - O
the - - O
cyclin - - B-MUT
E - - I-MUT
promoter - - I-MUT
revealed - - O
several - - O
regions - - O
of - - O
protection - - O
and - - O
hypersensitivity - - O
that - - O
were - - O
unique - - O
to - - O
infected - - O
cells - - O
. - - O

Prognostic - - O
value - - O
of - - O
a - - O
treadmill - - O
exercise - - O
score - - O
in - - O
symptomatic - - O
patients - - O
with - - O
nonspecific - - O
ST-T - - O
abnormalities - - O
on - - O
resting - - O
ECG - - O
. - - O

Nonvascular - - O
ophthalmic - - O
and - - O
neurologic - - O
disorders - - O
that - - O
can - - O
be - - O
confused - - O
with - - O
amaurosis - - O
fugax - - O
are - - O
listed - - O
, - - O
and - - O
an - - O
algorithm - - O
for - - O
evaluation - - O
( - - O
which - - O
includes - - O
ophthalmic - - O
examination - - O
, - - O
laboratory - - O
studies - - O
, - - O
and - - O
noninvasive - - O
carotid - - O
artery - - O
studies - - O
) - - O
is - - O
given - - O
. - - O

OND - - O
8 - - O
mg - - O
tid - - O
days - - O
2-3 - - O
, - - O
and - - O
8 - - O
mg - - O
tid - - O
prn - - O
days - - O
4-5 - - O
and - - O
prednisolone - - O
75-100 - - O
mg - - O
qds - - O
days - - O
2-5 - - O
and - - O
2 - - O
) - - O
MCP - - O
30 - - O
mg - - O
metylprednisolone - - O
80 - - O
mg - - O
i - - O
. - - O
v - - O
. - - O
before - - O
CT - - O
and - - O
MCP - - O
20 - - O
mg - - O
p - - O
. - - O
r - - O
. - - O
after - - O
4 - - O
and - - O
8 - - O
h - - O
respectively - - O
. - - O

Aspirin - - O
intolerance - - O
: - - O
unaltered - - O
susceptibility - - O
of - - O
platelet - - B-MUT
cyclo-oxygenase - - I-MUT
to - - O
inhibition - - O
by - - O
aspirin - - O
in - - O
vitro - - O
. - - O

The - - O
second - - O
group - - O
of - - O
homologous - - O
elements - - O
is - - O
present - - O
in - - O
the - - O
upstream - - O
region - - O
of - - O
both - - O
genes - - O
. - - O

In - - O
SN-48 - - O
neuronal - - O
cells - - O
that - - O
express - - O
MR - - B-MUT
, - - O
GR - - B-MUT
, - - O
and - - O
5-HT1A - - B-MUT
receptors - - I-MUT
, - - O
deletion - - O
or - - O
inactivation - - O
of - - O
the - - O
nGRE - - B-MUT
( - - O
negative - - B-MUT
GRE - - I-MUT
) - - O
eliminated - - O
negative - - O
regulation - - O
of - - O
the - - O
rat - - B-MUT
5-HT1A - - I-MUT
or - - O
heterologous - - O
promoters - - O
by - - O
corticosteroids - - O
, - - O
whereas - - O
its - - O
inclusion - - O
conferred - - O
corticosteroid-induced - - O
inhibition - - O
to - - O
a - - O
heterologous - - O
promoter - - O
. - - O

To - - O
evaluate - - O
the - - O
cost - - O
and - - O
benefits - - O
of - - O
screening - - O
tests - - O
for - - O
Chlamydia - - O
trachomatis - - O
in - - O
adolescent - - O
males - - O
, - - O
we - - O
developed - - O
a - - O
decision - - O
analysis - - O
model - - O
and - - O
compared - - O
the - - O
leukocyte - - B-MUT
esterase - - I-MUT
urine - - O
dipstick - - O
test - - O
with - - O
culture - - O
, - - O
with - - O
direct-smear - - O
fluorescent - - O
antibody - - O
( - - O
DFA - - O
) - - O
, - - O
and - - O
with - - O
the - - O
option - - O
of - - O
no - - O
screening - - O
( - - O
no - - O
treatment - - O
) - - O
. - - O

No - - O
hypotension - - O
was - - O
noted - - O
in - - O
patients - - O
with - - O
toxemia - - O
and - - O
only - - O
2 - - O
ran - - O
a - - O
fever - - O
above - - O
37 - - O
. - - O
5 - - O
degrees - - O
C - - O
. - - O

Initial - - O
screening - - O
of - - O
a - - O
rat - - O
liver - - O
cDNA - - O
library - - O
with - - O
an - - O
oligonucleotide - - O
probe - - O
derived - - O
from - - O
the - - O
rat - - O
SCP2 - - B-MUT
protein - - O
sequence - - O
revealed - - O
an - - O
825-base - - O
pair - - O
cDNA - - O
clone - - O
coding - - O
for - - O
the - - O
complete - - O
SCP2 - - B-MUT
protein - - O
sequence - - O
. - - O

It - - O
seems - - O
that - - O
the - - O
way - - O
in - - O
which - - O
drugs - - O
modify - - O
a - - O
patient's - - O
serum - - O
chemistry - - O
may - - O
be - - O
used - - O
to - - O
assess - - O
the - - O
efficacy - - O
with - - O
which - - O
they - - O
control - - O
the - - O
inflammatory - - O
process - - O
. - - O

Two - - O
experiments - - O
( - - O
N - - O
= - - O
20 - - O
each - - O
) - - O
were - - O
carried - - O
out - - O
to - - O
explore - - O
the - - O
nature - - O
of - - O
ERP - - O
negativities - - O
in - - O
a - - O
visuospatial - - O
memory - - O
task - - O
and - - O
in - - O
an - - O
auditory - - O
spatial - - O
memory - - O
task - - O
, - - O
respectively - - O
. - - O

A - - O
coiled-coil - - O
related - - O
protein - - O
specific - - O
for - - O
synapsed - - O
regions - - O
of - - O
meiotic - - O
prophase - - O
chromosomes - - O
. - - O

The - - O
COOH-terminus - - O
of - - O
this - - O
new - - O
isoform - - O
, - - O
which - - O
we - - O
designate - - O
beta - - B-MUT
4 - - I-MUT
, - - O
lacks - - O
a - - O
22 - - O
amino - - O
acid - - O
lysine-rich - - O
sequence - - O
common - - O
to - - O
both - - O
the - - O
human - - B-MUT
red - - I-MUT
cell - - I-MUT
alpha- - - I-MUT
and - - I-MUT
beta-adducin - - I-MUT
subunits - - I-MUT
and - - O
homologous - - O
to - - O
a - - O
highly - - O
conserved - - O
region - - O
in - - O
MARCKS - - B-MUT
, - - O
a - - O
filamentous - - O
actin-cross - - O
linking - - O
protein - - O
regulated - - O
by - - O
protein - - B-MUT
kinase - - I-MUT
C - - I-MUT
and - - O
calcium - - O
calmodulin - - O
. - - O
beta - - O
4-adducin - - B-MUT
preserves - - I-MUT
a - - O
previously - - O
identified - - O
calmodulin - - O
binding - - B-MUT
domain - - I-MUT
. - - I-MUT

Lack - - O
of - - O
sufficient - - O
data - - O
on - - O
vibration - - O
measurements - - O
and - - O
employment - - O
durations - - O
add - - O
to - - O
the - - O
uncertainty - - O
, - - O
as - - O
do - - O
variations - - O
in - - O
tool - - O
conditions - - O
( - - O
grinder - - O
wheels - - O
, - - O
etc - - O
) - - O
and - - O
inherent - - O
difficulties - - O
in - - O
measurement - - O
. - - O

These - - O
results - - O
suggest - - O
that - - O
Thr115 - - O
may - - O
play - - O
an - - O
important - - O
role - - O
in - - O
the - - O
regulation - - O
of - - O
MyoD - - B-MUT
function - - O
under - - O
conditions - - O
of - - O
high - - O
mitogenesis - - O
. - - O

To - - O
determine - - O
whether - - O
vanadate - - O
could - - O
inhibit - - O
PEPCK - - B-MUT
gene - - I-MUT
transcription - - O
, - - O
a - - O
series - - O
of - - O
chimeric - - O
genes - - O
containing - - O
several - - O
deletions - - O
in - - O
the - - O
P-enolypyruvate - - B-MUT
carboxykinase - - I-MUT
promoter - - I-MUT
between - - O
-550 - - O
and - - O
-68 - - O
was - - O
linked - - O
to - - O
the - - O
structural - - O
genes - - O
for - - O
either - - O
amino-3-glycosyl - - B-MUT
phosphotransferase - - I-MUT
( - - O
neo - - B-MUT
) - - O
or - - O
chloramphenicol - - B-MUT
acetyltransferase - - I-MUT
and - - O
introduced - - O
into - - O
hepatoma - - O
cells - - O
using - - O
three - - O
methods - - O
: - - O
( - - O
a - - O
) - - O
infection - - O
with - - O
a - - O
Moloney - - O
murine - - O
leukemia - - O
virus-based - - O
retrovirus - - O
, - - O
( - - O
b - - O
) - - O
transfection - - O
and - - O
stable - - O
selection - - O
for - - O
neo - - O
expression - - O
, - - O
or - - O
( - - O
c - - O
) - - O
transient - - O
expression - - O
of - - O
chloroamphenicol - - B-MUT
acetyltransferase - - I-MUT
. - - O

Peptide - - O
sequences - - O
of - - O
the - - O
zinc - - B-MUT
finger - - I-MUT
protein - - I-MUT
Ttk - - I-MUT
and - - O
the - - O
transcription - - B-MUT
factor - - I-MUT
Adf-1 - - I-MUT
were - - O
obtained - - O
. - - O

Endoscopic - - O
examinations - - O
, - - O
peripheral - - O
white - - O
blood - - O
cell - - O
( - - O
WBC - - O
) - - O
counts - - O
, - - O
and - - O
assays - - O
of - - O
myeloperoxidase - - B-MUT
activity - - O
( - - O
MPO - - B-MUT
) - - O
in - - O
homogenates - - O
of - - O
colon - - O
mucosa - - O
were - - O
performed - - O
after - - O
one - - O
week - - O
( - - O
4% - - O
DSS - - O
model - - O
) - - O
and - - O
eight - - O
weeks - - O
( - - O
1% - - O
DSS - - O
model - - O
) - - O
. - - O

Both - - O
resting - - O
blood - - O
flow - - O
( - - O
RBF - - O
) - - O
and - - O
maximal - - O
blood - - O
flow - - O
( - - O
NBF - - O
) - - O
were - - O
studied - - O
by - - O
Xenon - - O
133 - - O
clearance - - O
. - - O

INO2 - - B-MUT
, - - O
a - - O
regulatory - - O
gene - - O
in - - O
yeast - - O
phospholipid - - O
biosynthesis - - O
, - - O
affects - - O
nuclear - - O
segregation - - O
and - - O
bud - - O
pattern - - O
formation - - O
. - - O

We - - O
established - - O
that - - O
the - - O
2 - - B-MUT
. - - I-MUT
6 - - I-MUT
kb - - I-MUT
mRNA - - I-MUT
V-1 - - I-MUT
and - - O
the - - O
2 - - B-MUT
. - - I-MUT
3 - - I-MUT
kb - - I-MUT
GGT - - I-MUT
mRNA - - I-MUT
V-2 - - I-MUT
derive - - O
, - - O
by - - O
alternate - - O
splicing - - O
, - - O
from - - O
a - - O
primary - - O
transcript - - O
initiated - - O
on - - O
a - - O
distal - - O
promoter - - O
on - - O
the - - O
rat - - B-MUT
GGT - - I-MUT
gene - - I-MUT
. - - O

Pulmonary - - O
hypertension - - O
, - - O
with - - O
or - - O
without - - O
coronary - - O
arterial - - O
narrowing - - O
, - - O
is - - O
the - - O
major - - O
condition - - O
leading - - O
to - - O
isolated - - O
atrial - - O
infarction - - O
. - - O

Citrate - - B-MUT
synthase - - I-MUT
activity - - O
was - - O
increased - - O
in - - O
the - - O
medial - - O
head - - O
( - - O
81% - - O
, - - O
P - - O
< - - O
0 - - O
. - - O
001 - - O
) - - O
and - - O
the - - O
red - - O
long - - O
head - - O
( - - O
88% - - O
, - - O
P - - O
< - - O
0 - - O
. - - O
001 - - O
) - - O
of - - O
the - - O
triceps - - O
brachii - - O
muscle - - O
in - - O
R - - O
rats - - O
but - - O
not - - O
in - - O
the - - O
white - - O
long - - O
head - - O
( - - O
25% - - O
, - - O
P - - O
= - - O
0 - - O
. - - O
06 - - O
) - - O
. - - O

These - - O
results - - O
suggest - - O
that - - O
mitochondrial - - O
presequences - - O
interact - - O
with - - O
the - - O
mt-hsp70 - - B-MUT
during - - O
or - - O
after - - O
mitochondrial - - O
protein - - O
import - - O
. - - O

METHODS - - O
AND - - O
RESULTS - - O
: - - O
In - - O
25 - - O
open-chest - - O
, - - O
anesthetized - - O
dogs - - O
, - - O
progressive - - O
circumflex - - O
artery - - O
stenosis - - O
led - - O
to - - O
a - - O
concordant - - O
decrease - - O
of - - O
circumflex - - O
artery - - O
resting - - O
and - - O
hyperemic - - O
flow - - O
, - - O
coronary - - O
flow - - O
reserve - - O
, - - O
and - - O
inverse - - O
angiographic - - O
mean - - O
transit - - O
time - - O
Tmicro-1 - - O
( - - O
P - - O
< - - O
. - - O
01 - - O
) - - O
. - - O

Conversely - - O
, - - O
the - - O
central - - O
regions - - O
are - - O
highly - - O
variable - - O
. - - O

In - - O
an - - O
attempt - - O
to - - O
understand - - O
Wee1 - - B-MUT
regulation - - O
during - - O
cell - - O
cycle - - O
, - - O
yeast - - O
two-hybrid - - O
screening - - O
was - - O
used - - O
to - - O
identify - - O
Wee1-binding - - B-MUT
protein - - I-MUT
( - - I-MUT
s - - I-MUT
) - - I-MUT
. - - O

Alternatively - - O
, - - O
the - - O
similarity - - O
in - - O
apparent - - O
regulatory - - O
action - - O
of - - O
the - - O
genes - - O
may - - O
indicate - - O
allelic - - O
differences - - O
wherein - - O
the - - O
IS1112C - - B-MUT
Rf3 - - B-MUT
allele - - I-MUT
may - - O
differ - - O
from - - O
alleles - - O
of - - O
maintainer - - O
lines - - O
by - - O
the - - O
capability - - O
to - - O
regulate - - O
both - - O
orf107 - - B-MUT
and - - O
urf209 - - B-MUT
processing - - O
activities - - O
. - - O

This - - O
philosophy - - O
was - - O
instituted - - O
for - - O
the - - O
compound - - O
RP - - O
73401 - - O
, - - O
a - - O
specific - - O
phosphodiesterase - - B-MUT
IV - - I-MUT
inhibitor - - O
, - - O
that - - O
was - - O
being - - O
developed - - O
simultaneously - - O
for - - O
delivery - - O
by - - O
both - - O
oral - - O
and - - O
pulmonary - - O
routes - - O
of - - O
administration - - O
. - - O

We - - O
have - - O
previously - - O
demonstrated - - O
that - - O
expression - - O
of - - O
the - - O
gene - - O
for - - O
the - - O
reproductive - - O
neuropeptide - - O
, - - O
GnRH - - B-MUT
, - - O
is - - O
repressed - - O
by - - O
the - - O
glutamate - - O
NO - - O
cyclic - - O
GMP - - O
( - - O
cGMP - - O
) - - O
signal - - O
transduction - - O
pathway - - O
through - - O
cGMP-dependent - - O
protein - - O
kinase - - B-MUT
in - - I-MUT
the - - I-MUT
hypothalamic - - O
GnRH-secreting - - O
neuronal - - O
cell - - O
line - - O
GT1-7 - - O
. - - O

To - - O
evaluate - - O
the - - O
effects - - O
of - - O
HRT - - O
on - - O
those - - O
factors - - O
in - - O
end-stage - - O
renal - - O
disease - - O
( - - O
ESRD - - O
) - - O
patients - - O
, - - O
we - - O
evaluated - - O
the - - O
changes - - O
of - - O
lipid - - O
profile - - O
, - - O
coagulation - - O
and - - O
fibrinolysis - - O
markers - - O
, - - O
and - - O
plasma - - O
homocysteine - - O
levels - - O
after - - O
treatment - - O
. - - O

Decreased - - O
serum - - B-MUT
ceruloplasmin - - I-MUT
and - - O
copper - - O
levels - - O
in - - O
cervical - - O
dystonia - - O
. - - O

Symptoms - - O
due - - O
to - - O
the - - O
action - - O
of - - O
mastocyte - - O
mediators - - O
were - - O
observed - - O
. - - O

The - - O
encoded - - O
sequence - - O
revealed - - O
a - - O
typical - - O
signal - - O
peptide - - O
, - - O
a - - O
predominantly - - O
hydrophilic - - O
707 - - O
amino - - O
acid - - O
residue - - O
domain - - O
with - - O
8 - - O
N-glycosylation - - O
sites - - O
, - - O
a - - O
transmembrane - - O
domain - - O
, - - O
and - - O
a - - O
C-terminal - - O
domain - - O
of - - O
52 - - O
amino - - O
acids - - O
. - - O

Oncogenic - - O
signalling - - O
by - - O
E2F1 - - B-MUT
has - - O
recently - - O
been - - O
linked - - O
to - - O
stabilization - - O
and - - O
activation - - O
of - - O
the - - O
tumour - - O
suppressor - - O
p53 - - B-MUT
( - - O
refs - - O
1 - - O
, - - O
3 - - O
, - - O
4 - - O
) - - O
. - - O

PPD-specific - - B-MUT
IgG - - I-MUT
subclass - - O
responses - - O
were - - O
evident - - O
to - - O
all - - O
four - - O
IgG - - B-MUT
subclasses - - O
. - - O

Biohydrogenation - - O
of - - O
linoleic - - O
acid - - O
into - - O
octadecenoic - - O
acid - - O
was - - O
observed - - O
. - - O

Similarly - - O
, - - O
we - - O
observed - - O
synthetic - - O
phenotypes - - O
between - - O
mutations - - O
in - - O
MIF2 - - B-MUT
and - - O
trans-acting - - O
mutations - - O
in - - O
three - - O
known - - O
yeast - - B-MUT
centromere - - I-MUT
protein - - I-MUT
genes-CEP1 - - I-MUT
CBF1 - - I-MUT
CPF1 - - I-MUT
, - - I-MUT
NDC10 - - I-MUT
CBF2 - - O
, - - B-MUT
and - - I-MUT
CEP3 - - I-MUT
CBF3B - - O
. - - O

( - - O
total - - O
soluble - - O
solids - - O
) - - O
and - - O
organoleptic - - O
characteristics - - O
under - - O
the - - O
influence - - O
of - - O
different - - O
treatments - - O
. - - O

Furthermore - - O
, - - O
in - - O
vivo - - O
and - - O
in - - O
vitro - - O
protein-protein - - O
interaction - - O
experiments - - O
have - - O
shown - - O
that - - O
SR33 - - B-MUT
protein - - I-MUT
interacts - - O
with - - O
itself - - O
and - - O
with - - O
SR45 - - B-MUT
protein - - I-MUT
but - - O
not - - O
with - - O
two - - O
other - - O
members - - O
( - - O
SRZ21 - - B-MUT
and - - O
SRZ22 - - B-MUT
) - - O
of - - O
the - - O
SR - - B-MUT
family - - I-MUT
that - - O
are - - O
known - - O
to - - O
interact - - O
with - - O
the - - O
Arabidopsis - - O
full-length - - O
U-70K - - B-MUT
only - - O
. - - O

The - - O
prophylactic - - O
use - - O
of - - O
new - - O
medication - - O
for - - O
patients - - O
between - - O
the - - O
first - - O
and - - O
second - - O
cycle - - O
of - - O
chemotherapy - - O
, - - O
in - - O
agreement - - O
with - - O
the - - O
estimates - - O
calculated - - O
, - - O
does - - O
not - - O
save - - O
health - - O
care - - O
costs - - O
but - - O
may - - O
improve - - O
the - - O
quality - - O
of - - O
life - - O
in - - O
these - - O
patients - - O
and - - O
permit - - O
the - - O
continuation - - O
of - - O
a - - O
therapeutic - - O
schedule - - O
without - - O
interruption - - O
which - - O
may - - O
improve - - O
the - - O
life - - O
expectancy - - O
of - - O
the - - O
patient - - O
. - - O

Alveolar - - O
lymphocytes - - O
were - - O
surprisingly - - O
increased - - O
in - - O
most - - O
patients - - O
with - - O
AIDS - - O
( - - O
mean - - O
26 - - O
. - - O
1 - - O
+ - - O
- - - O
21 - - O
. - - O
9% - - O
; - - O
range - - O
1-76% - - O
) - - O
and - - O
CGL - - O
( - - O
mean - - O
26 - - O
. - - O
6 - - O
+ - - O
- - - O
22 - - O
. - - O
6% - - O
; - - O
range - - O
3-76% - - O
) - - O
with - - O
criteria - - O
of - - O
activation - - O
contrasting - - O
with - - O
the - - O
blood - - O
lymphopenia - - O
. - - O

Control - - O
Tmuscle - - O
was - - O
35 - - O
. - - O
8 - - O
+ - - O
- - - O
0 - - O
. - - O
7 - - O
degrees - - O
C - - O
, - - O
with - - O
control - - O
Wi - - O
, - - O
max - - O
being - - O
51 - - O
. - - O
6 - - O
( - - O
SD - - O
8 - - O
. - - O
7 - - O
) - - O
W - - O
. - - O
kg-1 - - O
. - - O

Overexpression - - O
of - - O
SCS1 - - B-MUT
could - - O
not - - O
complement - - O
an - - O
HSP60-null - - B-MUT
allele - - I-MUT
, - - O
indicating - - O
that - - O
suppression - - O
was - - O
not - - O
due - - O
to - - O
the - - O
bypassing - - O
of - - O
Hsp60 - - B-MUT
activity - - O
. - - O

Eastern - - O
Cooperative - - O
Oncology - - O
Group - - O
trial - - O
E3186 - - O
was - - O
initiated - - O
to - - O
explore - - O
this - - O
question - - O
. - - O

Through - - O
Southern - - O
blot - - O
analyses - - O
of - - O
DNA - - O
from - - O
backcross - - O
and - - O
cogenic - - O
mice - - O
, - - O
recombinant - - O
inbred - - O
strains - - O
, - - O
and - - O
somatic - - O
cell - - O
hybrids - - O
, - - O
the - - O
genetic - - O
loci - - O
that - - O
produce - - O
the - - O
cyclin - - B-MUT
B1-related - - I-MUT
sequences - - I-MUT
( - - O
designated - - O
loci - - B-MUT
Cycb1-rs1 - - I-MUT
to - - O
Cycb1-rs9 - - B-MUT
) - - O
were - - O
mapped - - O
on - - O
mouse - - O
chromosomes - - O
5 - - O
, - - O
1 - - O
, - - O
17 - - O
, - - O
4 - - O
, - - O
14 - - O
, - - O
13 - - O
, - - O
7 - - O
, - - O
X - - O
, - - O
and - - O
8 - - O
, - - O
respectively - - O
. - - O

The - - O
diet - - O
of - - O
migrants - - O
showed - - O
both - - O
positive - - O
( - - O
macronutrients - - O
) - - O
and - - O
negative - - O
( - - O
micronutrients - - O
) - - O
differences - - O
with - - O
the - - O
general - - O
Dutch - - O
diet - - O
. - - O

METHODS - - O
: - - O
9 - - O
cases - - O
of - - O
conventional - - O
intermittent - - O
tissue - - O
expansion - - O
( - - O
CITE - - O
) - - O
and - - O
9 - - O
cases - - O
of - - O
continuous - - O
pressure-controlled - - O
tissue - - O
expansion - - O
( - - O
CPTE - - O
) - - O
were - - O
chosen - - O
for - - O
the - - O
study - - O
. - - O

Greater - - O
rupture - - O
force - - O
was - - O
required - - O
in - - O
the - - O
adult - - O
pigs - - O
than - - O
in - - O
the - - O
young - - O
pigs - - O
. - - O

Identical - - O
effects - - O
were - - O
obtained - - O
when - - O
inhibitors - - O
and - - O
dominant - - O
negative - - O
mutants - - O
were - - O
tested - - O
on - - O
the - - O
-29 - - O
to - - O
+139 - - O
bp - - O
region - - O
of - - O
the - - O
cyclin - - B-MUT
D1 - - I-MUT
promoter - - I-MUT
. - - O

Recent - - O
literature - - O
has - - O
suggested - - O
that - - O
beta-2 - - B-MUT
transferrin - - I-MUT
can - - O
also - - O
be - - O
used - - O
as - - O
a - - O
clinical - - O
marker - - O
for - - O
perilymph - - O
. - - O

Expression - - O
of - - O
the - - O
human - - B-MUT
heat - - I-MUT
shock - - I-MUT
protein - - I-MUT
70 - - I-MUT
gene - - I-MUT
( - - O
hsp70 - - B-MUT
) - - O
is - - O
induced - - O
by - - O
various - - O
kinds - - O
of - - O
stress - - O
and - - O
by - - O
oncogenes - - O
. - - O

Cultivation - - O
technics - - O
for - - O
Codonopsis - - O
pilosula - - O
. - - O

We - - O
have - - O
investigated - - O
the - - O
requirements - - O
of - - O
the - - O
CH - - B-MUT
gene - - I-MUT
switch - - O
by - - O
characterizing - - O
two - - O
rearranged - - B-MUT
gamma - - I-MUT
2b - - I-MUT
genes - - I-MUT
from - - O
a - - O
gamma - - B-MUT
2b - - I-MUT
producing - - O
mouse - - O
myeloma - - O
( - - O
MPC-11 - - O
) - - O
. - - O

Exchanging - - O
the - - O
human - - O
propeptide - - O
in - - O
this - - O
chimera - - O
with - - O
either - - O
the - - O
murine - - B-MUT
MIC-1 - - I-MUT
or - - O
TGF-beta1 - - B-MUT
propeptide - - I-MUT
resulted - - O
in - - O
secretion - - O
of - - O
the - - O
unprocessed - - O
, - - O
monomeric - - O
chimera - - O
, - - O
suggesting - - O
a - - O
specific - - O
interaction - - O
between - - O
the - - O
human - - B-MUT
MIC-1 - - I-MUT
propeptide - - I-MUT
and - - O
mature - - O
peptide - - O
. - - O

CONCLUSION - - O
: - - O
Although - - O
quantitative - - O
and - - O
qualitative - - O
criteria - - O
for - - O
diagnosing - - O
fatty - - O
liver - - O
on - - O
helical - - O
CT - - O
can - - O
be - - O
determined - - O
, - - O
they - - O
are - - O
protocol-specific - - O
. - - O

Syndecan-4 - - B-MUT
is - - O
a - - O
focal - - O
adhesion - - O
component - - O
, - - O
and - - O
this - - O
interaction - - O
may - - O
both - - O
localize - - O
PKC - - B-MUT
and - - O
amplify - - O
its - - O
activity - - O
at - - O
sites - - O
of - - O
forming - - O
adhesions - - O
. - - O

Who - - O
says - - O
'National - - O
Health - - O
Dis-service' - - O
. - - O

A-69-year-old - - O
patient - - O
with - - O
postoperative - - O
small-bowel - - O
obstruction - - O
underwent - - O
laparotomy - - O
three - - O
times - - O
. - - O

The - - O
VirR - - B-MUT
response - - I-MUT
regulator - - I-MUT
from - - O
Clostridium - - O
perfringens - - O
binds - - O
independently - - O
to - - O
two - - O
imperfect - - O
direct - - O
repeats - - O
located - - O
upstream - - O
of - - O
the - - O
pfoA - - B-MUT
promoter - - I-MUT
. - - O

Ion - - O
injection - - O
. - - O

These - - O
data - - O
suggest - - O
that - - O
AP-A - - B-MUT
may - - O
be - - O
potentially - - O
useful - - O
in - - O
the - - O
management - - O
of - - O
heart - - O
failure - - O
. - - O

Significance - - O
of - - O
thin - - O
glomerular - - O
basement - - O
membranes - - O
in - - O
hematuric - - O
children - - O
. - - O

The - - O
effect - - O
of - - O
low-profile - - O
serine - - O
substitutions - - O
in - - O
the - - O
V3 - - O
loop - - O
of - - O
HIV-1 - - B-MUT
gp120 - - I-MUT
IIIB - - I-MUT
LAI - - I-MUT
on - - I-MUT
the - - O
immunogenicity - - O
of - - O
the - - O
envelope - - O
protein - - B-MUT
. - - O

Laboratory - - O
pyrolyses - - O
have - - O
indeed - - O
shown - - O
that - - O
PCBs - - O
give - - O
significant - - O
yields - - O
of - - O
PCDFs - - O
, - - O
and - - O
chlorobenzenes - - O
give - - O
both - - O
PCDFs - - O
and - - O
PCDDs - - O
. - - O

A - - O
marked - - O
decrease - - O
in - - O
the - - O
type - - B-MUT
1 - - I-MUT
insulin-like - - I-MUT
growth - - I-MUT
factor - - I-MUT
( - - I-MUT
IGF - - I-MUT
) - - I-MUT
receptor - - I-MUT
( - - O
IGF-IR - - B-MUT
) - - O
occurs - - O
in - - O
prostate - - O
epithelial - - O
cells - - O
during - - O
transformation - - O
from - - O
the - - O
benign - - O
to - - O
the - - O
metastatic - - O
state - - O
. - - O

Pokeweed - - B-MUT
antiviral - - I-MUT
protein - - I-MUT
( - - O
PAP - - B-MUT
) - - O
from - - O
Phytolacca - - O
americana - - O
is - - O
a - - O
highly - - O
specific - - O
N-glycosidase - - B-MUT
removing - - O
adenine - - O
residues - - O
( - - O
A4324 - - O
in - - O
28S - - B-MUT
rRNA - - I-MUT
and - - O
A2660 - - O
in - - O
23S - - B-MUT
rRNA - - I-MUT
) - - O
from - - O
intact - - O
ribosomes - - O
of - - O
both - - O
eukaryotes - - O
and - - O
prokaryotes - - O
. - - O

We - - O
also - - O
identified - - O
Sp1 - - B-MUT
, - - O
Sp3 - - B-MUT
, - - O
and - - O
NGFI-A - - B-MUT
Egr-1 - - O
as - - B-MUT
the - - O
primary - - O
nuclear - - O
transcription - - O
factors - - O
binding - - O
to - - O
TRE1 - - O
which - - B-MUT
mediate - - O
Tax - - O
responsiveness - - B-MUT
. - - O

This - - O
study - - O
indicated - - O
that - - O
the - - O
Japanese - - O
quail - - O
was - - O
less - - O
sensitive - - O
to - - O
particulate - - O
Mn3O4 - - O
exposure - - O
than - - O
rodents - - O
treated - - O
comparably - - O
. - - O

The - - O
significance - - O
of - - O
these - - O
palindromic - - O
domains - - O
in - - O
this - - O
ORF - - O
is - - O
unclear - - O
but - - O
the - - O
coincidence - - O
of - - O
the - - O
end - - O
of - - O
one - - O
larger - - O
palindrome - - O
with - - O
the - - O
end - - O
of - - O
the - - O
translated - - O
protein - - O
sequence - - O
that - - O
has - - O
homology - - O
with - - O
the - - O
B - - B-MUT
chain - - I-MUT
of - - O
insulin - - B-MUT
suggests - - O
that - - O
the - - O
palindromes - - O
may - - O
divide - - O
the - - O
T2 - - B-MUT
protein - - I-MUT
into - - O
several - - O
functional - - O
units - - O
. - - O

In - - O
contrast - - O
, - - O
when - - O
the - - O
isoform - - O
containing - - O
the - - O
C - - B-MUT
epsilon4 - - I-MUT
domain - - I-MUT
joined - - O
directly - - O
to - - O
the - - O
M2 - - B-MUT
exon - - I-MUT
( - - O
IgE - - B-MUT
grande - - I-MUT
) - - O
is - - O
expressed - - O
in - - O
the - - O
J558L - - O
cell - - O
line - - O
, - - O
it - - O
is - - O
degraded - - O
intracellularly - - O
, - - O
suggesting - - O
a - - O
cell - - O
line-dependent - - O
regulation - - O
of - - O
secretion - - O
. - - O

Positive - - O
correlations - - O
were - - O
seen - - O
between - - O
the - - O
measurements - - O
for - - O
protein - - O
intake - - O
( - - O
r - - O
= - - O
. - - O
58 - - O
, - - O
P - - O
= - - O
. - - O
0026 - - O
) - - O
energy - - O
intake - - O
( - - O
r - - O
= - - O
. - - O
78 - - O
, - - O
P - - O
< - - O
. - - O
00001 - - O
) - - O
, - - O
with - - O
mean - - O
differences - - O
of - - O
. - - O
066 - - O
g - - O
kg - - O
d - - O
( - - O
SD - - O
. - - O
38 - - O
) - - O
2 - - O
. - - O
04 - - O
kcal - - O
kg - - O
day - - O
( - - O
SD - - O
6 - - O
. - - O
67 - - O
) - - O
, - - O
respectively - - O
. - - O

Grimelius - - O
stain - - O
was - - O
positive - - O
, - - O
Masson - - O
Fontana - - O
stain - - O
negative - - O
. - - O

SPP41 - - B-MUT
was - - O
cloned - - O
and - - O
sequenced - - O
and - - O
found - - O
to - - O
be - - O
essential - - O
. - - O
spp43 - - B-MUT
is - - O
allelic - - O
to - - O
the - - O
previously - - O
identified - - O
suppressor - - B-MUT
srn1 - - I-MUT
, - - O
which - - O
encodes - - O
a - - O
negative - - O
regulator - - O
of - - O
gene - - O
expression - - O
. - - O

Thus - - O
, - - O
phosphodiesterase - - B-MUT
inhibitors - - O
that - - O
produce - - O
an - - O
opiate - - O
quasi-withdrawal - - O
syndrome - - O
potentiate - - O
interoceptive - - O
stimuli - - O
and - - O
weight - - O
loss - - O
associated - - O
with - - O
the - - O
withdrawal - - O
syndrome - - O
precipitated - - O
by - - O
naltrexone - - O
in - - O
morphine-dependent - - O
rats - - O
. - - O

No - - O
differences - - O
in - - O
fixation - - O
quality - - O
were - - O
observed - - O
between - - O
cochleas - - O
fixed - - O
by - - O
intravascular - - O
perfusion - - O
and - - O
cochleas - - O
fixed - - O
by - - O
intralabyrinthine - - O
perfusion - - O
. - - O

Effects - - O
of - - O
diltiazem - - O
on - - O
netilmicin-induced - - O
nephrotoxicity - - O
in - - O
rabbits - - O
. - - O

Substitution - - O
of - - O
serine - - O
residues - - O
at - - O
the - - O
C-terminus - - O
indicated - - O
that - - O
loss - - O
of - - O
phosphorylation - - O
sites - - O
did - - O
not - - O
appear - - O
to - - O
have - - O
any - - O
effect - - O
on - - O
transcription - - O
and - - O
replication - - O
. - - O

The - - O
results - - O
show - - O
that - - O
cognitive - - O
stimulation - - O
enhanced - - O
performance - - O
on - - O
the - - O
Boston - - O
Naming - - O
Test - - O
and - - O
a - - O
Word - - O
List - - O
Recognition - - O
Task - - O
; - - O
physical - - O
intervention - - O
, - - O
however - - O
, - - O
did - - O
not - - O
reach - - O
statistical - - O
significance - - O
. - - O

A - - O
DNA - - O
fragment - - O
encoding - - O
the - - O
DNA-binding - - O
domain - - O
( - - O
amino - - O
acids - - O
1-60 - - O
) - - O
of - - O
the - - O
Escherichia - - B-MUT
coli - - I-MUT
fru - - I-MUT
transcriptional - - I-MUT
regulator - - I-MUT
was - - O
cloned - - O
into - - O
the - - O
pGEX-KT - - O
vector - - O
and - - O
expressed - - O
in - - O
frame - - O
with - - O
the - - O
fused - - O
gene - - O
encoding - - O
glutathione - - B-MUT
S-transferase - - I-MUT
. - - O

It - - O
is - - O
believed - - O
that - - O
these - - O
domains - - O
are - - O
important - - O
for - - O
directing - - O
specific - - O
protein-protein - - O
interactions - - O
necessary - - O
for - - O
the - - O
proper - - O
functioning - - O
of - - O
Src - - B-MUT
. - - O

Obesity - - O
was - - O
strongly - - O
associated - - O
with - - O
the - - O
proportions - - O
of - - O
nonprotein-bound - - O
and - - O
albumin-bound - - O
estradiol - - O
, - - O
and - - O
inversely - - O
associated - - O
with - - O
sex - - B-MUT
hormone - - I-MUT
binding - - I-MUT
globulin - - I-MUT
( - - O
SHBG - - B-MUT
) - - O
levels - - O
and - - O
the - - O
proportion - - O
of - - O
SHBG-bound - - O
estradiol - - O
. - - O

Although - - O
a - - O
carboxyl-terminal - - O
HSF - - B-MUT
transcriptional - - O
activation - - O
domain - - O
is - - O
critical - - O
for - - O
the - - O
activation - - O
of - - O
CUP1 - - B-MUT
transcription - - O
in - - O
response - - O
to - - O
both - - O
heat - - O
shock - - O
stress - - O
and - - O
glucose - - O
starvation - - O
, - - O
this - - O
region - - O
is - - O
dispensable - - O
for - - O
transient - - O
heat - - O
shock - - O
activation - - O
of - - O
at - - O
least - - O
two - - O
genes - - O
encoding - - O
members - - O
of - - O
the - - O
S - - O
. - - O
cerevisiae - - O
hsp70 - - B-MUT
family - - I-MUT
. - - O

METHODS - - O
: - - O
We - - O
obtained - - O
maximal - - O
inspiratory - - O
and - - O
expiratory - - O
flow-volume - - O
curves - - O
in - - O
41 - - O
unselected - - O
patients - - O
with - - O
essential - - O
tremor - - O
( - - O
14 - - O
males - - O
, - - O
27 - - O
females - - O
, - - O
age - - O
61 - - O
. - - O
7 - - O
+ - - O
- - - O
2 - - O
. - - O
14 - - O
years - - O
) - - O
. - - O

This - - O
correlated - - O
with - - O
reduced - - O
levels - - O
of - - O
secreted - - O
hepatitis - - B-MUT
B - - I-MUT
e - - I-MUT
antigen - - I-MUT
and - - O
increased - - O
intracellular - - O
levels - - O
of - - O
core - - B-MUT
and - - O
Pol - - B-MUT
proteins - - I-MUT
and - - O
replicative - - O
HBV - - O
DNA - - O
intermediates - - O
. - - O

Relapse - - O
of - - O
leukemia - - O
after - - O
prolonged - - O
remission - - O
. - - O

A - - O
new - - O
physiopathological - - O
treatment - - O
of - - O
HBV-related - - O
polyarteritis - - O
inspired - - O
by - - O
advances - - O
in - - O
the - - O
treatment - - O
of - - O
chronic - - O
active - - O
hepatitis - - O
B - - O
was - - O
tested - - O
in - - O
7 - - O
patients - - O
. - - O

The - - O
ipsilateral - - O
breast - - O
tumor - - O
relapse - - O
rate - - O
was - - O
similar - - O
between - - O
the - - O
PALP - - O
and - - O
MGDET - - O
groups - - O
. - - O

Possibilities - - O
of - - O
needleless - - O
administration - - O
of - - O
various - - O
substances - - O
to - - O
animals - - O
. - - O

No - - O
significant - - O
correlation - - O
was - - O
found - - O
between - - O
LVM - - O
or - - O
wall - - O
thickness - - O
and - - O
body - - O
surface - - O
area - - O
, - - O
age - - O
, - - O
blood - - O
pressure - - O
, - - O
heart - - O
rate - - O
, - - O
cardiac - - O
output - - O
, - - O
total - - O
peripheral - - O
resistance - - O
and - - O
left - - O
ventricular - - O
systolic - - O
wall - - O
stress - - O
, - - O
whereas - - O
CD25 - - O
was - - O
correlated - - O
with - - O
urinary - - O
catecholamines - - O
only - - O
in - - O
hypertensive - - O
patients - - O
( - - O
r - - O
= - - O
0 - - O
. - - O
606 - - O
, - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
001 - - O
) - - O
. - - O

Uses - - O
of - - O
orthoclone - - O
OKT3 - - O
for - - O
prophylaxis - - O
of - - O
rejection - - O
and - - O
induction - - O
in - - O
initial - - O
nonfunction - - O
in - - O
kidney - - O
transplantation - - O
. - - O

( - - O
iv - - O
) - - O
Although - - O
UCRBP - - B-MUT
has - - O
been - - O
previously - - O
shown - - O
to - - O
act - - O
as - - O
a - - O
transcriptional - - O
repressor - - O
, - - O
we - - O
show - - O
here - - O
that - - O
UCRBP - - B-MUT
can - - O
also - - O
act - - O
as - - O
a - - O
positive - - O
transactivator - - O
of - - O
a - - O
reporter - - O
driven - - O
by - - O
UCR - - B-MUT
elements - - I-MUT
when - - O
used - - O
in - - O
co-transfection - - O
assays - - O
. - - O

RNase - - B-MUT
protection - - O
assays - - O
reveal - - O
that - - O
this - - O
gene - - O
, - - O
unr - - B-MUT
, - - O
is - - O
transcribed - - O
in - - O
the - - O
same - - O
direction - - O
as - - O
N-ras - - B-MUT
and - - O
that - - O
its - - O
3' - - O
end - - O
is - - O
located - - O
just - - O
130 - - O
base - - O
pairs - - O
away - - O
from - - O
the - - O
point - - O
at - - O
which - - O
N-ras - - B-MUT
transcription - - O
begins - - O
. - - O

Collectively - - O
, - - O
these - - O
data - - O
indicate - - O
that - - O
HIP - - B-MUT
is - - O
a - - O
membrane-associated - - O
HP-binding - - O
protein - - O
expressed - - O
on - - O
the - - O
surface - - O
of - - O
normal - - O
human - - O
uterine - - O
epithelia - - O
and - - O
uterine - - O
epithelial - - O
cell - - O
lines - - O
. - - O

The - - O
second - - O
mutation - - O
present - - O
in - - O
the - - O
original - - O
mutant - - O
proved - - O
to - - O
be - - O
an - - O
allele - - O
of - - O
a - - O
known - - O
gene - - O
, - - O
PBS2 - - B-MUT
, - - O
which - - O
encodes - - O
a - - O
putative - - O
protein - - B-MUT
kinase - - I-MUT
that - - O
functions - - O
in - - O
the - - O
high - - O
osmolarity - - O
stress - - O
pathway - - O
. - - O

Clinical - - O
implication - - O
of - - O
protein - - O
levels - - O
of - - O
IL-5 - - B-MUT
in - - O
induced - - O
sputum - - O
in - - O
asthmatic - - O
patients - - O
. - - O

The - - O
enzyme - - O
displays - - O
optimal - - O
activity - - O
at - - O
about - - O
0 - - O
. - - O
5 - - O
mM - - O
pantoate - - O
( - - O
k - - O
( - - O
cat - - O
) - - O
0 - - O
. - - O
63 - - O
s - - O
( - - O
-1 - - O
) - - O
) - - O
and - - O
at - - O
pH - - O
7 - - O
. - - O
8 - - O
. - - O

Biol - - O
. - - O

These - - O
properties - - O
indicate - - O
that - - O
Gle1 - - B-MUT
is - - O
an - - O
RNA-export - - O
factor - - O
and - - O
that - - O
Rev - - B-MUT
may - - O
mediate - - O
viral - - O
RNA - - O
export - - O
by - - O
mimicking - - O
the - - O
function - - O
of - - O
Gle1 - - B-MUT
. - - O

Dynamic - - O
imaging - - O
of - - O
nuclear - - O
wave - - O
functions - - O
with - - O
ultrashort - - O
UV - - O
laser - - O
pulses - - O
. - - O

Co-administration - - O
of - - O
5FU - - O
, - - O
angiotensin - - B-MUT
II - - I-MUT
and - - O
microspheres - - O
via - - O
the - - O
hepatic - - O
artery - - O
may - - O
reduce - - O
drug - - O
exposure - - O
in - - O
the - - O
systemic - - O
compartment - - O
and - - O
therefore - - O
may - - O
increase - - O
the - - O
therapeutic - - O
ratio - - O
of - - O
5FU - - O
administration - - O
via - - O
the - - O
hepatic - - O
artery - - O
. - - O

Specific - - O
binding - - O
of - - O
the - - O
protein - - O
factors - - O
to - - O
the - - O
sites - - O
, - - O
possibly - - O
to - - O
the - - O
three - - O
Mt - - B-MUT
sequences - - I-MUT
, - - O
may - - O
play - - O
an - - O
important - - O
role - - O
in - - O
the - - O
coordinate - - O
regulation - - O
of - - O
the - - O
transcription - - O
of - - O
nuclear - - O
genes - - O
encoding - - O
subunits - - O
responsible - - O
for - - O
mitochondrial - - O
oxidative - - O
phosphorylation - - O
. - - O

The - - O
pattern - - O
for - - O
catalytic - - O
zinc - - O
sites - - O
included - - O
two - - O
ligands - - O
close - - O
in - - O
sequence - - O
, - - O
a - - O
sequence-distant - - O
ligand - - O
, - - O
and - - O
a - - O
main-chain - - O
hydrogen - - O
bond - - O
joining - - O
two - - O
ligands - - O
. - - O

Neutrophil - - O
: - - O
lymphocyte - - O
ratio - - O
, - - O
plasma - - O
haptoglobin - - B-MUT
, - - O
and - - O
CBG - - B-MUT
levels - - O
were - - O
greater - - O
( - - O
P - - O
< - - O
0 - - O
. - - O
01 - - O
) - - O
during - - O
the - - O
INITIAL - - O
period - - O
than - - O
during - - O
the - - O
PRE - - O
or - - O
POST - - O
periods - - O
but - - O
did - - O
not - - O
differ - - O
between - - O
treatments - - O
. - - O

In - - O
a - - O
prospective - - O
randomized - - O
study - - O
, - - O
287 - - O
patients - - O
with - - O
advanced - - O
non-small - - O
cell - - O
lung - - O
cancer - - O
( - - O
NSCLC - - O
) - - O
stage - - O
IIIb - - O
or - - O
IV - - O
with - - O
ECOG - - O
performance - - O
status - - O
( - - O
PS - - O
) - - O
0-1 - - O
or - - O
2 - - O
were - - O
randomly - - O
assigned - - O
to - - O
receive - - O
either - - O
best - - O
supportive - - O
care - - O
( - - O
BSC - - O
) - - O
or - - O
supportive - - O
care - - O
plus - - O
combination - - O
chemotherapy - - O
( - - O
IEP - - O
regimen - - O
: - - O
ifosfamide - - O
3 - - O
gm - - O
m2 - - O
IV - - O
with - - O
mesna - - O
uroprotection - - O
, - - O
epirubicin - - O
60 - - O
mg - - O
m2 - - O
IV - - O
on - - O
day - - O
1 - - O
and - - O
cisplatin - - O
60 - - O
mg - - O
m2 - - O
IV - - O
on - - O
day - - O
2 - - O
; - - O
or - - O
MVP - - O
regimen - - O
: - - O
mitomycin-C - - O
8 - - O
mg - - O
m2 - - O
, - - O
cisplatin - - O
100 - - O
mg - - O
m2 - - O
IV - - O
on - - O
day - - O
1 - - O
, - - O
vinblastine - - O
4 - - O
mg - - O
m2 - - O
IV - - O
on - - O
days - - O
1 - - O
and - - O
15 - - O
) - - O
. - - O

In - - O
gel - - O
mobility - - O
shift - - O
assays - - O
, - - O
low - - O
binding - - O
activity - - O
of - - O
CBF - - B-MUT
to - - O
the - - O
wild-type - - B-MUT
AtpC - - I-MUT
promoter - - I-MUT
sequence - - I-MUT
was - - O
observed - - O
with - - O
nuclear - - O
extracts - - O
from - - O
tissue - - O
with - - O
low - - O
AtpC - - B-MUT
expression - - O
levels - - O
, - - O
i - - O
. - - O
e - - O
. - - O
extracts - - O
from - - O
etiolated - - O
and - - O
photobleached - - O
seedlings - - O
, - - O
whereas - - O
high - - O
binding - - O
activity - - O
was - - O
detectable - - O
with - - O
extracts - - O
from - - O
tissues - - O
with - - O
high - - O
AtpC - - B-MUT
expression - - O
levels - - O
, - - O
i - - O
. - - O
e - - O
. - - O
extracts - - O
from - - O
light-grown - - O
seedlings - - O
and - - O
etiolated - - O
seedlings - - O
treated - - O
with - - O
cytokinin - - B-MUT
. - - O

The - - O
data - - O
indicate - - O
that - - O
calcitonin - - B-MUT
induced - - O
a - - O
beta-endorphin - - B-MUT
increase - - O
independent - - O
of - - O
enhanced - - O
corticotrophin-cortisol - - O
release - - O
. - - O

Electrocardiographic - - O
right - - O
ventricular - - O
hypertrophy - - O
was - - O
seen - - O
in - - O
4 - - O
, - - O
and - - O
biventricular - - O
hypertrophy - - O
in - - O
5 - - O
patients - - O
. - - O

The - - O
plasmin-derived - - B-MUT
D - - I-MUT
( - - I-MUT
approximately - - I-MUT
105-kDa - - I-MUT
) - - I-MUT
product - - I-MUT
, - - O
however - - O
, - - O
could - - O
be - - O
cross-linked - - O
into - - O
DD - - B-MUT
dimers - - I-MUT
. - - O

Furthermore - - O
, - - O
the - - O
deletion - - O
of - - O
bcp - - B-MUT
from - - O
the - - O
chromosome - - O
had - - O
no - - O
effect - - O
on - - O
gcv-lacZ - - B-MUT
expression - - O
. - - O

The - - O
amino-terminal - - O
region - - O
of - - O
E1A - - B-MUT
binds - - O
several - - O
high - - O
molecular - - O
weight - - O
proteins - - O
and - - O
inhibits - - O
the - - O
transcriptional - - O
coactivator - - O
function - - O
of - - O
p300 - - B-MUT
and - - O
the - - O
homologous - - O
cAMP - - B-MUT
response - - I-MUT
element - - I-MUT
( - - I-MUT
CRE - - I-MUT
) - - I-MUT
-binding - - I-MUT
protein - - I-MUT
. - - O

To - - O
investigate - - O
the - - O
effects - - O
of - - O
exogenous - - O
hyaluronic - - O
acid - - O
, - - O
the - - O
development - - O
of - - O
port-site - - O
metastasis - - O
was - - O
examined - - O
using - - O
mouse - - O
adenocarcinoma - - O
cell-line - - O
colon - - O
26 - - O
cells - - O
. - - O

Some - - O
users - - O
will - - O
willingly - - O
comply - - O
with - - O
management - - O
measures - - O
, - - O
other - - O
users - - O
will - - O
comply - - O
in - - O
response - - O
to - - O
education - - O
, - - O
but - - O
there - - O
will - - O
be - - O
another - - O
group - - O
who - - O
will - - O
only - - O
respond - - O
to - - O
enforcement - - O
activities - - O
. - - O

The - - O
extraction - - O
was - - O
subsequently - - O
rated - - O
as - - O
'easy' - - O
or - - O
'difficult' - - O
. - - O
Taking - - O
Pell-Gregory - - O
class - - O
C - - O
as - - O
a - - O
predictor - - O
of - - O
a - - O
'difficult' - - O
extraction - - O
, - - O
specificity - - O
was - - O
88% - - O
but - - O
sensitivity - - O
was - - O
low - - O
at - - O
15% - - O
. - - O

Chrispeels - - O
[ - - O
1993 - - O
] - - O
EMBO - - O
J - - O
12 - - O
: - - O
2241-2247 - - O
) - - O
. - - O

Therefore - - O
, - - O
vitamin - - O
D3 - - O
analogues - - O
have - - O
a - - O
substantial - - O
antipsoriatic - - O
effect - - O
. - - O

A - - O
mutant - - B-MUT
areA - - I-MUT
product - - I-MUT
truncated - - O
immediately - - O
after - - O
the - - O
last - - O
residue - - O
of - - O
the - - O
highly - - O
conserved - - O
GATA - - B-MUT
( - - O
DNA-binding - - O
) - - O
domain - - O
retains - - O
partial - - O
function - - O
. - - O

Thus - - O
, - - O
the - - O
CCAAT - - O
box - - O
also - - O
has - - O
tissue-specific - - O
characteristics - - O
that - - O
assist - - O
in - - O
targeting - - O
expression - - O
of - - O
the - - O
alpha-subunit - - B-MUT
gene - - I-MUT
to - - O
trophoblasts - - O
. - - O

The - - O
identification - - O
of - - O
the - - O
hepatitis - - O
C - - O
virus - - O
as - - O
the - - O
major - - O
cause - - O
of - - O
liver - - O
disease - - O
both - - O
in - - O
dialysis - - O
patients - - O
and - - O
in - - O
transplant - - O
patients - - O
has - - O
focused - - O
attention - - O
on - - O
the - - O
epidemiology - - O
and - - O
the - - O
impact - - O
of - - O
continuing - - O
infection - - O
in - - O
these - - O
patient - - O
groups - - O
. - - O

IL-1 - - B-MUT
and - - O
TNF - - B-MUT
increase - - O
AND-34 - - B-MUT
transcript - - I-MUT
levels - - O
in - - O
thymic - - O
cortical - - O
reticular - - O
, - - O
thymic - - O
nurse - - O
, - - O
and - - O
fibroblast - - O
cell - - O
lines - - O
. - - O

Sequence - - O
divergence - - O
is - - O
observed - - O
in - - O
untranslated - - O
regions - - O
which - - O
allows - - O
the - - O
definition - - O
of - - O
gene-specific - - O
probes - - O
. - - O

This - - O
site - - O
is - - O
upstream - - O
from - - O
the - - O
TATA - - O
box - - O
used - - O
in - - O
somatic - - O
cells - - O
. - - O

It - - O
also - - O
suggests - - O
that - - O
there - - O
is - - O
another - - O
pathway - - O
which - - O
can - - O
activate - - O
SWI4 - - B-MUT
transcription - - O
in - - O
the - - O
absence - - O
of - - O
SWI6 - - B-MUT
. - - O

Furthermore - - O
, - - O
45Ca-binding - - O
assays - - O
revealed - - O
that - - O
CCaMK - - B-MUT
directly - - O
binds - - O
Ca2+ - - O
. - - O

To - - O
analyze - - O
the - - O
regulatory - - O
activity - - O
of - - O
Gtx - - B-MUT
, - - O
we - - O
first - - O
identified - - O
the - - O
optimal - - O
Gtx-binding - - B-MUT
sequence - - I-MUT
using - - O
an - - O
in - - O
vitro - - O
DNA-binding - - O
assay - - O
. - - O

Generally - - O
the - - O
differences - - O
between - - O
short - - O
gut - - O
and - - O
sham - - O
operation - - O
animals - - O
disappeared - - O
when - - O
the - - O
data - - O
were - - O
normalised - - O
for - - O
mucosal - - O
weight - - O
. - - O

Dopaminergic - - O
modulation - - O
of - - O
transcallosal - - O
activity - - O
of - - O
cat - - O
motor - - O
cortical - - O
neurons - - O
. - - O

In - - O
children - - O
unable - - O
to - - O
perform - - O
forced - - O
expiratory - - O
maneuvers - - O
( - - O
n - - O
= - - O
25 - - O
) - - O
, - - O
FOT - - O
, - - O
contrary - - O
to - - O
the - - O
interrupter - - O
technique - - O
, - - O
clearly - - O
identified - - O
a - - O
subgroup - - O
of - - O
young - - O
children - - O
with - - O
high - - O
resistance - - O
values - - O
at - - O
baseline - - O
, - - O
which - - O
returned - - O
to - - O
normal - - O
after - - O
bronchodilation - - O
. - - O

An - - O
increase - - O
in - - O
bone - - O
mineral - - O
density - - O
at - - O
the - - O
spine - - O
, - - O
total - - O
hip - - O
, - - O
and - - O
total - - O
body - - O
has - - O
been - - O
reported - - O
with - - O
raloxifene - - O
but - - O
seems - - O
to - - O
be - - O
less - - O
than - - O
that - - O
seen - - O
with - - O
estrogen - - O
or - - O
alendronate - - O
therapy - - O
. - - O

The - - O
retinoid - - B-MUT
Z - - I-MUT
receptor - - I-MUT
beta - - I-MUT
( - - O
RZR - - B-MUT
beta - - I-MUT
) - - O
, - - O
an - - O
orphan - - B-MUT
receptor - - I-MUT
, - - O
is - - O
a - - O
member - - O
of - - O
the - - O
retinoic - - B-MUT
acid - - I-MUT
receptor - - I-MUT
( - - O
RAR - - B-MUT
) - - B-MUT
thyroid - - I-MUT
hormone - - I-MUT
receptor - - I-MUT
( - - I-MUT
TR - - O
) - - B-MUT
subfamily - - O
of - - O
nuclear - - O
receptors - - O
. - - O

We - - O
conclude - - O
that - - O
grade - - O
III - - O
BGCT - - O
can - - O
be - - O
treated - - O
by - - O
modified - - O
intralesional - - O
excision - - O
provided - - O
the - - O
articular - - O
surfaces - - O
and - - O
part - - O
of - - O
the - - O
metaphysis - - O
are - - O
intact - - O
. - - O

A - - O
reversed-phase - - O
high-performance - - O
liquid - - O
chromatographic - - O
( - - O
HPLC - - O
) - - O
method - - O
for - - O
the - - O
determination - - O
of - - O
cocaine - - O
metabolites - - O
produced - - O
in - - O
vitro - - O
by - - O
serum - - B-MUT
and - - I-MUT
liver - - I-MUT
esterases - - I-MUT
is - - O
described - - O
. - - O

The - - O
functions - - O
of - - O
isolated - - O
portions - - O
of - - O
the - - O
insulin - - B-MUT
, - - O
IAPP - - B-MUT
, - - O
and - - O
beta - - B-MUT
GK - - I-MUT
promoters - - I-MUT
were - - O
studied - - O
by - - O
using - - O
transient - - O
expression - - O
and - - O
DNA - - O
binding - - O
assays - - O
. - - O

Caries - - O
prevention - - O
in - - O
the - - O
dental - - O
office - - O
. - - O

Use - - O
of - - O
the - - O
vena - - O
cava - - O
to - - O
extend - - O
the - - O
right - - O
renal - - O
vein - - O
for - - O
cadaver - - O
transplantation - - O
is - - O
controversial - - O
. - - O

During - - O
the - - O
observation - - O
period - - O
of - - O
0 - - O
. - - O
4-30 - - O
weeks - - O
, - - O
cardiac - - O
white - - O
spots - - O
on - - O
the - - O
right - - O
ventricle - - O
of - - O
BALB - - O
c - - O
mice - - O
were - - O
first - - O
detected - - O
at - - O
three - - O
weeks - - O
( - - O
6 - - O
of - - O
20 - - O
mice - - O
; - - O
30% - - O
) - - O
, - - O
and - - O
the - - O
maximal - - O
incidence - - O
of - - O
cardiac - - O
white - - O
spots - - O
was - - O
obtained - - O
at - - O
nine - - O
weeks - - O
( - - O
39 - - O
of - - O
44 - - O
mice - - O
; - - O
88% - - O
) - - O
. - - O

We - - O
have - - O
used - - O
the - - O
hydrophobic - - O
repeats - - O
of - - O
the - - O
HSF1 - - B-MUT
trimerization - - I-MUT
domain - - I-MUT
in - - O
the - - O
yeast - - O
two-hybrid - - O
protein - - O
interaction - - O
assay - - O
to - - O
identify - - O
heat - - B-MUT
shock - - I-MUT
factor - - I-MUT
binding - - I-MUT
protein - - I-MUT
1 - - I-MUT
( - - O
HSBP1 - - B-MUT
) - - O
, - - O
a - - O
novel - - O
, - - O
conserved - - O
, - - O
76-amino-acid - - O
protein - - O
that - - O
contains - - O
two - - O
extended - - O
arrays - - O
of - - O
hydrophobic - - O
repeats - - O
that - - O
interact - - O
with - - O
the - - O
HSF1 - - B-MUT
heptad - - I-MUT
repeats - - I-MUT
. - - O

The - - O
CNXA - - B-MUT
domain - - I-MUT
is - - O
similar - - O
at - - O
the - - O
amino - - O
acid - - O
level - - O
to - - O
the - - O
Escherichia - - B-MUT
coli - - I-MUT
moaA - - I-MUT
gene - - I-MUT
product - - I-MUT
, - - O
while - - O
CNXC - - B-MUT
is - - O
similar - - O
to - - O
the - - O
E - - B-MUT
. - - I-MUT
coli - - I-MUT
moaC - - I-MUT
product - - I-MUT
, - - O
with - - O
both - - O
E - - O
. - - O
coli - - O
products - - O
encoded - - O
by - - O
different - - O
cistrons - - O
. - - O

One - - O
of - - O
its - - O
unique - - O
features - - O
appears - - O
to - - O
be - - O
the - - O
unusually - - O
short - - O
5'-untranslated - - O
regions - - O
( - - O
UTR - - O
) - - O
( - - O
1-6 - - O
nucleotides - - O
( - - O
nts - - O
) - - O
) - - O
and - - O
the - - O
apparent - - O
absence - - O
of - - O
5'-cap - - O
structures - - O
from - - O
its - - O
mRNAs - - O
. - - O

The - - O
COP-PAWP - - O
gradient - - O
was - - O
markedly - - O
decreased - - O
in - - O
both - - O
shock - - O
and - - O
non-shock - - O
patients - - O
with - - O
pulmonary - - O
edema - - O
. - - O

Chick - - B-MUT
brain - - I-MUT
actin - - I-MUT
depolymerizing - - I-MUT
factor - - I-MUT
( - - O
ADF - - B-MUT
) - - O
is - - O
a - - O
19-kDa - - O
protein - - O
that - - O
severs - - O
actin - - B-MUT
filaments - - I-MUT
and - - O
binds - - O
actin - - B-MUT
monomers - - I-MUT
. - - O

CodY - - B-MUT
does - - O
not - - O
have - - O
any - - O
homologues - - O
in - - O
the - - O
data-bases - - O
. - - O

A - - O
15 - - O
. - - O
1 - - O
kb - - O
fragment - - O
of - - O
the - - O
yeast - - O
genome - - O
was - - O
allocated - - O
to - - O
the - - O
centromeric - - O
region - - O
of - - O
chromosome - - O
XIV - - O
by - - O
genetic - - O
mapping - - O
. - - O

The - - O
test - - O
for - - O
alpha-naphthyl - - B-MUT
esterase - - I-MUT
and - - O
quantitation - - O
of - - O
macrophages - - O
( - - O
absolute - - O
number - - O
) - - O
per - - O
infiltration - - O
area - - O
unit - - O
adjacent - - O
to - - O
the - - O
abscess - - O
suggest - - O
a - - O
direct - - O
correlation - - O
between - - O
the - - O
absolute - - O
number - - O
of - - O
macrophages - - O
and - - O
the - - O
width - - O
of - - O
the - - O
capsule - - O
. - - O

Here - - O
, - - O
we - - O
have - - O
more - - O
closely - - O
investigated - - O
transactivation - - O
of - - O
the - - O
human - - B-MUT
HSP70 - - I-MUT
promoter - - I-MUT
by - - O
Myb - - B-MUT
proteins - - I-MUT
. - - O

Varieties - - O
of - - O
envious - - O
experience - - O
. - - O

In - - O
the - - O
absence - - O
of - - O
histological - - O
criteria - - O
, - - O
which - - O
it - - O
is - - O
difficult - - O
to - - O
demand - - O
in - - O
view - - O
of - - O
the - - O
variability - - O
of - - O
results - - O
and - - O
potential - - O
dangers - - O
of - - O
endomyocardial - - O
biopsy - - O
involving - - O
such - - O
thin - - O
and - - O
fragile - - O
ventricular - - O
walls - - O
, - - O
the - - O
diagnosis - - O
of - - O
ACRV - - O
is - - O
based - - O
upon - - O
the - - O
concomitant - - O
existence - - O
of - - O
: - - O
( - - O
1 - - O
) - - O
electrophysiological - - O
criteria - - O
: - - O
ventricular - - O
arrhythmias - - O
, - - O
in - - O
particular - - O
sustained - - O
monomorphous - - O
VT - - O
, - - O
with - - O
the - - O
particular - - O
feature - - O
of - - O
a - - O
very - - O
high - - O
degree - - O
of - - O
sensitivity - - O
to - - O
adrenergic - - O
stimulation - - O
( - - O
exercise - - O
) - - O
, - - O
the - - O
existence - - O
of - - O
late - - O
potentials - - O
on - - O
the - - O
high - - O
amplification - - O
ECG - - O
, - - O
a - - O
highly - - O
specific - - O
sign - - O
, - - O
though - - O
unfortunately - - O
of - - O
poor - - O
sensitivity - - O
in - - O
localized - - O
froms - - O
, - - O
those - - O
which - - O
are - - O
most - - O
difficult - - O
to - - O
identify - - O
( - - O
2 - - O
) - - O
; - - O
segmentary - - O
morphological - - O
and - - O
kinetic - - O
RV - - O
abnormalities - - O
, - - O
most - - O
often - - O
resulting - - O
in - - O
localized - - O
akinetic - - O
or - - O
dyskinetic - - O
parietal - - O
vaulting - - O
, - - O
with - - O
stasis - - O
"in - - O
situ" - - O
. - - O

We - - O
show - - O
here - - O
that - - O
v-Rel - - B-MUT
specifically - - O
increased - - O
expression - - O
from - - O
a - - O
reporter - - O
plasmid - - O
containing - - O
multiple - - O
Sp1 - - B-MUT
binding - - I-MUT
sites - - I-MUT
approximately - - O
sixfold - - O
in - - O
chicken - - O
embryo - - O
fibroblasts - - O
( - - O
CEFs - - O
) - - O
, - - O
even - - O
though - - O
v-Rel - - B-MUT
did - - O
not - - O
bind - - O
directly - - O
to - - O
these - - O
sites - - O
. - - O
v-Rel - - B-MUT
also - - O
increased - - O
expression - - O
from - - O
a - - O
reporter - - O
plasmid - - O
containing - - O
a - - O
human - - B-MUT
immunodeficiency - - I-MUT
virus - - I-MUT
type - - I-MUT
1 - - I-MUT
( - - I-MUT
HIV-1 - - I-MUT
) - - I-MUT
long - - I-MUT
terminal - - I-MUT
repeat - - I-MUT
( - - O
LTR - - B-MUT
) - - O
in - - O
which - - O
the - - O
kappa - - B-MUT
B - - I-MUT
binding - - I-MUT
sites - - I-MUT
were - - O
mutated - - O
but - - O
which - - O
still - - O
contained - - O
intact - - O
Sp1 - - B-MUT
binding - - I-MUT
sites - - I-MUT
. - - O

Use - - O
of - - O
Medi-Jector - - O
EZ - - O
dermojet - - O
for - - O
anesthesia - - O
in - - O
minor - - O
surgery - - O
. - - O

Each - - O
half - - O
molecule - - O
contains - - O
four - - O
disulfide - - O
linkages - - O
and - - O
four - - O
cis - - O
peptides - - O
. - - O

The - - O
alpha-subunit - - O
by - - O
itself - - O
binds - - O
to - - O
telomeric - - O
DNA - - O
. - - O

The - - O
positive-acting - - O
global - - O
sulfur - - O
regulatory - - O
protein - - O
, - - O
CYS3 - - B-MUT
, - - O
of - - O
Neurospora - - O
crassa - - O
turns - - O
on - - O
the - - O
expression - - O
of - - O
a - - O
family - - O
of - - O
unlinked - - O
structural - - O
genes - - O
that - - O
encode - - O
enzymes - - O
of - - O
sulfur - - O
catabolism - - O
. - - O

Mechanism - - O
of - - O
immunogenesis - - O
in - - O
vaccination - - O
with - - O
streptomycin-dependent - - O
mutants - - O
of - - O
salmonellae - - O
and - - O
shigellae - - O
. - - O

Cortisol - - O
excretion - - O
, - - O
appeared - - O
to - - O
be - - O
markedly - - O
affected - - O
by - - O
the - - O
season - - O
although - - O
other - - O
factors - - O
such - - O
as - - O
social - - O
and - - O
environmental - - O
stress - - O
cannot - - O
be - - O
discounted - - O
. - - O

The - - O
minimal - - O
promoter - - O
of - - O
the - - O
RII - - B-MUT
beta - - I-MUT
gene - - I-MUT
was - - O
composed - - O
of - - O
two - - O
adjacent - - O
functional - - O
elements - - O
. - - O

Our - - O
results - - O
, - - O
however - - O
, - - O
were - - O
obtained - - O
for - - O
Z - - O
itself - - O
and - - O
not - - O
for - - O
[ - - O
Z - - O
] - - O
. - - O

Structure - - O
and - - O
expression - - O
of - - O
the - - O
mouse - - B-MUT
growth - - I-MUT
hormone - - I-MUT
receptor - - I-MUT
growth - - I-MUT
hormone - - I-MUT
binding - - I-MUT
protein - - I-MUT
gene - - I-MUT
. - - I-MUT

Among - - O
individuals - - O
, - - O
however - - O
, - - O
changes - - O
were - - O
strongly - - O
correlated - - O
with - - O
ACR - - O
levels - - O
at - - O
baseline - - O
. - - O

Investigations - - O
using - - O
hippocampal - - O
slices - - O
maintained - - O
in - - O
vitro - - O
have - - O
demonstrated - - O
that - - O
bursts - - O
of - - O
oscillatory - - O
field - - O
potentials - - O
in - - O
the - - O
gamma - - O
frequency - - O
range - - O
( - - O
30-80 - - O
Hz - - O
) - - O
are - - O
followed - - O
by - - O
a - - O
slower - - O
oscillation - - O
in - - O
the - - O
beta - - O
1 - - O
range - - O
( - - O
12-20 - - O
Hz - - O
) - - O
. - - O

We - - O
suggest - - O
that - - O
CT - - O
scan - - O
be - - O
preferable - - O
in - - O
diagnosis - - O
of - - O
tumors - - O
in - - O
that - - O
area - - O
. - - O

Several - - O
features - - O
of - - O
10 - - O
. - - O
24 - - O
. - - O
6 - - O
cells - - O
suggest - - O
that - - O
the - - O
mutation - - O
disrupts - - O
normal - - O
intracellular - - O
formation - - O
of - - O
peptide - - B-MUT
DR - - I-MUT
complexes - - I-MUT
. - - I-MUT

Human - - O
antitetanus - - O
serum - - O
: - - O
an - - O
unused - - O
wealth - - O
. - - O

Depending - - O
on - - O
treatment - - O
exposures - - O
, - - O
this - - O
at-risk - - O
population - - O
may - - O
experience - - O
life-threatening - - O
late - - O
effects - - O
, - - O
such - - O
as - - O
cirrhosis - - O
secondary - - O
to - - O
hepatitis - - O
C - - O
or - - O
late-onset - - O
anthracycline-induced - - O
cardiomyopathy - - O
, - - O
or - - O
life-changing - - O
late - - O
effects - - O
, - - O
such - - O
as - - O
cognitive - - O
dysfunction - - O
. - - O

Their - - O
effect - - O
on - - O
the - - O
guinea - - O
pig - - O
vas - - O
deferens - - O
. - - O

This - - O
enabled - - O
the - - O
formation - - O
of - - O
stem-loop - - O
templates - - O
with - - O
the - - O
fusion - - O
point - - O
of - - O
the - - O
chimeric - - O
transcript - - O
in - - O
the - - O
loop - - O
and - - O
the - - O
use - - O
of - - O
MLL - - B-MUT
primers - - O
in - - O
two-sided - - O
PCR - - O
. - - O

We - - O
recently - - O
reported - - O
a - - O
placenta-specific - - O
enhancer - - O
in - - O
the - - O
human - - B-MUT
leukemia - - I-MUT
inhibitory - - I-MUT
factor - - I-MUT
receptor - - I-MUT
( - - O
LIFR - - B-MUT
) - - O
gene - - O
and - - O
now - - O
show - - O
detailed - - O
characterization - - O
of - - O
the - - O
226-base - - O
pair - - O
enhancer - - O
( - - O
-4625 - - O
-4400 - - O
nucleotides - - O
) - - O
. - - O

Factors - - O
influencing - - O
semen - - O
characteristics - - O
in - - O
young - - O
boars - - O
reared - - O
in - - O
a - - O
subtropical - - O
environment - - O
were - - O
studied - - O
. - - O

These - - O
equilibrium - - O
solutions - - O
are - - O
then - - O
shown - - O
to - - O
arise - - O
from - - O
the - - O
vertices - - O
of - - O
a - - O
particular - - O
convex - - O
polyhedron - - O
. - - O

The - - O
studied - - O
protein - - O
fragments - - O
consist - - O
of - - O
residues - - O
Arg183-His267 - - O
of - - O
the - - O
human - - B-MUT
ER - - I-MUT
and - - O
residues - - O
Lys438-Gln520 - - O
of - - O
the - - O
rat - - B-MUT
GR - - B-MUT
. - - O

Micro - - O
high-performance - - O
liquid - - O
chromatographic - - O
system - - O
with - - O
micro - - O
precolumn - - O
and - - O
dual - - O
electrochemical - - O
detector - - O
for - - O
direct - - O
injection - - O
analysis - - O
of - - O
catecholamines - - O
in - - O
body - - O
fluids - - O
. - - O

Human - - B-MUT
cytomegalovirus - - I-MUT
immediate-early - - I-MUT
protein - - I-MUT
IE2 - - I-MUT
tethers - - O
a - - O
transcriptional - - O
repression - - O
domain - - O
to - - O
p53 - - B-MUT
. - - O

Neither - - O
verapamil - - O
nor - - O
nifedipine - - O
changed - - O
collateral - - O
myocardial - - O
blood - - O
flow - - O
from - - O
0 - - O
. - - O
10 - - O
+ - - O
- - - O
0 - - O
. - - O
02 - - O
in - - O
the - - O
subendocardium - - O
and - - O
0 - - O
. - - O
17 - - O
+ - - O
- - - O
0 - - O
. - - O
03 - - O
ml - - O
min - - O
g - - O
in - - O
the - - O
subepicardium - - O
. - - O

Sequence - - O
comparison - - O
of - - O
the - - O
0 - - O
. - - O
38 - - O
kb - - O
promoter - - O
sequence - - O
with - - O
the - - O
promoters - - O
of - - O
the - - O
Sm-E - - B-MUT
gene - - O
and - - O
U1 - - B-MUT
snRNA - - I-MUT
genes - - I-MUT
revealed - - O
several - - O
homologous - - O
motifs - - O
, - - O
suggesting - - O
that - - O
genes - - O
encoding - - O
the - - O
snRNP - - B-MUT
components - - O
may - - O
be - - O
coordinately - - O
regulated - - O
. - - O

The - - O
most - - O
common - - O
cause - - O
of - - O
renal - - O
deterioration - - O
in - - O
the - - O
spinal - - O
cord - - O
injured - - O
patient - - O
is - - O
irreversible - - O
vesicoureteral - - O
reflux - - O
. - - O

Identification - - O
of - - O
eotaxin-3 - - B-MUT
will - - O
further - - O
promote - - O
our - - O
understanding - - O
of - - O
the - - O
control - - O
of - - O
eosinophil - - O
trafficking - - O
and - - O
other - - O
CCR3-mediated - - O
biological - - O
phenomena - - O
. - - O

The - - O
efficacy - - O
of - - O
a - - O
Propionibacterium - - O
acnes - - O
product - - O
for - - O
treatment - - O
of - - O
coliform - - O
mastitis - - O
was - - O
evaluated - - O
following - - O
intramammary - - O
infusion - - O
of - - O
Escherichia - - O
coli - - O
. - - O

Patients - - O
had - - O
to - - O
have - - O
adequate - - O
liver - - O
, - - O
renal - - O
, - - O
and - - O
marrow - - O
functions - - O
. - - O

Comparison - - O
with - - O
the - - O
bovine - - O
gene - - O
showed - - O
that - - O
the - - O
5'-flanking - - O
region - - O
of - - O
the - - O
hATP1 - - B-MUT
gene - - I-MUT
has - - O
an - - O
unconserved - - O
guanine-cytosine - - O
( - - O
GC - - O
) - - O
rich - - O
region - - O
, - - O
including - - O
several - - O
binding - - O
motifs - - O
of - - O
transcriptional - - O
factors - - O
, - - O
such - - O
as - - O
Sp1 - - B-MUT
, - - O
AP-2 - - B-MUT
, - - O
and - - O
GCF - - B-MUT
. - - O

Reconstitution - - O
of - - O
Raf-1 - - B-MUT
activity - - O
was - - O
observed - - O
only - - O
with - - O
kinase - - B-MUT
active - - O
Jak1 - - B-MUT
in - - O
both - - O
cell - - O
lines - - O
. - - O

Binding - - O
of - - O
meAda - - B-MUT
is - - O
necessary - - O
to - - O
activate - - O
transcription - - O
of - - O
the - - O
adaptive - - O
response - - O
genes - - O
; - - O
accordingly - - O
, - - O
in - - O
vitro - - O
transcription - - O
of - - O
aidB - - B-MUT
is - - O
dependent - - O
on - - O
the - - O
presence - - O
of - - O
meAda - - B-MUT
. - - O

Spatiotemporal - - O
expression - - O
of - - O
the - - O
PAX3 - - B-MUT
gene - - I-MUT
is - - O
tightly - - O
regulated - - O
during - - O
development - - O
. - - O

Neural - - O
blockade - - O
in - - O
chronic - - O
and - - O
cancer - - O
pain - - O
. - - O

OBJECTIVES - - O
: - - O
1 - - O
) - - O
to - - O
determine - - O
serum - - B-MUT
ACE - - I-MUT
activity - - O
in - - O
patients - - O
with - - O
COPD - - O
treated - - O
with - - O
and - - O
without - - O
continuous - - O
ambulatory - - O
oxygen - - O
therapy - - O
( - - O
CAOT - - O
) - - O
; - - O
2 - - O
) - - O
to - - O
verify - - O
whether - - O
there - - O
is - - O
a - - O
correlation - - O
between - - O
ACE - - B-MUT
and - - O
any - - O
hematological - - O
, - - O
spirometric - - O
or - - O
gasometric - - O
parameter - - O
. - - O

Lymphoproliferative - - O
disorders - - O
arising - - O
under - - O
immunosuppression - - O
with - - O
FK - - O
506 - - O
: - - O
initial - - O
observations - - O
in - - O
a - - O
large - - O
transplant - - O
population - - O
. - - O

Furthermore - - O
, - - O
plasma - - O
fibrinogen - - B-MUT
levels - - O
increased - - O
by - - O
a - - O
mean - - O
of - - O
17 - - O
. - - O
6% - - O
, - - O
a - - O
potentially - - O
adverse - - O
effect - - O
of - - O
gemfibrozil - - O
that - - O
has - - O
not - - O
been - - O
previously - - O
reported - - O
. - - O

This - - O
5' - - O
splice - - O
site - - O
sequence - - O
was - - O
required - - O
for - - O
enhanced - - O
polyadenylation - - O
and - - O
was - - O
recognized - - O
by - - O
both - - O
U1 - - B-MUT
small - - I-MUT
nuclear - - I-MUT
ribonucleoproteins - - I-MUT
( - - O
snRNPs - - B-MUT
) - - O
and - - O
alternative - - B-MUT
splicing - - I-MUT
factor - - I-MUT
splicing - - O
factor - - B-MUT
2 - - I-MUT
( - - I-MUT
ASF - - O
SF2 - - B-MUT
) - - O
. - - B-MUT

One - - O
R-EST - - O
and - - O
one - - O
Pto-like - - B-MUT
sequence - - I-MUT
each - - O
mapped - - O
to - - O
two - - O
locations - - O
. - - O

Expression - - O
of - - O
a - - O
dominant - - B-MUT
negative - - I-MUT
Smad2 - - I-MUT
significantly - - O
reduces - - O
the - - O
level - - O
of - - O
luciferase - - B-MUT
reporter - - I-MUT
activity - - O
induced - - O
by - - O
nodal - - O
treatment - - O
. - - O

SELECTION - - O
CRITERIA - - O
: - - O
Randomised - - O
and - - O
possibly - - O
randomised - - O
trials - - O
using - - O
acupuncture - - O
to - - O
treat - - O
asthma - - O
and - - O
asthma-like - - O
symptoms - - O
. - - O

The - - O
size - - O
of - - O
the - - O
mutant - - O
molecule - - O
corresponds - - O
to - - O
the - - O
unprocessed - - O
cytoplasmic - - O
precursor - - O
( - - O
pre-super-pro-PrB - - B-MUT
) - - O
, - - O
as - - O
detected - - O
in - - O
sec61 - - B-MUT
mutants - - I-MUT
, - - O
when - - O
translocation - - O
into - - O
the - - O
endoplasmic - - O
reticulum - - O
is - - O
blocked - - O
. - - O

Malonate - - O
decarboxylation - - O
in - - O
Malonomonas - - O
rubra - - O
involves - - O
the - - O
formation - - O
of - - O
malonyl-S- - - B-MUT
[ - - I-MUT
acyl-carrier - - I-MUT
protein - - I-MUT
] - - I-MUT
from - - O
acetyl-S- - - B-MUT
[ - - I-MUT
acyl-carrier - - I-MUT
protein - - I-MUT
] - - I-MUT
and - - O
malonate - - O
, - - O
carboxyltransfer - - O
to - - O
a - - O
biotin - - B-MUT
protein - - I-MUT
and - - O
its - - O
decarboxylation - - O
that - - O
is - - O
coupled - - O
to - - O
delta - - O
mu - - O
Na+ - - O
generation - - O
. - - O

Production - - O
of - - O
C - - B-MUT
mu - - I-MUT
RNAs - - I-MUT
, - - O
unlike - - O
mu - - B-MUT
mRNAs - - I-MUT
, - - O
does - - O
not - - O
require - - O
recombination - - O
with - - O
the - - O
joining - - B-MUT
region - - I-MUT
( - - I-MUT
JH - - I-MUT
) - - I-MUT
locus - - I-MUT
. - - O

Finally - - O
, - - O
a - - O
role - - O
for - - O
NF-kappaB - - B-MUT
in - - O
preventing - - O
apoptosis - - O
induced - - O
by - - O
ER - - O
calcium - - O
release - - O
was - - O
demonstrated - - O
by - - O
data - - O
showing - - O
that - - O
sAPPalpha - - B-MUT
prevents - - O
thapsigargin-induced - - O
apoptosis - - O
, - - O
an - - O
effect - - O
blocked - - O
by - - O
kappaB - - B-MUT
decoy - - O
DNA - - O
. - - O

Neurons - - O
were - - O
held - - O
at - - O
-67 - - O
mV - - O
to - - O
equate - - O
voltage-dependent - - O
effects - - O
. - - O

Prenatal - - O
diagnosis - - O
of - - O
galactosaemia - - O
[ - - O
letter - - O
] - - O
. - - O

All - - O
tumors - - O
proved - - O
histologically - - O
to - - O
be - - O
neuroendocrine - - O
in - - O
origin - - O
. - - O

Mechanisms - - O
of - - O
tachyphylaxis - - O
in - - O
regional - - O
anesthesia - - O
of - - O
long - - O
duration - - O
. - - O

Patients - - O
with - - O
more - - O
than - - O
250 - - O
PVC - - O
24 - - O
hours - - O
were - - O
selected - - O
for - - O
distribution - - O
of - - O
PVC - - O
and - - O
CI - - O
evaluation - - O
. - - O

This - - O
dynamic - - O
response - - O
strongly - - O
suggests - - O
that - - O
the - - O
p53 - - B-MUT
and - - O
Rb - - B-MUT
tumor - - O
suppressor - - O
pathways - - O
are - - O
intact - - O
in - - O
HeLa - - O
cells - - O
and - - O
that - - O
repression - - O
of - - O
HPV - - B-MUT
E6 - - I-MUT
and - - O
E7 - - B-MUT
mobilizes - - O
these - - O
pathways - - O
in - - O
an - - O
orderly - - O
fashion - - O
to - - O
deliver - - O
growth - - O
inhibitory - - O
signals - - O
to - - O
the - - O
cells - - O
. - - O

Taken - - O
together - - O
, - - O
our - - O
data - - O
suggest - - O
that - - O
prostate - - O
carcinomas - - O
with - - O
the - - O
Ras - - B-MUT
MAPK - - I-MUT
pathway - - I-MUT
activation - - O
might - - O
have - - O
a - - O
selective - - O
growth - - O
advantage - - O
by - - O
autocrine - - O
TGF-beta1 - - O
production - - B-MUT
. - - O

Optima - - O
) - - O
genomic - - O
library - - O
by - - O
hybridizing - - O
with - - O
elicitor-induced - - O
stilbene - - B-MUT
synthase - - I-MUT
cDNA - - I-MUT
as - - O
a - - O
probe - - O
. - - O

The - - O
GTPase - - B-MUT
activity - - O
of - - O
CDC42Ce - - B-MUT
is - - O
moderately - - O
stimulated - - O
by - - O
human - - B-MUT
n-chimaerin - - I-MUT
, - - O
a - - O
GTPase-activating - - B-MUT
protein - - I-MUT
for - - O
the - - O
related - - O
p21 - - B-MUT
rac1 - - I-MUT
. - - O

Renin - - O
studies - - O
performed - - O
in - - O
34 - - O
hypertensive - - O
patients - - O
and - - O
in - - O
a - - O
control - - O
group - - O
of - - O
11 - - O
recipients - - O
showed - - O
that - - O
elevation - - O
of - - O
plasma - - B-MUT
renin - - I-MUT
activity - - O
and - - O
of - - O
plasma - - O
aldosterone - - O
level - - O
is - - O
frequent - - O
but - - O
difficult - - O
to - - O
interpret - - O
, - - O
particularly - - O
when - - O
a - - O
renal - - O
artery - - O
stenosis - - O
is - - O
observed - - O
. - - O

The - - O
CCAAT - - B-MUT
core - - I-MUT
sequence - - I-MUT
mutants - - I-MUT
in - - O
which - - O
both - - O
CIII - - B-MUT
and - - O
CI - - B-MUT
CII - - I-MUT
were - - I-MUT
abolished - - O
, - - O
also - - O
increased - - O
the - - O
promoter - - O
activity - - O
. - - O

In - - O
the - - O
present - - O
study - - O
, - - O
beta-funaltrexamine - - O
( - - O
beta-FNA - - O
) - - O
and - - O
naltrindole - - O
( - - O
NTI - - O
) - - O
( - - O
nonequilibrium - - O
mu- - - O
and - - O
delta-antagonist - - O
, - - O
respectively - - O
) - - O
were - - O
used - - O
to - - O
precipitate - - O
withdrawal - - O
in - - O
butorphanol-dependent - - O
rats - - O
. - - O

The - - O
frequency - - O
of - - O
SPs - - O
for - - O
both - - O
the - - O
moderate - - O
and - - O
severe - - O
groups - - O
was - - O
significantly - - O
higher - - O
than - - O
that - - O
in - - O
patients - - O
with - - O
a - - O
normal - - O
MMFCV - - O
( - - O
p - - O
< - - O
. - - O
01 - - O
) - - O
; - - O
of - - O
154 - - O
arms - - O
with - - O
a - - O
normal - - O
MMFCV - - O
, - - O
only - - O
9 - - O
( - - O
6% - - O
) - - O
had - - O
an - - O
SP - - O
. - - O

The - - O
pattern - - O
and - - O
timing - - O
of - - O
CARP - - B-MUT
mRNA - - I-MUT
expression - - O
, - - O
including - - O
transient - - O
expression - - O
in - - O
the - - O
tongue - - O
at - - O
14 - - O
. - - O
5 - - O
days - - O
p - - O
. - - O
c - - O
. - - O
, - - O
coincides - - O
with - - O
that - - O
of - - O
Nkx2 - - B-MUT
. - - I-MUT
5 - - I-MUT
Csx - - I-MUT
( - - I-MUT
a - - O
putative - - O
homolog - - O
of - - O
tinman - - O
, - - B-MUT
the - - O
Drosophila - - O
melanogaster - - O
gene - - O
responsible - - O
for - - O
cardiac - - O
development - - O
) - - O
. - - O

188 - - O
patients - - O
received - - O
cimetidine - - O
400 - - O
mg - - O
q - - O
. - - O
i - - O
. - - O
d - - O
. - - O
intravenously - - O
and - - O
1 - - O
, - - O
000 - - O
mg - - O
daily - - O
orally - - O
in - - O
divided - - O
doses - - O
. - - O

Mechanism - - O
of - - O
activation - - O
of - - O
the - - O
vav - - B-MUT
protooncogene - - I-MUT
. - - O
vav - - B-MUT
is - - O
a - - O
human - - O
locus - - O
that - - O
appears - - O
to - - O
be - - O
specifically - - O
expressed - - O
in - - O
cells - - O
of - - O
hematopoietic - - O
origin - - O
regardless - - O
of - - O
their - - O
differentiation - - O
lineage - - O
. - - O

Not - - O
even - - O
extensive - - O
pancreatic - - O
resection - - O
could - - O
prevent - - O
pancreatic - - O
remnant - - O
infection - - O
. - - O

This - - O
concept - - O
is - - O
supported - - O
by - - O
the - - O
identification - - O
of - - O
RH-like - - B-MUT
genes - - I-MUT
in - - O
non - - O
human - - O
primates - - O
. - - O

The - - O
ultrastructural - - O
findings - - O
, - - O
as - - O
well - - O
as - - O
the - - O
urinary - - O
C-peptide - - B-MUT
excretion - - O
, - - O
confirmed - - O
that - - O
the - - O
glycemic - - O
effects - - O
should - - O
not - - O
be - - O
thought - - O
to - - O
be - - O
due - - O
to - - O
a - - O
direct - - O
action - - O
of - - O
the - - O
drugs - - O
used - - O
on - - O
the - - O
endocrine - - O
pancreas - - O
. - - O

HIV-1 - - O
infection - - O
in - - O
rural - - O
Africa - - O
: - - O
is - - O
there - - O
a - - O
difference - - O
in - - O
median - - O
time - - O
to - - O
AIDS - - O
and - - O
survival - - O
compared - - O
with - - O
that - - O
in - - O
industrialized - - O
countries - - O
? - - O
OBJECTIVES - - O
: - - O
To - - O
describe - - O
the - - O
progression - - O
times - - O
of - - O
HIV-1 - - O
infection - - O
from - - O
seroconversion - - O
to - - O
AIDS - - O
and - - O
to - - O
death - - O
, - - O
and - - O
time - - O
from - - O
first - - O
developing - - O
AIDS - - O
to - - O
death - - O
in - - O
rural - - O
Uganda - - O
. - - O

Both - - O
functional - - O
analyses - - O
in - - O
undifferentiated - - O
and - - O
differentiated - - O
F9 - - O
cells - - O
and - - O
characterization - - O
of - - O
DNA-protein - - O
complexes - - O
in - - O
vitro - - O
have - - O
identified - - O
the - - O
sequence - - B-MUT
motifs - - I-MUT
GTGACT - - I-MUT
( - - I-MUT
C - - I-MUT
) - - I-MUT
, - - O
ATTGT - - B-MUT
, - - O
and - - O
GATA - - B-MUT
as - - O
the - - O
key - - O
transcription - - O
factor - - O
binding - - O
sites - - O
. - - O

Estrogen - - O
replacement - - O
therapy - - O
and - - O
risk - - O
of - - O
breast - - O
cancer - - O
: - - O
results - - O
of - - O
two - - O
meta-analyses - - O
. - - O

The - - O
first - - O
gene - - O
, - - O
NSR1 - - B-MUT
, - - O
a - - O
previously - - O
identified - - O
gene - - O
, - - O
encodes - - O
a - - O
protein - - O
involved - - O
in - - O
ribosomal - - O
RNA - - O
maturation - - O
and - - O
possibly - - O
in - - O
transport - - O
of - - O
proteins - - O
into - - O
the - - O
nucleus - - O
. - - O

Northern-blot - - O
analysis - - O
of - - O
mRNA - - O
from - - O
Avicel-grown - - O
N - - O
. - - O
patriciarum - - O
showed - - O
that - - O
xynB - - B-MUT
hybridized - - O
to - - O
a - - O
3 - - O
. - - O
4 - - O
kb - - O
mRNA - - O
species - - O
. - - O

There - - O
were - - O
9 - - O
patients - - O
in - - O
NYHA - - O
class - - O
III - - O
and - - O
8 - - O
in - - O
class - - O
IV - - O
. - - O
( - - O
ABSTRACT - - O
TRUNCATED - - O
AT - - O
250 - - O
WORDS - - O
) - - O

To - - O
assess - - O
the - - O
relationship - - O
between - - O
G - - O
( - - O
q - - O
) - - O
G - - O
( - - O
11 - - O
) - - O
function - - O
with - - O
the - - O
phosphatidylinositol - - O
3-kinase - - B-MUT
dependent - - I-MUT
pathway - - O
, - - O
expression - - O
of - - O
a - - O
dominant-interfering - - O
p85 - - O
regulatory - - B-MUT
subunit - - I-MUT
, - - I-MUT
as - - O
well - - O
as - - O
wortmannin - - O
treatment - - O
inhibited - - O
insulin-stimulated - - O
but - - O
not - - O
G - - O
( - - O
q - - O
) - - O
Q209L-stimulated - - O
GLUT4-EGFP - - O
translocation - - O
. - - B-MUT

Changes - - O
of - - O
the - - O
DB - - B-MUT
sequence - - I-MUT
without - - O
affecting - - O
the - - O
postulated - - O
stem - - O
structure - - O
led - - O
to - - O
drastic - - O
losses - - O
of - - O
translation - - O
efficiency - - O
. - - O

Northern - - O
blot - - O
analysis - - O
of - - O
LeMT - - B-MUT
( - - I-MUT
A - - I-MUT
) - - I-MUT
and - - O
LeMT - - B-MUT
( - - I-MUT
B - - I-MUT
) - - I-MUT
showed - - O
that - - O
transcripts - - O
of - - O
both - - O
MT-like - - B-MUT
genes - - I-MUT
were - - O
more - - O
abundant - - O
in - - O
leaves - - O
than - - O
roots - - O
in - - O
tomato - - O
plants - - O
grown - - O
without - - O
addition - - O
of - - O
extra - - O
metal - - O
ions - - O
, - - O
a - - O
characteristic - - O
of - - O
type - - B-MUT
II - - I-MUT
MTs - - I-MUT
. - - O

Blood - - O
variables - - O
measured - - O
at - - O
eight - - O
intervals - - O
before - - O
, - - O
during - - O
, - - O
and - - O
after - - O
operation - - O
were - - O
as - - O
follows - - O
: - - O
seven - - O
plasma - - O
proteins - - O
, - - O
free - - O
hemoglobin - - B-MUT
, - - O
formed - - O
elements - - O
, - - O
and - - O
clotting - - O
functions - - O
. - - O

Results - - O
of - - O
electron - - O
therapy - - O
of - - O
tumors - - O
in - - O
different - - O
sites - - O
. - - O

Echo - - O
modulation - - O
in - - O
Pr3+ - - O
: - - O
YAlO3 - - O
. - - O

The - - O
various - - O
forms - - O
of - - O
sickle - - O
cell - - O
disease - - O
share - - O
the - - O
common - - O
feature - - O
of - - O
an - - O
abnormal - - O
globin - - B-MUT
chain - - I-MUT
that - - O
, - - O
under - - O
certain - - O
conditions - - O
such - - O
as - - O
hypoxia - - O
, - - O
results - - O
in - - O
the - - O
sickling - - O
of - - O
red - - O
blood - - O
cells - - O
and - - O
obstruction - - O
of - - O
blood - - O
vessels - - O
. - - O

No - - O
TATA - - O
box - - O
was - - O
found - - O
in - - O
the - - O
putative - - O
promoter - - O
region - - O
, - - O
but - - O
multiple - - O
GC - - O
boxes - - O
were - - O
found - - O
around - - O
the - - O
cap - - O
sites - - O
, - - O
supporting - - O
the - - O
previously - - O
inferred - - O
housekeeping - - O
nature - - O
of - - O
CYP51 - - B-MUT
gene - - I-MUT
and - - O
the - - O
existence - - O
of - - O
the - - O
multiple - - O
transcription - - O
initiation - - O
sites - - O
. - - O

Sequencing - - O
the - - O
gene - - O
for - - O
an - - O
imipenem-cefoxitin-hydrolyzing - - O
enzyme - - O
( - - O
CfiA - - B-MUT
) - - O
from - - O
Bacteroides - - O
fragilis - - O
TAL2480 - - O
reveals - - O
strong - - O
similarity - - O
between - - O
CfiA - - B-MUT
and - - O
Bacillus - - B-MUT
cereus - - I-MUT
beta-lactamase - - I-MUT
II - - I-MUT
. - - O

The - - O
ED30 - - O
values - - O
were - - O
2 - - O
. - - O
4 - - O
and - - O
2 - - O
. - - O
2 - - O
mg - - O
kg - - O
and - - O
similar - - O
to - - O
the - - O
respective - - O
values - - O
of - - O
nifedipine - - O
( - - O
ED - - O
30 - - O
: - - O
2 - - O
. - - O
4 - - O
, - - O
2 - - O
. - - O
1 - - O
mg - - O
kg - - O
) - - O
. - - O

The - - O
SH2 - - B-MUT
domain-containing - - I-MUT
inositol - - I-MUT
5'-phosphatase - - I-MUT
( - - O
SHIP - - B-MUT
) - - O
recruits - - O
the - - O
p85 - - B-MUT
subunit - - I-MUT
of - - O
phosphoinositide - - B-MUT
3-kinase - - I-MUT
during - - O
FcgammaRIIb1-mediated - - O
inhibition - - O
of - - O
B - - B-MUT
cell - - I-MUT
receptor - - I-MUT
signaling - - O
. - - O

In - - O
the - - O
face - - O
of - - O
the - - O
outbreak - - O
, - - O
there - - O
was - - O
a - - O
delay - - O
before - - O
vaccination - - O
was - - O
able - - O
to - - O
stop - - O
deaths - - O
. - - O

Hydrocortisone - - O
seems - - O
to - - O
be - - O
unable - - O
to - - O
hinder - - O
the - - O
postdenervation - - O
changes - - O
in - - O
the - - O
muscle - - O
membrane - - O
whereas - - O
high - - O
doses - - O
of - - O
the - - O
hormone - - O
are - - O
able - - O
to - - O
induce - - O
changes - - O
in - - O
the - - O
muscle - - O
membrane - - O
. - - O

The - - O
recovered - - O
calves - - O
were - - O
tested - - O
for - - O
immunity - - O
to - - O
homologous - - O
severe - - O
challenge - - O
, - - O
50 - - O
or - - O
73 - - O
days - - O
after - - O
the - - O
first - - O
infection - - O
. - - O

The - - O
transport - - O
of - - O
a - - O
genetically - - O
engineered - - O
chimeric - - O
transmembrane - - O
protein - - O
connected - - O
to - - O
this - - O
ER - - O
leader - - O
sequence - - O
was - - O
as - - O
efficient - - O
as - - O
that - - O
of - - O
the - - O
original - - O
protein - - O
from - - O
which - - O
the - - O
ER - - O
sequence - - O
has - - O
been - - O
derived - - O
. - - O

J - - O
. - - O

Results - - O
from - - O
in - - O
vitro - - O
transcription-translation - - O
analysis - - O
and - - O
maxicell - - O
experiments - - O
suggested - - O
that - - O
the - - O
447-bp - - O
ORF - - O
was - - O
the - - O
one - - O
being - - O
actively - - O
expressed - - O
. - - O

Extensive - - O
DNA - - O
rearrangement - - O
occurs - - O
during - - O
the - - O
development - - O
of - - O
the - - O
somatic - - O
macronucleus - - O
from - - O
the - - O
germ - - O
line - - O
micronucleus - - O
in - - O
ciliated - - O
protozoans - - O
. - - O

Thus - - O
, - - O
dpp - - B-MUT
and - - O
omb - - B-MUT
promote - - O
both - - O
dorsal - - O
leg - - O
cell - - O
fate - - O
as - - O
well - - O
as - - O
transdetermination-competent - - O
leg - - O
disc - - O
cells - - O
. - - O

Germ-free - - O
rabbits - - O
given - - O
mouse - - O
CRF-flora - - O
showed - - O
values - - O
quite - - O
different - - O
from - - O
control - - O
animals - - O
for - - O
most - - O
parameters - - O
, - - O
indicating - - O
unsuitability - - O
of - - O
mouse - - O
CRF - - O
flora - - O
to - - O
'normalize' - - O
rabbits - - O
. - - O

Based - - O
on - - O
mutational - - O
data - - O
and - - O
possible - - O
mRNA - - O
structure - - O
, - - O
we - - O
hypothesized - - O
about - - O
the - - O
effect - - O
of - - O
mRNA - - O
structure - - O
on - - O
translation - - O
of - - O
the - - O
two - - O
major - - O
C - - B-MUT
EBPepsilon - - I-MUT
isoforms - - I-MUT
: - - I-MUT
p32 - - O
and - - B-MUT
p30 - - O
. - - B-MUT

Moreover - - O
, - - O
unlike - - O
control - - O
rats - - O
operated - - O
animals - - O
did - - O
not - - O
show - - O
aversion - - O
to - - O
the - - O
highest - - O
concentrations - - O
of - - O
saccharin - - O
solutions - - O
. - - O

We - - O
recently - - O
found - - O
that - - O
17 - - O
beta-estradiol - - O
( - - O
E2 - - O
) - - O
not - - O
only - - O
suppresses - - O
bone - - O
resorption - - O
but - - O
also - - O
stimulates - - O
bone - - O
formation - - O
in - - O
the - - O
cancellous - - O
bone - - O
of - - O
female - - O
rats - - O
. - - O

Although - - O
the - - O
E-box - - O
consensus - - O
is - - O
minimally - - O
defined - - O
as - - O
CANNTG - - B-MUT
, - - O
the - - O
adjacent - - O
nucleotides - - O
of - - O
functional - - O
E-boxes - - O
are - - O
variable - - O
for - - O
genes - - O
regulated - - O
by - - O
the - - O
bHLH - - B-MUT
proteins - - I-MUT
. - - O

Forty - - O
patients - - O
, - - O
divided - - O
according - - O
to - - O
their - - O
initial - - O
total - - O
gastrointestinal - - O
transit - - O
times - - O
and - - O
presenting - - O
symptoms - - O
, - - O
were - - O
treated - - O
with - - O
cimetropium - - O
bromide - - O
50 - - O
mg - - O
t - - O
. - - O
d - - O
. - - O
s - - O
. - - O
or - - O
placebo - - O
for - - O
1 - - O
month - - O
according - - O
to - - O
a - - O
double-blind - - O
, - - O
parallel - - O
group - - O
design - - O
. - - O

Far - - O
Western - - O
blot - - O
analysis - - O
suggested - - O
that - - O
the - - O
tandem - - O
SH2 - - B-MUT
domains - - I-MUT
of - - O
SHP2 - - B-MUT
bind - - O
to - - O
Gab1 - - B-MUT
in - - O
a - - O
specific - - O
orientation - - O
, - - O
in - - O
which - - O
the - - O
N-SH2 - - B-MUT
domain - - I-MUT
binds - - O
to - - O
phosphotyrosine - - O
( - - O
Tyr - - O
( - - O
P - - O
) - - O
) - - O
-627 - - O
and - - O
the - - O
C-SH2 - - B-MUT
domain - - I-MUT
binds - - O
to - - O
Tyr - - O
( - - O
P - - O
) - - O
-659 - - O
. - - O

These - - O
results - - O
suggest - - O
that - - O
G - - O
beta - - O
gamma-stimulated - - O
Shc - - B-MUT
phosphorylation - - O
represents - - O
an - - O
early - - O
step - - O
in - - O
the - - O
pathway - - O
leading - - O
to - - O
p21ras - - B-MUT
activation - - O
, - - O
similar - - O
to - - O
the - - O
mechanism - - O
utilized - - O
by - - O
growth - - B-MUT
factor - - I-MUT
tyrosine - - I-MUT
kinase - - I-MUT
receptors - - I-MUT
. - - O

The - - O
Oct-2 - - B-MUT
glutamine-rich - - O
and - - O
proline-rich - - O
activation - - O
domains - - O
can - - O
synergize - - O
with - - O
each - - O
other - - O
or - - O
duplicates - - O
of - - O
themselves - - O
to - - O
activate - - O
transcription - - O
. - - O

This - - O
sequence - - O
also - - O
confers - - O
VDR - - B-MUT
and - - O
vitamin - - O
D - - O
responsiveness - - O
to - - O
a - - O
heterologous - - O
promoter - - O
. - - O

A - - O
follow-up - - O
study - - O
of - - O
22 - - O
patients - - O
with - - O
Ebstein's - - O
anomaly - - O
has - - O
been - - O
performed - - O
. - - O

Processivity - - O
of - - O
DNA - - O
synthesis - - O
by - - O
the - - O
mutant - - O
holoenzyme - - O
containing - - O
pcna-79 - - B-MUT
was - - O
unaffected - - O
on - - O
poly - - O
( - - O
dA - - O
) - - O
x - - O
oligo - - O
( - - O
dT - - O
) - - O
but - - O
was - - O
dramatically - - O
reduced - - O
on - - O
a - - O
natural - - O
template - - O
with - - O
secondary - - O
structure - - O
. - - O

The - - O
present - - O
treatment - - O
strategy - - O
in - - O
progressive - - O
disorders - - O
is - - O
mainly - - O
based - - O
on - - O
the - - O
complementary - - O
effect - - O
of - - O
intensive - - O
radiochemotherapy - - O
, - - O
autologous - - O
stem-cell - - O
transplantation - - O
and - - O
the - - O
rational - - O
use - - O
of - - O
cytokines - - O
, - - O
mostly - - O
colony-stimulating - - B-MUT
factors - - I-MUT
. - - O

Competition - - O
electrophoretic - - O
mobility - - O
shift - - O
and - - O
immunoshift - - O
assays - - O
confirmed - - O
that - - O
NF1 - - B-MUT
factors - - I-MUT
present - - O
in - - O
nuclear - - O
extracts - - O
of - - O
HeLa - - O
and - - O
CV-1 - - O
cells - - O
bind - - O
to - - O
the - - O
BKV-MLP - - B-MUT
. - - O

CKbeta4GT-II - - B-MUT
is - - O
predicted - - O
to - - O
encode - - O
a - - O
type - - B-MUT
II - - I-MUT
transmembrane - - I-MUT
glycoprotein - - I-MUT
of - - O
43 - - O
kDa - - O
with - - O
five - - O
potential - - O
N-linked - - O
glycosylation - - O
sites - - O
. - - O

Analysis - - O
of - - O
the - - O
binding - - O
of - - O
Lrp - - B-MUT
to - - O
a - - O
set - - O
of - - O
circularly - - O
permuted - - O
DNA - - O
fragments - - O
from - - O
this - - O
region - - O
indicates - - O
that - - O
Lrp - - B-MUT
induces - - O
DNA - - O
bending - - O
. - - O

Plasmids - - O
were - - O
constructed - - O
with - - O
the - - O
mouse - - O
promoter - - O
region - - O
linked - - O
to - - O
the - - O
reporter - - B-MUT
gene - - I-MUT
chloramphenicol - - I-MUT
acetyltransferase - - I-MUT
( - - O
CAT - - B-MUT
) - - O
, - - O
and - - O
transiently - - O
and - - O
stably - - O
transfected - - O
in - - O
the - - O
INS-1 - - O
cells - - O
. - - O

A - - O
set - - O
of - - O
peptides - - O
corresponding - - O
to - - O
the - - O
individual - - O
elements - - O
of - - O
secondary - - O
structure - - O
derived - - O
from - - O
the - - O
N-terminal - - O
domain - - O
of - - O
the - - O
ribosomal - - B-MUT
protein - - I-MUT
L9 - - I-MUT
have - - O
been - - O
synthesized - - O
. - - O

Both - - O
can - - O
be - - O
elevated - - O
on - - O
a - - O
single - - O
vascular - - O
pedicle - - O
based - - O
on - - O
the - - O
superficial - - O
temporal - - O
artery - - O
, - - O
the - - O
double-layered - - O
temporal - - O
fascia - - O
flap - - O
. - - O

The - - O
two-wave - - O
, - - O
1995-1996 - - O
National - - O
Longitudinal - - O
Study - - O
of - - O
Adolescent - - O
Health - - O
uses - - O
a - - O
measure - - O
of - - O
depressive - - O
symptomatology - - O
across - - O
a - - O
12-month - - O
interval - - O
. - - O

Although - - O
the - - O
consumption - - O
of - - O
myoglobin-bound - - O
O2 - - O
( - - O
MbO2 - - O
) - - O
stores - - O
in - - O
seal - - O
muscles - - O
has - - O
been - - O
demonstrated - - O
in - - O
seal - - O
muscles - - O
during - - O
laboratory - - O
simulations - - O
of - - O
diving - - O
, - - O
this - - O
may - - O
not - - O
be - - O
a - - O
feature - - O
of - - O
normal - - O
field - - O
diving - - O
in - - O
which - - O
measurements - - O
of - - O
heart - - O
rate - - O
and - - O
lactate - - O
production - - O
show - - O
marked - - O
differences - - O
from - - O
the - - O
profound - - O
diving - - O
response - - O
induced - - O
by - - O
forced - - O
immersion - - O
. - - O

Postprandial - - O
plasma - - B-MUT
enteroglucagon - - I-MUT
concentration - - O
after - - O
90 - - O
minutes - - O
in - - O
untreated - - O
patients - - O
correlated - - O
positively - - O
to - - O
the - - O
faecal - - O
fat - - O
excretion - - O
( - - O
r - - O
= - - O
0 - - O
. - - O
58 - - O
, - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
02 - - O
) - - O
. - - O

In - - O
addition - - O
, - - O
the - - O
megabase - - O
region - - O
surrounding - - O
the - - O
dagA - - B-MUT
locus - - I-MUT
was - - O
mapped - - O
. - - O

In - - O
an - - O
attempt - - O
to - - O
investigate - - O
whether - - O
the - - O
intergenic - - O
region - - O
between - - O
the - - O
oleosin - - B-MUT
and - - O
a - - O
second - - O
open - - O
reading - - O
frame - - O
( - - O
ORFII - - O
) - - O
in - - O
Brassica - - O
napus - - O
( - - O
L - - O
. - - O
) - - O
is - - O
a - - O
divergent - - O
promoter - - O
, - - O
and - - O
also - - O
to - - O
characterize - - O
the - - O
ORFII - - B-MUT
, - - O
cDNA - - B-MUT
clones - - I-MUT
homologous - - I-MUT
to - - I-MUT
ORFII - - I-MUT
were - - O
isolated - - O
from - - O
a - - O
leaf - - O
cDNA - - O
library - - O
. - - O

The - - O
protein - - O
is - - O
composed - - O
of - - O
a - - O
central - - O
alpha-helical - - O
portion - - O
with - - O
globular - - O
domains - - O
at - - O
both - - O
NH2 - - O
and - - O
COOH - - O
termini - - O
, - - O
and - - O
the - - O
epitope - - O
to - - O
the - - O
monoclonal - - O
antibody - - O
resides - - O
in - - O
the - - O
central - - O
alpha-helical - - O
stalk - - O
. - - O

Furthermore - - O
, - - O
using - - O
transgenic - - O
mouse - - O
technology - - O
we - - O
localized - - O
independent - - O
cis-regulatory - - O
elements - - O
controlling - - O
the - - O
tissue-specific - - O
expression - - O
of - - O
Pax6 - - B-MUT
. - - O

Indirect - - O
plasma - - O
parameters - - O
such - - O
as - - O
vitamin - - O
E - - O
, - - O
thiol - - O
and - - O
uric - - O
acid - - O
levels - - O
were - - O
also - - O
quantified - - O
. - - O

In - - O
addition - - O
, - - O
we - - O
did - - O
not - - O
detect - - O
significant - - O
differences - - O
in - - O
CDR3 - - B-MUT
sequences - - I-MUT
of - - O
endogenous - - B-MUT
Ig - - I-MUT
lambdaL - - I-MUT
and - - O
kappaL - - B-MUT
chain - - I-MUT
gene - - I-MUT
loci - - I-MUT
cloned - - O
from - - O
peripheral - - O
blood - - O
lymphocytes - - O
of - - O
an - - O
NBS - - O
patient - - O
and - - O
of - - O
healthy - - O
individuals - - O
. - - O

To - - O
investigate - - O
the - - O
convergent - - O
role - - O
of - - O
the - - O
insulin - - B-MUT
IGF-I - - I-MUT
effector - - I-MUT
pathway - - O
mediating - - O
bihormonal - - O
stimulation - - O
of - - O
LDL - - O
receptor - - B-MUT
promoter - - I-MUT
expression - - I-MUT
, - - O
transfected - - O
granulosa-luteal - - O
cells - - O
were - - O
pretreated - - O
for - - O
30 - - O
min - - O
with - - O
two - - O
specific - - O
inhibitors - - O
of - - O
phophatidylinositol - - O
3-kinase - - B-MUT
, - - I-MUT
wortmannin - - O
( - - O
100 - - O
nM - - O
) - - O
and - - O
LY - - O
294002 - - O
( - - O
10 - - O
microM - - O
) - - O
, - - O
or - - O
of - - O
mitogen-activated - - O
protein - - B-MUT
kinase - - I-MUT
kinase - - I-MUT
, - - I-MUT
PD - - O
98059 - - O
( - - O
50 - - O
microM - - O
) - - O
, - - O
U0126 - - O
( - - O
10 - - O
microM - - O
) - - O
, - - O
or - - O
the - - O
latter's - - O
inactive - - O
derivative - - O
, - - O
U0124 - - O
( - - O
10 - - O
microM - - O
) - - O
. - - O

Thus - - O
, - - O
the - - O
consensus - - O
sequences - - O
for - - O
phosphatase - - B-MUT
regulation - - O
are - - O
5'-GCACGTGGG-3' - - B-MUT
and - - O
5'-GCACGTTTT-3' - - B-MUT
which - - O
differ - - O
from - - O
the - - O
binding - - O
sequences - - O
for - - O
the - - O
Cpflp - - B-MUT
protein - - O
required - - O
for - - O
transcription - - O
of - - O
the - - O
genes - - O
in - - O
methionine - - O
biosynthesis - - O
and - - O
for - - O
centromere - - O
function - - O
. - - O

We - - O
conclude - - O
from - - O
this - - O
study - - O
that - - O
Arix - - B-MUT
and - - O
NBPhox - - B-MUT
exhibit - - O
indistinguishable - - O
and - - O
independent - - O
transcriptional - - O
regulatory - - O
properties - - O
on - - O
the - - O
DBH - - B-MUT
promoter - - I-MUT
. - - O

The - - O
human - - B-MUT
T - - I-MUT
cell - - I-MUT
leukemia - - I-MUT
lymphotropic - - I-MUT
virus - - I-MUT
type - - I-MUT
1 - - I-MUT
Tax - - I-MUT
protein - - I-MUT
represses - - I-MUT
MyoD-dependent - - O
transcription - - O
by - - O
inhibiting - - O
MyoD-binding - - O
to - - O
the - - O
KIX - - O
domain - - B-MUT
of - - I-MUT
p300 - - O
. - - B-MUT

With - - O
current - - O
methodology - - O
beta-2 - - B-MUT
transferrin - - I-MUT
does - - O
not - - O
appear - - O
to - - O
be - - O
a - - O
reliable - - O
clinical - - O
marker - - O
for - - O
perilymph - - O
in - - O
the - - O
operative - - O
setting - - O
. - - O

This - - O
sequence - - O
is - - O
almost - - O
identical - - O
with - - O
that - - O
of - - O
human - - B-MUT
luteinizing - - I-MUT
hormone - - I-MUT
( - - O
Sairam - - O
, - - O
M - - O
. - - O

However - - O
, - - O
little - - O
is - - O
known - - O
regarding - - O
the - - O
genomic - - O
organization - - O
and - - O
developmental - - O
expression - - O
of - - O
the - - O
caveolin - - B-MUT
gene - - I-MUT
family - - I-MUT
. - - O

Avian - - O
reproductive - - O
system - - O
: - - O
daily - - O
variations - - O
in - - O
responses - - O
to - - O
hormones - - O
. - - O
pp - - O
. - - O

The - - O
number - - O
of - - O
polymerases - - B-MUT
active - - O
in - - O
vitro - - O
at - - O
the - - O
E - - B-MUT
strand - - I-MUT
promoter - - I-MUT
was - - O
similar - - O
to - - O
the - - O
number - - O
of - - O
polymerases - - B-MUT
at - - O
the - - O
L - - B-MUT
strand - - I-MUT
promoter - - I-MUT
. - - O

Our - - O
data - - O
suggest - - O
that - - O
it - - O
may - - O
be - - O
possible - - O
to - - O
individualize - - O
hCG - - B-MUT
administration - - O
at - - O
midcycle - - O
by - - O
determining - - O
the - - O
number - - O
of - - O
follicles - - O
greater - - O
than - - O
1 - - O
cm - - O
by - - O
ultrasound - - O
on - - O
cycle - - O
day - - O
12 - - O
or - - O
13 - - O
and - - O
giving - - O
hCG - - B-MUT
when - - O
serum - - O
E2 - - O
levels - - O
reach - - O
1100 - - O
to - - O
1200 - - O
pmol - - O
l - - O
per - - O
follicle - - O
. - - O

An - - O
electrophoretic - - O
mobility - - O
shift - - O
assay - - O
was - - O
performed - - O
to - - O
characterize - - O
the - - O
binding - - O
property - - O
of - - O
TR2 - - B-MUT
and - - O
its - - O
truncated - - O
isoform - - O
. - - O

Adrenergic - - O
nerve - - O
function - - O
, - - O
noradrenaline - - O
level - - O
and - - O
noradrenaline - - O
uptake - - O
in - - O
cat - - O
nictitating - - O
membrane - - O
after - - O
reserpine - - O
treatment - - O
. - - O

STAT5A - - B-MUT
mutations - - O
in - - O
the - - O
Src - - B-MUT
homology - - I-MUT
2 - - I-MUT
( - - O
SH2 - - B-MUT
) - - O
and - - O
SH3 - - B-MUT
domains - - I-MUT
did - - O
not - - O
alter - - O
the - - O
BTK-mediated - - O
tyrosine - - O
phosphorylation - - O
. - - O

After - - O
determining - - O
isoflurane - - O
MAC - - O
in - - O
triplicate - - O
, - - O
birds - - O
were - - O
given - - O
a - - O
mu-opioid - - O
agonist - - O
( - - O
morphine - - O
, - - O
n - - O
= - - O
9 - - O
) - - O
or - - O
a - - O
kappa-opioid - - O
agonist - - O
( - - O
U50488H - - O
, - - O
n - - O
= - - O
9 - - O
) - - O
. - - O

Functional - - O
disorders - - O
of - - O
the - - O
ureter - - O
following - - O
gynecologic - - O
surgery - - O
. - - O

Based - - O
on - - O
the - - O
comparison - - O
of - - O
the - - O
predicted - - O
amino - - O
acid - - O
sequences - - O
of - - O
1-sst - - B-MUT
and - - O
1-fft - - B-MUT
with - - O
those - - O
of - - O
other - - O
plant - - O
fructosyl - - B-MUT
transferase - - I-MUT
genes - - I-MUT
, - - O
we - - O
postulate - - O
that - - O
both - - O
plant - - O
fructan - - B-MUT
genes - - I-MUT
have - - O
evolved - - O
from - - O
plant - - O
invertase - - B-MUT
genes - - O
. - - O

Further - - O
investigations - - O
are - - O
necessary - - O
to - - O
elucidate - - O
the - - O
biochemical - - O
and - - O
physiological - - O
properties - - O
of - - O
DLIS - - O
. - - O

Animals - - O
may - - O
be - - O
immunized - - O
by - - O
oral - - O
vaccination - - O
, - - O
but - - O
natural - - O
mechanisms - - O
that - - O
also - - O
can - - O
terminate - - O
outbreaks - - O
are - - O
discussed - - O
. - - O

Together - - O
with - - O
a - - O
considerably - - O
shortened - - O
and - - O
interrupted - - O
aromatic - - O
aa - - O
stretch - - O
in - - O
this - - O
region - - O
, - - O
these - - O
differences - - O
are - - O
discussed - - O
in - - O
terms - - O
of - - O
the - - O
peculiar - - O
affinity - - O
of - - O
cyanobacterial - - B-MUT
cytochrome - - I-MUT
oxidases - - I-MUT
for - - O
acidic - - O
c-type - - B-MUT
cytochromes - - I-MUT
. - - O

Comparison - - O
of - - O
sequences - - O
from - - O
-215 - - O
to - - O
+1 - - O
bp - - O
identified - - O
consensus - - O
binding - - O
sites - - O
for - - O
the - - O
homeodomain - - B-MUT
transcription - - I-MUT
factor - - I-MUT
thyroid - - B-MUT
transcription - - I-MUT
factor-1 - - I-MUT
( - - O
TTF-1 - - B-MUT
) - - O
. - - O

An - - O
approach - - O
to - - O
a - - O
biomathematical - - O
model - - O
of - - O
lymphocytopoiesis - - O
. - - O

A - - O
five-phase - - O
experiment - - O
was - - O
designed - - O
to - - O
investigate - - O
( - - O
a - - O
) - - O
whether - - O
contingent - - O
music-listening - - O
would - - O
act - - O
as - - O
a - - O
reinforcer - - O
to - - O
increase - - O
arithmetic - - O
performance - - O
of - - O
EMR - - O
children - - O
and - - O
( - - O
b - - O
) - - O
whether - - O
this - - O
contingent - - O
reinforcement - - O
would - - O
affect - - O
preference - - O
for - - O
that - - O
reinforcer - - O
. - - O

Purified - - O
PLB - - B-MUT
showed - - O
optimal - - O
lyase - - B-MUT
activity - - O
at - - O
pH - - O
10 - - O
. - - O
0 - - O
. - - O

We - - O
now - - O
show - - O
that - - O
RNU2 - - B-MUT
fragility - - O
can - - O
be - - O
induced - - O
by - - O
transfection - - O
with - - O
an - - O
expression - - O
vector - - O
encoding - - O
Ad12 - - B-MUT
E1B - - I-MUT
55 - - O
kDa - - O
alone - - O
but - - O
not - - O
by - - O
an - - O
E1 - - B-MUT
vector - - O
encoding - - O
all - - O
E1 - - B-MUT
products - - I-MUT
( - - O
3 - - O
E1A - - B-MUT
proteins - - I-MUT
, - - O
as - - O
well - - O
as - - O
the - - O
E1B - - B-MUT
19 - - O
kDa - - O
and - - O
55 - - O
kDa - - O
proteins - - O
) - - O
. - - O

A - - O
case - - O
report - - O
with - - O
angiographic - - O
follow-up - - O
study - - O
. - - O

The - - O
PAI-2 - - B-MUT
gene - - I-MUT
is - - O
one - - O
of - - O
the - - O
most - - O
TNF-responsive - - B-MUT
genes - - I-MUT
known - - O
and - - O
is - - O
also - - O
highly - - O
induced - - O
by - - O
the - - O
phorbol - - O
ester - - O
phorbol - - O
12-myristate - - O
13-acetate - - O
( - - O
PMA - - O
) - - O
and - - O
the - - O
phosphatase - - B-MUT
inhibitor - - O
, - - O
okadaic - - O
acid - - O
, - - O
in - - O
both - - O
HT-1080 - - O
fibrosarcoma - - O
and - - O
U-937 - - O
histiocytic - - O
cells - - O
. - - O

Mutational - - O
analyses - - O
showed - - O
that - - O
in-frame - - O
stop - - O
codons - - O
introduced - - O
into - - O
five - - O
of - - O
seven - - O
RNA - - B-MUT
2 - - I-MUT
ORFs - - I-MUT
did - - O
not - - O
affect - - O
accumulation - - O
of - - O
progeny - - O
LIYV - - B-MUT
RNA - - I-MUT
1 - - I-MUT
or - - O
RNA - - B-MUT
2 - - I-MUT
, - - O
confirming - - O
that - - O
RNA - - B-MUT
2 - - I-MUT
does - - O
not - - O
encode - - O
proteins - - O
necessary - - O
for - - O
LIYV - - B-MUT
RNA - - I-MUT
replication - - O
. - - O

CPT-11 - - O
was - - O
administered - - O
as - - O
a - - O
30-minute - - O
i - - O
. - - O
v - - O
. - - O
infusion - - O
at - - O
a - - O
dose - - O
of - - O
350 - - O
mg - - O
m2 - - O
diluted - - O
in - - O
250 - - O
ml - - O
normal - - O
saline - - O
every - - O
3 - - O
weeks - - O
. - - O

Responses - - O
of - - O
TLD - - O
Mg2SiO4 - - O
: - - O
Tb - - O
and - - O
radiophotoluminescent - - O
glass - - O
to - - O
heavy - - O
charged - - O
particles - - O
and - - O
space - - O
radiation - - O
. - - O

Because - - O
of - - O
the - - O
increased - - O
CPK - - B-MUT
activity - - O
found - - O
in - - O
normal - - O
newborns - - O
, - - O
screening - - O
for - - O
Duchenne-type - - O
muscular - - O
dystrophy - - O
should - - O
be - - O
postponed - - O
for - - O
a - - O
few - - O
weeks - - O
after - - O
delivery - - O
. - - O

CYC2 - - B-MUT
encodes - - O
a - - O
24-kDa - - O
protein - - O
that - - O
has - - O
sequence - - O
identity - - O
to - - O
the - - O
Neurospora - - B-MUT
crassa - - I-MUT
PREG1 - - I-MUT
and - - O
the - - O
S - - B-MUT
. - - I-MUT
cerevisiae - - I-MUT
PHO80 - - I-MUT
cyclin - - I-MUT
. - - O

Similarly - - O
, - - O
overexpression - - O
of - - O
increasing - - O
concentration - - O
of - - O
COUP-TFI - - B-MUT
, - - O
but - - O
not - - O
COUP-TFI - - B-MUT
delta35 - - I-MUT
, - - O
can - - O
squelch - - O
the - - O
silencing - - O
activity - - O
of - - O
the - - O
unliganded - - O
TRbeta - - B-MUT
. - - O

It - - O
was - - O
concluded - - O
, - - O
that - - O
on - - O
a - - O
given - - O
section - - O
, - - O
75 - - O
, - - O
7 - - O
per - - O
cent - - O
of - - O
the - - O
trabeculae - - O
were - - O
in - - O
contact - - O
with - - O
vascular - - O
cavities - - O
. - - O

The - - O
immuno-purified - - O
mRNA - - O
in - - O
the - - O
polysome - - O
complex - - O
was - - O
used - - O
to - - O
prepare - - O
cDNA - - O
with - - O
which - - O
to - - O
probe - - O
a - - O
D - - O
. - - O
melanogaster - - O
genomic - - O
library - - O
. - - O

Retrogradely - - O
labelled - - O
neurons - - O
significantly - - O
prevailed - - O
in - - O
the - - O
ipsilateral - - O
substantia - - O
nigra - - O
pars - - O
compacta - - O
. - - O

Mechanism - - O
of - - O
the - - O
t - - O
( - - O
14 - - O
; - - O
18 - - O
) - - O
chromosomal - - O
translocation - - O
: - - O
structural - - O
analysis - - O
of - - O
both - - O
derivative - - O
14 - - O
and - - O
18 - - O
reciprocal - - O
partners - - O
. - - O

In - - O
the - - O
free-swimming - - O
rotatory - - O
test - - O
mice - - O
spend - - O
most - - O
of - - O
the - - O
time - - O
swimming - - O
close - - O
to - - O
the - - O
wall - - O
of - - O
the - - O
container - - O
attempting - - O
to - - O
escape - - O
from - - O
an - - O
aversive - - O
test - - O
situation - - O
. - - O

We - - O
have - - O
examined - - O
by - - O
in - - O
vitro - - O
footprinting - - O
a - - O
region - - O
located - - O
downstream - - O
of - - O
the - - O
human - - O
immunodeficiency - - O
virus - - O
, - - O
type - - O
1 - - O
( - - O
HIV-1 - - O
) - - O
promoter - - O
found - - O
to - - O
be - - O
hypersensitive - - O
to - - O
DNase - - B-MUT
I - - I-MUT
digestion - - O
in - - O
vivo - - O
. - - O

Sequencing - - O
of - - O
the - - O
three - - O
pag-3 - - B-MUT
alleles - - I-MUT
showed - - O
that - - O
two - - O
apparent - - O
null - - O
alleles - - O
encode - - O
a - - O
nonsense - - O
mutation - - O
before - - O
the - - O
zinc - - O
fingers - - O
and - - O
a - - O
missense - - O
mutation - - O
in - - O
the - - O
fourth - - O
zinc - - O
finger - - O
that - - O
changes - - O
a - - O
coordinating - - O
histidine - - O
to - - O
a - - O
tyrosine - - O
. - - O

Codon - - O
usage - - O
in - - O
C - - O
. - - O
reinhardtii - - O
mitochondria - - O
is - - O
highly - - O
biased - - O
, - - O
with - - O
eight - - O
codons - - O
entirely - - O
absent - - O
from - - O
all - - O
protein-coding - - O
genes - - O
; - - O
however - - O
, - - O
even - - O
though - - O
codon - - O
usage - - O
is - - O
restricted - - O
, - - O
it - - O
appears - - O
that - - O
C - - O
. - - O
reinhardtii - - O
mtDNA - - O
cannot - - O
encode - - O
the - - O
minimum - - O
number - - O
of - - O
tRNAs - - O
needed - - O
to - - O
support - - O
mitochondrial - - O
protein - - O
synthesis - - O
. - - O

Dialyzable - - O
transfer - - B-MUT
factor - - I-MUT
. - - O

Together - - O
, - - O
these - - O
results - - O
indicate - - O
that - - O
IL-1 - - B-MUT
beta - - I-MUT
induces - - O
VEGF - - B-MUT
gene - - I-MUT
expression - - O
at - - O
both - - O
transcriptional - - O
and - - O
post-transcriptional - - O
levels - - O
, - - O
and - - O
IL-1 - - B-MUT
beta - - I-MUT
evokes - - O
p38 - - B-MUT
MAPK - - I-MUT
and - - O
JNK - - B-MUT
signalings - - O
, - - O
which - - O
in - - O
turn - - O
stimulate - - O
the - - O
transcription - - O
of - - O
the - - O
VEGF - - B-MUT
gene - - I-MUT
through - - O
Sp1-binding - - B-MUT
sites - - I-MUT
. - - O

We - - O
measured - - O
basal - - O
plasma - - O
prolactin - - B-MUT
concentrations - - O
( - - O
in - - O
samples - - O
obtained - - O
during - - O
the - - O
early - - O
follicular - - O
phase - - O
) - - O
in - - O
25 - - O
normal - - O
( - - O
control - - O
) - - O
women - - O
and - - O
in - - O
a - - O
similar - - O
group - - O
of - - O
40 - - O
patients - - O
with - - O
a - - O
long-standing - - O
history - - O
of - - O
infertility - - O
. - - O

We - - O
report - - O
here - - O
the - - O
discovery - - O
of - - O
a - - O
new - - O
actin-related - - B-MUT
gene - - I-MUT
in - - O
this - - O
organism - - O
, - - O
which - - O
we - - O
have - - O
named - - O
ACT4 - - B-MUT
. - - O

In - - O
this - - O
method - - O
, - - O
PLP - - O
in - - O
plasma - - O
can - - O
be - - O
determined - - O
with - - O
high - - O
sensitivity - - O
using - - O
derivatization - - O
with - - O
sodium - - O
bisulfite - - O
in - - O
the - - O
mobile - - O
phase - - O
. - - O

Polypeptide - - B-MUT
growth - - I-MUT
factors - - I-MUT
and - - O
cytokines - - O
mediate - - O
their - - O
biochemical - - O
functions - - O
through - - O
their - - O
responsive - - O
receptors - - O
. - - O

Auditory - - O
clicks - - O
were - - O
given - - O
at - - O
a - - O
rate - - O
of - - O
20 - - O
s - - O
( - - O
-1 - - O
) - - O
. - - O

PPAR - - B-MUT
gamma - - I-MUT
mRNA - - I-MUT
levels - - O
were - - O
reduced - - O
by - - O
95% - - O
with - - O
3 - - O
nM - - O
TNF - - B-MUT
alpha - - I-MUT
treatment - - O
for - - O
24 - - O
h - - O
. - - O

We - - O
studied - - O
the - - O
functional - - O
interaction - - O
between - - O
human - - O
embryonic - - O
zeta - - B-MUT
2 - - I-MUT
globin - - I-MUT
promoter - - O
and - - O
the - - O
alpha - - B-MUT
globin - - I-MUT
regulatory - - I-MUT
element - - I-MUT
( - - O
HS-40 - - B-MUT
) - - O
located - - O
40 - - O
kb - - O
upstream - - O
of - - O
the - - O
zeta - - B-MUT
2 - - I-MUT
globin - - I-MUT
gene - - I-MUT
. - - O

The - - O
HiNF-D - - B-MUT
( - - I-MUT
CDP - - I-MUT
cut - - I-MUT
) - - I-MUT
complex - - I-MUT
with - - I-MUT
the - - O
H4 - - O
promoter - - B-MUT
is - - I-MUT
immunoreactive - - O
with - - O
antibodies - - O
against - - O
CDP - - O
cut - - B-MUT
and - - I-MUT
pRB - - I-MUT
but - - O
not - - B-MUT
p107 - - O
, - - O
whereas - - B-MUT
the - - O
CDP - - O
cut - - O
complex - - B-MUT
with - - I-MUT
a - - I-MUT
nonhistone - - I-MUT
promoter - - O
( - - O
gp91-phox - - B-MUT
) - - I-MUT
reacts - - O
only - - B-MUT
with - - O
CDP - - O
and - - O
p107 - - O
antibodies - - B-MUT
. - - O

The - - O
genome - - O
of - - O
all - - O
retroviruses - - O
consists - - O
of - - O
two - - O
identical - - O
RNAs - - O
noncovalently - - O
linked - - O
near - - O
their - - O
5' - - O
end - - O
. - - O

Adding - - O
phytase - - B-MUT
and - - O
nP - - O
improved - - O
the - - O
orderliness - - O
of - - O
development - - O
, - - O
mineralization - - O
and - - O
arrangement - - O
of - - O
cartilage - - O
and - - O
bone - - O
cells - - O
, - - O
and - - O
alleviated - - O
the - - O
effects - - O
of - - O
P - - O
deficiency - - O
on - - O
the - - O
histological - - O
and - - O
gross - - O
structure - - O
of - - O
the - - O
tibias - - O
. - - O

Characterization - - O
of - - O
the - - O
microtubule - - B-MUT
binding - - I-MUT
domain - - I-MUT
of - - O
microtubule - - B-MUT
actin - - I-MUT
crosslinking - - I-MUT
factor - - I-MUT
( - - O
MACF - - B-MUT
) - - O
: - - O
identification - - O
of - - O
a - - O
novel - - O
group - - O
of - - O
microtubule - - B-MUT
associated - - I-MUT
proteins - - I-MUT
. - - O

Somatostatin - - B-MUT
gene - - I-MUT
expression - - O
in - - O
pancreatic - - O
islet - - O
cells - - O
is - - O
directed - - O
by - - O
cell-specific - - O
DNA - - O
control - - O
elements - - O
and - - O
DNA-binding - - O
proteins - - O
. - - O

In - - O
about - - O
one - - O
third - - O
of - - O
the - - O
cases - - O
this - - O
operation - - O
results - - O
in - - O
tonal - - O
and - - O
vocal - - O
improvement - - O
for - - O
patients - - O
suffering - - O
from - - O
progressive - - O
perceptive - - O
deafness - - O
. - - O

Apart - - O
from - - O
iron - - O
regulation - - O
, - - O
sodA - - B-MUT
expression - - O
was - - O
affected - - O
by - - O
changes - - O
in - - O
DNA - - O
topology - - O
induced - - O
by - - O
coumermycin - - O
A - - O
but - - O
not - - O
by - - O
the - - O
global - - O
virulence - - O
regulatory - - O
Bvg - - B-MUT
system - - I-MUT
. - - O

Influence - - O
of - - O
neural - - O
regulation - - O
on - - O
anti-arrhythmic - - O
effects - - O
of - - O
GABA - - O
in - - O
rats - - O
. - - O

The - - O
wild-type - - O
and - - O
altered - - O
forms - - O
of - - O
the - - O
F - - B-MUT
protein - - I-MUT
were - - O
expressed - - O
in - - O
BHK-21 - - O
and - - O
HeLa - - O
T4 - - O
cells - - O
by - - O
use - - O
of - - O
the - - O
recombinant - - B-MUT
vaccinia - - I-MUT
virus-encoding - - I-MUT
T7 - - I-MUT
polymerase - - I-MUT
system - - O
. - - O

Nuclear - - O
localization - - O
and - - O
protein - - O
sequence - - O
similarities - - O
suggested - - O
that - - O
the - - O
SPT2 - - B-MUT
SIN1 - - I-MUT
protein - - I-MUT
may - - I-MUT
be - - O
related - - O
to - - O
the - - O
nonhistone - - O
chromosomal - - B-MUT
protein - - I-MUT
HMG1 - - I-MUT
. - - I-MUT

In - - O
contrast - - O
with - - O
previous - - O
two-pool - - O
models - - O
, - - O
provisions - - O
were - - O
made - - O
for - - O
folate - - O
turnover - - O
by - - O
urinary - - O
folate - - O
excretion - - O
( - - O
as - - O
measured - - O
here - - O
) - - O
and - - O
by - - O
fecal - - O
excretion - - O
and - - O
catabolic - - O
processes - - O
. - - O

These - - O
results - - O
suggest - - O
that - - O
, - - O
for - - O
the - - O
HML - - B-MUT
ARS - - B-MUT
cluster - - I-MUT
( - - O
ARS303 - - B-MUT
, - - O
ARS320 - - B-MUT
, - - O
and - - O
ARS302 - - B-MUT
) - - O
, - - O
inactivity - - O
of - - O
origins - - O
is - - O
independent - - O
of - - O
local - - O
transcriptional - - O
silencing - - O
, - - O
even - - O
though - - O
origins - - O
and - - O
silencers - - O
share - - O
key - - O
cis- - - O
and - - O
trans-acting - - O
components - - O
. - - O

Finally - - O
, - - O
we - - O
demonstrate - - O
that - - O
C - - B-MUT
EBP - - I-MUT
alpha - - I-MUT
can - - I-MUT
also - - O
active - - O
the - - O
GM-CSF - - O
receptor - - B-MUT
alpha - - I-MUT
promoter - - I-MUT
in - - O
nonmyeloid - - O
cells - - O
. - - O
( - - O
ABSTRACT - - O
TRUNCATED - - O
AT - - O
400 - - O
WORDS - - O
) - - O

Resources - - O
for - - O
helping - - O
patients - - O
to - - O
quit - - O
smoking - - O
. - - O

Antibiotic - - O
effect - - O
of - - O
the - - O
mud - - O
from - - O
heviz - - O
. - - O

A - - O
case - - O
observed - - O
in - - O
Saigon - - O
. - - O

Sequences - - O
required - - O
for - - O
interaction - - O
of - - O
mu2 - - B-MUT
and - - O
CTLA-4 - - B-MUT
were - - O
localized - - O
to - - O
residues - - O
, - - O
161TTGVY - - B-MUT
in - - O
CTLA-4 - - B-MUT
; - - O
this - - O
sequence - - O
is - - O
N-terminal - - O
to - - O
, - - O
but - - O
overlaps - - O
with - - O
, - - O
a - - O
previously - - O
identified - - O
SH2 - - B-MUT
binding - - I-MUT
motif - - I-MUT
, - - O
165YVKM - - B-MUT
, - - O
involved - - O
in - - O
CTLA-4 - - B-MUT
signaling - - O
. - - O

The - - O
accuracies - - O
of - - O
presence - - O
or - - O
absence - - O
of - - O
neuroblastoma - - O
were - - O
compared - - O
between - - O
131I-MIBG - - O
imaging - - O
and - - O
several - - O
tumor - - O
markers - - O
. - - O

Cytosolic - - O
extracts - - O
from - - O
a - - O
variety - - O
of - - O
mammalian - - O
cell - - O
lines - - O
( - - O
monkey - - O
Cos7 - - O
, - - O
several - - O
mouse - - O
fibrosarcomas - - O
and - - O
human - - O
HeLa - - O
S3 - - O
) - - O
demonstrated - - O
similar - - O
TGF-beta - - B-MUT
1 - - I-MUT
dependent - - O
RNA-protein - - O
band - - O
shifts - - O
as - - O
cell - - O
extract - - O
from - - O
BALB - - O
c - - O
3T3 - - O
mouse - - O
fibroblasts - - O
. - - O

We - - O
determined - - O
whether - - O
regional - - O
myocardial - - O
work - - O
efficiency - - O
( - - O
segment - - O
work - - O
regional - - O
O2 - - O
consumption - - O
) - - O
would - - O
be - - O
elevated - - O
by - - O
surgically-augmented - - O
inflow - - O
. - - O

Phylogenetic - - O
analysis - - O
showed - - O
that - - O
the - - O
ToLCV - - O
isolates - - O
from - - O
Bangalore - - O
constitute - - O
a - - O
group - - O
of - - O
viruses - - O
separated - - O
from - - O
those - - O
of - - O
Northern - - O
India - - O
. - - O

Recombinant - - B-MUT
HRMT1L2 - - I-MUT
protein - - I-MUT
encoded - - O
by - - O
the - - O
most - - O
common - - O
5'-variant - - O
exhibited - - O
methyltransferase - - B-MUT
activity - - O
in - - O
vitro - - O
. - - O

These - - O
results - - O
indicate - - O
that - - O
the - - O
effect - - O
of - - O
the - - O
isomers - - O
of - - O
pentobarbital - - O
and - - O
secobarbital - - O
on - - O
mult - - O
FR30 - - O
FI600 - - O
responding - - O
and - - O
on - - O
suppressed - - O
responding - - O
are - - O
qualitatively - - O
similar - - O
. - - O
( - - O
ABSTRACT - - O
TRUNCATED - - O
AT - - O
250 - - O
WORDS - - O
) - - O

The - - O
infection - - O
rate - - O
was - - O
five - - O
times - - O
greater - - O
in - - O
patients - - O
with - - O
Hickman - - O
catheters - - O
than - - O
in - - O
those - - O
with - - O
Broviac - - O
catheters - - O
( - - O
p - - O
= - - O
0 - - O
. - - O
01 - - O
) - - O
. - - O

SKP1-SnRK - - B-MUT
protein - - I-MUT
kinase - - I-MUT
interactions - - O
mediate - - O
proteasomal - - O
binding - - O
of - - O
a - - O
plant - - O
SCF - - B-MUT
ubiquitin - - I-MUT
ligase - - I-MUT
. - - O

IdB - - O
1031 - - O
was - - O
first - - O
extracted - - O
by - - O
liquid-solid - - O
partition - - O
and - - O
the - - O
extracts - - O
were - - O
evaporated - - O
and - - O
analysed - - O
on - - O
a - - O
reversed-phase - - O
column - - O
under - - O
isocratic - - O
conditions - - O
, - - O
using - - O
either - - O
an - - O
electrochemical - - O
or - - O
a - - O
UV - - O
detector - - O
. - - O

This - - O
study - - O
represents - - O
the - - O
first - - O
published - - O
long-term - - O
follow-up - - O
regarding - - O
this - - O
mode - - O
of - - O
treatment - - O
in - - O
patients - - O
with - - O
alveolar - - O
hypoventilation - - O
. - - O

Moreover - - O
, - - O
the - - O
same - - O
mutations - - O
alter - - O
the - - O
structure - - O
of - - O
junB - - B-MUT
5' - - O
flanking - - O
DNA - - O
within - - O
chromatin - - O
. - - O

These - - O
articles - - O
both - - O
report - - O
the - - O
results - - O
of - - O
multi-institutional - - O
, - - O
randomized - - O
, - - O
phase - - O
3 - - O
trials - - O
for - - O
the - - O
treatment - - O
of - - O
patients - - O
with - - O
localized - - O
( - - O
T1-3 - - O
N0-1 - - O
M0 - - O
) - - O
esophageal - - O
squamous - - O
cell - - O
carcinoma - - O
( - - O
SCC - - O
) - - O
or - - O
esophageal - - O
adenocarcinoma - - O
. - - O

Basal - - O
FSH - - B-MUT
and - - O
LH - - B-MUT
levels - - O
were - - O
significantly - - O
lower - - O
in - - O
addicts - - O
; - - O
after - - O
GnRH - - B-MUT
stimulation - - O
the - - O
addicts' - - O
FSH - - B-MUT
and - - O
LH - - B-MUT
values - - O
increased - - O
but - - O
not - - O
significantly - - O
compared - - O
to - - O
controls - - O
. - - O

Secretory - - O
function - - O
of - - O
the - - O
prostate - - O
gland - - O
. - - O

Mitogen-activated - - B-MUT
protein - - I-MUT
( - - I-MUT
MAP - - I-MUT
) - - I-MUT
kinase - - I-MUT
phosphatase-3 - - I-MUT
( - - O
MKP-3 - - B-MUT
) - - O
is - - O
a - - O
dual - - O
specificity - - O
phosphatase - - B-MUT
that - - O
inactivates - - O
extracellular - - B-MUT
signal-regulated - - I-MUT
kinase - - I-MUT
( - - O
ERK - - B-MUT
) - - O
MAP - - B-MUT
kinases - - I-MUT
. - - O

It - - O
is - - O
clear - - O
that - - O
subclinical - - O
and - - O
silent - - O
CD - - O
exist - - O
in - - O
a - - O
large - - O
subgroup - - O
of - - O
the - - O
celiac - - O
population - - O
. - - O

Furthermore - - O
, - - O
MOM-4 - - B-MUT
and - - O
TAK1 - - B-MUT
bind - - O
related - - O
proteins - - O
that - - O
promote - - O
their - - O
kinase - - B-MUT
activities - - O
. - - O

METHODS - - O
AND - - O
RESULTS - - O
: - - O
Palmaz-Schatz - - O
stents - - O
were - - O
dip-coated - - O
with - - O
paclitaxel - - O
( - - O
0 - - O
, - - O
0 - - O
. - - O
2 - - O
, - - O
15 - - O
, - - O
or - - O
187 - - O
microgram - - O
stent - - O
) - - O
by - - O
immersion - - O
in - - O
ethanolic - - O
paclitaxel - - O
and - - O
evaporation - - O
of - - O
the - - O
solvent - - O
. - - O

Furthermore - - O
, - - O
unlike - - O
the - - O
case - - O
for - - O
HIS3 - - B-MUT
where - - O
only - - O
a - - O
limited - - O
subset - - O
of - - O
TATA-like - - B-MUT
sequences - - I-MUT
can - - O
activate - - O
transcription - - O
in - - O
conjunction - - O
with - - O
GCN4p - - B-MUT
, - - O
many - - O
divergent - - O
TATA-like - - B-MUT
sequences - - I-MUT
allowed - - O
GCN4p - - B-MUT
activation - - O
of - - O
TRP3 - - B-MUT
. - - O

The - - O
peptide - - O
sequences - - O
reveal - - O
that - - O
the - - O
factor - - O
consists - - O
of - - O
GABP - - B-MUT
alpha - - I-MUT
and - - O
GABP - - B-MUT
beta - - I-MUT
1 - - I-MUT
with - - O
Ets - - B-MUT
and - - O
Notch - - B-MUT
motifs - - I-MUT
, - - O
respectively - - O
. - - O

The - - O
ubiquitous - - O
transcription - - O
factor - - O
Oct-1 - - B-MUT
forms - - O
complexes - - O
with - - O
an - - O
octamer - - O
motif - - O
present - - O
within - - O
FPIV - - O
by - - O
gel - - O
shift - - O
analysis - - O
with - - O
liver - - O
and - - O
kidney - - O
extracts - - O
, - - O
making - - O
Oct-1 - - B-MUT
an - - O
intriguing - - O
candidate - - O
for - - O
partnership - - O
in - - O
androgen - - O
regulation - - O
. - - O

The - - O
effect - - O
of - - O
acute - - O
, - - O
mid-cervical - - O
spinal - - O
cord - - O
lesions - - O
on - - O
neuronal - - O
and - - O
reflex - - O
activity - - O
evoked - - O
by - - O
the - - O
noxious - - O
visceral - - O
stimulus - - O
, - - O
colorectal - - O
distension - - O
( - - O
CRD - - O
; - - O
80 - - O
mmHg - - O
, - - O
20 - - O
s - - O
) - - O
, - - O
was - - O
determined - - O
in - - O
halothane-anesthetized - - O
rats - - O
. - - O

These - - O
two - - O
mRNA - - O
species - - O
are - - O
produced - - O
by - - O
differential - - O
polyadenylation - - O
site - - O
usage - - O
. - - O

When - - O
mixed - - O
with - - O
aqueous - - O
solutions - - O
of - - O
TMT-55 - - O
, - - O
aqueous - - O
solutions - - O
of - - O
either - - O
reagent-grade - - O
zinc - - O
, - - O
cadmium - - O
, - - O
or - - O
lead - - O
salts - - O
precipitate - - O
crystalline - - O
"Zn-TMT" - - O
, - - O
amorphous - - O
or - - O
crystalline - - O
"Cd-TMT" - - O
or - - O
amorphous - - O
"Pb-TMT" - - O
( - - O
M3 - - O
[ - - O
S3C3N3 - - O
] - - O
2 - - O
. - - O
nH2O - - O
, - - O
where - - O
M - - O
= - - O
Cd2+ - - O
, - - O
Pb2+ - - O
, - - O
and - - O
Zn2+ - - O
and - - O
n - - O
> - - O
or - - O
= - - O
0 - - O
) - - O
that - - O
may - - O
eventually - - O
crystallize - - O
if - - O
stored - - O
in - - O
air - - O
. - - O

We - - O
report - - O
the - - O
isolation - - O
of - - O
genomic - - O
and - - O
cDNA - - O
clones - - O
of - - O
the - - O
light-independent - - O
Sn - - B-MUT
: - - I-MUT
bol3 - - I-MUT
allele - - I-MUT
. - - O

Pharmacokinetics - - O
of - - O
FK - - O
506 - - O
in - - O
transplant - - O
patients - - O
. - - O

A - - O
receptor-like - - B-MUT
protein - - I-MUT
kinase - - I-MUT
, - - O
OsPK10 - - B-MUT
, - - O
has - - O
been - - O
cloned - - O
from - - O
rice - - O
( - - O
Oryza - - O
sativa - - O
) - - O
. - - O

Therefore - - O
, - - O
the - - O
strD - - B-MUT
and - - O
strE - - B-MUT
genes - - I-MUT
could - - O
serve - - O
as - - O
universal - - O
probes - - O
indicative - - O
of - - O
the - - O
presence - - O
of - - O
biosynthetic - - O
capacity - - O
for - - O
6-deoxyhexose - - O
moieties - - O
. - - O

The - - O
1 - - O
, - - O
2 - - O
, - - O
3 - - O
and - - O
4 - - O
year - - O
survival - - O
rates - - O
were - - O
94% - - O
, - - O
84% - - O
, - - O
76% - - O
and - - O
63% - - O
, - - O
respectively - - O
. - - O

For - - O
the - - O
study - - O
of - - O
the - - O
transition - - O
of - - O
long - - O
to - - O
short - - O
waves - - O
( - - O
deep-water - - O
waves - - O
) - - O
a - - O
closed-form - - O
solution - - O
is - - O
advantageous - - O
; - - O
this - - O
can - - O
, - - O
however - - O
, - - O
only - - O
be - - O
obtained - - O
at - - O
the - - O
cost - - O
of - - O
further - - O
simplification - - O
. - - O

TcPO2 - - O
measurement - - O
appears - - O
to - - O
be - - O
a - - O
reliable - - O
technique - - O
that - - O
can - - O
influence - - O
ischaemic - - O
ulcer - - O
management - - O
. - - O

Production - - O
costs - - O
included - - O
feed - - O
, - - O
non-feed - - O
operating - - O
, - - O
fixed - - O
, - - O
and - - O
replacement - - O
stock - - O
costs - - O
. - - O

Molecular - - O
modelling - - O
suggested - - O
that - - O
the - - O
tetramerization - - O
domain - - O
was - - O
a - - O
four-helix - - O
bundle - - O
, - - O
stabilized - - O
by - - O
interactions - - O
of - - O
seven - - O
conserved - - O
aromatic - - O
amino - - O
acids - - O
. - - O

It - - O
is - - O
concluded - - O
that - - O
suppression - - O
of - - O
elevated - - O
prolactin - - B-MUT
levels - - O
in - - O
progressive - - O
metastatic - - O
breast - - O
cancer - - O
patients - - O
is - - O
not - - O
effective - - O
in - - O
restoring - - O
tumor - - O
sensitivity - - O
to - - O
chemotherapy - - O
. - - O

Apart - - O
from - - O
two - - O
proline-rich - - O
regions - - O
( - - O
amino - - O
acids - - O
1-117 - - O
and - - O
239-270 - - O
) - - O
, - - O
p230 - - B-MUT
contains - - O
a - - O
very - - O
high - - O
frequency - - O
of - - O
heptad - - O
repeats - - O
, - - O
characteristic - - O
of - - O
alpha-helices - - O
that - - O
form - - O
dimeric - - O
coiled-coil - - O
structures - - O
. - - O
p230 - - B-MUT
also - - O
includes - - O
the - - O
sequence - - B-MUT
ESLALEELEL - - I-MUT
( - - I-MUT
amino - - I-MUT
acids - - I-MUT
538-546 - - I-MUT
) - - I-MUT
, - - O
a - - O
motif - - O
found - - O
in - - O
the - - O
granin - - B-MUT
family - - I-MUT
of - - O
acidic - - O
proteins - - O
present - - O
in - - O
secretory - - O
granules - - O
of - - O
neuroendocrine - - O
cells - - O
. - - O

Constantly - - O
rectilinear - - O
pressure - - O
curves - - O
without - - O
uterine - - O
activities - - O
are - - O
interpreted - - O
as - - O
characteristic - - O
tocographic - - O
criteria - - O
of - - O
an - - O
advanced - - O
ectopic - - O
gravidity - - O
. - - O

Ask - - O
AONE's - - O
experts - - O
. - - O
. - - O
. - - O
about - - O
productivity - - O
indicators - - O
. - - O

Use - - O
of - - O
a - - O
dual-pulse - - O
lithotripter - - O
to - - O
generate - - O
a - - O
localized - - O
and - - O
intensified - - O
cavitation - - O
field - - O
. - - O

Critical - - O
study - - O
. - - O

No - - O
post-operative - - O
haemorrhages - - O
from - - O
the - - O
prostheses - - O
were - - O
observed - - O
. - - O

CONCLUSIONS - - O
: - - O
Adding - - O
MMF - - O
, - - O
a - - O
potent - - O
topical - - O
corticosteroid - - O
, - - O
to - - O
an - - O
emollient - - O
cream - - O
is - - O
statistically - - O
significantly - - O
more - - O
effective - - O
than - - O
emollient - - O
cream - - O
alone - - O
in - - O
reducing - - O
acute - - O
radiation - - O
dermatitis - - O
. - - O

TbRAB31 - - B-MUT
behaviour - - O
was - - O
also - - O
studied - - O
during - - O
the - - O
cell - - O
cycle - - O
; - - O
TbRAB31 - - B-MUT
always - - O
localised - - O
to - - O
a - - O
discrete - - O
structure - - O
that - - O
duplicated - - O
very - - O
early - - O
in - - O
mitosis - - O
and - - O
relocated - - O
to - - O
daughter - - O
cells - - O
in - - O
a - - O
coordinate - - O
manner - - O
with - - O
the - - O
basal - - O
body - - O
and - - O
kinetoplast - - O
, - - O
suggesting - - O
the - - O
involvement - - O
of - - O
microtubules - - O
. - - O

Yeast - - B-MUT
Gal11 - - I-MUT
protein - - I-MUT
mediates - - O
the - - O
transcriptional - - O
activation - - O
signal - - O
of - - O
two - - O
different - - O
transacting - - O
factors - - O
, - - O
Gal4 - - B-MUT
and - - O
general - - B-MUT
regulatory - - I-MUT
factor - - I-MUT
I - - I-MUT
repressor - - I-MUT
activator - - I-MUT
site - - I-MUT
binding - - I-MUT
protein - - I-MUT
1 - - I-MUT
translation - - I-MUT
upstream - - I-MUT
factor - - I-MUT
. - - I-MUT

It - - O
was - - O
concluded - - O
that - - O
Scotchbond - - O
2 - - O
and - - O
Prisma - - O
Universal - - O
Bond - - O
2 - - O
are - - O
effective - - O
and - - O
are - - O
the - - O
dentine - - O
bonding - - O
agents - - O
of - - O
choice - - O
. - - O

The - - O
activity - - O
of - - O
serum - - B-MUT
lipase - - I-MUT
and - - O
amylase - - B-MUT
distinctly - - O
increased - - O
at - - O
3 - - O
h - - O
and - - O
went - - O
up - - O
to - - O
the - - O
maximum - - O
at - - O
12 - - O
h - - O
after - - O
injection - - O
of - - O
Na-Tc - - O
. - - O

Characterization - - O
of - - O
polymorphic - - O
TNRs - - B-MUT
in - - O
novel - - O
and - - O
even - - O
known - - O
genes - - O
expressed - - O
in - - O
human - - O
spinal - - O
cord - - O
is - - O
likely - - O
to - - O
help - - O
in - - O
the - - O
identification - - O
of - - O
new - - O
candidates - - O
for - - O
genes - - O
involved - - O
in - - O
neurodegenerative - - O
disorders - - O
. - - O

This - - O
slow - - O
progression - - O
through - - O
the - - O
early - - O
G1-phase - - O
resulted - - O
in - - O
decreased - - O
phosphorylation - - O
of - - O
the - - O
RB - - B-MUT
protein - - I-MUT
and - - O
subsequent - - O
delay - - O
into - - O
the - - O
S - - O
phase - - O
transition - - O
. - - O

The - - O
RAD18 - - B-MUT
gene - - I-MUT
open - - I-MUT
reading - - I-MUT
frame - - I-MUT
encodes - - O
a - - O
protein - - O
of - - O
487 - - O
amino - - O
acids - - O
, - - O
with - - O
a - - O
calculated - - O
molecular - - O
weight - - O
of - - O
55 - - O
, - - O
512 - - O
. - - O

In - - O
the - - O
10 - - O
patients - - O
with - - O
a - - O
more - - O
severe - - O
degree - - O
of - - O
steatorrhea - - O
the - - O
decrease - - O
in - - O
fat - - O
loss - - O
approached - - O
20% - - O
and - - O
a - - O
close - - O
relationship - - O
was - - O
found - - O
( - - O
r - - O
= - - O
0 - - O
. - - O
84 - - O
, - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
01 - - O
) - - O
between - - O
the - - O
extent - - O
of - - O
the - - O
fatty - - O
acid - - O
loss - - O
on - - O
placebo - - O
and - - O
the - - O
decrease - - O
of - - O
this - - O
loss - - O
on - - O
taurine - - O
. - - O

Laryngographic - - O
changes - - O
following - - O
endotracheal - - O
intubation - - O
in - - O
adults - - O
. - - O

The - - O
partial - - O
sequence - - O
of - - O
the - - O
62-kDa - - B-MUT
nuclear - - I-MUT
pore - - I-MUT
glycoprotein - - I-MUT
shows - - O
little - - O
similarity - - O
to - - O
other - - O
characterized - - O
proteins - - O
and - - O
elucidates - - O
structural - - O
features - - O
of - - O
a - - O
member - - O
of - - O
the - - O
family - - O
of - - O
nuclear - - B-MUT
pore - - I-MUT
glycoproteins - - I-MUT
. - - O

Data - - O
collection - - O
was - - O
made - - O
with - - O
a - - O
query - - O
language - - O
, - - O
and - - O
data - - O
analysis - - O
performed - - O
with - - O
an - - O
interactive - - O
knowledge-based - - O
statistical - - O
tool - - O
, - - O
MAXITAB - - O
, - - O
employing - - O
a - - O
multivariate - - O
tabular - - O
analysis - - O
technique - - O
. - - O

In - - O
order - - O
to - - O
investigate - - O
how - - O
these - - O
expression - - O
patterns - - O
are - - O
established - - O
, - - O
we - - O
fused - - O
promoter - - O
regions - - O
of - - O
an - - O
acidic - - O
and - - O
a - - O
basic - - O
glucanase - - B-MUT
gene - - I-MUT
to - - O
the - - O
beta-glucuronidase - - B-MUT
( - - O
GUS - - B-MUT
) - - O
reporter - - O
gene - - O
and - - O
examined - - O
expression - - O
of - - O
these - - O
constructs - - O
in - - O
transgenic - - O
tobacco - - O
plants - - O
. - - O

Sixty-five - - O
patients - - O
( - - O
aged - - O
between - - O
3 - - O
years - - O
5 - - O
months - - O
and - - O
60 - - O
years - - O
) - - O
suffering - - O
from - - O
medically - - O
resistant - - O
temporal - - O
lobe - - O
epilepsy - - O
( - - O
TLE - - O
) - - O
were - - O
operated - - O
on - - O
over - - O
a - - O
period - - O
of - - O
33 - - O
months - - O
in - - O
Bethel - - O
Epilepsy - - O
Center - - O
. - - O

The - - O
results - - O
showed - - O
that - - O
IFN-gamma - - B-MUT
stimulated - - O
the - - O
rapid - - O
accumulation - - O
of - - O
interferon - - B-MUT
regulated - - I-MUT
factor - - I-MUT
( - - I-MUT
IRF - - I-MUT
) - - I-MUT
-1 - - I-MUT
mRNA - - I-MUT
, - - O
followed - - O
by - - O
a - - O
delayed - - O
and - - O
dose-dependent - - O
inhibition - - O
of - - O
alpha1 - - B-MUT
( - - I-MUT
I - - I-MUT
) - - I-MUT
procollagen - - I-MUT
mRNA - - I-MUT
expression - - O
in - - O
skin - - O
fibroblasts - - O
from - - O
several - - O
different - - O
donors - - O
. - - O

A - - O
split - - O
motor - - O
domain - - O
in - - O
a - - O
cytoplasmic - - B-MUT
dynein - - I-MUT
. - - O

Effect - - O
of - - O
heparin - - O
on - - O
the - - O
inactivation - - O
of - - O
serum - - B-MUT
lipoprotein - - I-MUT
lipase - - I-MUT
by - - O
the - - O
liver - - O
in - - O
unanesthetized - - O
dogs - - O
. - - O

CONCLUSIONS - - O
: - - O
The - - O
largest - - O
value - - O
of - - O
the - - O
joint - - O
space - - O
may - - O
be - - O
used - - O
when - - O
evaluating - - O
rheumatoid - - O
AC - - O
joint - - O
space - - O
. - - O

We - - O
then - - O
demonstrated - - O
that - - O
1 - - O
) - - O
GAL4-REV-erbA - - B-MUT
alpha - - I-MUT
chimeras - - I-MUT
that - - O
contain - - O
the - - O
'AB' - - B-MUT
region - - I-MUT
and - - O
lack - - O
the - - O
'E' - - B-MUT
region - - I-MUT
activated - - O
transcription - - O
of - - O
GAL4 - - B-MUT
response - - I-MUT
elements - - I-MUT
in - - O
the - - O
presence - - O
of - - O
8-Br-cAMP - - O
and - - O
2 - - O
) - - O
the - - O
ligand-binding - - O
domain - - O
( - - O
LBD - - O
) - - O
contains - - O
an - - O
active - - O
transcriptional - - O
silencer - - O
. - - O

When - - O
transfected - - O
into - - O
Drosophila - - O
SL-2 - - O
cells - - O
, - - O
pCAT - - O
plasmid - - O
containing - - O
2 - - O
, - - O
090 - - O
bp - - O
of - - O
5'-flanking - - O
region - - O
shows - - O
a - - O
3 - - O
. - - O
0- - - O
to - - O
3 - - O
. - - O
5-fold - - O
increase - - O
in - - O
chloramphenicol - - B-MUT
acetyltransferase - - I-MUT
activity - - O
after - - O
induction - - O
with - - O
retinoic - - O
acid - - O
and - - O
or - - O
8-bromo-cAMP - - O
. - - O

In - - O
the - - O
course - - O
of - - O
screening - - O
for - - O
transcription - - O
factors - - O
which - - O
interact - - O
with - - O
the - - O
human - - B-MUT
myeloperoxidase - - I-MUT
( - - O
MPO - - B-MUT
) - - O
promoter - - O
we - - O
, - - O
for - - O
the - - O
first - - O
time - - O
, - - O
identified - - O
and - - O
cloned - - O
the - - O
cDNA - - O
and - - O
genomic - - O
DNA - - O
for - - O
human - - B-MUT
HBP1 - - I-MUT
( - - O
HMG-Box - - B-MUT
containing - - I-MUT
protein - - I-MUT
1 - - I-MUT
) - - O
, - - O
a - - O
member - - O
of - - O
the - - O
high - - B-MUT
mobility - - I-MUT
group - - I-MUT
of - - I-MUT
non-histone - - I-MUT
chromosomal - - I-MUT
proteins - - I-MUT
. - - O

This - - O
analysis - - O
revealed - - O
that - - O
SAP - - B-MUT
145 - - I-MUT
, - - O
together - - O
with - - O
four - - O
other - - O
SF3a - - B-MUT
SF3b - - I-MUT
subunits - - I-MUT
, - - I-MUT
UV - - O
cross-links - - O
to - - O
pre-mRNA - - O
in - - O
a - - O
20-nucleotide - - O
region - - O
upstream - - O
of - - O
the - - O
BPS - - O
. - - B-MUT

The - - O
first - - O
contains - - O
ATF - - B-MUT
CRE - - O
and - - B-MUT
TBP - - O
TATA - - B-MUT
sequence - - O
motifs - - O
within - - O
an - - O
87-bp - - O
region - - O
. - - O

OBJECTIVE - - O
: - - O
To - - O
evaluate - - O
the - - O
accuracy - - O
of - - O
working - - O
casts - - O
for - - O
crown - - O
and - - O
bridge - - O
restorations - - O
made - - O
from - - O
twin - - O
mix - - O
putty - - O
wash - - O
silicone - - O
elastomeric - - O
impression - - O
materials - - O
using - - O
different - - O
types - - O
of - - O
stock - - O
tray - - O
. - - O

The - - O
final - - O
predicted - - O
structure - - O
has - - O
an - - O
overall - - O
backbone - - O
deviation - - O
of - - O
0 - - O
. - - O
7 - - O
A - - O
from - - O
that - - O
of - - O
ras-p21 - - B-MUT
. - - O

As - - O
a - - O
consequence - - O
of - - O
dark - - O
rearing - - O
, - - O
the - - O
numerical - - O
density - - O
of - - O
cortical - - O
neurons - - O
in - - O
area - - O
17 - - O
amounted - - O
to - - O
about - - O
double - - O
of - - O
the - - O
value - - O
observed - - O
in - - O
normally - - O
reared - - O
kittens - - O
and - - O
was - - O
also - - O
significantly - - O
higher - - O
in - - O
area - - O
18 - - O
. - - O

The - - O
role - - O
of - - O
ascorbic - - O
acid - - O
in - - O
the - - O
prevention - - O
of - - O
bladder - - O
tumor - - O
formation - - O
. - - O

Ten - - O
out - - O
of - - O
10 - - O
patients - - O
with - - O
progressive - - O
disease - - O
had - - O
mast - - O
cells - - O
greater - - O
than - - O
or - - O
equal - - O
to - - O
0 - - O
. - - O
5% - - O
, - - O
hyaluronan - - O
greater - - O
than - - O
or - - O
equal - - O
to - - O
50 - - O
micrograms - - O
. - - O
l-1 - - O
and - - O
fibronectin - - B-MUT
greater - - O
than - - O
or - - O
equal - - O
to - - O
350 - - O
micrograms - - O
. - - O
l-1 - - O
compared - - O
to - - O
eight - - O
out - - O
of - - O
41 - - O
patients - - O
with - - O
stable - - O
or - - O
regressive - - O
disease - - O
. - - O
( - - O
ABSTRACT - - O
TRUNCATED - - O
AT - - O
250 - - O
WORDS - - O
) - - O

Since - - O
1990 - - O
the - - O
University - - O
Hospital - - O
of - - O
Tromso - - O
has - - O
provided - - O
local - - O
hospitals - - O
in - - O
northern - - O
Norway - - O
with - - O
a - - O
remote - - O
frozen - - O
section - - O
service - - O
and - - O
with - - O
access - - O
to - - O
video - - O
conferences - - O
for - - O
the - - O
review - - O
of - - O
microscopic - - O
findings - - O
and - - O
for - - O
the - - O
discussion - - O
of - - O
major - - O
diagnostic - - O
issues - - O
. - - O

NSCL-1 - - B-MUT
is - - O
expressed - - O
in - - O
a - - O
larger - - O
number - - O
of - - O
these - - O
cell - - O
lines - - O
. - - O

Both - - O
of - - O
these - - O
dogs - - O
had - - O
low - - O
serum - - O
IgG - - B-MUT
( - - O
3 - - O
. - - O
5 - - O
to - - O
7 - - O
. - - O
2 - - O
mg - - O
ml - - O
) - - O
and - - O
the - - O
second - - O
littermate - - O
also - - O
had - - O
reduced - - O
serum - - O
IgA - - O
( - - B-MUT
< - - O
0 - - O
. - - O
1 - - O
to - - O
0 - - O
. - - O
15 - - O
mg - - O
ml - - O
) - - O
. - - O

However - - O
, - - O
we - - O
did - - O
not - - O
observe - - O
a - - O
correlation - - O
between - - O
serum - - O
and - - O
seminal - - B-MUT
plasma - - I-MUT
PSA - - I-MUT
levels - - O
. - - O

A - - O
. - - O

Direct - - O
proof - - O
that - - O
the - - O
heightened - - O
renal - - O
cellular - - O
apoptosis - - O
in - - O
PKD - - O
is - - O
not - - O
occurring - - O
through - - O
p53 - - B-MUT
was - - O
obtained - - O
by - - O
successive - - O
matings - - O
between - - O
SBM - - O
and - - O
p53 - - B-MUT
( - - O
- - - O
- - - O
) - - O
mice - - O
. - - O

Evoked - - O
electromyographic - - O
response - - O
to - - O
indirect - - O
supramaximal - - O
stimulation - - O
at - - O
1 - - O
Hz - - O
was - - O
monitored - - O
in - - O
ten - - O
adult - - O
goats - - O
under - - O
thiopentone-halothane - - O
anaesthesia - - O
. - - O

It - - O
has - - O
been - - O
demonstrated - - O
previously - - O
that - - O
Pax-6 - - B-MUT
, - - O
a - - O
paired - - B-MUT
domain - - I-MUT
( - - I-MUT
PD - - I-MUT
) - - I-MUT
homeodomain - - I-MUT
( - - I-MUT
HD - - I-MUT
) - - I-MUT
transcription - - I-MUT
factor - - I-MUT
critical - - I-MUT
for - - O
eye - - O
development - - O
, - - O
contributes - - O
to - - O
the - - O
activation - - O
of - - O
the - - O
alphaB- - - O
, - - B-MUT
alphaA- - - O
, - - B-MUT
delta1- - - O
, - - B-MUT
and - - O
zeta-crystallin - - O
genes - - B-MUT
in - - I-MUT
the - - O
lens - - O
. - - O

TCR - - B-MUT
alpha - - I-MUT
and - - I-MUT
beta - - I-MUT
gene - - I-MUT
expression - - O
may - - O
be - - O
regulated - - O
by - - O
a - - O
common - - O
set - - O
of - - O
T-cell - - B-MUT
nuclear - - I-MUT
proteins - - I-MUT
in - - O
that - - O
the - - O
T - - B-MUT
beta - - I-MUT
2 - - I-MUT
element - - I-MUT
binding - - O
a - - O
set - - O
of - - O
cyclic - - B-MUT
AMP - - I-MUT
response - - I-MUT
element-binding - - I-MUT
proteins - - I-MUT
that - - O
are - - O
also - - O
bound - - O
by - - O
the - - O
T - - B-MUT
alpha - - I-MUT
1 - - I-MUT
element - - I-MUT
of - - O
the - - O
human - - O
TCR - - B-MUT
alpha - - I-MUT
enhancer - - O
and - - O
the - - O
decamer - - O
element - - O
present - - O
in - - O
a - - O
large - - O
number - - O
of - - O
human - - O
and - - O
murine - - O
TCR - - B-MUT
beta - - I-MUT
promoters - - O
. - - O

The - - O
transverse - - O
relaxation - - O
time - - O
( - - O
T2 - - O
) - - O
and - - O
apparent - - O
diffusion - - O
coefficient - - O
of - - O
water - - O
were - - O
determined - - O
. - - O

Female - - O
mice - - O
were - - O
significantly - - O
more - - O
resistant - - O
to - - O
infection - - O
than - - O
males - - O
. - - O

Three - - O
ORFs - - O
( - - O
9765orfR002 - - B-MUT
, - - O
9765orfR011 - - B-MUT
and - - O
9765orfR013 - - B-MUT
) - - O
were - - O
found - - O
to - - O
be - - O
homologous - - O
with - - O
Schizosaccharomyces - - O
pombe - - O
polyadenylate - - B-MUT
binding - - I-MUT
protein - - I-MUT
, - - O
Escherichia - - O
coli - - O
hypothetical - - O
38 - - O
. - - O
1-kDa - - O
protein - - O
in - - O
the - - O
BCR - - B-MUT
5' - - O
region - - O
, - - O
and - - O
transcription - - O
regulatory - - O
protein - - O
Swi3 - - B-MUT
, - - O
respectively - - O
. - - O

EBNA-2 - - B-MUT
and - - O
the - - O
cis-acting - - O
CD23 - - B-MUT
element - - I-MUT
increased - - O
TK-promoted - - O
mRNA - - O
and - - O
did - - O
not - - O
alter - - O
the - - O
herpes - - B-MUT
simplex - - I-MUT
virus - - I-MUT
TK - - I-MUT
promoter - - I-MUT
transcription - - I-MUT
start - - I-MUT
site - - I-MUT
. - - O

Analysis - - O
of - - O
ace2Delta - - O
cells - - O
reveals - - O
that - - O
Ace2p - - B-MUT
is - - O
required - - O
for - - O
cell - - O
separation - - O
but - - O
not - - O
for - - O
polarized - - O
growth - - O
. - - O

The - - O
case - - O
described - - O
is - - O
that - - O
of - - O
a - - O
72-year-old - - O
man - - O
with - - O
ochronosis - - O
who - - O
suffered - - O
a - - O
hyperextension - - O
injury - - O
to - - O
his - - O
spine - - O
in - - O
a - - O
fall - - O
, - - O
resulting - - O
in - - O
a - - O
fracture - - O
through - - O
an - - O
ankylosed - - O
L2-L3 - - O
disk - - O
space - - O
. - - O

Although - - O
stone-formers - - O
were - - O
not - - O
found - - O
to - - O
display - - O
any - - O
features - - O
of - - O
magnesium - - O
metabolism - - O
that - - O
were - - O
different - - O
from - - O
those - - O
in - - O
the - - O
control - - O
group - - O
, - - O
their - - O
lower - - O
urinary - - O
excretion - - O
of - - O
magnesium - - O
in - - O
relation - - O
to - - O
calcium - - O
may - - O
be - - O
a - - O
factor - - O
in - - O
their - - O
increased - - O
stone-forming - - O
propensity - - O
. - - O

Phosphoamino - - O
acid - - O
analysis - - O
of - - O
radiolabeled - - O
ASGPR - - B-MUT
subunits - - I-MUT
identified - - O
Ser - - O
( - - O
P - - O
) - - O
as - - O
the - - O
predominant - - O
( - - O
approximately - - O
95% - - O
) - - O
and - - O
Thr - - O
( - - O
P - - O
) - - O
as - - O
a - - O
minor - - O
( - - O
approximately - - O
5% - - O
) - - O
phosphoamino - - O
acid - - O
in - - O
each - - O
polypeptide - - O
and - - O
confirmed - - O
the - - O
presence - - O
of - - O
Tyr - - O
( - - O
P - - O
) - - O
( - - O
approximately - - O
1% - - O
) - - O
in - - O
RHL1 - - B-MUT
. - - O

Cheung - - O
and - - O
S - - O
. - - O

Pentobarbital - - O
( - - O
1 - - O
, - - O
3 - - O
, - - O
10 - - O
, - - O
and - - O
17 - - O
. - - O
5 - - O
mg - - O
kg - - O
) - - O
was - - O
also - - O
tested - - O
in - - O
combination - - O
with - - O
rate-decreasing - - O
doses - - O
of - - O
normeperidine - - O
( - - O
17 - - O
. - - O
5 - - O
mg - - O
kg - - O
) - - O
, - - O
anileridine - - O
( - - O
10 - - O
mg - - O
kg - - O
) - - O
, - - O
alphaprodine - - O
( - - O
10 - - O
mg - - O
kg - - O
) - - O
, - - O
and - - O
fentanyl - - O
( - - O
0 - - O
. - - O
3 - - O
mg - - O
kg - - O
) - - O
. - - O

Dentalplaque - - O
was - - O
controlled - - O
by - - O
the - - O
oral - - O
higienic - - O
index - - O
of - - O
the - - O
whole - - O
dentition - - O
daily - - O
, - - O
after - - O
staining - - O
with - - O
1 - - O
per - - O
cent - - O
alkaline - - O
fuxin - - O
. - - O

The - - O
antinociceptive - - O
properties - - O
, - - O
as - - O
measured - - O
by - - O
the - - O
tail-flick - - O
and - - O
hot-plate - - O
tests - - O
, - - O
and - - O
the - - O
motor - - O
effects - - O
of - - O
an - - O
intrathecally-administered - - O
benzodiazepine - - O
agonist - - O
midazolam - - O
, - - O
alone - - O
, - - O
and - - O
in - - O
combination - - O
with - - O
morphine - - O
, - - O
was - - O
examined - - O
in - - O
rats - - O
. - - O

This - - O
is - - O
the - - O
first - - O
report - - O
of - - O
the - - O
successful - - O
resection - - O
of - - O
a - - O
MFH - - O
originating - - O
in - - O
the - - O
renal - - O
capsular - - O
tissue - - O
and - - O
extending - - O
into - - O
the - - O
inferior - - O
vena - - O
cava - - O
. - - O

In - - O
connective - - O
tissue - - O
, - - O
cell - - O
structure - - O
contributes - - O
to - - O
type - - B-MUT
I - - I-MUT
collagen - - I-MUT
expression - - O
. - - O

Pathways - - O
linking - - O
the - - O
olfactory - - O
bulbs - - O
with - - O
the - - O
medial - - O
preoptic - - O
anterior - - O
hypothalamus - - O
are - - O
important - - O
for - - O
intermale - - O
aggression - - O
in - - O
mice - - O
. - - O

In - - O
this - - O
study - - O
, - - O
we - - O
have - - O
cloned - - O
the - - O
human - - B-MUT
DSG3 - - I-MUT
gene - - I-MUT
and - - O
examined - - O
the - - O
transcriptional - - O
regulation - - O
of - - O
its - - O
expression - - O
. - - O

In - - O
simpler - - O
organisms - - O
, - - O
the - - O
ATP - - B-MUT
sulfurylase - - I-MUT
and - - O
APS - - B-MUT
kinase - - I-MUT
reactions - - O
are - - O
catalyzed - - O
by - - O
separate - - O
enzymes - - O
encoded - - O
by - - O
two - - O
or - - O
three - - O
genes - - O
, - - O
suggesting - - O
that - - O
a - - O
fusion - - O
of - - O
separate - - O
genes - - O
during - - O
the - - O
course - - O
of - - O
evolution - - O
generated - - O
the - - O
bifunctional - - O
enzyme - - O
. - - O

The - - O
protein - - O
predicted - - O
by - - O
the - - O
sequence - - O
of - - O
the - - O
human - - B-MUT
pim-1 - - I-MUT
proto-oncogene - - I-MUT
shares - - O
extensive - - O
homology - - O
with - - O
known - - O
serine - - B-MUT
threonine - - I-MUT
protein - - I-MUT
kinases - - I-MUT
, - - I-MUT
and - - O
yet - - O
the - - O
human - - O
Pim-1 - - B-MUT
enzyme - - I-MUT
has - - I-MUT
previously - - O
been - - O
reported - - O
to - - O
exhibit - - O
protein - - O
tyrosine - - B-MUT
kinase - - I-MUT
activity - - I-MUT
both - - O
in - - O
vitro - - O
and - - O
in - - O
vivo - - O
. - - O

Compared - - O
to - - O
its - - O
counterpart - - O
in - - O
the - - O
GPB - - B-MUT
gene - - I-MUT
, - - O
exon - - O
3 - - O
of - - O
the - - O
GPE - - B-MUT
gene - - I-MUT
contains - - O
several - - O
point - - O
mutations - - O
, - - O
an - - O
insertion - - O
of - - O
24 - - O
bp - - O
, - - O
and - - O
a - - O
stop - - O
codon - - O
which - - O
shortens - - O
the - - O
reading - - O
frame - - O
. - - O

Taken - - O
together - - O
, - - O
these - - O
data - - O
suggest - - O
that - - O
the - - O
Mif2 - - B-MUT
protein - - I-MUT
interacts - - O
with - - O
Cep1p - - B-MUT
at - - O
the - - O
centromere - - O
and - - O
that - - O
the - - O
yeast - - O
centromere - - O
indeed - - O
exists - - O
as - - O
a - - O
higher - - O
order - - O
protein-DNA - - O
complex - - O
. - - O

These - - O
findings - - O
demonstrate - - O
that - - O
signature-tagged - - O
mutagenesis - - O
is - - O
a - - O
viable - - O
approach - - O
to - - O
identify - - O
bacterial - - O
genes - - O
associated - - O
with - - O
the - - O
ability - - O
to - - O
infect - - O
the - - O
urinary - - O
tract - - O
. - - O

CONCLUSION - - O
: - - O
Monitoring - - O
SpO2 - - O
at - - O
the - - O
nasal - - O
septum - - O
site - - O
is - - O
more - - O
reliable - - O
than - - O
monitoring - - O
it - - O
at - - O
the - - O
finger - - O
site - - O
in - - O
hypothermic - - O
patients - - O
. - - O

Hemorrhagic - - O
shock - - O
and - - O
bacterial - - O
translocation - - O
in - - O
a - - O
swine - - O
model - - O
. - - O

Induction - - O
of - - O
the - - O
CINC - - B-MUT
promoter - - I-MUT
by - - O
IL-17 - - B-MUT
in - - O
IEC-6 - - O
cells - - O
was - - O
TNF - - B-MUT
receptor-associated - - I-MUT
factor-6 - - I-MUT
( - - O
TRAF6 - - B-MUT
) - - O
, - - O
but - - O
not - - O
TRAF2 - - B-MUT
, - - O
dependent - - O
. - - O

This - - O
study - - O
reports - - O
the - - O
isolation - - O
of - - O
a - - O
P - - O
. - - O
hybrida - - O
gene - - O
, - - O
jaf13 - - B-MUT
, - - O
encoding - - O
a - - O
basic - - B-MUT
helix-loop-helix - - I-MUT
protein - - I-MUT
that - - O
, - - O
on - - O
the - - O
basis - - O
of - - O
sequence - - O
homology - - O
and - - O
intron - - O
exon - - O
structure - - O
, - - O
represents - - O
the - - O
P - - O
. - - O
hybrida - - O
orthologue - - O
of - - O
the - - O
Z - - O
. - - B-MUT
mays - - I-MUT
r - - I-MUT
genes - - I-MUT
. - - I-MUT

However - - O
, - - O
while - - O
IL-1beta - - B-MUT
and - - O
TNF-alpha - - B-MUT
both - - O
induced - - O
nuclear - - O
binding - - O
of - - O
the - - O
Rel - - B-MUT
proteins - - I-MUT
p50 - - B-MUT
and - - O
p65 - - B-MUT
to - - O
an - - O
NF-kappaB - - B-MUT
consensus - - I-MUT
oligonucleotide - - I-MUT
in - - O
gel - - O
shift - - O
assays - - O
and - - O
caused - - O
transient - - O
degradation - - O
of - - O
inhibitor - - B-MUT
of - - I-MUT
NF-kappaB-alpha - - I-MUT
( - - O
IkappaB-alpha - - B-MUT
) - - O
in - - O
the - - O
cytoplasm - - O
of - - O
myofibroblasts - - O
, - - O
only - - O
IL-1beta - - B-MUT
upregulated - - O
PDGF-Ralpha - - B-MUT
. - - O

Oculus-500 - - O
is - - O
a - - O
group - - O
of - - O
high - - O
resolution - - O
imaging - - O
boards - - O
for - - O
use - - O
with - - O
IBM-AT - - O
and - - O
compatible - - O
computers - - O
. - - O

The - - O
mRNA - - O
from - - O
this - - O
gene - - O
, - - O
termed - - O
HES1 - - B-MUT
, - - O
is - - O
ubiquitously - - O
expressed - - O
, - - O
but - - O
strongly - - O
so - - O
in - - O
heart - - O
and - - O
skeletal - - O
muscle - - O
. - - O

When - - O
ligated - - O
to - - O
the - - O
proIL-1 - - B-MUT
beta - - I-MUT
cap - - I-MUT
site-proximal - - I-MUT
region - - I-MUT
( - - O
located - - O
between - - O
-131 - - O
to - - O
+12 - - O
) - - O
, - - O
both - - O
the - - O
proIL-1 - - B-MUT
beta - - I-MUT
and - - O
the - - O
simian - - B-MUT
virus - - I-MUT
40 - - I-MUT
enhancer - - I-MUT
elements - - I-MUT
functioned - - O
more - - O
efficiently - - O
in - - O
monocytes - - O
than - - O
in - - O
HeLa - - O
cells - - O
, - - O
which - - O
are - - O
not - - O
normally - - O
competent - - O
for - - O
IL-1 - - B-MUT
beta - - I-MUT
expression - - O
. - - O

Minor - - O
differences - - O
were - - O
noted - - O
with - - O
latamoxef - - O
producing - - O
mild - - O
persistant - - O
elevation - - O
of - - O
prothrombin - - B-MUT
time - - O
( - - O
0 - - O
. - - O
7 - - O
second - - O
) - - O
associated - - O
with - - O
depression - - O
of - - O
factor - - B-MUT
II - - I-MUT
and - - O
factor - - B-MUT
VII - - I-MUT
. - - O

We - - O
report - - O
two - - O
patients - - O
receiving - - O
maintenance - - O
valproate - - O
, - - O
one - - O
with - - O
resolving - - O
acute - - O
hepatitis - - O
C - - O
and - - O
the - - O
other - - O
with - - O
chronic - - O
persistent - - O
hepatitis - - O
C - - O
, - - O
with - - O
incidental - - O
microvesicular - - O
steatosis - - O
demonstrated - - O
on - - O
oil-red - - O
O - - O
stains - - O
. - - O

One - - O
of - - O
these - - O
, - - O
the - - O
origin - - O
core - - O
, - - O
is - - O
required - - O
only - - O
for - - O
DNA - - O
replication - - O
. - - O

Levels - - O
of - - O
serum - - O
IgE - - B-MUT
were - - O
measured - - O
monthly - - O
, - - O
and - - O
nasal - - O
IgE - - B-MUT
was - - O
measured - - O
at - - O
the - - O
height - - O
and - - O
end - - O
of - - O
the - - O
season - - O
. - - O

PDGF - - B-MUT
A-chain - - I-MUT
levels - - O
increase - - O
in - - O
cultured - - O
vascular - - O
smooth - - O
muscle - - O
cells - - O
( - - O
SMCs - - O
) - - O
exposed - - O
to - - O
ATII - - B-MUT
. - - O

Standardized - - O
gastric - - O
wall - - O
specimens - - O
from - - O
the - - O
area - - O
of - - O
grossly - - O
healed - - O
ulcers - - O
were - - O
obtained - - O
, - - O
processed - - O
, - - O
and - - O
evaluated - - O
by - - O
light - - O
microscopy - - O
and - - O
by - - O
transmission - - O
electron - - O
microscopy - - O
. - - O

Likewise - - O
, - - O
at - - O
150 - - O
degrees - - O
C - - O
with - - O
2% - - O
APS - - O
the - - O
surface - - O
density - - O
of - - O
NH2 - - O
groups - - O
reached - - O
a - - O
maximum - - O
at - - O
24 - - O
hr - - O
and - - O
remained - - O
relatively - - O
constant - - O
up - - O
to - - O
96 - - O
hr - - O
. - - O

HeLa - - O
and - - O
Jurkat - - O
cell - - O
lines - - O
carrying - - O
the - - O
nef - - B-MUT
gene - - I-MUT
linked - - O
to - - O
the - - O
CMV - - O
promoter - - O
or - - O
the - - O
HIV-1 - - O
LTR - - O
were - - O
isolated - - O
by - - O
coselection - - O
for - - O
neomycin - - O
resistance - - O
. - - O

We - - O
have - - O
isolated - - O
and - - O
characterized - - O
the - - O
GCD6 - - B-MUT
and - - O
GCD7 - - B-MUT
genes - - I-MUT
and - - O
shown - - O
that - - O
their - - O
products - - O
are - - O
required - - O
to - - O
repress - - O
GCN4 - - B-MUT
translation - - O
under - - O
nonstarvation - - O
conditions - - O
. - - O

We - - O
have - - O
visualized - - O
DNA-protein - - O
complexes - - O
by - - O
electron - - O
microscopy - - O
and - - O
a - - O
high-affinity - - O
binding - - O
site - - O
of - - O
WDV - - B-MUT
Rep - - I-MUT
protein - - I-MUT
within - - O
the - - O
core - - O
element - - O
has - - O
been - - O
mapped - - O
to - - O
approximately - - O
144 - - O
+ - - O
- - - O
18 - - O
bp - - O
upstream - - O
from - - O
the - - O
initiation - - O
site - - O
, - - O
between - - O
the - - O
start - - O
site - - O
for - - O
complementary-sense - - O
transcription - - O
and - - O
the - - O
TATA - - O
box - - O
. - - O

Both - - O
in - - O
vitro-synthesized - - O
S2 - - B-MUT
protein - - I-MUT
and - - O
synthetic - - O
peptides - - O
corresponding - - O
to - - O
S2 - - B-MUT
are - - O
shown - - O
to - - O
react - - O
positively - - O
with - - O
sera - - O
obtained - - O
from - - O
EIAV-infected - - O
horses - - O
, - - O
providing - - O
the - - O
first - - O
direct - - O
evidence - - O
of - - O
expression - - O
of - - O
this - - O
protein - - O
in - - O
infected - - O
animals - - O
. - - O

For - - O
these - - O
patients - - O
the - - O
introduction - - O
of - - O
a - - O
separate - - O
category - - O
"extended - - O
oligoarthritis - - O
at - - O
onset" - - O
should - - O
be - - O
considered - - O
to - - O
establish - - O
comparable - - O
patient - - O
groups - - O
. - - O

The - - O
number - - O
of - - O
bacteria - - O
in - - O
the - - O
lung - - O
, - - O
peripheral - - O
white - - O
blood - - O
cell - - O
and - - O
BAL - - O
fluid - - O
cell - - O
also - - O
decreased - - O
by - - O
the - - O
administration - - O
of - - O
FN - - B-MUT
. - - O

A - - O
major - - O
mechanism - - O
by - - O
which - - O
estrogens - - O
prevent - - O
osteoporosis - - O
seems - - O
to - - O
be - - O
repression - - O
of - - O
transcription - - O
of - - O
NF-kappa - - B-MUT
B - - I-MUT
target - - I-MUT
genes - - I-MUT
, - - O
such - - O
as - - O
the - - O
osteoclast-activating - - O
cytokines - - O
interleukin-6 - - B-MUT
and - - O
interleukin-1 - - B-MUT
. - - O

Suppressors - - O
of - - O
defective - - O
silencing - - O
in - - O
yeast - - O
: - - O
effects - - O
on - - O
transcriptional - - O
repression - - O
at - - O
the - - O
HMR - - B-MUT
locus - - I-MUT
, - - O
cell - - O
growth - - O
and - - O
telomere - - O
structure - - O
. - - O

Following - - O
extended - - O
recovery - - O
hippocampal - - O
EEG - - O
was - - O
normal - - O
despite - - O
extensive - - O
cellular - - O
loss - - O
in - - O
areas - - O
CA3 - - O
and - - O
CA4 - - O
. - - O

Patients - - O
received - - O
either - - O
diltiazem - - O
CD - - O
180 - - O
mg - - O
or - - O
placebo - - O
once - - O
day - - O
in - - O
combination - - O
with - - O
existing - - O
antianginal - - O
therapy - - O
. - - O

A - - O
haemolytic - - O
enterotoxigenic - - O
strain - - O
of - - O
E - - O
. - - O
coli - - O
( - - O
O149 - - O
: - - O
K88 - - O
: - - O
H10 - - O
) - - O
was - - O
regularly - - O
recovered - - O
from - - O
piglets - - O
with - - O
PWD - - O
while - - O
rotavirus - - O
was - - O
demonstrated - - O
on - - O
a - - O
number - - O
of - - O
occasions - - O
. - - O

These - - O
findings - - O
indicate - - O
that - - O
hypergastrinemia - - O
induced - - O
by - - O
surgical - - O
removal - - O
of - - O
acid-producing - - O
mucosa - - O
in - - O
the - - O
rat - - O
has - - O
the - - O
same - - O
effects - - O
on - - O
oxyntical - - O
mucosal - - B-MUT
HDC - - I-MUT
activity - - O
, - - O
histamine - - O
concentration - - O
and - - O
ECL - - O
cell - - O
density - - O
as - - O
hypergastrinemia - - O
induced - - O
by - - O
continuous - - O
gastrin - - B-MUT
infusion - - O
or - - O
by - - O
long-term - - O
treatment - - O
with - - O
effective - - O
antisecretagogues - - O
. - - O

We - - O
have - - O
isolated - - O
and - - O
analyzed - - O
human - - B-MUT
CTCF - - I-MUT
cDNA - - I-MUT
clones - - O
and - - O
show - - O
here - - O
that - - O
the - - O
ubiquitously - - O
expressed - - O
11-zinc-finger - - B-MUT
factor - - I-MUT
CTCF - - I-MUT
is - - O
an - - O
exceptionally - - O
highly - - O
conserved - - O
protein - - O
displaying - - O
93% - - O
identity - - O
between - - O
avian - - O
and - - O
human - - O
amino - - O
acid - - O
sequences - - O
. - - O

The - - O
influence - - O
of - - O
patient-related - - O
factors - - O
on - - O
inter-observer - - O
variability - - O
in - - O
the - - O
evaluation - - O
of - - O
neurological - - O
signs - - O
was - - O
investigated - - O
. - - O

The - - O
glucose - - O
areas - - O
following - - O
the - - O
ingestion - - O
of - - O
the - - O
foods - - O
were - - O
: - - O
Study - - O
1 - - O
: - - O
glucose - - O
11 - - O
. - - O
7 - - O
, - - O
orange - - O
juice - - O
7 - - O
. - - O
3 - - O
, - - O
sucrose - - O
5 - - O
. - - O
2 - - O
, - - O
glucose - - O
+ - - O
fructose - - O
6 - - O
. - - O
3 - - O
, - - O
and - - O
fructose - - O
0 - - O
. - - O
7 - - O
mmol - - O
X - - O
h - - O
l - - O
; - - O
Study - - O
2 - - O
: - - O
glucose - - O
14 - - O
. - - O
6 - - O
, - - O
orange - - O
juice - - O
7 - - O
. - - O
3 - - O
, - - O
apples - - O
5 - - O
. - - O
5 - - O
, - - O
and - - O
apple - - O
juice - - O
4 - - O
. - - O
7 - - O
mmol - - O
X - - O
h - - O
l - - O
; - - O
Study - - O
3 - - O
: - - O
glucose - - O
12 - - O
. - - O
6 - - O
, - - O
ice - - O
cream - - O
8 - - O
. - - O
1 - - O
, - - O
milk - - O
3 - - O
. - - O
7 - - O
, - - O
and - - O
lactose - - O
4 - - O
. - - O
1 - - O
mmol - - O
X - - O
h - - O
l - - O
. - - O

Nevertheless - - O
, - - O
protein - - B-MUT
kinase - - I-MUT
A - - I-MUT
stimulation - - O
induces - - O
CREMalpha - - B-MUT
to - - O
activate - - O
the - - O
complex - - O
native - - O
promoter - - O
in - - O
the - - O
phosphoenolpyruvate - - B-MUT
carboxykinase - - I-MUT
( - - O
PEPCK - - B-MUT
) - - O
gene - - O
. - - O

The - - O
calcitonin-induced - - O
tyrosine - - O
phosphorylation - - O
of - - O
HEF1 - - B-MUT
increased - - O
in - - O
a - - O
time- - - O
and - - O
dose-dependent - - O
manner - - O
. - - O

These - - O
data - - O
locate - - O
the - - O
aniridia - - B-MUT
gene - - I-MUT
( - - O
AN2 - - B-MUT
) - - O
and - - O
a - - O
recurrent - - O
T-cell - - B-MUT
leukemia - - I-MUT
breakpoint - - I-MUT
( - - O
TCL2 - - B-MUT
) - - O
in - - O
the - - O
marker - - O
sequence - - O
, - - O
on - - O
opposite - - O
sides - - O
of - - O
MIC1 - - B-MUT
. - - O

The - - O
p130 - - B-MUT
and - - O
p62 - - B-MUT
tyrosine-phosphorylated - - O
proteins - - O
that - - O
complexed - - O
v-Src - - B-MUT
SH2 - - B-MUT
in - - O
vitro - - O
also - - O
associated - - O
with - - O
v-Src - - B-MUT
in - - O
v-src-transformed - - O
Rat-2 - - O
cells - - O
; - - O
this - - O
in - - O
vivo - - O
binding - - O
was - - O
dependent - - O
on - - O
the - - O
v-Src - - B-MUT
SH2 - - B-MUT
domain - - O
. - - O

A - - O
study - - O
was - - O
conducted - - O
of - - O
a - - O
human - - O
male - - O
who - - O
had - - O
inhaled - - O
a - - O
mixture - - O
of - - O
241Am - - O
and - - O
Pu - - O
. - - O

In - - O
slightly - - O
older - - O
embryos - - O
, - - O
the - - O
expression - - O
was - - O
skewed - - O
to - - O
one - - O
side - - O
of - - O
the - - O
embryo - - O
and - - O
by - - O
E6 - - O
. - - O
5 - - O
, - - O
at - - O
the - - O
onset - - O
of - - O
gastrulation - - O
, - - O
expression - - O
was - - O
seen - - O
in - - O
the - - O
epiblast - - O
, - - O
visceral - - O
endoderm - - O
, - - O
nascent - - O
mesoderm - - O
, - - O
and - - O
the - - O
primitive - - O
streak - - O
. - - O

As - - O
for - - O
31 - - O
stage - - O
I-II - - O
lung - - O
cancer - - O
patients - - O
, - - O
CR - - O
has - - O
been - - O
observed - - O
in - - O
82 - - O
. - - O
8% - - O
of - - O
them - - O
and - - O
PR - - O
in - - O
13 - - O
. - - O
8% - - O
; - - O
the - - O
response - - O
was - - O
always - - O
assessed - - O
with - - O
chest - - O
radiography - - O
, - - O
CT - - O
, - - O
FBS - - O
, - - O
cytology - - O
and - - O
or - - O
histology - - O
. - - O

The - - O
technique - - O
of - - O
the - - O
TEE - - O
visualization - - O
of - - O
the - - O
proximal - - O
coronary - - O
arteries - - O
is - - O
described - - O
. - - O

This - - O
negative - - O
regulatory - - O
pathway - - O
may - - O
be - - O
important - - O
for - - O
determining - - O
cell - - O
fate - - O
or - - O
maintaining - - O
an - - O
inducible - - O
state - - O
in - - O
the - - O
ventroposterior - - O
region - - O
of - - O
the - - O
embryo - - O
. - - O

Myogenic - - O
differentiation - - O
can - - O
be - - O
inhibited - - O
by - - O
the - - O
adenovirus - - O
E1a - - B-MUT
protein - - I-MUT
in - - O
the - - O
rat - - O
L6 - - O
muscle - - O
cell - - O
line - - O
. - - O

Two - - O
points - - O
are - - O
indicated - - O
: - - O
first - - O
, - - O
the - - O
photosensitized - - O
damage - - O
of - - O
YHPD - - O
is - - O
interrelated - - O
to - - O
not - - O
only - - O
1O2 - - O
, - - O
but - - O
also - - O
free - - O
radicals - - O
( - - O
O2- - - O
. - - O
. - - O
OH - - O
and - - O
YHPD- - - O
. - - O
) - - O
; - - O
second - - O
, - - O
although - - O
the - - O
photosensitized - - O
damage - - O
of - - O
YHPD - - O
is - - O
stronger - - O
than - - O
that - - O
of - - O
BHPD - - O
, - - O
yet - - O
the - - O
photosensitized - - O
damage - - O
is - - O
negatively - - O
correlated - - O
to - - O
the - - O
yield - - O
of - - O
1O2 - - O
but - - O
positively - - O
correlated - - O
to - - O
those - - O
of - - O
O2- - - O
. - - O
and - - O
OH - - O
. - - O

Selection - - O
using - - O
SC - - O
EPD - - O
was - - O
more - - O
effective - - O
than - - O
phenotypic - - O
selection - - O
in - - O
reducing - - O
age - - O
at - - O
puberty - - O
in - - O
daughters - - O
. - - O

The - - O
results - - O
indicate - - O
that - - O
increased - - O
pulmonary - - O
blood - - O
flow - - O
and - - O
decreased - - O
pulmonary - - O
vascular - - O
resistance - - O
with - - O
advancing - - O
gestation - - O
are - - O
due - - O
to - - O
an - - O
increase - - O
in - - O
the - - O
total - - O
number - - O
of - - O
vessels - - O
and - - O
increased - - O
vasomotor - - O
reactivity - - O
is - - O
related - - O
to - - O
an - - O
increase - - O
in - - O
the - - O
total - - O
amount - - O
of - - O
smooth - - O
muscle - - O
while - - O
the - - O
thickness - - O
of - - O
muscle - - O
in - - O
individual - - O
vessels - - O
remains - - O
constant - - O
. - - O

Immunofixation - - O
experiments - - O
of - - O
C4A - - B-MUT
and - - O
C4B - - B-MUT
demonstrate - - O
> - - O
41 - - O
allotypes - - O
in - - O
the - - O
two - - O
classes - - O
of - - O
proteins - - O
. - - O

Thirty - - O
of - - O
the - - O
clones - - O
contained - - O
a - - O
complete - - O
340 - - O
base-pair - - O
dimer - - O
unit - - O
of - - O
the - - O
repeat - - O
. - - O

Primer - - O
extension - - O
and - - O
cDNA - - O
cloning - - O
were - - O
used - - O
to - - O
isolate - - O
the - - O
complete - - O
5' - - O
end - - O
of - - O
the - - O
Nramp1 - - B-MUT
mRNA - - I-MUT
. - - O

A - - O
736-bp - - O
sequence - - O
of - - O
the - - O
5' - - O
flanking - - O
region - - O
adjacent - - O
to - - O
the - - O
cap - - O
site - - O
of - - O
the - - O
human - - B-MUT
AFP - - I-MUT
gene - - I-MUT
shows - - O
a - - O
61% - - O
similarity - - O
with - - O
the - - O
corresponding - - O
region - - O
of - - O
the - - O
mouse - - B-MUT
AFP - - I-MUT
gene - - I-MUT
. - - O

A - - O
new - - O
species - - O
of - - O
Euspondylus - - O
is - - O
described - - O
based - - O
on - - O
a - - O
female - - O
( - - O
taken - - O
within - - O
a - - O
bromeliad - - O
) - - O
from - - O
Cerro - - O
El - - O
Humo - - O
, - - O
Sucre - - O
, - - O
northeastern - - O
Venezuela - - O
. - - O

The - - O
effect - - O
of - - O
site-specific - - O
mutations - - O
in - - O
the - - O
mouse - - B-MUT
platelet-derived - - I-MUT
growth - - I-MUT
factor - - I-MUT
( - - I-MUT
PDGF - - I-MUT
) - - I-MUT
beta-receptor - - I-MUT
on - - O
activation - - O
of - - O
the - - O
Na+ - - B-MUT
H+ - - I-MUT
exchanger - - I-MUT
was - - I-MUT
examined - - O
in - - O
normal - - O
murine - - O
mammary - - O
gland - - O
epithelial - - O
( - - O
NMuMG - - O
) - - O
and - - O
Chinese - - O
hamster - - O
ovary - - O
( - - O
CHO - - O
) - - O
cells - - O
. - - O

The - - O
Og4C3 - - B-MUT
enzyme-linked - - O
immunosorbent - - O
assay - - O
( - - O
ELISA - - O
) - - O
to - - O
detect - - O
circulating - - O
Wuchereria - - B-MUT
bancrofti - - I-MUT
antigen - - I-MUT
uses - - O
50 - - O
microL - - O
of - - O
serum - - O
. - - O

Pharmacological - - O
desympathization - - O
leads - - O
to - - O
the - - O
development - - O
of - - O
hyper-reactivity - - O
of - - O
the - - O
true - - O
pacemakers - - O
to - - O
noradrenaline - - O
and - - O
dopamine - - O
and - - O
triggers - - O
off - - O
changes - - O
in - - O
the - - O
regulation - - O
of - - O
the - - O
electric - - O
activity - - O
of - - O
these - - O
cells - - O
by - - O
catecholamines - - O
. - - O

The - - O
inhibition - - O
of - - O
focus - - O
formation - - O
observed - - O
in - - O
the - - O
presence - - O
of - - O
C3G - - B-MUT
was - - O
not - - O
due - - O
to - - O
toxic - - O
effects - - O
on - - O
cell - - O
viability - - O
, - - O
since - - O
transfected - - O
C3G - - B-MUT
cells - - O
exhibited - - O
the - - O
same - - O
survival - - O
and - - O
growth - - O
rates - - O
as - - O
untransfected - - O
NIH3T3 - - O
cells - - O
or - - O
cells - - O
transfected - - O
with - - O
plasmid - - O
vector - - O
alone - - O
. - - O

In - - O
rubella - - O
patients - - O
with - - O
serologic - - O
confirmation - - O
by - - O
HI - - O
, - - O
the - - O
IF - - O
test - - O
detected - - O
significant - - O
rises - - O
in - - O
219 - - O
( - - O
99 - - O
. - - O
1% - - O
) - - O
of - - O
221 - - O
patients - - O
and - - O
the - - O
PHA - - B-MUT
test - - O
detected - - O
antibody - - O
conversion - - O
in - - O
68 - - O
( - - O
93% - - O
) - - O
of - - O
73 - - O
patients - - O
. - - O

Exposure - - O
of - - O
peripheral - - O
blood - - O
T - - O
cells - - O
from - - O
young - - O
subjects - - O
to - - O
PHA - - O
or - - O
cross-linked - - O
anti-CD3 - - B-MUT
monoclonal - - I-MUT
antibodies - - I-MUT
stimulated - - O
rapid - - O
increases - - O
in - - O
MAPK - - B-MUT
and - - O
MEK - - B-MUT
enzymatic - - O
activity - - O
. - - O

Southern - - O
blotting - - O
analysis - - O
implied - - O
the - - O
occurrence - - O
of - - O
multiple - - O
COXVb - - B-MUT
genes - - I-MUT
in - - O
the - - O
rat - - O
genome - - O
. - - O

Cryopreservation - - O
straws - - O
filled - - O
with - - O
media - - O
plus - - O
additive - - O
are - - O
emersed - - O
below - - O
the - - O
surface - - O
of - - O
an - - O
unprocessed - - O
donor - - O
ejaculate - - O
. - - O

Clinical - - O
course - - O
and - - O
nursing - - O
care - - O
of - - O
patients - - O
with - - O
decubitus - - O
ulcer--use - - O
of - - O
pillows - - O
stuffed - - O
with - - O
buckwheat - - O
chaff - - O
. - - O

An - - O
examination - - O
was - - O
performed - - O
in - - O
15 - - O
patients - - O
who - - O
had - - O
developed - - O
pronounced - - O
osteomalacia - - O
following - - O
gastric - - O
resection - - O
. - - O

Adjacent - - O
to - - O
those - - O
lesions - - O
, - - O
and - - O
in - - O
homologous - - O
contralateral - - O
structures - - O
, - - O
FMZ - - O
binding - - O
was - - O
analysed - - O
in - - O
four - - O
pairs - - O
of - - O
cortical - - O
9 - - O
x - - O
9-mm - - O
regions - - O
of - - O
interest - - O
( - - O
ROIs - - O
) - - O
placed - - O
on - - O
transaxial - - O
and - - O
coronal - - O
slices - - O
, - - O
respectively - - O
, - - O
as - - O
well - - O
as - - O
in - - O
the - - O
lesion - - O
volume - - O
and - - O
its - - O
mirror - - O
region - - O
. - - O

Doppler - - O
ultrasound - - O
studies - - O
of - - O
long-term - - O
follow-up - - O
of - - O
children - - O
with - - O
hemolytic-uremic - - O
syndrome - - O
. - - O

The - - O
contrasting - - O
effects - - O
of - - O
dopaminergic - - O
stimulation - - O
on - - O
the - - O
motor - - O
performance - - O
and - - O
on - - O
some - - O
aspects - - O
of - - O
cognitive - - O
processing - - O
suggest - - O
the - - O
existence - - O
of - - O
complex - - O
interactions - - O
within - - O
pre- - - O
and - - O
postsynaptic - - O
brain - - B-MUT
dopamine - - I-MUT
receptors - - I-MUT
, - - O
and - - O
an - - O
intervention - - O
of - - O
segregated - - O
basal - - O
ganglia-prefrontal - - O
cortex - - O
loops - - O
in - - O
motor - - O
and - - O
cognitive - - O
behaviour - - O
. - - O

As - - O
in - - O
Tb - - O
, - - O
U6 - - B-MUT
is - - O
a - - O
single-copy - - O
gene - - O
and - - O
two - - O
tRNA - - B-MUT
genes - - I-MUT
, - - O
tRNAGln - - B-MUT
and - - O
tRNAIle - - B-MUT
, - - O
are - - O
found - - O
upstream - - O
to - - O
the - - O
gene - - O
. - - O

Experimental - - O
adhesion - - O
prophylaxis - - O
with - - O
recombinant - - B-MUT
tissue - - I-MUT
plasminogen - - I-MUT
activator - - I-MUT
. - - O

Thigh - - O
girth - - O
correlated - - O
positively - - O
with - - O
HDL - - B-MUT
and - - O
HDL2-C - - B-MUT
and - - O
mass - - O
, - - O
and - - O
with - - O
LDL - - B-MUT
particle - - O
size - - O
among - - O
women - - O
. - - O

Cotransfection - - O
analyses - - O
of - - O
the - - O
T - - B-MUT
EBP - - I-MUT
promoter-reporter - - I-MUT
constructs - - I-MUT
with - - I-MUT
a - - O
T - - O
EBP - - B-MUT
expression - - I-MUT
vector - - I-MUT
into - - O
human - - O
HepG2 - - O
cells - - O
, - - O
which - - O
do - - O
not - - O
express - - O
T - - O
EBP - - O
, - - B-MUT
suggested - - I-MUT
that - - I-MUT
autoregulation - - O
may - - O
be - - O
involved - - O
in - - O
controlling - - O
both - - O
rat - - O
and - - O
human - - O
T - - O
EBP - - O
gene - - B-MUT
expression - - I-MUT
. - - I-MUT

A - - O
newly - - O
developed - - O
broad-spectrum - - O
fluoroquinolone - - O
, - - O
levofloxacin - - O
( - - O
LVFX - - O
, - - O
DR-3355 - - O
) - - O
, - - O
was - - O
evaluated - - O
in - - O
vitro - - O
and - - O
in - - O
vivo - - O
in - - O
comparison - - O
with - - O
ciprofloxacin - - O
( - - O
CPFX - - O
) - - O
, - - O
ofloxacin - - O
( - - O
OFLX - - O
) - - O
and - - O
norfloxacin - - O
( - - O
NFLX - - O
) - - O
. - - O

Previous - - O
studies - - O
indicated - - O
that - - O
the - - O
20S - - B-MUT
proteasome - - I-MUT
is - - O
a - - O
catalytic - - O
core - - O
of - - O
the - - O
26S - - B-MUT
proteolytic - - I-MUT
complex - - I-MUT
that - - O
possesses - - O
a - - O
latent - - O
multicatalytic - - O
proteinase - - B-MUT
activity - - O
and - - O
catalyzes - - O
an - - O
ATP-dependent - - O
, - - O
selective - - O
breakdown - - O
of - - O
proteins - - O
ligated - - O
to - - O
ubiquitin - - B-MUT
. - - O

The - - O
fission - - B-MUT
yeast - - I-MUT
dsk1+ - - I-MUT
gene - - I-MUT
, - - O
a - - O
multicopy - - O
suppressor - - O
for - - O
cold-sensitive - - O
dis1 - - B-MUT
mutants - - I-MUT
, - - O
encodes - - O
a - - O
novel - - O
61-kd - - B-MUT
protein - - I-MUT
kinase - - I-MUT
. - - O

The - - O
results - - O
were - - O
as - - O
follows - - O
: - - O
1 - - O
) - - O
Total - - O
integrated - - O
EMG - - O
activity - - O
of - - O
FB - - O
group - - O
was - - O
approximately - - O
equal - - O
in - - O
any - - O
occluded - - O
position - - O
, - - O
whereas - - O
that - - O
of - - O
CG - - O
and - - O
GF - - O
group - - O
varied - - O
from - - O
position - - O
to - - O
position - - O
. - - O

The - - O
requirement - - O
of - - O
different - - O
essential - - O
fatty - - O
acids - - O
in - - O
patients - - O
with - - O
total - - O
parenteral - - O
nutrition - - O
after - - O
heavy - - O
injury - - O
is - - O
of - - O
special - - O
interest - - O
with - - O
respect - - O
to - - O
the - - O
development - - O
and - - O
prognosis - - O
of - - O
shock - - O
, - - O
sepsis - - O
or - - O
adult - - O
respiratory - - O
distress - - O
syndrome - - O
. - - O

These - - O
consisted - - O
of - - O
beading - - O
and - - O
strictures - - O
mainly - - O
of - - O
the - - O
intrahepatic - - O
biliary - - O
tree - - O
( - - O
IHB - - O
) - - O
. - - O

Comparison - - O
of - - O
the - - O
genomes - - O
of - - O
PMTV - - O
, - - O
BNYVV - - O
, - - O
and - - O
SBWMV - - O
shows - - O
that - - O
furoviruses - - O
exhibit - - O
considerable - - O
heterogeneity - - O
in - - O
genome - - O
organization - - O
. - - O

Hybrid-selection - - O
experiments - - O
against - - O
total - - O
PB-inducible - - O
RNA - - O
were - - O
performed - - O
with - - O
plasmid - - O
DNA - - O
derived - - O
from - - O
clones - - O
enriched - - O
in - - O
PB-inducible - - O
information - - O
. - - O

Sterol - - O
analysis - - O
of - - O
the - - O
disrupted - - O
mutant - - O
demonstrated - - O
the - - O
accumulation - - O
of - - O
ignosterol - - O
, - - O
indicating - - O
a - - O
loss - - O
of - - O
Erg24p - - B-MUT
activity - - O
. - - O

However - - O
, - - O
tyrA - - B-MUT
can - - O
be - - O
expressed - - O
efficiently - - O
from - - O
an - - O
internal - - O
promoter - - O
which - - O
appears - - O
to - - O
lie - - O
within - - O
the - - O
3' - - O
portion - - O
of - - O
aroF - - B-MUT
. - - O

The - - O
interaction - - O
between - - O
U - - O
( - - O
L - - O
) - - O
3 - - O
. - - O

The - - O
percutaneous - - O
absorption - - O
of - - O
clindamycin - - O
was - - O
studied - - O
in - - O
healthy - - O
male - - O
volunteers - - O
, - - O
comparing - - O
two - - O
investigative - - O
clindamycin - - O
( - - O
% - - O
w - - O
v - - O
) - - O
tretinoin - - O
( - - O
0 - - O
. - - O
025% - - O
w - - O
v - - O
) - - O
gels - - O
, - - O
containing - - O
clindamycin - - O
phosphate - - O
ester - - O
and - - O
clindamycin - - O
HCl - - O
, - - O
respectively - - O
, - - O
relative - - O
to - - O
a - - O
clindamycin - - O
phosphate - - O
lotion - - O
( - - O
1% - - O
clindamycin - - O
; - - O
Dalacin - - O
T - - O
) - - O
. - - O

Urinary - - B-MUT
N-acetylglucosaminidase - - I-MUT
activity - - O
per - - O
mg - - O
creatinine - - O
did - - O
not - - O
differ - - O
significantly - - O
between - - O
groups - - O
. - - O

To - - O
those - - O
of - - O
us - - O
who - - O
are - - O
not - - O
satisfied - - O
with - - O
the - - O
present - - O
outlook - - O
there - - O
is - - O
much - - O
to - - O
be - - O
investigated - - O
and - - O
much - - O
to - - O
be - - O
contributed - - O
. - - O

Ritanserin - - O
is - - O
a - - O
new - - O
substance - - O
with - - O
highly - - O
selective - - O
blocking - - O
activity - - O
on - - O
S2 - - B-MUT
receptors - - I-MUT
for - - O
5-HT - - O
in - - O
the - - O
central - - O
nervous - - O
system - - O
. - - O

Mortality - - O
on - - O
the - - O
last - - O
ranch - - O
was - - O
particularly - - O
severe - - O
among - - O
certain - - O
segregated - - O
groups - - O
of - - O
turkeys - - O
that - - O
included - - O
toms - - O
, - - O
heavier - - O
birds - - O
, - - O
and - - O
birds - - O
undergoing - - O
a - - O
stressful - - O
event - - O
such - - O
as - - O
artificial - - O
insemination - - O
. - - O

NERVTRACK - - O
contains - - O
4000 - - O
anatomical - - O
data - - O
items - - O
arranged - - O
in - - O
a - - O
tree-like - - O
manner - - O
reflecting - - O
structural - - O
and - - O
functional - - O
relationships - - O
. - - O

Myocardial - - O
infarction - - O
in - - O
patients - - O
with - - O
previous - - O
bypass - - O
surgery - - O
. - - O

Lung - - O
density - - O
increased - - O
in - - O
quartz-exposed - - O
, - - O
but - - O
not - - O
in - - O
volcanic-ash-exposed - - O
animals - - O
. - - O

Management - - O
of - - O
hypertension - - O
in - - O
the - - O
elderly - - O
. - - O

By - - O
using - - O
the - - O
full-length - - O
cytoplasmic - - O
domain - - O
and - - O
mutants - - O
with - - O
progressive - - O
carboxy-terminal - - O
deletions - - O
, - - O
internal - - O
deletions - - O
, - - O
or - - O
point - - O
mutations - - O
, - - O
we - - O
identified - - O
the - - O
first - - O
150 - - O
amino - - O
acid - - O
residues - - O
of - - O
LIFR - - B-MUT
as - - O
the - - O
minimal - - O
region - - O
necessary - - O
for - - O
signaling - - O
. - - O

In - - O
the - - O
predicted - - O
transmembrane - - O
domain - - O
, - - O
Casr-rs2 - - B-MUT
and - - O
Casr-rs3 - - B-MUT
are - - O
95% - - O
identical - - O
to - - O
Casr-rs1 - - B-MUT
. - - O

Serum - - O
magnesium - - O
in - - O
79 - - O
patients - - O
of - - O
gynecologic - - O
neoplasms - - O
treated - - O
with - - O
cisplatin - - O
and - - O
their - - O
controls - - O
was - - O
measured - - O
. - - O

A - - O
new - - O
intron - - O
of - - O
476 - - O
base - - O
pairs - - O
was - - O
found - - O
in - - O
the - - O
middle - - O
of - - O
the - - O
5'-untranslated - - O
leader - - O
sequence - - O
and - - O
was - - O
shown - - O
to - - O
robustly - - O
enhance - - O
the - - O
promoter - - O
activity - - O
. - - O

In - - O
order - - O
to - - O
overcome - - O
the - - O
false - - O
positive - - O
readings - - O
that - - O
are - - O
possible - - O
in - - O
sphincter - - O
manometry - - O
, - - O
we - - O
proposed - - O
to - - O
use - - O
secretin - - B-MUT
stimulated - - O
endoscopic - - O
ultrasound - - O
( - - O
SSEUS - - O
) - - O
to - - O
measure - - O
pancreatic - - O
ductal - - O
response - - O
as - - O
an - - O
adjunctive - - O
method - - O
to - - O
aid - - O
and - - O
supplement - - O
the - - O
diagnosis - - O
. - - O

CES4 - - B-MUT
on - - O
a - - O
multicopy - - O
plasmid - - O
was - - O
unable - - O
to - - O
suppress - - O
tif1-A79V - - B-MUT
. - - O

A - - O
prospective - - O
trial - - O
was - - O
undertaken - - O
to - - O
determine - - O
( - - O
1 - - O
) - - O
clinical - - O
characteristics - - O
of - - O
patients - - O
with - - O
chest - - O
pain - - O
; - - O
( - - O
2 - - O
) - - O
value - - O
of - - O
cardiac - - O
markers - - O
troponin - - B-MUT
T - - I-MUT
, - - O
myoglobin - - B-MUT
and - - O
CK-MB - - B-MUT
mass - - O
in - - O
differentiating - - O
cardiac - - O
and - - O
noncardiac - - O
chest - - O
pain - - O
; - - O
( - - O
3 - - O
) - - O
the - - O
proportion - - O
of - - O
patients - - O
with - - O
ACS - - O
in - - O
whom - - O
these - - O
markers - - O
provided - - O
helpful - - O
additional - - O
information - - O
on - - O
admission - - O
and - - O
afterwards - - O
. - - O

Mutational - - O
analysis - - O
of - - O
the - - O
major - - O
homology - - O
region - - O
of - - O
Mason-Pfizer - - O
monkey - - O
virus - - O
by - - O
use - - O
of - - O
saturation - - O
mutagenesis - - O
. - - O

We - - O
report - - O
here - - O
the - - O
isolation - - O
of - - O
a - - O
full-length - - O
cDNA - - O
clone - - O
coding - - O
for - - O
a - - O
hitherto - - O
undiscovered - - O
isoform - - O
of - - O
the - - O
bovine - - B-MUT
C-subunit - - I-MUT
. - - O

STUDY - - O
OBJECTIVE - - O
: - - O
This - - O
study - - O
assessed - - O
several - - O
methodological - - O
aspects - - O
related - - O
to - - O
the - - O
quality - - O
of - - O
published - - O
controlled - - O
clinical - - O
trials - - O
( - - O
CCTs - - O
) - - O
in - - O
relation - - O
to - - O
the - - O
participation - - O
of - - O
an - - O
epidemiologist - - O
biostatistician - - O
( - - O
E - - O
B - - O
) - - O
. - - O

Neuronal - - O
signaling - - O
properties - - O
are - - O
largely - - O
determined - - O
by - - O
the - - O
quantity - - O
and - - O
combination - - O
of - - O
ion - - O
channels - - O
expressed - - O
. - - O

Triumph - - O
of - - O
Leninist - - O
national - - O
policy - - O
. - - O

If - - O
no - - O
reply - - O
was - - O
received - - O
, - - O
telephone - - O
contact - - O
or - - O
home - - O
visits - - O
were - - O
made - - O
. - - O

The - - O
effect - - O
of - - O
sodium - - O
saccharin - - O
in - - O
the - - O
diet - - O
on - - O
caecal - - O
microflora - - O
. - - O

A - - O
cDNA - - O
encoding - - O
the - - O
amino-terminal - - O
17% - - O
of - - O
apoB - - B-MUT
( - - O
apoB17 - - B-MUT
) - - O
was - - O
fused - - O
to - - O
a - - O
cDNA - - O
coding - - O
for - - O
the - - O
last - - O
37 - - O
amino - - O
acids - - O
of - - O
decay-accelerating - - B-MUT
factor - - I-MUT
( - - O
DAF - - B-MUT
) - - O
, - - O
which - - O
contains - - O
the - - O
signal - - O
for - - O
glycosylphosphatidylinositol - - O
anchor - - O
attachment - - O
. - - O

It - - O
then - - O
merged - - O
with - - O
right - - O
ventricular - - O
wavefronts - - O
ending - - O
along - - O
the - - O
right - - O
ventricular - - O
anterior - - O
atrioventricular - - O
groove - - O
and - - O
outflow - - O
tract - - O
. - - O

Selective - - O
visual - - O
attention - - O
involves - - O
dynamic - - O
interplay - - O
between - - O
attentional - - O
control - - O
systems - - O
and - - O
sensory - - O
brain - - O
structures - - O
. - - O

A - - O
variety - - O
of - - O
receptor-mediated - - O
signaling - - O
pathways - - O
are - - O
controlled - - O
by - - O
both - - O
positive - - O
and - - O
negative - - O
extracellular - - O
regulators - - O
. - - O

Comparison - - O
with - - O
the - - O
sequence - - O
databanks - - O
show - - O
that - - O
Tactile - - B-MUT
is - - O
a - - O
member - - O
of - - O
the - - O
immunoglobulin - - B-MUT
gene - - I-MUT
superfamily - - I-MUT
, - - O
with - - O
similarity - - O
to - - O
Drosophila - - B-MUT
amalgam - - I-MUT
, - - O
the - - O
melanoma - - B-MUT
Ag - - I-MUT
MUC-18 - - I-MUT
, - - O
members - - O
of - - O
the - - O
carcinoembryonic - - B-MUT
Ag - - I-MUT
family - - I-MUT
, - - O
the - - O
poliovirus - - B-MUT
receptor - - I-MUT
, - - O
and - - O
the - - O
neural - - B-MUT
cell - - I-MUT
adhesion - - I-MUT
molecule - - I-MUT
. - - O

Statistical - - O
Analysis - - O
included - - O
ANOVA - - O
, - - O
the - - O
Pearson - - O
Product - - O
Moment - - O
Correlation - - O
Coefficient - - O
, - - O
Principal - - O
Components - - O
Analysis - - O
and - - O
Discriminant - - O
Function - - O
Analysis - - O
and - - O
the - - O
calculation - - O
of - - O
Cronbach's - - O
alpha - - O
( - - O
alpha - - O
) - - O
RESULTS - - O
: - - O
Both - - O
Sensitivity - - O
and - - O
specificity - - O
exceed - - O
90 - - O
. - - O
00 - - O
at - - O
23 - - O
24 - - O
, - - O
Chronbach's - - O
alpha - - O
for - - O
the - - O
total - - O
scale - - O
was - - O
equal - - O
to - - O
0 - - O
. - - O
95 - - O
. - - O

Mnt - - B-MUT
: - - I-MUT
Max - - I-MUT
complexes - - I-MUT
also - - O
efficiently - - O
suppress - - O
Myc-dependent - - O
activation - - O
from - - O
the - - O
same - - O
promoter - - O
. - - O

An - - O
epidemiological - - O
survey - - O
of - - O
rheumatic - - O
valve - - O
disease - - O
and - - O
rheumatic - - O
fever - - O
in - - O
primary - - O
and - - O
secondary - - O
school - - O
students - - O
in - - O
Jiangxi - - O
Province - - O
. - - O

Haplotype - - O
mapping - - O
and - - O
sequence - - O
analysis - - O
of - - O
the - - O
mouse - - O
Nramp - - B-MUT
gene - - I-MUT
predict - - O
susceptibility - - O
to - - O
infection - - O
with - - O
intracellular - - O
parasites - - O
. - - O

Because - - O
RNase - - B-MUT
III - - I-MUT
host - - I-MUT
mutants - - I-MUT
are - - O
defective - - O
in - - O
sib - - B-MUT
regulation - - O
, - - O
processing - - O
of - - O
the - - O
PL - - B-MUT
mRNA - - I-MUT
at - - O
sib - - B-MUT
by - - O
this - - O
endoribonuclease - - B-MUT
may - - O
cause - - O
int - - B-MUT
mRNA - - I-MUT
decay - - O
and - - O
decrease - - O
int - - B-MUT
synthesis - - O
. - - O

Transient - - O
cotransfection - - O
of - - O
tat - - B-MUT
cDNA - - I-MUT
in - - O
sense - - O
orientation - - O
( - - O
tat - - B-MUT
S - - I-MUT
) - - I-MUT
, - - O
together - - O
with - - O
a - - O
plasmid - - O
containing - - O
the - - O
c-fos - - O
promoter - - B-MUT
( - - I-MUT
FC3 - - O
, - - B-MUT
from - - O
-711 - - O
to - - O
+42 - - O
) - - O
in - - O
front - - O
of - - O
the - - O
bacterial - - O
chloramphenicol - - B-MUT
acetyltransferase - - I-MUT
( - - I-MUT
CAT - - O
) - - B-MUT
gene - - O
significantly - - O
enhanced - - O
CAT - - O
activity - - B-MUT
in - - O
Jurkat - - O
cells - - O
activated - - O
by - - O
the - - O
addition - - O
of - - O
15% - - O
fetal - - O
calf - - O
serum - - O
( - - O
FCS - - O
) - - O
or - - O
5 - - O
micrograms - - O
mL - - O
phytohemagglutinin - - O
plus - - O
10 - - B-MUT
( - - O
-7 - - O
) - - O
mol - - O
L - - O
phorbol - - O
myristate - - O
acetate - - O
( - - O
PMA - - O
) - - O
and - - O
U937 - - O
cells - - O
activated - - O
by - - O
15% - - O
FCS - - O
or - - O
10 - - O
( - - O
-7 - - O
) - - O
mol - - O
L - - O
PMA - - O
. - - O

The - - O
most - - O
important - - O
one - - O
among - - O
them - - O
is - - O
Cyclosporin - - O
A - - O
, - - O
which - - O
is - - O
a - - O
selective - - O
immunosuppressive - - O
drug - - O
. - - O

A - - O
genetic - - O
complementation - - O
system - - O
was - - O
developed - - O
in - - O
which - - O
tobacco - - B-MUT
etch - - I-MUT
virus - - I-MUT
( - - I-MUT
TEV - - I-MUT
) - - I-MUT
polymerase - - I-MUT
( - - O
NIb - - B-MUT
) - - O
-expressing - - O
transgenic - - O
plants - - O
or - - O
protoplasts - - O
were - - O
inoculated - - O
with - - O
NIb-defective - - O
TEV - - B-MUT
mutants - - I-MUT
. - - O

Furthermore - - O
, - - O
as - - O
in - - O
the - - O
human - - O
gene - - O
, - - O
the - - O
3' - - O
end - - O
of - - O
the - - O
Cacna1f - - B-MUT
gene - - I-MUT
maps - - O
within - - O
5 - - O
kb - - O
of - - O
the - - O
5' - - O
end - - O
of - - O
the - - O
mouse - - B-MUT
synaptophysin - - I-MUT
gene - - I-MUT
in - - O
a - - O
region - - O
orthologous - - O
to - - O
Xp11 - - O
. - - O
23 - - O
. - - O

The - - O
following - - O
evidence - - O
indicates - - O
that - - O
the - - O
69-kD - - O
protein - - O
is - - O
a - - O
common - - O
, - - O
rather - - O
than - - O
a - - O
U1-specific - - O
, - - O
protein - - O
, - - O
possibly - - O
associating - - O
with - - O
the - - O
snRNP - - B-MUT
core - - I-MUT
particles - - I-MUT
by - - O
protein-protein - - O
interaction - - O
. - - O

The - - O
logistic - - O
regression - - O
analysis - - O
of - - O
the - - O
manual - - O
method - - O
( - - O
percentage - - O
normal - - O
morphology - - O
) - - O
and - - O
IVOS - - O
indicated - - O
that - - O
both - - O
were - - O
predictors - - O
of - - O
fertilization - - O
. - - O

In - - O
this - - O
study - - O
, - - O
we - - O
demonstrate - - O
that - - O
BOX - - B-MUT
DNA - - I-MUT
enhances - - O
transcription - - O
from - - O
the - - O
thymidine - - B-MUT
kinase - - I-MUT
( - - O
TK - - B-MUT
) - - O
promoter - - O
in - - O
various - - O
EC - - O
cells - - O
. - - O

The - - O
clinical - - O
efficacy - - O
rates - - O
evaluated - - O
in - - O
151 - - O
cases - - O
( - - O
KS-R1 - - O
group - - O
in - - O
77 - - O
cases - - O
, - - O
oral - - O
group - - O
in - - O
74 - - O
cases - - O
) - - O
on - - O
standard - - O
criteria - - O
of - - O
committee - - O
members - - O
were - - O
88 - - O
. - - O
3% - - O
for - - O
the - - O
KS-R1 - - O
group - - O
and - - O
86 - - O
. - - O
5% - - O
for - - O
the - - O
oral - - O
group - - O
, - - O
respectively - - O
. - - O

We - - O
show - - O
here - - O
that - - O
the - - O
third - - O
SH3 - - B-MUT
domain - - I-MUT
binds - - O
to - - O
Sos - - B-MUT
, - - O
a - - O
guanine - - B-MUT
nucleotide - - I-MUT
exchange - - I-MUT
factor - - I-MUT
for - - O
Ras - - B-MUT
and - - O
Rac - - B-MUT
, - - O
both - - O
in - - O
vitro - - O
and - - O
in - - O
vivo - - O
. - - O

Its - - O
predicted - - O
amino - - O
acid - - O
sequence - - O
shows - - O
extensive - - O
homology - - O
to - - O
those - - O
of - - O
Drosophila - - B-MUT
hsp70 - - I-MUT
, - - O
trout - - B-MUT
hsp70 - - I-MUT
, - - O
Xenopus - - B-MUT
hsp70 - - I-MUT
, - - O
yeast - - B-MUT
hsp70 - - I-MUT
, - - O
and - - O
some - - O
homology - - O
to - - O
the - - O
heat-inducible - - B-MUT
dnaK - - I-MUT
gene - - I-MUT
product - - I-MUT
of - - O
Escherichia - - O
coli - - O
. - - O

A - - O
dose - - O
of - - O
3 - - O
and - - O
6 - - O
micrograms - - O
kg - - O
day - - O
GM-CSF - - O
reduces - - O
the - - O
severity - - O
of - - O
neutropenia - - O
and - - O
thrombocytopenia - - O
after - - O
carboplatin-cyclophosphamide - - O
chemotherapy - - O
, - - O
which - - O
may - - O
lead - - O
to - - O
more - - O
effective - - O
chemotherapy - - O
for - - O
ovarian - - O
cancer - - O
in - - O
the - - O
future - - O
. - - O

SH2D1A - - B-MUT
protein - - I-MUT
levels - - O
are - - O
up-regulated - - O
by - - O
CD40 - - B-MUT
cross-linking - - O
and - - O
down-regulated - - O
by - - O
B - - B-MUT
cell - - I-MUT
receptor - - I-MUT
ligation - - O
. - - O

[ - - O
82Br - - O
] - - O
MISO - - O
was - - O
prepared - - O
by - - O
irradiating - - O
samples - - O
of - - O
Br-MISO - - O
in - - O
a - - O
SLOWPOKE - - O
reactor - - O
for - - O
2 - - O
h - - O
at - - O
a - - O
thermal - - O
neutron - - O
flux - - O
of - - O
10 - - O
( - - O
12 - - O
) - - O
n - - O
cm-2 - - O
s-1 - - O
. - - O

A - - O
partial - - O
cDNA - - O
sequence - - O
indicated - - O
that - - O
the - - O
T - - B-MUT
lymphocyte - - I-MUT
early-activation - - I-MUT
gene - - I-MUT
( - - O
Tea - - B-MUT
) - - O
encodes - - O
a - - O
protein - - O
related - - O
to - - O
the - - O
dual-function - - O
ecotropic - - B-MUT
retrovirus - - I-MUT
receptor - - I-MUT
cationic - - I-MUT
amino - - I-MUT
acid - - I-MUT
transporter - - I-MUT
( - - I-MUT
ecoR - - O
CAT1 - - B-MUT
) - - I-MUT
, - - I-MUT
and - - O
RNA - - O
blots - - O
suggested - - O
highest - - O
Tea - - O
expression - - O
in - - B-MUT
T - - O
lymphocytes - - O
and - - O
liver - - O
( - - O
MacLeod - - O
, - - O
C - - O
. - - O
L - - O
. - - O
, - - O
Finley - - O
, - - O
K - - O
. - - O
, - - O
Kakuda - - O
, - - O
D - - O
. - - O

Vitrectomy - - O
with - - O
an - - O
alternative - - O
instrument - - O
system - - O
. - - O
pp - - O
. - - O

Precipitating - - O
antibodies - - O
for - - O
Thermophilic - - O
actinomycetes - - O
and - - O
M - - O
. - - O
f - - O
. - - O
were - - O
negative - - O
. - - O

UbiA - - B-MUT
is - - O
also - - O
unique - - O
among - - O
known - - O
polyubiquitin - - B-MUT
genes - - I-MUT
in - - O
containing - - O
four - - O
cis-spliced - - O
introns - - O
within - - O
its - - O
coding - - O
sequence - - O
. - - O

Stress-inducible - - B-MUT
protein - - I-MUT
kinases - - I-MUT
capable - - O
of - - O
activating - - O
c-jun - - B-MUT
expression - - O
include - - O
stress-activated - - B-MUT
protein - - I-MUT
kinase - - I-MUT
c-Jun - - O
N-terminal - - B-MUT
protein - - I-MUT
kinase - - I-MUT
( - - I-MUT
SAPK - - O
JNK - - B-MUT
) - - O
and - - B-MUT
p38 - - O
members - - O
of - - B-MUT
the - - O
mitogen-activated - - O
protein - - O
kinase - - B-MUT
( - - I-MUT
MAPK - - I-MUT
) - - O
superfamily - - B-MUT
of - - O
signaling - - O
molecules - - O
. - - O

The - - O
variable - - O
regions - - O
of - - O
vertebrate - - O
striated - - O
TnT - - B-MUT
isoforms - - I-MUT
reflect - - O
the - - O
subsequent - - O
addition - - O
and - - O
modification - - O
of - - O
genomic - - O
sequences - - O
to - - O
give - - O
rise - - O
to - - O
members - - O
of - - O
the - - O
TnT - - B-MUT
multigene - - I-MUT
family - - I-MUT
. - - O

RESULTS - - O
: - - O
Factors - - O
associated - - O
with - - O
significantly - - O
( - - O
P - - O
< - - O
. - - O
05 - - O
) - - O
increased - - O
risk - - O
of - - O
treatment - - O
failure - - O
in - - O
a - - O
Cox - - O
multivariate - - O
analysis - - O
included - - O
age - - O
older - - O
than - - O
45 - - O
years - - O
( - - O
relative - - O
hazard - - O
, - - O
1 - - O
. - - O
17 - - O
; - - O
95% - - O
confidence - - O
interval - - O
[ - - O
CI - - O
] - - O
, - - O
1 - - O
. - - O
02-1 - - O
. - - O
33 - - O
) - - O
, - - O
Karnofsky - - O
performance - - O
score - - O
less - - O
than - - O
90% - - O
( - - O
1 - - O
. - - O
27 - - O
; - - O
95% - - O
CI - - O
, - - O
1 - - O
. - - O
07-1 - - O
. - - O
51 - - O
) - - O
, - - O
absence - - O
of - - O
hormone - - O
receptors - - O
( - - O
1 - - O
. - - O
31 - - O
; - - O
95% - - O
CI - - O
, - - O
1 - - O
. - - O
15-1 - - O
. - - O
51 - - O
) - - O
, - - O
prior - - O
use - - O
of - - O
adjuvant - - O
chemotherapy - - O
( - - O
1 - - O
. - - O
31 - - O
; - - O
95% - - O
CI - - O
, - - O
1 - - O
. - - O
10-1 - - O
. - - O
56 - - O
) - - O
, - - O
initial - - O
disease-free - - O
survival - - O
interval - - O
after - - O
adjuvant - - O
treatment - - O
of - - O
no - - O
more - - O
than - - O
18 - - O
months - - O
( - - O
1 - - O
. - - O
99 - - O
; - - O
95% - - O
CI - - O
, - - O
1 - - O
. - - O
62-2 - - O
. - - O
43 - - O
) - - O
, - - O
metastases - - O
in - - O
the - - O
liver - - O
( - - O
1 - - O
. - - O
47 - - O
; - - O
95% - - O
CI - - O
, - - O
1 - - O
. - - O
20-1 - - O
. - - O
80 - - O
) - - O
or - - O
central - - O
nervous - - O
system - - O
( - - O
1 - - O
. - - O
56 - - O
; - - O
95% - - O
CI - - O
, - - O
0 - - O
. - - O
99-2 - - O
. - - O
46 - - O
[ - - O
approaches - - O
significance - - O
] - - O
) - - O
vs - - O
soft - - O
tissue - - O
, - - O
bone - - O
, - - O
or - - O
lung - - O
, - - O
3 - - O
or - - O
more - - O
sites - - O
of - - O
metastatic - - O
disease - - O
( - - O
1 - - O
. - - O
32 - - O
; - - O
95% - - O
CI - - O
, - - O
1 - - O
. - - O
13-1 - - O
. - - O
54 - - O
) - - O
, - - O
and - - O
incomplete - - O
response - - O
vs - - O
complete - - O
response - - O
to - - O
standard-dose - - O
chemotherapy - - O
( - - O
1 - - O
. - - O
65 - - O
; - - O
95% - - O
CI - - O
, - - O
1 - - O
. - - O
36-1 - - O
. - - O
99 - - O
) - - O
. - - O

Alternative - - O
splicing - - O
of - - O
the - - O
cytoplasmic - - O
tail - - O
appears - - O
to - - O
generate - - O
multiple - - O
PECAM-1 - - B-MUT
isoforms - - I-MUT
that - - O
may - - O
regulate - - O
phosphorylation - - O
, - - O
cytoskeletal - - O
association - - O
, - - O
and - - O
affinity - - O
modulation - - O
of - - O
the - - O
mature - - O
protein - - O
. - - O

In - - O
26 - - O
patients - - O
with - - O
angina - - O
pectoris - - O
, - - O
the - - O
changes - - O
of - - O
LVEF - - O
, - - O
LVESV - - O
and - - O
PSP - - O
LVESV - - O
were - - O
more - - O
sensitive - - O
for - - O
the - - O
detection - - O
of - - O
exercise-induced - - O
ischemia - - O
than - - O
the - - O
appearance - - O
of - - O
chest - - O
pain - - O
and - - O
the - - O
changes - - O
of - - O
ECG - - O
. - - O

Here - - O
, - - O
we - - O
have - - O
used - - O
specific - - O
antibody - - O
to - - O
identify - - O
and - - O
characterize - - O
the - - O
SSN6 - - B-MUT
protein - - I-MUT
. - - O

Many - - O
mammary - - O
tumors - - O
induced - - O
by - - O
mouse - - O
mammary - - O
tumor - - O
virus - - O
( - - O
MMTV - - O
) - - O
contain - - O
a - - O
provirus - - O
in - - O
the - - O
same - - O
region - - O
of - - O
the - - O
host-cell - - O
genome - - O
, - - O
leading - - O
to - - O
expression - - O
of - - O
a - - O
putative - - O
cellular - - O
oncogene - - O
called - - O
int-1 - - B-MUT
. - - O

Bifunctionality - - O
of - - O
the - - O
AcMNPV - - B-MUT
homologous - - I-MUT
region - - I-MUT
sequence - - I-MUT
( - - O
hr1 - - B-MUT
) - - O
: - - O
enhancer - - O
and - - O
ori - - O
functions - - O
have - - O
different - - O
sequence - - O
requirements - - O
. - - O

Grossly - - O
, - - O
the - - O
incidence - - O
of - - O
a - - O
type - - O
IIc - - O
carcinoma - - O
was - - O
46 - - O
. - - O
5% - - O
and - - O
that - - O
of - - O
a - - O
IIc - - O
+ - - O
III - - O
type - - O
was - - O
20 - - O
. - - O
5% - - O
, - - O
respectively - - O
. - - O

In - - O
XO - - O
males - - O
, - - O
two - - O
her-1 - - B-MUT
mRNAs - - I-MUT
, - - O
her-1a - - B-MUT
and - - O
her-1b - - B-MUT
, - - O
are - - O
transcribed - - O
from - - O
two - - O
separate - - O
promoters - - O
: - - O
P1 - - O
, - - O
located - - O
in - - O
the - - O
5'-flanking - - O
region - - O
, - - O
and - - O
P2 - - O
, - - O
located - - O
in - - O
the - - O
large - - O
second - - O
intron - - O
. - - O

One - - O
hundred - - O
fifty - - O
patients - - O
were - - O
reviewed - - O
at - - O
1 - - O
year - - O
after - - O
arthroplasty - - O
. - - O

The - - O
human - - B-MUT
CD38 - - I-MUT
gene - - I-MUT
consists - - O
of - - O
8 - - O
exons - - O
that - - O
extend - - O
more - - O
than - - O
77 - - O
kb - - O
on - - O
the - - O
human - - O
genome - - O
. - - O

MED1 - - B-MUT
has - - O
a - - O
weak - - O
glycosylase - - B-MUT
activity - - O
on - - O
the - - O
mutagenic - - O
adduct - - O
3 - - O
, - - O
N - - O
( - - O
4 - - O
) - - O
-ethenocytosine - - O
, - - O
a - - O
metabolite - - O
of - - O
vinyl - - O
chloride - - O
and - - O
ethyl - - O
carbamate - - O
. - - O

Screening - - O
of - - O
asthma - - O
patients - - O
by - - O
determination - - O
of - - O
IgE - - B-MUT
and - - O
by - - O
comprehension - - O
of - - O
spectrum - - O
of - - O
allergospecific - - B-MUT
IgE - - I-MUT
antibodies - - I-MUT
. - - O

To - - O
evaluate - - O
the - - O
relative - - O
accuracy - - O
of - - O
continuous - - O
wave - - O
( - - O
CW - - O
) - - O
and - - O
high - - O
pulse - - O
repetition - - O
frequency - - O
( - - O
HPRF - - O
) - - O
Doppler - - O
for - - O
estimating - - O
aortic - - O
transvalvular - - O
pressure - - O
gradients - - O
, - - O
Doppler - - O
examinations - - O
with - - O
both - - O
devices - - O
were - - O
obtained - - O
in - - O
87 - - O
consecutive - - O
patients - - O
with - - O
aortic - - O
valve - - O
disease - - O
. - - O

PABP - - B-MUT
is - - O
a - - O
modular - - O
protein - - O
, - - O
with - - O
four - - O
N-terminal - - O
RNA-binding - - O
domains - - O
and - - O
an - - O
extensive - - O
C - - O
terminus - - O
. - - O

Pit-1 - - B-MUT
is - - O
a - - O
tissue-specific - - O
POU - - B-MUT
domain - - I-MUT
factor - - I-MUT
obligatory - - O
for - - O
the - - O
appearance - - O
of - - O
three - - O
cell - - O
phenotypes - - O
in - - O
the - - O
anterior - - O
pituitary - - O
gland - - O
. - - O

Deletion - - O
of - - O
an - - O
intergenic - - O
DNA-binding - - O
site - - O
for - - O
this - - O
complex - - O
from - - O
a - - O
human - - B-MUT
beta-globin - - I-MUT
locus - - I-MUT
construct - - I-MUT
results - - O
in - - O
delayed - - O
human - - B-MUT
gamma- - - I-MUT
to - - O
beta-globin - - B-MUT
switching - - O
in - - O
transgenic - - O
mice - - O
, - - O
suggesting - - O
that - - O
the - - O
PYR - - B-MUT
complex - - I-MUT
acts - - O
to - - O
facilitate - - O
the - - O
switch - - O
. - - O

Proteins - - O
immunoprecipitated - - O
from - - O
lysates - - O
of - - O
control- - - O
and - - O
VEGF-stimulated - - O
BAEC - - O
with - - O
antisera - - O
to - - O
phospholipase - - B-MUT
C-gamma - - I-MUT
( - - O
PLC-gamma - - B-MUT
) - - O
were - - O
fractionated - - O
by - - O
SDS-polyacrylamide - - O
gel - - O
electrophoresis - - O
and - - O
transferred - - O
to - - O
Immobilon-P - - O
. - - O

Dissociation - - O
and - - O
complexation - - O
of - - O
the - - O
fluoroquinolone - - O
antimicrobials--an - - O
update - - O
. - - O

These - - O
data - - O
suggest - - O
that - - O
other - - O
Ras - - B-MUT
effectors - - I-MUT
can - - O
collaborate - - O
with - - O
PI - - B-MUT
3-kinase - - I-MUT
and - - O
with - - O
each - - O
other - - O
to - - O
activate - - O
Pak - - B-MUT
. - - O

Blood - - O
flow - - O
and - - O
velocity - - O
( - - O
measured - - O
using - - O
Doppler - - O
ultrasound - - O
) - - O
gradually - - O
decreased - - O
during - - O
diastole - - O
and - - O
ultimately - - O
reversed - - O
in - - O
direction - - O
as - - O
cotyledon - - O
resistance - - O
was - - O
increased - - O
up - - O
to - - O
14 - - O
fold - - O
. - - O

The - - O
ORF1 - - O
product - - O
was - - O
required - - O
for - - O
competence - - O
, - - O
while - - O
ORF2 - - O
, - - O
which - - O
was - - O
cotranscribed - - O
with - - O
ORF1 - - O
and - - O
encoded - - O
a - - O
predicted - - O
protein - - O
of - - O
126 - - O
amino - - O
acids - - O
, - - O
was - - O
not - - O
. - - O

Harel - - O
, - - O
E - - O
. - - O
M - - O
. - - O

Daily - - O
and - - O
seasonal - - O
rhythmicity - - O
in - - O
the - - O
methylation - - O
of - - O
pineal - - O
indolic - - O
compounds - - O
in - - O
adult - - O
male - - O
golden - - O
hamsters - - O
, - - O
kept - - O
under - - O
natural - - O
conditions - - O
. - - O

Seventy-one - - O
percent - - O
of - - O
patients - - O
treated - - O
with - - O
ticarcillin - - O
alone - - O
responded - - O
favorably - - O
. - - O

Isolation - - O
and - - O
characterization - - O
of - - O
a - - O
TATA-less - - O
promoter - - O
for - - O
the - - O
human - - B-MUT
beta - - I-MUT
3 - - I-MUT
integrin - - I-MUT
gene - - I-MUT
. - - O

OBJECTIVE - - O
: - - O
To - - O
demonstrate - - O
a - - O
lack - - O
of - - O
effect - - O
of - - O
steady-state - - O
concentrations - - O
of - - O
cilomilast - - O
, - - O
a - - O
new - - O
oral - - O
phosphodiesterase - - B-MUT
4 - - I-MUT
inhibitor - - O
for - - O
the - - O
treatment - - O
of - - O
chronic - - O
obstructive - - O
pulmonary - - O
disease - - O
, - - O
on - - O
warfarin-induced - - O
anticoagulation - - O
. - - O

Histopathologic - - O
response - - O
of - - O
gingival - - O
tissues - - O
to - - O
hemodent - - O
and - - O
aluminum - - O
chloride - - O
solutions - - O
as - - O
tissue - - O
displacement - - O
materials - - O
. - - O

Deglutition - - O
is - - O
considered - - O
to - - O
be - - O
immature - - O
in - - O
infants - - O
and - - O
to - - O
mature - - O
postnatally - - O
. - - O

Antidepressant-like - - O
properties - - O
of - - O
some - - O
serotonin - - B-MUT
receptor - - I-MUT
ligands - - O
and - - O
calcium - - O
channel - - O
antagonists - - O
measured - - O
with - - O
the - - O
forced - - O
swimming - - O
test - - O
in - - O
mice - - O
. - - O

Regulation - - O
of - - O
avian - - B-MUT
fibroblast - - I-MUT
growth - - I-MUT
factor - - I-MUT
receptor - - I-MUT
1 - - I-MUT
( - - O
FGFR-1 - - B-MUT
) - - O
gene - - O
expression - - O
during - - O
skeletal - - O
muscle - - O
differentiation - - O
. - - O

Data - - O
on - - O
the - - O
line - - O
spread - - O
function - - O
( - - O
LSF - - O
) - - O
were - - O
obtained - - O
from - - O
the - - O
image - - O
of - - O
a - - O
0 - - O
. - - O
2 - - O
mm - - O
wide - - O
slit - - O
between - - O
tungsten - - O
blocks - - O
that - - O
were - - O
positioned - - O
at - - O
the - - O
isocentre - - O
in - - O
front - - O
of - - O
a - - O
polystyrene - - O
phantom - - O
. - - O

To - - O
confirm - - O
the - - O
binding - - O
of - - O
protein - - O
to - - O
these - - O
sites - - O
in - - O
cells - - O
, - - O
we - - O
carried - - O
out - - O
an - - O
in - - O
vivo - - O
genomic - - O
footprinting - - O
analysis - - O
of - - O
this - - O
portion - - O
of - - O
the - - O
TGF - - B-MUT
alpha - - I-MUT
promoter - - I-MUT
in - - O
normal - - O
and - - O
transformed - - O
rat - - O
liver - - O
epithelial - - O
cell - - O
lines - - O
that - - O
express - - O
the - - O
endogenous - - O
gene - - O
at - - O
varying - - O
levels - - O
. - - O

Grade - - O
3-4 - - O
mucositis - - O
was - - O
present - - O
in - - O
13% - - O
of - - O
the - - O
cycles - - O
. - - O

Subdural - - O
electrodes - - O
may - - O
yield - - O
larger - - O
VEP - - O
amplitudes - - O
than - - O
skull - - O
or - - O
scalp - - O
electrodes - - O
. - - O

The - - O
desirability - - O
function - - O
is - - O
based - - O
on - - O
the - - O
search - - O
for - - O
a - - O
global - - O
optimum - - O
[ - - O
D - - O
= - - O
f - - O
( - - O
Y1 - - O
, - - O
Y2 - - O
, - - O
. - - O
. - - O
. - - O
, - - O
Yn - - O
) - - O
] - - O
by - - O
the - - O
transformation - - O
of - - O
the - - O
measured - - O
property - - O
to - - O
a - - O
dimensionless - - O
scale - - O
for - - O
each - - O
criterion - - O
. - - O

Three - - O
groups - - O
of - - O
patients - - O
who - - O
had - - O
undergone - - O
subtotal - - O
thyroidectomy - - O
for - - O
Graves's - - O
disease - - O
, - - O
toxic - - O
multinodular - - O
goitre - - O
, - - O
or - - O
euthyroid - - O
multinodular - - O
goitre - - O
12 - - O
to - - O
15 - - O
years - - O
before - - O
and - - O
in - - O
whom - - O
a - - O
normal - - O
serum - - O
thyroxine - - O
( - - O
T-4 - - O
) - - O
level - - O
was - - O
found - - O
were - - O
each - - O
divided - - O
into - - O
two - - O
subgroups - - O
on - - O
the - - O
basis - - O
of - - O
a - - O
normal - - O
or - - O
a - - O
raised - - O
serum - - O
thyrotrophin - - O
concentration - - O
. - - O

( - - O
ii - - O
) - - O
opening - - O
of - - O
KATP - - O
attenuates - - O
, - - O
inhibition - - O
of - - O
the - - O
channel - - O
exacerbates - - O
functional - - O
consequences - - O
of - - O
coronary - - O
occlusion - - O
, - - O
and - - O
( - - O
iii - - O
) - - O
KATP - - O
opening - - O
attenuates - - O
reperfusion-induced - - O
VF - - O
, - - O
but - - O
it - - O
triggers - - O
ischemia-induced - - O
VF - - O
. - - O

CONCLUSIONS - - O
AND - - O
CLINICAL - - O
RELEVANCE - - O
: - - O
Increased - - O
cortical - - O
thickness - - O
and - - O
geometric - - O
properties - - O
of - - O
left - - O
MCB-IV - - O
and - - O
-V - - O
of - - O
Greyhounds - - O
, - - O
together - - O
with - - O
altered - - O
turnover - - O
and - - O
orientation - - O
of - - O
osteons - - O
in - - O
the - - O
dorsal - - O
quadrants - - O
of - - O
left - - O
MCB - - O
, - - O
are - - O
site-specific - - O
adaptive - - O
responses - - O
associated - - O
with - - O
asymmetric - - O
cyclic - - O
loading - - O
as - - O
a - - O
result - - O
of - - O
racing - - O
on - - O
circular - - O
tracks - - O
. - - O

In - - O
the - - O
present - - O
study - - O
, - - O
we - - O
show - - O
that - - O
SRm160 - - B-MUT
300 - - I-MUT
is - - I-MUT
required - - O
for - - O
a - - O
purine-rich - - O
ESE - - O
to - - B-MUT
promote - - O
the - - O
splicing - - O
of - - O
a - - O
pre-mRNA - - O
derived - - O
from - - O
the - - O
Drosophila - - O
doublesex - - B-MUT
gene - - I-MUT
. - - I-MUT

In - - O
addition - - O
, - - O
we - - O
have - - O
isolated - - O
a - - O
genomic - - O
fragment - - O
containing - - O
the - - O
most - - O
distal - - O
5' - - O
sequences - - O
of - - O
the - - O
major - - O
GGT - - B-MUT
mRNA - - I-MUT
in - - O
HepG2 - - O
cells - - O
. - - O

The - - O
seventh - - O
cysteine - - O
residue - - O
of - - O
CTSE - - B-MUT
is - - O
located - - O
within - - O
the - - O
activation - - O
peptide - - O
region - - O
of - - O
the - - O
proenzyme - - O
. - - O

( - - O
5 - - O
) - - O
No - - O
changes - - O
were - - O
observed - - O
in - - O
the - - O
gastric - - O
venous - - O
blood - - O
flow - - O
by - - O
continuous - - O
intravenous - - O
injection - - O
of - - O
cimetidine - - O
, - - O
but - - O
by - - O
rapid - - O
injection - - O
both - - O
the - - O
flow - - O
was - - O
augmented - - O
and - - O
the - - O
systemic - - O
blood - - O
pressure - - O
decreased - - O
transiently - - O
. - - O

To - - O
determine - - O
the - - O
signal - - B-MUT
recognition - - I-MUT
particle - - I-MUT
( - - I-MUT
SRP - - I-MUT
) - - I-MUT
-SRP - - I-MUT
receptor - - I-MUT
( - - I-MUT
Srb - - I-MUT
) - - I-MUT
system - - I-MUT
in - - I-MUT
Bacillus - - I-MUT
subtilis - - I-MUT
( - - I-MUT
Bs - - I-MUT
) - - I-MUT
, - - O
we - - O
cloned - - O
the - - O
Bs - - B-MUT
srb - - I-MUT
gene - - I-MUT
, - - O
which - - O
encodes - - O
a - - O
homologue - - O
of - - O
the - - O
mammalian - - B-MUT
SRP - - I-MUT
receptor - - I-MUT
alpha-subunit - - I-MUT
[ - - O
Oguro - - O
et - - O
al - - O
. - - O
, - - O
DNA - - O
Res - - O
. - - O

TREB7 - - B-MUT
and - - O
TREB36 - - B-MUT
protected - - O
all - - O
three - - O
repeats - - O
of - - O
the - - O
21 - - O
bp - - O
, - - O
but - - O
TREB5 - - B-MUT
protected - - O
only - - O
the - - O
second - - O
repeat - - O
. - - O

Biol - - O
. - - O

Preheparin - - O
LPL - - O
mass - - O
level - - O
did - - O
not - - O
significantly - - O
differ - - O
in - - O
individuals - - O
from - - O
19 - - O
to - - O
70 - - O
years - - O
old - - O
, - - O
for - - O
both - - O
men - - O
and - - O
women - - O
. - - O

OODG - - O
is - - O
a - - O
diagnostic - - O
method - - O
permitting - - O
assessment - - O
of - - O
ocular - - O
pulse - - O
curves - - O
and - - O
objective - - O
determination - - O
of - - O
blood - - O
pressures - - O
in - - O
the - - O
ophthalmic - - O
circulatory - - O
system - - O
( - - O
retinal - - O
and - - O
ciliary - - O
arterial - - O
blood - - O
pressures - - O
) - - O
simultaneously - - O
for - - O
both - - O
eyes - - O
, - - O
without - - O
dilatation - - O
of - - O
the - - O
pupils - - O
. - - O

The - - O
carboxyl-terminal - - B-MUT
CCCC - - I-MUT
module - - I-MUT
is - - O
structurally - - O
related - - O
to - - O
the - - O
DNA-binding - - O
domain - - O
of - - O
the - - O
erythroid - - B-MUT
transcription - - I-MUT
factor - - I-MUT
GATA-1 - - I-MUT
. - - O

The - - O
median - - O
levels - - O
of - - O
particles - - O
with - - O
50% - - O
cut-off - - O
aerodynamic - - O
diameters - - O
of - - O
10 - - O
( - - O
PM10 - - O
) - - O
and - - O
2 - - O
. - - O
5 - - O
microm - - O
( - - O
PM2 - - O
. - - O
5 - - O
) - - O
were - - O
170 - - O
( - - O
range - - O
103-613 - - O
) - - O
and - - O
95 - - O
( - - O
range - - O
61-218 - - O
) - - O
micro - - O
x - - O
m-3 - - O
, - - O
respectively - - O
. - - O

The - - O
novel - - O
approach - - O
to - - O
insulin - - B-MUT
administration - - O
known - - O
as - - O
chronic - - O
intermittent - - O
intravenous - - O
insulin - - B-MUT
therapy - - O
( - - O
CIIIT - - O
) - - O
delivers - - O
insulin - - B-MUT
in - - O
a - - O
pulsatile - - O
fashion - - O
and - - O
achieves - - O
physiological - - O
insulin - - B-MUT
concentration - - O
in - - O
the - - O
portal - - O
vein - - O
. - - O

The - - O
kallistatin - - B-MUT
gene - - I-MUT
was - - O
localized - - O
by - - O
in - - O
situ - - O
hybridization - - O
to - - O
human - - O
chromosome - - O
14q31-q32 - - O
. - - O
1 - - O
, - - O
close - - O
to - - O
the - - O
serpin - - B-MUT
genes - - I-MUT
encoding - - O
alpha - - B-MUT
1-antichymotrypsin - - I-MUT
, - - O
protein - - B-MUT
C - - I-MUT
inhibitor - - I-MUT
, - - O
alpha - - B-MUT
1-antitrypsin - - I-MUT
, - - O
and - - O
corticosteroid-binding - - B-MUT
globulin - - I-MUT
. - - O

The - - O
shift - - O
to - - O
the - - O
nonpermissive - - O
temperature - - O
is - - O
accompanied - - O
by - - O
the - - O
loss - - O
of - - O
guanyl - - O
nucleotide-dependent - - O
activity - - O
of - - O
adenylylcyclase - - B-MUT
in - - O
vitro - - O
. - - O

In - - O
vitro - - O
translation - - O
of - - O
the - - O
mTRF1 - - B-MUT
cDNA - - I-MUT
resulted - - O
in - - O
a - - O
56 - - O
kDa - - O
protein - - O
that - - O
binds - - O
to - - O
TTAGGG - - B-MUT
repeat - - I-MUT
arrays - - O
. - - O
mTRF1 - - B-MUT
displayed - - O
the - - O
same - - O
sequence - - O
specificity - - O
as - - O
hTRF1 - - B-MUT
, - - O
preferring - - O
arrays - - O
of - - O
TTAGGG - - B-MUT
repeats - - I-MUT
as - - O
a - - O
binding - - O
substrate - - O
over - - O
TTAGGC - - B-MUT
and - - O
TTGGGG - - B-MUT
repeats - - I-MUT
. - - O

4 - - O
. - - O

Our - - O
study - - O
differs - - O
from - - O
previous - - O
studies - - O
in - - O
that - - O
it - - O
is - - O
limited - - O
to - - O
one - - O
diagnostic - - O
entity - - O
, - - O
yet - - O
at - - O
the - - O
same - - O
time - - O
evaluates - - O
a - - O
broad - - O
range - - O
of - - O
social - - O
and - - O
work-related - - O
factors - - O
in - - O
disability - - O
. - - O

From - - O
these - - O
results - - O
, - - O
we - - O
concluded - - O
that - - O
this - - O
ORF - - O
is - - O
the - - O
FRDS - - B-MUT
gene - - I-MUT
. - - O

Oral - - O
candidiasis - - O
. - - O

Intron-exon - - O
structure - - O
of - - O
the - - O
porcine - - B-MUT
I - - I-MUT
kappa - - I-MUT
B - - I-MUT
alpha-encoding - - I-MUT
gene - - I-MUT
. - - O

Interleukin-6 - - B-MUT
( - - O
IL-6 - - B-MUT
) - - O
is - - O
a - - O
pleiotropic - - O
cytokine - - O
, - - O
which - - O
is - - O
involved - - O
in - - O
inflammatory - - O
and - - O
immune - - O
responses - - O
, - - O
acute - - O
phase - - O
reactions - - O
, - - O
and - - O
hematopoiesis - - O
. - - O

Bacterial - - O
metabolism - - O
of - - O
4-chlorophenoxyacetate - - O
. - - O

Serotonin - - O
levels - - O
in - - O
infant - - O
hypothyroidism - - O
. - - O

The - - O
character - - O
of - - O
specific - - O
immune - - O
response - - O
in - - O
101 - - O
immunized - - O
children - - O
and - - O
in - - O
12 - - O
adults - - O
belonging - - O
to - - O
a - - O
high - - O
risk - - O
group - - O
with - - O
respect - - O
to - - O
VHB - - O
. - - O

A - - O
short - - O
history - - O
of - - O
dermatology - - O
in - - O
Lagos - - O
, - - O
Nigeria - - O
. - - O

We - - O
report - - O
the - - O
identification - - O
and - - O
characterization - - O
of - - O
myr - - B-MUT
4 - - I-MUT
( - - O
myosin - - B-MUT
from - - I-MUT
rat - - I-MUT
) - - O
, - - O
the - - O
first - - O
mammalian - - B-MUT
myosin - - I-MUT
I - - I-MUT
that - - O
is - - O
not - - O
closely - - O
related - - O
to - - O
brush - - O
border - - O
myosin - - B-MUT
I - - I-MUT
. - - O

Only - - O
nine - - O
patients - - O
were - - O
offered - - O
surgery - - O
( - - O
six - - O
were - - O
resected - - O
and - - O
three - - O
were - - O
found - - O
inoperable - - O
) - - O
. - - O

The - - O
time - - O
course - - O
of - - O
RNA1 - - B-MUT
replication - - O
and - - O
RNA3 - - B-MUT
synthesis - - O
in - - O
induced - - O
yeast - - O
paralleled - - O
that - - O
in - - O
yeast - - O
transfected - - O
with - - O
natural - - O
FHV - - O
virion - - O
RNA - - O
. - - O

The - - O
relevance - - O
of - - O
these - - O
elements - - O
in - - O
conferring - - O
anaerobic - - O
induction - - O
of - - O
gpc4 - - B-MUT
gene - - I-MUT
expression - - O
is - - O
discussed - - O
. - - O

The - - O
genomic - - O
structure - - O
and - - O
chromosomal - - O
location - - O
of - - O
the - - O
human - - B-MUT
TR2 - - I-MUT
orphan - - I-MUT
receptor - - I-MUT
, - - O
a - - O
member - - O
of - - O
the - - O
steroid - - B-MUT
receptor - - I-MUT
superfamily - - I-MUT
. - - O

We - - O
identify - - O
considerable - - O
spatio-temporal - - O
similarities - - O
between - - O
reported - - O
expression - - O
patterns - - O
of - - O
Ypr10 - - B-MUT
genes - - I-MUT
and - - O
ribonuclease - - B-MUT
genes - - I-MUT
, - - O
which - - O
, - - O
together - - O
with - - O
the - - O
significant - - O
sequence - - O
similarity - - O
to - - O
the - - O
ginseng - - B-MUT
ribonuclease - - I-MUT
, - - O
support - - O
the - - O
hypothesis - - O
of - - O
a - - O
ribonuclease - - B-MUT
function - - O
for - - O
PR-10 - - B-MUT
proteins - - I-MUT
and - - O
allow - - O
the - - O
prediction - - O
of - - O
possible - - O
biological - - O
roles - - O
. - - O

The - - O
p20-CGGBP - - B-MUT
gene - - I-MUT
is - - O
conserved - - O
among - - O
mammals - - O
but - - O
shows - - O
no - - O
homology - - O
to - - O
non-vertebrate - - O
species - - O
. - - O

Estimated - - O
nucleic - - O
acid - - O
N - - O
absorption - - O
is - - O
7-8% - - O
of - - O
N - - O
intake - - O
. - - O

The - - O
diagnostic - - O
significance - - O
of - - O
creatine - - B-MUT
phosphokinase - - I-MUT
antibodies - - O
in - - O
the - - O
cardiac - - O
muscle - - O
in - - O
non-coronarogenic - - O
myocardial - - O
diseases - - O
. - - O

Note - - O
on - - O
Slot's - - O
method - - O
for - - O
the - - O
specific - - O
determination - - O
of - - O
creatinine - - O
. - - O

When - - O
the - - O
blood - - O
clot - - O
is - - O
formed - - O
in - - O
the - - O
vitreous - - O
cavity - - O
, - - O
intravitreal - - O
injection - - O
of - - O
t-PA - - B-MUT
can - - O
convert - - O
plasminogen - - B-MUT
to - - O
plasmin - - O
and - - O
remove - - O
the - - O
clot - - O
. - - O

We - - O
report - - O
herein - - O
the - - O
case - - O
of - - O
a - - O
30-year-old - - O
man - - O
in - - O
whom - - O
ectopic - - O
mediastinal - - O
parathyroid - - O
adenoma - - O
was - - O
detected - - O
by - - O
99mTc-methoxyisobutylisonitrile - - O
scintigraphy - - O
( - - O
99mTc-MIBI - - O
) - - O
. - - O

1 - - O
( - - O
"long - - O
method" - - O
) - - O
and - - O
the - - O
HML - - O
method - - O
. - - O

The - - O
distinguishing - - O
features - - O
involved - - O
eight - - O
amino - - O
acid - - O
changes - - O
, - - O
including - - O
a - - O
single - - O
lysine - - O
deletion - - O
relative - - O
to - - O
a - - O
primate - - O
consensus - - O
sequence - - O
in - - O
the - - O
first - - O
complementary-determing - - O
region - - O
of - - O
V1J1 - - B-MUT
. - - O

We - - O
cloned - - O
a - - O
complete - - O
cDNA - - O
( - - O
2 - - O
. - - O
9 - - O
kb - - O
) - - O
for - - O
HET - - B-MUT
from - - O
an - - O
MCF-7 - - O
cDNA - - O
library - - O
. - - O

NF-kappaB - - B-MUT
is - - O
a - - O
redox-sensitive - - O
transcription - - O
factor - - O
known - - O
to - - O
be - - O
activated - - O
by - - O
oxidative - - O
stress - - O
as - - O
well - - O
as - - O
chemical - - O
and - - O
biological - - O
reductants - - O
. - - O

Many - - O
of - - O
the - - O
important - - O
genes - - O
associated - - O
with - - O
G1 - - O
regulation - - O
have - - O
been - - O
shown - - O
to - - O
play - - O
a - - O
key - - O
role - - O
in - - O
proliferation - - O
, - - O
differentiation - - O
and - - O
oncogenic - - O
transformation - - O
and - - O
programmed - - O
cell - - O
death - - O
( - - O
apoptosis - - O
) - - O
. - - O

On - - O
a - - O
separate - - O
occasion - - O
the - - O
T1 - - O
weighted - - O
and - - O
T2 - - O
weighted - - O
sagittal - - O
and - - O
T2 - - O
weighted - - O
axial - - O
sequences - - O
were - - O
reported - - O
blind - - O
in - - O
relation - - O
to - - O
the - - O
initial - - O
assessment - - O
. - - O

Enoxacin - - O
appears - - O
to - - O
be - - O
well - - O
suited - - O
for - - O
the - - O
treatment - - O
of - - O
complicated - - O
UTI - - O
. - - O

The - - O
primary - - O
pancreatic - - O
insult - - O
seemed - - O
to - - O
be - - O
unaffected - - O
by - - O
the - - O
treatment - - O
, - - O
because - - O
neither - - O
the - - O
rise - - O
in - - O
plasma - - B-MUT
lipase - - I-MUT
nor - - O
the - - O
development - - O
of - - O
ascites - - O
or - - O
the - - O
extension - - O
of - - O
the - - O
pancreatic - - O
necrosis - - O
were - - O
diminished - - O
. - - O

Detailed - - O
analysis - - O
of - - O
alpha1 - - B-MUT
, - - I-MUT
3GT - - I-MUT
transcripts - - I-MUT
revealed - - O
two - - O
major - - O
alternative - - O
splicing - - O
patterns - - O
in - - O
the - - O
5'-untranslated - - O
region - - O
( - - O
5'-UTR - - O
) - - O
and - - O
evidence - - O
for - - O
minor - - O
splicing - - O
activity - - O
that - - O
occurs - - O
in - - O
a - - O
tissue-specific - - O
manner - - O
. - - O

The - - O
segmental - - O
and - - O
regional - - O
projections - - O
of - - O
the - - O
sciatic - - O
, - - O
tibial - - O
and - - O
common - - O
peroneal - - O
nerves - - O
to - - O
the - - O
substantia - - O
gelatinosa - - O
of - - O
the - - O
spinal - - O
cord - - O
in - - O
rats--an - - O
experimental - - O
study - - O
by - - O
means - - O
of - - O
an - - O
acid - - B-MUT
phosphatase - - I-MUT
( - - O
ACP - - B-MUT
) - - O
method - - O
. - - O

Angiotensin - - B-MUT
converting - - I-MUT
enzyme - - I-MUT
inhibitors - - O
enhance - - O
the - - O
antihypertensive - - O
efficacy - - O
of - - O
diuretics - - O
and - - O
blunt - - O
or - - O
prevent - - O
adverse - - O
metabolic - - O
effects - - O
. - - O

Two - - O
closely - - O
related - - O
variants - - O
of - - O
Stat5 - - B-MUT
, - - O
Stat5a - - B-MUT
and - - O
Stat5b - - B-MUT
, - - O
are - - O
encoded - - O
by - - O
distinct - - O
genes - - O
. - - O

Also - - O
, - - O
small - - O
, - - O
sense - - O
and - - O
antisense - - O
approximately - - O
22 - - O
nt - - O
RNAs - - O
, - - O
derived - - O
from - - O
the - - O
satRNA - - B-MUT
, - - O
were - - O
associated - - O
with - - O
the - - O
replicating - - O
satellite - - O
. - - O

Induction - - O
of - - O
both - - O
potential - - O
transcripts - - O
follows - - O
heat - - O
shock - - O
in - - O
vivo - - O
. - - O

Limb - - O
allografts - - O
in - - O
rats - - O
immunosuppressed - - O
with - - O
cyclosporin - - O
A - - O
. - - O

Pseudomembranous - - O
conjunctivitis - - O
following - - O
bone - - O
marrow - - O
transplantation - - O
: - - O
immunopathological - - O
and - - O
ultrastructural - - O
study - - O
of - - O
one - - O
case - - O
. - - O

Regulation - - O
of - - O
myosin - - B-MUT
phosphatase - - I-MUT
activity - - O
involves - - O
changes - - O
in - - O
subunit - - O
interactions - - O
, - - O
although - - O
molecular - - O
mechanisms - - O
are - - O
not - - O
defined - - O
. - - O

However - - O
, - - O
the - - O
history - - O
of - - O
acute - - O
severe - - O
complications - - O
from - - O
otitis - - O
media - - O
revealed - - O
a - - O
higher - - O
frequency - - O
in - - O
those - - O
individuals - - O
with - - O
alpha - - B-MUT
1-antitrypsin - - I-MUT
deficiency - - O
as - - O
compared - - O
to - - O
normals - - O
. - - O

Unlike - - O
P135gag-myb-ets - - B-MUT
and - - O
the - - O
Mr - - O
75 - - O
, - - O
000 - - O
translation - - O
product - - O
of - - O
c-myb - - B-MUT
( - - O
P75c-myb - - B-MUT
) - - O
, - - O
which - - O
are - - O
nuclear - - O
proteins - - O
, - - O
P54c-ets - - B-MUT
was - - O
found - - O
to - - O
be - - O
predominantly - - O
cytoplasmic - - O
. - - O

Although - - O
differences - - O
were - - O
not - - O
significant - - O
, - - O
infants - - O
in - - O
the - - O
experimental - - O
group - - O
had - - O
more - - O
changes - - O
in - - O
the - - O
intermittent - - O
mandatory - - O
ventilation - - O
( - - O
IMV - - O
) - - O
settings - - O
during - - O
transport - - O
, - - O
and - - O
more - - O
such - - O
infants - - O
arrived - - O
at - - O
the - - O
receiving - - O
hospital - - O
with - - O
acceptable - - O
pH - - O
and - - O
PCO2 - - O
values - - O
. - - O

We - - O
now - - O
describe - - O
a - - O
second - - O
RIM - - B-MUT
protein - - I-MUT
, - - O
called - - O
RIM2 - - B-MUT
, - - O
that - - O
is - - O
highly - - O
homologous - - O
to - - O
RIM1 - - B-MUT
and - - O
also - - O
expressed - - O
primarily - - O
in - - O
brain - - O
. - - O

The - - O
priming - - O
activity - - O
of - - O
DNA - - O
incised - - O
by - - O
either - - O
of - - O
the - - O
Drosophila - - O
enzymes - - O
can - - O
be - - O
enhanced - - O
, - - O
however - - O
, - - O
by - - O
an - - O
additional - - O
incubation - - O
with - - O
E - - B-MUT
. - - I-MUT
coli - - I-MUT
endonuclease - - I-MUT
IV - - I-MUT
, - - O
which - - O
is - - O
known - - O
to - - O
cleave - - O
depurinated - - O
DNA - - O
on - - O
the - - O
5'-side - - O
of - - O
an - - O
apurinic - - O
site - - O
. - - O

Subsequently - - O
, - - O
these - - O
coordinates - - O
must - - O
be - - O
interpreted - - O
to - - O
define - - O
particular - - O
tissues - - O
and - - O
organs - - O
. - - O

To - - O
assess - - O
the - - O
functional - - O
importance - - O
of - - O
these - - O
NBS - - O
in - - O
the - - O
overall - - O
drug - - O
resistance - - O
phenotype - - O
conferred - - O
by - - O
mdr1 - - B-MUT
, - - O
we - - O
introduced - - O
amino - - O
acid - - O
substitutions - - O
in - - O
the - - O
core - - O
consensus - - O
sequence - - O
for - - O
nucleotide - - O
binding - - O
, - - O
GXGKST - - B-MUT
. - - O

Excision - - O
repair - - O
at - - O
the - - O
level - - O
of - - O
the - - O
nucleotide - - O
in - - O
the - - O
Saccharomyces - - B-MUT
cerevisiae - - I-MUT
MFA2 - - I-MUT
gene - - I-MUT
: - - O
mapping - - O
of - - O
where - - O
enhanced - - O
repair - - O
in - - O
the - - O
transcribed - - O
strand - - O
begins - - O
or - - O
ends - - O
and - - O
identification - - O
of - - O
only - - O
a - - O
partial - - O
rad16 - - B-MUT
requisite - - O
for - - O
repairing - - O
upstream - - O
control - - O
sequences - - O
. - - O

After - - O
4 - - O
h - - O
, - - O
lesions - - O
in - - O
the - - O
secretory - - O
part - - O
of - - O
the - - O
stomach - - O
were - - O
scored - - O
and - - O
mucosal - - O
prostaglandin - - O
E2 - - O
synthesis - - O
was - - O
determined - - O
by - - O
the - - O
ex - - O
vivo - - O
prostaglandin - - O
generation - - O
technique - - O
. - - O

Behavior - - O
of - - O
aspartate - - B-MUT
aminotransferase - - I-MUT
( - - O
EC - - B-MUT
2 - - I-MUT
. - - I-MUT
6 - - I-MUT
. - - I-MUT
1 - - I-MUT
. - - I-MUT
1 - - I-MUT
) - - O
and - - O
alanine - - B-MUT
aminotransferase - - I-MUT
( - - O
EC - - B-MUT
2 - - I-MUT
. - - I-MUT
6 - - I-MUT
. - - I-MUT
1 - - I-MUT
. - - I-MUT
2 - - I-MUT
) - - O
in - - O
rat - - O
serum - - O
during - - O
the - - O
course - - O
of - - O
acute - - O
radiation - - O
syndrome - - O
following - - O
whole - - O
body - - O
X-irradiation - - O
. - - O

NUP145 - - B-MUT
was - - O
previously - - O
identified - - O
by - - O
using - - O
a - - O
genetic - - O
synthetic - - O
lethal - - O
screen - - O
( - - O
E - - O
. - - O

However - - O
, - - O
there - - O
is - - O
still - - O
a - - O
subset - - O
of - - O
tumors - - O
that - - O
displayed - - O
no - - O
changes - - O
in - - O
these - - O
genes - - O
. - - O

Results - - O
confirmed - - O
that - - O
stress - - O
produced - - O
CA3 - - O
dendritic - - O
atrophy - - O
and - - O
tianeptine - - O
prevented - - O
it - - O
. - - O

TPBF - - B-MUT
has - - O
two - - O
potential - - O
coiled-coil - - O
regions - - O
, - - O
a - - O
basic - - O
region - - O
, - - O
a - - O
proline-rich - - O
region - - O
, - - O
a - - O
histidine-rich - - O
N - - O
terminus - - O
, - - O
and - - O
a - - O
nuclear - - O
targeting - - O
sequence - - O
. - - O

This - - O
led - - O
to - - O
the - - O
conclusion - - O
that - - O
the - - O
metatarsal - - O
artery - - O
should - - O
be - - O
used - - O
for - - O
toe - - O
MP - - O
joint - - O
grafts - - O
, - - O
while - - O
the - - O
unilateral - - O
proper - - O
digital - - O
artery - - O
is - - O
suitable - - O
for - - O
toe - - O
PIP - - O
joint - - O
grafts - - O
, - - O
together - - O
with - - O
concomitant - - O
or - - O
dorsal - - O
cutaneous - - O
vein - - O
. - - O

Clinical - - O
trials - - O
with - - O
1 - - O
, - - O
3-bis - - O
( - - O
2-chloroethyl - - O
) - - O
-1-nitrosourea - - O
, - - O
NSC-409962 - - O
. - - O

Identity - - O
elements - - O
in - - O
tRNA - - B-MUT
for - - O
mono- - - O
and - - O
dimethylation - - O
reactions - - O
by - - O
the - - O
recombinant - - B-MUT
pfTrm1p - - I-MUT
were - - O
identified - - O
using - - O
in - - O
vitro - - O
T7 - - O
transcripts - - O
of - - O
33 - - O
variants - - O
of - - O
tRNA - - B-MUT
( - - I-MUT
Asp - - I-MUT
) - - I-MUT
and - - I-MUT
tRNA - - I-MUT
( - - I-MUT
Phe - - I-MUT
) - - I-MUT
from - - I-MUT
yeast - - I-MUT
. - - O

Results - - O
indicate - - O
that - - O
KNM-LU - - O
335 - - O
differs - - O
from - - O
both - - O
human - - O
and - - O
chimpanzee - - O
M1s - - O
in - - O
relative - - O
distances - - O
( - - O
measured - - O
in - - O
three - - O
dimensions - - O
) - - O
between - - O
crown - - O
fissure - - O
termini - - O
. - - O

This - - O
E - - B-MUT
box - - I-MUT
sequence - - I-MUT
( - - I-MUT
CACGTG - - I-MUT
) - - I-MUT
is - - O
identical - - O
to - - O
the - - O
binding - - O
element - - O
for - - O
USF - - B-MUT
( - - O
upstream - - B-MUT
stimulatory - - I-MUT
factor - - I-MUT
) - - O
, - - O
a - - O
member - - O
of - - O
the - - O
helix-loop-helix - - B-MUT
family - - I-MUT
of - - I-MUT
transcription - - I-MUT
factors - - I-MUT
. - - O

We - - O
have - - O
demonstrated - - O
previously - - O
that - - O
two - - O
binding - - O
sites - - O
in - - O
the - - O
-184 - - B-MUT
HNF-3 - - I-MUT
beta - - I-MUT
promoter - - I-MUT
are - - O
recognized - - O
by - - O
widely - - O
distributed - - O
factors - - O
and - - O
that - - O
there - - O
is - - O
also - - O
a - - O
critical - - O
autoregulatory - - O
site - - O
, - - O
we - - O
identified - - O
a - - O
binding - - O
site - - O
for - - O
a - - O
cell-specific - - O
factor - - O
, - - O
LF-H3 - - B-MUT
beta - - I-MUT
, - - O
that - - O
may - - O
function - - O
in - - O
restricting - - O
HNF-3 - - B-MUT
beta - - I-MUT
gene - - I-MUT
expression - - O
to - - O
hepatocytes - - O
. - - O

Overlapping - - O
clones - - O
representing - - O
full-length - - O
cDNAs - - O
for - - O
MMI - - B-MUT
alpha - - I-MUT
were - - O
obtained - - O
from - - O
mouse - - O
brain - - O
. - - O

Since - - O
GAGs - - O
are - - O
the - - O
components - - O
of - - O
cartilage - - O
matrix - - O
, - - O
the - - O
depletion - - O
of - - O
which - - O
is - - O
associated - - O
with - - O
osteoarthrosis - - O
, - - O
a - - O
method - - O
for - - O
measuring - - O
sulphated - - O
GAG - - O
synthesis - - O
in - - O
culture - - O
has - - O
been - - O
investigated - - O
. - - O

Chagas' - - O
disease - - O
, - - O
visceral - - O
leishmaniasis - - O
, - - O
anti-nuclear - - B-MUT
factor - - I-MUT
, - - O
schistosomiasis - - O
, - - O
rheumatoid - - B-MUT
factor - - I-MUT
and - - O
normal - - O
controls - - O
. - - O

MZF-1 - - B-MUT
represses - - O
CAT - - B-MUT
reporter - - I-MUT
gene - - I-MUT
expression - - O
via - - O
GAL4 - - B-MUT
binding - - I-MUT
sites - - I-MUT
in - - O
the - - O
nonhematopoietic - - O
cell - - O
lines - - O
NIH - - O
3T3 - - O
and - - O
293 - - O
. - - O

The - - O
bcl-2 - - B-MUT
gene - - I-MUT
can - - O
potentially - - O
encode - - O
26- - - O
and - - O
22-kDa - - O
proteins - - O
that - - O
differ - - O
only - - O
in - - O
their - - O
carboxyl - - O
tails - - O
because - - O
of - - O
an - - O
alternative - - O
splicing - - O
mechanism - - O
. - - O

We - - O
have - - O
identified - - O
a - - O
strong - - O
Tas-responsive - - B-MUT
element - - I-MUT
, - - O
designated - - O
TRE - - B-MUT
( - - O
GP - - B-MUT
) - - O
, - - O
near - - O
the - - O
3' - - O
end - - O
of - - O
the - - O
gag - - B-MUT
gene - - I-MUT
and - - O
preceding - - O
the - - O
pol - - B-MUT
gene - - I-MUT
of - - O
SFV-1 - - O
. - - O

In - - O
gel - - O
mobility - - O
shift - - O
assays - - O
, - - O
factors - - O
present - - O
in - - O
nuclear - - O
extracts - - O
derived - - O
from - - O
differentiated - - O
osteoblast - - O
bound - - O
to - - O
oligonucleotide - - O
probes - - O
containing - - O
the - - O
E-box - - B-MUT
1 - - I-MUT
and - - O
E-box - - B-MUT
2 - - I-MUT
elements - - I-MUT
. - - O

Induction - - O
of - - O
proto-oncogene - - B-MUT
fos - - I-MUT
transcription - - O
through - - O
the - - O
adenylate - - B-MUT
cyclase - - I-MUT
pathway - - I-MUT
: - - O
characterization - - O
of - - O
a - - O
cAMP-responsive - - B-MUT
element - - I-MUT
. - - O

Role - - O
of - - O
g2 - - O
in - - O
relating - - O
the - - O
Schwinger - - O
and - - O
Gerasimov-Drell-Hearn - - O
sum - - O
rules - - O
. - - O

We - - O
conclude - - O
that - - O
common - - O
upstream - - O
signals - - O
cause - - O
activation - - O
of - - O
Ras - - B-MUT
and - - O
TC21 - - B-MUT
, - - O
but - - O
activated - - O
TC21 - - B-MUT
controls - - O
cell - - O
growth - - O
via - - O
distinct - - O
Raf-independent - - O
downstream - - O
signaling - - O
pathways - - O
. - - O

Our - - O
experiments - - O
suggest - - O
that - - O
the - - O
SCL - - B-MUT
gene - - I-MUT
can - - O
be - - O
a - - O
target - - O
for - - O
the - - O
erythroid - - B-MUT
transcription - - I-MUT
factor - - I-MUT
GATA-1 - - I-MUT
and - - O
that - - O
the - - O
SCL - - B-MUT
gene - - I-MUT
product - - I-MUT
serves - - O
as - - O
a - - O
positive - - O
regulator - - O
of - - O
erythroid - - O
differentiation - - O
. - - O

Because - - O
GH-induced - - O
Akt - - B-MUT
activation - - O
was - - O
completely - - O
inhibited - - O
in - - O
both - - O
cells - - O
by - - O
the - - O
same - - O
concentration - - O
of - - O
LY294002 - - O
, - - O
these - - O
findings - - O
indicate - - O
that - - O
the - - O
wortmannin - - O
sensitivity - - O
of - - O
both - - O
the - - O
IRS-1-independent - - O
and - - O
-dependent - - O
GH-induced - - O
MAP - - B-MUT
kinase - - I-MUT
activation - - O
may - - O
reflect - - O
the - - O
activity - - O
of - - O
another - - O
wortmannin-sensitive - - O
target - - O
( - - O
s - - O
) - - O
in - - O
addition - - O
to - - O
PI3K - - B-MUT
in - - O
mediation - - O
of - - O
GH-induced - - O
MAP - - B-MUT
kinase - - I-MUT
activation - - O
in - - O
these - - O
cells - - O
. - - O

These - - O
results - - O
indicate - - O
that - - O
Rb - - B-MUT
protein - - I-MUT
is - - O
interacting - - O
with - - O
some - - O
component - - O
( - - O
s - - O
) - - O
of - - O
the - - O
cell - - O
cycle-regulatory - - O
machinery - - O
during - - O
G2 - - O
phase - - O
. - - O

A - - O
small - - O
amount - - O
of - - O
HSP81-1 - - B-MUT
mRNA - - I-MUT
was - - O
detected - - O
only - - O
in - - O
roots - - O
. - - O

The - - O
RS447 - - B-MUT
human - - B-MUT
megasatellite - - I-MUT
tandem - - I-MUT
repetitive - - I-MUT
sequence - - I-MUT
encodes - - O
a - - O
novel - - O
deubiquitinating - - O
enzyme - - O
with - - O
a - - O
functional - - O
promoter - - O
. - - O

There - - O
was - - O
no - - O
correlation - - O
between - - O
secretor - - O
status - - O
and - - O
clinical - - O
status - - O
, - - O
spirometry - - O
measurements - - O
, - - O
salivary - - O
and - - O
serum - - B-MUT
lysozyme - - I-MUT
levels - - O
or - - O
rates - - O
of - - O
respiratory - - O
tract - - O
colonization - - O
with - - O
P - - O
. - - O
aeruginosa - - O
and - - O
S - - O
. - - O
aureus - - O
. - - O

Urine - - O
specimens - - O
containing - - O
either - - O
phencyclidine - - O
( - - O
PCP - - O
) - - O
or - - O
11-nor-delta - - O
9-tetrahydrocannabinol-9-carboxylic - - O
acid - - O
( - - O
9-THC-COOH - - O
) - - O
were - - O
adulterated - - O
with - - O
sodium - - O
chloride - - O
, - - O
bleach - - O
, - - O
vinegar - - O
, - - O
potassium - - O
hydroxide - - O
, - - O
liquid - - O
soap - - O
, - - O
2-propanol - - O
, - - O
and - - O
ammonia - - O
. - - O

We - - O
sought - - O
to - - O
determine - - O
whether - - O
such - - O
differences - - O
in - - O
polyadenylation - - O
affect - - O
the - - O
steady-state - - O
levels - - O
of - - O
DHFR - - B-MUT
and - - O
mRNAs - - O
expressed - - O
from - - O
either - - O
allele - - O
and - - O
, - - O
in - - O
a - - O
more - - O
general - - O
sense - - O
, - - O
to - - O
ask - - O
whether - - O
differences - - O
in - - O
3' - - O
end - - O
RNA - - O
processing - - O
in - - O
a - - O
gene - - O
containing - - O
multiple - - O
poly - - O
( - - O
A - - O
) - - O
sites - - O
affects - - O
the - - O
final - - O
level - - O
of - - O
gene - - O
expression - - O
. - - O

Schizosaccharomyces - - O
pombe - - O
cells - - O
respond - - O
to - - O
nutrient - - O
deprivation - - O
by - - O
altering - - O
G2 - - O
M - - O
cell - - O
size - - O
control - - O
. - - O

ACTH - - B-MUT
release - - O
is - - O
transiently - - O
suppressed - - O
in - - O
some - - O
children - - O
after - - O
exogenous - - O
ACTH - - B-MUT
treatment - - O
. - - O

In - - O
the - - O
cell-free - - O
import - - O
assay - - O
, - - O
beta-catenin - - B-MUT
rapidly - - O
migrates - - O
into - - O
the - - O
nucleus - - O
without - - O
the - - O
exogenous - - O
addition - - O
of - - O
cytosol - - O
, - - O
Ran - - B-MUT
, - - O
or - - O
ATP - - O
GTP - - O
. - - O

The - - O
protein - - O
sequence - - O
contains - - O
seven - - O
potential - - O
N-linked - - O
glycosylation - - O
sites - - O
and - - O
a - - O
threonine - - O
serine-rich - - O
region - - O
which - - O
is - - O
a - - O
potential - - O
site - - O
for - - O
attachment - - O
of - - O
O-linked - - O
carbohydrate - - O
. - - O

Inverse - - O
relation - - O
between - - O
serum - - O
IgG - - B-MUT
concentration - - O
and - - O
glucose - - O
and - - O
xylose - - O
absorption - - O
in - - O
Zambian - - O
African - - O
adults - - O
. - - O

Moreover - - O
, - - O
glucan - - B-MUT
synthase - - I-MUT
activity - - O
, - - O
which - - O
is - - O
activated - - O
by - - O
Rho1p - - B-MUT
, - - O
was - - O
significantly - - O
reduced - - O
in - - O
the - - O
deltabem4 - - B-MUT
mutant - - I-MUT
. - - O

The - - O
authors - - O
report - - O
the - - O
results - - O
of - - O
a - - O
series - - O
of - - O
toxicological - - O
tests - - O
conducted - - O
on - - O
plastic - - O
materials - - O
( - - O
polyethylene - - O
) - - O
activated - - O
with - - O
tetraphenylbutadiene - - O
( - - O
TPB - - O
) - - O
an - - O
additive - - O
recently - - O
proposed - - O
as - - O
a - - O
sensitizer - - O
capable - - O
of - - O
photodegrading - - O
plastic - - O
materials - - O
. - - O

The - - O
human - - B-MUT
T - - I-MUT
cell - - I-MUT
lymphotropic - - I-MUT
retrovirus - - I-MUT
type - - I-MUT
I - - I-MUT
( - - I-MUT
HTLV-I - - I-MUT
) - - I-MUT
trans-activator - - I-MUT
, - - O
Tax - - B-MUT
, - - O
interacts - - O
specifically - - O
with - - O
the - - O
basic-domain - - B-MUT
leucine-zipper - - I-MUT
( - - I-MUT
bZip - - I-MUT
) - - I-MUT
protein - - I-MUT
, - - I-MUT
cAMP - - O
response - - B-MUT
element - - I-MUT
binding - - I-MUT
protein - - I-MUT
( - - I-MUT
CREB - - O
) - - B-MUT
, - - O
bound - - O
to - - O
the - - O
viral - - O
Tax-responsive - - B-MUT
element - - I-MUT
consisting - - I-MUT
of - - O
three - - O
imperfect - - O
21-base - - O
pair - - O
repeats - - O
, - - O
each - - O
with - - O
a - - O
cAMP - - O
response - - B-MUT
element - - I-MUT
core - - I-MUT
flanked - - I-MUT
by - - O
G - - O
C-rich - - O
sequences - - O
. - - O

METHODS - - O
: - - O
Von - - B-MUT
Willebrand - - I-MUT
factor - - I-MUT
( - - O
vWF - - B-MUT
) - - O
and - - O
the - - O
fibrinolytic - - O
factors - - O
tissue - - B-MUT
plasminogen - - I-MUT
activator - - I-MUT
( - - O
tPA - - B-MUT
) - - O
, - - O
measured - - O
as - - O
tPA - - B-MUT
capacity - - O
, - - O
and - - O
plasminogen - - B-MUT
activator - - I-MUT
inhibitor - - I-MUT
1 - - I-MUT
( - - O
PAI-1 - - B-MUT
) - - O
, - - O
platelets - - O
, - - O
fibrinogen - - B-MUT
, - - O
and - - O
inflammatory - - O
markers - - O
were - - O
measured - - O
in - - O
74 - - O
patients - - O
with - - O
active - - O
seropositive - - O
RA - - O
. - - O

Regressing - - O
microaneurysms - - O
in - - O
5 - - O
cases - - O
of - - O
hepatitis - - O
B - - O
virus - - O
related - - O
polyarteritis - - O
nodosa - - O
. - - O

Prevention - - O
by - - O
a - - O
heparin-antithrombin - - B-MUT
III - - I-MUT
combination - - O
. - - O

Positron - - O
emission - - O
tomography - - O
radioligands - - O
for - - O
dopamine - - B-MUT
transporters - - I-MUT
and - - O
studies - - O
in - - O
human - - O
and - - O
nonhuman - - O
primates - - O
. - - O

Several - - O
cDNAs - - O
corresponding - - O
to - - O
the - - O
human - - B-MUT
PWP2 - - I-MUT
gene - - I-MUT
were - - O
identified - - O
and - - O
partially - - O
sequenced - - O
. - - O

The - - O
primary - - O
structure - - O
and - - O
cotranscription - - O
of - - O
the - - O
petCA - - B-MUT
genes - - I-MUT
encoding - - O
the - - O
Rieske-FeS - - B-MUT
( - - O
nuclear - - B-MUT
encoded - - I-MUT
in - - I-MUT
plants - - I-MUT
) - - O
and - - O
apocytochrome - - B-MUT
f - - I-MUT
proteins - - I-MUT
has - - O
been - - O
described - - O
previously - - O
( - - O
Kallas - - O
, - - O
T - - O
. - - O
, - - O
Spiller - - O
, - - O
S - - O
. - - O
, - - O
and - - O
Malkin - - O
, - - O
R - - O
. - - O

Nonteratogenicity - - O
in - - O
rats - - O
of - - O
blighted - - O
potatoes - - O
and - - O
compounds - - O
contained - - O
in - - O
them - - O
. - - O

Pregnant - - O
women - - O
at - - O
term - - O
had - - O
the - - O
lowest - - O
levels - - O
of - - O
antithrombin - - B-MUT
III - - I-MUT
. - - O

Herpes - - O
virus - - O
infection - - O
was - - O
characterized - - O
by - - O
inversion - - O
of - - O
the - - O
T4 - - O
T8 - - O
ratio - - O
below - - O
1 - - O
. - - O
0 - - O
( - - O
sensitivity - - O
90% - - O
, - - O
specificity - - O
88% - - O
) - - O
, - - O
caused - - O
by - - O
proliferation - - O
of - - O
the - - O
T8 - - O
subpopulation - - O
, - - O
which--compared - - O
with - - O
the - - O
findings - - O
in - - O
patients - - O
with - - O
rejection - - O
crises--was - - O
significantly - - O
raised - - O
( - - O
P - - O
less - - O
than - - O
0 - - O
. - - O
001 - - O
) - - O
. - - O

Sequence - - O
analysis - - O
revealed - - O
significant - - O
differences - - O
between - - O
the - - O
5' - - O
region - - O
of - - O
the - - O
beta - - B-MUT
subunit - - I-MUT
gene - - I-MUT
and - - O
the - - O
corresponding - - O
regions - - O
of - - O
the - - O
homologous - - B-MUT
GlyR - - I-MUT
alpha - - I-MUT
subunit - - I-MUT
genes - - I-MUT
; - - O
it - - O
also - - O
identified - - O
a - - O
novel - - O
exon - - O
( - - O
exon - - O
0 - - O
) - - O
that - - O
encodes - - O
most - - O
of - - O
the - - O
5'-untranslated - - O
portion - - O
of - - O
the - - O
GlyR - - B-MUT
beta - - I-MUT
mRNA - - I-MUT
. - - O

A - - O
study - - O
in - - O
vivo - - O
of - - O
adrenergic - - B-MUT
receptors - - I-MUT
in - - O
the - - O
rectum - - O
and - - O
in - - O
the - - O
internal - - O
and - - O
sphincter - - O
of - - O
the - - O
cat - - O
. - - O

The - - O
unfolded - - O
protein - - O
response - - O
regulates - - O
multiple - - O
aspects - - O
of - - O
secretory - - O
and - - O
membrane - - O
protein - - O
biogenesis - - O
and - - O
endoplasmic - - O
reticulum - - O
quality - - O
control - - O
. - - O

The - - O
resulting - - O
mutants - - O
were - - O
coexpressed - - O
with - - O
gE - - B-MUT
in - - O
the - - O
vaccinia - - O
virus-based - - O
vTF7-3 - - O
system - - O
, - - O
and - - O
the - - O
formation - - O
and - - O
endoplasmic - - O
reticulum - - O
( - - O
ER - - O
) - - O
-to-Golgi - - O
transport - - O
of - - O
the - - O
hetero-oligomeric - - O
complex - - O
were - - O
monitored - - O
. - - O

Molecular - - O
dissection - - O
of - - O
the - - O
multimeric - - B-MUT
CD3-TCR - - I-MUT
complex - - I-MUT
revealed - - O
that - - O
at - - O
least - - O
two - - O
associated - - O
polypeptides - - O
, - - O
CD3 - - B-MUT
zeta - - I-MUT
and - - O
CD3 - - B-MUT
epsilon - - I-MUT
, - - O
autonomously - - O
couple - - O
antigenic - - O
recognition - - O
event - - O
to - - O
early - - O
and - - O
late - - O
events - - O
of - - O
the - - O
intracytoplasmic - - O
activation - - O
cascade - - O
. - - O

Comparison - - O
with - - O
alkaline - - B-MUT
phosphatases - - I-MUT
and - - O
5-nucleotidase - - B-MUT
. - - O

The - - O
GAC1 - - B-MUT
gene - - I-MUT
encodes - - O
the - - O
regulatory - - O
subunit - - O
for - - O
a - - O
type - - B-MUT
1 - - I-MUT
serine - - I-MUT
threonine - - I-MUT
phosphoprotein - - I-MUT
phosphatase - - I-MUT
, - - I-MUT
Glc7 - - O
. - - B-MUT

These - - O
results - - O
are - - O
consistent - - O
with - - O
the - - O
roles - - O
that - - O
CCK - - B-MUT
and - - O
trypsin - - B-MUT
inhibitors - - O
are - - O
believed - - O
to - - O
play - - O
in - - O
the - - O
negative - - O
feedback - - O
control - - O
of - - O
pancreatic - - O
exocrine - - O
function - - O
. - - O

Leukocyte - - O
enzyme - - O
activity - - O
and - - O
blood - - O
lymphocyte - - O
blast - - O
transformation - - O
in - - O
chronic - - O
bronchitis - - O
. - - O

The - - O
numerous - - O
tests - - O
demonstrate - - O
that - - O
the - - O
HDL-2M - - O
can - - O
be - - O
extensively - - O
and - - O
successfully - - O
used - - O
for - - O
therapy - - O
of - - O
insulin-dependent - - O
diabetes - - O
mellitus - - O
in - - O
clinical - - O
practice - - O
. - - O

These - - O
findings - - O
indicate - - O
that - - O
the - - O
t - - O
( - - O
4 - - O
; - - O
14 - - O
) - - O
( - - O
p16 - - O
. - - O
3 - - O
; - - O
q32 - - O
) - - O
represents - - O
a - - O
novel - - O
, - - O
recurrent - - O
chromosomal - - O
translocation - - O
in - - O
MM - - O
, - - O
and - - O
suggest - - O
that - - O
the - - O
FGFR3 - - B-MUT
gene - - I-MUT
may - - O
be - - O
the - - O
target - - O
of - - O
this - - O
abnormality - - O
and - - O
thus - - O
contribute - - O
to - - O
tumorigenesis - - O
in - - O
MM - - O
. - - O

All - - O
injections - - O
of - - O
CSF - - B-MUT
were - - O
given - - O
after - - O
the - - O
initiation - - O
of - - O
neutropenia - - O
and - - O
continued - - O
until - - O
the - - O
occurrence - - O
of - - O
an - - O
absolute - - O
neutrophil - - O
recovery - - O
. - - O
rHu - - B-MUT
GM-CSF - - I-MUT
and - - O
rHu - - B-MUT
G-CSF - - I-MUT
, - - O
administered - - O
once - - O
daily - - O
at - - O
the - - O
250 - - O
microg - - O
m - - O
( - - O
-2 - - O
) - - O
day - - O
( - - O
-1 - - O
) - - O
and - - O
5 - - O
microg - - O
kg - - O
( - - O
-1 - - O
) - - O
day - - O
( - - O
-1 - - O
) - - O
level - - O
, - - O
were - - O
effective - - O
in - - O
increasing - - O
the - - O
absolute - - O
neutrophil - - O
count - - O
and - - O
neutrophil - - O
function - - O
, - - O
as - - O
measured - - O
by - - O
an - - O
automated - - O
chemiluminescence - - O
system - - O
. - - O

Stringent - - O
hybridization - - O
of - - O
EHS-1 - - B-MUT
back - - O
to - - O
primate - - O
genomic - - O
DNA - - O
indicates - - O
two - - O
distinct - - O
EHS-1 - - B-MUT
loci - - I-MUT
in - - O
normal - - O
human - - O
DNA - - O
, - - O
an - - O
identical - - O
band - - O
pattern - - O
in - - O
chimpanzee - - O
DNA - - O
, - - O
and - - O
a - - O
single - - O
locus - - O
in - - O
rhesus - - O
monkey - - O
DNA - - O
. - - O

All - - O
subsequent - - O
patients - - O
were - - O
treated - - O
at - - O
the - - O
maximal - - O
tolerated - - O
dose - - O
of - - O
EDXR - - O
( - - O
35 - - O
mg - - O
m2 - - O
day - - O
) - - O
. - - O

The - - O
results - - O
suggest - - O
that - - O
the - - O
calcium - - O
antagonist - - O
, - - O
diltiazem - - O
, - - O
may - - O
modify - - O
the - - O
effects - - O
of - - O
isoflurane - - O
on - - O
myocardial - - O
function - - O
. - - O

Twenty - - O
eligible - - O
patients - - O
with - - O
cirrhosis - - O
were - - O
randomized - - O
into - - O
two - - O
groups - - O
: - - O
10 - - O
patients - - O
treated - - O
with - - O
6 - - O
million - - O
units - - O
of - - O
natural - - O
IFN-beta - - B-MUT
twice - - O
a - - O
week - - O
for - - O
36 - - O
months - - O
and - - O
10 - - O
patients - - O
without - - O
IFN - - B-MUT
therapy - - O
. - - O

The - - O
multidomain - - O
structure - - O
includes - - O
a - - O
cysteine-rich - - O
motif - - O
resembling - - O
those - - O
of - - O
protein - - B-MUT
kinase - - I-MUT
C - - I-MUT
and - - O
n-chimaerin - - B-MUT
and - - O
a - - O
putative - - O
pleckstrin - - B-MUT
homology - - I-MUT
domain - - I-MUT
. - - O

For - - O
the - - O
sample - - O
of - - O
systematic - - O
reviews - - O
drawn - - O
from - - O
ACP - - O
Journal - - O
Club - - O
( - - O
n - - O
= - - O
103 - - O
) - - O
, - - O
the - - O
PubMed - - O
strategy - - O
achieved - - O
a - - O
sensitivity - - O
of - - O
97% - - O
( - - O
CI - - O
, - - O
91% - - O
to - - O
99% - - O
) - - O
. - - O

Method - - O
of - - O
synthesis - - O
of - - O
the - - O
rheumatoid - - B-MUT
factor - - I-MUT
in - - O
clinico-immunological - - O
studies - - O
. - - O

Trypanosoma - - O
cruzi - - O
. - - O

Dangers - - O
in - - O
use - - O
of - - O
live-virus - - O
vaccines - - O
[ - - O
letter - - O
] - - O
. - - O

Expression - - O
plasmids - - O
harboring - - O
full-length - - O
or - - O
kinase - - O
domain - - O
of - - O
PKC - - B-MUT
alpha - - I-MUT
and - - O
PKC - - B-MUT
delta - - I-MUT
( - - O
PKC - - B-MUT
alpha - - I-MUT
K - - I-MUT
and - - O
PKC - - B-MUT
delta - - I-MUT
K - - I-MUT
) - - O
were - - O
constructed - - O
. - - O

The - - O
major - - O
transcription - - O
factors - - O
controlling - - O
arginine - - O
metabolism - - O
in - - O
Escherichia - - O
coli - - O
and - - O
Bacillus - - O
subtilis - - O
, - - O
ArgR - - B-MUT
and - - O
AhrC - - B-MUT
, - - O
respectively - - O
, - - O
are - - O
homologous - - O
multimeric - - O
proteins - - O
that - - O
form - - O
l - - O
-arginine-dependent - - O
DNA-binding - - O
complexes - - O
capable - - O
of - - O
repressing - - O
transcription - - O
of - - O
the - - O
biosynthetic - - O
genes - - O
( - - O
both - - O
) - - O
, - - O
activating - - O
transcription - - O
of - - O
catabolic - - O
genes - - O
( - - O
AhrC - - B-MUT
only - - O
) - - O
or - - O
facilitating - - O
plasmid - - O
dimer - - O
resolution - - O
( - - O
both - - O
) - - O
. - - O

The - - O
asymmetric - - O
methylation - - O
was - - O
associated - - O
with - - O
tissue-specific - - O
disruption - - O
of - - O
H19 - - B-MUT
genomic - - O
imprinting - - O
in - - O
fetal - - O
brain - - O
. - - O

On - - O
Cox - - O
proportional - - O
hazards - - O
regression - - O
adenocarcinoma - - O
( - - O
P - - O
= - - O
0 - - O
. - - O
006 - - O
) - - O
, - - O
the - - O
development - - O
of - - O
BPF - - O
( - - O
P - - O
= - - O
0 - - O
. - - O
003 - - O
) - - O
, - - O
older - - O
age - - O
( - - O
P - - O
= - - O
0 - - O
. - - O
03 - - O
) - - O
and - - O
higher - - O
pathological - - O
stage - - O
( - - O
P - - O
= - - O
0 - - O
. - - O
02 - - O
) - - O
were - - O
independent - - O
adverse - - O
predictors - - O
of - - O
survival - - O
. - - O

Interestingly - - O
, - - O
however - - O
, - - O
it - - O
is - - O
homologous - - O
to - - O
several - - O
expressed - - O
sequence - - O
tags - - O
( - - O
EST - - O
) - - O
of - - O
unknown - - O
function - - O
from - - O
Caenorhabditis - - O
elegans - - O
, - - O
Oryza - - O
sativa - - O
and - - O
Homo - - O
sapiens - - O
. - - O

A - - O
poor - - O
correlation - - O
was - - O
also - - O
observed - - O
between - - O
PbB - - O
and - - O
ALAD - - B-MUT
activity - - O
of - - O
the - - O
stearate - - O
workers - - O
. - - O

Analysis - - O
of - - O
several - - O
Tat - - B-MUT
mutants - - I-MUT
indicated - - O
that - - O
both - - O
the - - O
cysteine-rich - - O
and - - O
the - - O
core - - O
domains - - O
of - - O
this - - O
transactivator - - O
are - - O
necessary - - O
and - - O
sufficient - - O
to - - O
activate - - O
transcription - - O
when - - O
TBP - - B-MUT
is - - O
overexpressed - - O
. - - O

Rice - - B-MUT
dwarf - - I-MUT
phytoreovirus - - I-MUT
segment - - I-MUT
S12 - - I-MUT
transcript - - I-MUT
is - - O
tricistronic - - O
in - - O
vitro - - O
. - - O

These - - O
results - - O
indicate - - O
that - - O
both - - O
N- - - O
and - - O
C-terminal - - O
mutations - - O
are - - O
required - - O
to - - O
inhibit - - O
transrepression - - O
by - - O
FBR - - B-MUT
protein - - I-MUT
and - - O
that - - O
multiple - - O
structural - - O
mutations - - O
accompanied - - O
by - - O
posttranslational - - O
protein - - O
modification - - O
alter - - O
gene - - O
regulation - - O
by - - O
FBR - - B-MUT
protein - - I-MUT
. - - O

Alveolar - - O
growth - - O
, - - O
contemporary - - O
with - - O
dental - - O
eruption - - O
, - - O
is - - O
sufficient - - O
to - - O
compensate - - O
possible - - O
hypotrophy - - O
of - - O
maxillary - - O
bone - - O
bases - - O
. - - O

The - - O
results - - O
of - - O
this - - O
study - - O
suggest - - O
that - - O
NF-kappaB - - B-MUT
activity - - O
may - - O
be - - O
regulated - - O
by - - O
its - - O
interaction - - O
with - - O
the - - O
cell - - O
cycle - - O
regulatory - - O
protein - - O
, - - O
E2F-1 - - B-MUT
. - - O

In - - O
accordance - - O
with - - O
clinical - - O
improvement - - O
we - - O
found - - O
a - - O
decrease - - O
of - - O
laboratory - - O
indicators - - O
of - - O
inflammation - - O
( - - O
C-reactive - - B-MUT
protein - - I-MUT
, - - O
alpha - - B-MUT
2-globuline - - I-MUT
, - - O
prostaglandin - - O
E2 - - O
) - - O
. - - O

Dominant - - O
negative - - O
Sos - - B-MUT
did - - O
not - - O
affect - - O
carbachol - - O
stimulation - - O
of - - O
HA-ERK2 - - B-MUT
but - - O
inhibited - - O
the - - O
stimulatory - - O
effect - - O
of - - O
EGF - - B-MUT
by - - O
60% - - O
. - - O

The - - O
PRB-1b - - B-MUT
gene - - I-MUT
encodes - - O
for - - O
a - - O
basic-type - - O
component - - O
of - - O
the - - O
pathogenesis-related - - O
PR-1 - - B-MUT
protein - - I-MUT
family - - I-MUT
. - - O

Two-dimensional - - O
phosphotryptic - - O
analyses - - O
indicate - - O
that - - O
phosphorylation - - O
on - - O
Ser-12 - - O
and - - O
Ser-48 - - O
in - - O
unstimulated - - O
cells - - O
is - - O
associated - - O
with - - O
the - - O
ability - - O
of - - O
overexpressed - - O
pp60c-src - - B-MUT
to - - O
potentiate - - O
beta-adrenergic - - O
signalling - - O
. - - O

Methods - - O
included - - O
24-hour - - O
dietary - - O
recall - - O
, - - O
menu - - O
weights - - O
, - - O
and - - O
recipe - - O
analysis - - O
. - - O

A - - O
2 - - O
. - - O
3-kb - - O
full-length - - O
cDNA - - O
clone - - O
of - - O
an - - O
Atlantic - - B-MUT
halibut - - I-MUT
Mx - - I-MUT
gene - - I-MUT
was - - O
isolated - - O
from - - O
a - - O
liver - - O
cDNA - - O
library - - O
. - - O

A - - O
20-base - - O
pair - - O
oligonucleotide - - O
containing - - O
this - - O
nonamer - - O
confers - - O
up-regulation - - O
by - - O
hypoxia - - O
and - - O
inhibition - - O
by - - O
unsaturated - - O
fatty - - O
acids - - O
when - - O
placed - - O
upstream - - O
of - - O
a - - O
heterologous - - O
promoter - - O
in - - O
a - - O
lacZ - - B-MUT
reporter - - I-MUT
construct - - I-MUT
. - - O

Mapping - - O
the - - O
cAMP - - B-MUT
receptor - - I-MUT
protein - - I-MUT
contact - - I-MUT
site - - I-MUT
on - - O
the - - O
alpha - - O
subunit - - O
of - - O
Escherichia - - B-MUT
coli - - I-MUT
RNA - - I-MUT
polymerase - - I-MUT
. - - O

Transforming - - B-MUT
growth - - I-MUT
factor - - I-MUT
( - - I-MUT
TGF - - I-MUT
) - - I-MUT
-beta1 - - I-MUT
induces - - O
extracellular - - O
matrix - - O
deposition - - O
and - - O
proliferation - - O
of - - O
mesenchymal - - O
cells - - O
. - - O

Results - - O
were - - O
supported - - O
by - - O
the - - O
agar - - O
diffusion - - O
method - - O
for - - O
Y - - O
. - - O
enterocolitica - - O
, - - O
whereas - - O
inhibition - - O
activity - - O
was - - O
not - - O
found - - O
for - - O
A - - O
. - - O
hydrophila - - O
. - - O

JCAHO - - O
revised - - O
interpretation - - O
. - - O

Cattaneo - - O
, - - O
and - - O
J - - O
. - - O

These - - O
data - - O
suggest - - O
that - - O
mammalian - - O
erythroid - - O
alpha-spectrin - - B-MUT
evolved - - O
by - - O
duplication - - O
and - - O
rapid - - O
divergence - - O
from - - O
an - - O
ancestral - - O
alpha-fodrin-like - - B-MUT
gene - - I-MUT
. - - O

Immunologically - - O
reactive - - O
insulin - - B-MUT
levels - - O
were - - O
determined - - O
in - - O
freely-moving - - O
normal - - O
rats - - O
offered - - O
three - - O
different - - O
test-meals - - O
. - - O

Transcriptional - - O
blockade - - O
was - - O
reversed - - O
by - - O
co-transfections - - O
of - - O
a - - O
wild-type - - B-MUT
SRF - - I-MUT
expression - - O
vector - - O
, - - O
but - - O
was - - O
not - - O
rescued - - O
by - - O
the - - O
expression - - O
of - - O
other - - O
myogenic - - O
factors - - O
, - - O
such - - O
as - - O
MyoD - - B-MUT
and - - O
Mef-2C - - B-MUT
. - - O

The - - O
significance - - O
of - - O
structural - - O
integrity - - O
of - - O
lymphoid - - O
tissue - - O
for - - O
antibody - - O
production - - O
in - - O
culture - - O
in - - O
vivo - - O
. - - O

Displacement - - O
thresholds - - O
of - - O
peripheral - - O
sites - - O
in - - O
monocular - - O
human - - O
vision - - O
were - - O
obtained - - O
. - - O

Losartan - - O
Intervention - - O
For - - O
Endpoint - - O
. - - O

In - - O
the - - O
evening - - O
, - - O
the - - O
amplitude - - O
of - - O
the - - O
responses - - O
to - - O
both - - O
O2 - - O
and - - O
CO2 - - O
increased - - O
but - - O
the - - O
increase - - O
in - - O
CO2 - - O
sensitivity - - O
was - - O
proportionally - - O
more - - O
important - - O
. - - O

The - - O
lethal - - O
toxicity - - O
of - - O
inorganic - - O
( - - O
HgCl2 - - O
) - - O
and - - O
organic - - O
( - - O
CH3HgCl - - O
) - - O
mercury - - O
chloride - - O
was - - O
compared - - O
for - - O
Coturnix - - O
( - - O
Japanese - - O
quail - - O
, - - O
Coturnix - - O
japonica - - O
) - - O
of - - O
different - - O
ages - - O
from - - O
hatch - - O
through - - O
adulthood - - O
by - - O
single-dose - - O
acute - - O
oral - - O
and - - O
intramuscular - - O
injections - - O
and - - O
by - - O
a - - O
5-d - - O
dietary - - O
trial - - O
. - - O

Distal - - O
tubular - - O
acidification - - O
and - - O
the - - O
threshold - - O
for - - O
proximal - - O
tubular - - O
bicarbonate - - O
reabsorption - - O
were - - O
normal - - O
, - - O
as - - O
was - - O
urine - - O
concentrating - - O
capacity - - O
. - - O

By - - O
negatively - - O
regulating - - O
GRK-mediated - - O
receptor - - O
phosphorylation - - O
, - - O
beta-arrestin-mediated - - O
processes - - O
such - - O
as - - O
Src - - B-MUT
recruitment - - O
and - - O
clathrin-mediated - - O
internalization - - O
, - - O
which - - O
are - - O
required - - O
for - - O
GPCR-mediated - - O
ERK - - B-MUT
activation - - O
, - - O
are - - O
inhibited - - O
, - - O
thus - - O
dampening - - O
further - - O
ERK - - B-MUT
activation - - O
. - - O

Of - - O
the - - O
patients - - O
in - - O
each - - O
regimen - - O
who - - O
reached - - O
study - - O
end - - O
points - - O
, - - O
17 - - O
of - - O
29 - - O
( - - O
59% - - O
) - - O
were - - O
in - - O
regimen - - O
A - - O
, - - O
11 - - O
of - - O
20 - - O
( - - O
55% - - O
) - - O
were - - O
in - - O
regimen - - O
B - - O
, - - O
and - - O
28 - - O
of - - O
43 - - O
( - - O
65% - - O
) - - O
were - - O
in - - O
regimen - - O
C - - O
met - - O
the - - O
treatment - - O
success - - O
criterion - - O
. - - O

The - - O
patients - - O
who - - O
presented - - O
with - - O
mucocutaneous - - O
disease - - O
also - - O
had - - O
low - - O
CD4+ - - B-MUT
T - - O
lymphocyte - - O
counts - - O
, - - O
and - - O
most - - O
of - - O
them - - O
had - - O
AIDS - - O
defining - - O
illnesses - - O
. - - O

The - - O
results - - O
indicate - - O
that - - O
the - - O
relationship - - O
between - - O
comprehension - - O
and - - O
production - - O
is - - O
different - - O
at - - O
different - - O
stages - - O
in - - O
development - - O
. - - O

C - - O
. - - O
D2-Chr - - O
4 - - O
congenic - - O
strains - - O
harboring - - O
DBA - - B-MUT
2 - - I-MUT
alleles - - I-MUT
associated - - I-MUT
with - - O
the - - O
Pctr1 - - O
locus - - B-MUT
contained - - I-MUT
DBA - - O
2 - - B-MUT
"resistant" - - I-MUT
alleles - - I-MUT
of - - I-MUT
the - - I-MUT
CDK4 - - O
CDK6 - - O
inhibitors - - B-MUT
p16 - - I-MUT
and - - I-MUT
p15 - - O
. - - B-MUT

We - - O
previously - - O
showed - - O
that - - O
this - - O
proteolysis - - O
1 - - O
) - - O
can - - O
be - - O
acutely - - O
promoted - - O
by - - O
the - - O
phorbol - - O
ester - - O
phorbol - - O
12-myristate - - O
13-acetate - - O
( - - O
PMA - - O
) - - O
, - - O
2 - - O
) - - O
requires - - O
a - - O
metalloprotease - - B-MUT
activity - - O
, - - O
3 - - O
) - - O
generates - - O
both - - O
shed - - O
GHBP - - B-MUT
and - - O
a - - O
membrane-associated - - B-MUT
GHR - - I-MUT
transmembrane - - I-MUT
cytoplasmic - - I-MUT
domain - - I-MUT
remnant - - I-MUT
, - - O
and - - O
4 - - O
) - - O
results - - O
in - - O
down-regulation - - O
of - - O
GHR - - O
abundance - - B-MUT
and - - O
GH - - O
signaling - - B-MUT
. - - O

Finally - - O
, - - O
Cas - - B-MUT
existed - - O
mainly - - O
in - - O
cytosol - - O
and - - O
membrane - - O
cytoskeleton - - O
fractions - - O
in - - O
the - - O
resting - - O
state - - O
, - - O
and - - O
remained - - O
unchanged - - O
during - - O
platelet - - O
aggregation - - O
, - - O
when - - O
FAK - - B-MUT
translocated - - O
to - - O
the - - O
cytoskeletal - - O
fraction - - O
. - - O

On - - O
the - - O
basis - - O
of - - O
serum - - B-MUT
alpha1AT - - I-MUT
quantitation - - O
, - - O
newborn - - O
infants - - O
may - - O
be - - O
separated - - O
into - - O
two - - O
groups - - O
, - - O
characterized - - O
respectively - - O
by - - O
concentrations - - O
above - - O
or - - O
below - - O
150 - - O
mg% - - O
. - - O

Elimination - - O
of - - O
bagassosis - - O
in - - O
Louisiana - - O
paper - - O
manufacturing - - O
plant - - O
workers - - O
. - - O

The - - O
present - - O
data - - O
also - - O
suggest - - O
that - - O
when - - O
compared - - O
to - - O
the - - O
systemic - - O
vascular - - O
bed - - O
, - - O
the - - O
pulmonary - - O
vascular - - O
bed - - O
is - - O
less - - O
responsive - - O
to - - O
bolus - - O
administration - - O
of - - O
ET-1 - - B-MUT
. - - O

Intracavitary - - O
irradiation - - O
was - - O
carried - - O
out - - O
with - - O
a - - O
microSelectron - - O
HDR - - O
afterloading - - O
device - - O
and - - O
usually - - O
22 - - O
. - - O
5 - - O
Gy - - O
was - - O
given - - O
in - - O
three - - O
fractions - - O
repeated - - O
weekly - - O
. - - O

The - - O
POEMS - - O
syndrome - - O
( - - O
Polyneuropathy - - O
, - - O
Organomegaly - - O
, - - O
Endocrinopathy - - O
, - - O
Monoclonal - - O
component - - O
, - - O
Skin - - O
) - - O
. - - O

Neuronal - - O
mechanisms - - O
underlying - - O
stimulus-response - - O
( - - O
S-R - - O
) - - O
associations - - O
in - - O
S-R - - O
compatibility - - O
tasks - - O
were - - O
identified - - O
in - - O
2 - - O
experiments - - O
with - - O
monkeys - - O
. - - O

Identification - - O
of - - O
Ste4 - - B-MUT
as - - O
a - - O
potential - - O
regulator - - O
of - - O
Byr2 - - B-MUT
in - - O
the - - O
sexual - - O
response - - O
pathway - - O
of - - O
Schizosaccharomyces - - O
pombe - - O
. - - O

After - - O
two - - O
successive - - O
rounds - - O
of - - O
selection - - O
by - - O
focus - - O
formation - - O
assay - - O
, - - O
a - - O
transforming - - B-MUT
ribozyme - - I-MUT
( - - O
Rz007 - - B-MUT
) - - O
was - - O
identified - - O
. - - O

Analysis - - O
of - - O
an - - O
autopsy - - O
population - - O
. - - O

This - - O
work - - O
unravels - - O
a - - O
new - - O
model - - O
for - - O
the - - O
ets-1 - - B-MUT
ets-2 - - I-MUT
gene's - - I-MUT
evolution - - O
, - - O
based - - O
for - - O
the - - O
first - - O
time - - O
on - - O
both - - O
structural - - O
and - - O
functional - - O
evidences - - O
. - - O

Molecular - - O
cloning - - O
and - - O
sequencing - - O
of - - O
a - - O
cDNA - - O
encoding - - O
SR - - B-MUT
beta - - I-MUT
revealed - - O
that - - O
SR - - B-MUT
beta - - I-MUT
is - - O
a - - O
transmembrane - - O
protein - - O
and - - O
, - - O
like - - O
SR - - B-MUT
alpha - - I-MUT
and - - O
SRP54 - - B-MUT
, - - O
is - - O
a - - O
member - - O
of - - O
the - - O
GTPase - - B-MUT
superfamily - - I-MUT
. - - O

The - - O
major - - O
findings - - O
of - - O
our - - O
studies - - O
are - - O
as - - O
follows - - O
: - - O
1 - - O
) - - O
There - - O
are - - O
no - - O
detectable - - O
signals - - O
around - - O
GDF-9-deficient - - O
follicles - - O
for - - O
several - - O
theca - - O
cell - - O
layer - - O
markers - - O
[ - - O
i - - O
. - - O
e - - O
. - - O

W - - O
. - - O
G - - O
. - - O

RACK1 - - B-MUT
, - - O
a - - O
receptor - - O
for - - O
activated - - B-MUT
C - - I-MUT
kinase - - I-MUT
and - - O
a - - O
homolog - - O
of - - O
the - - O
beta - - O
subunit - - O
of - - O
G - - B-MUT
proteins - - I-MUT
, - - O
inhibits - - O
activity - - O
of - - O
src - - B-MUT
tyrosine - - I-MUT
kinases - - I-MUT
and - - O
growth - - O
of - - O
NIH - - O
3T3 - - O
cells - - O
. - - O

The - - O
polyubiquitin - - B-MUT
gene - - I-MUT
was - - O
transcribed - - O
throughout - - O
the - - O
Volvox - - O
life - - O
cycle - - O
with - - O
peaks - - O
in - - O
the - - O
1 - - O
. - - O
6-kb - - O
mRNA - - O
levels - - O
during - - O
pre-cleavage - - O
, - - O
cleavage - - O
, - - O
and - - O
post-inversion - - O
. - - O

DNase - - B-MUT
I - - I-MUT
and - - O
1 - - O
, - - O
10-phenanthroline-copper - - O
footprinting - - O
of - - O
MURA-Mu1 - - B-MUT
TIR - - I-MUT
complexes - - I-MUT
indicate - - O
that - - O
MURA - - B-MUT
binds - - O
to - - O
a - - O
conserved - - O
approximately - - O
32-bp - - O
region - - O
in - - O
the - - O
TIR - - B-MUT
of - - O
Mu1 - - B-MUT
. - - O

We - - O
and - - O
others - - O
have - - O
demonstrated - - O
that - - O
the - - O
c-cbl - - B-MUT
proto-oncogene - - I-MUT
product - - I-MUT
is - - O
one - - O
of - - O
the - - O
earliest - - O
targets - - O
of - - O
tyrosine - - O
phosphorylation - - O
upon - - O
T - - B-MUT
cell - - I-MUT
receptor - - I-MUT
stimulation - - O
. - - O

Analysis - - O
of - - O
the - - O
DNA - - O
from - - O
15 - - O
cases - - O
of - - O
sporadic - - O
and - - O
familial - - O
Wilms' - - O
tumor - - O
did - - O
not - - O
reveal - - O
any - - O
changes - - O
, - - O
indicating - - O
that - - O
the - - O
translocation - - O
breakpoint - - O
does - - O
not - - O
reside - - O
in - - O
this - - O
gene - - O
. - - O

In - - O
order - - O
to - - O
study - - O
the - - O
structural - - O
and - - O
functional - - O
organization - - O
of - - O
the - - O
eukaryotic - - O
nucleolus - - O
, - - O
we - - O
have - - O
started - - O
to - - O
isolate - - O
and - - O
characterize - - O
nucleolar - - O
components - - O
of - - O
the - - O
yeast - - O
Saccharomyces - - O
cerevisiae - - O
. - - O

The - - O
use - - O
of - - O
specific - - O
antibodies - - O
allowed - - O
the - - O
identification - - O
of - - O
at - - O
least - - O
RAR - - B-MUT
beta - - I-MUT
in - - O
some - - O
of - - O
the - - O
DNA-protein - - O
complexes - - O
, - - O
although - - O
the - - O
four - - O
sequences - - O
bind - - O
single - - O
RARs - - B-MUT
transfected - - O
in - - O
COS - - O
cells - - O
much - - O
less - - O
efficiently - - O
, - - O
or - - O
not - - O
at - - O
all - - O
, - - O
when - - O
compared - - O
to - - O
a - - O
canonical - - O
RAR - - B-MUT
responsive - - I-MUT
element - - I-MUT
. - - O

Although - - O
increased - - O
expression - - O
of - - O
the - - O
HMG-I - - B-MUT
Y - - I-MUT
proteins - - I-MUT
is - - I-MUT
associated - - O
with - - O
cellular - - O
proliferation - - O
, - - O
neoplastic - - O
transformation - - O
, - - O
and - - O
several - - O
human - - O
cancers - - O
, - - O
the - - O
role - - O
of - - O
these - - O
proteins - - O
in - - O
the - - O
pathogenesis - - O
of - - O
malignancy - - O
remains - - O
unclear - - O
. - - O

The - - O
hydropathy - - O
plot - - O
revealed - - O
a - - O
rather - - O
hydrophilic - - O
N-terminal - - O
region - - O
and - - O
the - - O
absence - - O
of - - O
a - - O
hydrophobic - - O
signal - - O
peptide - - O
. - - O

These - - O
results - - O
demonstrate - - O
that - - O
sequences - - O
in - - O
the - - O
SH2 - - B-MUT
SH3 - - I-MUT
SH2 - - I-MUT
region - - I-MUT
of - - I-MUT
p120 - - I-MUT
GAP - - O
are - - B-MUT
required - - I-MUT
for - - O
full - - O
catalytic - - O
activity - - O
toward - - O
Ras - - O
. - - O

We - - O
have - - O
isolated - - O
a - - O
binding - - O
partner - - O
for - - O
the - - O
Fanconi - - B-MUT
anemia - - I-MUT
group - - I-MUT
C - - I-MUT
protein - - I-MUT
( - - O
FANCC - - B-MUT
) - - O
by - - O
yeast - - O
two-hybrid - - O
screening - - O
. - - O

The - - O
effects - - O
of - - O
coenzyme - - B-MUT
Q10 - - I-MUT
( - - O
CoQ - - B-MUT
) - - O
and - - O
captopril - - O
on - - O
functional - - O
capacity - - O
, - - O
hemodynamics - - O
and - - O
survival - - O
were - - O
studied - - O
in - - O
154 - - O
rats - - O
that - - O
recovered - - O
after - - O
experimental - - O
myocardial - - O
infarction - - O
. - - O

Novel - - O
intronic - - O
promoter - - O
in - - O
the - - O
rat - - B-MUT
ER - - I-MUT
alpha - - I-MUT
gene - - I-MUT
responsible - - O
for - - O
the - - O
transient - - O
transcription - - O
of - - O
a - - O
variant - - O
receptor - - O
. - - O

In - - O
assays - - O
with - - O
purified - - O
enzymes - - O
, - - O
wild-type - - O
but - - O
not - - O
PTPS-S19A - - B-MUT
was - - O
a - - O
specific - - O
substrate - - O
for - - O
the - - O
cGMP-dependent - - B-MUT
protein - - I-MUT
kinase - - I-MUT
( - - I-MUT
cGK - - I-MUT
) - - I-MUT
type - - I-MUT
I - - I-MUT
and - - I-MUT
II - - O
. - - O

A - - O
decanucleotide - - O
promoter - - O
sequence - - O
homologous - - O
to - - O
those - - O
found - - O
in - - O
humans - - O
and - - O
mice - - O
was - - O
located - - O
in - - O
the - - O
5' - - O
untranslated - - O
region - - O
of - - O
one - - O
horse - - O
gene - - O
. - - O

Effects - - O
of - - O
rhG-CSF - - B-MUT
on - - O
neutrophil - - O
functions - - O
and - - O
survival - - O
in - - O
sepsis - - O
induced - - O
diabetic - - O
rats - - O
. - - O

Each - - O
of - - O
these - - O
genes - - O
contains - - O
a - - O
putative - - O
upstream - - O
ORF - - O
, - - O
while - - O
STA2 - - B-MUT
has - - O
two - - O
additional - - O
in-frame - - O
AUG - - O
codons - - O
5' - - O
to - - O
the - - O
major - - O
cistron - - O
. - - O

BRCA1 - - B-MUT
protein - - I-MUT
contains - - O
an - - O
amino-terminal - - O
zinc - - O
finger - - O
motif - - O
and - - O
a - - O
carboxy-terminal - - O
acidic - - O
region - - O
. - - O

Eleven - - O
patients - - O
tested - - O
positive - - O
for - - O
the - - O
hepatitis - - B-MUT
B - - I-MUT
surface - - I-MUT
antigen - - I-MUT
( - - O
HBsAg - - B-MUT
) - - O
. - - O

Gel-mobility - - O
shift - - O
analysis - - O
was - - O
also - - O
performed - - O
for - - O
the - - O
CCAAT - - O
motif - - O
at - - O
-67 - - O
. - - O

Vesicles - - O
could - - O
be - - O
induced - - O
only - - O
with - - O
multiple - - O
exposures - - O
to - - O
UVA - - O
. - - O

Hrs - - B-MUT
has - - O
a - - O
FYVE - - B-MUT
double - - I-MUT
zinc - - I-MUT
finger - - I-MUT
domain - - I-MUT
, - - O
which - - O
specifically - - O
binds - - O
phosphatidylinositol - - O
( - - O
3 - - O
) - - O
-phosphate - - O
and - - O
is - - O
conserved - - O
in - - O
several - - O
proteins - - O
involved - - O
in - - O
vesicular - - O
traffic - - O
. - - O

PATIENTS - - O
AND - - O
METHODS - - O
: - - O
In - - O
807 - - O
consecutive - - O
patients - - O
from - - O
the - - O
Chilean - - O
National - - O
Registry - - O
of - - O
Acute - - O
Myocardial - - O
Infarction - - O
we - - O
analyzed - - O
the - - O
resolution - - O
of - - O
chest - - O
pain - - O
and - - O
ST - - O
segment - - O
elevation - - O
over - - O
50% - - O
within - - O
the - - O
first - - O
90 - - O
min - - O
, - - O
abrupt - - O
CK - - O
rise - - O
within - - O
8 - - O
h - - O
and - - O
T - - O
wave - - O
inversion - - O
in - - O
infarct - - O
related - - O
EKG - - O
leads - - O
within - - O
the - - O
first - - O
24 - - O
h - - O
after - - O
thrombolysis - - O
. - - O

For - - O
each - - O
night - - O
, - - O
the - - O
diary - - O
allowed - - O
the - - O
subjective - - O
measurement - - O
of - - O
bedtime - - O
, - - O
wake - - O
time - - O
, - - O
time - - O
in - - O
bed - - O
( - - O
TIB - - O
) - - O
, - - O
sleep - - O
efficiency - - O
, - - O
number - - O
of - - O
minutes - - O
of - - O
wake - - O
after - - O
sleep - - O
onset - - O
( - - O
WASO - - O
) - - O
, - - O
alertness - - O
on - - O
awakening - - O
, - - O
and - - O
percentage - - O
of - - O
morning - - O
needing - - O
an - - O
alarm - - O
( - - O
or - - O
a - - O
person - - O
functioning - - O
as - - O
one - - O
) - - O
. - - O

Mutational - - O
analysis - - O
of - - O
the - - O
L1 - - B-MUT
binding - - I-MUT
site - - I-MUT
of - - O
23S - - B-MUT
rRNA - - I-MUT
in - - I-MUT
Escherichia - - I-MUT
coli - - I-MUT
. - - O

We - - O
propose - - O
that - - O
the - - O
reduced - - O
responsiveness - - O
of - - O
CYP3A2 - - B-MUT
is - - O
the - - O
result - - O
of - - O
preferential - - O
binding - - O
of - - O
COUP-TF - - B-MUT
at - - O
the - - O
CYP3A2 - - B-MUT
DexRE-1 - - I-MUT
site - - I-MUT
. - - O

Location - - O
and - - O
orientation - - O
of - - O
an - - O
activating - - O
region - - O
in - - O
the - - O
Escherichia - - O
coli - - O
transcription - - O
factor - - O
, - - O
FNR - - B-MUT
. - - O

( - - O
iii - - O
) - - O
The - - O
mRNA - - O
is - - O
not - - O
efficiently - - O
polyadenylated - - O
at - - O
sequences - - O
in - - O
the - - O
3' - - O
end - - O
of - - O
the - - O
DHFR - - B-MUT
cDNA - - I-MUT
but - - O
rather - - O
uses - - O
polyadenylation - - O
signals - - O
downstream - - O
from - - O
the - - O
DHFR - - B-MUT
cDNA - - I-MUT
. - - O

Northern - - O
blot - - O
analysis - - O
with - - O
one - - O
of - - O
the - - O
PARNAs - - B-MUT
revealed - - O
a - - O
highly - - O
abundant - - O
signal - - O
of - - O
approximately - - O
2 - - O
. - - O
0 - - O
kilobases - - O
( - - O
kb - - O
) - - O
present - - O
in - - O
all - - O
cell - - O
lines - - O
tested - - O
. - - O

Therefore - - O
, - - O
the - - O
impaired - - O
floor - - O
plate - - O
development - - O
in - - O
oep - - B-MUT
mutants - - I-MUT
is - - O
not - - O
caused - - O
by - - O
the - - O
absence - - O
of - - O
the - - O
floor - - B-MUT
plate - - I-MUT
inducer - - I-MUT
shh - - I-MUT
. - - O

The - - O
cellular - - O
sequences - - O
5' - - O
to - - O
the - - O
viral - - O
integration - - O
site - - O
exhibited - - O
85 - - O
to - - O
97% - - O
identity - - O
to - - O
several - - O
sequences - - O
belonging - - O
to - - O
the - - O
mouse - - B-MUT
L1 - - I-MUT
family - - I-MUT
of - - O
long - - O
interspersed - - O
repetitive - - O
sequences - - O
. - - O

The - - O
gene - - O
is - - O
separated - - O
into - - O
four - - O
exons - - O
by - - O
three - - O
short - - O
introns - - O
, - - O
and - - O
the - - O
open - - O
reading - - O
frame - - O
consists - - O
of - - O
6660 - - O
base - - O
pairs - - O
( - - O
bp - - O
) - - O
capable - - O
of - - O
encoding - - O
a - - O
polypeptide - - O
of - - O
2220 - - O
amino - - O
acid - - O
residues - - O
. - - O

METHODS - - O
: - - O
IgG - - B-MUT
antibodies - - I-MUT
vs - - O
HHV-6 - - O
( - - O
anti-HHV-6-IgG - - B-MUT
) - - O
were - - O
determined - - O
by - - O
indirect - - O
immunofluorescence - - O
in - - O
100 - - O
IVDA - - O
( - - O
29 - - O
seronegative - - O
and - - O
71 - - O
seropositive - - O
for - - O
HIV-1 - - O
of - - O
which - - O
45 - - O
were - - O
in - - O
stage - - O
II - - O
and - - O
26 - - O
in - - O
IV-C1 - - O
of - - O
CDC - - O
) - - O
as - - O
well - - O
as - - O
in - - O
100 - - O
healthy - - O
subjects - - O
of - - O
a - - O
similar - - O
age - - O
( - - O
control - - O
group - - O
) - - O
. - - O

An - - O
analysis - - O
of - - O
sequence - - O
of - - O
the - - O
mutant - - B-MUT
recN - - I-MUT
gene - - I-MUT
revealed - - O
a - - O
G - - O
: - - O
C - - O
to - - O
T - - O
: - - O
A - - O
transversion - - O
near - - O
the - - O
3' - - O
end - - O
of - - O
the - - O
coding - - O
region - - O
. - - O

Overexpression - - O
of - - O
Sed5p - - B-MUT
allowed - - O
growth - - O
in - - O
the - - O
absence - - O
of - - O
Vti1p - - B-MUT
. - - O

Testosterone - - O
, - - O
free - - O
testosterone - - O
, - - O
non-sex - - O
hormone-binding - - O
globulin-bound - - O
testosterone - - O
, - - O
and - - O
free - - O
androgen - - O
index - - O
: - - O
which - - O
testosterone - - O
measurement - - O
is - - O
most - - O
relevant - - O
to - - O
reproductive - - O
and - - O
sexual - - O
function - - O
in - - O
men - - O
with - - O
epilepsy - - O
? - - O

Kodak - - O
XV-2 - - O
film - - O
is - - O
wrapped - - O
around - - O
a - - O
cylindrical - - O
water-filled - - O
phantom - - O
and - - O
the - - O
dose - - O
distribution - - O
is - - O
recorded - - O
. - - O

When - - O
two-dimensional - - O
polyacrylamide - - O
gel - - O
electrophoretic - - O
patterns - - O
of - - O
[ - - O
35S - - O
] - - O
methionine-labeled - - O
proteins - - O
secreted - - O
from - - O
cells - - O
infected - - O
with - - O
parental - - O
and - - O
recombinant - - O
viruses - - O
were - - O
compared - - O
, - - O
a - - O
spot - - O
missing - - O
from - - O
the - - O
latter - - O
corresponded - - O
in - - O
molecular - - O
weigh - - O
and - - O
isoelectric - - O
point - - O
with - - O
that - - O
predicted - - O
from - - O
the - - O
N1L - - B-MUT
ORF - - I-MUT
. - - O

T - - O
cells - - O
express - - O
two - - O
isoforms - - O
of - - O
S6k1 - - B-MUT
: - - O
a - - O
70 - - B-MUT
kDa - - I-MUT
cytoplasmic - - I-MUT
kinase - - I-MUT
and - - O
an - - O
85 - - O
kDa - - O
isoform - - O
that - - O
has - - O
a - - O
classic - - O
nuclear - - O
localisation - - O
. - - O

Western - - O
blot - - O
analysis - - O
showed - - O
a - - O
rapid - - O
corresponding - - O
increase - - O
in - - O
p21WAF1 - - B-MUT
CIP1 - - I-MUT
protein - - I-MUT
, - - I-MUT
whereas - - O
protein - - O
levels - - O
of - - O
another - - O
member - - O
of - - O
the - - O
cyclin-dependent - - O
kinase - - B-MUT
inhibitor - - I-MUT
family - - I-MUT
, - - I-MUT
p27kip1 - - O
, - - B-MUT
were - - O
unchanged - - O
. - - O

C - - B-MUT
EBPbeta - - I-MUT
LIP - - I-MUT
overexpressing - - I-MUT
HC11 - - O
cells - - O
did - - O
not - - O
express - - O
beta-casein - - O
mRNA - - B-MUT
( - - I-MUT
mammary - - O
epithelial - - O
cell - - O
differentiation - - O
marker - - O
) - - O
in - - O
response - - O
to - - O
lactogenic - - O
hormones - - O
. - - O

Effects - - O
of - - O
beta-adrenergic - - B-MUT
receptor - - I-MUT
blockade - - O
on - - O
airway - - O
conductance - - O
and - - O
lung - - O
volume - - O
in - - O
normal - - O
and - - O
asthmatic - - O
subjects - - O
. - - O

Co-transfection - - O
of - - O
the - - O
Sp1 - - B-MUT
expression - - O
plasmid - - O
and - - O
the - - O
-58 - - O
promoter - - O
construct - - O
into - - O
Drosophila - - O
Schneider - - O
cells - - O
revealed - - O
that - - O
Sp1 - - B-MUT
contributed - - O
to - - O
the - - O
kinase - - B-MUT
basal - - I-MUT
promoter - - I-MUT
activity - - O
by - - O
binding - - O
to - - O
the - - O
non-consensus - - O
site - - O
in - - O
the - - O
-58 - - O
region - - O
. - - O

Incidental - - O
findings - - O
in - - O
the - - O
epidermis - - O
and - - O
in - - O
the - - O
intraepidermal - - O
eccrine - - O
sweat - - O
duct - - O
units - - O
. - - O

Protein - - O
sequence - - O
analysis - - O
reveals - - O
that - - O
MAN1 - - B-MUT
shares - - O
a - - O
conserved - - O
globular - - O
domain - - O
of - - O
approximately - - O
40 - - O
amino - - O
acids - - O
, - - O
which - - O
we - - O
term - - O
the - - O
LEM - - B-MUT
module - - I-MUT
, - - O
with - - O
inner - - O
nuclear - - O
membrane - - O
proteins - - O
lamina-associated - - B-MUT
polypeptide - - I-MUT
2 - - I-MUT
and - - O
emerin - - B-MUT
. - - O

This - - O
shows - - O
that - - O
the - - O
characteristically - - O
diffuse - - O
banding - - O
pattern - - O
of - - O
plant - - O
nuclear - - O
proteins - - O
interacting - - O
with - - O
the - - O
G-box - - O
is - - O
also - - O
observed - - O
in - - O
a - - O
binding - - O
assay - - O
using - - O
only - - O
one - - O
recombinant - - B-MUT
GBF - - I-MUT
. - - O

Based - - O
on - - O
these - - O
results - - O
and - - O
because - - O
Cdc68 - - B-MUT
has - - O
been - - O
implicated - - O
as - - O
a - - O
regulator - - O
of - - O
chromatin - - O
structure - - O
, - - O
we - - O
postulate - - O
that - - O
polymerase - - B-MUT
alpha - - I-MUT
may - - O
interact - - O
with - - O
these - - O
proteins - - O
to - - O
gain - - O
access - - O
to - - O
its - - O
template - - O
or - - O
to - - O
origins - - O
of - - O
replication - - O
in - - O
vivo - - O
. - - O

Mutants - - O
lacking - - O
any - - O
tyrosine - - O
residues - - O
in - - O
the - - O
cytoplasmic - - O
domain - - O
maintain - - O
their - - O
ability - - O
to - - O
activate - - O
STAT5 - - B-MUT
and - - O
STAT1 - - B-MUT
but - - O
cannot - - O
activate - - O
STAT3 - - B-MUT
, - - O
implying - - O
that - - O
STAT5 - - B-MUT
and - - O
STAT1 - - B-MUT
activation - - O
does - - O
not - - O
require - - O
receptor - - O
tyrosine - - O
phosphorylation - - O
. - - O

Tyrosine - - O
112 - - O
of - - O
latent - - B-MUT
membrane - - I-MUT
protein - - I-MUT
2A - - I-MUT
is - - O
essential - - O
for - - O
protein - - B-MUT
tyrosine - - I-MUT
kinase - - I-MUT
loading - - O
and - - O
regulation - - O
of - - O
Epstein-Barr - - O
virus - - O
latency - - O
. - - O

The - - O
status - - O
of - - O
education - - O
and - - O
training - - O
programs - - O
in - - O
speech - - O
pathology - - O
and - - O
audiology--1971-72 - - O
. - - O

These - - O
results - - O
support - - O
the - - O
hypothesis - - O
that - - O
in - - O
the - - O
presence - - O
of - - O
tryptophan - - O
the - - O
ribosome - - O
translating - - O
tnaC - - B-MUT
blocks - - O
Rho's - - O
access - - O
to - - O
the - - O
boxA - - B-MUT
and - - O
rut - - B-MUT
sites - - I-MUT
, - - O
thereby - - O
preventing - - O
transcription - - O
termination - - O
. - - O

Recently - - O
, - - O
an - - O
alternatively - - O
spliced - - O
form - - O
of - - O
c-myb-encoded - - B-MUT
mRNA - - I-MUT
has - - O
been - - O
identified - - O
in - - O
murine - - O
cells - - O
containing - - O
either - - O
normal - - O
or - - O
rearranged - - O
c-myb - - B-MUT
genes - - I-MUT
. - - O

A - - O
comparative - - O
study - - O
was - - O
undertaken - - O
between - - O
an - - O
enzymatic - - O
immunohistochemical - - O
technique - - O
( - - O
EIT - - O
) - - O
developed - - O
for - - O
the - - O
diagnosis - - O
of - - O
human - - O
trichinellosis - - O
and - - O
the - - O
indirect - - O
immunofluorescence - - O
test - - O
( - - O
IIF - - O
) - - O
, - - O
analysing - - O
sera - - O
from - - O
outbreaks - - O
of - - O
human - - O
trichinellosis - - O
in - - O
Argentina - - O
. - - O

Endogenous - - O
RMP - - B-MUT
was - - O
immunologically - - O
detected - - O
interacting - - O
with - - O
assembled - - O
RPB5 - - B-MUT
in - - O
RNA - - B-MUT
polymerase - - I-MUT
in - - O
mammalian - - O
cells - - O
. - - O

Transcriptional - - O
activation - - O
by - - O
thyroid - - O
hormone - - O
( - - O
T3 - - O
) - - O
requires - - O
interactions - - O
between - - O
the - - O
T3 - - B-MUT
receptor - - I-MUT
( - - O
TR - - B-MUT
) - - O
and - - O
T3 - - B-MUT
response - - I-MUT
elements - - I-MUT
( - - O
TREs - - B-MUT
) - - O
composed - - O
of - - O
two - - O
copies - - O
of - - O
sequences - - O
related - - O
to - - O
AGGTCA - - B-MUT
. - - O

Fufang - - O
wuzi - - O
yanzong - - O
pills - - O
have - - O
strong - - O
leukogenic - - O
effect - - O
on - - O
cyclophosphamide - - O
induced - - O
leukopenia - - O
in - - O
mice - - O
. - - O

Rhizobium - - O
meliloti - - O
large - - O
plasmid - - O
pRmeGR4b - - O
carries - - O
the - - O
nodulation - - O
competitiveness - - O
locus - - O
nfe - - B-MUT
responsible - - O
for - - O
the - - O
nodulation - - O
efficiency - - O
and - - O
competitive - - O
ability - - O
of - - O
strain - - O
GR4 - - O
on - - O
alfalfa - - O
roots - - O
. - - O

Sp1 - - B-MUT
binds - - O
the - - O
CTC - - O
repeat - - O
with - - O
an - - O
affinity - - O
, - - O
KD - - O
= - - O
0 - - O
. - - O
37 - - O
nM - - O
, - - O
at - - O
least - - O
as - - O
high - - O
as - - O
the - - O
consensus - - O
GC - - O
box - - O
. - - O

Clinical - - O
aspects - - O
of - - O
early - - O
increase - - O
in - - O
serum - - O
gamma-glutamyl - - B-MUT
transferase - - I-MUT
in - - O
cerebral - - O
infarction - - O
. - - O

However - - O
, - - O
bilateral - - O
diffuse - - O
pulmonary - - O
infiltrations - - O
developed - - O
21 - - O
days - - O
later - - O
. - - O

A - - O
cause - - O
of - - O
increase - - O
of - - O
alkaline - - B-MUT
phosphatase - - I-MUT
in - - O
children - - O
. - - O

The - - O
physical - - O
linkage - - O
of - - O
the - - O
FHR2 - - B-MUT
and - - O
the - - O
factor - - B-MUT
H - - I-MUT
genes - - I-MUT
provides - - O
additional - - O
evidence - - O
for - - O
a - - O
close - - O
relatedness - - O
of - - O
complement - - B-MUT
factor - - I-MUT
H - - I-MUT
and - - O
the - - O
factor - - B-MUT
H-related - - I-MUT
proteins - - I-MUT
. - - O

Protein - - B-MUT
kinase - - I-MUT
A-Ialpha - - I-MUT
subunit-directed - - O
antisense - - O
inhibition - - O
of - - O
ovarian - - O
cancer - - O
cell - - O
growth - - O
: - - O
crosstalk - - O
with - - O
tyrosine - - B-MUT
kinase - - I-MUT
signaling - - O
pathway - - O
. - - O

BiP670 - - B-MUT
retains - - O
basal - - O
and - - O
Ca2+ - - O
ionophore - - O
A23187-inducible - - O
activities - - O
. - - O

This - - O
is - - O
in - - O
contrast - - O
to - - O
PPARgamma2 - - B-MUT
, - - O
which - - O
was - - O
previously - - O
shown - - O
to - - O
be - - O
phosphorylated - - O
at - - O
a - - O
single - - O
site - - O
in - - O
a - - O
motif - - O
that - - O
is - - O
not - - O
homologous - - O
to - - O
the - - O
sites - - O
now - - O
described - - O
in - - O
PPARalpha - - B-MUT
. - - O

Materials - - O
science - - O
studies - - O
on - - O
the - - O
soldering - - O
of - - O
different - - O
orthodontic - - O
wires - - O
. - - O

Also - - O
, - - O
the - - O
EWS - - B-MUT
protein - - I-MUT
stimulates - - O
transcription - - O
mediated - - O
by - - O
the - - O
COOH-terminal - - O
transactivation - - O
domain - - O
of - - O
the - - O
cofactor - - O
CREB-binding - - B-MUT
protein - - I-MUT
( - - O
CBP - - B-MUT
) - - O
. - - O

This - - O
is - - O
the - - O
first - - O
study - - O
in - - O
which - - O
mutation - - O
screening - - O
has - - O
been - - O
performed - - O
for - - O
both - - O
the - - O
EXT1 - - B-MUT
and - - O
EXT2 - - B-MUT
genes - - I-MUT
prior - - O
to - - O
any - - O
linkage - - O
analysis - - O
. - - O

In - - O
a - - O
stepwise - - O
logistic - - O
regression - - O
analysis - - O
of - - O
SPT - - O
and - - O
RAST - - O
data - - O
, - - O
the - - O
occurrence - - O
of - - O
serum - - B-MUT
IgE - - I-MUT
antibodies - - I-MUT
to - - I-MUT
P - - I-MUT
. - - I-MUT
orbiculare - - I-MUT
had - - O
the - - O
highest - - O
explanatory - - O
value - - O
for - - O
current - - O
eczema - - O
. - - O

Group - - O
I - - O
consisted - - O
of - - O
six - - O
noncholestatic - - O
patients - - O
; - - O
group - - O
II - - O
consisted - - O
of - - O
nine - - O
mildly - - O
cholestatic - - O
patients - - O
with - - O
mild - - O
hepatic - - O
impairment - - O
( - - O
conjugated - - O
bilirubin - - O
, - - O
47 - - O
mumol - - O
liter-1 - - O
; - - O
alkaline - - B-MUT
phosphatase - - I-MUT
, - - O
280 - - O
IU - - O
liter-1 - - O
; - - O
gamma-glutamyltranspeptidase - - B-MUT
, - - O
190 - - O
IU - - O
liter-1 - - O
) - - O
; - - O
group - - O
III - - O
consisted - - O
of - - O
six - - O
benign - - O
intrahepatic - - O
cholestatic - - O
patients - - O
with - - O
high - - O
isolated - - O
conjugated - - O
hyperbilirubinemia - - O
( - - O
98 - - O
. - - O
1 - - O
mumol - - O
liter-1 - - O
) - - O
. - - O

Genitography - - O
in - - O
intersexual - - O
states - - O
. - - O

To - - O
understand - - O
the - - O
function - - O
of - - O
receptor-linked - - B-MUT
tyrosine - - I-MUT
phosphatases - - I-MUT
in - - O
neural - - O
development - - O
, - - O
we - - O
sought - - O
to - - O
identify - - O
LAR - - B-MUT
isoforms - - I-MUT
preferentially - - O
expressed - - O
in - - O
the - - O
nervous - - O
system - - O
and - - O
cellular - - O
processes - - O
regulating - - O
LAR - - B-MUT
alternative - - O
splicing - - O
. - - O

There - - O
was - - O
a - - O
positive - - O
correlation - - O
between - - O
pyridinium - - O
cross-link - - O
excretion - - O
and - - O
thyroid - - O
hormone - - O
concentrations - - O
. - - O

An - - O
analysis - - O
of - - O
the - - O
steady - - O
state - - O
RNA - - O
levels - - O
in - - O
T-lymphoid - - O
cell - - O
lines - - O
showed - - O
that - - O
at - - O
least - - O
three - - O
different - - O
incomplete - - O
proviral - - O
transcripts - - O
and - - O
their - - O
spliced - - O
products - - O
made - - O
up - - O
the - - O
majority - - O
of - - O
expressed - - O
RD-114 - - B-MUT
mRNA - - I-MUT
, - - O
and - - O
further - - O
demonstrated - - O
that - - O
partially - - O
deleted - - O
proviral - - O
loci - - O
have - - O
the - - O
potential - - O
to - - O
be - - O
transcriptionally - - O
vigorous - - O
in - - O
certain - - O
feline - - O
cell - - O
types - - O
. - - O

The - - O
ATR-X - - O
syndrome - - O
results - - O
from - - O
mutations - - O
of - - O
the - - O
XH2 - - B-MUT
gene - - I-MUT
, - - O
located - - O
on - - O
the - - O
X - - O
chromosome - - O
( - - O
Xq13 - - O
. - - O
3 - - O
) - - O
and - - O
coding - - O
for - - O
a - - O
transacting - - O
factor - - O
which - - O
regulates - - O
gene - - O
expression - - O
. - - O

MPO - - O
was - - O
labeled - - O
with - - O
1 - - O
mCi - - O
125I - - O
by - - O
a - - O
technique - - O
of - - O
self-labeling - - O
in - - O
the - - O
presence - - O
of - - O
10 - - O
( - - O
-4 - - O
) - - O
M - - O
hydrogen - - O
peroxide - - O
. - - O

These - - O
data - - O
establish - - O
Smd1p - - B-MUT
as - - O
a - - O
required - - O
component - - O
of - - O
the - - O
cellular - - O
splicing - - O
apparatus - - O
and - - O
a - - O
factor - - O
in - - O
snRNA - - O
maturation - - O
and - - O
stability - - O
. - - O

Erratum - - O
to - - O
: - - O
corticostriatal - - O
and - - O
corticosubthalamic - - O
input - - O
zones - - O
from - - O
the - - O
presupplementary - - O
motor - - O
area - - O
in - - O
the - - O
macaque - - O
monkey - - O
: - - O
comparison - - O
with - - O
the - - O
input - - O
zones - - O
from - - O
the - - O
supplementary - - O
motor - - O
area - - O
. - - O

Their - - O
use - - O
resulted - - O
in - - O
a - - O
sensitivity - - O
of - - O
73% - - O
and - - O
a - - O
specificity - - O
of - - O
74% - - O
with - - O
regard - - O
to - - O
predictability - - O
of - - O
ALT - - B-MUT
levels - - O
increasing - - O
during - - O
the - - O
trial - - O
. - - O

It - - O
contains - - O
25 - - O
exons - - O
coding - - O
for - - O
a - - O
4 - - O
. - - O
7kb - - O
transcript - - O
including - - O
large - - O
5'- - - O
and - - O
3'- - - O
( - - O
1218bp - - O
and - - O
701bp - - O
, - - O
respectively - - O
) - - O
untranslated - - O
regions - - O
( - - O
UTRs - - O
) - - O
. - - O

This - - O
repression - - O
was - - O
mediated - - O
through - - O
binding - - O
to - - O
the - - O
E2 - - B-MUT
DNA-binding - - I-MUT
site - - I-MUT
immediately - - O
upstream - - O
of - - O
the - - O
P105 - - B-MUT
promoter - - O
TATA - - O
box - - O
and - - O
could - - O
be - - O
abrogated - - O
by - - O
preincubation - - O
of - - O
the - - O
HPV-18 - - B-MUT
P105 - - I-MUT
promoter - - I-MUT
template - - O
with - - O
the - - O
nuclear - - O
extract - - O
allowing - - O
the - - O
formation - - O
of - - O
the - - O
preinitiation - - O
complex - - O
. - - O

These - - O
results - - O
were - - O
corroborated - - O
in - - O
a - - O
subsequent - - O
study - - O
in - - O
which - - O
30 - - O
hypogonadal - - O
men - - O
were - - O
supplemented - - O
with - - O
SLT - - O
5 - - O
mg - - O
three - - O
times - - O
daily - - O
for - - O
6 - - O
months - - O
. - - O

We - - O
demonstrate - - O
here - - O
that - - O
the - - O
-DEDDDL - - B-MUT
sequence - - I-MUT
stabilizes - - O
GDP - - O
binding - - O
to - - O
Ran - - B-MUT
, - - O
and - - O
that - - O
the - - O
domain - - O
is - - O
required - - O
for - - O
high - - O
affinity - - O
interaction - - O
with - - O
a - - O
Ran-binding - - B-MUT
protein - - I-MUT
, - - O
HTF9A - - B-MUT
RanBP1 - - I-MUT
. - - I-MUT

We - - O
conclude - - O
that - - O
c-Abl - - B-MUT
activates - - O
c-myc - - B-MUT
transcription - - O
indirectly - - O
with - - O
no - - O
requirement - - O
for - - O
DNA - - O
binding - - O
by - - O
c-Abl - - B-MUT
. - - O

Differential - - O
regulation - - O
of - - O
the - - O
pre-C - - O
and - - O
pregenomic - - O
promoters - - O
of - - O
human - - O
hepatitis - - O
B - - O
virus - - O
by - - O
members - - O
of - - O
the - - O
nuclear - - B-MUT
receptor - - I-MUT
superfamily - - I-MUT
. - - O

Despite - - O
this - - O
DNA - - O
binding - - O
activity - - O
, - - O
AP-1 - - B-MUT
reporter - - I-MUT
activity - - O
was - - O
suppressed - - O
in - - O
these - - O
cells - - O
. - - O

Multiple - - O
mitogen-activated - - B-MUT
protein - - I-MUT
kinase - - I-MUT
signaling - - O
pathways - - O
connect - - O
the - - O
cot - - B-MUT
oncoprotein - - I-MUT
to - - O
the - - O
c-jun - - B-MUT
promoter - - I-MUT
and - - O
to - - O
cellular - - O
transformation - - O
. - - O

Inspection - - O
of - - O
enhancer - - O
mutants - - O
suggests - - O
that - - O
trans-activation - - O
by - - O
hLEF - - B-MUT
GAL4 - - I-MUT
is - - I-MUT
especially - - O
dependent - - O
on - - O
TCF-2 - - O
, - - B-MUT
a - - O
distinct - - O
T-cell-enriched - - O
protein - - O
that - - O
binds - - O
to - - O
sequences - - O
flanking - - O
the - - O
hLEF-binding - - O
site - - B-MUT
in - - I-MUT
the - - O
enhancer - - O
. - - O

Mapping - - O
features - - O
of - - O
HIV-1 - - B-MUT
integrase - - I-MUT
near - - O
selected - - O
sites - - O
on - - O
viral - - O
and - - O
target - - O
DNA - - O
molecules - - O
in - - O
an - - O
active - - O
enzyme-DNA - - O
complex - - O
by - - O
photo-cross-linking - - O
. - - O

Surprisingly - - O
, - - O
calf - - B-MUT
thymus - - I-MUT
CstF - - I-MUT
contained - - O
an - - O
additional - - O
, - - O
novel - - O
form - - O
of - - O
the - - O
64-kDa - - O
subunit - - O
with - - O
a - - O
molecular - - O
mass - - O
of - - O
70 - - O
kDa - - O
. - - O

The - - O
circadian - - O
rhythm - - O
, - - O
however - - O
, - - O
was - - O
not - - O
affected - - O
and - - O
the - - O
difference - - O
between - - O
minimum - - O
( - - O
12 - - O
. - - O
00 - - O
h - - O
) - - O
and - - O
maximum - - O
( - - O
18 - - O
. - - O
50 - - O
h - - O
) - - O
serum - - O
concentrations - - O
was - - O
31 - - O
. - - O
3% - - O
. - - O

In - - O
vitro - - O
DNase - - B-MUT
I - - I-MUT
footprinting - - O
showed - - O
that - - O
OxyR-C199S - - B-MUT
protected - - O
Pmom - - B-MUT
from - - O
-104 - - O
to - - O
-46 - - O
on - - O
the - - O
top - - O
strand - - O
and - - O
produced - - O
a - - O
protection - - O
pattern - - O
characteristic - - O
of - - O
reduced - - B-MUT
wild-type - - I-MUT
OxyR - - I-MUT
. - - O

Growth - - B-MUT
factors - - I-MUT
induce - - O
the - - O
expression - - O
of - - O
the - - O
immediate - - B-MUT
early - - I-MUT
gene - - I-MUT
products - - I-MUT
MAP - - B-MUT
kinase - - I-MUT
phosphatase-1 - - I-MUT
( - - O
MKP-1 - - B-MUT
) - - O
, - - O
c-Fos - - B-MUT
and - - O
c-Jun - - B-MUT
. - - O

There - - O
are - - O
regions - - O
with - - O
long - - O
runs - - O
of - - O
up - - O
to - - O
45% - - O
C - - O
or - - O
35% - - O
G - - O
residues - - O
. - - O

7 - - O
. - - O

Three - - O
monopolar - - O
electrodes - - O
were - - O
inserted - - O
into - - O
the - - O
left - - O
and - - O
right - - O
lateral - - O
vestibulospinal - - O
tract - - O
( - - O
LVST - - O
) - - O
and - - O
medial - - O
vestibulospinal - - O
tract - - O
( - - O
MVST - - O
) - - O
of - - O
the - - O
C1 - - O
segment - - O
, - - O
to - - O
determine - - O
the - - O
pathway - - O
of - - O
axons - - O
. - - O

The - - O
corresponding - - O
inhibition - - O
of - - O
acid - - B-MUT
phosphatase - - I-MUT
activity - - O
in - - O
control - - O
male - - O
and - - O
female - - O
guinea - - O
pigs - - O
was - - O
15 - - O
. - - O
91% - - O
and - - O
20 - - O
. - - O
33% - - O
respectively - - O
. - - O

It - - O
also - - O
contains - - O
a - - O
picornaviral - - B-MUT
3C-like - - I-MUT
protease - - I-MUT
domain - - I-MUT
and - - O
two - - O
papain-like - - B-MUT
protease - - I-MUT
domains - - I-MUT
. - - O

It - - O
is - - O
concluded - - O
that - - O
stereotypy - - O
can - - O
be - - O
evoked - - O
also - - O
in - - O
the - - O
case - - O
when - - O
the - - O
striatal - - O
dopaminergic - - O
tone - - O
is - - O
normal - - O
or - - O
even - - O
below - - O
normal - - O
: - - O
it - - O
is - - O
the - - O
equilibrium - - O
of - - O
the - - O
striatal - - O
cholinergic-dopaminergic - - O
systems - - O
which - - O
must - - O
be - - O
shifted - - O
towards - - O
dopamine - - O
, - - O
which - - O
is - - O
necessary - - O
for - - O
the - - O
development - - O
of - - O
this - - O
behavioral - - O
manifestation - - O
. - - O

All - - O
other - - O
normal - - O
and - - O
transformed - - O
lymphoid - - O
and - - O
nonlymphoid - - O
cell - - O
lines - - O
and - - O
normal - - O
tissues - - O
were - - O
negative - - O
for - - O
PANG - - B-MUT
expression - - O
except - - O
for - - O
the - - O
brain - - O
, - - O
wherein - - O
unique - - O
4 - - O
. - - O
0- - - O
and - - O
6 - - O
. - - O
1-kb - - O
transcripts - - O
were - - O
detected - - O
. - - O

A - - O
cDNA - - O
, - - O
cak1At - - B-MUT
, - - O
was - - O
isolated - - O
that - - O
suppressed - - O
the - - O
CAK - - B-MUT
mutation - - I-MUT
in - - O
budding - - O
yeast - - O
, - - O
and - - O
it - - O
also - - O
complemented - - O
a - - O
fission - - B-MUT
yeast - - I-MUT
CAK - - I-MUT
mutant - - I-MUT
. - - O
cak1At - - B-MUT
encodes - - O
a - - O
protein - - O
related - - O
to - - O
animal - - B-MUT
CAKs - - I-MUT
. - - O

The - - O
main - - O
aim - - O
of - - O
the - - O
contribution - - O
, - - O
which - - O
opens - - O
an - - O
arena - - O
for - - O
discussion - - O
on - - O
the - - O
Rivista - - O
dell'Infermiere - - O
is - - O
to - - O
critically - - O
appraise - - O
published - - O
research - - O
works - - O
focusing - - O
both - - O
on - - O
strengths - - O
and - - O
novelty - - O
and - - O
weaknesses - - O
in - - O
the - - O
hypothesis - - O
formulation - - O
, - - O
methods - - O
and - - O
instruments - - O
used - - O
, - - O
discussion - - O
of - - O
results - - O
. - - O

The - - O
result - - O
suggests - - O
that - - O
this - - O
non-invasive - - O
TTD - - O
method - - O
is - - O
easily - - O
available - - O
and - - O
useful - - O
in - - O
monitoring - - O
the - - O
intraoperative - - O
cardiac - - O
output - - O
. - - O

The - - O
HGF-induced - - O
cell - - O
motility - - O
was - - O
mimicked - - O
by - - O
12-0-tetradecanoyl-phorbol-13-acetate - - O
, - - O
a - - O
protein - - B-MUT
kinase - - I-MUT
C-activating - - O
phorbol - - O
ester - - O
, - - O
but - - O
not - - O
by - - O
Ca2+ - - O
ionophore - - O
. - - O

These - - O
results - - O
demonstrate - - O
that - - O
a - - O
class - - O
of - - O
proline-rich - - O
activator - - O
proteins - - O
and - - O
RNA - - B-MUT
polymerase - - I-MUT
II - - I-MUT
possess - - O
a - - O
common - - O
structural - - O
and - - O
functional - - O
component - - O
which - - O
can - - O
interact - - O
with - - O
the - - O
same - - O
target - - O
in - - O
the - - O
general - - O
transcription - - O
machinery - - O
. - - O

In - - O
this - - O
paper - - O
, - - O
such - - O
lesions - - O
in - - O
two - - O
cases - - O
were - - O
evaluated - - O
by - - O
ultrasonography - - O
. - - O

Another - - O
mutant - - O
, - - O
T255A - - O
, - - O
lost - - O
the - - O
ability - - O
to - - O
bind - - O
E4orf6 - - B-MUT
, - - O
but - - O
unexpectedly - - O
, - - O
viral - - O
late-gene - - O
expression - - O
was - - O
not - - O
affected - - O
. - - O

In - - O
addition - - O
, - - O
they - - O
display - - O
common - - O
features - - O
that - - O
make - - O
them - - O
strikingly - - O
related - - O
to - - O
snoRNA - - B-MUT
U14 - - I-MUT
. - - O

The - - O
second - - O
class - - O
of - - O
cDNA - - O
hybridized - - O
to - - O
a - - O
13 - - O
kb - - O
transcript - - O
, - - O
which - - O
was - - O
approximately - - O
twice - - O
as - - O
large - - O
as - - O
the - - O
mammalian - - B-MUT
lactase - - I-MUT
mRNA - - I-MUT
. - - O

Five - - O
modalities - - O
of - - O
nonpharmacologic - - O
approaches - - O
are - - O
recommended - - O
at - - O
present - - O
for - - O
lifestyle - - O
modification - - O
and - - O
control - - O
of - - O
arterial - - O
blood - - O
pressure - - O
elevation - - O
: - - O
1 - - O
) - - O
weight - - O
reduction - - O
to - - O
ideal - - O
body - - O
weight - - O
, - - O
since - - O
it - - O
reduces - - O
risk - - O
of - - O
hypertension - - O
as - - O
well - - O
as - - O
overall - - O
cardiovascular - - O
morbidity - - O
and - - O
mortality - - O
; - - O
2 - - O
) - - O
dietary - - O
sodium - - O
restriction - - O
to - - O
less - - O
than - - O
2 - - O
g - - O
a - - O
day - - O
, - - O
without - - O
assurance - - O
that - - O
it - - O
will - - O
normalize - - O
arterial - - O
pressure - - O
although - - O
it - - O
may - - O
help - - O
reduce - - O
dosage - - O
and - - O
numbers - - O
of - - O
prescribed - - O
antihypertensive - - O
drugs - - O
; - - O
3 - - O
) - - O
moderation - - O
of - - O
alcohol - - O
consumption - - O
to - - O
less - - O
than - - O
1 - - O
ounce - - O
a - - O
day - - O
; - - O
4 - - O
) - - O
a - - O
regular - - O
isotonic - - O
exercise - - O
program - - O
; - - O
and - - O
5 - - O
) - - O
cessation - - O
of - - O
tobacco - - O
consumption - - O
. - - O

The - - O
corresponding - - O
differences - - O
in - - O
FVIIa - - B-MUT
and - - O
PAI-1 - - B-MUT
were - - O
not - - O
statistically - - O
significant - - O
. - - O

Deletion - - O
mapping - - O
of - - O
the - - O
human - - B-MUT
presenilin-1 - - I-MUT
( - - O
PS1 - - B-MUT
) - - O
promoter - - O
delineated - - O
the - - O
most - - O
active - - O
fragment - - O
from - - O
-118 - - O
to - - O
+178 - - O
in - - O
relation - - O
to - - O
the - - O
transcription - - O
start - - O
site - - O
mapped - - O
in - - O
this - - O
study - - O
, - - O
in - - O
both - - O
human - - O
neuroblastoma - - O
SK-N-SH - - O
and - - O
hepatoma - - O
HepG2 - - O
cells - - O
. - - O

Ariga - - O
, - - O
Biochem - - O
. - - O

The - - O
feed - - O
given - - O
to - - O
young - - O
broiler - - O
chickens - - O
was - - O
contaminated - - O
artificially - - O
with - - O
Salmonella - - O
kedougou - - O
, - - O
a - - O
serotype - - O
associated - - O
with - - O
both - - O
subclinical - - O
infections - - O
in - - O
commercially - - O
reared - - O
chickens - - O
and - - O
food - - O
poisoning - - O
in - - O
humans - - O
. - - O

Src - - B-MUT
homology - - I-MUT
( - - O
SH - - B-MUT
) - - O
domain - - O
dependent - - O
protein-protein - - O
interactions - - O
are - - O
important - - O
to - - O
tyrosine - - B-MUT
kinase - - I-MUT
receptor - - I-MUT
signal - - O
transduction - - O
. - - O

J - - O
. - - O

It - - O
suggests - - O
a - - O
sequence - - O
of - - O
surgical - - O
planning - - O
that - - O
can - - O
prevent - - O
them - - O
and - - O
also - - O
offers - - O
ways - - O
of - - O
dealing - - O
with - - O
the - - O
problems - - O
should - - O
they - - O
occur - - O
. - - O

To - - O
gain - - O
insight - - O
into - - O
the - - O
possible - - O
involvement - - O
of - - O
p21 - - B-MUT
in - - O
liver - - O
cell - - O
growth - - O
, - - O
the - - O
expression - - O
and - - O
regulation - - O
of - - O
the - - O
p21 - - B-MUT
gene - - I-MUT
was - - O
evaluated - - O
in - - O
rodent - - O
models - - O
of - - O
liver - - O
regeneration - - O
and - - O
specimens - - O
of - - O
human - - O
liver - - O
diseases - - O
. - - O

In - - O
a - - O
randomised - - O
double-blind - - O
study - - O
, - - O
46 - - O
first - - O
episode - - O
schizophrenics - - O
were - - O
given - - O
pimozide - - O
or - - O
flupenthixol - - O
for - - O
up - - O
to - - O
5 - - O
weeks - - O
; - - O
the - - O
mean - - O
daily - - O
dose - - O
at - - O
the - - O
end - - O
was - - O
18 - - O
. - - O
8 - - O
mg - - O
pimozide - - O
and - - O
20 - - O
mg - - O
flupenthixol - - O
. - - O

A - - O
limited - - O
study - - O
in - - O
a - - O
glassware - - O
factory - - O
( - - O
As2O3 - - O
exposure - - O
) - - O
involving - - O
the - - O
measurement - - O
of - - O
total - - O
airborne - - O
arsenic - - O
, - - O
the - - O
determination - - O
of - - O
urinary - - O
arsenic - - O
, - - O
and - - O
the - - O
evaluation - - O
of - - O
hand - - O
and - - O
mouth - - O
contamination - - O
by - - O
arsenic - - O
before - - O
and - - O
after - - O
the - - O
workshift - - O
suggests - - O
that - - O
the - - O
high - - O
urinary - - O
arsenic - - O
levels - - O
( - - O
300 - - O
microgram - - O
g - - O
creatinine - - O
) - - O
are - - O
likely - - O
to - - O
be - - O
more - - O
related - - O
to - - O
an - - O
increased - - O
oral - - O
intake - - O
from - - O
contaminated - - O
hands - - O
than - - O
to - - O
an - - O
increased - - O
absorption - - O
from - - O
the - - O
lungs - - O
. - - O

The - - O
enzyme - - O
activities - - O
studied - - O
are - - O
important - - O
elements - - O
in - - O
the - - O
pathophysiology - - O
of - - O
dental - - O
caries - - O
and - - O
may - - O
even - - O
be - - O
addressed - - O
as - - O
virulence - - O
factors - - O
. - - O

A - - O
central - - O
finding - - O
is - - O
the - - O
identification - - O
of - - O
a - - O
GC-rich - - O
sequence - - O
in - - O
the - - O
-99 - - O
-91 - - O
Cp - - O
region - - O
that - - O
is - - O
essential - - O
for - - O
oriPI-EBNA1-independent - - O
as - - O
well - - O
as - - O
oriPI-EBNA1-dependent - - O
activity - - O
of - - O
the - - O
promoter - - O
. - - O

Moreover - - O
, - - O
we - - O
found - - O
that - - O
cyclin - - B-MUT
E - - I-MUT
, - - O
in - - O
contrast - - O
to - - O
cyclin - - B-MUT
D1 - - I-MUT
, - - O
was - - O
required - - O
for - - O
the - - O
G1 - - O
S - - O
transition - - O
even - - O
in - - O
cells - - O
lacking - - O
retinoblastoma - - O
protein - - B-MUT
function - - I-MUT
. - - O

In - - O
patients - - O
resistant - - O
to - - O
VAD - - O
, - - O
high-dose - - O
therapies - - O
with - - O
intravenous - - O
melphalan - - O
, - - O
a - - O
CBV - - O
combination - - O
( - - O
cyclophosphamide-BCNU-VP-16 - - O
) - - O
or - - O
an - - O
EDAP - - O
regimen - - O
( - - O
VP-16 - - O
-platinum - - O
) - - O
produced - - O
responses - - O
in - - O
about - - O
40% - - O
of - - O
patients - - O
. - - O

Whereas - - O
p82 - - B-MUT
expression - - O
had - - O
no - - O
effect - - O
on - - O
ERK2 - - B-MUT
activation - - O
by - - O
p126 - - B-MUT
, - - O
p70 - - B-MUT
completely - - O
abrogated - - O
this - - O
activity - - O
. - - O

We - - O
tested - - O
10 - - O
rats - - O
with - - O
electrophysiologically - - O
guided - - O
, - - O
ibotenic - - O
acid - - O
lesions - - O
of - - O
the - - O
PBN - - O
( - - O
PBNx - - O
) - - O
to - - O
determine - - O
whether - - O
they - - O
could - - O
acquire - - O
a - - O
LiCl-induced - - O
CTA - - O
to - - O
l-alanine - - O
( - - O
0 - - O
. - - O
3 - - O
M - - O
) - - O
or - - O
demonstrate - - O
a - - O
sodium - - O
appetite - - O
following - - O
furosemide - - O
treatment - - O
and - - O
overnight - - O
access - - O
to - - O
sodium - - O
deficient - - O
chow - - O
. - - O

Electrophoretic - - O
mobility - - O
shift - - O
assays - - O
and - - O
competition - - O
experiments - - O
showed - - O
that - - O
site - - O
A - - O
is - - O
recognized - - O
by - - O
an - - O
NF1 - - B-MUT
protein - - I-MUT
. - - O

Drosophila - - B-MUT
orthodenticle - - I-MUT
( - - O
otd - - B-MUT
) - - O
and - - O
murine - - B-MUT
Otx - - I-MUT
genes - - I-MUT
exemplify - - O
this - - O
, - - O
both - - O
in - - O
terms - - O
of - - O
expression - - O
patterns - - O
and - - O
mutant - - O
phenotypes - - O
. - - O

The - - O
ARG - - B-MUT
SH2 - - B-MUT
domain - - I-MUT
exhibited - - O
relatively - - O
weak - - O
affinity - - O
for - - O
BCR - - B-MUT
and - - O
was - - O
determined - - O
to - - O
bind - - O
about - - O
10-fold - - O
less - - O
strongly - - O
than - - O
the - - O
ABL - - B-MUT
SH2 - - B-MUT
domain - - I-MUT
. - - O

At - - O
an - - O
ambient - - O
temperature - - O
of - - O
25 - - O
degrees - - O
C - - O
, - - O
the - - O
responses - - O
to - - O
spinal - - O
cooling - - O
are - - O
reduced - - O
during - - O
the - - O
dark - - O
phase - - O
. - - O

Time - - O
delay - - O
effects - - O
on - - O
the - - O
tensile - - O
bond - - O
strength - - O
developed - - O
by - - O
the - - O
Silicoater - - O
. - - O

Liver - - O
TG - - O
and - - O
serum - - O
NEFA - - O
concentrations - - O
were - - O
positively - - O
correlated - - O
. - - O

We - - O
show - - O
that - - O
HRI - - B-MUT
and - - O
dsRNA-PK - - B-MUT
phosphorylate - - O
yeast - - B-MUT
eIF-2 - - I-MUT
alpha - - I-MUT
in - - O
vitro - - O
and - - O
in - - O
vivo - - O
and - - O
functionally - - O
substitute - - O
for - - O
GCN2 - - B-MUT
protein - - I-MUT
to - - O
stimulate - - O
GCN4 - - B-MUT
translation - - O
in - - O
yeast - - O
. - - O

Two - - O
soybean - - O
cDNA - - O
clones - - O
, - - O
SPK-3 - - B-MUT
and - - O
SPK-4 - - B-MUT
, - - O
encoding - - O
putative - - O
protein - - B-MUT
kinases - - I-MUT
were - - O
isolated - - O
and - - O
characterized - - O
. - - O

At - - O
60 - - O
days - - O
the - - O
amount - - O
of - - O
gangliosides - - O
was - - O
on - - O
average - - O
lower - - O
in - - O
females - - O
than - - O
in - - O
males - - O
, - - O
even - - O
if - - O
with - - O
some - - O
exception - - O
. - - O

Mechanism - - O
in - - O
the - - O
sequential - - O
control - - O
of - - O
cell - - O
morphology - - O
and - - O
S - - O
phase - - O
entry - - O
by - - O
epidermal - - B-MUT
growth - - I-MUT
factor - - I-MUT
involves - - O
distinct - - O
MEK - - B-MUT
ERK - - I-MUT
activations - - I-MUT
. - - O

Eleven - - O
strains - - O
of - - O
Fusarium - - O
poae - - O
and - - O
F - - O
. - - O
sporotrichioides - - O
from - - O
the - - O
U - - O
. - - O
S - - O
. - - O
S - - O
. - - O
R - - O
. - - O
and - - O
7 - - O
strains - - O
of - - O
these - - O
species - - O
and - - O
one - - O
of - - O
F - - O
. - - O
sporotrichioides - - O
var - - O
. - - O
tricinctum - - O
from - - O
U - - O
. - - O
S - - O
. - - O
A - - O
. - - O
and - - O
France - - O
have - - O
been - - O
compared - - O
as - - O
to - - O
their - - O
capacity - - O
to - - O
yield - - O
T-2 - - B-MUT
toxin - - I-MUT
. - - O

In - - O
a - - O
randomized - - O
double-blind - - O
cross-over - - O
study - - O
, - - O
the - - O
subjects - - O
received - - O
theophylline - - O
5 - - O
mg - - O
. - - O
kg-1 - - O
per - - O
day - - O
with - - O
omeprazole - - O
20 - - O
mg - - O
per - - O
day - - O
or - - O
identical - - O
placebo - - O
during - - O
two - - O
periods - - O
, - - O
each - - O
of - - O
7 - - O
days - - O
, - - O
separated - - O
by - - O
a - - O
washout - - O
period - - O
of - - O
7 - - O
days - - O
. - - O

This - - O
conclusion - - O
was - - O
confirmed - - O
by - - O
Northern - - O
blotting - - O
analysis - - O
of - - O
the - - O
5'-flanking - - O
region - - O
of - - O
CAD - - B-MUT
gene - - I-MUT
. - - O

The - - O
ARF - - B-MUT
promoter - - I-MUT
was - - O
also - - O
found - - O
to - - O
be - - O
highly - - O
responsive - - O
to - - O
E2F1 - - B-MUT
expression - - O
, - - O
in - - O
keeping - - O
with - - O
previous - - O
results - - O
at - - O
the - - O
RNA - - O
level - - O
. - - O

Thus - - O
, - - O
chronic - - O
hematocrit - - O
decrease - - O
induced - - O
by - - O
H - - O
or - - O
P - - O
resulted - - O
in - - O
a - - O
significant - - O
fall - - O
in - - O
blood - - O
pressure - - O
compared - - O
to - - O
control - - O
( - - O
201 - - O
+ - - O
- - - O
3 - - O
v - - O
175 - - O
+ - - O
- - - O
4 - - O
, - - O
167 - - O
+ - - O
- - - O
4 - - O
mm - - O
Hg - - O
, - - O
respectively - - O
; - - O
P - - O
< - - O
. - - O
05 - - O
) - - O
. - - O

Radiation - - O
therapy - - O
was - - O
effective - - O
in - - O
controlling - - O
symptomatic - - O
metastasis - - O
in - - O
all - - O
three - - O
patients - - O
. - - O

Further - - O
analysis - - O
of - - O
this - - O
DNA - - O
fragment - - O
showed - - O
that - - O
four - - O
genes - - O
are - - O
present - - O
encoding - - O
proteins - - O
of - - O
16 - - O
, - - O
18 - - O
. - - O
5 - - O
, - - O
21 - - O
and - - O
89 - - O
kDal - - O
. - - O

Since - - O
the - - O
integrated - - O
13h00-16h00 - - O
plasma - - O
cortisol - - O
estimation - - O
is - - O
cheaper - - O
and - - O
simpler - - O
than - - O
the - - O
mean - - O
13h00-16h00 - - O
plasma - - O
cortisol - - O
estimation - - O
, - - O
we - - O
recommend - - O
it - - O
as - - O
an - - O
adjunct - - O
in - - O
the - - O
diagnosis - - O
of - - O
Cushing's - - O
syndrome - - O
. - - O

Using - - O
an - - O
interspecific - - O
backcross - - O
panel - - O
, - - O
we - - O
localized - - O
both - - O
Gng3 - - B-MUT
and - - O
Gng3lg - - B-MUT
to - - O
the - - O
same - - O
locus - - O
on - - O
chromosome - - O
19 - - O
. - - O

Brucellosis--1990 - - O
. - - O

An - - O
ELISA - - O
procedure - - O
was - - O
developed - - O
for - - O
monitoring - - O
the - - O
specific - - O
IgE - - B-MUT
response - - O
in - - O
dogs - - O
to - - O
Dirofilaria - - O
immitis - - O
infection - - O
. - - O

The - - O
malignity - - O
of - - O
nevoid - - O
lentigo - - O
. - - O

In - - O
adherent - - O
macrophages - - O
, - - O
absence - - O
of - - O
CD45 - - B-MUT
led - - O
to - - O
the - - O
hyperphosphorylation - - O
and - - O
hyperactivation - - O
of - - O
p56 - - B-MUT
59 - - O
( - - O
hck - - O
) - - B-MUT
and - - O
p53 - - O
56 - - B-MUT
( - - O
lyn - - O
) - - O
, - - B-MUT
but - - O
not - - O
of - - O
p58 - - O
( - - O
c-fgr - - B-MUT
) - - I-MUT
. - - I-MUT

Additionally - - O
, - - O
I - - B-MUT
kappa - - I-MUT
B - - I-MUT
beta - - I-MUT
, - - O
but - - O
not - - O
I - - B-MUT
kappa - - I-MUT
B - - I-MUT
alpha - - I-MUT
, - - O
also - - O
prevented - - O
the - - O
binding - - O
of - - O
Rel - - B-MUT
to - - O
the - - O
kappa - - B-MUT
B - - I-MUT
site - - I-MUT
. - - O

Although - - O
Pho85 - - B-MUT
is - - O
not - - O
essential - - O
for - - O
viability - - O
, - - O
Pcl1 - - B-MUT
, - - I-MUT
2-Pho85 - - I-MUT
kinase - - I-MUT
complexes - - I-MUT
become - - O
essential - - O
for - - O
Start - - O
in - - O
the - - O
absence - - O
of - - O
Cln1 - - B-MUT
, - - I-MUT
2-Cdc28 - - I-MUT
kinases - - I-MUT
. - - O

Exploratory-motor - - O
task - - O
to - - O
evaluate - - O
right - - O
frontal - - O
lobe - - O
damage - - O
. - - O

Study - - O
of - - O
the - - O
alterations - - O
of - - O
intestinal - - O
absorption - - O
, - - O
by - - O
means - - O
of - - O
I-131-triolein - - O
, - - O
in - - O
the - - O
whole - - O
body - - O
irradiated - - O
rat - - O
. - - O

Cortisone - - O
induced - - O
bone - - O
changes - - O
and - - O
its - - O
response - - O
to - - O
lipid - - O
clearing - - O
agents - - O
. - - O

The - - O
purpose - - O
of - - O
this - - O
study - - O
was - - O
to - - O
develop - - O
a - - O
reliable - - O
and - - O
culturally - - O
meaningful - - O
exercise - - O
self-efficacy - - O
questionnaire - - O
for - - O
older - - O
Mexican - - O
American - - O
women - - O
. - - O

Following - - O
seizure - - O
induction - - O
, - - O
MABP - - O
increased - - O
to - - O
105 - - O
mm - - O
Hg - - O
and - - O
brain - - O
pHi - - O
fell - - O
to - - O
6 - - O
. - - O
79 - - O
+ - - O
- - - O
0 - - O
. - - O
03 - - O
within - - O
15 - - O
min - - O
and - - O
remained - - O
at - - O
this - - O
level - - O
for - - O
1 - - O
h - - O
( - - O
P - - O
< - - O
0 - - O
. - - O
001 - - O
) - - O
. - - O

However - - O
, - - O
in - - O
the - - O
subgroup - - O
with - - O
normal - - O
Ht - - O
( - - O
< - - O
0 - - O
. - - O
45 - - O
l - - O
l - - O
; - - O
n - - O
= - - O
201 - - O
) - - O
there - - O
was - - O
a - - O
significant - - O
reduction - - O
( - - O
p - - O
< - - O
0 - - O
. - - O
05 - - O
) - - O
of - - O
the - - O
mortality - - O
after - - O
3 - - O
months - - O
( - - O
27% - - O
and - - O
16% - - O
, - - O
respectively - - O
) - - O
and - - O
an - - O
increase - - O
of - - O
independence - - O
at - - O
home - - O
( - - O
35% - - O
and - - O
48% - - O
, - - O
respectively - - O
) - - O
due - - O
to - - O
a - - O
reduction - - O
of - - O
the - - O
viscosity - - O
by - - O
means - - O
of - - O
haemodilution - - O
with - - O
albumin - - O
( - - B-MUT
a - - O
specific - - O
viscosity - - O
effect - - O
in - - O
the - - O
normovolaemic - - O
group - - O
) - - O
. - - O

A - - O
stable - - O
heterologous - - O
cell - - O
line - - O
containing - - O
the - - O
mouse - - B-MUT
TRH - - I-MUT
receptor - - I-MUT
was - - O
constructed - - O
by - - O
transfection - - O
of - - O
nonexcitable - - O
293 - - O
cells - - O
, - - O
which - - O
lack - - O
L - - O
channel - - O
activity - - O
. - - O

These - - O
data - - O
suggest - - O
that - - O
the - - O
function - - O
of - - O
the - - O
DS2 - - B-MUT
may - - O
be - - O
the - - O
protection - - O
of - - O
the - - O
nuclear - - O
DNA - - O
from - - O
desiccation - - O
. - - O

A - - O
recently - - O
described - - O
protein - - O
, - - O
metaxin - - B-MUT
1 - - I-MUT
, - - O
serves - - O
as - - O
a - - O
component - - O
of - - O
a - - O
preprotein - - O
import - - O
complex - - O
in - - O
the - - O
outer - - O
membrane - - O
of - - O
the - - O
mammalian - - O
mitochondrion - - O
. - - O

Thyrotoxicosis - - O
due - - O
to - - O
amiodarone - - O
is - - O
difficult - - O
to - - O
treat - - O
and - - O
is - - O
further - - O
complicated - - O
by - - O
the - - O
pro-arrhythmic - - O
potential - - O
of - - O
thyrotoxicosis - - O
and - - O
the - - O
fading - - O
antiarrhythmic - - O
effect - - O
after - - O
amiodarone - - O
withdrawal - - O
. - - O

RESULTS - - O
: - - O
The - - O
age - - O
distribution - - O
was - - O
28 - - O
to - - O
83 - - O
years - - O
old - - O
( - - O
mean - - O
was - - O
54 - - O
. - - O
1 - - O
years - - O
) - - O
. - - O

Univariate - - O
statistical - - O
analysis - - O
based - - O
on - - O
Kaplan-Meier-estimates - - O
and - - O
Log-Rank-Test - - O
showed - - O
the - - O
following - - O
prognostically - - O
beneficial - - O
factors - - O
: - - O
Limited - - O
disease - - O
stage - - O
( - - O
p - - O
= - - O
0 - - O
. - - O
009 - - O
) - - O
, - - O
NSE - - O
serum - - O
level - - O
less - - O
than - - O
25 - - O
micrograms - - O
l - - O
( - - O
p - - O
= - - O
0 - - O
. - - O
016 - - O
) - - O
, - - O
serum - - O
alkaline - - O
phosphatase - - B-MUT
less - - I-MUT
than - - O
200 - - O
U - - O
l - - O
( - - O
p - - O
= - - O
0 - - O
. - - O
035 - - O
) - - O
, - - O
normal - - O
serum - - O
albumin - - O
( - - O
p - - B-MUT
= - - O
0 - - O
. - - O
003 - - O
) - - O
and - - O
activity - - O
index - - O
of - - O
minimum - - O
of - - O
70 - - O
( - - O
p - - O
< - - O
0 - - O
. - - O
001 - - O
) - - O
. - - O

GAP - - O
JUNCTIONS - - O
IN - - O
THE - - O
BRAIN - - O
: - - O
PREFACE - - O
. - - O

The - - O
new - - O
semi-synthetic - - O
oral - - O
cephalosporin - - O
, - - O
CGP - - O
9 - - O
, - - O
000 - - O
, - - O
has - - O
been - - O
evaluated - - O
in - - O
a - - O
large - - O
number - - O
of - - O
hospitalized - - O
patients - - O
with - - O
urinary - - O
infections - - O
. - - O

Piroxicam - - O
produced - - O
a - - O
lower - - O
incidence - - O
of - - O
gastric - - O
ulcers - - O
than - - O
equivalent - - O
doses - - O
of - - O
indomethacin - - O
. - - O

Electrophoretic - - O
mobility - - O
shift - - O
assays - - O
with - - O
each - - O
of - - O
these - - O
sequences - - O
demonstrated - - O
complexes - - O
with - - O
mobilities - - O
identical - - O
to - - O
those - - O
of - - O
the - - O
NF-kappa - - B-MUT
B - - I-MUT
site - - I-MUT
from - - O
the - - O
kappa - - B-MUT
light-chain - - I-MUT
gene - - I-MUT
. - - O

Taken - - O
together - - O
, - - O
these - - O
findings - - O
show - - O
that - - O
16K - - B-MUT
hPRL - - I-MUT
inhibits - - O
the - - O
VEGF-induced - - O
Ras - - B-MUT
activation - - O
; - - O
this - - O
antagonism - - O
represents - - O
a - - O
novel - - O
and - - O
potentially - - O
important - - O
mechanism - - O
for - - O
the - - O
control - - O
of - - O
angiogenesis - - O
. - - O

Transfection - - O
with - - O
a - - O
CSF-1R - - B-MUT
expression - - O
plasmid - - O
permitted - - O
CSF-1-dependent - - O
activation - - O
of - - O
the - - O
signalling - - O
pathway - - O
targeting - - O
an - - O
Ets - - B-MUT
AP1 - - I-MUT
( - - I-MUT
activator - - O
protein - - B-MUT
1 - - I-MUT
) - - I-MUT
element - - O
in - - O
the - - O
uPA - - O
promoter - - B-MUT
that - - I-MUT
has - - O
been - - O
shown - - O
previously - - O
to - - O
be - - O
a - - O
target - - O
of - - O
oncogenic - - O
ras - - B-MUT
and - - I-MUT
protein - - O
kinase - - B-MUT
C - - I-MUT
pathways - - I-MUT
. - - I-MUT

During - - O
the - - O
1980's - - O
, - - O
quantifications - - O
of - - O
immunoserological - - O
testings - - O
, - - O
especially - - O
C - - B-MUT
reactive - - I-MUT
protein - - I-MUT
, - - O
rheumatoid - - B-MUT
factor - - I-MUT
and - - O
antistreptolysin - - B-MUT
O - - I-MUT
, - - O
progressed - - O
rapidly - - O
. - - O

It - - O
is - - O
shown - - O
that - - O
, - - O
for - - O
any - - O
periodic - - O
input - - O
, - - O
the - - O
map - - O
representing - - O
the - - O
relation - - O
between - - O
input - - O
phases - - O
at - - O
consecutive - - O
discharge - - O
times - - O
can - - O
be - - O
restricted - - O
to - - O
a - - O
piecewise - - O
continuous - - O
, - - O
orientation - - O
preserving - - O
circle - - O
map - - O
. - - O

Evidence - - O
that - - O
therapeutic - - O
alterations - - O
of - - O
a - - O
circadian - - O
rhythm - - O
for - - O
gastric - - O
emptying - - O
response - - O
may - - O
be - - O
possible - - O
. - - O

It - - O
is - - O
the - - O
human - - O
homolog - - O
of - - O
the - - O
mouse - - B-MUT
Mx - - I-MUT
protein - - I-MUT
involved - - O
in - - O
resistance - - O
to - - O
influenza - - O
virus - - O
. - - O

Accumulations - - O
of - - O
Tl+1 - - O
( - - O
202Tl - - O
label - - O
) - - O
were - - O
6 - - O
times - - O
those - - O
for - - O
Ga - - O
or - - O
In - - O
in - - O
the - - O
brain - - O
and - - O
muscles - - O
, - - O
and - - O
. - - O
1 - - O
times - - O
in - - O
plasma - - O
. - - O

These - - O
results - - O
indicate - - O
that - - O
during - - O
pregnancy - - O
there - - O
are - - O
increases - - O
in - - O
bone - - O
formation - - O
rates - - O
contributing - - O
to - - O
the - - O
increases - - O
in - - O
skeletal - - O
mass - - O
. - - O

CBT - - O
is - - O
discussed - - O
in - - O
comparison - - O
with - - O
the - - O
Wisconsin - - O
Card - - O
Sorting - - O
Test - - O
as - - O
a - - O
potential - - O
cognitive - - O
activation - - O
task - - O
for - - O
functional - - O
neuroimaging - - O
of - - O
the - - O
frontal - - O
lobes - - O
. - - O

In - - O
a - - O
recent - - O
measles - - O
epidemic - - O
in - - O
El - - O
Paso - - O
, - - O
TX - - O
, - - O
120 - - O
, - - O
000 - - O
records - - O
were - - O
screened - - O
using - - O
these - - O
criteria - - O
, - - O
and - - O
as - - O
a - - O
result - - O
13 - - O
, - - O
000 - - O
students - - O
were - - O
vaccinated - - O
. - - O

Recently - - O
, - - O
we - - O
have - - O
reported - - O
the - - O
cloning - - O
of - - O
the - - O
germ - - O
cell-specific - - O
, - - O
nuclear - - B-MUT
orphan - - I-MUT
receptor - - I-MUT
germ - - I-MUT
cell - - I-MUT
nuclear - - I-MUT
factor - - I-MUT
( - - I-MUT
GCNF - - I-MUT
) - - I-MUT
RTR - - I-MUT
. - - I-MUT

( - - O
1991 - - O
) - - O
. - - O

Appropriate - - O
restriction - - O
sites - - O
allow - - O
one - - O
to - - O
insert - - O
virtually - - O
any - - O
desired - - O
cDNA - - O
fragment - - O
directly - - O
behind - - O
the - - O
epitope-specific - - O
sequence - - O
and - - O
before - - O
a - - O
long - - O
poly - - O
( - - O
A - - O
) - - O
tail - - O
. - - O

Transcriptional - - O
regulation - - O
of - - O
the - - O
estrogen-inducible - - O
pS2 - - B-MUT
breast - - B-MUT
cancer - - I-MUT
marker - - I-MUT
gene - - I-MUT
by - - O
the - - O
ERR - - B-MUT
family - - I-MUT
of - - O
orphan - - B-MUT
nuclear - - I-MUT
receptors - - I-MUT
. - - O

The - - O
promoter - - O
activity - - O
of - - O
the - - O
proximal - - O
region - - O
was - - O
found - - O
to - - O
be - - O
restricted - - O
to - - O
a - - O
subset - - O
of - - O
prestalk - - O
cells - - O
. - - O

Such - - O
an - - O
increase - - O
in - - O
the - - O
steady-state - - O
testicular - - B-MUT
TIMP-2 - - I-MUT
mRNA - - I-MUT
level - - O
apparently - - O
is - - O
not - - O
the - - O
result - - O
of - - O
an - - O
up-regulation - - O
by - - O
germ - - O
cells - - O
because - - O
germ - - O
cells - - O
cocultured - - O
with - - O
Sertoli - - O
cells - - O
failed - - O
to - - O
elicit - - O
an - - O
increase - - O
in - - O
the - - O
Sertoli - - O
cell - - O
steady-state - - O
TIMP-2 - - B-MUT
mRNA - - I-MUT
level - - O
. - - O

Transgenic - - O
mice - - O
harboring - - O
the - - O
rat - - B-MUT
TnI-CAT - - I-MUT
fusion - - I-MUT
gene - - I-MUT
expressed - - O
the - - O
reporter - - O
specifically - - O
in - - O
the - - O
skeletal - - O
muscle - - O
. - - O

Taken - - O
together - - O
, - - O
these - - O
observations - - O
indicate - - O
that - - O
the - - O
C-terminal - - O
24 - - O
amino - - O
acids - - O
are - - O
sufficient - - O
for - - O
NodO - - B-MUT
secretion - - O
although - - O
the - - O
region - - O
adjacent - - O
to - - O
this - - O
domain - - O
appears - - O
to - - O
affect - - O
secretion - - O
efficiency - - O
. - - O

A - - O
rabbit - - O
antiserum - - O
was - - O
raised - - O
against - - O
a - - O
synthetic - - O
peptide - - O
corresponding - - O
to - - O
a - - O
hydrophilic - - O
portion - - O
of - - O
the - - O
translated - - O
murine - - O
cDNA - - O
sequence - - O
. - - O

Substantial - - O
evidence - - O
supports - - O
a - - O
critical - - O
role - - O
for - - O
the - - O
activation - - O
of - - O
the - - O
Raf-1 - - B-MUT
MEK - - I-MUT
mitogen-activated - - I-MUT
protein - - I-MUT
kinase - - I-MUT
pathway - - I-MUT
in - - I-MUT
oncogenic - - I-MUT
Ras-mediated - - O
transformation - - O
. - - O

The - - O
3' - - O
fragment - - O
was - - O
shown - - O
to - - O
accumulate - - O
as - - O
full-length - - O
mRNA - - O
disappeared - - O
in - - O
actinomycin - - O
D-treated - - O
cells - - O
, - - O
indicating - - O
a - - O
precursor-product - - O
relationship - - O
. - - O

Relation - - O
between - - O
mixing - - O
ratio - - O
of - - O
raw - - O
materials - - O
and - - O
composition - - O
of - - O
products - - O
in - - O
the - - O
synthesis - - O
of - - O
aluminosilicates - - O
. - - O

I - - O
. - - O

The - - O
purified - - O
recombinant - - O
enzyme - - O
catalyzed - - O
specific - - O
phosphoryl - - O
transfer - - O
from - - O
ATP - - O
to - - O
UMP - - O
and - - O
CMP - - O
. - - O

The - - O
course - - O
of - - O
endotoxin - - B-MUT
fever - - O
remained - - O
uninfluenced - - O
by - - O
ALS - - O
. - - O

The - - O
brackets - - O
were - - O
bonded - - O
to - - O
100 - - O
freshly - - O
extracted - - O
bovine - - O
incisors - - O
, - - O
and - - O
, - - O
after - - O
storage - - O
in - - O
tap - - O
water - - O
at - - O
room - - O
temperature - - O
for - - O
24 - - O
hours - - O
, - - O
they - - O
were - - O
subsequently - - O
tested - - O
in - - O
a - - O
shear - - O
mode - - O
using - - O
a - - O
universal - - O
testing - - O
machine - - O
. - - O

Potential - - O
consensus - - O
sequences - - O
for - - O
early - - O
and - - O
late - - O
regulatory - - O
elements - - O
were - - O
identified - - O
. - - O

Sequencing - - O
of - - O
a - - O
1 - - O
. - - O
3-kilobase - - O
fragment - - O
of - - O
the - - O
5'-flanking - - O
region - - O
of - - O
the - - O
TSG6 - - B-MUT
gene - - I-MUT
identified - - O
TATA-like - - O
and - - O
CAAT - - O
sequences - - O
near - - O
the - - O
transcription - - O
start - - O
site - - O
. - - O

In - - O
support - - O
of - - O
clinical - - O
antianginal - - O
studies - - O
, - - O
the - - O
vasodilator - - O
nicorandil - - O
( - - O
NIC - - O
) - - O
was - - O
combined - - O
with - - O
the - - O
beta-adrenergic - - B-MUT
receptor - - I-MUT
antagonists - - O
propranolol - - O
( - - O
PRO - - O
) - - O
and - - O
atenolol - - O
( - - O
ATN - - O
) - - O
and - - O
with - - O
the - - O
calcium - - O
channel - - O
blocker - - O
diltiazem - - O
( - - O
DTZ - - O
) - - O
to - - O
determine - - O
their - - O
cardiovascular - - O
and - - O
pharmacokinetic - - O
interactions - - O
. - - O

When - - O
the - - O
downstream - - O
operator - - O
was - - O
altered - - O
, - - O
there - - O
was - - O
a - - O
fourfold - - O
reduction - - O
in - - O
reporter - - O
enzyme - - O
levels - - O
. - - O

Tyrosine - - O
phosphorylated - - O
STATs - - B-MUT
dimerize - - O
and - - O
translocate - - O
into - - O
the - - O
nucleus - - O
to - - O
activate - - O
specific - - O
genes - - O
. - - O

The - - O
fepA-entD - - B-MUT
and - - O
fes-entF - - B-MUT
operons - - I-MUT
in - - O
the - - O
enterobactin - - O
synthesis - - O
and - - O
transport - - O
system - - O
are - - O
divergently - - O
transcribed - - O
from - - O
overlapping - - O
promoters - - O
, - - O
and - - O
both - - O
are - - O
inhibited - - O
by - - O
the - - O
Fur - - B-MUT
repressor - - I-MUT
protein - - I-MUT
under - - O
iron-replete - - O
conditions - - O
. - - O

Results - - O
from - - O
transient - - O
assays - - O
using - - O
these - - O
mutants - - O
showed - - O
that - - O
the - - O
DE1 - - B-MUT
received - - O
signals - - O
from - - O
phytochromes - - O
A - - O
and - - O
B - - O
, - - O
demonstrating - - O
that - - O
this - - O
element - - O
is - - O
indeed - - O
a - - O
light-responsive - - O
element - - O
. - - O

Experiments - - O
on - - O
23 - - O
white - - O
rats - - O
and - - O
10 - - O
guinea - - O
pigs - - O
have - - O
shown - - O
that - - O
preliminarily - - O
indomethacin-induced - - O
inhibition - - O
of - - O
prostaglandins - - O
synthesis - - O
prevented - - O
development - - O
of - - O
pulmonary - - O
oedema - - O
, - - O
evoked - - O
by - - O
heterologous - - O
serum - - O
in - - O
rats - - O
and - - O
by - - O
vagotomy - - O
in - - O
guinea - - O
pigs - - O
. - - O

After - - O
1 - - O
. - - O
5 - - O
years - - O
of - - O
such - - O
photoperiodic - - O
control - - O
, - - O
all - - O
ewes - - O
were - - O
blinded - - O
by - - O
bilateral - - O
orbital - - O
enucleation - - O
. - - O

Refined - - O
Cox - - O
models - - O
using - - O
a - - O
CD4 - - B-MUT
count - - O
of - - O
150 - - O
microL - - O
rather - - O
than - - O
200 - - O
microL - - O
to - - O
distinguish - - O
I0 - - O
and - - O
I1 - - O
yielded - - O
a - - O
simplified - - O
model - - O
with - - O
better - - O
fit - - O
to - - O
the - - O
observed - - O
data - - O
. - - O

The - - O
RPO1 - - B-MUT
of - - O
LCDV - - O
shows - - O
the - - O
highest - - O
similarity - - O
to - - O
the - - O
RPO1 - - B-MUT
of - - O
IIV6 - - O
and - - O
significant - - O
lower - - O
similarity - - O
to - - O
the - - O
eukaryotic - - B-MUT
polymerases - - I-MUT
II - - I-MUT
and - - I-MUT
III - - I-MUT
as - - O
well - - O
as - - O
to - - O
the - - O
archaebacteral - - O
subunit - - O
. - - O

Other - - O
assays - - O
also - - O
distinguished - - O
the - - O
processive - - O
replication - - O
of - - O
pNeo - - O
. - - O
Myc-2 - - B-MUT
. - - O
4 - - O
from - - O
the - - O
dispersive - - O
labeling - - O
of - - O
control - - O
plasmids - - O
. - - O

Next - - O
, - - O
to - - O
identify - - O
regions - - O
of - - O
the - - O
promoter - - O
involved - - O
, - - O
we - - O
examined - - O
a - - O
series - - O
of - - O
tenascin-C - - B-MUT
promoter - - I-MUT
constructs - - I-MUT
with - - O
5' - - O
deletions - - O
and - - O
showed - - O
that - - O
denatured - - O
collagen-dependent - - B-MUT
promoter - - I-MUT
activity - - O
was - - O
retained - - O
by - - O
a - - O
122-base - - O
pair - - O
element - - O
, - - O
located - - O
-43 - - O
to - - O
-165 - - O
bp - - O
upstream - - O
of - - O
the - - O
RNA - - O
start - - O
site - - O
. - - O

Thus - - O
adaptation - - O
to - - O
continuous - - O
mild - - O
stress - - O
has - - O
a - - O
potent - - O
antiarrhythmic - - O
effect - - O
which - - O
occurs - - O
due - - O
to - - O
the - - O
increased - - O
vagal - - O
tone - - O
. - - O

Because - - O
Trp53 - - B-MUT
( - - O
the - - O
mouse - - B-MUT
homolog - - I-MUT
of - - I-MUT
human - - I-MUT
TP53 - - I-MUT
) - - O
is - - O
located - - O
with - - O
Tk1 - - B-MUT
on - - O
chromosome - - O
11 - - O
and - - O
is - - O
critical - - O
in - - O
regulating - - O
cellular - - O
responses - - O
following - - O
exposure - - O
to - - O
DNA - - O
damaging - - O
agents - - O
, - - O
we - - O
wanted - - O
to - - O
determine - - O
if - - O
these - - O
mouse - - O
lymphoma - - O
cells - - O
harbor - - O
mutations - - O
in - - O
Trp53 - - B-MUT
. - - O

We - - O
concluded - - O
that - - O
activation - - O
of - - O
c-fosER - - B-MUT
mediated - - O
transcriptional - - O
inhibition - - O
of - - O
p21 - - B-MUT
( - - I-MUT
Cip1 - - I-MUT
WAF1 - - I-MUT
) - - I-MUT
through - - I-MUT
a - - O
previously - - O
uncharacterized - - O
AP-1 - - O
site - - B-MUT
, - - I-MUT
revealing - - O
an - - O
important - - O
role - - O
for - - O
c-fos - - O
in - - B-MUT
negative - - O
control - - O
of - - O
cell - - O
cycle - - O
regulatory - - O
genes - - O
. - - O

On - - O
the - - O
other - - O
hand - - O
, - - O
phosphatidyl - - O
inositol - - O
4 - - O
, - - O
5 - - O
bisphosphate - - O
( - - O
PIP2 - - O
) - - O
hydrolysis - - O
requires - - O
direct - - O
phosphorylation - - O
at - - O
tyrosine - - O
residue - - O
of - - O
the - - O
PLC-gamma1 - - B-MUT
isozyme - - I-MUT
. - - O

In - - O
the - - O
IA - - O
task - - O
, - - O
post-training - - O
intraperitoneal - - O
injections - - O
of - - O
picrotoxin - - O
and - - O
bicuculline - - O
induced - - O
a - - O
dose-dependent - - O
enhancement - - O
of - - O
retention - - O
measured - - O
24 - - O
h - - O
after - - O
the - - O
training - - O
, - - O
while - - O
retention - - O
was - - O
not - - O
affected - - O
by - - O
bicuculline - - O
methiodide - - O
( - - O
a - - O
GABA - - B-MUT
receptor - - I-MUT
antagonist - - O
that - - O
does - - O
not - - O
readily - - O
cross - - O
the - - O
blood-brain - - O
barrier - - O
) - - O
. - - O

The - - O
actA - - B-MUT
gene - - I-MUT
is - - O
present - - O
as - - O
a - - O
single - - O
copy - - O
in - - O
the - - O
genome - - O
of - - O
A - - O
. - - O
chrysogenum - - O
; - - O
and - - O
its - - O
expression - - O
level - - O
, - - O
opposite - - O
to - - O
pcbC - - B-MUT
and - - O
cefEF - - B-MUT
cephalosporin - - I-MUT
biosynthetic - - I-MUT
genes - - I-MUT
, - - O
was - - O
steady - - O
during - - O
cephalosporin - - B-MUT
fermentation - - O
, - - O
showing - - O
a - - O
single - - O
1 - - O
. - - O
4-kb - - O
transcript - - O
. - - O

The - - O
antibody - - O
titer - - O
of - - O
202 - - O
chickens - - O
to - - O
SA-11 - - O
rotavirus - - O
was - - O
determined - - O
by - - O
enzyme-linked - - O
immunosorbent - - O
blocking - - O
assay - - O
. - - O

Therefore - - O
, - - O
recombinant - - O
human - - O
Ads - - O
that - - O
express - - O
noninfectious - - O
HIV - - O
or - - O
other - - O
microbial - - O
proteins - - O
are - - O
attractive - - O
vaccine - - O
candidates - - O
. - - O

Based - - O
on - - O
a - - O
morphological - - O
study - - O
of - - O
the - - O
resin-dentine - - O
interface - - O
, - - O
a - - O
broad - - O
selection - - O
of - - O
dentine - - O
adhesive - - O
systems - - O
was - - O
classified - - O
following - - O
their - - O
adhesion-strategy - - O
. - - O

Chronic - - O
graft-versus-host - - O
disease - - O
( - - O
cGVHD - - O
) - - O
is - - O
a - - O
major - - O
complication - - O
of - - O
allogeneic - - O
hematopoietic - - O
cell - - O
transplantation - - O
. - - O

These - - O
women - - O
should - - O
not - - O
be - - O
given - - O
the - - O
current - - O
estrogen - - O
PPI - - O
, - - O
which - - O
was - - O
designed - - O
to - - O
warn - - O
women - - O
of - - O
the - - O
risks - - O
of - - O
long-term - - O
estrogen - - O
use - - O
; - - O
a - - O
PPI - - O
should - - O
be - - O
written - - O
specifically - - O
for - - O
patients - - O
receiving - - O
short - - O
courses - - O
. - - O

For - - O
SMX - - O
at - - O
pH - - O
7 - - O
. - - O
0 - - O
, - - O
a - - O
1 - - O
: - - O
1 - - O
complex - - O
is - - O
formed - - O
, - - O
but - - O
at - - O
pH - - O
7 - - O
. - - O
5 - - O
HPCD - - O
has - - O
little - - O
effect - - O
on - - O
the - - O
solubility - - O
of - - O
the - - O
highly - - O
ionized - - O
SMX - - O
, - - O
presumably - - O
since - - O
only - - O
un-ionized - - O
molecules - - O
can - - O
form - - O
inclusion - - O
complexes - - O
with - - O
the - - O
HPCD - - O
. - - O

With - - O
such - - O
analysis - - O
, - - O
one - - O
can - - O
test - - O
hypotheses - - O
about - - O
the - - O
structure - - O
of - - O
latent - - O
variability - - O
within - - O
a - - O
given - - O
data - - O
set - - O
. - - O

Here - - O
, - - O
we - - O
propose - - O
that - - O
an - - O
antagonistic - - O
, - - O
BMP - - O
ALK2 - - O
Smad-mediated - - O
signaling - - O
pathway - - O
is - - O
active - - O
on - - O
the - - O
right - - O
side - - O
of - - O
the - - O
Xenopus - - O
embryo - - O
. - - O

The - - O
hsp70 - - B-MUT
gene - - I-MUT
family - - I-MUT
of - - O
Neurospora - - O
crassa - - O
: - - O
cloning - - O
, - - O
sequence - - O
analysis - - O
, - - O
expression - - O
, - - O
and - - O
genetic - - O
mapping - - O
of - - O
the - - O
major - - O
stress-inducible - - O
member - - O
. - - O

The - - O
process - - O
has - - O
been - - O
applied - - O
to - - O
the - - O
river - - O
reclamation - - O
in - - O
Yangpu - - O
District - - O
of - - O
Shanghai - - O
City - - O
, - - O
China - - O
. - - O

FK - - O
33-824 - - O
, - - O
a - - O
methionine-enkephalin - - O
analogue - - O
, - - O
suppressed - - O
plasma - - O
ACTH - - B-MUT
to - - O
85% - - O
of - - O
basal - - O
level - - O
, - - O
while - - O
bromocriptine - - O
( - - O
CB-154 - - O
) - - O
caused - - O
no - - O
significant - - O
change - - O
. - - O

Most - - O
of - - O
the - - O
patients - - O
had - - O
locally - - O
advanced - - O
lesions - - O
( - - O
63 - - O
T3-4 - - O
: - - O
91 - - O
. - - O
5% - - O
) - - O
according - - O
to - - O
the - - O
adopted - - O
TNM - - O
system - - O
( - - O
Lederman-Gadeberg - - O
, - - O
Sisson-Jesse - - O
) - - O
. - - O

Previously - - O
, - - O
we - - O
showed - - O
that - - O
SNF2 - - B-MUT
, - - O
SNF5 - - B-MUT
, - - O
and - - O
SNF6 - - B-MUT
function - - O
interdependently - - O
in - - O
transcriptional - - O
activation - - O
, - - O
possibly - - O
forming - - O
a - - O
heteromeric - - O
complex - - O
. - - O

There - - O
were - - O
5 - - O
treatments - - O
: - - O
control - - O
( - - O
C - - O
) - - O
; - - O
a - - O
wooden - - O
surround - - O
in - - O
one - - O
rear - - O
corner - - O
of - - O
the - - O
cage - - O
( - - O
S - - O
) - - O
; - - O
a - - O
fiberglass - - O
rollaway - - O
hollow - - O
in - - O
one - - O
rear - - O
corner - - O
of - - O
the - - O
cage - - O
( - - O
H - - O
) - - O
; - - O
a - - O
hollow - - O
and - - O
a - - O
surround - - O
( - - O
H - - O
S - - O
) - - O
; - - O
a - - O
nest - - O
box - - O
attached - - O
to - - O
the - - O
back - - O
of - - O
the - - O
cage - - O
, - - O
containing - - O
a - - O
hollow - - O
( - - O
N - - O
) - - O
. - - O

Sinusoidal - - O
oscillations - - O
of - - O
a - - O
gas - - O
dilution - - O
indicator - - O
. - - O

Shoulder - - O
forearm - - O
support - - O
for - - O
the - - O
subluxed - - O
shoulder - - O
. - - O

The - - O
effects - - O
of - - O
glutaraldehyde - - O
on - - O
dimensions - - O
and - - O
ultrastructure - - O
of - - O
microvascular - - O
beds - - O
in - - O
rat - - O
mesentery - - O
were - - O
studied - - O
in - - O
two - - O
kinds - - O
of - - O
experiment - - O
, - - O
administering - - O
the - - O
fixative - - O
by - - O
intra-arterial - - O
perfusion - - O
at - - O
a - - O
pressure - - O
of - - O
80 - - O
mm - - O
Hg - - O
and - - O
by - - O
superfusion - - O
of - - O
the - - O
exteriorized - - O
mesenteric - - O
membrane - - O
. - - O

METHODS - - O
: - - O
Rats - - O
received - - O
continuous - - O
intragastric - - O
infusion - - O
of - - O
elemental - - O
diet - - O
or - - O
with - - O
supplementation - - O
of - - O
oatbase - - O
, - - O
Lactobacillus - - O
reuteri - - O
R2LC - - O
, - - O
and - - O
Lactobacillus - - O
plantarum - - O
DSM - - O
9843 - - O
, - - O
with - - O
and - - O
without - - O
fermentation - - O
, - - O
from - - O
the - - O
beginning - - O
of - - O
the - - O
study - - O
. - - O

The - - O
examinations - - O
were - - O
performed - - O
on - - O
two - - O
groups - - O
of - - O
20 - - O
( - - O
using - - O
AmF - - O
SnF2 - - O
) - - O
- - - O
, - - O
resp - - O
. - - O

The - - O
Ntl1 - - B-MUT
gene - - I-MUT
is - - O
present - - O
as - - O
a - - O
unique - - O
copy - - O
in - - O
the - - O
diploid - - O
N - - O
. - - O
plumbaginifolia - - O
species - - O
. - - O

Overexpression - - O
of - - O
PTTG - - B-MUT
in - - O
transfected - - O
NIH - - O
3T3 - - O
cells - - O
also - - O
stimulated - - O
expression - - O
and - - O
secretion - - O
of - - O
basic - - B-MUT
fibroblast - - I-MUT
growth - - I-MUT
factor - - I-MUT
, - - O
a - - O
human - - O
pituitary - - O
tumor - - O
growth-regulating - - O
factor - - O
. - - O

Apropos - - O
of - - O
a - - O
case - - O
. - - O

After - - O
age - - O
30 - - O
, - - O
mean - - O
hemoglobin - - B-MUT
levels - - O
for - - O
men - - O
gradually - - O
declined - - O
, - - O
while - - O
those - - O
in - - O
women - - O
rose - - O
, - - O
so - - O
that - - O
the - - O
sex - - O
difference - - O
diminished - - O
after - - O
60 - - O
years - - O
of - - O
age - - O
. - - O

Familial - - O
autoimmune - - O
hepatitis - - O
and - - O
C4 - - B-MUT
deficiency - - O
. - - O

Biol - - O
. - - O

Among - - O
unusual - - O
features - - O
, - - O
we - - O
report - - O
numerous - - O
large - - O
G - - O
+ - - O
C-rich - - O
conserved - - O
sequences - - O
located - - O
in - - O
the - - O
first - - O
intron - - O
. - - O

The - - O
Nur77 - - B-MUT
protein - - I-MUT
can - - O
act - - O
as - - O
a - - O
potent - - O
transcription - - O
activator - - O
and - - O
may - - O
function - - O
to - - O
regulate - - O
the - - O
expression - - O
of - - O
downstream - - O
genes - - O
in - - O
response - - O
to - - O
extracellular - - O
stimuli - - O
. - - O

DNase - - B-MUT
I - - I-MUT
footprinting - - O
with - - O
rat - - O
liver - - O
nuclear - - O
extracts - - O
identified - - O
7 - - O
major - - O
protein-binding - - O
domains - - O
termed - - O
P1 - - B-MUT
through - - O
P7 - - B-MUT
in - - O
a - - O
796 - - O
base - - O
pair - - O
DNA - - O
fragment - - O
( - - O
base - - O
pairs - - O
-763 - - O
to - - O
+33 - - O
) - - O
. - - O

The - - O
observed - - O
triplexes - - O
depend - - O
on - - O
the - - O
length - - O
of - - O
the - - O
repeat - - O
. - - O

This - - O
element - - O
, - - O
termed - - O
CREsp-a - - B-MUT
( - - O
TGACCTCA - - B-MUT
) - - O
, - - O
differs - - O
by - - O
one - - O
nucleotide - - O
from - - O
a - - O
palindromic - - O
CRE - - B-MUT
( - - O
CREpal - - B-MUT
, - - O
TGACGTCA - - B-MUT
) - - O
, - - O
which - - O
is - - O
known - - O
to - - O
bind - - O
CREB - - B-MUT
as - - O
a - - O
homodimer - - O
. - - O

Its - - O
vasodilatory - - O
, - - O
anti-vasopressor - - O
, - - O
and - - O
platelet - - O
stabilizing - - O
effects - - O
could - - O
be - - O
expected - - O
to - - O
counteract - - O
the - - O
placental - - O
ischemia - - O
, - - O
hypertension - - O
and - - O
excessive - - O
coagulation - - O
that - - O
are - - O
seen - - O
in - - O
pre-eclampsia - - O
. - - O

Transient - - O
transfection - - O
assays - - O
using - - O
P19 - - O
cells - - O
revealed - - O
that - - O
expression - - O
of - - O
NDRF - - B-MUT
NeuroD2 - - I-MUT
increased - - I-MUT
the - - O
transactivation - - O
of - - O
the - - O
rat - - O
insulin - - B-MUT
promoter - - I-MUT
element - - I-MUT
3 - - I-MUT
( - - I-MUT
RIPE3 - - O
) - - B-MUT
enhancer - - O
up - - O
to - - O
approximately - - O
12-fold - - O
and - - O
that - - O
co-expression - - O
of - - O
catalytically - - O
active - - O
form - - O
of - - O
PKN - - O
, - - B-MUT
but - - O
not - - O
kinase-deficient - - O
derivative - - O
, - - O
resulted - - O
in - - O
a - - O
further - - O
threefold - - O
increase - - O
of - - O
NDRF - - O
NeuroD2-mediated - - O
transcription - - O
. - - O

Platelet - - O
aggregation - - O
in - - O
response - - O
to - - O
10 - - O
micrograms - - O
collagen - - O
ml - - O
was - - O
decreased - - O
in - - O
parallel - - O
after - - O
treatment - - O
with - - O
ASA - - O
. - - O

Low-dose - - O
aspirin - - O
and - - O
recurrent - - O
miscarriage - - O
. - - O

Arhythmacanthus - - O
Yamaguti - - O
, - - O
1935 - - O
is - - O
maintained - - O
as - - O
a - - O
synonym - - O
of - - O
Heterosentis - - O
because - - O
the - - O
distinction - - O
between - - O
two - - O
and - - O
three - - O
hook - - O
types - - O
is - - O
made - - O
equivocal - - O
when - - O
the - - O
transition - - O
between - - O
the - - O
apical - - O
and - - O
subapical - - O
hooks - - O
is - - O
gradual - - O
. - - O

Autorosette-forming - - O
cells - - O
are - - O
characterized - - O
by - - O
a - - O
high - - O
activity - - O
of - - O
alkaline - - B-MUT
and - - I-MUT
acid - - I-MUT
phosphatases - - I-MUT
and - - O
low - - O
NBT-test - - O
values - - O
. - - O

The - - O
spectrum - - O
of - - O
histologically - - O
diagnosed - - O
malignant - - O
neoplasms - - O
in - - O
Sabah - - O
, - - O
1983-1988 - - O
. - - O

Eight - - O
recombinant - - O
DNA - - O
clones - - O
of - - O
endogenous - - O
murine - - O
leukemia - - O
virus - - O
( - - O
MuLV - - O
) - - O
-related - - O
DNA - - O
sequences - - O
have - - O
been - - O
isolated - - O
from - - O
a - - O
lambdaphage - - O
genomic - - O
library - - O
of - - O
Balb - - O
c - - O
mouse - - O
DNA - - O
. - - O

A - - O
cDNA - - O
cloning - - O
vector - - O
that - - O
permits - - O
expression - - O
of - - O
cDNA - - O
inserts - - O
in - - O
mammalian - - O
cells - - O
. - - O

When - - O
transiently - - O
transfected - - O
into - - O
K562 - - O
cells - - O
, - - O
this - - O
Lg - - B-MUT
genomic - - O
clone - - O
is - - O
actively - - O
transcribed - - O
, - - O
suggesting - - O
that - - O
, - - O
although - - O
it - - O
possesses - - O
the - - O
characteristics - - O
of - - O
a - - O
processed - - O
pseudogene - - O
, - - O
it - - O
is - - O
likely - - O
to - - O
correspond - - O
to - - O
the - - O
gene - - O
encoding - - O
this - - O
new - - O
ferritin - - B-MUT
subunit - - I-MUT
. - - O

The - - O
murine - - O
Htf9-a - - B-MUT
RanBP1 - - O
and - - B-MUT
Htf9-c - - O
genes - - B-MUT
are - - I-MUT
divergently - - O
transcribed - - O
from - - O
a - - O
shared - - O
TATA-less - - O
promoter - - O
. - - O

Under - - O
these - - O
schedules - - O
, - - O
a - - O
reinforced - - O
response - - O
run - - O
consisted - - O
of - - O
responding - - O
between - - O
eight - - O
and - - O
12 - - O
times - - O
on - - O
one - - O
response - - O
key - - O
( - - O
work - - O
key - - O
) - - O
and - - O
then - - O
responding - - O
once - - O
on - - O
a - - O
second - - O
response - - O
key - - O
( - - O
reinforced - - O
key - - O
) - - O
. - - O

AIMS - - O
: - - O
To - - O
evaluate - - O
the - - O
role - - O
of - - O
environmental - - O
intra-uterine - - O
factors - - O
in - - O
determining - - O
the - - O
birthweights - - O
of - - O
twins - - O
with - - O
increased - - O
susceptibility - - O
to - - O
diabetes - - O
and - - O
discordant - - O
for - - O
abnormal - - O
responses - - O
to - - O
the - - O
oral - - O
glucose - - O
tolerance - - O
test - - O
( - - O
OGTT - - O
) - - O
and - - O
verify - - O
the - - O
possible - - O
association - - O
of - - O
within-pair - - O
birthweight - - O
differences - - O
and - - O
metabolic - - O
abnormalities - - O
in - - O
adult - - O
life - - O
. - - O

Although - - O
large - - O
epidemiologic - - O
studies - - O
are - - O
best - - O
able - - O
to - - O
identify - - O
the - - O
relative - - O
contributions - - O
of - - O
specific - - O
risk - - O
factors - - O
while - - O
controlling - - O
for - - O
other - - O
risk - - O
factors - - O
, - - O
new - - O
studies - - O
need - - O
to - - O
focus - - O
on - - O
important - - O
unresolved - - O
questions - - O
. - - O

Amino - - O
acid - - O
sequence - - O
comparison - - O
revealed - - O
significant - - O
homology - - O
between - - O
the - - O
yeast - - B-MUT
and - - I-MUT
Escherichia - - I-MUT
coli - - I-MUT
gamma-glutamyl - - I-MUT
kinases - - I-MUT
throughout - - O
their - - O
lengths - - O
. - - O

Tumours - - O
of - - O
the - - O
cavum - - O
oris - - O
and - - O
oropharynx - - O
of - - O
T1-stage - - O
are - - O
possible - - O
only - - O
in - - O
1 - - O
of - - O
3 - - O
cases - - O
. - - O

Expression - - O
and - - O
regulation - - O
by - - O
interferon - - O
of - - O
a - - O
double-stranded-RNA-specific - - B-MUT
adenosine - - I-MUT
deaminase - - I-MUT
from - - O
human - - O
cells - - O
: - - O
evidence - - O
for - - O
two - - O
forms - - O
of - - O
the - - O
deaminase - - B-MUT
. - - O

The - - O
ZNF274 - - B-MUT
gene - - I-MUT
is - - O
mapped - - O
distal - - O
to - - O
marker - - O
RP - - O
S28 - - O
1 - - O
in - - O
the - - O
human - - O
chromosome - - O
19qter - - O
region - - O
, - - O
by - - O
RH - - O
mapping - - O
. - - O

In - - O
ICU - - O
patients - - O
, - - O
the - - O
LIS - - O
related - - O
to - - O
the - - O
postoperative - - O
rise - - O
in - - O
IL-6 - - B-MUT
level - - O
only - - O
, - - O
even - - O
though - - O
the - - O
rise - - O
in - - O
plasma - - O
concentrations - - O
of - - O
cytokines - - O
interrelated - - O
. - - O

Gene - - O
constructs - - O
possessing - - O
the - - O
complete - - B-MUT
tat - - I-MUT
, - - O
rev - - B-MUT
( - - O
tat+ - - B-MUT
rev+ - - B-MUT
) - - O
and - - O
env - - B-MUT
genes - - I-MUT
were - - O
transiently - - O
expressed - - O
in - - O
COS-1 - - O
cells - - O
as - - O
precursor - - B-MUT
SU-TM - - I-MUT
( - - O
gp160 - - B-MUT
) - - O
, - - O
SU - - B-MUT
. - - I-MUT
TM - - I-MUT
( - - O
gp120 - - B-MUT
x - - I-MUT
41 - - I-MUT
) - - O
, - - O
and - - O
nucleolar - - B-MUT
rev - - I-MUT
protein - - I-MUT
. - - O

The - - O
population - - O
studied - - O
comprised - - O
4472 - - O
men - - O
and - - O
5212 - - O
women - - O
aged - - O
30-74 - - O
years - - O
, - - O
without - - O
coronary - - O
heart - - O
disease - - O
, - - O
who - - O
had - - O
CRP - - O
measurements - - O
in - - O
the - - O
Third - - O
National - - O
Health - - O
and - - O
Nutrition - - O
Examination - - O
Survey - - O
( - - O
NHANES - - O
III - - O
) - - O
. - - O

V - - O
. - - O

Disruption - - O
of - - O
ARF2 - - B-MUT
causes - - O
no - - O
detectable - - O
phenotype - - O
. - - O

The - - O
analysis - - O
of - - O
two - - O
distinct - - O
mitogen-activated - - B-MUT
protein - - I-MUT
kinase - - I-MUT
pathways - - O
shows - - O
that - - O
stress-activated - - B-MUT
protein - - I-MUT
kinase-Jun - - I-MUT
N-terminal - - I-MUT
kinase - - I-MUT
activation - - O
, - - O
resulting - - O
in - - O
the - - O
phosphorylation - - O
of - - O
ATF-2 - - B-MUT
, - - O
c-Jun - - B-MUT
, - - O
and - - O
JunD - - B-MUT
, - - O
is - - O
required - - O
not - - O
only - - O
for - - O
the - - O
IL-1- - - O
but - - O
also - - O
for - - O
the - - O
TPA-dependent - - O
induction - - O
, - - O
while - - O
the - - O
extracellular - - B-MUT
signal-related - - I-MUT
kinase - - I-MUT
1 - - I-MUT
( - - O
ERK-1 - - B-MUT
) - - O
and - - O
ERK-2 - - B-MUT
activation - - O
is - - O
involved - - O
in - - O
the - - O
TPA- - - O
but - - O
not - - O
in - - O
the - - O
IL-1-dependent - - O
stimulation - - O
of - - O
the - - O
uPA - - B-MUT
enhancer - - I-MUT
. - - O

The - - O
specific - - O
electrical - - O
resistance - - O
of - - O
the - - O
cerebrospinal - - O
fluid - - O
was - - O
measured - - O
by - - O
means - - O
of - - O
conductometry - - O
in - - O
14 - - O
cases - - O
of - - O
meningitis - - O
purulenta - - O
, - - O
17 - - O
cases - - O
of - - O
meningitis - - O
serosa - - O
, - - O
10 - - O
cases - - O
of - - O
encephalitis - - O
and - - O
in - - O
32 - - O
control - - O
subjects - - O
. - - O

Incubation - - O
of - - O
the - - O
purified - - O
fusion - - O
proteins - - O
with - - O
[ - - O
gamma-32P - - O
] - - O
ATP - - O
in - - O
an - - O
in - - O
vitro - - O
assay - - O
showed - - O
that - - O
both - - O
proteins - - O
were - - O
capable - - O
of - - O
autophosphorylation - - O
. - - O

Overall - - O
, - - O
our - - O
results - - O
suggest - - O
that - - O
resistant - - O
genotypes - - O
exist - - O
among - - O
the - - O
WAD - - O
goat - - O
population - - O
. - - O

Complete - - O
nucleotide - - O
sequence - - O
of - - O
the - - O
bacteriophage - - B-MUT
K1F - - I-MUT
tail - - I-MUT
gene - - I-MUT
encoding - - O
endo-N-acylneuraminidase - - B-MUT
( - - O
endo-N - - B-MUT
) - - O
and - - O
comparison - - O
to - - O
an - - O
endo-N - - B-MUT
homolog - - I-MUT
in - - O
bacteriophage - - O
PK1E - - O
. - - O

In - - O
human - - O
brain - - O
, - - O
contactin - - B-MUT
was - - O
first - - O
identified - - O
by - - O
amino - - O
terminal - - O
and - - O
peptide - - O
sequencing - - O
of - - O
the - - O
lentil-lectin-binding - - B-MUT
glycoprotein - - I-MUT
Gp135 - - I-MUT
. - - O

It - - O
was - - O
argued - - O
that - - O
this - - O
arose - - O
from - - O
the - - O
possibility - - O
that - - O
the - - O
nature - - O
of - - O
blue - - O
collar - - O
jobs - - O
was - - O
physical - - O
, - - O
and - - O
that - - O
loss - - O
of - - O
myocardial - - O
tissue - - O
might - - O
be - - O
expected - - O
to - - O
more - - O
markedly - - O
interfere - - O
with - - O
their - - O
work - - O
efficiency - - O
( - - O
on - - O
returning - - O
to - - O
work - - O
) - - O
than - - O
it - - O
would - - O
the - - O
efficiency - - O
of - - O
the - - O
more - - O
sedentary - - O
jobs - - O
of - - O
white - - O
collar - - O
workers - - O
. - - O

Based - - O
on - - O
the - - O
occurrence - - O
of - - O
several - - O
transcription - - O
signals - - O
in - - O
the - - O
Thermus - - B-MUT
pyr - - I-MUT
promoter - - I-MUT
region - - I-MUT
and - - O
strong - - O
amino - - O
acid - - O
sequence - - O
identities - - O
( - - O
about - - O
60% - - O
) - - O
between - - O
Thermus - - B-MUT
PyrR - - I-MUT
and - - O
the - - O
PyrR - - B-MUT
attenuation - - I-MUT
proteins - - I-MUT
of - - O
two - - O
Bacillus - - O
sp - - O
. - - O
, - - O
we - - O
propose - - O
a - - O
regulatory - - O
mechanism - - O
involving - - O
transcriptional - - O
attenuation - - O
to - - O
control - - O
pyr - - B-MUT
gene - - I-MUT
expression - - O
in - - O
Thermus - - O
. - - O

The - - O
sensitivity - - O
of - - O
human - - O
neuroblastoma - - O
cells - - O
SK-N-SH - - O
to - - O
undergo - - O
apoptosis - - O
induced - - O
by - - O
thapsigargin - - O
was - - O
examined - - O
. - - O

Detection - - O
of - - O
airborne - - O
Mycobacterium - - O
tuberculosis - - O
by - - O
air - - O
filtration - - O
and - - O
polymerase - - B-MUT
chain - - O
reaction - - O
. - - O

Functional - - O
flow - - O
was - - O
evaluated - - O
using - - O
laser - - O
Doppler - - O
flowmetry - - O
( - - O
LDF - - O
) - - O
, - - O
for - - O
which - - O
the - - O
output - - O
signal - - O
, - - O
blood - - O
cell - - O
flux - - O
( - - O
BCF - - O
) - - O
, - - O
is - - O
expressed - - O
in - - O
terms - - O
of - - O
volts - - O
. - - O

The - - O
bHLH - - B-MUT
proteins - - I-MUT
function - - O
as - - O
potent - - O
transcriptional - - O
activators - - O
of - - O
tissue-specific - - O
genes - - O
by - - O
forming - - O
heterodimers - - O
between - - O
ubiquitous - - O
and - - O
cell-restricted - - O
family - - O
members - - O
. - - O

Evoked - - O
potential - - O
and - - O
single - - O
unit - - O
responses - - O
to - - O
olfactory - - O
nerve - - O
volleys - - O
in - - O
the - - O
isolated - - O
turtle - - O
olfactory - - O
bulb - - O
. - - O

Selection - - O
was - - O
based - - O
on - - O
expression - - O
of - - O
an - - O
integrated - - O
DNA - - O
fragment - - O
containing - - O
the - - O
con-10 - - B-MUT
promoter-regulatory - - I-MUT
region - - I-MUT
followed - - O
by - - O
the - - O
initial - - O
segment - - O
of - - O
the - - O
con-10 - - B-MUT
open - - I-MUT
reading - - I-MUT
frame - - I-MUT
fused - - O
in - - O
frame - - O
with - - O
the - - O
bacterial - - B-MUT
hygromycin - - I-MUT
B - - I-MUT
phosphotransferase - - I-MUT
structural - - I-MUT
gene - - I-MUT
( - - O
con10'-'hph - - B-MUT
) - - O
. - - O

3 - - O
Significant - - O
reductions - - O
in - - O
lying - - O
mean - - O
arterial - - O
blood - - O
pressure - - O
were - - O
observed - - O
with - - O
daily - - O
doses - - O
of - - O
200 - - O
mg - - O
( - - O
- - - O
9% - - O
) - - O
, - - O
400 - - O
mg - - O
( - - O
- - - O
10% - - O
) - - O
and - - O
800 - - O
mg - - O
( - - O
- - - O
14% - - O
) - - O
, - - O
and - - O
were - - O
associated - - O
with - - O
significant - - O
decreases - - O
in - - O
heart - - O
rate - - O
and - - O
plasma - - B-MUT
renin - - I-MUT
activity - - O
. - - O

The - - O
antilog - - O
transformation - - O
of - - O
pH - - O
did - - O
not - - O
improve - - O
the - - O
results - - O
. - - O

All - - O
33 - - O
subjects - - O
were - - O
given - - O
psychometric - - O
instruments - - O
for - - O
measuring - - O
various - - O
components - - O
of - - O
anger - - O
and - - O
anxiety - - O
: - - O
Spielberger's - - O
State-Trait - - O
Personality - - O
Inventory - - O
, - - O
the - - O
Anger - - O
Expression - - O
Scale - - O
, - - O
and - - O
the - - O
State - - O
Anger - - O
Reaction - - O
Scale - - O
. - - O

The - - O
data - - O
suggest - - O
that - - O
like - - O
in - - O
yeast - - O
, - - O
in - - O
plants - - O
a - - O
certain - - O
subfamily - - O
of - - O
UBC - - B-MUT
is - - O
specifically - - O
involved - - O
in - - O
the - - O
proteolytic - - O
degradation - - O
of - - O
abnormal - - O
proteins - - O
as - - O
result - - O
of - - O
stress - - O
. - - O

1 - - O
) - - O
CFDN - - O
, - - O
AMPC - - O
and - - O
MNZ - - O
showed - - O
a - - O
potent - - O
antimicrobial - - O
activity - - O
against - - O
H - - O
. - - O
pylori - - O
, - - O
and - - O
especially - - O
, - - O
AMPC - - O
showed - - O
a - - O
marked - - O
bactericidal - - O
activity - - O
in - - O
a - - O
short - - O
time - - O
. - - O

Tributyltin - - O
and - - O
its - - O
breakdown - - O
products - - O
, - - O
mono- - - O
and - - O
di-butyltin - - O
, - - O
were - - O
determined - - O
in - - O
water - - O
birds - - O
collected - - O
from - - O
Lake - - O
Huron - - O
( - - O
the - - O
Great - - O
Lakes - - O
) - - O
, - - O
marine - - O
coastal - - O
United - - O
States - - O
, - - O
and - - O
the - - O
west - - O
coast - - O
of - - O
British - - O
Columbia - - O
, - - O
Canada - - O
. - - O

Interleukin-8 - - B-MUT
( - - O
IL-8 - - B-MUT
) - - O
is - - O
a - - O
potent - - O
inflammatory - - O
mediator - - O
that - - O
belongs - - O
to - - O
the - - O
family - - O
of - - O
C-X-C - - B-MUT
chemokines - - I-MUT
. - - O

This - - O
motif - - O
, - - O
first - - O
described - - O
for - - O
the - - O
Drosophila - - B-MUT
homeobox - - I-MUT
activator - - I-MUT
DEAF-1 - - I-MUT
, - - O
identifies - - O
an - - O
emerging - - O
group - - O
of - - O
metazoan - - O
transcriptional - - O
modulators - - O
. - - O

Therefore - - O
, - - O
PC-PLC - - B-MUT
is - - O
a - - O
component - - O
of - - O
a - - O
signal - - O
transduction - - O
pathway - - O
leading - - O
to - - O
transcription - - O
of - - O
c-fos - - B-MUT
and - - O
junB - - B-MUT
that - - O
collaborates - - O
with - - O
c-myc - - B-MUT
and - - O
is - - O
independent - - O
of - - O
PKC-delta - - B-MUT
and - - O
Ras - - B-MUT
activation - - O
. - - O

Peripheral - - O
and - - O
preemptive - - O
opioid - - O
antinociception - - O
in - - O
a - - O
mouse - - O
visceral - - O
pain - - O
model - - O
. - - O

G-DNA - - B-MUT
is - - O
a - - O
four-stranded - - O
DNA - - O
structure - - O
with - - O
diverse - - O
putative - - O
biological - - O
roles - - O
. - - O

Mean - - O
total - - O
lung - - O
capacity - - O
, - - O
functional - - O
residual - - O
capacity - - O
, - - O
and - - O
residual - - O
volume - - O
increased - - O
significantly - - O
, - - O
and - - O
the - - O
mean - - O
closing - - O
volume - - O
, - - O
the - - O
lung - - O
volume - - O
above - - O
residual - - O
volume - - O
at - - O
which - - O
phase - - O
IV - - O
begins - - O
, - - O
decreased - - O
significantly - - O
with - - O
11 - - O
cm - - O
H20 - - O
continuous - - O
positive - - O
airway - - O
pressure - - O
; - - O
differences - - O
at - - O
5 - - O
cm - - O
H20 - - O
were - - O
not - - O
significant - - O
. - - O

Negatively - - O
supercoiled - - O
plasmid - - O
pUC19 - - O
did - - O
not - - O
compete - - O
, - - O
whereas - - O
an - - O
otherwise - - O
identical - - O
plasmid - - O
pUC19 - - O
( - - O
CG - - O
) - - O
, - - O
which - - O
contained - - O
a - - O
( - - O
dG-dC - - O
) - - O
7 - - O
segment - - O
in - - O
the - - O
Z-form - - O
was - - O
an - - O
excellent - - O
competitor - - O
. - - O

Deletion - - O
of - - O
the - - O
proximal - - O
octanucleotide - - O
motif - - O
from - - O
the - - O
plasmid - - O
containing - - O
the - - O
-461 - - O
fragment - - O
of - - O
the - - O
LPL - - B-MUT
promoter - - I-MUT
, - - O
resulted - - O
in - - O
a - - O
79 - - O
and - - O
76% - - O
decrease - - O
in - - O
the - - O
level - - O
of - - O
expression - - O
in - - O
transfected - - O
3T3-L1 - - O
adipocytes - - O
and - - O
HepG2 - - O
hepatocytes - - O
, - - O
respectively - - O
. - - O

Whereas - - O
MARTA1 - - B-MUT
is - - O
clearly - - O
detectable - - O
in - - O
crude - - O
lysates - - O
, - - O
cytosolic - - O
and - - O
ribosomal - - O
salt-wash - - O
fractions - - O
, - - O
and - - O
in - - O
nuclear - - O
extracts - - O
, - - O
MARTA2 - - B-MUT
is - - O
preferentially - - O
found - - O
in - - O
the - - O
ribosomal - - O
salt-wash - - O
preparation - - O
. - - O

Blood - - B-MUT
serum - - I-MUT
erythropoietin - - I-MUT
level - - O
and - - O
basic - - O
hematological - - O
indices - - O
during - - O
the - - O
adaptation - - O
of - - O
healthy - - O
newborn - - O
infants - - O
. - - O

Angiotensin - - B-MUT
II - - I-MUT
induces - - O
nuclear - - B-MUT
factor - - I-MUT
( - - I-MUT
NF - - I-MUT
) - - I-MUT
-kappaB1 - - I-MUT
isoforms - - I-MUT
to - - O
bind - - O
the - - O
angiotensinogen - - B-MUT
gene - - I-MUT
acute-phase - - O
response - - O
element - - O
: - - O
a - - O
stimulus-specific - - O
pathway - - O
for - - O
NF-kappaB - - B-MUT
activation - - O
. - - O

SETTING--Women - - O
, - - O
Infants - - O
, - - O
and - - O
Children - - O
clinics - - O
in - - O
Minneapolis - - O
, - - O
Minn - - O
. - - O

The - - O
transit - - O
time - - O
was - - O
significantly - - O
shortened - - O
. - - O

Roles - - O
of - - O
the - - O
Candida - - B-MUT
albicans - - I-MUT
mitogen-activated - - I-MUT
protein - - I-MUT
kinase - - I-MUT
homolog - - I-MUT
, - - O
Cek1p - - B-MUT
, - - O
in - - O
hyphal - - O
development - - O
and - - O
systemic - - O
candidiasis - - O
. - - O

By - - O
using - - O
reporter - - O
gene - - O
constructs - - O
, - - O
it - - O
is - - O
shown - - O
that - - O
upstream - - O
sequences - - O
of - - O
the - - O
P1 - - B-MUT
promoter - - I-MUT
contain - - O
several - - O
regions - - O
that - - O
modulate - - O
the - - O
expression - - O
either - - O
positively - - O
or - - O
negatively - - O
. - - O

RESULTS - - O
: - - O
Using - - O
information - - O
in - - O
the - - O
dbEST - - O
database - - O
of - - O
expressed - - O
sequence - - O
tags - - O
, - - O
we - - O
isolated - - O
an - - O
Arabidopsis - - O
thaliana - - O
gene - - O
( - - O
GCR1 - - B-MUT
) - - O
that - - O
encodes - - O
a - - O
protein - - O
with - - O
seven - - O
predicted - - O
membrane-spanning - - O
domains - - O
and - - O
other - - O
features - - O
characteristic - - O
of - - O
7TM - - B-MUT
receptors - - I-MUT
. - - O

Gentamicin - - O
given - - O
by - - O
DPI - - O
and - - O
SVN - - O
significantly - - O
decreased - - O
the - - O
sputum - - O
Psa - - O
density - - O
( - - O
p - - O
< - - O
0 - - O
. - - O
05 - - O
) - - O
, - - O
by - - O
almost - - O
one - - O
order - - O
of - - O
magnitude - - O
. - - O

The - - O
210 - - O
kDa - - O
precursor - - O
is - - O
converted - - O
slowly - - O
( - - O
t - - O
1 - - O
2 - - O
= - - O
2 - - O
h - - O
) - - O
by - - O
proteolytic - - O
processing - - O
into - - O
a - - O
125 - - O
kDa - - O
( - - O
alpha' - - O
) - - O
and - - O
83 - - O
kDa - - O
( - - O
beta' - - O
) - - O
species - - O
. - - O

TATA - - O
and - - O
CCAAT - - O
boxes - - O
are - - O
located - - O
34-bp - - O
and - - O
68-bp - - O
, - - O
respectively - - O
, - - O
upstream - - O
of - - O
the - - O
transcription - - O
start - - O
site - - O
, - - O
the - - O
5'-untranslated - - O
leader - - O
is - - O
78 - - O
nucleotides - - O
long - - O
, - - O
and - - O
the - - O
intronless - - O
gene - - O
has - - O
at - - O
least - - O
two - - O
different - - O
polyadenylation - - O
sites - - O
. - - O

We - - O
speculate - - O
that - - O
the - - O
human - - O
papillomavirus - - O
late - - O
mRNAs - - O
, - - O
produced - - O
from - - O
several - - O
hundred - - O
copies - - O
of - - O
the - - O
virus - - O
genome - - O
present - - O
in - - O
infected - - O
cells - - O
, - - O
compete - - O
with - - O
the - - O
c-fos - - B-MUT
mRNAs - - I-MUT
for - - O
destabilizing - - O
cellular - - O
factors - - O
and - - O
that - - O
this - - O
may - - O
lead - - O
to - - O
elevated - - O
Fos - - B-MUT
protein - - I-MUT
levels - - O
in - - O
human - - O
papillomavirus - - O
infected - - O
cells - - O
. - - O

The - - O
deduced - - O
amino - - O
acid - - O
sequence - - O
of - - O
the - - O
gene - - O
has - - O
significant - - O
homology - - O
to - - O
the - - O
interferon - - B-MUT
regulatory - - I-MUT
factors - - I-MUT
( - - O
IRFs - - B-MUT
) - - O
. - - O

PET - - O
activation - - O
studies - - O
are - - O
performed - - O
widely - - O
to - - O
study - - O
human - - O
brain - - O
function - - O
. - - O

Deterministic - - O
effects - - O
. - - O

Regulation - - O
of - - O
mitochondrial - - B-MUT
single-stranded - - I-MUT
DNA-binding - - I-MUT
protein - - I-MUT
gene - - I-MUT
expression - - O
links - - O
nuclear - - O
and - - O
mitochondrial - - O
DNA - - O
replication - - O
in - - O
drosophila - - O
. - - O

In - - O
mitogen-stimulated - - O
splenocytes - - O
, - - O
Gfi-1 - - B-MUT
expression - - O
begins - - O
to - - O
rise - - O
at - - O
12 - - O
h - - O
after - - O
stimulation - - O
and - - O
reaches - - O
very - - O
high - - O
levels - - O
after - - O
50 - - O
h - - O
, - - O
suggesting - - O
that - - O
it - - O
may - - O
be - - O
functionally - - O
involved - - O
in - - O
events - - O
occurring - - O
after - - O
the - - O
interaction - - O
of - - O
IL-2 - - B-MUT
with - - O
its - - O
receptor - - O
, - - O
perhaps - - O
during - - O
the - - O
transition - - O
from - - O
the - - O
G1 - - O
to - - O
the - - O
S - - O
phase - - O
of - - O
the - - O
cell - - O
cycle - - O
. - - O

The - - O
LAMMER - - B-MUT
protein - - B-MUT
kinase - - I-MUT
encoded - - O
by - - O
the - - O
Doa - - B-MUT
locus - - I-MUT
of - - O
Drosophila - - O
is - - O
required - - O
in - - O
both - - O
somatic - - O
and - - O
germline - - O
cells - - O
and - - O
is - - O
expressed - - O
as - - O
both - - O
nuclear - - O
and - - O
cytoplasmic - - O
isoforms - - O
throughout - - O
development - - O
. - - O

Several - - O
authors - - O
have - - O
recently - - O
reported - - O
interference - - O
in - - O
theophylline - - O
analysis - - O
by - - O
paraxanthine - - O
( - - O
1 - - O
, - - O
7-dimethylxanthine - - O
) - - O
, - - O
an - - O
important - - O
metabolite - - O
of - - O
caffeine - - O
. - - O

An - - O
immunoperoxidase - - B-MUT
reaction - - O
, - - O
PAP - - B-MUT
method - - O
, - - O
with - - O
the - - O
antiserum - - O
of - - O
Factor - - B-MUT
VIII - - I-MUT
as - - O
the - - O
primary - - O
antibody - - O
, - - O
was - - O
carried - - O
out - - O
in - - O
the - - O
endometrial - - O
biopsies - - O
to - - O
detect - - O
the - - O
Factor - - B-MUT
VIII - - I-MUT
activity - - O
in - - O
the - - O
endometrial - - O
endothelium - - O
before - - O
and - - O
after - - O
insertion - - O
of - - O
LNG-IUD-20 - - O
. - - O

Age - - O
was - - O
categorized - - O
into - - O
four - - O
groups - - O
: - - O
20-44 - - O
, - - O
45-64 - - O
, - - O
65-74 - - O
, - - O
and - - O
75+ - - O
. - - O
RESULTS - - O
: - - O
At - - O
the - - O
initiation - - O
of - - O
dialysis - - O
PD - - O
patients - - O
were - - O
approximately - - O
6 - - O
years - - O
younger - - O
( - - O
P - - O
< - - O
0 - - O
. - - O
0001 - - O
) - - O
than - - O
HD - - O
patients - - O
. - - O

UPMC - - O
is - - O
not - - O
the - - O
only - - O
organization - - O
pursuing - - O
controlled - - O
NHBC - - O
organ - - O
procurement - - O
, - - O
however - - O
. - - O

Multivariate - - O
Cox - - O
survival - - O
analysis - - O
identified - - O
baseline - - O
EF - - O
< - - O
or - - O
= - - O
30% - - O
, - - O
presence - - O
of - - O
significant - - O
mitral - - O
regurgitation - - O
( - - O
> - - O
2+ - - O
) - - O
before - - O
ablation - - O
, - - O
and - - O
failure - - O
to - - O
exhibit - - O
improved - - O
cardiac - - O
performance - - O
by - - O
1 - - O
month - - O
after - - O
ablation - - O
as - - O
the - - O
only - - O
independent - - O
predictors - - O
of - - O
death - - O
. - - O

Functional - - O
analysis - - O
of - - O
DNase-I - - B-MUT
hypersensitive - - O
sites - - O
at - - O
the - - O
mouse - - B-MUT
porphobilinogen - - I-MUT
deaminase - - I-MUT
gene - - I-MUT
locus - - I-MUT
. - - O

The - - O
synthetic - - O
DNA - - O
sequence - - O
was - - O
constructed - - O
to - - O
achieve - - O
efficient - - O
base - - O
pairing - - O
with - - O
Escherichia - - B-MUT
coli - - I-MUT
16S - - I-MUT
ribosomal - - I-MUT
RNA - - I-MUT
, - - O
avoidance - - O
of - - O
internal - - O
secondary - - O
structure - - O
, - - O
and - - O
optimal - - O
codon - - O
usage - - O
for - - O
high-level - - O
protein - - O
expression - - O
in - - O
accord - - O
with - - O
the - - O
known - - O
preferences - - O
in - - O
E - - O
. - - O
coli - - O
. - - O

Similarly - - O
, - - O
the - - O
sequence - - O
of - - O
the - - O
U2 - - B-MUT
RNA - - I-MUT
region - - I-MUT
shown - - O
to - - O
be - - O
involved - - O
in - - O
pre-mRNA - - O
branchpoint - - O
recognition - - O
in - - O
yeast - - O
, - - O
and - - O
exactly - - O
conserved - - O
in - - O
metazoan - - B-MUT
U2 - - I-MUT
RNAs - - I-MUT
, - - O
was - - O
totally - - O
divergent - - O
in - - O
trypanosomes - - O
. - - O

The - - O
Ras-related - - B-MUT
GTPases - - I-MUT
are - - O
small - - O
, - - O
20- - - O
to - - O
25-kDa - - O
proteins - - O
which - - O
cycle - - O
between - - O
an - - O
inactive - - O
GDP-bound - - O
form - - O
and - - O
an - - O
active - - O
GTP-bound - - O
state - - O
. - - O

Cognitive - - O
visual - - O
dysfunction - - O
in - - O
a - - O
child - - O
with - - O
cerebral - - O
damage - - O
. - - O

The - - O
most - - O
common - - O
characteristics - - O
of - - O
VRE - - O
patients - - O
were - - O
recent - - O
prior - - O
vancomycin - - O
use - - O
, - - O
recent - - O
prior - - O
susceptible - - O
enterococcal - - O
infection - - O
, - - O
coinfection - - O
with - - O
other - - O
microbial - - O
pathogens - - O
, - - O
and - - O
concurrent - - O
fungal - - O
infection - - O
. - - O

Northern - - O
and - - O
Western - - O
blot - - O
analyses - - O
demonstrated - - O
that - - O
Graf - - B-MUT
2 - - I-MUT
is - - O
expressed - - O
in - - O
several - - O
tissues - - O
, - - O
with - - O
the - - O
highest - - O
expression - - O
in - - O
skeletal - - O
muscle - - O
. - - O

3D - - O
image-processing - - O
permits - - O
to - - O
analyse - - O
ultrasound - - O
data - - O
interactively - - O
in - - O
three - - O
orthogonal - - O
planes - - O
( - - O
section - - O
mode - - O
) - - O
or - - O
in - - O
realistic - - O
3D - - O
views - - O
( - - O
rendering - - O
mode - - O
) - - O
. - - O

Lac - - O
operators - - O
were - - O
introduced - - O
into - - O
several - - O
positions - - O
within - - O
the - - O
CAB - - B-MUT
promoter - - I-MUT
and - - O
operator-free - - O
plasmid - - O
was - - O
used - - O
as - - O
control - - O
. - - O

c-Fos - - B-MUT
transcriptional - - O
activity - - O
stimulated - - O
by - - O
H-Ras-activated - - B-MUT
protein - - I-MUT
kinase - - I-MUT
distinct - - O
from - - O
JNK - - B-MUT
and - - O
ERK - - B-MUT
. - - O

However - - O
, - - O
if - - O
EMPD - - O
involves - - O
the - - O
glans - - O
penis - - O
or - - O
perianal - - O
area - - O
, - - O
a - - O
search - - O
for - - O
internal - - O
malignancy - - O
is - - O
still - - O
warranted - - O
. - - O

There - - O
was - - O
a - - O
significant - - O
effect - - O
of - - O
hematocrit - - O
on - - O
the - - O
General - - O
Health - - O
scale - - O
on - - O
the - - O
SF-36 - - O
( - - O
P - - O
= - - O
0 - - O
. - - O
03 - - O
) - - O
. - - O

The - - O
function - - O
of - - O
the - - O
C-terminal - - O
tail - - O
in - - O
telomere - - O
maintenance - - O
is - - O
not - - O
mediated - - O
through - - O
the - - O
RAP1 - - B-MUT
interacting - - I-MUT
factor - - I-MUT
RIF1 - - B-MUT
: - - O
rap1 - - B-MUT
alleles - - I-MUT
defective - - O
in - - O
both - - O
the - - O
C-terminal - - O
tail - - O
and - - O
RIF1 - - B-MUT
interaction - - I-MUT
domains - - I-MUT
have - - O
additive - - O
effects - - O
on - - O
telomere - - O
length - - O
. - - O

Cloning - - O
by - - O
complementation - - O
and - - O
subsequent - - O
physical - - O
and - - O
genetic - - O
analysis - - O
revealed - - O
that - - O
it - - O
maps - - O
to - - O
RAF1 - - B-MUT
. - - O

An - - O
RNA-binding - - B-MUT
protein - - I-MUT
gene - - I-MUT
( - - O
rbp1 - - B-MUT
) - - O
from - - O
Drosophila - - O
melanogaster - - O
, - - O
encoding - - O
an - - O
RNA - - O
recognition - - O
motif - - O
and - - O
an - - O
Arg-Ser - - O
rich - - O
( - - O
RS - - O
) - - O
domain - - O
, - - O
has - - O
been - - O
characterized - - O
. - - O

These - - O
single - - O
mutational - - O
defects - - O
in - - O
the - - O
eRF1-eRF3 - - B-MUT
interaction - - O
became - - O
evident - - O
when - - O
either - - O
truncated - - O
protein - - O
eRF3C - - B-MUT
or - - O
C-terminally - - O
altered - - O
eRF1 - - B-MUT
proteins - - O
were - - O
used - - O
for - - O
the - - O
authentic - - O
protein - - O
, - - O
providing - - O
further - - O
support - - O
for - - O
the - - O
presence - - O
of - - O
a - - O
C-terminal - - O
interaction - - O
. - - O

Eight-four - - O
ACOAs - - O
were - - O
tested - - O
in - - O
order - - O
to - - O
examine - - O
the - - O
fit - - O
of - - O
the - - O
model - - O
to - - O
the - - O
data - - O
by - - O
path - - O
analysis - - O
with - - O
LISREL - - O
VII - - O
. - - O

In - - O
conclusion - - O
, - - O
marmoset - - B-MUT
monkey - - I-MUT
LHR - - I-MUT
seems - - O
to - - O
lack - - O
the - - O
sequence - - O
corresponding - - O
to - - O
exon - - O
10 - - O
of - - O
the - - O
LHR - - B-MUT
gene - - I-MUT
in - - O
other - - O
mammalian - - O
species - - O
. - - O

By - - O
deletion - - O
analysis - - O
of - - O
the - - O
MLS1 - - B-MUT
control - - O
region - - O
, - - O
we - - O
identified - - O
two - - O
sites - - O
, - - O
UAS1 - - B-MUT
and - - O
UAS2 - - B-MUT
, - - O
as - - O
important - - O
for - - O
efficient - - O
derepression - - O
of - - O
the - - O
gene - - O
. - - O

3' - - O
RNA - - O
boundary - - O
experiments - - O
indicate - - O
that - - O
the - - O
5' - - O
structure - - O
reduces - - O
the - - O
number - - O
of - - O
( - - O
G - - O
U - - O
) - - O
AG - - O
repeats - - O
required - - O
for - - O
stable - - O
TRAP-trp - - O
leader - - B-MUT
RNA - - I-MUT
association - - I-MUT
. - - O

Human - - O
neutrophil - - O
response - - O
to - - O
short-term - - O
exposure - - O
to - - O
F-75 - - O
cobalt-based - - O
alloy - - O
. - - O

Overexpressing - - O
the - - O
coactivator - - O
, - - O
SRC1a - - B-MUT
or - - O
GRIP1 - - B-MUT
, - - O
further - - O
enhances - - O
ERRalpha1-induced - - O
transcriptional - - O
activity - - O
. - - O

Individuals - - O
attending - - O
the - - O
GUM - - O
Department - - O
in - - O
the - - O
Royal - - O
Infirmary - - O
of - - O
Edinburgh - - O
between - - O
1990 - - O
and - - O
1994 - - O
with - - O
the - - O
diagnosis - - O
of - - O
HIV - - O
infection - - O
, - - O
genital - - O
warts - - O
, - - O
genital - - O
herpes - - O
, - - O
non-specific - - O
genital - - O
infection - - O
( - - O
NSGI - - O
) - - O
, - - O
gonorrhoea - - O
and - - O
syphilis - - O
were - - O
included - - O
in - - O
the - - O
study - - O
. - - O

DMI - - O
and - - O
2-OH-DMI - - O
concentrations - - O
were - - O
determined - - O
in - - O
a - - O
similar - - O
group - - O
of - - O
61 - - O
DMI-treated - - O
patients - - O
. - - O

In - - O
addition - - O
, - - O
insulin - - B-MUT
induced - - O
AP-1 - - B-MUT
DNA - - O
binding - - O
activity - - O
, - - O
this - - O
effect - - O
being - - O
totally - - O
prevented - - O
in - - O
the - - O
presence - - O
of - - O
MEK-1 - - B-MUT
inhibitor - - O
. - - O

A - - O
rate-decreasing - - O
dose - - O
of - - O
physostigmine - - O
, - - O
an - - O
acetylcholinesterase - - B-MUT
inhibitor - - O
, - - O
was - - O
studied - - O
in - - O
combination - - O
with - - O
the - - O
range - - O
of - - O
atropine - - O
doses - - O
. - - O

( - - O
5 - - O
) - - O
An - - O
increase - - O
in - - O
leukocyte-counts - - O
occurred - - O
on - - O
the - - O
administration - - O
of - - O
serum - - O
obtained - - O
from - - O
rabbit - - O
during - - O
phase-2 - - O
. - - O

In - - O
addition - - O
, - - O
we - - O
identified - - O
a - - O
novel - - O
type - - O
of - - O
inhibitory - - O
domain - - O
in - - O
the - - O
N-terminal - - O
60 - - O
amino - - O
acids - - O
of - - O
IRF-1 - - B-MUT
which - - O
strongly - - O
inhibits - - O
its - - O
transcriptional - - O
activity - - O
. - - O

Similarly - - O
, - - O
expression - - O
of - - O
a - - O
transiently - - O
transfected - - O
wild-type - - B-MUT
prothymosin - - I-MUT
alpha - - I-MUT
gene - - I-MUT
as - - O
the - - O
reporter - - O
was - - O
not - - O
affected - - O
by - - O
a - - O
repertoire - - O
of - - O
myc-derived - - B-MUT
genes - - I-MUT
, - - O
including - - O
myc - - B-MUT
itself - - O
and - - O
dominant - - O
or - - O
recessive - - O
negative - - O
myc - - B-MUT
mutants - - I-MUT
. - - O

Identification - - O
of - - O
a - - O
novel - - O
E2F3 - - B-MUT
product - - I-MUT
suggests - - O
a - - O
mechanism - - O
for - - O
determining - - O
specificity - - O
of - - O
repression - - O
by - - O
Rb - - B-MUT
proteins - - I-MUT
. - - O

In - - O
this - - O
paper - - O
, - - O
a - - O
comparison - - O
between - - O
the - - O
number - - O
and - - O
shape - - O
of - - O
corneal - - O
endothelial - - O
cells - - O
has - - O
been - - O
performed - - O
in - - O
25 - - O
patients - - O
before - - O
and - - O
6 - - O
months - - O
after - - O
PRK - - O
. - - O

Experimental - - O
study - - O
of - - O
ta - - O
chengchi - - O
tang - - O
decoction - - O
for - - O
relieving - - O
lung - - O
injury - - O
during - - O
acute - - O
necrotizing - - O
pancreatitis - - O
The - - O
objectives - - O
of - - O
the - - O
study - - O
were - - O
to - - O
investigate - - O
the - - O
changes - - O
of - - O
leukocyte - - O
adhesiveness - - O
and - - O
tumor - - B-MUT
necrosis - - I-MUT
factor - - I-MUT
( - - O
TNF - - B-MUT
) - - O
in - - O
the - - O
early - - O
stage - - O
of - - O
acute - - O
necrotizing - - O
pancreatitis - - O
( - - O
ANP - - O
) - - O
, - - O
to - - O
go - - O
further - - O
into - - O
the - - O
relation - - O
of - - O
those - - O
changes - - O
to - - O
lung - - O
injury - - O
of - - O
ANP - - O
, - - O
and - - O
to - - O
evaluate - - O
the - - O
prohibitive - - O
effect - - O
of - - O
ta - - O
chengchi - - O
tang - - O
Decoction - - O
on - - O
leukocyte - - O
adhesion - - O
and - - O
TNF - - B-MUT
secretion - - O
. - - O

Processing - - O
of - - O
the - - O
NS3'-5B - - B-MUT
polyprotein - - I-MUT
was - - O
complex - - O
and - - O
occurred - - O
rapidly - - O
. - - O

Sequential - - O
cleavage - - O
by - - O
metallopeptidases - - B-MUT
and - - O
proteasomes - - O
is - - O
involved - - O
in - - O
processing - - O
HIV-1 - - B-MUT
ENV - - I-MUT
epitope - - I-MUT
for - - O
endogenous - - O
MHC - - B-MUT
class - - I-MUT
I - - I-MUT
antigen - - I-MUT
presentation - - O
. - - O

The - - O
recombinant - - O
enzymes - - O
exist - - O
as - - O
monomers - - O
. - - O

Identification - - O
of - - O
a - - O
new - - O
gene - - O
in - - O
the - - O
streptococcal - - O
plasmid - - O
pLS1 - - O
: - - O
the - - O
rnaI - - B-MUT
gene - - I-MUT
. - - O

We - - O
recommend - - O
that - - O
ovarian - - O
stimulation - - O
is - - O
done - - O
only - - O
if - - O
there - - O
is - - O
a - - O
valid - - O
indication - - O
after - - O
proper - - O
assessment - - O
of - - O
the - - O
ovaries - - O
, - - O
and - - O
that - - O
women - - O
who - - O
have - - O
had - - O
ovarian - - O
stimulation - - O
are - - O
followed - - O
for - - O
longer - - O
than - - O
at - - O
present - - O
. - - O

In - - O
Experiment - - O
1 - - O
, - - O
pups - - O
that - - O
had - - O
received - - O
an - - O
injection - - O
of - - O
the - - O
noncompetitive - - O
N-methyl-D-aspartate - - B-MUT
receptor - - I-MUT
antagonist - - O
MK-801 - - O
( - - O
0 - - O
. - - O
1 - - O
mg - - O
kg - - O
, - - O
i - - O
. - - O
p - - O
. - - O
) - - O
either - - O
30 - - O
min - - O
before - - O
or - - O
immediately - - O
after - - O
conditioning - - O
spent - - O
less - - O
time - - O
over - - O
the - - O
conditioned - - O
odor - - O
than - - O
saline-treated - - O
controls - - O
. - - O

Group - - O
A - - O
was - - O
treated - - O
with - - O
three - - O
or - - O
four - - O
doses - - O
of - - O
hepatitis - - B-MUT
B - - I-MUT
immune - - I-MUT
globulin - - I-MUT
( - - O
HBIG - - B-MUT
) - - O
in - - O
one - - O
of - - O
three - - O
different - - O
schedules - - O
. - - O

The - - O
flow - - O
rate - - O
of - - O
phosphate - - O
buffered - - O
saline - - O
through - - O
dermis - - O
was - - O
measured - - O
as - - O
a - - O
function - - O
of - - O
applied - - O
pressure - - O
. - - O

Vestibular - - O
adaptation - - O
exercises - - O
and - - O
recovery - - O
: - - O
acute - - O
stage - - O
after - - O
acoustic - - O
neuroma - - O
resection - - O
. - - O

SEA - - O
was - - O
recorded - - O
with - - O
bidirectional - - O
filters - - O
at - - O
25-250 - - O
HZ - - O
and - - O
40-250 - - O
Hz - - O
using - - O
Simson - - O
method - - O
. - - O

( - - O
Cactaceae - - O
) - - O
waste - - O
matter - - O
. - - O

During - - O
chronic - - O
treatment - - O
, - - O
when - - O
plasma - - O
concentrations - - O
fluctuated - - O
between - - O
23 - - O
. - - O
5 - - O
ng - - O
. - - O
ml-1 - - O
at - - O
8 - - O
h - - O
and - - O
14 - - O
ng - - O
. - - O
ml-1 - - O
at - - O
24 - - O
h - - O
post-dosing - - O
, - - O
ST - - O
segment - - O
depression - - O
at - - O
an - - O
individually - - O
comparable - - O
workload - - O
was - - O
significantly - - O
decreased - - O
by - - O
28% - - O
compared - - O
with - - O
placebo - - O
( - - O
P - - O
< - - O
0 - - O
. - - O
005 - - O
) - - O
at - - O
both - - O
points - - O
in - - O
time - - O
. - - O

Both - - O
inhaled - - O
and - - O
superfused - - O
isoflurane - - O
dilated - - O
the - - O
baseline - - O
vein - - O
diameter - - O
before - - O
stimulation - - O
. - - O

Immunoblotting - - O
of - - O
expressed - - O
recombinant - - O
proteins - - O
with - - O
the - - O
monoclonal - - B-MUT
08L - - I-MUT
antibody - - I-MUT
localized - - O
the - - O
08L - - B-MUT
epitope - - O
to - - O
the - - O
carboxyl - - O
end - - O
of - - O
the - - O
protein - - O
. - - O

Consistently - - O
, - - O
activation - - O
of - - O
c-Jun - - B-MUT
N-terminal - - I-MUT
kinase - - I-MUT
downstream - - O
of - - O
Rho - - B-MUT
family - - I-MUT
GTP-binding - - I-MUT
proteins - - I-MUT
was - - O
also - - O
enhanced - - O
when - - O
Dbl - - B-MUT
was - - O
tyrosine-phosphorylated - - O
. - - O

However - - O
, - - O
both - - O
TPN - - O
groups - - O
showed - - O
a - - O
marked - - O
increase - - O
in - - O
activities - - O
of - - O
liver - - B-MUT
lysosomal - - I-MUT
enzymes - - I-MUT
. - - O

267 - - O
, - - O
4870-4877 - - O
) - - O
) - - O
indicates - - O
an - - O
overall - - O
identity - - O
of - - O
58 - - O
and - - O
56% - - O
, - - O
respectively - - O
, - - O
with - - O
a - - O
91 - - O
and - - O
92% - - O
identity - - O
in - - O
the - - O
highly - - O
conserved - - O
transmembrane - - O
and - - O
cytoplasmic - - O
domains - - O
. - - O

Endo16 - - B-MUT
transcripts - - I-MUT
are - - O
confined - - O
to - - O
the - - O
definitive - - O
vegetal - - O
plate - - O
in - - O
blastula - - O
stage - - O
embryos - - O
; - - O
at - - O
gastrula - - O
stage - - O
this - - O
gene - - O
is - - O
expressed - - O
throughout - - O
the - - O
archenteron - - O
, - - O
but - - O
later - - O
only - - O
in - - O
the - - O
midgut - - O
. - - O

Nuclear - - B-MUT
beta - - I-MUT
II - - I-MUT
PKC - - I-MUT
, - - O
like - - O
p34cdc2 - - B-MUT
kinase - - I-MUT
, - - O
may - - O
function - - O
to - - O
regulate - - O
nuclear - - O
lamina - - O
structural - - O
stability - - O
during - - O
cell - - O
cycle - - O
. - - O

When - - O
Hy-Vac - - O
SPF - - O
type - - O
V - - O
embryos - - O
were - - O
exposed - - O
to - - O
either - - O
0 - - O
. - - O
20 - - O
ml - - O
50% - - O
ethanol - - O
in - - O
CRS - - O
or - - O
to - - O
0 - - O
. - - O
20 - - O
ml - - O
CRS - - O
( - - O
controls - - O
) - - O
, - - O
ethanol-treated - - O
embryos - - O
showed - - O
a - - O
VSD - - O
incidence - - O
of - - O
34 - - O
. - - O
1% - - O
compared - - O
with - - O
a - - O
3 - - O
. - - O
6% - - O
incidence - - O
in - - O
the - - O
controls - - O
( - - O
P - - O
= - - O
0 - - O
. - - O
0017 - - O
) - - O
. - - O

Gains - - O
increased - - O
3 - - O
. - - O
5% - - O
( - - O
P - - O
less - - O
than - - O
. - - O
10 - - O
) - - O
and - - O
feed - - O
conversion - - O
improved - - O
5 - - O
. - - O
9% - - O
( - - O
P - - O
less - - O
than - - O
. - - O
07 - - O
) - - O
in - - O
steers - - O
fed - - O
. - - O
28% - - O
AS-VFA - - O
compared - - O
with - - O
gain - - O
and - - O
feed - - O
conversion - - O
of - - O
the - - O
control - - O
steers - - O
. - - O

Endocrine - - O
cells - - O
were - - O
studied - - O
by - - O
means - - O
of - - O
Grimelius' - - O
silver - - O
staining - - O
and - - O
immunostaining - - O
for - - O
chromogranin - - B-MUT
, - - O
a - - O
general - - O
marker - - O
of - - O
endocrine - - O
cells - - O
. - - O

The - - O
gene - - O
encoding - - O
TRP-2 - - B-MUT
maps - - O
to - - O
mouse - - O
chromosome - - O
14 - - O
, - - O
in - - O
the - - O
region - - O
of - - O
the - - O
coat - - B-MUT
colour - - I-MUT
mutation - - I-MUT
slaty - - I-MUT
. - - O

Genetic - - O
and - - O
molecular - - O
data - - O
indicate - - O
that - - O
wild-type - - B-MUT
Pan - - I-MUT
and - - O
CiD - - B-MUT
compete - - O
for - - O
binding - - O
to - - O
Arm - - B-MUT
, - - O
leading - - O
to - - O
a - - O
compromised - - O
transduction - - O
of - - O
the - - O
Wg - - B-MUT
signal - - O
in - - O
heterozygous - - O
ciD - - B-MUT
+ - - I-MUT
animals - - I-MUT
and - - O
to - - O
a - - O
dramatic - - O
enhancement - - O
of - - O
the - - O
gain-of-function - - O
activity - - O
of - - O
CiD - - O
in - - B-MUT
homozygous - - O
mutants - - O
. - - O

Our - - O
data - - O
therefore - - O
indicate - - O
that - - O
it - - O
is - - O
possible - - O
to - - O
engineer - - O
the - - O
HA - - B-MUT
envelope - - I-MUT
glycoprotein - - I-MUT
by - - O
fusing - - O
ligands - - O
to - - O
its - - O
amino-terminal - - O
end - - O
without - - O
affecting - - O
its - - O
fusion - - O
activity - - O
. - - O

Drug - - O
and - - O
nutrient - - O
interactions - - O
. - - O

The - - O
protein - - O
first - - O
identified - - O
by - - O
the - - O
monoclonal - - B-MUT
antibody - - I-MUT
Q18 - - I-MUT
is - - O
encoded - - O
by - - O
a - - O
gene - - O
located - - O
in - - O
57A - - O
on - - O
polytene - - O
chromosomes - - O
and - - O
has - - O
been - - O
consequently - - O
named - - O
Hrb57A - - B-MUT
. - - O

This - - O
analysis - - O
supports - - O
the - - O
use - - O
of - - O
fluticasone - - O
propionate - - O
88 - - O
microg - - O
twice - - O
daily - - O
as - - O
first-line - - O
treatment - - O
in - - O
patients - - O
with - - O
persistent - - O
asthma - - O
previously - - O
treated - - O
with - - O
short-acting - - O
beta2-agonist - - O
alone - - O
. - - O

On - - O
admission - - O
to - - O
our - - O
department - - O
in - - O
September - - O
, - - O
1987 - - O
, - - O
the - - O
patient - - O
was - - O
alert - - O
and - - O
had - - O
spastic - - O
paraparesis - - O
, - - O
the - - O
impairment - - O
of - - O
all - - O
sensory - - O
modalities - - O
below - - O
the - - O
level - - O
of - - O
Th - - O
10 - - O
and - - O
urinary - - O
disturbance - - O
. - - O

In - - O
conclusion - - O
, - - O
changes - - O
in - - O
carotid - - O
sinus - - O
stimulation - - O
alters - - O
blood - - O
flow - - O
to - - O
the - - O
hindlimb - - O
through - - O
changes - - O
in - - O
both - - O
Pcrit - - O
and - - O
Ra - - O
. - - O

This - - O
R-domain - - O
may - - O
modulate - - O
the - - O
interaction - - O
with - - O
SRF - - B-MUT
, - - O
providing - - O
a - - O
mechanism - - O
that - - O
would - - O
be - - O
unique - - O
to - - O
FLI1 - - B-MUT
and - - O
EWS-FLI1 - - B-MUT
, - - O
thus - - O
implicating - - O
a - - O
novel - - O
function - - O
for - - O
these - - O
ETS - - B-MUT
transcription - - I-MUT
factors - - I-MUT
in - - O
the - - O
regulation - - O
of - - O
the - - O
Egr1 - - B-MUT
gene - - I-MUT
. - - O

A - - O
new - - O
generation - - O
of - - O
information - - O
retrieval - - O
tools - - O
for - - O
biologists - - O
: - - O
the - - O
example - - O
of - - O
the - - O
ExPASy - - O
WWW - - O
server - - O
. - - O

Histamine-2 - - O
blockade - - O
in - - O
psoriasis - - O
. - - O

We - - O
have - - O
cloned - - O
and - - O
sequenced - - O
the - - O
mouse - - B-MUT
NMO1 - - I-MUT
cDNA - - I-MUT
, - - O
which - - O
encodes - - O
the - - O
NAD - - B-MUT
( - - I-MUT
P - - I-MUT
) - - I-MUT
H - - I-MUT
: - - I-MUT
menadione - - I-MUT
oxidoreductase - - I-MUT
[ - - O
also - - O
called - - O
NAD - - B-MUT
( - - I-MUT
P - - I-MUT
) - - I-MUT
H - - I-MUT
: - - I-MUT
( - - I-MUT
quinone - - I-MUT
acceptor - - I-MUT
) - - I-MUT
oxidoreductase - - I-MUT
; - - I-MUT
quinone - - I-MUT
reductase - - I-MUT
; - - O
azo - - B-MUT
dye - - I-MUT
reductase - - I-MUT
; - - O
DT - - B-MUT
diaphorase - - I-MUT
; - - O
EC - - B-MUT
1 - - I-MUT
. - - I-MUT
6 - - I-MUT
. - - I-MUT
99 - - I-MUT
. - - I-MUT
2 - - I-MUT
] - - I-MUT
. - - O

Type - - O
I - - O
cysts - - O
( - - O
with - - O
a - - O
high - - O
K+ - - O
Na+ - - O
ratio - - O
) - - O
tend - - O
to - - O
have - - O
higher - - O
total - - O
PSA - - O
than - - B-MUT
Type - - O
II - - O
cysts - - O
. - - O

The - - O
presence - - O
of - - O
local - - O
abnormalities - - O
in - - O
both - - O
patients - - O
can - - O
support - - O
the - - O
hypothesis - - O
that - - O
the - - O
cortex - - O
, - - O
especially - - O
of - - O
the - - O
temporal - - O
anterior - - O
lobe - - O
, - - O
is - - O
involved - - O
in - - O
the - - O
origin - - O
of - - O
the - - O
laughing - - O
seizures - - O
. - - O

In - - O
summary - - O
, - - O
WT1 - - B-MUT
is - - O
enriched - - O
by - - O
oligo - - O
( - - O
dT - - O
) - - O
chromatography - - O
, - - O
as - - O
are - - O
U2AF65 - - B-MUT
, - - O
the - - O
U5 - - B-MUT
small - - I-MUT
nuclear - - I-MUT
RNP-associated - - I-MUT
protein - - I-MUT
p116 - - I-MUT
and - - O
hnRNP - - B-MUT
A1 - - B-MUT
. - - O

Predictors - - O
of - - O
success - - O
in - - O
pharmacy - - O
school - - O
: - - O
PCAT - - O
vs - - O
. - - O
other - - O
admission - - O
criteria - - O
. - - O

Electrophoretic - - O
mobility - - O
shift - - O
assays - - O
and - - O
coimmunoprecipitation - - O
studies - - O
suggest - - O
that - - O
homo- - - O
and - - O
heterodimerization - - O
occurs - - O
between - - O
cKrox - - B-MUT
family - - I-MUT
members - - I-MUT
. - - O

A - - O
new - - O
bioencapsulation - - O
technology - - O
for - - O
microbial - - O
inoculants - - O
. - - O

This - - O
indicates - - O
that - - O
recruitment - - O
of - - O
large - - B-MUT
T - - I-MUT
antigen - - I-MUT
to - - O
the - - O
rRNA - - O
promoter - - O
by - - O
SL1 - - B-MUT
constitutes - - O
a - - O
crucial - - O
step - - O
in - - O
the - - O
activation - - O
process - - O
. - - O

Anatomy - - O
of - - O
the - - O
RNA - - O
and - - O
gene - - O
products - - O
of - - O
MC29 - - O
and - - O
MH2 - - O
, - - O
two - - O
defective - - O
avian - - O
tumor - - O
viruses - - O
causing - - O
acute - - O
leukemia - - O
and - - O
carcinoma - - O
: - - O
evidence - - O
for - - O
a - - O
new - - O
class - - O
of - - O
transforming - - O
genes - - O
. - - O

Concomitant - - O
chronic - - O
lymphocytic - - O
leukemia - - O
, - - O
acute - - O
myeloid - - O
leukemia - - O
, - - O
and - - O
thrombosis - - O
with - - O
protein - - B-MUT
C - - I-MUT
deficiency - - O
. - - O

NO - - O
metabolites - - O
were - - O
determined - - O
by - - O
the - - O
measurement - - O
of - - O
nitrate - - O
nitrite - - O
( - - O
NOx - - O
, - - O
micromol - - O
mmol - - O
creatinine - - O
) - - O
and - - O
cyclic - - O
guanosine - - O
monophosphate - - O
( - - O
cGMP - - O
, - - O
nmol - - O
mmol - - O
creatinine - - O
) - - O
in - - O
plasma - - O
and - - O
urine - - O
. - - O

The - - O
therapeutic - - O
protocole - - O
used - - O
at - - O
the - - O
Gustave - - O
Roussy - - O
Institute - - O
for - - O
invasive - - O
epithelioma - - O
of - - O
the - - O
uterine - - O
cervix - - O
rests - - O
, - - O
for - - O
limited - - O
forms - - O
( - - O
T1B-T2 - - O
proximal - - O
) - - O
, - - O
on - - O
combined - - O
radiology - - O
and - - O
surgery - - O
. - - O

Thus - - O
, - - O
NART-R - - O
performance - - O
may - - O
not - - O
be - - O
a - - O
valid - - O
estimate - - O
of - - O
baseline - - O
IQ - - O
for - - O
patients - - O
with - - O
neurologic - - O
disorders - - O
with - - O
suspected - - O
language - - O
impairment - - O
. - - O

Staphylococcal - - B-MUT
enterotoxin - - I-MUT
A - - I-MUT
involvement - - O
in - - O
the - - O
illness - - O
of - - O
a - - O
20-month-old - - O
burn - - O
patient - - O
. - - O

Surface - - O
spin - - O
waves - - O
in - - O
a - - O
Heisenberg - - O
ferrimagnet - - O
with - - O
a - - O
single-ion - - O
anisotropy - - O
( - - O
uniaxial - - O
and - - O
nonuniaxial - - O
) - - O
. - - O

Importantly - - O
, - - O
concomitant - - O
expression - - O
of - - O
constitutive - - O
activated - - O
Raf - - B-MUT
and - - O
V12N38 - - B-MUT
Ras - - I-MUT
results - - O
in - - O
almost - - O
complete - - O
loss - - O
of - - O
TTF-1 - - B-MUT
activity - - O
. - - O

Using - - O
an - - O
audiotape - - O
cassette - - O
and - - O
headphones - - O
the - - O
duration - - O
of - - O
the - - O
hallucinations - - O
decreased - - O
significantly - - O
. - - O

These - - O
studies - - O
indicate - - O
that - - O
the - - O
acidimetric - - O
test - - O
was - - O
less - - O
sensitive - - O
than - - O
the - - O
chromogenic - - O
cephalosporin - - O
substrates - - O
and - - O
that - - O
nitrocefin - - O
and - - O
S1 - - O
could - - O
be - - O
used - - O
to - - O
screen - - O
for - - O
beta-lactamase - - B-MUT
production - - O
in - - O
these - - O
tested - - O
species - - O
. - - O

We - - O
performed - - O
the - - O
present - - O
study - - O
to - - O
clarify - - O
the - - O
relationship - - O
between - - O
the - - O
DOX - - O
binding - - O
ability - - O
( - - O
%DB - - O
) - - O
and - - O
the - - O
histologic - - O
response - - O
, - - O
rate - - O
of - - O
decrease - - O
in - - O
tumor - - O
volume - - O
of - - O
malignant - - O
soft - - O
tissue - - O
tumors - - O
after - - O
preoperative - - O
chemotherapy - - O
and - - O
prognosis - - O
. - - O

Gel-shift - - O
assays - - O
identified - - O
two - - O
Sp1 - - B-MUT
binding - - I-MUT
sites - - I-MUT
within - - O
this - - O
element - - O
. - - O

2000 - - O
update - - O
of - - O
recommendations - - O
for - - O
the - - O
use - - O
of - - O
hematopoietic - - B-MUT
colony-stimulating - - I-MUT
factors - - I-MUT
: - - O
evidence-based - - O
, - - O
clinical - - O
practice - - O
guidelines - - O
. - - O

The - - O
beta - - O
chain - - O
contains - - O
five - - O
potential - - O
N-linked - - O
glycosylation - - O
sites - - O
, - - O
and - - O
endoglycosidase - - B-MUT
digestion - - O
suggested - - O
that - - O
the - - O
beta - - O
chain - - O
contained - - O
multiple - - O
complex - - O
carbohydrate - - O
side - - O
chains - - O
. - - O

Rapid - - O
detection - - O
of - - O
this - - O
mutation - - O
is - - O
achieved - - O
by - - O
restriction - - O
digestion - - O
of - - O
PCR-amplified - - O
genomic - - O
DNA - - O
; - - O
a - - O
mismatch - - O
primer - - O
combined - - O
with - - O
the - - O
point - - O
mutation - - O
creates - - O
a - - O
Tru9I - - B-MUT
restriction - - I-MUT
site - - I-MUT
. - - O

Transactivation - - O
domain - - O
is - - O
located - - O
downstream - - O
of - - O
the - - O
128-amino-acid - - B-MUT
runt - - I-MUT
homology - - I-MUT
region - - I-MUT
, - - O
referred - - O
to - - O
as - - O
the - - O
Runt - - B-MUT
domain - - I-MUT
. - - O

This - - O
generally - - O
means - - O
an - - O
energy - - O
intake - - O
of - - O
1 - - O
. - - O
4 - - O
to - - O
1 - - O
. - - O
6 - - O
times - - O
the - - O
energy - - O
expenditure - - O
, - - O
with - - O
a - - O
N - - O
intake - - O
of - - O
250 - - O
to - - O
400 - - O
mg - - O
kg - - O
day - - O
. - - O

Mutational - - O
analysis - - O
showed - - O
that - - O
the - - O
U-box - - O
, - - O
like - - O
the - - O
RING - - O
finger - - O
in - - O
other - - O
proteins - - O
, - - O
forms - - O
the - - O
physical - - O
basis - - O
for - - O
the - - O
interaction - - O
with - - O
E2 - - B-MUT
enzymes - - I-MUT
. - - O

Pb - - O
foil - - O
( - - O
0 - - O
. - - O
55 - - O
gcm-2 - - O
) - - O
provided - - O
the - - O
best - - O
overall - - O
improvement - - O
. - - O

This - - O
article - - O
reviews - - O
recent - - O
information - - O
on - - O
the - - O
frequency - - O
, - - O
characteristics - - O
, - - O
and - - O
possible - - O
pathogenic - - O
mechanisms - - O
of - - O
the - - O
vasculitides - - O
occurring - - O
in - - O
patients - - O
with - - O
the - - O
main - - O
connective - - O
tissue - - O
diseases - - O
. - - O

During - - O
activity - - O
III - - O
, - - O
one - - O
patient - - O
developed - - O
angina - - O
. - - O

A - - O
4 - - B-MUT
. - - I-MUT
8-kilobase - - I-MUT
BamHI-HindIII - - I-MUT
fragment - - I-MUT
encoding - - O
the - - O
entire - - B-MUT
Neurospora - - I-MUT
crassa - - I-MUT
CuZn - - I-MUT
superoxide - - I-MUT
dismutase - - I-MUT
gene - - I-MUT
( - - O
herein - - O
designated - - O
sod-1 - - B-MUT
) - - O
was - - O
isolated - - O
from - - O
a - - O
genomic - - O
library - - O
using - - O
two - - O
60-base - - O
deoxyoligonucleotide - - O
probes - - O
corresponding - - O
to - - O
the - - O
published - - O
N - - O
. - - O
crassa - - O
amino - - O
acid - - O
sequence - - O
. - - O

Eight - - O
hr - - O
of - - O
acidosis - - O
caused - - O
a - - O
significant - - O
( - - O
P - - O
less - - O
than - - O
0 - - O
. - - O
01 - - O
) - - O
decrease - - O
in - - O
P50 - - O
in - - O
vitro - - O
which - - O
fell - - O
from - - O
29 - - O
. - - O
0 - - O
to - - O
24 - - O
. - - O
4 - - O
torr - - O
. - - O

Neutron - - O
scattering - - O
measurements - - O
of - - O
critical - - O
exponents - - O
in - - O
CsMnBr3 - - O
: - - O
A - - O
Z2 - - O
> - - O
= - - O
1 - - O
antiferromagnet - - O
. - - O

Thus - - O
, - - O
the - - O
B-S - - O
mutant - - O
does - - O
not - - O
mimic - - O
efficiently - - O
the - - O
chloroplastic - - B-MUT
GAPDHs - - I-MUT
, - - O
and - - O
long-range - - O
and - - O
or - - O
second-layer - - O
effects - - O
, - - O
not - - O
easily - - O
predictable - - O
from - - O
visual - - O
inspection - - O
of - - O
three-dimensional - - O
structures - - O
, - - O
need - - O
to - - O
be - - O
taken - - O
into - - O
account - - O
for - - O
designing - - O
a - - O
true - - O
"chloroplastic-like" - - O
mutant - - O
of - - O
cytosolic - - O
GAPDH - - B-MUT
. - - I-MUT

It - - O
has - - O
been - - O
proposed - - O
that - - O
the - - O
parCBA - - B-MUT
operon - - I-MUT
encodes - - O
a - - O
plasmid - - O
partitioning - - O
system - - O
( - - O
M - - O
. - - O

The - - O
oral - - O
temperature - - O
rose - - O
and - - O
the - - O
serum - - B-MUT
creatine - - I-MUT
kinase - - I-MUT
levels - - O
fell - - O
only - - O
in - - O
those - - O
patients - - O
who - - O
were - - O
actively - - O
warmed - - O
. - - O

Genome - - O
plasticity - - O
in - - O
the - - O
distal - - B-MUT
tail - - I-MUT
fiber - - I-MUT
locus - - I-MUT
of - - O
the - - O
T-even - - O
bacteriophage - - O
: - - O
recombination - - O
between - - O
conserved - - O
motifs - - O
swaps - - O
adhesin - - B-MUT
specificity - - O
. - - O

Because - - O
of - - O
its - - O
great - - O
reliability - - O
, - - O
conventional - - O
arteriography - - O
occupies - - O
a - - O
place - - O
of - - O
choice - - O
among - - O
the - - O
medical - - O
imaging - - O
techniques - - O
. - - O

They - - O
were - - O
checked - - O
for - - O
anti-HCV - - B-MUT
( - - O
anti-C100-3 - - B-MUT
) - - O
with - - O
HCV - - O
EIA - - O
kit - - O
( - - O
Abbott - - O
Lab - - O
. - - O
, - - O
North - - O
Chicago - - O
, - - O
IL - - O
) - - O
. - - O

Therefore - - O
more - - O
active - - O
and - - O
tolerable - - O
salvage - - O
regimens - - O
are - - O
needed - - O
. - - O

Furthermore - - O
, - - O
upstream - - O
insertion - - O
of - - O
the - - O
GSTP1 - - B-MUT
silencer - - I-MUT
element - - I-MUT
failed - - O
to - - O
inhibit - - O
activity - - O
of - - O
a - - O
heterologous - - O
promoter - - O
in - - O
MCF7 - - O
cells - - O
. - - O

A - - O
variety - - O
of - - O
professional - - O
and - - O
self-applied - - O
fluoride - - O
products - - O
are - - O
available - - O
and - - O
new - - O
fluoride - - O
delivery - - O
systems - - O
have - - O
recently - - O
entered - - O
the - - O
market - - O
. - - O

These - - O
results - - O
indicate - - O
that - - O
K-glypican - - B-MUT
is - - O
a - - O
novel - - O
GPI-anchored - - B-MUT
HSPG - - I-MUT
involved - - O
in - - O
embryonic - - O
development - - O
. - - O

Serum - - O
gastrin - - B-MUT
levels - - O
did - - O
not - - O
change - - O
in - - O
either - - O
group - - O
; - - O
however - - O
, - - O
background - - O
serum - - O
gastrin - - B-MUT
concentrations - - O
were - - O
significantly - - O
greater - - O
for - - O
V&P - - O
patients - - O
than - - O
V&A - - O
patients - - O
throughout - - O
the - - O
study - - O
. - - O

These - - O
residues - - O
, - - O
Ile244 - - O
at - - O
the - - O
extracellular - - O
end - - O
of - - O
transmembrane - - O
helix - - O
3 - - O
, - - O
and - - O
Tyr318 - - O
at - - O
the - - O
COOH-terminal - - O
portion - - O
of - - O
extracellular - - O
loop - - O
2 - - O
, - - O
are - - O
replaced - - O
by - - O
Leu - - O
and - - O
Ile - - O
in - - O
the - - O
PTH-1 - - B-MUT
receptor - - I-MUT
, - - O
respectively - - O
. - - O

Lung - - O
mesenchyme - - O
serves - - O
as - - O
a - - O
'compleat' - - O
inducer - - O
of - - O
lung - - O
morphogenesis - - O
by - - O
secreting - - O
soluble - - O
peptide - - O
growth - - O
factors - - O
. - - O

Viable - - O
flap - - O
areas - - O
were - - O
established - - O
following - - O
vascular - - O
pedicle - - O
ligation - - O
( - - O
both - - O
vessels - - O
or - - O
only - - O
artery - - O
or - - O
vein - - O
) - - O
, - - O
on - - O
the - - O
third - - O
day - - O
after - - O
flap - - O
replantation - - O
in - - O
both - - O
island - - O
and - - O
free - - O
flaps - - O
. - - O

Using - - O
backcross - - O
analysis - - O
, - - O
both - - O
exons - - O
1 - - O
and - - O
4 - - O
mapped - - O
to - - O
a - - O
proximal - - O
region - - O
of - - O
murine - - O
Chromosome - - O
4 - - O
indistinguishable - - O
from - - O
the - - O
vacillans - - B-MUT
gene - - I-MUT
. - - O

It - - O
was - - O
found - - O
that - - O
under - - O
the - - O
selected - - O
conditions - - O
a - - O
linear - - O
dependence - - O
exists - - O
between - - O
the - - O
betaI% - - O
value - - O
and - - O
lgC - - O
within - - O
the - - O
range - - O
of - - O
0 - - O
. - - O
5--10 - - O
mug - - O
ruscogenin - - O
. - - O

Characterization - - O
of - - O
the - - O
transcription - - B-MUT
factor - - I-MUT
MTF-1 - - I-MUT
from - - O
the - - O
Japanese - - O
pufferfish - - O
( - - O
Fugu - - O
rubripes - - O
) - - O
reveals - - O
evolutionary - - O
conservation - - O
of - - O
heavy - - O
metal - - O
stress - - O
response - - O
. - - O

We - - O
characterized - - O
cDNA - - O
clones - - O
specific - - O
for - - O
the - - O
extracellular - - O
matrix - - O
glycoprotein - - O
undulin - - B-MUT
. - - O

Furthermore - - O
, - - O
no - - O
Shine-Dalgarno - - O
sequences - - O
are - - O
present - - O
upstream - - O
of - - O
the - - O
presumed - - O
translational - - O
start - - O
codons - - O
. - - O

Holger - - O
v - - O
. - - O

Tolerance - - O
to - - O
ADAL-2 - - O
was - - O
similar - - O
to - - O
that - - O
of - - O
Vicryl - - O
suture - - O
and - - O
tolerance - - O
to - - O
ADAL-2 - - O
was - - O
superior - - O
to - - O
that - - O
to - - O
Tisuacryl - - O
. - - O

PKNbeta - - B-MUT
had - - O
high - - O
sequence - - O
homology - - O
with - - O
PKNalpha - - B-MUT
, - - O
originally - - O
isolated - - O
PKN - - B-MUT
, - - O
especially - - O
in - - O
the - - O
repeats - - O
of - - O
charged - - O
amino - - O
acid-rich - - O
region - - O
with - - O
leucine-zipper - - O
like - - O
sequences - - O
( - - O
CZ - - B-MUT
region - - I-MUT
HR1 - - I-MUT
) - - I-MUT
, - - O
in - - O
the - - O
carboxyl-terminal - - O
catalytic - - O
domain - - O
, - - O
and - - O
in - - O
approximately - - O
130 - - O
amino - - O
acid - - O
stretch - - O
( - - O
D - - O
region - - B-MUT
HR2 - - I-MUT
) - - I-MUT
, - - I-MUT
located - - O
between - - O
CZ - - O
region - - O
HR1 - - B-MUT
and - - I-MUT
the - - I-MUT
catalytic - - I-MUT
domain - - O
. - - O

Results - - O
have - - O
surprisingly - - O
revealed - - O
the - - O
presence - - O
of - - O
three - - O
U14 - - B-MUT
snRNA-homologous - - I-MUT
regions - - I-MUT
positioned - - O
within - - O
introns - - O
5 - - O
, - - O
6 - - O
, - - O
and - - O
8 - - O
of - - O
the - - O
mouse - - O
cognate - - O
hsc70 - - B-MUT
heat - - O
shock - - O
gene - - O
. - - O

[ - - O
figure - - O
: - - O
see - - O
text - - O
] - - O
The - - O
Stille - - O
coupling - - O
reaction - - O
has - - O
been - - O
performed - - O
in - - O
1-butyl-3-methylimidazolium - - O
tetrafluoroborate - - O
( - - O
BMIM - - O
BF4 - - O
) - - O
, - - O
a - - O
room-temperature - - O
ionic - - O
liquid - - O
( - - O
RTIL - - O
) - - O
. - - O

In - - O
general - - O
, - - O
the - - O
values - - O
obtained - - O
by - - O
the - - O
two - - O
methods - - O
were - - O
in - - O
agreement - - O
for - - O
each - - O
species - - O
of - - O
epidermal - - B-MUT
growth - - I-MUT
factor - - I-MUT
and - - O
followed - - O
the - - O
order - - O
: - - O
wild - - O
type - - O
greater - - O
than - - O
Glu24----Gly - - O
greater - - O
than - - O
Asp27----Gly - - O
much - - O
greater - - O
than - - O
Pro7----Thr - - O
greater - - O
than - - O
Tyr29----Gly - - O
greater - - O
than - - O
Leu47----His - - O
. - - O

The - - O
ensembles - - O
are - - O
considered - - O
to - - O
be - - O
one - - O
of - - O
the - - O
forms - - O
of - - O
activity - - O
of - - O
the - - O
structured - - O
morphofunctional - - O
cortical - - O
units - - O
, - - O
i - - O
. - - O
e - - O
. - - O
the - - O
columns - - O
. - - O

The - - O
mouse - - B-MUT
platelet-derived - - I-MUT
growth - - I-MUT
factor - - I-MUT
( - - I-MUT
PDGF - - I-MUT
) - - I-MUT
beta-receptor - - I-MUT
promoter - - I-MUT
contains - - O
a - - O
CCAAT - - O
motif - - O
, - - O
and - - O
NF-Y - - B-MUT
plays - - O
an - - O
essential - - O
role - - O
in - - O
its - - O
transcription - - O
. - - O

Sequence - - O
and - - O
genetic - - O
organization - - O
of - - O
a - - O
Zymomonas - - O
mobilis - - O
gene - - O
cluster - - O
that - - O
encodes - - O
several - - O
enzymes - - O
of - - O
glucose - - O
metabolism - - O
. - - O

The - - O
growth-promoting - - O
properties - - O
of - - O
the - - O
retroviral - - B-MUT
v-erbA - - I-MUT
oncogene - - I-MUT
, - - O
a - - O
highly - - O
mutated - - O
version - - O
of - - O
the - - O
chicken - - B-MUT
thyroid - - I-MUT
hormone - - I-MUT
receptor - - I-MUT
( - - I-MUT
TR - - I-MUT
) - - I-MUT
alpha - - I-MUT
, - - O
have - - O
so - - O
far - - O
exclusively - - O
been - - O
linked - - O
to - - O
dominant - - O
repression - - O
of - - O
the - - O
antimitogenic - - O
roles - - O
of - - O
TR - - B-MUT
and - - O
retinoic - - B-MUT
acid - - I-MUT
receptors - - I-MUT
. - - O

With - - O
a - - O
population - - O
of - - O
853 - - O
million - - O
there - - O
should - - O
be - - O
51 - - O
, - - O
204 - - O
patients - - O
with - - O
hemophilia - - O
A - - O
in - - O
India - - O
assuming - - O
a - - O
prevalence - - O
of - - O
6 - - O
100 - - O
, - - O
000 - - O
population - - O
. - - O

Restriction - - O
enzyme - - O
mapping - - O
and - - O
Southern - - O
analysis - - O
indicated - - O
further - - O
that - - O
the - - O
human - - B-MUT
MZF-1 - - I-MUT
gene - - I-MUT
is - - O
a - - O
single-copy - - O
gene - - O
. - - O

Anti-CRK - - B-MUT
antibodies - - I-MUT
detect - - O
a - - O
53kDa - - O
protein - - O
in - - O
extracts - - O
of - - O
C - - O
. - - O
fasciculata - - O
in - - O
agreement - - O
with - - O
the - - O
size - - O
predicted - - O
from - - O
the - - O
nucleotide - - O
sequence - - O
of - - O
the - - O
cloned - - O
gene - - O
. - - O

To - - O
identify - - O
critical - - O
regions - - O
mediating - - O
growth - - O
signal - - O
transduction - - O
by - - O
hG-CSFR - - B-MUT
, - - O
deletions - - O
or - - O
site-directed - - O
amino - - O
acid - - O
substitutions - - O
were - - O
introduced - - O
into - - O
the - - O
cytoplasmic - - O
domain - - O
of - - O
hG-CSFR - - B-MUT
, - - O
and - - O
the - - O
mutant - - O
cDNAs - - O
were - - O
transfected - - O
into - - O
the - - O
murine - - B-MUT
interleukin-3 - - I-MUT
( - - O
IL-3 - - B-MUT
) - - O
-dependent - - O
Ba - - O
F3 - - O
and - - O
FDCP - - O
cell - - O
lines - - O
. - - O

We - - O
developed - - O
a - - O
system - - O
for - - O
domain - - O
shuffling - - O
to - - O
establish - - O
the - - O
function - - O
of - - O
C1 - - B-MUT
domains - - I-MUT
from - - O
human - - B-MUT
Raf - - I-MUT
kinase - - I-MUT
and - - O
rat - - B-MUT
PKC - - I-MUT
eta - - I-MUT
in - - O
yeast - - O
. - - O

This - - O
survey - - O
included - - O
3000 - - O
randomly - - O
selected - - O
Norwegians - - O
above - - O
18 - - O
years - - O
of - - O
age - - O
who - - O
received - - O
the - - O
European - - O
Organization - - O
for - - O
Research - - O
and - - O
Treatment - - O
of - - O
Cancer - - O
Core - - O
Quality - - O
of - - O
Life - - O
Questionnaire - - O
( - - O
EORTC - - O
QLQ-C30 - - O
( - - O
+3 - - O
) - - O
by - - O
mail - - O
. - - O

To - - O
isolate - - O
this - - O
gene - - O
, - - O
a - - O
P-1 - - O
artificial - - O
chromosome - - O
( - - O
PAC - - O
) - - O
library - - O
was - - O
screened - - O
with - - O
a - - O
full - - B-MUT
length - - I-MUT
UGT2B7 - - I-MUT
probe - - O
and - - O
a - - O
clone - - O
of - - O
approximately - - O
100 - - O
kb - - O
in - - O
length - - O
was - - O
isolated - - O
. - - O

Simple - - O
method - - O
for - - O
determination - - O
of - - O
the - - O
cephalosporin - - O
DQ-2556 - - O
in - - O
biological - - O
fluids - - O
by - - O
high-performance - - O
liquid - - O
chromatography - - O
. - - O

Repair - - O
of - - O
double-strand - - O
breaks - - O
( - - O
DSBs - - O
) - - O
in - - O
chromosomal - - O
DNA - - O
by - - O
nonhomologous - - O
end-joining - - O
( - - O
NHEJ - - O
) - - O
is - - O
not - - O
well - - O
characterized - - O
in - - O
the - - O
yeast - - O
Saccharomyces - - O
cerevisiae - - O
. - - O

Two - - O
new - - O
flavone - - O
glucosides - - O
, - - O
nevadensin - - O
5-O-beta-D-glucoside - - O
and - - O
nevadensin - - O
5-O-beta-D-glucosyl - - O
( - - O
1-- - - O
> - - O
6 - - O
) - - O
beta-D-glucoside - - O
, - - O
have - - O
been - - O
isolated - - O
from - - O
the - - O
aerial - - O
parts - - O
of - - O
Lysionotus - - O
pauciflorus - - O
. - - O

Molecule - - O
( - - O
s - - O
) - - O
secreted - - O
by - - O
neuronal - - O
cultures - - O
contribute - - O
to - - O
this - - O
induction - - O
of - - O
GLT-1 - - B-MUT
, - - O
but - - O
little - - O
is - - O
known - - O
about - - O
the - - O
signaling - - O
pathways - - O
mediating - - O
this - - O
regulation - - O
. - - O

The - - O
six - - O
commonest - - O
causes - - O
of - - O
death - - O
varied - - O
in - - O
the - - O
three - - O
ethnic - - O
groups - - O
. - - O

These - - O
"nucleocapsid-like" - - O
structures - - O
were - - O
readily - - O
purified - - O
by - - O
density - - O
gradient - - O
centrifugation - - O
. - - O

Similar - - O
to - - O
Hp140 - - B-MUT
, - - O
isolated - - O
Hp55 - - B-MUT
binds - - O
DNA - - O
with - - O
moderate - - O
strength - - O
and - - O
was - - O
a - - O
specificity - - O
for - - O
double-stranded - - O
primer-template - - O
DNA - - O
. - - O

Montelukast - - O
reduces - - O
airway - - O
eosinophilic - - O
inflammation - - O
in - - O
asthma - - O
: - - O
a - - O
randomized - - O
, - - O
controlled - - O
trial - - O
. - - O

This - - O
is - - O
particularly - - O
intriguing - - O
because - - O
SKUT-1B-20 - - O
cells - - O
lack - - O
the - - O
transcription - - O
factor - - O
Pit-1 - - B-MUT
. - - O

Surprisingly - - O
, - - O
a - - O
C - - O
to - - O
G - - O
transversion - - O
at - - O
the - - O
first - - O
residue - - O
of - - O
the - - O
CAT - - B-MUT
pentanucleotide - - I-MUT
, - - O
which - - O
severely - - O
impairs - - O
the - - O
activity - - O
of - - O
both - - O
promoters - - O
, - - O
appears - - O
to - - O
increase - - O
affinity - - O
of - - O
the - - O
CAT - - B-MUT
binding - - I-MUT
protein - - I-MUT
. - - O

Using - - O
a - - O
polymerase - - B-MUT
chain - - O
reaction-based - - O
approach - - O
, - - O
we - - O
cloned - - O
a - - O
150-base - - O
pair - - O
fragment - - O
of - - O
a - - O
new - - O
sialymotif - - O
from - - O
human - - O
placenta - - O
mRNA - - O
, - - O
which - - O
was - - O
then - - O
used - - O
as - - O
a - - O
probe - - O
to - - O
clone - - O
the - - O
complete - - O
coding - - O
sequence - - O
of - - O
the - - O
corresponding - - O
gene - - O
from - - O
a - - O
cDNA - - O
library - - O
. - - O

PULSE - - O
is - - O
used - - O
to - - O
set - - O
such - - O
NMR - - O
spectroscopic - - O
parameters - - O
as - - O
the - - O
delay - - O
and - - O
duration - - O
of - - O
rf - - O
transmit - - O
and - - O
receive - - O
gates - - O
, - - O
rf - - O
phase - - O
, - - O
sampling - - O
times - - O
, - - O
and - - O
such - - O
imaging - - O
parameters - - O
as - - O
rf - - O
pulse - - O
shape - - O
and - - O
gradient - - O
waveforms - - O
. - - O

The - - O
biosynthesis - - O
and - - O
stability - - O
of - - O
the - - O
three - - O
mutant - - O
proteins - - O
were - - O
similar - - O
to - - O
those - - O
of - - O
the - - O
wild-type - - B-MUT
erbB - - I-MUT
protein - - I-MUT
, - - O
and - - O
all - - O
three - - O
retained - - O
the - - O
ability - - O
to - - O
transform - - O
chicken - - O
embryo - - O
fibroblasts - - O
. - - O

The - - O
results - - O
indicate - - O
that - - O
rep - - B-MUT
strongly - - O
enhances - - O
the - - O
function - - O
of - - O
negative - - O
regulatory - - O
elements - - O
of - - O
the - - O
LTR - - O
. - - O

A - - O
genetic - - O
system - - O
was - - O
devised - - O
to - - O
select - - O
for - - O
pi - - B-MUT
protein - - I-MUT
mutants - - I-MUT
which - - O
discriminate - - O
between - - O
IR - - O
and - - O
DR - - O
( - - O
York - - O
et - - O
al - - O
. - - O
, - - O
Gene - - O
( - - O
Amst - - O
. - - O
) - - O
116 - - O
, - - O
7-12 - - O
, - - O
1992 - - O
; - - O
York - - O
and - - O
Filutowicz - - O
, - - O
J - - O
. - - O

Mitochondria-lytic - - O
action - - O
of - - O
warfarin - - O
in - - O
lymphocytes - - O
. - - O

TT - - O
cells - - O
, - - O
a - - O
human - - O
MTC - - O
cell - - O
line - - O
expressing - - O
MEN - - B-MUT
2A - - I-MUT
type - - I-MUT
RET - - I-MUT
, - - O
display - - O
transcriptionally - - O
active - - O
RelA - - B-MUT
( - - O
p65 - - B-MUT
) - - O
in - - O
the - - O
nucleus - - O
. - - O

Zarix - - O
expected - - O
patient - - O
enrollment - - O
in - - O
Canadian - - O
clinical - - O
sites - - O
to - - O
begin - - O
in - - O
Spring - - O
2001 - - O
[ - - O
397955 - - O
] - - O
, - - O
[ - - O
405928 - - O
] - - O
. - - O

Members - - O
of - - O
SVA - - B-MUT
are - - O
also - - O
present - - O
in - - O
the - - O
complement - - B-MUT
C2 - - I-MUT
gene - - I-MUT
located - - O
about - - O
20 - - O
kilobases - - O
upstream - - O
of - - O
RP1 - - B-MUT
in - - O
the - - O
HLA - - B-MUT
and - - O
in - - O
the - - O
cytochrome - - B-MUT
CYP1A1 - - I-MUT
gene - - I-MUT
. - - O

The - - O
reduced - - O
efficiency - - O
in - - O
the - - O
glycosylase - - B-MUT
activity - - O
is - - O
also - - O
reflected - - O
in - - O
a - - O
reduced - - O
ability - - O
of - - O
S120K - - B-MUT
MutY - - I-MUT
to - - O
prevent - - O
DNA - - O
mutations - - O
in - - O
vivo - - O
. - - O

The - - O
plasma - - O
half-life - - O
of - - O
slow - - O
disposition - - O
phase - - O
t1 - - O
2 - - O
beta - - O
, - - O
increases - - O
from - - O
0 - - O
. - - O
26 - - O
hour - - O
in - - O
rabbits - - O
with - - O
normal - - O
renal - - O
function - - O
to - - O
5 - - O
. - - O
41 - - O
hours - - O
in - - O
rabbits - - O
with - - O
severe - - O
renal - - O
impairment - - O
. - - O

Fermentation - - O
process - - O
after - - O
supplementation - - O
of - - O
nitrate - - O
, - - O
nitrite - - O
, - - O
lactic - - O
acid - - O
bacteria - - O
and - - O
formic - - O
acid - - O
. - - O

TOR2 - - B-MUT
is - - O
part - - O
of - - O
two - - O
related - - O
signaling - - O
pathways - - O
coordinating - - O
cell - - O
growth - - O
in - - O
Saccharomyces - - O
cerevisiae - - O
. - - O

The - - O
T-cyt - - B-MUT
promoter - - I-MUT
, - - O
although - - O
of - - O
bacterial - - O
origin - - O
is - - O
active - - O
in - - O
planta - - O
and - - O
the - - O
30 - - B-MUT
bp - - I-MUT
cyt-1 - - I-MUT
element - - I-MUT
is - - O
located - - O
within - - O
a - - O
region - - O
that - - O
is - - O
essential - - O
for - - O
T-cyt - - B-MUT
promotor - - I-MUT
activity - - O
in - - O
leaf - - O
, - - O
stem - - O
and - - O
root - - O
cells - - O
of - - O
tobacco - - O
plants - - O
. - - O

The - - O
weak - - O
base - - O
ketoconazole - - O
showed - - O
complete - - O
dissolution - - O
from - - O
a - - O
tablet - - O
formulation - - O
in - - O
Simulated - - O
Gastric - - O
Fluid - - O
without - - O
pepsin - - B-MUT
( - - O
SGFsp - - O
) - - O
within - - O
30 - - O
minutes - - O
, - - O
70% - - O
dissolution - - O
in - - O
2 - - O
hours - - O
under - - O
fed - - O
state - - O
simulated - - O
upper - - O
jejunal - - O
conditions - - O
but - - O
only - - O
6% - - O
dissolution - - O
in - - O
2 - - O
hours - - O
under - - O
fasted - - O
state - - O
conditions - - O
. - - O

Phosphorylation - - O
analyses - - O
indicated - - O
that - - O
inhibition - - O
of - - O
ERK-1 - - B-MUT
2 - - I-MUT
decreased - - I-MUT
okadaic - - O
acid-elevated - - O
phosphorylation - - O
of - - O
JunD - - O
and - - B-MUT
FosB - - O
. - - B-MUT

This - - O
sequenced - - O
region - - O
of - - O
the - - O
V - - B-MUT
beta - - I-MUT
locus - - I-MUT
contains - - O
an - - O
average - - O
number - - O
of - - O
repetitive - - O
DNA - - O
elements - - O
( - - O
21 - - O
Alu - - O
, - - O
three - - O
L1 - - O
, - - O
three - - O
MER - - O
, - - O
and - - O
three - - O
retrovirus-related - - O
elements - - O
. - - O

A - - O
total - - O
of - - O
174 - - O
primer - - O
pairs - - O
gave - - O
interpretable - - O
banding - - O
patterns - - O
, - - O
137 - - O
( - - O
79% - - O
) - - O
of - - O
which - - O
revealed - - O
at - - O
least - - O
two - - O
alleles - - O
on - - O
native - - O
polyacrylamide - - O
gels - - O
. - - O

All - - O
problems - - O
were - - O
associated - - O
with - - O
fractured - - O
or - - O
lost - - O
screws - - O
. - - O

Following - - O
baseline - - O
clinical - - O
examination - - O
and - - O
initial - - O
periodontal - - O
therapy - - O
, - - O
32 - - O
patients - - O
received - - O
mucogingival - - O
surgery - - O
with - - O
free - - O
gingival - - O
grafts - - O
for - - O
treatment - - O
of - - O
insufficient - - O
attached - - O
gingiva - - O
. - - O

This - - O
effect - - O
was - - O
not - - O
seen - - O
in - - O
conjunction - - O
with - - O
oxycodone - - O
, - - O
a - - O
morphine-like - - B-MUT
mu-receptor - - I-MUT
agonist - - O
. - - O

RESULTS - - O
: - - O
Significant - - O
changes - - O
from - - O
pretreatment - - O
to - - O
posttreatment - - O
were - - O
observed - - O
( - - O
p - - O
< - - O
0 - - O
. - - O
001 - - O
) - - O
. - - O

Here - - O
we - - O
demonstrate - - O
that - - O
the - - O
mechanism - - O
of - - O
activation - - O
of - - O
HIF-1alpha - - B-MUT
is - - O
a - - O
multi-step - - O
process - - O
which - - O
includes - - O
hypoxia-dependent - - O
nuclear - - O
import - - O
and - - O
activation - - O
( - - O
derepression - - O
) - - O
of - - O
the - - O
transactivation - - O
domain - - O
, - - O
resulting - - O
in - - O
recruitment - - O
of - - O
the - - O
CREB-binding - - B-MUT
protein - - I-MUT
( - - O
CBP - - B-MUT
) - - O
p300 - - B-MUT
coactivator - - I-MUT
. - - I-MUT

There - - O
were - - O
15 - - O
deaths - - O
, - - O
seven - - O
of - - O
which - - O
were - - O
felt - - O
to - - O
be - - O
avoidable - - O
. - - O

Sequence - - O
comparison - - O
of - - O
cytochromes - - B-MUT
bd - - I-MUT
and - - O
their - - O
homologs - - O
from - - O
various - - O
organisms - - O
demonstrates - - O
that - - O
the - - O
proteins - - O
can - - O
be - - O
classified - - O
into - - O
two - - O
subfamilies - - O
, - - O
a - - O
proteobacterial - - O
type - - O
including - - O
E - - B-MUT
. - - I-MUT
coli - - I-MUT
bd - - I-MUT
and - - O
a - - O
more - - O
widely - - O
distributed - - O
type - - O
including - - O
the - - O
B - - O
. - - O
stearothermophilus - - O
enzyme - - O
, - - O
suggesting - - O
that - - O
the - - O
latter - - O
type - - O
is - - O
evolutionarily - - O
older - - O
. - - O

The - - O
beta - - O
subunit - - O
of - - O
the - - O
heterotrimeric - - B-MUT
G - - I-MUT
proteins - - I-MUT
that - - O
transduce - - O
signals - - O
across - - O
the - - O
plasma - - O
membrane - - O
is - - O
made - - O
up - - O
of - - O
an - - O
amino-terminal - - O
alpha-helical - - O
segment - - O
followed - - O
by - - O
seven - - O
repeating - - O
units - - O
called - - O
WD - - O
( - - O
Trp-Asp - - O
) - - O
repeats - - O
that - - O
occur - - O
in - - O
about - - O
140 - - O
different - - O
proteins - - O
. - - O

The - - O
combination - - O
of - - O
ifosfamide - - O
, - - O
epirubicin - - O
and - - O
etoposide - - O
( - - O
IEV - - O
) - - O
is - - O
an - - O
effective - - O
salvage - - O
regimen - - O
for - - O
lymphoproliferative - - O
disease - - O
. - - O

Administration - - O
of - - O
RIFA - - O
at - - O
200 - - O
mg - - O
kg - - O
day - - O
in - - O
combination - - O
with - - O
ATO - - O
at - - O
100 - - O
mg - - O
kg - - O
day - - O
resulted - - O
in - - O
a - - O
marked - - O
prolongation - - O
of - - O
survival - - O
compared - - O
with - - O
that - - O
for - - O
mice - - O
that - - O
received - - O
ATO - - O
or - - O
RIFA - - O
alone - - O
. - - O

The - - O
patients - - O
and - - O
their - - O
families - - O
were - - O
closely - - O
questioned - - O
, - - O
and - - O
full - - O
clinical - - O
examination - - O
included - - O
a - - O
test - - O
for - - O
orthostasia - - O
. - - O

Thyroid - - O
lymphoma - - O
and - - O
its - - O
management - - O
. - - O

In - - O
eukaryotic - - O
cells - - O
, - - O
premature - - O
termination - - O
of - - O
translation - - O
at - - O
nonsense - - O
codons - - O
has - - O
been - - O
implicated - - O
as - - O
the - - O
cause - - O
of - - O
a - - O
variety - - O
of - - O
posttranscriptional - - O
events - - O
, - - O
including - - O
rapid - - O
mRNA - - O
decay - - O
in - - O
the - - O
cytoplasm - - O
or - - O
the - - O
nucleus - - O
, - - O
altered - - O
splice - - O
site - - O
selection - - O
, - - O
and - - O
exon - - O
skipping - - O
. - - O

The - - O
two - - O
methods - - O
identify - - O
the - - O
same - - O
patients - - O
only - - O
if - - O
micturitional - - O
pressures - - O
are - - O
normal - - O
( - - O
40 - - O
to - - O
60 - - O
cmH2O - - O
) - - O
to - - O
high - - O
( - - O
over - - O
60 - - O
cmH2O - - O
) - - O
and - - O
the - - O
Sussett - - O
formula - - O
is - - O
used - - O
with - - O
a - - O
higher - - O
( - - O
95th - - O
centile - - O
) - - O
cutoff - - O
. - - O

Thus - - O
, - - O
the - - O
N-Nus - - B-MUT
complex - - I-MUT
may - - O
be - - O
affected - - O
through - - O
contacts - - O
with - - O
the - - O
CTD - - O
of - - O
the - - O
alpha - - O
subunit - - O
of - - O
RNA - - B-MUT
polymerase - - I-MUT
, - - O
as - - O
is - - O
a - - O
group - - O
of - - O
regulatory - - O
proteins - - O
that - - O
influences - - O
initiation - - O
of - - O
transcription - - O
. - - O

The - - O
highly - - O
amyloidogenic - - O
42-residue - - O
form - - O
of - - O
Abeta - - B-MUT
( - - O
Abeta42 - - B-MUT
) - - O
is - - O
the - - O
first - - O
species - - O
to - - O
be - - O
deposited - - O
in - - O
both - - O
sporadic - - O
and - - O
familial - - O
AD - - O
. - - O

Kaposi's - - O
sarcoma-associated - - O
herpesvirus - - O
viral - - B-MUT
interferon - - I-MUT
regulatory - - I-MUT
factor - - I-MUT
confers - - O
resistance - - O
to - - O
the - - O
antiproliferative - - O
effect - - O
of - - O
interferon-alpha - - B-MUT
. - - O

Regulatory - - O
motifs - - O
for - - O
gene - - O
expression - - O
such - - O
as - - O
nuclear-factor-kappaB-binding-site-like - - B-MUT
sequence - - I-MUT
( - - O
kappaB - - B-MUT
site - - I-MUT
) - - O
and - - O
nuclear-factor-interleukin-6-binding-site-like - - B-MUT
sequence - - I-MUT
( - - O
NF-IL-6 - - B-MUT
site - - I-MUT
) - - O
were - - O
found - - O
in - - O
the - - O
5'-upstream - - O
regulatory - - O
region - - O
. - - O

In - - O
vitro - - O
DNase - - B-MUT
I - - I-MUT
footprinting - - O
of - - O
the - - O
200-bp - - O
proximal - - O
region - - O
of - - O
the - - O
promoter - - O
with - - O
a - - O
murine - - O
Hepa - - O
1-6 - - O
cell - - O
nuclear - - O
extract - - O
revealed - - O
a - - O
clear - - O
footprint - - O
of - - O
a - - O
region - - O
corresponding - - O
to - - O
-80 - - O
to - - O
-28 - - O
bp - - O
of - - O
the - - O
murine - - B-MUT
fVII - - I-MUT
gene - - I-MUT
, - - O
suggesting - - O
that - - O
liver - - O
factors - - O
interact - - O
with - - O
this - - O
region - - O
of - - O
the - - O
DNA - - O
. - - O

Nuclear - - B-MUT
factor - - I-MUT
III - - I-MUT
( - - O
NFIII - - B-MUT
) - - O
is - - O
a - - O
protein - - O
from - - O
HeLa - - O
cells - - O
that - - O
stimulates - - O
the - - O
initiation - - O
of - - O
adenovirus - - O
type - - O
2 - - O
( - - O
Ad2 - - O
) - - O
DNA - - O
replication - - O
by - - O
binding - - O
to - - O
a - - O
specific - - O
nucleotide - - O
sequence - - O
in - - O
the - - O
origin - - O
, - - O
adjacent - - O
to - - O
the - - O
nuclear - - B-MUT
factor - - I-MUT
I - - I-MUT
recognition - - I-MUT
site - - I-MUT
. - - O

We - - O
have - - O
measured - - O
the - - O
kinetics - - O
of - - O
the - - O
recovery - - O
of - - O
mRNA - - O
synthesis - - O
in - - O
the - - O
inducible - - O
GAL10 - - B-MUT
and - - O
RNR3 - - B-MUT
genes - - I-MUT
after - - O
exposure - - O
of - - O
yeast - - O
cells - - O
to - - O
ultraviolet - - O
( - - O
UV - - O
) - - O
radiation - - O
. - - O

These - - O
data - - O
define - - O
a - - O
conserved - - O
pathway - - O
wherein - - O
sequential - - O
histone - - B-MUT
modifications - - O
establish - - O
a - - O
"histone - - O
code" - - O
essential - - O
for - - O
the - - O
epigenetic - - O
inheritance - - O
of - - O
heterochromatin - - O
assembly - - O
. - - O

UGA - - O
codon - - O
position - - O
affects - - O
the - - O
efficiency - - O
of - - O
selenocysteine - - O
incorporation - - O
into - - O
glutathione - - B-MUT
peroxidase-1 - - I-MUT
. - - O

Using - - O
the - - O
yeast - - O
one-hybrid - - O
screen - - O
with - - O
integrated - - O
NRE - - O
and - - O
flanking - - O
DNA - - O
as - - O
bait - - O
, - - O
the - - O
predominant - - O
clone - - O
obtained - - O
was - - O
bovine - - B-MUT
Nrl - - I-MUT
. - - O

The - - O
regions - - O
of - - O
the - - O
tooth - - O
fracture - - O
are - - O
determined - - O
. - - O

It - - O
consists - - O
of - - O
2185 - - O
amino - - O
acid - - O
residues - - O
encoded - - O
by - - O
a - - O
9-kilobase - - O
pair - - O
mRNA - - O
; - - O
several - - O
splice - - O
variants - - O
have - - O
been - - O
detected - - O
in - - O
human - - O
and - - O
rat - - O
cDNA - - O
libraries - - O
. - - O

A - - O
correlation - - O
coefficient - - O
was - - O
used - - O
for - - O
assessing - - O
the - - O
similarity - - O
of - - O
each - - O
map - - O
pattern - - O
with - - O
the - - O
normal - - O
mean - - O
IQRST - - O
map - - O
. - - O

Furthermore - - O
, - - O
this - - O
element - - O
confers - - O
p53 - - B-MUT
induction - - O
to - - O
the - - O
otherwise - - O
nonresponsive - - O
adenovirus - - O
major - - O
late - - O
promoter - - O
. - - O

RESULTS - - O
: - - O
The - - O
diagnostic - - O
quality - - O
of - - O
FDG - - O
images - - O
was - - O
at - - O
least - - O
as - - O
good - - O
as - - O
that - - O
of - - O
their - - O
Tl-201 - - O
counterparts - - O
, - - O
with - - O
less - - O
liver - - O
background - - O
in - - O
all - - O
but - - O
one - - O
FDG - - O
study - - O
. - - O

Systemic - - O
impact - - O
of - - O
risk-sharing - - O
arrangements - - O
. - - O

By - - O
screening - - O
a - - O
cDNA - - O
library - - O
with - - O
a - - O
probe - - O
derived - - O
from - - O
sequences - - O
downstream - - O
of - - O
the - - O
p53p2 - - B-MUT
start - - O
site - - O
, - - O
we - - O
have - - O
cloned - - O
and - - O
characterized - - O
a - - O
cDNA - - O
that - - O
represents - - O
a - - O
mRNA - - O
that - - O
appears - - O
to - - O
have - - O
been - - O
initiated - - O
from - - O
the - - O
p53p2 - - B-MUT
promoter - - I-MUT
. - - O

Manipulation - - O
of - - O
the - - O
checkpoint - - O
regulators - - O
involved - - O
in - - O
cell - - O
cycle - - O
arrest - - O
and - - O
apoptosis - - O
may - - O
thus - - O
provide - - O
a - - O
novel - - O
strategy - - O
to - - O
cancer - - O
therapy - - O
. - - O

Induction - - O
was - - O
reversed - - O
by - - O
coexpression - - O
of - - O
A-Fos - - B-MUT
, - - O
a - - O
dominant - - O
negative - - O
to - - O
AP-1 - - B-MUT
. - - O

Plasma - - B-MUT
leptin - - I-MUT
concentrations - - O
were - - O
higher - - O
in - - O
women - - O
than - - O
men - - O
, - - O
even - - O
after - - O
the - - O
adjustment - - O
for - - O
differences - - O
in - - O
fat - - O
mass - - O
( - - O
28 - - O
+ - - O
- - - O
3 - - O
ng - - O
ml - - O
for - - O
women - - O
vs - - O
. - - O

Conservation - - O
of - - O
function - - O
of - - O
Drosophila - - B-MUT
melanogaster - - I-MUT
abl - - I-MUT
and - - O
murine - - B-MUT
v-abl - - I-MUT
proteins - - I-MUT
in - - O
transformation - - O
of - - O
mammalian - - O
cells - - O
. - - O

There - - O
are - - O
, - - O
however - - O
, - - O
several - - O
differences - - O
between - - O
the - - O
two - - O
new - - O
ars - - B-MUT
sequences - - I-MUT
. - - O

These - - O
sorting - - B-MUT
nexins - - I-MUT
also - - O
associated - - O
with - - O
the - - O
long - - O
isoform - - O
of - - O
the - - O
leptin - - B-MUT
receptor - - I-MUT
but - - O
not - - O
with - - O
the - - O
short - - O
and - - O
medium - - O
isoforms - - O
. - - O

Molecular - - O
cloning - - O
of - - O
the - - O
polypeptide - - O
component - - O
of - - O
the - - O
Rel-related - - B-MUT
human - - I-MUT
p75 - - I-MUT
nucleoprotein - - I-MUT
complex - - I-MUT
has - - O
revealed - - O
its - - O
identity - - O
with - - O
the - - O
65-kDa - - O
( - - O
p65 - - B-MUT
) - - O
subunit - - O
of - - O
NF-kappa - - B-MUT
B - - I-MUT
. - - O

Following - - O
the - - O
results - - O
of - - O
toxicological - - O
experiments - - O
in - - O
the - - O
target - - O
animals - - O
"Toxicological - - O
Drinking - - O
Water - - O
Standards - - O
for - - O
Animals" - - O
can - - O
be - - O
established - - O
. - - O

We - - O
find - - O
that - - O
3T1-3T2 - - O
mixing - - O
has - - O
a - - O
pronounced - - O
effect - - O
on - - O
the - - O
line - - O
shape - - O
and - - O
radiative - - O
decay - - O
rate - - O
of - - O
emission - - O
from - - O
the - - O
3T2 - - O
state - - O
and - - O
that - - O
the - - O
extent - - O
of - - O
mixing - - O
depends - - O
critically - - O
on - - O
the - - O
magnitude - - O
of - - O
nontetrahedral - - O
distortions - - O
. - - O

This - - O
cohort - - O
of - - O
patients - - O
was - - O
selected - - O
on - - O
the - - O
basis - - O
of - - O
clinical - - O
stage - - O
. - - O

Systemic - - O
lupus - - O
erythematosus - - O
was - - O
diagnosed - - O
. - - O

We - - O
describe - - O
the - - O
identification - - O
and - - O
initial - - O
characterization - - O
of - - O
neurobeachin - - B-MUT
, - - O
a - - O
neuron-specific - - O
multidomain - - O
protein - - O
of - - O
327 - - O
kDa - - O
with - - O
a - - O
high-affinity - - O
binding - - O
site - - O
( - - O
K - - O
( - - O
d - - O
) - - O
, - - O
10 - - O
nm - - O
) - - O
for - - O
the - - O
type - - B-MUT
II - - I-MUT
regulatory - - I-MUT
subunit - - I-MUT
of - - I-MUT
protein - - I-MUT
kinase - - I-MUT
A - - I-MUT
( - - O
PKA - - B-MUT
RII - - I-MUT
) - - O
. - - O

Senior - - O
systems--45 - - O
; - - O
Mental - - O
health - - O
and - - O
illness - - O
in - - O
old - - O
age--3 - - O
. - - O

Intron - - O
1 - - O
is - - O
6 - - O
. - - O
5 - - O
kb - - O
long - - O
, - - O
and - - O
the - - O
minimal - - O
sizes - - O
of - - O
introns - - O
2 - - O
and - - O
3 - - O
are - - O
estimated - - O
to - - O
be - - O
32 - - O
kb - - O
each - - O
. - - O

In - - O
3Y1 - - O
and - - O
3Y1 - - O
v-crk-transformed - - O
fibroblasts - - O
, - - O
almost - - O
all - - O
of - - O
the - - O
total - - O
PTP1B - - B-MUT
and - - O
about - - O
40% - - O
of - - O
total - - O
p130 - - B-MUT
( - - I-MUT
Cas - - I-MUT
) - - I-MUT
co-sediment - - O
with - - O
membranes - - O
composed - - O
primarily - - O
of - - O
endoplasmic - - O
reticulum - - O
. - - O

Several - - O
agents - - O
have - - O
been - - O
tried - - O
for - - O
treatment - - O
, - - O
often - - O
limited - - O
by - - O
toxic - - O
side - - O
effects - - O
. - - O

These - - O
studies - - O
have - - O
shown - - O
that - - O
the - - O
majority - - O
of - - O
tested - - O
staphylococci - - O
were - - O
resistant - - O
to - - O
penicillin - - O
G - - O
, - - O
erythromycin - - O
, - - O
and - - O
produced - - O
beta-lactamase - - B-MUT
. - - O

Renal - - O
clearance - - O
fell - - O
from - - O
19 - - O
. - - O
0 - - O
+ - - O
- - - O
4 - - O
. - - O
9 - - O
ml - - O
min - - O
1 - - O
. - - O
73 - - O
m2 - - O
( - - O
group - - O
I - - O
) - - O
to - - O
1 - - O
. - - O
0 - - O
+ - - O
- - - O
0 - - O
. - - O
4 - - O
ml - - O
min - - O
1 - - O
. - - O
73 - - O
m2 - - O
( - - O
group - - O
IV - - O
) - - O
. - - O

19-32 - - O
. - - O

Treatment - - O
with - - O
amphotericin - - O
B - - O
and - - O
flucytosine - - O
led - - O
to - - O
improvement - - O
of - - O
the - - O
symptoms - - O
but - - O
did - - O
not - - O
eradicate - - O
the - - O
micro-organisms - - O
from - - O
the - - O
cerebrospinal - - O
fluid - - O
( - - O
CSF - - O
) - - O
. - - O

The - - O
yeast - - O
silent - - B-MUT
information - - I-MUT
regulator - - I-MUT
Sir4p - - I-MUT
anchors - - O
and - - O
partitions - - O
plasmids - - O
. - - O

Antituberculosis - - O
agents - - O
. - - O

A - - O
poor - - O
correlation - - O
was - - O
found - - O
between - - O
a - - O
mildly-atypical - - O
( - - O
inflammatory - - O
) - - O
cytological - - O
result - - O
( - - O
class - - O
2 - - O
) - - O
and - - O
a - - O
benign - - O
histological - - O
diagnosis - - O
: - - O
48% - - O
of - - O
class-2 - - O
smears - - O
were - - O
diagnosed - - O
histologically - - O
as - - O
dysplasia - - O
or - - O
worse - - O
. - - O

SRY-related - - B-MUT
cDNA - - I-MUT
encoding - - O
a - - O
protein - - O
with - - O
a - - O
high-mobility-group - - B-MUT
( - - O
HMG - - B-MUT
) - - O
box - - O
and - - O
a - - O
leucine - - O
zipper - - O
motif - - O
, - - O
which - - O
was - - O
designated - - O
SOX-LZ - - B-MUT
, - - O
was - - O
isolated - - O
from - - O
a - - O
rainbow - - O
trout - - O
testis - - O
cDNA - - O
library - - O
. - - O

These - - O
results - - O
indicate - - O
a - - O
possible - - O
involvement - - O
of - - O
endogenous - - B-MUT
opioid - - I-MUT
peptides - - I-MUT
in - - O
the - - O
cardiac - - O
effects - - O
due - - O
to - - O
myocardial - - O
ischaemia - - O
and - - O
reperfusion - - O
, - - O
mediated - - O
by - - O
opiate - - B-MUT
receptors - - I-MUT
through - - O
opiate - - O
antagonism - - O
. - - O

In - - O
addition - - O
, - - O
a - - O
wild-type - - O
strain - - O
containing - - O
a - - O
temperature-sensitive - - B-MUT
threonyl-tRNA - - I-MUT
synthetase - - I-MUT
mutation - - I-MUT
showed - - O
increased - - O
thr - - B-MUT
operon - - I-MUT
expression - - O
at - - O
the - - O
non-permissive - - O
temperature - - O
, - - O
whereas - - O
none - - O
of - - O
the - - O
mutants - - O
showed - - O
any - - O
change - - O
. - - O

Ten - - O
patients - - O
with - - O
advanced - - O
, - - O
diffuse - - O
Hodgkin's - - O
and - - O
non-Hodgkin's - - O
lymphomas - - O
responding - - O
poorly - - O
to - - O
the - - O
most - - O
widely - - O
employed - - O
primary - - O
chemotherapy - - O
regimens - - O
were - - O
treated - - O
with - - O
a - - O
high-dose - - O
chemotherapy - - O
( - - O
HDC - - O
) - - O
followed - - O
by - - O
rescue - - O
with - - O
non-frozen - - O
autologous - - O
bone - - O
marrow - - O
infusion - - O
( - - O
ABMT - - O
) - - O
. - - O

Maternal - - O
seizures - - O
had - - O
occurred - - O
during - - O
pregnancy - - O
in - - O
52 - - O
per - - O
cent - - O
. - - O

All - - O
four - - O
doubly - - O
tyrosine - - O
phosphorylated - - O
TAM - - B-MUT
peptides - - I-MUT
cross-compete - - O
with - - O
each - - O
other - - O
for - - O
binding - - O
to - - O
the - - O
tandem - - O
SH2 - - B-MUT
domains - - I-MUT
of - - O
ZAP-70 - - B-MUT
. - - O

Axillary - - O
nodal - - O
status - - O
, - - O
tumour - - O
progesterone - - B-MUT
receptor - - I-MUT
status - - O
, - - O
and - - O
season - - O
of - - O
tumour - - O
detection - - O
significantly - - O
influenced - - O
survival - - O
in - - O
both - - O
older - - O
( - - O
greater - - O
than - - O
50 - - O
yrs - - O
) - - O
and - - O
younger - - O
( - - O
less - - O
than - - O
50 - - O
yrs - - O
) - - O
patients - - O
. - - O

Adjustment - - O
for - - O
age - - O
, - - O
total - - O
cholesterol - - O
, - - O
HDL - - O
cholesterol - - O
, - - O
triglycerides - - O
, - - O
current - - O
smoking - - O
, - - O
and - - O
systolic - - O
pressure - - O
slightly - - O
reduced - - O
the - - O
association - - O
between - - O
fibrinogen - - B-MUT
and - - O
atherosclerosis - - O
. - - O

However - - O
, - - O
a - - O
cosmid - - O
clone - - O
containing - - O
the - - O
entire - - O
mouse - - B-MUT
alpha - - I-MUT
1 - - I-MUT
( - - I-MUT
I - - I-MUT
) - - I-MUT
gene - - I-MUT
, - - O
including - - O
3 - - O
. - - O
7 - - O
kb - - O
of - - O
5'- - - O
and - - O
4 - - O
kb - - O
of - - O
3'-flanking - - O
DNA - - O
, - - O
was - - O
expressed - - O
at - - O
reduced - - O
levels - - O
in - - O
fibroblasts - - O
overexpressing - - O
oncogenic - - B-MUT
ras - - I-MUT
. - - O

It - - O
is - - O
striking - - O
that - - O
the - - O
active - - O
CHO - - B-MUT
spacer - - I-MUT
promoter - - I-MUT
violated - - O
the - - O
otherwise - - O
universal - - O
rule - - O
that - - O
metazoan - - B-MUT
RNA - - I-MUT
polymerase - - I-MUT
I - - I-MUT
promoters - - I-MUT
all - - O
have - - O
a - - O
G - - O
residue - - O
at - - O
position - - O
-16 - - O
. - - O

To - - O
understand - - O
the - - O
regulatory - - O
mechanism - - O
controlling - - O
its - - O
expression - - O
at - - O
low - - O
temperature - - O
, - - O
the - - O
promoter - - O
region - - O
has - - O
been - - O
characterized - - O
. - - O

2 - - O
. - - O
--concepts - - O
of - - O
higher - - O
nervous - - O
function - - O
in - - O
the - - O
USSR - - O
. - - O

The - - O
mature - - O
AP-2 - - B-MUT
mRNA - - I-MUT
is - - O
spliced - - O
from - - O
7 - - O
exons - - O
distributed - - O
over - - O
a - - O
region - - O
of - - O
18 - - O
kb - - O
genomic - - O
DNA - - O
. - - O

Nonsynonymous - - O
substitution - - O
in - - O
abalone - - O
sperm - - O
fertilization - - O
genes - - O
exceeds - - O
substitution - - O
in - - O
introns - - O
and - - O
mitochondrial - - O
DNA - - O
. - - O

The - - O
molecular - - O
associations - - O
dictating - - O
INCENP - - B-MUT
behavior - - O
during - - O
mitosis - - O
are - - O
currently - - O
unknown - - O
. - - O

202-8 - - O
. - - O

There - - O
were - - O
differences - - O
between - - O
males - - O
( - - O
p - - O
< - - O
0 - - O
. - - O
05 - - O
) - - O
for - - O
most - - O
of - - O
the - - O
characteristics - - O
studied - - O
. - - O

The - - O
results - - O
of - - O
this - - O
study - - O
demonstrate - - O
that - - O
strongyloidiasis - - O
was - - O
the - - O
cause - - O
of - - O
sudden - - O
death - - O
. - - O

Many - - O
canonical - - O
TATA - - O
sequences - - O
are - - O
present - - O
upstream - - O
from - - O
these - - O
VZV - - O
transcriptional - - O
start - - O
sites - - O
but - - O
, - - O
apparently - - O
, - - O
are - - O
not - - O
used - - O
. - - O

Van - - O
der - - O
Ende - - O
, - - O
R - - O
. - - O

A - - O
comparative - - O
study - - O
of - - O
the - - O
cortical - - O
end - - O
of - - O
the - - O
auditory - - O
analyzer - - O
during - - O
postnatal - - O
ontogenesis - - O
in - - O
lower - - O
monkeys - - O
and - - O
man - - O
. - - O

Constitutive - - O
function - - O
of - - O
a - - O
positively - - O
regulated - - O
promoter - - O
reveals - - O
new - - O
sequences - - O
essential - - O
for - - O
activity - - O
. - - O

Analysis - - O
in - - O
3 - - O
groups - - O
of - - O
patients - - O
suffering - - O
from - - O
simple - - O
acute - - O
and - - O
pernicious - - O
malarial - - O
flare-ups - - O
. - - O

The - - O
mobility - - O
shift - - O
assay - - O
of - - O
the - - O
65 - - O
bp - - O
( - - O
-318 - - O
-254 - - O
) - - O
fragment - - O
with - - O
nuclear - - O
extract - - O
from - - O
the - - O
dark-adapted - - O
sample - - O
showed - - O
an - - O
additional - - O
band - - O
, - - O
not - - O
seen - - O
with - - O
the - - O
light-grown - - O
sample - - O
. - - O

Grasso - - O
, - - O
and - - O
A - - O
. - - O

Feed - - O
intake - - O
was - - O
not - - O
affected - - O
by - - O
dietary - - O
KCl - - O
or - - O
NaHCO3 - - O
supplementation - - O
, - - O
but - - O
average - - O
daily - - O
gain - - O
increased - - O
with - - O
increased - - O
K - - O
and - - O
tended - - O
to - - O
be - - O
reduced - - O
by - - O
dietary - - O
NaHCO3 - - O
. - - O

The - - O
high - - O
degree - - O
of - - O
sequence - - O
identity - - O
( - - O
96% - - O
) - - O
between - - O
hydrolase - - B-MUT
B - - I-MUT
and - - I-MUT
C - - I-MUT
, - - O
particularly - - O
in - - O
the - - O
3' - - O
untranslated - - O
region - - O
, - - O
suggests - - O
that - - O
the - - O
genes - - O
encoding - - O
these - - O
two - - O
carboxylesterases - - B-MUT
evolved - - O
by - - O
duplication - - O
and - - O
divergence - - O
of - - O
a - - O
common - - O
ancestral - - O
gene - - O
. - - O

Hypotension - - O
was - - O
produced - - O
by - - O
head - - O
up - - O
tilt - - O
. - - O

Immunodepression - - O
was - - O
combined - - O
with - - O
the - - O
increase - - O
of - - O
glucocorticoid - - O
activity - - O
of - - O
adrenal - - O
cortex - - O
, - - O
while - - O
no - - O
significant - - O
changes - - O
in - - O
thyroid - - O
hormones - - O
were - - O
registered - - O
. - - O

Determination - - O
of - - O
potassium - - O
iodide - - O
in - - O
Polish - - O
edible - - O
salt - - O
. - - O

Enhanced - - O
period-peak - - O
analysis - - O
of - - O
electro-encephalograms - - O
using - - O
a - - O
fast - - O
sinc - - O
function - - O
. - - O

These - - O
sequence - - O
analyses - - O
suggest - - O
that - - O
xIRS-u - - B-MUT
is - - O
a - - O
novel - - O
member - - O
of - - O
the - - O
IRS - - B-MUT
family - - I-MUT
rather - - O
than - - O
a - - O
Xenopus - - O
homolog - - O
of - - O
an - - O
existing - - O
member - - O
. - - O

Analysis - - O
with - - O
additional - - O
anti-peptide - - O
antibodies - - O
specific - - O
for - - O
alpha - - B-MUT
, - - I-MUT
beta - - I-MUT
, - - I-MUT
or - - I-MUT
gamma - - I-MUT
PKC - - I-MUT
indicated - - O
that - - O
all - - O
three - - O
types - - O
of - - O
PKC - - B-MUT
are - - O
expressed - - O
in - - O
JK - - O
cells - - O
; - - O
however - - O
, - - O
JKPE - - O
cells - - O
lost - - O
a - - O
major - - O
approximately - - O
82 - - O
kDa - - O
immunoreactive - - O
cytosolic - - O
protein - - O
detectable - - O
with - - O
anti-PKC - - B-MUT
alpha - - I-MUT
antibody - - I-MUT
. - - O

Reverse - - O
transcription - - O
( - - O
RT - - O
) - - O
-PCR - - O
products - - O
were - - O
synthesized - - O
with - - O
two - - O
degenerate - - O
primers - - O
derived - - O
from - - O
the - - O
conserved - - O
motifs - - O
of - - O
various - - O
tyrosine - - B-MUT
kinases - - I-MUT
. - - O

The - - O
experiment - - O
included - - O
6 - - O
male - - O
and - - O
4 - - O
female - - O
healthy - - O
subjects - - O
who - - O
, - - O
during - - O
a - - O
24-hour - - O
stay - - O
in - - O
the - - O
respiration - - O
chambers - - O
, - - O
performed - - O
, - - O
in - - O
the - - O
morning - - O
and - - O
afternoon - - O
, - - O
15 - - O
min - - O
cycling - - O
with - - O
the - - O
total - - O
work - - O
of - - O
6 - - O
, - - O
750 - - O
kg - - O
m - - O
. - - O

Mutations - - O
in - - O
a - - O
region - - O
located - - O
15 - - O
to - - O
30 - - O
bp - - O
downstream - - O
from - - O
the - - O
major - - O
transcription - - O
start - - O
site - - O
that - - O
shows - - O
good - - O
homology - - O
to - - O
a - - O
sequence - - O
in - - O
the - - O
first - - O
exon - - O
of - - O
c-fos - - B-MUT
implicated - - O
as - - O
a - - O
negative - - O
regulatory - - O
element - - O
resulted - - O
in - - O
a - - O
significant - - O
increase - - O
in - - O
basal - - O
gene - - O
expression - - O
but - - O
did - - O
not - - O
affect - - O
regulation - - O
. - - O

After - - O
all - - O
doses - - O
of - - O
d-amphetamine - - O
, - - O
responding - - O
occurred - - O
largely - - O
on - - O
the - - O
saline - - O
key - - O
under - - O
both - - O
schedules - - O
. - - O

Thrombosis - - O
of - - O
the - - O
renal - - O
vein - - O
may - - O
be - - O
dramatic - - O
and - - O
include - - O
renal - - O
failure - - O
. - - O

The - - O
experimental - - O
group - - O
consisted - - O
of - - O
61 - - O
examinees - - O
class - - O
II - - O
2 - - O
orthodontic - - O
anomalies - - O
. - - O

Many - - O
eukaryotic - - O
cell - - O
surface - - O
proteins - - O
are - - O
anchored - - O
in - - O
the - - O
lipid - - O
bilayer - - O
through - - O
glycosylphosphatidylinositol - - O
( - - O
GPI - - O
) - - O
. - - O

Contrary - - O
to - - O
expectations - - O
, - - O
we - - O
find - - O
a - - O
relatively - - O
high - - O
level - - O
of - - O
variation - - O
in - - O
the - - O
stripe - - B-MUT
2 - - I-MUT
enhancer - - I-MUT
region - - I-MUT
, - - O
including - - O
point - - O
substitutions - - O
and - - O
insertion - - O
deletions - - O
in - - O
binding - - O
sites - - O
, - - O
and - - O
a - - O
comparable - - O
level - - O
of - - O
variation - - O
in - - O
the - - O
other - - O
noncoding - - O
regions - - O
. - - O

Thyreoliberin - - O
VUFB - - O
in - - O
thyroid - - O
gammagraphy - - O
. - - O

A - - O
soluble - - O
62-kDa - - O
protein - - O
was - - O
produced - - O
without - - O
the - - O
proteolytic - - O
processing - - O
by - - O
inserting - - O
the - - O
coding - - O
sequence - - O
of - - O
amino - - O
acids - - O
112 - - O
to - - O
660 - - O
of - - O
ORF-2 - - O
in - - O
a - - O
baculovirus - - O
expression - - O
vector - - O
and - - O
using - - O
the - - O
corresponding - - O
virus - - O
to - - O
infect - - O
Sf9 - - O
cells - - O
. - - O

While - - O
these - - O
findings - - O
may - - O
reflect - - O
the - - O
sensitivity - - O
of - - O
a - - O
thick - - O
myocardial - - O
wall - - O
to - - O
ischaemia - - O
during - - O
surgery - - O
, - - O
the - - O
postoperative - - O
recovery - - O
was - - O
not - - O
related - - O
to - - O
the - - O
serum - - B-MUT
CK-MB - - I-MUT
level - - O
. - - O

Recombinant - - B-MUT
erythropoietin - - I-MUT
( - - O
r-HuEPO - - B-MUT
) - - O
in - - O
the - - O
treatment - - O
of - - O
anemia - - O
in - - O
multiple - - O
myeloma - - O
. - - O

Model - - O
predictions - - O
were - - O
in - - O
accord - - O
with - - O
the - - O
nine-year - - O
survival - - O
experience - - O
of - - O
women - - O
in - - O
the - - O
HIP - - O
trial - - O
, - - O
and - - O
, - - O
with - - O
the - - O
exception - - O
of - - O
women - - O
40-44 - - O
years - - O
old - - O
, - - O
with - - O
HIP - - O
data - - O
on - - O
18-year - - O
survival - - O
. - - O

Eleven - - O
biopsy - - O
specimens - - O
( - - O
five - - O
papules - - O
and - - O
six - - O
dusky - - O
or - - O
crusted - - O
lesions - - O
) - - O
from - - O
four - - O
patients - - O
with - - O
pityriasis - - O
lichenoides - - O
et - - O
varioliformis - - O
acuta - - O
( - - O
PLEVA - - O
) - - O
were - - O
studied - - O
by - - O
direct - - O
immunofluorescence - - O
and - - O
immunoperoxidase - - O
technics - - O
. - - O

Detection - - O
of - - O
poisoning - - O
by - - O
Impila - - O
( - - O
Callilepis - - O
laureola - - O
) - - O
in - - O
a - - O
mother - - O
and - - O
child - - O
. - - O

Screening - - O
, - - O
counseling - - O
, - - O
and - - O
treatment - - O
for - - O
alcohol - - O
and - - O
illicit - - O
drug - - O
use - - O
should - - O
be - - O
essential - - O
components - - O
in - - O
comprehensive - - O
HBP - - O
care - - O
. - - O

Analyses - - O
of - - O
tyrosine - - O
residue-mutated - - O
PDGF - - B-MUT
receptors - - I-MUT
show - - O
that - - O
Src - - B-MUT
homology - - I-MUT
2 - - I-MUT
domain-containing - - I-MUT
proteins - - I-MUT
including - - O
Src - - B-MUT
family - - I-MUT
kinases - - I-MUT
, - - O
phosphatidylinositol - - B-MUT
3-kinase - - I-MUT
, - - O
the - - O
GTPase-activating - - B-MUT
protein - - I-MUT
of - - O
Ras - - B-MUT
, - - O
the - - O
Src - - B-MUT
homology - - I-MUT
2 - - I-MUT
domain-containing - - I-MUT
phosphatase - - I-MUT
SHP-2 - - B-MUT
, - - O
phospholipase - - B-MUT
C-gamma - - I-MUT
, - - O
and - - O
Crk - - B-MUT
do - - O
not - - O
play - - O
a - - O
major - - O
role - - O
in - - O
mediating - - O
the - - O
PDGF-induced - - O
activation - - O
of - - O
p38 - - B-MUT
. - - O

The - - O
serum - - O
levels - - O
of - - O
IgE - - B-MUT
, - - O
and - - O
asIgE - - B-MUT
and - - O
IgG-4 - - B-MUT
against - - O
14 - - O
common - - O
food - - O
allergens - - O
were - - O
determined - - O
. - - O

Also - - O
, - - O
the - - O
amplitude - - O
of - - O
the - - O
oscillatory - - O
potentials - - O
( - - O
O1+O2+O3+O4 - - O
) - - O
was - - O
significantly - - O
reduced - - O
in - - O
the - - O
early - - O
postoperative - - O
period - - O
. - - O

Differential - - O
expression - - O
of - - O
the - - O
"B" - - O
subunit - - O
of - - O
the - - O
vacuolar - - B-MUT
H - - I-MUT
( - - I-MUT
+ - - I-MUT
) - - I-MUT
-ATPase - - I-MUT
in - - O
bovine - - O
tissues - - O
. - - O

Pediatric - - O
medical - - O
emergencies - - O
in - - O
a - - O
regional - - O
hospital - - O
: - - O
appropriate - - O
locale - - O
? - - O

CONCLUSION - - O
: - - O
During - - O
chronic - - O
treatment - - O
, - - O
the - - O
haemodynamic - - O
response - - O
to - - O
oral - - O
cilazapril - - O
was - - O
attenuated - - O
, - - O
indicating - - O
that - - O
continued - - O
clinical - - O
improvement - - O
in - - O
patients - - O
with - - O
CHF - - O
on - - O
CLZ - - O
is - - O
independent - - O
of - - O
to - - O
its - - O
acute - - O
haemodynamic - - O
effects - - O
. - - O

Trichloroethylene - - O
, - - O
in - - O
turn - - O
, - - O
increased - - O
the - - O
AUC - - O
5 - - O
. - - O
0 - - O
( - - O
1 - - O
. - - O
9-13 - - O
. - - O
4 - - O
) - - O
, - - O
25 - - O
. - - O
8 - - O
( - - O
8 - - O
. - - O
2-80 - - O
. - - O
8 - - O
) - - O
and - - O
2 - - O
. - - O
9 - - O
( - - O
1 - - O
. - - O
6-5 - - O
. - - O
4 - - O
) - - O
, - - O
respectively - - O
, - - O
whereas - - O
the - - O
corresponding - - O
values - - O
for - - O
n-hexane - - O
were - - O
1 - - O
. - - O
9 - - O
( - - O
0 - - O
. - - O
7-5 - - O
. - - O
1 - - O
) - - O
, - - O
1 - - O
. - - O
5 - - O
( - - O
0 - - O
. - - O
5-4 - - O
. - - O
6 - - O
) - - O
, - - O
and - - O
3 - - O
. - - O
2 - - O
( - - O
1 - - O
. - - O
8-5 - - O
. - - O
9 - - O
) - - O
. - - O

The - - O
interaction - - O
of - - O
U1-70K - - B-MUT
with - - O
the - - O
SRZ - - B-MUT
proteins - - I-MUT
is - - O
confirmed - - O
further - - O
in - - O
vitro - - O
using - - O
a - - O
blot - - O
overlay - - O
assay - - O
. - - O

Analysis - - O
of - - O
various - - O
deletion - - O
mutants - - O
indicates - - O
that - - O
the - - O
sequence - - O
requirements - - O
for - - O
binding - - O
by - - O
QBP - - B-MUT
in - - O
vitro - - O
are - - O
indistinguishable - - O
from - - O
those - - O
necessary - - O
for - - O
Q - - B-MUT
activity - - O
in - - O
vivo - - O
, - - O
strongly - - O
suggesting - - O
that - - O
QBP - - B-MUT
is - - O
required - - O
for - - O
the - - O
function - - O
of - - O
this - - O
TATA-independent - - O
promoter - - O
. - - O

Common - - O
history - - O
and - - O
prospects - - O
in - - O
surgical - - O
gynecology - - O
of - - O
the - - O
Charite - - O
and - - O
the - - O
Vienna - - O
University - - O
Clinic - - O
. - - O

Therefore - - O
, - - O
we - - O
have - - O
developed - - O
a - - O
system - - O
to - - O
study - - O
nuclear - - O
targeting - - O
in - - O
plants - - O
and - - O
have - - O
established - - O
that - - O
the - - O
nuclear - - O
transport - - O
machinery - - O
is - - O
similar - - O
in - - O
monocots - - O
and - - O
dicots - - O
. - - O

CONCLUSIONS - - O
: - - O
Under - - O
current - - O
immunization - - O
practices - - O
, - - O
the - - O
authors - - O
estimate - - O
that - - O
nearly - - O
13 - - O
, - - O
000 - - O
Asian - - O
and - - O
Pacific - - O
Islander - - O
children - - O
living - - O
in - - O
the - - O
United - - O
States - - O
today - - O
will - - O
become - - O
infected - - O
with - - O
HBV - - O
in - - O
the - - O
future - - O
, - - O
resulting - - O
in - - O
more - - O
than - - O
600 - - O
liver - - O
carcinoma - - O
deaths - - O
. - - O

Steroids - - O
in - - O
germfree - - O
and - - O
conventional - - O
rats - - O
. - - O

Cardiac - - O
output - - O
at - - O
anaerobic - - O
threshold - - O
( - - O
COAT - - O
) - - O
< - - O
or - - O
= - - O
7 - - O
. - - O
3 - - O
L - - O
min - - O
was - - O
the - - O
best - - O
cutoff - - O
value - - O
for - - O
identifying - - O
multivessel - - O
coronary - - O
artery - - O
disease - - O
( - - O
relative - - O
risk - - O
, - - O
3 - - O
. - - O
1 - - O
) - - O
. - - O

We - - O
show - - O
that - - O
cytR - - B-MUT
expression - - O
is - - O
negatively - - O
controlled - - O
by - - O
the - - O
CytR - - B-MUT
protein - - I-MUT
and - - O
positively - - O
affected - - O
by - - O
the - - O
cAMP - - B-MUT
CAP - - I-MUT
complex - - I-MUT
. - - I-MUT

The - - O
topography - - O
and - - O
trajectories - - O
of - - O
the - - O
commissural - - O
fibers - - O
of - - O
the - - O
superior - - O
temporal - - O
region - - O
( - - O
STR - - O
) - - O
are - - O
studied - - O
using - - O
the - - O
autoradiographic - - O
technique - - O
. - - O

SSG1 - - B-MUT
, - - O
a - - O
gene - - O
encoding - - O
a - - O
sporulation-specific - - B-MUT
1 - - I-MUT
, - - I-MUT
3-beta-glucanase - - I-MUT
in - - O
Saccharomyces - - O
cerevisiae - - O
. - - O

T4 - - O
and - - O
FT4I - - O
followed - - O
parallel - - O
courses - - O
in - - O
both - - O
groups - - O
; - - O
during - - O
the - - O
first - - O
45 - - O
days - - O
, - - O
however - - O
, - - O
the - - O
values - - O
were - - O
significantly - - O
lower - - O
in - - O
premature - - O
infants - - O
under - - O
34 - - O
weeks' - - O
EGA - - O
than - - O
in - - O
term - - O
infants - - O
( - - O
P - - O
less - - O
than - - O
0 - - O
. - - O
001 - - O
) - - O
. - - O

Multiple - - O
regression - - O
analysis - - O
performed - - O
between - - O
these - - O
long-term - - O
abiotic - - O
factors - - O
and - - O
nymphal - - O
abundance - - O
in - - O
positive - - O
sites - - O
showed - - O
high - - O
relationship - - O
( - - O
R2 - - O
coefficients - - O
) - - O
for - - O
every - - O
habitat - - O
category - - O
and - - O
explained - - O
> - - O
50% - - O
of - - O
the - - O
variation - - O
in - - O
tick - - O
abundance - - O
. - - O

The - - O
regulation - - O
of - - O
PGHS-2 - - B-MUT
mRNA - - I-MUT
and - - O
protein - - O
was - - O
studied - - O
in - - O
primary - - O
cultures - - O
of - - O
bovine - - O
uterine - - O
stromal - - O
cells - - O
stimulated - - O
with - - O
phorbol - - O
12-myristate - - O
13-acetate - - O
( - - O
PMA - - O
; - - O
100 - - O
nM - - O
) - - O
. - - O

When - - O
cells - - O
were - - O
microinjected - - O
with - - O
TFOs - - O
designed - - O
to - - O
bind - - O
to - - O
a - - O
30-bp - - O
polypurine - - O
site - - O
situated - - O
between - - O
the - - O
two - - O
TK - - B-MUT
genes - - I-MUT
, - - O
recombination - - O
was - - O
observed - - O
at - - O
frequencies - - O
in - - O
the - - O
range - - O
of - - O
1% - - O
, - - O
2 - - O
, - - O
500-fold - - O
above - - O
the - - O
background - - O
. - - O

Moreover - - O
, - - O
the - - O
ability - - O
to - - O
selectivity - - O
arrest - - O
elongation - - O
by - - O
polIII - - B-MUT
at - - O
defined - - O
positions - - O
within - - O
the - - O
tRNA - - B-MUT
gene - - I-MUT
transcription - - I-MUT
unit - - I-MUT
has - - O
permitted - - O
the - - O
identification - - O
of - - O
discrete - - O
functional - - O
properties - - O
of - - O
paused - - O
mammalian - - B-MUT
polIII - - I-MUT
ternary - - I-MUT
complexes - - I-MUT
. - - O

The - - O
effect - - O
of - - O
food - - O
on - - O
procainamide - - O
absorption - - O
. - - O

Approximately - - O
50% - - O
of - - O
the - - O
ribosomal - - O
DNA - - O
( - - O
rDNA - - O
) - - O
units - - O
of - - O
Drosophila - - O
melanogaster - - O
are - - O
inactivated - - O
by - - O
two - - O
different - - O
28 - - B-MUT
S - - I-MUT
RNA - - I-MUT
ribosomal - - I-MUT
gene - - I-MUT
insertions - - O
( - - O
type - - O
I - - O
and - - O
type - - O
II - - O
) - - O
. - - O

Based - - O
on - - O
restriction - - O
enzyme - - O
analysis - - O
, - - O
Southern - - O
blots - - O
, - - O
polymerase - - O
chain - - O
reaction - - O
analysis - - O
and - - O
DNA - - O
sequencing - - O
, - - O
it - - O
was - - O
confirmed - - O
that - - O
the - - O
three - - O
overlapping - - O
clones - - O
isolated - - O
cover - - O
the - - O
entire - - O
cHO-1 - - B-MUT
gene - - I-MUT
, - - O
as - - O
well - - O
as - - O
approximately - - O
10 - - O
kb - - O
of - - O
the - - O
flanking - - O
regions - - O
on - - O
both - - O
ends - - O
. - - O

GafChromic - - O
( - - O
MD-55-2 - - O
) - - O
radiochromic - - O
film - - O
has - - O
become - - O
increasingly - - O
popular - - O
for - - O
medical - - O
applications - - O
and - - O
has - - O
proven - - O
to - - O
be - - O
useful - - O
for - - O
brachytherapy - - O
dosimetry - - O
. - - O

The - - O
pharmacokinetics - - O
of - - O
each - - O
tetracycline - - O
in - - O
serum - - O
and - - O
dermal - - O
, - - O
suction - - O
blister - - O
fluid - - O
were - - O
determined - - O
after - - O
oral - - O
doses - - O
of - - O
300 - - O
mg - - O
lymecycline - - O
or - - O
100 - - O
mg - - O
doxycycline - - O
on - - O
the - - O
3rd - - O
day - - O
. - - O

Defects - - O
in - - O
the - - O
Schizosaccharomyces - - O
pombe - - O
( - - O
Sp - - O
) - - O
cell - - O
cycle-controlling - - O
genes - - O
prevent - - O
the - - O
cell - - O
cycle - - O
progression - - O
. - - O

Problems - - O
remain - - O
to - - O
be - - O
resolved - - O
in - - O
the - - O
area - - O
of - - O
quantitative - - O
risk - - O
assessment - - O
. - - O

The - - O
binding - - O
of - - O
transcription - - O
factor - - O
AP-1 - - B-MUT
and - - O
vitamin - - B-MUT
D - - I-MUT
receptor - - I-MUT
( - - O
VDR - - B-MUT
) - - O
to - - O
the - - O
composite - - O
AP-1 - - B-MUT
plus - - O
vitamin-D-responsive - - B-MUT
promoter - - I-MUT
region - - I-MUT
( - - O
AP-1 - - B-MUT
+ - - I-MUT
VDRE - - I-MUT
) - - O
of - - O
the - - O
human - - B-MUT
osteocalcin - - I-MUT
gene - - I-MUT
was - - O
characterized - - O
in - - O
osteocalcin-producing - - O
( - - O
MG-63 - - O
) - - O
and - - O
non-producing - - O
( - - O
U2-Os - - O
, - - O
SaOs-2 - - O
) - - O
human - - O
osteosarcoma - - O
cell - - O
lines - - O
. - - O

Ultrasound - - O
effect - - O
on - - O
the - - O
cytochrome - - B-MUT
oxidase - - I-MUT
activity - - O
. - - O

To - - O
examine - - O
the - - O
role - - O
of - - O
this - - O
CE2 - - B-MUT
element - - I-MUT
in - - O
regulating - - O
Hoxa1 - - B-MUT
expression - - O
in - - O
vivo - - O
, - - O
transgenic - - O
mice - - O
were - - O
generated - - O
which - - O
express - - O
a - - O
Hoxa1 - - B-MUT
beta-galactosidase - - B-MUT
reporter - - O
gene - - O
that - - O
contains - - O
a - - O
mutation - - O
in - - O
the - - O
CE2 - - B-MUT
element - - I-MUT
. - - O

We - - O
produced - - O
transgenic - - O
plants - - O
expressing - - O
the - - O
antisense - - B-MUT
Arabidopsis - - I-MUT
HD - - I-MUT
( - - O
AtHD1 - - B-MUT
) - - O
gene - - O
. - - O

To - - O
determine - - O
the - - O
relationship - - O
of - - O
these - - O
viruses - - O
, - - O
the - - O
complete - - O
DNA - - O
sequence - - O
of - - O
KV - - O
consisting - - O
of - - O
4754 - - O
bp - - O
was - - O
determined - - O
. - - O

We - - O
have - - O
investigated - - O
the - - O
role - - O
of - - O
cellular - - B-MUT
p21ras - - I-MUT
protein - - I-MUT
in - - O
insulin - - B-MUT
and - - O
insulin-like - - B-MUT
growth - - I-MUT
factor-I - - I-MUT
( - - O
IGF-I - - B-MUT
) - - O
signaling - - O
pathways - - O
. - - O

This - - O
effect - - O
was - - O
abolished - - O
once - - O
the - - O
EM - - B-MUT
motif - - I-MUT
in - - O
the - - O
promoter-reporter - - O
construct - - O
was - - O
mutated - - O
, - - O
thus - - O
suggesting - - O
that - - O
the - - O
synergistic - - O
transactivation - - O
function - - O
of - - O
the - - O
TEF-1-Max - - B-MUT
heterotypic - - I-MUT
complex - - I-MUT
is - - O
mediated - - O
through - - O
binding - - O
of - - O
the - - O
complex - - O
to - - O
the - - O
EM - - B-MUT
motif - - I-MUT
. - - O

A - - O
stable - - O
interface - - O
depends - - O
on - - O
overall - - O
stress - - O
and - - O
microstress - - O
distribution - - O
on - - O
the - - O
bone - - O
, - - O
particularly - - O
trabecular - - O
bone - - O
. - - O

Variation - - O
in - - O
the - - O
temporal-spatial - - O
distribution - - O
of - - O
228Ra - - O
and - - O
224Ra - - O
in - - O
the - - O
RES - - O
and - - O
marrow-free - - O
skeleton - - O
after - - O
incorporation - - O
of - - O
colloidal - - O
ThO2 - - O
. - - O

Hypoglycemic - - O
and - - O
antidiabetic - - O
properties - - O
. - - O

The - - O
method - - O
is - - O
applied - - O
to - - O
determine - - O
aberration - - O
constants - - O
of - - O
a - - O
CM300 - - O
FEG - - O
UT - - O
microscope - - O
with - - O
correction - - O
of - - O
the - - O
three-fold - - O
astigmatism - - O
. - - O

B - - B-MUT
cell - - I-MUT
antigen - - I-MUT
receptor - - I-MUT
( - - O
BCR - - B-MUT
) - - O
-induced - - O
apoptosis - - O
in - - O
the - - O
WEHI-231 - - O
B - - O
lymphoma - - O
cell - - O
line - - O
can - - O
be - - O
prevented - - O
by - - O
engaging - - O
CD40 - - B-MUT
. - - O

Gel - - O
retardation - - O
assays - - O
detected - - O
ZiaR-dependent - - O
complexes - - O
forming - - O
with - - O
the - - O
zia - - B-MUT
operator-promoter - - I-MUT
and - - O
ZiaR-DNA - - O
binding - - O
was - - O
enhanced - - O
by - - O
treatment - - O
with - - O
a - - O
metal-chelator - - O
in - - O
vitro - - O
. - - O

Similarly - - O
, - - O
co-expression - - O
of - - O
a - - O
dominant-negative - - O
mutant - - O
of - - O
p38alpha - - B-MUT
, - - O
but - - O
not - - O
of - - O
ERK1 - - B-MUT
, - - O
ERK2 - - B-MUT
, - - O
JNK1 - - B-MUT
, - - O
or - - O
JNK2 - - B-MUT
, - - O
reduces - - O
basal - - O
and - - O
cadmium-induced - - O
pE1-luc - - B-MUT
activity - - O
. - - O

A - - O
contiguous - - O
and - - O
sequentially - - O
occupied - - O
secondary - - O
Fur-binding - - B-MUT
site - - I-MUT
in - - O
entC - - B-MUT
was - - O
protected - - O
at - - O
higher - - O
Fur - - B-MUT
concentrations - - O
, - - O
extending - - O
the - - O
protected - - O
region - - O
to - - O
+49 - - O
, - - O
and - - O
sequestering - - O
the - - O
putative - - O
Shine-Dalgarno - - O
sequence - - O
. - - O

The - - O
biochemistry - - O
of - - O
amniotic - - O
fluid - - O
with - - O
poor - - O
fetal - - O
growth - - O
. - - O

Northern - - O
analysis - - O
of - - O
the - - O
3 - - B-MUT
. - - I-MUT
1-kb - - I-MUT
PWP2H - - I-MUT
cDNA - - I-MUT
revealed - - O
that - - O
a - - O
3 - - O
. - - O
3-kb - - O
major - - O
transcript - - O
is - - O
ubiquitously - - O
expressed - - O
in - - O
human - - O
adult - - O
tissues - - O
. - - O

Application - - O
of - - O
the - - O
2-deoxy-D-glucose - - O
method - - O
to - - O
the - - O
coupling - - O
of - - O
cerebral - - O
metabolism - - O
and - - O
blood - - O
flow - - O
. - - O

Genetic - - O
analysis - - O
has - - O
subsequently - - O
identified - - O
subpathways - - O
of - - O
the - - O
DNA - - O
structure - - O
checkpoints - - O
, - - O
including - - O
the - - O
reversible - - O
arrest - - O
of - - O
DNA - - O
synthesis - - O
. - - O

One - - O
linker-peptide - - O
insertion - - O
in - - O
the - - O
RsaA - - B-MUT
C - - I-MUT
terminus - - I-MUT
( - - I-MUT
amino - - I-MUT
acid - - I-MUT
784 - - I-MUT
) - - I-MUT
had - - O
no - - O
effect - - O
on - - O
S-layer - - O
biogenesis - - O
, - - O
while - - O
another - - O
( - - O
amino - - O
acid - - O
907 - - O
) - - O
disrupted - - O
secretion - - O
of - - O
the - - O
protein - - O
, - - O
suggesting - - O
that - - O
RsaA - - B-MUT
possesses - - O
a - - O
secretion - - O
signal - - O
lying - - O
C - - O
terminal - - O
to - - O
amino - - O
acid - - O
784 - - O
, - - O
near - - O
or - - O
including - - O
amino - - O
acid - - O
907 - - O
. - - O

Dipetalonema - - O
( - - O
Alafilaria - - O
) - - O
hydrochoerus - - O
subgen - - O
. - - O
et - - O
sp - - O
. - - O
n - - O
. - - O

The - - O
Laser - - O
Scanning - - O
Ophthalmoscope - - O
enables - - O
a - - O
fundus-based - - O
examination - - O
and - - O
therefore - - O
allows - - O
exact - - O
comparison - - O
between - - O
morphologic - - O
appearance - - O
and - - O
corresponding - - O
function - - O
. - - O

356 - - O
, - - O
93-98 - - O
] - - O
. - - O

DESIGN - - O
AND - - O
METHODS - - O
: - - O
Case - - O
study - - O
. - - O

Like - - O
pineal - - O
melatonin - - O
, - - O
serum - - O
melatonin - - O
was - - O
high - - O
at - - O
mid-dark - - O
and - - O
low - - O
at - - O
mid-light - - O
. - - O

After - - O
an - - O
initial - - O
titration - - O
period - - O
and - - O
adjustment - - O
of - - O
the - - O
therapeutic - - O
dose - - O
, - - O
the - - O
individual - - O
doses - - O
were - - O
from - - O
21 - - O
to - - O
500 - - O
micrograms - - O
24 - - O
hrs - - O
( - - O
mean - - O
160 - - O
micrograms - - O
24 - - O
hrs - - O
) - - O
. - - O

For - - O
an - - O
unsupervised - - O
program - - O
, - - O
the - - O
costs - - O
were - - O
estimated - - O
at - - O
$311 - - O
for - - O
the - - O
first - - O
year - - O
and - - O
$73 - - O
for - - O
all - - O
additional - - O
years - - O
. - - O

The - - O
model - - O
indicates - - O
that - - O
a - - O
0 - - O
. - - O
076% - - O
reduction - - O
in - - O
cigarette - - O
consumption - - O
is - - O
associated - - O
with - - O
the - - O
availability - - O
of - - O
nicotine - - O
patches - - O
after - - O
1992 - - O
. - - O

E1 - - B-MUT
, - - O
a - - O
DNA - - B-MUT
helicase - - I-MUT
, - - O
collaborates - - O
with - - O
the - - O
HPV - - B-MUT
E2 - - I-MUT
protein - - I-MUT
in - - O
ori-dependent - - O
replication - - O
. - - O

Tec - - B-MUT
kinase - - I-MUT
signaling - - O
in - - O
T - - O
cells - - O
is - - O
regulated - - O
by - - O
phosphatidylinositol - - B-MUT
3-kinase - - I-MUT
and - - O
the - - O
Tec - - B-MUT
pleckstrin - - B-MUT
homology - - I-MUT
domain - - I-MUT
. - - O

Together - - O
, - - O
our - - O
results - - O
show - - O
that - - O
tinman - - B-MUT
is - - O
controlled - - O
by - - O
an - - O
array - - O
of - - O
discrete - - O
enhancer - - O
elements - - O
that - - O
are - - O
activated - - O
successively - - O
by - - O
differential - - O
genetic - - O
inputs - - O
, - - O
as - - O
well - - O
as - - O
by - - O
closely - - O
linked - - O
activator - - O
and - - O
repressor - - O
binding - - O
sites - - O
within - - O
an - - O
early-acting - - O
enhancer - - O
, - - O
which - - O
restrict - - O
twist - - B-MUT
activity - - O
to - - O
specific - - O
areas - - O
within - - O
the - - O
twist - - B-MUT
expression - - I-MUT
domain - - I-MUT
. - - O

Effects - - O
of - - O
alterations - - O
of - - O
primer-binding - - O
site - - O
sequences - - O
on - - O
human - - O
immunodeficiency - - O
virus - - O
type - - O
1 - - O
replication - - O
. - - O

Infant - - O
aged - - O
3 - - O
. - - O
5 - - O
years - - O
presents - - O
persistence - - O
of - - O
primordial - - O
vitreous - - O
body - - O
with - - O
crystalline - - O
dislocation - - O
in - - O
the - - O
camera - - O
aquosa - - O
and - - O
secondary - - O
buphthalmos - - O
of - - O
the - - O
left - - O
eye - - O
and - - O
microphthalmos - - O
with - - O
dislocation - - O
of - - O
the - - O
crystalline - - O
in - - O
the - - O
vitreous - - O
body - - O
of - - O
the - - O
right - - O
eye - - O
. - - O

The - - O
scr - - B-MUT
regulon - - I-MUT
of - - O
pUR400 - - O
and - - O
the - - O
chromosomally - - B-MUT
encoded - - I-MUT
scr - - I-MUT
regulon - - I-MUT
of - - I-MUT
Klebsiella - - I-MUT
pneumoniae - - I-MUT
KAY2026 - - I-MUT
are - - O
both - - O
negatively - - O
controlled - - O
by - - O
a - - O
specific - - O
repressor - - O
( - - O
ScrR - - B-MUT
) - - O
. - - O

A - - O
215-base-pair - - O
( - - O
bp - - O
) - - O
region - - O
of - - O
the - - O
mouse - - B-MUT
MOPC - - I-MUT
41 - - I-MUT
kappa - - I-MUT
light-chain - - I-MUT
immunoglobulin - - I-MUT
gene - - I-MUT
enhancer - - I-MUT
has - - O
been - - O
analyzed - - O
for - - O
specific - - O
binding - - O
of - - O
lymphoid - - O
and - - O
nonlymphoid - - O
nuclear - - O
factors - - O
. - - O

These - - O
mutants - - O
had - - O
deletions - - O
of - - O
the - - O
extreme - - O
amino-terminal - - O
residues - - O
as - - O
far - - O
as - - O
amino - - O
acid - - O
residue - - O
30 - - O
. - - O

This - - O
transition - - O
is - - O
regulated - - O
positively - - O
by - - O
G1-specific - - B-MUT
cyclin-dependent - - I-MUT
kinases - - I-MUT
( - - O
cdks - - B-MUT
) - - O
and - - O
negatively - - O
by - - O
the - - O
product - - O
of - - O
the - - O
retinoblastoma - - B-MUT
tumour - - I-MUT
suppressor - - I-MUT
gene - - I-MUT
, - - O
pRb - - B-MUT
. - - O

She - - O
was - - O
able - - O
to - - O
stand - - O
unaided - - O
by - - O
3 - - O
years - - O
of - - O
age - - O
with - - O
then - - O
progressive - - O
worsening - - O
of - - O
motor - - O
abilities - - O
. - - O

These - - O
RZR - - B-MUT
subtypes - - O
represent - - O
members - - O
of - - O
a - - O
new - - O
family - - O
of - - O
orphan - - B-MUT
nuclear - - I-MUT
receptors - - I-MUT
that - - O
most - - O
likely - - O
regulate - - O
specific - - O
gene - - O
expression - - O
. - - O

To - - O
study - - O
the - - O
in - - O
vivo - - O
role - - O
of - - O
p16 - - B-MUT
. - - I-MUT
7 - - I-MUT
, - - O
a - - O
phi29 - - O
mutant - - O
containing - - O
a - - O
suppressible - - O
mutation - - O
in - - O
gene - - B-MUT
16 - - I-MUT
. - - I-MUT
7 - - I-MUT
was - - O
constructed - - O
. - - O

In - - O
an - - O
in - - O
vitro - - O
study - - O
, - - O
10 - - O
0 - - O
nylon - - O
was - - O
found - - O
to - - O
require - - O
a - - O
significantly - - O
lower - - O
laser - - O
energy - - O
density - - O
to - - O
produce - - O
suture - - O
lysis - - O
following - - O
a - - O
single - - O
shot - - O
than - - O
either - - O
10 - - O
0 - - O
Dacron - - O
or - - O
10 - - O
0 - - O
prolene - - O
. - - O

In - - O
order - - O
to - - O
screen - - O
for - - O
such - - O
cofactors - - O
, - - O
we - - O
have - - O
used - - O
a - - O
transcriptionally - - O
inactive - - O
mutant - - O
of - - O
Xenopus - - B-MUT
MEF2D - - I-MUT
in - - O
a - - O
yeast - - O
two-hybrid - - O
screen - - O
. - - O

A - - O
decamer - - O
sequence - - O
, - - O
5'-CGA-CCCCUCC-3' - - B-MUT
, - - O
complementary - - O
to - - O
a - - O
conserved - - O
sequence - - O
adjacent - - O
to - - O
the - - O
enzymatic - - O
cleavage - - O
site - - O
on - - O
the - - O
mitochondrial - - O
RNA - - O
substrate - - O
, - - O
is - - O
present - - O
in - - O
the - - O
RNAase - - B-MUT
MRP - - I-MUT
RNA - - I-MUT
. - - O

In - - O
vitro - - O
translation - - O
of - - O
RNA - - O
synthesized - - O
from - - O
the - - O
cloned - - O
cDNAs - - O
predicts - - O
that - - O
P0 - - B-MUT
transcripts - - I-MUT
are - - O
translated - - O
into - - O
a - - O
novel - - O
12 - - O
. - - O
5-kilodalton - - O
protein - - O
corresponding - - O
to - - O
the - - O
first - - O
open - - O
reading - - O
frame - - O
. - - O

In - - O
the - - O
remaining - - O
case - - O
, - - O
the - - O
aneurysm - - O
originated - - O
from - - O
the - - O
proximal - - O
end - - O
of - - O
the - - O
associated - - O
A1 - - O
fenestration - - O
. - - O

The - - O
diagnosis - - O
of - - O
amyloidosis - - O
was - - O
determined - - O
from - - O
a - - O
labial - - O
salivary - - O
gland - - O
biopsy - - O
. - - O

CASE - - O
REPORT - - O
: - - O
Referred - - O
because - - O
of - - O
a - - O
right - - O
corneal - - O
perforation - - O
with - - O
cellular - - O
reaction - - O
in - - O
anterior - - O
chamber - - O
, - - O
a - - O
patient - - O
was - - O
sutured - - O
and - - O
treated - - O
with - - O
a - - O
single - - O
intravitreal - - O
injection - - O
of - - O
0 - - O
. - - O
2 - - O
ml - - O
( - - O
1 - - O
mg - - O
) - - O
Amikacin - - O
and - - O
0 - - O
. - - O
2 - - O
ml - - O
( - - O
1 - - O
mg - - O
) - - O
Vancomycin - - O
. - - O

We - - O
further - - O
found - - O
that - - O
KmMig1p - - B-MUT
is - - O
fully - - O
functional - - O
when - - O
expressed - - O
in - - O
S - - O
. - - O
cerevisiae - - O
. - - O

It - - O
has - - O
repeatedly - - O
been - - O
shown - - O
that - - O
HCMV - - O
IE1 - - B-MUT
IE2 - - O
can - - B-MUT
independently - - O
transactivate - - O
HIV-1 - - O
LTR - - B-MUT
. - - I-MUT

Terbutaline - - O
; - - O
a - - O
beta2-adrenergic - - O
agonist - - O
, - - O
and - - O
aminophyllin - - O
, - - O
a - - O
phosphodiesterase - - B-MUT
inhibitor - - O
, - - O
were - - O
given - - O
separately - - O
, - - O
or - - O
in - - O
combination - - O
, - - O
to - - O
rabbit - - O
fetuses - - O
on - - O
the - - O
28th - - O
day - - O
of - - O
gestation - - O
. - - O

Comparison - - O
to - - O
other - - O
coxI - - B-MUT
genes - - I-MUT
revealed - - O
a - - O
966-bp - - B-MUT
group - - I-MUT
I - - I-MUT
intron - - I-MUT
, - - O
which - - O
, - - O
based - - O
on - - O
homology - - O
with - - O
the - - O
related - - O
yeast - - B-MUT
coxI - - I-MUT
intron - - I-MUT
aI4 - - I-MUT
, - - O
potentially - - O
encodes - - O
a - - O
279-amino-acid - - B-MUT
site-specific - - I-MUT
DNA - - I-MUT
endonuclease - - I-MUT
. - - O

In - - O
conclusion - - O
, - - O
tube - - O
size - - O
estimated - - O
by - - O
Cole's - - O
formula - - O
tends - - O
to - - O
be - - O
smaller - - O
than - - O
practically - - O
appropriate - - O
tube - - O
size - - O
for - - O
pediatric - - O
cardiac - - O
anesthesia - - O
, - - O
and - - O
therefore - - O
we - - O
suggest - - O
new - - O
formula - - O
to - - O
estimate - - O
the - - O
tube - - O
size - - O
. - - O

Antipyretic - - O
therapy - - O
: - - O
physiologic - - O
rationale - - O
, - - O
diagnostic - - O
implications - - O
, - - O
and - - O
clinical - - O
consequences - - O
. - - O

Upon - - O
analysis - - O
of - - O
the - - O
tissue - - O
distribution - - O
of - - O
AAMP - - B-MUT
, - - O
it - - O
was - - O
found - - O
to - - O
be - - O
expressed - - O
strongly - - O
in - - O
endothelial - - O
cells - - O
, - - O
cytotrophoblasts - - O
, - - O
and - - O
poorly - - O
differentiated - - O
colon - - O
adenocarcinoma - - O
cells - - O
found - - O
in - - O
lymphatics - - O
. - - O

We - - O
propose - - O
that - - O
noi - - B-MUT
pax2 - - I-MUT
. - - I-MUT
1 - - I-MUT
participates - - I-MUT
in - - O
sequential - - O
signaling - - O
processes - - O
as - - O
a - - O
key - - O
integrator - - O
of - - O
midbrain-hindbrain - - O
boundary - - O
development - - O
. - - O

Finally - - O
, - - O
over - - O
a - - O
similar - - O
range - - O
of - - O
QO2 - - O
, - - O
oxygen - - O
extraction - - O
was - - O
greater - - O
in - - O
patients - - O
with - - O
ARDS - - O
compared - - O
to - - O
patients - - O
with - - O
non-ARDS - - O
respiratory - - O
failure - - O
( - - O
r - - O
= - - O
-0 - - O
. - - O
67 - - O
and - - O
slope - - O
= - - O
-0 - - O
. - - O
62 - - O
vs - - O
r - - O
= - - O
-0 - - O
. - - O
45 - - O
and - - O
slope - - O
= - - O
-0 - - O
. - - O
35 - - O
; - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
05 - - O
) - - O
. - - O

In - - O
the - - O
commercially - - O
available - - O
intravenous - - O
formulation - - O
of - - O
Cyclosporin - - O
A - - O
( - - O
Sandimmun - - O
) - - O
, - - O
polyoxyethylated - - O
castor - - O
oil - - O
( - - O
Cremophor - - O
EL - - O
) - - O
is - - O
used - - O
as - - O
a - - O
solubilizing - - O
agent - - O
. - - O

Inhibition - - O
of - - O
histalog-stimulated - - O
gastric - - O
secretion - - O
by - - O
40 - - O
749 - - O
RP - - O
, - - O
a - - O
new - - O
long-acting - - O
gastric - - O
antisecretory - - O
agent - - O
. - - O

The - - O
HMG - - B-MUT
CoA - - I-MUT
reductase - - I-MUT
inhibitors - - O
are - - O
the - - O
most - - O
effective - - O
cholesterol-lowering - - O
agents - - O
currently - - O
available - - O
. - - O

The - - O
activity - - O
of - - O
the - - O
EGF - - B-MUT
receptor - - I-MUT
promoter - - I-MUT
can - - O
be - - O
modulated - - O
by - - O
E1A - - B-MUT
protein - - I-MUT
and - - O
receptor - - O
RNA - - O
levels - - O
increased - - O
by - - O
stimulation - - O
with - - O
phorbol - - O
ester - - O
or - - O
fetal - - O
calf - - O
serum - - O
. - - O

Moreover - - O
, - - O
the - - O
observation - - O
of - - O
enhanced - - O
luteal - - B-MUT
HSP-27 - - I-MUT
phosphorylation - - O
in - - O
vivo - - O
, - - O
in - - O
late - - O
pregnancy - - O
, - - O
when - - O
PKC-delta - - B-MUT
is - - O
abundant - - O
and - - O
active - - O
, - - O
suggests - - O
that - - O
select - - O
PKC - - B-MUT
family - - I-MUT
members - - I-MUT
contribute - - O
to - - O
sHSP - - B-MUT
phosphorylation - - O
events - - O
in - - O
vivo - - O
. - - O

Analysis - - O
of - - O
the - - O
5' - - O
flanking - - O
region - - O
of - - O
the - - O
gene - - O
also - - O
revealed - - O
the - - O
presence - - O
of - - O
multiple - - O
TATA - - O
and - - O
CAAT - - O
sequences - - O
. - - O

Sural - - O
nerve - - O
biopsy - - O
showed - - O
mild - - O
thickening - - O
of - - O
the - - O
perineurium - - O
, - - O
vascular - - O
alterations - - O
with - - O
inflammatory - - O
cell - - O
infiltration - - O
in - - O
the - - O
perineurium - - O
, - - O
and - - O
remarkable - - O
loss - - O
of - - O
large - - O
and - - O
small - - O
myelinated - - O
fibers - - O
. - - O

Family - - O
environment - - O
was - - O
an - - O
important - - O
influence - - O
on - - O
interpersonal - - O
relationships - - O
, - - O
substance - - O
use - - O
, - - O
and - - O
social - - O
support - - O
. - - O

Finally - - O
, - - O
we - - O
compared - - O
the - - O
differential - - O
screening - - O
techniques - - O
in - - O
terms - - O
of - - O
sensitivity - - O
, - - O
efficiency - - O
and - - O
occurrence - - O
of - - O
false - - O
positives - - O
. - - O

There - - O
has - - O
been - - O
similar - - O
improvement - - O
in - - O
treating - - O
ampullary - - O
and - - O
periampullary - - O
cancer - - O
, - - O
gallbladder - - O
cancer - - O
, - - O
or - - O
extrahepatic - - O
bile - - O
duct - - O
cancer - - O
. - - O

Modification - - O
of - - O
the - - O
growth - - O
of - - O
Tetrahymena - - O
by - - O
compounds - - O
which - - O
affect - - O
the - - O
adrenergic - - O
mechanism - - O
. - - O

Editorial - - O
: - - O
Low-dose - - O
heparin - - O
and - - O
the - - O
prevention - - O
of - - O
venous - - O
thromboembolic - - O
disease - - O
. - - O

These - - O
genes - - O
were - - O
expressed - - O
in - - O
a - - O
Saccharomyces - - O
cerevisiae - - O
mutant - - O
in - - O
which - - O
the - - O
endogenous - - B-MUT
ferrochelatase - - I-MUT
gene - - I-MUT
( - - O
HEM15 - - B-MUT
) - - O
had - - O
been - - O
deleted - - O
, - - O
and - - O
the - - O
phenotypes - - O
of - - O
the - - O
transformants - - O
were - - O
characterized - - O
. - - O

Lyn - - B-MUT
kinase - - I-MUT
immunoprecipitated - - O
from - - O
lysates - - O
of - - O
irradiated - - O
BCP - - O
as - - O
well - - O
as - - O
a - - O
full-length - - B-MUT
glutathione - - I-MUT
S-transferase - - I-MUT
( - - O
GST - - B-MUT
) - - O
-Lyn - - O
fusion - - O
protein-phosphorylated - - O
recombinant - - B-MUT
human - - I-MUT
p34cdc2 - - I-MUT
on - - O
tyrosine - - O
15 - - O
. - - O

Computer-aided - - O
"FRAME" - - O
analysis - - O
revealed - - O
four - - O
possible - - O
open - - O
reading - - O
frames - - O
( - - O
ORFs - - O
) - - O
, - - O
three - - O
in - - O
one - - O
direction - - O
and - - O
one - - O
in - - O
the - - O
opposite - - O
direction - - O
. - - O

Our - - O
observations - - O
suggest - - O
that - - O
members - - O
of - - O
the - - O
HMG-I - - B-MUT
family - - I-MUT
play - - O
an - - O
important - - O
role - - O
in - - O
SRF-dependent - - O
transcription - - O
and - - O
that - - O
their - - O
effect - - O
is - - O
mediated - - O
primarily - - O
by - - O
a - - O
protein-protein - - O
interaction - - O
. - - O

I - - O
. - - O

The - - O
corresponding - - O
orifice - - O
voltages - - O
for - - O
the - - O
three - - O
instruments - - O
were - - O
20 - - O
50 - - O
80 - - O
V - - O
( - - O
API - - O
365 - - O
) - - O
, - - O
30 - - O
90 - - O
130 - - O
V - - O
( - - O
API - - O
2000 - - O
) - - O
and - - O
40 - - O
80 - - O
120 - - O
V - - O
( - - O
API - - O
3000 - - O
) - - O
. - - O

Schnell - - O
, - - O
J - - O
. - - O

Continued - - O
development - - O
of - - O
the - - O
rat - - O
conditioning - - O
paradigm - - O
is - - O
especially - - O
warranted - - O
because - - O
of - - O
the - - O
ability - - O
to - - O
record - - O
sympathetic - - O
nerve - - O
activity - - O
in - - O
intact - - O
, - - O
awake - - O
subjects - - O
and - - O
the - - O
large - - O
number - - O
of - - O
readily - - O
available - - O
genetic - - O
strains - - O
, - - O
which - - O
model - - O
human - - O
pathological - - O
states - - O
. - - O

These - - O
results - - O
with - - O
clozapine - - O
illustrate - - O
that - - O
LI - - O
is - - O
sensitive - - O
to - - O
antipsychotics - - O
which - - O
differ - - O
in - - O
their - - O
mode - - O
of - - O
action - - O
and - - O
furthermore - - O
emphasize - - O
the - - O
value - - O
of - - O
LI - - O
as - - O
a - - O
test - - O
model - - O
for - - O
detecting - - O
the - - O
antipsychotic - - O
potential - - O
of - - O
novel - - O
drugs - - O
. - - O

Patients - - O
who - - O
have - - O
undergone - - O
thyroidectomy - - O
for - - O
thyroid - - O
carcinoma - - O
are - - O
frequently - - O
subjected - - O
to - - O
periods - - O
of - - O
induced - - O
severe - - O
hypothyroidism - - O
in - - O
preparation - - O
for - - O
131I - - O
whole - - O
body - - O
scanning - - O
and - - O
measurement - - O
of - - O
serum - - O
TG - - O
. - - O

In - - O
metabolic - - O
acidosis - - O
there - - O
was - - O
a - - O
marked - - O
stimulation - - O
when - - O
clamped - - O
at - - O
-10 - - O
to - - O
-100 - - O
mV - - O
. - - O

Synergistic - - O
transactivation - - O
of - - O
the - - O
BMRF1 - - B-MUT
promoter - - I-MUT
by - - O
the - - O
Z - - B-MUT
c-myb - - I-MUT
combination - - I-MUT
appears - - O
to - - O
involve - - O
direct - - O
binding - - O
by - - O
the - - O
Z - - O
protein - - B-MUT
but - - I-MUT
not - - O
the - - O
c-myb - - O
protein - - B-MUT
. - - I-MUT

Insulin-like - - B-MUT
growth - - I-MUT
factor-I - - I-MUT
induces - - O
bcl-2 - - B-MUT
promoter - - I-MUT
through - - O
the - - O
transcription - - O
factor - - O
cAMP-response - - B-MUT
element-binding - - I-MUT
protein - - I-MUT
. - - O

METHODS - - O
: - - O
We - - O
determined - - O
an - - O
odds - - O
ratio - - O
( - - O
OR - - O
) - - O
, - - O
as - - O
a - - O
measure - - O
of - - O
the - - O
relative - - O
risk - - O
of - - O
being - - O
exposed - - O
to - - O
a - - O
potential - - O
interaction - - O
, - - O
comparing - - O
the - - O
use - - O
of - - O
the - - O
H2-receptor - - B-MUT
antagonist - - I-MUT
, - - O
cimetidine - - O
, - - O
with - - O
that - - O
of - - O
the - - O
noninteracting - - O
agents - - O
ranitidine - - O
, - - O
famotidine - - O
and - - O
nizatidine - - O
in - - O
users - - O
and - - O
nonusers - - O
of - - O
warfarin - - O
, - - O
phenytoin - - O
and - - O
theophylline - - O
. - - O

Long-range - - O
comparison - - O
of - - O
human - - B-MUT
and - - I-MUT
mouse - - I-MUT
SCL - - I-MUT
loci - - I-MUT
: - - O
localized - - O
regions - - O
of - - O
sensitivity - - O
to - - O
restriction - - B-MUT
endonucleases - - I-MUT
correspond - - O
precisely - - O
with - - O
peaks - - O
of - - O
conserved - - O
noncoding - - O
sequences - - O
. - - O

In - - O
TNF-resistant - - O
T24 - - O
bladder - - O
carcinoma - - O
cells - - O
, - - O
TNF - - B-MUT
failed - - O
to - - O
alter - - O
EGF-R - - B-MUT
tyrosine - - B-MUT
protein - - I-MUT
kinase - - I-MUT
activity - - O
although - - O
both - - O
EGF - - B-MUT
and - - O
phorbol - - O
ester - - O
were - - O
shown - - O
to - - O
modulate - - O
the - - O
enzymatic - - O
activity - - O
of - - O
the - - O
receptor - - O
in - - O
these - - O
cells - - O
. - - O

We - - O
isolated - - O
a - - O
ribosomal - - B-MUT
protein - - I-MUT
L18 - - I-MUT
by - - O
interaction - - O
with - - O
PKR - - B-MUT
. - - O

Sequence - - O
determination - - O
of - - O
isolated - - O
peptides - - O
suggested - - O
that - - O
Asn120 - - O
is - - O
glycosylated - - O
, - - O
Asn65 - - O
and - - O
Asn109 - - O
glycosylated - - O
in - - O
some - - O
molecules - - O
but - - O
not - - O
in - - O
others - - O
, - - O
and - - O
Asn72 - - O
not - - O
glycosylated - - O
. - - O

Qualitatively - - O
, - - O
the - - O
results - - O
are - - O
similar - - O
for - - O
the - - O
two - - O
species - - O
: - - O
Both - - O
rhesus - - O
monkey - - O
and - - O
man - - O
have - - O
photopic - - O
and - - O
scotopic - - O
branches - - O
, - - O
which - - O
cross - - O
at - - O
approximately - - O
the - - O
same - - O
time - - O
in - - O
the - - O
dark - - O
and - - O
at - - O
approximately - - O
the - - O
same - - O
background - - O
luminance - - O
. - - O

Insertional - - O
inactivation - - O
of - - O
sms - - B-MUT
led - - O
to - - O
increased - - O
sensitivity - - O
to - - O
the - - O
alkylating - - O
agent - - O
methylmethane - - O
sulfonate - - O
, - - O
but - - O
not - - O
to - - O
a - - O
requirement - - O
for - - O
serine - - O
or - - O
other - - O
metabolites - - O
. - - O

Since - - O
the - - O
5'-flanking - - O
region - - O
of - - O
this - - O
gene - - O
is - - O
likely - - O
involved - - O
in - - O
hormonal - - O
regulation - - O
of - - O
its - - O
expression - - O
, - - O
we - - O
have - - O
isolated - - O
and - - O
partially - - O
characterized - - O
an - - O
avian - - O
fatty - - B-MUT
acid - - I-MUT
synthase - - I-MUT
gene - - O
. - - O

Improved - - O
cosmesis - - O
, - - O
extension - - O
of - - O
the - - O
scope - - O
of - - O
the - - O
problems - - O
that - - O
can - - O
be - - O
addressed - - O
with - - O
this - - O
repair - - O
( - - O
including - - O
treatment - - O
of - - O
a - - O
distal - - O
urethrocutaneous - - O
fistula - - O
) - - O
and - - O
the - - O
ease - - O
with - - O
which - - O
the - - O
Arap - - O
procedure - - O
can - - O
be - - O
performed - - O
are - - O
the - - O
advantages - - O
that - - O
this - - O
operation - - O
has - - O
over - - O
other - - O
1-stage - - O
distal - - O
hypospadias - - O
repairs - - O
. - - O

Thirty - - O
percent - - O
of - - O
patients - - O
were - - O
tapered - - O
off - - O
all - - O
steroids - - O
, - - O
and - - O
the - - O
average - - O
steroid - - O
dose - - O
in - - O
the - - O
group - - O
who - - O
received - - O
steroids - - O
was - - O
8 - - O
. - - O
6 - - O
mg - - O
of - - O
prednisone - - O
per - - O
day - - O
. - - O

However - - O
, - - O
in - - O
contrast - - O
with - - O
previous - - O
in - - O
vitro - - O
cell-free - - O
integration - - O
studies - - O
, - - O
alteration - - O
of - - O
the - - O
highly - - O
conserved - - O
CA - - O
dinucleotide - - O
resulted - - O
in - - O
a - - O
mutant - - O
which - - O
still - - O
retained - - O
40% - - O
of - - O
wild-type - - O
integration - - O
activity - - O
. - - O

Spontaneous - - O
recovery - - O
occurs - - O
within - - O
30 - - O
min - - O
to - - O
2 - - O
hrs - - O
. - - O

A - - O
p21 - - B-MUT
peptide - - I-MUT
spanning - - O
amino - - O
acids - - O
139-164 - - O
was - - O
found - - O
to - - O
bind - - O
PCNA - - B-MUT
in - - O
a - - O
filter - - O
binding - - O
assay - - O
and - - O
this - - O
peptide - - O
suppressed - - O
recombinant - - B-MUT
p21-PCNA - - I-MUT
interaction - - O
. - - O

Molecular - - O
characterization - - O
of - - O
malignant - - O
melanoma - - O
of - - O
soft - - O
parts - - O
or - - O
soft - - O
tissue - - O
clear - - O
cell - - O
sarcoma - - O
which - - O
shares - - O
t - - O
( - - O
12 - - O
; - - O
22 - - O
) - - O
chromosome - - O
translocation - - O
revealed - - O
fusion - - O
of - - O
EWS - - B-MUT
with - - O
a - - O
transcriptional - - O
factor - - O
gene - - B-MUT
ATF-1 - - I-MUT
. - - O

Thus - - O
, - - O
these - - O
studies - - O
on - - O
rat - - B-MUT
Std - - I-MUT
promoter - - I-MUT
function - - O
indicate - - O
that - - O
( - - O
i - - O
) - - O
HNF1 - - B-MUT
and - - O
C - - B-MUT
EBP - - I-MUT
are - - I-MUT
responsible - - O
for - - O
liver - - O
specificity - - O
of - - O
the - - O
rat - - O
Std - - B-MUT
gene - - I-MUT
; - - I-MUT
( - - O
ii - - O
) - - O
androgenic - - O
repression - - O
of - - O
the - - O
gene - - O
requires - - O
the - - O
presence - - O
of - - O
all - - O
of - - O
the - - O
OCT-1 - - O
and - - B-MUT
C - - O
EBP - - B-MUT
elements - - I-MUT
between - - I-MUT
positions - - I-MUT
-231 - - O
and - - O
-292 - - O
; - - O
and - - O
( - - O
iii - - O
) - - O
AR - - O
may - - O
exert - - B-MUT
its - - O
negative - - O
regulatory - - O
effect - - O
indirectly - - O
through - - O
transcriptional - - O
interference - - O
of - - O
OCT-1 - - O
and - - O
C - - B-MUT
EBP - - O
rather - - B-MUT
than - - I-MUT
through - - I-MUT
a - - O
direct - - O
DNA-AR - - O
interaction - - O
. - - O

The - - O
R - - B-MUT
. - - I-MUT
meliloti - - I-MUT
nifH - - I-MUT
promoter - - I-MUT
but - - O
not - - O
the - - O
K - - B-MUT
. - - I-MUT
pneumoniae - - I-MUT
nifH - - I-MUT
promoter - - I-MUT
showed - - O
sigma - - O
54-dependent - - O
methylation - - O
protection - - O
of - - O
guanine - - O
residues - - O
at - - O
-14 - - O
, - - O
-25 - - O
and - - O
-26 - - O
, - - O
the - - O
most - - O
conserved - - O
nucleotides - - O
characteristic - - O
of - - O
sigma - - B-MUT
54-dependent - - I-MUT
promoters - - I-MUT
. - - O

Competition - - O
EMSA - - O
established - - O
that - - O
constitutively - - O
expressed - - O
nuclear - - O
proteins - - O
bound - - O
the - - O
KCS - - B-MUT
element - - I-MUT
selectively - - O
; - - O
KCS - - B-MUT
protein - - I-MUT
binding - - O
activity - - O
correlated - - O
with - - O
promoter - - O
activity - - O
in - - O
the - - O
transient - - O
transfection - - O
reporter - - O
assay - - O
. - - O

CONCLUSION - - O
: - - O
In - - O
Cdks - - B-MUT
functioning - - O
throughout - - O
the - - O
cell - - O
cycle - - O
, - - O
tyrosine - - O
phosphorylation - - O
is - - O
inhibitory - - O
to - - O
the - - O
activation - - O
of - - O
kinase - - O
, - - O
whereas - - O
the - - O
phosphorylation - - O
of - - O
threonine - - O
in - - O
the - - O
T-loop - - O
is - - O
essential - - O
for - - O
activation - - O
. - - O

For - - O
the - - O
first - - O
time - - O
we - - O
describe - - O
deletion - - O
and - - O
point - - O
mutations - - O
within - - O
the - - O
plasma - - B-MUT
membrane - - I-MUT
family - - I-MUT
of - - I-MUT
guanylyl - - I-MUT
cyclase - - I-MUT
receptors - - I-MUT
that - - O
result - - O
in - - O
the - - O
formation - - O
of - - O
effective - - O
dominant - - O
negative - - O
proteins - - O
. - - O

No - - O
difference - - O
in - - O
the - - O
clinical - - O
acceptability - - O
could - - O
be - - O
ascertained - - O
between - - O
the - - O
two - - O
groups - - O
. - - O

MSSPs - - B-MUT
are - - O
believed - - O
to - - O
regulate - - O
DNA - - O
replication - - O
, - - O
transcription - - O
, - - O
apopotosis - - O
and - - O
cell - - O
cycle - - O
progression - - O
by - - O
interacting - - O
with - - O
the - - O
C-MYC - - B-MUT
protein - - I-MUT
. - - O

The - - O
clinical - - O
picture - - O
of - - O
the - - O
disease - - O
was - - O
significantly - - O
different - - O
from - - O
anthropogenic - - O
cutaneous - - O
leishmaniasis - - O
caused - - O
by - - O
L - - O
. - - O
tropica - - O
but - - O
similar - - O
to - - O
cutaneous - - O
patterns - - O
caused - - O
by - - O
L - - O
. - - O
infantum - - O
which - - O
was - - O
a - - O
prevalent - - O
pattern - - O
in - - O
the - - O
southern - - O
France - - O
. - - O

The - - O
human - - B-MUT
2' - - I-MUT
, - - I-MUT
5'-oligoadenylate - - I-MUT
( - - I-MUT
2-5A - - I-MUT
) - - I-MUT
synthetases - - I-MUT
are - - O
members - - O
of - - O
a - - O
family - - O
interferon - - B-MUT
( - - O
IFN - - B-MUT
) - - O
-inducible - - O
anti-viral - - B-MUT
proteins - - I-MUT
. - - O

Taken - - O
together - - O
, - - O
we - - O
provide - - O
evidence - - O
for - - O
the - - O
existence - - O
of - - O
an - - O
activator - - O
, - - O
NFE - - B-MUT
, - - O
which - - O
in - - O
combination - - O
with - - O
the - - O
p50 - - B-MUT
and - - O
c-Rel - - B-MUT
proteins - - I-MUT
, - - O
are - - O
part - - O
of - - O
the - - O
transcription - - O
factor - - O
machinery - - O
that - - O
regulates - - O
3' - - O
enhancer - - O
activity - - O
, - - O
and - - O
thus - - O
the - - O
control - - O
of - - O
the - - O
IgH - - B-MUT
locus - - I-MUT
in - - O
late - - O
B - - O
lymphocyte - - O
development - - O
. - - O

We - - O
show - - O
that - - O
the - - O
mouse - - O
genome - - O
contains - - O
four - - O
copies - - O
of - - O
the - - O
ubc-9 - - B-MUT
gene - - I-MUT
. - - O

The - - O
AtERF - - B-MUT
genes - - I-MUT
were - - O
differentially - - O
regulated - - O
by - - O
ethylene - - O
and - - O
by - - O
abiotic - - O
stress - - O
conditions - - O
, - - O
such - - O
as - - O
wounding - - O
, - - O
cold - - O
, - - O
high - - O
salinity - - O
, - - O
or - - O
drought - - O
, - - O
via - - O
ETHYLENE-INSENSITIVE2 - - B-MUT
( - - O
EIN2 - - B-MUT
) - - O
-dependent - - O
or - - O
-independent - - O
pathways - - O
. - - O

In - - O
resting - - O
3T3 - - O
cells - - O
, - - O
jun-D - - B-MUT
is - - O
expressed - - O
at - - O
a - - O
higher - - O
level - - O
compared - - O
to - - O
c-jun - - B-MUT
and - - O
jun-B - - B-MUT
, - - O
and - - O
its - - O
transcription - - O
is - - O
stimulated - - O
only - - O
slightly - - O
by - - O
serum - - O
growth - - B-MUT
factors - - I-MUT
. - - O

A - - O
method - - O
is - - O
described - - O
for - - O
the - - O
simultaneous - - O
determination - - O
of - - O
1 - - O
, - - O
alpha-acetylmethadol - - O
( - - O
LAAM - - O
) - - O
and - - O
five - - O
active - - O
metabolites--noracetylmethadol - - O
, - - O
dinoracetylmethadol - - O
, - - O
methadol - - O
, - - O
normethadol - - O
, - - O
and - - O
dinormethadol--in - - O
biofluids - - O
by - - O
high-performance - - O
liquid - - O
chromatography - - O
using - - O
a - - O
normal-phase - - O
column - - O
and - - O
a - - O
UV - - O
detector - - O
at - - O
218 - - O
nm - - O
. - - O

The - - O
goal - - O
of - - O
this - - O
study - - O
was - - O
to - - O
identify - - O
neuronal - - O
cell - - O
cultures - - O
that - - O
express - - O
RC3 - - B-MUT
neurogranin - - I-MUT
, - - I-MUT
to - - O
check - - O
whether - - O
they - - O
are - - O
sensitive - - O
to - - O
T3 - - O
, - - O
and - - O
to - - O
examine - - O
the - - O
mechanism - - O
of - - O
regulation - - O
. - - O

Self-emasculation - - O
is - - O
the - - O
end - - O
result - - O
of - - O
an - - O
unusual - - O
psychiatric - - O
disorder - - O
, - - O
which - - O
initially - - O
requires - - O
surgical - - O
treatment - - O
. - - O

Here - - O
, - - O
it - - O
is - - O
shown - - O
that - - O
TAFII250 - - B-MUT
, - - O
the - - O
largest - - O
subunit - - O
of - - O
TFIID - - B-MUT
, - - O
contains - - O
two - - O
tandem - - O
bromodomain - - O
modules - - O
that - - O
bind - - O
selectively - - O
to - - O
multiply - - O
acetylated - - O
histone - - B-MUT
H4 - - I-MUT
peptides - - I-MUT
. - - O

Reovirus - - O
mRNAs - - O
are - - O
efficiently - - O
translated - - O
within - - O
host - - O
cells - - O
despite - - O
the - - O
absence - - O
of - - O
3' - - O
polyadenylated - - O
tails - - O
. - - O

The - - O
disturbance - - O
of - - O
pulmonary - - O
gas - - O
exchange - - O
, - - O
as - - O
revealed - - O
by - - O
the - - O
high - - O
value - - O
of - - O
AaDO2 - - O
, - - O
existed - - O
without - - O
left - - O
ventricular - - O
dysfunction - - O
, - - O
and - - O
AaDO2 - - O
had - - O
no - - O
significant - - O
relationship - - O
with - - O
any - - O
of - - O
the - - O
hemodynamic - - O
parameters - - O
including - - O
the - - O
difference - - O
between - - O
plasma - - O
colloid - - O
osmotic - - O
pressure - - O
and - - O
PCW - - O
. - - O

Transfection - - O
of - - O
cDNAs - - O
for - - O
three - - O
mutant - - O
enzymes - - O
into - - O
FPGS-null - - O
Chinese - - O
hamster - - O
ovary - - O
cells - - O
restored - - O
a - - O
reduced - - O
level - - O
of - - O
clonal - - O
growth - - O
, - - O
whereas - - O
a - - O
T339I - - O
mutant - - O
supported - - O
growth - - O
at - - O
a - - O
level - - O
comparable - - O
to - - O
that - - O
of - - O
the - - O
wild-type - - O
enzyme - - O
. - - O

A - - O
vector - - O
containing - - O
a - - O
transcriptionally - - O
inactive - - O
neomycin - - B-MUT
phosphotransferase - - I-MUT
II - - I-MUT
gene - - I-MUT
was - - O
used - - O
to - - O
select - - O
promoter - - O
sequences - - O
from - - O
a - - O
pool - - O
of - - O
random - - O
genomic - - O
DNA - - O
fragments - - O
. - - O

None - - O
of - - O
the - - O
measured - - O
parameters - - O
( - - O
heart - - O
contents - - O
of - - O
neutral - - O
lipids - - O
, - - O
total - - O
phospholipids - - O
, - - O
phosphatidylcholine - - O
, - - O
phosphatidylethanolamine - - O
, - - O
diphosphatidylglycerol - - O
, - - O
sphingomyelin - - O
and - - O
fatty - - O
acid - - O
composition - - O
of - - O
each - - O
phospholipid - - O
class - - O
) - - O
appeared - - O
to - - O
be - - O
related - - O
with - - O
the - - O
grading - - O
of - - O
the - - O
lesions - - O
. - - O

In - - O
co-transfection - - O
studies - - O
, - - O
the - - O
expression - - O
of - - O
c-Jun - - B-MUT
plus - - O
c-Fos - - B-MUT
enhanced - - O
the - - O
transactivation - - O
of - - O
oIFNtau-CAT - - B-MUT
but - - O
the - - O
expression - - O
of - - O
GATA-1 - - B-MUT
, - - O
GATA-2 - - B-MUT
or - - O
GATA-3 - - B-MUT
did - - O
not - - O
. - - O

In - - O
the - - O
DNAs - - O
of - - O
all - - O
Ph1-positive - - O
chronic - - O
myelocytic - - O
leukemia - - O
patients - - O
studied - - O
to - - O
date - - O
, - - O
a - - O
breakpoint - - O
on - - O
chromosome - - O
22 - - O
( - - O
the - - O
Ph1 - - O
chromosome - - O
) - - O
can - - O
be - - O
demonstrated - - O
with - - O
a - - O
probe - - O
from - - O
the - - O
bcr - - O
( - - O
breakpoint - - O
cluster - - O
region - - O
) - - O
. - - O

The - - O
bactericidal - - O
effect - - O
of - - O
disinfectants - - O
against - - O
biofilm - - O
cells - - O
was - - O
found - - O
to - - O
be - - O
considerably - - O
enhanced - - O
by - - O
increasing - - O
the - - O
concentrations - - O
of - - O
the - - O
disinfectants - - O
. - - O

Domain - - O
II - - O
is - - O
highly - - O
homologous - - O
to - - O
the - - O
LDL - - B-MUT
receptor - - I-MUT
and - - O
contains - - O
four - - O
repeats - - O
with - - O
perfect - - O
conservation - - O
of - - O
all - - O
6 - - O
consecutive - - O
cysteines - - O
. - - O

In - - O
light - - O
of - - O
the - - O
importance - - O
of - - O
GnRHR - - B-MUT
, - - O
the - - O
molecular - - O
mechanisms - - O
underlying - - O
the - - O
transcriptional - - O
regulation - - O
of - - O
the - - O
human - - B-MUT
GnRHR - - I-MUT
( - - O
hGnRHR - - B-MUT
) - - O
gene - - O
become - - O
a - - O
key - - O
issue - - O
in - - O
understanding - - O
human - - O
reproduction - - O
. - - O

Sequencing - - O
of - - O
a - - O
40-kb - - O
DNA - - O
segment - - O
of - - O
the - - O
FK506 - - B-MUT
gene - - I-MUT
cluster - - O
from - - O
Streptomyces - - O
sp - - O
. - - O

Thus - - O
, - - O
replication - - O
fork - - O
movement - - O
near - - O
HML - - B-MUT
pauses - - O
at - - O
a - - O
silent - - O
origin - - O
which - - O
is - - O
competent - - O
for - - O
replication - - O
initiation - - O
but - - O
kept - - O
silent - - O
through - - O
Orc2p - - B-MUT
, - - O
a - - O
component - - O
of - - O
the - - O
replication - - O
initiator - - O
. - - O

Assessment - - O
of - - O
nutrient - - O
media - - O
in - - O
the - - O
diagnosis - - O
of - - O
diptheria - - O
. - - O

Histological - - O
changes - - O
, - - O
including - - O
cortical - - O
cell - - O
involution - - O
and - - O
hemorrhage - - O
occurring - - O
during - - O
the - - O
neonatal - - O
period - - O
, - - O
would - - O
seem - - O
to - - O
have - - O
crucial - - O
relevance - - O
to - - O
the - - O
remodeling - - O
of - - O
the - - O
adrenal - - O
vasculature - - O
. - - O

The - - O
cglIM - - B-MUT
gene - - I-MUT
is - - O
organized - - O
in - - O
an - - O
unusual - - O
operon - - O
which - - O
contains - - O
, - - O
in - - O
addition - - O
, - - O
two - - O
genes - - O
encoding - - O
stress-sensitive - - O
restriction - - B-MUT
enzymes - - I-MUT
. - - O

The - - O
Gap69C - - B-MUT
is - - O
a - - O
single-copy - - O
gene - - O
producing - - O
a - - O
major - - O
2 - - O
. - - O
1-kb - - O
mRNA - - O
throughout - - O
development - - O
, - - O
but - - O
its - - O
amount - - O
is - - O
decreased - - O
in - - O
larvae - - O
. - - O

The - - O
relationship - - O
of - - O
the - - O
factor - - B-MUT
V - - I-MUT
Leiden - - I-MUT
mutation - - I-MUT
or - - O
the - - O
deletion-deletion - - O
polymorphism - - O
of - - O
the - - O
angiotensin - - B-MUT
converting - - I-MUT
enzyme - - I-MUT
to - - O
postoperative - - O
thromboembolic - - O
events - - O
following - - O
total - - O
joint - - O
arthroplasty - - O
. - - O

End-tidal - - O
PO2 - - O
and - - O
the - - O
ratio - - O
of - - O
minute - - O
ventilation - - O
to - - O
oxygen - - O
consumption - - O
( - - O
VE - - O
VO2 - - O
) - - O
were - - O
lower - - O
while - - O
PETCO2 - - O
was - - O
higher - - O
for - - O
Hyp - - O
( - - O
P - - O
< - - O
or - - O
= - - O
0 - - O
. - - O
01 - - O
) - - O
. - - O

Considering - - O
these - - O
sources - - O
of - - O
error - - O
some - - O
of - - O
the - - O
variability - - O
in - - O
the - - O
present - - O
investigation - - O
might - - O
be - - O
avoided - - O
by - - O
systematic - - O
instructions - - O
. - - O

Results - - O
obtained - - O
for - - O
chloramphenicol-containing - - O
preparations - - O
are - - O
presented - - O
, - - O
and - - O
both - - O
dissolution - - O
curves - - O
and - - O
cup-plate - - O
assays - - O
demonstrate - - O
that - - O
chloramphenicol - - O
has - - O
far - - O
superior - - O
release - - O
( - - O
and - - O
hence - - O
activity - - O
) - - O
from - - O
creams - - O
than - - O
from - - O
ophthalmic - - O
ointments - - O
. - - O

Diagnosis - - O
of - - O
prostatic - - O
carcinoma - - O
: - - O
the - - O
yield - - O
of - - O
serum - - B-MUT
prostate - - I-MUT
specific - - I-MUT
antigen - - I-MUT
, - - O
digital - - O
rectal - - O
examination - - O
and - - O
transrectal - - O
ultrasonography - - O
. - - O

The - - O
deduced - - O
amino - - O
acid - - O
sequence - - O
of - - O
LvUSF2 - - B-MUT
is - - O
nearly - - O
identical - - O
to - - O
LvUSF1 - - B-MUT
except - - O
at - - O
the - - O
amino - - O
end - - O
, - - O
where - - O
they - - O
are - - O
sharply - - O
divergent - - O
. - - O

In - - O
retrospect - - O
, - - O
the - - O
diagnoses - - O
were - - O
reconsidered - - O
applying - - O
strict - - O
criteria - - O
. - - O

A - - O
consensus - - O
sequence - - O
indicates - - O
a - - O
highly - - O
conserved - - O
lysine - - O
residue - - O
, - - O
K120 - - O
of - - O
endonuclease - - B-MUT
III - - I-MUT
or - - O
K241 - - O
of - - O
Ogg1 - - B-MUT
, - - O
respectively - - O
. - - O

Examination - - O
of - - O
various - - O
promoter - - O
deletion - - O
mutants - - O
indicated - - O
that - - O
SF-1 - - B-MUT
acts - - O
through - - O
the - - O
proximal - - O
promoter - - O
region - - O
and - - O
upstream - - O
promoter - - O
sequences - - O
. - - O

The - - O
data - - O
show - - O
conclusively - - O
that - - O
phosphorylation - - O
of - - O
His-304 - - O
is - - O
not - - O
essential - - O
for - - O
any - - O
of - - O
the - - O
known - - O
functions - - O
of - - O
A - - B-MUT
. - - I-MUT
vinelandii - - I-MUT
NifL - - I-MUT
. - - O

The - - O
maximal - - O
effect - - O
was - - O
seen - - O
at - - O
100 - - O
ng - - O
ml - - O
EGF - - O
, - - B-MUT
with - - O
a - - O
time - - O
lag - - O
of - - O
about - - O
5 - - O
h - - O
. - - O

Effects - - O
of - - O
aerosol-vapor - - O
JP-8 - - O
jet - - O
fuel - - O
on - - O
the - - O
functional - - O
observational - - O
battery - - O
, - - O
and - - O
learning - - O
and - - O
memory - - O
in - - O
the - - O
rat - - O
. - - O

The - - O
Saccharomyces - - B-MUT
cerevisiae - - I-MUT
GAL1 - - I-MUT
and - - O
GAL10 - - B-MUT
genes - - I-MUT
are - - O
controlled - - O
in - - O
response - - O
to - - O
the - - O
availability - - O
of - - O
galactose - - O
and - - O
glucose - - O
by - - O
multiple - - O
activating - - O
and - - O
repressing - - O
proteins - - O
bound - - O
at - - O
adjacent - - O
or - - O
overlapping - - O
sites - - O
in - - O
UASG - - B-MUT
. - - O

These - - O
activities - - O
are - - O
all - - O
required - - O
for - - O
stimulation - - O
of - - O
cell - - O
growth - - O
by - - O
middle-T - - B-MUT
and - - O
activate - - O
members - - O
of - - O
the - - O
MAP - - B-MUT
kinase - - I-MUT
family - - I-MUT
. - - O

When - - O
differentiated - - O
G0-arrested - - O
leaf - - O
cells - - O
were - - O
induced - - O
to - - O
resume - - O
cell - - O
division - - O
by - - O
treatment - - O
with - - O
plant - - O
hormones - - O
, - - O
cycMs4 - - B-MUT
transcription - - O
was - - O
induced - - O
before - - O
the - - O
onset - - O
of - - O
DNA - - O
synthesis - - O
. - - O

Also - - O
, - - O
component - - O
I - - O
significantly - - O
correlated - - O
with - - O
fasting - - O
insulin - - B-MUT
and - - O
VO2 - - O
max - - O
for - - O
both - - O
sexes - - O
and - - O
with - - O
basal - - O
metabolism - - O
and - - O
HDL-cholesterol - - B-MUT
for - - O
females - - O
and - - O
males - - O
, - - O
respectively - - O
. - - O

Desmethyltrimebutine - - O
was - - O
inactive - - O
. - - O

The - - O
antibodies - - O
inhibited - - O
specifically - - O
the - - O
transcription - - O
of - - O
DNA - - B-MUT
polymerase - - I-MUT
alpha - - I-MUT
promoter - - O
in - - O
vitro - - O
. - - O

Architecture - - O
and - - O
anatomy - - O
of - - O
the - - O
genomic - - O
locus - - O
encoding - - O
the - - O
human - - O
leukemia-associated - - O
transcription - - O
factor - - O
RUNX1 - - B-MUT
AML1 - - O
. - - B-MUT

RNase - - B-MUT
protection - - O
experiments - - O
confirmed - - O
the - - O
presence - - O
of - - O
the - - O
GHR1-279 - - B-MUT
variant - - I-MUT
in - - O
IM-9 - - O
cells - - O
and - - O
human - - O
liver - - O
. - - O

The - - O
open - - O
reading - - O
frames - - O
of - - O
rbsD - - B-MUT
, - - O
rbsA - - B-MUT
, - - O
and - - O
rbsC - - B-MUT
encode - - O
proteins - - O
of - - O
139 - - O
, - - O
501 - - O
, - - O
and - - O
321 - - O
amino - - O
acid - - O
residues - - O
, - - O
respectively - - O
. - - O

Sucrose-specific - - O
regulation - - O
of - - O
scrB - - B-MUT
was - - O
also - - O
lost - - O
upon - - O
deletion - - O
of - - O
4 - - O
bp - - O
of - - O
a - - O
palindromic - - O
sequence - - O
( - - O
OB - - O
) - - O
covering - - O
positions - - O
+6 - - O
to - - O
+21 - - O
downstream - - O
of - - O
the - - O
scrB - - B-MUT
transcriptional - - O
start - - O
site - - O
. - - O

High - - O
concentrations - - O
of - - O
tumor-associated - - O
trypsin - - B-MUT
inhibitor - - O
in - - O
hemodialyzed - - O
patients - - O
. - - O

A - - O
mutation - - O
which - - O
abrogates - - O
the - - O
binding - - O
of - - O
these - - O
factors - - O
reduces - - O
Wp - - B-MUT
reporter - - I-MUT
activity - - O
specifically - - O
in - - O
B - - O
cell - - O
lines - - O
, - - O
whereas - - O
a - - O
mutation - - O
which - - O
converts - - O
the - - O
site - - O
to - - O
a - - O
consensus - - O
CREB-binding - - B-MUT
sequence - - I-MUT
maintains - - O
wild-type - - O
promoter - - O
function - - O
. - - O

There - - O
was - - O
a - - O
gradual - - O
increase - - O
in - - O
the - - O
myocyte - - O
diameter - - O
according - - O
to - - O
age - - O
in - - O
the - - O
biopsy - - O
and - - O
autopsy - - O
specimens - - O
. - - O

Mutation - - O
of - - O
the - - O
Sp1 - - B-MUT
element - - I-MUT
, - - O
which - - O
abolishes - - O
Sp1 - - B-MUT
binding - - O
, - - O
results - - O
in - - O
a - - O
6-10-fold - - O
reduction - - O
in - - O
reporter - - O
activity - - O
. - - O

INTERVENTIONS - - O
: - - O
Subcutaneous - - O
tissue - - O
PO2 - - O
and - - O
PCO2 - - O
tensions - - O
were - - O
measured - - O
directly - - O
in - - O
patients - - O
with - - O
necrotising - - O
fasciitis - - O
and - - O
in - - O
healthy - - O
volunteers - - O
during - - O
normobaric - - O
and - - O
hyperbaric - - O
conditions - - O
. - - O

Because - - O
of - - O
the - - O
potential - - O
implications - - O
of - - O
these - - O
findings - - O
in - - O
human - - O
physiology - - O
, - - O
we - - O
cloned - - O
the - - O
hPACAP-R - - B-MUT
gene - - I-MUT
. - - O

The - - O
Tax - - B-MUT
IKKgamma - - I-MUT
interaction - - I-MUT
serves - - O
to - - O
recruit - - O
Tax - - O
to - - B-MUT
the - - O
IKK - - O
catalytic - - B-MUT
subunits - - I-MUT
, - - I-MUT
IKKalpha - - O
and - - B-MUT
IKKbeta - - O
, - - B-MUT
and - - O
this - - O
recruitment - - O
appears - - O
to - - O
be - - O
an - - O
essential - - O
mechanism - - O
by - - O
which - - O
Tax - - O
stimulates - - B-MUT
the - - O
activity - - O
of - - O
IKK - - O
. - - B-MUT

Modifications - - O
of - - O
the - - O
involuntary - - O
postcontraction - - O
in - - O
diseased - - O
people - - O
. - - O

Although - - O
noninhibitory - - O
fluid - - O
had - - O
higher - - O
mean - - O
concentrations - - O
of - - O
phosphorus - - O
and - - O
zinc - - O
, - - O
these - - O
differences - - O
did - - O
not - - O
hold - - O
after - - O
meconium-stained - - O
samples - - O
were - - O
excluded - - O
. - - O

Normal - - O
baseline - - O
( - - O
day-8 - - O
) - - O
PC - - O
levels - - O
( - - O
86 - - O
and - - O
89% - - O
) - - O
were - - O
markedly - - O
reduced - - O
in - - O
both - - O
patients - - O
at - - O
the - - O
time - - O
of - - O
VOD - - O
manifestation - - O
on - - O
day - - O
20 - - O
and - - O
40 - - O
, - - O
respectively - - O
( - - O
26 - - O
and - - O
31% - - O
) - - O
. - - O

The - - O
sequence - - O
upstream - - O
of - - O
the - - O
rhlA - - B-MUT
promoter - - I-MUT
contains - - O
two - - O
inverted - - O
repeats - - O
which - - O
define - - O
putative - - O
binding - - O
sites - - O
for - - O
the - - O
RhlR - - B-MUT
regulator - - I-MUT
. - - O

In - - O
this - - O
model - - O
, - - O
eltoprazine - - O
has - - O
a - - O
very - - O
specific - - O
anti-aggressive - - O
( - - O
serenic - - O
) - - O
profile - - O
, - - O
inhibiting - - O
aggression - - O
while - - O
social - - O
interaction - - O
and - - O
exploration - - O
are - - O
not - - O
decreased - - O
but - - O
even - - O
enhanced - - O
; - - O
inactivity - - O
, - - O
a - - O
measure - - O
for - - O
sedation - - O
, - - O
is - - O
not - - O
affected - - O
. - - O

A - - O
second - - O
aim - - O
was - - O
to - - O
determine - - O
whether - - O
the - - O
decrease - - O
in - - O
muscle-tendon - - O
unit - - O
rest - - O
length - - O
produced - - O
by - - O
prolonged - - O
immobilisation - - O
in - - O
a - - O
shortened - - O
position - - O
is - - O
mediated - - O
primarily - - O
by - - O
adaptations - - O
of - - O
the - - O
muscle - - O
or - - O
tendon - - O
. - - O

Analysis - - O
of - - O
clearance - - O
curve - - O
of - - O
rose - - O
bengal-I-131 - - O
. - - O

Intravenous - - O
administration - - O
( - - O
25 - - O
mg - - O
kg - - O
) - - O
of - - O
carbonic - - O
anhydrase - - B-MUT
inhibitors - - I-MUT
( - - O
acetazolamide - - O
, - - O
methazolamide - - O
, - - O
dichlorphenamide - - O
, - - O
sulthiame - - O
) - - O
induced - - O
an - - O
early - - O
important - - O
rise - - O
of - - O
cortical - - O
p - - O
O2 - - O
, - - O
which - - O
is - - O
not - - O
dependent - - O
on - - O
increase - - O
of - - O
p - - O
O2 - - O
and - - O
p - - O
CO2 - - O
and - - O
decrease - - O
of - - O
pH - - O
in - - O
arterial - - O
blood - - O
. - - O

Cholinesterase - - B-MUT
. - - O

RESULTS - - O
: - - O
Surprisingly - - O
, - - O
PAF - - B-MUT
blockade - - O
increased - - O
mortality - - O
after - - O
trauma - - O
( - - O
5 - - O
of - - O
11 - - O
WEB-2086 - - O
animals - - O
versus - - O
1 - - O
of - - O
9 - - O
vehicle - - O
animals - - O
; - - O
p - - O
= - - O
0 - - O
. - - O
15 - - O
) - - O
and - - O
depressed - - O
cardiac - - O
index - - O
and - - O
O2 - - O
delivery - - O
at - - O
72 - - O
hours - - O
( - - O
p - - O
< - - O
0 - - O
. - - O
05 - - O
) - - O
. - - O

Moritta - - O
) - - O
and - - O
contains - - O
Bis-GMA - - O
. - - O

Single - - O
amino - - O
acid - - O
substitutions - - O
at - - O
the - - O
acyl-CoA-binding - - O
domain - - O
interrupt - - O
14 - - O
[ - - O
C - - O
] - - O
palmitoyl-CoA - - O
binding - - O
of - - O
ACBP2 - - B-MUT
, - - O
an - - O
Arabidopsis - - O
acyl-CoA-binding - - B-MUT
protein - - I-MUT
with - - O
ankyrin - - B-MUT
repeats - - O
. - - O

Expression - - O
of - - O
GlcNAc-TI - - B-MUT
mRNA - - I-MUT
in - - O
tobacco - - O
leaves - - O
was - - O
detected - - O
using - - O
RT-PCR - - O
. - - O

At - - O
a - - O
systolic - - O
blood - - O
pressure - - O
( - - O
BP - - O
) - - O
of - - O
60 - - O
mmHg - - O
, - - O
C02 - - O
responsiveness - - O
was - - O
abolished - - O
, - - O
but - - O
was - - O
maintained - - O
at - - O
higher - - O
levels - - O
of - - O
BP - - O
. - - O

Both - - O
methods - - O
were - - O
employed - - O
for - - O
various - - O
focal-film - - O
distances - - O
, - - O
image - - O
intensifier - - O
tube - - O
modes - - O
and - - O
laser - - O
printer - - O
formats - - O
. - - O

Colorectal - - O
cancer - - O
was - - O
shown - - O
to - - O
disproportionately - - O
overburden - - O
Ashkenazi - - O
Jews - - O
, - - O
who - - O
may - - O
also - - O
be - - O
at - - O
increased - - O
risk - - O
for - - O
ovarian - - O
, - - O
pancreatic - - O
and - - O
stomach - - O
cancer - - O
, - - O
and - - O
non-Hodgkin's - - O
lymphoma - - O
. - - O

HIV-1 - - O
and - - O
hepatitis - - O
B - - O
virus - - O
infections - - O
in - - O
adolescents - - O
lodged - - O
in - - O
security - - O
institutes - - O
of - - O
Buenos - - O
Aires - - O
. - - O

Covalent - - O
modification - - O
of - - O
the - - O
transactivator - - B-MUT
protein - - I-MUT
IE2-p86 - - I-MUT
of - - O
human - - O
cytomegalovirus - - O
by - - O
conjugation - - O
to - - O
the - - O
ubiquitin-homologous - - B-MUT
proteins - - I-MUT
SUMO-1 - - B-MUT
and - - O
hSMT3b - - B-MUT
. - - O

The - - O
full - - O
protocol - - O
was - - O
completed - - O
by - - O
33 - - O
patients - - O
( - - O
45% - - O
of - - O
original - - O
cohort - - O
) - - O
. - - O

Forskolin - - O
significantly - - O
enhanced - - O
heregulin-stimulated - - O
expression - - O
of - - O
cyclin - - B-MUT
D - - I-MUT
and - - O
phosphorylation - - O
of - - O
the - - O
retinoblastoma - - B-MUT
gene - - I-MUT
product - - I-MUT
. - - O

TaqMan - - O
analysis - - O
of - - O
gene - - O
expression - - O
following - - O
chronic - - O
FA - - O
treatment - - O
showed - - O
neither - - O
a - - O
decrease - - O
in - - O
the - - O
amount - - O
of - - O
leptin - - B-MUT
receptor - - I-MUT
( - - O
Ob-R - - B-MUT
) - - O
mRNA - - O
, - - O
nor - - O
an - - O
increase - - O
in - - O
the - - O
negative - - O
regulators - - O
of - - O
STAT - - B-MUT
signalling - - O
, - - O
SOCS3 - - B-MUT
( - - O
suppressors - - B-MUT
of - - I-MUT
cytokine - - I-MUT
signalling - - I-MUT
) - - O
or - - O
cytokine - - B-MUT
inducible - - I-MUT
sequence - - I-MUT
( - - O
CIS - - B-MUT
) - - O
. - - O

It - - O
was - - O
shown - - O
by - - O
transient - - O
expression - - O
assay - - O
that - - O
HS-40 - - B-MUT
behaved - - O
as - - O
an - - O
authentic - - O
enhancer - - O
for - - O
high-level - - O
zeta - - B-MUT
2 - - I-MUT
globin - - I-MUT
promoter - - I-MUT
activity - - O
in - - O
K562 - - O
cells - - O
, - - O
an - - O
erythroid - - O
cell - - O
line - - O
of - - O
embryonic - - O
and - - O
or - - O
fetal - - O
origin - - O
. - - O

Despite - - O
the - - O
presence - - O
of - - O
one - - O
additional - - O
ribonucleotide - - B-MUT
reductase - - I-MUT
, - - O
the - - O
nrdAB-encoded - - B-MUT
enzyme - - I-MUT
is - - O
essential - - O
to - - O
the - - O
aerobic - - O
growth - - O
of - - O
the - - O
cell - - O
because - - O
nrdAB-defective - - B-MUT
mutants - - I-MUT
of - - O
both - - O
species - - O
are - - O
not - - O
viable - - O
in - - O
the - - O
presence - - O
of - - O
oxygen - - O
. - - O

We - - O
studied - - O
the - - O
human - - O
vestibulo-ocular - - O
reflex - - O
( - - O
VOR - - O
) - - O
in - - O
response - - O
to - - O
head - - O
'impulses' - - O
: - - O
brief - - O
, - - O
unpredictable - - O
, - - O
passive - - O
, - - O
high-acceleration - - O
( - - O
up - - O
to - - O
4000 - - O
degrees - - O
s2 - - O
) - - O
, - - O
low-amplitude - - O
( - - O
20-30 - - O
degrees - - O
) - - O
head - - O
rotations - - O
. - - O

A - - O
suspected - - O
hypothalamic - - O
dysfunction - - O
and - - O
a - - O
slightly - - O
impaired - - O
pituitary - - O
function - - O
manifested - - O
as - - O
GH - - B-MUT
deficiency - - O
were - - O
their - - O
common - - O
endocrinological - - O
features - - O
. - - O

CXCR4 - - B-MUT
is - - O
a - - O
chemokine - - B-MUT
receptor - - I-MUT
and - - O
a - - O
coreceptor - - O
for - - O
T-cell-line-tropic - - O
( - - O
X4 - - O
) - - O
and - - O
dual-tropic - - O
( - - O
R5X4 - - O
) - - O
human - - O
immunodeficiency - - O
virus - - O
type - - O
1 - - O
( - - O
HIV-1 - - O
) - - O
isolates - - O
. - - O

Implication - - O
of - - O
PAF - - B-MUT
and - - O
acetylhydrolase - - B-MUT
( - - O
PAF-AH - - B-MUT
) - - O
activity - - O
in - - O
periodontal - - O
disease - - O
. - - O

Coactivation - - O
of - - O
endogenous - - O
or - - O
exogenous - - O
G - - B-MUT
( - - I-MUT
q - - I-MUT
) - - I-MUT
-coupled - - I-MUT
receptors - - I-MUT
with - - O
the - - O
delta-opioid - - B-MUT
receptor - - I-MUT
produced - - O
strong - - O
stimulations - - O
of - - O
PLCbeta - - B-MUT
and - - O
such - - O
responses - - O
could - - O
be - - O
partially - - O
blocked - - O
by - - O
pertussis - - B-MUT
toxin - - I-MUT
. - - O

CONCLUSION - - O
: - - O
The - - O
results - - O
demonstrate - - O
that - - O
at - - O
the - - O
site - - O
of - - O
lumbar - - O
disc - - O
herniation - - O
, - - O
inflammatory - - O
cytokines - - O
such - - O
as - - O
interleukin-1 - - B-MUT
alpha - - I-MUT
are - - O
produced - - O
, - - O
which - - O
increases - - O
prostaglandin - - O
E2 - - O
production - - O
. - - O

Currents - - O
aspects - - O
of - - O
H2 - - B-MUT
receptor - - I-MUT
antagonists - - O
in - - O
the - - O
treatment - - O
of - - O
ulcers - - O
. - - O

Here - - O
, - - O
we - - O
report - - O
the - - O
complete - - O
structure - - O
of - - O
the - - O
human - - B-MUT
topoisomerase - - I-MUT
IIalpha - - I-MUT
gene - - I-MUT
, - - O
which - - O
consists - - O
of - - O
35 - - O
exons - - O
spanning - - O
27 - - O
. - - O
5 - - O
kb - - O
. - - O

100 - - O
of - - O
the - - O
patients - - O
who - - O
would - - O
have - - O
died - - O
survive - - O
. - - O

Calcitonin - - B-MUT
simultaneously - - O
regulates - - O
both - - O
periosteal - - O
hyperostosis - - O
and - - O
trabecular - - O
osteopenia - - O
in - - O
the - - O
spinal - - O
hyperostotic - - O
mouse - - O
( - - O
twy - - B-MUT
twy - - I-MUT
) - - I-MUT
in - - O
vivo - - O
. - - O

SCA - - B-MUT
was - - O
resistant - - O
to - - O
inhibitors - - O
of - - O
serine - - O
, - - O
aspartyl - - O
, - - O
and - - O
metalloproteases - - B-MUT
, - - O
but - - O
it - - O
was - - O
sensitive - - O
to - - O
N-ethylmaleimide - - O
. - - O

A - - O
pyrazolo-quinoline - - O
compound - - O
, - - O
6-methoxy-4- - - O
[ - - O
2- - - O
[ - - O
( - - O
2-hydroxyethoxyl - - O
) - - O
-ethyl - - O
] - - O
amino - - O
] - - O
-3-methyl-1M-pyrazo - - O
lo - - O
[ - - O
3 - - O
, - - O
4-b - - O
] - - O
quinoline - - O
( - - O
SCH - - O
51344 - - O
) - - O
, - - O
was - - O
identified - - O
based - - O
on - - O
its - - O
ability - - O
to - - O
derepress - - O
human - - O
smooth - - O
muscle - - O
alpha-actin - - B-MUT
promoter - - I-MUT
activity - - O
in - - O
ras-transformed - - O
cells - - O
. - - O

The - - O
failures - - O
frequently - - O
were - - O
related - - O
to - - O
patient - - O
intolerance - - O
or - - O
poor - - O
mechanical - - O
fit - - O
and - - O
occurred - - O
in - - O
the - - O
first - - O
few - - O
days - - O
or - - O
first - - O
few - - O
months - - O
after - - O
insertion - - O
. - - O

Recovery - - O
of - - O
radiolabelled - - O
BA - - O
through - - O
urine - - O
( - - O
28% - - O
) - - O
and - - O
faeces - - O
( - - O
22% - - O
) - - O
up - - O
to - - O
96 - - O
hrs - - O
averaged - - O
50% - - O
, - - O
whereas - - O
residual - - O
radioactivity - - O
in - - O
liver - - O
and - - O
testis - - O
experienced - - O
a - - O
recovery - - O
of - - O
29% - - O
in - - O
scorbutic - - O
animals - - O
. - - O

Epstein-Barr - - B-MUT
virus - - I-MUT
nuclear - - I-MUT
protein - - I-MUT
2 - - I-MUT
( - - I-MUT
EBNA2 - - I-MUT
) - - I-MUT
binds - - O
to - - O
a - - O
component - - O
of - - O
the - - O
human - - B-MUT
SNF-SWI - - I-MUT
complex - - I-MUT
, - - O
hSNF5 - - B-MUT
Ini1 - - O
. - - B-MUT

HIV-1 - - O
C - - O
subtype - - O
in - - O
IDUs - - O
accounted - - O
for - - O
61 - - O
. - - O
3% - - O
. - - O

The - - O
gene - - O
was - - O
expressed - - O
as - - O
an - - O
approximately - - O
1 - - O
. - - O
5-kb - - O
mRNA - - O
in - - O
most - - O
nonlymphoid - - O
human - - O
cells - - O
tissues - - O
including - - O
prostate - - O
, - - O
lung - - O
, - - O
liver - - O
, - - O
and - - O
colon - - O
. - - O

METHODS - - O
: - - O
rHb1 - - B-MUT
. - - I-MUT
1 - - I-MUT
or - - O
human - - B-MUT
serum - - I-MUT
albumin - - I-MUT
was - - O
administered - - O
intravenously - - O
to - - O
fasting - - O
male - - O
volunteers - - O
. - - O

EsaR - - B-MUT
can - - O
repress - - O
its - - O
own - - O
expression - - O
but - - O
seems - - O
not - - O
to - - O
regulate - - O
the - - O
expression - - O
of - - O
esaI - - B-MUT
. - - O

Administration - - O
of - - O
dexamethasone - - O
was - - O
associated - - O
with - - O
progressive - - O
rises - - O
in - - O
plasma - - O
17 - - O
alpha - - O
OH - - O
progesterone - - O
, - - O
11 - - O
beta-desoxycortisol - - O
, - - O
DHEA - - O
sulphate - - O
, - - O
androstenedione - - O
and - - O
testosterone - - O
, - - O
together - - O
with - - O
increased - - O
urinary - - O
excretion - - O
of - - O
androsterone - - O
, - - O
11 - - O
beta - - O
OH - - O
androsterone - - O
, - - O
etiocholanolone - - O
, - - O
DHEA - - O
, - - O
and - - O
16 - - O
alpha - - O
OH - - O
DHEA - - O
. - - O

In - - O
the - - O
course - - O
of - - O
investigating - - O
the - - O
mechanisms - - O
by - - O
which - - O
OF5 - - B-MUT
and - - O
OF3 - - B-MUT
regulated - - O
CYP11A1 - - B-MUT
transcription - - O
, - - O
we - - O
found - - O
that - - O
OF5 - - B-MUT
and - - O
OF3 - - B-MUT
bound - - O
Sp1 - - B-MUT
and - - O
Sp3 - - B-MUT
in - - O
JEG-3 - - O
cells - - O
. - - O

The - - O
TEA1 - - B-MUT
( - - O
Ty - - B-MUT
enhancer - - I-MUT
activator - - I-MUT
) - - O
gene - - O
sequence - - O
predicts - - O
a - - O
protein - - O
of - - O
86 - - O
. - - O
9 - - O
kDa - - O
whose - - O
N - - O
terminus - - O
contains - - O
a - - O
zinc - - O
cluster - - O
and - - O
dimerization - - O
motif - - O
typical - - O
of - - O
the - - O
Gal4-type - - B-MUT
family - - I-MUT
of - - O
DNA-binding - - O
proteins - - O
. - - O

Several - - O
secondary - - O
structure - - O
elements - - O
were - - O
identified - - O
. - - O

Streptococcal - - O
preparation - - O
( - - O
OK-432 - - O
) - - O
, - - O
a - - O
new - - O
type - - O
of - - O
anti-cancer - - O
agent - - O
, - - O
was - - O
given - - O
to - - O
the - - O
patients - - O
with - - O
advanced - - O
cancer - - O
in - - O
combination - - O
with - - O
Mitomycin-C - - O
, - - O
5-FU - - O
and - - O
Cytosine - - O
arabinoside - - O
. - - O

The - - O
genomic - - O
fragments - - O
were - - O
fused - - O
upstream - - O
of - - O
the - - O
luciferase - - B-MUT
reporter - - I-MUT
gene - - I-MUT
. - - O

At - - O
1 - - O
, - - O
5 - - O
, - - O
and - - O
9 - - O
months - - O
after - - O
initial - - O
isolation - - O
of - - O
C - - O
. - - O
kutscheri - - O
from - - O
the - - O
oral - - O
cavity - - O
, - - O
hamsters - - O
were - - O
euthanatized - - O
, - - O
and - - O
attempts - - O
were - - O
made - - O
to - - O
culture - - O
C - - O
. - - O
kutscheri - - O
from - - O
13 - - O
additional - - O
sites - - O
. - - O

Copyright - - O
2000 - - O
John - - O
Wiley - - O
& - - O
Sons - - O
, - - O
Ltd - - O
. - - O

Incidence - - O
rate - - O
ranging - - O
between - - O
122 - - O
100 - - O
, - - O
000 - - O
year - - O
and - - O
190 - - O
100 - - O
, - - O
000 - - O
year - - O
were - - O
found - - O
( - - O
minimum - - O
, - - O
estimated - - O
and - - O
raw - - O
datasets - - O
) - - O
. - - O

An - - O
automated - - O
method - - O
for - - O
the - - O
quantitative - - O
analysis - - O
of - - O
the - - O
polyamines - - O
putrescine - - O
, - - O
spermidine - - O
and - - O
spermine - - O
in - - O
cerebrospinal - - O
fluid - - O
( - - O
CSF - - O
) - - O
was - - O
used - - O
to - - O
analyze - - O
CSF - - O
samples - - O
from - - O
37 - - O
patients - - O
with - - O
central - - O
nervous - - O
system - - O
( - - O
CNS - - O
) - - O
tumors - - O
and - - O
from - - O
13 - - O
patients - - O
without - - O
tumors - - O
. - - O

Further - - O
studies - - O
established - - O
that - - O
the - - O
Ep-induced - - O
increase - - O
in - - O
beta-globin - - B-MUT
mRNA - - I-MUT
could - - O
be - - O
inhibited - - O
by - - O
the - - O
tyrosine - - B-MUT
kinase - - I-MUT
inhibitor - - O
genistein - - O
and - - O
the - - O
protein - - B-MUT
kinase - - I-MUT
C - - I-MUT
inhibitor - - O
Compound - - O
3 - - O
. - - O
( - - O
ABSTRACT - - O
TRUNCATED - - O
AT - - O
250 - - O
WORDS - - O
) - - O

The - - O
relationship - - O
between - - O
estrogenic - - O
properties - - O
of - - O
Tamoxifen - - O
and - - O
breast - - O
cancer - - O
management - - O
is - - O
discussed - - O
. - - O

Disciplinary - - O
action - - O
for - - O
DNA - - O
violation - - O
. - - O

In - - O
PC - - O
, - - O
rare - - O
MNGCs - - O
had - - O
intranuclear - - O
inclusions - - O
and - - O
grooves - - O
. - - O

The - - O
costs - - O
were - - O
DM - - O
11 - - O
, - - O
562 - - O
for - - O
a - - O
PE - - O
, - - O
DM - - O
12 - - O
, - - O
477 - - O
for - - O
a - - O
VR - - O
and - - O
DM - - O
7 - - O
, - - O
532 - - O
for - - O
a - - O
MR - - O
. - - O

The - - O
provisional - - O
reports - - O
are - - O
based - - O
mainly - - O
upon - - O
macroscopic - - O
findings - - O
, - - O
whereas - - O
the - - O
final - - O
reports - - O
include - - O
the - - O
information - - O
provided - - O
by - - O
supplementary - - O
investigations - - O
such - - O
as - - O
microscopy - - O
, - - O
histochemistry - - O
, - - O
more - - O
rarely - - O
electron - - O
microscopy - - O
, - - O
immunohistochemistry - - O
and - - O
or - - O
microbiology - - O
. - - O

Cells - - O
containing - - O
alpha - - O
subunits - - O
that - - O
lacked - - O
a - - O
distal - - B-MUT
domain - - O
( - - O
term-3 - - B-MUT
) - - O
or - - O
had - - O
the - - O
alternatively - - O
spliced - - O
alpha-2 - - B-MUT
distal - - I-MUT
domain - - I-MUT
showed - - O
markedly - - O
decreased - - O
ability - - O
to - - O
support - - O
tyrosine - - O
phosphorylation - - O
of - - O
Jak-2 - - B-MUT
and - - O
its - - O
substrates - - O
or - - O
to - - O
up-regulate - - O
CD86 - - B-MUT
. - - O

Consistent - - O
with - - O
this - - O
possibility - - O
, - - O
a - - O
non-MBD - - O
region - - O
of - - O
Bin1 - - B-MUT
was - - O
sufficient - - O
to - - O
recruit - - O
a - - O
repression - - O
function - - O
to - - O
DNA - - O
that - - O
was - - O
unrelated - - O
to - - O
histone - - B-MUT
deacetylase - - I-MUT
. - - O

Abundant - - O
infiltration - - O
of - - O
lymphocytes - - O
and - - O
plasma - - O
cells - - O
was - - O
also - - O
wide-spread - - O
beneath - - O
the - - O
carcinoma - - O
in - - O
situ - - O
, - - O
together - - O
with - - O
the - - O
lymphoid - - O
follicles - - O
. - - O

Addition - - O
of - - O
Rap - - O
or - - O
KN62 - - O
after - - O
exposure - - O
of - - O
cells - - O
to - - O
progesterone - - O
agonist - - O
Org - - O
2058 - - O
had - - O
no - - O
effect - - O
on - - O
induction - - O
of - - O
CAT - - B-MUT
activity - - O
. - - O

Teicoplanin - - O
was - - O
given - - O
most - - O
often - - O
because - - O
of - - O
persistent - - O
fever - - O
or - - O
initial - - O
Gram-positive - - O
bacteraemia - - O
and - - O
only - - O
one-third - - O
of - - O
these - - O
cases - - O
responded - - O
. - - O

A - - O
peculiar - - O
people - - O
: - - O
"the - - O
physiological - - O
aspects - - O
of - - O
Mormonism - - O
1850-1975 - - O
. - - O
" - - O

Two - - O
nuclear - - O
medicine - - O
physicians - - O
blinded - - O
to - - O
the - - O
surgical - - O
findings - - O
interpreted - - O
all - - O
available - - O
images - - O
and - - O
various - - O
Tc-99m - - O
MIBI - - O
image - - O
combinations - - O
at - - O
15 - - O
minutes - - O
alone - - O
; - - O
15 - - O
minutes - - O
and - - O
2 - - O
hours - - O
, - - O
15 - - O
minutes - - O
and - - O
4 - - O
hours - - O
; - - O
and - - O
15 - - O
minutes - - O
and - - O
2 - - O
and - - O
4 - - O
hours - - O
each - - O
with - - O
and - - O
without - - O
correlative - - O
pertechnetate - - O
thyroid - - O
imaging - - O
. - - O

Keck - - O
, - - O
C - - O
. - - O
J - - O
. - - O

E2F - - B-MUT
-1 - - I-MUT
is - - O
a - - O
transcription - - O
factor - - O
that - - O
regulates - - O
cell - - O
cycle - - O
progression - - O
into - - O
S-phase - - O
. - - O

L3-L4 - - O
compressive - - O
load - - O
was - - O
calculated - - O
using - - O
a - - O
model - - O
of - - O
the - - O
anatomy - - O
of - - O
the - - O
trunk - - O
musculoskeletal - - O
system - - O
. - - O

Transactivation - - O
of - - O
oIFNtau - - B-MUT
enhancer-reporter - - O
constructs - - O
was - - O
primarily - - O
regulated - - O
by - - O
three - - O
regions - - O
containing - - O
AP-1 - - B-MUT
site - - I-MUT
, - - O
GATA - - B-MUT
like - - O
sequence - - O
and - - O
site - - O
( - - O
s - - O
) - - O
unidentified - - O
. - - O

Interestingly - - O
, - - O
continuation - - O
of - - O
the - - O
interferon - - B-MUT
therapy - - O
in - - O
the - - O
presence - - O
of - - O
a - - O
mild-to-moderate - - O
exacerbation - - O
of - - O
sarcoidosis - - O
may - - O
be - - O
safe - - O
in - - O
a - - O
minority - - O
of - - O
patients - - O
with - - O
noncritical - - O
organ - - O
involvement - - O
. - - O

The - - O
lengths - - O
of - - O
the - - O
complete - - O
polypeptide - - O
chain - - O
of - - O
the - - O
recombinant - - O
enzyme - - O
and - - O
its - - O
transit - - O
peptide - - O
are - - O
388 - - O
and - - O
53 - - O
residues - - O
, - - O
respectively - - O
. - - O

Transfection - - O
analyses - - O
indicate - - O
that - - O
mutation - - O
of - - O
any - - O
one - - O
of - - O
these - - O
TGACCT - - B-MUT
motifs - - I-MUT
or - - O
truncation - - O
of - - O
the - - O
entire - - O
HD - - B-MUT
PPRE - - B-MUT
into - - O
a - - O
separate - - O
DR1 - - B-MUT
and - - O
DR2 - - B-MUT
element - - I-MUT
significantly - - O
reduced - - O
the - - O
transcriptional - - O
response - - O
of - - O
HD - - B-MUT
PPRE - - B-MUT
to - - O
peroxisome - - O
proliferators - - O
. - - O

The - - O
amino - - O
acid - - O
changes - - O
D206A - - O
and - - O
D208A - - O
abolish - - O
singly - - O
or - - O
in - - O
combination - - O
the - - O
exonuclease - - B-MUT
activity - - O
in - - O
vivo - - O
. - - O

Chem - - O
. - - O

( - - O
Emeritus - - O
) - - O
John - - O
Henri - - O
Roosegaarde - - O
Bisschop - - O
. - - O

A - - O
case - - O
of - - O
AIDS-related - - O
complex - - O
( - - O
ARC - - O
LAS - - O
) - - O
in - - O
a - - O
health - - O
worker - - O
. - - O

There - - O
occurred - - O
a - - O
linear - - O
relationship - - O
between - - O
the - - O
drop - - O
in - - O
glucose-6-phosphatase - - B-MUT
dehydrogenase - - I-MUT
activity - - O
and - - O
in - - O
vitamin - - O
E - - O
level - - O
, - - O
on - - O
one - - O
hand - - O
, - - O
and - - O
the - - O
duration - - O
of - - O
poisoning - - O
with - - O
sodium - - O
nitrite - - O
. - - O

A - - O
cis-acting - - O
DNA - - O
element - - O
located - - O
between - - O
TATA - - O
box - - O
and - - O
transcription - - O
initiation - - O
site - - O
is - - O
critical - - O
in - - O
response - - O
to - - O
regulatory - - O
sequences - - O
in - - O
human - - O
angiotensinogen - - B-MUT
gene - - I-MUT
. - - O

Hepatic - - O
oxygen - - O
supply - - O
and - - O
selected - - O
blood - - O
parameters - - O
were - - O
recorded - - O
in - - O
fasted - - O
male - - O
rates - - O
given - - O
20--30 - - O
mg - - O
kg - - O
Escherichia - - O
coli - - B-MUT
endotoxin - - I-MUT
intraperitoneally - - I-MUT
. - - O

The - - O
addition - - O
of - - O
culture - - O
to - - O
the - - O
CC - - O
and - - O
CC - - O
: - - O
SW - - O
by-products - - O
resulted - - O
in - - O
pH - - O
values - - O
lower - - O
( - - O
P - - O
< - - O
0 - - O
. - - O
05 - - O
) - - O
than - - O
those - - O
without - - O
culture - - O
on - - O
Day - - O
21 - - O
, - - O
and - - O
the - - O
15% - - O
carbohydrate - - O
treatment - - O
significantly - - O
reduced - - O
pH - - O
beyond - - O
the - - O
5% - - O
carbohydrate - - O
. - - O

Branch - - O
occlusion - - O
of - - O
Heubner's - - O
artery - - O
, - - O
or - - O
perforators - - O
from - - O
the - - O
proximal - - O
anterior - - O
or - - O
middle - - O
cerebral - - O
arteries - - O
were - - O
the - - O
posited - - O
mechanism - - O
of - - O
infarction - - O
. - - O

We - - O
propose - - O
that - - O
Gly84 - - O
is - - O
part - - O
of - - O
a - - O
putative - - O
"oxyanion - - O
hole" - - O
involved - - O
in - - O
the - - O
stabilization - - O
of - - O
the - - O
transition - - O
state - - O
similar - - O
to - - O
the - - O
C - - B-MUT
group - - I-MUT
of - - O
the - - O
esterase - - B-MUT
lipase - - O
family - - B-MUT
. - - O

While - - O
important - - O
for - - O
ligand-dependent - - O
transactivation - - O
, - - O
this - - O
interaction - - O
surface - - O
is - - O
not - - O
directly - - O
involved - - O
in - - O
transrepression - - O
of - - O
AP-1 - - B-MUT
activity - - O
. - - O

To - - O
elucidate - - O
whether - - O
potential - - O
endocrine - - O
changes - - O
resulted - - O
from - - O
acute - - O
hypoxaemia - - O
alone - - O
, - - O
the - - O
underlying - - O
disease - - O
, - - O
or - - O
unspecific - - O
influences - - O
connected - - O
with - - O
the - - O
ICU - - O
setting - - O
, - - O
all - - O
measurements - - O
were - - O
compared - - O
to - - O
those - - O
of - - O
a - - O
completely - - O
healthy - - O
reference - - O
group - - O
( - - O
REF - - O
) - - O
with - - O
comparable - - O
acute - - O
experimental - - O
hypoxaemia - - O
. - - O

An - - O
integrated - - O
RTC - - O
algorithm - - O
for - - O
the - - O
urban - - O
wastewater - - O
system - - O
is - - O
formulated - - O
, - - O
the - - O
parameters - - O
of - - O
which - - O
are - - O
optimized - - O
using - - O
various - - O
global - - O
optimization - - O
routines - - O
. - - O

Their - - O
function - - O
is - - O
not - - O
only - - O
to - - O
recruit - - O
Pho2 - - B-MUT
to - - O
the - - O
promoter - - O
but - - O
to - - O
allow - - O
cooperative - - O
binding - - O
of - - O
Pho4 - - B-MUT
together - - O
with - - O
Pho2 - - B-MUT
. - - O

EUK-8 - - O
is - - O
a - - O
novel - - O
, - - O
synthetic - - O
, - - O
low-molecular-weight - - O
salen-manganese - - O
complex - - O
that - - O
exhibits - - O
both - - O
superoxide - - B-MUT
dismutase - - I-MUT
and - - O
catalase - - B-MUT
activities - - O
in - - O
vitro - - O
. - - O

Ras - - B-MUT
p21Val - - I-MUT
inhibits - - O
myogenesis - - O
without - - O
altering - - O
the - - O
DNA - - O
binding - - O
or - - O
transcriptional - - O
activities - - O
of - - O
the - - O
myogenic - - B-MUT
basic - - I-MUT
helix-loop-helix - - I-MUT
factors - - I-MUT
. - - O

The - - O
patient - - O
underwent - - O
two - - O
intracytoplasmic - - O
sperm - - O
injection - - O
cycles - - O
with - - O
thawed - - O
epididymal - - O
spermatozoa - - O
, - - O
in - - O
which - - O
, - - O
due - - O
to - - O
a - - O
pharmacist's - - O
mistake - - O
, - - O
ovarian - - O
stimulation - - O
was - - O
carried - - O
out - - O
by - - O
a - - O
combination - - O
of - - O
long-acting - - O
gonadotrophin-releasing - - B-MUT
hormone - - I-MUT
agonist - - O
( - - O
leuprolide - - O
depot - - O
) - - O
and - - O
gonadotrophins - - B-MUT
. - - O

In - - O
F42A-stimulated - - O
internalization - - O
assays - - O
on - - O
forskolin-induced - - O
YT-1 - - O
cells - - O
, - - O
the - - O
IL-2R - - B-MUT
alpha - - I-MUT
chain - - I-MUT
is - - O
consistently - - O
endocytosed - - O
together - - O
with - - O
the - - O
IL-2R - - B-MUT
beta - - I-MUT
subunit - - I-MUT
indicating - - O
that - - O
IL-2R - - B-MUT
alpha - - I-MUT
is - - O
stably - - O
associated - - O
with - - O
the - - O
F42A-IL-2R - - B-MUT
beta - - I-MUT
complex - - I-MUT
even - - O
though - - O
the - - O
alpha-subunit - - O
contributes - - O
little - - O
if - - O
any - - O
affinity - - O
to - - O
the - - O
F42A - - B-MUT
binding - - O
reaction - - O
. - - O

These - - O
findings - - O
suggest - - O
that - - O
an - - O
intracellular - - B-MUT
WT1 - - I-MUT
Hsal - - I-MUT
2 - - I-MUT
pathway - - I-MUT
may - - O
play - - O
a - - O
role - - O
in - - O
development - - O
and - - O
hematopoiesis - - O
. - - O

Adjuvant - - O
and - - O
neoadjuvant - - O
treatment - - O
of - - O
breast - - O
cancer - - O
. - - O

This - - O
was - - O
obtained - - O
with - - O
the - - O
thermal - - O
neutron - - O
fluency - - O
2 - - O
. - - O
0 - - O
x - - O
10 - - O
( - - O
10 - - O
) - - O
n - - O
cm2 - - O
. - - O

In - - O
contrast - - O
to - - O
T - - O
cells - - O
, - - O
in - - O
fibroblasts - - O
PILOT - - B-MUT
gene - - I-MUT
expression - - O
requires - - O
only - - O
one - - O
signal - - O
( - - O
PMA - - O
) - - O
and - - O
is - - O
not - - O
affected - - O
by - - O
CyA - - O
. - - O

Similar - - O
experiments - - O
with - - O
TR - - B-MUT
support - - O
the - - O
high - - O
affinity - - O
of - - O
RIP140 - - B-MUT
to - - O
the - - O
RXR - - B-MUT
subunit - - I-MUT
and - - O
also - - O
suggest - - O
that - - O
either - - O
partner - - O
in - - O
the - - O
TR - - B-MUT
RXR - - I-MUT
heterodimer - - I-MUT
can - - I-MUT
independently - - O
respond - - O
to - - O
ligand - - O
. - - O

The - - O
findings - - O
are - - O
compatible - - O
with - - O
the - - O
idea - - O
that - - O
the - - O
genes - - O
encoding - - O
PDGF - - B-MUT
receptors - - I-MUT
in - - O
glioma - - O
cells - - O
are - - O
regulated - - O
in - - O
concert - - O
with - - O
other - - O
genes - - O
, - - O
the - - O
expression - - O
of - - O
which - - O
may - - O
reflect - - O
the - - O
developmental - - O
program - - O
of - - O
normal - - O
glia - - O
cell - - O
lineages - - O
. - - O

Current - - O
clinical - - O
trials - - O
should - - O
answer - - O
the - - O
question - - O
of - - O
which - - O
of - - O
the - - O
therapeutic - - O
options - - O
impairs - - O
quality - - O
of - - O
life - - O
less - - O
. - - O

Several - - O
genes - - O
or - - O
transcriptional - - O
units - - O
were - - O
identified - - O
, - - O
including - - O
the - - O
3' - - O
end - - O
of - - O
ribosomal - - B-MUT
s6 - - I-MUT
kinase - - I-MUT
( - - O
Rsk3 - - B-MUT
) - - O
; - - O
two - - O
apparently - - O
intronless - - O
and - - O
ORF-less - - O
genes - - O
; - - O
and - - O
Gpr31 - - B-MUT
, - - O
an - - O
intronless - - O
, - - O
putative - - O
G-protein - - B-MUT
coupled - - I-MUT
receptor - - I-MUT
. - - O

Using - - O
gel - - O
retardation - - O
assays - - O
with - - O
HepG2 - - O
nuclear - - O
extract - - O
, - - O
we - - O
demonstrated - - O
the - - O
presence - - O
of - - O
a - - O
specific - - O
protein - - O
which - - O
bound - - O
to - - O
the - - O
NRE - - B-MUT
fragment - - O
. - - O

Xenopus - - B-MUT
homolog - - I-MUT
of - - I-MUT
the - - I-MUT
mos - - I-MUT
protooncogene - - I-MUT
transforms - - O
mammalian - - O
fibroblasts - - O
and - - O
induces - - O
maturation - - O
of - - O
Xenopus - - O
oocytes - - O
. - - O

In - - O
contrast - - O
, - - O
a - - O
similar - - O
fragment - - O
lacking - - O
the - - O
38-base-pair - - O
region - - O
had - - O
no - - O
such - - O
stabilizing - - O
effect - - O
. - - O

Here - - O
, - - O
we - - O
describe - - O
a - - O
tyrosine-phosphorylated - - O
nuclear - - O
protein - - O
, - - O
YT521-B - - B-MUT
, - - O
and - - O
show - - O
that - - O
it - - O
interacts - - O
with - - O
the - - O
nuclear - - B-MUT
transcriptosomal - - I-MUT
component - - I-MUT
scaffold - - I-MUT
attachment - - I-MUT
factor - - I-MUT
B - - I-MUT
, - - O
and - - O
the - - O
68-kDa - - B-MUT
Src - - I-MUT
substrate - - O
associated - - O
during - - O
mitosis - - O
, - - O
Sam68 - - B-MUT
. - - O

The - - O
exon - - O
: - - O
intron - - O
structure - - O
of - - O
chicken - - B-MUT
IL8 - - I-MUT
corresponds - - O
almost - - O
exactly - - O
to - - O
that - - O
of - - O
human - - B-MUT
IL8 - - I-MUT
and - - O
differs - - O
from - - O
those - - O
of - - O
other - - O
known - - O
mammalian - - B-MUT
CXC - - I-MUT
chemokine - - I-MUT
genes - - I-MUT
. - - O

Brain - - O
scan - - O
with - - O
99mTc-labelled - - O
macroaggregated - - O
albumin - - B-MUT
( - - O
MAA - - O
brain - - O
scan - - O
) - - O
and - - O
computed - - O
tomography - - O
studies - - O
( - - O
CT - - O
) - - O
were - - O
performed - - O
on - - O
78 - - O
patients - - O
with - - O
intracranial - - O
diseases - - O
. - - O

Procion - - O
yellow - - O
dye - - O
was - - O
injected - - O
intracellularly - - O
into - - O
large - - O
auditory - - O
fibers - - O
of - - O
goldfish - - O
to - - O
investigate - - O
the - - O
relationship - - O
between - - O
the - - O
response - - O
type - - O
of - - O
these - - O
fibers - - O
and - - O
their - - O
site - - O
of - - O
termination - - O
in - - O
the - - O
saccular - - O
macula - - O
. - - O

First - - O
, - - O
each - - O
lung - - O
was - - O
cut - - O
into - - O
slices - - O
, - - O
from - - O
which - - O
primary - - O
disectors - - O
were - - O
sampled - - O
systematically - - O
with - - O
a - - O
known - - O
sampling - - O
fraction - - O
. - - O

Tumor - - O
cells - - O
were - - O
focally - - O
immunoreactive - - O
for - - O
neuron-specific - - B-MUT
enolase - - I-MUT
, - - O
insulin - - B-MUT
, - - O
glucagon - - B-MUT
and - - O
VIP - - B-MUT
. - - O

Analysis - - O
of - - O
viral - - O
mutants - - O
in - - O
vivo - - O
demonstrated - - O
that - - O
the - - O
NFIII - - B-MUT
OCT-1 - - O
binding - - B-MUT
site - - O
and - - O
a - - O
conserved - - O
ATF - - O
motif - - B-MUT
were - - I-MUT
important - - O
for - - O
efficient - - O
viral - - O
growth - - O
. - - O

E1A - - B-MUT
autoactivation - - O
mediated - - O
by - - O
these - - O
sites - - O
was - - O
about - - O
twofold - - O
compared - - O
with - - O
a - - O
ninefold - - O
activation - - O
described - - O
for - - O
the - - O
complete - - O
E1A - - B-MUT
promoter - - I-MUT
. - - O

We - - O
report - - O
here - - O
the - - O
molecular - - O
cloning - - O
of - - O
a - - O
putative - - O
adhesive - - O
molecule - - O
from - - O
P - - O
. - - O
falciparum - - O
that - - O
shares - - O
both - - O
sequence - - O
and - - O
structural - - O
similarities - - O
with - - O
a - - O
sporozoite - - O
surface - - O
molecule - - O
from - - O
Plasmodium - - O
termed - - O
the - - O
thrombospondin-related - - B-MUT
anonymous - - I-MUT
protein - - I-MUT
( - - O
TRAP - - B-MUT
) - - O
and - - O
, - - O
to - - O
a - - O
lesser - - O
extent - - O
, - - O
with - - O
the - - O
circumsporozoite - - O
( - - O
CS - - O
) - - O
protein - - O
. - - O

In - - O
a - - O
second - - O
patient - - O
the - - O
VT - - O
became - - O
nonsustained - - O
. - - O

Further - - O
, - - O
the - - O
PIP2 - - O
content - - O
of - - O
the - - O
85-90 - - O
kDa - - O
protein - - O
appeared - - O
to - - O
decrease - - O
with - - O
CSF-1 - - B-MUT
treatment - - O
. - - O

The - - O
epitope-protected - - O
lysine - - O
( - - O
K - - O
) - - O
was - - O
present - - O
in - - O
a - - O
30-aa - - B-MUT
TPO - - I-MUT
fragment - - I-MUT
that - - O
, - - O
by - - O
N-terminal - - O
sequencing - - O
, - - O
was - - O
found - - O
to - - O
be - - O
K713 - - O
. - - O

Therefore - - O
, - - O
magnetic - - O
resonance - - O
imaging - - O
was - - O
used - - O
to - - O
determine - - O
liver - - O
volume - - O
in - - O
pediatric - - O
and - - O
adolescent - - O
patients - - O
, - - O
in - - O
whom - - O
systemic - - O
clearance - - O
of - - O
three - - O
model - - O
substrates - - O
[ - - O
lorazepam - - O
( - - O
0 - - O
. - - O
03 - - O
mg - - O
kg - - O
) - - O
, - - O
antipyrine - - O
( - - O
10 - - O
mg - - O
kg - - O
) - - O
, - - O
and - - O
indocyanine - - O
green - - O
( - - O
ICG - - O
; - - O
0 - - O
. - - O
5 - - O
mg - - O
kg - - O
) - - O
] - - O
was - - O
also - - O
determined - - O
. - - O

Northern - - O
blotting - - O
analysis - - O
indicates - - O
that - - O
expression - - O
of - - O
the - - O
genes - - O
corresponding - - O
to - - O
these - - O
clones - - O
is - - O
confined - - O
to - - O
pollen - - O
tissue - - O
. - - O

Like - - O
scrotal - - O
testes - - O
, - - O
undescended - - O
testes - - O
were - - O
hypointense - - O
to - - O
fat - - O
on - - O
sequences - - O
with - - O
a - - O
short - - O
repetition - - O
time - - O
( - - O
TR - - O
) - - O
and - - O
echo - - O
time - - O
( - - O
TE - - O
) - - O
in - - O
all - - O
cases - - O
, - - O
and - - O
hyperintense - - O
or - - O
isointense - - O
to - - O
fat - - O
on - - O
long - - O
TR - - O
TE - - O
sequences - - O
in - - O
all - - O
but - - O
two - - O
cases - - O
. - - O

Samples - - O
from - - O
1415 - - O
neurological - - O
patients - - O
were - - O
used - - O
to - - O
study - - O
the - - O
diagnostic - - O
value - - O
of - - O
acid - - B-MUT
alpha - - I-MUT
1-glycoprotein - - I-MUT
in - - O
the - - O
lumbar - - O
cerebrospinal - - O
fluid - - O
. - - O

In - - O
addition - - O
, - - O
a - - O
comparison - - O
of - - O
the - - O
hCHLR - - B-MUT
gene - - I-MUT
sequences - - I-MUT
with - - O
available - - O
databases - - O
indicates - - O
that - - O
a - - O
large - - O
portion - - O
of - - O
these - - O
genes - - O
, - - O
including - - O
exons - - O
encoding - - O
two - - O
functional - - O
domains - - O
of - - O
the - - O
carboxyl-terminal - - O
region - - O
of - - O
these - - O
proteins - - O
, - - O
has - - O
been - - O
duplicated - - O
as - - O
part - - O
of - - O
a - - O
larger - - O
human - - O
telomeric - - O
repeat - - O
sequence - - O
found - - O
on - - O
many - - O
human - - O
chromosomes - - O
. - - O

The - - O
pulmonary - - O
effects - - O
observed - - O
, - - O
became - - O
more - - O
pronounced - - O
with - - O
increasing - - O
NO2 - - O
concentrations - - O
( - - O
0 - - O
, - - O
25 - - O
, - - O
75 - - O
, - - O
125 - - O
, - - O
175 - - O
or - - O
200 - - O
ppm - - O
, - - O
1 - - O
ppm - - O
NO2 - - O
= - - O
1 - - O
. - - O
88 - - O
mg - - O
m-3 - - O
NO2 - - O
) - - O
and - - O
exposure - - O
times - - O
( - - O
5 - - O
, - - O
10 - - O
, - - O
20 - - O
or - - O
30 - - O
min - - O
) - - O
. - - O

Moreover - - O
, - - O
increasing - - O
the - - O
dosage - - O
of - - O
wild-type - - B-MUT
Fus3 - - I-MUT
intensifies - - O
the - - O
inhibition - - O
of - - O
both - - O
Ty1 - - B-MUT
transposition - - O
and - - O
invasive - - O
growth - - O
. - - O

Type - - B-MUT
2 - - I-MUT
deiodinase - - I-MUT
( - - O
D2 - - B-MUT
) - - O
catalyzes - - O
the - - O
5'-deiodination - - O
of - - O
thyroxine - - O
to - - O
form - - O
3 - - O
, - - O
5 - - O
, - - O
3'-triiodothyronine - - O
. - - O

Comparison - - O
of - - O
genomic - - O
sequence - - O
shows - - O
that - - O
the - - O
ph - - B-MUT
locus - - I-MUT
has - - O
been - - O
duplicated - - O
, - - O
and - - O
that - - O
it - - O
contains - - O
proximal - - O
and - - O
distal - - O
transcription - - O
units - - O
. - - O

Pao2 - - O
increased - - O
from - - O
15 - - O
. - - O
5 - - O
+ - - O
- - - O
5 - - O
. - - O
6 - - O
kPa - - O
( - - O
116 - - O
+ - - O
- - - O
42 - - O
mm - - O
Hg - - O
) - - O
to - - O
17 - - O
. - - O
3 - - O
+ - - O
- - - O
6 - - O
. - - O
3 - - O
kPa - - O
( - - O
130 - - O
+ - - O
- - - O
47 - - O
mm - - O
Hg - - O
) - - O
( - - O
P - - O
< - - O
0 - - O
. - - O
05 - - O
) - - O
. - - O

The - - O
efficacy - - O
and - - O
safety - - O
of - - O
a - - O
novel - - O
percutaneous - - O
anaesthetic - - O
preparation - - O
based - - O
on - - O
amethocaine - - O
has - - O
been - - O
investigated - - O
in - - O
the - - O
paediatric - - O
clinical - - O
environment - - O
. - - O

Phosphopeptide - - O
mapping - - O
revealed - - O
the - - O
same - - O
autophosphorylation - - O
sites - - O
utilized - - O
by - - O
EGFR-IC - - B-MUT
as - - O
those - - O
identified - - O
in - - O
wild-type - - B-MUT
EGFR - - I-MUT
. - - O

Cell - - O
. - - O

The - - O
drug - - O
sensitivity - - O
was - - O
100% - - O
for - - O
vancomycin - - O
( - - O
VCM - - O
) - - O
, - - O
30% - - O
for - - O
imipenam - - O
( - - O
IMP - - O
) - - O
, - - O
31% - - O
for - - O
minomycin - - O
( - - O
MINO - - O
) - - O
, - - O
31% - - O
for - - O
amikacin - - O
( - - O
AMK - - O
) - - O
, - - O
and - - O
7% - - O
for - - O
fosfomycin - - O
( - - O
FOM - - O
) - - O
. - - O

Induction - - O
of - - O
CD86 - - B-MUT
expression - - O
by - - O
stimulation - - O
of - - O
U937 - - O
cells - - O
with - - O
IFN-gamma - - B-MUT
revealed - - O
the - - O
presence - - O
of - - O
two - - O
functional - - O
GAS - - B-MUT
( - - O
gamma-interferon - - B-MUT
activation - - I-MUT
site - - I-MUT
) - - O
elements - - O
. - - O

Measurements - - O
of - - O
perfusion - - O
also - - O
showed - - O
significantly - - O
higher - - O
values - - O
under - - O
active - - O
therapy - - O
. - - O

BACKGROUND - - O
: - - O
It - - O
is - - O
generally - - O
accepted - - O
that - - O
smoking - - O
increases - - O
blood - - O
pressure - - O
and - - O
inhibits - - O
muscle - - O
sympathetic - - O
nerve - - O
activity - - O
( - - O
SNA - - O
) - - O
. - - O

Serum - - O
and - - O
peritoneal - - O
dialysis - - O
fluid - - O
( - - O
PDF - - O
) - - O
were - - O
collected - - O
for - - O
assay - - O
throughout - - O
the - - O
course - - O
of - - O
the - - O
study - - O
and - - O
for - - O
5 - - O
days - - O
thereafter - - O
. - - O

These - - O
results - - O
show - - O
that - - O
Ski - - B-MUT
is - - O
a - - O
component - - O
of - - O
the - - O
HDAC - - B-MUT
complex - - I-MUT
and - - O
that - - O
Ski - - B-MUT
is - - O
required - - O
for - - O
the - - O
transcriptional - - O
repression - - O
mediated - - O
by - - O
this - - O
complex - - O
. - - O

Theory - - O
and - - O
applications - - O
of - - O
pulse - - O
dosing - - O
: - - O
a - - O
summary - - O
of - - O
the - - O
symposium - - O
. - - O

The - - O
structural - - O
genes - - O
encoding - - O
glyceraldehyde-3-phosphate - - B-MUT
dehydrogenase - - I-MUT
( - - O
GAPDH - - B-MUT
) - - O
, - - O
3-phosphoglycerate - - B-MUT
kinase - - I-MUT
( - - O
PGK - - B-MUT
) - - O
and - - O
the - - O
N-terminal - - O
part - - O
of - - O
triosephosphate - - B-MUT
isomerase - - I-MUT
( - - O
TIM - - B-MUT
) - - O
from - - O
mesophilic - - O
Bacillus - - O
megaterium - - O
DSM319 - - O
have - - O
been - - O
cloned - - O
as - - O
a - - O
gene - - O
cluster - - O
( - - O
gap - - B-MUT
operon - - I-MUT
) - - O
by - - O
complementation - - O
of - - O
an - - O
Escherichia - - O
coli - - O
gap - - B-MUT
amber - - I-MUT
mutant - - I-MUT
. - - O

An - - O
E - - O
box - - O
element - - O
is - - O
required - - O
for - - O
the - - O
expression - - O
of - - O
the - - O
ad4bp - - B-MUT
gene - - I-MUT
, - - O
a - - O
mammalian - - B-MUT
homologue - - I-MUT
of - - I-MUT
ftz-f1 - - I-MUT
gene - - I-MUT
, - - O
which - - O
is - - O
essential - - O
for - - O
adrenal - - O
and - - O
gonadal - - O
development - - O
. - - O

1- - - O
( - - O
m-Chlorophenyl - - O
) - - O
piperazine - - O
( - - O
mCPP - - O
, - - O
0 - - O
. - - O
1-3 - - O
. - - O
0 - - O
mg - - O
kg - - O
) - - O
and - - O
1- - - O
( - - O
m-trifluoromethylphenyl - - O
) - - O
piperazine - - O
( - - O
TFMPP - - O
, - - O
0 - - O
. - - O
1-3 - - O
. - - O
0 - - O
mg - - O
kg - - O
) - - O
, - - O
both - - O
thought - - O
to - - O
act - - O
primarily - - O
at - - O
5-HT1 - - O
sites - - O
, - - B-MUT
also - - I-MUT
decreased - - O
responding - - O
and - - O
this - - O
effect - - O
was - - O
blocked - - O
by - - O
methysergide - - O
and - - O
by - - O
1-NP - - O
, - - O
but - - O
not - - O
by - - O
ketanserin - - O
. - - O

METHOD - - O
: - - O
The - - O
sample - - O
of - - O
subjects - - O
was - - O
drawn - - O
from - - O
the - - O
Suffolk - - O
County - - O
Mental - - O
Health - - O
Project - - O
, - - O
a - - O
longitudinal - - O
epidemiologic - - O
study - - O
of - - O
first-hospitalized - - O
subjects - - O
with - - O
psychotic - - O
disorders - - O
; - - O
the - - O
present - - O
study - - O
focused - - O
on - - O
patients - - O
with - - O
schizophrenic - - O
disorders - - O
. - - O

The - - O
temporal - - O
component - - O
lacked - - O
a - - O
mandibular - - O
fossa - - O
as - - O
well - - O
as - - O
articular - - O
eminence - - O
. - - O

Ang - - B-MUT
II-induced - - I-MUT
fibronectin - - I-MUT
mRNA - - I-MUT
was - - O
not - - O
affected - - O
by - - O
PKC - - B-MUT
inhibitors - - O
or - - O
PKC - - B-MUT
depletion - - O
, - - O
whereas - - O
specific - - O
inhibition - - O
of - - O
EGF-R - - B-MUT
function - - O
by - - O
a - - O
dominant - - B-MUT
negative - - I-MUT
EGF-R - - I-MUT
mutant - - I-MUT
and - - O
tyrphostin - - O
AG1478 - - O
abolished - - O
induction - - O
of - - O
fibronectin - - B-MUT
mRNA - - I-MUT
. - - O

These - - O
fusions - - O
are - - O
contained - - O
on - - O
plasmids - - O
which - - O
have - - O
both - - O
yeast - - O
and - - O
E - - O
. - - O
coli - - O
replication - - O
origins - - O
and - - O
selectable - - O
markers - - O
and - - O
, - - O
therefore - - O
, - - O
can - - O
be - - O
used - - O
to - - O
transform - - O
either - - O
yeast - - O
or - - O
E - - O
. - - O
coli - - O
cells - - O
. - - O

Furthermore - - O
, - - O
although - - O
the - - O
regional - - O
distribution - - O
of - - O
lean - - O
tissue - - O
mass - - O
in - - O
the - - O
trunk - - O
and - - O
legs - - O
remained - - O
fairly - - O
constant - - O
at - - O
different - - O
pubertal - - O
stages - - O
, - - O
the - - O
regional - - O
distribution - - O
of - - O
fat - - O
was - - O
altered - - O
significantly - - O
, - - O
becoming - - O
more - - O
central - - O
and - - O
less - - O
peripheral - - O
. - - O

Coliphage - - B-MUT
186 - - I-MUT
B - - I-MUT
is - - O
a - - O
72-amino - - O
acid - - O
protein - - O
belonging - - O
to - - O
the - - O
Ogr - - B-MUT
family - - O
of - - O
analogous - - O
transcription - - O
factors - - O
present - - O
in - - O
P2-like - - O
phage - - O
, - - O
which - - O
contain - - O
a - - O
Cys-X2-Cys-X22-Cys-X4-Cys - - O
presumptive - - O
zinc-finger - - O
motif - - O
. - - O

In - - O
a - - O
maxicell - - O
system - - O
a - - O
protein - - O
with - - O
an - - O
approximate - - O
molecular - - O
weight - - O
of - - O
36 - - O
, - - O
000 - - O
was - - O
synthesized - - O
. - - O

Vac1p - - B-MUT
was - - O
found - - O
to - - O
bind - - O
the - - O
Sec1p - - B-MUT
homologue - - I-MUT
Vps45p - - B-MUT
. - - O

Interspecific - - O
complementation - - O
tests - - O
showed - - O
that - - O
the - - O
P7 - - B-MUT
proteins - - I-MUT
are - - O
unable - - O
to - - O
complement - - O
P1 - - B-MUT
parA - - I-MUT
or - - O
parB - - B-MUT
mutants - - I-MUT
, - - O
and - - O
the - - O
P1 - - B-MUT
proteins - - I-MUT
fail - - O
to - - O
complement - - O
the - - O
P7 - - B-MUT
mutations - - I-MUT
. - - O

The - - O
Aie1 - - B-MUT
locus - - I-MUT
was - - O
mapped - - O
to - - O
mouse - - O
chromosome - - O
7A2-A3 - - O
by - - O
fluorescent - - O
in - - O
situ - - O
hybridization - - O
. - - O

Effects - - O
of - - O
point - - O
defects - - O
on - - O
lattice - - O
parameters - - O
of - - O
semiconductors - - O
. - - O

There - - O
was - - O
no - - O
difference - - O
in - - O
apnea - - O
duration - - O
between - - O
the - - O
supine - - O
and - - O
prone - - O
positions - - O
. - - O

Cell - - O
49 - - O
, - - O
753-761 - - O
] - - O
. - - O

Erratum - - O
to - - O
"Cholesteryl - - B-MUT
ester - - I-MUT
transfer - - I-MUT
protein - - I-MUT
and - - O
atherosclerosis - - O
in - - O
Japanese - - O
subjects - - O
: - - O
a - - O
study - - O
based - - O
on - - O
coronary - - O
angiography" - - O
. - - O

After - - O
PTCA - - O
, - - O
ejection - - O
fraction - - O
increased - - O
from - - O
54 - - O
+ - - O
- - - O
8% - - O
to - - O
59 - - O
+ - - O
- - - O
8% - - O
( - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
05 - - O
) - - O
and - - O
regional - - O
function - - O
improved - - O
significantly - - O
( - - O
maximal - - O
standard - - O
deviation - - O
before - - O
PTCA - - O
: - - O
2 - - O
. - - O
8 - - O
+ - - O
- - - O
0 - - O
. - - O
8 - - O
; - - O
after - - O
PTCA - - O
: - - O
1 - - O
. - - O
9 - - O
+ - - O
- - - O
0 - - O
. - - O
9- - - O
segments - - O
below - - O
the - - O
first - - O
standard - - O
deviation - - O
before - - O
PTCA - - O
: - - O
31 - - O
+ - - O
- - - O
16 - - O
; - - O
after - - O
PTCA - - O
: - - O
19 - - O
+ - - O
- - - O
17 - - O
) - - O
. - - O

The - - O
concentrations - - O
of - - O
plasma - - O
ACTH - - B-MUT
and - - O
cortisol - - O
increased - - O
by - - O
40% - - O
and - - O
60% - - O
after - - O
MPTP - - O
treatment - - O
, - - O
respectively - - O
. - - O

This - - O
distribution - - O
parallels - - O
that - - O
of - - O
the - - O
neurotransmitters - - O
glutamate - - O
and - - O
aspartate - - O
; - - O
however - - O
, - - O
neither - - O
of - - O
these - - O
excitatory - - O
amino - - O
acids - - O
is - - O
a - - O
substrate - - O
for - - O
transport - - O
. - - O

Only - - O
two - - O
of - - O
the - - O
isoforms - - O
possess - - O
the - - O
N-terminal - - O
zinc - - O
finger - - O
domain - - O
that - - O
is - - O
necessary - - O
and - - O
sufficient - - O
for - - O
TdT - - B-MUT
promoter - - I-MUT
binding - - O
. - - O

RT-PCR - - O
indicated - - O
that - - O
p21 - - B-MUT
mRNA - - I-MUT
was - - O
induced - - O
1 - - O
. - - O
4- - - O
, - - O
2 - - O
. - - O
0- - - O
, - - O
and - - O
3 - - O
. - - O
1-fold - - O
in - - O
the - - O
2-day - - O
neonatal - - O
, - - O
7-day - - O
neonatal - - O
, - - O
and - - O
adult - - O
stages - - O
, - - O
respectively - - O
, - - O
compared - - O
to - - O
the - - O
17-day - - O
fetal - - O
stage - - O
. - - O

This - - O
demonstrates - - O
that - - O
treatment - - O
of - - O
the - - O
graft - - O
recipient - - O
for - - O
a - - O
relatively - - O
short - - O
period - - O
during - - O
and - - O
after - - O
surgery - - O
has - - O
a - - O
favorable - - O
effect - - O
on - - O
the - - O
survival - - O
of - - O
grafted - - O
dopaminergic - - O
neurons - - O
. - - O

Three-dimensional - - O
structural - - O
studies - - O
using - - O
electron - - O
cryomicroscopy - - O
showed - - O
that - - O
the - - O
binding - - O
of - - O
one - - O
Fab - - B-MUT
( - - O
8H2 - - O
G5 - - O
) - - O
does - - O
not - - O
affect - - O
the - - O
conformation - - O
of - - O
the - - O
capsid - - O
, - - O
and - - O
the - - O
efficiency - - O
of - - O
mRNA - - O
production - - O
is - - O
similar - - O
to - - O
that - - O
of - - O
the - - O
native - - O
subviral - - O
particle - - O
. - - O

Femoral - - O
strain - - O
adaptation - - O
after - - O
total - - O
hip - - O
replacement - - O
: - - O
a - - O
comparison - - O
of - - O
cemented - - O
and - - O
porous - - O
ingrowth - - O
components - - O
in - - O
canines - - O
. - - O

The - - O
ability - - O
of - - O
chronic - - O
UM-272 - - O
( - - O
dimethylpropranolol - - O
) - - O
treatment - - O
to - - O
prevent - - O
the - - O
induction - - O
of - - O
reentrant - - O
ventricular - - O
tachyarrhythmias - - O
was - - O
assessed - - O
in - - O
the - - O
conscious - - O
dog - - O
subjected - - O
to - - O
serial - - O
programmed - - O
electrical - - O
stimulation - - O
on - - O
days - - O
3--5 - - O
after - - O
myocardial - - O
infarction - - O
. - - O

The - - O
detectability - - O
of - - O
the - - O
defects - - O
in - - O
RCA - - O
or - - O
LAD - - O
region - - O
was - - O
80% - - O
in - - O
single-position - - O
scans - - O
in - - O
stress - - O
studies - - O
. - - O

MR - - O
imaging - - O
of - - O
traumatic - - O
head - - O
injuries - - O
using - - O
FLAIR - - O
technique - - O
. - - O

With - - O
0 - - O
. - - O
5 - - O
vol - - O
. - - O
-% - - O
, - - O
the - - O
corresponding - - O
values - - O
were - - O
345 - - O
mumol - - O
1 - - O
( - - O
5 - - O
. - - O
72 - - O
mg - - O
100 - - O
ml - - O
) - - O
and - - O
137 - - O
mumol - - O
1 - - O
( - - O
2 - - O
. - - O
25 - - O
mg - - O
100 - - O
ml - - O
) - - O
respectively - - O
. - - O

Given - - O
its - - O
relative - - O
longevity - - O
on - - O
the - - O
Web - - O
, - - O
TIE - - O
researchers - - O
have - - O
been - - O
in - - O
a - - O
unique - - O
position - - O
to - - O
observe - - O
trends - - O
in - - O
telemedicine - - O
. - - O

She - - O
improved - - O
with - - O
a - - O
combination - - O
of - - O
benzodiazepines - - O
and - - O
the - - O
acetylcholinesterase - - B-MUT
inhibitor - - O
physostigmine - - O
. - - O

Platelet - - B-MUT
activating - - I-MUT
factor - - I-MUT
was - - O
given - - O
in - - O
six - - O
doses - - O
at - - O
15 - - O
minute - - O
intervals - - O
and - - O
airway - - O
response - - O
measured - - O
as - - O
change - - O
in - - O
partial - - O
expiratory - - O
flow - - O
at - - O
30% - - O
of - - O
vital - - O
capacity - - O
( - - O
Vp30 - - O
) - - O
. - - O

Those - - O
radiological - - O
aspects - - O
were - - O
distributed - - O
in - - O
two - - O
categories - - O
: - - O
1 - - O
) - - O
type - - O
I-presenting - - O
variable - - O
sinusoidal - - O
filling - - O
. - - O

Since - - O
we - - O
have - - O
observed - - O
effects - - O
of - - O
growth - - B-MUT
factors - - I-MUT
and - - O
cAMP - - O
as - - O
well - - O
as - - O
estradiol - - O
( - - O
E2 - - O
) - - O
on - - O
regulation - - O
of - - O
expression - - O
of - - O
some - - O
genes - - O
stimulated - - O
by - - O
the - - O
estrogen - - B-MUT
receptor - - I-MUT
( - - O
ER - - B-MUT
) - - O
, - - O
we - - O
have - - O
undertaken - - O
studies - - O
to - - O
examine - - O
directly - - O
whether - - O
activators - - O
of - - O
protein - - B-MUT
kinases - - I-MUT
can - - O
modulate - - O
transcriptional - - O
activity - - O
of - - O
the - - O
ER - - B-MUT
. - - O

BCL-2 - - B-MUT
, - - O
an - - O
inhibitor - - O
of - - O
apoptosis - - O
in - - O
a - - O
wide - - O
variety - - O
of - - O
cell - - O
types - - O
, - - O
has - - O
been - - O
reported - - O
to - - O
prevent - - O
oxidative - - O
stress-induced - - O
cell - - O
death - - O
. - - O

This - - O
mechanism - - O
is - - O
not - - O
due - - O
to - - O
the - - O
observed - - O
grain - - O
boundary - - O
precipitates - - O
. - - O

Mature - - B-MUT
tobacco - - I-MUT
L12 - - I-MUT
protein - - I-MUT
has - - O
44% - - O
amino - - O
acid - - O
identity - - O
with - - O
ribosomal - - B-MUT
protein - - I-MUT
L7 - - I-MUT
L12 - - I-MUT
of - - I-MUT
Escherichia - - I-MUT
coli - - I-MUT
. - - I-MUT

Taste - - O
reactivity - - O
tests - - O
were - - O
used - - O
to - - O
examine - - O
the - - O
orofacial - - O
responses - - O
of - - O
alcohol - - O
preferring - - O
( - - O
P - - O
) - - O
rats - - O
and - - O
alcohol - - O
nonpreferring - - O
( - - O
NP - - O
) - - O
rats - - O
to - - O
the - - O
taste - - O
of - - O
alcohol - - O
. - - O

On - - O
the - - O
other - - O
side - - O
, - - O
when - - O
the - - O
aortic - - O
ring - - O
was - - O
perfused - - O
with - - O
L-NNA - - O
( - - O
NO-synthesis - - O
inhibitor - - O
) - - O
or - - O
methylene - - O
blue - - O
( - - O
soluble - - O
cGMPase - - B-MUT
inhibitor - - O
) - - O
, - - O
the - - O
changes - - O
could - - O
be - - O
attenuated - - O
. - - O

Effects - - O
of - - O
verapamil - - O
and - - O
propranolol - - O
on - - O
early - - O
afterdepolarizations - - O
and - - O
ventricular - - O
arrhythmias - - O
induced - - O
by - - O
epinephrine - - O
in - - O
congenital - - O
long - - O
QT - - O
syndrome - - O
. - - O

This - - O
implies - - O
that - - O
the - - O
groups - - O
do - - O
not - - O
just - - O
differ - - O
along - - O
one - - O
dimension - - O
, - - O
but - - O
along - - O
three - - O
dimensions - - O
. - - O

These - - O
results - - O
are - - O
very - - O
useful - - O
for - - O
deciding - - O
on - - O
the - - O
doses - - O
of - - O
hormones - - O
and - - O
the - - O
expected - - O
serum - - O
estradiol - - O
level - - O
in - - O
HRT - - O
for - - O
Japanese - - O
women - - O
. - - O

Poor - - O
response - - O
when - - O
laboratory - - O
recommended - - O
range - - O
for - - O
serum - - O
lithium - - O
is - - O
changed - - O
. - - O

Hydrocoele - - O
is - - O
common - - O
in - - O
men - - O
in - - O
Wuchereria - - O
bancrofti-endemic - - O
areas - - O
, - - O
the - - O
treatment - - O
for - - O
which - - O
is - - O
currently - - O
surgical - - O
intervention - - O
. - - O

Replication - - O
of - - O
bovine - - O
papillomavirus-1 - - O
( - - O
BPV-1 - - O
) - - O
DNA - - O
requires - - O
two - - O
viral - - O
gene - - O
products - - O
, - - O
the - - O
E1 - - B-MUT
protein - - I-MUT
and - - O
the - - O
full-length - - B-MUT
E2 - - I-MUT
protein - - I-MUT
. - - O

We - - O
have - - O
been - - O
able - - O
to - - O
map - - O
specific - - O
DNA - - O
fragments - - O
at - - O
the - - O
bases - - O
of - - O
chromatin - - O
loops - - O
with - - O
the - - O
help - - O
of - - O
a - - O
novel - - O
extraction - - O
procedure - - O
by - - O
using - - O
lithium-3' - - O
, - - O
5'-diiodosalicylate - - O
. - - O

The - - O
gene - - B-MUT
encoding - - I-MUT
human - - I-MUT
tissue-type - - I-MUT
plasminogen - - I-MUT
activator - - I-MUT
( - - O
t-PA - - B-MUT
) - - O
is - - O
regulated - - O
in - - O
a - - O
cell-type-specific - - O
manner - - O
. - - O

One - - O
month - - O
after - - O
the - - O
DTaP - - O
booster - - O
vaccination - - O
, - - O
both - - O
groups - - O
had - - O
6- - - O
to - - O
40-fold - - O
increases - - O
in - - O
serum - - O
antibody - - O
concentrations - - O
to - - O
all - - O
antigens - - O
tested - - O
; - - O
the - - O
concentrations - - O
against - - O
the - - O
three - - O
pertussis - - B-MUT
antigens - - I-MUT
were - - O
higher - - O
in - - O
the - - O
DTaP-primed - - O
children - - O
( - - O
p - - O
< - - O
0 - - O
. - - O
05 - - O
) - - O
. - - O

The - - O
iron - - O
dependence - - O
of - - O
transcription - - O
and - - O
expression - - O
of - - O
cvaA - - B-MUT
, - - O
which - - O
encodes - - O
a - - O
transporter - - O
accessory - - O
protein - - O
, - - O
and - - O
cvi - - B-MUT
, - - O
encoding - - O
the - - O
colicin - - B-MUT
V - - I-MUT
immunity - - I-MUT
protein - - I-MUT
, - - O
was - - O
assessed - - O
under - - O
conditions - - O
of - - O
iron - - O
excess - - O
or - - O
depletion - - O
. - - O

Synthetic - - O
ligands - - O
have - - O
been - - O
identified - - O
that - - O
reset - - O
and - - O
amplify - - O
the - - O
cycle - - O
of - - O
pulsatile - - O
GH - - B-MUT
secretion - - O
by - - O
interacting - - O
with - - O
the - - O
orphan - - B-MUT
GH-secretagogue - - I-MUT
receptor - - I-MUT
( - - O
GHS-R - - B-MUT
) - - O
. - - O

Self-heating - - O
after - - O
deep - - O
hypothermia - - O
( - - O
20 - - O
degrees - - O
C - - O
) - - O
causes - - O
a - - O
considerable - - O
increase - - O
in - - O
the - - O
brain - - O
tissues - - O
glutaminase - - B-MUT
activity - - O
at - - O
all - - O
studied - - O
incubation - - O
temperatures - - O
( - - O
37 - - O
, - - O
30 - - O
, - - O
20 - - O
and - - O
10 - - O
degrees - - O
C - - O
) - - O
as - - O
compared - - O
to - - O
control - - O
rats - - O
and - - O
rats - - O
under - - O
hypothermia - - O
. - - O

RESULTS - - O
: - - O
Within - - O
7 - - O
days - - O
, - - O
all - - O
groups - - O
re-acquired - - O
responding - - O
for - - O
heroin - - O
under - - O
CRF - - O
at - - O
rates - - O
similar - - O
to - - O
their - - O
pre-lesion - - O
performance - - O
. - - O

HFA - - O
134a - - O
had - - O
a - - O
greater - - O
tendency - - O
to - - O
take - - O
up - - O
moisture - - O
from - - O
the - - O
environment - - O
than - - O
did - - O
HFA - - O
227 - - O
. - - O

We - - O
also - - O
show - - O
that - - O
in - - O
fusions - - O
with - - O
the - - O
DNA - - O
binding - - O
domain - - O
of - - O
GAL4 - - B-MUT
, - - O
full - - O
activity - - O
requires - - O
the - - O
entire - - O
BHV-alpha - - B-MUT
TIF - - I-MUT
, - - O
although - - O
both - - O
amino - - O
and - - O
carboxyl - - O
termini - - O
display - - O
some - - O
activity - - O
on - - O
their - - O
own - - O
. - - O

Effects - - O
of - - O
a - - O
booster - - O
dose - - O
of - - O
tetanus - - O
toxoid - - O
after - - O
different - - O
primary - - O
courses - - O
of - - O
vaccination - - O
: - - O
implications - - O
on - - O
the - - O
use - - O
of - - O
immune - - B-MUT
globulin - - I-MUT
. - - O

In - - O
Xenopus - - O
, - - O
BMPs - - B-MUT
act - - O
as - - O
epidermal - - O
inducers - - O
and - - O
also - - O
as - - O
negative - - O
regulators - - O
of - - O
neurogenesis - - O
. - - O

These - - O
early - - O
structural - - O
processes - - O
are - - O
assumed - - O
to - - O
be - - O
subserved - - O
by - - O
the - - O
anterior - - O
parts - - O
of - - O
the - - O
left - - O
hemisphere - - O
, - - O
as - - O
event-related - - O
brain - - O
potentials - - O
show - - O
this - - O
area - - O
to - - O
be - - O
maximally - - O
activated - - O
when - - O
phrase - - O
structure - - O
violations - - O
are - - O
processed - - O
and - - O
as - - O
circumscribed - - O
lesions - - O
in - - O
this - - O
area - - O
lead - - O
to - - O
an - - O
impairment - - O
of - - O
the - - O
on-line - - O
structural - - O
assignment - - O
. - - O

Characterization - - O
of - - O
fus1 - - B-MUT
of - - O
Schizosaccharomyces - - O
pombe - - O
: - - O
a - - O
developmentally - - O
controlled - - O
function - - O
needed - - O
for - - O
conjugation - - O
. - - O

Southern - - O
analysis - - O
on - - O
genomic - - O
DNA - - O
isolated - - O
from - - O
tissues - - O
and - - O
cell - - O
lines - - O
from - - O
several - - O
mouse - - O
strains - - O
using - - O
mCD22 - - B-MUT
cDNA - - I-MUT
demonstrated - - O
that - - O
the - - O
Cd22 - - B-MUT
locus - - I-MUT
encoding - - O
mCD22 - - B-MUT
is - - O
a - - O
single - - O
copy - - O
gene - - O
of - - O
< - - O
or - - O
= - - O
30 - - O
kb - - O
. - - O

Importance - - O
of - - O
determining - - O
the - - O
blood - - O
sulfhydryl - - O
groups - - O
in - - O
fractures - - O
of - - O
the - - O
long - - O
tubular - - O
bones - - O
complicated - - O
by - - O
infection - - O
. - - O

Similar - - O
observations - - O
have - - O
been - - O
made - - O
previously - - O
for - - O
other - - O
genes - - O
. - - O

A - - O
general - - O
model - - O
for - - O
ARE-mediated - - O
mRNA - - O
degradation - - O
involving - - O
a - - O
potential - - O
role - - O
for - - O
certain - - O
heterogeneous - - O
nuclear - - O
ribonucleoproteins - - O
and - - O
ARE-binding - - O
proteins - - O
is - - O
proposed - - O
. - - O

Therefore - - O
, - - O
we - - O
conclude - - O
that - - O
DnaA - - B-MUT
may - - O
contact - - O
the - - O
beta - - O
subunit - - O
of - - O
RNA - - B-MUT
polymerase - - I-MUT
during - - O
activation - - O
of - - O
the - - O
pR - - B-MUT
promoter - - I-MUT
. - - O

Letter - - O
: - - O
Salmonella - - O
detection - - O
. - - O

Fourth - - O
, - - O
the - - O
3'-region - - O
splice - - O
junctions - - O
of - - O
the - - O
MSRs - - B-MUT
during - - O
latent - - O
and - - O
productive - - O
infection - - O
were - - O
determined - - O
by - - O
sequencing - - O
RNA-PCR - - O
products - - O
generated - - O
with - - O
primers - - O
that - - O
flank - - O
the - - O
3' - - O
splice - - O
region - - O
. - - O

A - - O
neuropsychological - - O
test - - O
battery - - O
was - - O
used - - O
that - - O
contained - - O
the - - O
Wisconsin - - O
card - - O
sorting - - O
test - - O
, - - O
Street - - O
completion - - O
test - - O
, - - O
Stroop - - O
test - - O
, - - O
a - - O
dichotic - - O
memory - - O
listening - - O
test - - O
, - - O
and - - O
a - - O
facial - - O
recognition - - O
test - - O
. - - O

LON-72 - - O
( - - O
34 - - O
isolates - - O
) - - O
, - - O
LON-73 - - O
( - - O
1 - - O
) - - O
, - - O
LON-71 - - O
( - - O
2 - - O
) - - O
and - - O
LON-10 - - O
( - - O
2 - - O
) - - O
were - - O
found - - O
at - - O
altitudes - - O
around - - O
2000 - - O
m - - O
, - - O
3 - - O
of - - O
them - - O
in - - O
a - - O
single - - O
village - - O
. - - O

Treatment - - O
of - - O
hypertension - - O
with - - O
a - - O
combination - - O
of - - O
the - - O
adrenergic - - B-MUT
beta - - I-MUT
receptor - - I-MUT
blockader - - O
, - - O
obsidan - - O
, - - O
and - - O
the - - O
vasodilator - - O
, - - O
apressin - - O
. - - O

The - - O
results - - O
of - - O
these - - O
studies - - O
demonstrate - - O
that - - O
the - - O
rat - - B-MUT
HDL - - I-MUT
receptor - - I-MUT
SR-BI - - I-MUT
promoter - - I-MUT
contains - - O
two - - O
sterol - - B-MUT
response - - I-MUT
elements - - I-MUT
( - - O
pSRE - - B-MUT
and - - O
dSRE - - B-MUT
) - - O
through - - O
which - - O
SREBP-1a - - B-MUT
can - - O
bind - - O
and - - O
activate - - O
transcription - - O
of - - O
this - - O
gene - - O
. - - O

Disruption - - O
demonstrates - - O
that - - O
CDC14 - - B-MUT
is - - O
an - - O
essential - - O
gene - - O
. - - O

The - - O
sites - - O
targeted - - O
for - - O
mutagenesis - - O
, - - O
residues - - O
60 - - O
, - - O
61 - - O
, - - O
and - - O
66 - - O
, - - O
are - - O
located - - O
within - - O
a - - O
putative - - O
helical - - O
loop - - O
structure - - O
which - - O
may - - O
be - - O
involved - - O
in - - O
substrate - - O
recognition - - O
by - - O
the - - O
enzyme - - O
. - - O

Further - - O
support - - O
for - - O
a - - O
direct - - O
interaction - - O
of - - O
Tub4p - - B-MUT
, - - O
Spc98p - - B-MUT
and - - O
Spc97p - - B-MUT
comes - - O
from - - O
the - - O
toxicity - - O
of - - O
strong - - O
SPC97 - - B-MUT
overexpression - - O
which - - O
is - - O
suppressed - - O
by - - O
co-overexpression - - O
of - - O
TUB4 - - B-MUT
or - - O
SPC98 - - B-MUT
. - - O

The - - O
amino - - O
acid - - O
sequences - - O
of - - O
the - - O
yeast - - O
and - - O
mammalian - - O
mitochondrial - - O
targeting - - O
sequences - - O
are - - O
similar - - O
but - - O
less - - O
related - - O
than - - O
the - - O
mature - - O
polypeptides - - O
. - - O

Our - - O
previous - - O
studies - - O
have - - O
shown - - O
that - - O
SHP-1 - - B-MUT
, - - O
a - - O
SH2 - - B-MUT
domain-containing - - I-MUT
protein-tyrosine - - I-MUT
phosphatase - - I-MUT
, - - O
is - - O
expressed - - O
not - - O
only - - O
in - - O
cells - - O
of - - O
hematopoietic - - O
lineages - - O
, - - O
but - - O
also - - O
in - - O
many - - O
non-hematopoietic - - O
cells - - O
under - - O
the - - O
control - - O
of - - O
an - - O
alternative - - O
tissue-specific - - O
promoter - - O
, - - O
P1 - - B-MUT
. - - O

Owing - - O
to - - O
parental - - O
attitude - - O
, - - O
a - - O
low - - O
protein - - O
diet - - O
( - - O
1-5 - - O
g - - O
kg - - O
) - - O
was - - O
introduced - - O
only - - O
late - - O
. - - O

Current - - O
status - - O
of - - O
telepathology - - O
. - - O

The - - O
Y-type - - B-MUT
structural - - I-MUT
motif - - I-MUT
is - - O
also - - O
conserved - - O
among - - O
a - - O
number - - O
of - - O
divergent - - O
BiP - - B-MUT
mRNAs - - I-MUT
. - - O

Effects - - O
of - - O
dioxins - - O
on - - O
thyroid - - O
function - - O
in - - O
newborn - - O
babies - - O
. - - O

Potentiation - - O
of - - O
the - - O
thrombolytic - - O
efficacy - - O
of - - O
single-chain - - B-MUT
urokinase - - I-MUT
( - - O
Pro-urokinase - - B-MUT
) - - O
by - - O
heparin - - O
. - - O

Effect - - O
of - - O
biliary - - O
obstruction - - O
and - - O
cholangitis - - O
on - - O
serum - - B-MUT
SPan-1 - - I-MUT
level - - O
. - - O

The - - O
overexpressed - - O
His6-tagged - - B-MUT
GrsA - - I-MUT
derivatives - - I-MUT
were - - O
affinity-purified - - O
, - - O
and - - O
the - - O
catalytic - - O
properties - - O
of - - O
the - - O
deletion - - O
mutants - - O
were - - O
examined - - O
by - - O
biochemical - - O
studies - - O
including - - O
ATP-dependent - - O
amino - - O
acid - - O
activation - - O
, - - O
carboxyl - - O
thioester - - O
formation - - O
, - - O
and - - O
the - - O
ability - - O
to - - O
racemize - - O
the - - O
covalently - - O
bound - - O
phenylalanine - - O
from - - O
L- - - O
to - - O
the - - O
D-isomer - - O
. - - O

Induction - - O
requires - - O
the - - O
ACE1 - - B-MUT
gene - - I-MUT
product - - I-MUT
, - - O
which - - O
binds - - O
to - - O
specific - - O
sites - - O
in - - O
the - - O
promoter - - O
region - - O
of - - O
the - - O
CUP1 - - B-MUT
gene - - I-MUT
. - - O

Fatal - - O
encephalitis - - O
in - - O
a - - O
patient - - O
with - - O
chronic - - O
graft-versus-host - - O
disease - - O
. - - O

The - - O
need - - O
in - - O
the - - O
small - - O
hospital - - O
. - - O

Mechanical - - O
ventilation - - O
in - - O
control - - O
lungs - - O
produced - - O
a - - O
47% - - O
decrease - - O
in - - O
chord - - O
compliance - - O
, - - O
an - - O
increase - - O
in - - O
lung - - O
lavage - - O
levels - - O
of - - O
tumor - - B-MUT
necrosis - - I-MUT
factor - - I-MUT
( - - I-MUT
TNF - - I-MUT
) - - I-MUT
-alpha - - I-MUT
( - - O
722 - - O
+ - - O
- - - O
306 - - O
pg - - O
ml - - O
) - - O
, - - O
interleukin - - O
( - - O
IL - - B-MUT
) - - I-MUT
-1beta - - I-MUT
( - - I-MUT
902 - - I-MUT
+ - - O
- - - O
322 - - O
pg - - O
ml - - O
) - - O
, - - O
and - - O
macrophage - - O
inflammatory - - O
protein-2 - - O
( - - O
MIP-2 - - B-MUT
) - - I-MUT
( - - I-MUT
363 - - O
+ - - B-MUT
- - - O
104 - - O
pg - - O
ml - - O
) - - O
as - - O
compared - - O
with - - O
low - - O
levels - - O
of - - O
cytokines - - O
detected - - O
in - - O
preventilation - - O
data - - O
, - - O
and - - O
no - - O
change - - O
in - - O
percentage - - O
of - - O
surfactant - - O
large - - O
aggregates - - O
( - - O
LA - - O
) - - O
. - - O

Of - - O
the - - O
compounds - - O
tested - - O
, - - O
alpha- - - O
( - - O
3-methyl-2-quinoxalinyl - - O
) - - O
-N-methylnitrone - - O
1 - - O
, - - O
4-dioxide - - O
( - - O
2 - - O
) - - O
was - - O
the - - O
most - - O
active - - O
agent - - O
in - - O
vivo - - O
against - - O
the - - O
gram-negative - - O
and - - O
the - - O
gram-positive - - O
organisms - - O
. - - O

A - - O
chromosome - - O
transmission - - O
fidelity - - O
( - - O
ctf - - O
) - - O
mutant - - O
, - - O
s138 - - O
, - - O
of - - O
Saccharomyces - - O
cerevisiae - - O
was - - O
identified - - O
by - - O
its - - O
centromere - - O
( - - O
CEN - - O
) - - O
transcriptional - - O
readthrough - - O
phenotype - - O
, - - O
suggesting - - O
perturbed - - O
kinetochore - - O
integrity - - O
in - - O
vivo - - O
. - - O

Immunohistochemical - - O
studies - - O
revealed - - O
positive - - O
staining - - O
for - - O
S100 - - B-MUT
protein - - I-MUT
in - - O
all - - O
the - - O
granular - - O
cell - - O
tumors - - O
of - - O
the - - O
adult - - O
but - - O
in - - O
none - - O
of - - O
the - - O
congenital - - O
granular - - O
cell - - O
epulides - - O
. - - O

In - - O
a - - O
prospective - - O
, - - O
randomized - - O
clinical - - O
trial - - O
we - - O
compared - - O
the - - O
efficacy - - O
of - - O
subcutaneously - - O
( - - O
SC - - O
) - - O
administered - - O
( - - O
every - - O
8 - - O
h - - O
) - - O
calcium - - O
heparin - - O
to - - O
intravenous - - O
( - - O
IV - - O
) - - O
sodium - - O
heparin - - O
in - - O
the - - O
treatment - - O
of - - O
proximal - - O
deep-vein - - O
thrombosis - - O
( - - O
DVT - - O
) - - O
. - - O

Mean - - O
increase - - O
of - - O
milk - - O
protein - - O
yield - - O
was - - O
46 - - O
g - - O
d - - O
with - - O
Met - - O
plus - - O
Lys - - O
, - - O
and - - O
mean - - O
increase - - O
of - - O
true - - O
protein - - O
content - - O
was - - O
1 - - O
. - - O
1 - - O
g - - O
kg - - O
of - - O
milk - - O
. - - O

V - - O
. - - O

Alignment - - O
of - - O
the - - O
amino - - O
acid - - O
sequences - - O
surrounding - - O
Tyr-766 - - O
with - - O
corresponding - - O
regions - - O
of - - O
other - - O
FGFRs - - B-MUT
revealed - - O
conserved - - O
tyrosine - - O
residues - - O
in - - O
all - - O
known - - O
members - - O
of - - O
the - - O
FGFR - - B-MUT
family - - I-MUT
. - - O

Mss4 - - B-MUT
also - - O
acts - - O
as - - O
a - - O
relatively - - O
inefficient - - O
guanine - - B-MUT
nucleotide - - I-MUT
exchange - - I-MUT
factor - - I-MUT
( - - O
GEF - - B-MUT
) - - O
. - - O

Treatment - - O
of - - O
Graves' - - O
disease - - O
. - - O

Some - - O
artificial - - O
promoter - - O
constructs - - O
containing - - O
multiple - - O
Sp1 - - B-MUT
sites - - I-MUT
were - - O
highly - - O
responsive - - O
to - - O
ethanol - - O
, - - O
but - - O
others - - O
were - - O
not - - O
, - - O
suggesting - - O
that - - O
the - - O
organization - - O
of - - O
the - - O
proximal - - O
promoter - - O
region - - O
was - - O
an - - O
additional - - O
factor - - O
that - - O
affected - - O
the - - O
ethanol - - O
response - - O
. - - O

Polysome - - B-MUT
and - - O
40S - - B-MUT
ribosome - - I-MUT
fractions - - O
were - - O
severely - - O
decreased - - O
in - - O
the - - O
krr1 - - B-MUT
mutant - - I-MUT
and - - O
Kri1p-depleted - - O
cells - - O
. - - O

The - - O
alpha - - B-MUT
4 - - I-MUT
gene - - I-MUT
5' - - O
flanking - - O
region - - O
acted - - O
as - - O
a - - O
promoter - - O
in - - O
transfection - - O
assays - - O
. - - O

Atopic - - O
allergy - - O
and - - O
other - - O
hypersensitivities - - O
. - - O

Reaction - - O
time - - O
( - - O
RT - - O
) - - O
and - - O
P300 - - O
were - - O
collected - - O
simultaneously - - O
. - - O

There - - O
was - - O
no - - O
evidence - - O
of - - O
any - - O
persistent - - O
oscillation - - O
within - - O
the - - O
ULF - - O
band - - O
. - - O

From - - O
March - - O
5 - - O
through - - O
October - - O
26 - - O
, - - O
1991 - - O
, - - O
eight - - O
persons - - O
were - - O
diagnosed - - O
with - - O
elevated - - O
blood - - O
lead - - O
levels - - O
( - - O
BLLs - - O
) - - O
at - - O
a - - O
local - - O
hospital - - O
and - - O
were - - O
reported - - O
to - - O
the - - O
notifiable - - O
disease - - O
surveillance - - O
system - - O
maintained - - O
by - - O
the - - O
Alabama - - O
Department - - O
of - - O
Public - - O
Health - - O
( - - O
ADPH - - O
) - - O
. - - O

Delineating - - O
the - - O
molecular - - O
basis - - O
for - - O
agonist-induced - - O
destabilization - - O
of - - O
mRNA - - O
of - - O
G-protein-linked - - B-MUT
receptors - - I-MUT
that - - O
contributes - - O
to - - O
receptor - - O
down-regulation - - O
is - - O
fundamental - - O
to - - O
our - - O
understanding - - O
of - - O
long-term - - O
regulation - - O
of - - O
receptors - - O
by - - O
agonist - - O
. - - O

The - - O
cloned - - O
alcR - - B-MUT
gene - - I-MUT
provided - - O
in - - O
trans - - O
restored - - O
these - - O
siderophore - - O
system - - O
activities - - O
to - - O
the - - O
mutants - - O
. - - O

Amikacin - - O
concentrations - - O
in - - O
serum - - O
and - - O
blister - - O
fluid - - O
in - - O
healthy - - O
volunteers - - O
and - - O
in - - O
patients - - O
with - - O
renal - - O
impairment - - O
. - - O

We - - O
conclude - - O
that - - O
the - - O
gp54 - - B-MUT
structural - - I-MUT
gene - - I-MUT
is - - O
required - - O
for - - O
initiation - - O
or - - O
amplification - - O
of - - O
the - - O
splenic - - O
erythroblast - - O
hyperplasia - - O
which - - O
characterizes - - O
the - - O
preleukemic - - O
phase - - O
of - - O
Rauscher - - O
disease - - O
. - - O

With - - O
Sair - - O
and - - O
So2 - - O
, - - O
mean - - O
vital - - O
capacity - - O
was - - O
reduced - - O
by - - O
44% - - O
from - - O
control - - O
. - - O

The - - O
bronchial - - O
epithelia - - O
of - - O
all - - O
smoke-exposed - - O
animals - - O
were - - O
hyperplastic - - O
, - - O
and - - O
their - - O
ultrastructure - - O
showed - - O
invaginations - - O
, - - O
tilt - - O
of - - O
nuclear - - O
axes - - O
, - - O
an - - O
increase - - O
in - - O
the - - O
number - - O
and - - O
size - - O
of - - O
lysosomes - - O
and - - O
multivesiculated - - O
bodies - - O
, - - O
and - - O
increased - - O
numbers - - O
of - - O
enlarged - - O
intramitochondrial - - O
granules - - O
. - - O

Transcription - - O
of - - O
the - - O
first - - O
operon - - O
coding - - O
for - - O
m-xylene-degrading - - O
enzymes - - O
on - - O
the - - O
TOL - - O
plasmid - - O
of - - O
Pseudomonas - - O
putida - - O
is - - O
activated - - O
by - - O
the - - O
xylR - - B-MUT
gene - - I-MUT
product - - I-MUT
in - - O
the - - O
presence - - O
of - - O
m-xylene - - O
. - - O

Three - - O
patients - - O
received - - O
additional - - O
cycles - - O
of - - O
5-fluorouracil - - O
+ - - O
- - - O
leucovorin - - O
as - - O
maintenance - - O
chemotherapy - - O
. - - O
RESULTS - - O
: - - O
Thirty - - O
males - - O
and - - O
21 - - O
females - - O
with - - O
a - - O
median - - O
age - - O
of - - O
55 - - O
years - - O
( - - O
range - - O
31--73 - - O
years - - O
) - - O
were - - O
treated - - O
. - - O

Epididymal - - O
growth - - O
was - - O
retarded - - O
in - - O
animals - - O
maintained - - O
solely - - O
on - - O
chickpea - - O
haulm - - O
and - - O
improved - - O
with - - O
supplementation - - O
. - - O

The - - O
mean - - O
extracted - - O
concentration - - O
of - - O
flucloxacillin - - O
obtained - - O
at - - O
operation - - O
was - - O
12 - - O
. - - O
9 - - O
micrograms - - O
ml - - O
( - - O
SD - - O
5 - - O
. - - O
25 - - O
) - - O
in - - O
synovial - - O
fluid - - O
; - - O
2 - - O
. - - O
9 - - O
micrograms - - O
g - - O
( - - O
SD - - O
3 - - O
. - - O
59 - - O
) - - O
in - - O
synovium - - O
; - - O
2 - - O
. - - O
0 - - O
micrograms - - O
g - - O
( - - O
SD - - O
1 - - O
. - - O
48 - - O
) - - O
in - - O
cancellous - - O
bone - - O
and - - O
1 - - O
. - - O
3 - - O
micrograms - - O
g - - O
( - - O
SD - - O
1 - - O
. - - O
25 - - O
) - - O
in - - O
cortical - - O
bone - - O
. - - O

MDBP - - B-MUT
from - - O
HeLa - - O
and - - O
Raji - - O
cells - - O
formed - - O
DNA-protein - - O
complexes - - O
with - - O
X-box - - O
oligonucleotides - - O
that - - O
coelectrophoresed - - O
with - - O
those - - O
containing - - O
standard - - O
MDBP - - B-MUT
sites - - I-MUT
. - - O

Interestingly - - O
, - - O
segment - - O
nesting - - O
differentially - - O
increases - - O
the - - O
copy - - O
number - - O
of - - O
genes - - O
encoded - - O
by - - O
segment - - O
W - - O
, - - O
suggesting - - O
that - - O
the - - O
unusual - - O
genomic - - O
organization - - O
of - - O
PDVs - - O
may - - O
be - - O
directly - - O
linked - - O
to - - O
the - - O
unique - - O
functions - - O
of - - O
this - - O
virus - - O
in - - O
its - - O
obligate - - O
mutualistic - - O
association - - O
with - - O
parasitic - - O
wasps - - O
. - - O

Molecular - - O
mimicry - - O
of - - O
human - - O
cytokine - - O
and - - O
cytokine - - O
response - - O
pathway - - O
genes - - O
by - - O
KSHV - - O
. - - O

The - - O
insulin - - B-MUT
therapy - - O
regimen - - O
did - - O
not - - O
affect - - O
the - - O
evolution - - O
of - - O
the - - O
patients - - O
and - - O
no - - O
significant - - O
relationship - - O
existed - - O
between - - O
the - - O
age - - O
at - - O
diagnosis - - O
, - - O
duration - - O
of - - O
diabetes - - O
, - - O
daily - - O
insulin - - B-MUT
dosage - - O
or - - O
metabolic - - O
control - - O
and - - O
height - - O
or - - O
BMI - - O
. - - O

Cutis - - O
aplasia - - O
. - - O

As - - O
in - - O
mammals - - O
, - - O
considerable - - O
nucleotide - - O
diversity - - O
was - - O
observed - - O
at - - O
the - - O
junctions - - O
of - - O
the - - O
variable - - O
, - - O
diversity - - O
, - - O
and - - O
joining - - O
elements - - O
in - - O
chicken - - B-MUT
TCR - - I-MUT
beta - - I-MUT
cDNAs - - I-MUT
. - - O

Two - - O
alternatively - - O
spliced - - O
5' - - O
UTRs - - O
, - - O
designated - - O
type - - O
I - - O
and - - O
type - - O
II - - O
, - - O
of - - O
222 - - O
and - - O
115 - - O
bp - - O
, - - O
respectively - - O
, - - O
were - - O
found - - O
associated - - O
with - - O
PFP - - B-MUT
. - - O

Our - - O
data - - O
, - - O
combined - - O
with - - O
those - - O
of - - O
Hershey - - O
and - - O
co-workers - - O
, - - O
suggest - - O
that - - O
mammalian - - B-MUT
eIF3 - - I-MUT
is - - O
composed - - O
of - - O
at - - O
least - - O
10 - - O
subunits - - O
: - - O
p170 - - B-MUT
, - - O
p116 - - B-MUT
( - - O
hPrt1 - - B-MUT
) - - O
, - - O
p110 - - B-MUT
, - - O
p66 - - B-MUT
, - - O
p48 - - B-MUT
, - - O
p47 - - B-MUT
, - - O
p44 - - B-MUT
, - - O
p40 - - B-MUT
, - - O
p36 - - B-MUT
, - - O
and - - O
p35 - - B-MUT
. - - O

A - - O
controlled - - O
trial - - O
of - - O
recombinant - - B-MUT
human - - I-MUT
granulocyte-macrophage - - I-MUT
colony-stimulating - - I-MUT
factor - - I-MUT
after - - O
total - - O
body - - O
irradiation - - O
, - - O
high-dose - - O
chemotherapy - - O
, - - O
and - - O
autologous - - O
bone - - O
marrow - - O
transplantation - - O
for - - O
acute - - O
lymphoblastic - - O
leukemia - - O
or - - O
malignant - - O
lymphoma - - O
. - - O

The - - O
development - - O
of - - O
a - - O
data - - O
base - - O
is - - O
described - - O
which - - O
can - - O
be - - O
used - - O
as - - O
common - - O
reference - - O
for - - O
ECG - - O
computer - - O
programs - - O
analyzing - - O
12 - - O
or - - O
15 - - O
simultaneously - - O
recorded - - O
leads - - O
. - - O

However - - O
, - - O
we - - O
did - - O
detect - - O
lot-to-lot - - O
variation - - O
and - - O
differences - - O
in - - O
performance - - O
between - - O
narrow - - O
bandpass - - O
and - - O
wide - - O
bandpass - - O
spectrophotometers - - O
. - - O

The - - O
ability - - O
of - - O
sodium - - O
phenobarbital - - O
( - - O
60 - - O
mg - - O
kg - - O
) - - O
and - - O
sodium - - O
barbital - - O
( - - O
80 - - O
mg - - O
kg - - O
) - - O
to - - O
produce - - O
a - - O
taste - - O
aversion - - O
in - - O
23 - - O
hr - - O
fluid - - O
deprived - - O
rats - - O
was - - O
examined - - O
using - - O
a - - O
discrimination - - O
or - - O
two - - O
bottle - - O
taste - - O
aversion - - O
task - - O
( - - O
0 - - O
. - - O
125% - - O
sodium - - O
saccharin - - O
solution - - O
or - - O
water - - O
) - - O
. - - O

Study - - O
on - - O
the - - O
evagination - - O
of - - O
Cysticercus - - O
pisiformis - - O
. - - O

Gaucher's - - O
disease - - O
is - - O
a - - O
rare - - O
metabolic - - O
disorder - - O
characterized - - O
by - - O
the - - O
lack - - O
of - - O
beta-glucocerebrosidase - - B-MUT
enzyme - - I-MUT
. - - O

In - - O
order - - O
to - - O
infer - - O
shape - - O
from - - O
contour - - O
, - - O
the - - O
human - - O
visual - - O
system - - O
must - - O
selectively - - O
integrate - - O
fragments - - O
projecting - - O
from - - O
a - - O
common - - O
object - - O
while - - O
keeping - - O
fragments - - O
from - - O
different - - O
objects - - O
separate - - O
. - - O

Simultaneous - - O
right - - O
and - - O
left - - O
adrenal - - O
and - - O
peripheral - - O
blood - - O
samples - - O
were - - O
collected - - O
for - - O
determination - - O
of - - O
oestrone - - O
( - - O
E1 - - O
) - - O
and - - O
oestradiol - - O
( - - O
E2 - - O
) - - O
. - - O

The - - O
NIT2 - - B-MUT
protein - - I-MUT
is - - O
localised - - O
in - - O
nuclei - - O
and - - O
could - - O
not - - O
be - - O
detected - - O
in - - O
the - - O
cytoplasmic - - O
fraction - - O
of - - O
cells - - O
subjected - - O
to - - O
nitrogen - - O
derepression - - O
or - - O
nitrogen - - O
repression - - O
, - - O
indicating - - O
that - - O
the - - O
nuclear - - O
import - - O
of - - O
NIT2 - - B-MUT
is - - O
not - - O
regulated - - O
. - - O

Prostaglandins - - O
F - - O
( - - O
PGF - - O
) - - O
were - - O
measured - - O
in - - O
uterine - - O
vein - - O
, - - O
ovarian - - O
artery - - O
, - - O
and - - O
jugular - - O
vein - - O
plasma - - O
and - - O
in - - O
the - - O
endometrial - - O
tissues - - O
at - - O
various - - O
times - - O
during - - O
the - - O
bovine - - O
estrous - - O
cycle - - O
, - - O
and - - O
were - - O
compared - - O
to - - O
peripheral - - O
plasma - - O
progesterone - - O
levels - - O
. - - O

SELECTION - - O
CRITERIA - - O
: - - O
Randomised - - O
trials - - O
comparing - - O
children - - O
undergoing - - O
systematic - - O
therapy - - O
focusing - - O
on - - O
the - - O
family - - O
in - - O
conjunction - - O
with - - O
asthma - - O
medication - - O
, - - O
with - - O
children - - O
taking - - O
asthma - - O
medication - - O
only - - O
. - - O

All - - O
numbers - - O
refer - - O
to - - O
nucleotide - - O
positions - - O
on - - O
the - - O
wild-type - - O
HIV-1 - - O
transcript - - O
. - - O

Promoter - - O
analysis - - O
demonstrated - - O
that - - O
the - - O
sequence - - O
identical - - O
to - - O
consensus - - B-MUT
cAMP-responsive - - I-MUT
element - - I-MUT
( - - O
CRE - - B-MUT
) - - O
located - - O
at - - O
-481 - - O
of - - O
the - - O
SMemb - - B-MUT
promoter - - I-MUT
was - - O
critical - - O
for - - O
Hex - - B-MUT
responsiveness - - O
. - - O

PLUS-3 - - O
is - - O
a - - O
new - - O
Swedish - - O
protocol - - O
of - - O
natural - - O
speech - - O
in - - O
3-year-old - - O
children - - O
. - - O

Transfection - - O
of - - O
increasing - - O
amounts - - O
of - - O
delta5ERalpha - - B-MUT
expression - - O
vector - - O
into - - O
[ - - O
ERalpha+ - - O
] - - O
OS - - O
cells - - O
resulted - - O
in - - O
potentiation - - O
of - - O
E2-stimulated - - O
ERELuc - - B-MUT
activity - - O
in - - O
a - - O
synergistic - - O
, - - O
dose-dependent - - O
manner - - O
. - - O

Specialist - - O
in - - O
family - - O
practice--prototype - - O
of - - O
a - - O
doctor - - O
. - - O

The - - O
effect - - O
of - - O
low - - O
dosage - - O
radiation - - O
on - - O
metabolism - - O
and - - O
function - - O
of - - O
the - - O
rat - - O
kidney - - O
damaged - - O
by - - O
ischemia - - O
. - - O

By - - O
introducing - - O
a - - O
series - - O
of - - O
deletions - - O
in - - O
the - - O
vimentin - - B-MUT
promoter - - O
, - - O
we - - O
further - - O
restrict - - O
these - - O
sequences - - O
to - - O
30 - - O
base - - O
pairs - - O
, - - O
located - - O
between - - O
241 - - O
and - - O
210 - - O
base - - O
pairs - - O
upstream - - O
of - - O
the - - O
mRNA - - O
cap - - O
site - - O
. - - O

Transformation - - O
of - - O
the - - O
sconC3 - - B-MUT
mutant - - I-MUT
with - - O
sconB+ - - B-MUT
restores - - O
the - - O
wild-type - - O
phenotype - - O
. - - O

We - - O
have - - O
attempted - - O
to - - O
clone - - O
two - - O
recessive - - O
extragenic - - O
suppressors - - O
of - - O
such - - O
ts - - O
mutants - - O
( - - O
sdp1 - - O
for - - O
mutation - - B-MUT
pol3-14 - - I-MUT
and - - O
sdp5-1 - - O
for - - O
mutation - - B-MUT
pol3-11 - - I-MUT
) - - O
by - - O
transforming - - O
thermoresistant - - O
haploid - - O
strains - - O
pol3-14 - - B-MUT
sdp1 - - I-MUT
and - - O
pol3-11 - - B-MUT
sdp5-1 - - I-MUT
with - - O
wild-type - - O
genomic - - O
libraries - - O
in - - O
singlecopy - - O
or - - O
multicopy - - O
vectors - - O
. - - O

Alternative - - O
splicing - - O
of - - O
CDC25B - - B-MUT
may - - O
therefore - - O
contribute - - O
to - - O
the - - O
control - - O
of - - O
cell - - O
proliferation - - O
. - - O

After - - O
i - - O
. - - O
v - - O
. - - O
administration - - O
of - - O
500 - - O
mg - - O
acetazolamide - - O
and - - O
disinfection - - O
of - - O
the - - O
conjunctiva - - O
, - - O
50 - - O
micrograms - - O
rt-PA - - O
in - - O
0 - - O
. - - O
1 - - O
ml - - O
( - - O
BSS - - O
) - - O
and - - O
0 - - O
. - - O
5 - - O
ml - - O
SF6 - - O
were - - O
injected - - O
intravitreally - - O
. - - O

Of - - O
202 - - O
initially - - O
seronegative - - O
caretakers - - O
( - - O
observed - - O
for - - O
an - - O
average - - O
of - - O
305 - - O
days - - O
per - - O
woman - - O
) - - O
, - - O
19 - - O
seroconverted - - O
, - - O
for - - O
an - - O
annual - - O
seroconversion - - O
rate - - O
of - - O
11 - - O
percent - - O
. - - O

Enhancer - - O
and - - O
promoter - - O
elements - - O
directing - - O
activation - - O
and - - O
glucocorticoid - - O
repression - - O
of - - O
the - - O
alpha - - B-MUT
1-fetoprotein - - I-MUT
gene - - I-MUT
in - - O
hepatocytes - - O
. - - O

The - - O
terminator - - O
region - - O
supported - - O
termination - - O
of - - O
transcripts - - O
initiated - - O
by - - O
RNA - - B-MUT
polymerase - - I-MUT
I - - I-MUT
in - - O
vivo - - O
. - - O

The - - O
level - - O
of - - O
the - - O
SUP4A53T61 - - B-MUT
transcript - - I-MUT
was - - O
threefold - - O
higher - - O
in - - O
the - - O
tap1-1 - - B-MUT
mutant - - I-MUT
than - - O
in - - O
the - - O
wild - - O
type - - O
. - - O

However - - O
, - - O
for - - O
the - - O
evaluable - - O
cases - - O
, - - O
the - - O
performances - - O
of - - O
the - - O
CD3500 - - O
and - - O
the - - O
STKS - - O
were - - O
broadly - - O
similar - - O
and - - O
generally - - O
correlated - - O
well - - O
with - - O
the - - O
manual - - O
reference - - O
procedure - - O
. - - O

The - - O
application - - O
of - - O
ultrafiltration - - O
to - - O
sample - - O
preparation - - O
in - - O
the - - O
detection - - O
and - - O
quantification - - O
of - - O
ethylene - - O
glycol - - O
in - - O
plasma - - O
by - - O
gas - - O
chromatography - - O
is - - O
described - - O
. - - O

Familial - - O
juvenile - - O
nephronophthisis - - O
. - - O

A - - O
note - - O
on - - O
some - - O
consequences - - O
of - - O
UV - - O
vision - - O
in - - O
birds - - O
. - - O

Biol - - O
. - - O

The - - O
data - - O
indicates - - O
the - - O
presence - - O
of - - O
5-HT2 - - B-MUT
serotonergic - - I-MUT
receptors - - I-MUT
in - - O
the - - O
bronchial - - O
artery - - O
of - - O
these - - O
species - - O
. - - O

There - - O
are - - O
no - - O
introns - - O
within - - O
the - - O
gene - - O
, - - O
which - - O
contains - - O
a - - O
9360-bp - - O
open - - O
reading - - O
frame - - O
and - - O
encodes - - O
a - - O
377-kDa - - O
protein - - O
. - - O

At - - O
4 - - O
wk - - O
however - - O
, - - O
tumor - - O
relapse - - O
was - - O
noted - - O
in - - O
6 - - O
of - - O
7 - - O
group - - O
4 - - O
responders - - O
, - - O
10 - - O
of - - O
12 - - O
in - - O
group - - O
5 - - O
, - - O
13 - - O
of - - O
16 - - O
in - - O
group - - O
7 - - O
, - - O
but - - O
only - - O
4 - - O
of - - O
19 - - O
group - - O
8 - - O
responders - - O
( - - O
p - - O
less - - O
than - - O
. - - O
001 - - O
group - - O
8 - - O
versus - - O
4 - - O
, - - O
5 - - O
, - - O
7 - - O
) - - O
. - - O

This - - O
study - - O
shows - - O
that - - O
C - - B-MUT
EBPbeta - - I-MUT
is - - I-MUT
the - - O
predominant - - O
C - - O
EBP - - B-MUT
isoform - - I-MUT
found - - I-MUT
in - - I-MUT
activated - - O
stellate - - O
cells - - O
and - - O
that - - O
increased - - O
C - - O
EBPbeta - - O
protein - - B-MUT
and - - I-MUT
C - - I-MUT
EBPbeta - - I-MUT
binding - - O
to - - B-MUT
a - - I-MUT
proximal - - I-MUT
C - - O
EBP - - O
binding - - O
site - - O
in - - B-MUT
the - - I-MUT
promoter - - I-MUT
mediates - - I-MUT
the - - I-MUT
activating - - O
effect - - O
of - - O
acetaldehyde - - O
. - - O

The - - O
mean - - O
thickness - - O
of - - O
the - - O
visceral - - O
peritoneum - - O
was - - O
comparable - - O
in - - O
both - - O
groups - - O
of - - O
animals - - O
, - - O
but - - O
, - - O
macroscopically - - O
, - - O
more - - O
severe - - O
fibrosis - - O
was - - O
found - - O
in - - O
the - - O
peritoneum - - O
of - - O
rats - - O
exposed - - O
to - - O
CAPD - - O
3 - - O
as - - O
compared - - O
with - - O
animals - - O
treated - - O
with - - O
CAPD - - O
3 - - O
Balance - - O
( - - O
p - - O
< - - O
0 - - O
. - - O
05 - - O
) - - O
. - - O

Hence - - O
temperature - - O
and - - O
virF - - B-MUT
are - - O
both - - O
required - - O
for - - O
the - - O
induction - - O
of - - O
the - - O
yop - - B-MUT
regulon - - I-MUT
. - - O

However - - O
, - - O
it - - O
is - - O
not - - O
known - - O
whether - - O
the - - O
recently - - O
identified - - O
isoforms - - O
Vav2 - - B-MUT
and - - O
Vav3 - - B-MUT
, - - O
which - - O
are - - O
broadly - - O
expressed - - O
, - - O
can - - O
couple - - O
with - - O
similar - - O
classes - - O
of - - O
receptors - - O
, - - O
nor - - O
is - - O
it - - O
known - - O
whether - - O
all - - O
Vav - - B-MUT
isoforms - - I-MUT
possess - - O
identical - - O
functional - - O
activities - - O
. - - O

Lymphatics - - O
in - - O
the - - O
aorta - - O
of - - O
rats - - O
treated - - O
with - - O
a - - O
soy-bean - - O
oil - - O
extract - - O
( - - O
lipofundin - - O
) - - O
. - - O

Two - - O
distinct - - O
recessive - - O
susceptibility - - O
loci - - O
for - - O
vasculitis - - O
were - - O
mapped - - O
on - - O
chromosome - - O
( - - O
Chr - - O
) - - O
4 - - O
at - - O
D4Mit89 - - B-MUT
and - - O
D4Mit147 - - B-MUT
in - - O
both - - O
progenies - - O
. - - O

These - - O
cell - - O
lines - - O
, - - O
selected - - O
for - - O
the - - O
ability - - O
to - - O
support - - O
the - - O
replication - - O
of - - O
a - - O
temperature-sensitive - - O
VP5 - - B-MUT
mutant - - I-MUT
, - - O
were - - O
used - - O
to - - O
isolate - - O
VP5 - - B-MUT
and - - O
VP23 - - B-MUT
null - - O
mutants - - O
. - - O

The - - O
toxicological - - O
evaluation - - O
of - - O
chlorofluorocarbon - - O
22 - - O
( - - O
CFC - - O
22 - - O
) - - O
. - - O

Resolution - - O
of - - O
thermographic - - O
asymmetry - - O
and - - O
or - - O
decrease - - O
in - - O
Delta - - O
T - - O
was - - O
demonstrated - - O
in - - O
approximately - - O
81% - - O
of - - O
the - - O
post-treatment - - O
population - - O
. - - O

The - - O
cochlear - - O
compromise - - O
. - - O

The - - O
Cut9 - - B-MUT
subunit - - I-MUT
is - - O
likely - - O
to - - O
be - - O
a - - O
target - - O
for - - O
regulating - - O
APC - - B-MUT
cyclosome - - I-MUT
function - - I-MUT
through - - O
protein-protein - - O
interactions - - O
and - - O
phosphorylation - - O
. - - O

Bacteria - - O
can - - O
also - - O
cause - - O
a - - O
labyrinthitis - - O
acting - - O
directly - - O
on - - O
the - - O
inner - - O
ear - - O
: - - O
among - - O
these - - O
, - - O
Treponemas - - O
Pallidum - - O
, - - O
a - - O
spirochaete - - O
which - - O
causes - - O
syphilis - - O
and - - O
Borrelia - - O
Burgdorferi - - O
, - - O
a - - O
spirochaete - - O
that - - O
causes - - O
Lyme - - O
Disease - - O
, - - O
must - - O
be - - O
mentioned - - O
. - - O

We - - O
have - - O
examined - - O
the - - O
role - - O
of - - O
two - - O
recombination- - - O
and - - O
repair-defective - - O
mutations - - O
, - - O
rad1 - - B-MUT
and - - O
rad52 - - B-MUT
, - - O
on - - O
direct - - O
repeat - - O
recombination - - O
in - - O
transcriptionally - - O
active - - O
and - - O
inactive - - O
sequences - - O
. - - O

The - - O
following - - O
markers - - O
were - - O
looked - - O
for - - O
in - - O
the - - O
serum - - O
, - - O
skin - - O
and - - O
liver - - O
of - - O
all - - O
patients - - O
with - - O
chronic - - O
hepatitis - - O
: - - O
HBV - - O
( - - O
HBs - - O
Ag - - O
and - - O
HBe - - O
Ag - - O
, - - O
anti-HBs - - B-MUT
, - - O
anti-HBe - - B-MUT
and - - O
anti-HBc - - B-MUT
in - - O
the - - O
serum - - O
, - - O
HBs - - O
and - - O
HBc - - O
Ag - - O
in - - O
the - - O
liver - - O
) - - O
; - - O
non-A - - O
non-B - - O
( - - O
non-A - - O
, - - O
non-B - - O
Ag - - O
and - - O
antibody - - O
, - - O
anti - - B-MUT
non-A - - I-MUT
non-Bc - - I-MUT
in - - O
the - - O
serum - - O
, - - O
non-A - - O
, - - O
non-Bc - - O
Ag - - O
in - - O
the - - O
liver - - O
) - - O
. - - O

The - - O
harpin-encoding - - O
hrpZ - - B-MUT
gene - - I-MUT
is - - O
located - - O
in - - O
an - - O
operon - - O
that - - O
also - - O
encodes - - O
Hrp - - B-MUT
secretion - - I-MUT
pathway - - I-MUT
components - - I-MUT
and - - O
is - - O
part - - O
of - - O
the - - O
functional - - O
cluster - - O
of - - O
hrp - - B-MUT
genes - - I-MUT
carried - - O
on - - O
cosmid - - O
pHIR11 - - O
that - - O
enables - - O
saprophytic - - O
bacteria - - O
like - - O
Escherichia - - O
coli - - O
and - - O
Pseudomonas - - O
fluorescens - - O
to - - O
elicit - - O
the - - O
HR - - O
in - - O
tobacco - - O
leaves - - O
. - - O

Lactation - - O
of - - O
baboons - - O
fed - - O
a - - O
low - - O
protein - - O
maintenance - - O
diet - - O
. - - O

We - - O
present - - O
here - - O
a - - O
detailed - - O
genomic - - O
sequencing - - O
analysis - - O
of - - O
the - - O
cytosine - - O
methylation - - O
patterns - - O
of - - O
the - - O
transposase - - O
binding - - O
sites - - O
within - - O
both - - O
Ac - - B-MUT
ends - - O
in - - O
the - - O
wx-m9 - - B-MUT
: - - O
: - - O
Ac - - B-MUT
allele - - I-MUT
, - - O
where - - O
Ac - - B-MUT
is - - O
inserted - - O
into - - O
the - - O
tenth - - O
exon - - O
of - - O
the - - O
Waxy - - B-MUT
gene - - I-MUT
. - - O

During - - O
an - - O
8-wk - - O
follow-up - - O
, - - O
parasites - - O
reappeared - - O
in - - O
10 - - O
patients - - O
, - - O
5 - - O
after - - O
each - - O
drug - - O
, - - O
between - - O
1 - - O
and - - O
7 - - O
wk - - O
after - - O
treatment - - O
. - - O

Expression - - O
of - - O
herpes - - B-MUT
simplex - - I-MUT
virus - - I-MUT
type - - I-MUT
2 - - I-MUT
US3 - - I-MUT
affects - - O
the - - O
Cdc42 - - B-MUT
Rac - - O
pathway - - B-MUT
and - - O
attenuates - - O
c-Jun - - O
N-terminal - - B-MUT
kinase - - I-MUT
activation - - I-MUT
. - - O

Pure - - O
T1 - - O
and - - O
dual-T1 - - O
images - - O
were - - O
visually - - O
evaluated - - O
for - - O
image - - O
quality - - O
( - - O
IQ - - O
) - - O
on - - O
a - - O
five-point - - O
scale - - O
( - - O
0 - - O
= - - O
unacceptable - - O
to - - O
4 - - O
= - - O
excellent - - O
) - - O
. - - O

Changing - - O
and - - O
predicting - - O
doses - - O
of - - O
Cs137 - - O
irradiation - - O
. - - O

Thus - - O
, - - O
the - - O
positive - - O
effect - - O
of - - O
NS1 - - B-MUT
on - - O
the - - O
steady-state - - O
levels - - O
of - - O
P4 - - B-MUT
transcripts - - I-MUT
depends - - O
on - - O
the - - O
amplification - - O
of - - O
gene - - O
copy - - O
number - - O
and - - O
the - - O
integrity - - O
of - - O
the - - O
terminal - - O
repeats - - O
. - - O

However - - O
, - - O
the - - O
requirement - - O
of - - O
rev3 - - B-MUT
for - - O
the - - O
production - - O
of - - O
G - - O
. - - O
C-- - - O
> - - O
T - - O
. - - O
A - - O
transversions - - O
by - - O
the - - O
rad18 - - B-MUT
mutator - - I-MUT
, - - O
which - - O
induces - - O
only - - O
these - - O
substitutions - - O
, - - O
was - - O
similar - - O
to - - O
that - - O
for - - O
rad6-mediated - - O
G - - O
. - - O
C-- - - O
> - - O
T - - O
. - - O
A - - O
transversion - - O
. - - O

All - - O
clones - - O
and - - O
strains - - O
produced - - O
have - - O
been - - O
deposited - - O
in - - O
the - - O
EUROFAN - - O
genetic - - O
stock - - O
centre - - O
( - - O
EUROSCARF - - O
, - - O
Frankfurt - - O
) - - O
. - - O

METHODS - - O
: - - O
The - - O
passive - - O
and - - O
active - - O
transport - - O
of - - O
fluorescein - - O
through - - O
the - - O
BRB - - O
was - - O
quantitated - - O
by - - O
vitreous - - O
fluorometry - - O
. - - O

As - - O
a - - O
result - - O
, - - O
the - - O
subendocardial - - O
subepicardial - - O
blood - - O
flow - - O
ratio - - O
( - - O
ENDO - - O
EPI - - O
) - - O
increased - - O
from - - O
0 - - O
. - - O
44 - - O
+ - - O
- - - O
0 - - O
. - - O
09 - - O
during - - O
control - - O
stenosis - - O
to - - O
0 - - O
. - - O
85 - - O
+ - - O
- - - O
0 - - O
. - - O
13 - - O
after - - O
ITF - - O
1129 - - O
( - - O
10 - - O
micrograms - - O
kg - - O
min - - O
i - - O
. - - O
v - - O
. - - O
) - - O
and - - O
to - - O
0 - - O
. - - O
81 - - O
+ - - O
- - - O
0 - - O
. - - O
12 - - O
after - - O
NTG - - O
. - - O

The - - O
risk - - O
factors - - O
for - - O
hematuria - - O
in - - O
patients - - O
with - - O
renal - - O
hypouricemia - - O
are - - O
the - - O
elevation - - O
of - - O
urinary - - O
urate - - O
concentration - - O
and - - O
the - - O
subtypes - - O
of - - O
Post - - O
and - - O
Secretion - - O
. - - O

Results - - O
demonstrated - - O
that - - O
the - - O
presence - - O
of - - O
myofibroblasts - - O
varied - - O
considerably - - O
from - - O
case - - O
to - - O
case - - O
and - - O
was - - O
always - - O
related - - O
to - - O
smooth - - O
muscle - - O
cell - - O
dispersion - - O
, - - O
which - - O
occurred - - O
around - - O
medium-sized - - O
damaged - - O
portal - - O
vein - - O
branches - - O
. - - O

Serum - - B-MUT
insulin-like - - I-MUT
growth - - I-MUT
factor - - I-MUT
I - - I-MUT
( - - O
IGF-I - - B-MUT
) - - O
SD - - O
score - - O
increased - - O
from - - O
-2 - - O
. - - O
2 - - O
and - - O
-4 - - O
. - - O
2 - - O
in - - O
men - - O
and - - O
women - - O
, - - O
respectively - - O
, - - O
to - - O
1 - - O
. - - O
8 - - O
and - - O
-0 - - O
. - - O
9 - - O
at - - O
6 - - O
months - - O
and - - O
0 - - O
. - - O
8 - - O
and - - O
-0 - - O
. - - O
7 - - O
at - - O
12 - - O
months - - O
. - - O

The - - O
N1 - - O
and - - O
P2 - - O
were - - O
comparable - - O
in - - O
amplitude - - O
and - - O
both - - O
had - - O
prolonged - - O
refractory - - O
periods - - O
. - - O

These - - O
human - - O
IFN-beta-transformed - - O
cell - - O
populations - - O
have - - O
acquired - - O
a - - O
low - - O
, - - O
constitutive - - O
production - - O
of - - O
human - - B-MUT
IFN - - I-MUT
, - - O
while - - O
replicating - - O
at - - O
a - - O
rate - - O
similar - - O
to - - O
that - - O
of - - O
untransformed - - O
cells - - O
and - - O
of - - O
cells - - O
transformed - - O
with - - O
the - - O
control - - O
vector - - O
carrying - - O
a - - O
human - - B-MUT
IFN-beta - - I-MUT
sequence - - I-MUT
encoding - - O
an - - O
inactive - - O
, - - O
mutated - - O
protein - - O
. - - O

Thirty-five - - O
strains - - O
of - - O
Legionnaires' - - O
disease - - O
bacteria - - O
were - - O
shown - - O
to - - O
belong - - O
in - - O
four - - O
distinct - - O
serologic - - O
groups - - O
on - - O
the - - O
basis - - O
of - - O
findings - - O
obtained - - O
with - - O
direct - - O
fluorescent - - O
antibody - - O
testing - - O
. - - O

An - - O
additional - - O
advantage - - O
is - - O
that - - O
the - - O
resin - - O
can - - O
be - - O
removed - - O
and - - O
the - - O
immunoperoxidase - - O
technique - - O
carried - - O
out - - O
on - - O
thin - - O
sections - - O
. - - O

CONCLUSIONS - - O
: - - O
A - - O
50-mg - - O
daily - - O
dose - - O
of - - O
bicalutamide - - O
is - - O
sufficient - - O
when - - O
given - - O
in - - O
combination - - O
with - - O
an - - O
agent - - O
, - - O
such - - O
as - - O
a - - O
LHRH-A - - O
, - - O
that - - O
lowers - - O
serum - - O
testosterone - - O
, - - O
but - - O
higher - - O
doses - - O
of - - O
bicalutamide - - O
may - - O
be - - O
needed - - O
when - - O
the - - O
drug - - O
is - - O
given - - O
as - - O
monotherapy - - O
. - - O

The - - O
alternative - - O
exon - - O
introduces - - O
the - - O
novel - - O
carboxyl - - O
terminus - - O
and - - O
a - - O
new - - O
translation - - O
stop - - O
signal - - O
, - - O
while - - O
simultaneously - - O
converting - - O
the - - O
coding - - O
sequence - - O
for - - O
40 - - O
carboxyl-terminal - - O
residues - - O
in - - O
CeCAT - - B-MUT
alpha - - I-MUT
into - - O
3'-untranslated - - O
nucleotides - - O
. - - O

Studies - - O
on - - O
alcoholic - - O
liver - - O
injury - - O
. - - O

However - - O
, - - O
the - - O
serum - - B-MUT
TNF-a - - I-MUT
concentration - - O
decreased - - O
significantly - - O
in - - O
patients - - O
receiving - - O
pentoxifylline - - O
( - - O
basal - - O
623+ - - O
-366 - - O
pg - - O
ml - - O
; - - O
6th - - O
month - - O
562+ - - O
-358 - - O
pg - - O
ml - - O
, - - O
p - - O
< - - O
0 - - O
. - - O
01 - - O
) - - O
, - - O
but - - O
not - - O
in - - O
the - - O
control - - O
group - - O
. - - O

While - - O
no - - O
significant - - O
differences - - O
in - - O
the - - O
tensile - - O
responses - - O
or - - O
failure - - O
characteristics - - O
were - - O
noted - - O
for - - O
irradiated - - O
and - - O
nonirradiated - - O
grafts - - O
in - - O
the - - O
drip - - O
, - - O
in - - O
the - - O
bath - - O
environment - - O
the - - O
nonirradiated - - O
tissues - - O
had - - O
greater - - O
strength - - O
and - - O
modulus - - O
. - - O

Isolation - - O
of - - O
Proteus - - O
vulgaris - - O
MC-63 - - O
from - - O
carcinoma - - O
63 - - O
and - - O
its - - O
antitumor - - O
effect - - O
on - - O
Crocker - - O
sarcoma - - O
180 - - O
and - - O
Ehrlich - - O
carcinoma - - O
. - - O

Pretreatment - - O
of - - O
cells - - O
with - - O
the - - O
mitogen-activated - - B-MUT
protein-extracellular - - I-MUT
signal-regulated - - I-MUT
kinase - - I-MUT
kinase - - I-MUT
( - - O
MEK - - B-MUT
) - - O
inhibitor - - O
U0126 - - O
inhibited - - O
S6K2 - - B-MUT
activation - - O
to - - O
a - - O
greater - - O
extent - - O
than - - O
S6K1 - - B-MUT
. - - O

No - - O
symptomatic - - O
abnormality - - O
has - - O
been - - O
noted - - O
in - - O
the - - O
neonatal - - O
period - - O
except - - O
periventricular - - O
calcifications - - O
. - - O

The - - O
differences - - O
were - - O
as - - O
follows - - O
: - - O
for - - O
overall - - O
response - - O
rate - - O
p - - O
= - - O
0 - - O
. - - O
004 - - O
; - - O
power - - O
( - - O
for - - O
p - - O
= - - O
0 - - O
. - - O
05 - - O
) - - O
85% - - O
; - - O
for - - O
survival - - O
p - - O
= - - O
0 - - O
. - - O
09 - - O
; - - O
for - - O
grade - - O
IV - - O
granulocytopenia - - O
p - - O
= - - O
0 - - O
. - - O
3 - - O
; - - O
and - - O
for - - O
febrile - - O
neutropenia - - O
p - - O
= - - O
0 - - O
. - - O
61 - - O
. - - O

The - - O
N-terminal - - O
amino - - O
acid - - O
sequence - - O
of - - O
Mop - - B-MUT
has - - O
sequence - - O
homology - - O
with - - O
DNA - - O
binding - - O
proteins - - O
. - - O

A - - O
catalytic - - O
domain - - O
of - - O
eukaryotic - - B-MUT
DNA - - I-MUT
topoisomerase - - I-MUT
I - - I-MUT
. - - O

Nutritional - - O
status - - O
in - - O
adults - - O
on - - O
an - - O
alternative - - O
or - - O
traditional - - O
diet - - O
BACKGROUND - - O
: - - O
Plant - - O
food - - O
lacks - - O
vitamin - - O
B12 - - O
, - - O
vitamin - - O
D - - O
and - - O
higher - - O
n-3 - - O
polyunsaturated - - O
fatty - - O
acids - - O
. - - O

Thus - - O
, - - O
the - - O
effects - - O
of - - O
father - - O
absence - - O
under - - O
routine - - O
conditions - - O
in - - O
relatively - - O
healthy - - O
samples - - O
may - - O
exert - - O
no - - O
significant - - O
effects - - O
independent - - O
of - - O
intervening - - O
family - - O
stressors - - O
or - - O
maternal - - O
psychopathology - - O
. - - O

Common - - O
foot - - O
pathologies - - O
are - - O
heel - - O
pain - - O
, - - O
metatarsalgia - - O
, - - O
hammertoes - - O
and - - O
clawtoes - - O
, - - O
bunions - - O
, - - O
hallux - - O
rigidus - - O
, - - O
corns - - O
and - - O
calluses - - O
, - - O
nail - - O
pathologies - - O
, - - O
arthritis - - O
, - - O
and - - O
neuropathies - - O
. - - O

Using - - O
an - - O
oligomer - - O
duplex - - O
5'-A - - B-MUT
( - - I-MUT
GGGTTA - - I-MUT
) - - I-MUT
( - - I-MUT
5 - - I-MUT
) - - I-MUT
-3' - - I-MUT
5'- - - I-MUT
( - - I-MUT
TAACCC - - I-MUT
) - - I-MUT
( - - I-MUT
5 - - I-MUT
) - - I-MUT
T-3' - - I-MUT
as - - I-MUT
a - - O
template-primer - - O
, - - O
we - - O
show - - O
that - - O
both - - O
the - - O
Klenow - - O
fragment - - B-MUT
of - - I-MUT
Escherichia - - I-MUT
coli - - I-MUT
DNA - - I-MUT
polymerase - - I-MUT
I - - I-MUT
and - - I-MUT
HIV - - O
reverse - - B-MUT
transcriptase - - I-MUT
could - - I-MUT
expand - - O
telomere - - O
DNA - - O
sequences - - O
as - - O
well - - O
, - - O
giving - - O
products - - O
greater - - O
than - - O
the - - O
size - - O
of - - O
the - - O
template - - O
DNA - - O
. - - O

VIII - - O
in - - O
doses - - O
2-3 - - O
times - - O
higher - - O
than - - O
usually - - O
used - - O
in - - O
haemophiliacs - - O
without - - O
inhibitor - - O
were - - O
successful - - O
. - - O

Endotoxemia - - O
induced - - O
by - - O
gram-negative - - O
bacteria - - O
leads - - O
to - - O
endotoxic - - O
shock - - O
pathogenetically - - O
stemming - - O
from - - O
the - - O
integral - - O
component - - O
of - - O
the - - O
bacterial - - O
wall--lipid - - O
A - - O
. - - O

Constitutive - - O
phosphorylation - - O
of - - O
the - - O
CD30v - - B-MUT
protein - - I-MUT
was - - O
demonstrated - - O
by - - O
in - - O
vitro - - O
labeling - - O
with - - O
[ - - O
32P - - O
] - - O
. - - O

Baseline - - O
BMD - - O
values - - O
were - - O
significantly - - O
lower - - O
in - - O
the - - O
oligo-amenorrheic - - O
group - - O
than - - O
in - - O
the - - O
two - - O
others - - O
at - - O
the - - O
level - - O
of - - O
lumbar - - O
spine - - O
( - - O
anteroposterior - - O
view - - O
: - - O
0 - - O
. - - O
941+ - - O
-0 - - O
. - - O
039 - - O
in - - O
oligo-amenorrheic - - O
vs - - O
1 - - O
. - - O
077+ - - O
-0 - - O
. - - O
029 - - O
or - - O
1 - - O
. - - O
051 - - O
+ - - O
-0 - - O
. - - O
017 - - O
g - - O
x - - O
cm - - O
( - - O
-2 - - O
) - - O
, - - O
P - - O
< - - O
0 - - O
. - - O
005 - - O
, - - O
in - - O
the - - O
eumenorrheic - - O
and - - O
contraceptive - - O
user - - O
groups - - O
, - - O
respectively - - O
) - - O
but - - O
not - - O
in - - O
weight-bearing - - O
bone - - O
such - - O
as - - O
proximal - - O
and - - O
midshaft - - O
femur - - O
. - - O

Antithrombin - - B-MUT
III - - I-MUT
( - - O
AT - - B-MUT
III - - I-MUT
) - - O
is - - O
a - - O
plasma - - O
protein - - O
which - - O
acts - - O
as - - O
the - - O
principal - - O
inhibitor - - O
of - - O
thrombin - - B-MUT
and - - O
is - - O
a - - O
major - - O
modulator - - O
of - - O
intravascular - - O
coagulation - - O
. - - O

The - - O
effects - - O
of - - O
cardioselective - - O
beta-1 - - O
adrenergic - - O
agonist - - O
, - - O
1- - - O
( - - O
4-hydroxyphenoxy - - O
) - - O
-isopropylamino-2-propanol - - O
) - - O
, - - O
i - - O
. - - O
e - - O
. - - O
, - - O
prenalterol - - O
, - - O
were - - O
examined - - O
on - - O
direct - - O
and - - O
continuous - - O
measurements - - O
of - - O
left - - O
ventricular - - O
( - - O
LV - - O
) - - O
pressure - - O
, - - O
diameter - - O
, - - O
dP - - O
dt - - O
, - - O
velocity - - O
of - - O
shortening - - O
, - - O
arterial - - O
pressure - - O
, - - O
iliac - - O
blood - - O
flow - - O
and - - O
heart - - O
rate - - O
in - - O
10 - - O
conscious - - O
dogs - - O
. - - O

These - - O
defects - - O
no - - O
doubt - - O
impair - - O
the - - O
folding - - O
and - - O
configuration - - O
necessary - - O
for - - O
normal - - O
processing - - O
of - - O
the - - O
AVP - - B-MUT
gene - - I-MUT
precursor - - I-MUT
. - - O

The - - O
results - - O
presented - - O
here - - O
show - - O
that - - O
AR1 - - B-MUT
of - - O
the - - O
promoter-proximal - - O
CAP - - B-MUT
subunit - - I-MUT
was - - O
required - - O
for - - O
papBA - - B-MUT
transcription - - O
even - - O
in - - O
the - - O
absence - - O
of - - O
the - - O
histone-like - - B-MUT
protein - - I-MUT
H-NS - - B-MUT
. - - O

In - - O
Ka13 - - O
cells - - O
, - - O
CoCl - - O
( - - O
2 - - O
) - - O
stimulated - - O
expression - - O
of - - O
a - - O
luciferase - - B-MUT
reporter - - I-MUT
gene - - I-MUT
under - - O
the - - O
control - - O
of - - O
a - - O
15-kilobase - - B-MUT
pair - - I-MUT
mouse - - I-MUT
ho-1 - - I-MUT
promoter - - I-MUT
( - - O
pHO15luc - - B-MUT
) - - O
. - - O

Hybridization - - O
data - - O
indicate - - O
that - - O
6F6 - - B-MUT
. - - I-MUT
2 - - I-MUT
corresponds - - O
to - - O
the - - O
previously - - O
characterized - - O
m6F6 - - B-MUT
cDNA - - I-MUT
clone - - I-MUT
and - - O
that - - O
6F6 - - B-MUT
. - - I-MUT
1 - - I-MUT
and - - O
6F6 - - B-MUT
. - - I-MUT
3 - - I-MUT
, - - O
but - - O
not - - O
6F6 - - B-MUT
. - - I-MUT
2 - - I-MUT
, - - O
are - - O
adjacent - - O
to - - O
alpha-type - - B-MUT
genes - - I-MUT
. - - O

Neither - - O
ethanol - - O
nor - - O
estrogen - - O
has - - O
been - - O
shown - - O
to - - O
cause - - O
UROD-deficiency - - O
in - - O
animals - - O
. - - O

The - - O
test - - O
was - - O
not - - O
performed - - O
in - - O
3923 - - O
patients - - O
because - - O
of - - O
contraindications - - O
. - - O

The - - O
viral - - B-MUT
oncoprotein - - I-MUT
E1A - - I-MUT
inhibits - - O
NFAT-dependent - - O
transactivation - - O
in - - O
a - - O
p300-dependent - - O
manner - - O
. - - O

EEG - - O
theta - - O
waves - - O
and - - O
psychological - - O
phenomena - - O
: - - O
a - - O
review - - O
and - - O
analysis - - O
. - - O

Correlation - - O
between - - O
intraocular - - O
involvement - - O
and - - O
systemic - - O
outcome - - O
was - - O
poor - - O
. - - O

Health - - O
: - - O
an - - O
integrative - - O
reticulum - - O
. - - O

Genomic - - O
DNA - - O
clones - - O
containing - - O
the - - O
T-cell-specific - - B-MUT
human - - I-MUT
MAL - - I-MUT
gene - - I-MUT
were - - O
isolated - - O
. - - O

Hematopoietic - - B-MUT
growth - - I-MUT
factors - - I-MUT
have - - O
already - - O
had - - O
an - - O
enormous - - O
impact - - O
on - - O
transfusion - - O
practice - - O
by - - O
eliminating - - O
or - - O
reducing - - O
the - - O
need - - O
for - - O
red - - O
blood - - O
cell - - O
transfusions - - O
in - - O
a - - O
variety - - O
of - - O
anemic - - O
states - - O
characterized - - O
by - - O
an - - O
absolute - - O
or - - O
relative - - O
decrease - - O
in - - O
erythropoietin - - B-MUT
. - - O

Increased - - O
blood - - O
pressure - - O
during - - O
CyA - - O
treatment - - O
was - - O
independent - - O
of - - O
circulating - - O
ET-1 - - B-MUT
levels - - O
. - - O

An - - O
NF1-related - - B-MUT
vitellogenin - - I-MUT
activator - - I-MUT
element - - I-MUT
mediates - - O
transcription - - O
from - - O
the - - O
estrogen-regulated - - O
Xenopus - - B-MUT
laevis - - I-MUT
vitellogenin - - I-MUT
promoter - - I-MUT
. - - O

Engagement - - O
of - - O
human - - B-MUT
CD2 - - I-MUT
by - - O
mitogenic - - O
pairs - - O
of - - O
anti-CD2 - - B-MUT
mAb - - I-MUT
induces - - O
tyrosine - - O
phosphorylation - - O
of - - O
a - - O
number - - O
of - - O
intracellular - - O
proteins - - O
including - - O
a - - O
120 - - O
kDa - - O
phosphoprotein - - O
that - - O
we - - O
identify - - O
as - - O
the - - O
proto-oncogene - - B-MUT
c-Cbl - - I-MUT
. - - O

As - - O
an - - O
extension - - O
of - - O
our - - O
structural - - O
characterization - - O
of - - O
the - - O
exon-intron - - O
organization - - O
of - - O
the - - O
mouse - - B-MUT
Pkr - - I-MUT
gene - - I-MUT
, - - O
we - - O
now - - O
have - - O
isolated - - O
and - - O
characterized - - O
the - - O
mouse - - B-MUT
Pkr - - I-MUT
promoter - - I-MUT
region - - I-MUT
required - - O
for - - O
IFN-inducible - - O
transcription - - O
. - - O

Therefore - - O
the - - O
binding - - O
sites - - O
for - - O
liver-enriched - - O
factors - - O
, - - O
present - - O
in - - O
the - - O
hamster - - B-MUT
CYP7A1 - - I-MUT
proximal - - I-MUT
promoter - - I-MUT
in - - O
close - - O
vicinity - - O
and - - O
conserved - - O
between - - O
species - - O
, - - O
constitute - - O
a - - O
regulatory - - O
unit - - O
important - - O
for - - O
basal - - O
hepatic - - O
expression - - O
and - - O
tissue - - O
restriction - - O
of - - O
the - - O
action - - O
of - - O
hormones - - O
such - - O
as - - O
insulin - - B-MUT
. - - O

I - - O
. - - O

Although - - O
antisperm - - B-MUT
antibodies - - I-MUT
are - - O
associated - - O
with - - O
infertility - - O
, - - O
many - - O
hospital - - O
laboratories - - O
do - - O
not - - O
test - - O
for - - O
these - - O
antibodies - - O
. - - O

We - - O
demonstrated - - O
that - - O
, - - O
under - - O
serum-starved - - O
conditions - - O
, - - O
KMS-11 - - O
and - - O
OPM-2 - - O
cells - - O
express - - O
appreciable - - O
levels - - O
of - - O
phosphorylated - - O
FGFR3 - - B-MUT
mutants - - I-MUT
indicating - - O
a - - O
constitutive - - O
activation - - O
of - - O
the - - O
Y373C - - B-MUT
and - - O
K650E - - B-MUT
receptors - - I-MUT
; - - O
the - - O
addition - - O
of - - O
the - - O
aFGF - - B-MUT
ligand - - I-MUT
further - - O
increased - - O
the - - O
level - - O
of - - O
receptor - - O
phosphorylation - - O
. - - O

Is - - O
desensitization' - - O
for - - O
ragweed - - O
hay - - O
fever - - O
immunologically - - O
specific - - O
? - - O

Here - - O
we - - O
show - - O
that - - O
calpeptin - - B-MUT
inhibits - - O
tyrosine - - B-MUT
phosphatases - - I-MUT
, - - O
enhancing - - O
tyrosine - - O
phosphorylation - - O
particularly - - O
of - - O
paxillin - - B-MUT
. - - O

We - - O
show - - O
here - - O
that - - O
the - - O
LIM - - B-MUT
domain - - I-MUT
homeobox - - B-MUT
protein - - I-MUT
isl-1 - - B-MUT
activates - - O
the - - O
rat - - B-MUT
amylin - - I-MUT
promoter - - I-MUT
in - - O
both - - O
fibroblast - - O
and - - O
islet - - O
cell - - O
lines - - O
. - - O

The - - O
ability - - O
of - - O
spt2 - - B-MUT
mutations - - I-MUT
to - - O
suppress - - O
the - - O
transcriptional - - O
interference - - O
caused - - O
by - - O
the - - O
delta - - B-MUT
promoter - - I-MUT
insertion - - I-MUT
his-4-912 - - I-MUT
delta - - I-MUT
correlates - - O
with - - O
an - - O
increase - - O
in - - O
wild-type - - B-MUT
HIS4 - - I-MUT
mRNA - - I-MUT
levels - - O
. - - O

The - - O
Pro-258-- - - O
> - - O
Leu - - O
( - - O
P258L - - O
) - - O
mutation - - O
caused - - O
constitutive - - O
receptor - - O
signaling - - O
that - - O
was - - O
equivalent - - O
to - - O
about - - O
45% - - O
of - - O
the - - O
maximum - - O
level - - O
observed - - O
in - - O
wild-type - - O
cells - - O
stimulated - - O
with - - O
alpha-factor - - B-MUT
. - - O

The - - O
proportion - - O
of - - O
the - - O
biopsies - - O
found - - O
to - - O
be - - O
seropositive - - O
for - - O
HBs - - O
antigen - - O
was - - O
27 - - O
. - - O
9% - - O
, - - O
and - - O
these - - O
showed - - O
either - - O
MGN - - O
or - - O
MPGN - - O
pattern - - O
. - - O

A - - O
sterol-regulated - - B-MUT
protease - - I-MUT
initiates - - O
release - - O
of - - O
the - - O
NH2-terminal - - O
segments - - O
of - - O
sterol - - B-MUT
regulatory - - I-MUT
element-binding - - I-MUT
proteins - - I-MUT
( - - O
SREBPs - - B-MUT
) - - O
from - - O
cell - - O
membranes - - O
, - - O
thereby - - O
allowing - - O
them - - O
to - - O
enter - - O
the - - O
nucleus - - O
and - - O
to - - O
stimulate - - O
transcription - - O
of - - O
genes - - O
involved - - O
in - - O
the - - O
uptake - - O
and - - O
synthesis - - O
of - - O
cholesterol - - O
and - - O
fatty - - O
acids - - O
. - - O

Initial - - O
experience - - O
with - - O
a - - O
microprocessor - - O
controlled - - O
current - - O
based - - O
defibrillator - - O
. - - O

The - - O
following - - O
technique - - O
describes - - O
a - - O
modification - - O
to - - O
a - - O
bar - - O
superstructure - - O
that - - O
provided - - O
the - - O
advantages - - O
of - - O
convenience - - O
, - - O
security - - O
, - - O
and - - O
consistent - - O
positioning - - O
even - - O
though - - O
one - - O
implant - - O
was - - O
lost - - O
and - - O
the - - O
angulation - - O
of - - O
implants - - O
limited - - O
accuracy - - O
. - - O

Cell - - O
survival - - O
by - - O
Epo - - B-MUT
did - - O
not - - O
require - - O
activation - - O
of - - O
other - - O
known - - O
signaling - - O
pathways - - O
including - - O
PI-3 - - B-MUT
kinase - - I-MUT
, - - O
PLC-gamma - - B-MUT
, - - O
Ras - - B-MUT
or - - O
Stats - - B-MUT
. - - O

Phase - - O
II - - O
study - - O
of - - O
paclitaxel - - O
and - - O
oral - - O
etoposide - - O
in - - O
patients - - O
with - - O
locally - - O
advanced - - O
or - - O
metastatic - - O
non-small - - O
cell - - O
lung - - O
cancer - - O
. - - O

After - - O
termination - - O
of - - O
medication - - O
the - - O
animals - - O
were - - O
kindled - - O
electrically - - O
in - - O
the - - O
nucleus - - O
amygdala - - O
. - - O

Account - - O
was - - O
taken - - O
of - - O
noncellular - - O
and - - O
nonhuman - - O
elements - - O
in - - O
the - - O
smears - - O
; - - O
they - - O
included - - O
mucus - - O
, - - O
Charcot-Layden - - O
crystals - - O
, - - O
pollen - - O
grains - - O
, - - O
vegetal - - O
fragments - - O
and - - O
fungi - - O
. - - O

We - - O
have - - O
now - - O
identified - - O
, - - O
after - - O
21 - - O
serial - - O
undiluted - - O
passages - - O
of - - O
MHV - - O
, - - O
a - - O
small - - B-MUT
DI - - I-MUT
RNA - - I-MUT
, - - O
DIssF - - B-MUT
, - - O
which - - O
is - - O
efficiently - - O
packaged - - O
into - - O
virions - - O
. - - O

No - - O
homology - - O
was - - O
found - - O
between - - O
RNA14 - - B-MUT
and - - O
RNA15 - - B-MUT
or - - O
between - - O
RNA14 - - B-MUT
and - - O
other - - O
proteins - - O
contained - - O
in - - O
data - - O
banks - - O
. - - O

Physical - - O
principles - - O
in - - O
therapeutic - - O
apheresis - - O
. - - O

E2F - - B-MUT
is - - O
a - - O
heterodimeric - - O
complex - - O
consisting - - O
of - - O
E2F - - B-MUT
family - - I-MUT
members - - I-MUT
( - - I-MUT
1-5 - - I-MUT
) - - I-MUT
and - - O
DP - - B-MUT
proteins - - I-MUT
( - - I-MUT
1-3 - - I-MUT
) - - I-MUT
. - - O

We - - O
screened - - O
a - - O
K562 - - O
cDNA - - O
library - - O
and - - O
identified - - O
novel - - O
transcripts - - O
, - - O
MZF1B - - B-MUT
and - - O
MZF1C - - B-MUT
. - - O

Ischemic - - O
stroke - - O
due - - O
to - - O
protein - - B-MUT
C - - I-MUT
deficiency - - O
. - - O

CONCLUSIONS - - O
: - - O
Our - - O
findings - - O
suggest - - O
that - - O
pre-treatment - - O
with - - O
coenzyme - - O
Q10 - - O
may - - O
play - - O
a - - O
protective - - O
role - - O
during - - O
routine - - O
vascular - - O
procedures - - O
requiring - - O
abdominal - - O
aortic - - O
cross - - O
clamping - - O
by - - O
attenuating - - O
the - - O
degree - - O
of - - O
peroxidative - - O
damage - - O
. - - O

The - - O
kinase - - B-MUT
is - - O
essential - - O
in - - O
vivo - - O
for - - O
normal - - O
phosphorylation - - O
of - - O
the - - O
CTD - - O
and - - O
for - - O
normal - - O
growth - - O
and - - O
differentiation - - O
. - - O

The - - O
hit1-1 - - B-MUT
mutation - - O
caused - - O
a - - O
defect - - O
in - - O
synthesis - - O
of - - O
a - - O
74-kD - - B-MUT
heat - - I-MUT
shock - - I-MUT
protein - - I-MUT
. - - O

A - - O
new - - O
DNA - - B-MUT
repair - - I-MUT
gene - - I-MUT
from - - I-MUT
Schizosaccharomyces - - I-MUT
pombe - - I-MUT
with - - O
homology - - O
to - - O
RecA - - B-MUT
was - - O
identified - - O
and - - O
characterized - - O
. - - O

Recombinant - - O
, - - O
bacterially - - O
expressed - - O
PIP5KIalpha - - B-MUT
possessed - - O
PIP5K - - B-MUT
activity - - O
and - - O
was - - O
immunoreactive - - O
with - - O
erythroid - - B-MUT
PIP5KI - - I-MUT
antibodies - - I-MUT
. - - O

After - - O
transfection - - O
, - - O
specific - - O
TSH - - B-MUT
beta - - I-MUT
promoter - - I-MUT
activity - - O
was - - O
evident - - O
in - - O
both - - O
TRH-responsive - - O
pituitary-derived - - O
GH3 - - O
and - - O
primary - - O
pituitary - - O
cell - - O
cultures - - O
. - - O

The - - O
results - - O
show - - O
that - - O
ROS - - O
production - - O
by - - O
viable - - O
spermatozoa - - O
is - - O
highly - - O
correlated - - O
with - - O
the - - O
concentration - - O
of - - O
PMN - - B-MUT
elastase - - I-MUT
and - - O
the - - O
number - - O
of - - O
both - - O
peroxidase-positive - - O
and - - O
round - - O
cells - - O
. - - O

Recombinant - - O
unr - - B-MUT
acts - - O
synergistically - - O
with - - O
recombinant - - O
PTB - - B-MUT
to - - O
stimulate - - O
translation - - O
dependent - - O
on - - O
the - - O
rhinovirus - - O
IRES - - O
. - - O

GATA-1 - - B-MUT
mRNA - - I-MUT
was - - O
present - - O
in - - O
equivalent - - O
levels - - O
in - - O
both - - O
erythroid - - O
cell - - O
lines - - O
, - - O
but - - O
at - - O
a - - O
low - - O
level - - O
in - - O
FDC-P1 - - O
cells - - O
. - - O

DNA - - O
sequence - - O
and - - O
evolution - - O
of - - O
the - - O
CPS - - B-MUT
domain - - I-MUT
of - - O
the - - O
Syrian - - B-MUT
hamster - - I-MUT
multifunctional - - I-MUT
protein - - I-MUT
CAD - - I-MUT
. - - O

The - - O
short-term - - O
synthesis - - O
and - - O
infant-regulated - - O
removal - - O
of - - O
milk - - O
in - - O
lactating - - O
women - - O
. - - O

Together - - O
, - - O
these - - O
data - - O
support - - O
a - - O
model - - O
in - - O
which - - O
Tax - - B-MUT
anchors - - O
CBP - - B-MUT
to - - O
the - - O
HTLV-1 - - B-MUT
promoter - - I-MUT
, - - O
with - - O
strong - - O
transcriptional - - O
activation - - O
resulting - - O
from - - O
the - - O
CBP-associated - - O
activities - - O
of - - O
nucleosome - - O
remodeling - - O
and - - O
recruitment - - O
of - - O
the - - O
general - - O
transcription - - O
machinery - - O
. - - O

ORF - - B-MUT
E8 - - I-MUT
colinear - - O
with - - O
ORF - - B-MUT
E6 - - I-MUT
, - - O
which - - O
could - - O
generate - - O
a - - O
50-amino-acid - - O
protein - - O
with - - O
a - - O
hydrophobic - - O
segment - - O
, - - O
did - - O
not - - O
transform - - O
cells - - O
when - - O
cloned - - O
into - - O
the - - O
pZipNeo - - O
vector - - O
. - - O

Rep-Rep - - B-MUT
protein - - I-MUT
interaction - - O
was - - O
confirmed - - O
in - - O
vitro - - O
through - - O
coimmunoprecipitation - - O
experiments - - O
with - - O
a - - O
bacterially - - O
expressed - - O
maltose-binding - - B-MUT
protein-Rep78 - - I-MUT
fusion - - I-MUT
protein - - I-MUT
in - - O
combination - - O
with - - O
[ - - O
35S - - O
] - - O
methionine-labeled - - O
Rep78 - - B-MUT
synthesized - - O
in - - O
a - - O
coupled - - O
in - - O
vitro - - O
transcription-translation - - O
system - - O
. - - O

The - - O
repression - - O
domain - - O
, - - O
and - - O
indeed - - O
the - - O
entire - - O
Cdc68 - - B-MUT
protein - - I-MUT
, - - O
is - - O
highly - - O
conserved - - O
, - - O
as - - O
shown - - O
by - - O
the - - O
sequence - - O
of - - O
the - - O
Cdc68 - - B-MUT
functional - - I-MUT
homolog - - I-MUT
from - - O
the - - O
yeast - - O
Kluyveromyces - - O
lactis - - O
and - - O
by - - O
database - - O
searches - - O
. - - O

These - - O
findings - - O
suggest - - O
that - - O
the - - O
adapter - - O
Gab1 - - B-MUT
may - - O
redirect - - O
c-Met - - B-MUT
signaling - - O
through - - O
PI3K - - B-MUT
away - - O
from - - O
a - - O
c-Akt - - B-MUT
Pak1 - - I-MUT
cell - - I-MUT
survival - - O
pathway - - O
. - - O

( - - O
2 - - O
) - - O
Erythroid - - O
32D - - O
Epo1 - - B-MUT
cells - - O
showed - - O
a - - O
lower - - O
level - - O
of - - O
bulk - - O
PKC - - B-MUT
catalytic - - O
activity - - O
, - - O
lacked - - O
the - - O
expression - - O
of - - O
epsilon - - B-MUT
and - - O
eta - - B-MUT
PKC - - I-MUT
isoforms - - I-MUT
, - - O
and - - O
showed - - O
a - - O
weak - - O
or - - O
absent - - O
upregulation - - O
of - - O
the - - O
remaining - - O
isoforms - - O
, - - O
except - - O
betaI - - B-MUT
, - - O
upon - - O
readdition - - O
of - - O
Epo - - B-MUT
to - - O
growth - - O
factor-starved - - O
cells - - O
. - - O

Downstream - - O
of - - O
the - - O
G-A - - O
anastomosis - - O
, - - O
the - - O
RD - - O
, - - O
CC - - O
, - - O
E - - O
( - - O
p - - O
) - - O
and - - O
loop - - O
areas - - O
were - - O
significantly - - O
different - - O
from - - O
REF - - O
, - - O
but - - O
significantly - - O
different - - O
from - - O
A-A - - O
. - - O

Secretion - - O
in - - O
milk - - O
and - - O
transplacental - - O
transfer - - O
of - - O
two - - O
iodized - - O
oils - - O
, - - O
Lipiodol - - O
UF - - O
and - - O
Oriodol - - O
, - - O
in - - O
rabbits - - O
. - - O

Catecholamines - - O
and - - O
aversive - - O
learning - - O
: - - O
a - - O
review - - O
. - - O

S6K2 - - B-MUT
is - - O
highly - - O
homologous - - O
to - - O
S6K1 - - B-MUT
in - - O
the - - O
core - - B-MUT
kinase - - I-MUT
and - - O
linker - - O
regulatory - - O
domains - - O
but - - O
differs - - O
from - - O
S6K1 - - B-MUT
in - - O
the - - O
N- - - O
and - - O
C-terminal - - O
regions - - O
and - - O
is - - O
differently - - O
localized - - O
primarily - - O
to - - O
the - - O
nucleus - - O
because - - O
of - - O
a - - O
C-terminal - - O
nuclear - - O
localization - - O
signal - - O
unique - - O
to - - O
S6K2 - - B-MUT
. - - O

LMP2A - - B-MUT
enhances - - O
Lyn - - B-MUT
and - - O
Syk - - B-MUT
ubiquitination - - O
in - - O
vivo - - O
in - - O
a - - O
fashion - - O
that - - O
depends - - O
on - - O
the - - O
activity - - O
of - - O
Nedd4 - - B-MUT
family - - O
members - - O
and - - O
correlates - - O
with - - O
destabilization - - O
of - - O
the - - O
Lyn - - B-MUT
tyrosine - - I-MUT
kinase - - I-MUT
. - - O

Amyloid - - B-MUT
beta-protein - - I-MUT
( - - O
Abeta - - B-MUT
) - - O
is - - O
the - - O
main - - O
constituent - - O
of - - O
amyloid - - O
fibrils - - O
found - - O
in - - O
senile - - O
plaques - - O
and - - O
cerebral - - O
vessels - - O
in - - O
Alzheimer's - - O
disease - - O
( - - O
AD - - O
) - - O
and - - O
is - - O
derived - - O
by - - O
proteolysis - - O
from - - O
the - - O
beta-amyloid - - B-MUT
precursor - - I-MUT
protein - - I-MUT
( - - O
APP - - B-MUT
) - - O
. - - O

Drug - - O
interactions - - O
have - - O
been - - O
found - - O
with - - O
drugs - - O
that - - O
compete - - O
for - - O
the - - O
same - - O
CYP450 - - B-MUT
isoenzymes - - I-MUT
as - - O
statins - - B-MUT
. - - O

The - - O
Clb5 - - B-MUT
kinase - - I-MUT
, - - O
which - - O
promotes - - O
S - - O
phase - - O
, - - O
remains - - O
active - - O
during - - O
the - - O
G2-phase - - O
arrest - - O
of - - O
cells - - O
of - - O
the - - O
parental - - O
strain - - O
, - - O
but - - O
its - - O
activity - - O
declines - - O
rapidly - - O
in - - O
sim - - B-MUT
mutants - - I-MUT
. - - O

The - - O
mean - - O
marginal - - O
discrepancy - - O
of - - O
provisional - - O
restorations - - O
was - - O
compared - - O
for - - O
restorations - - O
fabricated - - O
from - - O
stone - - O
, - - O
low-viscosity - - O
poly - - O
( - - O
vinyl - - O
siloxane - - O
) - - O
, - - O
and - - O
medium-viscosity - - O
poly - - O
( - - O
vinyl - - O
siloxane - - O
) - - O
. - - O

A - - O
site-directed - - O
R618K - - B-MUT
mutation - - I-MUT
in - - O
the - - O
Stat5 - - B-MUT
SH2 - - B-MUT
domain - - I-MUT
abolished - - O
the - - O
phosphorylation - - O
by - - O
Jak2 - - B-MUT
, - - O
while - - O
deletion - - O
of - - O
the - - O
C - - O
terminus - - O
led - - O
to - - O
Stat5 - - B-MUT
hyperphosphorylation - - O
. - - O

Another - - O
putative - - O
HNF3 - - B-MUT
site - - I-MUT
in - - O
close - - O
apposition - - O
to - - O
a - - O
NF1 - - B-MUT
CTF - - I-MUT
site - - I-MUT
was - - I-MUT
localized - - O
upstream - - O
of - - O
the - - O
silencer-like - - O
element - - B-MUT
. - - I-MUT

In - - O
patients - - O
with - - O
complete - - O
or - - O
partial - - O
remission - - O
of - - O
the - - O
tumor - - O
, - - O
the - - O
neopterine - - O
excretion - - O
dropped - - O
to - - O
normal - - O
values - - O
. - - O

The - - O
child - - O
left - - O
behind - - O
. - - O

With - - O
respect - - O
to - - O
the - - O
distribution - - O
of - - O
active - - O
MREs - - B-MUT
over - - O
the - - O
promoter - - O
region - - O
, - - O
the - - O
hMT-IIA - - B-MUT
gene - - I-MUT
is - - O
largely - - O
different - - O
from - - O
the - - O
mouse - - O
metallothionein-I - - B-MUT
gene - - I-MUT
, - - O
suggesting - - O
that - - O
MRE - - B-MUT
arrangement - - O
is - - O
not - - O
an - - O
important - - O
factor - - O
for - - O
metal - - O
regulation - - O
. - - O

Electrocardiograms - - O
of - - O
the - - O
month - - O
. - - O

Symposium - - O
on - - O
presenile - - O
spongy - - O
encephalopathies - - O
. - - O

The - - O
hIGF-I - - B-MUT
gene - - I-MUT
has - - O
two - - O
promoters - - O
, - - O
P1 - - O
and - - O
P2 - - O
. - - O

In - - O
this - - O
animal - - O
, - - O
infected - - O
with - - O
what - - O
was - - O
judged - - O
previously - - O
to - - O
be - - O
the - - O
less - - O
virulent - - O
of - - O
the - - O
two - - O
T - - O
. - - O
cruzi - - O
stocks - - O
used - - O
( - - O
'strain - - O
7' - - O
) - - O
, - - O
there - - O
was - - O
severe - - O
myocarditis - - O
, - - O
with - - O
myofibre - - O
degeneration - - O
, - - O
and - - O
lesions - - O
of - - O
the - - O
oesophagus - - O
. - - O

Five - - O
families - - O
of - - O
Ashkenazi - - O
Jewish - - O
descent - - O
carried - - O
the - - O
185delAG - - O
mutation - - O
and - - O
shared - - O
the - - O
same - - O
haplotype - - O
at - - O
eight - - O
polymorphic - - O
markers - - O
spanning - - O
approximately - - O
850 - - O
kb - - O
at - - O
BRCA1 - - B-MUT
. - - O

3 - - O
) - - O
and - - O
one - - O
distal - - O
( - - O
-11 - - O
. - - O
8 - - O
-10 - - O
. - - O
9 - - O
) - - O
, - - O
presented - - O
an - - O
enhancer - - O
activity - - O
in - - O
pituitary - - O
cells - - O
when - - O
placed - - O
upstream - - O
of - - O
the - - O
SV40 - - O
promoter - - O
. - - O

RESULTS - - O
: - - O
There - - O
is - - O
a - - O
considerable - - O
amount - - O
of - - O
variation - - O
between - - O
the - - O
results - - O
of - - O
TRA1 - - O
and - - O
TRA2 - - O
and - - O
between - - O
the - - O
results - - O
of - - O
both - - O
TRA's - - O
and - - O
the - - O
door-to-door - - O
survey - - O
. - - O

Clinical - - O
use - - O
of - - O
absorbable - - O
polyglycolic - - O
acid - - O
suture - - O
in - - O
Blalock-Taussig's - - O
operation - - O
. - - O

The - - O
standard - - O
dosage - - O
of - - O
anti-D - - B-MUT
currently - - O
given - - O
at - - O
all - - O
gestational - - O
ages - - O
is - - O
1 - - O
ampoule - - O
containing - - O
125 - - O
micrograms - - O
of - - O
anti-D - - B-MUT
. - - O

3'-Methyl - - O
, - - O
8-methyl - - O
, - - O
and - - O
8-phenyl - - O
derivatives - - O
of - - O
5 - - O
, - - O
9-dimethyl-6 - - O
, - - O
7-benzomorphans - - O
. - - O

Mean - - O
ROI-A - - O
B - - O
ratio - - O
was - - O
49 - - O
. - - O
6 - - O
+ - - O
- - - O
1 - - O
. - - O
7% - - O
in - - O
the - - O
diabetic - - O
group - - O
, - - O
significantly - - O
lower - - O
than - - O
the - - O
57 - - O
. - - O
9 - - O
+ - - O
- - - O
1 - - O
. - - O
6% - - O
at - - O
the - - O
nondiabetic - - O
group - - O
( - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
005 - - O
) - - O
. - - O

Recovery - - O
of - - O
carbimazole-induced - - O
agranulocytosis - - O
following - - O
recombinant - - B-MUT
granulocyte-macrophage - - I-MUT
colony - - I-MUT
stimulating - - I-MUT
factor - - I-MUT
( - - O
rhGM-CSF - - B-MUT
) - - O
administration - - O
. - - O

This - - O
locus - - O
maps - - O
approximately - - O
160 - - O
kbp - - O
from - - O
the - - O
genes - - O
encoding - - O
cytadherence-associated - - O
proteins - - O
HMW1 - - B-MUT
and - - O
HMW3 - - B-MUT
, - - O
and - - O
yet - - O
insertions - - O
therein - - O
result - - O
in - - O
loss - - O
of - - O
these - - O
proteins - - O
and - - O
a - - O
hemadsorption-negative - - O
( - - O
HA- - - O
) - - O
phenotype - - O
, - - O
prompting - - O
the - - O
designation - - O
cytadherence-regulatory - - B-MUT
locus - - I-MUT
( - - O
crl - - B-MUT
) - - O
. - - O

The - - O
effect - - O
of - - O
diffusion - - O
limitation - - O
was - - O
quantified - - O
in - - O
terms - - O
of - - O
the - - O
ratio - - O
O2 - - O
uptake - - O
O2 - - O
requirement - - O
( - - O
= - - O
fraction - - O
of - - O
cross-sectional - - O
area - - O
supplied - - O
with - - O
O2 - - O
) - - O
, - - O
assuming - - O
local - - O
O2 - - O
requirement - - O
per - - O
unit - - O
volume - - O
to - - O
be - - O
constant - - O
and - - O
independent - - O
of - - O
PO2 - - O
at - - O
PO2 - - O
greater - - O
than - - O
0 - - O
. - - O

Analysis - - O
of - - O
intragenic - - O
revertants - - O
shows - - O
that - - O
this - - O
function - - O
depends - - O
on - - O
the - - O
amino - - O
acid - - O
preceding - - O
the - - O
first - - O
cysteine - - O
residue - - O
of - - O
the - - O
DNA-binding - - O
domain - - O
of - - O
Hap1p - - B-MUT
. - - O

Here - - O
we - - O
investigate - - O
the - - O
role - - O
of - - O
c-Cbl - - B-MUT
in - - O
development - - O
and - - O
homeostasis - - O
in - - O
mice - - O
by - - O
targeted - - O
disruption - - O
of - - O
the - - O
c-Cbl - - B-MUT
locus - - I-MUT
. - - O
c-Cbl-deficient - - O
mice - - O
were - - O
viable - - O
, - - O
fertile - - O
, - - O
and - - O
outwardly - - O
normal - - O
in - - O
appearance - - O
. - - O

Acoust - - O
. - - O

The - - O
modification - - O
of - - O
P32 - - O
uptake - - O
into - - O
the - - O
Jensen - - O
sarcoma - - O
in - - O
vitro - - O
by - - O
adding - - O
of - - O
peroxide - - O
to - - O
the - - O
nutritive - - O
medium - - O
. - - O

Detailed - - O
molecular - - O
organization - - O
of - - O
the - - O
coding - - O
and - - O
upstream - - O
regulatory - - O
regions - - O
of - - O
the - - O
murine - - O
homeodomain-containing - - O
gene - - O
, - - O
Msx-1 - - B-MUT
, - - O
is - - O
reported - - O
. - - O

There - - O
is - - O
growing - - O
evidence - - O
that - - O
mammalian - - B-MUT
AMP-activated - - I-MUT
protein - - I-MUT
kinase - - I-MUT
( - - O
AMPK - - B-MUT
) - - O
plays - - O
a - - O
role - - O
in - - O
protecting - - O
cells - - O
from - - O
stresses - - O
that - - O
cause - - O
ATP - - O
depletion - - O
by - - O
switching - - O
off - - O
ATP-consuming - - O
biosynthetic - - O
pathways - - O
. - - O

Studies - - O
are - - O
necessary - - O
to - - O
assess - - O
the - - O
source - - O
of - - O
contamination - - O
and - - O
potential - - O
role - - O
of - - O
MRSA-contaminated - - O
milk - - O
in - - O
the - - O
transmission - - O
of - - O
MRSA - - O
to - - O
neonates - - O
. - - O

A - - O
suspected - - O
new - - O
storage - - O
disease - - O
in - - O
cattle - - O
. - - O

Reduced - - O
NK - - O
activity - - O
correlates - - O
with - - O
active - - O
disease - - O
in - - O
HIV- - - O
patients - - O
with - - O
multidrug-resistant - - O
pulmonary - - O
tuberculosis - - O
. - - O

These - - O
results - - O
indicate - - O
that - - O
evaluation - - O
of - - O
exposure - - O
to - - O
S - - O
. - - O
neurona - - O
by - - O
WB - - O
analysis - - O
of - - O
serum - - O
may - - O
be - - O
misleading - - O
in - - O
young - - O
horses - - O
. - - O

Because - - O
of - - O
the - - O
probable - - O
causal - - O
relationship - - O
between - - O
constitutive - - O
p210 - - B-MUT
( - - I-MUT
bcr - - I-MUT
abl - - I-MUT
) - - I-MUT
protein - - I-MUT
tyrosine - - B-MUT
kinase - - I-MUT
activity - - I-MUT
and - - O
manifestations - - O
of - - O
chronic-phase - - O
chronic - - O
myelogenous - - O
leukemia - - O
( - - O
CML - - O
; - - O
myeloid - - O
expansion - - O
) - - O
, - - O
a - - O
key - - O
goal - - O
is - - O
to - - O
identify - - O
relevant - - O
p210 - - O
substrates - - B-MUT
in - - O
primary - - O
chronic-phase - - O
CML - - O
hematopoietic - - O
progenitor - - O
cells - - O
. - - O

The - - O
PC2 - - B-MUT
protein - - I-MUT
also - - O
shows - - O
great - - O
similarity - - O
to - - O
the - - O
incomplete - - O
NH2-terminal - - O
sequence - - O
of - - O
the - - O
human - - B-MUT
furin - - I-MUT
gene - - I-MUT
product - - I-MUT
, - - O
a - - O
putative - - O
membrane-inserted - - O
receptor-like - - O
molecule - - O
. - - O

Difficulties - - O
bound - - O
to - - O
measuring - - O
of - - O
sputum - - O
viscosity - - O
. - - O

Whether - - O
or - - O
not - - O
there - - O
are - - O
sequences - - O
conferring - - O
cAMP - - O
responsiveness - - O
which - - O
are - - O
common - - O
both - - O
to - - O
P-450scc - - B-MUT
and - - O
the - - O
other - - O
steroidogenic - - O
P-450 - - B-MUT
genes - - I-MUT
remains - - O
to - - O
be - - O
established - - O
. - - O

We - - O
have - - O
also - - O
tested - - O
Src - - B-MUT
SH2 - - I-MUT
mutants - - I-MUT
for - - O
their - - O
binding - - O
properties - - O
and - - O
have - - O
interpreted - - O
our - - O
results - - O
in - - O
light - - O
of - - O
the - - O
recent - - O
crystal - - O
structure - - O
solution - - O
for - - O
the - - O
Src - - B-MUT
SH2 - - I-MUT
domain - - I-MUT
. - - O

This - - O
protein - - O
encoded - - O
by - - O
this - - O
cDNA - - O
, - - O
which - - O
we - - O
have - - O
termed - - O
p150TSP - - B-MUT
( - - O
for - - O
TPR-containing - - B-MUT
, - - I-MUT
SH2-binding - - I-MUT
phosphoprotein - - I-MUT
) - - O
, - - O
is - - O
located - - O
predominantly - - O
in - - O
the - - O
nucleus - - O
and - - O
is - - O
highly - - O
conserved - - O
in - - O
evolution - - O
. - - O

We - - O
linked - - O
hypersensitivity - - B-MUT
site - - I-MUT
2 - - I-MUT
( - - O
HS2 - - B-MUT
) - - O
from - - O
the - - O
locus - - O
control - - O
region - - O
( - - O
LCR - - O
) - - O
to - - O
a - - O
A - - B-MUT
gamma-globin - - I-MUT
gene - - O
( - - O
A - - B-MUT
gamma* - - I-MUT
) - - O
mutationally - - O
marked - - O
to - - O
allow - - O
its - - O
transcript - - O
to - - O
be - - O
distinguished - - O
from - - O
endogenous - - O
gamma-globin - - B-MUT
mRNA - - O
. - - O

In - - O
controls - - O
, - - O
only - - O
modest - - O
differences - - O
were - - O
observed - - O
. - - O

Our - - O
results - - O
suggest - - O
that - - O
a - - O
sequence - - O
match - - O
between - - O
enhancers - - O
and - - O
certain - - O
promoter - - O
elements - - O
is - - O
critical - - O
. - - O

A - - O
conserved - - O
role - - O
for - - O
L1 - - B-MUT
as - - O
a - - O
transmembrane - - O
link - - O
between - - O
neuronal - - O
adhesion - - O
and - - O
membrane - - O
cytoskeleton - - O
assembly - - O
. - - O

The - - O
most - - O
frequent - - O
causes - - O
of - - O
the - - O
meningitis - - O
was - - O
the - - O
external - - O
ventricular - - O
drainage - - O
( - - O
14 - - O
. - - O
8% - - O
) - - O
, - - O
post-neurosurgical - - O
( - - O
0 - - O
. - - O
8% - - O
) - - O
and - - O
head - - O
injury - - O
( - - O
0 - - O
. - - O
0007% - - O
) - - O
. - - O

Cicatricial - - O
pemphigoid - - O
is - - O
an - - O
autoimmune - - O
systemic - - O
disease - - O
characterized - - O
by - - O
chronic - - O
conjunctival - - O
cicatrization - - O
. - - O

1 - - O
. - - O

We - - O
conclude - - O
that - - O
the - - O
alpha-subunit - - O
of - - O
the - - O
telomere-binding - - B-MUT
protein - - I-MUT
, - - O
like - - O
many - - O
transcription - - O
factors - - O
, - - O
has - - O
separable - - O
DNA-binding - - O
and - - O
protein-protein - - O
interaction - - O
domains - - O
. - - O

In - - O
the - - O
electrophoresis - - O
mobility - - O
shift - - O
assay - - O
using - - O
nuclear - - O
extracts - - O
of - - O
the - - O
myogenic - - O
cells - - O
, - - O
MyoD - - B-MUT
and - - O
myogenin - - B-MUT
bound - - O
to - - O
the - - O
right - - O
E-box - - O
in - - O
the - - O
enhancer - - O
region - - O
of - - O
the - - O
MCK - - B-MUT
gene - - I-MUT
even - - O
in - - O
the - - O
presence - - O
of - - O
BMP-2 - - B-MUT
. - - O

The - - O
reduced - - O
rate - - O
of - - O
F - - O
absorption - - O
and - - O
slower - - O
rise - - O
in - - O
plasma - - O
F - - O
concentration - - O
accompanying - - O
delayed - - O
gastric - - O
emptying - - O
indicate - - O
that - - O
passage - - O
of - - O
F - - O
into - - O
the - - O
small - - O
intestine - - O
is - - O
the - - O
major - - O
factor - - O
in - - O
rapid - - O
F - - O
absorption - - O
. - - O

1 - - O
, - - O
3-bis - - O
( - - O
2-chloroethyl - - O
) - - O
-1-nitrosourea - - O
( - - O
bcnu - - O
) - - O
and - - O
other - - O
nitrosoureas - - O
in - - O
cancer - - O
treatment - - O
: - - O
a - - O
review - - O
. - - O

9 - - O
, - - O
1498-1506 - - O
) - - O
. - - O

Therefore - - O
, - - O
to - - O
understand - - O
how - - O
ErbB1 - - B-MUT
ErbB2 - - I-MUT
signaling - - I-MUT
contributes - - O
to - - O
this - - O
process - - O
, - - O
we - - O
used - - O
the - - O
ErbB - - O
kinase - - B-MUT
inhibitor - - I-MUT
AG1478in - - O
ErbB2-dependent - - O
BT-474 - - O
and - - O
SKBR-3 - - O
human - - O
breast - - O
cancer - - O
cells - - O
. - - O

Infants - - O
who - - O
died - - O
in - - O
the - - O
first - - O
12 - - O
hours - - O
from - - O
'IVH - - O
only' - - O
had - - O
suffered - - O
severe - - O
birth - - O
asphyxia - - O
but - - O
in - - O
those - - O
who - - O
died - - O
later - - O
the - - O
main - - O
symptom - - O
was - - O
recurrent - - O
apnoea - - O
. - - O

Various - - O
treatment - - O
modalities - - O
are - - O
reviewed - - O
in - - O
the - - O
context - - O
of - - O
the - - O
psychology - - O
as - - O
well - - O
as - - O
the - - O
physiology - - O
of - - O
severe - - O
intractable - - O
pain - - O
. - - O

When - - O
vascular - - O
pressure - - O
( - - O
Pvas - - O
) - - O
was - - O
raised - - O
abruptly - - O
from - - O
-5 - - O
to - - O
+25 - - O
cmH2O - - O
by - - O
air - - O
inflation - - O
for - - O
60 - - O
min - - O
, - - O
Px - - O
( - - O
f - - O
) - - O
became - - O
abruptly - - O
less - - O
negative - - O
, - - O
then - - O
remained - - O
stable - - O
. - - O

Consistent - - O
with - - O
this - - O
finding - - O
, - - O
beta-catenin - - B-MUT
interacted - - O
directly - - O
with - - O
the - - O
RA - - B-MUT
receptor - - I-MUT
( - - O
RAR - - B-MUT
) - - O
in - - O
a - - O
retinoid-dependent - - O
manner - - O
, - - O
but - - O
not - - O
with - - O
the - - O
retinoid - - B-MUT
X - - I-MUT
receptor - - I-MUT
( - - O
RXR - - B-MUT
) - - O
, - - O
and - - O
RAR - - B-MUT
competed - - O
with - - O
TCF - - B-MUT
for - - O
beta-catenin - - B-MUT
binding - - O
. - - O

Measurement - - O
of - - O
anti-HCV - - B-MUT
IgM - - I-MUT
antibodies - - I-MUT
with - - O
an - - O
experimental - - O
kit - - O
. - - O

In - - O
three - - O
cases - - O
( - - O
21 - - O
. - - O
4% - - O
) - - O
, - - O
the - - O
MR - - O
imaging - - O
was - - O
interpreted - - O
as - - O
negative - - O
, - - O
but - - O
microscopic - - O
tumor - - O
was - - O
shown - - O
around - - O
seroma - - O
on - - O
reexcision - - O
. - - O

In - - O
both - - O
settings - - O
, - - O
it - - O
can - - O
be - - O
phosphorylated - - O
by - - O
cyclin - - B-MUT
D-dependent - - I-MUT
kinases - - I-MUT
, - - O
suggesting - - O
that - - O
its - - O
transcriptional - - O
activity - - O
may - - O
normally - - O
be - - O
regulated - - O
through - - O
such - - O
mechanisms - - O
. - - O

Protein - - B-MUT
phosphatase - - I-MUT
2A - - I-MUT
is - - O
a - - O
critical - - O
regulator - - O
of - - O
protein - - B-MUT
kinase - - I-MUT
C - - I-MUT
zeta - - I-MUT
signaling - - O
targeted - - O
by - - O
SV40 - - B-MUT
small - - I-MUT
t - - I-MUT
to - - O
promote - - O
cell - - O
growth - - O
and - - O
NF-kappaB - - B-MUT
activation - - O
. - - O

The - - O
homology - - O
to - - O
v-mil - - B-MUT
starts - - O
within - - O
the - - O
coding - - O
sequence - - O
of - - O
exon - - O
1 - - O
and - - O
ends - - O
within - - O
the - - O
3' - - O
untranslated - - O
region - - O
of - - O
exon - - O
11 - - O
, - - O
12 - - O
nucleotides - - O
downstream - - O
from - - O
the - - O
nonsense - - O
codon - - O
terminating - - O
the - - O
large - - O
open - - O
reading - - O
frame - - O
shared - - O
between - - O
c-mil - - B-MUT
and - - O
v-mil - - B-MUT
. - - O

DESIGN - - O
: - - O
Retrospective - - O
study - - O
. - - O

The - - O
R2 - - O
between - - O
MFI - - O
of - - O
fresh - - O
and - - O
frozen - - O
muscle - - O
was - - O
0 - - O
. - - O
94 - - O
and - - O
0 - - O
. - - O
92 - - O
for - - O
lamb - - O
and - - O
pork - - O
longissimus - - O
, - - O
respectively - - O
. - - O

Riboflavin - - O
did - - O
not - - O
affect - - O
the - - O
percentage - - O
of - - O
aflatoxin-treated - - O
animals - - O
with - - O
abnormal - - O
urinary - - O
excretion - - O
patterns - - O
, - - O
but - - O
did - - O
increase - - O
the - - O
magnitude - - O
of - - O
the - - O
disturbances - - O
in - - O
elimination - - O
of - - O
kynurenic - - O
and - - O
xanthurenic - - O
acids - - O
. - - O

The - - O
spectrum - - O
of - - O
age-associated - - O
brain - - O
abnormalities - - O
: - - O
their - - O
measurement - - O
and - - O
histopathological - - O
correlates - - O
. - - O

The - - O
mechanism - - O
of - - O
action - - O
is - - O
explored - - O
in - - O
some - - O
detail - - O
, - - O
specifically - - O
as - - O
it - - O
relates - - O
to - - O
reticuloendothelial - - O
system - - O
( - - O
RES - - O
) - - O
Fc - - B-MUT
receptor - - I-MUT
blockade - - O
and - - O
suppression - - O
of - - O
antiplatelet - - O
antibody - - O
synthesis - - O
. - - O

During - - O
this - - O
period - - O
, - - O
administration - - O
of - - O
additional - - O
exogenous - - B-MUT
PRL - - I-MUT
did - - O
not - - O
stimulate - - O
further - - O
activation - - O
( - - O
binding - - O
) - - O
of - - O
the - - O
Stat - - B-MUT
factors - - I-MUT
. - - O

Differential - - O
screening - - O
of - - O
mitochondrial - - O
cDNA - - O
libraries - - O
from - - O
male-fertile - - O
and - - O
cytoplasmic - - O
male-sterile - - O
sugar-beet - - O
reveals - - O
genome - - O
rearrangements - - O
at - - O
atp6 - - B-MUT
and - - O
atpA - - B-MUT
loci - - I-MUT
. - - O

ALT - - B-MUT
levels - - O
in - - O
responders - - O
were - - O
lowered - - O
by - - O
46% - - O
and - - O
AST - - B-MUT
levels - - O
were - - O
lowered - - O
by - - O
35% - - O
after - - O
12 - - O
weeks - - O
of - - O
vitamin - - O
E - - O
treatment - - O
. - - O

No - - O
patient - - O
had - - O
a - - O
history - - O
of - - O
excess - - O
alcohol - - O
intake - - O
, - - O
or - - O
prolonged - - O
intake - - O
of - - O
hepatotoxic - - O
drugs - - O
and - - O
steroids - - O
, - - O
and - - O
were - - O
not - - O
obese - - O
or - - O
malnourished - - O
. - - O

Chaperones - - B-MUT
HSPs - - I-MUT
thus - - I-MUT
play - - O
important - - O
roles - - O
within - - O
cell - - O
cycle - - O
processes - - O
. - - O

Experiences - - O
with - - O
the - - O
clinical - - O
and - - O
experimental - - O
use - - O
of - - O
Urat-I - - O
lithotriptor - - O
. - - O

Under - - O
resting - - O
conditions - - O
, - - O
activity - - O
levels - - O
of - - O
cardiac - - O
vagal - - O
and - - O
sympathetic - - O
outflows - - O
are - - O
not - - O
related - - O
across - - O
young - - O
, - - O
healthy - - O
human - - O
subjects - - O
and - - O
peripheral - - O
interaction - - O
is - - O
not - - O
manifest - - O
between - - O
the - - O
autonomic - - O
divisions - - O
. - - O

The - - O
distal - - O
portion - - O
of - - O
the - - O
rat - - B-MUT
insulin - - I-MUT
I - - I-MUT
gene - - I-MUT
5'-flanking - - I-MUT
DNA - - I-MUT
contains - - O
two - - O
sequence - - O
elements - - O
, - - O
the - - O
Far - - B-MUT
and - - O
FLAT - - B-MUT
elements - - I-MUT
, - - O
that - - O
can - - O
function - - O
in - - O
combination - - O
, - - O
but - - O
not - - O
separately - - O
, - - O
as - - O
a - - O
beta-cell-specific - - O
transcriptional - - O
enhancer - - O
. - - O

This - - O
study - - O
describes - - O
a - - O
new - - O
MADS - - B-MUT
box - - I-MUT
gene - - I-MUT
, - - O
nmhC5 - - B-MUT
, - - O
which - - O
along - - O
with - - O
nmh7 - - B-MUT
( - - O
J - - O
. - - O

To - - O
explore - - O
the - - O
functional - - O
significance - - O
of - - O
these - - O
subdomains - - O
in - - O
PRL - - B-MUT
binding - - O
and - - O
signal - - O
transduction - - O
, - - O
deletion - - O
mutants - - O
of - - O
S1 - - B-MUT
or - - O
and - - O
S2 - - O
subdomains - - B-MUT
were - - I-MUT
constructed - - O
. - - O

A - - O
second - - O
large - - O
group - - O
of - - O
disorders - - O
in - - O
pregnancy - - O
is - - O
caused - - O
by - - O
effects - - O
of - - O
infections - - O
of - - O
the - - O
mother - - O
without - - O
pathogens - - O
being - - O
transmitted - - O
to - - O
the - - O
embryo - - O
or - - O
the - - O
placenta - - O
. - - O

Melatonin - - O
and - - O
seasonality - - O
: - - O
filling - - O
the - - O
gap - - O
. - - O

Hantaan - - O
virus - - O
. - - O

Our - - O
laboratory - - O
has - - O
recently - - O
identified - - O
two - - O
phosducin-like - - B-MUT
orphan - - I-MUT
proteins - - I-MUT
( - - O
PhLOP1 - - B-MUT
and - - O
PhLOP2 - - B-MUT
) - - O
that - - O
lack - - O
the - - O
ability - - O
to - - O
interact - - O
with - - O
Gbetagamma - - B-MUT
. - - O

In - - O
18% - - O
lymphography - - O
was - - O
clearly - - O
positive - - O
and - - O
CT - - O
negative - - O
. - - O

Surprisingly - - O
, - - O
double - - O
mutants - - O
of - - O
the - - O
shy2-1D - - B-MUT
mutant - - I-MUT
with - - O
the - - O
phytochrome-deficient - - O
mutants - - O
hy2 - - B-MUT
, - - O
hy3 - - B-MUT
( - - O
phyB-1 - - B-MUT
) - - O
and - - O
fre1-1 - - B-MUT
( - - O
phyA-201 - - B-MUT
) - - O
showed - - O
reduced - - O
photomorphogenic - - O
response - - O
in - - O
darkness - - O
with - - O
a - - O
longer - - O
hypocotyl - - O
, - - O
a - - O
longer - - O
inflorescence - - O
stem - - O
, - - O
and - - O
a - - O
lower - - O
level - - O
expression - - O
of - - O
the - - O
CAB - - B-MUT
gene - - I-MUT
than - - O
the - - O
shy2-1D - - B-MUT
single - - I-MUT
mutant - - I-MUT
. - - O

1 - - O
. - - O

Validation - - O
of - - O
the - - O
survey - - O
of - - O
work - - O
styles - - O
: - - O
a - - O
profile - - O
measure - - O
of - - O
the - - O
type - - O
A - - O
behaviour - - O
pattern - - O
. - - O

During - - O
the - - O
CR - - O
PP - - O
diet - - O
only - - O
the - - O
HS - - O
subjects - - O
did - - O
not - - O
show - - O
the - - O
stress-induced - - O
rise - - O
in - - O
depression - - O
, - - O
decline - - O
in - - O
vigour - - O
and - - O
cortisol - - O
elevation - - O
that - - O
they - - O
showed - - O
after - - O
the - - O
PR - - O
CP - - O
diet - - O
. - - O

Overexpression - - O
of - - O
RORgamma - - B-MUT
has - - O
been - - O
shown - - O
to - - O
inhibit - - O
T - - O
cell - - O
receptor-mediated - - O
apoptosis - - O
in - - O
T - - O
cell - - O
hybridomas - - O
and - - O
to - - O
repress - - O
the - - O
induction - - O
of - - O
Fas-ligand - - B-MUT
and - - O
interleukin - - B-MUT
2 - - I-MUT
. - - O

Circularized - - B-MUT
Ac - - I-MUT
Ds - - I-MUT
transposons - - I-MUT
: - - I-MUT
formation - - O
, - - O
structure - - O
and - - O
fate - - O
. - - O

Since - - O
the - - O
latter - - O
is - - O
very - - O
small - - O
for - - O
physiological - - O
flows - - O
, - - O
the - - O
result - - O
is - - O
that - - O
alpha - - O
< - - O
1 - - O
even - - O
at - - O
relatively - - O
high - - O
values - - O
of - - O
the - - O
Reynolds - - O
number - - O
( - - O
i - - O
. - - O
e - - O
. - - O
, - - O
for - - O
non-negligible - - O
inertia - - O
) - - O
and - - O
we - - O
validate - - O
our - - O
perturbation - - O
theory - - O
results - - O
by - - O
comparison - - O
with - - O
a - - O
numerical - - O
integration - - O
of - - O
the - - O
full - - O
model - - O
. - - O

In - - O
cases - - O
of - - O
1 - - O
degrees - - O
HPT - - O
, - - O
the - - O
plasma - - O
1 - - O
, - - O
25- - - O
( - - O
OH - - O
) - - O
2D - - O
level - - O
rose - - O
significantly - - O
in - - O
all - - O
cases - - O
( - - O
P - - O
less - - O
than - - O
0 - - O
. - - O
05 - - O
) - - O
, - - O
although - - O
the - - O
pattern - - O
of - - O
the - - O
increase - - O
was - - O
not - - O
uniform - - O
. - - O

The - - O
study - - O
enrolled - - O
994 - - O
people - - O
co-infected - - O
with - - O
CMV - - O
and - - O
HIV - - O
, - - O
with - - O
at - - O
least - - O
one - - O
CD4 - - B-MUT
count - - O
recorded - - O
< - - O
100 - - O
x - - O
10 - - O
( - - O
6 - - O
) - - O
cells - - O
l - - O
. - - O

UK's - - O
biotechnology - - O
lacking - - O
specialists - - O
. - - O

Expression - - O
of - - O
a - - O
dominant-negative - - B-MUT
ras - - I-MUT
gene - - I-MUT
also - - O
blocks - - O
TIS10 - - B-MUT
PGS2 - - I-MUT
induction - - I-MUT
by - - O
v-src - - O
. - - B-MUT

High-affinity - - O
binding - - O
sites - - O
for - - O
both - - O
GR - - B-MUT
and - - O
AP-1 - - B-MUT
nucleoproteins - - I-MUT
were - - O
identified - - O
at - - O
adjacent - - O
elements - - O
within - - O
the - - O
nGRE - - B-MUT
. - - O

A - - O
significant - - O
herd - - O
X - - O
period - - O
interaction - - O
existed - - O
for - - O
liver - - O
TG - - O
and - - O
serum - - O
dextran - - O
precipitable - - O
cholesterol - - O
concentrations - - O
. - - O

The - - O
nucleotide - - O
sequence - - O
of - - O
3874 - - O
bp - - O
of - - O
cloned - - O
R - - O
. - - O
sphaeroides - - O
chromosomal - - O
DNA - - O
, - - O
including - - O
the - - O
three - - O
structural - - O
genes - - O
fbcF - - B-MUT
, - - O
fbcB - - B-MUT
and - - O
fbcC - - B-MUT
has - - O
been - - O
determined - - O
. - - O

We - - O
obtained - - O
quantitative - - O
evidence - - O
on - - O
the - - O
coding - - O
of - - O
interaural - - O
time - - O
differences - - O
( - - O
ITDs - - O
) - - O
of - - O
click - - O
stimuli - - O
by - - O
40 - - O
single - - O
neurons - - O
in - - O
the - - O
auditory - - O
cortex - - O
of - - O
anesthetized - - O
albino - - O
rats - - O
. - - O

Renal - - O
cell - - O
carcinoma - - O
in - - O
children - - O
: - - O
a - - O
single - - O
institution's - - O
experience - - O
. - - O

What - - O
to - - O
look - - O
for - - O
during - - O
a - - O
compliance - - O
review - - O
: - - O
10 - - O
common - - O
mistakes - - O
made - - O
by - - O
SNFs - - O
. - - O

NH2- - - O
and - - O
COOH-terminal - - O
deletion - - O
analysis - - O
revealed - - O
that - - O
both - - O
the - - O
PH - - B-MUT
and - - O
putative - - O
guanine - - B-MUT
nucleotide - - I-MUT
exchange - - I-MUT
factor - - I-MUT
domains - - I-MUT
are - - O
required - - O
, - - O
but - - O
the - - O
zinc - - O
butterfly - - O
is - - O
dispensable - - O
, - - O
for - - O
transformation - - O
. - - O

Following - - O
chondroitinase - - B-MUT
AC - - I-MUT
and - - O
ABC - - B-MUT
digestion - - O
, - - O
staining - - O
reactions - - O
suggested - - O
that - - O
the - - O
highest - - O
levels - - O
of - - O
dermatan - - O
sulfate - - O
were - - O
in - - O
the - - O
diabetes - - O
resistant - - O
group - - O
( - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
001 - - O
compared - - O
to - - O
diabetic - - O
, - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
001 - - O
compared - - O
to - - O
diabetes - - O
prone - - O
) - - O
and - - O
the - - O
highest - - O
levels - - O
of - - O
chondroitin - - O
sulfates - - O
were - - O
in - - O
the - - O
diabetes - - O
prone - - O
group - - O
( - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
001 - - O
) - - O
. - - O

In - - O
this - - O
paper - - O
we - - O
report - - O
that - - O
ligand - - O
binding - - O
induced - - O
tyrosine - - O
phosphorylation - - O
in - - O
BaF3 - - O
cells - - O
engineered - - O
to - - O
express - - O
the - - O
murine - - B-MUT
Mpl - - I-MUT
receptor - - I-MUT
( - - O
BaF3 - - B-MUT
mMpl - - I-MUT
) - - I-MUT
. - - O

New - - O
and - - O
successful - - O
steps - - O
have - - O
been - - O
made - - O
in - - O
immunodiagnostics - - O
, - - O
immunotherapy - - O
, - - O
and - - O
immunoprophylaxis - - O
of - - O
immunologically - - O
conditioned - - O
infertility - - O
. - - O

Localization - - O
of - - O
the - - O
intronless - - O
gene - - O
coding - - O
for - - O
calmodulin-like - - B-MUT
protein - - I-MUT
CLP - - B-MUT
to - - O
human - - O
chromosome - - O
10p13-ter - - O
. - - O

Sequence - - O
comparison - - O
between - - O
the - - O
translated - - O
ORF - - O
and - - O
a - - O
protein - - O
database - - O
reveal - - O
between - - O
26 - - O
. - - O
5 - - O
and - - O
23 - - O
. - - O
4% - - O
aa - - O
sequence - - O
homology - - O
to - - O
bacterial - - B-MUT
transmembrane - - I-MUT
( - - I-MUT
TM - - I-MUT
) - - I-MUT
proteins - - I-MUT
including - - O
those - - O
mediating - - O
chloramphenicol - - O
( - - O
Cm - - O
) - - O
and - - O
tetracycline - - O
( - - O
Tc - - O
) - - O
resistance - - O
and - - O
an - - O
arabinose-proton - - O
symport - - O
protein - - O
. - - O

Uroflowmetry - - O
can - - O
detect - - O
dysuria - - O
, - - O
which - - O
may - - O
be - - O
poorly - - O
perceived - - O
or - - O
even - - O
unknown - - O
to - - O
the - - O
subjects - - O
themselves - - O
. - - O

Removal - - O
of - - O
lipid - - O
fractions - - O
of - - O
plant - - O
extractions - - O
with - - O
hexane - - O
is - - O
recommended - - O
to - - O
avoid - - O
damage - - O
to - - O
the - - O
HPLC - - O
column - - O
. - - O

However - - O
, - - O
the - - O
signaling - - O
cascade - - O
utilized - - O
by - - O
the - - O
urokinase - - B-MUT
receptor - - I-MUT
is - - O
only - - O
incompletely - - O
understood - - O
. - - O

Substrate - - O
specificity - - O
of - - O
the - - O
RNase - - B-MUT
activity - - O
of - - O
yeast - - B-MUT
RNA - - I-MUT
polymerase - - I-MUT
III - - I-MUT
. - - O

Despite - - O
its - - O
requirement - - O
for - - O
enhancer-dependent - - O
splicing - - O
activity - - O
in - - O
vitro - - O
, - - O
the - - O
dU2AF38 - - B-MUT
RS - - I-MUT
domain - - I-MUT
was - - O
also - - O
inessential - - O
in - - O
vivo - - O
. - - O

The - - O
rear - - O
silver - - O
liquid - - O
chamber - - O
was - - O
threefold - - O
thick - - O
to - - O
17 - - O
MeV - - O
protons - - O
in - - O
water - - O
and - - O
it - - O
efficiently - - O
produced - - O
either - - O
13N - - O
by - - O
the - - O
16O - - O
( - - O
p - - O
, - - O
alpha - - O
) - - O
13N - - O
reaction - - O
or - - O
[ - - O
18F - - O
] - - O
fluoride - - O
ion - - O
by - - O
the - - O
18O - - O
( - - O
p - - O
, - - O
n - - O
) - - O
18F - - O
reaction - - O
. - - O

Furthermore - - O
, - - O
analysis - - O
of - - O
deletion - - O
promoter-reporter - - O
constructs - - O
found - - O
that - - O
the - - O
basal - - O
activity - - O
of - - O
P2 - - O
resided - - O
in - - O
the - - O
proximal - - O
region - - O
of - - O
P2 - - O
. - - O

We - - O
introduced - - O
the - - O
gel - - O
technique - - O
as - - O
a - - O
routine - - O
assay - - O
for - - O
antibody - - O
detection - - O
and - - O
identification - - O
in - - O
1993 - - O
. - - O

Their - - O
conduction - - O
velocity - - O
ranged - - O
from - - O
0 - - O
. - - O
23 - - O
to - - O
0 - - O
. - - O
98 - - O
m - - O
sec - - O
( - - O
group - - O
C - - O
) - - O
. - - O

Similar - - O
results - - O
were - - O
seen - - O
on - - O
Western - - O
blots - - O
of - - O
Autographa - - O
californica - - O
MNPV - - O
( - - O
AcMNPV - - O
) - - O
-infected - - O
Spodoptera - - O
frugiperda - - O
cells - - O
. - - O

Fasting - - O
gastrin - - B-MUT
levels - - O
( - - O
normal - - O
range - - O
: - - O
25-110 - - O
mU - - O
L - - O
) - - O
varied - - O
from - - O
48 - - O
. - - O
78 - - O
mU - - O
L-168 - - O
. - - O
20 - - O
( - - O
mean - - O
: - - O
85 - - O
. - - O
23 - - O
mU - - O
L - - O
) - - O
. - - O

CONCLUSION - - O
: - - O
Sonographic - - O
angiography - - O
has - - O
a - - O
possible - - O
role - - O
in - - O
the - - O
detection - - O
of - - O
small - - O
nodules - - O
in - - O
patients - - O
with - - O
CRF - - O
. - - O

To - - O
examine - - O
transcriptional - - O
regulation - - O
of - - O
the - - O
rat - - B-MUT
eIF4E - - I-MUT
gene - - I-MUT
, - - O
2 - - O
. - - O
1 - - O
kB - - O
of - - O
the - - O
rat - - B-MUT
eIF4E - - I-MUT
promoter - - I-MUT
region - - I-MUT
was - - O
cloned - - O
and - - O
the - - O
contribution - - O
of - - O
specific - - O
elements - - O
in - - O
regulating - - O
transcription - - O
was - - O
determined - - O
in - - O
primary - - O
cultures - - O
of - - O
rat - - O
cardiocytes - - O
and - - O
in - - O
a - - O
murine - - O
C - - O
( - - O
2 - - O
) - - O
C - - O
( - - O
12 - - O
) - - O
myoblast - - O
cell - - O
line - - O
. - - O

Cytochrome - - B-MUT
b - - I-MUT
in - - O
human - - B-MUT
complex - - I-MUT
II - - I-MUT
( - - O
succinate-ubiquinone - - B-MUT
oxidoreductase - - I-MUT
) - - O
: - - O
cDNA - - O
cloning - - O
of - - O
the - - O
components - - O
in - - O
liver - - O
mitochondria - - O
and - - O
chromosome - - O
assignment - - O
of - - O
the - - O
genes - - O
for - - O
the - - O
large - - O
( - - O
SDHC - - B-MUT
) - - O
and - - O
small - - O
( - - O
SDHD - - B-MUT
) - - O
subunits - - O
to - - O
1q21 - - O
and - - O
11q23 - - O
. - - O

Molecular - - O
cloning - - O
and - - O
characterization - - O
of - - O
a - - O
new - - O
member - - O
of - - O
the - - O
rat - - B-MUT
placental - - I-MUT
prolactin - - I-MUT
( - - O
PRL - - B-MUT
) - - O
family - - O
, - - O
PRL-like - - B-MUT
protein - - I-MUT
H - - O
. - - O

During - - O
latency - - O
, - - O
more - - O
than - - O
1% - - O
of - - O
neurons - - O
in - - O
ganglia - - O
that - - O
innervate - - O
the - - O
footpad - - O
expressed - - O
beta-galactosidase - - B-MUT
, - - O
with - - O
the - - O
number - - O
of - - O
positive - - O
cells - - O
remaining - - O
constant - - O
for - - O
at - - O
least - - O
5 - - O
months - - O
. - - O

Using - - O
a - - O
novel - - O
method - - O
combining - - O
chromatin - - O
immunoprecipitation - - O
and - - O
genomic - - O
array - - O
hybridization - - O
, - - O
we - - O
have - - O
identified - - O
a - - O
460-kb - - B-MUT
CENP-A-binding - - I-MUT
DNA - - I-MUT
domain - - I-MUT
of - - O
a - - O
neocentromere - - O
derived - - O
from - - O
the - - O
20p12 - - O
region - - O
of - - O
an - - O
invdup - - O
( - - O
20p - - O
) - - O
human - - O
marker - - O
chromosome - - O
. - - O

The - - O
effects - - O
of - - O
oral - - O
vanadyl - - O
sulfate - - O
( - - O
VOSO4 - - O
) - - O
( - - O
0 - - O
. - - O
5 - - O
mg - - O
kg - - O
day - - O
) - - O
on - - O
anthropometry - - O
, - - O
body - - O
composition - - O
, - - O
and - - O
performance - - O
were - - O
investigated - - O
in - - O
a - - O
12-week - - O
, - - O
double-blind - - O
, - - O
placebo-controlled - - O
trial - - O
involving - - O
weight-training - - O
volunteers - - O
. - - O

A - - O
new - - O
instrument - - O
has - - O
been - - O
designed - - O
for - - O
freeze-fracturing - - O
of - - O
biological - - O
material - - O
in - - O
ultra - - O
high - - O
vacuum - - O
. - - O

Ang - - B-MUT
II - - I-MUT
significantly - - O
induced - - O
Ang2 - - B-MUT
mRNA - - I-MUT
accumulations - - O
without - - O
affecting - - O
Ang1 - - B-MUT
or - - O
Tie2 - - B-MUT
expression - - O
, - - O
which - - O
was - - O
inhibited - - O
by - - O
protein - - B-MUT
kinase - - I-MUT
C - - I-MUT
inhibitors - - O
and - - O
by - - O
intracellular - - O
Ca - - O
( - - O
2+ - - O
) - - O
chelating - - O
agents - - O
. - - O

Antibodies - - O
against - - O
this - - O
purified - - O
protein - - O
localize - - O
RIM1 - - B-MUT
to - - O
mitochondria - - O
. - - O

RESULTS - - O
: - - O
Of - - O
the - - O
29 - - O
patients - - O
who - - O
received - - O
concurrent - - O
chemotherapy - - O
and - - O
G-CSF - - B-MUT
, - - O
ten - - O
( - - O
34% - - O
; - - O
95% - - O
confidence - - O
interval - - O
[ - - O
CI - - O
] - - O
, - - O
17 - - O
. - - O
9 - - O
to - - O
54 - - O
. - - O
3% - - O
) - - O
were - - O
believed - - O
to - - O
have - - O
clinically - - O
significant - - O
bleomycin - - O
toxicity - - O
. - - O

The - - O
growth - - O
of - - O
Aer - - O
. - - O
hydrophila - - O
in - - O
filter-sterilized - - O
lettuce - - O
extract - - O
was - - O
completely - - O
inhibited - - O
by - - O
0 - - O
. - - O
1% - - O
( - - O
v - - O
v - - O
) - - O
BMC - - O
whereas - - O
that - - O
of - - O
Ps - - O
. - - O
fluorescens - - O
was - - O
not - - O
significantly - - O
affected - - O
by - - O
1% - - O
( - - O
v - - O
v - - O
) - - O
BMC - - O
. - - O

Crystal - - O
structure - - O
of - - O
an - - O
oligomer - - O
of - - O
proteolytic - - B-MUT
zymogens - - I-MUT
: - - O
detailed - - O
conformational - - O
analysis - - O
of - - O
the - - O
bovine - - O
ternary - - O
complex - - O
and - - O
implications - - O
for - - O
their - - O
activation - - O
. - - O

MSMS - - O
Council - - O
hears - - O
new - - O
public - - O
health - - O
director - - O
. - - O

Maize - - B-MUT
rbcS - - I-MUT
promoter - - I-MUT
activity - - O
depends - - O
on - - O
sequence - - O
elements - - O
not - - O
found - - O
in - - O
dicot - - B-MUT
rbcS - - I-MUT
promoters - - I-MUT
. - - O

COUP - - B-MUT
transcription - - I-MUT
factor - - I-MUT
is - - O
a - - O
member - - O
of - - O
the - - O
steroid - - B-MUT
receptor - - I-MUT
superfamily - - I-MUT
. - - O

When - - O
a - - O
plateau - - O
of - - O
enhancement - - O
was - - O
reached - - O
, - - O
a - - O
single - - O
lesion - - O
in - - O
each - - O
patient - - O
was - - O
imaged - - O
using - - O
five - - O
different - - O
continuous - - O
scanning - - O
modes - - O
, - - O
fundamental - - O
grey - - O
scale - - O
( - - O
FGS - - O
) - - O
; - - O
fundamental - - O
colour - - O
Doppler - - O
( - - O
FCD - - O
) - - O
; - - O
fundamental - - O
power - - O
Doppler - - O
( - - O
FPD - - O
) - - O
; - - O
second - - O
harmonic - - O
grey - - O
scale - - O
( - - O
HGS - - O
) - - O
; - - O
and - - O
pulse - - O
inversion - - O
mode - - O
( - - O
Pim - - O
) - - O
using - - O
an - - O
HDI5000 - - O
scanner - - O
and - - O
C5-2 - - O
probe - - O
( - - O
ATL - - O
, - - O
Bothell - - O
, - - O
WA - - O
) - - O
. - - O

Cat - - B-MUT
proteins - - I-MUT
are - - O
tyrosine-phosphorylated - - O
when - - O
co-expressed - - O
in - - O
cells - - O
with - - O
the - - O
focal - - B-MUT
adhesion - - I-MUT
kinase - - I-MUT
Fak - - B-MUT
and - - O
Src - - B-MUT
. - - O

Less - - O
antibacterial - - O
activity - - O
was - - O
shown - - O
toward - - O
the - - O
Gram-negative - - O
bacilli - - O
, - - O
i - - O
. - - O
e - - O
. - - O
, - - O
Pseudomonas - - O
, - - O
Klebsiella-Enterobacter - - O
, - - O
Shigella - - O
, - - O
Escherichia - - O
coli - - O
, - - O
Serratia - - O
marcescens - - O
and - - O
Proteus - - O
. - - O

From - - O
Pap - - O
to - - O
ApUp - - O
. - - O

This - - O
transcriptional - - O
regulation - - O
occurs - - O
through - - O
modulation - - O
of - - O
the - - O
forkhead - - B-MUT
transcription - - I-MUT
factor - - I-MUT
FKHR-L1 - - B-MUT
, - - O
and - - O
IL-3 - - B-MUT
inhibited - - O
FKHR-L1 - - B-MUT
activity - - O
in - - O
a - - O
PI3K-dependent - - O
manner - - O
. - - O

Utero-placental - - O
blood - - O
flow - - O
and - - O
the - - O
effect - - O
of - - O
beta - - B-MUT
2-adrenoceptor - - I-MUT
stimulating - - O
drugs - - O
. - - O

Intron - - O
8 - - O
harbored - - O
a - - O
strong - - O
erythroid-specific - - O
enhancer - - O
activity - - O
which - - O
was - - O
orientation-dependent - - O
. - - O

Dermoid - - O
cyst - - O
in - - O
a - - O
free - - O
skin - - O
flap - - O
as - - O
the - - O
complication - - O
after - - O
treatment - - O
of - - O
recurring - - O
hernia - - O
. - - O

Hodgkin's - - O
disease - - O
. - - O

The - - O
relationship - - O
between - - O
the - - O
rare - - O
complications - - O
mentioned - - O
above - - O
and - - O
the - - O
pathophysiology - - O
of - - O
Bartter's - - O
syndrome - - O
is - - O
still - - O
obscure - - O
. - - O

Examination - - O
of - - O
the - - O
mitochondrial - - B-MUT
bc1 - - I-MUT
complex - - I-MUT
crystal - - I-MUT
structure - - I-MUT
[ - - O
Zhang - - O
, - - O
Z - - O
. - - O
, - - O
Huang - - O
, - - O
L - - O
. - - O
, - - O
Shulmeister - - O
, - - O
V - - O
. - - O

Sequence - - O
analysis - - O
of - - O
the - - O
sMtCK - - B-MUT
genomic - - I-MUT
upstream - - I-MUT
sequences - - I-MUT
reveals - - O
a - - O
typical - - O
TATAA - - O
box - - O
within - - O
the - - O
80 - - O
base - - O
pairs - - O
( - - O
bp - - O
) - - O
that - - O
, - - O
by - - O
transfection - - O
experiments - - O
, - - O
are - - O
sufficient - - O
to - - O
promote - - O
expression - - O
of - - O
chimeric - - O
plasmids - - O
with - - O
the - - O
chloramphenicol - - B-MUT
acetyltransferase - - I-MUT
reporter - - I-MUT
. - - O

Gonadal - - O
dysfunction - - O
in - - O
patients - - O
with - - O
ataxia - - O
telangiectasia - - O
. - - O

The - - O
MAP - - B-MUT
kinase - - I-MUT
cascade - - I-MUT
is - - O
highly - - O
conserved - - O
in - - O
all - - O
eukaryotes - - O
and - - O
involved - - O
in - - O
numerous - - O
cellular - - O
responses - - O
. - - O

Taken - - O
together - - O
, - - O
these - - O
observations - - O
indicate - - O
that - - O
inhibition - - O
of - - O
p27 - - B-MUT
( - - O
KIP1 - - B-MUT
) - - O
transcription - - O
through - - O
PI3K-induced - - B-MUT
FKHR-L1 - - I-MUT
phosphorylation - - O
provides - - O
a - - O
novel - - O
mechanism - - O
of - - O
regulating - - O
cytokine-mediated - - O
survival - - O
and - - O
proliferation - - O
. - - O

The - - O
effects - - O
of - - O
c-myc - - B-MUT
were - - O
further - - O
dissected - - O
by - - O
showing - - O
that - - O
c-myc - - B-MUT
can - - O
inhibit - - O
differentiation - - O
independently - - O
of - - O
Id - - B-MUT
, - - O
a - - O
negative - - O
regulator - - O
of - - O
muscle - - O
differentiation - - O
. - - O

Statement - - O
of - - O
the - - O
American - - O
Academy - - O
of - - O
Implant - - O
Dentistry - - O
. - - O

The - - O
NAUSICAA - - O
system - - O
gives - - O
a - - O
good - - O
knowledge - - O
of - - O
LET - - O
spectra - - O
for - - O
the - - O
first - - O
time - - O
in - - O
space - - O
dosimetry - - O
. - - O

Other - - O
adverse - - O
events - - O
with - - O
incidences - - O
significantly - - O
higher - - O
than - - O
with - - O
placebo - - O
were - - O
dizziness - - O
, - - O
constipation - - O
, - - O
sweating - - O
, - - O
nervousness - - O
, - - O
and - - O
abnormal - - O
ejaculation - - O
. - - O

Bacillus - - O
cereus - - O
cross-infection - - O
in - - O
a - - O
maternity-unit - - O
. - - O

The - - O
effect - - O
of - - O
smoking - - O
was - - O
not - - O
examined - - O
in - - O
this - - O
study - - O
, - - O
as - - O
such - - O
data - - O
were - - O
not - - O
available - - O
. - - O

The - - O
S229A - - O
variant - - O
can - - O
better - - O
flip - - O
modified - - O
bases - - O
but - - O
does - - O
not - - O
tightly - - O
lock - - O
the - - O
flipped - - O
base - - O
into - - O
the - - O
adenine-binding - - O
pocket - - O
, - - O
suggesting - - O
that - - O
Ser229 - - O
could - - O
form - - O
a - - O
contact - - O
to - - O
the - - O
flipped - - O
adenine - - O
. - - O

Dynamics - - O
of - - O
hospital - - O
stay - - O
in - - O
peptic - - O
ulcer - - O
patients - - O
. - - O

Characterization - - O
and - - O
hormonal - - O
regulation - - O
of - - O
the - - O
promoter - - O
of - - O
the - - O
rat - - B-MUT
prostaglandin - - I-MUT
endoperoxide - - I-MUT
synthase - - I-MUT
2 - - I-MUT
gene - - I-MUT
in - - O
granulosa - - O
cells - - O
. - - O

Cerebral - - O
flow - - O
and - - O
resistance - - O
showed - - O
minor - - O
reductions - - O
with - - O
HD - - O
. - - O

Losses - - O
of - - O
dichlofluanid - - O
( - - O
54% - - O
) - - O
, - - O
chlozolinate - - O
( - - O
22% - - O
) - - O
, - - O
and - - O
etridiazole - - O
( - - O
40% - - O
) - - O
, - - O
previously - - O
reported - - O
to - - O
occur - - O
during - - O
ambient - - O
processing - - O
of - - O
apples - - O
, - - O
were - - O
reduced - - O
to - - O
barely - - O
significant - - O
levels - - O
( - - O
10 - - O
, - - O
17 - - O
, - - O
and - - O
14% - - O
, - - O
respectively - - O
) - - O
by - - O
cryogenic - - O
processing - - O
. - - O

Further - - O
studies - - O
of - - O
mandibular - - O
movement - - O
at - - O
initial - - O
tooth - - O
contact - - O
. - - O

Serum - - O
concentrations - - O
of - - O
E2 - - O
and - - O
TBOH - - O
were - - O
measured - - O
on - - O
d - - O
0 - - O
, - - O
1 - - O
, - - O
3 - - O
, - - O
5 - - O
, - - O
7 - - O
, - - O
13 - - O
, - - O
21 - - O
, - - O
28 - - O
, - - O
42 - - O
, - - O
56 - - O
, - - O
84 - - O
, - - O
112 - - O
, - - O
and - - O
140 - - O
in - - O
finishing - - O
heifers - - O
administered - - O
the - - O
following - - O
treatments - - O
: - - O
1 - - O
) - - O
control - - O
; - - O
2 - - O
) - - O
MGA - - O
, - - O
. - - O
5 - - O
mg - - O
per - - O
heifer - - O
daily - - O
; - - O
3 - - O
) - - O
Revalor-H - - O
( - - O
140 - - O
mg - - O
TBA - - O
+ - - O
14 - - O
mg - - O
E2 - - O
) - - O
; - - O
4 - - O
) - - O
Revalor-H - - O
+ - - O
MGA - - O
; - - O
5 - - O
) - - O
Finaplix-H - - O
( - - O
200 - - O
mg - - O
TBA - - O
) - - O
; - - O
and - - O
6 - - O
) - - O
Finaplix-H - - O
+ - - O
MGA - - O
. - - O

This - - O
finding - - O
is - - O
consistent - - O
with - - O
the - - O
notion - - O
that - - O
the - - O
dsRNA - - O
binding - - O
domains - - O
may - - O
be - - O
composed - - O
of - - O
two - - O
separate - - O
functional - - O
subdomains - - O
. - - O

The - - O
molecular - - O
basis - - O
for - - O
commitment - - O
of - - O
progenitors - - O
to - - O
the - - O
eosinophil - - O
lineage - - O
and - - O
mechanisms - - O
by - - O
which - - O
eosinophil-specific - - O
genes - - O
are - - O
expressed - - O
and - - O
regulated - - O
during - - O
differentiation - - O
is - - O
unknown - - O
. - - O

To - - O
test - - O
the - - O
hypothesis - - O
that - - O
these - - O
elements - - O
are - - O
required - - O
for - - O
promoter - - O
activity - - O
, - - O
we - - O
compared - - O
the - - O
reporter - - O
expression - - O
activity - - O
of - - O
segments - - O
containing - - O
mutations - - O
of - - O
these - - O
elements - - O
with - - O
activity - - O
of - - O
the - - O
parent - - B-MUT
Hlx - - I-MUT
promoter - - I-MUT
sequence - - I-MUT
. - - O

2 - - O
: - - O
The - - O
dynamic - - O
moduli - - O
of - - O
microcrystalline - - B-MUT
cellulose - - I-MUT
. - - O

N-Substituted - - O
trimethylsilylcarbamates - - O
were - - O
tested - - O
as - - O
derivatizing - - O
reagents - - O
for - - O
gas - - O
chromatographic - - O
analysis - - O
. - - O

Glomerular - - O
lesions - - O
in - - O
renal - - O
allografts - - O
. - - O

At - - O
the - - O
genomic - - O
level - - O
, - - O
the - - O
sequences - - O
of - - O
two - - O
members - - O
of - - O
this - - O
family - - O
are - - O
known - - O
in - - O
the - - O
rat - - O
Rattus - - O
norvegicus - - O
: - - O
the - - O
VCSA1 - - B-MUT
gene - - I-MUT
, - - O
encoding - - O
the - - O
prohormone-like - - B-MUT
polypeptide - - I-MUT
SMR1 - - I-MUT
, - - O
and - - O
the - - O
VCSB1 - - B-MUT
gene - - I-MUT
, - - O
encoding - - O
a - - O
salivary - - O
Pro-rich - - O
polypeptide - - O
. - - O

Angiotensin - - B-MUT
effect - - O
in - - O
the - - O
human - - O
kidney - - O
. - - O

The - - O
RNA - - O
genome - - O
of - - O
rabbit - - O
hemorrhagic - - O
disease - - O
virus - - O
( - - O
RHDV - - O
) - - O
was - - O
molecularly - - O
cloned - - O
. - - O

We - - O
have - - O
introduced - - O
a - - O
mutation - - O
( - - O
Ser36 - - O
-- - - O
> - - O
Asn - - O
) - - O
into - - O
this - - O
domain - - O
of - - O
p190 - - B-MUT
that - - O
decreased - - O
its - - O
ability - - O
to - - O
bind - - O
guanine - - O
nucleotide - - O
when - - O
expressed - - O
as - - O
a - - O
hemagglutinin - - B-MUT
( - - O
HA - - B-MUT
) - - O
-tagged - - O
protein - - O
in - - O
COS - - O
cells - - O
. - - O

Increased - - O
p53 - - B-MUT
activity - - O
induced - - O
by - - O
OP - - O
is - - O
not - - O
due - - O
to - - O
elevated - - O
p53 - - B-MUT
mRNA - - I-MUT
nor - - O
to - - O
protein - - O
levels - - O
. - - O

In - - O
an - - O
ongoing - - O
study - - O
the - - O
performance - - O
of - - O
the - - O
SMSP - - O
is - - O
being - - O
compared - - O
with - - O
that - - O
of - - O
the - - O
Mini - - O
Speech - - O
Processor - - O
( - - O
MSP - - O
) - - O
. - - O

Tumor - - B-MUT
necrosis - - I-MUT
factor - - I-MUT
( - - O
TNF - - B-MUT
) - - O
is - - O
reported - - O
to - - O
cause - - O
a - - O
shock - - O
syndrome - - O
similar - - O
to - - O
that - - O
produced - - O
by - - O
endotoxin - - B-MUT
( - - O
LPS - - B-MUT
) - - O
. - - O

Phylogenetic - - O
analyses - - O
of - - O
19 - - O
amino - - O
acid - - O
sequences - - O
of - - O
6 - - O
related - - O
protein - - O
types - - O
indicate - - O
that - - O
actin-associated - - O
proteins - - O
related - - O
to - - O
gelsolin - - B-MUT
are - - O
monophyletic - - O
to - - O
a - - O
common - - O
ancestor - - O
and - - O
include - - O
flightless - - B-MUT
proteins - - I-MUT
. - - O

Whereas - - O
the - - O
mutant - - O
enzymes - - O
terminate - - O
normally - - O
at - - O
the - - O
late - - O
terminator - - O
in - - O
T7 - - O
DNA - - O
( - - O
T - - O
( - - O
phi - - O
) - - O
) - - O
and - - O
rrnB - - O
T2 - - O
, - - O
they - - O
fail - - O
to - - O
terminate - - O
at - - O
one - - O
of - - O
the - - O
termination - - O
sites - - O
of - - O
rrnB - - O
T1 - - O
, - - O
and - - O
also - - O
fail - - O
to - - O
recognize - - O
the - - O
PTH - - B-MUT
and - - O
CJ - - O
signals - - O
. - - O

Anoxia - - O
was - - O
introduced - - O
by - - O
perfusing - - O
the - - O
gill - - O
with - - O
water - - O
deprived - - O
of - - O
oxygen - - O
or - - O
by - - O
halting - - O
the - - O
water - - O
flow - - O
to - - O
the - - O
gill - - O
. - - O

Alternative - - O
splicing - - O
of - - O
ClC-6 - - B-MUT
( - - O
a - - O
member - - O
of - - O
the - - O
CIC - - B-MUT
chloride-channel - - I-MUT
family - - I-MUT
) - - O
transcripts - - O
generates - - O
three - - O
truncated - - O
isoforms - - O
one - - O
of - - O
which - - O
, - - O
ClC-6c - - B-MUT
, - - O
is - - O
kidney-specific - - O
. - - O

Strategies - - O
for - - O
blood - - O
screening - - O
for - - O
the - - O
hepatitis - - O
C - - O
virus - - O
and - - O
for - - O
the - - O
human - - O
immunodeficiency - - O
virus - - O
in - - O
high - - O
risk - - O
groups - - O
. - - O

We - - O
purified - - O
both - - O
proteins - - O
from - - O
human - - O
platelet - - O
membranes - - O
using - - O
DEAE-Sepharose - - O
chromatography - - O
followed - - O
by - - O
mAb - - B-MUT
F11 - - I-MUT
affinity - - O
chromatography - - O
. - - O

The - - O
evaluation - - O
of - - O
amniotic - - O
fluid - - O
delta - - O
OD450 - - O
is - - O
considered - - O
to - - O
be - - O
the - - O
cornerstone - - O
of - - O
clinical - - O
management - - O
. - - O

5 - - O
) - - O
Before - - O
and - - O
ten - - O
days - - O
after - - O
DOTC - - O
infusion - - O
, - - O
laboratory - - O
tests - - O
for - - O
liver - - O
and - - O
renal - - O
functions - - O
and - - O
blood - - O
were - - O
performed - - O
. - - O

A - - O
recombinant - - O
with - - O
a - - O
5' - - O
end - - O
from - - O
src - - B-MUT
and - - O
a - - O
3' - - O
end - - O
from - - O
ros - - B-MUT
, - - O
called - - O
SRC - - B-MUT
x - - O
ROS - - B-MUT
, - - O
transformed - - O
chicken - - O
embryo - - O
fibroblasts - - O
( - - O
CEF - - O
) - - O
to - - O
a - - O
spindle - - O
shape - - O
morphology - - O
, - - O
mimicking - - O
that - - O
of - - O
UR2 - - B-MUT
. - - O

After - - O
one - - O
accommodation - - O
night - - O
, - - O
sleep - - O
EEG - - O
recordings - - O
were - - O
performed - - O
during - - O
three - - O
consecutive - - O
nights - - O
in - - O
ten - - O
drug-free - - O
inpatients - - O
presenting - - O
generalized - - O
anxiety - - O
disorder - - O
( - - O
GAD - - O
) - - O
with - - O
significant - - O
depression - - O
, - - O
compared - - O
with - - O
a - - O
age- - - O
and - - O
sex-matched - - O
group - - O
of - - O
patients - - O
with - - O
GAD - - O
and - - O
a - - O
group - - O
of - - O
primary - - O
major - - O
depressive - - O
disorder - - O
( - - O
MDD - - O
) - - O
patients - - O
. - - O

S6 - - B-MUT
kinase - - I-MUT
activation - - O
requires - - O
displacement - - O
of - - O
this - - O
inhibitory - - O
segment - - O
, - - O
which - - O
is - - O
proposed - - O
to - - O
occur - - O
consequent - - O
to - - O
its - - O
multiple - - O
phosphorylation - - O
. - - O

Thus - - O
, - - O
the - - O
PCE - - B-MUT
binds - - O
a - - O
Pbx - - B-MUT
dimer - - I-MUT
partner - - I-MUT
that - - O
behaves - - O
unlike - - O
Class - - B-MUT
I - - I-MUT
Hox - - I-MUT
proteins - - I-MUT
. - - O

Most - - O
recently - - O
, - - O
the - - O
use - - O
of - - O
the - - O
product - - O
of - - O
brain - - O
weight - - O
and - - O
clearance - - O
has - - O
been - - O
proposed - - O
. - - O

Purified - - B-MUT
P7 - - I-MUT
could - - O
be - - O
assembled - - O
onto - - O
particles - - O
lacking - - O
P7 - - B-MUT
and - - O
particles - - O
lacking - - O
both - - O
P2 - - B-MUT
( - - O
RNA - - B-MUT
polymerase - - I-MUT
) - - O
and - - O
P7 - - O
. - - O

Deletion - - O
analyses - - O
of - - O
the - - O
pCD41 - - B-MUT
ORF-A - - I-MUT
and - - O
the - - O
use - - O
of - - O
promoter - - O
constructs - - O
further - - O
mapped - - O
an - - O
internal - - O
functional - - O
promoter - - O
within - - O
the - - O
pCD41 - - B-MUT
sequence - - I-MUT
that - - O
can - - O
direct - - O
the - - O
synthesis - - O
of - - O
the - - O
trans-activating - - O
protein - - O
. - - O

Reproductive - - O
period - - O
affects - - O
water - - O
intake - - O
in - - O
heat-stressed - - O
dehydrated - - O
goats - - O
. - - O

Our - - O
data - - O
suggest - - O
that - - O
trans-activation - - O
from - - O
the - - O
prothymosin - - B-MUT
intron - - I-MUT
enhancer - - I-MUT
is - - O
a - - O
faithful - - O
reflection - - O
of - - O
the - - O
transforming - - O
properties - - O
of - - O
the - - O
Myc - - B-MUT
protein - - I-MUT
. - - O

The - - O
mRNA - - O
expression - - O
of - - O
RFX1 - - B-MUT
, - - O
RFX2 - - B-MUT
, - - O
and - - O
RFX3 - - B-MUT
was - - O
detected - - O
ubiquitously - - O
, - - O
but - - O
in - - O
transient-transfection - - O
assays - - O
, - - O
multimerized - - B-MUT
RFX - - I-MUT
binding - - I-MUT
sites - - I-MUT
in - - O
front - - O
of - - O
a - - O
basal - - O
promoter - - O
efficiently - - O
functioned - - O
in - - O
a - - O
tissue- - - O
and - - O
lineage-specific - - O
manner - - O
. - - O

To - - O
study - - O
the - - O
role - - O
of - - O
heavy - - B-MUT
chain - - I-MUT
motifs - - I-MUT
in - - O
substrate - - O
recognition - - O
, - - O
secreted - - O
variants - - O
of - - O
recombinant - - B-MUT
bovine - - I-MUT
proenteropeptidase - - I-MUT
were - - O
constructed - - O
by - - O
replacing - - O
the - - O
transmembrane - - O
domain - - O
with - - O
a - - O
signal - - O
peptide - - O
. - - O

The - - O
centromedial - - O
amygdala - - O
and - - O
gastric - - O
pathology - - O
in - - O
rats - - O
. - - O

The - - O
p53-homolog - - B-MUT
p73beta - - B-MUT
also - - O
activated - - O
the - - O
PIG3 - - B-MUT
promoter - - I-MUT
, - - O
but - - O
in - - O
contrast - - O
to - - O
p53 - - B-MUT
, - - O
the - - O
proline-rich - - O
domain - - O
of - - O
p73beta - - B-MUT
( - - I-MUT
residues - - I-MUT
81-113 - - I-MUT
) - - I-MUT
was - - O
dispensable - - O
to - - O
induce - - O
the - - O
PIG3 - - B-MUT
promoter - - I-MUT
. - - O

The - - O
predicted - - O
amino - - O
acid - - O
sequence - - O
of - - O
m-Staf - - B-MUT
is - - O
highly - - O
homologous - - O
to - - O
that - - O
of - - O
Staf - - B-MUT
, - - O
another - - O
selenocysteine - - B-MUT
tRNA - - I-MUT
gene - - I-MUT
transcription - - I-MUT
activating - - I-MUT
factor - - I-MUT
of - - O
Xenopus - - O
laevis - - O
. - - O

The - - O
DRF-2 - - B-MUT
nuclear - - I-MUT
protein - - I-MUT
has - - O
characteristics - - O
similar - - O
to - - O
those - - O
of - - O
the - - O
muscle-specific - - O
regulatory - - O
factor - - O
, - - O
MEF-2 - - B-MUT
( - - O
Buskin - - O
and - - O
Hauschka - - O
1989 - - O
; - - O
Gossett - - O
et - - O
al - - O
. - - O
, - - O
1989 - - O
) - - O
. - - O

Pulmonary - - O
vein - - O
varix - - O
in - - O
association - - O
with - - O
bilateral - - O
pulmonary - - O
vein - - O
stenosis - - O
. - - O

RESULTS - - O
: - - O
At - - O
the - - O
beginning - - O
of - - O
the - - O
QA - - O
QI - - O
process - - O
, - - O
monitoring - - O
of - - O
blood - - O
administration - - O
practices - - O
revealed - - O
that - - O
a - - O
variance - - O
from - - O
institutional - - O
blood - - O
administration - - O
policy - - O
occurred - - O
during - - O
50 - - O
percent - - O
of - - O
blood - - O
and - - O
component - - O
transfusions - - O
. - - O

TNFalpha - - B-MUT
and - - O
IL-6 - - B-MUT
levels - - O
were - - O
determined - - O
in - - O
the - - O
culture - - O
supernatants - - O
. - - O

The - - O
human - - B-MUT
papillomavirus - - I-MUT
type - - I-MUT
16 - - I-MUT
E7 - - I-MUT
protein - - I-MUT
complements - - O
adenovirus - - B-MUT
type - - I-MUT
5 - - I-MUT
E1A - - I-MUT
amino-terminus-dependent - - O
transactivation - - O
of - - O
adenovirus - - O
type - - O
5 - - O
early - - O
genes - - O
and - - O
increases - - O
ATF - - B-MUT
and - - O
Oct-1 - - B-MUT
DNA - - O
binding - - O
activity - - O
. - - O

In - - O
two - - O
further - - O
cases - - O
( - - O
one - - O
type - - O
I - - O
and - - O
one - - O
type - - O
III - - O
SMA - - O
) - - O
, - - O
de - - O
novo - - O
deletions - - O
of - - O
only - - O
one - - O
copy - - O
of - - O
Ag1-CA - - B-MUT
and - - O
C212 - - B-MUT
were - - O
found - - O
. - - O

In - - O
supine - - O
position - - O
, - - O
plasma - - O
ANP - - B-MUT
levels - - O
ranged - - O
from - - O
12 - - O
pg - - O
ml - - O
to - - O
51 - - O
. - - O
5 - - O
pg - - O
ml - - O
, - - O
with - - O
an - - O
average - - O
level - - O
of - - O
35 - - O
. - - O
3 - - O
+ - - O
- - - O
11 - - O
. - - O
5 - - O
pg - - O
ml - - O
. - - O

NIK-244 - - O
suppressed - - O
coronary - - O
ligation- - - O
and - - O
digitalis-induced - - O
arrhythmias - - O
, - - O
and - - O
the - - O
minimum - - O
effective - - O
plasma - - O
concentrations - - O
for - - O
arrhythmias - - O
induced - - O
by - - O
24-h - - O
and - - O
48-h - - O
coronary - - O
ligation - - O
and - - O
digitalis - - O
were - - O
0 - - O
. - - O
41 - - O
+ - - O
- - - O
0 - - O
. - - O
10 - - O
( - - O
by - - O
1 - - O
mg - - O
kg - - O
i - - O
. - - O
v - - O
. - - O
) - - O
, - - O
0 - - O
. - - O
70 - - O
+ - - O
- - - O
0 - - O
. - - O
13 - - O
( - - O
by - - O
1 - - O
mg - - O
kg - - O
i - - O
. - - O
v - - O
. - - O
) - - O
, - - O
and - - O
0 - - O
. - - O
21 - - O
+ - - O
- - - O
0 - - O
. - - O
08 - - O
( - - O
by - - O
0 - - O
. - - O
5 - - O
mg - - O
kg - - O
i - - O
. - - O
v - - O
. - - O
) - - O
microgram - - O
ml - - O
, - - O
respectively - - O
( - - O
mean - - O
+ - - O
- - - O
SD - - O
of - - O
the - - O
mean - - O
, - - O
n - - O
= - - O
6 - - O
) - - O
. - - O

The - - O
5' - - O
external - - O
transcribed - - O
spacer - - O
( - - O
ETS - - O
) - - O
region - - O
of - - O
the - - O
pre-rRNA - - O
in - - O
Saccharomyces - - O
cerevisiae - - O
contains - - O
a - - O
sequence - - O
with - - O
10 - - O
bp - - O
of - - O
perfect - - O
complementarity - - O
to - - O
the - - O
U3 - - B-MUT
snoRNA - - I-MUT
. - - O

This - - O
constitutes - - O
evidence - - O
for - - O
an - - O
in - - O
vivo - - O
role - - O
of - - O
SRC-1 - - B-MUT
in - - O
dimerization-induced - - O
activation - - O
by - - O
OR1 - - B-MUT
RXRalpha - - I-MUT
. - - I-MUT

To - - O
further - - O
define - - O
the - - O
structural - - O
requirements - - O
for - - O
ZAP-70 - - B-MUT
interaction - - O
with - - O
the - - O
TCR - - B-MUT
, - - O
we - - O
developed - - O
a - - O
binding - - O
assay - - O
using - - O
immobilized - - O
glutathione - - B-MUT
S-transferase - - I-MUT
fusion - - I-MUT
proteins - - I-MUT
containing - - O
the - - O
NH2- - - O
and - - O
or - - O
COOH-terminal - - O
SH2 - - B-MUT
domains - - I-MUT
of - - I-MUT
ZAP-70 - - O
, - - B-MUT
and - - O
soluble - - O
synthetic - - O
peptides - - O
with - - O
the - - O
sequence - - O
of - - O
the - - O
cytoplasmic - - O
region - - O
of - - O
the - - O
TCR - - O
zeta - - B-MUT
chain - - I-MUT
( - - I-MUT
TCR - - O
zeta - - B-MUT
cyt - - I-MUT
) - - I-MUT
or - - O
individual - - O
TCR - - O
zeta - - B-MUT
and - - I-MUT
CD3 - - O
epsilon - - B-MUT
TAM - - I-MUT
motifs - - I-MUT
. - - I-MUT

The - - O
inspiratory - - O
oxygen - - O
concentration - - O
needed - - O
( - - O
FiO2 - - O
) - - O
and - - O
the - - O
Horowitz - - O
quotient - - O
differed - - O
in - - O
a - - O
highly - - O
significant - - O
manner - - O
beginning - - O
on - - O
the - - O
1st - - O
day - - O
after - - O
trauma - - O
. - - O

The - - O
sera - - O
and - - O
nasal - - O
secretions - - O
of - - O
142 - - O
patients - - O
, - - O
who - - O
were - - O
positive - - O
in - - O
HD - - O
or - - O
mites - - O
skin - - O
test - - O
, - - O
were - - O
subjected - - O
to - - O
a - - O
radioallergosorbent - - O
test - - O
( - - O
RAST - - O
) - - O
for - - O
estimating - - O
the - - O
specific - - O
IgE - - B-MUT
antibody - - I-MUT
activity - - O
to - - O
mites - - O
. - - O

This - - O
organization - - O
suggests - - O
that - - O
duplication - - O
events - - O
that - - O
have - - O
generated - - O
the - - O
primate - - B-MUT
FUT3-FUT5-FUT6 - - I-MUT
cluster - - I-MUT
might - - O
have - - O
occurred - - O
through - - O
a - - O
long-interspersed-nuclear-element-based - - O
mechanism - - O
of - - O
unequal - - O
crossing - - O
over - - O
, - - O
as - - O
described - - O
for - - O
the - - O
globin - - B-MUT
cluster - - I-MUT
. - - O

Structure - - O
determination - - O
of - - O
an - - O
adsorbate-induced - - O
multilayer - - O
reconstruction - - O
: - - O
( - - O
1 - - O
x - - O
2 - - O
) - - O
-H - - O
Ni - - O
( - - O
110 - - O
) - - O
. - - O

BACKGROUND - - O
: - - O
In - - O
the - - O
ubiquitin-dependent - - O
proteolysis - - O
pathway - - O
, - - O
a - - O
ubiquitin - - B-MUT
ligase - - I-MUT
( - - O
E3 - - B-MUT
) - - O
is - - O
responsible - - O
for - - O
substrate - - O
selectivity - - O
and - - O
timing - - O
of - - O
degradation - - O
. - - O

The - - O
initial - - O
phase - - O
of - - O
increased - - O
vascular - - O
permeability - - O
in - - O
the - - O
peritoneal - - O
cavity - - O
and - - O
LTB4 - - O
production - - O
was - - O
dose - - O
dependently - - O
inhibited - - O
by - - O
the - - O
5-LO - - O
inhibitors - - O
phenidone - - O
, - - O
BW - - O
A4C - - O
, - - O
A63162 - - O
, - - O
and - - O
ICI - - O
207 - - O
968 - - O
but - - O
not - - O
by - - O
dexamethasone - - O
or - - O
colchicine - - O
. - - O

Circulatory - - O
arrest - - O
in - - O
the - - O
operating - - O
room - - O
. - - O

This - - O
study - - O
is - - O
a - - O
further - - O
and - - O
more - - O
extensive - - O
validation - - O
of - - O
the - - O
clinician - - O
rated - - O
NIMH-LCM-p - - O
. - - O

The - - O
Mean - - O
was - - O
74 - - O
, - - O
3 - - O
+ - - O
- - - O
53 - - O
, - - O
6 - - O
micrograms - - O
J - - O
g - - O
Cr - - O
, - - O
the - - O
Median - - O
61 - - O
micrograms - - O
J - - O
g - - O
Cr - - O
. - - O

Left - - O
atrial - - O
volumes - - O
were - - O
greater - - O
in - - O
old - - O
compared - - O
with - - O
young - - O
subjects - - O
( - - O
maximal - - O
: - - O
31 - - O
+ - - O
- - - O
10 - - O
cm3 - - O
m2 - - O
vs - - O
24 - - O
+ - - O
- - - O
8 - - O
cm3 - - O
m2 - - O
, - - O
p - - O
= - - O
0 - - O
. - - O
02 - - O
; - - O
at - - O
onset - - O
of - - O
atrial - - O
systole - - O
: - - O
23 - - O
+ - - O
- - - O
8 - - O
cm3 - - O
m2 - - O
vs - - O
15 - - O
+ - - O
- - - O
5 - - O
cm3 - - O
m2 - - O
, - - O
p - - O
= - - O
0 - - O
. - - O
0002 - - O
; - - O
minimal - - O
: - - O
13 - - O
+ - - O
- - - O
5 - - O
cm3 - - O
m2 - - O
vs - - O
9 - - O
+ - - O
- - - O
4 - - O
cm3 - - O
m2 - - O
, - - O
p - - O
= - - O
0 - - O
. - - O
001 - - O
) - - O
. - - O

This - - O
article - - O
describes - - O
the - - O
collaborative - - O
care - - O
of - - O
the - - O
woman - - O
participating - - O
in - - O
maternal - - O
blood - - O
donation - - O
for - - O
intrauterine - - O
transfusion - - O
. - - O

Gestational - - O
trophoblastic - - O
diseases - - O
: - - O
recent - - O
advances - - O
in - - O
the - - O
understanding - - O
of - - O
cytogenetics - - O
, - - O
histopathology - - O
, - - O
and - - O
natural - - O
history - - O
. - - O

A - - O
genetic - - O
screen - - O
applied - - O
to - - O
mutants - - O
in - - O
the - - O
branch - - O
site - - O
region - - O
shows - - O
that - - O
all - - O
positions - - O
in - - O
the - - O
conserved - - O
TACTAAC - - O
sequence - - O
are - - O
important - - O
for - - O
intron - - O
recognition - - O
. - - O

A - - O
global - - O
response - - O
rate - - O
was - - O
17% - - O
( - - O
95% - - O
confidence - - O
interval - - O
( - - O
95% - - O
CI - - O
) - - O
: - - O
2%-32% - - O
) - - O
and - - O
the - - O
median - - O
overall - - O
survival - - O
was - - O
12 - - O
months - - O
. - - O

The - - O
system - - O
consisted - - O
of - - O
the - - O
intact - - O
canine - - O
heart - - O
connected - - O
to - - O
a - - O
microcomputer - - O
that - - O
operated - - O
as - - O
the - - O
modulated - - O
parasystolic - - O
pacemaker - - O
. - - O

Immunological - - O
and - - O
biochemical - - O
characterization - - O
of - - O
streptococcal - - B-MUT
pyrogenic - - I-MUT
exotoxins - - I-MUT
I - - I-MUT
and - - I-MUT
J - - I-MUT
( - - O
SPE-I - - B-MUT
and - - O
SPE-J - - B-MUT
) - - O
from - - O
Streptococcus - - O
pyogenes - - O
. - - O

Patients - - O
with - - O
an - - O
enzymatic - - O
activity - - O
below - - O
X--1 - - O
manifested - - O
a - - O
decrease - - O
of - - O
the - - O
content - - O
of - - O
IgA - - B-MUT
, - - O
IgG - - B-MUT
, - - O
IgM - - B-MUT
, - - O
T - - O
and - - O
B - - O
lymphocytes - - O
, - - O
and - - O
of - - O
phagocytic - - O
activity - - O
of - - O
neutrophils - - O
as - - O
compared - - O
to - - O
patients - - O
exhibiting - - O
a - - O
high - - O
enzymatic - - O
activity - - O
. - - O

These - - O
data - - O
suggest - - O
that - - O
the - - O
combined - - O
treatment - - O
with - - O
a - - O
thromboxane - - B-MUT
synthetase - - I-MUT
inhibitor - - O
and - - O
a - - O
thromboxane - - B-MUT
receptor - - I-MUT
antagonist - - O
provides - - O
a - - O
better - - O
protection - - O
against - - O
digoxin - - O
intoxication - - O
than - - O
with - - O
either - - O
agent - - O
alone - - O
. - - O

RESULTS - - O
: - - O
Cholinergic - - O
nerves - - O
are - - O
mainly - - O
involved - - O
in - - O
the - - O
regulation - - O
of - - O
enteric - - O
nerve - - O
responses - - O
to - - O
EFS - - O
in - - O
the - - O
normal - - O
IAS - - O
. - - O

These - - O
are - - O
the - - O
long - - B-MUT
terminal - - I-MUT
repeat - - I-MUT
( - - I-MUT
LTR - - I-MUT
) - - I-MUT
promoter - - I-MUT
, - - O
which - - O
regulates - - O
expression - - O
of - - O
the - - O
viral - - O
structural - - O
proteins - - O
, - - O
and - - O
a - - O
second - - O
internal - - O
promoter - - O
, - - O
located - - O
towards - - O
the - - O
3' - - O
end - - O
of - - O
the - - O
env - - B-MUT
gene - - I-MUT
, - - O
that - - O
directs - - O
expression - - O
of - - O
the - - O
viral - - O
auxiliary - - O
proteins - - O
. - - O

The - - O
1 - - O
. - - O
1- - - O
and - - O
1 - - O
. - - O
3-kb - - O
mRNA - - O
species - - O
were - - O
found - - O
only - - O
in - - O
the - - O
heart - - O
, - - O
and - - O
the - - O
2 - - O
. - - O
6-kb - - O
species - - O
was - - O
found - - O
in - - O
the - - O
heart - - O
, - - O
kidney - - O
and - - O
brain - - O
, - - O
but - - O
not - - O
in - - O
skeletal - - O
muscle - - O
or - - O
liver - - O
. - - O

It - - O
has - - O
been - - O
reported - - O
that - - O
rat - - O
blood - - O
chloroform - - O
levels - - O
were - - O
significantly - - O
decreased - - O
after - - O
treatment - - O
with - - O
ClO2 - - O
. - - O

A - - O
DNA - - O
motif - - O
related - - O
to - - O
the - - O
cAMP-responsive - - B-MUT
element - - I-MUT
and - - O
an - - O
exon-located - - B-MUT
activator - - I-MUT
protein-2 - - I-MUT
binding - - I-MUT
site - - I-MUT
in - - O
the - - O
human - - B-MUT
tissue-type - - I-MUT
plasminogen - - I-MUT
activator - - I-MUT
gene - - I-MUT
promoter - - I-MUT
cooperate - - O
in - - O
basal - - O
expression - - O
and - - O
convey - - O
activation - - O
by - - O
phorbol - - O
ester - - O
and - - O
cAMP - - O
. - - O

To - - O
facilitate - - O
the - - O
availability - - O
of - - O
important - - O
new - - O
therapeutic - - O
agents - - O
, - - O
the - - O
Food - - O
and - - O
Drug - - O
Administration - - O
( - - O
FDA - - O
) - - O
in - - O
the - - O
mid-1970s - - O
began - - O
assigning - - O
therapeutic - - O
ratings - - O
to - - O
investigational - - O
new - - O
drugs - - O
and - - O
holding - - O
end-of-phase - - O
II - - O
conferences - - O
with - - O
drug - - O
sponsors - - O
. - - O

Band - - O
structure - - O
effects - - O
of - - O
transport - - O
properties - - O
in - - O
icosahedral - - O
quasicrystals - - O
. - - O

Each - - O
dietary - - O
treatment - - O
was - - O
fed - - O
to - - O
six - - O
pen - - O
replicates - - O
of - - O
five - - O
chicks - - O
per - - O
pen - - O
for - - O
21 - - O
d - - O
. - - O

Repression - - O
of - - O
glucocorticoid - - O
receptor-mediated - - O
transcriptional - - O
activation - - O
by - - O
unliganded - - O
thyroid - - B-MUT
hormone - - I-MUT
receptor - - I-MUT
( - - O
TR - - B-MUT
) - - O
is - - O
TR - - B-MUT
isoform-specific - - O
. - - O

cDNA - - O
encoding - - O
a - - O
functional - - O
feline - - B-MUT
liver - - I-MUT
bone - - I-MUT
kidney-type - - I-MUT
alkaline - - I-MUT
phosphatase - - I-MUT
. - - I-MUT

Goodpasture's-like - - O
syndrome - - O
and - - O
effect - - O
of - - O
extracorporeal - - O
membrane - - O
oxygenator - - O
support - - O
. - - O

RNase - - B-MUT
protection - - O
assays - - O
revealed - - O
a - - O
correlation - - O
between - - O
the - - O
levels - - O
of - - O
dorsal - - O
and - - O
ventral - - O
skin - - O
expression - - O
with - - O
pigmentation - - O
phaeomelanin - - O
phenotypes - - O
. - - O

Because - - O
chromosome - - O
X - - O
is - - O
frequently - - O
involved - - O
in - - O
structural - - O
alterations - - O
in - - O
neoplastic - - O
Syrian - - O
hamster - - O
cells - - O
transformed - - O
by - - O
chemical - - O
carcinogens - - O
and - - O
oncogenic - - O
viruses - - O
, - - O
the - - O
localization - - O
of - - O
the - - O
cph - - B-MUT
locus - - I-MUT
on - - O
this - - O
chromosome - - O
supports - - O
the - - O
notion - - O
that - - O
the - - O
cph - - B-MUT
oncogene - - I-MUT
plays - - O
a - - O
role - - O
in - - O
the - - O
malignant - - O
conversion - - O
of - - O
chemically - - O
transformed - - O
hamster - - O
fibroblasts - - O
. - - O

In - - O
this - - O
paper - - O
, - - O
the - - O
current - - O
status - - O
of - - O
the - - O
understanding - - O
of - - O
the - - O
interaction - - O
mechanisms - - O
of - - O
ultrasound - - O
with - - O
biological - - O
media - - O
and - - O
the - - O
factors - - O
that - - O
govern - - O
different - - O
biological - - O
effects - - O
are - - O
surveyed - - O
. - - O

Most - - O
of - - O
the - - O
phenomena - - O
of - - O
azotaemic - - O
osteodystrophy - - O
are - - O
encountered - - O
in - - O
simple - - O
vitamin - - O
D - - O
deficiency - - O
; - - O
as - - O
in - - O
that - - O
condition - - O
, - - O
deficiency - - O
of - - O
1 - - O
, - - O
25-dihydroxycholecalciferol - - O
may - - O
be - - O
of - - O
primary - - O
significance - - O
in - - O
causing - - O
secondary - - O
hyperparathyroidism - - O
in - - O
renal - - O
failure - - O
. - - O

A - - O
G22V - - B-MUT
mutant - - I-MUT
of - - O
M-Ras - - B-MUT
was - - O
constitutively - - O
active - - O
and - - O
its - - O
expression - - O
in - - O
an - - O
interleukin-3 - - B-MUT
( - - O
IL-3 - - B-MUT
) - - O
-dependent - - O
mast - - O
cell - - O
megakaryocyte - - O
cell - - O
line - - O
resulted - - O
in - - O
increased - - O
survival - - O
in - - O
the - - O
absence - - O
of - - O
IL-3 - - O
, - - B-MUT
increased - - O
growth - - O
in - - O
IL-4 - - O
, - - B-MUT
and - - O
, - - O
at - - O
high - - O
expression - - O
levels - - O
, - - O
in - - O
factor-independent - - O
growth - - O
. - - O

Diabetes - - O
care - - O
: - - O
a - - O
guideline - - O
to - - O
the - - O
facilities - - O
needed - - O
to - - O
support - - O
internationally - - O
endorsed - - O
standards - - O
. - - O

However - - O
, - - O
the - - O
N63S - - O
mutation - - O
in - - O
the - - O
wild-type - - B-MUT
VP5 - - I-MUT
background - - O
increased - - O
the - - O
interaction - - O
, - - O
as - - O
judged - - O
by - - O
the - - O
beta-galactosidase - - B-MUT
activity - - O
, - - O
by - - O
a - - O
factor - - O
of - - O
9 - - O
relative - - O
to - - O
when - - O
the - - O
PR7 - - O
mutation - - O
was - - O
present - - O
. - - O

The - - O
possibility - - O
of - - O
a - - O
hereditary - - O
disorder - - O
leading - - O
to - - O
a - - O
minor - - O
defect - - O
in - - O
elastic - - O
fibre - - O
structure - - O
which - - O
could - - O
be - - O
responsible - - O
for - - O
the - - O
spontaneous - - O
lesions - - O
is - - O
discussed - - O
. - - O

The - - O
binding - - O
of - - O
PH - - B-MUT
domains - - I-MUT
to - - O
Gbetagamma - - B-MUT
was - - O
inhibited - - O
by - - O
preincubation - - O
of - - O
Gbetagamma - - B-MUT
with - - O
the - - O
GDP-bound - - O
but - - O
not - - O
the - - O
GTP-bound - - O
form - - O
of - - O
Gialpha - - B-MUT
. - - O

It - - O
was - - O
shown - - O
that - - O
estradiol - - O
concentrations - - O
obtained - - O
after - - O
estradiol - - O
valerate - - O
and - - O
micronized - - O
estradiol - - O
ingestion - - O
were - - O
dependent - - O
on - - O
the - - O
patient's - - O
age - - O
as - - O
well - - O
as - - O
on - - O
the - - O
constitutional - - O
type - - O
. - - O

False - - O
positive - - O
amniotic - - B-MUT
fluid - - I-MUT
alpha - - I-MUT
fetoprotein - - I-MUT
levels - - O
resulting - - O
from - - O
contamination - - O
with - - O
fetal - - O
blood - - O
: - - O
results - - O
of - - O
an - - O
experiment - - O
. - - O

Piperacillin-tazobactam - - O
can - - O
be - - O
used - - O
for - - O
the - - O
treatment - - O
of - - O
infections - - O
caused - - O
by - - O
gram-negative - - O
, - - O
gram-positive - - O
, - - O
aerobic - - O
, - - O
and - - O
anaerobic - - O
bacteria - - O
. - - O

Identification - - O
of - - O
RNase - - B-MUT
T - - I-MUT
as - - O
a - - O
high-copy - - O
suppressor - - O
of - - O
the - - O
UV - - O
sensitivity - - O
associated - - O
with - - O
single-strand - - B-MUT
DNA - - I-MUT
exonuclease - - I-MUT
deficiency - - O
in - - O
Escherichia - - O
coli - - O
. - - O

All - - O
patients - - O
had - - O
elevated - - O
levels - - O
of - - O
serum - - B-MUT
IgE - - I-MUT
antibodies - - I-MUT
to - - O
the - - O
crude - - O
soybean - - O
extract - - O
; - - O
binding - - O
values - - O
ranged - - O
from - - O
2 - - O
. - - O
3 - - O
to - - O
28 - - O
. - - O
1 - - O
times - - O
that - - O
of - - O
a - - O
negative - - O
control - - O
serum - - O
. - - O

The - - O
gene - - O
includes - - O
three - - O
exons - - O
and - - O
two - - O
introns - - O
within - - O
1 - - O
. - - O
6 - - O
kilobases - - O
of - - O
DNA - - O
, - - O
and - - O
the - - O
entire - - O
open - - O
reading - - O
frame - - O
for - - O
glycoprotein - - B-MUT
IX - - I-MUT
is - - O
included - - O
within - - O
the - - O
third - - O
exon - - O
. - - O

DNA - - B-MUT
polymerase - - I-MUT
E - - I-MUT
, - - O
DNA - - B-MUT
ligase - - I-MUT
III - - I-MUT
and - - O
a - - O
DNA - - B-MUT
structure-specific - - I-MUT
endonuclease - - I-MUT
co-purify - - O
with - - O
the - - O
five - - O
polypeptide - - O
complex - - O
. - - O

Yeast - - B-MUT
U1 - - I-MUT
snRNP - - I-MUT
therefore - - O
contains - - O
16 - - O
different - - O
proteins - - O
, - - O
including - - O
seven - - O
snRNP - - B-MUT
core - - I-MUT
proteins - - I-MUT
, - - O
three - - O
homologues - - O
of - - O
the - - O
metazoan - - B-MUT
U1 - - I-MUT
snRNP-specific - - I-MUT
proteins - - I-MUT
, - - O
and - - O
six - - O
yeast-specific - - B-MUT
U1 - - I-MUT
snRNP - - I-MUT
proteins - - I-MUT
. - - O

Strontium - - O
chloride - - O
Sr - - O
89 - - O
is - - O
costly - - O
, - - O
but - - O
preliminary - - O
analysis - - O
indicates - - O
that - - O
it - - O
may - - O
reduce - - O
management - - O
expenditures - - O
overall - - O
. - - O
( - - O
ABSTRACT - - O
TRUNCATED - - O
AT - - O
250 - - O
WORDS - - O
) - - O

Measurement - - O
of - - O
magnesium - - O
absorption - - O
in - - O
man - - O
using - - O
stable - - O
26Mg - - O
as - - O
a - - O
tracer - - O
. - - O

On - - O
the - - O
basis - - O
of - - O
this - - O
anatomic - - O
concept - - O
, - - O
the - - O
brachioplasty - - O
procedure - - O
was - - O
modified - - O
to - - O
provide - - O
secure - - O
anchoring - - O
of - - O
the - - O
arm - - O
flap - - O
to - - O
the - - O
axillary - - O
fascia - - O
along - - O
with - - O
strong - - O
superficial - - O
fascial - - O
system - - O
repair - - O
of - - O
incisions - - O
, - - O
reducing - - O
the - - O
risk - - O
of - - O
widening - - O
or - - O
migration - - O
of - - O
scars - - O
and - - O
unnatural - - O
contours - - O
. - - O

The - - O
frameshift - - O
initiated - - O
by - - O
ADEx2 - - O
is - - O
believed - - O
to - - O
alter - - O
the - - O
regular - - O
coding - - O
sequence - - O
, - - O
acting - - O
as - - O
a - - O
loss-of-function - - O
ASIP - - B-MUT
mutation - - I-MUT
. - - O

Distant - - O
spread - - O
was - - O
found - - O
in - - O
46 - - O
patients - - O
( - - O
34% - - O
) - - O
, - - O
42 - - O
of - - O
whom - - O
had - - O
serum - - O
Tg - - O
greater - - O
than - - O
10 - - O
micrograms - - O
l - - O
. - - O

METHODS - - O
: - - O
Out - - O
of - - O
171 - - O
patients - - O
receiving - - O
anticoagulation - - O
between - - O
July - - O
1992 - - O
and - - O
December - - O
1993 - - O
, - - O
83 - - O
patients - - O
with - - O
hemispheric - - O
embolisms - - O
received - - O
heparin - - O
within - - O
72 - - O
hours - - O
from - - O
onset - - O
( - - O
activated - - O
partial - - O
thromboplastin - - B-MUT
time - - O
[ - - O
aPTT - - O
] - - O
1 - - O
. - - O
5 - - O
times - - O
control - - O
value - - O
) - - O
. - - O

These - - O
probable - - O
border - - O
sequences - - O
are - - O
closely - - O
related - - O
to - - O
those - - O
of - - O
other - - O
known - - O
T-regions - - O
and - - O
define - - O
a - - O
second - - O
T-region - - O
of - - O
pTiChry5 - - O
, - - O
called - - O
T-right - - O
( - - O
TR - - O
) - - O
, - - O
that - - O
confers - - O
production - - O
of - - O
the - - O
Amadoriopines - - O
. - - O

Open - - O
reading - - O
frames - - O
in - - O
a - - O
4556 - - O
nucleotide - - O
sequence - - O
within - - O
MDV-1 - - B-MUT
BamHI-D - - I-MUT
DNA - - I-MUT
fragment - - I-MUT
: - - O
evidence - - O
for - - O
splicing - - O
of - - O
mRNA - - O
from - - O
a - - O
new - - O
viral - - O
glycoprotein - - O
gene - - O
. - - O

The - - O
structural - - O
changes - - O
in - - O
intra-acinar - - O
artery - - O
manifested - - O
mainly - - O
by - - O
an - - O
increase - - O
in - - O
number - - O
of - - O
muscular - - O
artery - - O
resulting - - O
from - - O
muscularization - - O
of - - O
precursor - - O
cells - - O
( - - O
pericytes - - O
and - - O
intermediate - - O
cells - - O
) - - O
located - - O
within - - O
partially - - O
muscular - - O
and - - O
nonmuscular - - O
arterial - - O
wall - - O
to - - O
smooth - - O
muscle - - O
cell - - O
, - - O
and - - O
by - - O
the - - O
medial - - O
wall - - O
thickened - - O
due - - O
to - - O
hypertrophy - - O
and - - O
hyperplasia - - O
of - - O
smooth - - O
muscle - - O
cells - - O
as - - O
well - - O
as - - O
accumulation - - O
of - - O
a - - O
large - - O
amount - - O
of - - O
collagen - - B-MUT
, - - O
especially - - O
the - - O
type - - B-MUT
1 - - I-MUT
collagen - - I-MUT
. - - O

In - - O
subjects - - O
( - - O
n - - O
= - - O
5 - - O
) - - O
with - - O
quadriplegia - - O
and - - O
reduced - - O
sympathetic - - O
tone - - O
secondary - - O
to - - O
cervical - - O
cord - - O
trauma - - O
, - - O
TcpO2 - - O
at - - O
42 - - O
degrees - - O
C - - O
and - - O
vasodilation - - O
index - - O
were - - O
increased - - O
( - - O
45 - - O
. - - O
0 - - O
mmHg - - O
and - - O
0 - - O
. - - O
61 - - O
) - - O
; - - O
TcpO2 - - O
at - - O
45 - - O
degrees - - O
C - - O
did - - O
not - - O
change - - O
. - - O

Letter - - O
: - - O
Is - - O
actinic - - O
( - - O
solar - - O
) - - O
damage - - O
the - - O
provoking - - O
cause - - O
of - - O
'post-inflammatory - - O
elastolysis - - O
and - - O
cutis - - O
laxa - - O
( - - O
PECL - - O
) - - O
' - - O
? - - O

The - - O
size - - O
discrepancy - - O
is - - O
not - - O
due - - O
to - - O
glycosylation - - O
or - - O
phosphorylation - - O
of - - O
Ag35 - - B-MUT
but - - O
may - - O
result - - O
from - - O
a - - O
proline-rich - - O
sequence - - O
which - - O
occurs - - O
in - - O
this - - O
polypeptide - - O
. - - O

The - - O
criterion - - O
was - - O
reached - - O
after - - O
two - - O
sessions - - O
and - - O
generalization - - O
to - - O
a - - O
variety - - O
of - - O
pills - - O
and - - O
capsules - - O
occurred - - O
. - - O

Moreover - - O
, - - O
LD50 - - O
in - - O
mice - - O
of - - O
RP-170 - - O
( - - O
4 - - O
. - - O
3 - - O
g - - O
kg - - O
on - - O
i - - O
. - - O
v - - O
. - - O
) - - O
was - - O
increased - - O
to - - O
5 - - O
. - - O
2 - - O
g - - O
kg - - O
by - - O
oral - - O
administration - - O
. - - O

The - - O
co-existence - - O
of - - O
TE - - B-MUT
domains - - I-MUT
within - - O
modular - - O
PKSs - - B-MUT
along - - O
with - - O
physically - - O
separated - - O
, - - O
monofunctional - - O
TEs - - B-MUT
( - - O
TE - - B-MUT
IIs - - I-MUT
) - - O
has - - O
been - - O
reported - - O
for - - O
a - - O
number - - O
of - - O
modular - - O
polyketide - - O
and - - O
non-ribosomal - - B-MUT
peptide - - I-MUT
synthases - - I-MUT
( - - O
NRPS - - B-MUT
) - - O
. - - O

The - - O
complete - - O
circular - - O
TTV - - O
genome - - O
contained - - O
a - - O
novel - - O
sequence - - O
of - - O
113 - - O
nt - - O
( - - O
nt - - O
3740 - - O
to - - O
3852 - - O
[ - - O
= - - O
0 - - O
] - - O
) - - O
in - - O
between - - O
the - - O
known - - O
3'- - - O
and - - O
5'-end - - O
arms - - O
, - - O
forming - - O
a - - O
117-nt - - O
GC-rich - - O
stretch - - O
( - - O
GC - - O
content - - O
, - - O
90 - - O
. - - O
6% - - O
at - - O
nt - - O
3736 - - O
to - - O
3852 - - O
) - - O
. - - O

SNAP-23 - - B-MUT
plays - - O
an - - O
important - - O
role - - O
in - - O
the - - O
regulation - - O
of - - O
vesicle - - O
trafficking - - O
in - - O
mammalian - - O
cells - - O
. - - O

Recombinant - - O
plasmid - - O
pFV100 - - O
was - - O
subsequently - - O
isolated - - O
by - - O
its - - O
ability - - O
to - - O
complement - - O
B-band - - O
expression - - O
in - - O
ge6 - - B-MUT
. - - O

Surprisingly - - O
, - - O
there - - O
is - - O
no - - O
sequence - - O
homology - - O
between - - O
this - - O
region - - O
of - - O
Ly-6E - - B-MUT
and - - O
the - - O
established - - O
consensus - - O
for - - O
the - - O
interferon-stimulated - - B-MUT
response - - I-MUT
element - - I-MUT
, - - O
which - - O
has - - O
been - - O
shown - - O
functionally - - O
important - - O
to - - O
all - - O
previously - - O
characterized - - O
alpha - - B-MUT
beta - - I-MUT
interferon-inducible - - I-MUT
promoters - - I-MUT
. - - I-MUT

Ectopic - - O
expression - - O
of - - O
the - - O
dominant - - B-MUT
mutant - - I-MUT
Lg3 - - I-MUT
allele - - I-MUT
is - - O
believed - - O
to - - O
cause - - O
the - - O
phenotype - - O
. - - O

Expression - - O
of - - O
the - - O
dibasic - - O
proprotein - - O
processing - - O
enzyme - - O
furin - - B-MUT
is - - O
directed - - O
by - - O
multiple - - O
promoters - - O
. - - O

Structural - - O
changes - - O
in - - O
the - - O
kinetically - - O
more - - O
damaged - - O
E44D - - O
mutant - - O
detected - - O
in - - O
( - - O
1 - - O
) - - O
H- - - O
( - - O
15 - - O
) - - O
N - - O
HSQC - - O
spectra - - O
were - - O
largely - - O
limited - - O
to - - O
the - - O
loop - - O
I-helix - - O
I - - O
motif - - O
, - - O
suggesting - - O
that - - O
Glu-44 - - O
stabilizes - - O
the - - O
active - - O
site - - O
region - - O
. - - O

A - - O
motif - - O
( - - O
TGATGTCA - - B-MUT
) - - O
which - - O
matches - - O
a - - O
CREB - - B-MUT
site - - I-MUT
and - - O
is - - O
similar - - O
to - - O
an - - O
AP-1 - - B-MUT
site - - I-MUT
is - - O
embedded - - O
within - - O
ER2 - - B-MUT
. - - O

Between - - O
1967 - - O
and - - O
1994 - - O
, - - O
495 - - O
patients - - O
underwent - - O
surgery - - O
for - - O
primary - - O
PTC - - O
at - - O
the - - O
Department - - O
of - - O
Surgery - - O
, - - O
Helsinki - - O
University - - O
Central - - O
Hospital - - O
. - - O

According - - O
to - - O
the - - O
literature - - O
, - - O
second - - O
malignant - - O
epithelial - - O
tumours - - O
are - - O
, - - O
in - - O
contrast - - O
to - - O
mesenchymal - - O
tumours - - O
such - - O
as - - O
osteosarcoma - - O
, - - O
very - - O
rare - - O
in - - O
retinoblastoma - - O
survivors - - O
. - - O

In - - O
patients - - O
, - - O
the - - O
effect - - O
of - - O
CCK-PZ - - O
on - - O
the - - O
movement - - O
of - - O
the - - O
terminal - - O
part - - O
of - - O
the - - O
bile - - O
duct - - O
was - - O
measured - - O
with - - O
a - - O
pressure - - O
sensor - - O
using - - O
a - - O
duodenofiberscope - - O
. - - O

Intestinal - - O
adaptation - - O
( - - O
first - - O
of - - O
two - - O
parts - - O
) - - O
. - - O

Their - - O
chemical - - O
structures - - O
were - - O
elucidated - - O
as - - O
1 - - O
alpha - - O
, - - O
2 - - O
alpha-diacetoxy-8 - - O
beta-isobutanoyloxy- - - O
9 - - O
alpha-benzoyloxy-13- - - O
( - - O
alpha-methyl - - O
) - - O
butanoyloxy-4 - - O
beta - - O
, - - O
6 - - O
beta-dihydroxy-beta-dihydroagarofuran - - O
( - - O
1 - - O
) - - O
, - - O
1 - - O
alpha - - O
, - - O
2 - - O
alpha-diacetoxy-8 - - O
beta- - - O
( - - O
beta- - - O
furancarbonyloxy - - O
) - - O
-9 - - O
alpha-benzoyloxy-13-isobutanoyloxy-4 - - O
beta - - O
, - - O
6 - - O
beta-dihydroxy-beta-dihydroagarofuran - - O
( - - O
2 - - O
) - - O
and - - O
1 - - O
alpha - - O
, - - O
6 - - O
beta - - O
, - - O
8 - - O
alpha - - O
, - - O
13-tetraacetoxy-9 - - O
alpha-benzoyloxy-2 - - O
alpha-hydroxy-beta-dihydroagarofuran - - O
( - - O
3 - - O
) - - O
mainly - - O
by - - O
analyses - - O
NMR - - O
and - - O
MS - - O
spectral - - O
data - - O
. - - O

Tissue - - O
samples - - O
were - - O
obtained - - O
either - - O
from - - O
rats - - O
that - - O
had - - O
been - - O
exposed - - O
to - - O
opiate - - O
withdrawal - - O
following - - O
a - - O
seven - - O
day - - O
morphine - - O
infusion - - O
or - - O
sham - - O
treated - - O
control - - O
subjects - - O
. - - O

The - - O
optimal - - O
sequence - - O
for - - O
interaction - - O
with - - O
mu - - B-MUT
2 - - I-MUT
and - - O
with - - O
AP-2 - - B-MUT
has - - O
tyrosine - - O
as - - O
an - - O
anchor - - O
and - - O
prefers - - O
arginine - - O
at - - O
position - - O
Y - - O
+ - - O
2 - - O
and - - O
leucine - - O
at - - O
position - - O
Y - - O
+ - - O
3 - - O
. - - O

Unlike - - O
most - - O
other - - O
small - - B-MUT
G - - I-MUT
proteins - - I-MUT
which - - O
are - - O
expressed - - O
ubiquitously - - O
, - - O
TTF - - B-MUT
was - - O
transcribed - - O
only - - O
in - - O
hemopoietic - - O
cells - - O
as - - O
a - - O
2 - - O
. - - O
2 - - O
kb - - O
transcript - - O
. - - O

The - - O
generally - - O
adopted - - O
criteria - - O
enabling - - O
to - - O
classify - - O
the - - O
examined - - O
persons - - O
into - - O
the - - O
following - - O
3 - - O
groups - - O
have - - O
been - - O
used - - O
: - - O
( - - O
a - - O
) - - O
diseased - - O
of - - O
BEN - - O
; - - O
( - - O
b - - O
) - - O
suspect - - O
to - - O
be - - O
diseased - - O
of - - O
BEN - - O
, - - O
and - - O
( - - O
c - - O
) - - O
individuals - - O
without - - O
signs - - O
of - - O
a - - O
renal - - O
disease - - O
. - - O

Nhp2p - - B-MUT
is - - O
a - - O
highly - - O
basic - - O
protein - - O
that - - O
belongs - - O
to - - O
a - - O
family - - O
of - - O
putative - - O
RNA-binding - - B-MUT
proteins - - I-MUT
. - - O

No - - O
changes - - O
were - - O
evident - - O
in - - O
the - - O
FR-task - - O
performance - - O
of - - O
controls - - O
that - - O
received - - O
daily - - O
saline - - O
injections - - O
. - - O

Of - - O
165 - - O
women - - O
with - - O
non-malignant - - O
diagnoses - - O
26 - - O
( - - O
16% - - O
) - - O
had - - O
CA - - B-MUT
125 - - I-MUT
levels - - O
in - - O
excess - - O
of - - O
35 - - O
U - - O
ml - - O
and - - O
8 - - O
( - - O
5% - - O
) - - O
greater - - O
than - - O
65 - - O
U - - O
ml - - O
. - - O

P-CIP1 - - B-MUT
, - - O
a - - O
novel - - O
protein - - O
that - - O
interacts - - O
with - - O
the - - O
cytosolic - - O
domain - - O
of - - O
peptidylglycine - - B-MUT
alpha-amidating - - I-MUT
monooxygenase - - I-MUT
, - - O
is - - O
associated - - O
with - - O
endosomes - - O
. - - O

Contagious - - O
bovine - - O
pleuropneumonia - - O
is - - O
a - - O
major - - O
threat - - O
for - - O
cattle - - O
in - - O
Africa - - O
. - - O

However - - O
, - - O
a - - O
10--15% - - O
lengthening - - O
of - - O
the - - O
partial - - O
thromboplastin - - B-MUT
time - - O
is - - O
evident - - O
after - - O
24 - - O
hours - - O
of - - O
storage - - O
. - - O

In - - O
the - - O
present - - O
study - - O
we - - O
have - - O
investigated - - O
the - - O
regulatory - - O
mechanism - - O
for - - O
CD95L - - B-MUT
expression - - O
. - - O

SELECTION - - O
CRITERIA - - O
: - - O
All - - O
randomised - - O
controlled - - O
trials - - O
comparing - - O
IUSs - - O
with - - O
other - - O
forms - - O
of - - O
reversible - - O
contraceptives - - O
and - - O
reporting - - O
on - - O
pre-determined - - O
outcomes - - O
in - - O
women - - O
of - - O
reproductive - - O
years - - O
. - - O

The - - O
experimental - - O
design - - O
incorporated - - O
a - - O
multiple - - O
regression - - O
model - - O
, - - O
sequential - - O
treatments - - O
and - - O
a - - O
proportional - - O
end - - O
point - - O
( - - O
95% - - O
) - - O
for - - O
protection - - O
time - - O
. - - O

In - - O
conclusion - - O
, - - O
we - - O
observed - - O
a - - O
great - - O
regeneration - - O
ability - - O
following - - O
mechanical - - O
injury - - O
in - - O
the - - O
nasal - - O
mucosa - - O
. - - O

Infect - - O
. - - O

Full-length - - B-MUT
FLAP - - I-MUT
clones - - O
were - - O
isolated - - O
from - - O
a - - O
mouse - - O
skeletal - - O
muscle - - O
cDNA - - O
library - - O
. - - O

Liver - - O
dysfunction - - O
in - - O
the - - O
presence - - O
of - - O
different - - O
adverse - - O
reactions - - O
presented - - O
with - - O
a - - O
higher - - O
activity - - O
in - - O
the - - O
blood - - O
serum - - O
of - - O
indicator - - O
liver - - O
enzymes - - O
and - - O
its - - O
impaired - - O
protein-forming - - O
function - - O
. - - O

Regulation - - O
of - - O
the - - O
Raf - - B-MUT
kinase - - I-MUT
in - - O
T - - O
cells - - O
differs - - O
from - - O
findings - - O
with - - O
a - - O
variety - - O
of - - O
cell - - O
lines - - O
that - - O
the - - O
catalytic - - B-MUT
domain - - I-MUT
of - - I-MUT
Raf - - I-MUT
( - - O
Raf - - B-MUT
( - - I-MUT
delta26-303 - - I-MUT
) - - O
) - - O
shows - - O
no - - O
activity - - O
. - - O

The - - O
experience - - O
of - - O
the - - O
lateral - - O
rhinotomy - - O
approach - - O
in - - O
transsphenoidal - - O
surgery - - O
of - - O
acromegaly - - O
has - - O
been - - O
favourable - - O
. - - O

Perceptual - - O
learning - - O
for - - O
a - - O
pattern - - O
discrimination - - O
task - - O
. - - O

BACKGROUND - - O
: - - O
Measurement - - O
of - - O
stereoacuity - - O
at - - O
varying - - O
distances - - O
, - - O
by - - O
real - - O
or - - O
simulated - - O
depth - - O
stereoacuity - - O
tests - - O
, - - O
is - - O
helpful - - O
in - - O
the - - O
evaluation - - O
of - - O
patients - - O
with - - O
binocular - - O
imbalance - - O
or - - O
strabismus - - O
. - - O

A - - O
comparison - - O
of - - O
the - - O
amino - - O
acid - - O
sequence - - O
of - - O
the - - O
T - - O
. - - O
thermophilus - - O
enzyme - - O
with - - O
that - - O
of - - O
the - - O
Escherichia - - O
coli - - O
enzyme - - O
showed - - O
( - - O
i - - O
) - - O
a - - O
37% - - O
overall - - O
similarity - - O
; - - O
( - - O
ii - - O
) - - O
the - - O
conservation - - O
of - - O
the - - O
Ser - - O
residue - - O
, - - O
which - - O
is - - O
known - - O
to - - O
be - - O
phosphorylated - - O
in - - O
the - - O
E - - O
. - - O
coli - - O
enzyme - - O
, - - O
and - - O
of - - O
the - - O
surrounding - - O
sequence - - O
; - - O
and - - O
( - - O
iii - - O
) - - O
the - - O
presence - - O
of - - O
141 - - O
extra - - O
residues - - O
at - - O
the - - O
C - - O
terminus - - O
of - - O
the - - O
T - - O
. - - O
thermophilus - - O
enzyme - - O
. - - O

The - - O
range - - O
of - - O
serum - - O
concentrations - - O
, - - O
mean - - O
values - - O
, - - O
median - - O
values - - O
, - - O
and - - O
standard - - O
deviations - - O
for - - O
each - - O
analyte - - O
are - - O
reported - - O
for - - O
males - - O
and - - O
females - - O
and - - O
for - - O
three - - O
age - - O
groups - - O
( - - O
25-44 - - O
, - - O
45-59 - - O
, - - O
60-70 - - O
) - - O
. - - O

Therapeutic - - O
effects - - O
of - - O
cefpirome - - O
( - - O
HR - - O
810 - - O
) - - O
on - - O
experimental - - O
mixed - - O
infections - - O
with - - O
Enterococcus - - O
faecalis - - O
and - - O
Escherichia - - O
coli - - O
in - - O
mice - - O
. - - O

The - - O
deduced - - O
amino - - O
acid - - O
sequence - - O
of - - O
the - - O
mouse - - B-MUT
HO-1 - - I-MUT
gene - - I-MUT
is - - O
identical - - O
to - - O
that - - O
of - - O
p32 - - B-MUT
, - - O
initially - - O
identified - - O
as - - O
a - - O
stress-induced - - O
protein - - O
in - - O
mouse - - O
BALBc - - O
3T3 - - O
cells - - O
. - - O

This - - O
is - - O
a - - O
challenging - - O
task - - O
insofar - - O
as - - O
direct - - O
measures - - O
of - - O
ISF - - O
glucose - - O
are - - O
not - - O
readily - - O
available - - O
. - - O

These - - O
results - - O
suggest - - O
that - - O
both - - O
transcription - - O
activators - - O
depend - - O
on - - O
or - - O
interact - - O
with - - O
different - - O
subunits - - O
of - - O
RNA - - B-MUT
polymerase - - I-MUT
, - - O
although - - O
their - - O
role - - O
in - - O
formation - - O
of - - O
proper - - O
DNA - - O
geometry - - O
may - - O
also - - O
be - - O
crucial - - O
. - - O

Inhibition - - O
assays - - O
performed - - O
with - - O
over - - O
30 - - O
different - - O
natural - - O
and - - O
synthetic - - O
sialylated - - O
and - - O
or - - O
sulfated - - O
compounds - - O
are - - O
utilized - - O
to - - O
define - - O
in - - O
greater - - O
detail - - O
specific - - O
structural - - O
features - - O
involved - - O
in - - O
oligosaccharide-protein - - O
binding - - O
. - - O

Molecular - - O
cloning - - O
of - - O
a - - O
cDNA - - O
encoding - - O
rat - - B-MUT
NADH-cytochrome - - I-MUT
b5 - - I-MUT
reductase - - I-MUT
and - - O
the - - O
corresponding - - O
gene - - O
. - - O

Pyrethroid - - O
insecticides - - O
are - - O
widely - - O
used - - O
in - - O
agriculture - - O
and - - O
private - - O
households - - O
. - - O

We - - O
also - - O
localized - - O
the - - O
Fra-2 - - B-MUT
phosphorylation - - I-MUT
sites - - I-MUT
by - - O
MAPK - - B-MUT
to - - O
three - - O
threonine - - O
and - - O
three - - O
serine - - O
residues - - O
in - - O
the - - O
COOH-terminal - - O
region - - O
by - - O
means - - O
of - - O
site-directed - - O
mutagenesis - - O
and - - O
showed - - O
that - - O
the - - O
threonine - - O
residues - - O
were - - O
more - - O
susceptible - - O
to - - O
MAPK - - B-MUT
. - - O

Deletion - - O
mapping - - O
studies - - O
revealed - - O
that - - O
the - - O
upstream - - O
DNA - - O
sequences - - O
up - - O
to - - O
-86 - - O
were - - O
sufficient - - O
for - - O
the - - O
optimal - - O
basal - - O
level - - O
transcription - - O
in - - O
HeLa - - O
cells - - O
and - - O
also - - O
for - - O
the - - O
EIA-induced - - O
transcription - - O
. - - O

The - - O
QT - - O
interval - - O
was - - O
related - - O
to - - O
various - - O
components - - O
of - - O
the - - O
insulin - - B-MUT
resistance - - O
syndrome - - O
, - - O
including - - O
BP - - O
and - - O
insulin - - B-MUT
sensitivity - - O
. - - O

The - - O
aim - - O
of - - O
this - - O
study - - O
was - - O
to - - O
investigate - - O
the - - O
effects - - O
of - - O
nebulized - - O
ipratropium - - O
in - - O
patients - - O
with - - O
acute - - O
asthma - - O
in - - O
order - - O
to - - O
determine - - O
whether - - O
it - - O
augments - - O
the - - O
bronchodilator - - O
effect - - O
of - - O
a - - O
beta - - O
agonist - - O
drug - - O
. - - O

Intravenous - - O
injections - - O
of - - O
SG-75 - - O
( - - O
0 - - O
. - - O
03-1 - - O
mg - - O
kg - - O
) - - O
decreased - - O
systemic - - O
blood - - O
pressure - - O
( - - O
SBP - - O
) - - O
and - - O
increased - - O
peripheral - - O
( - - O
coronary - - O
, - - O
renal - - O
, - - O
mesenteric - - O
and - - O
femoral - - O
) - - O
blood - - O
flow - - O
( - - O
PBF - - O
) - - O
dose-dependently - - O
. - - O

Ongoing - - O
and - - O
future - - O
investigations - - O
may - - O
better - - O
define - - O
the - - O
optimal - - O
approach - - O
for - - O
local - - O
control - - O
, - - O
the - - O
optimal - - O
duration - - O
of - - O
maintenance - - O
chemotherapy - - O
, - - O
and - - O
the - - O
possible - - O
role - - O
of - - O
biologic - - O
response - - O
modifiers - - O
and - - O
growth - - B-MUT
factors - - I-MUT
in - - O
further - - O
improving - - O
the - - O
outcome - - O
for - - O
patients - - O
with - - O
this - - O
disease - - O
. - - O

Effects - - O
of - - O
long-term - - O
parenteral - - O
nutrition - - O
on - - O
gastrin - - B-MUT
release - - O
in - - O
dogs - - O
. - - O

The - - O
predicted - - O
amino - - O
acid - - O
sequence - - O
of - - O
the - - O
SGC1 - - B-MUT
gene - - I-MUT
product - - I-MUT
includes - - O
a - - O
region - - O
with - - O
substantial - - O
similarity - - O
to - - O
the - - O
basic-helix-loop-helix - - O
domain - - O
of - - O
the - - O
Myc - - B-MUT
family - - I-MUT
of - - O
DNA-binding - - O
proteins - - O
. - - O

Evidence - - O
suggests - - O
that - - O
PHACES - - O
syndrome - - O
is - - O
not - - O
a - - O
random - - O
association - - O
but - - O
a - - O
true - - O
phakomatosis - - O
; - - O
further - - O
studies - - O
are - - O
awaited - - O
to - - O
shed - - O
light - - O
on - - O
a - - O
possible - - O
genetic - - O
background - - O
. - - O

To - - O
discern - - O
whether - - O
these - - O
disorders - - O
of - - O
GnRH - - B-MUT
deficiency - - O
are - - O
associated - - O
with - - O
altered - - O
melatonin - - O
secretion - - O
profiles - - O
, - - O
we - - O
compared - - O
untreated - - O
young - - O
males - - O
IGD - - O
( - - O
n - - O
= - - O
7 - - O
) - - O
and - - O
DP - - O
( - - O
n - - O
= - - O
7 - - O
) - - O
to - - O
normal - - O
pubertal - - O
male - - O
controls - - O
( - - O
n - - O
= - - O
6 - - O
) - - O
. - - O

Monitoring - - O
patients - - O
with - - O
acute - - O
leukemia - - O
for - - O
IL-1 - - B-MUT
and - - O
TNF - - B-MUT
levels - - O
throughout - - O
the - - O
clinical - - O
course - - O
of - - O
disease - - O
may - - O
help - - O
clarify - - O
the - - O
causes - - O
of - - O
febrile - - O
episodes - - O
. - - O

Virol - - O
. - - O

The - - O
P131 - - B-MUT
ORF - - I-MUT
is - - O
followed - - O
in-frame - - O
by - - O
a - - O
second - - O
ORF - - O
which - - O
is - - O
probably - - O
expressed - - O
by - - O
partial - - O
readthrough - - O
of - - O
the - - O
UGA - - O
termination - - O
codon - - O
of - - O
the - - O
P131 - - B-MUT
ORF - - I-MUT
to - - O
produce - - O
a - - O
polypeptide - - O
of - - O
M - - O
( - - O
r - - O
) - - O
191044 - - O
( - - O
P191 - - B-MUT
) - - O
. - - O

The - - O
CANNTG - - B-MUT
motifs - - I-MUT
were - - O
found - - O
to - - O
bind - - O
MyoD - - B-MUT
and - - O
myogenin - - B-MUT
fusion - - I-MUT
proteins - - I-MUT
and - - O
to - - O
interact - - O
with - - O
proteins - - O
in - - O
nuclear - - O
extracts - - O
from - - O
cultured - - O
myotubes - - O
. - - O

Baseline - - O
data - - O
were - - O
obtained - - O
from - - O
10 - - O
adults - - O
. - - O

D3S1261 - - B-MUT
is - - O
physically - - O
located - - O
at - - O
or - - O
near - - O
the - - O
MITF - - B-MUT
locus - - I-MUT
, - - O
while - - O
D3S2465 - - B-MUT
and - - O
D3S1766 - - B-MUT
are - - O
flanking - - O
the - - O
locus - - O
at - - O
about - - O
17 - - O
. - - O
5 - - O
cM - - O
genetic - - O
distance - - O
each - - O
side - - O
. - - O

CyIIa - - B-MUT
transcription - - O
follows - - O
, - - O
and - - O
is - - O
therefore - - O
downstream - - O
of - - O
, - - O
the - - O
initial - - O
specification - - O
of - - O
these - - O
embryonic - - O
domains - - O
. - - O

Determination - - O
of - - O
diquat - - O
in - - O
biological - - O
materials - - O
by - - O
electron - - O
spin - - O
resonance - - O
spectroscopy - - O
. - - O

As - - O
no - - O
complete - - O
PPARgamma - - B-MUT
antagonists - - O
have - - O
been - - O
described - - O
hitherto - - O
, - - O
we - - O
have - - O
constructed - - O
a - - O
dominant-negative - - O
mutant - - O
receptor - - O
to - - O
inhibit - - O
wild-type - - O
PPARgamma - - B-MUT
action - - O
. - - O

The - - O
present - - O
investigation - - O
conducted - - O
in - - O
a - - O
population - - O
of - - O
258 - - O
dentally - - O
aware - - O
individuals - - O
in - - O
the - - O
age - - O
range - - O
20-69 - - O
years - - O
, - - O
was - - O
initiated - - O
to - - O
elucidate - - O
the - - O
relationship - - O
between - - O
tobacco - - O
smoking - - O
and - - O
supragingival - - O
calculus - - O
, - - O
taking - - O
into - - O
account - - O
possible - - O
confounding - - O
factors - - O
such - - O
as - - O
age - - O
, - - O
gender - - O
, - - O
oral - - O
hygiene - - O
and - - O
gingival - - O
inflammation - - O
. - - O

PCNA - - B-MUT
mRNA - - I-MUT
has - - O
a - - O
3'UTR - - O
antisense - - O
to - - O
yellow - - O
crescent - - O
RNA - - O
and - - O
is - - O
localized - - O
in - - O
ascidian - - O
eggs - - O
and - - O
embryos - - O
. - - O

Anti-PTB - - B-MUT
antibodies - - I-MUT
did - - O
not - - O
inhibit - - O
the - - O
binding - - O
of - - O
PTB - - B-MUT
to - - O
RNA - - O
because - - O
they - - O
were - - O
able - - O
to - - O
supershift - - O
RNA-PTB - - B-MUT
complexes - - I-MUT
. - - O

Influence - - O
of - - O
different - - O
methods - - O
of - - O
chemical - - O
disinfection - - O
on - - O
the - - O
physical - - O
properties - - O
of - - O
type - - O
IV - - O
and - - O
V - - O
gypsum - - O
dies - - O
Several - - O
instruments - - O
and - - O
materials - - O
frequently - - O
used - - O
in - - O
prosthodontics--such - - O
as - - O
stone - - O
casts - - O
, - - O
dental - - O
impressions - - O
, - - O
interocclusal - - O
records--are - - O
classified - - O
, - - O
by - - O
the - - O
dental - - O
literature - - O
, - - O
as - - O
vehicles - - O
of - - O
transmission - - O
of - - O
infectious - - O
diseases - - O
to - - O
those - - O
who - - O
handle - - O
them - - O
. - - O

Spectrophotometric - - O
microanalysis - - O
of - - O
ethylenediaminotetracetic - - O
acid - - O
in - - O
pharmaceutical - - O
preparations - - O
. - - O

The - - O
measurement - - O
of - - O
the - - O
areas - - O
of - - O
fibrin - - B-MUT
, - - O
of - - O
tissue - - O
and - - O
fibrinolysis - - O
, - - O
at - - O
the - - O
above - - O
mentioned - - O
times - - O
, - - O
has - - O
been - - O
effected - - O
at - - O
standard - - O
magnification - - O
( - - O
15 - - O
X - - O
) - - O
by - - O
an - - O
image - - O
analyser - - O
( - - O
Videoplan - - O
) - - O
scale - - O
1 - - O
: - - O
8 - - O
. - - O

Pacing - - O
the - - O
Roux - - O
limb - - O
abolished - - O
the - - O
ectopic - - O
pacemakers - - O
, - - O
restored - - O
the - - O
slow - - O
emptying - - O
of - - O
liquids - - O
to - - O
the - - O
more - - O
rapid - - O
rate - - O
found - - O
in - - O
the - - O
Billroth - - O
dogs - - O
( - - O
t1 - - O
2 - - O
: - - O
paced - - O
Roux - - O
, - - O
72 - - O
+ - - O
- - - O
15 - - O
minutes - - O
; - - O
Billroth - - O
, - - O
43 - - O
+ - - O
- - - O
9 - - O
minutes - - O
; - - O
p - - O
greater - - O
than - - O
0 - - O
. - - O
05 - - O
) - - O
and - - O
did - - O
not - - O
change - - O
emptying - - O
of - - O
solids - - O
. - - O

Staining - - O
with - - O
IF - - B-MUT
MoAB - - O
alone - - O
of - - O
BAL - - O
fluid - - O
only - - O
seemed - - O
to - - O
be - - O
even - - O
more - - O
sensitive - - O
than - - O
silver - - O
methenamine - - O
staining - - O
of - - O
BAL - - O
, - - O
TBB - - O
and - - O
brushing - - O
material - - O
. - - O

Evidence - - O
for - - O
the - - O
involvement - - O
of - - O
the - - O
Glc7-Reg1 - - B-MUT
phosphatase - - I-MUT
and - - O
the - - O
Snf1-Snf4 - - B-MUT
kinase - - I-MUT
in - - O
the - - O
regulation - - O
of - - O
INO1 - - B-MUT
transcription - - O
in - - O
Saccharomyces - - O
cerevisiae - - O
. - - O

The - - O
effects - - O
of - - O
social - - O
isolation - - O
on - - O
morphine-induced - - O
locomotor - - O
activity - - O
were - - O
compared - - O
in - - O
: - - O
( - - O
i - - O
) - - O
animals - - O
with - - O
an - - O
intact - - O
hypothalamo-pituitary-adrenal - - O
( - - O
HPA - - O
) - - O
axis - - O
; - - O
( - - O
ii - - O
) - - O
animals - - O
in - - O
which - - O
stress-induced - - O
corticosterone - - O
secretion - - O
was - - O
blocked - - O
by - - O
adrenalectomy - - O
. - - O

Effects - - O
of - - O
intramammary - - O
endotoxin - - O
infusion - - O
on - - O
milking-induced - - O
oxytocin - - B-MUT
release - - O
. - - O

255-61 - - O
. - - O

Drug - - O
and - - O
personnel - - O
costs - - O
were - - O
reduced - - O
when - - O
batch - - O
manufacturing - - O
with - - O
40-mL - - O
multidose - - O
vials - - O
was - - O
compared - - O
with - - O
extemporaneous - - O
compounding - - O
with - - O
unit-dose - - O
vials - - O
. - - O

The - - O
MSL - - B-MUT
complex - - I-MUT
is - - O
specifically - - O
localized - - O
on - - O
the - - O
male - - O
X - - O
chromosome - - O
to - - O
increase - - O
its - - O
expression - - O
approximately - - O
2-fold - - O
. - - O

Transfer - - O
also - - O
correlated - - O
inversely - - O
with - - O
gastric - - O
juice - - O
pH - - O
( - - O
r - - O
= - - O
-0 - - O
. - - O
619 - - O
, - - O
P - - O
< - - O
0 - - O
. - - O
02 - - O
) - - O
. - - O

In - - O
several - - O
cases - - O
of - - O
definite - - O
SjS - - O
, - - O
labial - - O
salivary - - O
gland - - O
examinations - - O
after - - O
more - - O
than - - O
a - - O
one - - O
year - - O
interval - - O
were - - O
performed - - O
on - - O
two - - O
occasions - - O
, - - O
and - - O
the - - O
clinical - - O
and - - O
histopathological - - O
changes - - O
were - - O
investigated - - O
. - - O

Taken - - O
together - - O
, - - O
our - - O
results - - O
demonstrate - - O
that - - O
CAP1 - - B-MUT
is - - O
involved - - O
in - - O
multidrug - - O
resistance - - O
and - - O
oxidative - - O
stress - - O
response - - O
in - - O
C - - O
. - - O
albicans - - O
. - - O

Sequence - - O
analysis - - O
and - - O
identification - - O
of - - O
two - - O
hyp - - B-MUT
regulatory - - I-MUT
mutants - - I-MUT
. - - O

Acute - - O
pancreatitis - - O
is - - O
a - - O
rather - - O
common - - O
abdominal - - O
disorder - - O
. - - O

Using - - O
Scheffe's - - O
procedure - - O
as - - O
an - - O
illustration - - O
, - - O
comparisons - - O
are - - O
made - - O
to - - O
usual - - O
sample - - O
size - - O
methods - - O
that - - O
incorrectly - - O
ignore - - O
the - - O
stochastic - - O
nature - - O
of - - O
S2p - - O
. - - O

Refugees - - O
living - - O
in - - O
Lund - - O
and - - O
repatriated - - O
to - - O
Chile - - O
considered - - O
their - - O
health - - O
as - - O
bad - - O
in - - O
a - - O
higher - - O
proportion - - O
than - - O
their - - O
Swedish - - O
counterparts - - O
, - - O
with - - O
an - - O
odds - - O
ratio - - O
of - - O
3 - - O
. - - O
48 - - O
( - - O
2 - - O
. - - O
03-5 - - O
. - - O
66 - - O
) - - O
and - - O
4 - - O
. - - O
78 - - O
( - - O
2 - - O
. - - O
1-10 - - O
. - - O
25 - - O
) - - O
respectively - - O
. - - O

Recently - - O
, - - O
cell-surface - - O
TRAIL - - B-MUT
has - - O
been - - O
shown - - O
to - - O
be - - O
expressed - - O
by - - O
activated - - O
human - - O
and - - O
mouse - - O
T - - O
lymphocytes - - O
, - - O
raising - - O
the - - O
possibility - - O
that - - O
TRAIL - - B-MUT
might - - O
be - - O
involved - - O
in - - O
T - - O
cell-mediated - - O
cytotoxicity - - O
and - - O
or - - O
immune - - O
regulation - - O
. - - O

Classical - - O
ligand-activated - - B-MUT
nuclear - - I-MUT
receptors - - I-MUT
( - - O
e - - O
. - - O
g - - O
. - - O
thyroid - - B-MUT
hormone - - I-MUT
receptor - - I-MUT
, - - O
retinoic - - B-MUT
acid - - I-MUT
receptor - - I-MUT
) - - O
, - - O
orphan - - B-MUT
nuclear - - I-MUT
receptors - - I-MUT
( - - O
e - - O
. - - O
g - - O
. - - O

Therefore - - O
the - - O
procedure - - O
of - - O
Lich-Gregoir - - O
is - - O
not - - O
to - - O
be - - O
recommended - - O
in - - O
adults - - O
. - - O

In - - O
the - - O
posthospital - - O
phase - - O
of - - O
AMI - - O
, - - O
as - - O
well - - O
as - - O
in - - O
CCHD - - O
, - - O
the - - O
occurrence - - O
of - - O
high-grade - - O
VPBs - - O
usually - - O
indicates - - O
more - - O
advanced - - O
degrees - - O
of - - O
both - - O
coronary - - O
and - - O
left - - O
ventricular - - O
disease - - O
as - - O
well - - O
as - - O
the - - O
possibility - - O
of - - O
cardiac - - O
and - - O
or - - O
sudden - - O
death - - O
. - - O

Activities - - O
of - - O
hepatic - - O
cytochrome - - O
P-450-dependent - - O
metabolizing - - O
enzymes - - O
such - - O
as - - O
aminopyrine- - - B-MUT
and - - I-MUT
TMO - - I-MUT
N-demethylase - - I-MUT
and - - O
aniline - - B-MUT
hydroxylase - - I-MUT
activity - - O
were - - O
decreased - - O
by - - O
pretreatment - - O
of - - O
rats - - O
with - - O
cimetidine - - O
, - - O
whereas - - O
in - - O
the - - O
rats - - O
pretreated - - O
with - - O
ranitidine - - O
, - - O
these - - O
enzyme - - O
activities - - O
were - - O
not - - O
changed - - O
. - - O

Kinetics - - O
of - - O
calcium - - O
metabolism - - O
. - - O

However - - O
, - - O
essential - - O
contrast - - O
differences - - O
existing - - O
between - - O
the - - O
FSE - - O
sequences - - O
and - - O
their - - O
routine - - O
asymmetric - - O
dual - - O
SE - - O
counterpart - - O
can - - O
be - - O
identified - - O
. - - O

Management - - O
of - - O
postvitrectomy - - O
diabetic - - O
vitreous - - O
hemorrhage - - O
with - - O
tissue - - B-MUT
plasminogen - - I-MUT
activator - - I-MUT
( - - O
t-PA - - B-MUT
) - - O
and - - O
volume - - O
homeostatic - - O
fluid-fluid - - O
exchanger - - O
. - - O

After - - O
peripheral - - O
administration - - O
of - - O
both - - O
CRF - - B-MUT
and - - O
TRH - - B-MUT
, - - O
ACTH - - B-MUT
levels - - O
were - - O
significantly - - O
higher - - O
on - - O
the - - O
tumor - - O
side - - O
in - - O
all - - O
patients - - O
. - - O

PATIENTS - - O
AND - - O
METHODS - - O
: - - O
This - - O
study - - O
is - - O
a - - O
retrospective - - O
cohort - - O
study - - O
of - - O
all - - O
children - - O
with - - O
cancer - - O
admitted - - O
to - - O
a - - O
single - - O
institution - - O
with - - O
fever - - O
and - - O
neutropenia - - O
( - - O
defined - - O
as - - O
an - - O
absolute - - O
neutrophil - - O
count - - O
< - - O
500 - - O
cells - - O
mm3 - - O
) - - O
in - - O
a - - O
1-year - - O
period - - O
. - - O

The - - O
leader - - O
sequence - - O
of - - O
the - - O
isolated - - O
cDNA - - O
clone - - O
contains - - O
several - - O
small - - O
open - - O
reading - - O
frames - - O
upstream - - O
of - - O
the - - O
initiation - - O
codon - - O
of - - O
the - - O
largest - - O
open - - O
reading - - O
frame - - O
coding - - O
for - - O
the - - O
homeodomain - - O
protein - - O
. - - O

The - - O
foregoing - - O
results - - O
show - - O
that - - O
CXD - - O
has - - O
high - - O
efficacy - - O
and - - O
safety - - O
and - - O
it - - O
can - - O
be - - O
said - - O
that - - O
it - - O
is - - O
a - - O
drug - - O
required - - O
in - - O
the - - O
pediatric - - O
field - - O
. - - O

Three - - O
mutants - - O
were - - O
isolated - - O
from - - O
the - - O
widely - - O
used - - O
strain - - O
, - - O
PAO1 - - O
. - - O

No - - O
anisotropism - - O
was - - O
recorded - - O
in - - O
a - - O
tetrahydrofuran - - O
solution - - O
. - - O

This - - O
c-Jun - - B-MUT
activity - - O
is - - O
inhibited - - O
by - - O
c-Fos - - B-MUT
, - - O
another - - O
protooncoprotein - - O
that - - O
can - - O
dimerize - - O
with - - O
c-Jun - - B-MUT
to - - O
form - - O
the - - O
transcription - - O
factor - - O
AP-1 - - B-MUT
. - - O

The - - O
moduli - - O
of - - O
elasticity - - O
of - - O
the - - O
gray - - O
and - - O
white - - O
matter - - O
were - - O
3 - - O
. - - O
4+ - - O
-1 - - O
. - - O
4 - - O
kPa - - O
( - - O
mean - - O
+ - - O
- - - O
standard - - O
deviation - - O
) - - O
and - - O
3 - - O
. - - O
4+ - - O
-0 - - O
. - - O
9 - - O
kPa - - O
in - - O
the - - O
axial - - O
section - - O
, - - O
3+ - - O
-0 - - O
. - - O
3 - - O
kPa - - O
and - - O
3 - - O
. - - O
5+ - - O
-0 - - O
. - - O
5 - - O
kPa - - O
in - - O
the - - O
frontal - - O
section - - O
, - - O
and - - O
3 - - O
. - - O
5+ - - O
-0 - - O
. - - O
9 - - O
kPa - - O
and - - O
2 - - O
. - - O
8+ - - O
-0 - - O
. - - O
4 - - O
kPa - - O
in - - O
the - - O
sagittal - - O
section - - O
, - - O
respectively - - O
. - - O

The - - O
NF1 - - B-MUT
locus - - I-MUT
encodes - - O
a - - O
protein - - O
functionally - - O
related - - O
to - - O
mammalian - - B-MUT
GAP - - I-MUT
and - - O
yeast - - B-MUT
IRA - - I-MUT
proteins - - I-MUT
. - - O

In - - O
the - - O
second - - O
experiment - - O
, - - O
a - - O
stable - - O
nickel - - O
isotope - - O
, - - O
61Ni - - O
, - - O
was - - O
given - - O
in - - O
drinking - - O
water - - O
to - - O
20 - - O
nickel-sensitized - - O
women - - O
and - - O
20 - - O
age-matched - - O
controls - - O
, - - O
both - - O
groups - - O
having - - O
vesicular - - O
hand - - O
eczema - - O
of - - O
the - - O
pompholyx - - O
type - - O
. - - O

Subsequent - - O
to - - O
their - - O
secretion - - O
, - - O
the - - O
IGF-II - - B-MUT
in - - O
xz97 - - O
and - - O
G11 - - O
cells - - O
accumulated - - O
in - - O
the - - O
conditioned - - O
medium - - O
mostly - - O
as - - O
two - - O
partially - - O
processed - - O
species - - O
with - - O
appMr - - O
, - - O
of - - O
17K - - O
and - - O
14K - - O
, - - O
respectively - - O
. - - O

Five-year - - O
prospective - - O
study - - O
of - - O
peripheral - - O
white - - O
blood - - O
cells - - O
in - - O
infectious - - O
mononucleosis - - O
. - - O

Cold - - O
cardioplegia - - O
was - - O
administered - - O
at - - O
45 - - O
mm - - O
Hg - - O
every - - O
20 - - O
minutes - - O
for - - O
2 - - O
hours - - O
. - - O

Experimental - - O
data - - O
showed - - O
that - - O
these - - O
abnormal - - O
proteins - - O
are - - O
constitutively - - O
localized - - O
in - - O
the - - O
nucleus - - O
, - - O
have - - O
lost - - O
the - - O
transcriptional - - O
repressor - - O
functions - - O
typical - - O
of - - O
normal - - O
NF-kappa - - B-MUT
B2p52 - - I-MUT
and - - O
may - - O
be - - O
capable - - O
of - - O
transactivation - - O
activity - - O
. - - O

Ultrastructure - - O
of - - O
the - - O
heart - - O
muscle - - O
in - - O
experimental - - O
myocardial - - O
infarct - - O
following - - O
physical - - O
training - - O
. - - O

By - - O
using - - O
lacZ - - B-MUT
fusions - - I-MUT
, - - O
it - - O
was - - O
possible - - O
to - - O
localize - - O
the - - O
DNA - - O
sequences - - O
required - - O
to - - O
mediate - - O
nitrate - - O
repression - - O
to - - O
the - - O
pfl - - B-MUT
promoter-regulatory - - I-MUT
region - - I-MUT
. - - O

MVR - - O
typing - - O
of - - O
rare-length - - O
alleles - - O
indicates - - O
that - - O
they - - O
are - - O
comprised - - O
of - - O
disorganized - - O
sequences - - O
, - - O
although - - O
they - - O
usually - - O
bear - - O
a - - O
resemblance - - O
to - - O
one - - O
of - - O
the - - O
common - - O
alleles - - O
at - - O
the - - O
5'-most - - O
end - - O
. - - O

Splicing - - O
of - - O
the - - O
K-SAM - - B-MUT
alternative - - O
exon - - O
of - - O
the - - O
fibroblast - - B-MUT
growth - - I-MUT
factor - - I-MUT
receptor - - I-MUT
2 - - I-MUT
gene - - I-MUT
is - - O
heavily - - O
dependent - - O
on - - O
the - - O
U-rich - - O
sequence - - O
IAS1 - - B-MUT
lying - - O
immediately - - O
downstream - - O
from - - O
its - - O
5' - - O
splice - - O
site - - O
. - - O

Biochemical - - O
examinations - - O
of - - O
calcium-phosphorus - - O
metabolism - - O
included - - O
ions - - O
and - - O
PTH - - B-MUT
concentrations - - O
in - - O
blood - - O
serum - - O
, - - O
and - - O
the - - O
activity - - O
of - - O
bone - - O
isoenzyme - - O
of - - O
AP - - B-MUT
. - - O

Changes - - O
in - - O
prognosis - - O
of - - O
twin - - O
births - - O
over - - O
20 - - O
years - - O
. - - O

Losses - - O
during - - O
the - - O
complete - - O
procedure - - O
are - - O
corrected - - O
for - - O
using - - O
radioactive - - O
estrogen - - O
conjugates - - O
during - - O
the - - O
first - - O
steps - - O
and - - O
later - - O
by - - O
adding - - O
deuterated - - O
internal - - O
standards - - O
of - - O
all - - O
compounds - - O
measured - - O
( - - O
matairesinol - - O
, - - O
enterodiol - - O
, - - O
enterolactone - - O
, - - O
daidzein - - O
, - - O
O-desmethylangolensin - - O
, - - O
equol - - O
, - - O
and - - O
genistein - - O
) - - O
. - - O

Altogether - - O
, - - O
these - - O
data - - O
suggest - - O
that - - O
Ypt51p - - B-MUT
, - - O
Ypt52p - - B-MUT
, - - O
and - - O
Ypt53p - - B-MUT
are - - O
required - - O
for - - O
transport - - O
in - - O
the - - O
endocytic - - O
pathway - - O
and - - O
for - - O
correct - - O
sorting - - O
of - - O
vacuolar - - B-MUT
hydrolases - - I-MUT
suggesting - - O
a - - O
possible - - O
intersection - - O
of - - O
the - - O
endocytic - - O
with - - O
the - - O
vacuolar - - O
sorting - - O
pathway - - O
. - - O

Regionalization - - O
of - - O
drug - - O
delivery - - O
is - - O
a - - O
potential - - O
method - - O
to - - O
avoid - - O
this - - O
problem - - O
. - - O

Restriction - - O
mapping - - O
analysis - - O
localized - - O
this - - O
cDNA - - O
to - - O
the - - O
HHV-6A - - B-MUT
( - - I-MUT
U1102 - - I-MUT
) - - I-MUT
genomic - - I-MUT
BamHI - - I-MUT
G - - I-MUT
fragment - - I-MUT
, - - O
at - - O
the - - O
right - - O
end - - O
of - - O
the - - O
unique - - O
long - - O
segment - - O
of - - O
the - - O
genome - - O
and - - O
to - - O
the - - O
SalI - - B-MUT
L - - I-MUT
and - - O
SalI - - B-MUT
O - - I-MUT
fragments - - I-MUT
within - - O
the - - O
left - - O
and - - O
right - - O
terminal - - O
direct - - O
repeat - - O
regions - - O
, - - O
respectively - - O
. - - O

Fowlpox - - O
virus - - O
encodes - - O
nonessential - - O
homologs - - O
of - - O
cellular - - B-MUT
alpha-SNAP - - I-MUT
, - - O
PC-1 - - B-MUT
, - - O
and - - O
an - - O
orphan - - O
human - - O
homolog - - O
of - - O
a - - O
secreted - - O
nematode - - O
protein - - O
. - - O

The - - O
purpose - - O
of - - O
this - - O
study - - O
was - - O
to - - O
analyze - - O
the - - O
temporal - - O
characteristics - - O
and - - O
the - - O
spatial - - O
mapping - - O
of - - O
the - - O
independent - - O
components - - O
identified - - O
by - - O
ICA - - O
when - - O
the - - O
subject - - O
performs - - O
a - - O
finger-tapping - - O
task - - O
. - - O

CONCLUSIONS - - O
: - - O
Physiologic - - O
pacing - - O
provides - - O
little - - O
benefit - - O
over - - O
ventricular - - O
pacing - - O
for - - O
the - - O
prevention - - O
of - - O
stroke - - O
or - - O
death - - O
due - - O
to - - O
cardiovascular - - O
causes - - O
. - - O

Antiviral - - O
agents - - O
. - - O

The - - O
maintenance - - O
of - - O
increased - - O
myocardial - - O
capillary - - O
density - - O
required - - O
a - - O
similar - - O
amount - - O
of - - O
exercise - - O
, - - O
and - - O
at - - O
least - - O
1 - - O
h - - O
of - - O
exercise - - O
once - - O
a - - O
week - - O
was - - O
necessary - - O
to - - O
maintain - - O
the - - O
enlargement - - O
of - - O
ECA - - O
. - - O
20 - - O

RESULTS - - O
AND - - O
CONCLUSIONS - - O
: - - O
Brandt's - - O
double - - O
cuff-tubes - - O
( - - O
G2 - - O
) - - O
succeed - - O
in - - O
avoiding - - O
uncontrolled - - O
increase - - O
of - - O
cuff-pressure - - O
during - - O
anaesthesia - - O
with - - O
N2O - - O
. - - O

The - - O
effects - - O
produced - - O
by - - O
oral - - O
administration - - O
of - - O
500 - - O
mg - - O
kg - - O
p-xylene - - O
or - - O
toluene - - O
lasted - - O
at - - O
least - - O
8 - - O
hr - - O
, - - O
while - - O
the - - O
effect - - O
of - - O
inhaled - - O
p-xylene - - O
dissipated - - O
within - - O
75 - - O
min - - O
of - - O
removal - - O
from - - O
the - - O
exposure - - O
. - - O

One - - O
of - - O
these - - O
factors - - O
, - - O
IRF-2 - - B-MUT
, - - O
was - - O
initially - - O
cloned - - O
as - - O
an - - O
antagonistic - - O
counterpart - - O
to - - O
IRF-1 - - B-MUT
with - - O
oncogenic - - O
potential - - O
. - - O

This - - O
combined - - O
intravenous - - O
anaesthetic - - O
regimen - - O
gave - - O
good - - O
anaesthesia - - O
and - - O
analgesia - - O
to - - O
pigs - - O
for - - O
up - - O
to - - O
2 - - O
h - - O
as - - O
monitored - - O
by - - O
clinical - - O
signs - - O
. - - O

Serum - - O
E2 - - O
concentrations - - O
increased - - O
numerically - - O
two- - - O
to - - O
threefold - - O
from - - O
d - - O
56 - - O
to - - O
140 - - O
in - - O
controls - - O
fed - - O
MGA - - O
, - - O
compared - - O
with - - O
controls - - O
not - - O
fed - - O
MGA - - O
. - - O

The - - O
coding - - O
sequences - - O
of - - O
the - - O
Crry - - B-MUT
gene - - I-MUT
encompass - - O
over - - O
25 - - O
kb - - O
of - - O
DNA - - O
, - - O
whereas - - O
the - - O
Crry-ps - - B-MUT
sequences - - I-MUT
are - - O
included - - O
within - - O
a - - O
single - - O
5 - - B-MUT
. - - I-MUT
6-kb - - I-MUT
Eco-R1 - - I-MUT
fragment - - I-MUT
. - - O

A - - O
note - - O
on - - O
the - - O
phase-plane - - O
technique - - O
representation - - O
of - - O
cardiac - - O
action - - O
potentials - - O
. - - O

Prevention - - O
of - - O
acute - - O
paraquat - - O
toxicity - - O
in - - O
rats - - O
by - - O
superoxide - - B-MUT
dismutase - - I-MUT
. - - O

The - - O
amino - - O
acid - - O
sequence - - O
was - - O
determined - - O
to - - O
be - - O
residues - - O
716-724 - - O
and - - O
hence - - O
lysine - - O
residue - - O
721 - - O
is - - O
located - - O
within - - O
the - - O
ATP-binding - - O
site - - O
. - - O

Thus - - O
, - - O
hGRbeta - - B-MUT
potentially - - O
functions - - O
as - - O
a - - O
dominant - - O
negative - - O
inhibitor - - O
of - - O
hGRalpha - - B-MUT
activity - - O
. - - O

OBJECTIVE - - O
: - - O
To - - O
determine - - O
whether - - O
RSTD - - O
predicts - - O
coronary - - O
anatomy - - O
during - - O
acute - - O
coronary - - O
occlusion - - O
. - - O

Alignment - - O
of - - O
the - - O
cervical - - O
spine - - O
, - - O
vertebral - - O
abnormalities - - O
, - - O
and - - O
disc - - O
changes - - O
also - - O
were - - O
evaluated - - O
. - - O

CONCLUSION - - O
: - - O
Intravenous - - O
diazepam - - O
administration - - O
before - - O
EGD - - O
produces - - O
a - - O
significant - - O
fall - - O
in - - O
SpO2 - - O
during - - O
the - - O
procedure - - O
, - - O
and - - O
so - - O
should - - O
be - - O
avoided - - O
; - - O
continuous - - O
monitoring - - O
of - - O
SpO2 - - O
should - - O
be - - O
done - - O
during - - O
EGD - - O
. - - O

There - - O
are - - O
two - - O
immunogenic - - O
sites - - O
on - - O
the - - O
type - - B-MUT
A - - I-MUT
influenza - - I-MUT
A - - I-MUT
Japan - - I-MUT
57 - - I-MUT
( - - I-MUT
H2N2 - - I-MUT
) - - I-MUT
hemagglutinin - - I-MUT
( - - I-MUT
HA - - I-MUT
) - - O
that - - B-MUT
can - - O
be - - O
recognized - - O
by - - O
class - - O
I - - O
major - - B-MUT
histocompatibility - - I-MUT
complex - - I-MUT
( - - I-MUT
MHC - - I-MUT
) - - O
, - - B-MUT
H-2Kd-restricted - - O
cytolytic - - O
T - - O
lymphocytes - - O
( - - O
CTLs - - O
) - - O
. - - O

However - - O
, - - O
after - - O
PRK - - O
at - - O
5 - - O
weeks - - O
of - - O
age - - O
, - - O
partial - - O
retreatment - - O
may - - O
be - - O
necessary - - O
due - - O
to - - O
regression - - O
of - - O
the - - O
PRK - - O
effect - - O
. - - O

One - - O
maternal - - O
death - - O
, - - O
reduced - - O
body - - O
weight - - O
, - - O
and - - O
reduced - - O
weight - - O
gain - - O
were - - O
noted - - O
at - - O
the - - O
high - - O
dose - - O
; - - O
confirmed - - O
pregnancy - - O
rates - - O
were - - O
84 - - O
to - - O
100% - - O
for - - O
each - - O
group - - O
. - - O

Entry - - O
of - - O
yeast - - O
cells - - O
into - - O
the - - O
mitotic - - O
cell - - O
cycle - - O
( - - O
Start - - O
) - - O
involves - - O
a - - O
form - - O
of - - O
the - - O
CDC28 - - B-MUT
kinase - - I-MUT
that - - O
associates - - O
with - - O
G1-specific - - O
cyclins - - B-MUT
encoded - - O
by - - O
CLN1 - - B-MUT
and - - O
CLN2 - - B-MUT
( - - O
ref - - O
. - - O

The - - O
tip - - O
of - - O
the - - O
button - - O
caused - - O
a - - O
perforation - - O
of - - O
the - - O
posterior - - O
stomach - - O
wall - - O
, - - O
leading - - O
to - - O
death - - O
. - - O

In - - O
this - - O
study - - O
, - - O
we - - O
investigated - - O
STAT - - B-MUT
activation - - O
in - - O
a - - O
panel - - O
of - - O
rodent - - O
fibroblast - - O
cell - - O
lines - - O
stably - - O
transformed - - O
by - - O
diverse - - O
viral - - O
oncoproteins - - O
. - - O

Comparison - - O
with - - O
the - - O
crystal - - O
structure - - O
of - - O
Desulfovibrio - - O
gigas - - O
, - - O
Dg - - O
, - - O
Fd - - O
( - - O
Kissinger - - O
et - - O
al - - O
. - - O
, - - O
1991 - - O
) - - O
reveals - - O
a - - O
very - - O
similar - - O
folding - - O
topology - - O
, - - O
although - - O
several - - O
secondary - - O
structural - - O
elements - - O
are - - O
extended - - O
in - - O
Pf - - O
relative - - O
to - - O
Dg - - O
Fd - - O
. - - O

Thus - - O
, - - O
elongin - - B-MUT
C - - I-MUT
is - - O
found - - O
to - - O
oligomerize - - O
in - - O
solution - - O
and - - O
to - - O
undergo - - O
significant - - O
structural - - O
rearrangements - - O
upon - - O
binding - - O
of - - O
two - - O
different - - O
partner - - O
proteins - - O
. - - O

The - - O
gene - - B-MUT
lac-1 - - I-MUT
, - - O
encoding - - O
the - - O
enzyme - - O
laccase - - B-MUT
, - - O
is - - O
the - - O
best - - O
characterized - - O
of - - O
a - - O
number - - O
of - - O
genes - - O
in - - O
the - - O
chestnut - - O
blight - - O
fungus - - O
, - - O
Cryphonectria - - O
parasitica - - O
, - - O
that - - O
are - - O
repressed - - O
by - - O
hypoviruses - - O
, - - O
a - - O
group - - O
of - - O
virulence-attenuating - - O
mycoviruses - - O
. - - O
lac-1 - - B-MUT
has - - O
also - - O
been - - O
shown - - O
to - - O
be - - O
transcriptionally - - O
activated - - O
by - - O
low - - O
concentrations - - O
of - - O
the - - O
translational - - O
inhibitor - - O
cycloheximide - - O
( - - O
CHX - - O
) - - O
and - - O
by - - O
the - - O
immunosuppressant - - O
cyclosporin - - O
A - - O
. - - O

4 - - O
. - - O

Using - - O
sequence - - O
information - - O
from - - O
human - - B-MUT
BMAL1 - - I-MUT
( - - O
hBMAL1 - - B-MUT
) - - O
cDNAs - - O
previously - - O
reported - - O
by - - O
our - - O
laboratory - - O
, - - O
we - - O
have - - O
isolated - - O
and - - O
characterized - - O
cDNAs - - O
encoding - - O
three - - O
splice - - O
variants - - O
of - - O
the - - O
mouse - - B-MUT
BMAL1 - - I-MUT
( - - O
mBMAL1 - - B-MUT
) - - O
gene - - O
. - - O

In - - O
support - - O
of - - O
a - - O
role - - O
at - - O
the - - O
spindle - - O
, - - O
two-hybrid - - O
library - - O
screening - - O
with - - O
HEF1 - - B-MUT
identifies - - O
the - - O
human - - O
homolog - - O
of - - O
the - - O
G2 - - B-MUT
M - - I-MUT
spindle-regulatory - - I-MUT
protein - - I-MUT
Dim1p - - I-MUT
as - - I-MUT
a - - O
specific - - O
interactor - - O
with - - O
a - - O
region - - O
of - - O
HEF1 - - O
encompassed - - B-MUT
in - - O
p55 - - O
( - - B-MUT
HEF1 - - I-MUT
) - - I-MUT
. - - I-MUT

An - - O
endogenous - - O
mammalian - - O
regulator - - O
of - - O
this - - O
process - - O
, - - O
named - - O
Usurpin - - B-MUT
, - - O
has - - O
been - - O
identified - - O
( - - O
aliases - - O
for - - O
Usurpin - - B-MUT
include - - O
CASH - - B-MUT
, - - O
Casper - - B-MUT
, - - O
CLARP - - B-MUT
, - - O
FLAME-1 - - B-MUT
, - - O
FLIP - - B-MUT
, - - O
I-FLICE - - B-MUT
and - - O
MRIT - - B-MUT
) - - O
. - - O

In - - O
a - - O
similar - - O
fashion - - O
to - - O
adipose - - O
stromal - - O
cells - - O
, - - O
serum - - O
potentiated - - O
the - - O
response - - O
to - - O
dexamethasone - - O
but - - O
had - - O
no - - O
effect - - O
on - - O
phorbol - - O
ester-stimulated - - O
activity - - O
. - - O

Although - - O
MAP - - B-MUT
( - - I-MUT
mitogen-activated - - I-MUT
protein - - I-MUT
) - - I-MUT
kinases - - I-MUT
are - - O
implicated - - O
in - - O
cell - - O
proliferation - - O
and - - O
differentiation - - O
in - - O
many - - O
cell - - O
types - - O
, - - O
the - - O
role - - O
of - - O
MAP - - B-MUT
kinases - - I-MUT
in - - O
cardiac - - O
hypertrophy - - O
remains - - O
unclear - - O
. - - O

AGO1 - - B-MUT
is - - O
similar - - O
to - - O
QDE-2 - - B-MUT
required - - O
for - - O
quelling - - O
and - - O
RDE-1 - - B-MUT
required - - O
for - - O
RNAi - - O
. - - O

METHODS - - O
: - - O
Fifty-eight - - O
patients - - O
who - - O
underwent - - O
a - - O
curative - - O
hepatic - - O
resection - - O
for - - O
HCC - - O
and - - O
whose - - O
preoperative - - O
AFP - - B-MUT
levels - - O
were - - O
> - - O
100 - - O
ng - - O
ml - - O
, - - O
were - - O
selected - - O
for - - O
this - - O
study - - O
. - - O

Significant - - O
alterations - - O
in - - O
the - - O
vasectomized - - O
rats - - O
from - - O
sham - - O
rats - - O
included - - O
: - - O
testicular - - O
and - - O
epididymal - - O
hypertrophy - - O
, - - O
formation - - O
of - - O
pathologic - - O
vas - - O
deferens - - O
granulomas - - O
, - - O
decreased - - O
total - - O
serum - - O
protein - - O
, - - O
lowered - - O
alpha-globulin - - B-MUT
levels - - O
as - - O
shown - - O
by - - O
serum - - O
electrophoresis - - O
, - - O
and - - O
increased - - O
sperm - - O
agglutinin - - O
antibody - - O
titers - - O
. - - O

There - - O
was - - O
no - - O
difference - - O
in - - O
the - - O
hormone - - O
receptor - - O
status - - O
between - - O
the - - O
cases - - O
without - - O
lymph - - O
node - - O
metastases - - O
and - - O
with - - O
lymph - - O
node - - O
metastases - - O
, - - O
'clandestine' - - O
or - - O
macrometastases - - O
. - - O

It - - O
may - - O
be - - O
time - - O
to - - O
reevaluate - - O
the - - O
dichotomy - - O
between - - O
AD - - O
and - - O
VaD - - O
. - - O

Comparative - - O
mapping - - O
of - - O
the - - O
Brassica - - B-MUT
S - - I-MUT
locus - - I-MUT
region - - I-MUT
and - - O
its - - O
homeolog - - O
in - - O
Arabidopsis - - O
. - - O

In - - O
addition - - O
, - - O
we - - O
show - - O
that - - O
the - - O
expression - - O
of - - O
individual - - O
members - - O
of - - O
one - - O
subfamily - - O
of - - O
KRAB - - B-MUT
zinc - - I-MUT
finger - - I-MUT
genes - - I-MUT
is - - O
restricted - - O
to - - O
specific - - O
hematopoietic - - O
cell - - O
lineages - - O
. - - O

Two - - O
of - - O
the - - O
ORFs - - O
are - - O
completely - - O
internal - - O
to - - O
longer - - O
ones - - O
and - - O
a - - O
third - - O
is - - O
partially - - O
embedded - - O
in - - O
G2850 - - B-MUT
. - - O

Fast - - O
goal-directed - - O
voluntary - - O
movements - - O
of - - O
the - - O
human - - O
upper - - O
extremity - - O
are - - O
known - - O
to - - O
be - - O
associated - - O
with - - O
three - - O
distinct - - O
bursts - - O
of - - O
EMG - - O
activity - - O
in - - O
antagonistic - - O
muscles - - O
. - - O

A - - O
5-month-old - - O
infant - - O
with - - O
persistent - - O
congenital - - O
stridor - - O
and - - O
acute - - O
respiratory - - O
distress - - O
is - - O
presented - - O
. - - O

Nevertheless - - O
, - - O
antibodies - - O
directed - - O
against - - O
an - - O
epitope-tagged - - O
version - - O
of - - O
Prp42p - - B-MUT
specifically - - O
precipitate - - O
U1 - - B-MUT
snRNA - - I-MUT
from - - O
yeast - - O
extracts - - O
. - - O

They - - O
lack - - O
a - - O
predicted - - O
single - - O
stranded - - O
( - - O
ss - - O
) - - O
DNA - - O
binding - - O
motif - - O
that - - O
is - - O
unique - - O
the - - O
large - - O
terminase - - B-MUT
proteins - - I-MUT
in - - O
T4 - - B-MUT
gp17 - - I-MUT
, - - O
and - - O
that - - O
has - - O
been - - O
implicated - - O
in - - O
recognizing - - O
ssDNA - - O
regions - - O
in - - O
replicating - - O
and - - O
recombining - - O
T4DNA - - O
destined - - O
to - - O
be - - O
packaged - - O
. - - O

The - - O
Tullio - - O
phenomenon - - O
, - - O
fistula - - O
test - - O
, - - O
and - - O
Hennebert's - - O
sign - - O
: - - O
clinical - - O
significance - - O
. - - O

The - - O
ORF3 - - O
mutant - - O
produced - - O
reduced - - O
levels - - O
of - - O
tabtoxin - - B-MUT
, - - O
indicating - - O
that - - O
ORF3 - - O
may - - O
have - - O
a - - O
role - - O
in - - O
T - - B-MUT
beta - - I-MUT
L - - I-MUT
biosynthesis - - O
. - - O

No - - O
significant - - O
differences - - O
existed - - O
between - - O
the - - O
two - - O
age - - O
groups - - O
in - - O
baseline - - O
characteristics - - O
, - - O
including - - O
treatment - - O
protocol - - O
, - - O
performance - - O
status - - O
, - - O
and - - O
serum - - B-MUT
lactate - - I-MUT
dehydrogenase - - I-MUT
( - - O
LDH - - B-MUT
) - - O
level - - O
. - - O

Interferon - - B-MUT
stimulated - - I-MUT
gene - - I-MUT
factor - - I-MUT
3 - - I-MUT
( - - O
ISGF3 - - B-MUT
) - - O
is - - O
a - - O
trimeric - - O
transcription - - O
factor - - O
activated - - O
on - - O
treatment - - O
of - - O
cells - - O
with - - O
interferon-alpha - - B-MUT
and - - I-MUT
beta - - I-MUT
( - - O
type - - B-MUT
I - - I-MUT
IFNs - - I-MUT
) - - O
. - - O

Although - - O
heart - - O
rate - - O
and - - O
diastolic - - O
pressure - - O
rose - - O
in - - O
some - - O
degree - - O
1 - - O
min - - O
after - - O
intubation - - O
, - - O
free - - O
and - - O
total - - O
CA - - O
concentrations - - O
did - - O
not - - O
increase - - O
during - - O
study - - O
period - - O
. - - O

Biol - - O
. - - O

Activation - - O
of - - O
c-fos - - B-MUT
gene - - I-MUT
expression - - O
by - - O
a - - O
kinase-deficient - - O
epidermal - - B-MUT
growth - - I-MUT
factor - - I-MUT
receptor - - I-MUT
. - - O

Fifty - - O
six - - O
young - - O
patients - - O
( - - O
age - - O
< - - O
45 - - O
yr - - O
) - - O
with - - O
doppler-proven - - O
DVT - - O
were - - O
investigated - - O
for - - O
the - - O
presence - - O
of - - O
resistance - - O
to - - O
activated - - B-MUT
protein - - I-MUT
C - - I-MUT
( - - O
APC-R - - B-MUT
) - - O
, - - O
lupus - - O
anticoagulant - - O
( - - O
LA - - O
) - - O
, - - O
anticardiolipin - - B-MUT
antibodies - - I-MUT
and - - O
deficiencies - - O
of - - O
protein - - B-MUT
C - - I-MUT
, - - O
protein - - B-MUT
S - - I-MUT
, - - O
ATIII - - B-MUT
activities - - O
. - - O

The - - O
effects - - O
of - - O
procedural - - O
variations - - O
on - - O
lateralized - - O
Stroop - - O
effects - - O
. - - O

Host - - O
lipids - - O
in - - O
tuberculous - - O
infection - - O
. - - O

However - - O
, - - O
in - - O
those - - O
studies - - O
due - - O
to - - O
the - - O
presence - - O
of - - O
thiol - - O
agents - - O
in - - O
the - - O
PKC - - B-MUT
preparations - - O
, - - O
the - - O
sensitive - - O
reaction - - O
of - - O
BPO - - O
with - - O
redox-active - - O
cysteine - - O
residues - - O
in - - O
PKC - - B-MUT
was - - O
not - - O
observed - - O
. - - O

Increasing - - O
the - - O
cut-off - - O
point - - O
to - - O
3 - - O
positive - - O
responses - - O
decreased - - O
the - - O
sensitivity - - O
to - - O
81% - - O
and - - O
increased - - O
the - - O
specificity - - O
to - - O
94% - - O
. - - O

Recently - - O
, - - O
extremely - - O
high - - O
levels - - O
of - - O
endothelin-1 - - B-MUT
( - - O
ET-1 - - B-MUT
) - - O
were - - O
detected - - O
in - - O
the - - O
pericardial - - O
fluid - - O
of - - O
patients - - O
undergoing - - O
cardiac - - O
surgery - - O
. - - O

The - - O
3' - - O
stem-loop - - O
is - - O
highly - - O
divergent - - O
in - - O
structure - - O
among - - O
species - - O
and - - O
lies - - O
immediately - - O
upstream - - O
of - - O
the - - O
binding - - O
site - - O
for - - O
Sm - - B-MUT
proteins - - I-MUT
. - - O

The - - O
C-terminal - - O
domains - - O
( - - O
CTDs - - O
) - - O
of - - O
the - - O
RPase - - B-MUT
beta - - I-MUT
subunit - - I-MUT
and - - O
DNA - - B-MUT
primase - - I-MUT
( - - O
dnaG - - B-MUT
protein - - I-MUT
) - - O
were - - O
not - - O
only - - O
strongly - - O
homologous - - O
to - - O
each - - O
other - - O
but - - O
also - - O
considerably - - O
homologous - - O
to - - O
the - - O
RPase - - B-MUT
alpha - - I-MUT
, - - O
suggesting - - O
that - - O
an - - O
alpha - - O
subunit-like - - O
enzyme - - O
must - - O
have - - O
been - - O
commonly - - O
ancestral - - O
to - - O
core - - B-MUT
enzyme - - I-MUT
subunits - - I-MUT
and - - O
primase - - B-MUT
. - - O

In - - O
these - - O
cases - - O
, - - O
asbestos - - O
or - - O
erionite-tissue - - O
burden - - O
followed - - O
by - - O
fibrosis - - O
was - - O
frequently - - O
observed - - O
. - - O

OBJECTIVE - - O
: - - O
To - - O
determine - - O
the - - O
efficacy - - O
and - - O
safety - - O
of - - O
amphotericin - - O
B - - O
oral - - O
suspension - - O
( - - O
ABOS - - O
) - - O
for - - O
the - - O
treatment - - O
of - - O
fluconazole - - O
refractory - - O
oral - - O
candidiasis - - O
in - - O
persons - - O
with - - O
HIV - - O
infection - - O
. - - O

Chlamydial - - O
agents - - O
were - - O
isolated - - O
from - - O
the - - O
semen - - O
near - - O
the - - O
end - - O
of - - O
the - - O
chlamydemic - - O
phase - - O
. - - O

This - - O
study - - O
was - - O
undertaken - - O
to - - O
evaluate - - O
how - - O
couplers - - O
and - - O
their - - O
placement - - O
affect - - O
the - - O
ALGO2 - - O
click - - O
spectral - - O
properties - - O
. - - O

III - - O
. - - O

The - - O
arrangement - - O
of - - O
these - - O
cutoff-levels - - O
leads - - O
to - - O
a - - O
sensitivity - - O
of - - O
85% - - O
at - - O
a - - O
specificity - - O
of - - O
55% - - O
for - - O
Protein - - B-MUT
S100 - - I-MUT
when - - O
measured - - O
by - - O
RIA - - O
, - - O
and - - O
to - - O
a - - O
sensitivity - - O
of - - O
77% - - O
at - - O
a - - O
specificity - - O
of - - O
61% - - O
when - - O
measured - - O
by - - O
LIA - - O
. - - O

In - - O
memory - - O
of - - O
Magdelaine - - O
Comtesse - - O
. - - O

In - - O
the - - O
absence - - O
of - - O
Swi4 - - B-MUT
and - - O
Swi6 - - B-MUT
cell - - O
viability - - O
is - - O
lost - - O
, - - O
but - - O
can - - O
be - - O
regained - - O
by - - O
ectopic - - O
expression - - O
of - - O
the - - O
G1 - - B-MUT
cyclin - - I-MUT
encoding - - I-MUT
genes - - I-MUT
, - - O
CLN1 - - B-MUT
or - - O
CLN2 - - B-MUT
. - - O

The - - O
study - - O
made - - O
to - - O
define - - O
the - - O
ability - - O
of - - O
lipid - - B-MUT
A - - I-MUT
monoclonal - - I-MUT
antibodies - - I-MUT
to - - O
correct - - O
hemodynamic - - O
disturbances - - O
due - - O
to - - O
endotoxemia - - O
in - - O
dog - - O
experiments - - O
showed - - O
the - - O
efficacy - - O
of - - O
the - - O
antibodies - - O
administration - - O
. - - O

Data - - O
on - - O
prosthesis - - O
use - - O
are - - O
encouraging - - O
, - - O
although - - O
a - - O
follow-up - - O
study - - O
is - - O
required - - O
to - - O
determine - - O
the - - O
functional - - O
outcome - - O
for - - O
prosthesis - - O
users - - O
and - - O
non-users - - O
. - - O

HBx - - B-MUT
strongly - - O
elevates - - O
levels - - O
of - - O
GTP-bound - - O
Ras - - B-MUT
, - - O
activated - - O
and - - O
phosphorylated - - O
Raf - - B-MUT
, - - O
and - - O
tyrosine-phosphorylated - - O
and - - O
activated - - O
MAP - - B-MUT
kinase - - I-MUT
. - - O

These - - O
studies - - O
indicate - - O
that - - O
in - - O
vitro - - O
and - - O
in - - O
vivo - - O
electrical - - O
stimulation - - O
generate - - O
reactive - - O
oxygen - - O
species - - O
and - - O
affect - - O
SOD - - B-MUT
activity - - O
, - - O
which - - O
in - - O
part - - O
are - - O
responsible - - O
for - - O
decreased - - O
sperm - - O
motion - - O
and - - O
viability - - O
. - - O

In - - O
addition - - O
, - - O
the - - O
DNA-binding - - O
experiments - - O
show - - O
that - - O
either - - O
one - - O
of - - O
the - - O
two - - O
MADS - - B-MUT
domains - - I-MUT
of - - O
a - - O
dimer - - O
can - - O
be - - O
sufficient - - O
to - - O
confer - - O
a - - O
particular - - O
DNA-binding - - O
specificity - - O
to - - O
the - - O
complex - - O
and - - O
that - - O
sequences - - O
outside - - O
the - - O
amino-terminal - - O
basic - - O
region - - O
of - - O
the - - O
MADS - - B-MUT
domain - - O
can - - O
, - - O
in - - O
some - - O
cases - - O
, - - O
contribute - - O
to - - O
the - - O
DNA-binding - - O
specificity - - O
of - - O
the - - O
proteins - - O
. - - O

Finally - - O
, - - O
the - - O
mechanism - - O
of - - O
ASK1 - - B-MUT
activation - - O
involves - - O
, - - O
in - - O
part - - O
, - - O
homo-oligomerization - - O
. - - O

A - - O
third - - O
one - - O
is - - O
homologous - - O
in - - O
half - - O
of - - O
its - - O
length - - O
to - - O
the - - O
prokaryotic - - B-MUT
hydantoinase - - I-MUT
HyuA - - B-MUT
and - - O
in - - O
the - - O
other - - O
half - - O
to - - O
hydatoinase - - B-MUT
HyuB - - B-MUT
. - - O

One - - O
of - - O
the - - O
most - - O
relevant - - O
aspects - - O
in - - O
achieving - - O
the - - O
consistent - - O
survival - - O
of - - O
an - - O
animal - - O
undergoing - - O
the - - O
experimental - - O
implantation - - O
of - - O
a - - O
total - - O
artificial - - O
heart - - O
is - - O
obviously - - O
related - - O
to - - O
the - - O
correct - - O
anatomic - - O
placement - - O
of - - O
prosthetic - - O
ventricles - - O
inside - - O
the - - O
chest - - O
. - - O

In - - O
addition - - O
serum - - B-MUT
IgE - - I-MUT
concentrations - - O
were - - O
not - - O
statistically - - O
different - - O
. - - O

Our - - O
results - - O
demonstrate - - O
that - - O
distinct - - O
cytoplasmic - - O
domains - - O
of - - O
these - - O
cytokine - - B-MUT
receptors - - I-MUT
elicit - - O
convergent - - O
signaling - - O
pathways - - O
and - - O
provide - - O
evidence - - O
that - - O
beta - - B-MUT
c - - I-MUT
and - - O
IL-2R - - B-MUT
beta - - I-MUT
function - - O
as - - O
a - - O
complete - - O
signal - - O
transducer - - O
. - - O

H-7 - - O
, - - O
which - - O
specifically - - O
, - - O
although - - O
weakly - - O
, - - O
inhibited - - O
PKC - - B-MUT
activation - - O
, - - O
had - - O
no - - O
effect - - O
on - - O
tyrosine - - O
phosphorylation - - O
and - - O
PtdIns - - O
( - - O
3 - - O
, - - O
4 - - O
) - - O
P2 - - O
production - - O
. - - O

CONCLUSION - - O
: - - O
Extrusion - - O
cooking - - O
is - - O
effective - - O
for - - O
the - - O
inactivation - - O
of - - O
DON - - O
but - - O
is - - O
of - - O
limited - - O
value - - O
for - - O
AFB1 - - O
, - - O
even - - O
if - - O
metabisulphite - - O
is - - O
added - - O
. - - O

Efforts - - O
were - - O
made - - O
to - - O
determine - - O
the - - O
amount - - O
of - - O
time - - O
required - - O
for - - O
kidney - - O
lesions - - O
to - - O
develop - - O
and - - O
, - - O
if - - O
possible - - O
, - - O
to - - O
delineate - - O
the - - O
potential - - O
site - - O
of - - O
action - - O
of - - O
PBB - - O
. - - O

In - - O
summary - - O
, - - O
Ca - - O
( - - O
2+ - - O
) - - O
-dependent - - O
activation - - O
of - - O
NO - - O
production - - O
mediates - - O
apoptosis - - O
after - - O
TG - - O
exposure - - O
in - - O
JT - - O
Neo - - O
cells - - O
. - - O

All - - O
carcasses - - O
resulted - - O
in - - O
contamination - - O
with - - O
aerobic - - O
mesophilic - - O
bacteria - - O
in - - O
the - - O
range - - O
from - - O
6 - - O
x - - O
10 - - O
( - - O
3 - - O
) - - O
to - - O
1 - - O
. - - O
2 - - O
x - - O
10 - - O
( - - O
6 - - O
) - - O
CFU - - O
ml - - O
liquid - - O
washed - - O
, - - O
and - - O
94% - - O
them - - O
with - - O
sporulate - - O
bacteria - - O
, - - O
the - - O
threshold - - O
being - - O
under - - O
100 - - O
CFU - - O
ml - - O
( - - O
Figure - - O
1 - - O
) - - O
. - - O

Saccharomyces - - O
cerevisiae - - O
contains - - O
four - - O
known - - O
acyl-CoA - - B-MUT
synthetases - - I-MUT
( - - O
fatty - - B-MUT
acid - - I-MUT
activation - - I-MUT
proteins - - I-MUT
, - - O
Faaps - - B-MUT
) - - O
. - - O

Specific - - O
requirements - - O
for - - O
branched-chain - - O
amino - - O
acids - - O
, - - O
glutamine - - O
, - - O
and - - O
arginine - - O
are - - O
evaluated - - O
. - - O

The - - O
corn - - O
and - - O
mineral - - O
oil - - O
emulsions - - O
were - - O
almost - - O
as - - O
effective - - O
as - - O
milk - - O
but - - O
less - - O
effective - - O
than - - O
sucrose - - O
( - - O
0 - - O
. - - O
3M - - O
) - - O
in - - O
stimulating - - O
ingestion - - O
. - - O

In - - O
both - - O
shoots - - O
and - - O
roots - - O
, - - O
GT-2 - - B-MUT
protein - - I-MUT
is - - O
undetectable - - O
in - - O
meristematic - - O
tissue - - O
but - - O
becomes - - O
expressed - - O
at - - O
later - - O
stages - - O
of - - O
cellular - - O
development - - O
, - - O
consistent - - O
with - - O
a - - O
role - - O
in - - O
contributing - - O
to - - O
the - - O
pattern - - O
of - - O
phytochrome - - B-MUT
A - - I-MUT
gene - - I-MUT
expression - - O
. - - O

The - - O
calcium - - O
requirement - - O
for - - O
hypothermic - - O
storage - - O
of - - O
the - - O
cardiac - - O
explant - - O
. - - O

A - - O
cDNA - - O
library - - O
of - - O
tumour - - O
cells - - O
was - - O
screened - - O
with - - O
an - - O
interleukin - - B-MUT
2 - - I-MUT
gene-specific - - O
probe - - O
. - - O

An - - O
element - - O
within - - O
the - - O
5' - - O
untranslated - - O
region - - O
of - - O
human - - B-MUT
Hsp70 - - I-MUT
mRNA - - I-MUT
which - - O
acts - - O
as - - O
a - - O
general - - O
enhancer - - O
of - - O
mRNA - - O
translation - - O
. - - O

The - - O
ARX2 - - O
procedure - - O
models - - O
the - - O
recorded - - O
signal - - O
as - - O
the - - O
sum - - O
of - - O
three - - O
signals - - O
: - - O
( - - O
a - - O
) - - O
the - - O
background - - O
EEG - - O
activity - - O
, - - O
modelled - - O
as - - O
an - - O
autoregressive - - O
process - - O
driven - - O
by - - O
a - - O
white - - O
noise - - O
; - - O
( - - O
b - - O
) - - O
a - - O
filtered - - O
version - - O
of - - O
a - - O
reference - - O
signal - - O
carrying - - O
the - - O
average - - O
information - - O
contained - - O
in - - O
each - - O
sweep - - O
; - - O
( - - O
c - - O
) - - O
a - - O
signal - - O
due - - O
to - - O
the - - O
ocular - - O
artefact - - O
propagation - - O
. - - O

Diagnosis - - O
and - - O
treatment - - O
of - - O
insulin-secreting - - O
tumours - - O
. - - O

The - - O
coordinated - - O
expression - - O
of - - O
CD4 - - B-MUT
and - - O
CD8 - - B-MUT
during - - O
T-cell - - O
development - - O
is - - O
tightly - - O
coupled - - O
with - - O
the - - O
maturation - - O
state - - O
of - - O
the - - O
T - - O
cell - - O
. - - O

In - - O
contrast - - O
, - - O
recent - - O
evidence - - O
suggests - - O
that - - O
children - - O
with - - O
sickle-hemoglobin - - B-MUT
C - - I-MUT
disease - - O
do - - O
not - - O
develop - - O
functional - - O
asplenia - - O
before - - O
3 - - O
to - - O
4 - - O
years - - O
of - - O
age - - O
and - - O
thus - - O
may - - O
not - - O
benefit - - O
from - - O
penicillin - - O
prophylaxis - - O
. - - O

Contraction - - O
of - - O
the - - O
tracheal - - O
muscle - - O
and - - O
the - - O
activity - - O
of - - O
stretch - - O
receptors - - O
in - - O
the - - O
trachea - - O
. - - O

Imaging - - O
of - - O
D2 - - B-MUT
dopamine - - I-MUT
receptor - - I-MUT
. - - O

Modification - - O
of - - O
enteral - - O
resorption - - O
by - - O
cytostatic - - O
therapy - - O
. - - O

This - - O
mutation - - O
no - - O
longer - - O
repressed - - O
the - - O
HPV-11 - - O
upstream - - O
regulatory - - O
region-controlled - - O
reporter - - O
expression - - O
. - - O

The - - O
production - - O
of - - O
ceramide - - O
is - - O
emerging - - O
as - - O
a - - O
fixture - - O
of - - O
programmed - - O
cell - - O
death - - O
. - - O

Foveating - - O
saccades - - O
, - - O
therefore - - O
, - - O
can - - O
be - - O
distinguished - - O
from - - O
other - - O
FEMs - - O
on - - O
the - - O
basis - - O
of - - O
speed - - O
. - - O

RESULTS - - O
: - - O
In - - O
the - - O
AGA - - O
group - - O
, - - O
both - - O
fetal - - O
and - - O
maternal - - O
serum - - O
prolactin - - B-MUT
concentration - - O
increased - - O
significantly - - O
with - - O
gestation - - O
( - - O
P - - O
< - - O
0 - - O
. - - O
001 - - O
and - - O
P - - O
< - - O
0 - - O
. - - O
01 - - O
, - - O
respectively - - O
) - - O
. - - O

Colorimetric - - O
determination - - O
of - - O
urinary - - O
iron - - O
, - - O
chelated - - O
with - - O
deferoxamine - - O
B - - O
, - - O
using - - O
a - - O
single - - O
reagent - - O
. - - O

We - - O
hypothesize - - O
that - - O
proprioception - - O
may - - O
be - - O
used - - O
to - - O
calibrate - - O
the - - O
efference - - O
copy - - O
during - - O
development - - O
and - - O
in - - O
response - - O
to - - O
perturbations - - O
by - - O
signaling - - O
potential - - O
mismatches - - O
between - - O
eye - - O
movement - - O
information - - O
derived - - O
from - - O
the - - O
efferent - - O
command - - O
and - - O
the - - O
actual - - O
motion - - O
of - - O
the - - O
eye - - O
transduced - - O
by - - O
the - - O
proprioceptive - - O
organs - - O
. - - O

The - - O
maps - - O
of - - O
Case - - O
2 - - O
showed - - O
that - - O
a - - O
maximum - - O
first - - O
appeared - - O
on - - O
the - - O
upper - - O
right - - O
back - - O
and - - O
then - - O
moved - - O
down - - O
the - - O
right - - O
side - - O
of - - O
the - - O
posterior - - O
thorax - - O
. - - O

Assembly - - O
of - - O
a - - O
complex - - O
between - - O
FAK - - B-MUT
and - - O
Src - - B-MUT
kinases - - I-MUT
may - - O
serve - - O
to - - O
regulate - - O
the - - O
subcellular - - O
localization - - O
and - - O
the - - O
enzymatic - - O
activity - - O
of - - O
members - - O
of - - O
the - - O
Src - - B-MUT
family - - I-MUT
of - - O
kinases - - B-MUT
. - - O

Naphthalene - - O
and - - O
paradichlorobenzene - - O
in - - O
clinical - - O
toxicology - - O
. - - O

Role - - O
of - - O
the - - O
transcription - - O
start - - O
site - - O
core - - O
region - - O
and - - O
transcription - - B-MUT
factor - - I-MUT
YY1 - - I-MUT
in - - O
Rous - - B-MUT
sarcoma - - I-MUT
virus - - I-MUT
long - - I-MUT
terminal - - I-MUT
repeat - - I-MUT
promoter - - I-MUT
activity - - O
. - - O

Some - - O
8 - - O
. - - O
8 - - O
kb - - O
of - - O
the - - O
Lactobacillus - - O
sake - - O
plasmid - - O
pCIM1 - - O
was - - O
sequenced - - O
, - - O
revealing - - O
eight - - O
tightly - - O
clustered - - O
open - - O
reading - - O
frames - - O
( - - O
ORFs - - O
) - - O
downstream - - O
from - - O
lasA - - B-MUT
, - - O
which - - O
encodes - - O
pre-lactocin - - B-MUT
S - - O
. - - O

These - - O
overall - - O
results - - O
indicate - - O
that - - O
there - - O
is - - O
generally - - O
one - - O
PERV - - O
copy - - O
per - - O
integration - - O
site - - O
. - - O

Until - - O
now - - O
, - - O
each - - O
of - - O
these - - O
loci - - O
was - - O
considered - - O
to - - O
contain - - O
three - - O
genes - - O
( - - O
for - - O
regulator - - B-MUT
, - - O
permease - - B-MUT
and - - O
alpha-glucosidase - - B-MUT
) - - O
, - - O
but - - O
a - - O
fourth - - O
gene - - O
, - - O
presumably - - O
an - - O
extra - - O
alpha-glucosidase - - B-MUT
gene - - I-MUT
, - - O
was - - O
found - - O
at - - O
MAL1 - - B-MUT
adjacent - - O
to - - O
the - - O
usual - - O
cluster - - O
of - - O
three - - O
genes - - O
. - - O

In - - O
patients - - O
with - - O
type - - O
II - - O
tumors - - O
, - - O
the - - O
pattern - - O
of - - O
lymphatic - - O
spread - - O
was - - O
primarily - - O
directed - - O
toward - - O
the - - O
paracardial - - O
, - - O
lesser - - O
curvature - - O
, - - O
and - - O
left - - O
gastric - - O
artery - - O
nodes - - O
; - - O
esophagectomy - - O
offered - - O
no - - O
survival - - O
benefit - - O
over - - O
extended - - O
gastrectomy - - O
in - - O
these - - O
patients - - O
. - - O

INF-alpha - - B-MUT
therapy - - O
has - - O
been - - O
a - - O
major - - O
development - - O
in - - O
the - - O
treatment - - O
of - - O
CML - - O
. - - O

On - - O
the - - O
transport - - O
of - - O
mucus - - O
and - - O
its - - O
rheologic - - O
simulants - - O
in - - O
ciliated - - O
systems - - O
. - - O

The - - O
cAMP-dependent - - O
mitogenic - - O
pathway - - O
is - - O
unique - - O
as - - O
it - - O
is - - O
independent - - O
of - - O
mitogen-activated - - B-MUT
protein - - I-MUT
kinase - - I-MUT
activation - - O
and - - O
differs - - O
from - - O
growth - - O
factor-dependent - - O
pathways - - O
at - - O
the - - O
level - - O
of - - O
the - - O
expression - - O
of - - O
several - - O
protooncogenes - - O
transcription - - O
factors - - O
. - - O

If - - O
NCR-sensitive - - O
gene - - O
expression - - O
occurs - - O
exclusively - - O
by - - O
this - - O
pathway - - O
, - - O
as - - O
has - - O
been - - O
thought - - O
to - - O
be - - O
the - - O
case - - O
, - - O
then - - O
the - - O
NCR - - O
sensitivity - - O
of - - O
a - - O
gene's - - O
expression - - O
should - - O
be - - O
abolished - - O
by - - O
a - - O
ure2 - - B-MUT
delta - - I-MUT
mutation - - I-MUT
. - - O

These - - O
data - - O
show - - O
that - - O
heterologous - - O
virus - - O
RNAs - - O
( - - O
BSMV - - O
) - - O
can - - O
serve - - O
as - - O
primer - - O
donors - - O
for - - O
MStV - - O
mRNA - - O
capped - - O
RNA-primed - - O
transcription - - O
in - - O
doubly - - O
infected - - O
plants - - O
. - - O

With - - O
certain - - O
exceptions - - O
the - - O
method - - O
was - - O
considered - - O
suitable - - O
in - - O
the - - O
routine - - O
intravenous - - O
cholangiography - - O
. - - O

CDDP - - O
is - - O
active - - O
as - - O
a - - O
single - - O
agent - - O
in - - O
non-Hodgkin's - - O
lymphoma - - O
. - - O

Four - - O
possible - - O
isoforms - - O
( - - O
hGli2 - - B-MUT
alpha - - I-MUT
, - - I-MUT
beta - - I-MUT
, - - I-MUT
gamma - - I-MUT
, - - I-MUT
and - - I-MUT
delta - - I-MUT
) - - O
are - - O
formed - - O
by - - O
combinations - - O
of - - O
two - - O
independent - - O
alternative - - O
splicings - - O
, - - O
and - - O
all - - O
the - - O
isoforms - - O
could - - O
bind - - O
to - - O
a - - O
DNA - - O
motif - - O
, - - O
TRE2S - - B-MUT
, - - O
in - - O
the - - O
LTR - - O
. - - O

When - - O
the - - O
E1A - - B-MUT
N-terminus - - I-MUT
is - - O
used - - O
as - - O
a - - O
competitor - - O
in - - O
squelshing - - O
experiments - - O
it - - O
abolishes - - O
CBP-induced - - O
activation - - O
of - - O
E2F1 - - B-MUT
DP1 - - I-MUT
, - - I-MUT
whereas - - O
an - - O
E1A - - O
mutant - - B-MUT
lacking - - I-MUT
CBP - - O
binding - - B-MUT
ability - - O
fails - - O
to - - O
do - - O
so - - O
. - - O

Specialized - - O
actin - - B-MUT
tails - - O
that - - O
propel - - O
IEV - - O
particles - - O
to - - O
the - - O
periphery - - O
and - - O
virus-tipped - - O
microvilli - - O
( - - O
both - - O
common - - O
in - - O
wild-type-infected - - O
cells - - O
) - - O
were - - O
absent - - O
in - - O
cells - - O
infected - - O
with - - O
vA33delta - - O
. - - O

( - - O
1996a - - O
) - - O
Biochemistry - - O
35 - - O
, - - O
1589-1598 - - O
] - - O
. - - O

Schwab - - O
and - - O
England - - O
ADL - - O
scores - - O
in - - O
the - - O
"off" - - O
state - - O
were - - O
improved - - O
by - - O
18% - - O
and - - O
in - - O
the - - O
"on" - - O
state - - O
the - - O
scores - - O
declined - - O
by - - O
2% - - O
. - - O

TGF - - B-MUT
beta - - I-MUT
1 - - I-MUT
expression - - O
is - - O
largely - - O
governed - - O
by - - O
three - - O
AP-1 - - B-MUT
binding - - I-MUT
sites - - I-MUT
located - - O
in - - O
two - - O
different - - O
promoters - - O
of - - O
this - - O
gene - - O
. - - O

The - - O
pyramidal - - O
tract - - O
and - - O
Mesencephalic - - O
Reticular - - O
Formation - - O
( - - O
MRF - - O
) - - O
were - - O
stimulated - - O
before - - O
and - - O
after - - O
the - - O
transection - - O
. - - O

There - - O
were - - O
no - - O
significant - - O
differences - - O
in - - O
EF - - O
between - - O
the - - O
two - - O
studies - - O
, - - O
both - - O
at - - O
rest - - O
( - - O
56 - - O
. - - O
0 - - O
+ - - O
- - - O
13 - - O
. - - O
8% - - O
vs - - O
58 - - O
. - - O
2 - - O
+ - - O
- - - O
11 - - O
. - - O
7% - - O
, - - O
p - - O
= - - O
NS - - O
) - - O
and - - O
with - - O
exercise - - O
( - - O
51 - - O
. - - O
1 - - O
+ - - O
- - - O
17 - - O
. - - O
6% - - O
vs - - O
54 - - O
. - - O
3 - - O
+ - - O
- - - O
17 - - O
. - - O
6% - - O
, - - O
p - - O
= - - O
NS - - O
) - - O
and - - O
a - - O
highly - - O
significant - - O
correlation - - O
was - - O
shown - - O
between - - O
the - - O
two - - O
groups - - O
of - - O
values - - O
( - - O
rest - - O
r - - O
= - - O
0 - - O
. - - O
90 - - O
, - - O
exercise - - O
r - - O
= - - O
0 - - O
. - - O
93 - - O
, - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
001 - - O
) - - O
. - - O

Serum - - O
levels - - O
of - - O
testosterone - - O
also - - O
showed - - O
no - - O
significant - - O
changes - - O
by - - O
exposure - - O
to - - O
p - - O
, - - O
p'-DDE - - O
under - - O
the - - O
conditions - - O
of - - O
this - - O
study - - O
. - - O

Effects - - O
of - - O
repeated - - O
exposures - - O
of - - O
hydrogen - - O
sulphide - - O
on - - O
rat - - O
hippocampal - - O
EEG - - O
. - - O

CONCLUSIONS - - O
: - - O
ChromaFlo-enhanced - - O
IVUS - - O
demonstrates - - O
colorized - - O
blood - - O
flow - - O
inside - - O
the - - O
vessel - - O
lumen - - O
, - - O
which - - O
is - - O
helpful - - O
in - - O
distinguishing - - O
echolucent - - O
disease - - O
from - - O
luminal - - O
blood - - O
flow - - O
and - - O
can - - O
also - - O
be - - O
used - - O
to - - O
perform - - O
peripheral - - O
interventions - - O
in - - O
patients - - O
with - - O
renal - - O
failure - - O
or - - O
allergy - - O
, - - O
avoiding - - O
the - - O
use - - O
of - - O
contrast - - O
media - - O
. - - O

Disruption - - O
of - - O
microtubules - - O
did - - O
not - - O
affect - - O
the - - O
fidelity - - O
or - - O
kinetics - - O
of - - O
vacuolar - - O
protein - - O
sorting - - O
, - - O
indicating - - O
that - - O
Vps1p - - B-MUT
function - - O
is - - O
not - - O
dependent - - O
on - - O
microtubules - - O
. - - O

Transcription - - O
start - - O
sites - - O
of - - O
the - - O
plastid - - O
ACCase - - B-MUT
genes - - I-MUT
were - - O
estimated - - O
from - - O
the - - O
longest - - O
cDNA - - O
clones - - O
obtained - - O
by - - O
5'-RACE - - O
( - - O
rapid - - O
amplification - - O
of - - O
cDNA - - O
ends - - O
) - - O
. - - O

MKK3 - - B-MUT
autophosphorylation - - O
and - - O
activation - - O
of - - O
p38 - - B-MUT
was - - O
also - - O
observed - - O
following - - O
coexpression - - O
of - - O
MKK3 - - B-MUT
with - - O
MEKK3 - - B-MUT
, - - O
but - - O
not - - O
with - - O
MEKK2 - - B-MUT
. - - O

Oxygen - - O
profiles - - O
calculated - - O
for - - O
the - - O
Krogh - - O
model - - O
with - - O
excentric - - O
diffusion - - O
were - - O
similar - - O
to - - O
those - - O
derived - - O
for - - O
the - - O
two - - O
models - - O
of - - O
concentric - - O
diffusion - - O
. - - O

We - - O
investigate - - O
the - - O
reaction - - O
kinetics - - O
of - - O
small - - O
spherical - - O
particles - - O
with - - O
inertia - - O
, - - O
obeying - - O
coalescence - - O
type - - O
of - - O
reaction - - O
, - - O
B+B-- - - O
> - - O
B - - O
, - - O
and - - O
being - - O
advected - - O
by - - O
hydrodynamical - - O
flows - - O
with - - O
time-periodic - - O
forcing - - O
. - - O

These - - O
striations - - O
were - - O
caused - - O
by - - O
contact - - O
between - - O
the - - O
sharp - - O
edge - - O
of - - O
the - - O
upper - - O
canine - - O
and - - O
the - - O
P3 - - O
during - - O
honing - - O
( - - O
canine - - O
premolar - - O
complex - - O
) - - O
. - - O

At - - O
the - - O
very - - O
high - - O
dose - - O
levels - - O
used - - O
, - - O
sodium - - O
saccharin - - O
and - - O
sodium - - O
cyclamate - - O
were - - O
weak - - O
solitary - - O
carcinogens - - O
producing - - O
4 - - O
253 - - O
and - - O
3 - - O
228 - - O
bladder - - O
tumours - - O
respectively - - O
, - - O
and - - O
the - - O
first - - O
of - - O
these - - O
tumours - - O
did - - O
not - - O
appear - - O
for - - O
more - - O
than - - O
80 - - O
weeks - - O
. - - O

Our - - O
analysis - - O
of - - O
nonsense - - O
mutations - - O
indicates - - O
that - - O
the - - O
C - - O
terminus - - O
of - - O
eIF2Bepsilon - - B-MUT
( - - I-MUT
residues - - I-MUT
518 - - I-MUT
to - - I-MUT
712 - - I-MUT
) - - I-MUT
is - - O
required - - O
for - - O
both - - O
catalytic - - O
activity - - O
and - - O
interaction - - O
with - - O
eIF2 - - B-MUT
. - - O

This - - O
study - - O
demonstrates - - O
that - - O
inducible - - O
expression - - O
in - - O
response - - O
to - - O
either - - O
PMA - - O
or - - O
TPO - - B-MUT
is - - O
mediated - - O
through - - O
the - - O
Ets - - B-MUT
site - - I-MUT
in - - O
the - - O
proximal - - O
promoter - - O
of - - O
GPIX - - B-MUT
and - - O
is - - O
dependent - - O
upon - - O
the - - O
upstream - - O
activation - - O
of - - O
MAPK - - B-MUT
extracellular - - O
signal-regulated - - B-MUT
kinase - - I-MUT
. - - I-MUT

While - - O
these - - O
results - - O
are - - O
consistent - - O
with - - O
previously - - O
reported - - O
effects - - O
of - - O
the - - O
C-terminal - - O
domain - - O
on - - O
nucleotide - - O
binding - - O
, - - O
they - - O
also - - O
demonstrate - - O
that - - O
interactions - - O
with - - O
the - - O
N-terminal - - O
domains - - O
are - - O
necessary - - O
to - - O
inhibit - - O
proton - - O
transport - - O
. - - O

In - - O
contrast - - O
, - - O
the - - O
loss - - O
of - - O
MAD2 - - B-MUT
staining - - O
in - - O
meiosis - - O
was - - O
not - - O
correlated - - O
with - - O
initial - - O
microtubule - - O
attachment - - O
but - - O
was - - O
correlated - - O
with - - O
a - - O
measure - - O
of - - O
tension - - O
: - - O
the - - O
distance - - O
between - - O
homologous - - O
or - - O
sister - - O
kinetochores - - O
( - - O
in - - O
meiosis - - O
I - - O
and - - O
II - - O
, - - O
respectively - - O
) - - O
. - - O

Furthermore - - O
, - - O
Rac1 - - B-MUT
activation - - O
of - - O
JNK - - B-MUT
or - - O
SRF - - B-MUT
, - - O
or - - O
induction - - O
of - - O
lamellipodia - - O
, - - O
was - - O
neither - - O
necessary - - O
nor - - O
sufficient - - O
for - - O
Rac1 - - B-MUT
transforming - - O
activity - - O
. - - O

It - - O
is - - O
suggested - - O
that - - O
the - - O
observed - - O
clinical - - O
phenomena - - O
in - - O
response - - O
to - - O
morphine - - O
can - - O
be - - O
explained - - O
by - - O
differences - - O
in - - O
expression - - O
and - - O
sensitivity - - O
of - - O
some - - O
opioid - - B-MUT
receptor - - I-MUT
subtypes - - O
in - - O
migraine - - O
. - - O

Aggravating - - O
process - - O
induced - - O
by - - O
indomethacin - - O
on - - O
chronic - - O
gastric - - O
lesion - - O
in - - O
rat - - O
. - - O

These - - O
protective - - O
influences - - O
were - - O
observed - - O
throughout - - O
the - - O
range - - O
of - - O
filling - - O
pressures - - O
measured - - O
, - - O
from - - O
0 - - O
to - - O
30 - - O
mmHg - - O
. - - O

The - - O
levels - - O
of - - O
galactosyltransferase - - B-MUT
activity - - O
in - - O
sera - - O
from - - O
normal - - O
children - - O
and - - O
patients - - O
with - - O
cystic - - O
fibrosis - - O
. - - O

SSF - - O
experiments - - O
were - - O
carried - - O
out - - O
in - - O
bench-scale - - O
bioreactors - - O
( - - O
equipped - - O
with - - O
CO2 - - O
and - - O
volatile - - O
organic - - O
traps - - O
) - - O
containing - - O
a - - O
mixture - - O
of - - O
lignocellulosic - - O
materials - - O
and - - O
a - - O
radiolabeled - - O
pesticide - - O
. - - O

Since - - O
CENP-B - - B-MUT
gene - - I-MUT
is - - O
conserved - - O
in - - O
mammalian - - O
species - - O
and - - O
CENP-B - - B-MUT
boxes - - I-MUT
are - - O
found - - O
also - - O
in - - O
mouse - - O
centromere - - O
satellite - - O
DNA - - O
( - - O
minor - - O
satellite - - O
) - - O
, - - O
this - - O
sequence-specific - - O
DNA-protein - - O
interaction - - O
may - - O
be - - O
important - - O
for - - O
some - - O
kind - - O
of - - O
common - - O
centromere - - O
function - - O
. - - O

( - - O
1989 - - O
) - - O
, - - O
which - - O
is - - O
identical - - O
to - - O
the - - O
SSC1 - - B-MUT
gene - - I-MUT
( - - O
Smith - - O
et - - O
al - - O
. - - O
, - - O
1988 - - O
) - - O
. - - O

The - - O
paper - - O
is - - O
concerned - - O
with - - O
the - - O
data - - O
on - - O
change - - O
in - - O
the - - O
blood - - O
level - - O
of - - O
ACTH - - B-MUT
, - - O
STH - - B-MUT
, - - I-MUT
TSH - - I-MUT
, - - O
cortisol - - O
, - - O
T3 - - O
, - - O
insulin - - B-MUT
, - - O
C-peptide - - B-MUT
during - - O
a - - O
25-minute - - O
session - - O
of - - O
respiration - - O
using - - O
a - - O
gaseous - - O
hypoxic - - O
mixture - - O
with - - O
10% - - O
oxygen - - O
( - - O
GHM-10 - - O
) - - O
. - - O

Testing - - O
blood - - O
donors - - O
for - - O
non-A - - O
, - - O
non-B - - O
hepatitis - - O
: - - O
irrational - - O
, - - O
perhaps - - O
, - - O
but - - O
inescapable - - O
. - - O

Raes - - O
, - - O
P - - O
. - - O

Blocked - - O
shift - - O
supershift - - O
analysis - - O
indicates - - O
that - - O
Fos - - O
family - - B-MUT
member - - I-MUT
proteins - - O
especially - - O
Fra-1 - - O
and - - B-MUT
Fra-2 - - O
are - - B-MUT
related - - O
to - - O
progression - - O
and - - O
no - - O
changes - - O
found - - O
in - - O
the - - O
Jun - - O
family - - B-MUT
member - - I-MUT
proteins - - O
although - - O
they - - O
are - - O
present - - O
in - - O
the - - O
AP-1 - - O
DNA - - B-MUT
binding - - I-MUT
complex - - I-MUT
. - - I-MUT

A - - O
strong - - O
trithorax - - B-MUT
binding - - I-MUT
site - - I-MUT
was - - O
found - - O
at - - O
the - - O
cytological - - O
location - - O
of - - O
the - - O
fork - - B-MUT
head - - I-MUT
gene - - I-MUT
, - - O
a - - O
region-specific - - O
homeotic - - B-MUT
gene - - I-MUT
not - - O
located - - O
within - - O
a - - O
homeotic - - B-MUT
complex - - I-MUT
. - - O

To - - O
investigate - - O
the - - O
regulation - - O
of - - O
Spec - - B-MUT
gene - - I-MUT
activity - - O
, - - O
the - - O
region - - O
around - - O
the - - O
Spec1 - - B-MUT
transcriptional - - I-MUT
initiation - - I-MUT
site - - I-MUT
was - - O
analyzed - - O
for - - O
sites - - O
of - - O
protein-DNA - - O
interaction - - O
. - - O

In - - O
this - - O
study - - O
, - - O
we - - O
identified - - O
Sp1 - - B-MUT
and - - O
Sp3 - - B-MUT
as - - O
major - - O
factors - - O
binding - - O
to - - O
the - - O
Sp1 - - B-MUT
sites - - I-MUT
of - - O
the - - O
p21 - - B-MUT
WAF1 - - I-MUT
Cip1 - - I-MUT
promoter - - I-MUT
in - - I-MUT
MG63 - - I-MUT
cells - - O
through - - O
electrophoretic - - O
mobility - - O
shift - - O
assays - - O
and - - O
showed - - O
that - - O
TSA - - O
treatment - - O
did - - O
not - - O
change - - O
their - - O
binding - - O
activities - - O
. - - O

Experience - - O
with - - O
the - - O
restoration - - O
of - - O
agglutination - - O
properties - - O
of - - O
non-agglutinating - - O
dysenterial - - O
cultures - - O
with - - O
the - - O
use - - O
of - - O
Rzhaninov's - - O
method - - O
. - - O

Vitiligo - - O
in - - O
diabetes - - O
mellitus - - O
. - - O

It - - O
is - - O
possible - - O
that - - O
the - - O
telomeres - - O
of - - O
the - - O
two - - O
nuclei - - O
have - - O
different - - O
functions - - O
. - - O

Therefore - - O
, - - O
we - - O
studied - - O
ninety - - O
coagulopathic - - O
patients - - O
with - - O
the - - O
aim - - O
of - - O
determining - - O
the - - O
prevalence - - O
of - - O
hepatitis - - O
C - - O
virus - - O
( - - O
HCV - - O
) - - O
antibodies - - O
using - - O
the - - O
ELISA - - O
and - - O
RIBA - - O
methods - - O
. - - O

Direct - - O
superoxide - - O
scavenging - - O
activity - - O
of - - O
nonsteroidal - - O
anti-inflammatory - - O
drugs - - O
: - - O
determination - - O
by - - O
electron - - O
spin - - O
resonance - - O
using - - O
the - - O
spin - - O
trap - - O
method - - O
. - - O

Low - - O
affinity - - O
binding - - O
of - - O
Rab6A-GTP - - B-MUT
was - - O
also - - O
observed - - O
( - - O
K - - O
( - - O
d - - O
) - - O
= - - O
16 - - O
&mgr - - O
; - - O
m - - O
) - - O
, - - O
whereas - - O
Rab1B - - B-MUT
, - - I-MUT
-5 - - I-MUT
, - - I-MUT
-7 - - I-MUT
, - - I-MUT
-8 - - I-MUT
, - - I-MUT
or - - I-MUT
-11A - - I-MUT
did - - O
not - - O
bind - - O
. - - O

CM-ACO3 - - B-MUT
is - - O
expressed - - O
in - - O
flowers - - O
and - - O
is - - O
not - - O
induced - - O
by - - O
any - - O
of - - O
the - - O
stimuli - - O
tested - - O
. - - O

The - - O
contribution - - O
of - - O
skin - - O
flow - - O
to - - O
the - - O
changes - - O
in - - O
760-800 - - O
nm - - O
absorption - - O
was - - O
investigated - - O
by - - O
simultaneous - - O
measurement - - O
of - - O
skin - - O
flow - - O
by - - O
laser - - O
flow - - O
Doppler - - O
and - - O
NIR - - O
recordings - - O
during - - O
hot - - O
water - - O
immersion - - O
. - - O

PCR - - O
analysis - - O
indicates - - O
that - - O
this - - O
new - - O
beta-adducin - - B-MUT
isoform - - I-MUT
is - - O
expressed - - O
in - - O
fetal - - O
brain - - O
and - - O
liver - - O
, - - O
bone - - O
marrow - - O
, - - O
and - - O
NT-2 - - O
( - - O
neuroepithelial - - O
) - - O
cells - - O
, - - O
but - - O
is - - O
not - - O
detected - - O
in - - O
several - - O
other - - O
tissues - - O
. - - O

Both - - O
PPC-1 - - O
and - - O
ALVA-31 - - O
cells - - O
display - - O
tumorigenesis - - O
and - - O
invasiveness - - O
in - - O
nude - - O
mice - - O
, - - O
whereas - - O
LNCap - - O
cells - - O
exhibit - - O
a - - O
less - - O
malignant - - O
phenotype - - O
, - - O
suggesting - - O
a - - O
correlation - - O
between - - O
CD44 - - B-MUT
variant - - I-MUT
( - - O
CD44v - - B-MUT
) - - O
expression - - O
and - - O
aggressive - - O
prostate - - O
tumor - - O
behavior - - O
. - - O

The - - O
mMIWC1 - - B-MUT
promoter - - I-MUT
was - - O
identified - - O
and - - O
contained - - O
TATA - - O
, - - O
CAAT - - O
, - - O
GATA - - B-MUT
, - - O
and - - O
AP-2 - - B-MUT
elements - - I-MUT
; - - O
primer - - O
extension - - O
revealed - - O
mMIWC - - B-MUT
transcription - - O
initiation - - O
at - - O
621 - - O
bp - - O
upstream - - O
from - - O
the - - O
mMIWC1 - - B-MUT
translational - - O
initiation - - O
site - - O
. - - O

RESULTS - - O
: - - O
CK-MB - - B-MUT
elevation - - O
was - - O
detected - - O
in - - O
313 - - O
patients - - O
( - - O
18 - - O
. - - O
7% - - O
) - - O
, - - O
with - - O
1-3x - - O
in - - O
12 - - O
. - - O
8% - - O
, - - O
3-5x - - O
in - - O
3 - - O
. - - O
5% - - O
and - - O
> - - O
5x - - O
normal - - O
in - - O
2 - - O
. - - O
4% - - O
of - - O
patients - - O
. - - O

In - - O
similar - - O
transient - - O
transfection - - O
experiments - - O
in - - O
HeLa - - O
cells - - O
, - - O
overexpression - - O
of - - O
the - - O
wt - - B-MUT
human - - I-MUT
retinoblastoma - - I-MUT
susceptibility - - I-MUT
gene - - I-MUT
product - - I-MUT
, - - O
RB - - B-MUT
, - - O
was - - O
found - - O
to - - O
repress - - O
the - - O
serum-induced - - O
IL-6 - - B-MUT
( - - O
-225 - - O
to - - O
+13 - - O
) - - O
, - - O
c-fos - - B-MUT
( - - O
-711 - - O
to - - O
+42 - - O
) - - O
, - - O
and - - O
beta-actin - - B-MUT
( - - O
-3400 - - O
to - - O
+912 - - O
) - - O
promoters - - O
but - - O
not - - O
the - - O
PRV-induced - - O
IL-6 - - B-MUT
( - - O
-110 - - O
to - - O
+13 - - O
) - - O
or - - O
the - - O
serum-induced - - O
MHC - - B-MUT
( - - O
-528 - - O
to - - O
-38 - - O
) - - O
promoters - - O
. - - O

This - - O
gene - - O
joins - - O
the - - O
group - - O
of - - O
genes - - O
whose - - O
members - - O
are - - O
rapidly - - O
transcribed - - O
in - - O
response - - O
to - - O
insulin - - B-MUT
and - - O
other - - O
mitogens - - O
. - - O

The - - O
deleted - - O
nucleotide - - O
sequence - - O
corresponded - - O
to - - O
sequences - - O
that - - O
, - - O
by - - O
analogy - - O
to - - O
the - - O
organization - - O
of - - O
the - - O
type - - B-MUT
I - - I-MUT
collagen - - I-MUT
genes - - I-MUT
, - - O
should - - O
be - - O
precisely - - O
encoded - - O
by - - O
exon - - O
41 - - O
of - - O
the - - O
COL3A1 - - B-MUT
gene - - I-MUT
. - - O

A - - O
highly - - O
significant - - O
correlation - - O
was - - O
found - - O
between - - O
the - - O
presence - - O
of - - O
fibrinolytic - - O
degradation - - O
products - - O
( - - O
FDP - - O
) - - O
and - - O
the - - O
incidence - - O
of - - O
nephropathy - - O
and - - O
renal - - O
insufficiency - - O
, - - O
as - - O
well - - O
as - - O
between - - O
the - - O
presence - - O
of - - O
fibrin - - B-MUT
monomers - - I-MUT
( - - O
Godal's - - O
ethanol-gelification - - O
test - - O
) - - O
and - - O
the - - O
evolutive - - O
signs - - O
of - - O
the - - O
primary - - O
disease - - O
( - - O
fever - - O
, - - O
accelerated - - O
ESR - - O
) - - O
. - - O

The - - O
perifascicular - - O
connective - - O
tissue - - O
sheath - - O
is - - O
important - - O
in - - O
organising - - O
the - - O
contraction - - O
of - - O
the - - O
myocardium - - O
by - - O
preventing - - O
lateral - - O
spread - - O
of - - O
conduction - - O
and - - O
by - - O
permitting - - O
transmission - - O
of - - O
the - - O
impulse - - O
only - - O
at - - O
the - - O
termination - - O
of - - O
the - - O
purkinje - - O
fibre - - O
. - - O

Neurospora - - O
crassa - - O
CYT-18 - - B-MUT
, - - O
can - - O
rescue - - O
the - - O
exonic - - O
trap - - O
and - - O
intron - - O
mutants - - O
which - - O
cause - - O
a - - O
structural - - O
defect - - O
. - - O

During - - O
the - - O
past - - O
decade - - O
, - - O
different - - O
types - - O
of - - O
endogenous - - O
retroviral - - O
sequences - - O
have - - O
been - - O
defined - - O
in - - O
the - - O
human - - O
genome - - O
usually - - O
by - - O
low - - O
stringency - - O
hybridization - - O
employing - - O
DNA - - O
probes - - O
of - - O
evolutionary - - O
conserved - - O
animal - - O
retrovirus - - O
genes - - O
. - - O

Previous - - O
work - - O
showed - - O
that - - O
repA - - B-MUT
( - - O
initiator - - B-MUT
protein - - I-MUT
) - - O
expression - - O
requires - - O
tap - - B-MUT
( - - O
leader - - B-MUT
peptide - - I-MUT
) - - O
translation - - O
. - - O

In - - O
addition - - O
, - - O
IgM - - B-MUT
can - - O
be - - O
absent - - O
in - - O
children - - O
with - - O
congenital - - O
toxoplasmosis - - O
or - - O
subjects - - O
with - - O
secondary - - O
reactivation - - O
. - - O

The - - O
high - - O
level - - O
of - - O
transformation-associated - - O
deletions - - O
in - - O
the - - O
human - - O
YACs - - O
was - - O
reduced - - O
over - - O
10-fold - - O
when - - O
the - - O
host - - O
was - - O
a - - O
recombination-deficient - - O
strain - - O
deleted - - O
for - - O
the - - O
RAD52 - - B-MUT
gene - - I-MUT
. - - O

Notably - - O
, - - O
SRF - - B-MUT
has - - O
been - - O
found - - O
to - - O
be - - O
a - - O
key - - O
regulator - - O
of - - O
members - - O
of - - O
a - - O
class - - O
of - - O
cellular - - O
response - - O
genes - - O
termed - - O
immediate-early - - B-MUT
genes - - I-MUT
( - - O
IEGs - - B-MUT
) - - O
, - - O
many - - O
of - - O
which - - O
are - - O
believed - - O
to - - O
be - - O
involved - - O
in - - O
regulating - - O
cell - - O
growth - - O
and - - O
differentiation - - O
. - - O

Total - - O
body - - O
water - - O
, - - O
rhodanide - - O
space - - O
and - - O
I-131-albumin - - B-MUT
space - - O
under - - O
the - - O
acute - - O
effect - - O
of - - O
furosemide - - O
. - - O

Furthermore - - O
, - - O
an - - O
upstream - - O
element - - O
, - - O
collagen - - B-MUT
element - - I-MUT
I - - I-MUT
( - - I-MUT
-370 - - I-MUT
-344 - - I-MUT
) - - I-MUT
, - - I-MUT
which - - O
shares - - O
homology - - O
with - - O
the - - O
LAP - - O
binding - - B-MUT
cis-element - - O
of - - O
the - - O
albumin - - O
promoter - - B-MUT
( - - I-MUT
9 - - O
of - - O
13 - - O
bp - - O
) - - O
is - - O
described - - O
. - - O

Cut-off - - O
levels - - O
that - - O
define - - O
abnormality - - O
are - - O
rather - - O
arbitrary - - O
and - - O
this - - O
decreases - - O
the - - O
specificity - - O
of - - O
the - - O
test - - O
in - - O
apparently - - O
healthy - - O
patients - - O
. - - O

The - - O
Oct-3 - - B-MUT
4 - - I-MUT
gene - - I-MUT
product - - I-MUT
, - - I-MUT
which - - O
belongs - - O
to - - O
the - - O
POU - - O
family - - B-MUT
of - - I-MUT
transcription - - I-MUT
factors - - I-MUT
, - - I-MUT
is - - O
a - - O
good - - O
candidate - - O
for - - O
regulating - - O
initial - - O
differentiation - - O
decisions - - O
. - - O

Fatal - - O
apneusis - - O
was - - O
observed - - O
under - - O
following - - O
conditions - - O
: - - O
( - - O
1 - - O
) - - O
Persistent - - O
apnea - - O
was - - O
produced - - O
after - - O
a - - O
single - - O
KA - - O
microinjection - - O
in - - O
one - - O
side - - O
of - - O
the - - O
VRG-Apa - - O
( - - O
5 - - O
animals - - O
) - - O
. - - O

Value - - O
of - - O
Normotest - - O
and - - O
antithrombin - - B-MUT
3 - - I-MUT
in - - O
the - - O
assessment - - O
of - - O
liver - - O
function - - O
. - - O

Orthop - - O
. - - O

Recombinant - - B-MUT
Ffh - - I-MUT
has - - O
a - - O
melting - - O
point - - O
of - - O
tm - - O
= - - O
89 - - O
degreesC - - O
. - - O

In - - O
a - - O
similar - - O
experiment - - O
, - - O
simultaneous - - O
nitrofurazone - - O
administration - - O
and - - O
S - - O
. - - O
enteritidis - - O
challenge - - O
resulted - - O
in - - O
no - - O
significant - - O
differences - - O
in - - O
S - - O
. - - O
enteritidis - - O
isolation - - O
frequency - - O
. - - O

The - - O
front - - O
( - - O
F - - O
) - - O
interaction - - O
occurs - - O
ahead - - O
of - - O
the - - O
growing - - O
end - - O
of - - O
RNA - - O
. - - O

Normocapnic - - O
( - - O
PACO2 - - O
= - - O
40 - - O
mm - - O
Hg - - O
) - - O
ventilatory - - O
drive - - O
increased - - O
significantly - - O
( - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
05 - - O
) - - O
in - - O
six - - O
subjects - - O
( - - O
Type - - O
1 - - O
response - - O
) - - O
and - - O
decreased - - O
substantially - - O
in - - O
the - - O
others - - O
( - - O
Type - - O
2 - - O
response - - O
) - - O
; - - O
with - - O
hypercapnia - - O
, - - O
the - - O
changes - - O
in - - O
drive - - O
were - - O
attenuated - - O
in - - O
both - - O
groups - - O
. - - O

MOP5 - - B-MUT
contained - - O
the - - O
characteristic - - O
PAS - - B-MUT
domain - - I-MUT
and - - O
a - - O
variable - - O
C - - O
terminus - - O
; - - O
it - - O
is - - O
possible - - O
that - - O
the - - O
cDNA - - O
contains - - O
a - - O
bHLH - - B-MUT
domain - - O
, - - O
but - - O
the - - O
entire - - O
open - - O
reading - - O
frame - - O
has - - O
yet - - O
to - - O
be - - O
completed - - O
. - - O

Sequence - - O
analysis - - O
of - - O
the - - O
5' - - O
flanking - - O
region - - O
revealed - - O
several - - O
GC - - O
boxes - - O
but - - O
no - - O
identifiable - - O
TATA - - O
box - - O
. - - O

Drug - - O
use - - O
in - - O
trauma - - O
victims - - O
. - - O

Haycocknema - - O
perplexum - - O
n - - O
. - - O
g - - O
. - - O
, - - O
n - - O
. - - O
sp - - O
. - - O

It - - O
applies - - O
Udry's - - O
biosocial - - O
perspective - - O
, - - O
which - - O
attempts - - O
to - - O
reconcile - - O
the - - O
biological - - O
and - - O
sociological - - O
models - - O
of - - O
premarital - - O
sexual - - O
and - - O
reproductive - - O
behaviour - - O
. - - O

We - - O
conclude - - O
that - - O
( - - O
i - - O
) - - O
we - - O
have - - O
identified - - O
several - - O
candidate - - O
latency - - O
genes - - O
of - - O
murine - - O
gammaHV68 - - O
, - - O
( - - O
ii - - O
) - - O
expression - - O
of - - O
genes - - O
during - - O
latency - - O
may - - O
be - - O
different - - O
in - - O
different - - O
organs - - O
, - - O
consistent - - O
with - - O
multiple - - O
latency - - O
programs - - O
and - - O
or - - O
multiple - - O
cellular - - O
sites - - O
of - - O
latency - - O
, - - O
and - - O
( - - O
iii - - O
) - - O
regions - - O
of - - O
the - - O
viral - - O
genome - - O
( - - O
v-bcl-2 - - O
gene - - B-MUT
, - - I-MUT
v-GCR - - O
gene - - B-MUT
, - - I-MUT
and - - O
gene - - O
73 - - B-MUT
) - - I-MUT
are - - O
transcribed - - O
during - - O
latency - - O
with - - O
both - - O
gammaHV68 - - O
and - - O
primate - - O
gammaherpesviruses - - O
. - - O

Co-immunoprecipitation - - O
and - - O
DNA - - O
affinity - - O
chromatography - - O
prove - - O
that - - O
Sp1 - - B-MUT
heterodimerizes - - O
with - - O
ZBP-89 - - B-MUT
when - - O
bound - - O
to - - O
the - - O
silencer - - O
element - - O
to - - O
yield - - O
a - - O
DNA-protein - - O
complex - - O
whose - - O
mobility - - O
is - - O
indistinguishable - - O
from - - O
that - - O
displayed - - O
by - - O
HeLa - - O
nuclear - - O
extract - - O
in - - O
band - - O
shift - - O
assays - - O
. - - O

The - - O
location - - O
of - - O
multiple - - O
GRK2 - - B-MUT
and - - O
GRK5 - - B-MUT
phosphoacceptor - - I-MUT
sites - - I-MUT
at - - O
the - - O
extreme - - O
carboxyl - - O
terminus - - O
of - - O
the - - O
beta2AR - - B-MUT
is - - O
highly - - O
reminiscent - - O
of - - O
GRK1-mediated - - O
phosphorylation - - O
of - - O
rhodopsin - - B-MUT
. - - O

Immobilization - - O
of - - O
the - - O
fracture - - O
in - - O
a - - O
collar - - O
and - - O
cuff - - O
sling - - O
was - - O
as - - O
effective - - O
as - - O
more - - O
elaborate - - O
methods - - O
. - - O

Focused - - O
beams - - O
of - - O
classical - - O
light - - O
ablate - - O
elements - - O
of - - O
the - - O
cell - - O
division - - O
machinery - - O
and - - O
switch - - O
the - - O
beating - - O
of - - O
hearts - - O
on - - O
a - - O
cellular - - O
basis - - O
. - - O

In - - O
Exp - - O
. - - O

This - - O
last - - O
region - - O
contains - - O
two - - O
sites - - O
that - - O
bind - - O
Ets-related - - B-MUT
proteins - - I-MUT
present - - O
in - - O
liver - - O
nuclear - - O
extracts - - O
as - - O
well - - O
as - - O
recombinant - - B-MUT
purified - - I-MUT
Ets-1 - - I-MUT
protein - - I-MUT
. - - O

Sequence - - O
analysis - - O
of - - O
the - - O
promoter - - O
region - - O
showed - - O
no - - O
TATA - - O
box - - O
but - - O
identified - - O
consensus - - O
binding - - O
motifs - - O
for - - O
Sp1 - - B-MUT
, - - O
CREB - - B-MUT
, - - O
and - - O
half - - O
sites - - O
of - - O
the - - O
estrogen - - B-MUT
receptor - - I-MUT
binding - - I-MUT
site - - I-MUT
. - - O

The - - O
problem - - O
of - - O
disablement - - O
due - - O
to - - O
pulmonary - - O
tuberculosis - - O
, - - O
on - - O
the - - O
basis - - O
of - - O
an - - O
analysis - - O
of - - O
the - - O
history - - O
of - - O
395 - - O
cases - - O
as - - O
observed - - O
in - - O
Gdansk - - O
in - - O
the - - O
years - - O
1946-1965 - - O
. - - O

Cytohesin-1 - - B-MUT
, - - O
a - - O
protein - - O
abundant - - O
in - - O
cells - - O
of - - O
the - - O
immune - - O
system - - O
, - - O
has - - O
been - - O
proposed - - O
to - - O
be - - O
a - - O
human - - O
homolog - - O
of - - O
the - - O
Saccharomyces - - B-MUT
cerevisiae - - I-MUT
Sec7 - - I-MUT
gene - - I-MUT
product - - I-MUT
, - - O
which - - O
is - - O
crucial - - O
in - - O
protein - - O
transport - - O
. - - O

Also - - O
in - - O
the - - O
spectrum - - O
of - - O
mutants - - O
with - - O
TGN - - O
sorting - - O
defects - - O
are - - O
isolates - - O
with - - O
mutations - - O
in - - O
the - - O
following - - O
: - - O
RIC1 - - B-MUT
, - - O
encoding - - O
a - - O
product - - O
originally - - O
proposed - - O
to - - O
participate - - O
in - - O
ribosome - - O
biogenesis - - O
; - - O
LUV1 - - B-MUT
, - - O
encoding - - O
a - - O
product - - O
potentially - - O
involved - - O
in - - O
vacuole - - O
and - - O
microtubule - - O
organization - - O
; - - O
and - - O
INP53 - - B-MUT
, - - O
encoding - - O
a - - O
synaptojanin-like - - B-MUT
inositol - - I-MUT
polyphosphate - - I-MUT
5-phosphatase - - I-MUT
. - - O

Transcriptional - - O
activation - - O
by - - O
the - - O
HIV-1 - - B-MUT
Tat - - I-MUT
protein - - I-MUT
requires - - O
specific - - O
residues - - O
in - - O
the - - O
hexanucleotide - - O
loop - - O
and - - O
trinucleotide - - O
bulge - - O
of - - O
the - - O
TAR - - B-MUT
RNA - - I-MUT
stem-loop - - O
structure - - O
found - - O
in - - O
the - - O
5'-untranslated - - O
leader - - O
of - - O
all - - O
viral - - O
transcripts - - O
. - - O

Ligand-independent - - O
activation - - O
of - - O
platelet-derived - - B-MUT
growth - - I-MUT
factor - - I-MUT
receptor - - I-MUT
is - - O
a - - O
necessary - - O
intermediate - - O
in - - O
lysophosphatidic - - O
, - - O
acid-stimulated - - O
mitogenic - - O
activity - - O
in - - O
L - - O
cells - - O
. - - O

The - - O
general - - O
transcription - - B-MUT
factor - - I-MUT
IIA - - I-MUT
( - - O
TFIIA - - B-MUT
) - - O
interacts - - O
with - - O
the - - O
TATA - - B-MUT
binding - - I-MUT
protein - - I-MUT
( - - O
TBP - - B-MUT
) - - O
and - - O
promoter - - O
DNA - - O
to - - O
mediate - - O
transcription - - O
activation - - O
in - - O
vitro - - O
. - - O

Since - - O
August - - O
1994 - - O
, - - O
the - - O
ENRP - - O
has - - O
retained - - O
70 - - O
. - - O
3 - - O
metric - - O
tons - - O
of - - O
TP - - O
that - - O
otherwise - - O
would - - O
have - - O
entered - - O
the - - O
Everglades - - O
. - - O

These - - O
findings - - O
suggest - - O
a - - O
functional - - O
cross-talk - - O
between - - O
RB - - B-MUT
protein - - I-MUT
and - - O
p21ras - - B-MUT
, - - O
which - - O
balances - - O
the - - O
cell - - O
phenotype - - O
between - - O
normal - - O
and - - O
transformed - - O
states - - O
. - - O

Previous - - O
studies - - O
have - - O
demonstrated - - O
that - - O
tissue-restricted - - O
transcription - - O
factors - - O
including - - O
PU - - B-MUT
. - - I-MUT
1 - - I-MUT
and - - O
PU - - B-MUT
. - - I-MUT
1 - - I-MUT
interaction - - I-MUT
partner - - I-MUT
( - - O
PIP - - B-MUT
) - - O
function - - O
synergistically - - O
with - - O
c-Fos - - B-MUT
plus - - O
c-Jun - - B-MUT
to - - O
stimulate - - O
the - - O
kappaE3'-enhancer - - B-MUT
in - - O
3T3 - - O
cells - - O
. - - O

The - - O
origins - - O
of - - O
reflected - - O
light - - O
changes - - O
associated - - O
with - - O
neuronal - - O
activity - - O
( - - O
optical - - O
signals - - O
) - - O
were - - O
investigated - - O
in - - O
rat - - O
somatosensory - - O
cortex - - O
with - - O
optical - - O
imaging - - O
, - - O
microspectrophotometry - - O
, - - O
and - - O
laser-Doppler - - O
flowmetry - - O
, - - O
and - - O
dynamic - - O
changes - - O
in - - O
local - - O
hemoglobin - - B-MUT
concentration - - O
and - - O
oxygenation - - O
were - - O
focused - - O
on - - O
. - - O

Reverse - - O
transcriptase-polymerase - - O
chain - - O
reaction - - O
( - - O
RT-PCR - - O
) - - O
was - - O
performed - - O
using - - O
eyestalk - - O
complementary - - O
DNA - - O
of - - O
the - - O
sand - - O
shrimp - - O
Metapenaeus - - O
ensis - - O
. - - O

This - - O
reveals - - O
a - - O
new - - O
test - - O
for - - O
short - - O
saphenous - - O
incompetence - - O
and - - O
shows - - O
that - - O
14 - - O
per - - O
cent - - O
of - - O
varices - - O
stem - - O
from - - O
a - - O
saphenopopliteal - - O
reflux - - O
. - - O

These - - O
observations - - O
, - - O
together - - O
with - - O
the - - O
occurrence - - O
of - - O
putative - - O
4'-phosphopantetheine-attachment - - O
sites - - O
and - - O
a - - O
putative - - O
thioesterase - - B-MUT
site - - I-MUT
, - - O
are - - O
discussed - - O
with - - O
reference - - O
to - - O
the - - O
reaction - - O
sequence - - O
leading - - O
to - - O
production - - O
of - - O
the - - O
ACV - - B-MUT
tripeptide - - I-MUT
. - - O

Examination - - O
of - - O
DNA - - O
: - - O
protein - - O
binding - - O
complexes - - O
by - - O
gel-shift - - O
analysis - - O
indicated - - O
that - - O
nuclear - - O
factors - - O
from - - O
both - - O
proliferative - - O
and - - O
growth-arrested - - O
cells - - O
bound - - O
to - - O
the - - O
DNA - - O
fragment - - O
spanning - - O
-949- - - O
-722 - - O
bp - - O
. - - O

The - - O
pharmacokinetic - - O
patterns - - O
of - - O
estradiol - - O
( - - O
CAS - - O
50-28-2 - - O
) - - O
and - - O
of - - O
estrone - - O
( - - O
CAS - - O
53-16-7 - - O
) - - O
were - - O
investigated - - O
in - - O
18 - - O
women - - O
in - - O
natural - - O
or - - O
surgical - - O
menopause - - O
during - - O
the - - O
application - - O
of - - O
a - - O
new - - O
estradiol - - O
transdermal - - O
patch - - O
with - - O
active - - O
matrix - - O
and - - O
without - - O
absorption - - O
enhancers - - O
designed - - O
for - - O
epicutaneous - - O
applications - - O
of - - O
7 - - O
days - - O
( - - O
hereinafter - - O
called - - O
"patch - - O
7D" - - O
) - - O
. - - O

A - - O
striking - - O
finding - - O
in - - O
all - - O
of - - O
the - - O
studies - - O
was - - O
a - - O
positive - - O
correlation - - O
between - - O
PI - - O
ACTH - - B-MUT
and - - O
MSH - - B-MUT
contents - - O
. - - O

The - - O
capacity - - O
to - - O
repair - - O
8-OxoG - - O
has - - O
been - - O
measured - - O
in - - O
cell-free - - O
extracts - - O
of - - O
wild-type - - O
and - - O
ogg1 - - B-MUT
strains - - O
using - - O
a - - O
34mer - - O
DNA - - O
fragment - - O
containing - - O
a - - O
single - - O
8-OxoG - - O
residue - - O
paired - - O
with - - O
a - - O
cytosine - - O
( - - O
8-OxoG - - O
C - - O
) - - O
as - - O
a - - O
substrate - - O
. - - O

The - - O
maximum - - O
stress - - O
due - - O
to - - O
the - - O
hygroscopic - - O
examination - - O
of - - O
the - - O
composite - - O
was - - O
0 - - O
. - - O
74 - - O
kg - - O
mm2 - - O
at - - O
equilibrium - - O
of - - O
the - - O
water - - O
absorbed - - O
of - - O
the - - O
composite - - O
. - - O

VirD2 - - B-MUT
is - - O
one - - O
of - - O
the - - O
key - - O
Agrobacterium - - O
tumefaciens - - O
proteins - - O
involved - - O
in - - O
T-DNA - - O
processing - - O
and - - O
transfer - - O
. - - O

The - - O
dnaK - - B-MUT
operon - - I-MUT
of - - I-MUT
Bacillus - - I-MUT
subtilis - - I-MUT
is - - O
heptacistronic - - O
. - - O

NIRS - - O
was - - O
used - - O
for - - O
the - - O
quantitative - - O
measurement - - O
of - - O
muscle - - O
O - - O
( - - O
2 - - O
) - - O
consumption - - O
( - - O
mV - - O
. - - O
O - - O
( - - O
2 - - O
) - - O
) - - O
and - - O
forearm - - O
blood - - O
flow - - O
( - - O
FBF - - O
) - - O
in - - O
78 - - O
healthy - - O
subjects - - O
. - - O

Alterations - - O
in - - O
DNase - - B-MUT
I - - I-MUT
reactivity - - O
of - - O
the - - O
GC-response - - O
element - - O
region - - O
suggest - - O
that - - O
GC - - B-MUT
receptor-GC - - I-MUT
complexes - - I-MUT
may - - O
associate - - O
, - - O
in - - O
a - - O
transient - - O
manner - - O
, - - O
with - - O
the - - O
promoter - - O
in - - O
the - - O
actively - - O
transcribing - - O
control - - O
state - - O
. - - O

Reconstitution - - O
of - - O
complexes - - O
containing - - O
p62 - - B-MUT
and - - O
the - - O
src - - B-MUT
family - - I-MUT
kinase - - I-MUT
p59fyn - - B-MUT
in - - O
HeLa - - O
cells - - O
demonstrated - - O
that - - O
complex - - O
formation - - O
resulted - - O
in - - O
tyrosine - - O
phosphorylation - - O
of - - O
p62 - - B-MUT
and - - O
was - - O
mediated - - O
by - - O
both - - O
the - - O
SH3 - - B-MUT
and - - O
SH2 - - B-MUT
domains - - I-MUT
of - - O
p59fyn - - B-MUT
. - - O

Sixteen - - O
out - - O
of - - O
52 - - O
seropositive - - O
MS - - O
patients - - O
( - - O
30 - - O
. - - O
8% - - O
) - - O
showed - - O
intrathecal - - O
synthesis - - O
of - - O
C - - B-MUT
. - - I-MUT
pneumoniae-specific - - I-MUT
IgG - - I-MUT
but - - O
only - - O
one - - O
of - - O
43 - - O
seropositive - - O
controls - - O
( - - O
2 - - O
. - - O
3% - - O
) - - O
. - - O

The - - O
N-terminus - - O
of - - O
another - - O
open - - O
reading - - O
frame - - O
was - - O
found - - O
3' - - O
from - - O
nifA - - B-MUT
and - - O
tentatively - - O
identified - - O
as - - O
nifB - - B-MUT
by - - O
amino - - O
acid - - O
sequence - - O
comparison - - O
. - - O

Phosphatidylinositol - - B-MUT
3-kinase - - I-MUT
requirement - - O
in - - O
activation - - O
of - - O
the - - O
ras - - B-MUT
C-raf-1 - - I-MUT
MEK - - I-MUT
ERK - - I-MUT
and - - I-MUT
p70 - - I-MUT
( - - I-MUT
s6k - - O
) - - B-MUT
signaling - - I-MUT
cascade - - I-MUT
by - - I-MUT
the - - O
insulinomimetic - - O
agent - - O
vanadyl - - O
sulfate - - O
. - - O

Cortical - - O
dysplasias - - O
, - - O
genetics - - O
, - - O
and - - O
epileptogenesis - - O
. - - O

In - - O
addition - - O
to - - O
homologues - - O
of - - O
the - - O
human - - B-MUT
genes - - I-MUT
PSMB5 - - I-MUT
through - - O
PSMB9 - - B-MUT
, - - O
two - - O
new - - O
genes - - O
, - - O
PSMB11 - - B-MUT
and - - O
PSMB12 - - B-MUT
, - - O
have - - O
been - - O
found - - O
for - - O
which - - O
there - - O
are - - O
no - - O
known - - O
corresponding - - O
genes - - O
in - - O
humans - - O
. - - O

We - - O
conclude - - O
that - - O
the - - O
conservation - - O
of - - O
nucleotides - - O
154 - - O
to - - O
156 - - O
is - - O
likely - - O
to - - O
be - - O
a - - O
consequence - - O
of - - O
their - - O
role - - O
as - - O
a - - O
sequence-specific - - O
recognition - - O
element - - O
for - - O
the - - O
SRP54 - - B-MUT
protein - - I-MUT
. - - O

The - - O
genetic - - O
basis - - O
for - - O
the - - O
expression - - O
of - - O
a - - O
latent - - O
VH - - B-MUT
allotype - - I-MUT
in - - O
the - - O
rabbit - - O
was - - O
investigated - - O
. - - O

Open - - O
head-brain - - O
injuries - - O
. - - O

Administration - - O
of - - O
a - - O
second - - O
dose - - O
of - - O
vaccine - - O
during - - O
the - - O
outbreak - - O
was - - O
not - - O
protective - - O
. - - O

Clipping - - O
resulted - - O
in - - O
a - - O
serious - - O
mislocalization - - O
of - - O
the - - O
position - - O
of - - O
the - - O
peak - - O
of - - O
the - - O
epicortical - - O
potential - - O
field - - O
. - - O

Unexpectedly - - O
, - - O
Arg1-expressing - - O
COS1 - - O
cells - - O
showed - - O
no - - O
significant - - O
proteinase - - B-MUT
activity - - O
to - - O
various - - O
synthesized - - O
substrates - - O
under - - O
neutral - - O
or - - O
acidic - - O
conditions - - O
in - - O
this - - O
study - - O
. - - O

In - - O
the - - O
duodenum - - O
a - - O
small - - O
part - - O
of - - O
the - - O
administered - - O
dose - - O
was - - O
transformed - - O
to - - O
3H-alpha-acetyldigoxin - - O
. - - O

Effects - - O
of - - O
a - - O
perfluorochemical - - O
blood - - O
substitute - - O
on - - O
diazepam - - O
binding - - O
by - - O
human - - B-MUT
albumin - - I-MUT
. - - O

These - - O
findings - - O
suggest - - O
one - - O
potential - - O
mechanism - - O
for - - O
direct - - O
recruitment - - O
of - - O
distal - - O
regulatory - - O
regions - - O
of - - O
the - - O
globin - - B-MUT
loci - - I-MUT
to - - O
the - - O
individual - - O
promoters - - O
. - - O

GETS-1 - - B-MUT
is - - O
expressed - - O
in - - O
many - - O
tissues - - O
, - - O
but - - O
is - - O
enriched - - O
in - - O
retina - - O
and - - O
brain - - O
. - - O

A - - O
second - - O
isotype - - O
of - - O
Raja - - B-MUT
immunoglobulin - - I-MUT
heavy - - I-MUT
chain - - I-MUT
genes - - I-MUT
has - - O
been - - O
detected - - O
by - - O
screening - - O
a - - O
spleen - - O
cDNA - - O
library - - O
with - - O
homologous - - O
Raja - - O
VH- - - O
and - - O
CH1-specific - - O
probes - - O
complementing - - O
the - - O
respective - - O
regions - - O
of - - O
the - - O
mu-like - - B-MUT
isotype - - I-MUT
. - - O

Thereafter - - O
, - - O
the - - O
aggregation - - O
rose - - O
to - - O
the - - O
initial - - O
100% - - O
value - - O
4 - - O
h - - O
after - - O
drug - - O
application - - O
and - - O
remained - - O
at - - O
this - - O
level - - O
during - - O
the - - O
observation - - O
period - - O
. - - O
( - - O
ABSTRACT - - O
TRUNCATED - - O
AT - - O
250 - - O
WORDS - - O
) - - O

Lack - - O
of - - O
cyclin - - B-MUT
D-Cdk - - I-MUT
complexes - - I-MUT
in - - O
Rb-negative - - O
cells - - O
correlates - - O
with - - O
high - - O
levels - - O
of - - O
p16INK4 - - B-MUT
MTS1 - - O
tumour - - B-MUT
suppressor - - O
gene - - O
product - - O
. - - O

At - - O
the - - O
time - - O
of - - O
the - - O
seizure - - O
, - - O
the - - O
patient - - O
was - - O
asked - - O
to - - O
read - - O
a - - O
test - - O
phrase - - O
aloud - - O
until - - O
it - - O
was - - O
read - - O
correctly - - O
and - - O
clearly - - O
. - - O

Two - - O
new - - O
artifacts - - O
in - - O
automated - - O
coagulation - - O
testing - - O
. - - O

This - - O
study - - O
examines - - O
the - - O
cooperative - - O
effects - - O
of - - O
a - - O
human - - O
estrogen - - B-MUT
receptor-alpha - - I-MUT
( - - O
ERalpha - - B-MUT
) - - O
isoform - - O
on - - O
estrogen - - B-MUT
( - - O
E2 - - B-MUT
) - - O
-mediated - - O
gene - - O
activation - - O
in - - O
U2-OS - - O
osteosarcoma - - O
cells - - O
. - - O

Three - - O
mog-1 - - B-MUT
alleles - - I-MUT
possess - - O
premature - - O
stop - - O
codons - - O
and - - O
are - - O
likely - - O
to - - O
be - - O
null - - O
alleles - - O
, - - O
and - - O
one - - O
is - - O
a - - O
missense - - O
mutation - - O
and - - O
is - - O
likely - - O
to - - O
retain - - O
residual - - O
activity - - O
. - - O
mog-1 - - B-MUT
mRNA - - I-MUT
is - - O
expressed - - O
in - - O
both - - O
germ - - O
line - - O
and - - O
somatic - - O
tissues - - O
and - - O
appears - - O
to - - O
be - - O
ubiquitous - - O
. - - O

The - - O
distribution - - O
of - - O
cryptosporidia - - O
in - - O
the - - O
intestine - - O
and - - O
number - - O
of - - O
cryptosporidia - - O
per - - O
ileal - - O
villus - - O
on - - O
different - - O
DPI - - O
were - - O
also - - O
estimated - - O
for - - O
detailed - - O
characterization - - O
of - - O
the - - O
infection - - O
in - - O
kids - - O
as - - O
a - - O
model - - O
for - - O
experimental - - O
cryptosporidiosis - - O
. - - O

Marked - - O
hemolysis - - O
significantly - - O
increased - - O
plasma - - O
values - - O
of - - O
potassium - - O
, - - O
phosphorus - - O
, - - O
total - - O
protein - - O
, - - O
and - - O
aspartate - - B-MUT
aminotransferase - - I-MUT
. - - O

The - - O
regurgitation - - O
of - - O
large - - O
vitreous - - O
injections - - O
. - - O

Assessment - - O
of - - O
the - - O
carcinogenicity - - O
of - - O
non-nutritive - - O
sweetners - - O
II - - O
: - - O
Cyclamates - - O
and - - O
cyclohexylamine - - O
. - - O

Blood - - O
from - - O
dams - - O
was - - O
collected - - O
prior - - O
to - - O
inoculation - - O
and - - O
at - - O
time - - O
of - - O
necropsy - - O
for - - O
measurement - - O
of - - O
IgM - - B-MUT
and - - O
IgG - - B-MUT
antibodies - - I-MUT
to - - O
M - - O
. - - O
pulmonis - - O
. - - O

We - - O
conclude - - O
that - - O
CPET - - O
is - - O
a - - O
useful - - O
investigation - - O
in - - O
the - - O
management - - O
of - - O
patients - - O
with - - O
cardiopulmonary - - O
disease - - O
and - - O
complements - - O
the - - O
various - - O
other - - O
investigations - - O
offered - - O
by - - O
a - - O
pulmonary - - O
function - - O
laboratory - - O
. - - O

Effects - - O
of - - O
cisapride - - O
on - - O
upper-gastrointestinal - - O
motility - - O
and - - O
digestive - - O
hormones - - O
. - - O

The - - O
cDNAs - - O
cross-hybridize - - O
with - - O
genomic - - O
sequences - - O
in - - O
rat - - O
, - - O
human - - O
, - - O
and - - O
chicken - - O
DNA - - O
, - - O
but - - O
not - - O
with - - O
DNA - - O
from - - O
frog - - O
, - - O
Drosophila - - O
, - - O
or - - O
sea - - O
urchin - - O
. - - O

Trials - - O
of - - O
sevine - - O
activity - - O
against - - O
mosquito - - O
larvae - - O
. - - O

Immediately - - O
before - - O
surgery - - O
patients - - O
received - - O
either - - O
intravenous - - O
hydrocortisone - - O
100 - - O
mg - - O
or - - O
placebo - - O
in - - O
random - - O
, - - O
double-blind - - O
order - - O
. - - O

In - - O
HeLa - - O
cells - - O
, - - O
the - - O
JNKK2-JNK1 - - B-MUT
fusion - - I-MUT
protein - - I-MUT
showed - - O
significant - - O
JNK - - B-MUT
activity - - O
, - - O
which - - O
was - - O
comparable - - O
with - - O
that - - O
of - - O
JNK1 - - B-MUT
activated - - O
by - - O
many - - O
stimuli - - O
and - - O
activators - - O
, - - O
including - - O
EGF - - B-MUT
, - - O
TNF-alpha - - B-MUT
, - - O
anisomycin - - O
, - - O
UV - - O
irradiation - - O
, - - O
MEKK1 - - B-MUT
, - - O
and - - O
small - - B-MUT
GTP - - I-MUT
binding - - I-MUT
proteins - - I-MUT
Rac1 - - I-MUT
and - - O
Cdc42Hs - - B-MUT
. - - O

In - - O
some - - O
early - - O
B - - O
cells - - O
and - - O
Abelson - - O
murine - - O
leukemia - - O
virus-transformed - - O
pre-B-cell - - O
lines - - O
, - - O
LT - - B-MUT
mRNA - - I-MUT
is - - O
constitutively - - O
expressed - - O
. - - O

Substitution - - O
of - - O
bulky - - O
hydrophobic - - O
residues - - O
with - - O
charged - - O
residues - - O
within - - O
PEP1 - - B-MUT
affects - - O
the - - O
fusion - - O
activity - - O
of - - O
the - - O
S - - B-MUT
protein - - I-MUT
without - - O
affecting - - O
processing - - O
and - - O
surface - - O
expression - - O
. - - O

The - - O
dying - - O
tTG-transfected - - O
cells - - O
exhibit - - O
both - - O
cytoplasmic - - O
and - - O
nuclear - - O
changes - - O
characteristic - - O
of - - O
cells - - O
undergoing - - O
apoptosis - - O
. - - O

Roizman - - O
, - - O
J - - O
. - - O

In - - O
this - - O
study - - O
, - - O
a - - O
common - - O
mechanism - - O
has - - O
been - - O
identified - - O
to - - O
coordinate - - O
the - - O
growth- - - O
and - - O
FC-dependent - - O
expression - - O
of - - O
caveolin - - B-MUT
. - - O

There - - O
are - - O
four - - O
polyglutamine - - O
motifs - - O
interspersed - - O
with - - O
histidine-rich - - O
regions - - O
. - - O

SL1 - - B-MUT
trans-splicing - - O
specified - - O
by - - O
AU-rich - - O
synthetic - - O
RNA - - O
inserted - - O
at - - O
the - - O
5' - - O
end - - O
of - - O
Caenorhabditis - - O
elegans - - O
pre-mRNA - - O
. - - O

When - - O
CSF - - O
[ - - O
HCO3- - - O
] - - O
is - - O
shown - - O
as - - O
a - - O
function - - O
of - - O
CSF - - O
PCO2 - - O
the - - O
data - - O
of - - O
K-depleted - - O
rats - - O
are - - O
no - - O
longer - - O
displaced - - O
when - - O
compared - - O
to - - O
controls - - O
but - - O
still - - O
have - - O
a - - O
significantly - - O
greater - - O
slope - - O
( - - O
1 - - O
. - - O
21 - - O
+ - - O
- - - O
0 - - O
. - - O
23 - - O
vs - - O
. - - O

The - - O
patient - - O
with - - O
a - - O
prolonged - - O
fever - - O
caused - - O
by - - O
dissecting - - O
aneurysm - - O
of - - O
the - - O
aorta - - O
in - - O
whom - - O
pleuropneumonia - - O
masked - - O
the - - O
real - - O
diseases - - O
has - - O
been - - O
presented - - O
. - - O

The - - O
low - - O
number - - O
of - - O
false - - O
positives - - O
indicates - - O
that - - O
our - - O
scheme - - O
would - - O
not - - O
confuse - - O
the - - O
radiologist - - O
by - - O
suggesting - - O
normal - - O
regions - - O
as - - O
suspicious - - O
. - - O

ENV - - B-MUT
also - - O
was - - O
secreted - - O
from - - O
P - - O
. - - O
pastoris - - O
using - - O
the - - O
S - - B-MUT
. - - I-MUT
cerevisiae - - I-MUT
alpha-factor - - I-MUT
prepro - - I-MUT
secretion - - I-MUT
leader - - I-MUT
and - - O
the - - O
S - - B-MUT
. - - I-MUT
cerevisiae - - I-MUT
invertase - - I-MUT
signal - - I-MUT
sequence - - I-MUT
. - - O

Androgens - - O
and - - O
growth - - O
. - - O

Arterial - - O
blood - - O
gas - - O
tensions - - O
were - - O
similar - - O
across - - O
all - - O
ventilation - - O
modes - - O
. - - O

Accordingly - - O
, - - O
no - - O
Ha-ras - - B-MUT
codon - - I-MUT
12 - - I-MUT
mutations - - O
are - - O
found - - O
in - - O
the - - O
EtNU-induced - - O
mammary - - O
tumors - - O
. - - O

The - - O
sequence - - O
and - - O
isolated - - O
cDNAs - - O
will - - O
provide - - O
useful - - O
reagents - - O
for - - O
studying - - O
the - - O
expression - - O
of - - O
Brca1 - - B-MUT
in - - O
the - - O
mouse - - O
, - - O
and - - O
for - - O
testing - - O
the - - O
importance - - O
of - - O
the - - O
evolutionarily - - O
conserved - - O
domains - - O
. - - O

Functional - - O
postnatal - - O
development - - O
of - - O
the - - O
rat - - O
primary - - O
visual - - O
cortex - - O
and - - O
the - - O
role - - O
of - - O
visual - - O
experience - - O
: - - O
dark - - O
rearing - - O
and - - O
monocular - - O
deprivation - - O
. - - O

The - - O
patients - - O
in - - O
one - - O
group - - O
had - - O
intrauterine - - O
catheters - - O
inserted - - O
and - - O
oxytocin - - O
was - - O
titrated - - O
to - - O
achieve - - O
the - - O
75th - - O
percentile - - O
of - - O
uterine - - O
activity - - O
observed - - O
in - - O
spontaneous - - O
normal - - O
labour - - O
according - - O
to - - O
parity - - O
. - - O

A - - O
mouse - - B-MUT
brain - - I-MUT
beta-spectrin - - I-MUT
of - - O
cDNA - - O
was - - O
identified - - O
within - - O
a - - O
lambda - - O
Gt11 - - O
expression - - O
library - - O
using - - O
an - - O
antibody - - O
which - - O
specifically - - O
binds - - O
with - - O
the - - O
235 - - B-MUT
kDa - - I-MUT
spectrin - - I-MUT
beta-subunit - - I-MUT
. - - O

Renal - - O
and - - O
extrarenal - - O
arterial - - O
fibromuscular - - O
hyperplasia - - O
with - - O
hypertension - - O
. - - O

Antibodies - - O
specific - - O
to - - O
rE12 - - B-MUT
and - - O
rNFIL-6 - - B-MUT
disrupt - - O
nucleoprotein - - O
complexes - - O
with - - O
these - - O
DNA-binding - - O
sites - - O
, - - O
confirming - - O
the - - O
interaction - - O
of - - O
native - - O
in - - O
vivo - - O
factors - - O
. - - O

The - - O
other - - O
transmembrane - - O
regions - - O
as - - O
well - - O
as - - O
the - - O
nucleoplasmic - - O
domain - - O
are - - O
not - - O
required - - O
for - - O
sorting - - O
. - - O

The - - O
major - - O
pathological - - O
findings - - O
of - - O
the - - O
placenta - - O
were - - O
prematuration - - O
and - - O
hypoplasia - - O
. - - O

Viral - - O
genomic - - O
RNA - - O
for - - O
these - - O
reactions - - O
was - - O
obtained - - O
directly - - O
from - - O
fecal - - O
specimens - - O
of - - O
infected - - O
infant - - O
rats - - O
. - - O

In - - O
two - - O
experiments - - O
, - - O
neonatal - - O
female - - O
BALB - - O
cCrgl - - O
or - - O
BALB - - O
cfC3HCrgl - - O
mice - - O
were - - O
given - - O
subcutaneous - - O
injections - - O
of - - O
5 - - O
micrograms - - O
17 - - O
beta-estradiol - - O
or - - O
sesame - - O
oil - - O
for - - O
the - - O
first - - O
3 - - O
days - - O
of - - O
life - - O
and - - O
were - - O
ovariectomized - - O
at - - O
60 - - O
days - - O
of - - O
age - - O
, - - O
at - - O
which - - O
time - - O
vaginal - - O
concretions - - O
( - - O
Experiments - - O
I - - O
and - - O
II - - O
) - - O
or - - O
silica - - O
( - - O
Experiment - - O
II - - O
) - - O
were - - O
implanted - - O
intravaginally - - O
. - - O

Evaluation - - O
of - - O
human - - O
and - - O
bovine - - O
modified-hemoglobin - - O
solution - - O
as - - O
oxygen-carrying - - O
fluid - - O
for - - O
blood - - O
volume - - O
replacement - - O
. - - O

Human - - B-MUT
thyroid - - I-MUT
stimulator - - I-MUT
( - - O
HTS - - B-MUT
) - - O
in - - O
thyroid - - O
diseases - - O
. - - O

Substituting - - O
a - - O
Ser - - O
for - - O
Gly69 - - O
or - - O
a - - O
Glu - - O
for - - O
Lys - - O
71 - - O
in - - O
the - - O
conserved - - O
TGEK - - B-MUT
tetrapeptide - - I-MUT
in - - O
finger - - O
II - - O
of - - O
TFIIIA - - B-MUT
resulted - - O
in - - O
the - - O
loss - - O
of - - O
DNA - - O
binding - - O
. - - O

Plasma - - O
thrombomodulin - - B-MUT
: - - O
a - - O
marker - - O
for - - O
microvascular - - O
complications - - O
in - - O
diabetes - - O
mellitus - - O
. - - O

Thus - - O
, - - O
the - - O
L45 - - B-MUT
sequence - - I-MUT
between - - O
kinase - - B-MUT
subdomains - - I-MUT
IV - - I-MUT
and - - I-MUT
V - - I-MUT
specifies - - O
TGF-beta - - B-MUT
responsiveness - - O
of - - O
the - - O
type - - B-MUT
I - - I-MUT
receptor - - I-MUT
. - - O

We - - O
have - - O
cloned - - O
and - - O
sequenced - - O
a - - O
region - - O
encoding - - O
a - - O
lipase - - B-MUT
operon - - I-MUT
and - - O
a - - O
putative - - O
, - - O
previously - - O
uncharacterized - - O
metalloprotease - - B-MUT
of - - I-MUT
Vibrio - - I-MUT
cholerae - - I-MUT
O1 - - I-MUT
. - - O

Epitopes - - O
of - - O
adhesion-perturbing - - O
monoclonal - - O
antibodies - - O
map - - O
within - - O
a - - O
predicted - - O
alpha-helical - - O
domain - - O
of - - O
the - - O
integrin - - B-MUT
beta - - I-MUT
1 - - I-MUT
subunit - - I-MUT
. - - O

In - - O
addition - - O
, - - O
the - - O
transcription - - O
of - - O
c-IAP2 - - B-MUT
promoter - - I-MUT
was - - O
strongly - - O
up-regulated - - O
when - - O
CD40 - - B-MUT
or - - O
Epstein-Barr - - B-MUT
virus - - I-MUT
latent - - I-MUT
membrane - - I-MUT
protein - - I-MUT
1 - - I-MUT
was - - O
overexpressed - - O
. - - O

A - - O
local - - O
, - - O
high-density - - O
, - - O
single-nucleotide - - O
polymorphism - - O
map - - O
used - - O
to - - O
clone - - O
Caenorhabditis - - B-MUT
elegans - - I-MUT
cdf-1 - - I-MUT
. - - O

Tiaprofenic - - O
acid - - O
overdose - - O
. - - O

PURPOSE - - O
: - - O
Previous - - O
WR-2721 - - O
human - - O
pharmacokinetic - - O
studies - - O
were - - O
limited - - O
to - - O
plasma - - O
levels - - O
in - - O
patients - - O
receiving - - O
platinum-based - - O
compounds - - O
, - - O
and - - O
none - - O
includes - - O
the - - O
effects - - O
of - - O
WR-2721 - - O
on - - O
endogenous - - O
thiols - - O
. - - O

Fentanyl - - O
, - - O
a - - O
prototypic - - O
mu-opiate - - B-MUT
receptor - - I-MUT
agonist - - O
, - - O
has - - O
been - - O
previously - - O
shown - - O
to - - O
produce - - O
a - - O
syndrome - - O
characterized - - O
by - - O
marked - - O
analgesia - - O
and - - O
locomotor - - O
stimulation - - O
as - - O
well - - O
as - - O
tachycardia - - O
, - - O
tachypnoea - - O
and - - O
behavioural - - O
arousal - - O
. - - O

CONCLUSIONS - - O
: - - O
In - - O
our - - O
patients - - O
and - - O
within - - O
the - - O
range - - O
of - - O
treatment - - O
variables - - O
studied - - O
, - - O
age - - O
, - - O
Karnofsky - - O
index - - O
, - - O
and - - O
graft-versus-host - - O
disease - - O
are - - O
the - - O
most - - O
important - - O
factors - - O
related - - O
with - - O
early - - O
mortality - - O
. - - O

Once - - O
P-450scc - - B-MUT
mRNA - - I-MUT
is - - O
induced - - O
as - - O
a - - O
consequence - - O
of - - O
the - - O
LH - - B-MUT
hCG - - I-MUT
surge - - I-MUT
it - - O
is - - O
constitutively - - O
maintained - - O
by - - O
luteinized - - O
cells - - O
in - - O
vivo - - O
( - - O
0-4 - - O
days - - O
) - - O
and - - O
in - - O
vitro - - O
( - - O
0-9 - - O
days - - O
) - - O
in - - O
the - - O
absence - - O
of - - O
gonadotropins - - O
, - - B-MUT
is - - O
susceptible - - O
to - - O
modulation - - O
by - - O
prolactin - - O
and - - B-MUT
is - - O
no - - O
longer - - O
regulated - - O
by - - O
cAMP - - O
. - - O

Effects - - O
of - - O
3' - - O
terminus - - O
modifications - - O
on - - O
mRNA - - O
functional - - O
decay - - O
during - - O
in - - O
vitro - - O
protein - - O
synthesis - - O
. - - O

A - - O
positive - - O
correlation - - O
between - - O
serum - - B-MUT
myoglobin - - I-MUT
and - - O
CA - - B-MUT
III - - I-MUT
concentrations - - O
( - - O
rs - - O
= - - O
0 - - O
. - - O
933 - - O
, - - O
P - - O
< - - O
0 - - O
. - - O
001 - - O
) - - O
was - - O
observed - - O
in - - O
hemodialyzed - - O
patients - - O
with - - O
chronic - - O
renal - - O
failure - - O
. - - O

The - - O
maximum - - O
period - - O
of - - O
treatment - - O
was - - O
73 - - O
( - - O
oral - - O
) - - O
, - - O
73 - - O
( - - O
intraperitoneal - - O
) - - O
or - - O
75 - - O
( - - O
dermal - - O
) - - O
weeks - - O
. - - O

Sequence - - O
analysis - - O
of - - O
the - - O
47-kilodalton - - B-MUT
major - - I-MUT
integral - - I-MUT
membrane - - I-MUT
immunogen - - I-MUT
of - - I-MUT
Treponema - - I-MUT
pallidum - - I-MUT
. - - O

By - - O
using - - O
total-protein - - O
extracts - - O
from - - O
mycelia - - O
grown - - O
under - - O
penicillin - - O
producing - - O
conditions - - O
we - - O
have - - O
detected - - O
a - - O
DNA-binding - - O
activity - - O
that - - O
specifically - - O
shifts - - O
a - - O
promoter - - O
fragment - - O
located - - O
between - - O
-654 - - O
and - - O
-455 - - O
( - - O
relative - - O
to - - O
IPNS - - B-MUT
tsp - - I-MUT
) - - O
. - - O

The - - O
RF - - O
values - - O
correlated - - O
well - - O
with - - O
the - - O
angiographic - - O
semiquantitative - - O
scale - - O
of - - O
severity - - O
of - - O
aortal - - O
insufficiency - - O
( - - O
r - - O
= - - O
0 - - O
. - - O
805 - - O
; - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
001 - - O
) - - O
, - - O
although - - O
they - - O
enabled - - O
the - - O
authors - - O
only - - O
to - - O
make - - O
a - - O
partial - - O
differentiation - - O
of - - O
haemodynamically - - O
severe - - O
regurgitations - - O
and - - O
mild - - O
or - - O
insignificant - - O
ones - - O
. - - O

Effect - - O
of - - O
alcohol - - O
on - - O
minimal - - O
effective - - O
nCPAP - - O
pressure - - O
. - - O

Hb - - B-MUT
levels - - O
remained - - O
adequate - - O
( - - O
Hb - - B-MUT
= - - O
10 - - O
. - - O
68 - - O
+ - - O
- - - O
0 - - O
. - - O
77 - - O
g - - O
dl - - O
) - - O
after - - O
14 - - O
. - - O
6 - - O
+ - - O
- - - O
7 - - O
. - - O
64 - - O
months - - O
. - - O

Their - - O
numbers - - O
have - - O
regularly - - O
increased - - O
since - - O
the - - O
mid-1970s - - O
. - - O

An - - O
unusual - - O
cysteine - - O
triplet - - O
conserved - - O
in - - O
the - - O
sequences - - O
of - - O
TB - - B-MUT
domains - - I-MUT
is - - O
localized - - O
to - - O
the - - O
hydrophobic - - O
core - - O
, - - O
at - - O
the - - O
C-terminus - - O
of - - O
an - - O
alpha-helix - - O
. - - O

BIM - - O
130 - - O
. - - O

The - - O
results - - O
corroborate - - O
the - - O
idea - - O
that - - O
the - - O
structure - - O
of - - O
relaxation - - O
curves - - O
contains - - O
information - - O
on - - O
the - - O
distance - - O
scale - - O
and - - O
on - - O
the - - O
architecture - - O
of - - O
the - - O
pore - - O
space - - O
, - - O
even - - O
if - - O
it - - O
is - - O
difficult - - O
to - - O
extract - - O
it - - O
without - - O
ambiguities - - O
. - - O

Prostate - - B-MUT
specific - - I-MUT
antigen - - I-MUT
shows - - O
the - - O
metastatic - - O
cases - - O
better - - O
[ - - O
correction - - O
of - - O
worse - - O
] - - O
than - - O
prostatic - - B-MUT
acid - - I-MUT
phosphatase - - I-MUT
. - - O

An - - O
industry-wide - - O
retrospective - - O
cohort - - O
mortality - - O
study - - O
was - - O
conducted - - O
on - - O
6 - - O
, - - O
152 - - O
chemical - - O
workers - - O
( - - O
2 - - O
, - - O
460 - - O
exposed - - O
and - - O
3 - - O
, - - O
692 - - O
nonexposed - - O
) - - O
engaged - - O
in - - O
chloromethyl - - O
ether - - O
manufacture - - O
at - - O
7 - - O
major - - O
U - - O
. - - O
S - - O
. - - O
companies - - O
between - - O
1948 - - O
and - - O
1980 - - O
. - - O

The - - O
cwg2-1 - - B-MUT
mutation - - I-MUT
was - - O
identified - - O
as - - O
a - - O
guanine - - O
to - - O
adenine - - O
substitution - - O
at - - O
nucleotide - - O
604 - - O
of - - O
the - - O
coding - - O
region - - O
, - - O
originating - - O
the - - O
change - - O
A202T - - O
in - - O
the - - O
cwg2p - - B-MUT
. - - O

Closure - - O
of - - O
an - - O
open - - O
high - - O
below-knee - - O
guillotine - - O
amputation - - O
wound - - O
using - - O
a - - O
skin-stretching - - O
device - - O
. - - O

